-DOCSTART- -1530836- O O

A DT N
comparison NN N
of IN N
the DT N
effects NNS N
of IN N
anticholinergic NN i
and CC i
beta VB i
2-agonist JJ i
and CC i
combination NN i
therapy NN i
on IN N
respiratory NN N
impedance NN N
in IN N
COPD NNP p
. . p

The DT N
effects NNS N
of IN N
three CD N
different JJ N
regimens NNS N
of IN N
inhaled JJ i
bronchodilators NNS i
on IN N
spirometry NN N
and CC N
respiratory JJ N
impedance NN N
as IN N
measured VBN N
with IN N
the DT N
technique NN N
of IN N
forced JJ N
oscillations NNS N
were VBD N
compared VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
study NN N
in IN N
22 CD p
patients NNS p
with IN p
stable JJ p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
FEV1 NNP p
less JJR p
than IN p
70 CD p
percent NN p
predicted VBN p
) ) p
. . p

On IN N
three CD N
trial NN N
days NNS N
, , N
patients NNS N
inhaled VBD N
, , N
in IN N
random JJ N
order NN N
, , N
40 CD N
micrograms NNS N
ipratropium JJ i
bromide NN i
, , N
200 CD N
micrograms NNS N
fenoterol JJ i
hydrobromide NN i
, , N
or CC N
a DT i
combination NN i
of IN i
40 CD i
micrograms NNS i
ipratropium NN i
and CC i
100 CD i
micrograms NNS i
fenoterol VBP i
from IN N
a DT N
powder NN N
inhaler NN N
, , N
followed VBN N
by IN N
a DT N
second JJ N
dose NN N
of IN N
the DT N
same JJ N
drug NN N
after IN N
60 CD N
min NN N
. . N

The DT N
effects NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
120 CD N
min NN N
after IN N
the DT N
first JJ N
inhalation NN N
. . N

No DT o
significant JJ o
decrease NN o
in IN o
total JJ o
respiratory NN o
resistance NN o
at IN o
8 CD o
Hz NNP o
( ( o
Rrs NNP o
[ VBZ o
8 CD o
] NN o
) ) o
was VBD o
observed VBN o
after IN o
ipratropium NN o
, , o
whereas JJ o
Rrs NNP o
( ( o
8 CD o
) ) o
decreased VBD o
significantly RB o
20 CD o
min NNS o
after IN o
fenoterol NN o
and CC o
40 CD o
min NN o
after IN o
the DT o
combination NN o
regimen NNS o
( ( o
p NN o
less JJR o
than IN o
0.05 CD o
) ) o
. . o

All DT o
three CD o
studied VBD o
drugs NNS o
resulted VBD o
in IN o
a DT o
significant JJ o
increase NN o
in IN o
the DT o
reactance NN o
( ( o
p NN o
less JJR o
than IN o
0.01 CD o
) ) o
and CC o
decrease NN o
in IN o
resonant JJ o
frequency NN o
. . o

Both DT o
fenoterol NN o
( ( o
delta JJ o
FEV1 NNP o
34 CD o
percent NN o
, , o
p NN o
less JJR o
than IN o
0.0001 CD o
) ) o
and CC o
the DT o
combination NN o
regimen NNS o
( ( o
delta JJ o
FEV1 NNP o
38 CD o
percent NN o
, , o
p NN o
less JJR o
than IN o
0.0001 CD o
) ) o
resulted VBD o
in IN o
a DT o
significantly RB o
larger JJR o
increase NN o
in IN o
FEV1 NNP o
than IN o
ipratropium NN o
alone RB o
( ( o
delta JJ o
FEV1 NNP o
17 CD o
percent NN o
, , o
p NN o
less JJR o
than IN o
0.0001 CD o
) ) o
. . o

A DT o
second JJ o
dose NN o
of IN o
fenoterol NN o
and CC o
of IN o
the DT o
combination NN o
regimen NNS o
resulted VBD o
in IN o
a DT o
further JJ o
significant JJ o
increase NN o
in IN o
FEV1 NNP o
after IN o
120 CD o
min NN o
( ( o
p NN o
less JJR o
than IN o
0.05 CD o
) ) o
. . o

A DT o
second JJ o
dose NN o
of IN o
ipratropium NN o
did VBD o
not RB o
result VB o
in IN o
a DT o
further JJ o
significant JJ o
increase NN o
in IN o
FEV1 NNP o
. . o

The DT N
changes NNS o
in IN o
respiratory NN o
impedance NN o
were VBD o
qualitatively RB o
similar JJ o
for IN o
all DT o
three CD o
drug NN o
regimens NNS o
, , o
but CC o
larger JJR o
in IN o
absolute NN o
terms NNS o
after IN o
fenoterol NN o
and CC o
the DT o
combination NN o
regimen NNS o
than IN o
after IN o
ipratropium NN o
. . o

The DT o
similar JJ o
effect NN o
of IN o
these DT o
drugs NNS o
on IN o
the DT o
reactance NN o
can MD o
be VB o
explained VBN o
by IN o
an DT o
increase NN o
in IN o
the DT o
capacitance NN o
of IN o
the DT o
respiratory NN o
system NN o
, , o
and CC o
in IN o
combination NN o
with IN o
a DT o
decrease NN o
in IN o
frequency NN o
dependence NN o
of IN o
resistance NN o
, , o
by IN o
assuming VBG o
a DT o
decrease NN o
in IN o
peripheral JJ o
airway NN o
resistance NN o
. . o

-DOCSTART- -380614- O O

Clofibrate NNP o
and CC o
diabetes VBZ o
control NN o
in IN N
patients NNS p
treated VBN p
with IN p
oral JJ i
hypoglycaemic JJ i
agents NNS i
. . i

1 CD N
. . N

Twenty-two JJ p
maturity-onset JJ p
type NN p
diabetics NNS p
treated VBD p
with IN p
oral JJ i
hypoglycaemic JJ i
agents NNS i
entered VBD N
a DT N
single-blind JJ N
crossover NN N
study NN N
using VBG N
placebo NN i
( ( N
periods VB N
A DT N
and CC N
C NNP N
, , N
2 CD N
months NNS N
each DT N
) ) N
and CC N
clofibrate NN i
( ( N
2 CD N
g/day NN N
; : N
period NN N
B NNP N
; : N
2 CD N
months NNS N
) ) N
. . N

2 CD N
. . N

In IN N
thirteen JJ p
patients NNS p
, , p
under IN p
reasonably RB p
good JJ p
control NN p
, , N
clofibrate NN i
did VBD N
not RB N
reduce VB o
fasting VBG o
or CC o
post-prandial JJ o
blood NN o
glucose NN o
, , N
nor CC N
24 CD o
h NN o
glycosuria NN o
; : o
no DT N
improvement NN N
was VBD N
noted VBN N
in IN N
the DT N
M-value NNP o
, , o
an DT o
index NN o
of IN o
diabetes NNS o
control NN o
. . o

3 CD N
. . N

In IN N
contrast NN N
, , N
in IN N
nine CD N
patients NNS N
, , N
with IN N
poor JJ N
diabetes NNS o
control NN o
, , N
clofibrate NN i
reduced VBD N
24 CD o
h NN o
glycosuria NN o
and CC N
significantly RB N
improved VBD N
the DT N
M-value NNP o
. . o

4 CD N
. . N

In IN N
all DT N
patients NNS N
, , N
clofibrate JJ i
therapy NN i
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
19-23 JJ N
% NN N
reduction NN N
in IN N
plasma NN o
fibrinogen NN o
. . o

5 CD N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
addition NN N
of IN N
clofibrate NN i
may MD N
be VB N
useful JJ N
in IN N
maturity-onset JJ p
diabetics NNS p
not RB p
adequately RB p
controlled VBN p
by IN p
diet NN p
combined VBN p
with IN p
oral JJ i
hypoglycaemic JJ i
agents NNS i
. . i

-DOCSTART- -7673658- O O

Cyproheptadine NNP N
augmentation NN N
of IN N
haloperidol NN i
in IN N
chronic JJ p
schizophrenic JJ p
patients NNS p
: : p
a DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

A DT N
6 CD N
week NN N
double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
cyproheptadine JJ i
augmentation NN i
of IN p
ongoing VBG p
haloperidol NN i
treatment NN p
was VBD N
conducted VBN N
in IN N
40 CD p
chronic JJ p
schizophrenic JJ p
in-patients NNS p
. . p

Cyproheptadine NNP N
augmentation NN N
, , N
compared VBN N
to TO N
administration NN N
of IN N
haloperidol NN i
with IN i
placebo NN i
, , N
did VBD N
not RB N
produce VB N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
psychotic JJ o
symptoms NNS o
. . o

Cyproheptadine NNP N
augmentation NN N
caused VBD N
significant JJ N
reduction NN N
in IN N
the DT N
extrapyramidal NN o
symptoms NNS o
, , N
which WDT N
supports VBZ N
the DT N
atypical JJ N
profile NN N
of IN N
antipsychotics NNS N
. . N

As IN N
to TO N
the DT N
neuroendocrinological JJ o
effect NN o
, , N
cyproheptadine JJ N
augmentation NN N
did VBD N
not RB N
reduce VB N
the DT N
plasma NN o
prolactin NN o
level NN o
but CC N
did VBD N
induce VB N
a DT N
decrease NN N
in IN N
the DT N
plasma NN o
cortisol NN o
level NN o
. . o

Although IN N
long-term JJ N
follow-up JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
confirm VB N
the DT N
results NNS N
, , N
this DT N
study NN N
suggests VBZ N
that IN N
cyproheptadine NN N
augmentation NN N
may MD N
be VB N
effective JJ N
in IN N
treating VBG N
chronic JJ o
schizophrenic JJ o
patients NNS o
who WP p
are VBP p
intolerant JJ p
of IN p
extrapyramidal JJ o
side NN o
effects NNS o
of IN p
conventional JJ p
antipsychotics NNS p
. . p

-DOCSTART- -2192405- O O

[ IN N
The DT N
equipotency NN N
of IN N
ropivacaine NN i
, , i
bupivacaine NN i
and CC N
etidocaine NN i
] NN i
. . N

Ropivacaine NNP i
, , N
congenerate NN N
to TO N
bupivacaine VB N
and CC N
mepivacaine VB N
has VBZ N
been VBN N
widely RB N
studied VBN N
in IN N
laboratory NN N
animals NNS N
, , N
but CC N
there RB N
have VBP N
been VBN N
few JJ N
investigations NNS N
of IN N
its PRP$ N
efficacy NN N
in IN N
human JJ N
epidural JJ N
anesthesia NN N
and CC N
peripheral JJ N
nerve NN N
blocks NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
three CD N
long-acting JJ N
local JJ N
anesthetics NNS N
( ( i
bupivacaine VB i
0.75 CD N
% NN N
, , N
ropivacaine VB i
1 CD N
% NN N
and CC N
etidocaine VB i
1 CD N
% NN N
) ) N
and CC N
to TO N
try VB N
, , N
with IN N
reference NN N
to TO N
previous JJ N
studies NNS N
, , N
to TO N
make VB N
some DT N
statement NN N
about IN N
the DT N
equipotency NN N
of IN N
ropivacaine JJ i
relative NN N
to TO N
bupivacaine VB i
and CC N
etidocaine VB i
. . i

METHODS NNP N
. . N

In IN N
a DT N
double JJ N
blind NN N
randomized VBN N
study NN N
, , N
epidural JJ N
anesthesia NN N
was VBD N
carried VBN N
out IN N
with IN N
20 CD N
ml NNS N
bupivacaine VBP i
0.75 CD N
% NN N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
and CC N
ropivacaine VB i
1 CD N
% NN N
( ( N
n JJ N
= NNP N
21 CD N
) ) N
. . N

Following VBG N
this DT N
study NN N
epidural JJ N
anesthesia NN N
was VBD N
carried VBN N
out IN N
with IN N
20 CD N
ml NNS N
etidocaine VBP i
1 CD N
% NN N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
in IN N
an DT N
open JJ N
study NN N
. . N

Patients NNS p
with IN p
ASA NNP p
I PRP p
or CC p
II NNP p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

All DT p
patients NNS p
were VBD p
scheduled VBN p
for IN p
varicose JJ p
vein NN p
stripping VBG p
. . p

Male NNP p
and CC p
female JJ p
patients NNS p
aged VBN p
18-70 JJ p
years NNS p
and CC p
weighing VBG p
50-100 JJ p
kg NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Patients NNS N
were VBD N
all DT N
placed VBN N
in IN N
a DT N
sitting JJ N
position NN N
, , N
after IN N
which WDT N
the DT N
epidural JJ N
space NN N
was VBD N
identified VBN N
by IN N
the DT N
loss NN N
of IN N
resistance NN N
technique NN N
and CC N
a DT N
midline NN N
approach NN N
, , N
at IN N
the DT N
L-3/4 JJ N
interspace NN N
. . N

Injections NNS i
of IN i
3 CD i
ml NN i
of IN i
the DT i
local JJ i
anesthetic NN i
were VBD N
given VBN N
, , N
followed VBN i
by IN i
the DT i
remainder NN i
of IN i
the DT i
local JJ i
anesthetic NN i
at IN i
10 CD i
ml/min NN i
1 CD i
min NN i
later RB i
. . i

Following VBG N
injection NN N
patients NNS N
were VBD N
immediately RB N
positioned VBN N
supine NN N
. . N

Analgesia NNP N
was VBD N
determined VBN N
by IN N
the DT N
pin-prick JJ o
method NN o
and CC N
motor NN N
blockade NN N
was VBD N
assessed VBN N
according VBG N
to TO N
the DT N
Bromage NNP o
scale NN o
. . o

Heart NNP o
rate NN o
and CC o
blood NN o
pressure NN o
were VBD N
monitored VBN N
until IN N
3 CD N
h NNS N
after IN N
injection NN N
. . N

RESULTS NNP N
. . N

The DT N
latency NN o
of IN o
analgesia NN o
for IN N
the DT N
first JJ N
blocked VBN N
segment NN N
( ( N
T NNP N
12 CD N
for IN N
bupivacaine NN N
and CC N
ropivacaine NN N
and CC N
L-1 NNP N
for IN N
etidocaine NN N
) ) N
was VBD N
6.0 CD N
min NN N
for IN N
bupivacaine NN i
0.75 CD N
, , N
5.5 CD N
min NN N
for IN N
ropivacaine JJ i
1 CD N
% NN N
, , N
and CC N
5.2 CD N
min NN N
for IN N
etidocaine JJ i
1 CD N
% NN N
, , N
and CC N
the DT N
highest JJS N
thoracic JJ N
dermatome NN N
( ( N
T NNP N
5 CD N
for IN N
bupivacaine NN i
, , N
T NNP N
4 CD N
for IN N
ropivacaine NN i
and CC N
T NNP N
7 CD N
for IN N
etidocaine NN i
) ) i
was VBD N
reached VBN N
after IN N
24 CD N
+/- JJ N
10 CD N
, , N
26 CD N
+/- JJ N
9 CD N
, , N
and CC N
30 CD N
+/- JJ N
18 CD N
min NN N
for IN N
bupivacaine NN i
, , i
ropivacaine NN i
, , N
and CC N
etidocaine NN i
, , N
respectively RB N
. . N

The DT N
duration NN o
of IN o
sensory JJ o
anesthesia NN o
at IN N
the DT N
T NNP N
10 CD N
dermatomal JJ N
level NN N
was VBD N
257 CD N
+/- JJ N
102 CD N
, , N
278 CD N
+/- JJ N
67 CD N
, , N
and CC N
191 CD N
+/- JJ N
86 CD N
min NN N
for IN N
bupivacaine NN i
, , i
ropivacaine NN i
, , N
and CC N
etidocaine NN i
, , N
respectively RB N
. . N

The DT N
two-segment JJ o
regression NN o
time NN o
was VBD N
199 CD N
+/- JJ N
80 CD N
min NN N
for IN N
bupivacaine NN i
, , N
201 CD N
+/- JJ N
52 CD N
min NN N
for IN N
ropivacaine NN i
, , N
and CC N
174 CD N
+/- JJ N
81 CD N
min NN N
for IN N
etidocaine NN i
. . i

The DT N
total JJ o
duration NN o
of IN o
sensory JJ o
block NN o
was VBD N
340 CD N
+/- JJ N
103 CD N
min NN N
for IN N
bupivacaine NN i
, , N
428 CD N
+/- JJ N
65 CD N
min NN N
for IN N
ropivacaine NN i
and CC N
223 CD N
+/- JJ N
62 CD N
min NN N
for IN N
etidocaine NN i
, , N
respectively RB N
. . N

In IN N
the DT N
ropivacaine NN i
and CC N
bupivacaine NN i
groups NNS N
sensory JJ N
anesthesia NN N
was VBD N
considered VBN N
adequate NN N
for IN N
surgery NN N
in IN N
all DT N
cases NNS N
but CC N
one CD N
in IN N
each DT N
group NN N
; : N
in IN N
the DT N
etidocaine NN i
group NN N
, , N
however RB N
60 CD N
% NN N
of IN N
the DT N
patients NNS N
showed VBD N
inadequate JJ o
analgesia NN o
and CC N
all PDT N
these DT N
patients NNS N
( ( N
12/20 CD N
) ) N
required VBN N
additional JJ N
analgesics NNS N
. . N

Bupivacaine NNP i
achieved VBD N
an DT N
average NN N
of IN N
motor NN N
block NN N
2.1 CD N
, , N
ropivacaine NN i
2.3 CD N
, , N
and CC N
etidocaine VB i
2.4 CD N
. . N

CONCLUSION NNP N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
ropivacaine NN i
is VBZ N
an DT N
effective JJ N
local JJ N
anesthetic JJ N
agent NN N
. . N

Its PRP$ N
potency NN N
is VBZ N
about RB N
equal JJ N
to TO N
that DT N
of IN N
bupivacaine NN i
and CC N
much RB N
higher JJR N
than IN N
that DT N
of IN N
etidocaine NN i
... : i
-DOCSTART- -19487623- O O

Lack NN N
of IN N
efficacy NN o
of IN N
citalopram NN i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
high JJ p
levels NNS p
of IN p
repetitive JJ p
behavior NN p
: : p
citalopram NN i
ineffective NN N
in IN N
children NNS p
with IN p
autism NN p
. . p

CONTEXT NNP N
Selective NNP i
serotonin NN i
reuptake NN i
inhibitors NNS i
are VBP N
widely RB N
prescribed VBN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
citalopram JJ i
hydrobromide NN i
therapy NN i
for IN N
repetitive JJ N
behavior NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

DESIGN NNP N
National NNP N
Institutes NNPS N
of IN N
Health-sponsored NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Six NNP p
academic JJ p
centers NNS p
, , p
including VBG p
Mount NNP p
Sinai NNP p
School NNP p
of IN p
Medicine NNP p
, , p
North NNP p
Shore-Long NNP p
Island NNP p
Jewish NNP p
Health NNP p
System NNP p
, , p
University NNP p
of IN p
North NNP p
Carolina NNP p
at IN p
Chapel NNP p
Hill NNP p
, , p
University NNP p
of IN p
California NNP p
at IN p
Los NNP p
Angeles NNP p
, , p
Yale NNP p
University NNP p
, , p
and CC p
Dartmouth NNP p
Medical NNP p
School NNP p
. . p

PARTICIPANTS NNP N
One CD p
hundred VBD p
forty-nine JJ p
volunteers NNS p
5 CD p
to TO p
17 CD p
years NNS p
old JJ p
( ( p
mean JJ p
[ NNP p
SD NNP p
] NNP p
age NN p
, , p
9.4 CD p
[ NN p
3.1 CD p
] CD p
years NNS p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
citalopram NN i
( ( N
n JJ N
= NNP N
73 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
76 CD N
) ) N
. . N

Participants NNS p
had VBD p
autistic JJ p
spectrum NN p
disorders NNS p
, , p
Asperger NNP p
disorder NN p
, , p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
, , p
not RB p
otherwise RB p
specified VBN p
; : p
had VBD p
illness JJ p
severity NN p
ratings NNS p
of IN p
at IN p
least JJS p
moderate JJ p
on IN p
the DT p
Clinical NNP p
Global NNP p
Impressions NNP p
, , p
Severity NNP p
of IN p
Illness NNP p
Scale NNP p
; : p
and CC p
scored VBD p
at IN p
least JJS p
moderate JJ p
on IN p
compulsive JJ p
behaviors NNS p
measured VBN p
with IN p
the DT p
Children NNP p
's POS p
Yale-Brown JJ p
Obsessive NNP p
Compulsive NNP p
Scales NNP p
modified VBD p
for IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

INTERVENTIONS NNP N
Twelve NNP N
weeks NNS N
of IN N
citalopram NN i
hydrobromide NN i
( ( i
10 CD i
mg/5 RB i
mL NN i
) ) i
or CC i
placebo NN i
. . i

The DT N
mean NN N
( ( N
SD NNP N
) ) N
maximum JJ N
dosage NN N
of IN N
citalopram NN i
hydrobromide NN i
was VBD N
16.5 CD N
( ( N
6.5 CD N
) ) N
mg/d NN N
by IN N
mouth NN N
( ( N
maximum JJ N
, , N
20 CD N
mg/d NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Positive NNP N
response NN N
was VBD N
defined VBN N
by IN N
a DT N
score NN N
of IN N
much JJ N
improved VBN N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
Clinical NNP o
Global NNP o
Impressions NNP o
, , o
Improvement NNP o
subscale NN o
. . o

An DT N
important JJ N
secondary JJ N
outcome NN N
was VBD N
the DT N
score NN N
on IN N
the DT N
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive NNP o
Compulsive NNP o
Scales NNP o
modified VBD o
for IN o
pervasive JJ o
developmental NN o
disorders NNS o
. . o

Adverse JJ o
events NNS o
were VBD N
systematically RB N
elicited VBN N
using VBG N
the DT N
Safety NNP N
Monitoring NNP N
Uniform NNP N
Report NNP N
Form NNP N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
positive JJ o
response NN o
on IN N
the DT N
Clinical NNP o
Global NNP o
Impressions NNP o
, , o
Improvement NNP o
subscale NN o
between IN N
the DT N
citalopram-treated JJ i
group NN N
( ( N
32.9 CD N
% NN N
) ) N
and CC N
the DT N
placebo NN i
group NN N
( ( N
34.2 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
, , N
0.96 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.61-1.51 JJ N
; : N
P NNP N
> NNP N
.99 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
score NN N
reduction NN N
on IN N
the DT N
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive NNP o
Compulsive NNP o
Scales NNP o
modified VBD N
for IN N
pervasive JJ N
developmental JJ o
disorders NNS o
from IN N
baseline NN N
( ( N
mean JJ N
[ NNP N
SD NNP N
] NNP N
, , N
-2.0 NNP N
[ VBZ N
3.4 CD N
] NN N
points NNS N
for IN N
the DT N
citalopram-treated JJ i
group NN N
and CC N
-1.9 NNP N
[ NNP N
2.5 CD N
] NN N
points NNS N
for IN N
the DT N
placebo NN i
group NN N
; : N
P NNP N
= NNP N
.81 NNP N
) ) N
. . N

Citalopram NNP i
use NN N
was VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
be VB N
associated VBN N
with IN N
adverse JJ N
events NNS N
, , N
particularly RB N
increased VBD N
energy NN o
level NN o
, , o
impulsiveness NN o
, , N
decreased VBN N
concentration NN o
, , o
hyperactivity NN o
, , o
stereotypy NN o
, , o
diarrhea NN o
, , o
insomnia NN o
, , o
and CC o
dry JJ o
skin NN o
or CC o
pruritus NN o
. . o

CONCLUSION NNP N
Results NNP N
of IN N
this DT N
trial NN N
do VBP N
not RB N
support VB N
the DT N
use NN N
of IN N
citalopram NN i
for IN N
the DT N
treatment NN N
of IN N
repetitive JJ N
behavior NN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Trial JJ N
Registration NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00086645 NN N
. . N

-DOCSTART- -2108990- O O

The DT N
effect NN N
of IN N
HCG NNP i
supplementation NN i
after IN N
combined VBN i
GnRH NNP i
agonist/HMG JJ i
treatment NN i
in IN p
an DT p
IVF NNP p
programme NN p
. . p

The DT N
necessity NN N
of IN N
luteal-phase JJ i
supplementation NN i
in IN N
an DT N
IVF NNP p
programme NN p
is VBZ N
of IN N
continuing VBG N
interest NN N
. . N

After IN N
ovarian JJ N
stimulation NN N
with IN N
clomiphene NN i
and CC N
human JJ i
menopausal NN i
gonadotrophin NN i
( ( i
HMG NNP i
) ) i
, , N
the DT N
beneficial JJ N
effect NN N
of IN N
supporting VBG N
the DT N
luteal NN N
phase NN N
has VBZ N
never RB N
been VBN N
scientifically RB N
demonstrated VBN N
. . N

After IN N
ovarian JJ N
stimulation NN N
with IN N
GnRH NNP i
agonist/HMG NN i
, , N
the DT N
luteal JJ N
phase NN N
seems VBZ N
to TO N
be VB N
inadequate JJ N
, , N
but CC N
in IN N
a DT N
previous JJ N
study NN N
we PRP N
did VBD N
not RB N
find VB N
evidence NN N
to TO N
support VB N
the DT N
need NN N
for IN N
oral JJ N
progesterone NN N
supplementation NN N
. . N

To TO N
evaluate VB N
the DT N
beneficial JJ N
effect NN N
of IN N
human JJ i
chorionic NN i
gonadotrophin NN i
( ( i
HCG NNP i
) ) i
supplementation NN i
, , N
we PRP N
performed VBD N
a DT N
multicentre NN N
, , N
double-blind NN N
, , N
randomized VBN N
study NN N
with IN N
HCG NNP i
( ( p
193 CD p
transfers NNS p
) ) p
against IN p
placebo NN i
( ( p
194 CD p
transfers NNS p
) ) p
. . p

The DT N
ongoing JJ o
pregnancy NN o
rate NN o
per IN o
transfer NN o
cycle NN o
was VBD N
significantly RB N
better RBR N
with IN N
HCG NNP i
( ( N
18.7 CD N
versus IN N
9.3 CD N
) ) N
. . N

This DT N
is VBZ N
the DT N
first JJ N
truly RB N
objective JJ N
( ( N
randomized VBN N
) ) N
study NN N
demonstrating VBG N
the DT N
beneficial JJ N
effect NN N
of IN N
supporting VBG N
the DT N
luteal JJ N
phase NN N
in IN N
an DT N
IVF NNP p
programme NN p
. . p

-DOCSTART- -22572567- O O

Roles NNS o
of IN o
adapalene NN o
in IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

BACKGROUND NNP N
Ketoconazole NNP i
is VBZ N
a DT N
typical JJ N
treatment NN N
available JJ N
for IN N
pityriasis NN p
versicolor NN p
; : p
tretinoin CC i
cream NN i
is VBZ N
effective JJ N
, , N
too RB N
. . N

Adapalene NNP i
gel NN i
is VBZ N
a DT N
tretinoin JJ N
derivative NN N
and CC N
has VBZ N
a DT N
lower JJR N
incidence NN N
of IN N
irritation NN o
compared VBN N
with IN N
other JJ N
topical JJ N
retinoid NN N
products NNS N
. . N

However RB N
, , N
there EX N
are VBP N
no DT N
reports NNS N
on IN N
adapalene NN i
gel NN i
for IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
adapalene NN i
gel NN i
comparing VBG N
the DT N
treatment NN N
with IN N
adapalene JJ i
gel NNS i
and CC i
2 CD i
% NN i
ketoconazole JJ i
cream NN i
in IN N
pityriasis NN p
versicolor NN p
. . p

METHODS NNP N
Eighty NNP p
patients NNS p
suffering VBG p
from IN p
pityriasis NN p
versicolor NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
; : N
one CD N
group NN N
were VBD N
treated VBN N
with IN N
2 CD i
% NN i
ketoconazole JJ i
cream NN i
topically RB N
twice JJ N
daily RB N
for IN N
2 CD N
weeks NNS N
, , N
adapalene JJ i
gel NN i
was VBD N
used VBN N
for IN N
the DT N
other JJ N
group NN N
in IN N
a DT N
similar JJ N
fashion NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
efficacy NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

No DT N
major JJ N
side NN o
effects NNS o
were VBD N
noted VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
either CC N
. . N

CONCLUSION NNP N
Adapalene NNP i
was VBD N
the DT N
favorable JJ N
option NN N
in IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

The DT N
probable JJ N
therapeutic JJ N
mechanism NN N
of IN N
adapalene NN i
is VBZ N
also RB N
discussed VBN N
. . N

-DOCSTART- -24433230- O O

Goodstart NN N
: : N
a DT N
cluster NN N
randomised VBD N
effectiveness JJ o
trial NN N
of IN N
an DT N
integrated VBN i
, , i
community-based JJ i
package NN i
for IN i
maternal JJ i
and CC i
newborn JJ i
care NN i
, , i
with IN i
prevention NN i
of IN i
mother-to-child JJ i
transmission NN i
of IN i
HIV NNP i
in IN p
a DT p
South JJ p
African JJ p
township NN p
. . p

BACKGROUND NNP N
Progress NNP N
towards NNS N
MDG4 NNP N
for IN N
child NN N
survival NN N
in IN N
South NNP N
Africa NNP N
requires VBZ N
effective JJ N
prevention NN N
of IN N
mother-to-child JJ N
transmission NN N
( ( N
PMTCT NNP N
) ) N
of IN N
HIV NNP N
including VBG N
increasing VBG N
exclusive JJ N
breastfeeding NN N
, , N
as RB N
well RB N
as IN N
a DT N
new JJ N
focus NN N
on IN N
reducing VBG N
neonatal JJ N
deaths NNS N
. . N

This DT N
necessitates VBZ N
increased JJ N
focus NN N
on IN N
the DT N
pregnancy NN N
and CC N
early JJ N
post-natal JJ N
periods NNS N
, , N
developing VBG N
and CC N
scaling VBG N
up RP N
appropriate JJ N
models NNS N
of IN N
community-based JJ N
care NN N
, , N
especially RB N
to TO N
reach VB N
the DT N
peri-urban JJ p
poor JJ p
. . p

METHODS NNP N
We PRP N
used VBD N
a DT N
randomised JJ N
controlled VBN N
trial NN N
with IN N
30 CD p
clusters NNS p
( ( p
15 CD p
in IN p
each DT p
arm NN p
) ) p
to TO p
evaluate VB p
an DT p
integrated VBN i
, , i
scalable JJ i
package NN i
providing VBG i
two CD i
pregnancy NN i
visits NNS i
and CC i
five CD i
post-natal JJ i
home NN i
visits NNS i
delivered VBN i
by IN i
community NN i
health NN i
workers NNS i
in IN p
Umlazi NNP p
, , p
Durban NNP p
, , p
South NNP p
Africa NNP p
. . p

Primary NNP N
outcomes NNS N
were VBD N
exclusive JJ o
and CC o
appropriate JJ o
infant NN o
feeding NN o
at IN o
12 CD o
weeks NNS o
post-natally RB o
and CC o
HIV-free JJ o
infant NN o
survival NN o
. . o

RESULTS NNP N
At IN N
12 CD p
weeks NNS p
of IN p
infant JJ p
age NN p
, , N
the DT N
intervention NN N
was VBD N
effective JJ N
in IN N
almost RB N
doubling VBG N
the DT N
rate NN o
of IN o
exclusive JJ o
breastfeeding NN o
( ( N
risk NN N
ratio VBP N
1.92 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.59-2.33 JJ N
) ) N
and CC N
increasing VBG N
infant JJ o
weight NN o
and CC o
length-for-age JJ o
z-scores NNS o
( ( N
weight JJ N
difference NN N
0.09 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.00-0.18 JJ N
, , N
length JJ N
difference NN N
0.11 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.03-0.19 NN N
) ) N
. . N

No DT N
difference NN N
was VBD N
seen VBN N
between IN N
study NN N
arms NNS N
in IN N
HIV-free JJ o
survival NN o
. . o

Women NNS N
in IN N
the DT N
intervention NN N
arm NN N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
take VB o
their PRP$ o
infant NN o
to TO o
the DT o
clinic NN o
within IN o
the DT o
first JJ o
week NN o
of IN o
life NN o
( ( N
risk NN N
ratio VBP N
1.10 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.04-1.18 JJ N
) ) N
. . N

CONCLUSIONS VB N
The DT N
trial NN N
coincided VBD N
with IN N
national JJ N
scale NN N
up IN N
of IN N
ARVs NNP N
for IN N
PMTCT NNP N
, , N
and CC N
this DT N
could MD N
have VB N
diluted VBN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
on IN N
HIV-free NNP o
survival NN o
. . o

We PRP N
have VBP N
demonstrated VBN N
that IN N
implementation NN N
of IN N
a DT N
pro-poor JJ N
integrated JJ N
PMTCT NNP N
and CC N
maternal JJ N
, , N
neonatal JJ N
and CC N
child JJ N
health NN N
home NN N
visiting VBG N
model NN N
is VBZ N
feasible JJ N
and CC N
effective JJ N
. . N

This DT N
trial NN N
could MD N
inform VB N
national JJ N
primary NN N
healthcare NN N
reengineering VBG N
strategies NNS N
in IN N
favour NN N
of IN N
home NN N
visits NNS N
. . N

The DT N
dose JJ N
effect NN N
on IN N
exclusive JJ N
breastfeeding NN N
is VBZ N
notable JJ N
as IN N
improving VBG N
exclusive JJ N
breastfeeding NN N
has VBZ N
been VBN N
resistant JJ N
to TO N
change VB N
in IN N
other JJ N
studies NNS N
targeting VBG N
urban JJ N
poor JJ N
families NNS N
. . N

-DOCSTART- -7907677- O O

Warfarin NNP i
versus NN N
aspirin NN i
for IN N
prevention NN N
of IN N
thromboembolism NN o
in IN N
atrial JJ N
fibrillation NN N
: : N
Stroke NNP N
Prevention NNP N
in IN N
Atrial NNP N
Fibrillation NNP N
II NNP N
Study NNP N
. . N

Warfarin NNP i
is VBZ N
an DT N
established JJ N
treatment NN N
for IN N
prevention NN N
of IN N
ischaemic JJ N
stroke NN N
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
, , N
but CC N
the DT N
value NN N
of IN N
this DT N
agent JJ N
relative NN N
to TO N
aspirin VB N
in IN N
unclear JJ N
. . N

In IN N
the DT N
first JJ N
Stroke NNP N
Prevention NNP N
in IN N
Atrial NNP N
Fibrillation NNP N
( ( N
SPAF-I NNP N
) ) N
study NN N
, , N
direct JJ N
comparison NN N
of IN N
warfarin NN i
with IN N
aspirin NN i
was VBD N
limited VBN N
by IN N
the DT N
small JJ N
number NN N
of IN N
thromboembolic JJ N
events NNS N
. . N

SPAF-II JJ N
aims NNS N
to TO N
address VB N
this DT N
issue NN N
and CC N
also RB N
to TO N
assess VB N
the DT N
differential JJ N
effects NNS N
of IN N
the DT N
two CD N
treatments NNS N
according VBG N
to TO N
age NN N
. . N

We PRP N
compared VBN N
warfarin NN i
( ( N
prothrombin JJ N
time NN N
ratio JJ N
1.3-1.8 JJ N
, , N
international JJ N
normalised JJ N
ratio NN N
2.0-4.5 JJ N
) ) N
with IN N
aspirin $ i
325 CD i
mg JJ i
daily RB i
for IN N
prevention NN N
of IN N
ischaemic JJ o
stroke NN o
and CC N
systemic JJ o
embolism NN o
( ( N
primary JJ N
events NNS N
) ) N
in IN N
two CD N
parallel NNS N
randomised VBD N
trials NNS N
involving VBG N
715 CD p
patients NNS p
aged VBN p
75 CD p
years NNS p
or CC p
less JJR p
and CC p
385 CD p
patients NNS p
older JJR p
than IN p
75 CD p
; : p
we PRP N
sought VBD N
reductions NNS N
in IN N
the DT N
absolute JJ N
rate NN N
of IN N
primary JJ N
events NNS N
by IN N
warfarin NNS i
compared VBN N
with IN N
aspirin NN i
of IN N
2 CD N
% NN N
per IN N
year NN N
and CC N
4 CD N
% NN N
per IN N
year NN N
, , N
respectively RB N
. . N

In IN N
the DT N
younger JJR N
patients NNS N
, , N
warfarin NNS i
decreased VBD N
the DT N
absolute JJ o
rate NN o
of IN o
primary JJ o
events NNS o
by IN N
0.7 CD N
% NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI-0.4 NNP N
to TO N
1.7 CD N
) ) N
. . N

The DT N
primary JJ o
event NN o
rate NN o
per IN o
year NN o
was VBD N
1.3 CD N
% NN N
with IN N
warfarin NN i
and CC N
1.9 CD N
% NN N
with IN N
aspirin NN i
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
0.67 CD N
, , N
p NN N
= NNP N
0.24 CD N
) ) N
. . N

The DT N
absolute JJ o
rate NN o
of IN o
primary JJ o
events NNS o
in IN N
low-risk JJ N
younger NN N
patients NNS N
( ( N
without IN N
hypertension NN N
, , N
recent JJ N
heart NN N
failure NN N
, , N
or CC N
previous JJ N
thromboembolism NN N
) ) N
on IN N
aspirin NN i
was VBD N
0.5 CD N
% NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI NNP N
0.1 CD N
to TO N
1.9 CD N
) ) N
. . N

Among IN N
older JJR N
patients NNS N
, , N
warfarin NNS i
decreased VBD N
the DT N
absolute JJ o
rate NN o
of IN o
primary JJ o
events NNS o
by IN N
1.2 CD N
% NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI-1.7 NNP N
to TO N
4.1 CD N
) ) N
. . N

The DT N
primary JJ o
event NN o
rate NN o
per IN o
year NN o
was VBD N
3.6 CD N
% NN N
with IN N
warfarin NN i
and CC N
4.8 CD N
% NN N
with IN N
aspirin NN i
( ( N
RR NNP N
0.73 CD N
, , N
p NN N
= NNP N
0.39 CD N
) ) N
. . N

In IN N
this DT N
older JJR N
group NN N
, , N
the DT N
rate NN o
of IN o
all DT o
stroke NN o
with IN o
residual JJ o
deficit NN o
( ( N
ischaemic JJ N
or CC N
haemorrhagic NN N
) ) N
was VBD N
4.3 CD N
% NN N
per IN N
year NN N
with IN N
aspirin NN i
and CC N
4.6 CD N
% NN N
per IN N
year NN N
with IN N
warfarin NN i
( ( N
RR NNP N
1.1 CD N
) ) N
. . N

Warfarin NNP i
may MD N
be VB N
more RBR N
effective JJ N
than IN N
aspirin NN i
for IN N
prevention NN N
of IN N
ischaemic JJ o
stroke NN o
in IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
, , N
but CC N
the DT N
absolute JJ o
reduction NN o
in IN N
stroke NN o
rate NN o
by IN N
warfarin NN i
is VBZ N
small JJ N
. . N

Younger JJR N
patients NNS N
without IN N
risk NN N
factors NNS N
had VBD N
a DT N
low JJ N
rate NN o
of IN o
stroke NN o
when WRB N
treated VBN N
with IN N
aspirin NN i
. . i

In IN N
older JJR N
patients NNS N
the DT N
rate NN o
of IN o
stroke NN o
( ( N
ischaemic JJ N
and CC N
haemorrhagic NN N
) ) N
was VBD N
substantial JJ N
, , N
irrespective NN N
of IN N
which WDT N
agent NN N
was VBD N
given VBN N
. . N

Patient JJ N
age NN N
and CC N
the DT N
inherent JJ N
risk NN N
of IN N
thromboembolism NN N
should MD N
be VB N
considered VBN N
in IN N
the DT N
choice NN N
of IN N
antithrombotic JJ N
prophylaxis NN N
for IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
. . N

-DOCSTART- -16750325- O O

Fifteen-year JJ N
results NNS N
of IN N
a DT N
randomized JJ N
prospective JJ N
trial NN N
of IN N
hyperfractionated VBN i
chest JJS i
wall NN i
irradiation NN i
versus IN i
once-daily RB i
chest JJS i
wall NN i
irradiation NN i
after IN i
chemotherapy NN i
and CC N
mastectomy NN N
for IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
noninflammatory JJ p
breast NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
analyze VB N
the DT N
results NNS N
of IN N
a DT N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
that WDT N
investigated VBD N
whether IN N
a DT N
hyperfractionated JJ i
radiotherapy NN i
( ( i
RT NNP i
) ) i
schedule NN N
could MD N
reduce VB N
the DT N
risk NN N
of IN N
locoregional JJ N
recurrence NN N
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
breast NN p
cancer NN p
treated VBN p
with IN p
chemotherapy NN p
and CC p
mastectomy NN p
. . p

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP p
1985 CD p
and CC p
1989 CD p
, , p
200 CD p
patients NNS p
with IN p
clinical JJ p
Stage NNP p
III NNP p
noninflammatory JJ p
breast NN p
cancer NN p
were VBD N
enrolled VBN N
in IN N
a DT N
prospective JJ N
study NN N
investigating VBG N
neoadjuvant JJ N
and CC N
adjuvant JJ N
chemotherapy NN N
. . N

Of IN p
the DT p
179 CD p
patients NNS p
treated VBN p
with IN p
mastectomy NN i
after IN i
neoadjuvant JJ i
chemotherapy NN i
, , p
108 CD p
participated VBN p
in IN N
a DT N
randomized JJ N
component NN N
of IN N
the DT N
trial NN N
that WDT N
compared VBN N
a DT N
dose-escalated JJ N
, , N
hyperfractionated VBN i
( ( i
twice-daily JJ i
, , i
b.i.d NN i
. . i

) ) i
chest JJS i
wall NN i
RT NNP i
schedule NN N
( ( N
72 CD N
Gy NNP N
in IN N
1.2-Gy JJ N
b.i.d NN N
. . N

fractions NNS N
) ) N
with IN N
a DT N
once-daily JJ N
( ( N
q.d JJ N
. . N

) ) N
schedule NN N
( ( N
60 CD N
Gy NNP N
in IN N
2-Gy JJ N
q.d NN N
. . N

fractions NNS N
) ) N
. . N

In IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
, , N
the DT N
supraclavicular JJ N
fossa NN N
and CC N
axillary JJ N
apex NN N
were VBD N
treated VBN N
once RB N
daily JJ N
to TO N
50 CD N
Gy NNP N
. . N

The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
15 CD N
years NNS N
. . N

RESULTS VB N
The DT N
15-year JJ o
actuarial JJ o
locoregional JJ o
recurrence NN o
rate NN o
was VBD N
7 CD N
% NN N
for IN N
the DT N
q.d NN i
. . i

arm NN i
and CC N
12 CD N
% NN N
for IN N
the DT N
b.i.d NN i
. . i

arm NN i
( ( N
p=0.36 NN N
) ) N
. . N

The DT N
rates NNS o
of IN o
severe JJ o
acute JJ o
toxicity NN o
were VBD N
similar JJ N
( ( N
4 CD N
% NN N
for IN N
q.d NN N
. . N

vs. FW N
5 CD N
% NN N
for IN N
b.i.d NN N
. . N

) ) N
, , N
but CC N
moist JJ N
desquamation NN N
developed VBD N
in IN N
42 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
b.i.d NN i
. . i

arm NN i
compared VBN N
with IN N
28 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
q.d NN i
. . i

arm NN i
( ( N
p=0.16 NN N
) ) N
. . N

The DT N
15-year JJ o
actuarial JJ o
rate NN o
of IN o
severe JJ o
late JJ o
RT NNP o
complications NNS o
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
arms NNS N
( ( N
6 CD N
% NN N
for IN N
q.d NN N
. . N

vs. FW N
11 CD N
% NN N
for IN N
b.i.d. NN N
, , N
p=0.54 NN N
) ) N
. . N

CONCLUSION NNP N
Although IN N
the DT N
sample JJ N
size NN N
of IN N
this DT N
study NN N
was VBD N
small JJ N
, , N
we PRP N
found VBD N
no DT N
evidence NN N
that IN N
this DT N
hyperfractionation NN N
schedule NN N
of IN N
postmastectomy NN i
RT NNP i
offered VBD N
a DT N
clinical JJ N
advantage NN N
. . N

Therefore RB N
, , N
we PRP N
have VBP N
concluded VBN N
that IN N
it PRP N
should MD N
not RB N
be VB N
further RB N
studied VBN N
in IN N
this DT N
cohort NN N
of IN N
patients NNS N
. . N

-DOCSTART- -11832869- O O

Changes NNS N
in IN N
selected VBN N
fitness NN o
parameters NNS o
following VBG N
six CD N
weeks NNS N
of IN N
snowshoe JJ i
training NN i
. . i

BACKGROUND NNP N
Recently RB N
, , N
there EX N
has VBZ N
been VBN N
an DT N
increase NN N
in IN N
popularity NN N
and CC N
participation NN N
in IN N
the DT N
sport NN N
of IN N
snowshoeing VBG i
. . i

While IN N
the DT N
sport NN N
has VBZ N
gained VBN N
considerable JJ N
recognition NN N
, , N
to TO N
date NN N
there EX N
is VBZ N
little JJ N
or CC N
no DT N
scientific JJ N
research NN N
regarding VBG N
training NN o
responses NNS o
to TO N
snowshoeing VBG N
as IN N
a DT N
form NN N
of IN N
exercise NN N
. . N

Therefore RB N
, , N
the DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
snowshoe JJ N
training NN N
could MD N
improve VB N
fitness NN o
measures NNS o
. . o

A DT N
further JJ N
purpose NN N
was VBD N
to TO N
compare VB N
responses NNS N
from IN N
a DT N
snowshoe JJ i
training NN i
program NN i
to TO N
a DT N
similarly RB N
designed VBN N
run RP i
training VBG i
program NN i
. . i

METHODS NNP N
This DT N
prospective JJ N
, , N
comparative JJ N
study NN N
was VBD N
conducted VBN N
with IN N
healthy JJ p
males NNS p
and CC p
females NNS p
between IN p
the DT p
ages NNS p
of IN p
19 CD p
and CC p
24 CD p
. . p

These DT p
subjects NNS p
were VBD p
recruited VBN p
from IN p
the DT p
University NNP p
of IN p
Vermont NNP p
population NN p
and CC p
surrounding VBG p
community NN p
. . p

Following VBG N
baseline NN N
measurements NNS N
in IN N
VO2max NNP o
, , o
running VBG o
time NN o
to TO o
exhaustion NN o
( ( o
RTE NNP o
) ) o
, , o
and CC o
anthropometry NN o
, , N
17 CD p
subjects NNS p
( ( p
10 CD p
snowshoers NNS p
and CC p
7 CD p
runners NNS p
) ) p
participated VBD p
in IN N
a DT N
six CD N
week NN N
conditioning VBG N
program NN N
. . N

Both DT N
groups NNS N
exercised VBD N
for IN N
30 CD N
min NNS N
at IN N
75-85 CD N
% NN N
age NN N
predicted VBD N
maximum JJ N
heart NN N
rate NN N
, , N
3-4 JJ N
times NNS N
per IN N
week NN N
, , N
for IN N
a DT N
total NN N
of IN N
18 CD N
sessions NNS N
. . N

RESULTS NNP N
VO2max NNP o
improved VBD N
significantly RB N
in IN N
both DT N
running NN N
and CC N
snowshoeing VBG N
groups NNS N
, , N
6.3 CD N
and CC N
8.5 CD N
% NN N
, , N
respectively RB N
. . N

Run VB o
time NN o
to TO o
exhaustion NN o
also RB N
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
23.3 CD N
and CC N
33.5 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
anthropometry NN o
for IN N
either DT N
group NN N
. . N

With IN N
the DT N
exception NN N
of IN N
RTE NNP o
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
any DT N
other JJ N
measurements NNS N
at IN N
baseline NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
support VBD N
the DT N
acceptability NN N
of IN N
snowshoeing VBG N
as IN N
a DT N
valid JJ N
means NN N
to TO N
improve VB N
or CC N
maintain VB N
cardiovascular JJ o
endurance NN o
. . o

-DOCSTART- -11379334- O O

Efficacy NN o
and CC o
tolerability NN o
of IN N
antibiotics NNS i
in IN N
patients NNS p
undergoing VBG p
H. NNP p
pylori JJ p
eradication NN p
. . p

BACKGROUND/AIMS NNP N
Helicobacter NNP N
pylori NN N
( ( N
H. NNP N
pylori NN N
) ) N
infection NN N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
common JJ N
gastrointestinal JJ N
diseases NNS N
. . N

An DT N
increasing VBG N
number NN N
of IN N
people NNS N
undergo JJ N
different JJ N
treatment NN N
options NNS N
. . N

Unfortunately RB N
, , N
H. NNP N
pylori FW N
therapy NN N
may MD N
be VB N
troublesome JJ N
for IN N
drug NN N
side NN N
effects NNS N
and CC N
inefficacious JJ N
for IN N
resistance NN N
to TO N
antibiotics NNS i
. . i

METHODOLOGY NNP N
One CD p
hundred CD p
and CC p
ninety-three JJ p
( ( p
193 CD p
) ) p
H. NNP p
pylori-positive JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
7-day JJ N
treatments NNS N
: : N
Group NNP p
A NNP p
( ( p
N NNP p
= NNP p
64 CD p
) ) p
: : p
amoxicillin NN i
, , i
clarithromycin NN i
and CC i
rabeprazole NN i
; : i
Group NNP p
B NNP p
( ( p
N NNP p
= NNP p
64 CD p
) ) p
: : p
tinidazole NN i
, , i
clarithromycin NN i
and CC i
ranitidine NN i
bismuth NN i
citrate NN i
; : i
Group NNP p
C NNP p
( ( p
N NNP p
= NNP p
65 CD p
) ) p
: : p
tinidazole NN i
, , i
clarithromycin NN i
and CC i
rabeprazole JJ i
Eradication NNP N
was VBD N
assessed VBN N
by IN N
13C-Urea JJ N
Breath NNP N
Test NNP N
6-8 JJ N
weeks NNS N
after IN N
the DT N
end NN N
of IN N
the DT N
therapy NN N
. . N

Not-eradicated JJ N
patients NNS N
underwent VBD N
a DT N
second JJ N
cycle NN N
with IN N
tinidazole NN i
, , i
tetracycline NN i
, , i
bismuth NN i
and CC i
rabeprazole NN i
. . i

All DT p
patients NNS p
were VBD N
asked VBN N
to TO N
complete VB N
a DT N
validated JJ N
questionnaire NN N
regarding VBG N
presence NN N
and CC N
intensity NN N
of IN N
drug NN N
side NN N
effects NNS N
. . N

RESULTS NNP N
One CD p
hundred CD p
and CC p
eighty-eight JJ p
out IN p
of IN p
the DT p
193 CD p
H. NNP p
pylori-positive JJ p
patients NNS p
( ( p
96 CD p
% NN p
) ) p
completed VBD p
therapy NN p
. . p

No DT N
significant JJ N
difference NN N
in IN N
eradication NN o
rates NNS o
was VBD N
observed VBN N
among IN N
the DT N
three CD N
groups NNS N
both DT N
in IN N
intention NN N
to TO N
treat VB N
analysis NN N
and CC N
in IN N
per IN N
protocol NN N
analysis NN N
. . N

No DT N
significant JJ N
difference NN N
in IN N
incidence NN o
of IN o
side NN o
effects NNS o
occurred VBD N
among IN N
groups NNS N
after IN N
the DT N
first-line JJ N
regimens NNS N
: : N
48 CD N
% NN N
in IN N
group NN N
A NNP N
, , N
44 CD N
% NN N
in IN N
group NN N
B NNP N
and CC N
46 CD N
% NN N
in IN N
group NN N
C. NNP N
Twenty-two NNP N
out IN N
of IN N
the DT N
193 CD p
enrolled JJ p
subjects NNS p
( ( N
11 CD N
% NN N
) ) N
were VBD N
not RB N
eradicated VBN o
after IN N
the DT N
first-line JJ N
therapy NN N
. . N

Among IN N
them PRP N
, , N
86 CD N
% NN N
were VBD N
successfully RB N
eradicated VBN o
by IN N
the DT N
tinidazole NN i
, , i
tetracycline NN i
, , i
bismuth NN i
and CC N
rabeprazole JJ i
therapy NN N
. . N

Moreover RB N
, , N
during IN N
quadruple JJ N
therapy NN N
, , N
a DT N
higher JJR N
prevalence NN o
and CC o
intensity NN o
of IN o
side NN o
effects NNS o
than IN N
in IN N
each DT N
one CD N
of IN N
the DT N
groups NNS N
submitted VBD N
to TO N
the DT N
first-line JJ N
triple JJ N
therapy NN N
was VBD N
observed VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
triple JJ i
rabeprazole-based JJ i
eradicating NN i
regimens NNS i
are VBP N
effective JJ o
and CC o
safe JJ o
. . o

Incidence NN N
of IN N
side NN o
effects NNS o
seems VBZ N
low JJ N
and CC N
similar JJ N
in IN N
different JJ N
three-drug JJ N
regimens NNS N
used VBN N
. . N

Quadruple JJ i
therapy NN i
, , N
which WDT N
appear VBP N
highly RB N
efficacious JJ N
as IN N
a DT N
second JJ N
line NN N
therapy NN N
, , N
is VBZ N
associated VBN N
with IN N
a DT N
significantly RB N
higher JJR N
incidence NN N
of IN N
side NN N
effects NNS N
when WRB N
compared VBN N
to TO N
first-line JJ N
treatment NN N
. . N

-DOCSTART- -3292597- O O

Antihypertensive JJ o
efficacy NN o
of IN N
cetamolol NN i
: : i
a DT N
dose-titrated JJ N
study NN N
. . N

This DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
multicenter NN N
study NN N
evaluated VBD N
the DT N
antihypertensive JJ o
efficacy NN o
and CC o
safety NN o
of IN N
cetamolol JJ i
hydrochloride NN i
in IN N
108 CD p
patients NNS p
diagnosed VBN p
as IN p
having VBG p
mild NN p
to TO p
moderate VB p
hypertension NN p
. . p

After IN N
a DT N
placebo JJ i
lead-in JJ N
period NN N
, , N
patients NNS N
received VBD N
either DT N
cetamolol JJ i
5-10-15 JJ i
mg/d NN i
( ( N
low JJ N
dose NN N
) ) N
, , N
cetamolol JJ i
15-25-50 JJ i
mg/d NN i
( ( N
high JJ N
dose NN N
) ) N
, , N
or CC N
placebo NN i
, , N
once RB N
daily JJ N
for IN N
four CD N
weeks NNS N
. . N

Patients NNS N
began VBD N
at IN N
the DT N
lowest JJS N
dose NN N
and CC N
were VBD N
titrated VBN N
to TO N
higher JJR N
doses NNS N
based VBN N
on IN N
the DT N
first JJ N
two CD N
assessments NNS N
of IN N
diastolic JJ o
blood NN o
pressure NN o
and CC o
heart NN o
rate NN o
, , N
which WDT N
were VBD N
conducted VBN N
each DT N
week NN N
after IN N
double-blind JJ N
treatment NN N
was VBD N
dispensed VBN N
. . N

After IN N
four CD N
weeks NNS N
of IN N
treatment NN N
82.4 CD N
% NN N
, , N
81.3 CD N
% NN N
, , N
and CC N
93.3 CD N
% NN N
of IN N
the DT N
low-dose JJ i
group NN N
, , N
high-dose JJ i
group NN N
, , N
and CC N
placebo NN i
group NN N
, , N
respectively RB N
, , N
were VBD N
titrated VBN N
to TO N
the DT N
maximum JJ N
dose JJ N
level NN N
. . N

After IN N
four CD N
weeks NNS N
of IN N
treatment NN N
and CC N
24 CD N
hours NNS N
since IN N
the DT N
patient NN N
's POS N
last JJ N
dose NN N
, , N
both DT N
cetamolol NN i
groups NNS N
showed VBD N
a DT N
significantly RB N
greater JJR N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
.05 VB N
) ) N
reduction NN N
in IN N
supine JJ o
systolic/diastolic JJ o
blood NN o
pressure NN o
( ( N
-18.1 JJ N
+/- JJ N
2.3/-9.2 JJ N
+/- JJ N
1.5 CD N
mm NN N
Hg NNP N
[ NNP N
low JJ N
dose NN N
] NN N
and CC N
-17.3 JJ N
+/- JJ N
2.3/-8.3 JJ N
+/- JJ N
1.6 CD N
mm NN N
Hg NNP N
[ NNP N
high JJ N
dose RB N
] NNP N
) ) N
than IN N
the DT N
placebo NN N
group NN N
( ( N
-9.9 JJ N
+/- JJ N
2.5/-3.5 JJ N
+/- JJ N
1.7 CD N
mm NN N
Hg NNP N
) ) N
. . N

In IN N
general JJ N
, , N
the DT N
changes NNS o
in IN o
standing VBG o
( ( o
stabilized VBN o
) ) o
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
in IN N
supine JJ N
measurements NNS N
. . N

Significantly RB N
more RBR N
patients NNS N
receiving VBG N
cetamolol NN N
than IN N
those DT N
receiving VBG N
placebo NN N
showed VBD N
a DT N
good JJ N
response NN N
( ( N
a DT N
decrease NN N
in IN N
diastolic JJ N
blood NN N
pressure NN N
of IN N
10 CD N
mm NNS N
Hg NNP N
or CC N
more JJR N
or CC N
measuring VBG N
less JJR N
than IN N
90 CD N
mm NNS N
Hg NNP N
with IN N
a DT N
decrease NN N
of IN N
at IN N
least JJS N
4 CD N
mm JJ N
Hg NNP N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -16411994- O O

Does VBZ N
a DT N
first JJ N
trimester NN N
dating VBG N
scan JJ N
using VBG N
crown JJ N
rump NN N
length NN N
measurement NN N
reduce VB N
the DT N
rate NN o
of IN o
induction NN o
of IN o
labour NN o
for IN N
prolonged JJ o
pregnancy NN o
? . N
An DT N
uncompleted JJ N
randomised VBD N
controlled JJ N
trial NN N
of IN N
463 CD p
women NNS p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
first JJ N
trimester NN N
ultrasound IN i
dating VBG i
scan JJ i
on IN N
the DT N
rate NN o
of IN o
induction NN o
of IN o
labour NN o
for IN N
prolonged JJ o
pregnancy NN o
. . o

DESIGN NNP N
Randomised VBD N
controlled VBN N
trial NN N
to TO N
include VB N
400 CD p
women NNS p
in IN p
each DT p
arm NN p
of IN p
the DT p
trial NN p
. . p

SETTING NN N
Participating VBG p
general JJ p
practices NNS p
and CC p
a DT p
district NN p
general JJ p
teaching NN p
hospital NN p
. . p

POPULATION NNP N
Women NNP p
attending VBG p
their PRP$ p
general JJ p
practitioner NN p
in IN p
the DT p
first JJ p
trimester NN p
to TO p
confirm VB p
pregnancy NN p
, , p
in IN p
whom WP p
a DT p
first JJ p
trimester NN p
ultrasound JJ i
scan NN i
was VBD p
not RB p
indicated VBN p
. . p

METHODS NNP N
Women NNP N
randomised VBD N
to TO N
the DT N
study NN N
group NN N
( ( N
scan JJ N
group NN N
) ) N
underwent VBD N
an DT N
ultrasound JJ i
dating NN i
scan NN i
between IN i
8 CD i
and CC i
12 CD i
weeks NNS i
, , i
measuring VBG i
crown-rump JJ i
length NN i
. . i

The DT N
estimated JJ N
date NN N
of IN N
delivery NN N
( ( N
EDD NNP N
) ) N
was VBD N
changed VBN N
if IN N
there EX N
was VBD N
a DT N
discrepancy NN N
of IN N
more JJR N
than IN N
5 CD N
days NNS N
from IN N
the DT N
gestation NN N
, , N
calculated VBN N
from IN N
the DT N
last JJ N
menstrual JJ N
period NN N
( ( N
LMP NNP N
) ) N
. . N

For IN N
the DT N
remaining VBG N
women NNS N
( ( N
no-scan JJ N
group NN N
) ) N
, , N
gestation NN N
was VBD N
determined VBN N
using VBG N
the DT N
LMP NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT o
rate NN o
of IN o
induction NN o
of IN o
labour NN o
for IN o
prolonged JJ o
pregnancy NN o
. . o

RESULTS NNP N
Due NNP N
to TO N
circumstances NNS N
beyond IN N
the DT N
researchers NNS N
' POS N
control NN N
, , N
recruitment NN N
was VBD N
abandoned VBN N
when WRB N
463 CD p
women NNS p
had VBD p
been VBN p
enrolled VBN p
. . p

The DT N
EDD NNP N
was VBD N
adjusted VBN N
in IN N
13 CD N
( ( N
5.7 CD N
% NN N
) ) N
women NNS N
in IN N
the DT N
scan JJ N
group NN N
and CC N
in IN N
2 CD N
( ( N
0.9 CD N
% NN N
) ) N
in IN N
the DT N
no-scan JJ N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
rate NN o
of IN o
induction NN o
for IN N
prolonged JJ o
pregnancy NN o
between IN N
the DT N
scan JJ N
( ( N
19 CD N
[ RB N
8.2 CD N
% NN N
] NN N
) ) N
and CC N
the DT N
no-scan JJ N
( ( N
17 CD N
[ RB N
7.4 CD N
% NN N
] NN N
) ) N
groups NNS N
( ( N
relative JJ N
risk NN N
1.10 CD N
; : N
95 CD N
% NN N
CI NNP N
0.59-2.07 NN N
) ) N
. . N

CONCLUSIONS NNP N
Acknowledging VBG N
the DT N
reduced JJ N
numbers NNS N
recruited VBN N
for IN N
study NN N
, , N
it PRP N
is VBZ N
concluded VBN N
that IN N
there EX N
is VBZ N
no DT N
evidence NN N
that IN N
a DT N
first JJ N
trimester NN N
ultrasound IN i
dating VBG i
scan JJ i
reduces NNS N
the DT N
rate NN o
of IN o
induction NN o
of IN o
labour NN o
for IN N
prolonged JJ o
pregnancy NN o
and CC N
may MD N
result VB N
in IN N
a DT N
more RBR N
expensive JJ N
healthcare NN N
strategy NN N
. . N

-DOCSTART- -2426069- O O

[ RB N
Preoperative NNP N
chemotherapy NN i
of IN N
esophageal JJ N
cancer NN N
] NNP N
. . N

A NNP p
series NN p
of IN p
25 CD p
patients NNS p
with IN p
advanced JJ p
esophageal NN p
cancer NN p
treated VBN p
from IN p
Mar NNP p
. . p

1981 CD p
to TO p
Sep. VB p
1982 CD p
by IN p
preoperative JJ i
chemotherapy NN i
plus CC i
surgery NN i
is VBZ N
reported VBN N
. . N

All PDT N
the DT N
patients NNS p
came VBD p
from IN p
the DT p
hospitals NNS p
of IN p
the DT p
cooperative JJ p
research NN p
group NN p
and CC N
were VBD N
randomized VBN N
into IN N
chemotherapy NN i
and CC N
control NN i
groups NNS N
. . N

They PRP N
were VBD N
proved VBN N
by IN N
X-ray NNP N
, , N
cytology NN N
and CC N
histopathology NN N
prior RB N
to TO N
treatment NN N
. . N

By IN p
histology NN p
, , p
22 CD p
cases NNS p
were VBD p
squamous JJ p
cell NN p
carcinoma NN p
, , p
1 CD p
adenocarcinoma NN p
and CC p
2 CD p
squamous JJ p
adenocarcinoma NN p
. . p

The DT N
COF NNP N
chemotherapy NN i
consisted VBD N
of IN N
Vincristine NNP i
1 CD i
mg NN i
, , i
cyclophosphamide RB i
600 CD i
mg NNS i
and CC i
5-fluorouracil JJ i
500 CD i
mg NN i
IV NNP i
on IN N
days NNS N
1 CD N
and CC N
8 CD N
with IN N
or CC N
without IN N
the DT N
addition NN N
of IN N
Pingyangmycin NNP i
, , N
a DT N
drug NN N
equivalent NN N
to TO N
Bleomycin NNP i
A5 NNP i
, , N
at IN N
the DT N
dose NN N
of IN N
10 CD N
mg NNS N
IM NNP N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
6 CD N
and CC N
8 CD N
. . N

The DT N
interval NN N
between IN N
the DT N
ending VBG N
of IN N
chemotherapy NN i
and CC N
the DT N
surgical JJ i
resection NN i
was VBD N
5-6 JJ N
days NNS N
. . N

The DT N
results NNS N
showed VBD N
that IN N
preoperative JJ N
chemotherapy NN N
caused VBD N
no DT o
myelosuppression NN o
, , N
but CC N
merely RB N
mild JJ o
gastrointestinal JJ o
symptoms NNS o
. . o

All DT N
patients NNS N
were VBD N
operated VBN N
and CC N
resected VBN N
without IN N
difficulty NN N
. . N

The DT N
subjective JJ N
improvement NN N
in IN N
various JJ N
degrees NNS N
and CC N
the DT N
shrinkage NN o
of IN o
tumor NN o
in IN o
the DT o
X-ray JJ o
films NNS o
were VBD N
present JJ N
in IN N
5/25 CD N
cases NNS N
who WP N
received VBD N
preoperative JJ N
chemotherapy NN i
. . i

The DT N
histopathological JJ o
changes NNS o
in IN N
the DT N
chemotherapy NN N
and CC N
control NN N
groups NNS N
( ( N
16 CD N
specimens NNS N
) ) N
were VBD N
different JJ N
. . N

In IN N
the DT N
chemotherapy NN i
group NN N
, , N
excessive JJ o
keratinization NN o
in IN o
the DT o
squamous JJ o
component NN o
of IN o
the DT o
esophageal NN o
cancerous JJ o
tissue NN o
appeared VBD N
in IN N
the DT N
resected JJ N
specimens NNS N
. . N

The DT N
incidence NN o
of IN o
degeneration NN o
and CC o
necrosis NN o
in IN o
the DT o
squamous JJ o
epithelium NN o
adjacent NN o
to TO o
carcinoma VB o
was VBD N
higher RBR N
in IN N
the DT N
chemotherapy NN i
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
results NNS N
suggested VBD N
that IN N
such JJ N
combined JJ N
modality NN N
is VBZ N
worth IN N
further JJ N
study NN N
. . N

-DOCSTART- -23566237- O O

Successful JJ N
treatment NN N
of IN N
depressed JJ p
, , p
distensible JJ p
acne NN p
scars NNS p
using VBG N
autologous JJ i
fibroblasts NNS i
: : i
a DT N
multi-site JJ N
, , N
prospective JJ N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND VB N
A DT N
previous JJ N
clinical JJ N
trial NN N
evaluating VBG N
autologous JJ i
fibroblasts NNS i
( ( i
human JJ i
dermal NN i
) ) i
injections NNS i
for IN N
the DT N
treatment NN N
of IN N
facial JJ N
contour NN N
deformities NNS N
found VBN N
significantly RB N
greater JJR N
improvements NNS N
in IN N
wrinkle NN o
and CC o
acne NN o
scar NN o
appearance NN o
than IN N
with IN N
placebo JJ i
treatment NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
autologous JJ i
fibroblast JJ i
treatment NN N
of IN N
moderate JJ p
to TO p
severe VB p
, , p
depressed JJ p
, , p
distensible JJ p
facial JJ p
acne NN p
scars NNS p
with IN N
that DT N
of IN N
vehicle NN N
control NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
multicenter NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
in IN N
subjects NNS p
with IN p
bilateral JJ p
moderate NN p
to TO p
severe VB p
acne JJ p
scarring NN p
; : p
subjects VBZ N
served VBN N
as IN N
their PRP$ N
own JJ N
controls NNS N
. . N

Skin NNP N
biopsies NNS N
were VBD N
obtained VBN N
from IN N
randomized JJ N
subjects NNS p
for IN N
fibroblast JJ N
production NN N
. . N

Subjects NNS p
( ( p
n JJ p
= NNP p
99 CD p
) ) p
underwent NN N
three CD N
intradermal JJ N
injection NN N
sessions NNS N
with IN N
2 CD i
mL NNS i
of IN i
autologous JJ i
fibroblast JJ i
suspension NN i
( ( N
10-20 CD N
million CD N
cells/mL NN N
) ) N
on IN N
one CD N
cheek NN N
and CC N
vehicle NN i
control NN i
( ( N
cell JJ N
culture NN N
medium NN N
) ) N
on IN N
the DT N
other JJ N
at IN N
14-day JJ N
intervals NNS N
. . N

Efficacy NNP N
was VBD N
based VBN N
on IN N
the DT N
blinded VBN N
subject NN o
's POS o
, , o
evaluator NN o
's POS o
, , o
and CC o
independent JJ o
photographic JJ o
viewer NN o
's POS o
( ( o
IPR NNP o
) ) o
assessment NN o
of IN o
acne NN o
scarring VBG o
1 CD N
to TO N
4 CD N
months NNS N
after IN N
the DT N
last JJ N
treatment NN N
. . N

RESULTS NNP N
Autologous JJ i
fibroblast JJ i
treatment NN i
was VBD N
associated VBN N
with IN N
significantly RB N
greater JJR N
treatment NN N
success NN N
than IN N
vehicle NN N
control NN N
for IN N
the DT N
subject NN N
( ( N
43 CD N
% NN N
vs.18 NN N
% NN N
) ) N
, , N
evaluator NN N
( ( N
59 CD N
% NN N
vs. FW N
2 CD N
% NN N
) ) N
, , N
and CC N
IPR NNP N
assessments NNS N
. . N

Autologous JJ i
fibroblast JJ i
injections NNS i
were VBD N
well RB N
tolerated VBN N
, , N
without IN N
permanent JJ N
adverse JJ N
effects NNS N
. . N

CONCLUSIONS NNP N
Autologous NNP i
fibroblast VBD i
injections NNS i
safely RB N
and CC N
effectively RB N
improved VBD N
the DT N
appearance NN o
of IN o
depressed JJ o
distensible JJ o
acne NN o
scars NNS o
. . o

-DOCSTART- -11748974- O O

Fibrin NNP i
application NN i
for IN N
preventing VBG N
lymphocysts NNS N
after IN N
retroperitoneal JJ N
lymphadenectomy NN N
in IN N
patients NNS p
with IN p
gynecologic JJ p
malignancies NNS p
. . p

OBJECTIVE IN N
We PRP N
performed VBD N
a DT N
randomized VBN N
, , N
prospective JJ N
trial NN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
fibrin JJ i
glue NN i
on IN N
the DT N
incidence NN N
of IN N
lymphocysts NNS N
after IN N
systematic JJ N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
in IN N
patients NNS p
with IN p
gynecologic JJ p
malignancies NNS p
. . p

METHODS NNP N
Ninety-three JJ p
consecutive JJ p
patients NNS p
with IN p
gynecologic JJ p
pelvic JJ p
malignancies NNS p
who WP p
underwent VBP p
surgery NN p
including VBG p
pelvic NN p
or CC p
pelvic NN p
and CC p
paraaortic JJ p
lymphadenectomy NN p
were VBD N
randomized VBN N
during IN N
surgery NN N
to TO N
be VB N
treated VBN i
with IN i
fibrin JJ i
glue NN i
or CC i
not RB i
. . i

Serial JJ i
computed JJ i
tomography NN i
( ( i
CT NNP i
) ) i
scans NNS i
were VBD N
performed VBN N
during IN N
follow-up JJ N
. . N

CT NNP N
findings NNS N
of IN N
a DT N
smooth JJ N
and CC N
thin-walled JJ N
cavity NN N
filled VBN N
with IN N
a DT N
water-equivalent JJ N
fluid NN N
, , N
sharply RB N
demarcated VBN N
from IN N
its PRP$ N
surroundings NNS N
and CC N
without IN N
signs NNS N
of IN N
infiltration NN N
were VBD N
interpreted VBN N
as IN N
lymphocysts NNS o
. . o

RESULTS NNP N
Forty-seven JJ N
patients NNS N
( ( N
51 CD N
% NN N
) ) N
were VBD N
treated VBN N
with IN N
fibrin JJ i
glue NN i
and CC N
46 CD N
( ( N
49 CD N
% NN N
) ) N
were VBD N
not RB N
. . N

All DT N
93 CD p
patients NNS p
underwent JJ N
pelvic JJ N
lymphadenectomy NN N
; : N
15 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
of IN N
the DT N
fibrin NN N
group NN N
and CC N
12 CD N
( ( N
26 CD N
% NN N
) ) N
of IN N
the DT N
controls NNS N
also RB N
underwent JJ N
paraaortic JJ N
lymphadenectomy NN N
. . N

We PRP N
found VBD N
no DT o
significant JJ o
differences NNS o
between IN N
patients NNS N
who WP N
received VBD N
fibrin JJ o
glue NN o
and CC N
those DT N
who WP N
did VBD N
not RB N
. . N

CONCLUSION NNP N
Intraoperative NNP N
application NN N
of IN N
fibrin JJ N
glue NN N
did VBD o
not RB o
reduce VB o
the DT o
rate NN o
of IN o
postoperative JJ o
lymphocysts NNS o
after IN N
lymphadenectomy NN N
and CC N
had VBD N
no DT o
impact NN o
on IN N
any DT N
follow-up JJ o
parameter NN o
. . o

Its PRP$ N
use NN N
seems VBZ N
not RB N
to TO N
be VB N
indicated VBN N
in IN N
systematic JJ N
gynecologic NN N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
. . N

-DOCSTART- -15857741- O O

Acustimulation NNP i
wrist NN i
bands NNS i
are VBP N
not RB N
effective JJ N
for IN N
the DT N
control NN N
of IN N
chemotherapy-induced JJ o
nausea NN o
in IN N
women NNS p
with IN p
breast NN p
cancer NN p
. . p

This DT N
experiment NN N
examined VBD N
the DT N
efficacy NN N
of IN N
an DT N
acustimulation NN i
wrist NN i
band NN i
for IN N
the DT N
relief NN N
of IN N
chemotherapy-induced JJ o
nausea NN o
using VBG N
a DT N
randomized JJ N
three-arm JJ N
clinical JJ N
trial NN N
( ( i
active JJ i
acustimulation NN i
, , i
sham JJ i
acustimulation NN i
, , N
and CC N
no DT i
acustimulation NN i
) ) i
in IN N
96 CD p
women NNS p
with IN p
breast NN p
cancer NN p
who WP p
experienced VBD p
nausea NN p
at IN p
their PRP$ p
first JJ p
chemotherapy NN i
treatment NN i
. . i

Five CD N
outcomes NNS N
related VBN N
to TO N
wrist VB o
band NN o
efficacy NN o
( ( o
acute JJ o
nausea NN o
, , o
delayed VBN o
nausea NN o
, , o
vomiting VBG o
, , o
QOL NNP o
, , o
and CC o
total JJ o
amount NN o
of IN o
antiemetic JJ o
medication NN o
used VBN o
) ) o
were VBD N
examined VBN N
. . N

The DT N
five CD N
outcomes NNS N
were VBD N
examined VBN N
separately RB N
using VBG N
analysis NN N
of IN N
covariance NN N
controlling VBG N
for IN N
age NN N
and CC N
severity NN o
of IN o
past JJ o
nausea NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
these DT N
study NN N
measures NNS N
among IN N
the DT N
three CD N
treatment NN N
conditions NNS N
( ( N
P NNP N
> VBZ N
0.1 CD N
for IN N
all DT N
) ) N
. . N

Study NNP N
results NNS N
do VBP N
not RB N
support VB N
the DT N
hypothesis NN N
that WDT N
acustimulation NN i
bands NNS i
are VBP N
efficacious JJ N
as IN N
an DT N
adjunct NN N
to TO N
pharmacological JJ N
antiemetics NNS N
for IN N
control NN N
of IN N
chemotherapy-related JJ o
nausea NN o
in IN N
female JJ p
breast NN p
cancer NN p
patients NNS p
. . p

-DOCSTART- -6849742- O O

Changes NNS N
in IN N
heart NN o
rate NN o
and CC o
forearm NN o
blood NN o
flow NN o
following VBG N
intravenous JJ N
boluses NNS N
of IN N
isoprenaline NN i
in IN N
the DT N
presence NN N
of IN N
practolol NN N
and CC N
propranolol NN N
. . N

1 CD N
Increases NNS N
in IN N
heart NN o
rate NN o
and CC o
forearm NN o
blood NN o
flow NN o
following VBG N
graded VBD N
intravenous JJ N
bolus JJ N
injections NNS N
of IN N
isoprenaline JJ i
sulphate NN i
, , N
were VBD N
measured VBN N
in IN N
a DT N
double-blind NN N
randomised VBN N
study NN N
of IN N
six CD p
subjects NNS p
who WP p
received VBD p
either DT p
placebo NN i
, , i
practolol VBP i
50 CD i
mg NN i
, , i
practolol VBP i
200 CD i
mg NN i
, , i
propranolol VBP i
10 CD i
mg NN i
or CC i
propranolol VB i
40 CD i
mg. NN i
2 CD N
Dose NNP N
related JJ N
increases NNS N
in IN N
forearm NN o
blood NN o
flow NN o
were VBD N
produced VBN N
by IN N
the DT N
graded JJ N
boluses NNS N
of IN N
isoprenaline JJ i
sulphate NN i
. . i

3 CD N
Practolol NNP i
50 CD N
mg NN N
attenuated VBD N
the DT N
heart NN o
rate NN o
response NN o
to TO N
isoprenaline VB N
but CC N
did VBD N
not RB N
significantly RB N
affect VB N
the DT N
changes NNS N
in IN N
forearm NN o
blood NN o
flow NN o
. . o

Practolol CC i
200 CD N
mg NN N
further RB N
attenuated VBD N
the DT N
heart NN o
rate NN o
responses NNS o
but CC N
also RB N
decreased VBD N
the DT N
forearm NN o
blood NN o
flow NN o
responses NNS o
. . o

4 CD N
Propranolol NNP i
10 CD N
mg NN N
and CC N
propranolol NN N
40 CD N
mg NN N
significantly RB N
attenuated VBD N
both DT N
the DT N
heart NN o
rate NN o
and CC o
forearm NN o
blood NN o
flow NN o
responses NNS o
. . o

The DT N
effect NN N
on IN N
forearm NN o
blood NN o
flow NN o
tended VBD N
to TO N
be VB N
greater JJR N
than IN N
the DT N
effect NN N
on IN N
heart NN o
rate NN o
. . o

5 CD N
Practolol NNP i
200 CD N
mg NN N
had VBD N
the DT N
same JJ N
effect NN N
on IN N
heart NN o
rate NN o
responses NNS o
as IN N
propranolol NN i
10 CD N
mg NN N
but CC N
a DT N
significantly RB N
smaller JJR N
effect NN N
on IN N
the DT N
forearm NN o
blood NN o
flow NN o
responses NNS o
. . o

6 CD N
The DT N
measurement NN N
of IN N
forearm NN o
blood NN o
flow NN o
following VBG N
intravenous JJ N
bolus JJ N
injections NNS N
of IN N
isoprenaline NN N
provides VBZ N
useful JJ N
information NN N
about IN N
the DT N
beta NN N
2-adrenoceptor JJ N
antagonism NN N
of IN N
propranolol NN i
and CC N
practolol NN i
. . N

However RB N
, , N
application NN N
of IN N
the DT N
technique NN N
may MD N
be VB N
limited VBN N
by IN N
the DT N
magnitude NN N
of IN N
the DT N
heart NN o
rate NN o
response NN N
and CC N
by IN N
the DT N
short-lived JJ N
nature NN N
of IN N
the DT N
increase NN N
in IN N
forearm JJ o
blood NN o
flow NN o
. . o

-DOCSTART- -10685722- O O

Efficacy NN o
and CC N
safety NN o
of IN N
a DT N
fixed JJ N
low-dose JJ N
perindopril/indapamide NN i
combination NN i
in IN N
essential JJ p
hypertension NN p
. . p

A DT N
randomised JJ N
controlled VBN N
study NN N
. . N

This DT N
multicenter NN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
efficacy NN o
and CC N
the DT N
safety NN o
of IN N
fixed JJ N
low JJ i
dose NN i
combination NN i
perindopril VBD i
2 CD i
mg/indapamide RB i
0.625 CD N
mg NN N
( ( N
Per/Ind NNP N
) ) N
versus NN N
atenolol $ i
50 CD N
mg NN N
( ( N
Ate NNP N
) ) N
. . N

After IN N
a DT N
4-week JJ N
placebo NN N
run-in NN N
, , N
446 CD p
hypertensive JJ p
patients NNS p
( ( p
mean JJ p
age NN p
: : p
55.8 CD p
+/- JJ p
11.0 CD p
years NNS p
) ) p
were VBD N
randomised VBN N
to TO N
receive VB N
Per/Ind NNP i
or CC i
Ate NNP i
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
changes NNS o
in IN o
trough JJ o
supine NN o
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
( ( o
sSBP NN o
, , o
sDBP NN o
) ) o
between IN N
baseline NN N
and CC N
the DT N
last JJ N
observation NN N
. . N

Equivalence NN o
was VBD N
assessed VBN o
in IN N
an DT N
intention-to-treat JJ N
analysis NN N
using VBG N
a DT N
two CD N
one-sided JJ N
tests NNS N
procedure NN N
. . N

Per/Ind NNP N
and CC N
Ate NNP N
decreased VBD o
sSBP NN o
by IN N
-20.5 NNP N
mmHg NN N
and CC N
-20.1 NNP N
mmHg NN N
, , N
respectively RB N
; : N
the DT N
90 CD N
% NN N
confidence NN o
interval NN o
[ NNP N
-2.3 NNP N
; : N
1.5 CD N
] NN N
of IN N
the DT N
intertreatment NN N
difference NN N
( ( N
-0.4 JJ N
mmHg NN N
) ) N
fell VBD N
within IN N
the DT N
predefined JJ o
equivalence NN o
interval NN o
[ NNP N
-8 NNP N
; : N
+8 NNP N
mmHg FW N
] NNP N
. . N

Similarly RB N
, , N
the DT N
sDBP NN o
decreased VBN o
by IN N
-15.1 NNP N
mmHg NN N
( ( N
Per/Ind NNP N
) ) N
and CC N
-16.2 $ N
mmHg NN N
( ( N
Ate NNP N
) ) N
with IN N
an DT N
intertreatment JJ N
difference NN N
of IN N
1.1 CD N
mmHg NNS N
whose WP$ N
90 CD N
% NN N
confidence NN o
interval NN o
[ NNP N
-0.1 NNP N
; : N
2.2 CD N
mmHg NN N
] NN N
fell VBD N
within IN N
the DT N
predefined JJ N
equivalence NN o
interval NN o
[ NNP N
-4 NNP N
; : N
+4 NNP N
mmHg VBZ N
] NNP N
; : N
thus RB N
antihypertensive JJ o
efficacy NN o
of IN N
Per/Ind NNP N
and CC N
Ate NNP N
were VBD N
equivalent JJ o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS N
older JJR N
than IN N
65 CD N
, , N
Per/Ind NNP N
induces VBZ N
a DT N
statistically RB N
greater JJR N
decrease NN N
in IN N
sSBP NN o
than IN N
Ate NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Per/Ind NNP N
was VBD N
well RB N
tolerated VBN o
. . o

Further RBR N
controlled JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
confirm VB N
these DT N
results NNS N
on IN N
a DT N
long-term JJ N
period NN N
. . N

-DOCSTART- -7981078- O O

Treatment NN N
of IN N
multiple JJ N
myeloma NN N
according VBG N
to TO N
the DT N
extension NN N
of IN N
the DT N
disease NN N
: : N
a DT N
prospective JJ N
, , N
randomised VBD N
study NN N
comparing VBG N
a DT N
less RBR N
with IN N
a DT N
more RBR N
aggressive JJ i
cystostatic JJ i
policy NN N
. . N

Cooperative NNP p
Group NNP p
of IN p
Study NNP p
and CC p
Treatment NNP p
of IN p
Multiple NNP p
Myeloma NNP p
. . p

The DT N
purpose NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
ascertain VB N
whether IN N
the DT N
prognostic JJ N
significance NN N
of IN N
staging VBG N
in IN N
multiple JJ N
myeloma NN N
( ( N
MM NNP N
) ) N
is VBZ N
influenced VBN N
by IN N
the DT N
aggressiveness NN i
of IN i
effective JJ i
induction NN i
treatment NN i
and/or NN N
by IN N
continuing VBG N
or CC N
discontinuing VBG N
maintenance NN i
chemotherapy NN i
. . i

Patients NNS p
with IN p
untreated JJ p
stage NN p
I PRP p
MM NNP p
( ( p
defined VBN p
according VBG p
to TO p
Durie NNP p
and CC p
Salmon NNP p
) ) p
were VBD N
randomised VBN N
between IN N
being VBG N
followed VBN i
without IN i
cytostatics NNS i
until IN N
the DT N
disease NN N
progressed VBD N
and CC N
receiving VBG i
six CD i
courses NNS i
of IN i
melphalan NN i
and CC i
prednisone NN i
( ( i
MP-P NNP i
) ) i
just RB N
after IN N
diagnosis NN N
; : N
stage NN p
II NNP p
patients NNS p
were VBD N
uniformly RB N
treated VBN N
with IN N
MPH-P NNP i
and CC N
stage NN p
III NNP p
patients NNS p
were VBD N
randomised VBN N
between IN N
MPH-P NNP i
and CC i
four CD i
courses NNS i
of IN i
combination NN i
chemotherapy NN i
with IN i
Peptichemio NNP i
, , i
vincristine NN i
and CC i
prednisone NN i
( ( i
PTC-VCR-P NNP i
) ) i
. . i

Within IN N
each DT N
stage NN N
, , N
responsive JJ N
patients NNS N
were VBD N
randomised VBN N
between IN N
receiving VBG N
additional JJ N
therapy NN N
only RB N
until IN N
maximal JJ N
tumour NNS N
reduction NN N
was VBD N
reached VBN N
( ( N
plateau JJ N
phase NN N
) ) N
and CC N
continuing VBG N
induction NN N
therapy NN N
indefinitely RB N
until IN N
relapse NN N
. . N

With IN N
resistant JJ N
, , N
progressive JJ N
or CC N
relapsing VBG N
disease NN N
, , N
patients NNS N
originally RB N
treated VBN N
with IN N
MPH-P NNP i
for IN N
induction NN N
received VBN N
combination NN N
chemotherapy NN N
and CC N
vice NN N
versa NN N
. . N

The DT N
overall JJ o
first JJ o
response NN o
rate NN o
was VBD N
43.8 CD N
% NN N
( ( N
42.2 CD N
% NN N
in IN N
206 CD N
stage NN N
I PRP N
, , N
II NNP N
and CC N
III NNP N
patients NNS N
treated VBD N
with IN N
MPH-P NNP i
and CC N
48.0 CD N
% NN N
in IN N
75 CD N
stage NN N
III NNP N
patients NNS N
treated VBD N
with IN N
combination NN i
chemotherapy NN i
, , N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

Combination NNP i
chemotherapy NN i
was VBD N
more RBR N
myelotoxic JJ o
than IN N
MPH-P NNP i
and CC N
, , N
in IN N
particular JJ N
, , N
caused VBD N
more RBR N
non-haematological JJ o
side-effects NNS o
. . o

Both CC N
the DT N
less JJR N
and CC N
the DT N
more RBR N
aggressive JJ N
induction NN N
policies NNS N
gave VBD N
the DT N
same JJ N
disease NN o
control NN o
. . o

Progression NN o
of IN o
disease NN o
was VBD N
statistically RB N
similar JJ N
in IN N
stage NN N
I PRP N
patients NNS N
who WP N
were VBD N
initially RB N
left VBN N
untreated JJ N
and CC N
in IN N
t JJ N
hose NN N
who WP N
received VBD N
MPH-P NNP i
just RB N
after IN N
diagnosis NN N
; : N
median JJ N
duration NN o
of IN o
first JJ o
response NN o
was VBD N
similar JJ N
in IN N
stage NN N
III NNP N
patients NNS N
receiving VBG N
MPH-P NNP i
and CC N
in IN N
those DT N
on IN N
combination NN i
chemotherapy NN i
. . i

In IN N
all DT N
stages NNS N
, , N
discontinuing VBG N
or CC N
continuing VBG N
maintenance NN N
did VBD N
not RB N
alter VB N
the DT N
median JJ o
duration NN o
of IN o
first JJ o
response NN o
. . o

The DT N
overall JJ o
second JJ o
response NN o
rate NN o
was VBD N
28.5 CD N
% NN N
( ( N
34.0 CD N
% NN N
to TO N
MPH-P NNP N
and CC N
25.3 CD N
% NN N
to TO N
combination NN N
chemotherapy NN i
, , N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

Median JJ o
survival NN o
was VBD N
greater JJR N
than IN N
78 CD N
months NNS N
in IN N
stage NN N
I PRP N
, , N
was VBD N
46.3 CD N
months NNS N
in IN N
stage NN N
II NNP N
and CC N
was VBD N
24.3 CD N
months NNS N
in IN N
stage NN N
III NNP N
patients NNS N
, , N
still RB N
independent JJ N
of IN N
both DT N
induction NN N
and CC N
post-induction NN N
policies NNS N
. . N

In IN N
MM NNP N
, , N
the DT N
significance NN N
of IN N
staging VBG N
for IN N
survival NN o
is VBZ N
independent JJ N
of IN N
both DT N
the DT N
aggressiveness NN N
of IN N
induction NN N
and CC N
of IN N
continuing VBG N
or CC N
discontinuing VBG N
maintenance NN N
chemotherapy NN N
after IN N
the DT N
maximal JJ N
tumor NN N
reduction NN N
has VBZ N
been VBN N
achieved VBN N
. . N

Both DT N
MPH-P NNP i
and CC N
and CC N
the DT N
association NN N
of IN N
PTC NNP i
, , i
VCR NNP i
and CC i
P NNP i
are VBP N
effective JJ N
in IN N
inducing VBG N
first JJ o
response NN o
and CC N
also RB N
second JJ o
response NN o
in IN N
patients NNS N
failing VBG N
on IN N
the DT N
alternative JJ N
regimen NNS N
, , N
but CC N
PTC-VCR-P NNP i
causes VBZ N
more JJR N
side JJ o
effects NNS o
. . o

Thus RB N
, , N
the DT N
overwhelming JJ N
majority NN N
of IN N
patients NNS N
with IN N
MM NNP N
can MD N
safely RB N
be VB N
given VBN N
MPH-P NNP i
as IN N
first JJ N
therapy NN N
, , N
and CC N
this DT N
treatment NN N
may MD N
be VB N
delayed VBN N
in IN N
early JJ N
diseases NNS N
. . N

-DOCSTART- -16562630- O O

The DT N
effect NN N
of IN N
random JJ i
modulation NN i
of IN i
functional JJ i
electrical JJ i
stimulation NN i
parameters NNS i
on IN N
muscle NN p
fatigue NN p
. . p

Muscle NNP N
contractions NNS N
induced VBN N
by IN N
functional JJ i
electrical JJ i
stimulation NN i
( ( N
FES NNP N
) ) N
tend VBP N
to TO N
result VB N
in IN N
rapid JJ o
muscle NN o
fatigue NN o
, , N
which WDT N
greatly RB N
limits VBZ N
activities NNS N
such JJ N
as IN N
FES-assisted JJ N
standing NN N
and CC N
walking NN N
. . N

It PRP N
was VBD N
hypothesized VBN N
that IN N
muscle NN o
fatigue NN o
caused VBN N
by IN N
FES NNP N
could MD N
be VB N
reduced VBN N
by IN N
randomly RB N
modulating VBG N
parameters NNS N
of IN N
the DT N
electrical JJ N
stimulus NN N
. . N

Seven NNP p
paraplegic JJ p
subjects NNS p
participated VBN p
in IN N
this DT N
study NN N
. . N

While IN N
subjects NNS N
were VBD N
seated VBN N
, , N
FES NNP N
was VBD N
applied VBN N
to TO N
quadriceps NNS N
and CC N
tibialis JJ N
anterior JJ N
muscles NNS N
bilaterally RB N
using VBG N
surface NN N
electrodes NNS N
. . N

The DT N
isometric JJ o
force NN o
was VBD N
measured VBN N
, , N
and CC N
the DT N
time NN N
for IN N
the DT N
force NN N
to TO N
drop VB N
by IN N
3 CD N
dB NN N
( ( N
fatigue JJ N
time NN N
) ) N
and CC N
the DT N
normalized JJ N
force-time JJ o
integral JJ o
( ( o
FTI NNP o
) ) o
were VBD N
determined VBN N
. . N

Four CD N
different JJ N
modes NNS N
of IN N
FES NNP N
were VBD N
applied VBN N
in IN N
random JJ N
order NN N
: : N
constant JJ N
stimulation NN N
, , N
randomized VBN N
frequency NN N
( ( N
mean JJ N
40 CD N
Hz NNP N
) ) N
, , N
randomized VBN N
current JJ N
amplitude NN N
, , N
and CC N
randomized VBD N
pulsewidth NN N
( ( N
mean JJ N
250 CD N
micros NN N
) ) N
. . N

In IN N
randomized JJ N
trials NNS N
, , N
stimulation NN N
parameters NNS N
were VBD N
stochastically RB N
modulated VBN N
every DT N
100 CD N
ms NN N
in IN N
a DT N
range NN N
of IN N
+/-15 NNP N
% NN N
using VBG N
a DT N
uniform JJ N
probability NN N
distribution NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
fatigue NN o
time NN o
measurements NNS o
for IN N
the DT N
four CD N
modes NNS N
of IN N
stimulation NN N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
FTI NNP o
measurements NNS o
. . o

Therefore RB N
, , N
our PRP$ N
particular JJ N
method NN N
of IN N
stochastic JJ N
modulation NN N
of IN N
the DT N
stimulation NN N
parameters NNS N
, , N
which WDT N
involved VBD N
moderate JJ N
( ( N
15 CD N
% NN N
) ) N
variations NNS N
updated VBN N
every DT N
100 CD N
ms NN N
and CC N
centered VBD N
around IN N
40 CD N
Hz NNP N
, , N
appeared VBD N
to TO N
have VB N
no DT N
effect NN N
on IN N
muscle NN o
fatigue NN o
. . o

There EX N
was VBD N
a DT N
strong JJ N
correlation NN N
between IN N
maximum JJ N
force NN N
measurements NNS N
and CC N
stimulation NN N
order NN N
, , N
which WDT N
was VBD N
not RB N
apparent JJ N
in IN N
the DT N
fatigue JJ o
time NN o
or CC o
FTI NNP o
measurements NNS o
. . o

It PRP N
was VBD N
concluded VBN N
that IN N
a DT N
10-min JJ N
rest NN N
period NN N
between IN N
stimulation NN N
trials NNS N
was VBD N
insufficient JJ N
to TO N
allow VB N
full JJ N
recovery NN o
of IN o
muscle NN o
strength NN o
. . o

-DOCSTART- -2183734- O O

Treatment NN p
of IN p
renal JJ o
failure NN o
associated VBN p
with IN p
multiple JJ p
myeloma NN p
. . p

Plasmapheresis NN N
, , N
hemodialysis NN N
, , N
and CC N
chemotherapy NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
the DT N
efficacy NN N
of IN N
plasmapheresis NN N
in IN N
preventing VBG N
irreversible JJ o
renal JJ o
failure NN o
in IN N
patients NNS p
with IN p
multiple JJ p
myeloma NN p
and CC N
to TO N
study VB N
the DT N
renal JJ N
biopsy NN N
tissues NNS N
from IN N
such JJ N
patients NNS N
. . N

Twenty-one CD p
patients NNS p
with IN p
active JJ p
myeloma NN p
and CC p
progressive JJ p
renal JJ p
failure NN p
were VBD N
randomized VBN i
to TO i
one CD i
of IN i
two CD i
groups NNS i
: : i
group NN i
1 CD i
, , i
forced VBN i
diuresis NN i
and CC i
chemotherapy NN i
( ( i
10 CD i
patients NNS i
) ) i
, , i
and CC i
group NN i
2 CD i
, , i
forced VBN i
diuresis NN i
, , i
chemotherapy NN i
, , i
and CC i
plasmapheresis NN i
( ( i
11 CD i
patients NNS i
) ) i
. . i

Plasmapheresis NN N
and CC N
chemotherapy NN N
lowered VBD N
the DT N
serum NN o
myeloma NN o
protein IN o
value NN o
much RB N
more RBR N
rapidly RB N
than IN N
chemotherapy VB N
alone JJ N
. . N

Of IN p
5 CD p
patients NNS p
who WP p
were VBD p
oliguric JJ p
and CC p
undergoing JJ p
dialysis NN p
at IN p
presentation NN p
, , N
only RB N
3 CD N
who WP N
were VBD N
treated VBN N
by IN N
plasmapheresis NN N
recovered VBN N
. . N

Of IN p
16 CD p
polyuric JJ p
patients NNS p
, , N
5 CD N
in IN N
group NN N
1 CD N
and CC N
7 CD N
in IN N
group NN N
2 CD N
showed VBD N
improvement NN N
in IN N
renal JJ o
function NN o
. . o

The DT N
main JJ N
factor NN N
that WDT N
determined VBD N
irreversibility NN N
of IN N
renal JJ N
failure NN N
was VBD N
the DT N
severity NN N
of IN N
myeloma NN N
cast NN N
formation NN N
. . N

-DOCSTART- -11570022- O O

A DT N
randomized VBN N
intervention NN N
to TO N
improve VB N
ongoing VBG o
participation NN o
in IN o
mammography NN o
. . o

OBJECTIVE UH N
To TO N
test VB N
the DT N
effectiveness NN N
of IN N
interventions NNS i
intended VBN i
to TO N
increase VB N
rates NNS o
of IN o
regular JJ o
breast NN o
cancer NN o
screening NN o
, , N
according VBG N
to TO N
recommended VBN N
guidelines NNS N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
2 CD N
outreach NN i
interventions NNS i
( ( i
a DT i
mail NN i
reminder NN i
and CC i
a DT i
telephone NN i
reminder NN i
plus CC i
appointment JJ i
scheduling NN i
) ) i
compared VBN N
with IN N
a DT N
routine JJ i
publicity NN i
campaign NN i
to TO N
encourage VB N
continued JJ o
participation NN o
in IN o
mammography NN o
screening NN o
. . o

PARTICIPANTS NNP N
AND CC N
METHODS NNP N
Participants NNS p
were VBD p
1908 CD p
women NNS p
aged VBD p
50 CD p
to TO p
75 CD p
years NNS p
continuously RB p
enrolled VBD p
in IN p
a DT p
large JJ p
group-model JJ p
HMO NNP p
during IN p
the DT p
study NN p
who WP p
underwent VBD p
a DT p
bilateral JJ p
mammogram NN p
during IN p
the DT p
first JJ p
quarter NN p
of IN p
1994 CD p
and CC p
no DT p
subsequent JJ p
mammogram NN p
during IN p
the DT p
next JJ p
18 CD p
to TO p
21 CD p
months NNS p
. . p

Data NNS N
were VBD N
obtained VBN N
from IN N
health NN N
plan NN N
administrative JJ N
data NNS N
files NNS N
supplemented VBN N
by IN N
medical JJ N
chart NN N
review NN N
. . N

Women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
( ( N
1 CD N
) ) N
a DT i
mail NN i
reminder NN i
, , i
( ( i
2 CD i
) ) i
a DT i
telephone NN i
reminder NN i
, , i
or CC i
( ( i
3 CD i
) ) i
routine JJ i
publicity NN i
on IN i
mammography NN i
for IN i
all DT i
women NNS i
. . i

The DT N
outcome NN N
measure NN N
was VBD N
a DT N
mammogram NN o
received VBN o
after IN o
the DT o
intervention NN o
period NN o
and CC o
within IN o
2 CD o
years NNS o
of IN o
the DT o
initial JJ o
mammogram NN o
date NN o
. . o

RESULTS NNP N
Bivariate NNP N
and CC N
multivariate VB N
statistical JJ N
analyses NNS N
showed VBD N
that IN N
participation NN N
was VBD N
significantly RB N
higher JJR N
for IN N
women NNS N
contacted VBN N
by IN N
telephone NN N
than IN N
through IN N
routine JJ N
publicity NN N
. . N

Mail NN N
reminders NNS N
were VBD N
no DT N
more RBR N
effective JJ N
than IN N
a DT N
routine JJ i
publicity NN i
campaign NN i
. . i

Primary NNP N
care NN N
physician NN N
and CC N
gynecologist JJ N
visits NNS N
increased VBD N
the DT N
likelihood NN N
of IN N
a DT N
subsequent JJ o
mammogram NN o
for IN N
women NNS N
in IN N
all DT N
intervention NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Telephone NNP i
contact NN i
by IN N
regular JJ N
health NN N
plan NN N
staff NN N
was VBD N
more RBR N
successful JJ N
than IN N
publicity NN N
in IN N
encouraging VBG N
continued JJ N
participation NN o
in IN N
mammography NN o
screening NN o
in IN N
women NNS N
enrolled VBN N
in IN N
a DT N
group-model JJ N
managed NN N
health NN N
care NN N
plan NN N
. . N

Because IN N
mailings NNS N
did VBD N
not RB N
influence VB N
participation NN N
in IN N
mammography NN o
screening NN o
, , N
health NN N
plans NNS N
should MD N
be VB N
cautious JJ N
about IN N
investing VBG N
in IN N
member NN N
mailings NNS N
without IN N
first JJ N
evaluating VBG N
their PRP$ N
effectiveness NN N
in IN N
the DT N
context NN N
of IN N
existing VBG N
outreach NN N
efforts NNS N
. . N

-DOCSTART- -1390473- O O

Cone NN N
biopsy NN N
: : N
has VBZ N
endocervical JJ i
sampling VBG i
a DT N
role NN N
? . N
OBJECTIVE UH N
To TO N
investigate VB N
the DT N
sensitivity NN N
, , N
specificity NN N
and CC N
predictive JJ N
value NN N
of IN N
endocervical JJ i
sampling NN i
in IN N
women NNS p
with IN p
abnormal JJ p
cervical JJ p
smears NNS p
. . p

DESIGN VB N
A DT N
randomized JJ N
study NN N
of IN N
two CD N
methods NNS N
of IN N
endocervical JJ i
sampling NN i
. . i

SETTING NN N
Colposcopy NNP p
clinic NN p
at IN p
Aberdeen NNP p
Royal NNP p
Infirmary NNP p
. . p

SUBJECTS NNP N
100 CD p
women NNS p
with IN p
abnormal JJ p
cervical JJ p
smears NNS p
selected VBN p
for IN p
cone NN p
biopsy NN p
according VBG p
to TO p
current JJ p
colposcopy NN p
criteria NNS p
. . p

INTERVENTIONS NNP N
53 CD N
women NNS N
were VBD N
randomized VBN N
to TO N
have VB N
endocervical JJ i
sampling VBG i
with IN i
the DT i
Kevorkian NNP i
curette NN i
and CC N
47 CD N
to TO N
have VB N
sampling VBG i
with IN i
the DT i
Medscand NNP i
endocervical JJ i
brush NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Cytology NNP o
and CC o
histology NN o
results NNS o
from IN o
endocervical JJ o
sampling NN o
compared VBN o
with IN o
cone NN o
biopsy NN o
histology NN o
. . o

RESULTS VB N
The DT N
overall JJ N
sensitivity NN o
of IN o
endocervical JJ o
sampling NN o
was VBD N
56 CD N
% NN N
, , N
with IN N
a DT N
false JJ o
negative JJ o
rate NN o
of IN N
44 CD N
% NN N
and CC N
a DT N
negative JJ o
predictive JJ o
value NN o
of IN N
26 CD N
% NN N
. . N

CONCLUSIONS NNP N
Endocervical NNP i
sampling VBG i
should MD N
not RB N
influence VB N
management NN N
when WRB N
colposcopy NN N
is VBZ N
unsatisfactory JJ N
. . N

-DOCSTART- -17872451- O O

Nateglinide NNP i
reduces VBZ N
carotid JJ o
intima-media JJ o
thickening NN o
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
under IN p
good JJ p
glycemic JJ p
control NN p
. . p

OBJECTIVE NNP N
Postprandial NNP N
hyperglycemia NN N
observed VBD N
in IN N
type NN p
2 CD p
diabetes NNS p
mellitus NN N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
atherosclerosis NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
strict JJ i
glycemic NNS i
control NN i
by IN N
nateglinide NN N
on IN N
common JJ N
carotid NN o
far RB o
wall JJ o
intima-media JJ o
thickness NN o
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
who WP p
were VBD p
already RB p
under IN p
good JJ p
glycemic JJ p
control NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
performed VBD N
an DT N
open JJ N
labeled VBN N
randomized JJ N
prospective JJ N
trial NN N
on IN N
78 CD i
drug-naive JJ i
type NN i
2 CD i
diabetic JJ i
patients NNS i
whose WP$ i
HbA1c NNP i
was VBD i
less JJR i
than IN i
6.5 CD i
% NN i
. . i

Thirty-eight JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
nateglinide NN i
( ( i
270 CD i
mg/dL NN i
) ) i
and CC i
40 CD i
to TO i
control VB i
group NN i
( ( i
no DT i
treatment NN i
) ) i
. . i

After IN N
12 CD N
months NNS N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
HbA1c NNP o
was VBD N
observed VBN N
in IN N
the DT N
nateglinide JJ N
group NN N
, , N
whereas IN N
a DT N
significant JJ N
increase NN N
of IN N
HbA1c NNP o
was VBD N
observed VBN N
in IN N
the DT N
untreated JJ N
group NN N
. . N

The DT N
carotid JJ o
intima-media JJ o
thickness NN o
at IN N
the DT N
end NN N
of IN N
1-year JJ N
follow-up NN N
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
nateglinide JJ N
group NN N
compared VBN N
with IN N
the DT N
untreated JJ i
group NN i
( ( N
-0.017+/-0.054 JJ N
mm/year VBP N
versus IN N
0.024+/-0.066 JJ N
mm/year NN N
, , N
P=0.0064 NNP N
) ) N
. . N

Whereas NNP N
nateglinide JJ N
treatment NN N
also RB N
reduced VBD N
triglyceride JJ o
, , o
highly-sensitive JJ o
C-reactive JJ o
protein NN o
, , o
and CC o
E-selectin NNP o
, , N
multiple JJ N
regression NN N
analysis NN N
identified VBN N
HbA1c NNP o
as IN N
the DT N
only JJ N
significant JJ N
independent JJ N
determinant NN N
of IN N
the DT N
change NN N
in IN N
carotid JJ o
intima-media JJ o
thickness NN o
. . o

CONCLUSION NNP N
In IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN p
good JJ p
glycemic NNS p
control NN p
, , N
further JJ N
strict JJ i
glycemic NNS i
control NN i
by IN i
nateglinide JJ i
results NNS N
in IN N
regression NN N
of IN N
carotid JJ o
intima-media JJ o
thickness NN o
. . o

-DOCSTART- -11392343- O O

Double-blind NNP N
, , N
placebo-controlled JJ i
study NN N
of IN N
amantadine JJ i
hydrochloride NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
amantadine JJ i
hydrochloride NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
treatment NN N
for IN N
behavioral JJ o
disturbances NNS o
-- : o
for IN o
example NN N
, , N
hyperactivity NN o
and CC o
irritability NN o
-- : o
in IN o
children NNS p
with IN p
autism NN p
. . p

METHOD NNP N
Thirty-nine JJ p
subjects NNS p
( ( p
intent NN p
to TO p
treat VB p
; : p
5-19 CD p
years NNS p
old JJ p
; : p
IQ NNP p
> NNP p
35 CD p
) ) p
had VBD p
autism NN p
diagnosed VBN p
according VBG p
to TO p
DSM-IV NNP p
and CC p
ICD-10 NNP p
criteria NNS p
using VBG p
the DT p
Autism NNP p
Diagnostic NNP p
Interview-Revised JJ p
and CC p
the DT p
Autism NNP p
Diagnostic NNP p
Observation NNP p
Schedule-Generic NNP p
. . p

The DT N
Aberrant JJ o
Behavior NNP o
Checklist-Community NNP o
Version NNP o
( ( o
ABC-CV NNP o
) ) o
and CC o
Clinical JJ o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
scale NN N
were VBD N
used VBN N
as IN N
outcome JJ N
variables NNS N
. . N

After IN N
a DT N
1-week JJ N
, , N
single-blind JJ N
placebo NN N
run-in NN N
, , N
patients NNS N
received VBD N
a DT N
single JJ i
daily JJ i
dose NN i
of IN i
amantadine NN i
( ( i
2.5 CD i
mg/kg NNS i
per IN i
day NN i
) ) i
or CC i
placebo NN i
for IN i
the DT i
next JJ i
week NN i
, , i
and CC i
then RB i
bid VB i
dosing VBG i
( ( i
5.0 CD i
mg/kg NNS i
per IN i
day NN i
) ) i
for IN i
the DT i
subsequent JJ i
3 CD i
weeks NNS i
. . i

RESULTS VB N
When WRB N
assessed VBN N
on IN N
the DT N
basis NN N
of IN N
parent-rated JJ o
ABC-CV NNP o
ratings NNS o
of IN o
irritability NN o
and CC o
hyperactivity NN o
, , N
the DT N
mean JJ N
placebo NN N
response NN N
rate NN N
was VBD N
37 CD N
% NN N
versus NN N
amantadine NN N
at IN N
47 CD N
% NN N
( ( N
not RB N
significant JJ N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
amantadine-treated JJ i
group NN N
there EX N
were VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
absolute JJ N
changes NNS N
in IN N
clinician-rated JJ N
ABC-CVs NNP o
for IN o
hyperactivity NN o
( ( N
amantadine JJ N
-6.4 NNP N
versus NN N
placebo NN N
-2.1 NNP N
; : N
p CC N
= NNP N
.046 NNP N
) ) N
and CC N
inappropriate JJ o
speech NN o
( ( N
-1.9 JJ N
versus NN N
0.4 CD N
; : N
p NN N
= NNP N
.008 NNP N
) ) N
. . N

CGI NNP o
scale JJ o
ratings NNS o
were VBD N
higher JJR N
in IN N
the DT N
amantadine NN N
group NN N
: : N
53 CD N
% NN N
improved JJ N
versus NN N
25 CD N
% NN N
( ( N
p JJ N
= NNP N
.076 NNP N
) ) N
. . N

Amantadine NNP i
was VBD N
well RB N
tolerated VBN N
. . N

CONCLUSIONS NNP N
Parents NNPS N
did VBD N
not RB N
report VB N
statistically RB N
significant JJ N
behavioral JJ o
change NN o
with IN N
amantadine NN N
. . N

However RB N
, , N
clinician-rated JJ o
improvements NNS o
in IN o
behavioral JJ o
ratings NNS o
following VBG N
treatment NN N
with IN N
amantadine JJ i
suggest VBP N
that IN N
further JJ N
studies NNS N
with IN N
this DT N
or CC N
other JJ N
drugs NNS N
acting VBG N
on IN N
the DT N
glutamatergic NN N
system NN N
are VBP N
warranted VBN N
. . N

The DT N
design NN N
of IN N
these DT N
and CC N
similar JJ N
drug NN N
trials NNS N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
must MD N
take VB N
into IN N
account NN N
the DT N
possibility NN N
of IN N
a DT N
large JJ N
placebo NN N
response NN N
. . N

-DOCSTART- -23611569- O O

Vilazodone NN i
lacks VBZ N
proarrhythmogenic JJ N
potential NN N
in IN N
healthy JJ p
participants NNS p
: : p
a DT N
thorough JJ N
ECG NNP N
study NN N
. . N

OBJECTIVE NNP N
Vilazodone NNP i
is VBZ N
a DT N
potent JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
and CC N
5-HT1A JJ N
receptor NN N
partial JJ N
agonist NN N
approved VBD N
for IN N
the DT N
treatment NN N
of IN N
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
in IN p
adults NNS p
. . p

The DT N
effect NN N
of IN N
clinical JJ N
and CC N
supratherapeutic JJ N
doses NNS N
of IN N
vilazodone NN i
on IN N
cardiac JJ N
repolarization NN N
was VBD N
determined VBN N
in IN N
healthy JJ p
volunteers NNS p
. . p

METHODS NNP N
In IN N
this DT N
Phase NNP N
1 CD N
, , N
randomized VBN N
, , N
doubleblind VB N
, , N
placebo- JJ i
and CC N
active-controlled JJ N
, , N
3-arm JJ N
, , N
parallel JJ N
, , N
single-center JJ N
study NN N
, , N
healthy JJ p
subjects NNS p
received VBD N
placebo NN i
; : i
moxifloxacin CC i
400 CD i
mg NN i
; : i
or CC i
vilazodone NN i
( ( N
sequentially RB N
escalated VBN N
every DT N
3 CD N
days NNS N
) ) N
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
80 CD N
mg/day NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
time-matched JJ N
change NN N
from IN N
baseline NN N
in IN N
the DT N
QT NNP o
interval NN o
corrected VBD o
for IN o
heart NN o
rate NN o
( ( o
QTc NNP o
) ) o
using VBG N
an DT N
individual JJ N
correction NN N
method NN N
( ( N
QTcI NNP N
) ) N
. . N

RESULTS JJ N
Placebo-corrected JJ i
time-matched JJ N
analysis NN N
of IN N
the DT N
QTcI NNP o
duration NN o
for IN N
the DT N
vilazodone NN i
treatment NN N
effect NN N
indicated VBD N
that IN N
no DT N
vilazodone NN i
dose NN N
had VBD N
an DT N
upper JJ N
bound NN N
that IN N
approached VBD N
or CC N
exceeded VBD N
10 CD N
ms NN N
, , N
demonstrating VBG N
no DT N
signal NN N
for IN N
a DT N
significant JJ N
vilazodone NN i
effect NN N
on IN N
cardiac JJ o
repolarization NN o
. . o

Vilazodone NNP i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
heart NN o
rate NN o
, , o
PR NNP o
, , o
or CC o
QRS NNP o
interval JJ o
duration NN o
. . o

The DT N
pharmacokinetic/pharmacodynamic JJ N
model NN N
showed VBD N
that IN N
the DT N
QTcI NNP o
slope NN N
for IN N
vilazodone NN i
was VBD N
not RB N
different JJ N
from IN N
0.0 CD N
and CC N
that IN N
the DT N
predicted JJ N
increase NN N
from IN N
baseline NN N
in IN N
the DT N
QTc NNP o
at IN o
Cmax NNP o
for IN N
the DT N
highest JJS N
therapeutic JJ N
dose NN N
( ( N
156 CD N
ng/ml RB N
after IN N
40 CD N
mg/day NN N
) ) N
was VBD N
< JJ N
1 CD N
ms NN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
was VBD N
higher RBR N
in IN N
the DT N
vilazodone NN i
group NN N
( ( N
57.6 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
moxifloxacin NN i
( ( N
37.0 CD N
% NN N
) ) N
and CC N
placebo NN i
( ( N
35.6 CD N
% NN N
) ) N
groups NNS N
, , N
though IN N
AEs NNP o
were VBD N
generally RB N
mild VBN N
to TO N
moderate VB N
in IN N
severity NN N
and CC N
resulted VBD N
in IN N
few JJ N
discontinuations NNS N
. . N

CONCLUSIONS NNP N
Vilazodone NNP i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
cardiac JJ o
repolarization NN o
, , o
heart NN o
rate NN o
, , o
PR NNP o
or CC o
QRS NNP o
interval JJ o
duration NN o
, , o
or CC o
ECG NNP o
morphology NN o
in IN N
healthy JJ p
adult NN p
participants NNS p
. . p

-DOCSTART- -14989068- O O

[ RB N
Clinical NNP N
study NN N
on IN N
dan NN i
shao NN i
tang NN i
in IN N
treating VBG N
IgA NNP N
nephropathy NN N
of IN N
deficiency NN N
of IN N
yin NN N
with IN N
damp-heat JJ N
symptom NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
effect NN N
of IN N
Dan NNP i
Shao NNP i
Tang NNP i
( ( i
DST NNP i
) ) i
in IN N
treating VBG N
IgA NNP N
nephropathy NN N
( ( N
IgAN NNP N
) ) N
of IN N
deficiency NN N
of IN N
Yin NNP N
with IN N
damp-heat JJ N
symptom NN N
. . N

METHODS NNP N
90 CD p
patients NNS p
with IN p
IgAN NNP p
of IN p
deficiency NN p
of IN p
Yin NNP p
with IN p
damp-heat JJ p
symptom NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

50 CD N
patients NNS N
in IN N
treatment NN N
group NN N
were VBD N
treated VBN N
with IN N
DST NNP i
and CC i
western JJ i
medicine NN i
and CC N
40 CD N
patients NNS N
in IN N
control NN N
group NN N
were VBD N
treated VBN N
only RB i
with IN i
western JJ i
medicine NN i
. . i

The DT N
effects NNS N
and CC N
changes NNS N
of IN N
the DT N
indexes NNS N
including VBG N
renal JJ o
function NN o
, , o
hematuria NN o
, , o
proteinuria NN o
, , o
blood NN o
IgA NNP o
before IN N
and CC N
after IN N
treatment NN N
were VBD N
observed VBN N
. . N

RESULTS NNP N
After IN N
six CD N
months NNS N
treatment NN N
, , N
the DT N
general JJ o
effective JJ o
rate NN o
in IN N
treatment NN N
group NN N
was VBD N
70.00 CD N
% NN N
, , N
which WDT N
was VBD N
markedly RB N
higher JJR N
than IN N
that DT N
in IN N
control NN N
group NN N
( ( N
37.50 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Treatment NNP N
group NN N
is VBZ N
obviously RB N
better JJR N
than IN N
control NN N
group NN N
on IN N
decreasing VBG o
hematuria NN o
, , o
proteinuria NN o
, , o
blood NN o
IgA NNP o
and CC o
improving VBG o
renal JJ o
function NN o
( ( o
P NNP o
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
DST NNP i
is VBZ N
effective JJ N
on IN N
IgAN NNP N
of IN N
deficiency NN N
of IN N
Yin NNP N
with IN N
damp-heat JJ N
symptom NN N
. . N

-DOCSTART- -20973459- O O

High-calcium JJ i
milk NN i
prevents NNS N
overweight JJ N
and CC N
obesity NN N
among IN N
postmenopausal JJ p
women NNS p
. . p

BACKGROUND IN N
The DT N
Sixth NNP N
National NNP N
Nutrition NNP N
Survey NNP N
2003 CD N
revealed VBD N
that IN N
the DT N
highest JJS N
prevalence NN N
of IN N
overweight NN N
and CC N
obesity NN N
among IN N
Filipino NNP p
female JJ p
adults NNS p
( ( p
30.8 CD p
% NN p
) ) p
was VBD p
found VBN p
in IN p
the DT p
age NN p
group NN p
from IN p
40 CD p
to TO p
59 CD p
years NNS p
. . p

Obesity NN N
is VBZ N
associated VBN N
with IN N
a DT N
number NN N
of IN N
chronic JJ N
diseases NNS N
, , N
including VBG N
cardiovascular JJ N
disease NN N
, , N
hypertension NN N
, , N
and CC N
diabetes NNS N
. . N

Low JJ N
calcium NN N
intake NN N
has VBZ N
been VBN N
identified VBN N
as IN N
a DT N
potential JJ N
contributing NN N
factor NN N
to TO N
overweight NN N
and CC N
obesity NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effect NN N
of IN N
a DT N
high-calcium NN i
, , i
fortified VBN i
, , i
low-fat JJ i
milk NN i
drink NN i
with IN N
added JJ i
vitamin NN i
D NNP i
versus VBZ N
a DT N
low-calcium JJ i
placebo NN i
drink NN i
on IN N
anthropometric JJ N
measurements NNS N
of IN N
postmenopausal JJ p
women NNS p
. . p

METHODS NNP N
Women NNP p
who WP p
were VBD p
at IN p
least JJS p
5 CD p
years NNS p
postmenopausal NN p
were VBD p
invited VBN p
to TO p
participate VB p
in IN N
the DT N
study NN N
. . N

Potential JJ N
participants NNS N
underwent JJ N
three CD N
stages NNS N
of IN N
screening NN N
: : N
initial JJ N
interview NN N
, , N
dual-energy JJ N
x-ray JJ N
absorptiometry NN N
, , N
and CC N
blood NN N
testing NN N
for IN N
biochemical JJ N
screening NN N
. . N

Anthropometric JJ o
indices NNS o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Sixty NNP p
women NNS p
were VBD p
qualified VBN p
to TO p
participate VB p
in IN N
the DT N
study NN N
. . N

The DT N
women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
, , N
one CD N
of IN N
which WDT N
received VBD N
400 CD N
ml NN N
of IN N
the DT N
high-calcium JJ i
milk NN i
daily RB N
for IN N
16 CD N
weeks NNS N
while IN N
the DT N
other JJ N
received VBD N
the DT N
placebo NN i
drink NN i
. . i

RESULTS NNP N
No NNP N
significant JJ N
increases NNS N
were VBD N
observed VBN N
in IN N
the DT N
anthropometric JJ o
indices NNS o
of IN N
the DT N
subjects NNS N
receiving VBG N
the DT N
high-calcium NN i
fortified VBD i
milk NN i
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

However RB N
, , N
there EX N
were VBD N
significant JJ N
increases NNS N
in IN N
the DT N
weight NN o
( ( N
p JJ N
= NNP N
.008 NNP N
) ) N
, , N
body JJ o
mass NN o
index NN o
( ( N
p JJ N
= NNP N
.007 NNP N
) ) N
, , N
and CC N
waist NN o
( ( N
p JJ N
= NNP N
.018 NNP N
) ) N
and CC N
hip NN o
( ( N
p JJ N
= NNP N
.003 NNP N
) ) N
circumferences NNS o
of IN N
the DT N
subjects NNS N
receiving VBG N
the DT N
placebo NN N
drink NN N
. . N

CONCLUSIONS VB N
A DT N
change NN N
in IN N
dietary JJ o
calcium NN o
intake NN o
may MD N
be VB N
a DT N
useful JJ N
measure NN N
as IN N
part NN N
of IN N
an DT N
overall JJ N
approach NN N
to TO N
prevent VB N
the DT N
occurrence NN N
of IN N
overweight NN N
and CC N
obesity NN N
among IN N
postmenopausal JJ p
women NNS p
. . p

-DOCSTART- -17113685- O O

B-vitamins NNS i
reduce VB N
plasma NN o
levels NNS o
of IN N
beta NN N
amyloid NN N
. . N

Elevated VBN N
plasma JJ N
homocysteine NN N
( ( N
tHcy NN N
) ) N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
Alzheimer NNP N
's POS N
disease NN N
( ( N
AD NNP N
) ) N
, , N
and CC N
thus RB N
B NNP i
vitamins NNS i
may MD N
have VB N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
tHcy JJ N
lowering NN N
vitamins NNS N
decrease VBP N
the DT N
circulating NN o
levels NNS o
of IN o
A-beta NNP o
protein NN o
1-40 JJ o
( ( o
A NNP o
beta RB o
40 CD o
) ) o
. . o

We PRP N
randomized VBD N
299 CD p
older JJR p
men NNS p
to TO N
treatment NN N
with IN N
2mg CD i
of IN i
folate NN i
, , i
plus CC i
25mg CD i
of IN i
B6 NNP i
and CC i
400 CD i
microg NN i
of IN i
B12 NNP i
, , i
or CC i
placebo NN i
. . i

After IN N
2 CD N
years NNS N
of IN N
treatment NN N
the DT N
mean NN o
( ( o
S.E NNP o
. . o

) ) o
increase NN o
of IN o
A NNP o
beta NN o
40 CD o
was VBD N
7.0 CD N
pg/ml NN N
( ( N
8.4 CD N
) ) N
in IN N
the DT N
vitamin NN N
group NN N
( ( N
4.9 CD N
% NN N
) ) N
, , N
and CC N
26.8 CD N
pg/ml NN N
( ( N
7.7 CD N
) ) N
( ( N
18.5 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
B NNP N
vitamins NNS N
may MD N
decrease VB N
the DT o
plasma JJ o
level NN o
of IN o
A NNP o
beta NN o
40 CD o
and CC N
have VBP N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
. . N

-DOCSTART- -22038637- O O

[ JJ i
Prophylactic NNP i
intraaortic JJ i
balloon NN i
pumping VBG i
in IN N
high-risk JJ p
cardiac JJ p
surgery NN p
patients NNS p
] VBP p
. . N

BACKGROUND NNP N
We PRP N
examined VBD N
the DT N
impact NN N
of IN N
prophylactic JJ i
IABP NNP i
insertion NN i
in IN N
EuroSCORE-stratified JJ p
high-risk JJ p
cardiac NN p
surgery NN p
patients NNS p
with IN p
a DT p
score NN p
?8 NN p
. . p

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP N
randomized JJ N
trial NN N
with IN p
104 CD p
patients NNS p
either CC i
without IN i
prophylactic JJ i
IABP NNP i
insertion NN i
( ( i
group NN i
A NNP p
, , p
n=52 NN p
) ) p
or CC p
with IN p
IABP NNP i
( ( i
group NN i
B NNP p
, , p
n=52 NN p
) ) p
was VBD p
conducted VBN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
30-day JJ o
mortality NN o
. . o

RESULTS VB o
The DT p
median JJ p
age NN p
of IN p
the DT p
patients NNS p
was VBD p
74 CD p
years NNS p
and CC p
43 CD p
% NN p
of IN p
participants NNS p
were VBD p
females NNS o
. . o

The DT o
30-day JJ o
mortality NN o
did VBD o
not RB o
differ VB N
between IN N
group NN N
A NNP N
( ( N
17.3 CD N
% NN N
) ) N
and CC N
group NN N
B NNP N
( ( N
13.4 CD N
% NN N
; : N
p=0.78 NN N
) ) N
. . N

The DT o
median JJ o
hospital NN o
stay NN o
was VBD o
14 CD N
days NNS N
in IN N
both DT N
groups NNS N
. . N

Intra- NNP N
and CC N
postoperative JJ i
IABP NNP i
support NN i
was VBD N
required VBN N
by IN N
13 CD N
patients NNS N
( ( N
21 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
. . N

The DT o
median JJ o
ventilation NN o
time NN o
( ( o
14 CD o
hours NNS N
versus VBD N
13 CD N
hours NNS N
) ) N
, , N
median JJ o
catecholamine NN o
dose NN o
, , o
frequency NN o
of IN o
dialysis-dependent JJ o
acute JJ o
renal JJ o
failure NN o
( ( o
28 CD o
% NN N
versus IN N
18 CD N
% NN N
) ) N
, , N
cardiac JJ o
indices NNS o
, , o
and CC o
frequency NN o
of IN o
a DT o
low JJ o
cardiac JJ o
output NN o
syndrome NN o
( ( o
26 CD o
% NN N
versus IN N
25 CD N
% NN N
) ) N
did VBD N
not RB N
significantly RB N
differ VBP N
between IN N
groups NNS N
. . N

CONCLUSION NNP N
Prophylactic NNP i
preoperative JJ i
IABP NNP i
insertion NN i
in IN i
EuroSCORE-stratified JJ p
high-risk JJ p
patients NNS p
is VBZ p
not RB N
associated VBN N
with IN N
decreased JJ N
30-day JJ N
mortality NN N
. . N

-DOCSTART- -20689977- O O

Cost-effectiveness NN o
of IN N
cognitive-behavioral JJ i
group NN i
therapy NN i
for IN N
dysfunctional JJ N
fear NN N
of IN N
progression NN N
in IN N
cancer NN p
patients NNS p
. . p

Anxiety NNP o
and CC o
fear NN o
are VBP N
often RB N
associated VBN N
with IN N
chronic JJ N
conditions NNS N
such JJ N
as IN N
cancer NN N
. . N

This DT N
paper NN N
targets VBZ N
the DT N
cost-effectiveness JJ o
analysis NN o
of IN N
a DT N
cognitive-behavioral JJ i
group NN i
therapy NN i
( ( i
CBT NNP i
) ) i
in IN N
comparison NN N
to TO N
a DT N
client-centered JJ i
, , i
supportive-experiential JJ i
group NN i
therapy NN i
( ( i
SET NNP i
) ) i
in IN N
cancer NN p
patients NNS p
with IN p
dysfunctional JJ p
fear NN p
of IN p
progression NN p
. . p

An DT N
incremental JJ N
cost-effectiveness JJ o
analysis NN o
was VBD N
performed VBN N
using VBG N
data NNS N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
among IN N
cancer NN p
patients NNS p
receiving VBG p
inpatient JJ p
rehabilitation NN p
. . p

The DT N
means NNPS o
, , o
95 CD o
% NN o
confidence NN o
intervals NNS o
[ VBP o
95 CD o
% NN o
CI NNP o
] NNP o
, , o
incremental JJ o
cost-effectiveness JJ o
graphic NN o
and CC o
acceptability NN o
curve NN o
were VBD N
obtained VBN N
from IN N
1,000 CD N
bootstrap NN N
replications NNS N
. . N

A DT p
total NN p
of IN p
174 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
economic JJ p
evaluation NN p
. . p

The DT N
estimated JJ o
means VBZ o
[ JJ N
95 CD N
% NN N
CI NNP N
] NNP N
of IN o
direct JJ o
costs NNS o
and CC o
reduction NN o
of IN o
fear NN o
of IN o
progression NN o
were VBD N
< JJ N
euro JJ N
> NN N
9,045.03 CD N
[ JJ N
6,359.07 CD N
; : N
12,091.87 CD N
] NN N
and CC N
1.41 CD N
[ JJ N
0.93 CD N
; : N
1.92 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
SET NNP N
and CC N
< NNP N
euro VBP N
> $ N
6,682.78 CD N
[ JJ N
4,998.09 CD N
; : N
8,440.95 CD N
] NN N
and CC N
1.44 CD N
[ JJ N
1.02 CD N
; : N
1.09 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
CBT NNP i
. . i

The DT N
incremental JJ o
cost-effectiveness JJ o
ratio NN o
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
amounts NNS N
to TO N
minus NNS N
< NNP N
euro VBP N
> $ N
78,741.66 CD N
[ NNP N
-154,987.20 NNP N
; : N
110,486.32 CD N
] NN N
for IN N
an DT N
additional JJ N
unit NN N
of IN N
effect NN N
. . N

Given VBN N
the DT N
acceptability NN o
curve NN o
, , N
there EX N
is VBZ N
a DT N
92.4 CD N
% NN N
chance NN N
that IN N
the DT N
CBT NNP i
, , N
compared VBN N
with IN N
the DT N
SET NNP i
, , N
is VBZ N
cost-effective JJ o
without IN N
the DT N
need NN N
of IN N
additional JJ N
costs NNS N
to TO N
payers NNS N
. . N

Our PRP$ N
main JJ N
result NN N
is VBZ N
the DT N
superior JJ N
cost-effectiveness NN o
of IN N
the DT N
cognitive-behavioral JJ i
intervention NN i
program NN N
in IN N
comparison NN N
to TO N
the DT N
non-directive JJ N
encounter NN N
group NN N
for IN N
our PRP$ N
sample NN N
of IN N
cancer NN p
patients NNS p
with IN p
high JJ p
levels NNS p
of IN p
anxiety NN o
. . o

-DOCSTART- -20976617- O O

Theory NN N
of IN N
Mind NNP i
training NN i
in IN N
children NNS p
with IN p
autism NN o
: : o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Many JJ N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
participate NN N
in IN N
social JJ N
skills NNS N
or CC N
Theory NN i
of IN i
Mind NNP i
( ( i
ToM NNP i
) ) i
treatments NNS i
. . i

However RB N
, , N
few JJ N
studies NNS N
have VBP N
shown VBN N
evidence NN N
for IN N
their PRP$ N
effectiveness NN N
. . N

The DT N
current JJ N
study NN N
used VBD N
a DT N
randomized JJ N
controlled JJ N
design NN N
to TO N
test VB N
the DT N
effectiveness NN o
of IN N
a DT N
16-week JJ N
ToM NNP i
treatment NN i
in IN N
8-13 JJ p
year NN p
old JJ p
children NNS p
with IN p
ASD NNP p
and CC p
normal JJ p
IQs NNP p
( ( p
n JJ p
= NNP p
40 CD p
) ) p
. . p

The DT p
results NNS N
showed VBD N
that IN N
, , N
compared VBN N
to TO N
controls NNS N
, , N
the DT N
treated JJ N
children NNS N
with IN N
ASD NNP N
improved VBN o
in IN o
their PRP$ o
conceptual JJ o
ToM NNP o
skills NNS o
, , o
but CC o
their PRP$ o
elementary JJ o
understanding NN o
, , o
self PRP o
reported VBD o
empathic JJ o
skills NNS o
or CC o
parent NN o
reported VBN o
social JJ o
behaviour NN o
did VBD o
not RB N
improve VB N
. . N

Despite IN N
the DT N
effects NNS N
on IN N
conceptual JJ N
understanding NN N
, , N
the DT N
current JJ N
study NN N
does VBZ N
not RB N
indicate VB N
strong JJ N
evidence NN N
for IN N
the DT N
effectiveness NN N
of IN N
a DT N
ToM NNP N
treatment NN N
on IN N
the DT N
daily JJ N
life NN o
mindreading VBG o
skills NNS o
. . N

-DOCSTART- -11238483- O O

Effect NN N
of IN N
protein NN i
ingestion NN i
on IN N
the DT N
glucose JJ o
appearance NN o
rate NN o
in IN N
people NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

Amino NNP N
acids NNS N
derived VBD N
from IN N
ingested VBN N
protein NN N
are VBP N
potential JJ N
substrates NNS N
for IN N
gluconeogenesis NN N
. . N

However RB N
, , N
several JJ N
laboratories NNS N
have VBP N
reported VBN N
that IN N
protein JJ N
ingestion NN N
does VBZ N
not RB N
result VB N
in IN N
an DT N
increase NN N
in IN N
the DT N
circulating NN o
glucose JJ o
concentration NN o
in IN N
people NNS N
with IN N
or CC N
without IN N
type JJ p
2 CD p
diabetes NNS p
. . p

The DT N
reason NN N
for IN N
this DT N
has VBZ N
remained VBN N
unclear JJ N
. . N

In IN N
people NNS N
without IN N
diabetes NNS N
it PRP N
seems VBZ N
to TO N
be VB N
due JJ N
to TO N
less RBR N
glucose JJ N
being VBG N
produced VBN N
and CC N
entering VBG N
the DT N
circulation NN N
than IN N
the DT N
calculated JJ N
theoretical JJ N
amount NN N
. . N

Therefore RB N
, , N
we PRP N
were VBD N
interested JJ N
in IN N
determining VBG N
whether IN N
this DT N
also RB N
was VBD N
the DT N
case NN N
in IN N
people NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

Ten CD p
male JJ p
subjects NNS p
with IN p
untreated JJ p
type NN p
2 CD p
diabetes NNS p
were VBD N
given VBN N
, , N
in IN N
random JJ N
sequence NN N
, , N
50 CD i
g NN i
protein NN i
in IN i
the DT i
form NN i
of IN i
very RB i
lean JJ i
beef NN i
or CC i
only RB i
water NN i
at IN i
0800 CD i
h NN i
and CC i
studied VBN i
over IN i
the DT i
subsequent JJ i
8 CD i
h. NN i
Protein NNP i
ingestion NN N
resulted VBD N
in IN N
an DT N
increase NN N
in IN N
circulating VBG o
insulin NN o
, , o
C-peptide NNP o
, , o
glucagon NN o
, , o
alpha NN o
amino NN o
and CC o
urea JJ o
nitrogen NN o
, , o
and CC o
triglycerides NNS o
; : o
a DT o
decrease NN o
in IN o
nonesterified JJ o
fatty JJ o
acids NNS o
; : o
and CC o
a DT o
modest JJ o
increase NN o
in IN o
respiratory JJ o
quotient NN o
. . o

The DT N
total JJ N
amount NN N
of IN N
protein NN o
deaminated VBN o
and CC o
the DT o
amino NN o
groups NNS o
incorporated VBD o
into IN o
urea NN o
was VBD N
calculated VBN N
to TO N
be VB N
approximately RB N
20-23 JJ N
g. VBP N
The DT N
net JJ N
amount NN N
of IN N
glucose NN o
estimated VBN N
to TO N
be VB N
produced VBN N
, , N
based VBN N
on IN N
the DT N
quantity NN o
of IN o
amino JJ o
acids NNS o
deaminated VBD o
, , N
was VBD N
approximately RB N
11-13 JJ N
g. NN N
However RB N
, , N
the DT N
amount NN o
of IN o
glucose JJ o
appearing VBG o
in IN o
the DT o
circulation NN o
was VBD N
only RB N
approximately RB N
2 CD N
g. VBD N
The DT N
peripheral JJ o
plasma NN o
glucose JJ o
concentration NN o
decreased VBN N
by IN N
approximately RB N
1 CD N
mM NNS N
after IN N
ingestion NN N
of IN N
either DT N
protein NN N
or CC N
water NN N
, , N
confirming VBG N
that IN N
ingested JJ N
protein NN N
does VBZ N
not RB N
result VB N
in IN N
a DT N
net JJ N
increase NN N
in IN N
glucose JJ o
concentration NN o
, , N
and CC N
results NNS N
in IN N
only RB N
a DT N
modest JJ N
increase NN N
in IN N
the DT N
rate NN o
of IN o
glucose JJ o
disappearance NN o
. . o

-DOCSTART- -25022743- O O

Weighted VBN i
blankets NNS i
and CC N
sleep NN N
in IN N
autistic JJ p
children NNS p
-- : p
a DT p
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
a DT N
weighted-blanket JJ i
intervention NN i
in IN N
treating VBG N
severe JJ p
sleep NN p
problems NNS p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

METHODS NNP N
This DT N
phase NN N
III NNP N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
crossover NN N
design NN N
. . N

Participants NNS p
were VBD p
aged VBN p
between IN p
5 CD p
years NNS p
and CC p
16 CD p
years NNS p
10 CD p
months NNS p
, , p
with IN p
a DT p
confirmed JJ p
ASD NNP p
diagnosis NN p
and CC p
severe JJ p
sleep NN p
problems NNS p
, , p
refractory NN p
to TO p
community-based JJ p
interventions NNS p
. . p

The DT N
interventions NNS N
were VBD N
either RB N
a DT N
commercially RB i
available JJ i
weighted JJ i
blanket NN i
or CC i
otherwise RB i
identical JJ i
usual JJ i
weight NN i
blanket NN i
( ( N
control NN N
) ) N
, , N
introduced VBN N
at IN N
bedtime NN N
; : N
each DT N
was VBD N
used VBN N
for IN N
a DT N
2-week JJ N
period NN N
before IN N
crossover NN N
to TO N
the DT N
other JJ N
blanket NN N
. . N

Primary JJ N
outcome NN N
was VBD N
total JJ o
sleep JJ o
time NN o
( ( o
TST NNP o
) ) o
recorded VBN N
by IN N
actigraphy NN N
over IN N
each DT N
2-week JJ N
period NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
actigraphically RB o
recorded VBN o
sleep-onset JJ o
latency NN o
, , o
sleep JJ o
efficiency NN o
, , o
assessments NNS o
of IN o
child NN o
behavior NN o
, , o
family NN o
functioning NN o
, , o
and CC o
adverse JJ o
events NNS o
. . o

Sleep NNP N
was VBD N
also RB N
measured VBN N
by IN N
using VBG N
parent-report JJ N
diaries NNS N
. . N

RESULTS NNP N
Seventy-three JJ p
children NNS p
were VBD p
randomized VBN p
and CC p
analysis NN p
conducted VBN p
on IN p
67 CD p
children NNS p
who WP p
completed VBD p
the DT p
study NN p
. . p

Using VBG N
objective JJ N
measures NNS N
, , N
the DT N
weighted JJ i
blanket NN i
, , N
compared VBN N
with IN N
the DT N
control NN i
blanket NN i
, , N
did VBD N
not RB N
increase VB N
TST NNP o
as IN N
measured VBN N
by IN N
actigraphy NN N
and CC N
adjusted VBN N
for IN N
baseline NN N
TST NNP N
. . N

There EX N
were VBD N
no DT N
group NN N
differences NNS N
in IN N
any DT N
other JJ N
objective NN o
or CC o
subjective JJ o
measure NN o
of IN o
sleep NN o
, , N
including VBG N
behavioral JJ N
outcomes NNS N
. . N

On IN N
subjective JJ N
preference NN N
measures NNS N
, , N
parents NNS N
and CC N
children NNS N
favored VBD N
the DT N
weighted JJ i
blanket NN i
. . i

CONCLUSIONS VB N
The DT N
use NN N
of IN N
a DT N
weighted JJ i
blanket NN i
did VBD N
not RB N
help VB N
children NNS p
with IN p
ASD NNP p
sleep NN N
for IN N
a DT N
longer JJR N
period NN N
of IN N
time NN N
, , N
fall VB N
asleep RB N
significantly RB N
faster RBR N
, , N
or CC N
wake VB N
less JJR N
often RB N
. . N

However RB N
, , N
the DT N
weighted JJ i
blanket NN i
was VBD N
favored VBN N
by IN N
children NNS N
and CC N
parents NNS N
, , N
and CC N
blankets NNS N
were VBD N
well RB o
tolerated VBN o
over IN N
this DT N
period NN N
. . N

-DOCSTART- -3812946- O O

Intravenous JJ i
regional JJ i
anaesthesia NN i
below IN N
the DT N
knee NN N
. . N

A DT N
cross-over JJ N
study NN N
with IN N
prilocaine NN i
in IN p
volunteers NNS p
. . p

The DT N
quality NN N
of IN N
anaesthesia NN N
provided VBN N
by IN N
three CD N
dosages NNS N
of IN N
prilocaine NN i
, , N
40 CD N
ml VBD N
0.5 CD N
% NN N
, , N
20 CD N
ml VBD N
1 CD N
% NN N
, , N
or CC N
40 CD N
ml JJ N
1 CD N
% NN N
, , N
administered VBN N
in IN N
random NN N
order NN N
, , N
for IN N
intravenous JJ N
regional JJ N
anaesthesia NN N
of IN N
the DT N
lower JJR N
extremity NN N
below IN N
the DT N
knee NN N
was VBD N
compared VBN N
in IN N
six CD p
volunteers NNS p
. . p

Limited JJ N
sensory NN N
blockade NN N
was VBD N
achieved VBN N
in IN N
the DT N
groups NNS N
with IN N
40 CD N
ml NNS N
0.5 CD N
% NN N
and CC N
20 CD N
ml NNS N
1 CD N
% NN N
during IN N
the DT N
30-minute JJ N
test NN N
period NN N
. . N

One CD N
subject NN N
was VBD N
not RB N
fully RB N
anaesthetised VBN N
with IN N
any DT N
of IN N
the DT N
dosages NNS N
used VBN N
. . N

Recovery NNP o
was VBD o
rapid JJ o
( ( N
mean JJ N
12-13 CD N
minutes NNS N
) ) N
in IN N
these DT N
two CD N
groups NNS N
. . N

In IN N
two CD N
subjects NNS N
given VBN N
40 CD N
ml NN N
of IN N
1 CD N
% NN N
, , N
complete JJ o
recovery NN o
took VBD N
90 CD N
minutes NNS N
. . N

At IN N
30 CD N
minutes NNS N
, , N
the DT N
degree NN o
of IN o
flexion NN o
remaining VBG o
in IN o
the DT o
great JJ o
toe NN o
( ( N
control VB N
100 CD N
% NN N
) ) N
was VBD N
4 CD N
% NN N
in IN N
the DT N
groups NNS N
who WP N
received VBD N
40 CD N
ml NN N
of IN N
0.5 CD N
% NN N
and CC N
1 CD N
% NN N
, , N
but CC N
34 CD N
% NN N
in IN N
those DT N
who WP N
received VBD N
20 CD N
ml NN N
of IN N
1 CD N
% NN N
respectively RB N
. . N

Full NNP o
motor NN o
recovery NN o
was VBD N
achieved VBN N
in IN N
8-9 JJ N
minutes NNS N
. . N

Five CD N
of IN N
six CD N
volunteers NNS N
who WP N
received VBD N
the DT N
400-mg JJ N
dose NN N
experienced VBD N
subjective JJ o
signs NNS o
of IN o
central JJ o
nervous JJ o
system NN o
side NN o
effects NNS o
when WRB N
the DT N
cuff NN N
was VBD N
released VBN N
. . N

In IN N
this DT N
group NN N
, , N
the DT N
mean JJ o
plasma JJ o
level NN o
of IN N
prilocaine NN i
at IN N
2 CD N
minutes NNS N
was VBD N
1.22 CD N
micrograms/ml NN N
, , N
maximum JJ N
2.12 CD N
micrograms/ml NN N
. . N

In IN N
a DT N
radiological JJ N
examination NN N
, , N
no DT o
leak NN o
of IN o
contrast NN o
medium NN o
under IN o
the DT o
tourniquet NN o
cuff NN o
( ( o
300 CD o
mmHg NN o
) ) o
was VBD N
detected VBN N
. . N

The DT N
development NN N
of IN N
anaesthesia NN N
was VBD N
fastest JJS o
following VBG N
the DT N
largest JJS N
dose NN N
, , N
but CC N
the DT N
large JJ o
number NN o
of IN o
central JJ o
side NN o
effects NNS o
makes VBZ N
that IN N
dosage NN N
less RBR o
suitable JJ o
for IN o
clinical JJ o
work NN o
. . o

-DOCSTART- -20305865- O O

Short-term JJ N
effects NNS N
of IN N
systemic JJ N
antibiotics NNS i
during IN N
periodontal JJ p
healing NN p
. . p

OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
short-term JJ N
effects NNS o
of IN N
nonsurgical JJ p
therapy NN p
( ( p
scaling VBG p
and CC p
root NN p
planing NN p
, , p
SRP NNP p
) ) p
on IN p
the DT p
subgingival NN p
microbiota NN p
in IN p
chronic NN p
( ( p
CP NNP p
) ) p
and CC p
aggressive JJ p
( ( p
AP NNP p
) ) p
periodontal JJ p
disease NN p
. . p

METHOD NNP N
AND CC N
MATERIALS NNP N
Ninety-seven NNP p
CP NNP p
and CC p
AP NNP p
subjects NNS p
underwent JJ p
full-mouth JJ p
SRP NNP p
on IN p
2 CD p
consecutive JJ p
days NNS p
. . p

AP JJ N
patients NNS N
were VBD N
randomly RB i
assigned VBN i
to TO i
either DT i
receive JJ i
systemic JJ i
metronidazole NN i
plus CC i
amoxicillin NN i
( ( i
AP+AB NNP i
) ) i
or CC i
were VBD i
treated VBN i
mechanically RB i
alone RB i
( ( i
AP NNP i
) ) i
. . i

Pathogens NNS N
were VBD N
identified VBN i
with IN i
16S CD o
rRNA NNS o
oligodeoxynucleotide JJ o
probes NNS o
and CC o
dot-blot JJ o
hybridization NN o
before IN i
and CC i
at IN i
days NNS i
2 CD i
, , i
3 CD i
, , i
4 CD i
, , i
7 CD i
, , i
10 CD i
, , i
and CC i
21 CD i
of IN i
healing VBG i
. . i

CP JJ N
subjects NNS N
were VBD N
treated VBN N
by IN N
scaling VBG N
and CC N
root JJ N
planing NN N
along IN N
with IN N
placebo JJ i
tablets NNS i
. . i

RESULTS NNP N
Initially NNP N
, , N
AP NNP o
cell NN o
counts NNS o
were VBD N
69.9- JJ N
( ( N
Porphyromonas NNP N
gingivalis NN N
) ) N
, , N
10.2- JJ N
( ( N
Aggregatibacter NNP N
actinomycetemcomitans NNS N
) ) N
, , N
5.7- JJ N
( ( N
Tannerella NNP N
forsythia NN N
) ) N
, , N
and CC N
3.3-fold JJ N
( ( N
Prevotella NNP N
intermedia NN N
) ) N
enhanced VBD N
compared VBN N
to TO N
CP NNP o
cell NN o
counts NNS o
. . o

Following VBG N
SRP NNP N
, , N
immediate JJ N
elimination NN N
occurred VBD N
in IN N
single JJ N
individuals NNS N
of IN N
all DT N
three CD N
treatment NN N
groups NNS N
at IN N
day NN N
2 CD N
. . N

After IN N
SRP NNP o
plus CC o
antibiotic JJ o
therapy NN o
( ( N
AP+AB NNP N
) ) N
, , N
the DT N
prevalence NN N
scores NNS N
dropped VBD N
beyond IN N
the DT N
levels NNS N
of IN N
AP NNP o
and CC o
CP NNP o
, , N
beginning VBG N
at IN N
day NN N
7 CD N
, , N
and CC N
remained VBD N
low JJ N
until IN N
day NN N
21 CD N
( ( N
P NNP N
=or NNP N
< NNP N
.05 NNP N
) ) N
. . N

Clinical JJ o
healing VBG o
statistically RB N
benefited VBN N
from IN N
SRP NNP N
with IN N
no DT N
differences NNS N
among IN N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
Nonsurgical NNP N
therapy NN N
resulted VBD N
in IN N
both DT N
a DT N
suppression NN N
and CC N
early JJ N
elimination NN N
of IN N
single JJ o
taxa NN o
immediately RB N
after IN N
completion NN N
of IN N
active JJ N
treatment NN N
. . N

Systemic NNP N
antibiotics NNS N
significantly RB N
accelerate VBP N
the DT N
suppression NN N
of IN N
the DT N
periodontal JJ o
microflora NN o
, , N
but CC N
have VBP N
limited VBN N
effect NN N
on IN N
the DT N
elimination NN o
of IN o
target NN o
isolates NNS o
during IN N
healing NN N
. . N

-DOCSTART- -10735900- O O

Use NNP N
of IN N
recombinant JJ i
human JJ i
granulocyte NN i
colony-stimulating NN i
factor NN i
to TO N
increase VB N
chemotherapy JJ i
dose-intensity NN N
: : N
a DT N
randomized JJ N
trial NN N
in IN N
very RB p
high-risk JJ p
childhood NN p
acute NN p
lymphoblastic JJ p
leukemia NN p
. . p

PURPOSE NNP N
To TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
recombinant JJ i
human JJ i
granulocyte NN i
colony-stimulating NN i
factor NN i
( ( i
[ JJ i
G-CSF NNP i
] NNP i
lenogastrim NN i
) ) i
can MD N
increase VB N
the DT N
chemotherapy JJ N
dose-intensity NN N
( ( N
CDI NNP N
) ) N
delivered VBD N
during IN N
consolidation NN i
chemotherapy NN i
of IN N
childhood NN p
acute NN p
lymphoblastic JJ p
leukemia NN p
( ( p
ALL DT p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Sixty-seven NNP p
children NNS p
with IN p
very RB p
high-risk JJ p
ALL NNP p
were VBD N
randomized VBN N
( ( N
slow JJ N
early JJ N
response NN N
to TO N
therapy VB N
, , N
55 CD N
patients NNS N
; : N
translocation NN N
t NN N
( ( N
9 CD N
; : N
22 CD N
) ) N
or CC N
t NN N
( ( N
4 CD N
; : N
11 CD N
) ) N
, , N
12 CD N
patients NNS N
) ) N
. . N

Consolidation NNP N
consisted VBD N
of IN N
six CD N
courses NNS N
of IN N
chemotherapy NN i
; : i
the DT N
first JJ N
, , N
third JJ N
, , N
and CC N
fifth JJ N
courses NNS N
were VBD N
a DT N
combination NN i
of IN i
high-dose JJ i
cytarabine NN i
, , i
etoposide RB i
, , i
and CC i
dexamethasone NN i
( ( i
R3 NNP i
) ) i
, , N
whereas VBD N
the DT N
second JJ N
, , N
fourth JJ N
, , N
and CC N
sixth JJ N
courses NNS N
included VBD N
vincristine NN i
, , i
prednisone NN i
, , i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
methotrexate NN i
( ( i
COPADM NNP i
) ) i
. . i

G-CSF NNP i
was VBD N
given VBN N
after IN N
each DT N
course NN N
, , N
and CC N
the DT N
next JJ N
scheduled JJ N
course NN N
was VBD N
started VBN N
as RB N
soon RB N
as IN N
neutrophil JJ N
count NN N
was VBD N
> JJ N
1 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
and CC N
platelet NN N
count NN N
was VBD N
> JJ N
100 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
. . N

CDI NNP o
was VBD N
calculated VBN N
using VBG N
the DT N
interval NN N
from IN N
day NN N
1 CD N
of IN N
the DT N
first JJ N
course NN N
to TO N
hematologic VB N
recovery NN N
after IN N
the DT N
fifth JJ N
course NN N
( ( N
100 CD N
% NN N
CDI NNP N
= NNP N
105-day JJ N
interval NN N
) ) N
. . N

RESULTS NNP N
CDI NNP o
was VBD N
significantly RB N
increased VBN o
in IN N
the DT N
G-CSF NNP i
group NN N
compared VBN N
with IN N
the DT N
non-G-CSF JJ i
group NN N
( ( N
mean JJ N
+/- JJ N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
105 CD N
+/- JJ N
5 CD N
% NN N
v JJ N
91 CD N
+/- JJ N
4 CD N
% NN N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

This DT N
higher JJR o
intensity NN o
was VBD N
a DT N
result NN N
of IN N
shorter JJR N
post-R3 NN o
intervals NNS o
in IN N
the DT N
G-CSF NNP i
group NN N
, , N
whereas IN N
the DT N
post-COPADM JJ i
intervals NNS N
were VBD N
not RB N
statistically RB N
reduced VBN N
. . N

After IN N
the DT N
R3 NNP N
courses NNS N
, , N
the DT N
number NN o
of IN o
days NNS o
with IN o
fever NN o
and CC o
intravenous JJ o
antibiotics NNS o
and CC o
duration NN o
of IN o
hospitalization NN o
were VBD o
significantly RB o
decreased VBN o
by IN N
G-CSF NNP i
, , N
whereas JJ N
reductions NNS o
observed VBD o
after IN o
COPADM NNP o
were VBD o
not RB o
statistically RB o
significant JJ o
. . o

Duration NN o
of IN o
granulocytopenia NN o
was VBD o
reduced VBN o
in IN N
the DT N
G-CSF NNP i
group NN N
, , N
but CC N
thrombocytopenia NN o
was VBD o
prolonged VBN o
, , N
and CC N
the DT N
number NN o
of IN o
platelet NN o
transfusions NNS o
was VBD o
increased VBN o
. . o

Finally RB N
, , N
the DT N
3-year JJ N
probability NN N
of IN N
event-free JJ o
survival NN o
was VBD N
not RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
G-CSF NNP i
can MD N
increase VB N
CDI NNP N
in IN N
high-risk JJ p
childhood NN p
ALL NNP p
. . N

Its PRP$ N
effects NNS N
depend VBP N
on IN N
the DT N
chemotherapy NN N
regimen NNS N
given VBN N
before IN N
G-CSF NNP i
administration NN i
. . i

In IN N
our PRP$ N
study NN N
, , N
a DT N
higher JJR N
CDI NNP N
did VBD N
not RB N
improve VB N
disease NN N
control NN N
. . N

-DOCSTART- -16940738- O O

A DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
oral JJ N
misoprostol NN i
and CC N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ p
stage NN p
of IN p
labor NN p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ N
misoprostol NN N
400 CD N
mug NN N
with IN N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ N
stage NN N
of IN N
labor NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
conducted VBN N
in IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
. . N

Three CD p
hundred VBD p
and CC p
fifty-five JJ p
women NNS p
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ i
misoprostol NN i
400 CD i
mug NN i
or CC i
intramuscular JJ i
syntometrine NN i
in IN N
the DT N
third JJ p
stage NN p
of IN p
labor NN p
were VBD N
studied VBN N
. . N

The DT N
change NN N
in IN N
hemoglobin JJ o
level NN o
from IN N
before IN N
to TO N
48 CD N
h NN N
after IN N
delivery NN N
, , N
use NN N
of IN N
additional JJ N
oxytocics NNS N
and CC N
treatment NN N
related JJ N
side NN N
effects NNS N
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
the DT N
change NN N
in IN N
hemoglobin JJ o
level NN o
and CC o
mean JJ o
blood NN o
loss NN o
. . o

The DT N
incidence NN N
of IN N
shivering NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
misoprostol NN i
group NN N
whilst VBD N
that IN N
of IN N
vomiting NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
syntometrine NN i
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
nausea NN o
, , o
headache NN o
, , o
diarrhea NN o
and CC o
pyrexia NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Orally RB N
administered VBD N
misoprostol NN i
at IN N
a DT N
dose NN N
of IN N
400 CD N
mug NN N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
in IN N
preventing VBG N
post-partum JJ N
blood NN o
loss NN o
, , N
as IN N
measured VBN N
by IN N
the DT N
peri-partum JJ N
change NN N
in IN N
hemoglobin JJ o
level NN o
and CC N
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
side NN N
effects NNS N
. . N

-DOCSTART- -20630604- O O

Effect NN N
of IN N
explicit JJ i
instruction NN i
on IN i
Japanese JJ i
Verbal NNP i
Learning NNP i
Test NNP i
in IN N
schizophrenia NN p
patients NNS p
. . p

After IN N
random JJ N
assignment NN N
of IN N
20 CD p
schizophrenia NN p
patients NNS p
to TO N
either DT N
an DT N
explicit NN i
or CC i
normal JJ i
instruction NN i
group NN N
, , N
the DT N
Japanese JJ i
Verbal NNP i
Learning NNP i
Test NNP i
was VBD N
administered VBN N
to TO N
them PRP N
. . N

Results VB N
reveal NN N
that IN N
explicit JJ N
instruction NN N
group NN N
patients NNS N
demonstrated VBD N
more RBR N
improved JJ o
memory NN o
performance NN o
using VBG N
semantic JJ N
clustering NN N
, , N
suggesting VBG N
that IN N
explicit NN N
and CC N
direct JJ N
teaching NN N
facilitates VBZ N
patients NNS N
' POS N
learning NN N
of IN N
information NN N
. . N

-DOCSTART- -21667200- O O

Design NN N
and CC N
subject JJ N
characteristics NNS N
in IN N
the DT N
federally-funded JJ N
citalopram NN i
trial NN N
in IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

The DT N
Studies NNPS N
to TO N
Advance NNP N
Autism NNP N
Research NNP N
and CC N
Treatment NNP N
Network NNP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
with IN N
citalopram NN i
in IN N
children NNS p
with IN p
Pervasive NNP p
developmental NN p
disorders NNS p
( ( p
PDDs NNP p
) ) p
. . p

We PRP N
present VBD N
the DT N
rationale NN N
, , N
design NN N
and CC N
sample JJ N
characteristics NNS N
of IN N
the DT N
citalopram JJ i
trial NN N
. . N

Subjects NNS p
( ( p
128 CD p
boys NNS p
, , p
21 CD p
girls NNS p
) ) p
had VBD p
a DT p
mean JJ p
age NN p
of IN p
9.3 CD p
( ( p
?3.12 NN p
) ) p
years NNS p
; : p
132 CD p
( ( p
88.6 CD p
% NN p
) ) p
were VBD p
diagnosed VBN p
with IN p
autistic JJ p
disorder NN p
( ( p
4.7 CD p
% NN p
with IN p
Asperger NNP p
's POS p
Disorder NNP p
; : p
6.7 CD p
% NN p
with IN p
PDD-not NNP p
otherwise RB p
specified VBD p
) ) p
. . p

Less JJR p
than IN p
half NN p
of IN p
the DT p
subjects NNS p
were VBD o
intellectually RB o
disabled VBN o
; : o
117 CD p
( ( p
78.5 CD p
% NN p
) ) p
were VBD p
rated VBN p
Moderate NNP p
or CC p
Marked VBN p
on IN p
the DT o
Clinical NNP o
Global NNP o
Impression NNP o
for IN o
Severity NNP o
. . o

Study NNP N
measures NNS N
were VBD N
similar JJ N
to TO N
previous JJ N
Research NNP N
Units NNP N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
trials NNS N
. . N

Subjects NNS p
in IN p
this DT p
trial NN p
were VBD p
slightly RB p
older JJR p
and CC p
more RBR p
likely JJ p
to TO p
have VB p
complaints NNS p
of IN o
repetitive JJ o
behavior NN o
than IN N
participants NNS N
in IN N
RUPP NNP N
trials NNS N
. . N

-DOCSTART- -16926619- O O

Children NNP N
's POS N
Yale-Brown JJ N
Obsessive NNP N
Compulsive NNP N
Scale NNP N
modified VBD N
for IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
psychometric JJ N
properties NNS N
of IN N
the DT N
Children NNP i
's POS i
Yale-Brown JJ i
Obsessive NNP i
Compulsive NNP i
Scales NNP i
( ( i
CYBOCS NNP i
) ) i
modified VBD i
for IN i
pervasive JJ i
developmental NN i
disorders NNS i
( ( i
PDDs NNP i
) ) i
. . i

METHOD NNP N
Raters NNPS N
from IN N
five CD N
Research NNP N
Units NNS N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
( ( N
RUPP NNP N
) ) N
Autism NNP N
Network NNP N
were VBD N
trained VBN N
to TO N
reliability NN N
. . N

The DT N
modified JJ N
scale NN N
( ( i
CYBOCS-PDD NNP i
) ) i
, , N
which WDT N
contains VBZ N
only RB N
the DT N
five CD i
Compulsion NNP i
severity NN i
items NNS i
( ( N
range VB N
0-20 NN N
) ) N
, , N
was VBD N
administered VBN p
to TO p
172 CD p
medication-free JJ p
children NNS p
( ( p
mean JJ p
8.2 CD p
+/- JJ p
2.6 CD p
years NNS p
) ) p
with IN p
PDD NNP p
( ( p
autistic JJ p
disorder NN p
, , p
n JJ p
= VBP p
152 CD p
; : p
Asperger NNP p
's POS p
disorder NN p
, , p
n JJ p
= VBP p
6 CD p
; : p
PDD NNP p
not RB p
otherwise RB p
specified VBN p
, , p
n JJ p
= NNP p
14 CD p
) ) p
participating NN p
in IN p
RUPP NNP p
clinical JJ p
trials NNS p
. . p

Reliability NNP o
was VBD N
assessed VBN N
by IN N
intraclass NN N
correlation NN N
coefficient NN N
( ( N
ICC NNP N
) ) N
and CC N
internal JJ N
consistency NN N
by IN N
Cronbach NNP N
's POS N
alpha JJ N
coefficient NN N
. . N

Correlations NNS N
with IN N
ratings NNS N
of IN N
repetitive JJ N
behavior NN N
and CC N
disruptive JJ N
behavior NN N
were VBD N
examined VBN N
for IN N
validity NN N
. . N

RESULTS NNP N
Eleven NNP N
raters NNS N
showed VBD N
excellent JJ N
reliability NN o
( ( N
ICC NNP N
= NNP N
0.97 CD N
) ) N
. . N

The DT N
mean JJ o
CYBOCS NNP o
score NN o
was VBD N
14.4 CD N
( ( N
+/- JJ N
3.86 CD N
) ) N
with IN N
excellent JJ N
internal JJ o
consistency NN o
( ( N
alpha JJ N
= NNP N
.85 NNP N
) ) N
. . N

Correlations NNS N
with IN N
other JJ N
measures NNS N
of IN N
repetitive JJ N
behavior NN N
ranged VBD N
from IN N
r NN N
= $ N
0.11 CD N
to TO N
r VB N
= JJ N
0.28 CD N
and CC N
were VBD N
similar JJ N
to TO N
correlations NNS N
with IN N
measures NNS o
of IN o
irritability NN o
( ( N
r JJ N
= NNP N
0.24 CD N
) ) N
and CC N
hyperactivity NN o
( ( N
r JJ N
= NNP N
0.25 CD N
) ) N
. . N

Children NNP p
with IN p
higher JJR p
scores NNS p
on IN N
the DT N
CYBOCS-PDD NNP N
had VBD N
higher JJR N
levels NNS N
of IN N
maladaptive JJ o
behaviors NNS o
and CC o
lower JJR o
adaptive JJ o
functioning NN o
. . o

CONCLUSIONS VB N
The DT N
five-item JJ N
CYBOCS-PDD NNP N
is VBZ N
reliable JJ N
, , N
distinct JJ N
from IN N
other JJ N
measures NNS N
of IN N
repetitive JJ N
behavior NN N
, , N
and CC N
sensitive JJ N
to TO N
change VB N
. . N

-DOCSTART- -21639806- O O

Exemestane NN i
for IN N
breast-cancer JJ p
prevention NN p
in IN p
postmenopausal JJ p
women NNS p
. . p

BACKGROUND NNP N
Tamoxifen NNP N
and CC N
raloxifene NN N
have VBP N
limited VBN N
patient JJ N
acceptance NN N
for IN N
primary JJ N
prevention NN N
of IN N
breast NN N
cancer NN N
. . N

Aromatase NNP N
inhibitors NNS N
prevent VBP N
more JJR N
contralateral JJ N
breast NN N
cancers NNS N
and CC N
cause NN N
fewer JJR N
side NN N
effects NNS N
than IN N
tamoxifen NN N
in IN N
patients NNS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
. . p

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
trial NN N
of IN N
exemestane NN i
designed VBN N
to TO N
detect VB N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN N
in IN N
invasive JJ N
breast NN N
cancer NN N
, , N
eligible JJ p
postmenopausal NN p
women NNS p
35 CD p
years NNS p
of IN p
age NN p
or CC p
older JJR p
had VBD p
at IN p
least JJS p
one CD p
of IN p
the DT p
following JJ p
risk NN p
factors NNS p
: : p
60 CD p
years NNS p
of IN p
age NN p
or CC p
older JJR p
; : p
Gail NNP p
5-year JJ p
risk NN p
score NN p
greater JJR p
than IN p
1.66 CD p
% NN p
( ( p
chances NNS p
in IN p
100 CD p
of IN p
invasive JJ p
breast NN p
cancer NN p
developing VBG p
within IN p
5 CD p
years NNS p
) ) p
; : p
prior JJ p
atypical JJ p
ductal NN p
or CC p
lobular JJ p
hyperplasia NN p
or CC p
lobular JJ p
carcinoma NN p
in IN p
situ NN p
; : p
or CC p
ductal JJ p
carcinoma NN p
in IN p
situ NN p
with IN p
mastectomy NN p
. . p

Toxic NNP o
effects NNS o
and CC o
health-related JJ o
and CC o
menopause-specific JJ o
qualities NNS o
of IN o
life NN o
were VBD N
measured VBN N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
4560 CD p
women NNS p
for IN p
whom WP p
the DT p
median JJ p
age NN p
was VBD p
62.5 CD p
years NNS p
and CC p
the DT p
median JJ o
Gail NNP o
risk NN o
score NN o
was VBD p
2.3 CD p
% NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
exemestane NN i
or CC i
placebo NN i
. . i

At IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
11 CD N
invasive JJ N
breast NN N
cancers NNS N
were VBD N
detected VBN N
in IN N
those DT N
given VBN N
exemestane NN i
and CC N
in IN N
32 CD N
of IN N
those DT N
given VBN N
placebo NNS i
, , N
with IN N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN o
in IN o
the DT o
annual JJ o
incidence NN o
of IN o
invasive JJ o
breast NN o
cancer NN o
( ( N
0.19 CD N
% NN N
vs. FW N
0.55 CD N
% NN N
; : N
hazard CC N
ratio NN N
, , N
0.35 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.18 CD N
to TO N
0.70 CD N
; : N
P=0.002 NNP N
) ) N
. . N

The DT N
annual JJ o
incidence NN o
of IN o
invasive JJ o
plus CC o
noninvasive JJ o
( ( o
ductal JJ o
carcinoma NN o
in IN o
situ NN o
) ) o
breast NN o
cancers NNS o
was VBD N
0.35 CD N
% NN N
on IN N
exemestane NN N
and CC N
0.77 CD N
% NN N
on IN N
placebo NN i
( ( N
hazard JJ N
ratio NN N
, , N
0.47 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.79 CD N
; : N
P=0.004 NNP N
) ) N
. . N

Adverse JJ o
events NNS o
occurred VBD N
in IN N
88 CD N
% NN N
of IN N
the DT N
exemestane NN N
group NN N
and CC N
85 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
( ( N
P=0.003 NNP N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
skeletal JJ o
fractures NNS o
, , o
cardiovascular JJ o
events NNS o
, , o
other JJ o
cancers NNS o
, , o
or CC o
treatment-related JJ o
deaths NNS o
. . o

Minimal JJ N
quality-of-life JJ o
differences NNS N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Exemestane NNP i
significantly RB N
reduced VBD N
invasive JJ p
breast NN p
cancers NNS p
in IN p
postmenopausal JJ p
women NNS p
who WP p
were VBD p
at IN p
moderately RB p
increased VBN p
risk NN p
for IN p
breast NN p
cancer NN p
. . p

During IN N
a DT N
median JJ N
follow-up JJ N
period NN N
of IN N
3 CD N
years NNS N
, , N
exemestane NN N
was VBD N
associated VBN N
with IN N
no DT N
serious JJ N
toxic NN N
effects NNS N
and CC N
only RB N
minimal JJ N
changes NNS N
in IN N
health-related JJ N
quality NN N
of IN N
life NN N
. . N

( ( N
Funded VBN N
by IN N
Pfizer NNP N
and CC N
others NNS N
; : N
NCIC NNP N
CTG NNP N
MAP.3 NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00083174 NNP N
. . N

) ) N
. . N

-DOCSTART- -2869714- O O

[ JJ N
Potentiation NNP N
of IN N
the DT N
effect NN N
of IN N
non-depolarizing JJ N
muscle NN p
relaxants NNS p
by IN N
acylaminopenicillins NNS i
. . i

Studies NNS N
on IN N
the DT N
example NN N
of IN N
vecuronium NN N
] NN N
. . N

In IN N
a DT N
prospective JJ N
controlled VBN N
clinical JJ N
study NN N
interactions NNS N
between IN N
nondepolarizing VBG i
muscle NN i
relaxants NNS i
and CC i
acylaminopenicillins NNS i
were VBD N
investigated VBN N
electromyographically RB N
. . N

Six CD p
patients NNS p
in IN p
each DT p
group NN p
received VBD N
either RB N
apalcillin JJ i
, , i
azlocillin NN i
, , i
mezlocillin NN i
or CC i
piperacillin NN i
during IN N
the DT N
operation NN N
. . N

Muscle NNP o
relaxation NN o
was VBD N
maintained VBN N
using VBG N
the DT N
short JJ N
acting VBG N
nondepolarizing VBG N
relaxant JJ N
vecuronium NN N
, , N
which WDT N
shows VBZ N
no DT N
cumulative JJ N
effect NN N
within IN N
clinical JJ N
dosages NNS N
. . N

The DT N
intra-individual JJ N
comparison NN N
with IN N
the DT N
control NN N
period NN N
( ( N
100 CD N
% NN N
) ) N
showed VBD N
a DT N
significant JJ N
prolongation NN o
of IN o
the DT o
duration NN o
of IN o
action NN o
after IN N
a DT N
fixed JJ N
dose NN N
of IN N
vecuronium NN N
. . N

The DT N
mean JJ o
increase NN o
was VBD N
+26 JJ N
% NN N
following VBG N
apalcillin NN N
, , N
+46 CD N
% NN N
after IN N
piperacillin NN N
, , N
+38 CD N
% NN N
following VBG N
mezlocillin NN N
and CC N
+55 CD N
% NN N
following VBG N
azlocillin NN N
. . N

The DT N
shortest JJ o
time NN o
of IN N
the DT N
control NN N
periods NNS N
was VBD N
8.6 CD N
min NN N
and CC N
the DT N
maximum JJ N
time NN N
was VBD N
32.6 CD N
min NN N
. . N

We PRP N
also RB N
found VBD N
a DT N
significant JJ N
depression NN o
of IN N
the DT N
EMG-response NNP o
. . o

No NNP N
significant JJ N
differences NNS N
could MD N
be VB N
detected VBN N
between IN N
the DT N
four CD N
antibiotics NNS N
. . N

The DT N
method NN N
described VBN N
here RB N
has VBZ N
proven VBN N
to TO N
be VB N
sensitive JJ N
enough RB N
to TO N
detect VB N
clinically RB o
relevant JJ o
interactions NNS o
with IN N
muscle NN o
relaxants NNS o
. . o

As IN N
a DT N
result NN N
of IN N
our PRP$ N
study NN N
, , N
caution NN N
seems VBZ N
to TO N
be VB N
necessary JJ N
if IN N
acylaminopenicillins NNS i
are VBP N
administered VBN N
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
. . N

-DOCSTART- -16230665- O O

Incidence NN o
of IN o
puberty NN o
in IN N
beef NN p
heifers NNS p
fed VBP p
high- JJ i
or CC i
low-starch JJ i
diets NNS i
for IN p
different JJ p
periods NNS p
before IN p
breeding VBG p
. . p

Spring-born JJ p
Hereford NNP p
x NNP p
Angus NNP p
heifers NNS p
( ( p
n JJ p
= NNP p
206 CD p
) ) p
were VBD N
used VBN N
to TO N
determine VB N
effects NNS N
of IN N
energy NN i
supplementation NN i
programs NNS i
and CC i
amount NN i
of IN i
starch NN i
in IN N
the DT N
diet NN N
on IN N
incidence NN N
of IN N
puberty NN o
. . o

In IN N
Exp NNP N
. . N

1 CD N
, , N
heifers NNS p
( ( p
205 CD p
+/- JJ p
5 CD p
kg NN p
; : p
n CC p
= VB p
68 CD p
) ) p
grazing NN p
dormant JJ p
native JJ p
pasture NN p
were VBD N
fed VBN N
0.9 CD N
kg/d NNS N
( ( N
as-fed JJ N
basis NN N
) ) N
of IN N
a DT N
42 CD N
% NN N
CP NNP i
supplement NN i
from IN N
November NNP N
until IN N
February NNP N
14 CD N
. . N

Heifers NNS p
were VBD N
stratified VBN N
by IN N
weaning VBG N
weight NN o
and CC N
allotted VBD N
randomly RB N
to TO N
treatment NN N
before IN N
breeding VBG N
( ( N
May NNP N
to TO N
July NNP N
) ) N
. . N

Treatments NNS N
were VBD N
1 CD N
) ) N
0.9 CD N
kg NN N
( ( N
as-fed JJ N
basis NN N
) ) N
of IN N
a DT N
42 CD N
% NN N
CP NNP i
supplement/d NN i
and CC i
pasture NN i
( ( N
control NN N
) ) N
; : N
2 CD N
) ) N
a DT i
high-starch NN i
( ( i
HS NNP i
) ) i
diet NN i
( ( i
73 CD i
% NN i
corn NN N
; : N
53 CD N
% NN N
starch NN N
) ) N
fed NN N
in IN N
a DT N
drylot NN N
for IN N
60 CD N
d NN N
( ( N
HS-60 NNP N
) ) N
; : N
3 CD N
) ) N
a DT N
HS NNP i
diet JJ i
fed NN i
in IN i
drylot NN i
for IN N
30 CD N
d NN N
( ( N
HS-30 NNP N
) ) N
; : N
or CC N
4 CD N
) ) N
a DT i
low-starch NN i
( ( i
LS NNP i
) ) i
diet NN i
( ( N
49 CD N
% NN N
corn NN N
; : N
37 CD N
% NN N
starch NN N
) ) N
self-fed NN i
on IN i
pasture NN i
for IN N
30 CD N
d NN N
( ( N
LS-30 NNP N
) ) N
. . N

The DT N
HS-60 JJ i
and CC N
HS-30 JJ i
heifers NNS N
were VBD N
limited-fed JJ N
to TO N
gain VB N
0.9 CD N
kg/d NN N
, , N
and CC N
the DT N
LS-30 JJ i
heifers NNS N
had VBD N
ad NN N
libitum NN N
access NN N
to TO N
the DT N
diet JJ N
. . N

High-starch-60 JJ i
and CC N
LS-30 JJ N
heifers NNS N
were VBD N
heavier JJR o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
control NN N
and CC N
HS-30 JJ N
heifers NNS N
at IN N
the DT N
beginning NN N
of IN N
the DT N
breeding NN N
season NN N
. . N

Thirty-one CD N
, , N
25 CD N
, , N
and CC N
26 CD N
% NN N
more JJR N
HS-60 JJ N
heifers NNS N
were VBD N
pubertal JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
on IN N
May NNP N
1 CD N
compared VBN N
with IN N
LS-30 NNP N
, , N
HS-30 NNP N
, , N
and CC N
control NN N
heifers NNS N
, , N
respectively RB N
. . N

At IN N
puberty NN o
, , N
HS-60 JJ N
heifers NNS N
were VBD N
24 CD N
and CC N
22 CD N
d NN N
younger JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
LS-30 NNP N
and CC N
control NN N
heifers NNS N
, , N
and CC N
31 CD N
kg NNS N
lighter JJR N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
than IN N
LS-30 JJ N
heifers NNS N
. . N

In IN N
Exp NNP N
. . N

2 CD N
, , N
heifers NNS N
grazed VBD N
dormant JJ N
pasture NN N
and CC N
were VBD N
fed VBN N
0.9 CD N
kg NNS N
( ( N
as-fed JJ N
basis NN N
) ) N
of IN N
a DT N
42 CD i
% NN i
CP NNP i
supplement/d NN i
from IN N
weaning VBG N
in IN N
October NNP N
to TO N
late VB N
February NNP N
; : N
then RB N
heifers NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
treatments NNS N
for IN N
60 CD N
d NN N
before IN N
the DT N
breeding NN N
season NN N
. . N

In IN N
two CD N
years NNS N
, , N
control NN N
heifers NNS N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
grazed VBN N
pasture NN N
and CC N
received VBD N
0.9 CD N
kg NN N
of IN N
SBM NNP i
supplement/d NN i
; : i
LS NNP N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
heifers NNS N
were VBD N
self-fed JJ N
a DT N
distiller NN i
's POS i
grain NN i
and CC i
soybean JJ i
hull-based JJ i
diet NN i
in IN N
drylot NN N
; : N
and CC N
HS NNP N
heifers NNS N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
were VBD N
limited-fed JJ i
a DT i
corn-based JJ i
diet NN i
in IN N
drylot NN N
. . N

During IN N
treatment NN N
, , N
HS NNP i
and CC p
LS NNP i
heifers NNS p
had VBD N
greater JJR N
weight NN o
gains NNS o
than IN N
control NN N
heifers NNS N
. . N

Pubertal JJ o
BW NNP o
( ( N
313 CD N
+/- JJ N
6 CD N
kg NN N
) ) N
was VBD N
not RB N
influenced VBN N
by IN N
treatment NN N
, , N
but CC N
HS NNP p
and CC p
LS NNP p
heifers NNS p
were VBD N
younger JJR N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
than IN N
control NN N
heifers NNS N
at IN N
puberty NN N
. . N

During IN N
a DT N
60-d JJ N
breeding NN N
period NN N
, , N
the DT N
incidence NN o
of IN o
puberty NN o
was VBD N
greater JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
for IN N
HS NNP p
and CC p
LS NNP p
heifers NNS p
than IN N
for IN N
control NN N
heifers NNS N
and CC N
was VBD N
greater JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
HS NNP N
than IN N
in IN N
LS NNP N
heifers NNS N
in IN N
Year JJ N
1 CD N
. . N

Feeding VBG N
a DT N
LS NNP i
or CC i
a DT i
HS NNP i
diet NN i
for IN N
30 CD N
d NN N
before IN N
breeding NN N
may MD N
be VB N
inadequate JJ N
to TO N
stimulate VB N
puberty NN o
in IN N
beef NN N
heifers NNS p
, , N
but CC N
feeding VBG N
a DT N
diet JJ N
with IN N
a DT N
greater JJR N
amount NN N
of IN N
starch NN N
for IN N
60 CD N
d NN N
before IN N
breeding NN N
may MD N
increase VB N
the DT N
incidence NN o
of IN o
puberty NN o
during IN N
breeding NN N
of IN N
heifers NNS N
that WDT N
have VBP N
inadequate JJ N
yearling NN N
weight NN N
. . N

-DOCSTART- -3553277- O O

Comparison NNP N
of IN N
inhaled JJ i
albuterol NN i
powder NN i
and CC i
aerosol NN i
in IN N
asthma NN p
. . p

In IN N
this DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
comparing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
aerosolized JJ i
albuterol NN i
with IN i
the DT i
dry JJ i
powder NN i
formulation NN i
, , N
231 CD p
patients NNS p
with IN p
chronic JJ p
reversible JJ p
obstructive JJ p
airway NN p
disease NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
placebo NN i
albuterol NN i
aerosol NN i
followed VBD N
immediately RB N
by IN N
active JJ i
albuterol NN i
powder NN i
( ( N
200 CD N
micrograms NNS N
) ) N
or CC N
active JJ i
albuterol NN i
aerosol NN i
( ( N
two CD N
puffs NNS N
, , N
180 CD N
micrograms NNS N
) ) N
followed VBD N
immediately RB N
by IN N
placebo NN i
lactose JJ i
powder NN i
four CD N
times NNS N
a DT N
day NN N
for IN N
a DT N
period NN N
of IN N
12 CD N
weeks NNS N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
powder NN i
and CC N
aerosol JJ i
formulations NNS N
with IN N
respect NN N
to TO N
pulmonary JJ o
function NN o
, , o
length NN o
of IN o
time NN o
mean JJ o
FEV1 NNP o
remained VBD N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
15 CD N
% NN N
above IN N
baseline NN N
, , N
physicians NNS o
' POS o
assessments NNS o
of IN o
patients NNS o
' POS o
clinical JJ o
response NN o
, , N
or CC N
patients NNS o
' POS o
subjective JJ o
symptom NN o
scores NNS o
. . o

There EX N
were VBD N
also RB N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
in IN N
cardiovascular JJ o
effects NNS o
, , o
laboratory NN o
values NNS o
, , o
or CC o
adverse JJ o
events NNS o
. . o

Among IN N
patients NNS N
who WP N
expressed VBD N
a DT N
preference NN o
for IN o
one CD o
of IN o
the DT o
delivery NN o
systems NNS o
, , N
half NN p
preferred VBD p
using VBG p
the DT p
powder NN p
. . p

Results NNS N
of IN N
this DT N
study NN N
demonstrate NN N
that IN N
200 CD N
micrograms NNS N
of IN N
albuterol NN i
powder NN i
is VBZ N
as IN N
safe JJ N
and CC N
effective JJ N
as IN N
180 CD N
micrograms NNS N
of IN N
albuterol NN i
aerosol NN i
. . i

-DOCSTART- -16889080- O O

[ NN N
Pilot NNP N
results NNS N
of IN N
using VBG N
tamsulone-FS JJ i
in IN N
patients NNS p
with IN p
prostatic JJ p
adenoma NN p
according VBG N
to TO N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
multicenter NN p
comparative JJ N
trial NN N
] NN N
. . N

Tamsulone-FS NNP i
-- : i
a DT i
novel JJ i
Russian JJ i
alpha1A/D-adrenoblocker NN i
( ( i
Farm-Syntez NNP i
) ) i
-- : i
was VBD i
studied VBN N
in IN N
a DT N
randomized JJ N
multicenter NN N
comparative JJ N
trial NN N
in IN N
patients NNS p
with IN p
prostatic JJ p
adenoma NN p
. . p

Pilot NNP N
results NNS N
agreed VBD N
with IN N
other JJ N
trials NNS N
published VBN N
in IN N
the DT N
literature NN N
and CC N
demonstrated VBD N
tamsulone-FS JJ i
efficacy NN o
and CC o
safety NN o
for IN o
management NN o
of IN o
lower JJR o
urinary JJ o
tract NN o
symptoms NNS o
caused VBN N
by IN N
prostatic JJ N
adenoma NN N
. . N

The DT o
efficacy NN o
and CC o
safety NN o
of IN o
tamsulone-FS NN o
was VBD o
comparable JJ o
to TO o
those DT o
of IN o
omnik FW o
. . o

This DT N
drug NN N
can MD N
be VB N
recommended VBN N
for IN N
wide JJ N
clinical JJ N
practice NN N
in IN N
prostatic JJ o
adenoma NN o
. . o

It PRP N
is VBZ N
registered VBN N
by IN N
Roszdravnadzor NNP N
( ( N
certificate JJ N
N NNP N
LC-000859 NNP N
of IN N
03.11.2005 CD N
) ) N
and CC N
allowed VBN N
for IN N
production NN N
and CC N
sale NN N
. . N

-DOCSTART- -21206549- O O

The DT N
nightly RB N
use NN N
of IN N
sodium NN i
oxybate NN i
is VBZ N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
nocturnal JJ o
sleep JJ o
disruption NN o
: : o
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
in IN N
patients NNS p
with IN p
narcolepsy JJ p
. . p

OBJECTIVE VB N
To TO N
further RB N
explore VB N
the DT N
effects NNS N
of IN N
sodium NN i
oxybate NN i
( ( i
SXB NNP i
) ) i
administration NN N
on IN N
nocturnal JJ o
sleep NN o
in IN N
narcolepsy JJ p
patients NNS p
during IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study VBD N
conducted VBN N
with IN N
228 CD p
adult NN p
patients NNS p
with IN p
narcolepsy/cataplexy NNS p
in IN p
the DT p
United NNP p
States NNPS p
, , p
Canada NNP p
, , p
and CC p
Europe NNP p
. . p

METHOD NNP N
Patients NNPS N
were VBD N
withdrawn VBN i
from IN i
antidepressants NNS i
and CC i
sedative/hypnotics NNS i
, , N
and CC N
then RB N
randomized VBN N
to TO N
receive VB N
4.5 CD N
, , N
6 CD N
, , N
or CC N
9 CD N
g JJ N
SXB NNP N
or CC N
placebo VB i
nightly RB N
for IN N
8 CD N
weeks NNS N
. . N

Patients NNS N
receiving VBG p
6 CD p
and CC p
9 CD p
g/night NN p
doses NNS p
were VBD N
titrated VBN N
to TO N
their PRP$ N
final JJ N
dose NN N
in IN N
weekly JJ N
1.5 CD N
g NN N
increments NNS N
, , N
while IN N
patients NNS N
receiving VBG N
placebo NN i
were VBD N
randomized VBN N
to TO N
undergo VB N
a DT N
similar JJ N
mock NN N
dose NN N
titration NN N
. . N

The DT N
use NN N
of IN N
stimulant JJ N
therapy NN N
continued VBD N
unchanged JJ N
. . N

Changes NNS o
in IN o
sleep JJ o
architecture NN o
were VBD o
measured VBN o
using VBG o
centrally RB o
scored VBN o
nocturnal JJ o
polysomnograms NNS o
. . o

Daily JJ N
diaries NNS N
were VBD N
used VBN N
to TO N
record VB N
changes NNS o
in IN o
narcolepsy NN o
symptoms NNS o
and CC o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
Following VBG N
8 CD N
weeks NNS N
of IN N
SXB NNP N
treatment NN N
, , N
study NN N
patients NNS N
demonstrated VBD N
significant JJ N
dose-related JJ N
increases NNS N
in IN N
the DT N
duration NN o
of IN o
stage NN o
3 CD o
and CC o
4 CD o
sleep NN o
, , N
reaching VBG N
a DT N
median JJ N
increase NN N
of IN N
52.5 CD N
minutes NNS N
in IN N
patients NNS N
receiving VBG N
9 CD N
g NN N
nightly RB N
. . N

Compared VBN N
to TO N
placebo-treated JJ N
patients NNS N
, , N
delta JJ o
power NN o
was VBD N
significantly RB N
increased VBN N
in IN N
all DT N
dose JJ N
groups NNS N
. . N

Stage NN o
1 CD o
sleep NN o
and CC o
the DT o
frequency NN o
of IN o
nocturnal JJ o
awakenings NNS o
were VBD N
each DT N
significantly RB N
decreased VBN N
at IN N
the DT N
6 CD N
and CC N
9 CD N
g/night NN N
doses NNS N
. . N

The DT N
changes NNS o
in IN o
nocturnal JJ o
sleep NN o
coincided VBD N
with IN N
significant JJ N
decreases NNS N
in IN N
the DT N
severity NN o
and CC o
frequency NN o
of IN o
narcolepsy NN o
symptoms NNS o
. . o

CONCLUSIONS VB N
The DT N
nightly JJ N
administration NN N
of IN N
SXB NNP N
to TO N
narcolepsy VB N
patients NNS N
significantly RB N
impacts VBZ N
measures NNS N
of IN N
slow JJ o
wave NN o
sleep NN o
, , o
wake VBP o
after IN o
sleep JJ o
onset NN o
, , o
awakenings NNS o
, , o
total JJ o
sleep JJ o
time NN o
, , o
and CC o
stage NN o
1 CD o
sleep NN o
in IN N
a DT N
dose-related JJ N
manner NN N
. . N

The DT N
frequency NN o
and CC o
severity NN o
of IN o
narcolepsy NN o
symptoms NNS o
decreased VBN N
with IN N
treatment NN N
. . N

-DOCSTART- -2319047- O O

Methylphenidate NNP i
and CC N
baseball NN N
playing NN N
in IN N
ADHD NNP p
children NNS p
: : p
who WP N
's VBZ N
on IN N
first JJ N
? . N
The DT N
effects NNS N
of IN N
0.3 CD i
and CC i
0.6 CD i
mg/kg NN i
methylphenidate NN i
were VBD N
analyzed VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
cross-over JJ N
study NN N
in IN N
which WDT N
17 CD p
boys NNS p
( ( p
ages IN p
7.8-9.9 CD p
years NNS p
) ) p
with IN p
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
played VBD N
in IN N
baseball NN N
games NNS N
. . N

Drug JJ N
effects NNS N
were VBD N
evaluated VBN N
on IN N
children NNS N
's POS N
attention NN o
during IN o
the DT o
game NN o
, , N
as IN N
indicated VBN N
by IN N
their PRP$ N
on-task JJ N
behavior NN N
on IN N
the DT N
field NN N
and CC N
their PRP$ N
ability NN o
to TO o
answer VB o
questions NNS o
about IN N
the DT N
status NN N
of IN N
the DT N
game NN N
at IN N
all DT N
times NNS N
. . N

Judgment NN o
during IN o
batting NN o
, , o
batting VBG o
skill NN o
during IN o
the DT o
game NN o
, , o
and CC o
performance NN o
on IN o
skill NN o
drills NNS o
prior RB o
to TO o
the DT o
game NN o
were VBD N
also RB N
assessed VBN N
as IN N
a DT N
function NN N
of IN N
medication NN N
. . N

Results NNS N
revealed VBD N
that IN N
methylphenidate NN i
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
attending VBG N
during IN N
the DT N
game NN N
. . N

-DOCSTART- -15200727- O O

Patterning VBG N
of IN N
pain NN o
and CC o
power NN o
with IN N
guided JJ i
imagery NN i
. . i

Using VBG N
Martha NNP N
Rogers NNP N
' POS N
science NN N
of IN N
unitary JJ N
human JJ N
beings NNS N
, , N
changes NNS N
in IN N
pain NN o
and CC o
power NN o
among IN N
42 CD p
patients NNS p
were VBD N
examined VBN N
in IN N
relation NN N
to TO N
the DT N
use NN N
of IN N
a DT N
guided JJ i
imagery NN i
modality NN i
. . i

Participants NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
treatment NN i
and CC i
control NN i
groups NNS i
and CC N
repeated VBD N
measures NNS N
MANCOVA NNP N
was VBD N
used VBN N
to TO N
detect VB N
differences NNS N
in IN N
pain NN o
and CC o
power NN o
over IN N
a DT i
4-day JJ i
period NN i
of IN i
time NN i
. . i

The DT N
treatment NN N
group NN N
's POS N
pain NN o
decreased VBD N
during IN N
the DT N
last JJ N
2 CD N
days NNS N
of IN N
the DT N
study NN N
. . N

No DT N
differences NNS N
in IN N
power NN o
emerged VBN N
. . N

Guided VBN i
imagery NN i
appeared VBD N
to TO N
have VB N
potential JJ N
as IN N
a DT N
useful JJ N
nursing NN p
modality NN p
for IN p
chronic JJ p
pain NN p
sufferers NNS p
. . p

-DOCSTART- -8623957- O O

Recovery NN N
profile NN N
after IN N
desflurane NN i
with IN i
or CC i
without IN i
ondansetron NNS i
compared VBN i
with IN i
propofol NN i
in IN N
patients NNS p
undergoing JJ p
outpatient JJ p
gynecological JJ i
laparoscopy NN i
. . i

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
combining VBG N
prophylactic JJ i
ondansetron NN i
( ( N
4 CD N
mg NN N
intravenously RB N
[ NNP N
IV NNP N
] NNP N
) ) N
to TO i
desflurane-based JJ i
anesthesia NN i
in IN N
90 CD p
ASA NNP p
grade NN p
I PRP p
or CC p
11 CD p
women NNS p
undergoing VBG p
outpatient JJ p
gynecological JJ i
laparoscopy NN i
. . i

Recovery NN N
after IN N
anesthesia NN N
, , N
with IN N
special JJ N
focus NN N
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
, , N
was VBD N
assessed VBN N
. . N

Control NNP N
groups NNS N
received VBD N
a DT N
similar JJ N
desflurane NN i
anesthetic NN i
( ( i
placebo NN i
) ) i
or CC i
a DT i
propofol-infusion-based JJ i
( ( i
active JJ i
control NN i
) ) i
anesthetic NN i
. . i

The DT N
study NN N
design NN N
was VBD N
randomized VBN N
, , N
controlled VBN N
, , N
and CC N
double-blind NN N
( ( N
regarding VBG N
ondansetron NN i
) ) i
and CC N
single-blind JJ N
( ( N
regarding VBG N
the DT N
anesthetic JJ N
technique NN N
) ) N
. . N

Early JJ N
recovery NN N
( ( N
eye NN N
opening NN N
, , N
orientation NN N
, , N
following VBG N
commands NNS N
, , N
sitting VBG N
) ) N
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

However RB N
, , N
overall JJ N
home NN o
readiness NN o
( ( N
toleration NN N
of IN N
oral JJ N
fluids NNS N
, , N
walking VBG N
, , N
pain NN N
tolerable JJ N
by IN N
oral JJ N
analgesics NNS N
, , N
no DT N
or CC N
only RB N
mild JJ N
nausea NN N
) ) N
was VBD N
achieved VBN N
faster RBR N
in IN N
the DT N
desflurane NN N
group NN N
receiving VBG N
ondansetron NN i
( ( N
109 CD N
[ RB N
21-937 JJ N
] NNP N
min NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
in IN N
the DT N
propofol NN N
group NN N
( ( N
110 CD N
[ RB N
33-642 JJ N
] NNP N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
when WRB N
compared VBN N
to TO N
the DT N
desflurane NN i
only RB N
group NN N
( ( N
372 CD N
[ RB N
45-723 JJ N
] NNP N
min NN N
) ) N
( ( N
median JJ N
[ NNP N
range NN N
] NN N
) ) N
. . N

The DT N
total JJ N
incidence NN N
of IN N
PONV NNP o
in IN N
the DT N
desflurane-only JJ i
group NN N
was VBD N
80 CD N
% NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
compared VBN N
to TO N
40 CD N
% NN N
and CC N
20 CD N
% NN N
in IN N
the DT N
desflurane NN i
group NN N
receiving VBG N
ondansetron NN N
and CC N
the DT N
propofol NN i
group NN N
, , N
respectively RB N
. . N

The DT N
postoperative JJ o
antiemetic JJ o
requirements NNS o
were VBD N
consistently RB N
and CC N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
higher JJR N
in IN N
the DT N
desflurane-only JJ i
group NN N
compared VBN N
to TO N
the DT N
other JJ N
two CD N
groups NNS N
. . N

Postoperative JJ o
sedation NN o
, , o
analgesic JJ o
requirements NNS o
, , o
and CC o
psychomotor NN o
recovery NN o
( ( N
assessed VBN N
by IN N
the DT N
Maddox NNP N
Wing NNP N
and CC N
the DT N
Digit NNP N
Symbol NNP N
Substitution NNP N
Tests NNP N
) ) N
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
in IN N
order NN N
to TO N
achieve VB N
a DT N
propofol-like JJ o
recovery NN o
profile NN o
in IN N
patients NNS N
with IN N
a DT N
high JJ N
likelihood NN N
of IN N
PONV NNP N
, , N
desflurane NN i
should MD N
be VB N
combined VBN N
with IN N
a DT N
potent JJ N
antiemetic JJ N
( ( N
e.g. JJ N
, , N
ondansetron NN N
) ) N
. . N

-DOCSTART- -22983407- O O

Randomized VBN N
trial NN N
of IN N
partial JJ i
vs. FW N
stepwise NN i
caries NNS p
removal NN N
: : N
3-year JJ N
follow-up NN N
. . N

This DT N
randomized JJ N
, , N
multicenter RB N
clinical JJ N
trial NN N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
2 CD N
treatments NNS N
for IN N
deep JJ p
caries NNS p
lesions NNS p
- : N
partial JJ i
caries NNS i
removal NN i
( ( i
PCR NNP i
) ) i
and CC i
stepwise JJ i
excavation NN i
( ( i
SW NNP i
) ) i
- : N
with IN N
respect NN N
to TO N
the DT N
primary JJ N
outcome NN N
of IN N
pulp NN N
vitality NN N
for IN N
a DT N
3-year JJ N
follow-up JJ N
period NN N
. . N

Inclusion NN p
criteria NNS p
were VBD p
as IN p
follows VBZ p
: : p
patients NNS p
with IN p
permanent JJ p
molars NNS p
presenting VBG p
deep JJ p
caries NNS p
lesions NNS p
( ( p
lesion NN p
affecting VBG p
? . p
1/2 CD p
of IN p
the DT p
dentin NN p
on IN p
radiographic JJ p
examination NN p
) ) p
, , p
positive JJ p
response NN p
to TO p
a DT p
cold JJ p
test NN p
, , p
absence NN p
of IN p
spontaneous JJ p
pain NN p
, , p
negative JJ p
sensitivity NN p
to TO p
percussion NN p
, , p
and CC p
absence NN p
of IN p
periapical JJ p
lesions NNS p
( ( p
radiographic JJ p
examination NN p
) ) p
. . p

Teeth NNP N
randomly RB N
assigned VBD N
to TO N
PCR NNP N
( ( N
test NN N
) ) N
received VBD N
incomplete JJ N
caries NNS N
removal NN N
and CC N
filling NN N
in IN N
a DT N
single JJ N
session NN N
. . N

Outcome NNP N
success NN N
was VBD N
evaluated VBN N
by IN N
assessment NN N
of IN N
pulp NN o
vitality NN o
, , o
determined VBN N
by IN N
pulp NN N
sensitivity NN N
to TO N
a DT N
cold JJ N
test NN N
and CC N
the DT N
absence NN N
of IN N
periapical JJ N
lesions NNS N
. . N

Data NNS N
were VBD N
analyzed VBN N
by IN N
a DT N
Weibull NNP N
regression NN N
model NN N
with IN N
shared VBN N
frailty NN N
term NN N
( ( N
survival JJ N
analysis NN N
) ) N
. . N

At IN N
baseline NN p
, , p
299 CD p
treatments NNS p
were VBD p
executed VBN p
: : p
PCR NNP p
, , N
152 CD N
and CC N
SW NNP N
, , N
147 CD p
. . p

By IN N
the DT N
end NN N
of IN N
the DT N
3-year JJ N
follow-up JJ N
period NN p
, , p
213 CD p
teeth NNS p
had VBD p
been VBN p
evaluated VBN o
. . o

Adjusted VBN o
survival JJ o
rates NNS o
were VBD o
91 CD N
% NN N
for IN N
PCR NNP N
and CC N
69 CD N
% NN N
for IN N
SW NNP N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
there EX N
is VBZ N
no DT N
need NN N
to TO N
re-open VB N
a DT N
cavity NN N
and CC N
perform VB N
a DT N
second JJ N
excavation NN N
for IN o
pulp NN o
vitality NN o
to TO o
be VB N
preserved VBN N
( ( N
Clinical JJ N
trials NNS N
registration VBP N
NCT00887952 NNP N
) ) N
. . N

-DOCSTART- -21704300- O O

Preoperative JJ N
beta-blocker NN i
usage NN i
: : i
is VBZ N
it PRP N
really RB N
worthy JJ N
of IN N
being VBG N
a DT N
quality NN N
indicator NN N
? . N
BACKGROUND NNP N
Since IN N
2007 CD N
, , N
the DT N
use NN N
of IN N
preoperative JJ i
?-blockers NNS i
has VBZ N
been VBN N
used VBN N
as IN N
a DT N
quality NN N
standard NN N
for IN p
patients NNS p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
. . p

Recent JJ N
studies NNS N
have VBP N
called VBN N
into IN N
question NN N
of IN N
the DT N
benefit NN N
of IN N
empiric JJ N
preoperative JJ N
?-blocker NN N
use NN N
. . N

METHODS NNP N
Data NNP N
were VBD N
extracted VBN N
from IN N
our PRP$ N
Society NN N
of IN N
Thoracic NNP N
Surgeons NNP N
certified VBD N
database NN N
for IN p
patients NNS p
undergoing VBG p
isolated JJ p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
from IN p
2000 CD p
to TO p
2008 CD p
. . p

We PRP N
compared VBN N
the DT N
outcomes NNS N
for IN p
patients NNS p
who WP p
received VBD i
preoperative JJ i
?-blockers NNS i
with IN i
those DT p
of IN p
patients NNS p
who WP p
did VBD p
not RB p
. . p

RESULTS VB p
The DT N
study NN N
group NN N
had VBD N
12,855 CD p
patients NNS p
, , p
of IN p
whom WP p
7,967 CD p
( ( p
62.0 CD p
% NN p
) ) p
were VBD p
treated VBN p
preoperatively RB p
with IN p
?-blockers NNS p
. . p

Using VBG p
propensity NN N
matching NN N
, , N
we PRP N
selected VBD N
two CD N
matched JJ N
groups NNS N
of IN N
4,474 CD N
patients NNS N
with IN N
preoperative JJ i
?-blocker NN i
use NN i
and CC N
4,474 CD N
not RB N
using VBG N
preoperative JJ N
?-blockers NNS N
. . N

In IN N
the DT N
unmatched JJ N
cohort NN N
, , N
only RB N
deep JJ o
sternal JJ o
infection NN o
( ( o
0.3 CD o
% NN o
versus IN N
0.5 CD N
% NN N
without IN N
?-blockers NNS N
; : N
p=0.032 NN N
) ) o
, , o
pneumonia NN o
( ( o
1.9 CD o
% NN o
versus IN N
2.4 CD N
% NN N
without IN N
?-blockers NNS N
; : N
p=0.039 NN N
) ) N
, , o
and CC o
intraoperative JJ o
blood NN o
usage NN o
( ( o
37.2 CD N
% NN N
versus IN N
34.1 CD N
% NN N
without IN N
?-blockers NNS N
; : N
p VB N
< $ N
0.001 CD N
) ) N
reached VBD N
statistically RB N
significant JJ N
difference NN N
. . N

In IN N
the DT N
matched JJ N
groups NNS N
, , N
there EX N
was VBD N
no DT N
difference NN o
between IN o
adverse JJ o
event NN o
rates NNS o
in IN o
patients NNS N
treated VBN N
with IN N
?-blockers NNS N
and CC N
those DT N
who WP N
were VBD N
not RB N
. . N

The DT N
number NN N
of IN N
patients NNS N
requiring VBG N
intraoperative JJ o
blood NN o
product NN o
use NN o
was VBD o
significantly RB o
higher JJR N
among IN N
?-blocker-treated JJ N
patients NNS N
( ( N
p=0.004 NN N
) ) N
. . N

Calculating VBG N
the DT N
adjusted VBN N
odds NNS N
ratios NNS N
showed VBD N
that IN N
in IN N
the DT N
matched JJ N
groups NNS N
, , N
the DT N
preoperative JJ N
use NN N
of IN N
?-blockers NNS N
was VBD N
not RB N
an DT N
independent JJ N
predictor NN N
of IN N
mortality NN N
. . N

CONCLUSIONS VB N
A DT N
rational NN N
for IN N
preoperative JJ N
?-blockade JJ N
exists NNS N
. . N

However RB N
, , N
as IN N
with IN N
any DT N
medical JJ N
intervention NN N
, , N
its PRP$ N
application NN N
should MD N
be VB N
tailored VBN N
to TO N
specific JJ N
clinical JJ N
scenarios NNS N
. . N

With IN N
no DT N
differences NNS N
in IN o
mortality NN o
or CC o
morbidity NN o
, , N
our PRP$ N
findings NNS N
do VBP N
not RB N
support VB N
preoperative JJ N
?-blockade NN N
as IN N
a DT N
useful JJ N
quality NN N
indicator NN o
for IN o
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
. . N

-DOCSTART- -23484763- O O

Efficacy NN N
of IN N
bepotastine NN i
besilate NN i
ophthalmic JJ i
solution NN i
1.5 CD N
% NN N
for IN N
seasonal JJ o
allergic JJ o
conjunctivitis NN o
: : o
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
natural JJ N
exposure NN N
, , N
clinical JJ N
trial NN N
. . N

Allergic NNP N
conjunctivitis NN N
( ( N
AC NNP N
) ) N
affects VBZ N
an DT N
estimated JJ N
20 CD N
% NN N
of IN N
the DT N
population NN N
in IN N
the DT N
Western JJ N
world NN N
, , N
with IN N
a DT N
large JJ N
fraction NN N
suffering VBG N
due JJ N
to TO N
seasonal JJ N
or CC N
perennial JJ N
allergen NN N
exposures NNS N
. . N

Bepotastine NNP i
besilate NN i
ophthalmic JJ i
solution NN i
( ( i
BBOS NNP i
) ) i
1.5 CD N
% NN N
, , N
a DT N
dual-acting JJ i
histamine NN i
( ( N
H NNP N
( ( N
1 CD N
) ) N
) ) N
receptor NN N
antagonist NN N
and CC N
mast NN N
cell NN N
stabilizer NN N
, , N
is VBZ N
indicated VBN N
for IN N
itching VBG N
associated VBN N
with IN N
AC NNP N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
BBOS NNP N
1.5 CD N
% NN N
for IN N
reducing VBG N
ocular JJ p
itching NN p
associated VBN p
with IN p
AC NNP p
in IN p
subjects NNS p
enrolled VBN p
in IN p
a DT p
natural JJ p
exposure NN p
trial NN p
. . p

Eligible JJ p
subjects NNS p
in IN N
a DT N
multicenter NN N
, , N
double-masked JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
, , N
natural JJ N
exposure NN N
clinical JJ N
trial NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
BBOS NNP i
1.5 CD N
% NN N
or CC i
placebo NN i
eyedrops NNS i
on IN N
a DT N
1:1 CD N
basis NN N
and CC N
instilled VBD N
1 CD N
drop NN N
of IN N
the DT N
test NN N
agent NN N
into IN N
both DT N
eyes NNS N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
instantaneous JJ N
and CC N
reflective JJ o
ocular JJ o
itching NN o
scores NNS o
at IN N
the DT N
end NN N
of IN N
2 CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
based VBN N
on IN N
subject-assessed JJ N
severity NN N
of IN N
instantaneous JJ N
and CC N
reflective JJ N
itching NN N
. . N

Subject-reported JJ o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
were VBD N
also RB N
recorded VBN N
for IN N
safety NN N
. . N

Treatment NN N
with IN N
BBOS NNP N
1.5 CD N
% NN N
significantly RB N
reduced VBN N
instantaneous JJ o
and CC o
reflective JJ o
ocular JJ o
itching NN o
scores NNS o
from IN N
baseline NN N
compared VBN N
with IN N
placebo NN N
over IN N
the DT N
2-week JJ N
study NN N
period NN N
( ( N
p JJ N
= NN N
0.007 CD N
and CC N
p VB N
= JJ N
0.005 CD N
, , N
respectively RB N
) ) N
. . N

BBOS $ N
1.5 CD N
% NN N
was VBD N
well RB N
tolerated VBN o
, , o
and CC o
AEs NNP o
were VBD N
generally RB N
transient JJ N
and CC N
mild JJ N
. . N

This DT N
clinical JJ N
study NN N
indicates VBZ N
BBOS NNP N
1.5 CD N
% NN N
effectively RB o
and CC o
safely RB o
treated VBD o
ocular JJ o
itching NN o
in IN N
a DT N
natural JJ N
exposure NN N
allergy NN N
study NN N
and CC N
is VBZ N
a DT N
useful JJ N
treatment NN N
option NN N
for IN N
the DT N
management NN N
of IN N
ocular JJ N
itching NN N
associated VBN N
with IN N
AC NNP N
. . N

( ( N
ClinicalTrials.gov NNP N
identifier VBZ N
number NN N
: : N
NCT01174823 NNP N
. . N

) ) N
-DOCSTART- -21546263- O O

Immediate JJ N
effects NNS N
of IN N
a DT N
tibiofibular JJ i
joint NN i
manipulation NN i
on IN N
lower JJR N
extremity NN N
H-reflex JJ o
measurements NNS o
in IN N
individuals NNS p
with IN p
chronic JJ p
ankle NN p
instability NN p
. . p

Persistent JJ N
muscle NN N
inhibition NN N
of IN N
the DT N
fibularis NN N
longus NN N
and CC N
soleus NN N
muscles NNS N
and CC N
altered VBD N
joint JJ N
arthrokinematics NNS N
may MD N
play VB N
a DT N
role NN N
in IN N
chronic JJ p
ankle NN p
instability NN p
( ( p
CAI NNP p
) ) p
. . p

Joint JJ N
mobilization NN N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
ankle NN N
joint JJ N
motion NN N
, , N
but CC N
effects NNS N
on IN N
surrounding VBG N
musculature NN N
is VBZ N
unknown JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
change NN N
in IN N
fibularis JJ N
longus NN N
and CC N
soleus JJ N
activation NN N
following VBG N
tibiofibular JJ i
joint JJ i
manipulation NN i
in IN N
individuals NNS p
with IN p
CAI NNP p
. . p

Forty-three JJ p
subjects NNS p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
( ( i
proximal JJ i
tibiofibular NN i
manipulation NN i
, , i
distal JJ i
tibiofibular JJ i
manipulation NN i
, , i
or CC i
control NN i
) ) i
. . N

A DT N
two-way JJ N
mixed JJ N
model NN N
ANOVA NNP N
was VBD N
used VBN N
to TO N
compare VB N
changes NNS N
in IN N
the DT N
ratio NN N
of IN N
the DT N
maximum JJ o
H-reflex NNP o
and CC N
maximum JJ o
M-wave JJ o
measurements NNS o
( ( N
H/M NNP N
ratio NN N
) ) N
of IN N
the DT N
fibularis NN N
longus NN N
and CC N
soleus NN N
between IN N
groups NNS N
over IN N
time NN N
( ( N
pre NN N
, , N
post NN N
0 CD N
, , N
10 CD N
, , N
20 CD N
, , N
30 CD N
min NN N
) ) N
. . N

The DT N
distal JJ N
tibiofibular JJ i
joint NN i
manipulation NN i
group NN N
demonstrated VBD N
a DT N
significant JJ N
increase NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
in IN N
soleus NN o
H/M NNP o
ratio NN o
at IN N
all DT N
post-intervention JJ N
time NN N
periods NNS N
except IN N
20 CD N
min JJ N
post-intervention NN N
( ( N
P=.48 NNP N
) ) N
. . N

The DT N
proximal JJ N
tibiofibular JJ i
joint NN i
manipulation NN i
and CC N
control NN i
groups NNS N
did VBD N
not RB N
demonstrate VB N
a DT N
change NN N
in IN N
soleus NN o
H/M NNP o
ratios NNS o
. . o

All DT N
groups NNS N
demonstrated VBD N
a DT N
decrease NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
from IN N
baseline NN N
values NNS N
in IN N
fibularis JJ o
longus NN o
( ( N
10-30 JJ N
min NN N
post-intervention NN N
) ) N
and CC N
soleus NN o
( ( N
30 CD N
min RB N
post-intervention NN N
) ) N
H/M NNP o
ratios NNS o
. . o

Interventions NNS N
directed VBD N
at IN N
the DT N
distal JJ N
tibiofibular JJ N
joint NN N
acutely RB N
increase VB N
soleus JJ o
muscle NN o
activation NN o
. . o

-DOCSTART- -15039684- O O

A DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
phenytoin NN i
for IN N
the DT N
prevention NN N
of IN N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS N
with IN N
moderate JJ N
to TO N
severe VB N
blunt NN N
head JJ N
injury NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
We PRP N
determine VBP N
the DT N
efficacy NN N
of IN N
prophylactic JJ N
phenytoin NN i
in IN N
preventing VBG N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS N
with IN N
moderate JJ N
to TO N
severe VB N
blunt NN N
head JJ N
injury NN N
. . N

METHODS NNP N
Children NNP p
younger JJR p
than IN p
16 CD p
years NNS p
and CC p
experiencing VBG p
moderate JJ p
to TO p
severe VB p
blunt NN p
head JJ p
injury NN p
were VBD N
randomized VBN N
to TO N
receive VB N
phenytoin NN i
or CC i
placebo NN i
within IN N
60 CD N
minutes NNS N
of IN N
presentation NN N
at IN N
3 CD N
pediatric JJ N
trauma NN N
centers NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
posttraumatic JJ o
seizures NNS o
within IN N
48 CD N
hours NNS N
; : N
secondary JJ N
endpoints NNS N
were VBD N
survival JJ N
and CC N
neurologic JJ N
outcome NN N
30 CD N
days NNS N
after IN N
injury NN N
. . N

A DT N
Bayesian JJ N
decision-theoretic JJ N
clinical JJ N
trial NN N
design NN N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
probability NN N
of IN N
remaining VBG N
posttraumatic JJ N
seizure NN N
free JJ N
for IN N
each DT N
treatment NN N
group NN p
. . p

RESULTS NNP N
One CD p
hundred VBD p
two CD p
patients NNS p
were VBD p
enrolled VBN p
, , p
with IN p
a DT p
median JJ p
age NN p
of IN p
6.1 CD p
years NNS p
. . p

Sixty-eight JJ p
percent NN p
were VBD p
boys NNS p
. . p

The DT N
2 CD p
treatment NN p
groups NNS p
were VBD N
well RB N
matched VBN N
. . N

During IN N
the DT N
48-hour JJ N
observation NN N
period NN N
, , N
3 CD p
( ( p
7 CD p
% NN p
) ) p
of IN p
46 CD p
patients NNS p
given VBN N
phenytoin NNS i
and CC N
3 CD p
( ( p
5 CD p
% NN p
) ) p
of IN p
56 CD p
patients NNS p
given VBN N
placebo NNS i
experienced VBD N
a DT N
posttraumatic JJ o
seizure NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS p
in IN N
survival NN o
or CC o
neurologic JJ o
outcome NN o
after IN N
30 CD N
days NNS N
. . N

According VBG N
to TO N
these DT N
results NNS N
, , N
the DT N
probability NN N
that WDT N
phenytoin NN i
has VBZ N
the DT N
originally RB N
hypothesized VBN N
effect NN N
of IN N
reducing VBG N
the DT N
rate NN o
of IN o
early JJ o
posttraumatic JJ o
seizures NNS o
by IN N
12.5 CD N
% NN N
is VBZ N
0.0053 CD N
. . N

The DT N
probability NN N
that WDT N
phenytoin NN i
has VBZ N
any DT N
prophylactic JJ o
efficacy NN o
is VBZ N
0.383 CD N
. . N

The DT N
median JJ N
effect NN N
size NN N
in IN N
this DT N
trial NN N
was VBD N
-0.015 NNP N
( ( p
seizure JJ p
rate NN p
increased VBN p
by IN p
1.5 CD p
% NN p
in IN p
the DT p
phenytoin NN i
group NN p
) ) p
, , N
95 CD N
% NN N
probability NN N
interval NN N
-0.127 NN N
to TO N
0.091 CD N
( ( N
12.7 CD N
% NN N
higher JJR N
rate NN N
of IN N
posttraumatic JJ o
seizures NNS o
to TO N
a DT N
9.1 CD N
% NN N
lower JJR N
rate NN N
of IN N
posttraumatic JJ N
seizures NNS N
with IN N
phenytoin NN i
) ) i
. . N

CONCLUSION VB N
The DT N
rate NN N
of IN N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS p
may MD p
be VB p
much RB p
lower JJR N
than IN N
previously RB N
reported VBN N
. . N

Phenytoin VB i
did VBD N
not RB N
substantially RB N
reduce VB N
that DT N
rate NN N
. . N

-DOCSTART- -17698601- O O

Predictors NNS N
of IN N
incident NN o
depression NN o
after IN p
hip NN p
fracture NN p
surgery NN p
. . p

OBJECTIVE NNP N
Depression NNP N
after IN N
hip NN i
fracture NN i
surgery NN i
is VBZ N
prevalent JJ N
and CC N
associated VBN N
with IN N
increased JJ N
mortality NN N
rates NNS N
and CC N
impaired JJ N
functional JJ N
recovery NN N
. . N

The DT N
incidence NN N
of IN N
new-onset JJ N
depressive NN N
symptoms NNS N
in IN N
patients NNS N
initially RB N
not RB N
depressed VBN N
after IN N
hip NN i
fracture NN i
surgery NN i
and CC N
their PRP$ N
relationship NN N
with IN N
functional JJ N
recovery NN N
is VBZ N
unknown JJ N
. . N

METHODS VB N
A DT N
cohort NN N
of IN N
139 CD p
nondepressed JJ p
elderly JJ p
patients NNS p
( ( p
> JJ p
60 CD p
years NNS p
) ) p
hospitalized VBD p
for IN p
hip NN i
fracture NN i
surgery NN i
were VBD N
followed VBN N
up RP N
for IN N
six CD N
months NNS N
. . N

Clinically NNP N
significant JJ N
depressive NN N
symptoms NNS N
were VBD N
defined VBN N
as IN N
a DT N
score NN N
of IN N
7 CD N
or CC N
more JJR N
on IN N
the DT N
15-item JJ o
Geriatric NNP o
Depression NNP o
Scale NNP o
. . o

RESULTS VB N
The DT N
authors NNS N
found VBD N
a DT N
cumulative JJ o
incidence NN o
rate NN o
of IN N
20.5 CD N
% NN N
adjusted VBN N
for IN N
dropouts NNS N
. . N

Multiple JJ N
Cox-regression JJ N
analyses NNS N
yielded VBD N
the DT N
presence NN N
of IN N
subthreshold JJ N
symptoms NNS N
of IN N
depression NN o
, , o
anxiety NN o
, , o
pain NN o
, , o
and CC o
cognitive JJ o
impairment NN o
at IN o
baseline NN o
, , o
the DT o
premorbid NN o
level NN o
of IN o
mobility NN o
, , o
and CC o
a DT o
history NN o
of IN o
( ( o
treated VBN o
) ) o
depression NN o
as IN o
risk NN o
factors NNS o
for IN o
incident JJ o
depression NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

A DT N
forward NN N
, , N
conditional JJ N
procedure NN N
identified VBN N
postoperative JJ o
pain NN o
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
= NNP N
1.32 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
1.14-1.53 JJ N
, , N
Wald NNP N
chi NN N
( ( N
2 CD N
) ) N
= NN N
13.57 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
baseline JJ o
anxiety NN o
( ( N
HR NNP N
= NNP N
1.25 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.08-1.44 JJ N
, , N
Wald NNP N
chi NN N
( ( N
2 CD N
) ) N
= NN N
8.86 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
as IN N
the DT N
strongest JJS N
independent JJ N
risk NN N
factors NNS N
. . N

Incident NNP o
depression NN o
was VBD N
associated VBN N
with IN N
a DT N
less RBR N
favorable JJ N
outcome NN N
at IN N
3 CD N
months NNS N
follow-up RB N
. . N

CONCLUSION VB N
This DT N
exploratory NN N
study NN N
identified VBD N
two CD N
treatable JJ N
baseline NN N
characteristics NNS N
that WDT N
predicted VBD N
incident JJ o
depression NN o
in IN N
nondepressed JJ p
patients NNS p
after IN p
hip-fracture JJ p
surgery NN p
. . p

-DOCSTART- -17961835- O O

Effects NNS N
of IN N
gabapentin NN i
on IN N
experimental JJ N
somatic JJ o
pain NN o
and CC o
temporal JJ o
summation NN o
. . o

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Gabapentin NNP i
is VBZ N
used VBN N
for IN N
treatment NN N
of IN N
neuropathic JJ N
pain NN N
, , N
but CC N
its PRP$ N
effect NN N
on IN N
different JJ N
somatic JJ N
pain NN N
modalities NNS N
and CC N
integrative JJ N
mechanisms NNS N
are VBP N
not RB N
completely RB N
understood JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
double-blind JJ N
, , N
placebo-controlled JJ i
experimental NN N
pain NN N
study NN N
, , N
conducted VBN N
on IN N
20 CD p
healthy JJ p
volunteers NNS p
, , N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
1200 CD N
mg NN N
gabapentin NN N
on IN N
multi-modal JJ N
experimental JJ N
cutaneous JJ N
and CC N
muscle NN N
pain NN N
models NNS N
. . N

METHODS NNP N
The DT N
following VBG N
pain NN N
models NNS N
were VBD N
applied VBN N
: : N
( ( N
1 CD N
) ) N
pain NN N
thresholds NNS N
to TO N
single JJ i
and CC i
repeated VBD i
cutaneous JJ i
and CC i
intramuscular JJ i
electrical JJ i
stimulation NN i
( ( i
temporal JJ i
summation NN i
to TO i
5 CD i
stimuli NNS i
delivered VBN i
at IN i
2 CD i
Hz NNP i
) ) i
; : i
( ( N
2 CD N
) ) N
stimulus-response NN i
function NN i
relating VBG i
pain NN o
intensity NN o
scores NNS o
( ( o
visual JJ o
analog NN o
scale NN o
, , o
VAS NNP o
) ) o
to TO i
increasing VBG i
current JJ i
intensities NNS i
for IN i
electrical JJ i
skin NN i
and CC i
muscle NN i
stimuli NNS i
( ( i
single JJ i
and CC i
repeated VBD i
, , i
determined VBD i
at IN i
baseline NN i
) ) i
; : i
and CC N
( ( N
3 CD N
) ) N
the DT N
pain NN o
intensity NN o
( ( o
VAS NNP o
) ) o
and CC o
pain $ o
areas NNS o
after IN o
intramuscular JJ o
injection NN o
of IN i
hypertonic JJ i
saline NN i
. . i

Pain NN o
assessments NNS N
were VBD N
performed VBN N
prior RB N
to TO N
, , N
and CC N
at IN N
4 CD N
, , N
6 CD N
, , N
and CC N
8 CD N
hours NNS N
after IN N
medication NN N
. . N

RESULTS VB N
When WRB N
responses NNS N
were VBD N
averaged VBN N
across IN N
the DT N
post-dose JJ N
times NNS N
, , N
gabapentin NN i
: : i
( ( N
1 CD N
) ) N
significantly RB N
increased VBD N
the DT N
temporal JJ o
summation NN o
pain NN o
threshold NN o
in IN N
skin NN N
compared VBN N
with IN N
placebo NN i
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
; : N
( ( N
2 CD N
) ) N
significantly RB N
reduced VBD N
the DT N
area NN o
under IN o
the DT o
pain NN o
intensity NN o
curve NN o
to TO o
hypertonic VB o
saline JJ o
injections NNS o
in IN N
the DT N
muscle NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
significantly RB N
reduced VBD N
the DT N
area NN o
of IN o
pain NN o
evoked VBN o
by IN o
hypertonic JJ o
saline NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Gabapentin NNP i
reduces VBZ N
temporal JJ o
summation NN o
of IN o
skin JJ o
stimuli NNS o
at IN o
pain NN o
threshold JJ o
intensities NNS o
; : o
this DT N
may MD N
have VB N
potential JJ N
as IN N
a DT N
biomarker NN N
for IN N
drugs NNS N
with IN N
efficacy NN N
on IN N
neurogenic JJ N
pain NN N
. . N

The DT N
data NN N
also RB N
suggest VBP N
that IN N
tonic JJ o
muscle NN o
pain NN o
is VBZ N
responsive JJ N
to TO N
gabapentin VB N
treatment NN N
and CC N
suggest VB N
further RB N
clinical JJ N
studies NNS N
. . N

-DOCSTART- -24225126- O O

Etomidate NN i
with IN i
or CC i
without IN i
flumazenil JJ i
anesthesia NN i
for IN N
stem NN N
cell NN N
transplantation NN N
in IN N
autistic JJ p
children NNS p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
etomidate JJ i
administration NN i
with IN i
or CC i
without IN i
flumazenil NNS i
in IN N
autistic JJ p
children NNS p
who WP p
underwent VBP p
intrathecal JJ p
transplantation NN p
of IN p
stem NN p
cells NNS p
by IN p
lumbar NN p
puncture NN p
. . p

METHODS NNP N
Forty NNP p
autistic JJ p
children NNS p
aged VBN p
2-12 CD p
, , p
who WP p
were VBD p
scheduled VBN p
for IN p
stem NN p
cell NN p
transplantation NN p
via IN p
lumbar NN p
puncture NN p
under IN p
anesthesia NN p
, , N
were VBD N
randomized VBN N
for IN N
a DT N
double-blind JJ N
study NN N
. . N

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
: : N
the DT i
flumazenil NN i
group NN i
( ( N
group NN N
F NNP N
, , N
n=20 NN N
) ) N
and CC N
the DT i
etomidate NN i
group NN i
( ( N
group NN N
E NNP N
, , N
n=20 NN N
) ) N
. . N

All DT N
children NNS N
received VBD N
0.2 CD N
mg/kg NN N
of IN N
etomidate NN i
. . i

In IN N
the DT N
case NN N
of IN N
inadequate JJ N
anesthesia NN N
, , N
patients NNS N
received VBD N
repeated JJ N
doses NNS N
of IN N
0.1 CD N
mg/kg NN N
of IN N
etomidate NN i
until IN N
reaching VBG N
deep JJ N
sedation NN N
. . N

After IN N
operation NN N
, , N
children NNS N
in IN N
group NN N
F NNP N
were VBD N
given VBN N
flumazenil NNS i
( ( N
0.01 CD N
mg/kg NN N
) ) N
and CC N
children NNS N
in IN N
group NN N
E NNP N
received VBD N
placebo NN i
. . i

Heart NNP o
rate NN o
( ( o
HR NNP o
) ) o
, , o
mean JJ o
arterial JJ o
pressure NN o
, , o
oxygen NN o
saturation NN o
, , o
respiratory NN o
rate NN o
, , o
the DT o
Ramsay NNP o
sedation NN o
score NN o
( ( o
RSS NNP o
) ) o
, , o
and CC o
recovery NN o
time NN o
of IN N
all DT N
children NNS N
were VBD N
continuously RB N
monitored VBN N
and CC N
recorded VBN N
during IN N
the DT N
entire JJ N
procedure NN N
. . N

RESULTS NNP N
After IN N
anesthesia NN N
, , N
blood NN o
pressure NN o
and CC o
HR NNP o
measurements NNS o
were VBD N
not RB N
significantly RB N
changed VBN N
in IN N
both DT N
groups NNS N
compared VBN N
with IN N
the DT N
baseline NN N
. . N

There EX N
were VBD N
no DT N
respiratory JJ o
depression NN o
, , o
bradycardia NN o
, , o
hypotension NN o
, , o
nausea NN o
, , o
and CC o
vomiting VBG o
. . o

Five CD N
patients NNS N
complained VBN N
of IN N
pain NN o
on IN o
the DT o
site NN o
of IN o
injection NN o
. . o

Myoclonus NNP o
occurred VBD N
in IN N
seven CD N
patients NNS N
. . N

Recovery JJ o
time NN o
in IN N
group NN N
F NNP N
was VBD N
significantly RB N
shorter JJR N
than IN N
in IN N
group NN N
E NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
after IN N
the DT N
injection NN N
of IN N
flumazenil NN i
, , N
RSS NNP o
in IN N
group NN N
F NNP N
significantly RB N
decreased VBD N
than IN N
in IN N
group NN N
E. NNP N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
operation NN o
time NN o
. . o

Physician JJ o
satisfaction NN o
in IN N
both DT N
groups NNS N
was VBD N
similar JJ N
. . N

CONCLUSIONS NNP N
Etomidate NNP i
resulted VBD N
in IN N
stable JJ N
hemodynamic JJ o
responses NNS o
and CC N
relatively RB N
less JJ N
adverse JJ o
effects NNS o
, , N
and CC N
flumazenil RB i
antagonized VBD N
the DT N
anesthetic JJ o
effect NN o
of IN N
etomidate NN N
; : N
thus RB N
, , N
etomidate NN N
with IN N
flumazenil NN N
is VBZ N
suitable JJ N
for IN N
performing VBG N
stem NN N
cell NN N
transplantation NN N
in IN N
autistic JJ p
children NNS p
. . p

-DOCSTART- -14716650- O O

Transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
for IN N
postoperative JJ p
pain NN p
relief NN p
after IN p
total JJ p
knee NN p
arthroplasty NN p
. . p

Transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
( ( i
TENS NNP i
) ) i
has VBZ N
been VBN N
used VBN N
to TO N
treat VB N
chronic JJ N
pain NN N
syndromes NNS N
and CC N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
of IN N
some DT N
utility NN N
in IN N
the DT N
treatment NN N
of IN N
postsurgical JJ N
pain NN N
. . N

A DT N
randomized JJ N
, , N
blinded VBD N
, , N
placebo-controlled JJ i
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
utility NN N
of IN N
TENS NNP N
after IN N
total JJ p
knee NN p
arthroplasty NN p
. . p

Patients NNS p
were VBD p
randomly RB p
enrolled VBN p
into IN p
patient-controlled JJ i
anesthesia NN i
( ( i
PCA NNP i
) ) i
alone RB i
, , i
PCA NNP i
plus CC i
TENS NNP i
, , i
or CC i
PCA NNP i
plus CC i
sham JJ i
TENS NNP i
. . i

The DT N
cumulative JJ o
dose NN o
of IN o
morphine NN o
by IN N
PCA NNP N
for IN N
each DT N
group NN N
was VBD N
used VBN N
as IN N
the DT N
end-point NN N
of IN N
the DT N
study NN N
. . N

There EX N
was VBD N
no DT o
significant JJ o
reduction NN o
in IN o
the DT o
requirement NN o
for IN o
patient-controlled JJ o
analgesia NN o
with IN N
or CC N
without IN N
TENS NNP N
. . N

We PRP N
conclude VBP N
that IN N
there EX N
is VBZ N
no DT N
utility NN N
for IN N
TENS NNP N
in IN N
the DT N
postoperative JJ N
management NN N
of IN N
pain NN N
after IN N
knee NN N
arthroplasty NN N
. . N

-DOCSTART- -21949005- O O

Learning VBG N
through IN N
interaction NN N
in IN N
children NNS p
with IN p
autism NN p
: : p
preliminary JJ N
data NNS N
from IN N
asocial-communication-based JJ N
intervention NN N
. . N

The DT N
study NN N
evaluates VBZ N
a DT N
social-communication-based JJ i
approach NN i
to TO N
autism VB N
intervention NN N
aimed VBN N
at IN N
improving VBG N
the DT N
social JJ o
interaction NN o
skills NNS o
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

We PRP N
report VBP N
preliminary JJ N
results NNS N
from IN N
an DT N
ongoing JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
51 CD p
children NNS p
aged VBN p
2 CD p
years NNS p
0 CD p
months NNS p
to TO p
4 CD p
years NNS p
11 CD p
months NNS p
. . p

Participants NNS N
were VBD N
assigned VBN N
to TO N
either VB N
a DT N
target NN N
treatment NN N
or CC N
community NN N
treatment NN N
group NN N
. . N

Families NNS N
in IN N
the DT N
target NN N
treatment NN N
group NN N
were VBD N
given VBN N
2 CD N
hours NNS N
of IN N
therapy NN i
and CC i
coaching VBG i
each DT N
week NN N
in IN N
an DT N
intervention NN N
emphasizing VBG N
social-interaction NN i
and CC i
the DT i
parent-child JJ i
relationship NN i
. . i

Children NNP N
in IN N
the DT N
community NN i
treatment NN i
group NN N
received VBD N
a DT N
variety NN i
of IN i
services NNS i
averaging VBG i
3.9 CD i
hours NNS i
per IN i
week NN i
. . i

After IN N
12 CD N
months NNS N
, , N
outcomes NNS N
were VBD N
measured VBN N
to TO N
determine VB N
changes NNS N
in IN N
the DT N
groups NNS N
in IN N
social JJ N
interaction NN N
and CC N
communication NN N
. . N

In IN N
addition NN N
, , N
a DT N
regression NN N
analysis NN N
was VBD N
conducted VBN N
to TO N
determine VB N
whether IN N
changes NNS N
in IN N
social JJ N
interaction NN N
skills NNS N
were VBD N
associated VBN N
with IN N
language NN N
development NN N
. . N

Results NNS N
suggest VBP N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB N
greater JJR N
gains NNS o
in IN o
social JJ o
interaction NN o
skills NNS o
in IN N
comparison NN N
to TO N
the DT N
community NN N
treatment NN N
group NN N
, , N
but CC N
no DT N
between-group JJ N
differences NNS N
were VBD N
found VBN N
for IN N
standard JJ o
language NN o
assessments NNS o
. . o

Initiation NN o
of IN o
joint JJ o
attention NN o
, , o
involvement NN o
, , o
and CC o
severity NN o
of IN o
language NN o
delay NN o
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
associated VBN N
with IN N
improvement NN N
of IN N
language NN o
skills NNS o
in IN N
children NNS p
with IN p
autism NN p
. . p

Finally RB N
caregiver JJ N
skills NNS N
targeted VBN N
by IN N
the DT N
intervention NN N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
associated VBN N
with IN N
changes NNS N
in IN N
children NNS o
's POS o
interaction NN o
skills NNS o
. . o

-DOCSTART- -8614420- O O

The DT N
sequencing NN N
of IN N
chemotherapy NN i
and CC N
radiation NN i
therapy NN i
after IN N
conservative JJ p
surgery NN p
for IN p
early-stage JJ p
breast NN p
cancer NN p
. . p

BACKGROUND NNP N
Patients NNPS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
who WP p
are VBP p
at IN p
substantial JJ p
risk NN p
for IN p
systemic JJ p
metastases NNS p
are VBP N
increasingly RB N
treated VBN N
with IN N
breast-conserving JJ i
therapy NN i
and CC i
adjuvant JJ i
chemotherapy NN i
. . i

However RB N
, , N
the DT N
optimal JJ N
sequencing NN N
of IN N
chemotherapy NN i
and CC i
radiation NN i
therapy NN i
is VBZ N
not RB N
clear JJ N
. . N

METHODS NNP N
Two CD p
hundred VBD p
forty-four JJ p
patients NNS p
with IN p
stage NN p
I PRP p
or CC p
II NNP p
breast NN p
cancer NN p
who WP p
were VBD p
at IN p
substantial JJ p
risk NN p
for IN p
distant JJ p
metastases NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
12-week JJ i
course NN i
of IN i
chemotherapy NN i
either CC i
before IN i
or CC i
after IN i
radiation NN i
therapy NN i
. . i

All DT p
had VBD p
had VBN p
breast-conserving JJ p
surgery NN p
. . p

The DT N
median JJ N
length NN N
of IN N
follow-up NN N
in IN N
surviving VBG N
patients NNS N
was VBD N
58 CD N
months NNS N
( ( N
range NN N
, , N
10 CD N
to TO N
124 CD N
) ) N
. . N

RESULTS VB N
The DT N
five-year JJ o
actuarial JJ o
rates NNS o
of IN o
cancer NN o
recurrence NN o
at IN N
any DT N
site NN N
and CC N
of IN N
distant JJ N
metastases NNS N
in IN N
the DT N
radiotherapy-first JJ i
group NN N
and CC N
the DT N
chemotherapy-first JJ i
group NN N
were VBD N
38 CD N
percent NN N
and CC N
31 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.17 CD N
) ) N
and CC N
36 CD N
percent NN N
and CC N
25 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

Overall JJ o
survival NN o
was VBD N
73 CD N
percent NN N
and CC N
81 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.11 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
five-year JJ o
crude NN o
rates NNS o
of IN o
first JJ o
recurrence NN o
according VBG N
to TO N
site NN N
in IN N
the DT N
radiotherapy-first JJ i
and CC i
chemotherapy-first JJ i
groups NNS N
, , N
respectively RB N
, , N
were VBD N
5 CD N
percent NN N
and CC N
14 CD N
percent NN N
for IN N
local JJ N
recurrence NN N
and CC N
32 CD N
percent NN N
and CC N
20 CD N
percent NN N
for IN N
distant NN N
or CC N
regional JJ N
recurrence NN N
or CC N
both DT N
. . N

This DT N
difference NN N
in IN N
the DT N
pattern NN o
of IN o
recurrence NN o
was VBD N
of IN N
borderline JJ N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
for IN N
patients NNS p
ar VBP p
substantial JJ p
risk NN p
for IN p
systemic JJ p
metastases NNS p
, , N
it PRP N
is VBZ N
preferable JJ N
to TO N
give VB N
a DT N
12-week JJ N
course NN N
of IN N
chemotherapy NN i
followed VBN N
by IN N
radiation NN i
therapy NN i
, , N
rather RB N
than IN N
radiation NN i
therapy NN i
followed VBN i
by IN i
chemotherapy NN i
. . i

-DOCSTART- -22967497- O O

Clinical JJ o
efficacy NN o
of IN N
antazoline NN i
in IN N
rapid JJ o
cardioversion NN o
of IN o
paroxysmal JJ o
atrial JJ o
fibrillation NN o
-- : o
a DT o
protocol NN N
of IN N
a DT N
single JJ N
center NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
( ( N
the DT N
AnPAF NNP N
Study NNP N
) ) N
. . N

BACKGROUND NNP N
Rapid NNP o
conversion NN o
of IN o
atrial JJ o
fibrillation NN o
( ( o
AF NNP o
) ) o
to TO o
sinus VB o
rhythm NN o
may MD N
be VB N
achieved VBN N
by IN N
the DT N
administration NN N
of IN N
class NN i
IA NNP i
, , i
IC NNP i
and CC i
III NNP i
antiarrhythmic JJ i
drugs NNS i
or CC i
vernakalant JJ i
hydrochloride NN i
. . i

However RB N
, , N
that IN N
treatment NN N
may MD N
be VB N
related VBN N
to TO N
potential JJ N
pro-arrhythmia NN N
, , N
lack NN N
of IN N
efficacy NN N
or CC N
the DT N
exceptionally RB N
high JJ N
cost NN N
of IN N
a DT N
compound NN N
used VBN N
. . N

Antazoline NNP i
is VBZ N
a DT N
first JJ N
generation NN N
antihistaminic JJ N
agent NN N
with IN N
chinidin-like JJ N
properties NNS N
. . N

When WRB N
administered VBN N
intravenously RB N
, , N
antazoline JJ i
exerts VBZ N
a DT N
strong JJ o
antiarrhythmic JJ o
effect NN o
on IN N
supraventricular JJ o
arrhythmia NN o
, , N
especially RB N
on IN N
AF NNP o
, , N
facilitating VBG N
rapid JJ o
conversion NN o
to TO o
sinus VB o
rhythm NN o
. . o

Despite IN N
a DT N
relative JJ N
lack NN N
of IN N
published VBN N
data NNS N
antazoline NN N
has VBZ N
been VBN N
marketed VBN N
in IN N
Poland NNP N
and CC N
widely RB N
used VBN N
in IN N
cardiology NN N
wards NNS N
and CC N
emergency NN N
rooms NNS N
for IN N
many JJ N
years NNS N
due JJ N
to TO N
its PRP$ N
efficacy NN N
, , N
safety NN N
and CC N
rapid JJ N
onset NN N
of IN N
action NN N
within IN N
minutes NNS N
of IN N
administration NN N
. . N

METHODS/DESIGN CC N
A DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
, , N
superiority JJ N
clinical JJ N
trial NN N
was VBD N
designed VBN N
to TO N
assess VB N
clinical JJ o
efficacy NN o
of IN N
antazoline NN i
in IN N
rapid JJ N
conversion NN N
of IN N
AF NNP N
to TO N
sinus VB N
rhythm NN N
. . N

Eligible JJ p
patients NNS p
will MD p
present VB p
AF NNP p
lasting VBG p
less JJR p
than IN p
43 CD p
hours NNS p
, , p
will MD p
be VB p
in IN p
stable JJ p
cardio-pulmonary JJ p
condition NN p
and CC p
will MD p
have VB p
no DT p
prior JJ p
history NN p
of IN p
advanced JJ p
heart NN p
failure NN p
or CC p
significant JJ p
valvular JJ p
disease NN p
. . p

Long-term JJ N
antiarrhythmic JJ N
therapy NN N
is VBZ N
not RB N
considered VBN N
an DT N
exclusion NN N
criterion NN N
. . N

Subjects NNS N
who WP N
fulfill VBP N
selection NN N
criteria NNS N
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
receive VB N
intravenously RB N
either DT N
antazoline NN i
or CC N
placebo NN i
in IN N
divided JJ N
doses NNS N
and CC N
observed VBD N
for IN N
1.5 CD N
hours NNS N
after IN N
conversion NN N
to TO N
sinus VB N
rhythm NN N
or CC N
after IN N
the DT N
last JJ N
i.v NN N
. . N

bolus NN N
. . N

Primary JJ N
end NN N
point NN N
will MD N
be VB N
the DT N
conversion NN o
of IN o
AF NNP o
to TO o
sinus VB o
rhythm NN o
confirmed VBN o
in IN o
an DT o
electrocardiogram NN o
( ( o
ECG NNP o
) ) o
during IN N
the DT N
observation NN N
period NN N
. . N

Secondary JJ N
end NN N
points NNS N
will MD N
be VB N
comprised VBN o
of IN o
time NN o
to TO o
conversion NN o
and CC o
return NN o
of IN o
AF NNP o
during IN N
the DT N
observation NN N
period NN N
. . N

Special JJ N
consideration NN N
will MD N
be VB N
given VBN N
to TO N
the DT N
observation NN N
of IN N
any DT N
adverse JJ o
events NNS o
. . o

A DT N
sample JJ p
size NN p
of IN p
80 CD p
patients NNS p
was VBD p
calculated VBN p
based VBN N
on IN N
the DT N
following JJ N
assumptions NNS N
: : N
two-tailed JJ N
test NN N
, , N
a DT N
type NN N
I PRP N
error VBP N
of IN N
0.01 CD N
, , N
a DT N
power NN N
of IN N
90 CD N
% NN N
, , N
efficacy NN o
of IN N
placebo JJ i
5 CD N
% NN N
, , N
efficacy NN N
of IN N
antazoline JJ i
50 CD N
% NN N
and CC N
20 CD N
% NN N
drop-out JJ N
rate NN N
to TO N
fulfill VB N
the DT N
criteria NNS N
of IN N
intention-to-treat JJ N
analysis NN N
. . N

Due NNP N
to TO N
the DT N
presumed JJ N
lack NN N
of IN N
statistical JJ N
power NN N
, , N
the DT N
secondary JJ N
end NN N
points NNS N
and CC N
safety NN N
endpoints NNS N
will MD N
be VB N
considered VBN N
exploratory JJ N
. . N

CLINICAL JJ N
TRIALS NNP N
REGISTRY NNP N
ClinicalTrials.gov NNP N
, , N
NCT01527279 NNP N
. . N

-DOCSTART- -8277075- O O

Altered NNP N
peripheral JJ o
vasodilator NN o
profile NN o
of IN N
nitroglycerin JJ N
during IN N
long-term JJ N
infusion NN N
of IN N
N-acetylcysteine NNP N
. . N

OBJECTIVES NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
short- JJ o
and CC o
long-term JJ o
effects NNS o
of IN N
intravenous JJ i
nitroglycerin JJ i
plus CC i
placebo JJ i
and CC N
nitroglycerin JJ i
plus CC i
N-acetylcysteine JJ i
on IN N
peripheral JJ N
arteries NNS N
, , N
veins NNS N
and CC N
microcirculation NN N
in IN N
humans NNS N
. . N

BACKGROUND IN N
The DT N
thiol JJ N
donor JJ N
N-acetylcysteine NN i
may MD N
potentiate VB N
the DT N
hemodynamic JJ N
response NN N
to TO N
nitrates NNS N
in IN N
nitrate-tolerant JJ N
and CC N
nontolerant JJ N
patients NNS N
. . N

The DT N
vascular JJ N
changes NNS N
responsible JJ N
for IN N
this DT N
effect NN N
are VBP N
not RB N
clear JJ N
. . N

METHODS NNP N
Eight NNP p
male NN p
volunteers NNS p
were VBD N
treated VBN N
with IN N
nitroglycerin NN i
( ( i
0.1 CD i
microgram/kg NN i
per IN i
min NN i
) ) i
combined VBN i
with IN i
N-acetylcysteine NNP i
( ( N
2 CD N
g NN N
intravenously RB N
, , N
followed VBN N
by IN N
5 CD N
mg/kg NNS N
per IN N
h NN N
) ) N
or CC N
placebo NN i
for IN N
23 CD N
h NN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
. . N

Venous JJ o
volume NN o
, , N
the DT N
diameter NN o
of IN o
the DT o
radial NN o
and CC o
temporal JJ o
arteries NNS o
, , o
calf NN o
blood NN o
flow NN o
and CC N
subcutaneous JJ o
blood NN o
flow NN o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
repeated VBD N
after IN N
1 CD N
and CC N
23 CD N
h NN N
of IN N
infusion NN N
. . N

RESULTS NNP N
Prolonged VBD N
coadministration NN N
of IN N
N-acetylcysteine NNP i
and CC i
nitroglycerin RB i
potentiated VBD N
the DT N
acute JJ o
venodilator NN o
effect NN o
of IN N
nitroglycerin NN N
as IN N
estimated VBN N
by IN N
changes NNS o
in IN o
venous JJ o
volume NN o
( ( i
nitroglycerin JJ i
plus CC i
N-acetylcysteine JJ i
, , N
4.45 CD N
+/- JJ N
0.36 CD N
ml/100 NN N
g NN N
; : N
nitroglycerin CC i
plus CC i
placebo NN i
, , N
3.65 CD N
+/- JJ N
0.46 CD N
ml/100 NN N
g NN N
, , N
mean JJ N
+/- JJ N
SEM NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
prevented VBD N
development NN o
of IN o
tolerance NN o
as IN N
seen VBN N
after IN N
23 CD N
h NN N
of IN N
treatment NN N
with IN N
nitroglycerin JJ N
plus CC N
placebo NN N
( ( N
4.35 CD N
+/- JJ N
0.25 CD N
vs. FW N
3.47 CD N
+/- JJ N
0.41 CD N
ml/100 NN N
g NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

N-acetylcysteine NNP i
had VBD N
no DT N
effect NN N
on IN N
nitroglycerin-induced JJ o
changes NNS o
in IN o
arterial JJ o
diameters NNS o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
but CC N
significantly RB N
increased VBD N
microcirculatory JJ o
subcutaneous JJ o
blood NN o
flow NN o
after IN o
1 CD o
h NN o
( ( i
nitroglycerin JJ i
plus CC i
N-acetylcysteine JJ i
: : i
6.3 CD N
+/- JJ N
1.3 CD N
ml/100 NN N
g NN N
per IN N
min NN N
vs. FW N
nitroglycerin JJ i
plus CC i
placebo NN i
: : i
3.5 CD N
+/- JJ N
0.3 CD N
ml/100 NN N
g NN N
per IN N
min NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
after IN N
23 CD N
h NN N
( ( N
4.4 CD N
+/- JJ N
0.6 CD N
vs. FW N
3.1 CD N
+/- JJ N
0.5 CD N
ml/100 NN N
g NN N
per IN N
min NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
coadministration NN N
of IN N
nitroglycerin JJ i
and CC i
N-acetylcysteine JJ i
in IN N
humans NNS N
1 CD N
) ) N
potentiates NNS N
and CC N
preserves VBZ N
nitroglycerin-induced JJ o
venodilation NN o
and CC N
2 CD N
) ) N
augments VBZ N
the DT N
effect NN o
of IN o
nitroglycerin NN o
on IN o
small JJ o
resistance NN o
vessels NNS o
( ( o
regulating VBG o
subcutaneous JJ o
blood NN o
flow NN o
) ) o
without IN o
affecting VBG o
the DT o
response NN o
to TO o
nitroglycerin VB o
in IN o
middle-sized JJ o
arteries NNS o
. . o

Both CC N
the DT N
development NN N
of IN N
nitrate JJ o
tolerance NN o
and CC N
the DT N
administration NN N
of IN N
N-acetylcysteine NNP i
significantly RB N
change VBP N
the DT N
normal JJ N
vasodilator NN o
profile NN o
of IN N
nitroglycerin NN i
in IN N
humans NNS N
. . N

-DOCSTART- -6337497- O O

A DT N
dose-response JJ N
study NN N
of IN N
the DT N
effect NN N
of IN N
levobunolol NN i
on IN N
ocular JJ o
hypertension NN o
. . o

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-masked JJ N
, , N
dose-response JJ N
study NN N
of IN N
the DT N
ocular JJ o
hypotensive JJ o
effect NN o
of IN N
the DT N
beta-adrenergic JJ N
blocker NN N
, , N
levobunolol NN N
. . N

A DT N
single JJ N
drop NN N
of IN N
placebo NN i
or CC i
levobunolol NN i
( ( N
at IN N
concentrations NNS N
of IN N
0.03 CD N
% NN N
, , N
0.3 CD N
% NN N
, , N
0.6 CD N
% NN N
, , N
1 CD N
% NN N
, , N
and CC N
2 CD N
% NN N
) ) N
was VBD N
administered VBN N
to TO N
one CD p
eye NN p
of IN p
each DT p
of IN p
48 CD p
patients NNS p
with IN p
ocular JJ p
hypertension NN p
. . p

The DT N
0.3 CD N
% NN N
and CC N
0.6 CD N
% NN N
concentrations NNS N
decreased VBD N
intraocular JJ o
pressure NN o
significantly RB N
from IN N
baseline NN N
levels NNS N
compared VBN N
to TO N
placebo VB N
at IN N
one CD N
, , N
two CD N
, , N
and CC N
four CD N
hours NNS N
after IN N
treatment NN N
. . N

The DT N
1 CD N
% NN N
and CC N
2 CD N
% NN N
concentrations NNS N
decreased VBD N
intraocular JJ o
pressure NN o
significantly RB o
from IN N
baseline NN N
compared VBN N
to TO N
placebo VB N
at IN N
one CD N
, , N
two CD N
, , N
four CD N
, , N
six CD N
, , N
eight CD N
, , N
and CC N
12 CD N
hours NNS N
after IN N
administration NN N
. . N

No DT N
objective JJ o
or CC o
subjective JJ o
side NN o
effects NNS o
were VBD N
noted VBN N
, , N
and CC N
no DT N
substantial JJ o
changes NNS o
in IN o
visual JJ o
acuity NN o
, , o
pupil NN o
diameter NN o
, , o
pulse JJ o
rate NN o
, , o
or CC o
blood NN o
pressure NN o
were VBD N
recorded VBN N
during IN N
the DT N
study NN N
. . N

These DT N
results NNS N
appear VBP N
to TO N
justify VB N
long-term JJ N
studies NNS N
of IN N
levobunolol NN i
for IN N
the DT N
treatment NN N
of IN N
increased JJ N
intraocular JJ o
pressure NN o
. . o

-DOCSTART- -20010551- O O

Divalproex NNP i
sodium NN i
vs NN i
placebo NN i
for IN N
the DT N
treatment NN N
of IN N
irritability NN o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Autism NNP N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
are VBP N
neurodevelopmental JJ N
disorders NNS N
characterized VBN N
by IN N
social JJ N
and CC N
language NN N
deficits NNS N
and CC N
by IN N
repetitive JJ N
behaviors NNS N
and CC N
interests NNS N
. . N

Irritability/aggression NN N
is VBZ N
a DT N
significant JJ N
comorbid NN N
symptom NN N
in IN N
this DT N
population NN N
, , N
which WDT N
greatly RB N
impacts VBZ N
burden NN N
of IN N
care NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
divalproex NN i
sodium NN i
for IN N
irritability/aggression NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
. . p

This DT N
was VBD N
a DT N
12-week JJ N
randomized NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

All DT N
efficacy NN N
measures NNS N
were VBD N
obtained VBN N
by IN N
an DT N
independent JJ N
evaluator NN N
blinded VBD N
to TO N
randomization VB N
condition NN N
and CC N
side NN N
effects NNS N
. . N

A DT N
total NN p
of IN p
55 CD p
subjects NNS p
gavetheir JJ p
consent NN p
and CC p
27 CD p
were VBD p
randomized VBN p
in IN p
a DT p
1 CD p
: : p
1 CD p
manner NN p
( ( p
mean JJ p
age NN p
9.46+/-2.46 CD p
, , p
mean FW p
nonverbal JJ p
IQ NNP p
63.3+/-23.9 NN p
) ) p
. . p

Two CD N
subjects NNS N
from IN N
the DT N
active JJ N
group NN N
and CC N
one CD N
subject NN N
from IN N
the DT N
placebo NN i
group NN N
discontinued VBD N
the DT N
study NN N
because IN N
of IN N
either CC N
a DT N
lack NN N
of IN N
efficacy NN o
or CC N
side NN o
effects NNS o
( ( N
increased JJ N
irritability NN N
) ) N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
Aberrant NNP o
Behavior NNP o
Checklist-Irritability NNP o
subscale NN o
and CC o
Clinical JJ o
Global NNP o
Impression-Improvement NNP o
, , N
which WDT N
focused VBD N
on IN N
irritability NN N
. . N

Overall NNP N
, , N
62.5 CD N
% NN N
of IN N
divalproex JJ i
subjects NNS N
vs VBP N
9 CD N
% NN N
of IN N
placebo JJ i
subjects NNS N
were VBD N
responders NNS o
( ( N
CGI-irritability NN N
OR NNP N
: : N
16.7 CD N
, , N
Fisher NNP N
's POS N
exact JJ N
p=0.008 NN N
) ) N
. . N

A DT N
statistically RB N
significant JJ N
improvement NN N
was VBD N
also RB N
noted VBN N
on IN N
the DT N
ABC-Irritability NNP o
subscale NN o
( ( N
p=0.048 NN N
) ) N
. . N

There EX N
was VBD N
a DT N
trend NN N
for IN N
responders NNS N
to TO N
have VB N
higher JJR N
valproate NN o
blood NN o
levels NNS o
compared VBN N
with IN N
nonresponders NNS N
. . N

This DT N
study NN N
suggests VBZ N
the DT N
efficacy NN o
of IN N
divalproex NN i
for IN N
the DT N
treatment NN N
of IN N
irritability NN o
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
ASD NNP N
. . N

Larger NNP N
sample JJ N
follow-up JJ N
studies NNS N
are VBP N
warranted VBN N
. . N

-DOCSTART- -23512255- O O

Lengthening VBG N
the DT N
moment NN N
arm NN N
of IN N
the DT N
patella NN N
confers NNS N
enhanced VBD N
extensor NN o
mechanism NN o
power NN o
following VBG p
total JJ p
knee JJ p
arthroplasty NN p
. . p

We PRP N
investigated VBD N
whether IN N
a DT N
postulated JJ N
biomechanical JJ N
advantage NN N
conferred VBD N
to TO N
the DT N
extensor NN N
mechanism NN N
by IN N
a DT N
change NN N
in IN N
knee NN N
implant JJ N
design NN N
was VBD N
detectable JJ N
in IN N
patients NNS p
by IN p
direct JJ p
physical JJ p
testing NN p
. . p

212 CD p
TKA JJ p
patients NNS p
were VBD N
enrolled VBN N
in IN N
a DT N
double JJ N
blind NN N
randomized VBD N
controlled VBN N
trial NN N
to TO N
receive VB N
either CC N
a DT N
traditional JJ i
implant NN i
or CC i
one CD i
which WDT i
incorporated VBD i
new JJ i
design NN i
features NNS i
. . i

Extensor NNP o
mechanism NN o
power NN o
output NN o
and CC o
physical JJ o
performance NN o
on IN o
a DT o
battery NN o
of IN o
timed JJ o
functional JJ o
activities NNS o
was VBD N
assessed VBN N
pre-operatively RB N
and CC N
then RB N
at IN N
6 CD N
, , N
26 CD N
, , N
and CC N
52 CD N
weeks NNS N
post-operatively RB N
. . N

Significantly RB N
enhanced JJ N
power NN o
output NN o
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
post-arthroplasty VBP N
; : N
however RB N
, , N
the DT N
new JJ i
design NN i
implant JJ i
group NN N
demonstrated VBD N
a DT N
greater JJR N
change NN o
in IN o
power NN o
output NN o
than IN N
the DT N
traditional JJ i
implant NN i
group NN N
. . N

Posthoc NNP o
testing VBG o
of IN N
between IN N
group NN N
differences NNS N
highlighted VBD N
greater JJR N
improvement NN N
at IN N
all DT o
post-operative JJ o
assessments NNS o
. . o

At IN N
52 CD N
weeks NNS N
, , N
patients NNS N
receiving VBG N
the DT N
implant NN N
with IN N
the DT N
postulated JJ N
biomechanical JJ N
advantage NN N
achieved VBD N
116 CD N
% NN N
of IN N
the DT N
power NN o
output NN o
of IN o
their PRP$ o
contralateral JJ o
limb NN o
, , N
whereas JJ N
patients NNS N
with IN N
the DT N
traditional JJ N
design NN N
achieved VBD N
90 CD N
% NN N
. . N

No DT N
between IN N
group NN N
difference NN N
was VBD N
detected VBN N
in IN N
the DT N
patient NN N
's POS N
time NN N
to TO N
complete VB N
functional JJ N
tasks NNS N
. . N

Thus RB N
, , N
patients NNS N
receiving VBG N
a DT N
knee NN i
implant NN i
of IN i
a DT i
modern JJ i
design NN i
( ( N
theoretically RB N
able JJ N
to TO N
confer VB N
a DT N
mechanical JJ N
advantage NN N
to TO N
the DT N
extensor NN N
mechanism NN N
) ) N
were VBD N
found VBN N
to TO N
generate VB N
significantly RB N
greater JJR N
extensor NN o
power NN o
than IN N
those DT N
receiving VBG N
a DT N
traditional JJ i
implant NN i
without IN N
the DT N
postulated JJ N
mechanical JJ N
advantage NN N
. . N

-DOCSTART- -6988462- O O

A DT N
comparative JJ N
trial NN N
of IN N
liver NN N
biopsy NN i
needles NNS N
. . N

A DT N
sheathed JJ i
needle NN i
( ( N
Tru-Cut NNP N
) ) N
was VBD N
compared VBN N
with IN N
a DT N
suction NN i
biopsy NN i
needle NN i
( ( i
Menghini NNP i
) ) i
in IN N
a DT N
randomised JJ N
prospective JJ N
trial NN N
over IN N
18 CD N
months NNS N
to TO N
determine VB N
whether IN N
the DT N
former JJ N
offered VBD N
any DT N
special JJ N
advantages NNS N
in IN N
routine JJ i
percutaneous JJ i
liver NN i
biopsy NN i
. . i

Seventy-seven JJ p
consecutive JJ p
biopsies NNS i
were VBD N
performed VBN N
by IN N
a DT p
single JJ p
operator NN p
. . p

Although IN N
biopsy JJ N
fragmentation NN N
was VBD N
commoner NN N
with IN N
the DT N
suction NN i
needle NN i
, , N
the DT N
length NN N
and CC N
volume NN N
of IN N
the DT N
largest JJS N
core NN N
obtained VBN N
was VBD N
similar JJ N
to TO N
results NNS N
with IN N
the DT N
sheathed JJ i
needle NN i
. . i

Cytology NNP N
provided VBD N
useful JJ N
additional JJ N
information NN N
with IN N
the DT N
Menghini NNP i
technique NN i
. . i

The DT N
suction NN i
needle NN i
was VBD N
repeatedly RB o
reusable JJ o
and CC o
considerably RB o
cheaper JJR o
than IN N
the DT N
sheathed JJ i
needle NN i
, , N
which WDT N
may MD N
be VB N
used VBN N
once RB N
only RB N
. . N

-DOCSTART- -16266472- O O

[ IN N
The DT N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
enalapril NN i
and CC i
indapamide NN i
on IN N
the DT N
peripheral JJ o
blood NN o
pressure NN o
and CC o
central JJ o
blood NN o
pressure NN o
through IN N
pulse JJ N
wave NN N
analysis NN N
] NNP N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS o
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitor NN i
enalapril NN i
and CC i
diuretic JJ i
indapamide NN i
on IN N
the DT N
peripheral JJ o
blood NN o
pressure NN o
and CC o
the DT o
central JJ o
blood NN o
pressure NN o
in IN N
Chinese JJ p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
double JJ N
blind NN N
, , N
randomized VBN N
study NN N
. . N

Informed VBN N
consent NN N
were VBD N
given VBN N
by IN N
all DT N
patients NNS N
. . N

After IN N
2 CD N
weeks NNS N
of IN N
placebo JJ i
run-in JJ N
period NN N
, , N
105 CD p
patients NNS p
with IN p
mild JJ p
or CC p
moderate JJ p
essential JJ p
hypertension NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
enalapril NN i
( ( N
10 CD N
mg NNS N
per IN N
day NN N
) ) N
or CC i
indapamide NN i
( ( N
2.5 CD N
mg NNS N
per IN N
day NN N
) ) N
for IN N
8 CD N
weeks NNS N
. . N

Radial JJ N
pulse JJ N
wave NN N
recordings NNS N
were VBD N
performed VBN N
in IN N
all PDT N
the DT N
patients NNS N
before IN N
the DT N
active JJ N
treatments NNS N
were VBD N
given VBN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Only RB p
those DT p
patients NNS p
who WP p
have VBP p
finished VBN p
8 CD p
weeks NNS p
of IN p
active JJ p
treatment NN p
in IN p
both DT p
groups NNS p
were VBD p
included VBN p
into IN p
the DT p
final JJ p
analysis NN p
. . p

RESULTS NNP N
One CD p
hundred VBD p
one CD p
patients NNS p
( ( p
51 CD p
in IN p
enalapril NN i
group NN p
and CC p
50 CD p
in IN p
indapamide JJ i
group NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

No DT N
significant JJ N
difference NN N
( ( N
all DT N
P NNP N
values NNS N
> VBP N
0.05 CD N
) ) N
was VBD N
found VBN N
in IN N
baseline NN N
data NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
all PDT N
the DT N
parameters NNS o
of IN o
pulse JJ o
wave NN o
( ( N
except IN N
heart NN N
rates NNS N
in IN N
both DT N
groups NNS N
and CC N
augmentation NN N
index NN N
in IN N
indapamide JJ i
group NN N
) ) N
decreased VBD N
significantly RB N
. . N

Comparison NNP N
of IN N
the DT N
2 CD N
groups NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
all DT N
P NNP N
values NNS N
> VBP N
0.05 CD N
) ) N
in IN N
all PDT N
the DT N
parameters NNS N
of IN N
pulse JJ N
wave NN N
except IN N
that IN N
the DT N
central JJ o
systolic JJ o
blood NN o
pressure NN o
, , o
augmentation NN o
and CC o
augmentation NN o
index NN o
were VBD N
significantly RB N
lower JJR N
in IN N
enalapril NN i
group NN N
than IN N
in IN N
indapamide JJ i
group NN N
. . N

In IN N
enalapril JJ i
group NN N
, , N
the DT N
reduced JJ N
values NNS N
of IN N
systolic JJ o
blood NN o
pressure NN o
and CC o
pulse JJ o
pressure NN o
in IN o
central JJ o
aorta NNS o
were VBD N
significantly RB N
larger JJR N
than IN N
those DT N
in IN N
brachial JJ N
artery NN N
. . N

However RB N
, , N
the DT N
difference NN o
was VBD N
not RB N
observed VBN N
in IN N
indapamide JJ i
group NN N
. . N

CONCLUSIONS NNP N
Enalapril NNP i
and CC i
indapamide NN i
are VBP N
both DT N
similarly RB N
effective JJ N
in IN N
reducing VBG N
peripheral JJ o
arterial JJ o
blood NN o
pressure NN o
. . o

Moreover RB N
, , N
enalapril NN i
is VBZ N
more RBR N
effective JJ N
in IN N
reducing VBG N
central JJ o
systolic JJ o
pressure NN o
and CC o
augmentation NN o
index NN o
than IN N
indapamide NN i
. . i

The DT N
difference NN N
is VBZ N
probably RB N
due JJ N
to TO N
the DT N
reduction NN N
of IN N
wave NN o
reflection NN o
caused VBN N
by IN N
enalapril NN i
. . i

-DOCSTART- -17356153- O O

Compliance NN N
with IN N
continuous JJ i
passive JJ i
movement NN i
is VBZ N
low JJ N
after IN N
surgical JJ N
treatment NN N
of IN N
idiopathic JJ p
club JJ p
foot NN p
in IN p
infants NNS p
: : p
a DT N
prospective JJ N
, , N
double-blinded JJ N
clinical JJ N
study NN N
. . N

Treatment NN N
by IN N
continuous JJ i
passive JJ i
movement NN i
at IN i
home NN i
is VBZ N
an DT N
alternative JJ N
to TO N
immobilisation NN N
in IN N
a DT N
cast NN N
after IN p
surgery NN p
for IN p
club JJ p
foot NN p
. . p

Compliance NN N
with IN N
the DT N
recommended JJ N
treatment NN N
, , N
of IN N
at IN N
least JJS N
four CD N
hours NNS N
daily RB N
, , N
is VBZ N
unknown JJ N
. . N

The DT N
duration NN N
of IN N
treatment NN N
was VBD N
measured VBN N
in IN N
24 CD p
of IN p
27 CD p
consecutive JJ p
children NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
24 CD p
months NNS p
( ( p
5 CD p
to TO p
75 CD p
) ) p
following VBG p
posteromedial JJ p
release NN p
for IN p
idiopathic JJ p
club JJ p
foot NN p
. . p

Only RB N
21 CD N
% NN N
( ( N
5 CD N
) ) N
of IN N
the DT N
children NNS N
used VBD N
the DT N
continuous JJ i
passive JJ i
movement NN i
machine NN N
as IN N
recommended JJ N
. . N

The DT N
mean JJ N
duration NN N
of IN N
treatment NN N
at IN N
home NN N
each DT N
day NN N
was VBD N
126 CD N
minutes NNS N
( ( N
11 CD N
to TO N
496 CD N
) ) N
. . N

The DT N
mean JJ o
range NN o
of IN o
movement NN o
for IN o
plantar NN o
flexion NN o
improved VBD o
from IN o
15.2 CD o
degrees NNS o
( ( o
10.0 CD o
degrees NNS o
to TO o
20.6 CD o
degrees NNS o
) ) o
to TO o
18.7 CD o
degrees NNS o
( ( o
10.0 CD o
degrees NNS o
to TO o
33.0 CD o
degrees NNS o
) ) o
and CC o
for IN o
dorsiflexion NN o
from IN o
12.3 CD o
degrees NNS o
( ( o
7.4 CD o
degrees NNS o
to TO o
19.4 CD o
degrees NNS o
) ) o
to TO o
18.9 CD o
degrees NNS o
( ( o
10.0 CD o
degrees NNS o
to TO o
24.1 CD o
degrees NNS o
) ) o
( ( o
both DT o
, , o
p NN o
= NNP o
0.0001 CD o
) ) o
when WRB o
the DT o
first JJ o
third NN o
of IN o
therapy NN o
was VBD o
compared VBN o
with IN o
the DT o
last JJ o
third JJ o
. . o

A DT N
low JJ N
level NN N
of IN N
patient JJ N
compliance NN N
must MD N
be VB N
considered VBN N
when WRB N
the DT N
outcome NN N
after IN N
treatment NN N
at IN N
home NN N
is VBZ N
interpreted VBN N
. . N

-DOCSTART- -341733- O O

The DT N
effect NN N
of IN N
metronidazole NN i
on IN N
the DT N
incidence NN o
of IN o
postoperative JJ o
wound NN o
infection NN o
in IN p
elective JJ p
colon NN p
surgery NN p
. . p

A DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
assessing VBG N
the DT N
relative JJ N
effectiveness NN N
of IN N
erythromycin-neomycin JJ i
and CC i
metronidazole-neomycin JJ i
as IN N
a DT N
preoperative JJ N
bowel NN N
preparation NN N
was VBD N
carried VBN N
out RP N
. . N

Bacteriologic NNP N
studies NNS N
of IN N
feces NNS N
and CC N
colon NN N
content NN N
revealed VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
reduction NN o
of IN o
aerobic JJ o
bacteria NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
a DT N
significantly RB N
greater JJR N
reduction NN o
in IN N
anaerobic JJ o
bacteria NNS o
in IN N
the DT N
feces NNS N
and CC N
colon NN N
contents NNS N
of IN N
patients NNS N
receiving VBG N
metronidazole NN N
. . N

Wound IN o
infection NN o
rate NN o
was VBD N
25 CD N
% NN N
in IN N
the DT N
erythromycin NN N
group NN N
, , N
and CC N
organisms NNS N
recovered VBN N
from IN N
the DT N
wound NN N
in IN N
all DT N
cases NNS N
were VBD N
fecal JJ N
in IN N
nature NN N
. . N

Two CD N
wound IN o
infections NNS o
occurred VBD N
in IN N
the DT N
metronidazole NN N
group NN N
( ( N
5 CD N
% NN N
) ) N
and CC N
in IN N
both DT N
cases NNS N
the DT N
organisms NNS N
recovered VBN N
were VBD N
staphylococci NNS o
of IN o
presumed JJ o
skin JJ o
origin NN o
. . o

These DT N
studies NNS N
suggest VBP N
that IN N
anaerobic JJ N
bacteria NNS N
are VBP N
the DT N
major JJ N
contributors NNS N
to TO N
wound VB o
infection NN o
after IN N
colon NN N
surgery NN N
and CC N
that IN N
their PRP$ N
specific JJ N
reduction NN N
is VBZ N
associated VBN N
with IN N
a DT N
lower JJR N
incidence NN N
of IN N
wound JJ o
infection NN o
. . o

-DOCSTART- -4154124- O O

Bites NNS N
by IN N
the DT N
saw-scaled JJ N
or CC N
carpet NN N
viper NN N
( ( N
Echis NNP N
carinatus NN N
) ) N
: : N
trial NN N
of IN N
two CD N
specific JJ N
antivenoms NNS N
. . N

Echis NNP N
carinatus NN N
is VBZ N
the DT N
most RBS N
important JJ N
cause NN N
of IN N
morbidity NN N
and CC N
mortality NN N
from IN N
snake JJ N
bite NN N
in IN N
Nigeria NNP N
and CC N
in IN N
many JJ N
other JJ N
parts NNS N
of IN N
the DT N
world NN N
. . N

Forty-six JJ p
patients NNS p
with IN p
systemic JJ p
poisoning NN p
by IN p
this DT p
snake NN p
were VBD N
given VBN N
echis JJ i
antivenom NN i
made VBD i
either CC i
by IN i
the DT i
South JJ i
African NNP i
Institute NNP i
for IN i
Medical NNP i
Research NNP i
( ( i
S.A.I.M.R NNP i
. . i

) ) i
or CC N
by IN N
Behringwerke NNP N
( ( i
North NNP i
and CC i
West NNP i
African NNP i
polyvalent NN i
antivenom NN i
) ) i
. . N

A DT N
simple JJ o
test NN o
of IN o
blood NN o
coagulability NN o
was VBD N
used VBN N
to TO N
assess VB N
whether IN N
an DT N
adequate JJ N
neutralizing NN N
dose NN N
of IN N
antivenom NN N
had VBD N
been VBN N
given VBN N
. . N

An DT N
average NN N
of IN N
15.2 CD N
ml NN N
S.A.I.M.R NNP i
. . i

antivenom RB i
restored VBD N
normal JJ o
coagulability NN o
permanently RB N
in IN N
all DT N
23 CD p
patients NNS p
in IN p
one CD p
group NN p
, , N
but CC N
in IN N
the DT N
other JJ N
group NN N
receiving VBG N
an DT N
average JJ N
dose NN N
of IN N
37.9 CD N
ml NNS N
Behringwerke NNP i
antivenom VBP i
normal JJ o
clotting NN o
resulted VBD N
in IN N
only RB N
18 CD N
out IN N
of IN N
23 CD N
patients NNS N
. . N

Local JJ o
tissue NN o
swelling NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
but CC N
local JJ o
necrosis NN o
occurred VBD N
in IN N
three CD N
patients NNS N
treated VBN N
with IN N
Behringwerke NNP i
antivenom NN i
and CC N
in IN N
none NN N
given VBN N
S.A.I.M.R NNP N
. . N

antivenom NN N
. . N

-DOCSTART- -3950826- O O

Nutrient JJ N
retention NN N
in IN N
preterm JJ p
infants NNS p
fed VBN p
standard JJ p
infant NN p
formulas NN p
. . p

Our PRP$ N
purpose NN N
was VBD N
to TO N
compare VB o
nitrogen NN o
, , o
mineral NN o
, , o
and CC o
zinc NN o
balance NN o
in IN N
preterm JJ p
infants NNS p
fed VBN p
standard JJ i
infant NN i
formulas NNS i
, , i
Similac NNP i
With IN i
Iron NNP i
and CC i
Similac NNP i
With IN i
Whey NNP i
+ NNP i
Iron NNP i
. . i

Nitrogen NNP o
and CC o
magnesium NN o
balances NNS o
were VBD N
similar JJ N
during IN N
both DT N
feeds NNS N
, , N
and CC N
met VBD N
estimated VBN N
fetal JJ N
requirements NNS N
. . N

Infants NNS N
absorbed VBD N
and CC N
retained VBD N
( ( N
milligrams FW N
per IN N
kilogram FW N
per IN N
day NN N
) ) N
more JJR N
calcium NN o
, , o
phosphorus NN o
, , o
and CC o
zinc NN o
when WRB N
fed VBN N
Similac NNP i
With IN i
Iron NNP i
. . i

However RB N
, , N
retention NN o
of IN o
calcium NN o
, , o
phosphorus NN o
( ( o
both DT o
formulas NN o
) ) o
, , o
and CC o
zinc NN o
( ( N
Similac NNP N
With IN N
Whey NNP N
+ NNP N
Iron NNP N
) ) N
was VBD N
inadequate JJ N
to TO N
meet VB N
estimated JJ N
fetal JJ N
requirements NNS N
. . N

These DT N
findings NNS N
are VBP N
important JJ N
in IN N
the DT N
rapidly RB p
growing VBG p
preterm JJ p
infant NN p
, , N
who WP N
is VBZ N
already RB N
at IN N
risk NN N
for IN N
the DT N
development NN N
of IN N
rickets NNS N
and CC N
zinc NN N
deficiency NN N
and CC N
may MD N
be VB N
fed VBN N
either DT N
formula NN N
on IN N
discharge NN N
from IN N
the DT N
newborn JJ N
nursery NN N
. . N

-DOCSTART- -15848979- O O

Treatment NNP N
outcome NN N
of IN N
appliance NN i
therapy NN i
in IN N
temporomandibular JJ p
disorder NN p
patients NNS p
with IN p
myofascial JJ o
pain NN o
after IN p
6 CD p
and CC p
12 CD p
months NNS p
. . p

AIM NNP N
To TO N
compare VB N
the DT N
long-term JJ N
effect NN N
of IN N
treatment NN N
with IN N
a DT N
stabilization NN i
appliance NN i
( ( N
group NN N
T NNP N
) ) N
and CC N
treatment NN N
with IN N
a DT N
control NN i
appliance NN i
( ( N
group NN N
C NNP N
) ) N
in IN N
temporomandibular JJ p
disorder NN p
( ( p
TMD NNP p
) ) p
patients NNS p
with IN p
myofascial JJ p
pain NN p
. . p

METHODS NNP N
In IN N
this DT N
controlled JJ N
trial NN N
, , N
60 CD p
patients NNS p
( ( p
mean JJ p
age NN p
29 CD p
years NNS p
) ) p
with IN p
myofascial JJ p
pain NN p
were VBD p
evaluated VBN p
after IN p
10 CD p
weeks NNS p
of IN p
treatment NN p
with IN p
either CC p
a DT p
stabilization NN i
appliance NN i
or CC p
a DT p
control JJ i
appliance NN i
. . i

All DT N
60 CD p
patients NNS p
were VBD N
then RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
according VBG N
to TO N
demand NN N
for IN N
treatment NN N
. . N

Seventeen JJ N
patients NNS N
from IN N
group NN N
C NNP N
requested VBD N
another DT N
appliance NN N
and CC N
were VBD N
given VBN N
a DT N
stabilization NN i
appliance NN i
, , N
thus RB N
creating VBG N
a DT N
mixed JJ N
group NN N
( ( N
group NN N
M NNP N
) ) N
. . N

RESULTS VB N
A DT N
significant JJ N
difference NN N
in IN N
improvement NN o
of IN o
overall JJ o
subjective JJ o
symptoms NNS o
in IN N
an DT N
intent-to-treat JJ N
analysis NN N
between IN N
groups NNS N
T NNP N
and CC N
C NNP N
was VBD N
found VBN N
at IN N
the DT N
follow-ups NNS N
. . N

In IN N
a DT N
survival JJ N
analysis NN N
of IN N
treatment NN N
compliance NN N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
groups NNS N
T NNP N
and CC N
C. NNP N
At IN N
the DT N
6- JJ N
and CC N
12-month JJ N
follow-ups NNS N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
myofascial JJ o
pain NN N
, , N
as IN N
measured VBN N
on IN N
a DT N
visual JJ o
analog NN o
scale NN o
, , N
was VBD N
found VBN N
in IN N
all DT N
three CD N
groups NNS N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
frequency NN o
and CC o
intensity NN o
of IN o
myofascial JJ o
pain NN o
was VBD N
found VBN N
in IN N
group NN N
T NNP N
at IN N
the DT N
follow-ups NNS N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
number NN o
of IN o
tender NN o
sites NNS o
on IN o
the DT o
masticatory NN o
muscles NNS o
was VBD N
found VBN N
in IN N
group NN N
T NNP N
at IN N
the DT N
follow-ups NNS N
. . N

CONCLUSION VB N
The DT N
results NNS N
support VBD N
the DT N
conclusion NN N
that IN N
the DT N
positive JJ N
treatment NN N
outcome NN N
obtained VBN N
by IN N
use NN N
of IN N
a DT N
stabilization NN i
appliance NN i
to TO N
alleviate VB N
the DT N
signs NNS N
and CC N
symptoms NNS N
in IN N
patients NNS p
with IN p
myofascial JJ p
pain NN p
persisted VBD N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
. . N

Most JJS N
patients NNS N
in IN N
groups NNS N
T NNP N
and CC N
M NNP N
reported VBD N
positive JJ N
changes NNS N
in IN N
overall JJ o
subjective JJ o
symptoms NNS o
in IN N
this DT N
trial NN N
. . N

We PRP N
therefore VBP N
recommend JJ N
use NN N
of IN N
the DT N
stabilization NN i
appliance NN i
in IN N
the DT N
treatment NN N
of IN N
TMD NNP p
patients NNS p
with IN p
myofascial JJ o
pain NN o
. . o

-DOCSTART- -22588803- O O

Ambient JJ i
temperature NN i
and CC i
biomarkers NNS i
of IN N
heart NN N
failure NN N
: : N
a DT N
repeated JJ N
measures NNS N
analysis NN N
. . N

BACKGROUND NNP N
Extreme NNP N
temperatures NNS N
have VBP N
been VBN N
associated VBN N
with IN N
hospitalization NN N
and CC N
death NN N
among IN p
individuals NNS p
with IN p
heart NN p
failure NN p
, , N
but CC N
few JJ N
studies NNS N
have VBP N
explored VBN N
the DT N
underlying JJ N
mechanisms NN N
. . N

OBJECTIVES IN N
We PRP N
hypothesized VBD N
that IN N
outdoor JJ N
temperature NN N
in IN N
the DT N
Boston NNP p
, , p
Massachusetts NNP p
, , N
area NN N
( ( N
1- JJ N
to TO N
4-day JJ N
moving NN N
averages NNS N
) ) N
would MD N
be VB N
associated VBN N
with IN N
higher JJR o
levels NNS o
of IN o
biomarkers NNS o
of IN o
inflammation NN o
and CC N
myocyte JJ o
injury NN o
in IN N
a DT N
repeated-measures JJ N
study NN N
of IN N
individuals NNS p
with IN p
stable JJ p
heart NN p
failure NN p
. . p

METHODS NNP N
We PRP N
analyzed VBD N
data NNS N
from IN N
a DT N
completed VBN N
clinical JJ N
trial NN N
that WDT N
randomized VBD N
100 CD p
patients NNS p
to TO N
12 CD i
weeks NNS i
of IN i
tai NN i
chi NN i
classes NNS i
or CC i
to TO i
time-matched JJ i
education NN i
control NN i
. . i

B-type NNP o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
, , o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
and CC o
tumor NN o
necrosis NN o
factor NN o
( ( o
TNF NNP o
) ) o
were VBD N
measured VBN N
at IN N
baseline NN N
, , N
6 CD N
weeks NNS N
, , N
and CC N
12 CD N
weeks NNS N
. . N

Endothelin-1 NNP o
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
12 CD N
weeks NNS N
. . N

We PRP N
used VBD N
fixed VBN N
effects NNS N
models NNS N
to TO N
evaluate VB N
associations NNS N
with IN N
measures NNS N
of IN N
temperature NN N
that WDT N
were VBD N
adjusted VBN N
for IN N
time-varying JJ N
covariates NNS N
. . N

RESULTS NNP N
Higher NNP N
apparent JJ N
temperature NN N
was VBD N
associated VBN N
with IN N
higher JJR N
levels NNS N
of IN N
BNP NNP o
beginning VBG N
with IN N
2-day JJ N
moving VBG N
averages NNS N
and CC N
reached VBD N
statistical JJ N
significance NN N
for IN N
3- JJ N
and CC N
4-day JJ N
moving NN N
averages NNS N
. . N

CRP NNP o
results NNS N
followed VBD N
a DT N
similar JJ N
pattern NN N
but CC N
were VBD N
delayed VBN N
by IN N
1 CD N
day NN N
. . N

A DT N
5?C CD N
change NN N
in IN N
3- JJ N
and CC N
4-day JJ N
moving NN N
averages NNS N
of IN N
apparent JJ o
temperature NN o
was VBD N
associated VBN N
with IN N
11.3 CD N
% NN N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
1.1 CD N
, , N
22.5 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
and CC N
11.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.2 CD N
, , N
22.5 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
higher JJR o
BNP NNP o
. . o

A DT N
5?C CD N
change NN N
in IN N
the DT N
4-day JJ N
moving JJ N
average NN N
of IN N
apparent JJ o
temperature NN o
was VBD o
associated VBN N
with IN N
21.6 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
2.5 CD N
, , N
44.2 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
higher JJR N
CRP NNP o
. . o

No DT N
clear JJ N
associations NNS N
with IN o
TNF NNP o
or CC o
endothelin-1 JJ o
were VBD o
observed VBN N
. . N

CONCLUSIONS NNP N
Among IN p
patients NNS p
undergoing VBG p
treatment NN p
for IN p
heart NN p
failure NN p
, , p
we PRP N
observed VBD N
positive JJ N
associations NNS N
between IN o
temperature NN o
and CC o
both DT o
BNP NNP o
and CC o
CRP-predictors NNS o
of IN o
heart NN o
failure NN o
prognosis NN o
and CC o
severity NN o
. . o

-DOCSTART- -2690913- O O

West NNP N
Midlands NNP N
Oncology NNP N
Association NNP N
trials NNS N
of IN N
adjuvant JJ i
chemotherapy NN i
in IN N
operable JJ p
breast NN p
cancer NN p
: : p
results NNS N
after IN N
a DT N
median JJ N
follow-up NN N
of IN N
7 CD N
years NNS N
. . N

I PRP N
. . N

Patients NNS p
with IN p
involved JJ p
axillary JJ p
lymph NN p
nodes NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
a DT N
regimen NNS i
of IN i
combination NN i
chemotherapy NN i
known VBN N
to TO N
be VB N
active JJ N
in IN N
advanced JJ N
breast NN N
cancer NN N
when WRB N
given VBN N
as IN N
an DT N
adjuvant JJ N
treatment NN N
after IN N
mastectomy NN N
. . N

A DT N
total NN N
of IN p
569 CD p
patients NNS p
with IN p
cancer NN p
of IN p
the DT p
breast NN p
and CC p
involvement NN p
of IN p
axillary JJ p
lymph NN p
nodes NNS p
were VBD p
randomised VBN p
, , p
after IN p
simple JJ i
mastectomy NN i
with IN i
axillary JJ i
sampling NN i
, , N
to TO N
receive VB N
either DT N
no DT i
adjuvant JJ i
treatment NN i
or CC i
intravenous JJ i
adriamycin NNS i
50 CD N
mg NN N
, , N
vincristine VBP i
1 CD N
mg NN N
, , N
cyclophosphamide RB i
250 CD N
mg NN N
, , N
methotrexate VB i
150 CD N
mg NN N
and CC N
fluorouracil NN i
250 CD N
mg NN N
( ( i
AVCMF NNP i
) ) i
every DT N
21 CD N
days NNS N
for IN N
eight CD N
cycles NNS N
. . N

Randomisation NN N
was VBD N
stratified VBN N
according VBG N
to TO N
menopausal NN N
status NN N
and CC N
tumour NN N
size NN N
. . N

Treatment NN N
was VBD N
started VBN N
within IN N
14 CD N
days NNS N
of IN N
surgery NN N
in IN N
94 CD N
% NN N
of IN N
patients NNS N
. . N

Eighty-eight JJ N
per IN N
cent NN N
of IN N
patients NNS N
received VBN N
at IN N
least JJS N
seven CD N
cycles NNS N
of IN N
chemotherapy NN N
with IN N
no DT N
dose JJ N
reduction NN N
. . N

The DT N
median JJ o
relapse-free JJ o
survival NN o
was VBD N
prolonged VBN N
by IN N
14 CD N
months NNS N
in IN N
patients NNS N
treated VBN N
with IN N
AVCMF NNP i
( ( N
chi2 JJ N
1 CD N
= JJ N
11.7 CD N
; : N
P NNP N
= NNP N
0.0006 CD N
) ) N
. . N

In IN N
the DT N
premenopausal NN p
group NN N
this DT N
period NN N
was VBD N
17 CD N
months NNS N
( ( N
chi2 JJ N
1 CD N
= JJ N
8.8 CD N
; : N
P NNP N
= NNP N
0.003 CD N
) ) N
compared VBN N
with IN N
8 CD N
months NNS N
in IN N
the DT N
post-menopausal JJ p
group NN N
( ( N
chi2 JJ N
1 CD N
= JJ N
3.3 CD N
; : N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

Neither CC N
overall JJ o
survival NN o
nor CC o
survival NN o
in IN N
these DT N
subgroups NNS N
was VBD N
significantly RB N
influenced VBN N
by IN N
treatment NN N
. . N

-DOCSTART- -6403413- O O

A DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
of IN N
melphalan NN i
and CC i
cis-platinum JJ i
versus NN N
hexamethylmelamine NN i
, , i
adriamycin NN i
, , i
and CC i
cyclophosphamide NN i
in IN N
advanced JJ p
ovarian JJ p
cancer NN p
. . p

From CD N
May NNP p
1978 CD p
until IN p
November NNP p
1980 CD p
, , p
169 CD p
previously RB p
untreated JJ p
patients NNS p
with IN p
advanced JJ p
epithelial JJ p
ovarian JJ p
cancer NN p
were VBD N
entered VBN N
into IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
comparing VBG N
the DT N
combination NN N
of IN N
hexamethylmelamine NN i
, , i
Adriamycin NNP i
, , i
and CC i
cyclophosphamide NN i
( ( i
HAC NNP i
) ) i
to TO i
a DT i
combination NN i
of IN i
melphalan NN i
and CC i
cis-platinum NN i
. . i

Eleven JJ p
patients NNS p
were VBD N
excluded VBN N
from IN N
analysis NN N
and CC N
another DT N
5 CD N
patients NNS N
were VBD N
excluded VBN N
from IN N
response NN N
analysis NN N
. . N

Of IN N
153 CD p
patients NNS p
evaluable JJ p
for IN p
response NN p
, , p
there EX p
were VBD p
47 CD p
, , p
or CC p
30.7 CD p
% NN p
, , p
complete JJ o
responders NNS o
( ( o
all DT o
determined VBN o
surgically RB o
) ) o
, , N
6 CD N
partial JJ N
responders NNS N
, , N
and CC N
100 CD N
nonresponders NNS N
. . N

The DT N
response NN o
rate NN o
for IN N
the DT N
HAC NNP i
group NN N
was VBD N
31 CD N
% NN N
and CC N
for IN N
the DT N
melphalan-platinum JJ i
group NN N
was VBD N
37.8 CD N
% NN N
. . N

The DT N
overall JJ N
response NN N
rate NN N
was VBD N
34.6 CD N
% NN N
. . N

Residual JJ N
tumor NN N
diameter NN N
( ( N
less JJR N
than IN N
or CC N
greater JJR N
than IN N
2 CD N
cm NN N
) ) N
exerted VBD N
a DT N
statistically RB N
significant JJ N
effect NN N
on IN N
response NN N
-- : N
47.8 CD N
vs JJ N
24.4 CD N
% NN N
. . N

Of IN N
the DT N
47 CD N
complete JJ N
responders NNS N
, , N
7 CD N
, , N
or CC N
14.9 CD N
% NN N
, , N
have VBP N
relapsed VBN N
, , N
with IN N
the DT N
median JJ N
duration NN N
of IN N
remission NN N
of IN N
44+ CD N
months NNS N
. . N

Of IN N
the DT N
158 CD p
patients NNS p
evaluable JJ N
for IN N
survival NN o
, , N
90 CD N
patients NNS N
have VBP N
died VBN N
, , N
with IN N
a DT N
median JJ o
survival NN o
time NN o
of IN N
27.9 CD N
months NNS N
( ( i
HAC NNP i
= VBZ N
26.4 CD N
months NNS N
, , N
melphalan-platinum JJ i
= NN N
29.6 CD N
months NNS N
) ) N
. . N

Age NNP N
, , N
FIGO NNP N
stage NN N
, , N
histologic JJ N
grade NN N
, , N
and CC N
residual JJ N
disease NN N
all DT N
exerted VBD N
a DT N
significant JJ N
effect NN N
on IN N
survival JJ N
time NN N
. . N

Second-line JJ N
therapy NN N
in IN N
the DT N
treatment NN N
failures NNS N
was VBD N
of IN N
no DT N
benefit NN N
. . N

Hematologic NNP o
toxicity NN o
was VBD N
greater JJR N
in IN N
the DT N
melphalan-platinum JJ i
group NN N
. . N

Gastrointestinal NNP o
toxicity NN o
was VBD N
severe JJ N
in IN N
both DT N
groups NNS N
. . N

Other JJ o
toxicities NNS o
were VBD N
minor JJ N
and CC N
infrequent NN N
. . N

-DOCSTART- -11208371- O O

Effect NN N
of IN N
surgical JJ i
technique NN i
in IN N
subtotal JJ i
and CC i
bilateral JJ i
thyroidectomy NN i
on IN N
risk NN N
of IN N
postoperative JJ N
parathyroid NN N
insufficiency NN N
development NN N
-- : N
our PRP$ N
experience NN N
. . N

One CD N
of IN N
the DT N
postoperative JJ N
complications NNS N
after IN N
strumectomy NN N
is VBZ N
hypoparathyroidism NN N
. . N

Therefore RB N
, , N
the DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
surgical JJ i
technique NN i
on IN N
the DT N
development NN o
of IN o
parathyroid JJ o
gland NN o
insufficiency NN o
in IN p
our PRP$ p
group NN p
of IN p
patients NNS p
. . p

Subtotal NNP N
, , N
bilateral JJ i
strumectomies NNS i
were VBD N
performed VBN N
according VBG N
to TO N
Rothmund NNP N
's POS N
suggestions NNS N
. . N

Randomized NNP N
controlled VBD N
trial NN N
was VBD N
performed VBN N
in IN N
two CD p
groups NNS p
. . p

In IN N
the DT N
first JJ p
group NN p
of IN p
19 CD p
patients NNS p
, , p
main JJ i
trunk NN i
of IN i
the DT i
inferior JJ i
thyroid JJ i
artery NN i
was VBD i
ligated VBN i
and CC p
in IN p
the DT p
second JJ p
one CD p
consisting NN p
of IN p
18 CD p
patients NNS p
, , p
only RB i
the DT i
branches NNS i
of IN i
this DT i
artery NN i
were VBD i
ligated VBN i
. . i

Total JJ o
calcium NN o
and CC o
PTH NNP o
levels NNS o
were VBD N
evaluated VBN N
pre- JJ N
and CC N
postoperatively RB N
. . N

Based VBN N
on IN N
the DT N
biochemical JJ N
and CC N
clinical JJ N
data NNS N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
development NN o
of IN o
postoperative JJ o
hypoparathyroidism NN o
in IN N
relation NN N
to TO N
performed VB N
surgical JJ i
techniques NNS i
were VBD N
observed VBN N
. . N

-DOCSTART- -9772038- O O

Involvement NN N
of IN N
cholecystokininA NN N
receptors NNS N
in IN N
transient NN N
lower JJR N
esophageal NN N
sphincter NN N
relaxations NNS N
triggered VBN N
by IN N
gastric JJ N
distension NN N
. . N

OBJECTIVE CC N
Transient NNP o
lower JJR o
esophageal NN o
sphincter NN o
relaxations NNS o
( ( o
TLESRs NNP o
) ) o
are VBP N
the DT N
main JJ N
mechanism NN N
underlying VBG N
gastroesophageal JJ N
reflux NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
loxiglumide NN N
, , N
a DT N
specific JJ N
cholecystokininA NN N
( ( N
CCKA NNP N
) ) N
-receptor NN N
antagonist NN N
, , N
on IN N
the DT N
occurrence NN N
of IN N
TLESRs NNP N
evoked VBN N
by IN N
gastric JJ N
distension NN N
. . N

METHODS NNP N
Eight NNP p
healthy JJ p
subjects NNS p
underwent JJ p
esophageal JJ p
manometry NN p
using VBG p
a DT p
10-lumen JJ i
sleeve NN i
assembly NN i
during IN i
placebo NN i
or CC i
loxiglumide NN i
( ( p
10 CD p
mg/kg/h NN p
) ) p
in IN p
a DT N
randomized JJ N
double-blind JJ N
order NN N
. . N

Gastric NNP N
distension NN N
was VBD N
induced VBN N
by IN N
inflation NN i
of IN i
400 CD i
ml NN i
of IN i
air NN i
. . i

RESULTS VB N
Basal NNP o
lower JJR o
esophageal NN o
pressure NN o
( ( o
LESP NNP o
) ) o
and CC o
swallow-induced JJ o
relaxation NN o
were VBD N
not RB N
affected VBN N
by IN N
loxiglumide NN N
. . N

Loxiglumide NNP N
significantly RB N
reduced VBD N
the DT N
number NN N
of IN N
TLESRs NNP o
, , N
from IN N
11.5 CD N
( ( N
5.8-18.3 JJ N
) ) N
to TO N
6.0 CD N
( ( N
3.3-14.3 JJ N
) ) N
during IN N
the DT N
total JJ N
recording JJ N
period NN N
of IN N
1 CD N
h NN N
, , N
and CC N
from IN N
5.5 CD N
( ( N
4.25-7.5 JJ N
) ) N
to TO N
2.0 CD N
( ( N
0.5-6.8 JJ N
) ) N
during IN N
the DT N
first JJ N
15 CD N
min NN N
. . N

The DT N
number NN o
of IN o
common JJ o
cavities NNS o
was VBD N
significantly RB N
decreased VBN N
by IN N
loxiglumide NN N
, , N
from IN N
8.0 CD N
( ( N
4.0-20.0 JJ N
) ) N
to TO N
5.0 CD N
( ( N
2.0-7.8 JJ N
) ) N
. . N

TLESRs NNP o
represented VBD N
the DT N
main JJ N
mechanism NN N
( ( N
60 CD N
% NN N
during IN N
placebo NN N
, , N
74 CD N
% NN N
during IN N
loxiglumide NN N
) ) N
underlying VBG N
common JJ N
cavities NNS N
, , N
followed VBN N
by IN N
swallow-induced JJ N
relaxation NN N
. . N

CONCLUSIONS NNP N
Loxiglumide NNP N
significantly RB N
reduces VBZ N
the DT N
number NN N
of IN N
TLESRs NNP o
triggered VBN N
by IN N
gastric JJ N
distension NN N
without IN N
interfering VBG N
with IN N
swallow-related JJ N
relaxation NN N
of IN N
the DT N
lower JJR N
esophageal NN N
sphincter NN N
, , N
suggesting VBG N
the DT N
involvement NN N
of IN N
CCKA NNP N
receptors NNS N
in IN N
the DT N
reflex JJ N
pathway NN N
mediating VBG N
TLESRs NNP N
. . N

-DOCSTART- -22850220- O O

Errors NNS N
during IN N
the DT N
preparation NN N
of IN N
drug NN N
infusions NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND IN N
We PRP N
investigated VBD N
the DT N
extent NN N
and CC N
frequency NN N
of IN N
dose JJ N
errors NNS N
and CC N
treatment NN N
delays NNS N
made VBN N
as IN N
a DT N
consequence NN N
of IN N
preparing VBG N
drug NN i
infusions NNS i
at IN i
the DT i
bedside NN i
, , N
rather RB N
than IN N
using VBG N
pre-filled JJ i
syringes NNS i
. . i

METHODS NNP N
Forty-eight JJ p
nurses NNS p
with IN p
critical JJ p
care NN p
experience NN p
volunteered VBD p
to TO p
take VB p
part NN p
in IN p
this DT p
randomized VBN p
, , p
blinded VBD p
, , p
controlled VBD p
study NN p
conducted VBN p
in IN p
the DT p
simulation NN p
centre NN p
of IN p
an DT p
urban JJ p
hospital NN p
. . p

They PRP N
assisted VBD N
in IN N
the DT N
management NN N
of IN N
a DT N
simulated JJ p
patient NN p
with IN p
septic JJ p
shock NN p
. . p

Vasopressor NNP i
infusions NNS i
were VBD N
prepared VBN N
either RB N
by IN N
diluting VBG i
concentrated VBN i
drugs NNS i
from IN i
ampoules NNS i
or CC N
were VBD N
provided VBN N
in IN N
syringes NNS i
pre-filled JJ i
beforehand NN N
by IN N
an DT N
intensive JJ N
care NN N
unit NN N
resident NN N
. . N

RESULTS VB N
The DT N
time NN N
taken VBN N
for IN N
the DT N
infusion NN N
to TO N
be VB N
started VBN N
and CC N
the DT N
final JJ o
concentration NN o
of IN o
the DT o
drugs NNS o
were VBD o
measured VBN o
. . o

We PRP N
also RB N
measured VBD N
the DT N
concentration NN o
of IN o
infusions NNS o
prepared VBN N
by IN N
a DT N
pharmacist NN N
and CC N
a DT N
pharmaceutical JJ N
company NN N
. . N

Nurses NNS N
took VBD N
156 CD N
s NN N
to TO N
start VB N
infusions NNS N
when WRB N
using VBG N
pre-filled JJ i
syringes NNS i
compared VBN N
with IN N
276 CD N
s NNS N
when WRB N
preparing VBG N
them PRP N
de FW N
novo FW N
, , N
a DT N
mean JJ N
delay NN N
of IN N
106 CD N
s NNS N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
73-140 CD N
s NN N
, , N
P NNP N
< VBZ N
0.0001 CD N
] NN N
. . N

One CD N
infusion NN N
prepared VBN N
from IN N
ampoules NNS N
contained VBN N
one-fifth CD N
of IN N
the DT N
expected JJ N
concentration NN N
of IN N
epinephrine NN i
; : i
another DT N
contained VBD N
none NN N
at IN N
all DT N
. . N

Medication NNP o
errors NNS o
were VBD N
17.0 CD N
times NNS N
less RBR N
likely JJ N
when WRB N
pre-filled JJ i
syringes NNS i
were VBD N
used VBN N
( ( N
95 CD N
% NN N
CI NNP N
5.2-55.5 CD N
) ) N
, , N
and CC N
infusions NNS i
prepared VBN N
by IN N
pharmacy NN N
and CC N
industry NN N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
contain VB N
the DT N
expected JJ N
concentration NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
for IN N
norepinephrine NN i
and CC N
P=0.001 NNP N
for IN N
epinephrine NN i
) ) i
. . N

CONCLUSIONS NNP N
Providing VBG N
drug NN i
infusions NNS i
in IN N
syringes NNS N
pre-filled VBN i
by IN N
pharmacists NNS N
or CC N
pharmaceutical JJ N
companies NNS N
would MD N
reduce VB N
medication NN o
errors NNS o
and CC o
treatment NN o
delays NNS o
, , N
and CC N
improve VB N
patient NN o
safety NN o
. . o

However RB N
, , N
this DT N
approach NN N
would MD N
have VB N
substantial JJ N
financial JJ N
implications NNS N
for IN N
healthcare NN N
providers NNS N
, , N
especially RB N
in IN N
less JJR N
developed JJ N
countries NNS N
. . N

-DOCSTART- -8614301- O O

Effect NN N
of IN N
marine NN i
oils NNS i
supplementation NN i
on IN N
coagulation NN N
and CC N
cellular JJ N
activation NN N
in IN N
whole JJ N
blood NN N
. . N

A DT N
study NN N
was VBD N
performed VBN N
to TO N
explore VB N
the DT N
effects NNS N
of IN N
supplemental JJ N
intake NN N
of IN N
various JJ N
marine NN N
oils NNS N
known VBN N
to TO N
be VB N
part NN N
of IN N
the DT N
Eskimo NNP p
diet NN p
. . p

Healthy JJ p
men NNS p
and CC p
women NNS p
( ( p
134 CD p
) ) p
were VBD N
randomly RB N
selected VBN N
to TO N
consume VB N
15 CD N
mL/d NN N
of IN N
oil NN i
from IN i
blubber NN i
of IN i
seal NN i
, , i
cod NN i
liver NN i
, , i
seal/cod NN i
liver NN i
, , i
blubber NN i
of IN i
Minke NNP i
whale NN i
, , i
or CC i
no DT i
oil NN i
for IN N
ten JJ N
weeks NNS N
. . N

Total JJ o
cholesterol NN o
was VBD N
unchanged JJ N
in IN N
the DT N
oil NN N
groups NNS N
, , N
whereas RB N
high JJ o
density NN o
lipoprotein VBP o
cholesterol NN o
increased VBD N
7 CD N
% NN N
in IN N
the DT N
seal/cod NN i
liver NN i
oil NN i
( ( N
CLO NNP N
) ) N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
11 CD N
% NN N
in IN N
the DT N
whale JJ i
oil NN i
group NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

Triacylglycerol NNP o
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
CLO NNP N
group NN N
only RB N
. . N

The DT N
concentration NN o
of IN o
prothrombin JJ o
fragment JJ o
1 CD o
+ JJ o
2 CD o
was VBD N
reduced VBN N
25 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
after IN N
whale JJ N
oil NN N
supplementation NN N
. . N

No DT N
change NN N
in IN N
fibrinogen NN o
or CC o
factor NN o
VIIc NNP o
was VBD N
detected VBN N
. . N

Tumor NNP o
necrosis NN o
factor NN o
generation NN o
in IN o
lipopolysaccharide NN o
( ( o
LPS NNP o
) ) o
-stimulated VBD o
blood NN o
was VBD N
30 CD N
% NN N
reduced VBN N
after IN N
whale JJ N
oil NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
was VBD N
unaffected VBN N
by IN N
intake NN N
of IN N
seal NN N
or CC N
CLO NNP N
. . N

The DT N
LPS-induced JJ o
tissue NN o
factor NN o
activity NN o
in IN o
monocytes NNS o
was VBD N
reduced VBN N
to TO N
a DT N
significant JJ N
degree NN N
only RB N
in IN N
the DT N
seal/CLO NN N
group NN N
( ( N
34 CD N
% NN N
) ) N
and CC N
whale JJ N
oil NN N
group NN N
( ( N
35 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
most RBS N
dramatic JJ N
change NN N
in IN N
thromboxane NN o
B2 NNP o
in IN N
LPS-stimulated NNP N
blood NN N
was VBD N
seen VBN N
after IN N
whale JJ N
oil NN N
intake NN N
with IN N
44 CD N
% NN N
reduction NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Supplementation NN N
of IN N
a DT N
regular JJ N
diet NN N
with IN N
a DT N
combination NN N
of IN N
seal JJ N
oil NN N
and CC N
CLO NNP N
and CC N
especially RB N
with IN N
whale JJ N
oil NN N
seems VBZ N
to TO N
have VB N
beneficial JJ N
effects NNS N
on IN N
several JJ N
products NNS N
thought VBN N
to TO N
be VB N
associated VBN N
with IN N
cardiovascular JJ N
and CC N
thrombotic JJ N
diseases NNS N
. . N

-DOCSTART- -1992319- O O

A DT N
placebo-controlled JJ i
trial NN N
of IN N
maintenance NN N
therapy NN N
with IN N
fluconazole JJ i
after IN p
treatment NN p
of IN p
cryptococcal JJ p
meningitis NN p
in IN p
the DT p
acquired JJ p
immunodeficiency NN p
syndrome NN p
. . p

California NNP N
Collaborative NNP N
Treatment NNP N
Group NNP N
. . N

BACKGROUND NNP N
AND NNP N
METHODS NNP N
In IN N
patients NNS p
with IN p
the DT p
acquired JJ p
immunodeficiency NN p
syndrome NN p
( ( p
AIDS NNP p
) ) p
, , N
the DT N
rate NN N
of IN N
relapse NN N
after IN N
primary JJ N
treatment NN N
for IN N
cryptococcal JJ N
meningitis NN N
remains VBZ N
high JJ N
. . N

We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
double-blind JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
maintenance NN N
therapy NN N
with IN N
fluconazole NN N
. . N

At IN N
entry NN N
into IN N
the DT N
study NN N
, , N
all DT p
participants NNS p
had VBD p
sterile JJ p
cultures NNS p
of IN p
cerebrospinal JJ p
fluid NN p
, , p
blood NN p
, , p
and CC p
urine JJ p
after IN p
following VBG p
a DT p
standardized JJ p
course NN p
of IN p
therapy NN p
for IN p
culture-proved JJ p
cryptococcal JJ p
meningitis NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
take VB N
either DT N
fluconazole NN i
or CC i
placebo NN i
as IN N
maintenance NN N
therapy NN N
. . N

The DT N
dose NN N
of IN N
fluconazole NN i
was VBD N
100 CD N
mg JJ N
daily RB N
in IN N
the DT N
first JJ N
phase NN N
of IN N
study NN N
and CC N
200 CD N
mg NNS N
daily RB N
in IN N
the DT N
second JJ N
phase NN N
. . N

RESULTS NNP N
Of IN p
84 CD p
patients NNS p
initially RB p
enrolled VBD p
, , p
16 CD p
( ( p
19 CD p
percent NN p
) ) p
were VBD p
found VBN p
to TO p
have VB p
silent JJ p
, , p
persistent JJ p
infection NN p
on IN p
the DT p
basis NN p
of IN p
cultures NNS p
that WDT p
became VBD p
positive JJ p
after IN p
entry NN p
into IN p
the DT p
study NN p
; : p
7 CD p
other JJ p
patients NNS p
were VBD p
lost VBN p
to TO p
follow-up NNS p
shortly RB p
after IN p
entry NN p
. . N

Of IN N
the DT N
remaining VBG p
61 CD p
patients NNS p
, , N
10 CD N
of IN N
27 CD N
assigned VBN N
to TO N
placebo VB i
( ( N
37 CD N
percent NN N
) ) N
and CC N
1 CD N
of IN N
34 CD N
assigned VBN N
to TO N
fluconazole VB i
( ( N
3 CD N
percent NN N
) ) N
had VBD N
a DT N
recurrence NN o
of IN o
cryptococcal JJ o
infection NN o
at IN o
any DT o
site NN o
( ( N
difference NN N
in IN N
risk NN N
, , N
34 CD N
percent NN N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
15 CD N
to TO N
53 CD N
) ) N
. . N

Of IN N
the DT N
11 CD N
recurrent NN N
infections NNS N
, , N
7 CD N
were VBD N
detected VBN N
in IN N
urine NN N
obtained VBN N
after IN N
prostatic JJ N
massage NN N
. . N

There EX N
were VBD N
four CD N
recurrent NN o
meningeal NN o
infections NNS o
in IN N
the DT N
patients NNS N
taking VBG N
placebo NN i
, , N
but CC N
none NN N
in IN N
those DT N
taking VBG N
fluconazole JJ i
( ( N
mean JJ N
duration NN N
of IN N
follow-up NN N
, , N
164 CD N
days NNS N
) ) N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

In IN N
multivariate NN N
analyses NNS N
, , N
the DT N
best JJS N
predictors NNS N
of IN N
recurrence-free JJ o
survival NN o
were VBD N
fluconazole JJ i
treatment NN i
( ( N
P NNP N
= NNP N
0.02 CD N
; : N
relative JJ N
hazard NN N
, , N
13.2 CD N
) ) N
, , N
a DT N
lower JJR N
serum NN N
cryptococcal-antigen NN N
titer NN N
( ( N
P NNP N
= NNP N
0.05 CD N
; : N
relative JJ N
hazard NN N
, , N
1.2 CD N
) ) N
, , N
and CC N
more JJR N
prolonged JJ N
primary JJ N
therapy NN N
with IN N
flucytosine NN N
( ( N
P NNP N
= NNP N
0.09 CD N
; : N
relative JJ N
hazard NN N
, , N
1.1 CD N
) ) N
. . N

Survival NNP o
and CC o
toxicity NN o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
maintenance-treatment JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
AIDS NNP p
, , N
silent JJ N
persistent JJ N
infection NN N
is VBZ N
common JJ N
after IN N
clinically RB N
successful JJ N
treatment NN N
for IN N
cryptococcal JJ N
meningitis NN N
. . N

Maintenance NNP N
therapy NN N
with IN N
fluconazole NN i
is VBZ N
highly RB N
effective JJ N
in IN N
preventing VBG N
recurrent JJ N
cryptococcal JJ N
infection NN N
. . N

-DOCSTART- -15623221- O O

Rapeseed NNP i
and CC i
soybean NN i
products NNS i
as IN N
protein NN N
sources NNS N
for IN N
growing VBG p
turkeys NNS p
of IN p
different JJ p
ages NNS p
. . p

( ( N
1 CD N
) ) N
Apparent NNP N
ileal NN N
and CC N
total JJ N
tract NN N
protein NN N
digestibilities NNS N
of IN N
rapeseed NN i
meal NN i
and CC i
cake NN i
and CC i
soybean NN i
meal NN i
and CC i
cake NN i
were VBD N
assayed VBN N
in IN N
growing VBG p
turkeys NNS p
at IN p
4 CD p
, , p
8 CD p
and CC p
12 CD p
weeks NNS p
of IN p
age NN p
. . p

( ( N
2 CD N
) ) N
In IN N
addition NN N
, , N
the DT N
effect NN N
of IN N
killing VBG N
technique NN N
on IN N
apparent JJ N
ileal NN N
protein NN N
digestibility NN N
values NNS N
obtained VBN N
by IN N
a DT N
slaughter NN N
method NN N
and CC N
effect NN N
of IN N
rapeseed NN i
feeding VBG i
on IN N
size NN N
of IN N
specific JJ N
organs NNS N
were VBD N
studied VBN N
. . N

( ( N
3 CD N
) ) N
Protein NNP o
digestibility NN o
coefficients NNS o
of IN o
rapeseed NN o
products NNS o
were VBD N
mostly RB N
0.10 CD N
to TO N
0.15 CD N
units NNS N
lower JJR N
than IN N
those DT N
of IN N
soybean JJ i
products NNS i
. . i

Ileal NNP o
digestibility NN o
of IN o
protein NN o
increased VBD N
slightly RB N
or CC N
remained VBD N
unchanged JJ N
from IN N
4 CD N
to TO N
8 CD N
weeks NNS N
and CC N
decreased JJ N
thereafter NN N
. . N

No DT N
effect NN N
of IN N
feed NN N
processing NN N
method NN N
( ( N
meal JJ N
vs NNS N
cake VBP N
) ) N
on IN N
ileal NN o
digestibility NN o
was VBD N
observed VBN N
. . N

( ( N
4 CD N
) ) N
Killing VBG N
the DT N
birds NNS N
by IN N
carbon NN N
dioxide NN N
inhalation NN N
and CC N
bleeding NN N
led VBD N
to TO N
slightly RB N
lower JJR N
ileal JJ o
digestibility NN o
values NNS o
than IN N
mechanical JJ N
stunning NN N
and CC N
neck NN N
dislocation NN N
. . N

( ( N
5 CD N
) ) N
Total NNP o
tract JJ o
digestibility NN o
of IN o
protein NN o
decreased VBN N
from IN N
4 CD N
to TO N
8 CD N
weeks NNS N
of IN N
age NN N
for IN N
soybean JJ i
meal NN i
and CC N
rapeseed VB i
meal NN i
but CC N
increased VBD N
for IN N
soybean JJ i
cake NN i
and CC N
rapeseed VB i
cake NN i
. . i

From IN N
8 CD N
to TO N
12 CD N
weeks NNS N
of IN N
age NN N
total JJ o
tract JJ o
digestibility NN o
of IN o
protein NN o
decreased VBN N
for IN N
all PDT N
the DT N
products NNS N
tested VBN N
. . N

( ( N
6 CD N
) ) N
Feed NN N
containing VBG N
rapeseed NN i
led VBD N
to TO N
enlargement VB N
of IN N
thyroid JJ N
glands NNS N
and CC N
hearts NNS N
, , N
but CC N
did VBD N
not RB N
affect VB N
liver NN o
size NN o
or CC o
mortality NN o
. . o

-DOCSTART- -8752181- O O

Prediction NN N
of IN N
the DT N
infarct-related JJ N
artery NN N
in IN N
acute JJ N
myocardial JJ N
infarction NN N
by IN N
a DT N
scoring NN N
system NN N
using VBG N
summary JJ i
ST-segment JJ i
and CC i
T-wave JJ i
changes NNS i
. . i

We PRP N
developed VBD N
a DT N
scoring NN N
system NN N
to TO N
predict VB N
the DT N
artery NN N
responsible JJ N
for IN N
an DT N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
using VBG N
ST-segment JJ i
and CC i
T-wave JJ i
changes NNS i
on IN i
the DT i
initial JJ i
electrocardiogram NN i
( ( i
ECG NNP i
) ) i
using VBG N
data NNS N
from IN N
228 CD p
patients NNS p
( ( p
development NN p
set VBN p
) ) p
with IN p
symptoms NNS p
compatible JJ p
with IN p
AMI NNP p
and CC p
tested VBN p
in IN p
a DT p
similar JJ p
group NN p
of IN p
223 CD p
patients NNS p
( ( p
test NN p
set VBN p
) ) p
from IN p
the DT p
Thrombolysis NNP p
and CC p
Angioplasty NNP p
in IN p
Myocardial NNP p
Infarction NNP p
( ( p
TAMI-5 NNP p
) ) p
Trial NNP p
. . p

Using VBG N
stepwise JJ N
logistic JJ N
regression NN N
we PRP N
were VBD N
able JJ N
to TO N
accurately RB N
predict VB N
the DT N
left NN N
anterior JJ N
descending NN N
( ( N
LAD NNP N
) ) N
, , N
right JJ N
, , N
or CC N
left VBD N
circumflex NN N
( ( N
LC NNP N
) ) N
coronary JJ N
artery NN N
as IN N
the DT N
infarct-related JJ N
artery NN N
using VBG N
2 CD N
variables NNS N
: : N
( ( N
1 CD N
) ) N
the DT N
summation NN N
of IN N
the DT N
ST-segment JJ N
elevation NN N
in IN N
leads VBZ N
V1 NNP N
to TO N
V4 NNP N
; : N
and CC N
( ( N
2 CD N
) ) N
the DT N
summation NN N
of IN N
the DT N
T-wave NNP N
negativity NN N
in IN N
leads NNS N
I PRP N
, , N
aVL RB N
, , N
and CC N
V5 NNP N
. . N

In IN N
the DT N
development NN N
set NN N
, , N
these DT N
2 CD N
variables NNS N
demonstrated VBD N
respective JJ N
sensitivity NN o
and CC o
specificity NN o
of IN N
98 CD N
% NN N
and CC N
90 CD N
% NN N
for IN N
LAD NNP N
lesions NNS N
, , N
82 CD N
% NN N
and CC N
85 CD N
% NN N
for IN N
right JJ N
narrowings NNS N
, , N
and CC N
82 CD N
% NN N
and CC N
84 CD N
% NN N
for IN N
LC NNP N
narrowings NNS N
. . N

In IN N
the DT N
test NN N
set NN N
, , N
the DT N
sensitivity NN o
and CC o
specificity NN o
were VBD N
97 CD N
% NN N
and CC N
95 CD N
% NN N
for IN N
LAD NNP N
lesions NNS N
, , N
85 CD N
% NN N
and CC N
86 CD N
% NN N
for IN N
right JJ N
lesions NNS N
, , N
and CC N
73 CD N
% NN N
and CC N
60 CD N
% NN N
for IN N
LC NNP o
coronary JJ o
artery NN o
lesions NNS o
. . o

Information NNP N
easily RB N
obtained VBD N
on IN N
the DT N
ECG NNP N
can MD N
accurately RB N
predict VB N
the DT N
likelihood NN N
of IN N
the DT N
LAD NNP N
, , N
right RB N
, , N
or CC N
LC NNP N
artery RB N
as IN N
the DT N
infarct-related JJ N
artery NN N
. . N

This DT N
may MD N
be VB N
useful JJ N
in IN N
the DT N
decision NN N
to TO N
administer VB N
thrombolytic JJ N
treatment NN N
. . N

-DOCSTART- -3114351- O O

Transdermal NNP i
nitroglycerin NN i
in IN N
angina JJ p
pectoris NN p
: : p
efficacy NN N
of IN N
intermittent JJ N
application NN N
. . N

Continuous JJ N
application NN N
of IN N
transdermal JJ i
nitroglycerin JJ i
appears VBZ N
to TO N
result VB N
in IN N
tolerance NN o
to TO o
the DT o
antianginal JJ o
effect NN o
. . o

In IN N
a DT N
double-blind NN N
study NN N
the DT N
effects NNS N
of IN N
continuous JJ N
( ( N
24 CD N
h/day NN N
) ) N
and CC N
intermittent NN N
( ( N
16 CD N
h/day NN N
) ) N
application NN N
of IN N
transdermal JJ i
nitroglycerin NN i
in IN i
a DT N
dosage NN N
of IN N
10 CD N
mg/day NN N
were VBD N
compared VBN N
with IN N
the DT N
effects NNS N
of IN N
placebo NN i
in IN N
12 CD p
patients NNS p
with IN p
chronic JJ p
stable JJ p
angina NN p
receiving VBG p
treatment NN p
with IN p
beta-adrenergic JJ i
blocking NN i
or CC i
calcium NN i
channel NNS i
blocking VBG i
agents NNS i
. . i

Exercise NN o
performance NN o
was VBD N
assessed VBN N
2 CD N
to TO N
4 CD N
hours NNS N
after IN N
initial JJ N
application NN N
and CC N
after IN N
1 CD N
week NN N
of IN N
each DT N
treatment NN N
given VBN N
in IN N
random JJ N
order NN N
with IN N
a DT N
3 CD N
day NN N
interval NN N
between IN N
treatments NNS N
. . N

Exercise NN o
time NN o
to TO o
onset VB o
of IN o
angina NN o
, , o
total JJ o
exercise NN o
duration NN o
and CC o
time NN o
to TO o
1 CD o
mm NNS o
ST NNP o
segment NN o
depression NN o
were VBD N
all DT N
significantly RB N
increased VBN N
after IN N
initial JJ N
application NN N
during IN N
the DT N
continuous JJ N
and CC N
intermittent JJ N
treatment NN N
periods NNS N
. . N

These DT N
increases NNS N
were VBD N
maintained VBN N
after IN N
1 CD N
week NN N
of IN N
intermittent NN N
but CC N
not RB N
continuous JJ N
treatment NN N
. . N

Thus VB N
the DT N
benefit NN N
of IN N
initial JJ N
application NN N
of IN N
transdermal JJ i
nitroglycerin NN i
is VBZ N
maintained VBN N
with IN N
intermittent JJ N
treatment NN N
and CC N
a DT N
daily JJ N
nitrate-free JJ N
interval NN N
, , N
whereas JJ N
tolerance NN o
to TO o
antianginal JJ o
effect NN o
occurs VBZ N
with IN N
continuous JJ N
treatment NN N
. . N

-DOCSTART- -12579266- O O

S-phase JJ i
kinase-associated JJ i
protein NN i
2 CD N
expression NN N
in IN N
laryngeal JJ p
squamous JJ p
cell NN p
carcinomas NN p
and CC N
its PRP$ N
prognostic JJ N
implications NNS N
. . N

The DT N
F-box JJ N
protein JJ N
S-phase JJ i
kinase-associated JJ i
protein NN i
2 CD N
( ( i
Skp2 NNP i
) ) i
positively RB N
regulates VBZ N
the DT N
G1-S JJ N
transition NN N
by IN N
controlling VBG N
the DT N
stability NN N
of IN N
several JJ N
G1 NNP N
regulators NNS N
, , N
such JJ N
as IN N
the DT N
cell NN N
cycle NN N
inhibitor NN N
p27kip1 NN N
. . N

However RB N
, , N
the DT N
clinical JJ N
significance NN N
of IN N
Skp2 NNP i
in IN N
patients NNS p
with IN p
laryngeal JJ p
squamous JJ p
cell NN p
carcinoma NN p
( ( p
LSCC NNP p
) ) p
remains VBZ N
unknown JJ N
. . N

In IN N
this DT N
study NN N
, , N
a DT N
potential JJ N
distribution NN N
of IN N
Skp2 NNP i
in IN N
LSCC NNP N
and CC N
its PRP$ N
clinical JJ N
implications NNS N
was VBD N
investigated VBN N
by IN N
an DT N
immunohistochemical JJ i
study NN i
. . i

Overall NNP N
, , N
Skp2 NNP o
overexpression NN o
was VBD N
observed VBN N
in IN N
36.7 CD p
% NN p
( ( p
37 CD p
of IN p
102 CD p
) ) p
patients NNS p
and CC N
was VBD N
significantly RB N
associated VBN N
with IN N
lymph JJ N
node JJ N
metastasis NN N
( ( N
p=0.002 NN N
) ) N
and CC N
was VBD N
inversely RB N
associated VBN N
with IN N
p27kip1 JJ N
expression NN N
( ( N
p=0.026 NN N
) ) N
. . N

Survival JJ o
analysis NN o
using VBG N
the DT N
Kaplan-Meier NNP N
method NN N
showed VBD N
that IN N
Skp2 NNP i
overexpression NN N
was VBD N
significantly RB N
associated VBN N
with IN N
shorter JJR N
disease-free NN o
and CC o
overall JJ o
survival NN o
( ( N
p=0.0051 NN N
and CC N
p=0.0002 NN N
, , N
respectively RB N
) ) N
. . N

When WRB N
Skp2 NNP o
expression NN o
and CC o
p27kip1 JJ o
expression NN o
were VBD N
combined VBN N
, , N
patients NNS N
with IN N
both DT N
Skp2 NNP i
overexpression NN N
and CC N
reduced JJ N
expression NN o
of IN o
p27kip1 NN o
revealed VBN N
poorest JJS o
disease-free JJ o
and CC N
overall JJ o
survival NN o
as IN N
compared VBN N
to TO N
the DT N
other JJ N
cases NNS N
( ( N
p=0.0017 NN N
and CC N
p NN N
< NN N
0.0001 CD N
, , N
respectively RB N
) ) N
. . N

Additionally RB N
, , N
in IN N
early JJ N
stage NN N
( ( N
I PRP N
, , N
II NNP N
) ) N
cases NNS N
, , N
Skp2 NNP i
expression NN N
was VBD N
also RB N
revealed VBN N
to TO N
possess VB N
a DT N
significant JJ N
prognostic JJ N
factor NN N
in IN N
overall JJ o
survival NN o
( ( o
p=0.0234 NN o
) ) o
, , N
but CC N
not RB N
in IN N
disease-free JJ o
survival NN o
( ( N
p=0.2055 NN N
) ) N
. . N

By IN N
multivariate NN N
analysis NN N
using VBG N
the DT N
Cox NNP o
proportional JJ o
hazards NNS o
model NN o
, , o
tumor NN o
grade NN o
, , o
tumor NN o
size NN o
, , o
clinical JJ o
stage NN o
and CC o
Skp2 NNP o
expression NN o
were VBD N
independent JJ N
prognostic JJ N
factors NNS N
both DT N
in IN N
disease-free JJ o
and CC o
overall JJ o
survival NN o
. . o

These DT N
findings NNS N
indicated VBD N
that IN N
Skp2 NNP o
expression NN o
was VBD N
closely RB N
associated VBN N
with IN N
tumor NN N
progression NN N
and CC N
represented VBD N
an DT N
independent JJ N
marker NN N
for IN N
prognosis NN N
of IN N
LSCC NNP N
. . N

-DOCSTART- -15965311- O O

Safety NN o
, , o
tolerability NN o
, , o
and CC o
changes NNS o
in IN o
amyloid JJ o
beta NN o
concentrations NNS o
after IN N
administration NN N
of IN N
a DT N
gamma-secretase JJ i
inhibitor NN i
in IN N
volunteers NNS p
. . p

Amyloid NNP N
beta NN N
( ( N
Abeta NNP N
) ) N
may MD N
play VB N
a DT N
central JJ N
role NN N
in IN N
the DT N
pathogenesis NN N
of IN N
Alzheimer NNP N
disease NN N
. . N

A DT N
functional JJ N
gamma-secretase NN N
inhibitor NN N
, , N
LY450139 NNP i
, , N
was VBD N
developed VBN N
that IN N
inhibits NNS N
Abeta NNP N
formation NN N
in IN N
whole JJ N
cell NN N
assays NNS N
, , N
transgenic JJ N
mice NN N
, , N
and CC N
beagle JJ N
dogs NNS N
. . N

The DT N
authors NNS N
wished VBD N
to TO N
determine VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
this DT N
drug NN N
, , N
and CC N
the DT N
reduction NN N
of IN N
Abeta NNP o
in IN o
plasma NN o
and CC o
cerebrospinal JJ o
fluid NN o
( ( o
CSF NNP o
) ) o
after IN N
multiple JJ N
doses NNS N
. . N

Volunteer NNP p
subjects NNS p
( ( p
N NNP p
= NNP p
37 CD p
) ) p
were VBD N
studied VBN N
using VBG i
doses NNS i
from IN i
5 CD i
to TO i
50 CD i
mg/day NN i
given VBN i
for IN i
14 CD i
days NNS i
. . i

Plasma NNP o
and CC o
CSF NNP o
concentrations NNS o
of IN o
LY450139 NNP o
, , o
Abeta NNP o
( ( o
1-40 JJ o
) ) o
and CC i
Abeta NNP o
( ( o
1-X JJ o
) ) o
( ( o
Abeta NNP o
( ( o
total JJ o
) ) o
) ) o
were VBD N
determined VBN N
, , N
and CC N
safety NN N
and CC N
tolerability NN N
were VBD N
assessed VBN N
. . N

The DT N
plasma JJ N
half-life NN N
of IN N
LY450139 NNP N
was VBD N
approximately RB N
2.5 CD N
hours NNS N
. . N

Pharmacokinetic JJ N
analyses NNS N
showed VBD N
a DT N
linear JJ N
relationship NN N
between IN N
dose NN N
and CC N
plasma JJ N
concentrations NNS N
, , N
with IN N
a DT N
Cmax NNP N
of IN N
828 CD N
+/- JJ N
19.2 CD N
ng/mL NN N
after IN N
a DT N
50-mg JJ N
dose NN N
. . N

Plasma NNP o
Abeta NNP o
concentrations NNS o
decreased VBD N
in IN N
a DT N
dose-dependent JJ N
manner NN N
over IN N
a DT N
6-hour JJ N
interval NN N
following VBG N
drug NN N
administration NN N
, , N
with IN N
a DT N
maximum JJ N
decrease NN N
of IN N
approximately RB N
40 CD N
% NN N
relative JJ N
to TO N
baseline VB N
. . N

After IN N
returning VBG N
to TO N
baseline VB N
, , N
Abeta NNP o
concentrations NNS o
were VBD N
transiently RB N
increased VBN N
. . N

CSF NNP o
Abeta NNP o
concentrations NNS o
were VBD N
unchanged JJ N
. . N

Adverse JJ o
events NNS o
reported VBN N
by IN N
subjects NNS N
taking VBG N
5-mg JJ N
, , N
20-mg JJ N
, , N
or CC N
40-mg JJ N
doses NNS N
were VBD N
similar JJ N
to TO N
those DT N
reported VBN N
by IN N
subjects NNS p
taking VBG p
placebo NN p
. . p

Two CD N
of IN N
7 CD N
subjects NNS N
taking VBG N
50 CD N
mg/day NN N
experienced VBD N
adverse JJ N
events NNS N
that WDT N
may MD N
have VB N
been VBN N
drug NN N
related VBN N
. . N

In IN N
this DT N
phase NN N
1 CD N
volunteer NN N
study NN N
, , N
reported VBD N
adverse JJ N
events NNS N
after IN N
taking VBG N
LY450139 NNP i
were VBD N
manageable JJ N
. . N

A DT N
dose-dependent JJ N
reduction NN N
in IN N
plasma NN o
Abeta NNP o
was VBD N
demonstrated VBN N
, , N
and CC N
changes NNS N
in IN N
plasma NN o
Abeta NNP o
concentrations NNS N
were VBD N
temporally RB N
related VBN N
to TO N
the DT N
pharmacokinetic JJ N
characteristics NNS N
of IN N
LY450139 NNP N
. . N

-DOCSTART- -8828933- O O

Regular JJ N
replacement NN N
of IN N
extended VBN i
wear NN i
rigid JJ i
gas NN i
permeable JJ i
contact NN i
lenses NNS i
. . i

PURPOSE NNP N
While IN N
the DT N
benefits NNS N
of IN N
planned JJ N
replacement NN N
of IN N
soft JJ i
contact NN i
lenses NNS i
have VBP N
been VBN N
investigated VBN N
, , N
the DT N
question NN N
of IN N
whether IN N
there EX N
are VBP N
any DT N
clinical JJ N
benefits NNS N
to TO N
planned VBN N
replacement NN N
of IN N
rigid JJ i
gas NN i
permeable NN i
( ( i
RGP NNP i
) ) i
lenses VBZ i
does VBZ N
not RB N
appear VB N
to TO N
have VB N
been VBN N
addressed VBN N
experimentally RB N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
benefits NNS N
of IN N
regular JJ i
replacement NN i
of IN N
extended VBN i
wear NN i
RGP NNP i
contact NN i
lenses VBZ i
. . i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
single-center JJ p
, , p
controlled VBN p
, , p
double-masked JJ p
study NN p
of IN p
39 CD p
RGP NNP p
lens VBZ p
wearers NNS p
. . p

The DT N
subjects NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
and CC N
wore NN i
extended VBD i
wear JJ i
Quantum NNP i
2 CD i
lenses NNS i
( ( N
Dk NNP N
= NNP N
120 CD N
) ) N
for IN N
12 CD N
months NNS N
. . N

Subjects NNS N
in IN N
Group NNP N
I PRP N
replaced VBD i
lenses NNS i
every DT i
3 CD i
months NNS i
, , N
whereas VBP N
those DT N
in IN N
Group NNP N
II NNP N
were VBD N
not RB i
scheduled VBN i
to TO i
replace VB i
their PRP$ i
lenses NNS i
. . i

The DT N
integrity NN o
of IN o
the DT o
lenses NNS o
and CC o
the DT o
ocular JJ o
responses NNS o
to TO N
lens NNS N
wear WDT N
were VBD N
monitored VBN N
in IN N
both DT N
groups NNS N
every DT N
three CD N
months NNS N
. . N

RESULTS NNP N
Compared VBD N
to TO N
lenses NNS N
worn VBN N
by IN N
subjects NNS N
in IN N
Group NNP N
I PRP N
, , N
lenses VBZ N
worn VBN N
by IN N
Group NNP N
II NNP N
subjects VBZ N
showed VBD N
significantly RB N
more RBR N
mucous JJ o
coating NN o
, , o
lens VBZ o
binding NN o
, , o
and CC o
corneal NN o
staining NN o
over IN N
time NN N
( ( N
P NNP N
< NNP N
0.05 CD N
; : N
ANCOVA NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
microcystic JJ o
or CC o
tarsal JJ o
conjunctiva JJ o
response NN o
, , o
lens VBZ o
comfort NN o
, , o
refractive JJ o
change NN o
, , o
or CC o
visual JJ o
acuity NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
We PRP N
advocate VBP N
that DT N
to TO N
maintain VB N
optimal JJ o
lens NNS o
integrity NN o
and CC o
ocular JJ o
health NN o
, , N
RGP NNP p
lenses VBZ p
used VBN N
for IN N
extended JJ N
wear NN N
should MD N
be VB N
replaced VBN N
every DT N
3 CD N
to TO N
6 CD N
months NNS N
. . N

-DOCSTART- -16160627- O O

Tetrahydrobiopterin NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
: : p
a DT N
double-blind JJ N
placebo-controlled JJ i
crossover NN N
study NN N
. . N

Twelve NNP p
children NNS p
, , p
all DT p
boys NNS p
, , p
aged VBD p
4 CD p
to TO p
7 CD p
years NNS p
, , p
with IN p
a DT p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
and CC p
low JJ p
concentrations NNS p
of IN p
spinal JJ p
6R-l-erythro-5,6,7,8-tetrahydrobiopterin JJ p
( ( p
tetrahydrobiopterin NN p
) ) p
were VBD N
selected VBN N
to TO N
participate VB N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

The DT N
children NNS N
received VBD N
a DT N
daily JJ N
dose NN N
of IN N
3 CD N
mg NNS N
tetrahydrobiopterin JJ i
per IN N
kilogram NN N
during IN N
6 CD N
months NNS N
alternating VBG N
with IN N
placebo NN i
. . i

Treatment-induced JJ o
effects NNS o
were VBD N
assessed VBN N
with IN N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
every DT N
third JJ N
month NN N
. . N

The DT N
results NNS N
showed VBD N
small JJ N
nonsignificant JJ N
changes NNS N
in IN N
the DT N
total JJ o
scores NNS o
of IN o
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
after IN N
3- JJ N
and CC N
6-month JJ N
treatment NN N
. . N

Post NNP N
hoc NN N
analysis NN N
looking VBG N
at IN N
the DT N
3 CD N
core NN N
symptoms NNS N
of IN N
autism NN N
, , N
that WDT N
is VBZ N
, , N
social JJ o
interaction NN o
, , o
communication NN o
, , o
and CC o
stereotyped VBD o
behaviors NNS o
, , N
revealed VBD N
a DT N
significant JJ N
improvement NN N
of IN N
the DT N
social JJ o
interaction NN o
score NN o
after IN N
6 CD N
months NNS N
of IN N
active JJ N
treatment NN N
. . N

In IN N
addition NN N
, , N
a DT N
high JJ N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
response NN o
of IN o
the DT o
social JJ o
interaction NN o
score NN o
and CC o
IQ NNP o
. . o

The DT N
results NNS N
indicate VBP N
a DT N
possible JJ N
effect NN N
of IN N
tetrahydrobiopterin NN i
treatment NN N
. . N

-DOCSTART- -14662278- O O

Determination NN N
of IN N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
DIG NNP N
trial NN N
. . N

The DT N
Digitalis NNP N
Investigation NNP N
Group NNP N
( ( N
DIG NNP N
) ) N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
placebo-controlled JJ i
trial NN N
whose WP$ N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
digoxin NN i
had VBD N
beneficial JJ N
, , N
harmful JJ N
, , N
or CC N
no DT N
effect NN N
on IN N
total JJ N
mortality NN N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
who WP p
were VBD p
in IN p
sinus NN p
rhythm NN p
and CC p
whose WP$ p
ejection NN p
fraction NN p
was VBD p
< JJ p
/=0.45 NNP p
. . p

The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
large JJ N
simple JJ N
trial NN N
with IN N
a DT p
large JJ p
number NN p
of IN p
centers NNS p
( ( p
302 CD p
) ) p
in IN p
the DT p
United NNP p
States NNPS p
and CC p
Canada NNP p
, , p
many JJ p
of IN p
which WDT p
were VBD p
inexperienced VBN p
in IN p
research NN p
. . p

To TO N
ensure VB N
that IN N
the DT N
results NNS N
of IN N
the DT N
trial NN N
would MD N
be VB N
reported VBN N
accurately RB N
without IN N
possible JJ N
bias NN N
due JJ N
to TO N
missing VBG N
data NNS N
, , N
the DT N
study NN N
leadership NN N
decided VBD N
that IN N
no DT N
outcome NN N
results NNS N
would MD N
be VB N
reported VBN N
until IN N
the DT N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
known VBN N
for IN N
at IN N
least JJS N
97 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
. . N

Planning VBG N
for IN N
closeout NN N
of IN N
the DT N
study NN N
began VBD N
a DT N
year NN N
prior RB N
to TO N
the DT N
common JJ N
end NN N
date NN N
of IN N
December NNP N
31 CD N
, , N
1995 CD N
and CC N
included VBD N
plans NNS N
for IN N
obtaining VBG N
vital JJ N
status NN N
on IN N
December NNP N
31 CD N
, , N
1995 CD N
. . N

Participants NNS N
were VBD N
given VBN i
postcards NNS i
at IN i
their PRP$ i
final JJ i
study NN i
visit NN i
to TO i
be VB i
completed VBN i
and CC i
mailed VBN i
on IN i
or CC i
after IN i
January NNP i
1 CD i
, , i
1996 CD i
. . i

Of IN p
5602 CD p
postcards NNS p
distributed VBN p
, , p
5070 CD p
( ( p
90.5 CD p
% NN p
) ) p
were VBD p
completed VBN p
and CC p
returned VBN p
. . p

A DT N
contract NN N
search NN N
agency NN N
was VBD N
hired VBN N
to TO N
locate VB N
the DT N
remaining VBG N
participants NNS N
. . N

Of IN p
the DT p
total JJ p
7788 CD p
participants NNS p
entered VBD p
into IN p
the DT p
DIG NNP p
trial NN p
, , p
only RB p
97 CD p
participants NNS p
( ( p
1.2 CD p
% NN p
) ) p
could MD p
not RB p
have VB p
their PRP$ p
vital JJ o
status NN o
as IN p
of IN p
December NNP p
31 CD p
, , p
1995 CD p
determined VBD p
. . p

It PRP N
is VBZ N
recommended VBN N
that IN N
investigators NNS N
having VBG N
an DT N
outcome NN N
measure NN N
with IN N
a DT N
common JJ N
end NN N
date NN N
include VBP N
plans NNS N
in IN N
their PRP$ N
protocols NNS N
for IN N
obtaining VBG N
their PRP$ N
measures NNS N
and CC N
activate VBP N
those DT N
plans NNS N
as RB N
early RB N
as IN N
possible JJ N
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -9308064- O O

Postoperative JJ N
analgesia NN N
with IN N
preoperative JJ N
oral JJ N
ibuprofen NN i
or CC N
acetaminophen NN i
in IN N
children NNS p
undergoing VBG p
myringotomy NN p
. . p

Previous JJ N
studies NNS N
have VBP N
shown VBN N
over IN N
70 CD p
% NN p
of IN p
children NNS p
require VBP N
analgesics NNS i
following VBG N
bilateral JJ p
myringotomy NNS p
and CC p
tube VB p
placement NN p
( ( p
BM NNP p
& CC p
T NNP p
) ) p
. . p

This DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
compared VBN N
the DT N
postoperative JJ N
analgesic JJ N
effects NNS N
of IN N
preoperatively RB N
administered VBN N
oral JJ N
acetaminophen NN i
or CC i
ibuprofen NN i
. . i

Forty NNP p
three CD p
ASA NNP p
I PRP p
or CC p
II NNP p
children NNS p
age NN p
six CD p
months NNS p
or CC p
older JJR p
scheduled VBN p
for IN p
elective JJ p
BM NNP p
& CC p
T NNP p
were VBD N
randomized VBN N
to TO N
receive VB N
acetaminophen NN i
( ( i
paracetamol NN i
) ) i
15 CD i
mg.kg-1 JJ i
, , i
ibuprofen JJ i
10 CD i
mg.kg-1 NN i
, , i
or CC i
placebo NN i
. . i

Postoperative JJ N
pain NN N
was VBD N
assessed VBN N
using VBG N
the DT N
Children NNP o
's POS o
Hospital NNP o
of IN o
Eastern NNP o
Ontario NNP o
Pain NNP o
Scale NNP o
( ( o
CHEOPS NNP o
) ) o
upon IN N
arrival NN N
to TO N
the DT N
PACU NNP N
and CC N
at IN N
5 CD N
, , N
10 CD N
, , N
15 CD N
, , N
30 CD N
, , N
45 CD N
, , N
and CC N
60 CD N
min NN N
. . N

CHEOP NNP N
scores NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
at IN N
any DT N
time NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
children NNS p
receiving VBG p
rescue NN o
analgesia NN o
. . o

This DT N
study NN N
showed VBD N
no DT N
benefit NN N
of IN N
preoperatively RB N
administered VBN N
oral JJ N
ibuprofen NN i
10 CD N
mg.kg-1 NN N
or CC N
acetaminophen VB i
15 CD N
mg.kg-1 NN N
over IN N
placebo NN N
for IN N
the DT N
relief NN N
of IN N
postoperative JJ N
pain NN N
in IN N
children NNS p
undergoing VBG p
BM NNP p
& CC p
T NNP p
. . p

-DOCSTART- -8832772- O O

Effects NNS N
of IN N
ORG-2766 NNP i
on IN N
brain NN N
event-related JJ N
potentials NNS N
of IN N
autistic JJ p
children NNS p
. . p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
6 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
the DT N
adrenocorticotropin4-9 JJ i
analogue NN i
ORG-2766 NNP i
( ( N
40 CD N
mg/day NN N
) ) N
on IN N
brain NN N
event-related JJ N
potentials NNS N
( ( N
ERPs NNP N
) ) N
of IN N
autistic JJ p
children NNS p
. . p

In IN N
visual JJ N
and CC N
auditory JJ N
oddball NN N
paradigms NN N
( ( N
with IN N
task NN N
and CC N
nontask JJ N
conditions NNS N
) ) N
, , N
standard JJ N
( ( N
80 CD N
% NN N
) ) N
, , N
target NN N
( ( N
10 CD N
% NN N
) ) N
, , N
and CC N
unexpected JJ N
novel NN N
stimuli NNS N
( ( N
10 CD N
% NN N
) ) N
were VBD N
presented VBN N
. . N

ORG-2766 NNP N
( ( N
a DT N
) ) N
increased VBD o
the DT o
occipital JJ o
P3 NNP o
component NN o
of IN o
the DT o
ERP NNP o
to TO o
visual JJ o
targets NNS o
, , o
( ( o
b NN o
) ) o
decreased VBD o
the DT o
occipital JJ o
P3 NNP o
component NN o
of IN o
the DT o
ERP NNP o
to TO o
auditory JJ o
targets NNS o
, , o
( ( o
c NN o
) ) o
did VBD o
not RB o
affect VB o
visual JJ o
and CC o
auditory JJ o
parietal JJ o
target NN o
P3 NNP o
components NNS o
, , o
and CC o
( ( o
d NN o
) ) o
also RB o
did VBD o
not RB o
affect VB o
the DT o
A/Pcz/300 NNP o
to TO o
auditory VB o
novel JJ o
stimuli NNS o
. . o

In IN N
addition NN N
, , N
ORG-2766 NNP N
treatment NN N
increased VBD o
the DT o
N1 NNP o
component NN o
of IN o
the DT o
ERP NNP o
to TO o
task-irrelevant JJ o
auditory NN o
stimuli NNS o
. . o

-DOCSTART- -1409770- O O

The DT N
cumulative JJ N
dose NN N
response NN N
effect NN N
of IN N
eicosapentaenoic NN i
and CC N
docosahexaenoic JJ i
acid NN i
on IN N
blood NN o
pressure NN o
, , o
plasma NN o
lipid JJ o
profile NN o
and CC o
diet JJ o
pattern NN o
in IN N
mild NN p
to TO p
moderate VB p
essential JJ p
hypertensive JJ p
black JJ p
patients NNS p
. . p

In IN N
this DT N
study NN N
eicosapentaenoic VBZ i
acid NNS i
( ( i
EPA NNP i
) ) i
and CC i
docosahexaenoic JJ i
acid NN i
( ( i
DHA NNP i
) ) i
were VBD N
given VBN N
in IN N
a DT N
cumulative JJ N
manner NN N
, , N
every DT N
6 CD N
weeks NNS N
, , N
starting VBG N
with IN N
10 CD N
mg NNS N
, , N
then RB N
100 CD N
mg NNS N
, , N
1000 CD N
mg NN N
and CC N
10,000 CD N
mg NNS N
EPA NNP i
daily RB N
to TO N
mild VB p
to TO p
moderate VB p
essential JJ p
hypertensive JJ p
black JJ p
patients NNS p
. . p

The DT N
corresponding JJ N
DHA NNP i
doses NNS N
were VBD N
3 CD N
, , N
33 CD N
, , N
333 CD N
and CC N
3333 CD N
mg. NN N
A NNP N
control NN N
group NN N
was VBD N
given VBN N
olive JJ i
oil NN i
as IN i
placebo NN i
for IN N
the DT N
entire JJ N
24 CD N
weeks NNS N
. . N

The DT N
placebo NN i
group NN N
had VBD N
lower JJR o
diastolic NN o
and CC o
systolic JJ o
blood NN o
pressures NNS o
after IN N
24 CD N
weeks NNS N
than IN N
the DT N
EPA NNP i
and CC N
DHA NNP i
group NN N
. . N

No DT N
effect NN o
was VBD N
seen VBN N
on IN N
plasma NN o
triglycerides NNS o
, , o
cholesterol NN o
, , o
HDL-cholesterol NNP o
and CC o
gamma-glutamyltranspeptidase NN o
at IN N
any DT N
stage NN N
of IN N
the DT N
trial NN N
. . N

In IN N
the DT N
EPA NNP i
group NN N
plasma VBD o
free-EPA NN o
increased VBN o
significantly RB o
from IN N
1000 CD N
mg NN N
onwards NNS N
and CC N
plasma JJ o
free-arachidonic JJ o
acid NN o
( ( o
AA NNP o
) ) o
decreased VBD o
after IN N
1000 CD N
mg NN N
EPA NNP i
. . i

No DT N
other JJ N
plasma NN o
free JJ o
essential JJ o
fatty NN o
acid RB o
changed VBD o
during IN N
the DT N
trial NN N
, , N
although IN N
the DT N
HDL NNP o
: : o
cholesterol NN o
increased VBD o
slightly RB o
but CC N
non-significantly RB o
with IN N
an DT N
increase NN o
in IN N
EPA NNP o
and CC o
DHA NNP o
. . o

No NNP N
significant JJ o
changes NNS o
in IN N
diet JJ o
pattern NN o
or CC o
body NN o
mass NN o
was VBD N
observed VBN o
. . o

It PRP N
is VBZ N
therefore RB N
concluded JJ N
that IN N
EPA NNP i
and CC N
DHA NNP i
supplementation NN i
had VBD N
no DT N
beneficial JJ N
effects NNS N
in IN N
mild NN p
to TO p
moderate VB p
essential JJ p
hypertensive JJ p
black JJ p
patients NNS p
except IN N
for IN N
a DT N
lowering NN o
of IN o
plasma NN o
AA NNP o
. . o

-DOCSTART- -16904970- O O

Patient-reported JJ N
outcomes NNS o
after IN N
inguinal JJ i
herniorrhaphy NN i
. . i

BACKGROUND NNP N
Patient-reported JJ N
outcomes NNS o
( ( N
PRO NNP N
) ) N
reflect VBP N
the DT N
functional JJ N
outcomes NNS N
of IN N
inguinal JJ i
herniorrhaphy NN i
. . i

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
hernia NN p
recurrence NN p
and CC p
complications NNS p
on IN p
PRO NNP p
for IN p
participants NNS p
in IN p
the DT p
Veterans NNP p
Affairs NNPS p
trial NN p
of IN p
Open NNP p
or CC p
Laparoscopic NNP p
Repair NNP p
of IN p
Inguinal NNP p
Hernia NNP p
. . p

METHODS NNP N
Analyzed NNP N
PRO NNP N
included VBD N
( ( N
1 CD N
) ) N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
Short NNP N
Form NNP N
36 CD N
, , N
version NN N
2 CD N
, , N
( ( N
2 CD N
) ) N
the DT N
Surgical NNP N
Pain NNP N
Scale NNP N
, , N
( ( N
3 CD N
) ) N
the DT N
Activities NNPS N
Assessment NNP N
Scale NNP N
, , N
and CC N
( ( N
4 CD N
) ) N
patient NN N
satisfaction NN N
. . N

Recurrences NNS N
and CC N
complications NNS N
were VBD N
recorded VBN N
at IN N
follow-up JJ N
visits NNS N
. . N

Complications NNS N
were VBD N
categorized VBN N
by IN N
( ( N
1 CD N
) ) N
hematoma/seroma NN o
, , N
( ( N
2 CD N
) ) N
orchitis NN o
, , N
( ( N
3 CD N
) ) N
neuralgia NN o
, , N
and CC N
( ( N
4 CD N
) ) N
other JJ N
. . N

Univariate NNP N
and CC N
multivariable JJ N
regression NN N
analyses NNS N
identified VBD N
variables NNS N
significantly RB N
associated VBN N
with IN N
postoperative JJ N
PRO NNP N
. . N

RESULTS NNP N
Of IN N
the DT N
1603 CD p
patients NNS p
with IN p
PRO NNP p
data NNS p
, , p
105 CD p
had VBD p
a DT p
recurrence NN o
and CC p
342 CD p
had VBD p
a DT p
complication NN p
at IN p
2 CD p
years NNS p
. . p

Multivariable JJ N
analyses NNS N
showed VBD N
neuralgia JJ o
( ( N
P NNP N
< NNP N
.0005 NNP N
) ) N
adversely RB N
affected VBD N
all DT N
PRO NNP N
, , N
and CC N
recurrence NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
affected VBD N
patient-reported JJ o
pain NN o
, , o
activity NN o
, , o
and CC o
satisfaction NN o
, , N
but CC N
not RB N
the DT N
score NN N
for IN N
the DT N
Medical NNP o
Outcomes NNP o
Study NNP o
Short NNP o
Form NNP o
3 CD o
. . o

Patients NNS N
with IN N
a DT N
recurrence NN N
after IN N
open JJ N
repair NN N
had VBD N
more RBR N
pain NN o
than IN N
those DT N
with IN N
a DT N
recurrence NN N
after IN N
laparoscopic JJ N
repair NN N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
. . N

Patients NNS N
with IN N
other JJ N
complications NNS N
after IN N
laparoscopic NN N
repair NN N
reported VBD N
more JJR N
pain NN o
and CC o
less JJR o
activity NN o
than IN N
those DT N
with IN N
other JJ N
complications NNS N
after IN N
open JJ N
repair NN N
( ( N
P NNP N
= NNP N
.003 NNP N
and CC N
P NNP N
= NNP N
.009 NNP N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS VB N
The DT N
effectiveness NN N
of IN N
inguinal JJ N
herniorrhaphy NN N
should MD N
be VB N
measured VBN N
by IN N
the DT N
rate NN N
of IN N
recurrence NN o
and CC o
neuralgia NN o
. . o

Postoperative JJ N
neuralgias NNS N
have VBP N
a DT N
deleterious JJ N
effect NN N
on IN N
all DT N
patient-reported JJ N
outcomes NNS N
. . N

-DOCSTART- -8394956- O O

The DT N
relative JJ N
contributions NNS N
of IN N
medication NN i
adherence NN i
and CC i
AA NNP i
meeting NN i
attendance NN i
to TO N
abstinent VB N
outcome NN N
for IN N
chronic JJ p
alcoholics NNS p
. . p

Our PRP$ N
preliminary JJ N
studies NNS N
of IN N
the DT N
efficacy NN N
of IN N
lithium NN i
carbonate NN i
therapy NN i
for IN N
alcoholism NN N
under IN N
double-blind NN N
, , N
placebo-controlled JJ N
conditions NNS N
demonstrated VBD N
that IN N
alcoholics NNS p
who WP p
took VBD p
their PRP$ p
assigned JJ p
medication NN p
( ( i
lithium NN i
or CC i
placebo NN i
) ) i
for IN p
the DT p
first JJ p
6 CD p
months NNS p
after IN p
discharge NN p
from IN p
an DT p
inpatient JJ p
rehabilitation NN p
program NN p
were VBD N
more RBR N
likely JJ N
to TO N
abstain VB N
from IN N
any DT N
alcohol NN N
use NN N
for IN N
18 CD N
months NNS N
following VBG N
discharge NN N
than IN N
were VBD N
alcoholics NNS p
who WP p
took VBD p
their PRP$ p
medication NN p
erratically RB p
or CC p
not RB p
at IN p
all DT p
. . p

Attendance NN p
at IN p
Alcoholics NNP p
Anonymous NNP p
( ( p
AA NNP p
) ) p
meetings NNS p
was VBD N
also RB N
associated VBN N
with IN N
medication NN N
adherence NN N
. . N

We PRP N
applied VBD N
a DT N
structural JJ N
equation NN N
model NN N
to TO N
data NNS N
on IN N
the DT N
relationships NNS N
between IN N
medication NN N
adherence NN N
, , N
AA NNP N
meeting NN N
attendance NN N
and CC N
abstinent JJ o
outcome NN o
to TO N
clarify VB N
whether IN N
medication NN N
adherence NN N
or CC N
AA NNP N
meeting NN N
attendance NN N
better RBR N
explains VBZ N
the DT N
positive-outcome JJ N
adherence NN o
effect NN N
we PRP N
observed VBD N
. . N

Both DT N
medication NN N
adherence NN N
and CC N
AA NNP N
meeting NN N
attendance NN N
evidenced VBD N
direct JJ N
and CC N
independent JJ N
influences NNS N
on IN N
abstinent JJ N
outcome NN N
: : N
medication NN N
adherence NN N
showed VBD N
a DT N
small JJ N
direct JJ N
influence NN N
, , N
and CC N
AA NNP N
meeting NN N
attendance NN N
showed VBD N
a DT N
much RB N
larger JJR N
, , N
independent JJ N
influence NN N
. . N

-DOCSTART- -8708726- O O

Randomized VBN N
trial NN N
comparing VBG N
induction NN i
chemotherapy NN i
versus NN N
induction NN i
chemotherapy NN i
followed VBN i
by IN i
maintenance NN i
chemotherapy NN i
in IN N
small-cell JJ p
lung NN p
cancer NN p
. . p

European JJ N
Lung NNP N
Cancer NNP N
Working NNP N
Party NNP N
. . N

PURPOSE NNP N
AND CC N
METHODS NNP N
The DT N
European NNP N
Lung NNP N
Cancer NNP N
Working NNP N
Party NNP N
( ( N
ELCWP NNP N
) ) N
performed VBD N
a DT N
randomized JJ N
trial NN N
with IN N
the DT N
primary JJ N
end NN N
point NN N
to TO N
determine VB N
if IN N
maintenance NN N
chemotherapy NN N
with IN N
12 CD N
courses NNS N
of IN N
etoposide NN i
( ( N
120 CD N
mg/m2 NN N
on IN N
days NNS N
1 CD N
and CC N
3 CD N
) ) N
and CC N
vindesine NN i
( ( N
3 CD N
mg/m2 NN N
on IN N
day NN N
3 CD N
) ) N
could MD N
improve VB N
progression-free JJ o
survival NN o
in IN N
small-cell JJ p
lung NN p
cancer NN p
( ( p
SCLC NNP p
) ) p
patients NNS p
who WP p
responded VBD p
to TO p
six CD p
courses NNS p
of IN p
induction NN i
chemotherapy NN i
with IN i
ifosfamide NN i
, , i
etoposide RB i
, , i
and CC i
an DT i
anthracycline NN i
( ( i
doxorubicin NN i
or CC i
epirubicin NN i
) ) i
. . i

RESULTS NNP N
Among IN p
235 CD p
eligible JJ p
patients NNS p
initially RB p
registered VBD p
, , p
91 CD p
were VBD p
randomized VBN p
to TO p
receive VB p
maintenance NN p
therapy NN p
, , p
including VBG p
seven CD p
patients NNS p
who WP p
were VBD p
no RB p
longer RBR p
responding VBG p
. . p

Among IN N
84 CD N
randomized JJ N
responders NNS N
, , N
progression-free JJ o
survival NN o
was VBD N
significantly RB N
improved VBN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
by IN N
maintenance NN N
therapy NN N
, , N
with IN N
median JJ N
durations NNS N
( ( N
maintenance NN N
v IN N
follow-up JJ N
) ) N
of IN N
25 CD N
versus NNS N
12 CD N
weeks NNS N
after IN N
the DT N
second JJ N
randomization NN N
, , N
but CC N
survival NN o
was VBD N
not RB N
significantly RB N
increased VBN N
( ( N
P NNP N
= NNP N
.10 NNP N
) ) N
, , N
with IN N
median JJ N
durations NNS N
of IN N
48 CD N
and CC N
38 CD N
weeks NNS N
. . N

However RB N
, , N
in IN N
a DT N
multi-variate JJ N
analysis NN N
that WDT N
took VBD N
into IN N
account NN o
disease NN o
extent NN o
, , o
maintenance NN o
therapy NN o
, , o
Karnofsky NNP o
performance NN o
status NN o
( ( o
PS NNP o
) ) o
, , o
and CC o
absolute JJ o
dose-intensity NN o
( ( o
ADI NNP o
) ) o
of IN o
anthracycline NN o
given VBN N
during IN N
induction NN N
, , N
limited JJ o
disease NN o
( ( o
LD NNP o
) ) o
and CC o
maintenance NN o
were VBD N
found VBN N
to TO N
be VB N
independent JJ N
positive JJ N
predictors NNS N
of IN N
survival NN o
. . o

CONCLUSION NNP N
We PRP N
conclude VBP N
that DT N
maintenance NN N
chemotherapy NN N
in IN N
responding VBG N
patients NNS N
is VBZ N
beneficial JJ N
in IN N
SCLC NNP N
. . N

-DOCSTART- -11683967- O O

Equivalent JJ N
efficacy NN o
of IN o
mitomycin NN o
C NNP o
plus CC o
doxorubicin JJ o
instillation NN N
to TO N
bacillus VB N
Calmette-Guerin NNP N
therapy NN N
for IN N
carcinoma NN p
in IN p
situ NN p
of IN p
the DT p
bladder NN p
. . p

BACKGROUND NNP N
To TO N
elucidate VB N
the DT N
most RBS N
efficient JJ N
topical JJ N
therapy NN N
for IN N
carcinoma NN N
in IN N
situ NN N
of IN N
the DT N
bladder NN N
, , N
the DT N
efficacy NN N
of IN N
intravesical JJ N
mitomycin NN N
C NNP N
plus CC N
doxorubicin JJ N
therapy NN N
was VBD N
compared VBN N
with IN N
bacillus JJ N
Calmette-Guerin NNP N
( ( N
BCG NNP N
) ) N
therapy NN N
. . N

The DT N
clinical JJ N
behavior NN N
of IN N
the DT N
tumor NN N
was VBD N
analysed VBN N
according VBG N
to TO N
the DT N
histological JJ N
grade NN N
. . N

METHODS NNP N
Forty-two JJ p
patients NNS p
with IN p
carcinoma NN p
in IN p
situ NN p
of IN p
the DT p
bladder NN p
were VBD N
randomized VBN N
to TO N
intravesical JJ i
BCG NNP i
( ( N
21 CD N
patients NNS N
) ) N
or CC N
mitomycin JJ i
C NNP i
plus CC i
doxorubicin JJ i
sequential JJ i
therapy NN i
( ( N
21 CD N
patients NNS N
) ) N
as IN N
first JJ N
line NN N
treatment NN N
. . N

The DT N
non-responders JJ N
underwent NN N
the DT N
subsequent JJ N
instillation NN N
of IN N
the DT N
other JJ N
intravesical JJ N
therapy NN N
alternately RB N
. . N

Of IN p
the DT p
patients NNS p
, , p
27 CD p
had VBD p
grade VBN p
2 CD p
and CC p
15 CD p
had VBD p
grade VBN p
3 CD p
cancer NN p
. . p

RESULTS NNP N
Both NNP N
topical JJ N
therapies NNS N
were VBD N
equally RB N
effective JJ N
with IN N
initial JJ N
response NN o
rates NNS o
of IN N
86 CD N
% NN N
( ( N
18/21 CD N
) ) N
for IN N
BCG NNP N
and CC N
81 CD N
% NN N
( ( N
17/21 CD N
) ) N
for IN N
mitomycin NN N
C NNP N
plus CC N
doxorubicin NN N
, , N
irrespective NN N
of IN N
the DT N
tumor NN N
grade NN N
. . N

Of IN N
seven CD N
initial JJ N
non-responders NNS N
, , N
five CD N
patients NNS N
achieved VBD N
a DT N
complete JJ N
response NN N
by IN N
subsequent JJ N
instillation NN N
, , N
resulting VBG N
in IN N
a DT N
total JJ o
response NN o
rate NN o
of IN N
95 CD N
% NN N
. . N

After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
47 CD N
months NNS N
, , N
five CD N
patients NNS N
( ( N
12 CD N
% NN N
) ) N
developed VBD N
disease JJ o
progression NN o
. . o

The DT N
progression NN o
rates NNS o
were VBD N
not RB N
different JJ N
between IN N
the DT N
topical JJ N
therapies NNS N
, , N
but CC N
were VBD N
significantly RB N
higher JJR N
in IN N
grade NN N
3 CD N
than IN N
in IN N
grade JJ N
2 CD N
cases NNS N
. . N

CONCLUSION VB N
It PRP N
appears VBZ N
likely JJ N
that IN N
mitomycin VBZ N
C NNP N
plus CC N
doxorubicin JJ N
instillation NN N
has VBZ N
an DT N
equivalent JJ N
efficacy NN o
to TO o
BCG NNP o
as IN N
the DT N
initial JJ N
therapy NN N
of IN N
carcinoma NN N
in IN N
situ NN N
and CC N
the DT N
combination NN N
of IN N
them PRP N
would MD N
be VB N
the DT N
most RBS N
efficient JJ N
treatment NN N
for IN N
the DT N
disease NN N
. . N

Moreover RB N
, , N
histological JJ N
grading NN N
would MD N
be VB N
clinically RB N
useful JJ N
in IN N
defining VBG N
the DT N
tumor NN N
characteristics NNS N
and CC N
behavior NN N
of IN N
carcinoma NN N
in IN N
situ NN N
of IN N
the DT N
bladder NN N
. . N

-DOCSTART- -20973712- O O

Line-item JJ N
analysis NN N
of IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
: : N
results NNS N
from IN N
two CD p
studies NNS p
of IN p
aripiprazole NN i
in IN p
the DT p
treatment NN p
of IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
aripiprazole NN i
in IN N
the DT N
treatment NN N
of IN N
discrete JJ N
symptoms NNS N
of IN N
irritability NN N
associated VBN N
with IN N
autistic JJ N
disorder NN N
, , N
as RB N
well RB N
as IN N
other JJ N
symptoms NNS N
captured VBN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
post NN N
hoc NN N
analysis NN N
of IN N
data NNS N
from IN N
two CD p
8-week JJ p
, , p
randomized VBN p
, , p
double-blind JJ p
, , p
multicenter JJ p
trials NNS p
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
aripiprazole NN i
dosed VBN i
flexibly RB i
( ( N
2-15 JJ N
mg/day NN N
, , N
n=47 NN N
) ) N
or CC N
fixed VBN N
( ( N
5 CD N
, , N
10 CD N
, , N
or CC N
15 CD N
mg/day NN N
, , N
n JJ N
= NNP N
166 CD N
) ) N
versus NN N
placebo NN i
( ( N
flexibly RB N
dosed VBN N
, , N
n JJ N
= VBP N
51 CD N
; : N
fixed VBN N
dose NN N
, , N
n JJ N
= NNP N
52 CD N
) ) N
. . N

The DT N
effects NNS N
of IN N
treatment NN N
on IN N
the DT N
58 CD N
ABC NNP N
items NNS N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Statistically NNP N
significantly RB N
greater JJR N
improvement NN N
was VBD N
seen VBN N
with IN N
aripiprazole JJ i
versus NN i
placebo NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
all DT N
arms NNS N
in IN N
both DT N
trials NNS N
on IN N
the DT N
ABC-Irritability NNP o
total JJ o
subscale NN o
score NN o
and CC o
on IN o
the DT o
following JJ o
individual JJ o
ABC-Irritability NNP o
items NNS o
: : o
Mood NNP o
changes NNS o
quickly RB o
, , o
cries/screams NNS o
inappropriately RB o
, , o
and CC o
stamps JJ o
feet/bangs NNS o
objects NNS o
. . o

Several JJ N
additional JJ N
items NNS N
measuring VBG N
tantrum-like JJ o
behaviors NNS o
improved VBN N
in IN N
the DT N
flexibly RB N
dosed VBN N
trial NN N
and CC N
at IN N
least JJS N
one CD N
arm NN N
of IN N
the DT N
fixed-dose JJ N
trial NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Measures NNS o
of IN o
self-injurious JJ o
behavior NN o
, , N
which WDT N
had VBD N
low JJ N
baseline NN N
values NNS N
, , N
demonstrated VBD N
numerical JJ N
, , N
but CC N
not RB N
statistically RB N
significant JJ N
, , N
improvement NN N
in IN N
both DT N
trials NNS N
. . N

Statistically RB N
significantly RB N
greater JJR N
improvement NN N
in IN N
ABC NNP o
Stereotypic NNP o
Behavior NNP o
and CC o
Hyperactivity NNP o
total JJ o
subscale NN o
scores NNS o
was VBD N
also RB N
consistent JJ N
across IN N
all DT N
arms NNS N
in IN N
both DT N
trials NNS N
. . N

In IN N
particular JJ N
, , N
there EX N
was VBD N
a DT N
cluster NN N
of IN N
items NNS N
related VBN N
to TO N
hyperkinesis VB o
that WDT N
were VBD N
consistently RB N
sensitive JJ N
to TO N
treatment NN N
. . N

CONCLUSIONS NNP N
Aripiprazole NNP i
is VBZ N
efficacious JJ N
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
, , N
particularly RB N
with IN N
respect NN N
to TO N
symptoms NNS N
associated VBN N
with IN N
tantrum JJ N
behavior NN N
. . N

-DOCSTART- -20616786- O O

Physician-pharmacist JJ i
cooperation NN i
program NN i
for IN N
blood NN o
pressure NN o
control NN o
in IN N
patients NNS p
with IN p
hypertension NN p
: : p
a DT N
randomized-controlled JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
aim NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
program NN N
of IN N
cooperation NN i
between IN i
physician NN i
and CC i
pharmacist NN i
to TO N
reduce VB N
cardiovascular JJ p
risk NN p
factors NNS p
in IN p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
by IN N
promoting VBG N
better JJR N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
control NN N
, , N
appropriate JJ N
changes NNS N
in IN N
antihypertensive JJ N
medications NNS N
, , N
and CC N
beneficial JJ N
changes NNS N
in IN N
lifestyle NN N
. . N

METHODS NNP N
The DT p
132 CD p
subjects NNS p
in IN p
this DT p
randomized VBN p
, , p
controlled VBN p
trial NN p
were VBD p
in IN p
the DT p
age NN p
range NN p
of IN p
40-79 JJ p
years NNS p
. . p

The DT p
inclusion NN p
criteria NNS p
were VBD p
: : p
systolic JJ o
BP NNP o
( ( o
SBP NNP o
) ) o
ranging VBG p
from IN p
140-179 JJ p
mm NN p
Hg NNP p
and/or VBZ p
diastolic JJ o
BP NNP o
( ( o
DBP NNP o
) ) o
ranging VBG p
from IN p
90-99 CD p
mm NNS p
Hg NNP p
and CC p
treatment-naive JJ p
( ( p
untreated JJ p
for IN p
hypertension NN p
) ) p
; : p
or CC p
on IN p
a DT p
regimen NN p
of IN p
medication NN p
for IN p
hypertension NN p
. . p

Of IN p
these DT p
132 CD p
subjects NNS p
, , p
124 CD p
( ( p
94 CD p
% NN p
) ) p
were VBD p
already RB p
receiving VBG p
treatment NN p
with IN p
antihypertensive JJ p
medications NNS p
. . p

Equal JJ N
numbers NNS N
of IN N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
: : N
a DT N
physician-pharmacist JJ i
intervention NN i
group NN i
( ( N
n JJ N
= NNP N
66 CD N
) ) N
and CC N
a DT N
control NN i
group NN i
( ( N
n JJ N
= NNP N
66 CD N
) ) N
. . N

RESULTS VB N
The DT N
6-month JJ N
follow-up JJ N
rate NN N
was VBD N
97 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
mean JJ N
decrease NN N
in IN N
SBP/DBP NNP o
, , N
as IN N
measured VBN N
at IN N
home NN N
in IN N
the DT N
morning NN N
, , N
was VBD N
2.9/3.3 CD N
mm NN N
Hg NNP N
in IN N
the DT N
intervention NN N
group NN N
relative VBP N
to TO N
baseline VB N
( ( N
P NNP N
= NNP N
0.02 CD N
and CC N
P NNP N
< NNP N
0.0001 CD N
for IN N
SBP NNP N
and CC N
DBP NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
mean JJ N
decrease NN N
in IN N
home NN o
morning NN o
SBP NNP o
in IN N
the DT N
intervention NN N
group NN N
was VBD N
not RB N
significantly RB N
greater JJR N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
the DT N
DBP NNP o
decline NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
intervention NN N
than IN N
control NN N
groups NNS N
, , N
which WDT N
showed VBD N
a DT N
mean JJ N
decrease NN N
of IN N
2.8 CD N
mm NNS N
Hg NNP N
( ( N
confidence NN N
interval NN N
: : N
-5.5 NN N
to TO N
-0.1 VB N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
percentage NN N
of IN N
patients NNS N
in IN N
whom WP N
control NN N
of IN N
home NN o
morning NN o
BP NNP o
was VBD N
achieved VBN N
was VBD N
53 CD N
% NN N
in IN N
the DT N
intervention NN N
group NN N
and CC N
47 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.40 CD N
) ) N
. . N

A DT N
higher JJR N
percentage NN N
of IN N
patients NNS N
in IN N
the DT N
intervention NN N
group NN N
, , N
relative VBP N
to TO N
the DT N
control NN N
group NN N
, , N
were VBD N
able JJ N
to TO N
reduce VB N
the DT N
use NN o
of IN o
antihypertensive JJ o
medications NNS o
( ( N
31 CD N
vs. FW N
8 CD N
% NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
fewer JJR N
patients NNS N
in IN N
this DT N
group NN N
required VBD N
additional JJ o
medications NNS o
or CC N
increases NNS N
in IN N
dosage NN N
relative NN N
to TO N
the DT N
controls NNS N
( ( N
11 CD N
vs. FW N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Patients NNS N
of IN N
the DT N
intervention NN N
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
show VB N
reduction NN N
in IN N
body NN o
mass NN o
index NN o
and CC o
sodium NN o
intake NN o
and CC o
to TO o
stop VB o
smoking NN o
, , N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS VB N
A DT N
program NN N
of IN N
cooperation NN N
between IN N
physician NN N
and CC N
pharmacist NN N
was VBD N
successful JJ N
in IN N
reducing VBG N
cardiovascular JJ N
risk NN N
factors NNS N
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
by IN N
promoting VBG N
better JJR N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
control NN N
, , N
appropriate JJ N
changes NNS N
in IN N
antihypertensive JJ N
medications NNS N
, , N
and CC N
beneficial JJ N
changes NNS N
in IN N
lifestyle NN N
. . N

-DOCSTART- -18547294- O O

The DT N
effect NN N
of IN N
intravenous JJ N
lidocaine NN i
on IN N
QT NNP o
changes NNS o
during IN N
tracheal JJ p
intubation NN p
. . p

Laryngoscopy NNP p
and CC p
tracheal JJ p
intubation NN p
may MD N
provoke VB N
changes NNS N
of IN N
cardiac JJ o
repolarisation NN o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
intravenous JJ N
lidocaine NN i
on IN N
the DT N
ECG NNP o
changes NNS o
induced VBN N
by IN N
laryngoscopy NN p
and CC p
tracheal JJ p
intubation NN p
. . p

Forty-three JJ p
female JJ p
patients NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
lidocaine NN i
( ( N
1.5 CD N
mg.kg NN N
( ( N
-1 NNP N
) ) N
) ) N
or CC N
placebo VB i
immediately RB N
after IN N
induction NN N
of IN N
anaesthesia NN N
and CC N
changes NNS N
in IN N
the DT N
ECG NNP o
and CC o
arterial JJ o
blood NN o
pressure NN o
were VBD N
recorded VBN N
. . N

Correction NN N
of IN N
QT NNP o
interval NN o
was VBD N
calculated VBN N
using VBG N
Bazett NNP N
's POS N
formula NN N
( ( N
QTcb NNP N
) ) N
, , N
Fridericia NNP N
's POS N
correction NN N
( ( N
QTcf NNP N
) ) N
, , N
and CC N
Framingham NNP N
formula NN N
( ( N
QTcF NNP N
) ) N
. . N

Transmural JJ o
dispersion NN o
of IN o
repolarisation NN o
( ( o
TDR NNP o
) ) o
was VBD N
determined VBN N
as IN N
Tpeak-Tend JJ N
time NN N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
the DT N
QTc NNP o
value NN o
in IN N
the DT N
lidocaine NN i
group NN N
. . N

In IN N
the DT N
placebo NN i
group NN N
, , N
significant JJ N
increases NNS N
in IN N
QTcb NNP o
, , o
QTcf NNP o
and CC o
QTcF NNP o
values NNS o
were VBD N
observed VBN N
after IN N
intubation NN N
compared VBN N
to TO N
either DT N
control NN N
measurements VBZ N
or CC N
to TO N
comparative JJ N
measurements NNS N
in IN N
the DT N
lidocaine NN i
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
TDR NNP o
either CC N
between IN N
or CC N
within IN N
the DT N
groups NNS N
. . N

Lidocaine NNP i
diminishes VBZ N
prolongation NN N
of IN N
QTc NNP o
, , N
induced VBN N
by IN N
tracheal JJ p
intubation NN p
but CC N
there EX N
is VBZ N
no DT N
effect NN N
of IN N
intubation NN N
on IN N
TDR NNP o
. . o

-DOCSTART- -19996335- O O

The DT N
6 CD N
minute NN N
walk NN N
in IN N
idiopathic JJ N
pulmonary JJ N
fibrosis NN N
: : N
longitudinal JJ N
changes NNS N
and CC N
minimum JJ N
important JJ N
difference NN N
. . N

RATIONALE VB N
The DT N
response NN N
characteristics NNS N
of IN N
the DT N
6 CD i
minute NN i
walk NN i
test NN i
( ( i
6MWT CD i
) ) i
in IN N
studies NNS N
of IN N
idiopathic JJ p
pulmonary JJ p
fibrosis NN p
( ( p
IPF NNP p
) ) p
are VBP N
only RB N
poorly RB N
understood JJ N
, , N
and CC N
the DT N
change NN N
in IN N
walk NN N
distance NN N
that WDT N
constitutes VBZ N
the DT N
minimum JJ N
important JJ N
difference NN N
( ( N
MID NNP N
) ) N
over IN N
time NN N
is VBZ N
unknown JJ N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
changes NNS N
over IN N
time NN o
in IN o
distance NN o
walked VBD o
( ( N
ie NN N
, , N
6MWD CD N
) ) N
during IN N
the DT N
6MWT CD i
and CC N
to TO N
estimate VB N
the DT N
change NN N
in IN N
distance NN N
that WDT N
constitutes VBZ N
the DT N
MID NNP N
in IN N
patients NNS p
with IN p
IPF NNP p
. . p

METHODS NNP N
Data NNP N
from IN N
a DT N
recently RB N
completed VBN N
trial NN N
that WDT N
included VBD N
subjects NNS p
with IN p
IPF NNP p
who WP p
completed VBD p
the DT p
6MWT CD i
, , p
Saint NNP p
George NNP p
's POS p
Respiratory NNP p
Questionnaire NNP p
( ( p
SGRQ NNP p
) ) p
and CC p
forced VBN p
vital JJ p
capacity NN p
( ( p
FVC NNP p
) ) p
at IN N
6 CD N
and CC N
12 CD N
months NNS N
were VBD N
used VBN N
to TO N
examine VB N
longitudinal JJ N
changes NNS N
in IN N
6MWD CD N
. . N

Both DT N
anchor- JJ N
and CC N
distribution-based JJ N
approaches NNS N
as RB N
well RB N
as IN N
linear JJ N
regression NN N
analyses NNS N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
MID NNP N
for IN N
6MWD CD N
. . N

The DT N
SGRQ NNP o
Total NNP o
score NN o
and CC o
FVC NNP o
were VBD N
used VBN N
as IN N
clinical JJ N
anchors NNS N
. . N

MAIN NNP N
RESULTS NNP N
Among IN N
123 CD p
subjects NNS p
alive JJ p
and CC p
able JJ p
to TO p
complete VB p
the DT p
6MWT CD p
at IN p
both DT p
follow-up JJ p
time NN p
points NNS p
, , N
6MWD CD o
did VBD N
not RB N
change VB N
significantly RB N
over IN N
time NN N
( ( N
378.1 CD N
m NN N
at IN N
baseline NN N
vs NN N
376.8 CD N
m NN N
at IN N
6 CD N
months NNS N
vs RB N
361.3 CD N
m NN N
at IN N
12 CD N
months NNS N
, , N
p=0.5 NN N
) ) N
. . N

The DT N
point NN N
estimate NN N
for IN N
the DT N
6MWD CD o
MID NNP o
was VBD N
28 CD N
m NN N
with IN N
a DT N
range NN N
of IN N
10.8-58.5 JJ N
m. JJ N
CONCLUSION NNP N
In IN N
a DT N
group NN N
of IN N
patients NNS p
with IN p
IPF NNP p
with IN p
moderate JJ p
physiological JJ p
impairment NN p
, , N
for IN N
those DT N
alive JJ N
and CC N
able JJ N
to TO N
complete VB N
a DT N
6MWT CD N
, , N
6MWD CD o
does VBZ N
not RB N
change VB N
over IN N
12 CD N
months NNS N
. . N

At IN N
the DT N
population NN N
level NN N
, , N
the DT N
MID NNP N
for IN N
6MWD CD o
appears VBZ N
to TO N
be VB N
approximately RB N
28 CD N
m. NNS N
Further NNP N
investigation NN N
using VBG N
other JJ N
anchors NNS N
and CC N
derivation NN N
methods NNS N
is VBZ N
required VBN N
to TO N
refine VB N
estimates NNS N
of IN N
the DT N
MID NNP N
for IN N
6MWD CD N
in IN N
this DT N
patient JJ p
population NN p
. . p

-DOCSTART- -10402369- O O

Adjuvant JJ N
L-arginine NNP i
treatment NN N
for IN N
in-vitro JJ N
fertilization NN N
in IN N
poor JJ p
responder NN p
patients NNS p
. . p

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
prospectively RB N
and CC N
randomly RB N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
L-arginine NNP i
in IN N
improving VBG N
uterine JJ o
and CC o
follicular JJ o
Doppler NNP o
flow NN o
and CC N
in IN N
improving VBG N
ovarian JJ o
response NN o
to TO o
gonadotrophin VB o
in IN N
poor JJ p
responder NN p
women NNS p
. . p

A DT N
total NN N
of IN N
34 CD p
patients NNS p
undergoing JJ p
assisted JJ p
reproduction NN p
was VBD N
divided VBN N
in IN N
two CD i
groups NNS i
according VBG i
to TO i
different JJ i
ovarian JJ i
stimulation NN i
protocols NNS i
: : i
( ( i
i NN i
) ) i
flare-up JJ i
gonadotrophin-releasing JJ i
hormone NN i
analogue NN i
( ( i
GnRHa NNP i
) ) i
plus CC i
elevated JJ i
pure NN i
follicle NN i
stimulating VBG i
hormone NN i
( ( i
pFSH NN i
) ) i
( ( i
n JJ i
= NNP i
17 CD i
) ) i
; : i
and CC i
( ( i
ii NN i
) ) i
flare-up NN i
GnRHa NNP i
plus CC i
elevated VBN i
pFSH JJ i
plus CC i
oral JJ i
L-arginine NNP i
( ( i
n JJ i
= NNP i
17 CD i
) ) i
. . i

During IN N
the DT N
ovarian JJ N
stimulation NN N
regimen NNS N
, , N
the DT i
patients NNS i
were VBD i
submitted VBN i
to TO i
hormonal VB i
( ( i
oestradiol NN i
and CC i
growth NN i
hormone NN i
) ) i
, , i
ultrasonographic JJ i
( ( i
follicular JJ i
number NN i
and CC i
diameter NN i
, , i
endometrial JJ i
thickness NN i
) ) i
and CC i
Doppler NNP i
( ( i
uterine JJ i
and CC i
perifollicular JJ i
arteries NNS i
) ) i
evaluations NNS i
. . i

Furthermore RB N
, , N
the DT N
plasma NN N
and CC N
follicular JJ N
fluid NN N
concentrations NNS N
of IN N
arginine NN N
, , N
citrulline NN N
, , N
nitrite/nitrate NN N
( ( N
NO2-/NO3- NNP N
) ) N
, , N
and CC N
insulin-like JJ N
growth NN N
factor-1 JJ N
( ( N
IGF-1 NNP N
) ) N
were VBD N
assayed VBN N
. . N

All DT N
34 CD p
patients NNS p
completed VBD N
the DT N
study NN N
. . N

In IN N
the DT N
L-arginine NNP i
treated VBD N
group NN N
a DT N
lower JJR o
cancellation NN o
rate NN o
, , o
an DT o
increased JJ o
number NN o
of IN o
oocytes NNS o
collected VBN o
, , o
and CC o
embryos RB o
transferred VBN o
were VBD N
observed VBN N
. . N

In IN N
the DT N
same JJ N
group NN N
, , N
increased VBD o
plasma NN o
and CC o
follicular JJ o
fluid NN o
concentrations NNS o
of IN o
arginine NN o
, , o
citrulline NN o
, , o
NO2-/NO3- NNP o
, , o
and CC o
IGF-1 NNP o
was VBD N
observed VBN N
. . N

Significant JJ o
Doppler NNP o
flow NN o
improvement NN o
was VBD N
obtained VBN N
in IN N
the DT N
L-arginine NNP i
supplemented VBD N
group NN N
. . N

Three CD N
pregnancies NNS o
were VBD N
registered VBN N
in IN N
these DT N
patients NNS N
. . N

No DT N
pregnancies NNS o
were VBD N
observed VBN N
in IN N
the DT N
other JJ N
group NN N
. . N

It PRP N
was VBD N
concluded VBN N
that IN N
oral JJ N
L-arginine JJ i
supplementation NN N
in IN N
poor JJ p
responder NN p
patients NNS p
may MD N
improve VB N
ovarian JJ o
response NN o
, , o
endometrial JJ o
receptivity NN o
and CC o
pregnancy NN o
rate NN o
. . o

-DOCSTART- -8940983- O O

The DT N
immunogenicity NN o
of IN N
three CD N
Haemophilus NNP i
influenzae NN i
type NN i
B NNP i
conjugate NN i
vaccines NNS i
after IN p
a DT p
primary JJ p
vaccination NN p
series NN p
in IN p
Philippine NNP p
infants NNS p
. . p

Serum NNP o
antibody NN o
responses NNS o
to TO N
three CD N
Haemophilus NNP i
influenzae NN i
type NN i
b NN i
( ( i
Hib NNP i
) ) i
capsular VBD i
polysaccharide-protein JJ i
conjugate NN i
vaccine NN i
( ( i
PRP-OMP NNP i
, , i
PRP-T NNP i
, , i
and CC i
HbOC NNP i
) ) i
were VBD N
evaluated VBN N
in IN p
174 CD p
Philippine JJ p
infants NNS p
after IN p
a DT p
primary JJ p
vaccination NN p
series NN p
. . p

Children NNP N
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
Hib NNP i
vaccines NNS i
( ( i
Hib NNP i
groups NNS i
) ) i
or CC i
into IN i
a DT i
control NN i
group NN i
. . i

Vaccination NNP N
was VBD N
carried VBN N
out RP N
at IN N
six CD N
, , N
10 CD N
and CC N
14 CD N
weeks NNS N
of IN N
age NN N
based VBN N
on IN N
the DT N
local JJ N
Expanded NNP N
Program NNP N
of IN N
Immunization NNP N
schedule NN N
. . N

Sera NN N
were VBD N
collected VBN N
at IN N
six CD N
weeks NNS N
of IN N
age NN N
for IN N
the DT N
Hib NNP N
groups NNS N
and CC N
one CD N
month NN N
after IN N
the DT N
third JJ N
dose NN N
for IN N
all DT N
subjects NNS N
. . N

Anti-Hib JJ o
concentrations NNS o
were VBD o
determined VBN o
by IN o
the DT o
Farr-type NNP o
radioimmunoassay NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
P NNP N
= NNP N
0.3626 CD N
) ) N
in IN N
the DT N
prevaccination NN o
anti-Hib JJ o
geometric JJ o
mean NN o
concentration NN o
( ( o
GMC NNP o
) ) o
among IN N
the DT N
three CD N
Hib NNP N
groups NNS N
. . N

Differences NNS N
in IN N
the DT N
GMC NNP o
after IN N
the DT N
primary JJ N
series NN N
of IN N
three CD N
doses NNS N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
; : N
GMC NNP o
was VBD N
highest JJS N
for IN N
PRP-T NNP N
( ( N
6.62 CD N
micrograms/ml NN N
) ) N
, , N
followed VBN N
by IN N
HbOC NNP N
( ( N
1.9 CD N
micrograms/ml NN N
) ) N
, , N
then RB N
PRP-OMP NNP N
( ( N
1.06 CD N
micrograms/ml NN N
) ) N
, , N
and CC N
lowest JJS N
for IN N
the DT N
control NN N
group NN N
( ( N
0.11 CD N
microgram/ml NN N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
all DT N
three CD N
Hib NNP i
conjugate NN i
vaccines NNS i
( ( i
PRP-T NNP i
, , i
HbOC NNP i
, , N
and CC N
PRP-OMP NNP i
) ) i
were VBD N
immunogenic JJ o
after IN N
three CD N
primary JJ N
doses NNS N
among IN N
Philippine JJ p
infants NNS p
. . p

-DOCSTART- -19897177- O O

Intranasal NNP N
oxytocin PRP i
improves VBZ N
emotion NN o
recognition NN o
for IN N
youth NN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

BACKGROUND VB N
A NNP N
diagnostic JJ N
hallmark NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
is VBZ N
a DT N
qualitative JJ N
impairment NN N
in IN N
social JJ N
communication NN N
and CC N
interaction NN N
. . N

Deficits NNS N
in IN N
the DT N
ability NN N
to TO N
recognize VB N
the DT N
emotions NNS N
of IN N
others NNS N
are VBP N
believed VBN N
to TO N
contribute VB N
to TO N
this DT N
. . N

There EX N
is VBZ N
currently RB N
no DT N
effective JJ N
treatment NN N
for IN N
these DT N
problems NNS N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
design NN N
, , N
we PRP N
administered VBD N
oxytocin RP i
nasal JJ i
spray NN i
( ( N
18 CD N
or CC N
24 CD N
IU NNPS N
) ) N
or CC N
a DT N
placebo NN i
to TO N
16 CD p
male NN p
youth NN p
aged VBD p
12 CD p
to TO p
19 CD p
who WP p
were VBD p
diagnosed VBN p
with IN p
Autistic NNP p
or CC p
Asperger NNP p
's POS p
Disorder NNP p
. . p

Participants NNS p
then RB N
completed VBD N
the DT N
Reading VBG o
the DT o
Mind NNP o
in IN o
the DT o
Eyes NNP o
Task NNP o
, , N
a DT N
widely RB N
used VBN N
and CC N
reliable JJ N
test NN N
of IN N
emotion NN o
recognition NN o
. . o

RESULTS NNP N
In IN N
comparison NN N
with IN N
placebo NN i
, , i
oxytocin JJ i
administration NN N
improved VBD N
performance NN o
on IN o
the DT o
Reading VBG o
the DT o
Mind NNP o
in IN o
the DT o
Eyes NNP o
Task NNP o
. . o

This DT N
effect NN N
was VBD N
also RB N
shown VBN N
when WRB N
analysis NN N
was VBD N
restricted VBN N
to TO N
the DT N
younger JJR p
participants NNS p
aged VBD p
12 CD p
to TO p
15 CD p
who WP N
received VBD N
the DT N
lower JJR N
dose NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
the DT N
first JJ N
evidence NN N
that IN N
oxytocin JJ N
nasal NN N
spray NN N
improves VBZ N
emotion NN o
recognition NN o
in IN N
young JJ p
people NNS p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Findings NNS N
suggest VBP N
the DT N
potential NN N
of IN N
earlier JJR N
intervention NN N
and CC N
further JJ N
evaluation NN N
of IN N
oxytocin JJ i
nasal JJ N
spray NN N
as IN N
a DT N
treatment NN N
to TO N
improve VB N
social JJ N
communication NN N
and CC N
interaction NN N
in IN N
young JJ p
people NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

-DOCSTART- -19805710- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
behavioral JJ N
intervention NN N
and CC N
nutrition NN N
education NN N
to TO N
improve VB N
caloric JJ N
intake NN N
and CC N
weight NN N
in IN N
children NNS p
with IN p
cystic JJ p
fibrosis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
, , N
Be NNP N
In IN N
CHARGE NNP N
! . N
, , N
compared VBN N
with IN N
that DT N
of IN N
a DT N
nutrition NN N
education NN N
intervention NN N
alone RB N
on IN N
caloric JJ o
intake NN o
and CC N
weight JJ o
gain NN o
in IN N
children NNS p
with IN p
cystic JJ p
fibrosis NN p
and CC p
pancreatic JJ p
insufficiency NN p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Cystic JJ p
fibrosis NN p
centers NNS p
in IN p
the DT p
eastern JJ p
, , p
midwestern JJ p
, , p
and CC p
southern JJ p
United NNP p
States NNPS p
. . p

PARTICIPANTS VB N
Seventy-nine JJ p
children NNS p
aged VBD p
4 CD p
to TO p
12 CD p
years NNS p
below IN p
the DT p
40th CD p
percentile NN p
for IN p
weight NN p
for IN p
age NN p
were VBD p
recruited VBN p
. . p

Sixty-seven JJ N
completed VBD N
the DT N
intervention NN N
and CC N
59 CD N
completed VBD N
a DT N
24-month JJ N
follow-up JJ N
assessment NN N
. . N

INTERVENTION NNP N
Comparison NNP N
of IN N
a DT N
behavioral JJ i
plus CC i
nutrition JJ i
education NN i
intervention NN i
with IN i
a DT i
nutrition NN i
education NN i
intervention NN i
alone RB i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
were VBD N
changes NNS N
from IN N
pretreatment NN N
to TO N
posttreatment VB N
in IN N
caloric JJ o
intake NN o
and CC o
weight JJ o
gain NN o
. . o

Secondary JJ N
outcomes NNS N
were VBD N
changes NNS N
from IN N
pretreatment NN N
to TO N
posttreatment VB N
in IN N
percentage NN o
of IN o
the DT o
estimated VBN o
energy NN o
requirement NN o
and CC o
body NN o
mass NN o
index NN o
z VBD o
score NN o
. . o

These DT N
outcomes NNS N
were VBD N
also RB N
examined VBN N
24 CD N
months NNS N
posttreatment NN N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
as IN N
compared VBN N
with IN N
the DT N
nutrition NN N
education NN N
intervention NN N
alone RB N
had VBD N
a DT N
statistically RB N
greater JJR N
average JJ N
increase NN N
on IN N
the DT N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
of IN N
caloric JJ o
intake NN o
( ( N
mean JJ N
, , N
872 CD N
vs NN N
489 CD N
cal/d NN N
, , N
respectively RB N
) ) N
, , N
percentage NN o
of IN o
the DT o
estimated VBN o
energy NN o
requirement NN o
( ( N
mean JJ N
, , N
148 CD N
% NN N
vs JJ N
127 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
weight JJ o
gain NN o
( ( N
mean JJ N
, , N
1.47 CD N
vs NN N
0.92 CD N
kg NN N
, , N
respectively RB N
) ) N
, , N
and CC N
body NN o
mass NN o
index NN o
z NN o
score NN o
( ( N
0.38 CD N
vs NN N
0.18 CD N
, , N
respectively RB N
) ) N
. . N

At IN N
the DT N
24-month JJ N
follow-up NN N
, , N
children NNS N
in IN N
both DT N
conditions NNS N
maintained VBD N
an DT N
estimated VBN N
energy NN o
requirement NN o
of IN N
around IN N
120 CD N
% NN N
and CC N
did VBD N
not RB N
significantly RB N
differ VB N
on IN N
any DT N
outcomes NNS N
. . N

CONCLUSIONS VB N
A DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
was VBD N
more RBR N
effective JJ N
than IN N
a DT N
nutrition JJ N
education NN N
intervention NN N
alone RB N
at IN N
increasing VBG N
dietary JJ N
intake NN N
and CC N
weight NN N
over IN N
a DT N
9-week JJ N
period NN N
. . N

However RB N
, , N
across IN N
the DT N
24-month JJ N
follow-up NN N
, , N
both DT N
treatments NNS N
achieved VBD N
similar JJ N
outcomes NNS N
. . N

Trial JJ N
Registration NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00006169 NN N
. . N

-DOCSTART- -3859359- O O

Comparison NNP N
of IN N
maintenance NN i
treatment NN i
regimens NNS i
for IN N
first JJ N
central JJ p
nervous JJ p
system NN p
relapse NN p
in IN p
children NNS p
with IN p
acute JJ p
lymphocytic JJ p
leukemia NN p
. . p

A DT N
Pediatric NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

Eighty-seven JJ p
children NNS p
with IN p
central JJ p
nervous JJ p
system NN p
( ( p
CNS NNP p
) ) p
leukemia NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT i
induction NN i
intrathecal JJ i
chemotherapy NN i
( ( i
ITC NNP i
) ) i
and CC i
cranial JJ i
irradiation NN i
( ( i
CRT NNP i
) ) i
plus CC i
maintenance NN i
ITC NNP i
, , i
or CC i
induction NN i
ITC NNP i
and CC i
craniospinal JJ i
irradiation NN i
( ( i
CSpRT NNP i
) ) i
with IN i
no DT i
maintenance NN i
ITC NNP i
. . i

ITC NNP N
consisted VBD N
of IN N
six CD N
weekly JJ N
injections NNS N
of IN N
methotrexate NN i
, , i
hydrocortisone NN i
, , i
and CC i
arabinosylcytosine NN i
. . i

Also RB N
, , N
intensification NN i
of IN i
systemic JJ i
induction NN i
and CC i
maintenance NN i
chemotherapy NN i
was VBD N
given VBN N
. . N

CRT NNP i
+ NNP i
ITC NNP i
was VBD N
given VBN N
as IN N
CRT NNP i
, , N
2400 CD N
rad NN N
in IN N
12 CD N
fractions NNS N
followed VBN N
by IN N
ITC NNP i
maintenance NN N
bimonthly NN N
for IN N
2 CD N
years NNS N
. . N

Craniospinal JJ i
irradiation NN i
consisted VBD i
of IN i
CRT NNP i
+ NNP N
1400 CD N
rad NN N
in IN N
ten JJ N
fractions NNS N
to TO N
the DT N
spine NN N
. . N

Randomization NN N
was VBD N
stratified VBN N
according VBG N
to TO N
whether IN N
CNS NNP N
leukemia NN N
occurred VBD N
at IN N
initial JJ N
diagnosis NN N
of IN N
acute JJ N
lymphocytic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
( ( N
Stratum NNP N
I PRP N
, , N
15 CD N
patients NNS N
) ) N
, , N
during IN N
first JJ N
bone NN N
marrow NN N
( ( N
BM NNP N
) ) N
remission NN N
( ( N
Stratum NNP N
II NNP N
, , N
49 CD N
patients NNS N
) ) N
, , N
simultaneous JJ N
with IN N
first JJ N
BM NNP N
relapse NN N
( ( N
Stratum NNP N
III NNP N
, , N
12 CD N
patients NNS N
) ) N
, , N
or CC N
during IN N
second JJ N
BM NNP N
remission NN N
( ( N
Stratum NNP N
IV NNP N
, , N
11 CD N
patients NNS N
) ) N
. . N

The DT N
median JJ N
follow-up NN N
for IN N
patients NNS N
who WP N
remain VBP N
at IN N
risk NN N
is VBZ N
15 CD N
+ JJ N
months NNS N
. . N

Eight NNP N
children NNS N
( ( N
seven CD N
on IN N
CRT NNP N
+ NNP N
ITC NNP N
, , N
one CD N
on IN N
CSpRT NNP N
) ) N
developed VBD N
presumed VBN o
therapy RB o
related VBN o
encephalopathy NN o
. . o

In IN N
Stratum NNP N
II NNP N
, , N
16 CD N
of IN N
29 CD N
( ( N
55 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
CRT NNP N
+ NNP N
ITC NNP N
experienced VBD N
adverse JJ o
events NNS o
: : o
3 CD N
deaths NNS o
during IN o
continuous JJ o
complete JJ o
remission NN o
( ( o
CCR NNP o
) ) o
and CC N
13 CD N
relapses NNS o
( ( N
2 CD N
CNS NNP N
, , N
1 CD N
CNS NNP N
+ NNP N
BM NNP N
, , N
1 CD N
BM NNP N
+ NNP N
testes VBZ N
, , N
and CC N
2 CD N
testes NNS N
) ) N
as IN N
compared VBN N
with IN N
only RB N
5 CD N
relapses NNS o
in IN N
20 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
on IN N
CSpRT NNP N
( ( N
1 CD N
CNS NNP N
, , N
1 CD N
CNS NNP N
+ NNP N
BM NNP N
, , N
1 CD N
BM NNP N
, , N
and CC N
2 CD N
testes NNS N
) ) N
. . N

The DT N
children NNS N
on IN N
both DT N
regimens NNS N
were VBD N
comparable JJ N
for IN N
sex NN N
, , N
race NN N
, , N
age NN N
at IN N
initial JJ N
ALL NNP N
diagnosis NN N
, , N
time NN o
from IN o
ALL NNP o
diagnosis NN o
to TO o
first JJ o
episode NN o
of IN o
CNS NNP o
leukemia NN o
, , o
systemic JJ o
therapy NN o
both DT o
before IN o
and CC o
after IN o
CNS NNP o
relapse NN o
, , o
and CC o
number NN o
of IN o
blasts NNS o
in IN o
the DT o
spinal JJ o
fluid NN o
at IN o
diagnosis NN o
of IN o
CNS NNP o
leukemia NN o
. . o

The DT N
conclusion NN N
is VBZ N
that IN N
children NNS N
with IN N
isolated JJ N
CNS NNP N
leukemia NN N
can MD N
achieve VB N
prolonged JJ o
survival NN o
with IN o
aggressive JJ o
therapy NN o
, , N
and CC N
that IN N
CSpRT NNP o
is VBZ o
possibly RB o
less RBR o
toxic JJ o
and CC N
more RBR N
likely JJ N
than IN N
is VBZ N
CRT NNP N
+ NNP N
ITC NNP N
to TO N
prevent VB N
subsequent JJ o
BM NNP o
and CC o
testicular JJ o
relapse NN o
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
, , N
but CC N
not RB N
subsequent JJ N
CNS NNP o
relapse NN o
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
. . N

A DT N
possible JJ N
systemic JJ N
therapy NN N
effect NN N
of IN N
spinal JJ o
irradiation NN o
is VBZ N
postulated VBN N
to TO N
explain VB N
the DT N
superiority NN o
of IN o
CSpRT NNP o
. . o

-DOCSTART- -16772581- O O

Milk NNP o
production NN o
of IN N
dairy NN p
cows NNS p
fed VBP N
wet JJ N
corn NN N
gluten NNS N
feed VBP N
during IN N
the DT N
dry JJ N
period NN N
and CC N
lactation NN N
. . N

An DT N
experiment NN N
was VBD N
conducted VBN N
with IN N
36 CD p
primiparous JJ p
and CC p
40 CD p
multiparous JJ p
Holstein NNP p
cows NNS p
to TO N
examine VB N
the DT N
effects NNS N
of IN N
feeding VBG N
wet JJ i
corn NN i
gluten NNS i
feed VBP i
( ( i
WCGF NNP i
) ) i
on IN N
305-d JJ N
milk NN o
production NN o
, , o
dry JJ o
matter NN o
( ( o
DM NNP o
) ) o
intake NN o
, , o
body NN o
condition NN o
score NN o
( ( o
BCS NNP o
) ) o
, , o
and CC o
health NN o
. . o

The DT N
experimental JJ N
treatments NNS N
included VBD N
: : N
1 CD N
) ) N
control NN i
-- : i
WCGF NNP i
not RB i
fed RB i
( ( i
n JJ i
= NNP i
27 CD i
) ) i
; : i
2 CD i
) ) i
WCGF-L-cows NNP i
received VBD i
diets NNS i
containing VBG i
WCGF NNP i
( ( i
38 CD i
% NN i
DM NNP i
basis NN i
) ) i
during IN i
lactation NN i
( ( i
n JJ i
= NNP i
23 CD i
) ) i
; : i
and CC i
3 CD i
) ) i
WCGF-DL NNP i
-- : i
cows VBZ i
received VBN i
diets NNS i
containing VBG i
WCGF NNP i
( ( i
38 CD i
% NN i
DM NNP i
basis NN i
) ) i
during IN i
the DT i
dry JJ i
period NN i
and CC i
lactation NN i
( ( i
n JJ i
= NNP i
26 CD i
) ) i
. . i

During IN N
the DT N
dry JJ N
period NN N
, , N
cows VBZ p
consuming VBG p
WCGF NNP p
were VBD N
observed VBN N
to TO N
have VB N
a DT N
significant JJ N
gain NN N
in IN N
BCS NNP N
( ( N
0.07 CD N
+/- JJ N
0.06 CD N
) ) N
compared VBN N
with IN N
a DT N
loss NN N
in IN N
BCS NNP N
in IN N
cows NNS N
fed VBP N
the DT N
control NN N
diet JJ N
( ( N
control VB N
= NNP N
-0.11 NNP N
+/- JJ N
0.06 CD N
and CC N
WCGF-L NNP N
= NNP N
-0.04 NNP N
+/- JJ N
0.06 CD N
) ) N
. . N

During IN N
lactation NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
by IN N
treatment NN N
on IN N
BCS NNP N
. . N

Cows NNP N
consuming VBG p
WCGF NNP p
during IN N
lactation NN N
consumed VBN N
more RBR N
feed JJ o
compared VBN N
with IN N
the DT N
control NN N
: : N
25.4 CD N
, , N
23.8 CD N
, , N
and CC N
21.2 CD N
+/- JJ N
0.76 CD N
kg/d NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
. . N

Milk NNP o
production NN o
was VBD N
higher JJR N
for IN N
cows NNS N
consuming VBG N
WCGF NNP N
: : N
35.0 CD N
, , N
34.7 CD N
, , N
and CC N
31.1 CD N
+/- JJ N
2.1 CD N
kg/d NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
. . N

No UH N
differences NNS N
were VBD N
found VBN N
in IN N
either DT N
DM NNP o
intake NN o
or CC o
actual JJ o
milk NN o
yield NN o
between IN N
the DT N
WCGF-L NNP N
and CC N
WCGF-DL NNP N
treatments NNS N
, , N
indicating VBG N
that IN N
prepartum JJ N
diets NNS N
did VBD N
not RB N
influence VB N
lactational JJ N
performance NN N
. . N

The DT N
WCGF NNP N
diets NNS N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
the DT N
concentration NN o
of IN o
milk NN o
fat NN o
( ( N
3.94 CD N
, , N
3.74 CD N
, , N
and CC N
4.15 CD N
+/- JJ N
0.08 CD N
% NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
) ) N
, , N
but CC N
because IN N
total JJ o
milk NN o
yield NN o
was VBD N
increased VBN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
total JJ N
milk NN N
fat JJ N
yield NN N
. . N

In IN N
addition NN N
, , N
3.5 CD N
% NN N
of IN N
fat-corrected JJ N
milk NN N
tended VBN N
to TO N
be VB N
affected VBN N
by IN N
diet JJ N
: : N
38.9 CD N
, , N
36.3 CD N
, , N
and CC N
34.7 CD N
+/- JJ N
1.93 CD N
kg/d NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
. . N

The DT N
increasing VBG N
effect NN N
of IN N
DM NNP o
intake NN o
and CC o
milk NN o
yield NN o
in IN N
cows NNS N
consuming VBG N
WCGF NNP N
resulted VBD N
in IN N
a DT N
similar JJ N
efficiency NN N
of IN N
3.5 CD N
% NN N
fat-corrected JJ N
milk NN o
production NN o
for IN N
all DT N
treatments NNS N
, , N
averaging VBG N
1.5 CD N
+/- JJ N
0.09 CD N
. . N

Total JJ o
protein JJ o
yields NNS o
were VBD N
significantly RB N
higher JJR N
for IN N
cows NNS N
consuming VBG N
WCGF NNP N
diets NNS N
during IN N
lactation NN N
: : N
1.15 CD N
, , N
1.10 CD N
, , N
1.00 CD N
+/- JJ N
0.06 CD N
kg/d NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
diets NNS N
may MD N
be VB N
formulated VBN N
to TO N
contain VB N
as RB N
much JJ N
as IN N
37.5 CD N
% NN N
WCGF NNP N
( ( N
DM NNP N
basis NN N
) ) N
. . N

-DOCSTART- -7956382- O O

Effect NN N
of IN N
TENS NNP N
on IN N
pain NN o
, , o
medications NNS o
, , o
and CC o
pulmonary JJ o
function NN o
following VBG p
coronary JJ p
artery JJ p
bypass NN p
graft NN p
surgery NN p
. . p

The DT N
efficacy NN N
of IN N
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
( ( i
TENS NNP i
) ) i
as IN N
an DT N
adjunct NN N
to TO N
narcotic JJ N
medications NNS N
for IN N
the DT N
management NN N
of IN N
postoperative JJ o
pain NN o
was VBD N
assessed VBN N
in IN N
a DT N
prospective JJ p
, , p
randomized VBN p
, , p
controlled VBD p
study NN p
of IN p
patients NNS p
following VBG p
coronary JJ p
artery JJ p
bypass NN p
graft NN p
( ( p
CABG NNP p
) ) p
surgery NN p
with IN p
the DT p
right NN p
or CC p
left VBD p
internal JJ p
thoracic NN p
artery NN p
( ( p
ITA NNP p
) ) p
. . p

Forty-five JJ p
male JJ p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
57 CD p
+/- JJ p
6 CD p
years NNS p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO N
( ( N
1 CD N
) ) N
TENS NN i
, , N
( ( N
2 CD N
) ) N
placebo NN i
TENS NNP i
, , i
or CC i
( ( i
3 CD i
) ) i
control NN i
treatments NNS i
( ( N
n JJ N
= RB N
15 CD N
each DT N
) ) N
, , N
following VBG N
extubation NN N
and CC N
during IN N
the DT N
24- JJ N
to TO N
72-h JJ N
postoperative JJ N
period NN N
. . N

Two-way JJ N
analysis NN N
of IN N
variance NN N
tests NNS N
indicated VBD N
no DT N
significant JJ N
differences NNS N
among IN N
treatment NN N
groups NNS N
for IN N
( ( o
1 CD o
) ) o
pain NN o
with IN o
cough NN o
, , o
( ( o
2 CD o
) ) o
narcotic JJ o
medication NN o
intake NN o
, , o
( ( o
3 CD o
) ) o
FVC NNP o
, , o
( ( o
4 CD o
) ) o
FEV1 NNP o
, , o
and CC o
( ( o
5 CD o
) ) o
PEFR NNP o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
pain VBP o
at IN o
rest NN o
reported VBN N
by IN N
the DT N
TENS NNP p
group NN p
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
reported VBN N
by IN N
the DT N
control NN N
group NN N
( ( N
treatment NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.04 CD N
) ) N
, , N
although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
TENS NNP N
and CC N
placebo NN N
or CC N
between IN N
the DT N
placebo NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

All DT N
six CD N
criterion NN N
measures NNS N
were VBD N
characterized VBN N
by IN N
significant JJ N
changes NNS N
over IN N
time NN N
for IN N
the DT N
entire JJ N
group NN N
( ( N
n JJ N
= VBZ N
45 CD N
; : N
time NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
, , N
as IN N
follows VBZ N
: : N
pain NN o
and CC o
medication NN o
intake NN o
were VBD N
similar JJ N
on IN N
days NNS N
1 CD N
and CC N
2 CD N
, , N
but CC N
were VBD N
significantly RB N
less JJR N
on IN N
day NN N
3 CD N
, , N
and CC N
pulmonary JJ o
functions NNS o
were VBD N
significantly RB N
lower JJR N
than IN N
preoperatively RB N
on IN N
day NN N
1 CD N
, , N
decreased VBD N
further RBR N
on IN N
day NN N
2 CD N
, , N
and CC N
despite IN N
an DT N
improvement NN N
on IN N
day NN N
3 CD N
, , N
remained VBD N
significantly RB N
lower JJR N
than IN N
preoperative JJ N
values NNS N
( ( N
p VB N
< RB N
0.01 CD N
) ) N
. . N

This DT N
study NN N
suggests VBZ N
that IN N
the DT N
addition NN N
of IN N
TENS NNP i
, , N
applied VBD N
continuously RB N
during IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
following VBG N
CABG NNP N
with IN N
ITA NNP N
, , N
may MD N
not RB N
be VB N
advantageous JJ N
in IN N
pain NN o
management NN o
or CC N
the DT N
prevention NN N
of IN N
pulmonary JJ o
dysfunction NN o
. . o

-DOCSTART- -18249478- O O

Evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
human JJ N
leukocyte JJ i
IFN-alpha NN i
on IN N
the DT N
immune JJ o
response NN o
to TO o
the DT o
HBV NNP o
vaccine NN o
in IN N
healthy JJ p
unvaccinated JJ p
individuals NNS p
. . p

HBV NNP i
vaccine NN i
needs VBZ N
3 CD N
injections NNS N
over IN N
6 CD N
months NNS N
to TO N
induce VB N
immunity NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
adjuvants NNS N
capable JJ N
of IN N
inducing VBG N
earlier JJR N
immune JJ N
protection NN N
would MD N
be VB N
highly RB N
desirable JJ N
. . N

Most JJS N
adjuvants NNS N
may MD N
act VB N
by IN N
inducing VBG N
cytokines NNS N
, , N
and CC N
among IN N
them PRP N
, , N
type NN N
I PRP N
interferons NNS N
( ( N
IFNs NNP N
) ) N
, , N
deserve VB N
a DT N
special JJ N
attention NN N
in IN N
view NN N
of IN N
the DT N
potent JJ N
immunomostimulatory NN N
activity NN N
observed VBN N
in IN N
mouse NN N
models NNS N
and CC N
on IN N
dendritic JJ N
cell NN N
functions NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
IFN-alpha NNP i
administered VBD N
as IN N
an DT N
adjuvant NN i
of IN i
HBV NNP i
vaccine NN i
in IN N
healthy JJ p
unvaccinated JJ p
individuals NNS p
. . p

No DT N
significant JJ N
enhancing VBG N
effect NN N
on IN N
the DT N
antibody NN o
response NN o
was VBD N
observed VBN N
, , N
in IN N
spite NN N
of IN N
an DT N
early JJ N
and CC N
transient JJ N
upregulation NN N
of IN N
costimulatory NN N
molecule NN N
expression NN N
on IN N
peripheral JJ o
blood NN o
mononuclear NN o
cells NNS o
, , N
which WDT N
may MD N
be VB N
suggestive JJ N
of IN N
an DT N
IFN-mediated JJ N
activation NN N
of IN N
antigen NN N
presenting VBG N
cells NNS N
. . N

We PRP N
conclude VBP N
that IN N
, , N
under IN N
the DT N
conditions NNS N
used VBN N
in IN N
this DT N
trial NN N
, , N
natural JJ N
IFN-alpha NNP i
does VBZ N
not RB N
act VB N
as IN N
an DT N
adjuvant NN N
of IN N
the DT N
HBV NNP N
vaccine NN N
in IN N
healthy JJ p
unvaccinated JJ p
individuals NNS p
. . p

-DOCSTART- -21935685- O O

Effect NN N
of IN N
intravenous JJ N
dezocine NN i
on IN N
fentanyl-induced JJ p
cough NN o
during IN p
general JJ p
anesthesia JJ p
induction NN p
: : p
a DT N
double-blinded JJ N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
suppressive JJ N
effect NN N
of IN N
intravenous JJ N
dezocine NN i
on IN N
fentanyl-induced JJ N
cough NN o
during IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

METHODS NNP N
A NNP N
total NN p
of IN p
120 CD p
patients NNS p
, , p
American NNP p
Society NNP p
of IN p
Anesthesiologists NNP p
( ( p
ASA NNP p
) ) p
physical JJ p
status NN p
I-II NNP p
, , p
were VBD p
randomized VBN p
into IN p
two CD p
equally RB p
sized JJ p
groups NNS p
( ( p
n JJ p
= NNP p
60 CD p
) ) p
. . p

These DT N
two CD N
groups NNS N
were VBD N
given VBN N
either RB N
intravenous JJ i
dezocine NN i
0.1 CD N
mg/kg NN N
or CC i
a DT i
matching JJ i
placebo NN i
( ( N
equal JJ N
volume NN N
of IN N
0.9 CD N
% NN N
saline NN N
) ) N
10 CD N
min NN N
before IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

Patients NNS N
were VBD N
induced VBN N
with IN N
midazolam JJ i
0.1 CD i
mg/kg NN i
, , i
fentanyl VBP i
5 CD i
?g/kg NN i
, , i
propofol JJ i
1-1.5 JJ i
mg/kg NN i
, , i
and CC i
suxamethonium NN i
1.5 CD N
mg/kg NN N
. . N

The DT N
injection NN N
time NN N
of IN N
fentanyl NN N
was VBD N
less JJR N
than IN N
2 CD N
s NNS N
in IN N
all DT N
patients NNS N
. . N

The DT N
occurrence NN N
of IN o
cough NN o
was VBD N
recorded VBN N
2 CD N
min NN N
after IN N
fentanyl JJ N
bolus NN N
. . N

RESULTS NNP p
No NNP p
patient NN p
in IN p
the DT p
dezocine NN p
group NN p
had VBD o
cough VBN o
, , o
and CC p
42 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
had VBD o
cough NN o
. . o

This DT N
difference NN N
was VBD N
statistically RB N
different JJ N
between IN N
these DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

CONCLUSION NNP N
These DT N
results NNS N
demonstrate VBP N
that IN N
intravenous JJ i
dezocine NN i
0.1 CD N
mg/kg NN N
10 CD N
min NN N
prior RB N
to TO N
induction NN N
was VBD N
effective JJ N
in IN N
suppressing VBG p
fentanyl-induced JJ o
cough NN o
in IN p
our PRP$ p
patients NNS p
. . p

-DOCSTART- -24277510- O O

Comparative JJ N
evaluation NN N
of IN N
percutaneous JJ i
laser NN i
and CC N
radiofrequency NN i
ablation NN i
in IN N
patients NNS p
with IN p
HCC NNP p
smaller JJR p
than IN p
4 CD p
cm NN p
. . p

OBJECTIVE CC N
This DT N
study NN N
was VBD N
done VBN N
to TO N
compare VB N
percutaneous JJ i
laser NN i
ablation NN i
( ( i
PLA NNP i
) ) i
and CC N
radiofrequency NN i
thermoablation NN i
( ( i
RFA NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
hepatocellular JJ p
carcinoma NN p
( ( p
HCC NNP p
) ) p
? . p
4 CD p
cm NN p
, , p
in IN p
patients NNS p
with IN p
liver JJ p
cirrhosis NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP p
Thirty NNP p
patients NNS p
with IN p
single JJ p
HCC NNP p
? . p
4 CD p
cm NN p
in IN p
diameter NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
two CD p
treatments NNS p
: : p
15 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
PLA NNP i
, , N
using VBG i
a DT i
multifibre NN i
system NN i
connected VBN i
to TO i
a DT i
neodymium JJ i
yttrium-aluminium-garnet NN i
laser NN i
source NN i
; : i
15 CD i
patients NNS p
were VBD p
treated VBN p
with IN p
RFA NNP i
, , i
using VBG i
an DT i
expandable JJ i
needle JJ i
electrode NN i
. . i

Patients NNS i
were VBD N
followed VBN N
up RP N
for IN N
up RB N
to TO N
12 CD N
months NNS N
. . N

RESULTS VB N
A NNP N
complete JJ N
response NN N
was VBD N
obtained VBN N
in IN N
87 CD N
% NN N
lesions NNS N
treated VBN N
with IN N
PLA NNP N
and CC N
in IN N
93 CD N
% NN N
lesions NNS N
treated VBN N
with IN N
RFA NNP N
( ( N
p JJ N
= NNP N
ns NN N
) ) N
. . N

The DT N
overall JJ o
local JJ o
recurrence-free JJ o
survival NN o
rates NNS o
at IN o
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
were VBD N
comparable JJ N
. . N

However RB N
, , N
a DT N
higher JJR o
rate NN o
of IN o
recurrence NN o
was VBD o
observed VBN N
in IN N
the DT N
PLA NNP N
group NN N
for IN N
lesions NNS N
? . N
21 CD N
mm NN N
( ( N
p JJ N
= NNP N
0.0081 CD N
) ) o
. . o

A DT o
postablation NN o
syndrome NN o
was VBD o
documented VBN o
in IN p
13 CD p
patients NNS p
( ( p
1 CD p
PLA NNP p
; : N
12 CD N
RFA NNP N
) ) N
. . N

Tumour JJ o
necrosis NN o
factor-? NN o
was VBD o
significantly RB o
higher JJR N
in IN N
the DT N
RFA NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
RFA NNP N
is VBZ N
more RBR N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
HCC NNP N
compared VBN i
to TO i
PLA NNP i
for IN N
lesions NNS N
? . N
21 CD N
mm NN N
. . N

However RB N
, , N
PLA NNP N
should MD N
be VB N
considered VBN N
a DT N
viable JJ N
treatment NN N
option NN N
for IN N
HCC NNP N
? . N
20 CD N
mm NN N
, , N
in IN N
view NN N
of IN N
the DT N
lower JJR N
incidence NN N
of IN N
complications NNS N
. . N

-DOCSTART- -15169706- O O

Weight NNP o
and CC o
leptin JJ o
changes NNS o
among IN N
risperidone-treated JJ i
youths NNS p
with IN p
autism NN p
: : p
6-month JJ N
prospective JJ N
data NNS N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
examined VBD N
the DT N
developmental JJ N
impact NN N
and CC N
temporal JJ N
characteristics NNS N
of IN N
risperidone-associated JJ i
weight NN o
change NN o
. . o

METHOD NNP N
Weight NNP o
change NN o
was VBD N
measured VBN N
for IN N
63 CD p
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
treated VBN p
with IN p
risperidone NN i
for IN p
6 CD p
months NNS p
. . p

Change NNP o
in IN o
serum NN o
leptin NN o
levels NNS o
after IN N
2 CD N
months NNS N
was VBD N
examined VBN N
as IN N
a DT N
predictor NN N
of IN N
final JJ o
weight NN o
gain NN o
in IN N
mixed JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
site NN N
, , N
gender NN N
, , N
age NN N
, , N
and CC N
risperidone NN i
dose NN N
. . N

RESULTS NNP N
Age- JJ N
and CC N
gender-standardized JJ N
weight NN o
increased VBD o
after IN N
6 CD N
months NNS N
of IN N
treatment NN N
( ( N
gross JJ N
: : N
mean=5.6 NN N
kg NN N
[ NNP N
SD=3.9 NNP N
] NNP N
; : N
standardized VBN N
: : N
mean=0.6 NN N
z NN N
[ NNP N
SD=0.5 NNP N
] NNP N
) ) N
and CC N
was VBD N
positively RB N
correlated VBN N
with IN N
weight NN o
gained VBN o
after IN N
1 CD N
month NN N
. . N

Change NN o
in IN o
leptin NN o
levels NNS o
after IN N
2 CD N
months NNS N
of IN N
treatment NN N
( ( N
mean=-0.3 JJ N
ng/ml NN N
, , N
SD=6.2 NNP N
) ) N
( ( N
N=48 NNP N
) ) N
did VBD N
not RB N
predict JJ N
final JJ o
weight NN o
gain NN o
. . o

CONCLUSIONS NNP N
Chronic NNP N
risperidone NN i
exposure NN N
in IN N
children NNS N
with IN N
autism NN N
causes NNS N
weight VBD o
gain NN o
in IN N
excess NN N
of IN N
developmentally RB N
expected VBN N
norms NNS N
that WDT N
follows VBZ N
a DT N
curvilinear JJ N
trajectory NN N
and CC N
decelerates VBZ N
over IN N
time NN N
. . N

Serum NNP o
leptin JJ o
change NN o
does VBZ N
not RB N
reliably VB N
predict JJ N
risperidone-associated JJ N
weight NN o
gain NN o
. . o

-DOCSTART- -23246790- O O

Differences NNS N
in IN N
reach NN o
and CC o
attrition NN o
between IN o
Web-based JJ o
and CC o
print-delivered JJ o
tailored JJ o
interventions NNS o
among IN N
adults NNS p
over IN p
50 CD p
years NNS p
of IN p
age NN p
: : p
clustered VBN N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
Internet NNP N
has VBZ N
the DT N
potential JJ N
to TO N
provide VB N
large JJ N
populations NNS N
with IN N
individual JJ N
health NN N
promotion NN N
advice NN N
at IN N
a DT N
relatively RB N
low JJ N
cost NN N
. . N

Despite IN N
the DT N
high JJ N
rates NNS N
of IN N
Internet NNP N
access NN N
, , N
actual JJ N
reach NN N
by IN N
Web-based JJ N
interventions NNS N
is VBZ N
often RB N
disappointingly RB N
low JJ N
, , N
and CC N
differences NNS N
in IN N
use NN N
between IN N
demographic JJ N
subgroups NNS N
are VBP N
present JJ N
. . N

Furthermore RB N
, , N
Web-based JJ N
interventions NNS N
often RB N
have VBP N
to TO N
deal VB N
with IN N
high JJ N
rates NNS N
of IN N
attrition NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
aims VBZ N
to TO N
assess VB N
user JJ o
characteristics NNS o
related VBN o
to TO o
participation NN o
and CC o
attrition NN o
when WRB N
comparing VBG N
Web-based JJ i
and CC i
print-delivered JJ i
tailored JJ i
interventions NNS i
containing VBG N
similar JJ N
content NN N
and CC N
thereby RB N
to TO N
provide VB N
recommendations NNS N
in IN N
choosing VBG N
the DT N
appropriate JJ N
delivery NN N
mode NN N
for IN N
a DT N
particular JJ N
target NN N
audience NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
the DT N
distribution NN N
of IN N
a DT N
Web-based JJ i
and CC i
a DT i
print-delivered JJ i
version NN i
of IN i
the DT i
Active NNP i
Plus NNP i
intervention NN i
in IN N
a DT N
clustered JJ N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
. . N

Participants NNS p
were VBD p
recruited VBN p
via IN p
direct JJ p
mailing NN p
within IN p
the DT p
participating VBG p
Municipal NNP p
Health NNP p
Council NNP p
regions NNS p
and CC p
randomized VBN p
to TO p
the DT p
printed VBN i
or CC i
Web-based VBN i
intervention NN i
by IN p
their PRP$ p
region NN p
. . p

Based VBN N
on IN N
the DT N
answers NNS N
given VBN N
in IN N
a DT N
prior JJ N
assessment NN N
, , N
participants NNS N
received VBD N
tailored JJ N
advice NN N
on IN N
3 CD N
occasions NNS N
: : N
( ( N
1 CD N
) ) N
within IN N
2 CD N
weeks NNS N
after IN N
the DT N
baseline NN N
, , N
( ( N
2 CD N
) ) N
2 CD N
months NNS N
after IN N
the DT N
baseline NN N
, , N
and CC N
( ( N
3 CD N
) ) N
within IN N
4 CD N
months NNS N
after IN N
the DT N
baseline NN N
( ( N
based VBN N
on IN N
a DT N
second JJ N
assessment NN N
at IN N
3 CD N
months NNS N
) ) N
. . N

The DT N
baseline NN N
( ( N
printed VBN N
or CC N
Web-based VBN N
) ) N
results NNS N
were VBD N
analyzed JJ N
using VBG N
ANOVA NNP N
and CC N
chi-square JJ N
tests NNS N
to TO N
establish VB N
the DT N
differences NNS N
in IN N
user JJ N
characteristics NNS N
between IN N
both DT N
intervention NN N
groups NNS N
. . N

We PRP N
used VBD N
logistic JJ N
regression NN N
analyses NNS N
to TO N
study VB N
the DT N
interaction NN N
between IN N
the DT N
user NN o
characteristics NNS o
and CC N
the DT N
delivery NN N
mode NN N
in IN N
the DT N
prediction NN N
of IN N
dropout NN o
rate NN o
within IN N
the DT N
intervention NN N
period NN N
. . N

RESULTS VB N
The DT N
printed JJ N
intervention NN N
resulted VBD N
in IN N
a DT N
higher JJR o
participation NN o
rate NN o
( ( N
19 CD N
% NN N
) ) N
than IN N
the DT N
Web-based JJ N
intervention NN N
( ( N
12 CD N
% NN N
) ) N
. . N

Participants NNS N
of IN N
the DT N
Web-based JJ N
intervention NN N
were VBD N
significantly RB N
younger JJR N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
more RBR N
often RB N
men NNS N
( ( N
P=.01 NNP N
) ) N
, , N
had VBD N
a DT N
higher JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
( ( N
P=.001 NNP N
) ) N
and CC N
a DT N
lower JJR N
intention NN N
to TO N
be VB N
physically RB N
active JJ N
( ( N
P=.03 NNP N
) ) N
than IN N
participants NNS N
of IN N
the DT N
printed VBN N
intervention NN N
. . N

The DT N
dropout NN o
rate NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
Web-based JJ N
intervention NN N
group NN N
( ( N
53 CD N
% NN N
) ) N
compared VBN N
to TO N
the DT N
print-delivered JJ N
intervention NN N
( ( N
39 CD N
% NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

A DT N
low JJ N
intention NN o
to TO o
be VB o
physically RB o
active JJ o
was VBD N
a DT N
strong JJ N
predictor NN N
for IN N
dropout NN o
within IN N
both DT N
delivery NN N
modes FW N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
difference NN N
in IN N
dropout NN o
rate NN o
between IN N
the DT N
Web-based JJ N
and CC N
the DT N
printed JJ N
intervention NN N
was VBD N
not RB N
explained VBN N
by IN N
user JJ N
characteristics NNS N
. . N

CONCLUSIONS VB N
The DT N
reach NN N
of IN N
the DT N
same JJ N
tailored JJ o
physical JJ o
activity NN o
( ( o
PA NNP o
) ) o
intervention NN N
in IN N
a DT N
printed JJ N
or CC N
Web-based JJ N
delivery NN N
mode NN N
differed VBD N
between IN N
sociodemographic JJ N
subgroups NNS N
of IN N
participants NNS N
over IN N
50 CD N
years NNS N
of IN N
age NN N
. . N

Although IN N
the DT N
reach NN N
of IN N
the DT N
Web-based JJ N
intervention NN N
is VBZ N
lower JJR N
, , N
Web-based JJ N
interventions NNS N
can MD N
be VB N
a DT N
good JJ N
channel NN N
to TO N
reach VB N
high-risk JJ N
populations NNS N
( ( N
lower JJR N
PA NNP N
intention NN N
and CC N
higher JJR N
BMI NNP N
) ) N
. . N

While IN N
the DT N
dropout NN o
rate NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
Web-based JJ N
intervention NN N
group NN N
, , N
no DT N
specific JJ N
user NN N
characteristics NNS N
explained VBD N
the DT N
difference NN N
in IN N
dropout NN o
rates NNS o
between IN N
the DT N
delivery NN N
modes NN N
. . N

More JJR N
research NN N
is VBZ N
needed VBN N
to TO N
determine VB N
what WP N
caused VBD N
the DT N
high JJ N
rate NN o
of IN o
dropout NN o
in IN N
the DT N
Web-based JJ N
intervention NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
( ( N
NTR NNP N
) ) N
: : N
2297 CD N
: : N
http NN N
: : N
//www.trialregister.nl/trialreg/admin/rctview.asp NN N
? . N
TC=2297 NNP N
( ( N
Archived VBN N
by IN N
WebCite NNP N
at IN N
http NN N
: : N
//www.webcitation.org/65TkwoESp NN N
) ) N
. . N

-DOCSTART- -14576501- O O

Prophylaxis NN N
with IN N
meropenem NN i
of IN N
septic JJ o
complications NNS o
in IN N
acute JJ N
pancreatitis NN N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
versus NN N
imipenem NN i
. . i

OBJECTIVES NNP N
Prophylactic JJ N
antibiotics NNS N
are VBP N
helpful JJ N
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
septic JJ o
complications NNS o
in IN N
acute JJ N
pancreatitis NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
meropenem NN i
, , N
a DT N
new JJ i
carbapenem NN i
antibiotic JJ i
, , N
with IN N
that DT N
of IN N
imipenem NN i
, , N
which WDT N
is VBZ N
the DT N
standard JJ N
prophylactic JJ i
treatment NN i
in IN N
patients NNS p
with IN p
severe JJ p
acute NN p
pancreatitis NN p
. . p

METHODS NNP N
One CD p
hundred VBD p
seventy-six JJ p
patients NNS p
with IN p
necrotizing JJ p
pancreatitis NN p
were VBD N
prospectively RB N
randomized VBN N
to TO N
prophylactic JJ i
treatment NN i
with IN N
0.5 CD i
g NNS i
meropenem JJ i
t.i.d NN i
. . i

intravenously RB i
or CC i
0.5 CD i
g NNS i
imipenem JJ i
q.i.d NN i
. . i

intravenously RB i
. . i

The DT N
occurrence NN o
of IN o
infection NN o
of IN o
pancreatic JJ o
necrosis NN o
, , o
rate NN o
of IN o
extrapancreatic JJ o
infections NNS o
, , o
systemic JJ o
and CC o
local JJ o
complications NNS o
, , o
need VBP o
for IN o
surgery NN o
, , o
mortality NN o
rate NN o
, , o
and CC o
length NN o
of IN o
hospitalization NN o
were VBD N
recorded VBN N
for IN N
each DT N
group NN N
. . N

When WRB N
a DT N
septic JJ o
complication NN o
of IN N
pancreatic JJ N
necrosis NN N
was VBD N
suspected VBN N
, , N
fine JJ N
needle JJ N
aspiration NN N
with IN N
cultures NNS N
of IN N
the DT N
sample NN N
was VBD N
performed VBN N
. . N

Surgery NN N
was VBD N
performed VBN N
in IN N
cases NNS N
of IN N
verified JJ N
infected JJ N
necrosis NN N
. . N

CONCLUSION NNP N
No NNP N
difference NN N
was VBD N
observed VBN N
between IN N
patients NNS p
treated VBN p
with IN p
meropenem NN i
and CC p
those DT p
treated VBN p
with IN p
imipenem NN i
in IN p
terms NNS p
of IN p
incidence NN o
of IN o
pancreatic JJ o
infection NN o
( ( p
11.4 CD p
% NN p
versus IN p
13.6 CD p
% NN p
) ) p
and CC p
extrapancreatic JJ o
infections NNS o
( ( p
21.6 CD p
% NN p
versus IN p
23.9 CD p
% NN p
) ) p
and CC p
clinical JJ o
outcome NN o
. . o

Meropenem NNP i
is VBZ N
as RB N
effective JJ N
as IN N
imipenem NN i
in IN N
preventing VBG N
septic JJ o
complications NNS o
of IN N
patients NNS N
with IN N
severe JJ N
acute NN N
pancreatitis NN N
. . N

-DOCSTART- -8892490- O O

The DT N
evolving VBG N
clinical JJ N
status NN N
of IN N
patients NNS p
after IN p
a DT p
myocardial JJ p
infarction NN p
: : p
the DT N
importance NN N
of IN N
post-hospital JJ i
data NNS i
for IN N
mortality NN N
prediction NN N
. . N

Studies NNPS N
predicting VBG N
mortality NN N
after IN N
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
usually RB N
rely VBP N
on IN N
in-hospital JJ i
data NNS i
, , N
and CC N
combine NN N
patients NNS p
admitted VBN p
for IN p
the DT p
first JJ p
MI NNP p
with IN p
recurrent JJ p
MI NNP p
patients NNS p
. . p

Since IN N
treatment NN N
decisions NNS N
are VBP N
often RB N
made VBN N
or CC N
modified VBN N
at IN N
the DT N
first JJ N
outpatient NN N
clinic JJ N
visit NN N
, , N
this DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
importance NN N
of IN N
post-hospital JJ i
data NNS i
on IN N
mortality NN N
prediction NN N
after IN N
a DT N
first JJ N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
. . N

An DT p
inception NN p
cohort NN p
of IN p
patients NNS p
enrolled VBN p
in IN p
the DT p
Beta-Blocker NNP p
in IN p
Heart NNP p
Attack NNP p
Trial NNP p
( ( p
n JJ p
= NN p
2830 CD p
) ) p
was VBD p
included VBN p
. . p

Forty-three JJ o
variables NNS o
( ( N
including VBG N
in-hospital JJ i
and CC i
post-hospital JJ i
data NNS i
) ) i
were VBD N
evaluated VBN N
using VBG N
stepwise NN N
logistic JJ N
regression NN N
. . N

Ten CD N
variables NNS N
were VBD N
independently RB N
associated VBN N
with IN N
1-year JJ N
mortality NN N
: : N
five CD N
used VBN N
in-hospital JJ N
data NNS N
( ( o
history NN o
of IN o
hypertension NN o
, , o
hypercholesterolemia NN o
, , o
congestive JJ o
heart NN o
failure NN o
[ NNP o
CHF NNP o
] NNP o
, , o
ventricular JJ o
tachycardia NN o
, , o
and CC o
age NN o
) ) o
; : o
and CC N
five CD N
variables NNS N
depended VBN N
on IN N
post-hospital JJ i
data NNS i
collected VBN N
at IN N
the DT N
first JJ N
outpatient JJ N
visit NN N
( ( o
CHF NNP o
after IN o
discharge NN o
, , o
New NNP o
York NNP o
Heart NNP o
Association NNP o
functional JJ o
class NN o
, , o
heart NN o
rate NN o
, , o
pulmonary JJ o
rates NNS o
, , o
and CC o
smoking NN o
) ) o
. . N

Two CD N
predictive JJ N
systems NNS N
were VBD N
developed VBN N
that IN N
partitioned JJ N
patients NNS N
into IN N
one CD N
of IN N
four CD N
classes NNS N
with IN N
distinct JJ N
mortality NN N
risks NNS N
: : N
a DT N
composite JJ N
system NN N
using VBG N
the DT N
10 CD N
in- JJ N
and CC N
post-hospital JJ N
variables NNS N
, , N
and CC N
a DT N
system NN N
using VBG N
only RB N
the DT N
5 CD N
in-hospital JJ N
variables NNS N
. . N

Mortality NNP o
risk NN o
for IN N
the DT N
composite JJ N
system NN N
classes NNS N
ranged VBD N
from IN N
0.6 CD N
to TO N
20.0 CD N
% NN N
( ( N
I PRP N
[ VBP N
n JJ N
= $ N
861 CD N
] NNP N
, , N
0.6 CD N
% NN N
; : N
II NNP N
[ NNP N
n RB N
= VBZ N
1151 CD N
] NN N
, , N
2.3 CD N
% NN N
; : N
III NNP N
[ NNP N
n MD N
=698 VB N
] NNP N
, , N
4.3 CD N
% NN N
; : N
IV NNP N
[ NNP N
n VBD N
= $ N
120 CD N
] NNP N
, , N
20.0 CD N
% NN N
) ) N
. . N

In IN N
contrast NN N
, , N
the DT N
range NN o
of IN o
mortality NN o
risk NN N
using VBG N
the DT N
in-hospital JJ i
data NNS i
only RB N
system NN N
was VBD N
less JJR N
( ( N
1 CD N
to TO N
8.3 CD N
% NN N
) ) N
. . N

Most JJS N
importantly RB N
, , N
a DT N
distinct JJ N
gradient NN N
within IN N
each DT N
class NN N
of IN N
the DT N
in-hospital JJ i
data NNS i
only RB N
system NN N
was VBD N
created VBN N
by IN N
the DT N
addition NN N
of IN N
the DT N
post-hospital JJ i
data NN i
. . i

This DT N
study NN N
demonstrates VBZ N
that IN N
risk NN N
stratification NN N
after IN N
an DT N
acute NN N
first RB N
MI NNP N
is VBZ N
improved VBN N
by IN N
the DT N
addition NN N
of IN N
post-hospital JJ i
data NNS i
. . i

-DOCSTART- -14996351- O O

Comparison NNP N
of IN N
quality NN o
of IN o
life NN o
, , o
work NN o
productivity NN o
and CC N
medical JJ o
resource NN o
utilization NN o
of IN N
peginterferon NN i
alpha NN i
2a CD i
vs IN N
the DT N
combination NN N
of IN N
interferon NN i
alpha NN i
2b CD i
plus CC i
ribavirin VB i
as IN N
initial JJ N
treatment NN N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
The DT N
on-treatment JJ N
impact NN N
of IN N
interferon-based JJ N
therapies NNS N
on IN N
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
, , o
work NN o
productivity NN o
, , o
and CC o
medical JJ o
resource NN o
utilization NN o
has VBZ N
not RB N
been VBN N
systematically RB N
studied VBN N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
treatment NN N
with IN N
peginterferon NN i
alpha NN i
( ( i
pegIFNalpha NN i
) ) i
2a CD i
monotherapy NN i
and CC N
the DT N
combination NN i
of IN i
interferon NN i
alpha NN i
( ( i
IFNalpha NNP i
) ) i
2b CD i
plus CC i
ribavirin NN i
( ( i
RBV NNP i
) ) i
on IN N
health-related JJ o
QOL NNP o
, , o
work NN o
productivity NN o
and CC o
resource NN o
utilization NN o
. . o

A DT N
total NN N
of IN N
412 CD p
patients NNS p
with IN p
hepatitis NN p
C NNP p
infection NN p
were VBD N
randomized VBN N
to TO N
open-label JJ i
treatment NN i
with IN i
either DT i
pegIFNalpha NN i
2a CD i
( ( i
n JJ i
= NNP i
206 CD i
) ) i
or CC i
IFNalpha $ i
2b/RBV CD i
( ( i
n JJ i
= NNP i
206 CD i
) ) i
. . i

PegIFNalpha $ i
2a CD i
was VBD N
administered VBN N
subcutaneously RB N
at IN N
a DT N
dose NN N
of IN N
180 CD N
microg NN N
once RB N
weekly JJ N
for IN N
48 CD N
weeks NNS N
; : N
and CC N
IFNalpha $ i
2b/RBV CD i
at IN N
doses NNS N
of IN N
3 CD N
MU NNP N
thrice JJ N
weekly RB N
subcutaneously RB N
and CC N
1000-1200 JJ N
mg/day NN N
orally RB N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
SF-36 NNP o
Health NNP o
Survey NNP o
Questionnaire NNP o
and CC o
additional JJ o
generic NN o
and CC o
specific JJ o
scales NNS o
. . o

During IN N
treatment NN N
, , N
for IN N
all DT N
SF-36 NNP N
summary NN N
and CC N
Hepatitis NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
HQLQ NNP o
) ) o
-specific NN o
scales NNS o
, , N
the DT N
pegIFNalpha NN i
2a CD i
group NN N
experienced VBD N
less JJR N
impairment JJ N
than IN N
did VBD N
the DT N
IFNalpha NNP i
2b/RBV CD i
patients NNS N
. . N

The DT N
between-treatment JJ N
differences NNS N
were VBD N
significant JJ N
for IN N
many JJ N
of IN N
the DT N
scores NNS N
particularly RB N
in IN N
the DT N
first JJ N
24 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Across IN N
all DT N
measures NNS N
of IN N
work NN N
functioning NN N
and CC N
productivity NN N
at IN N
each DT N
visit NN N
, , N
patients NNS N
randomized VBD N
to TO N
pegIFNalpha VB i
2a CD i
treatment NN N
showed VBD N
less RBR N
impairment JJ o
relative NN N
to TO N
the DT N
group NN N
treated VBD N
with IN N
IFNalpha NNP i
2b/RBV CD i
. . i

Hence NNP N
treatment NN N
with IN N
pegIFNalpha JJ i
2a CD i
relative JJ N
to TO N
IFNalpha NNP i
2b/RBV CD i
minimizes VBZ N
the DT N
adverse JJ N
impact NN N
of IN N
therapy NN N
on IN N
health-related JJ o
QOL NNP o
. . o

Patients NNS N
randomized VBD N
to TO N
pegIFNalpha VB i
2a CD i
had VBD N
improved VBN N
work NN o
productivity NN o
, , o
less JJR o
activity NN o
impairment NN o
, , o
decreased VBD o
need NN o
for IN o
prescription NN o
drugs NNS o
to TO o
treat VB o
adverse JJ o
effects NNS o
, , o
and CC o
better JJR o
adherence NN o
to TO o
therapy NN o
. . o

-DOCSTART- -21990307- O O

Phase NNP N
II NNP N
study NN N
of IN N
the DT N
effects NNS N
of IN N
ginger NN i
root NN i
extract NN i
on IN N
eicosanoids NNS N
in IN N
colon NN N
mucosa NN N
in IN N
people NNS p
at IN p
normal JJ p
risk NN p
for IN p
colorectal JJ p
cancer NN p
. . p

Inhibitors NNS N
of IN N
COX NNP N
indicate VBP N
that IN N
upregulation NN N
of IN N
inflammatory JJ N
eicosanoids NNS N
produced VBN N
by IN N
COX NNP N
, , N
and CC N
in IN N
particular JJ N
prostaglandin NN N
E NNP N
( ( N
2 CD N
) ) N
( ( N
PGE NNP N
( ( N
2 CD N
) ) N
) ) N
, , N
are VBP N
early JJ N
events NNS N
in IN N
the DT N
development NN N
of IN N
colorectal JJ N
cancer NN N
( ( N
CRC NNP N
) ) N
. . N

Ginger NNP N
has VBZ N
shown VBN N
downregulation NN N
of IN N
COX NNP N
in IN N
vitro NN N
and CC N
decreased JJ N
incidence/multiplicity NN N
of IN N
adenomas NN N
in IN N
rats NNS N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
if IN N
2.0 CD N
g/d NN N
of IN N
ginger NN i
could MD N
decrease VB N
the DT N
levels NNS N
of IN N
PGE NNP o
( ( o
2 CD o
) ) o
, , o
13-hydroxy-octadecadienoic JJ o
acids NNS o
, , o
and CC o
5- JJ o
, , o
12- JJ o
, , o
and CC o
15-hydroxyeicosatetraenoic JJ o
acid NN o
( ( o
5- JJ o
, , o
12- JJ o
, , o
and CC o
15-HETE JJ o
) ) o
, , N
in IN N
the DT N
colon NN N
mucosa NN N
of IN N
healthy JJ p
volunteers NNS p
. . p

To TO N
investigate VB N
this DT N
aim NN N
, , N
we PRP N
randomized VBD N
30 CD p
subjects NNS p
to TO N
2.0 CD i
g/d NN i
ginger NN i
or CC i
placebo NN i
for IN i
28 CD i
days NNS i
. . i

Flexible JJ o
sigmoidoscopy NN o
at IN N
baseline NN N
and CC N
day NN N
28 CD N
was VBD N
used VBN N
to TO N
obtain VB N
colon NN N
biopsies NNS N
. . N

A DT N
liquid JJ i
chromatography NN i
mass NN i
spectrometry NN i
method NN i
was VBD N
used VBN N
to TO N
determine VB N
eicosanoid JJ o
levels NNS o
in IN N
the DT N
biopsies NNS N
, , N
and CC N
levels NNS N
were VBD N
expressed VBN N
per IN N
protein NN N
or CC N
per IN N
free JJ N
arachidonic JJ N
acid NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
mean JJ o
percent NN o
change NN o
between IN N
baseline NN N
and CC N
day NN N
28 CD N
for IN N
any DT N
of IN N
the DT N
eicosanoids NNS o
, , N
when WRB N
normalized VBN N
to TO N
protein VB N
. . N

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
mean JJ o
percent NN o
change NN o
in IN o
PGE NNP o
( ( o
2 CD o
) ) o
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
5-HETE JJ o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
a DT N
trend NN N
toward IN N
significant JJ N
decreases NNS N
in IN N
12-HETE JJ o
( ( N
P NNP N
= NNP N
0.09 CD N
) ) N
and CC N
15-HETE JJ o
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
normalized VBN N
to TO N
free VB o
arachidonic JJ o
acid NN o
. . o

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
terms NNS N
of IN N
total JJ o
adverse JJ o
events NNS o
P NNP N
= NNP N
0.55 CD N
) ) N
. . N

On IN N
the DT N
basis NN N
of IN N
these DT N
results NNS N
, , N
it PRP N
seems VBZ N
that IN N
ginger NN N
has VBZ N
the DT N
potential JJ N
to TO N
decrease VB N
eicosanoid JJ o
levels NNS o
, , N
perhaps RB N
by IN N
inhibiting VBG N
their PRP$ N
synthesis NN N
from IN N
arachidonic JJ N
acid NN N
. . N

Ginger NNP i
also RB N
seemed VBD N
to TO N
be VB N
tolerable JJ o
and CC o
safe JJ o
. . o

Further JJ N
investigation NN N
in IN N
people NNS N
at IN N
high JJ N
risk NN N
for IN N
CRC NNP N
seems VBZ N
warranted VBN N
. . N

-DOCSTART- -19481433- O O

Clinical JJ N
impact NN N
of IN N
leak JJ N
compensation NN N
during IN N
non-invasive JJ N
ventilation NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
leak JJ N
compensation NN N
capabilities NNS N
during IN N
pressure- JJ i
and CC i
volume-limited JJ i
non-invasive JJ i
positive-pressure NN i
ventilation NN i
( ( i
NPPV NNP i
) ) i
in IN N
COPD NNP N
patients NNS N
. . N

METHODS NNP N
Fourteen NNP p
patients NNS p
with IN p
stable JJ p
hypercapnic JJ p
COPD NN p
who WP p
were VBD p
receiving VBG p
long-term JJ p
NPPV NNP p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

For IN N
both DT N
modes NNS N
of IN N
NPPV NNP N
, , N
a DT N
full JJ i
face NN i
mask NN i
and CC i
an DT i
artificial JJ i
leak NN i
in IN i
the DT i
ventilatory NN i
circuit NN i
were VBD N
used VBN N
at IN N
three CD N
different JJ N
settings NNS N
, , N
and CC N
applied VBD N
during IN N
daytime JJ N
NPPV NNP N
, , N
either RB i
without IN i
leakage NN i
( ( i
setting VBG i
I PRP i
) ) i
, , i
with IN i
leakage NN i
during IN i
inspiration NN i
only RB i
( ( i
setting VBG i
II NNP i
) ) i
, , i
and CC i
with IN i
leakage NN i
during IN i
inspiration NN i
and CC i
expiration NN i
( ( i
setting VBG i
III NNP i
) ) i
. . i

Ventilation NNP o
pattern NN o
was VBD N
pneumotachy-graphically RB N
recorded VBN N
. . N

RESULTS NNP N
NPPV NNP N
was VBD N
feasible JJ N
with IN N
negligible JJ N
leak NN o
volumes NNS o
, , N
indicating VBG N
optimal JJ N
mask NN N
fitting VBG N
during IN N
the DT N
daytime NN N
( ( N
setting VBG N
I PRP N
) ) N
. . N

In IN N
the DT N
presence NN N
of IN N
leakage NN o
( ( N
settings NNS N
II NNP N
and CC N
III NNP N
) ) N
, , N
the DT N
attempt NN N
to TO N
compensate VB N
for IN N
leak NN N
was VBD N
only RB N
evident JJ N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
since IN N
inspiratory NN o
volumes NNS o
delivered VBN o
by IN o
the DT o
ventilator NN o
increased VBD N
from IN N
726+/-129 NNP N
( ( N
setting VBG N
I PRP N
) ) N
to TO N
1104+/-164 JJ N
( ( N
setting VBG N
II NNP N
) ) N
, , N
and CC N
to TO N
1257+/-166 JJ N
( ( N
setting VBG N
III NNP N
) ) N
ml NN N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
respectively RB N
( ( N
all DT N
p VBP N
< $ N
0.001 CD N
) ) N
; : N
however RB N
, , N
they PRP N
remained VBD N
stable JJ N
during IN N
volume-limited JJ N
NPPV NNP N
. . N

Leak NNP N
compensation NN N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
leakage-induced JJ o
dyspnea NN o
. . o

However RB N
, , N
83 CD N
% NN N
/87 CD N
% NN N
( ( N
setting VBG N
II/III NNP N
) ) N
of IN N
the DT N
additionally-delivered JJ N
inspiratory NN N
volume NN N
during IN N
pressure-limited JJ N
NPPV NNP N
was VBD N
also RB N
lost VBN N
via IN N
leakage NN N
. . N

Expiratory JJ o
volume NN o
was VBD N
higher RBR N
in IN N
setting VBG N
II NNP N
compared VBN N
to TO N
setting VBG N
III NNP N
( ( N
both DT N
p VBP N
< $ N
0.001 CD N
) ) N
, , N
indicating VBG N
the DT N
presence NN N
of IN N
significant JJ N
expiratory JJ N
leakage NN N
. . N

CONCLUSIONS VB N
The DT N
attempt NN N
at IN N
leak JJ N
compensation NN N
largely RB N
feeds VBZ N
the DT N
leakage NN N
itself PRP N
and CC N
only RB N
results NNS N
in IN N
a DT N
marginal JJ N
increase NN N
of IN N
tidal JJ N
volume NN N
. . N

However RB N
, , N
pressure-limited JJ N
-- : N
but CC N
not RB N
volume-limited JJ N
-- : N
NPPV JJ N
results NNS N
in IN N
a DT N
clinically-important JJ N
leak JJ N
compensation NN N
in IN N
vivo NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
www.uniklinik-freiburg.de/zks/live/uklregister/Oeffentlich.html JJ N
Identifier NNP N
: : N
UKF001272 NN N
. . N

-DOCSTART- -15200998- O O

Chemotherapy NNP i
for IN N
patients NNS p
with IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
: : p
the DT N
surgical JJ N
setting NN N
of IN N
the DT N
Big NNP N
Lung NNP N
Trial NNP N
. . N

OBJECTIVES VB N
The DT N
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
meta-analysis NN N
suggested VBD N
a DT N
survival JJ N
benefit NN N
for IN N
cisplatin-based JJ i
chemotherapy NN i
when WRB N
given VBN N
in IN N
addition NN N
to TO N
surgery NN i
, , N
radical JJ N
radiotherapy NN N
or CC N
'best JJS N
supportive JJ N
care NN N
' POS N
. . N

However RB N
, , N
it PRP N
included VBD N
many JJ N
small JJ N
trials NNS N
and CC N
trials NNS N
with IN N
differing VBG N
eligibility NN N
criteria NNS N
and CC N
chemotherapy NN N
regimens NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
Big NNP N
Lung NNP N
Trial NNP N
was VBD N
therefore RB N
to TO N
run VB N
a DT N
large JJ N
pragmatic JJ N
trial NN N
to TO N
confirm VB N
the DT N
survival NN o
benefits NNS o
seen VBN N
in IN N
the DT N
meta-analysis NN N
. . N

METHODS NNP N
In IN N
the DT N
surgery NN i
setting NN N
, , N
a DT N
total NN N
of IN N
381 CD p
patients NNS p
were VBD p
randomised VBN p
to TO p
chemotherapy VB i
( ( p
C NNP p
, , p
192 CD p
patients NNS p
) ) p
or CC p
no DT i
chemotherapy NN i
( ( p
NoC NNP p
, , p
189 CD p
patients NNS p
) ) p
. . p

C NNP N
was VBD N
three CD N
3-weekly JJ N
cycles NNS N
of IN N
cisplatin/vindesine NN i
, , i
mitomycin/ifosfamide/cisplatin NN i
, , i
mitomycin/vinblastine/cisplatin NN i
or CC i
vinorelbine/cisplatin NN i
. . i

RESULTS NNP N
Chemotherapy NNP i
was VBD N
given VBN N
before RB N
surgery NN i
in IN N
3 CD N
% NN N
of IN N
patients NNS N
whilst VBP N
97 CD N
% NN N
received VBD N
adjuvant JJ i
chemotherapy NN i
. . i

Baseline NNP N
characteristics NNS N
were VBD N
: : N
median JJ N
age NN N
61 CD N
years NNS N
, , N
69 CD N
% NN N
male NN N
, , N
48 CD N
% NN N
squamous JJ N
cell NN N
, , N
93 CD N
% NN N
WHO NNP N
PS NNP N
0-1 NNP N
, , N
27 CD N
% NN N
stage NN N
I PRP N
, , N
38 CD N
% NN N
stage NN N
II NNP N
, , N
and CC N
34 CD N
% NN N
stage NN N
III NNP N
. . N

Complete NNP o
resection NN o
was VBD N
achieved VBN N
in IN N
approximately RB N
95 CD N
% NN N
of IN N
patients NNS N
. . N

In IN N
the DT N
C NNP N
group NN N
, , N
13 CD N
% NN N
received VBD N
no DT i
chemotherapy NN i
, , N
21 CD N
% NN N
one CD N
or CC N
two CD N
cycles NNS N
, , N
and CC N
64 CD N
% NN N
all DT N
three CD N
cycles NNS N
of IN N
their PRP$ N
prescribed JJ N
chemotherapy NN i
( ( N
60 CD N
% NN N
of IN N
the DT N
latter NN N
with IN N
no DT N
delays NNS N
or CC N
modification NN N
) ) N
. . N

30 CD N
% NN N
had VBD N
grade VBN N
3/4 CD N
toxicity NN o
, , o
mainly RB o
haematological JJ o
, , o
nausea/vomiting JJ o
and CC o
neutropenic JJ o
fever NN o
, , N
and CC N
six CD N
patients NNS N
were VBD N
reported VBN N
as IN N
having VBG N
a DT N
treatment-related JJ N
death NN o
. . o

198 CD N
( ( N
52 CD N
% NN N
) ) N
of IN N
patients NNS N
have VBP N
died VBN N
, , N
but CC N
there EX N
is VBZ N
currently RB N
no DT N
evidence NN N
of IN N
a DT N
benefit NN o
in IN o
overall JJ o
survival NN o
to TO N
the DT N
C NNP N
group NN N
: : N
HR $ N
1.02 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.77-1.35 NN N
) ) N
, , N
P NNP N
= NNP N
0.90 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
trial NN N
has VBZ N
failed VBN N
to TO N
observe VB N
a DT N
survival JJ o
benefit NN o
with IN N
adjuvant JJ i
chemotherapy NN i
following VBG N
complete JJ N
resection NN N
of IN N
stage NN N
I-III JJ N
NSCLC NNP N
. . N

However RB N
, , N
the DT N
hazard NN N
ratio NN N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
are VBP N
consistent JJ N
with IN N
the DT N
previously RB N
reported VBN N
meta-analysis NN N
and CC N
two CD N
large JJ N
recently RB N
reported VBD N
trials NNS N
, , N
which WDT N
suggest VBP N
a DT N
small JJ N
survival NN N
benefit NN N
with IN N
cisplatin-based JJ i
chemotherapy NN i
. . i

-DOCSTART- -24637941- O O

Sorafenib NNP i
dose JJ N
escalation NN N
is VBZ N
not RB N
uniformly RB N
associated VBN N
with IN N
blood NN N
pressure NN N
elevations NNS N
in IN N
normotensive JJ p
patients NNS p
with IN p
advanced JJ p
malignancies NNS p
. . p

Hypertension NN N
after IN N
treatment NN N
with IN N
vascular JJ i
endothelial JJ i
growth NN i
factor NN i
( ( i
VEGF NNP i
) ) i
receptor NN N
inhibitors NNS N
is VBZ N
associated VBN N
with IN N
superior JJ N
treatment NN N
outcomes NNS N
for IN N
advanced JJ p
cancer NN p
patients NNS p
. . p

To TO N
determine VB N
whether IN N
increased JJ N
sorafenib NN i
doses NNS N
cause VBP N
incremental JJ N
increases NNS N
in IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , N
we PRP N
measured VBD N
12-h JJ N
ambulatory NN N
BP NNP N
in IN N
41 CD p
normotensive JJ p
advanced VBD p
solid JJ p
tumor NN p
patients NNS p
in IN N
a DT N
randomized JJ N
dose-escalation NN N
study NN N
. . N

After IN N
7 CD N
days NNS N
' POS N
treatment NN N
( ( N
400 CD N
mg NN N
b.i.d NN o
. . o

) ) o
, , o
mean JJ o
diastolic JJ o
BP NNP o
( ( o
DBP NNP o
) ) o
increased VBD o
in IN N
both DT N
study NN N
groups NNS N
. . N

After IN N
dose JJ N
escalation NN N
, , N
group NN N
A NNP N
( ( N
400 CD N
mg NN N
t.i.d NN N
. . N

) ) N
had VBD N
marginally RB N
significant JJ N
further JJ N
increase NN o
in IN o
12-h JJ o
mean NN o
DBP NNP o
( ( N
P NNP N
= NNP N
0.053 CD N
) ) N
, , N
but CC N
group NN N
B NNP N
( ( N
600 CD N
mg NN N
b.i.d NN N
. . N

) ) N
did VBD N
not RB N
achieve VB N
statistically RB N
significant JJ N
increases NNS N
( ( N
P NNP N
= NNP N
0.25 CD N
) ) N
. . N

Within IN N
groups NNS N
, , N
individuals NNS N
varied VBD N
in IN o
BP NNP o
response NN o
to TO o
sorafenib VB o
dose JJ N
escalation NN N
, , N
but CC N
these DT N
differences NNS N
did VBD N
not RB N
correlate VB N
with IN N
changes NNS N
in IN N
steady-state JJ N
plasma NN N
sorafenib NN i
concentrations NNS i
. . N

These DT N
findings NNS p
in IN p
normotensive JJ p
patients NNS p
suggest VBP o
BP NNP o
is VBZ o
a DT N
complex JJ N
pharmacodynamic JJ N
biomarker NN N
of IN N
VEGF NNP N
inhibition NN N
. . N

Patients NNS N
have VBP N
intrinsic JJ N
differences NNS N
in IN N
sensitivity NN N
to TO N
sorafenib VB N
's POS N
BP-elevating JJ N
effects NNS N
. . N

-DOCSTART- -22904179- O O

Adult NNP p
height NN p
in IN p
short JJ p
children NNS p
born VBN p
SGA NNP p
treated VBD p
with IN p
growth NN i
hormone NN i
and CC i
gonadotropin NN i
releasing VBG i
hormone NN i
analog NN i
: : i
results NNS N
of IN N
a DT N
randomized JJ N
, , N
dose-response JJ N
GH NNP i
trial NN N
. . N

CONTEXT NNP N
GH NNP i
treatment NN i
is VBZ N
effective JJ N
in IN N
improving VBG N
height NN N
in IN N
short JJ p
children NNS p
born VBP p
small JJ p
for IN p
gestational JJ p
age NN p
( ( p
SGA NNP p
) ) p
. . p

GH NNP i
is VBZ N
thought VBN N
to TO N
have VB N
limited VBN N
effect NN N
when WRB N
started VBD N
during IN N
adolescence NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
GH NNP i
treatment NN i
efficacy NN o
in IN N
short JJ N
SGA NNP N
children NNS N
when WRB N
treatment NN N
was VBD N
started VBN N
during IN N
adolescence NN N
; : N
to TO N
assess VB N
whether IN N
GH NNP i
2 CD i
mg/m NN i
( ( i
2 CD i
) ) i
? . N
d NN N
during IN N
puberty JJ N
improves NNS o
adult VBP o
height NN o
( ( o
AH NNP o
) ) o
compared VBN N
with IN N
1 CD N
mg/m NNS N
( ( N
2 CD N
) ) N
? . N
d NN N
; : N
and CC N
to TO N
assess VB N
whether IN N
an DT N
additional JJ N
2-yr JJ N
postponement NN N
of IN N
puberty NN N
by IN N
GnRH NNP i
analog NN i
( ( i
GnRHa NNP i
) ) i
improves VBZ i
AH NNP N
in IN N
children NNS N
who WP N
are VBP N
short JJ N
at IN N
the DT N
start NN N
of IN N
puberty NN N
( ( N
< JJ N
140 CD N
cm NN N
) ) N
, , N
with IN N
a DT N
poor JJ N
AH NNP N
expectation NN p
. . p

PATIENTS NNP N
AND CC N
DESIGN NNP N
In IN N
this DT N
longitudinal JJ N
, , N
randomized VBN N
, , N
dose-response JJ N
GH NNP N
trial NN N
, , N
we PRP N
included VBD p
121 CD p
short JJ p
SGA NNP p
children NNS p
( ( p
60 CD p
boys NNS p
) ) p
at IN p
least JJS p
8 CD p
yr NN p
of IN p
age NN p
. . p

We PRP N
performed VBD p
intention-to-treat JJ p
analyses NNS p
on IN p
all DT p
children NNS p
and CC p
uncensored JJ p
case NN p
analyses VBZ p
on IN p
84 CD p
children NNS p
who WP p
reached VBD p
AH NNP p
. . p

Besides NNP N
, , N
we PRP N
evaluated VBD o
growth NN o
during IN o
2 CD N
yr NNS N
of IN N
combined JJ i
GH/GnRHa NNP i
and CC i
subsequent JJ i
GH NNP i
treatment NN i
until IN i
AH NNP N
in IN N
a DT N
subgroup NN N
of IN N
40 CD N
pubertal JJ N
children NNS N
with IN N
a DT N
height NN N
of IN N
less JJR N
than IN N
140 CD N
cm NN N
at IN N
the DT N
start NN N
. . N

RESULTS NNP p
Short NNP p
SGA NNP p
children NNS p
started VBD p
treatment NN N
at IN N
a DT N
median JJ N
age NN N
of IN N
11.2 CD N
yr NNS N
, , N
when WRB N
46 CD N
% NN N
had VBD N
already RB N
started VBN N
puberty NN o
. . o

Median JJ o
height NN o
increased VBD o
from IN N
-2.9 NN N
at IN N
start NN N
to TO N
-1.7 VB N
sd NN N
score NN N
( ( N
SDS NNP N
) ) N
at IN N
AH NNP N
( ( N
P NNP N
< NNP N
0.001 CD i
) ) i
. . i

Treatment NN i
with IN i
GH NNP i
2 CD i
vs. FW N
1 CD N
mg/m NN N
( ( N
2 CD N
) ) N
? . N
d NN N
during IN N
puberty NN N
resulted VBD N
in IN N
significantly RB N
better JJR o
AH NNP o
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
also RB N
after IN N
correction NN N
for IN N
gender NN N
, , N
age NN N
at IN N
start NN N
, , N
height VBD N
SDS NNP N
at IN N
start NN N
, , N
treatment NN N
years NNS N
before IN N
puberty NN N
, , N
and CC N
target VB N
height JJ N
SDS NNP N
. . o

AH NNP o
was VBD N
similar JJ N
in IN N
children NNS N
who WP N
started VBD N
puberty NN N
at IN N
less JJR N
than IN N
140 CD N
cm NN N
and CC N
received VBD i
GH/GnRHa NNP i
, , i
compared VBN i
with IN N
children NNS N
who WP N
started VBD N
puberty NN N
greater JJR N
than IN N
140 CD N
cm NN N
and CC N
received VBD i
GH NNP i
only RB i
( ( i
P NNP i
= NNP N
0.795 CD N
) ) N
. . N

CONCLUSION NN N
When WRB N
started VBN N
in IN N
adolescence NN i
, , i
GH NNP i
treatment NN i
significantly RB i
improves VBZ o
AH NNP o
in IN N
short JJ p
SGA NNP p
children NNS p
, , p
particularly RB p
with IN i
GH NNP i
2 CD p
mg/m NN p
( ( p
2 CD p
) ) p
? . p
d NN p
during IN p
puberty NN p
. . p

When WRB p
SGA NNP N
children NNS N
are VBP N
short JJ N
at IN N
the DT N
start NN N
of IN N
puberty NN N
, , N
they PRP N
can MD N
benefit VB N
from IN N
combined JJ i
GH/GnRHa NNP i
treatment NN i
. . i

-DOCSTART- -25101966- O O

That DT N
looks VBZ N
familiar JJ N
: : N
attention NN N
allocation NN N
to TO N
familiar JJ N
and CC N
unfamiliar JJ N
faces VBZ N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

INTRODUCTION NNP N
Existing VBG N
eye-tracking JJ i
literature NN N
has VBZ N
shown VBN N
that IN N
both DT N
adults NNS p
and CC p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
show VBP N
fewer JJR N
and CC N
slower JJR N
fixations NNS N
on IN N
faces VBZ N
. . N

Despite IN N
this DT N
reduced JJ N
saliency NN N
and CC N
processing NN N
of IN N
other JJ N
faces VBZ N
, , N
recognition NN N
of IN N
their PRP$ N
own JJ N
face NN N
is VBZ N
reported VBN N
to TO N
be VB N
more JJR N
typical JJ N
in IN N
nature NN N
. . N

This DT N
study NN N
uses VBZ N
eye-tracking VBG i
to TO N
explore VB N
the DT N
typicality NN N
of IN N
gaze NN N
patterns NNS N
when WRB N
children NNS p
with IN p
ASD NNP p
attend VBP N
their PRP$ N
own JJ N
faces VBZ N
compared VBN N
to TO N
other JJ N
familiar JJ N
and CC N
unfamiliar JJ N
faces VBZ N
. . N

METHODS NNP N
Eye-tracking JJ i
methodology NN i
was VBD N
used VBN N
to TO N
explore VB N
fixation NN o
duration NN o
and CC N
time NN o
taken VBN o
to TO o
fixate VB o
on IN o
the DT o
Eye NNP o
and CC o
Mouth NNP o
regions NNS o
of IN o
familiar JJ o
, , o
unfamiliar JJ o
and CC o
Self NNP o
Faces NNP o
. . o

Twenty-one CD p
children NNS p
with IN p
ASD NNP p
( ( p
9-16 CD p
years NNS p
) ) p
were VBD p
compared VBN p
to TO p
typically RB p
developing VBG p
matched VBN p
groups NNS p
. . p

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
children NNS p
with IN p
ASD NNP p
and CC N
typically RB p
matched VBD p
groups NNS p
for IN N
fixation NN o
patterns NNS o
to TO o
the DT o
Eye NNP o
and CC o
Mouth NNP o
areas NNS o
of IN N
all DT N
face NN N
types NNS N
( ( N
familiar JJ N
, , N
unfamiliar JJ N
and CC N
self NN N
) ) N
. . N

Correlational JJ N
analyses NNS N
showed VBD N
that IN N
attention NN N
to TO N
the DT N
Eye NNP N
area NN N
of IN N
unfamiliar JJ N
and CC N
Self NNP N
Faces NNP N
was VBD N
related VBN N
to TO N
socio-communicative JJ N
ability NN N
in IN N
children NNS p
with IN p
ASD NNP p
. . p

CONCLUSIONS NNP N
Levels NNP N
of IN N
socio-communicative JJ N
ability NN N
in IN N
children NNS p
with IN p
ASD NNP p
were VBD N
related VBN N
to TO N
gaze VB o
patterns NNS o
on IN o
unfamiliar JJ o
and CC o
Self NNP o
Faces NNP o
, , N
but CC N
not RB N
familiar JJ N
faces VBZ N
. . N

This DT N
lack NN N
of IN N
relationship NN N
between IN N
ability NN o
and CC o
attention NN o
to TO N
familiar JJ N
faces VBZ N
may MD N
indicate VB N
that IN N
children NNS N
across IN N
the DT N
autism NN N
spectrum NN N
are VBP N
able JJ N
to TO N
fixate VB N
these DT N
faces VBZ N
in IN N
a DT N
similar JJ N
way NN N
. . N

The DT N
implications NNS N
for IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -11374137- O O

[ JJ N
Advantages NNP N
of IN N
video NN i
assisted VBN i
thoracic NN i
surgery NN i
in IN N
the DT N
treatment NN N
of IN N
spontaneous JJ p
pneumothorax NN p
] NNP p
. . N

Spontaneous JJ p
pneumothorax NN p
( ( p
SP NNP p
) ) p
is VBZ N
a DT N
disabling VBG N
condition NN N
mostly RB N
affecting VBG N
young JJ p
, , p
thin JJ p
and CC p
otherwise RB p
healthy JJ p
males NNS p
. . p

It PRP N
is VBZ N
usually RB N
caused VBN N
by IN N
ruptured JJ N
pleural JJ N
blebs NN N
. . N

The DT N
first JJ N
treatment NN N
is VBZ N
the DT N
insertion NN i
of IN i
a DT i
chest NN i
tube NN i
( ( i
ICT NNP i
) ) i
but CC N
in IN N
a DT N
great JJ N
number NN N
of IN N
patients NNS N
there EX N
is VBZ N
recurrence NN N
of IN N
the DT N
disease NN N
. . N

We PRP N
believe VBP N
that IN N
the DT N
video NN i
assisted VBN i
thoracoscopy NN i
( ( i
VATS NNP i
) ) i
is VBZ N
the DT N
best JJS N
treatment NN N
possible JJ N
because IN N
it PRP N
allows VBZ N
us PRP N
to TO N
treat VB N
the DT N
ruptured JJ N
bleb NN N
radically RB N
avoiding VBG N
any DT N
recurrence NN N
. . N

In IN N
order NN N
to TO N
prove VB N
it PRP N
, , N
40 CD p
patients NNS p
admitted VBN p
in IN p
a DT p
five-year JJ p
period NN p
, , p
with IN p
a DT p
SP NNP p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
be VB N
treated VBN N
by IN N
ICT NNP i
or CC i
VATS NNP i
. . i

The DT N
ICT JJ i
patients NNS N
were VBD N
in IN N
the DT N
hospital NN N
a DT N
mean JJ o
time NN o
of IN N
7.5 CD N
( ( N
4 CD N
to TO N
15 CD N
) ) N
days NNS N
and CC N
the DT N
VATS NNP i
patients NNS N
, , N
5.3 CD N
( ( N
2 CD N
to TO N
7 CD N
) ) N
days NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

ICT JJ i
patients NNS N
required VBN N
analgesic JJ o
drugs NNS o
during IN N
76.8 CD N
+/- JJ N
31 CD N
hours NNS N
and CC N
VATS NNP i
patients NNS N
38.4 CD N
+/- JJ N
13 CD N
hours NNS N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

From IN N
the DT N
ICT NNP i
group NN N
, , N
8 CD N
( ( N
53 CD N
% NN N
) ) N
patients NNS N
had VBD N
recurrence NN o
of IN o
the DT o
disease NN o
and CC N
6 CD N
( ( N
40 CD N
% NN N
) ) N
had VBD N
a DT N
prolonged JJ N
air NN o
leak NN o
, , N
while IN N
none NN N
of IN N
the DT N
patients NNS N
of IN N
the DT N
VATS NNP i
group NN N
had VBD N
any DT N
complication NN o
( ( N
< NNP N
.001 NNP N
) ) N
. . N

Cost NN o
of IN o
ICT NNP o
and CC o
VATS NNP o
were VBD N
$ $ N
850 CD N
and CC N
$ $ N
1730 CD N
, , N
respectively RB N
. . N

According VBG N
to TO N
these DT N
results NNS N
, , N
VATS NNP i
should MD N
be VB N
the DT N
treatment NN N
of IN N
choice NN N
in IN N
SP NNP N
patients NNS N
. . N

It PRP N
treats VBZ N
the DT N
cause NN N
of IN N
the DT N
disease NN N
. . N

It PRP N
also RB N
reduces VBZ N
the DT N
hospitalization NN o
time NN o
, , N
the DT N
use NN N
of IN N
analgesic JJ N
drugs NNS N
post NN N
surgery NN N
, , N
decreases VBZ N
recurrence NN o
of IN o
the DT o
disease NN o
and CC o
the DT o
cost NN o
of IN o
the DT o
treatment NN o
. . o

Moreover RB N
, , N
the DT N
patients NNS N
were VBD N
back RB N
to TO N
work VB N
in IN N
less JJR N
than IN N
10 CD N
days NNS N
. . N

-DOCSTART- -1722167- O O

5 CD N
alpha-metabolism NN N
in IN N
finasteride-treated JJ i
subjects NNS p
and CC p
male JJ p
pseudohermaphrodites NNS p
with IN p
inherited JJ p
5 CD p
alpha-reductase JJ p
deficiency NN p
. . p

A DT N
review NN N
. . N

Male JJ p
pseudohermaphrodites NNS p
( ( p
MPHs NNP p
) ) p
with IN p
inherited JJ p
5 CD p
alpha-reductase JJ p
deficiency NN p
and CC p
decreased VBD p
dihydrotestosterone NN p
production NN p
have VBP N
a DT N
global JJ N
defect NN N
in IN N
5 CD N
alpha-metabolism NN N
affecting VBG N
both DT N
C19 NNP N
androgen NN N
metabolism NN N
and CC N
C21 NNP N
steroid VBP N
metabolism NN N
. . N

However RB N
, , N
the DT N
decreased JJ N
5 CD N
alpha-reduction NN N
of IN N
testosterone NN N
to TO N
dihydrotestosterone NN N
is VBZ N
the DT N
only RB N
impaired JJ N
steroid JJ N
conversion NN N
to TO N
have VB N
clinical JJ N
consequences NNS N
, , N
e.g. NN N
, , N
ambiguous JJ o
genitalia NN o
, , o
impaired JJ o
prostate NN o
differentiation NN o
and CC o
development NN o
, , N
and CC N
decreased VBD o
facial JJ o
and CC o
body JJ o
hair NN o
. . o

The DT p
5 CD o
alpha-steroid JJ o
metabolite NN o
profile NN o
in IN p
the DT p
MPHs NNP p
was VBD p
compared VBN p
with IN p
that DT p
of IN p
men NNS p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
who WP N
were VBD N
administered VBN N
varying VBG N
doses NNS N
of IN N
the DT N
5 CD i
alpha-reductase JJ i
inhibitor NN i
finasteride NN i
. . i

Finasteride NNP i
was VBD N
found VBN N
to TO N
be VB N
a DT N
potent JJ N
inhibitor NN N
of IN N
both DT N
C19 NNP o
androgen NN o
and CC o
C21 NNP o
5 CD o
alpha-steroid JJ o
metabolism NN o
affecting VBG N
both DT N
hepatic JJ o
and CC o
peripheral JJ o
5 CD o
alpha-metabolism NN o
. . o

The DT N
5 CD N
alpha-steroid JJ o
metabolite NN o
profile NN o
was VBD N
strikingly RB N
similar JJ N
to TO N
that DT N
of IN N
MPHs NNP N
with IN N
inherited JJ N
5 CD N
alpha-reductase JJ N
deficiency NN N
. . N

The DT N
data NN N
suggest NN N
that IN N
a DT N
5 CD N
alpha-reductase JJ N
gene NN N
codes NNS N
for IN N
an DT N
enzyme NN N
with IN N
affinity NN o
for IN o
multiple JJ o
steroid JJ o
substrates NNS o
. . o

-DOCSTART- -20394631- O O

The DT N
pulsed-dye JJ i
laser NN i
as IN N
an DT N
adjuvant JJ N
treatment NN N
modality NN N
in IN N
acne JJ p
vulgaris NN p
: : p
a DT N
randomized JJ N
controlled VBN N
single-blinded JJ N
trial NN N
. . N

BACKGROUND NNP N
Acne NNP N
vulgaris NN N
is VBZ N
the DT N
most RBS N
common JJ N
skin NN N
disease NN N
and CC N
can MD N
pose VB N
a DT N
substantial JJ N
therapeutic JJ N
challenge NN N
. . N

Recently RB N
, , N
several JJ N
phototherapeutic JJ N
modalities NNS N
, , N
most JJS N
notably RB N
pulsed-dye JJ i
laser NN i
( ( i
PDL NNP i
) ) i
treatment NN N
, , N
have VBP N
been VBN N
introduced VBN N
, , N
but CC N
the DT N
published VBN N
results NNS N
- : N
albeit IN N
promising VBG N
- : N
are VBP N
controversial JJ N
. . N

OBJECTIVES NNP N
To TO N
assess VB N
the DT N
efficacy NN o
of IN N
an DT N
adjuvant JJ N
PDL NNP i
treatment NN N
when WRB N
combined VBN N
with IN N
a DT N
proven JJ N
topical JJ N
treatment NN N
[ JJ N
fixed-combination NN N
clindamycin NN N
1 CD N
% NN N
-benzoyl NNP N
peroxide RB N
5 CD N
% NN N
hydrating VBG N
gel NN N
( ( N
C/BPO NNP N
) ) N
] NN N
. . N

METHODS NNP N
Eighty NNP p
patients NNS p
( ( p
38 CD p
males NNS p
and CC p
42 CD p
females NNS p
, , p
mean JJ p
+/- JJ p
SD NNP p
age NN p
19.7 CD p
+/- JJ p
5.9 CD p
years NNS p
) ) p
were VBD N
randomized VBN N
in IN N
a DT N
1 CD N
: : N
2 CD N
ratio NN N
to TO N
receive VB N
C/BPO NNP i
alone RB i
or CC i
in IN i
combination NN i
with IN i
PDL NNP i
treatment NN i
( ( N
wavelength JJ N
585 CD N
nm NN N
, , N
energy NN N
fluence NN N
3 CD N
J NNP N
cm NN N
( ( N
-2 NNP N
) ) N
, , N
pulse JJ N
duration NN N
0.35 CD N
ms NN N
, , N
spot NN N
size NN N
7 CD N
mm NN N
) ) N
. . N

Patients NNS N
were VBD N
evaluated VBN N
at IN N
baseline NN N
and CC N
at IN N
2 CD N
and CC N
4 CD N
weeks NNS N
after IN N
initial JJ N
treatment NN N
. . N

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
the DT N
Investigator NNP o
's POS o
Static JJ o
Global NNP o
Assessment NNP o
( ( o
ISGA NNP o
) ) o
score NN o
and CC N
lesion NN o
count NN o
; : o
the DT N
secondary JJ N
end NN N
point NN N
was VBD N
the DT N
Dermatology NNP o
Life NNP o
Quality NNP o
Index NNP o
( ( o
DLQI NNP o
) ) o
. . o

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
a DT N
significant JJ N
improvement NN N
during IN N
observation NN o
[ NNP N
ISGA NNP N
27.1 CD N
% NN N
( ( i
C/BPO NNP i
) ) i
and CC N
24.6 CD N
% NN N
( ( i
C/BPO NNP i
+ NNP i
laser NN i
) ) i
, , N
total JJ o
lesion NN o
count NN o
9.2 CD N
% NN N
and CC N
9.0 CD N
% NN N
, , N
inflammatory JJ o
lesion NN o
count NN o
36.3 CD N
% NN N
and CC N
36.9 CD N
% NN N
, , N
DLQI NNP N
54.5 CD N
% NN N
and CC N
42.5 CD N
% NN N
] NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
or CC N
otherwise RB N
appreciable JJ N
difference NN N
between IN N
treatment NN N
modalities NNS N
as RB N
far RB N
as IN N
the DT N
extent NN N
of IN N
improvement NN N
was VBD N
concerned VBN N
. . N

Patients NNS N
with IN N
more RBR N
severe JJ N
findings NNS N
at IN N
baseline NN N
had VBD N
a DT N
greater JJR N
benefit NN N
from IN N
either CC N
therapy JJ N
regimen NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
do VBP N
not RB N
support VB N
the DT N
concept NN N
of IN N
a DT N
substantial JJ N
benefit NN N
of IN N
PDL NNP i
treatment NN N
in IN N
acne JJ N
vulgaris NN N
. . N

-DOCSTART- -7840362- O O

Dexamethasone NN i
for IN N
the DT N
treatment NN N
of IN N
depression NN N
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

OBJECTIVE CC N
The DT N
authors NNS N
' POS N
goal NN N
was VBD N
to TO N
assess VB N
dexamethasone NN i
for IN N
the DT N
treatment NN N
of IN N
depression NN N
. . N

METHOD NNP N
Thirty-seven JJ p
outpatients NNS p
( ( p
11 CD p
men NNS p
and CC p
26 CD p
women NNS p
) ) p
meeting VBG p
DSM-III-R JJ p
criteria NNS p
for IN p
major JJ p
depressive JJ p
disorder NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
placebo NN i
or CC i
4 CD i
mg/day NN i
of IN i
oral JJ i
dexamethasone NN i
for IN i
4 CD i
days NNS i
. . i

Baseline NNP N
Hamilton NNP o
depression NN o
scale NN o
scores NNS o
were VBD N
compared VBN N
with IN N
scores NNS N
obtained VBN N
14 CD N
days NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
study NN N
medication NN N
. . N

Data NNS N
were VBD N
analyzed VBN N
by IN N
using VBG N
two-sample JJ N
t NN N
tests NNS N
, , N
chi-square JJ N
methods NNS N
, , N
and CC N
Fisher NNP N
's POS N
exact JJ N
test NN N
. . N

RESULTS VB N
Seven NNP N
( ( N
37 CD N
% NN N
) ) N
of IN N
the DT N
19 CD N
patients NNS N
given VBN N
dexamethasone NN N
but CC N
only RB N
one CD N
( ( N
6 CD N
% NN N
) ) N
of IN N
the DT N
18 CD N
patients NNS N
given VBN N
placebo NNS N
responded VBD N
positively RB N
. . N

No UH N
adverse JJ o
events NNS o
or CC o
side NN o
effects NNS o
were VBD N
reported VBN N
, , N
and CC N
all DT N
patients NNS N
who WP N
entered VBD N
the DT N
study NN N
completed VBD N
it PRP N
. . N

CONCLUSIONS VB N
A DT N
brief JJ N
course NN N
of IN N
oral JJ N
dexamethasone NN i
( ( N
4 CD N
days NNS N
) ) N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN i
within IN N
14 CD N
days NNS N
for IN N
the DT N
treatment NN N
of IN N
depression NN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
of IN N
depressed JJ N
outpatients NNS N
. . N

-DOCSTART- -16214598- O O

Secondary JJ N
prevention NN N
of IN N
macrovascular JJ o
events NNS o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
in IN p
the DT p
PROactive NNP p
Study NNP p
( ( N
PROspective NNP N
pioglitAzone RB N
Clinical JJ N
Trial NNP N
In IN N
macroVascular JJ N
Events NNS N
) ) N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Patients NNPS p
with IN p
type JJ p
2 CD p
diabetes NNS p
are VBP N
at IN N
high JJ N
risk NN N
of IN N
fatal JJ N
and CC N
non-fatal JJ N
myocardial JJ o
infarction NN o
and CC N
stroke NN o
. . o

There EX N
is VBZ N
indirect JJ N
evidence NN N
that IN N
agonists NNS N
of IN N
peroxisome JJ N
proliferator-activated JJ N
receptor NN N
gamma NN N
( ( N
PPAR NNP N
gamma NN N
) ) N
could MD N
reduce VB N
macrovascular JJ o
complications NNS o
. . o

Our PRP$ N
aim NN N
, , N
therefore RB N
, , N
was VBD N
to TO N
ascertain VB N
whether IN N
pioglitazone NN i
reduces NNS N
macrovascular JJ o
morbidity NN o
and CC N
mortality NN o
in IN N
high-risk JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

METHODS NNP N
We PRP N
did VBD N
a DT N
prospective NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
in IN N
5238 CD p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
who WP p
had VBD p
evidence NN p
of IN p
macrovascular JJ o
disease NN o
. . o

We PRP N
recruited VBD N
patients NNS p
from IN p
primary-care JJ p
practices NNS p
and CC p
hospitals NNS p
. . p

We PRP N
assigned VBD N
patients NNS N
to TO N
oral JJ i
pioglitazone NN i
titrated VBD i
from IN i
15 CD i
mg NNS i
to TO i
45 CD i
mg NN i
( ( N
n=2605 JJ N
) ) N
or CC i
matching VBG i
placebo NN i
( ( N
n=2633 JJ N
) ) N
, , N
to TO N
be VB N
taken VBN N
in IN i
addition NN i
to TO i
their PRP$ i
glucose-lowering JJ i
drugs NNS i
and CC i
other JJ i
medications NNS i
. . i

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
the DT N
composite NN o
of IN o
all-cause JJ o
mortality NN o
, , o
non JJ o
fatal JJ o
myocardial JJ o
infarction NN o
( ( o
including VBG o
silent JJ o
myocardial JJ o
infarction NN o
) ) o
, , o
stroke VBD o
, , o
acute JJ o
coronary JJ o
syndrome NN o
, , o
endovascular JJ o
or CC o
surgical JJ o
intervention NN o
in IN o
the DT o
coronary NN o
or CC o
leg NN o
arteries NNS o
, , o
and CC o
amputation NN o
above IN o
the DT o
ankle NN o
. . o

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
as IN N
an DT N
International NNP N
Standard NNP N
Randomised VBD N
Controlled NNP N
Trial NNP N
, , N
number NN N
ISRCTN NNP N
NCT00174993 NNP N
. . N

FINDINGS NNP N
Two CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up JJ N
, , N
but CC N
were VBD N
included VBN N
in IN N
analyses NNS N
. . N

The DT N
average JJ N
time NN N
of IN N
observation NN N
was VBD N
34.5 CD N
months NNS N
. . N

514 CD p
of IN p
2605 CD p
patients NNS p
in IN N
the DT N
pioglitazone NN N
group NN N
and CC N
572 CD N
of IN N
2633 CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
had VBD N
at IN N
least JJS N
one CD N
event NN N
in IN N
the DT N
primary JJ o
composite JJ o
endpoint NN o
( ( N
HR NNP N
0.90 CD N
, , N
95 CD N
% NN N
CI NNP N
0.80-1.02 CD N
, , N
p=0.095 NN N
) ) N
. . N

The DT N
main JJ N
secondary JJ N
endpoint NN N
was VBD N
the DT N
composite NN o
of IN o
all-cause JJ o
mortality NN o
, , o
non-fatal JJ o
myocardial JJ o
infarction NN o
, , o
and CC o
stroke VBD o
. . o

301 CD N
patients NNS N
in IN N
the DT N
pioglitazone NN N
group NN N
and CC N
358 CD N
in IN N
the DT N
placebo NN N
group NN N
reached VBD N
this DT N
endpoint NN o
( ( N
0.84 CD N
, , N
0.72-0.98 CD N
, , N
p=0.027 NN N
) ) N
. . N

Overall JJ o
safety NN o
and CC o
tolerability NN o
was VBD N
good JJ N
with IN N
no DT N
change NN N
in IN N
the DT N
safety NN o
profile NN o
of IN N
pioglitazone NN N
identified VBN N
. . N

6 CD N
% NN N
( ( N
149 CD N
of IN N
2065 CD N
) ) N
and CC N
4 CD N
% NN N
( ( N
108 CD N
of IN N
2633 CD N
) ) N
of IN N
those DT N
in IN N
the DT N
pioglitazone NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
, , N
were VBD N
admitted VBN N
to TO N
hospital VB N
with IN N
heart NN o
failure NN o
; : o
mortality NN o
rates NNS o
from IN o
heart NN o
failure NN o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

INTERPRETATION NNP N
Pioglitazone NNP N
reduces VBZ N
the DT N
composite NN N
of IN N
all-cause JJ N
mortality NN o
, , o
non-fatal JJ o
myocardial JJ o
infarction NN o
, , N
and CC N
stroke VBD o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
who WP p
have VBP p
a DT p
high JJ p
risk NN p
of IN p
macrovascular JJ p
events NNS p
. . p

-DOCSTART- -939970- O O

Radiotherapy NNP i
and CC N
CCNU NNP i
in IN N
the DT N
treatment NN N
of IN N
high-grade JJ N
supratentorial JJ N
astrocytomas NN N
. . N

Forty-one CD p
consecutive JJ p
patients NNS p
with IN p
supratentorial JJ p
primary JJ p
brain NN p
tumors NNS p
( ( p
38 CD p
Grade NNP p
III NNP p
and CC p
IV NNP p
astrocytomas RB p
, , p
one CD p
giant-cell NN p
astrocytoma NN p
, , p
and CC p
two CD p
cases NNS p
with IN p
insufficient JJ p
tissue NN p
for IN p
diagnosis NN p
) ) p
were VBD N
randomly RB N
allocated VBN N
within IN p
2 CD p
weeks NNS p
of IN p
surgery NN p
to TO N
one CD N
of IN N
three CD N
therapeutic JJ N
groups NNS N
. . N

Group NNP N
1 CD N
( ( N
15 CD N
patients NNS N
) ) N
received VBD N
radiation NN i
therapy NN i
totaling VBG N
4000 CD N
to TO N
4500 CD N
rads NNS N
in IN N
4 CD N
to TO N
5 CD N
weeks NNS N
. . N

Group NNP N
2 CD N
( ( N
13 CD N
patients NNS N
) ) N
received VBD N
1- JJ i
( ( i
2-chloroethyl JJ i
) ) i
-3-cyclohexyl-1-nitrosourea FW i
CCNU NNP i
) ) i
130 CD N
mg/sq JJ N
m NNS N
orally RB N
every DT N
6 CD N
weeks NNS N
. . N

Group NNP N
3 CD N
( ( N
13 CD N
patients NNS N
) ) N
received VBD N
radiation NN i
therapy NN i
plus CC i
CCNU NNP i
as IN N
for IN N
Groups NNP N
1 CD N
and CC N
2 CD N
. . N

When WRB N
the DT N
disease NN N
progressed VBD N
, , N
patients NNS N
in IN N
Groups NNP N
1 CD N
and CC N
2 CD N
were VBD N
crossed VBN N
over IN N
to TO N
receive VB N
CCNU NNP i
and CC N
irradiation NN N
respectively RB N
. . N

The DT N
median JJ o
survival NN o
time NN o
in IN N
these DT N
groups NNS N
was VBD N
188 CD N
, , N
259 CD N
, , N
and CC N
252 CD N
days NNS N
, , N
and CC N
the DT N
mean JJ N
survival NN o
263 CD N
, , N
262 CD N
, , N
and CC N
329 CD N
days NNS N
. . N

The DT N
median JJ o
time NN o
from IN o
diagnosis NN o
to TO o
crossover VB o
( ( o
Groups NNP o
1 CD o
and CC o
2 CD o
) ) o
or CC o
to TO o
progression NN o
( ( N
Group NNP N
3 CD N
) ) N
was VBD N
163 CD N
, , N
99 CD N
, , N
and CC N
220 CD N
days NNS N
, , N
and CC N
the DT N
mean JJ N
time NN N
was VBD N
172 CD N
, , N
108 CD N
, , N
and CC N
231 CD N
days NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
means NNS o
or CC o
medians NNS o
in IN N
any DT N
of IN N
these DT N
situations NNS N
. . N

-DOCSTART- -17438178- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
pentoxifylline NN i
for IN N
the DT N
treatment NN N
of IN N
recurrent NN p
aphthous JJ p
stomatitis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
pentoxifylline NN i
for IN N
the DT N
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
. . N

DESIGN VB N
A DT N
60-day JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
with IN N
a DT N
60-day JJ N
no DT N
treatment NN N
follow-up RB N
. . N

SETTING VBG N
An DT N
oral JJ N
medicine NN N
specialist NN N
referral JJ N
center NN N
in IN N
Manchester NNP N
. . N

PARTICIPANTS NNP N
Forty-nine JJ p
volunteers NNS p
who WP p
passed VBD p
the DT p
initial JJ p
assessment NN p
for IN p
recurrent NN p
aphthous JJ p
stomatitis NN p
entered VBD p
a DT p
pretrial JJ p
phase NN p
in IN p
which WDT p
their PRP$ p
eligibility NN p
for IN p
the DT p
trial NN p
phase NN p
of IN p
the DT p
study NN p
was VBD p
assessed VBN p
. . p

Sixteen JJ p
subjects NNS p
were VBD p
deemed VBN p
ineligible JJ p
, , N
and CC N
7 CD N
failed VBD N
to TO N
attend VB N
or CC N
withdrew VB N
. . N

The DT N
remaining VBG N
26 CD p
subjects NNS p
were VBD N
randomized VBN N
to TO N
placebo VB N
or CC N
treatment NN N
. . N

Six NNP N
subjects VBZ N
withdrew JJ N
because IN N
of IN N
adverse JJ N
effects NNS N
, , N
and CC N
1 CD N
was VBD N
unavailable JJ N
for IN N
follow-up NN N
. . N

INTERVENTION NNP N
Pentoxifylline NNP i
( ( N
also RB N
called VBN N
oxpentifylline NN N
) ) N
, , N
400 CD N
mg NN N
3 CD N
times NNS N
daily RB N
, , N
or CC N
matching VBG N
placebo NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
A NNP N
reduction NN N
in IN N
the DT N
median JJ o
pain NN o
score NN o
, , o
ulcer JJ o
size NN o
, , o
number NN o
of IN o
ulcers NNS o
, , o
or CC o
total JJ o
number NN o
of IN o
ulcer JJ o
episodes NNS o
. . o

RESULTS JJ N
Patients NNPS N
taking VBG N
pentoxifylline NN i
had VBD N
less JJR o
pain NN o
and CC N
reported VBD N
smaller JJR o
and CC o
fewer JJR o
ulcers NNS o
compared VBN N
with IN N
baseline NN N
. . N

Patients NNS N
taking VBG N
placebo NN i
reported VBD N
no DT o
improvement NN o
in IN N
these DT N
variables NNS N
. . N

Patients NNS N
taking VBG N
pentoxifylline NN i
also RB N
reported VBD N
more RBR o
ulcer-free JJ o
days NNS o
than IN N
those DT N
taking VBG N
placebo NN i
. . i

However RB N
, , N
the DT N
differences NNS o
were VBD o
small JJ o
and CC N
, , N
with IN N
the DT N
exception NN o
of IN o
median JJ o
ulcer NN o
size NN o
( ( N
P NNP N
= NNP N
.05 NNP N
) ) N
, , N
did VBD o
not RB o
reach VB o
statistical JJ o
significance NN o
. . o

Adverse JJ o
effects NNS o
were VBD N
common JJ N
with IN N
pentoxifylline NN i
, , N
but CC N
not RB o
significantly RB o
different JJ o
from IN N
those DT N
experienced VBN N
by IN N
patients NNS N
taking VBG N
placebo NN i
. . i

CONCLUSIONS NNP N
Although IN N
pentoxifylline NN i
may MD N
have VB N
some DT N
benefit NN N
in IN N
the DT N
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
, , N
the DT N
benefit NN N
is VBZ N
limited VBN N
. . N

It PRP N
may MD N
have VB N
a DT N
role NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
unresponsive JJ N
to TO N
other JJ N
treatments NNS N
, , N
but CC N
can MD N
not RB N
yet RB N
be VB N
recommended VBN N
as IN N
a DT N
first-line JJ N
treatment NN N
. . N

-DOCSTART- -20843746- O O

Pharmacokinetics NNS N
and CC N
follicular JJ N
dynamics NNS N
of IN N
corifollitropin NN i
alfa NN i
versus NN i
recombinant JJ i
FSH NNP i
during IN N
ovarian JJ p
stimulation NN p
for IN p
IVF NNP p
. . p

A NNP N
single JJ N
injection NN N
of IN N
corifollitropin NN i
alfa NN i
can MD N
replace VB N
seven CD N
daily JJ N
injections NNS N
of IN N
recombinant JJ i
FSH NNP i
( ( i
rFSH NN i
) ) i
using VBG N
a DT N
gonadotrophin-releasing JJ N
hormone NN N
antagonist NN N
protocol NN N
in IN N
ovarian JJ N
stimulation NN N
prior RB p
to TO p
IVF NNP p
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
. . N

This DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
assessed VBD N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
150?g CD i
corifollitropin NN i
alfa NN i
versus IN i
daily JJ i
200IU CD i
rFSH NN i
in IN p
1509 CD p
patients NNS p
. . p

Comparative JJ N
analyses NNS N
were VBD N
performed VBN N
on IN o
serum JJ o
concentrations NNS o
of IN o
FSH NNP o
immunoreactivity NN o
( ( N
pharmacokinetics NNS N
) ) N
, , N
and CC N
the DT o
number NN o
and CC o
size NN o
of IN o
growing VBG o
follicles NNS o
, , o
and CC o
inhibin NN o
B NNP o
and CC o
oestradiol JJ o
concentrations NNS o
as IN N
biomarkers NNS N
of IN N
ovarian JJ N
response NN N
( ( N
pharmacodynamics NNS N
) ) N
. . N

The DT o
rate NN o
of IN o
follicular JJ o
development NN o
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

By IN N
stimulation NN N
day NN N
8 CD N
, , N
33 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
corifollitropin NN N
alfa NN N
reached VBD N
the DT N
criterion NN N
for IN N
human JJ N
chorionic NN N
gonadotrophin NN N
( ( N
HCG NNP N
) ) N
injection NN N
. . N

The DT o
number NN o
of IN o
follicles NNS o
?11mm NNP o
was VBD o
slightly RB N
higher JJR N
after IN i
corifollitropin NN i
alfa NN i
compared VBN i
with IN N
daily JJ N
rFSH NN N
at IN N
stimulation NN N
day NN N
8 CD N
( ( N
difference NN N
, , N
1.2 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.5-1.8 NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
on IN N
the DT N
day NN N
of IN N
HCG NNP N
injection NN N
( ( N
difference NN N
, , N
2.1 CD N
; : N
95 CD N
% NN N
CI NNP N
1.4-2.8 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
rise NN o
of IN o
inhibin NN o
B NNP o
and CC o
oestradiol JJ o
concentrations NNS o
was VBD o
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Although IN N
the DT N
pharmacokinetics NNS N
of IN N
corifollitropin NN i
alfa NN i
and CC i
rFSH NN i
are VBP i
quite RB N
different JJ N
their PRP$ N
pharmacodynamic JJ N
profiles NNS N
at IN N
the DT N
dosages NNS N
used VBN N
are VBP N
similar JJ N
. . N

A DT N
single JJ N
injection NN N
of IN N
corifollitropin NN i
alfa NN i
can MD i
replace VB N
seven CD N
daily JJ N
injections NNS N
of IN N
recombinant JJ i
FSH NNP i
( ( i
rFSH NN i
) ) i
using VBG i
a DT N
gonadotrophin-releasing JJ N
hormone NN N
antagonist NN N
protocol NN N
in IN N
ovarian JJ N
stimulation NN N
prior RB N
to TO N
IVF NNP N
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
corifollitropin NN i
alfa JJ i
versus JJ i
daily JJ i
rFSH NN i
. . i

A DT i
total NN N
of IN N
1509 CD p
patients NNS p
were VBD p
randomized VBN N
in IN N
a DT N
double-blind NN N
, , N
controlled VBN N
trial NN N
to TO N
either VB N
a DT N
single JJ N
injection NN N
of IN N
150?g CD i
corifollitropin NN i
alfa NN i
or CC i
to TO N
daily JJ N
injections NNS N
of IN N
200IU CD i
rFSH NN i
for IN i
the DT N
first JJ N
7 CD N
days NNS N
of IN N
ovarian JJ N
stimulation NN o
. . o

Serum NNP o
levels NNS o
of IN o
FSH NNP o
immunoreactivity NN o
were VBD o
analysed VBN N
( ( N
pharmacokinetic JJ N
analysis NN N
) ) N
, , N
together RB N
with IN N
the DT N
number NN o
and CC o
size NN o
of IN o
growing VBG o
follicles NNS o
and CC o
serum NN o
inhibin NN o
B NNP o
and CC o
oestradiol JJ o
concentrations NNS o
as IN o
biomarkers NNS N
of IN N
the DT N
ovarian JJ N
response NN N
( ( N
pharmacodynamic JJ N
analysis NN o
) ) o
. . o

Serum NNP o
FSH NNP o
immunoreactivity NN o
levels NNS o
were VBD o
higher JJR N
up RB N
to TO N
stimulation VB N
day NN N
5 CD N
for IN N
corifollitropin NN i
alfa NN i
compared VBN i
with IN N
the DT N
daily JJ i
rFSH NN i
regimen NNS i
but CC N
were VBD N
similar JJ N
from IN N
day NN N
8 CD N
onwards NNS N
, , N
when WRB N
patients NNS N
started VBD N
rFSH RB N
if IN N
the DT N
criteria NN N
for IN N
human JJ N
chorionic NN N
gonadotrophin NN N
were VBD N
not RB N
yet RB N
reached VBN i
. . i

Corifollitropin NNP i
alfa JJ i
treatment NN i
resulted VBD N
in IN N
a DT N
similar JJ o
growth NN o
rate NN o
of IN o
follicles NNS o
though IN o
a DT N
slightly RB o
higher JJR o
number NN o
of IN o
follicles NNS o
were VBD o
recruited VBN N
compared VBN N
with IN N
daily JJ N
rFSH NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
pharmacokinetics NNS i
of IN i
corifollitropin NN i
alfa NN i
and CC i
rFSH NN i
are VBP i
quite RB N
different JJ N
but CC N
their PRP$ N
induced JJ o
pharmacodynamic JJ o
effects NNS o
at IN o
the DT N
dosages NNS N
used VBN N
are VBP N
similar JJ N
. . N

-DOCSTART- -8318411- O O

Continuous JJ i
chemotherapy NN i
in IN N
responsive JJ N
metastatic JJ p
breast NN p
cancer NN p
: : p
a DT N
role NN N
for IN N
tumour NN N
markers NNS N
? . N
A DT N
biochemical JJ N
response NN N
index NN N
comprising VBG N
ESR NNP N
, , N
CEA NNP N
and CC N
CA NNP N
15.3 CD N
was VBD N
evaluated VBN N
in IN N
67 CD p
patients NNS p
with IN p
systemic JJ p
breast NN p
cancer NN p
treated VBN p
by IN p
chemotherapy NN p
; : p
55 CD p
were VBD p
assessable JJ p
by IN p
UICC NNP p
criteria NNS p
and CC p
the DT p
response NN p
index NN p
( ( p
96 CD p
% NN p
of IN p
all DT p
UICC NNP p
assessable JJ p
patients NNS p
) ) p
. . p

Marker NNP N
changes NNS N
at IN N
2 CD N
and CC N
4 CD N
months NNS N
showed VBD N
a DT N
highly RB N
significant JJ N
correlation NN N
with IN N
the DT N
UICC NNP N
assessed VBD N
response NN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
sensitivity $ N
100 CD N
% NN N
, , N
specificity NN N
87 CD N
% NN N
; : N
positive JJ N
predictive JJ N
value NN N
85 CD N
% NN N
; : N
negative JJ N
predictive JJ N
value NN N
100 CD N
% NN N
. . N

This DT N
index NN N
was VBD N
then RB N
used VBN N
to TO N
select VB N
out RP N
truly RB N
responsive JJ N
patients NNS p
and CC N
to TO N
prospectively RB N
direct VB N
their PRP$ N
chemotherapy NN i
. . i

Twenty-six JJ N
responding NN N
( ( N
biochemical/clinical JJ N
) ) N
patients NNS N
were VBD N
randomised VBN N
to TO N
discontinue VB i
cytotoxics NNS i
after IN i
6 CD i
months NNS i
and CC i
move VB i
to TO i
maintenance VB i
hormones NNS i
( ( N
n JJ N
= NNP N
13 CD N
) ) N
or CC N
continue VB i
chemotherapy NN i
whilst IN N
the DT N
biochemical JJ N
markers NNS N
kept VBD N
falling VBG N
or CC N
remained VBN N
within IN N
the DT N
normal JJ N
range NN N
. . N

Biochemical JJ N
progression NN N
prompted VBD N
a DT N
change NN N
of IN N
chemotherapy NN N
. . N

Continuous JJ i
chemotherapy NN i
in IN N
biochemically RB N
defined JJ N
responders NNS N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
lengthening NN o
of IN o
remission NN o
duration NN o
and CC o
an DT o
improved JJ o
quality NN o
of IN o
life NN o
and CC o
survival NN o
. . o

We PRP N
are VBP N
now RB N
using VBG N
the DT N
index NN N
to TO N
routinely RB N
direct JJ N
chemotherapy NN N
and CC N
select VB N
out RP N
true JJ N
responders NNS N
for IN N
maintenance NN N
chemotherapy NN N
. . N

-DOCSTART- -12954577- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
multicenter JJ N
trial NN N
comparing VBG N
two CD N
doses NNS N
of IN N
arzoxifene NN i
( ( i
LY353381 NNP i
) ) i
in IN N
hormone-sensitive JJ p
advanced JJ p
or CC p
metastatic JJ p
breast NN p
cancer NN p
patients NNS p
. . p

BACKGROUND NNP N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
assessed VBD N
two CD N
doses NNS N
of IN N
the DT N
selective JJ i
estrogen NN i
receptor NN i
modulator NN i
arzoxifene NN i
in IN N
women NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
. . p

The DT N
primary JJ N
end NN N
point NN N
was VBD N
to TO N
choose VB N
the DT N
best JJS N
of IN N
two CD N
doses NNS N
of IN N
arzoxifene NN i
based VBN N
on IN N
the DT N
response NN o
rate NN o
or CC o
the DT o
clinical JJ o
benefit NN o
rate NN o
( ( o
CBR NNP o
) ) o
. . o

Pharmacokinetics NNPS o
and CC o
toxicities NNS o
were VBD N
also RB N
assessed VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Ninety-two NNP p
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
received VBD i
arzoxifene JJ i
20 CD i
or CC i
50 CD i
mg/day NN i
. . i

Tumor NNP o
response NN o
was VBD i
assessed VBN i
using VBG i
World NNP i
Health NNP i
Organization NNP i
criteria NNS i
. . i

Toxicities NNS o
were VBD i
graded VBN i
according VBG i
to TO i
the DT i
National NNP i
Cancer NNP i
Institute NNP i
Common NNP i
Toxicity NNP i
Criteria NNP i
( ( i
NCI-CTC NNP i
) ) i
system NN i
. . i

Pharmacokinetic JJ o
data NNS o
were VBD N
analyzed VBN N
using VBG N
the DT N
NONMEM NNP N
software NN N
program NN N
( ( N
GloboMax NNP N
, , N
Hanover NNP N
, , N
MD NNP N
, , N
USA NNP N
) ) N
. . N

RESULTS JJ N
Response JJ o
rates NNS o
in IN N
the DT N
20 CD N
mg NN N
arm NN N
were VBD N
numerically RB N
higher JJR N
than IN N
the DT N
50-mg JJ N
arm NN N
according VBG N
to TO N
the DT N
investigator NN N
( ( N
40.5 CD N
% NN N
versus IN N
36.4 CD N
% NN N
) ) N
and CC N
the DT N
independent JJ N
review NN N
panel NN N
( ( N
42.9 CD N
% NN N
versus IN N
27.3 CD N
% NN N
) ) N
. . N

CBR NNP o
was VBD N
higher RBR N
in IN N
the DT N
20 CD N
mg NN N
arm NN N
according VBG N
to TO N
the DT N
investigator NN N
( ( N
64.3 CD N
% NN N
versus IN N
61.4 CD N
% NN N
) ) N
and CC N
the DT N
independent JJ N
review NN N
panel NN N
( ( N
59.5 CD N
% NN N
versus IN N
47.7 CD N
% NN N
) ) N
. . N

Arzoxifene NNP i
was VBD N
well RB N
tolerated VBN N
. . N

There EX N
were VBD N
no DT N
study NN N
drug-related JJ o
deaths NNS o
. . o

Mean NNP N
observed VBD N
steady-state JJ o
plasma JJ o
concentrations NNS o
of IN N
arzoxifene NN i
were VBD N
3.62 CD N
and CC N
7.48 CD N
ng/ml NN N
for IN N
the DT N
20 CD N
and CC N
50 CD N
mg NN N
doses NNS N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
efficacy NN o
or CC N
safety NN o
between IN N
20 CD N
and CC N
50 CD N
mg NN N
of IN N
arzoxifene NN i
. . i

Accordingly RB N
, , N
arzoxifene VBZ i
20 CD N
mg/day NN N
was VBD N
selected VBN N
for IN N
further JJ N
study NN N
in IN N
patients NNS N
with IN N
breast JJ N
cancer NN N
. . N

-DOCSTART- -22678947- O O

The DT N
memory NN N
support NN N
system NN N
for IN N
mild JJ p
cognitive JJ p
impairment NN p
: : p
randomized JJ N
trial NN N
of IN N
a DT N
cognitive JJ i
rehabilitation NN i
intervention NN i
. . i

OBJECTIVE JJ N
Individuals NNS p
with IN p
amnestic JJ p
mild NNS p
cognitive JJ p
impairment NN p
( ( p
MCI NNP p
) ) p
have VBP N
few JJ N
empirically RB N
based VBN N
treatment NN N
options NNS N
for IN N
combating VBG N
their PRP$ N
memory NN o
loss NN o
. . o

This DT N
study NN N
sought VBD N
to TO N
examine VB N
the DT N
efficacy NN o
of IN N
a DT N
calendar/notebook NN i
rehabilitation NN i
intervention NN i
, , N
the DT N
memory NN o
support NN o
system NN o
( ( o
MSS NNP o
) ) o
, , N
for IN N
individuals NNS p
with IN p
amnestic JJ p
MCI NNP p
. . p

METHODS NNP N
Forty NNP p
individuals NNS p
with IN p
single JJ p
domain NN p
amnestic JJ i
MCI NNP i
and CC p
their PRP$ p
program NN p
partners NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
the DT N
MSS NNP N
, , N
either RB N
with IN N
training NN N
or CC N
without IN N
( ( N
controls NNS N
) ) N
. . N

Measures NNS o
of IN o
adherence NN o
, , o
activities NNS o
of IN o
daily JJ o
living NN o
, , o
and CC o
emotional JJ o
impact NN o
were VBD N
completed VBN N
at IN N
the DT N
first JJ N
and CC N
last JJ N
intervention NN N
sessions NNS N
and CC N
again RB N
at IN N
8 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
post VBN N
intervention NN N
. . N

RESULTS NNP N
Training NNP N
in IN N
use NN N
of IN N
a DT N
notebook/calendar NN N
system NN N
significantly RB N
improved VBN N
adherence NN o
over IN N
those DT N
who WP N
received VBD N
the DT N
calendars NNS N
but CC N
no DT N
training NN N
. . N

Functional NNP o
ability NN o
and CC o
memory NN o
self-efficacy NN o
significantly RB N
improved VBN N
for IN N
those DT N
who WP N
received VBD N
MSS NNP N
training NN N
. . N

Change NN o
in IN o
functional JJ o
ability NN o
remained VBD N
significantly RB N
better RBR N
in IN N
the DT N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
out IN N
to TO N
8-week JJ N
follow-up NN N
. . N

Care NNP N
partners NNS N
in IN N
the DT N
intervention NN N
group NN N
demonstrated VBD N
improved VBN N
mood NN o
by IN N
8-week JJ N
and CC N
6-month JJ N
follow-ups NNS N
, , N
whereas NNS N
control VBP N
care NN N
partners NNS N
reported VBD N
worse JJR N
caregiver NN o
burden NN o
by IN N
6-month JJ N
follow-up NN N
. . N

CONCLUSIONS NNP N
Memory NNP i
support NN i
system NN i
training NN i
resulted VBD N
in IN N
improvement NN N
in IN N
activities NNS o
of IN o
daily JJ o
living NN o
and CC o
sense NN o
of IN o
memory NN o
self-efficacy NN o
for IN N
individuals NNS N
with IN N
MCI NNP N
. . N

Although IN N
activities NNS N
of IN N
daily JJ N
living VBG N
benefits NNS N
were VBD N
maintained VBN N
out IN N
to TO N
8 CD N
weeks NNS N
post NN N
intervention NN N
, , N
future JJ N
inclusion NN N
of IN N
booster NN N
sessions NNS N
may MD N
help VB N
extend VB N
the DT N
therapeutic JJ N
effect NN N
out IN N
even RB N
further RBR N
. . N

Improved VBN o
mood NN o
of IN N
care NN N
partners NNS N
of IN N
trained JJ N
individuals NNS N
and CC N
worsening VBG o
sense NN o
of IN o
caregiver NN o
burden NN o
over IN N
time NN N
for IN N
partners NNS N
of IN N
untrained JJ N
individuals NNS N
further RBR N
support NN N
the DT N
efficacy NN N
of IN N
the DT N
MSS NNP N
for IN N
MCI NNP N
. . N

-DOCSTART- -6377221- O O

Effect NN N
of IN N
oral JJ N
diuretics NNS i
on IN N
pulmonary JJ N
mechanics NNS N
in IN N
infants NNS p
with IN p
chronic JJ p
bronchopulmonary JJ p
dysplasia NN p
: : p
results NNS N
of IN N
a DT N
double-blind JJ p
crossover NN p
sequential JJ p
trial NN p
. . p

In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
trial NN N
with IN N
sequential JJ N
analysis NN N
, , N
the DT N
effects NNS N
of IN N
oral JJ N
diuretics NNS i
were VBD N
compared VBN N
with IN N
the DT N
effects NNS N
of IN N
placebo NN i
on IN N
pulmonary JJ N
mechanics NNS N
in IN N
ten JJ p
infants NNS p
with IN p
bronchopulmonary JJ p
dysplasia NN p
( ( p
BPD NNP p
) ) p
. . p

Pulmonary JJ N
mechanics NNS N
were VBD N
measured VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
a DT N
week NN N
of IN N
treatment NN N
with IN N
oral JJ i
diuretics NNS i
( ( i
chlorothiazide NN i
, , i
20 CD i
mg/kg/dose NN i
and CC i
spironolactone NN i
, , i
1.5 CD i
mg/kg/dose NN i
) ) i
given VBN i
twice RB i
daily RB i
, , i
or CC i
placebo NN i
. . i

Mean NNP o
airway RB o
resistance NN o
decreased VBD N
35.3 CD N
cm NN N
H2O/L/s NNP N
, , N
mean NN N
specific JJ o
airway RB o
conductance NN o
increased VBD N
0.095 CD N
1/L/s/cm CD N
H2O NNP N
, , N
and CC N
mean JJ o
dynamic JJ o
pulmonary JJ o
compliance NN o
increased VBD N
1.74 CD N
mL/cm NN N
H2O NNP N
during IN N
treatment NN N
with IN N
diuretics NNS N
( ( N
all DT N
P NNP N
less JJR N
than IN N
.001 NN N
) ) N
, , N
but CC N
not RB N
during IN N
treatment NN N
with IN N
placebo NN N
. . N

The DT N
infants NNS p
' POS p
rate NN p
of IN p
weight NN o
gain NN o
decreased VBD N
on IN N
the DT N
first JJ N
three CD N
days NNS N
of IN N
diuretic JJ N
treatment NN N
, , N
but CC N
was VBD N
thereafter RB N
comparable JJ N
with IN N
weight JJ o
gain NN o
during IN N
treatment NN N
with IN N
placebo NN i
. . i

Fluid NNP o
intake NN o
was VBD N
similar JJ N
in IN N
infants NNS p
receiving VBG N
diuretics NNS N
and CC N
placebo NN i
. . i

But CC N
, , N
infants NNS p
receiving VBG N
diuretics NNS N
not RB N
only RB N
had VBD N
significantly RB N
increased VBN N
urine JJ o
output NN o
, , o
osmolal JJ o
clearance NN o
, , o
and CC o
potassium NN o
and CC o
phosphorus NN o
excretion NN o
, , N
but CC N
these DT N
infants NNS N
also RB N
retained VBD o
less JJR o
fluid NN o
, , N
and CC N
, , N
in IN N
addition NN N
, , N
excreted VBD o
less JJR o
calcium NN o
than IN N
infants NNS N
receiving VBG N
placebo NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
oral JJ N
diuretics NNS i
improve VBP N
lung NN o
function NN o
in IN N
infants NNS p
with IN N
chronic JJ N
bronchopulmonary JJ N
dysplasia NN N
; : N
however RB N
, , N
potassium NN N
and CC N
phosphorus NN N
depletion NN N
are VBP N
potential JJ N
complications NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -11413274- O O

Gabapentin NNP N
but CC N
not RB N
vigabatrin JJ N
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
acquired VBN p
nystagmus NN p
in IN p
multiple JJ p
sclerosis NN p
: : p
How NNP N
valid JJ N
is VBZ N
the DT N
GABAergic NNP N
hypothesis NN N
? . N
Acquired NNP N
nystagmus NN N
occurs VBZ N
frequently RB N
in IN N
patients NNS p
with IN p
multiple JJ p
sclerosis NN p
and CC N
is VBZ N
often RB N
the DT N
cause NN N
of IN N
illusory JJ N
motion NN N
of IN N
the DT N
environment NN N
( ( N
oscillopsia NN N
) ) N
, , N
and CC N
blurring NN N
of IN N
vision NN N
. . N

Based VBN N
primarily RB N
on IN N
the DT N
beneficial JJ N
effect NN N
of IN N
gabapentin NN N
on IN N
acquired VBN N
pendular JJ N
nystagmus NN N
( ( N
APN NNP N
) ) N
, , N
a DT N
GABAergic NNP N
mechanism NN N
in IN N
controlling VBG N
nystagmus NN N
has VBZ N
been VBN N
hypothesised VBN N
. . N

If IN N
increasing VBG N
GABA NNP N
concentrations NNS N
in IN N
the DT N
CNS NNP N
are VBP N
critical JJ N
for IN N
the DT N
treatment NN N
of IN N
nystagmus NN N
, , N
then RB N
a DT N
selective JJ N
GABAergic NNP N
drug NN N
should MD N
be VB N
highly RB N
successful JJ N
. . N

However RB N
, , N
as IN N
gabapentin NN N
is VBZ N
not RB N
a DT N
selective JJ N
GABAergic NNP N
agent NN N
, , N
vigabatrin NN N
, , N
a DT N
pure JJ N
GABAergic NNP N
medication NN N
, , N
and CC N
gabapentin NN N
, , N
were VBD N
compared VBN N
in IN N
a DT N
single JJ N
blind NN N
cross NN N
over IN N
trial NN N
in IN N
eight CD p
patients NNS p
with IN p
definite JJ p
multiple JJ p
sclerosis NN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
begin VB N
with IN N
gabapentin NN i
( ( i
1200 CD i
mg FW i
daily RB i
) ) i
or CC i
vigabatrin NN i
( ( i
2000 CD i
mg FW i
daily RB i
) ) i
. . N

Neuro-ophthalmological JJ N
and CC N
electro-oculographic JJ N
( ( N
EOG NNP N
) ) N
evaluations NNS N
were VBD N
performed VBN N
four CD N
and CC N
three CD N
times NNS N
, , N
respectively RB N
. . N

Treatment NNP N
efficacy NN o
was VBD N
based VBN N
on IN N
improving VBG N
visual JJ o
acuity NN o
and CC N
EOG NNP o
indices NNS o
( ( o
amplitude NN o
or CC o
frequency NN o
of IN o
nystagmus NN o
, , o
or CC o
both DT o
) ) o
by IN N
at IN N
least JJS N
50 CD N
% NN N
of IN N
pretreatment NN N
values NNS N
. . N

Three CD p
out IN p
of IN p
eight CD p
patients NNS p
dropped VBD p
out RP p
due JJ p
to TO p
adverse JJ o
effects NNS o
. . o

In IN N
the DT N
remaining VBG N
five CD N
patients NNS N
gabapentin NN N
improved VBN N
symptomatic JJ o
pendular NN o
or CC o
gaze NN o
evoked VBN o
jerk NN o
nystagmus NN o
in IN N
four CD N
. . N

Three CD p
patients NNS p
decided VBD p
to TO p
continue VB p
gabapentin JJ p
therapy NN p
. . p

Importantly RB N
, , N
vigabatrin FW N
proved VBD N
useful JJ N
in IN N
only RB N
one CD N
out IN N
of IN N
five CD N
patients NNS N
, , N
suggesting VBG N
that IN N
gabapentin NN N
effectiveness NN N
may MD N
be VB N
related VBN N
to TO N
additional JJ N
non-GABAergic JJ N
mechanisms NN N
of IN N
action NN N
. . N

Interaction NN N
with IN N
cerebral JJ N
glutamate NN N
transmission NN N
by IN N
inhibition NN N
of IN N
NMDA NNP N
receptor NN N
might MD N
be VB N
an DT N
alternative JJ N
hypothesis NN N
for IN N
the DT N
therapeutic JJ N
action NN N
of IN N
gabapentin NN N
. . N

-DOCSTART- -9474450- O O

Influence NN N
of IN N
special-effect JJ i
contact NN i
lenses NNS i
( ( i
Crazy NNP i
Lenses NNP i
) ) i
on IN N
visual JJ o
function NN o
. . o

PURPOSE NNP N
Special-effect JJ i
contact NN i
lenses NNS i
( ( N
opaque NN N
, , N
tinted VBD N
soft JJ N
contact NN N
lenses VBZ N
that IN N
incorporate JJ N
decorative JJ N
images NNS N
such JJ N
as IN N
cateyes NNS N
, , N
stars NNS N
, , N
or CC N
hearts NNS N
to TO N
alter VB N
eye NN N
color NN N
and CC N
structure NN N
) ) N
have VBP N
become VBN N
increasingly RB N
popular JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
such JJ N
lenses NNS N
impair VBP N
visual JJ o
function NN o
. . o

METHODS NNP N
A DT i
clear JJ i
soft JJ i
contact NN i
lens NNS i
and CC i
a DT i
special-effect JJ i
soft JJ i
contact NN i
lens NNS i
( ( i
Crazy NNP i
lens VBZ i
, , i
) ) i
were VBD N
fit JJ N
in IN N
changing VBG N
sequence NN N
in IN N
nine CD p
healthy JJ p
subjects NNS p
. . p

The DT N
parameters NNS N
studied VBD N
included VBN N
: : N
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
( ( o
with IN o
and CC o
without IN o
glare NN o
) ) o
, , o
visual JJ o
field NN o
, , o
and CC o
mesopic NN o
vision NN o
( ( o
with IN o
and CC o
without IN o
glare NN o
) ) o
. . o

RESULTS VB N
The DT N
following JJ N
parameters NNS N
displayed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Visual JJ o
acuity NN o
was VBD N
decreased VBN N
to TO N
0.9 CD N
+/- JJ N
0.23 CD N
in IN N
the DT N
Crazy NNP N
lens VBZ N
group NN N
as IN N
compared VBN N
with IN N
1.2 CD N
+/- JJ N
0.13 CD N
in IN N
the DT N
clear JJ i
lens NNS i
group NN N
. . N

Goldmann NNP o
visual JJ o
field NN o
displayed VBD N
a DT N
significant JJ N
constriction NN o
of IN o
the DT o
isopters NNS o
: : o
III/4 NNP N
, , N
I/4 NNP N
, , N
and CC N
I/3 NNP N
. . N

Mesopic NNP o
vision NN o
without IN o
glare NN o
was VBD N
reduced VBN N
from IN N
1:2.5 CD N
to TO N
1:7.4 CD N
. . N

Contrast NNP o
sensitivity NN o
was VBD N
significantly RB N
reduced VBN N
in IN N
a DT N
photopic JJ N
condition NN N
with IN N
and CC N
without IN N
glare NN N
and CC N
in IN N
a DT N
scotopic JJ N
condition NN N
without IN N
glare NN N
. . N

Furthermore RB N
, , N
the DT N
special-effect JJ i
lenses NNS i
were VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
lens NNS o
wearing VBG o
comfort NN o
. . o

CONCLUSIONS NNP N
Special-effect JJ i
contact NN i
lenses NNS i
were VBD N
associated VBN N
with IN N
a DT N
reduction NN N
of IN N
many JJ N
visual JJ o
functions NNS o
, , N
including VBG N
visual JJ o
acuity NN o
and CC o
contrast NN o
sensitivity NN o
. . o

For IN N
some DT N
wearers NNS p
this DT N
may MD N
interfere VB N
with IN N
activities NNS N
where WRB N
excellent JJ N
vision NN N
is VBZ N
crucial JJ N
, , N
such JJ N
as IN N
driving VBG N
a DT N
car NN N
. . N

-DOCSTART- -22617366- O O

A DT N
comparison NN N
of IN N
a DT N
short JJ i
nurse-based JJ i
and CC i
a DT i
long JJ i
multidisciplinary JJ i
version NN i
of IN i
structured JJ i
patient JJ i
education NN i
in IN N
irritable JJ p
bowel NN p
syndrome NN p
. . p

OBJECTIVE CC N
Structured NNP i
multidisciplinary JJ i
patient NN i
group NN i
education NN i
has VBZ N
positive JJ N
effects NNS N
on IN N
symptoms NNS N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
and CC N
disease-related JJ N
knowledge NN N
in IN N
patients NNS p
with IN p
irritable JJ p
bowel NN p
syndrome NN p
( ( p
IBS NNP p
) ) p
, , N
but CC N
few JJ N
studies NNS N
comparing VBG N
different JJ N
forms NNS N
of IN N
educational JJ N
interventions NNS N
are VBP N
available JJ N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
long JJ i
multidisciplinary JJ i
group NN i
education NN i
with IN N
a DT N
short JJ i
nurse-based JJ i
group NN i
education NN i
with IN N
regard NN N
to TO N
symptoms NNS N
, , N
knowledge NN N
, , N
quality NN N
of IN N
life NN N
, , N
and CC N
satisfaction NN N
with IN N
the DT N
intervention NN N
in IN N
IBS NNP p
patients NNS p
. . p

METHODS NNP N
Patients NNPS p
with IN p
IBS NNP p
according VBG p
to TO p
the DT p
Rome NNP p
II NNP p
criteria NNS p
were VBD N
randomized VBN N
to TO N
either DT N
short JJ i
nurse-based JJ i
or CC i
a DT i
long JJ i
multidisciplinary-based JJ i
education NN i
. . i

The DT N
effects NNS N
were VBD N
evaluated VBN N
by IN N
self-administered JJ i
questionnaires NNS i
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
baseline NN N
, , N
and CC N
compared VBN N
between IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
No NNP N
differences NNS N
in IN N
effects NNS N
were VBD N
detected VBN N
in IN N
the DT N
between-group JJ N
comparisons NNS N
at IN N
any DT N
of IN N
the DT N
follow-up JJ N
assessments NNS N
. . N

However RB N
, , N
positive JJ N
effects NNS N
on IN N
symptoms NNS o
, , o
knowledge NN o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
satisfaction NN o
with IN N
the DT N
intervention NN N
were VBD N
found VBN N
in IN N
both CC N
the DT N
short JJ N
and CC N
the DT N
long JJ N
version NN N
. . N

CONCLUSION VB N
A DT N
short JJ i
, , i
nurse-based JJ i
educational JJ i
intervention NN i
seems VBZ N
to TO N
be VB N
as RB N
efficacious JJ N
as IN N
a DT N
longer RBR i
multidisciplinary JJ i
version NN N
. . N

In IN N
both DT N
groups NNS N
, , N
positive JJ N
effects NNS N
on IN N
patients NNS N
' POS N
well-being NN N
were VBD N
found VBN N
to TO N
a DT N
similar JJ N
extent NN N
. . N

This DT N
is VBZ N
an DT N
important JJ N
finding NN N
that IN N
, , N
from IN N
a DT N
cost-effective JJ N
perspective NN N
, , N
could MD N
contribute VB N
toward IN N
an DT N
optimized JJ N
management NN N
of IN N
patients NNS N
with IN N
IBS NNP N
. . N

-DOCSTART- -22045826- O O

Single NNP i
negative JJ i
colposcopy NN i
: : i
is VBZ N
it PRP N
enough RB N
to TO N
rule VB N
out IN N
high-grade JJ N
disease NN N
? . N
It PRP N
has VBZ N
been VBN N
proposed VBN N
that IN N
women NNS p
who WP p
have VBP p
a DT p
negative JJ p
colposcopic NN p
examination NN p
or CC p
who WP p
have VBP p
no DT p
cervical JJ p
intraepithelial JJ p
neoplasia NN p
( ( p
CIN NNP p
) ) p
on IN p
colposcopic NN i
biopsy NN i
can MD N
be VB N
safely RB N
returned VBN N
to TO N
routine VB N
screening VBG N
with IN N
the DT N
next JJ N
visit NN N
being VBG N
three CD N
or CC N
five CD N
years NNS N
later RB N
. . N

We PRP N
present JJ N
data NNS N
regarding VBG N
551 CD p
women NNS p
who WP p
had VBD p
colposcopy NN i
in IN p
Wales NNP p
for IN p
a DT p
low-grade JJ p
cytological JJ p
abnormality NN p
and CC p
who WP p
were VBD p
followed VBN p
through IN p
Cervical NNP p
Screening NNP p
Wales NNP p
for IN p
subsequent JJ p
CIN NNP p
. . p

Of IN N
436 CD N
women NNS N
declared VBD N
CIN NNP o
free JJ o
initially RB N
, , N
26 CD N
( ( N
6.0 CD N
% NN N
) ) N
had VBD N
high-grade JJ o
CIN NNP o
diagnosed VBD N
on IN N
follow-up NN N
. . N

We PRP N
suggest VBP N
that IN N
additional JJ N
screening NN N
at IN N
an DT N
interval NN N
of IN N
less JJR N
than IN N
three CD N
years NNS N
should MD N
be VB N
offered VBN N
to TO N
women NNS p
with IN p
a DT p
negative JJ p
colposcopy NN p
or CC p
a DT p
biopsy NN p
without IN p
CIN NNP p
. . p

-DOCSTART- -23407221- O O

Rifampicin NNP i
plus CC i
isoniazid NN i
for IN N
the DT N
prevention NN N
of IN N
tuberculosis NN p
in IN p
an DT p
immigrant JJ p
population NN p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
tolerance NN N
, , N
adherence NN N
and CC N
effectiveness NN N
of IN N
two CD N
approaches NNS N
for IN N
the DT N
treatment NN N
of IN N
latent JJ N
tuberculosis NN N
infection NN N
( ( N
LTBI NNP N
) ) N
: : N
6 CD N
months NNS N
of IN N
isoniazid NN i
( ( i
6H CD i
) ) i
vs. FW N
3 CD N
months NNS N
of IN N
isoniazid JJ i
plus CC i
rifampicin JJ i
( ( i
3RH CD i
) ) i
. . i

POPULATION JJ N
Immigrants NNS p
with IN p
LTBI NNP p
. . p

METHODS NNP N
Participants NNPS N
were VBD N
enrolled VBN N
in IN N
a DT N
controlled VBN N
, , N
randomised VBD N
clinical JJ N
trial NN N
in IN p
Barcelona NNP p
, , p
Spain NNP p
, , p
from IN p
April NNP p
2001 CD p
to TO p
April NNP p
2005 CD p
. . p

Monthly JJ N
follow-up NN N
was VBD N
done VBN N
to TO N
assess VB N
tolerance NN N
, , N
side NN N
effects NNS N
and CC N
adherence NN N
. . N

Effectiveness NNP N
was VBD N
evaluated VBN N
at IN N
5 CD N
years NNS N
. . N

RESULTS NN N
In IN N
the DT N
590 CD p
subjects NNS p
enrolled VBN p
, , N
the DT N
rate NN o
of IN o
adherence NN o
was VBD N
greater JJR N
in IN N
the DT N
3RH CD N
than IN N
in IN N
the DT N
6H CD N
arm NN N
( ( N
72 CD N
% NN N
vs. FW N
52.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
study NN N
arms NNS N
were VBD N
observed VBN N
with IN N
respect NN N
to TO N
hepatotoxicity NN o
or CC o
side NN o
effects NNS o
. . o

Variables NNS N
associated VBN N
with IN N
non-adherence NN N
were VBD N
diagnosis VBN N
by IN N
screening VBG o
( ( N
OR CC N
1.88 CD N
, , N
95 CD N
% NN N
CI NNP N
1.26-2.82 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
illegal JJ o
immigration NN o
status NN o
( ( N
OR CC N
1.48 CD N
, , N
95 CD N
% NN N
CI NNP N
1.01-2.15 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
unemployment NN o
( ( N
OR CC N
1.91 CD N
, , N
95 CD N
% NN N
CI NNP N
1.28-2.85 CD N
, , N
P NNP N
= NNP N
0.0008 CD N
) ) N
, , N
illiteracy NN o
( ( N
OR CC N
1.73 CD N
, , N
95 CD N
% NN N
CI NNP N
1.04-2.88 CD N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
lack NN o
of IN o
family NN o
support NN o
( ( N
OR NNP N
3.7 CD N
, , N
95 CD N
% NN N
CI NNP N
2.54-5.4 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
the DT N
6-month JJ o
treatment NN o
regimen NNS o
( ( N
OR NNP N
2.45 CD N
, , N
95 CD N
% NN N
CI NNP N
1.68-3.57 CD N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

None NN N
of IN N
the DT N
patients NNS N
who WP N
completed VBD N
either CC N
treatment NN N
developed VBD N
tuberculosis NN o
. . o

CONCLUSIONS VB N
The DT N
3RH CD i
regimen NNS i
facilitates VBZ N
adherence NN N
to TO N
LTBI NNP N
treatment NN N
and CC N
offers VBZ N
a DT N
safe JJ N
, , N
well-tolerated JJ N
and CC N
effective JJ N
alternative NN N
. . N

-DOCSTART- -17624203- O O

Efficacy NN o
and CC o
safety NN o
of IN N
sildenafil NN i
in IN N
Asian JJ p
males NNS p
with IN p
erectile JJ p
dysfunction NN p
and CC p
cardiovascular JJ p
risk NN p
. . p

OBJECTIVE NNP N
Assess NNP N
the DT N
effectiveness NN N
of IN N
sildenafil NN i
in IN N
Asian JJ p
males NNS p
with IN p
erectile JJ p
dysfunction NN p
( ( p
ED NNP p
) ) p
and CC p
one CD p
or CC p
more JJR p
of IN p
the DT p
co-morbidities NNS p
, , p
mild-to-moderate JJ p
hypertension NN p
, , p
dyslipidemia NN p
, , p
and CC p
diabetes NNS p
. . p

MATERIAL NNP N
AND NNP N
METHOD NNP N
A NNP N
six-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
multicenter NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
Thailand NNP N
, , N
Malaysia NNP N
and CC N
Singapore NNP N
. . N

One CD p
hundred CD p
and CC p
fifty VB p
five CD p
male JJ p
subjects NNS p
were VBD N
randomized VBN N
( ( N
2:1 CD N
) ) N
to TO N
sildenafil VB i
( ( N
n JJ N
= NNP N
104 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
51 CD N
) ) N
. . N

Sildenafil NNP i
was VBD N
started VBN N
at IN N
50 CD N
mg NN N
and CC N
increased VBD N
( ( N
100 CD N
mg NN N
) ) N
or CC N
decreased VBN N
( ( N
25 CD N
mg NN N
) ) N
at IN N
week NN N
2 CD N
if IN N
necessary JJ N
. . N

RESULTS VB N
On IN N
the DT N
primary JJ N
efficacy NN N
endpoint NN N
, , N
sildenafil-treated JJ i
subjects NNS N
had VBD N
significantly RB N
better JJR N
scores NNS o
on IN N
the DT N
International NNP o
Index NNP o
of IN o
Erectile NNP o
Function NNP o
( ( o
IIEF NNP o
) ) o
questions NNS o
3 CD o
and CC o
4 CD o
than IN N
placebo NN N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
both DT N
questions NNS N
) ) N
. . N

When WRB N
accumulated VBN N
into IN N
IIEF NNP N
domains NNS N
, , N
all DT N
five CD N
domains NNS N
were VBD N
significant JJ N
in IN N
favor NN N
of IN N
sildenafil NN N
. . N

In IN N
addition NN N
, , N
sildenafil-treated JJ i
subjects NNS N
were VBD N
more RBR N
satisfied JJ o
with IN N
treatment NN N
and CC N
had VBD N
a DT N
higher JJR N
intercourse JJ o
success NN o
rate NN o
. . o

The DT N
majority NN N
of IN N
adverse JJ N
events NNS N
were VBD N
mild VBN N
in IN N
severity NN o
; : o
the DT N
most RBS N
commonly RB N
reported VBD N
treatment-related JJ N
events NNS N
were VBD N
dizziness NN o
( ( N
7.7 CD N
% NN N
) ) N
and CC N
tinnitus NN o
( ( N
2.9 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Sildenafil NNP N
( ( N
25 CD N
, , N
50 CD N
, , N
and CC N
100 CD N
mg NN N
) ) N
was VBD N
found VBN N
to TO N
be VB N
an DT N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
ED NNP N
in IN N
the DT N
present JJ N
study NN N
population NN N
of IN N
Thai NNP N
, , N
Malaysian NNP N
, , N
and CC N
Singaporean NNP N
males NNS N
who WP N
also RB N
had VBD N
increased VBN N
cardiovascular JJ N
risk NN N
-DOCSTART- -7944932- O O

Effect NN N
of IN N
interferon NN N
gamma NN N
on IN N
infection-related JJ N
death NN N
in IN N
patients NNS p
with IN p
severe JJ p
injuries NNS p
. . p

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
interferon NN i
gamma NN i
in IN N
reducing VBG N
infection NN o
and CC N
death NN N
in IN N
patients NNS p
sustaining VBG p
severe JJ p
injury NN p
. . p

DESIGN NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
with IN N
observation NN N
for IN N
60 CD N
days NNS N
and CC N
until IN N
discharge NN N
for IN N
patients NNS p
with IN p
major JJ p
infection NN p
on IN p
day NN p
60 CD p
. . p

SETTING CD N
Nine JJ p
university-affiliated JJ p
level NN p
1 CD p
trauma NN p
centers NNS p
. . p

PATIENTS VB N
Four CD p
hundred JJ p
sixteen JJ p
patients NNS p
with IN p
severe JJ p
injuries NNS p
, , p
assessed VBN p
by IN p
Injury NNP o
Severity NNP o
Score NNP o
and CC o
degree NN o
of IN o
contamination NN o
. . o

INTERVENTION NNP N
Recombinant NNP i
human JJ i
interferon NN i
gamma NN i
, , i
100 CD i
micrograms NNS i
, , i
was VBD i
administered VBN i
subcutaneously RB i
once RB i
daily JJ i
for IN i
21 CD i
days NNS i
( ( i
or CC i
until IN i
patient JJ i
discharge NN i
if IN i
prior JJ i
to TO i
21 CD i
days NNS i
) ) i
as IN i
an DT i
adjunct NN i
to TO i
standard VB i
antibiotic JJ i
and CC i
supportive JJ i
therapy NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Incidence NNP o
of IN o
major JJ o
infection NN o
, , o
death NN o
related VBN o
to TO o
infection NN o
, , o
and CC o
death NN o
. . o

RESULTS JJ N
Infection NN o
rates NNS o
were VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
; : N
however RB N
, , N
patients NNS N
treated VBD N
with IN N
interferon NN N
gamma NN N
experienced VBD N
fewer JJR N
deaths NNS o
related VBN N
to TO N
infection NN o
( ( N
seven CD N
[ RB N
3 CD N
% NN N
] NNP N
vs NN N
18 CD N
[ JJ N
9 CD N
% NN N
] NN N
; : N
P NNP N
= NNP N
.008 NNP N
) ) N
and CC N
fewer JJR N
overall JJ N
deaths NNS o
( ( N
21 CD N
[ RB N
10 CD N
% NN N
] NNP N
vs NN N
30 CD N
[ JJ N
14 CD N
% NN N
] NN N
; : N
P NNP N
= NNP N
.17 NNP N
) ) N
. . N

While IN N
12 CD N
early JJ o
deaths NNS o
( ( N
days NNS N
1 CD N
through IN N
7 CD N
) ) N
occurred VBD N
in IN N
each DT N
treatment NN N
group NN N
, , N
late RB N
death NN o
occurred VBD N
in IN N
18 CD N
placebo-treated JJ N
patients NNS N
and CC N
nine CD N
in IN N
interferon JJ i
gamma-treated JJ i
patients NNS N
. . N

The DT N
results NNS N
were VBD N
dominated VBN N
by IN N
findings NNS N
at IN N
one CD N
center NN N
, , N
which WDT N
had VBD N
the DT N
highest JJS N
enrollment NN N
and CC N
higher JJR N
infection NN N
and CC N
death NN N
rates NNS N
. . N

Statistical JJ N
analysis NN N
did VBD N
not RB N
eliminate VB N
the DT N
possibility NN N
of IN N
an DT N
unidentified JJ N
imbalance NN N
between IN N
arms NNS N
as IN N
an DT N
explanation NN N
for IN N
the DT N
results NNS N
. . N

CONCLUSION NNP N
Further NNP N
evaluation NN N
is VBZ N
required VBN N
to TO N
determine VB N
the DT N
validity NN N
of IN N
the DT N
observed JJ N
reduction NN N
in IN N
infection-related JJ o
deaths NNS N
in IN N
patients NNS p
treated VBN p
with IN p
interferon NN i
gamma NN i
. . i

-DOCSTART- -22401811- O O

Efficiency NN o
of IN N
slush NN i
nitrogen NN i
vitrification NN i
of IN N
human JJ N
oocytes NNS N
vitrified VBN i
with IN i
or CC i
without IN i
cumulus JJ i
cells NNS i
in IN N
relation NN N
to TO N
survival VB o
rate NN o
and CC N
meiotic JJ o
spindle NN o
competence NN o
. . o

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficiency NN o
of IN N
slush NN i
nitrogen NN i
vitrification NN i
of IN N
human JJ p
oocytes NNS p
with IN i
or CC i
without IN i
cumulus JJ i
cells NNS i
in IN N
terms NNS N
of IN N
survival NN o
rate NN o
and CC N
maintenance NN o
of IN o
meiotic JJ o
spindle NN o
. . o

DESIGN NNP N
Randomized NNP N
, , N
comparative JJ N
study NN N
. . N

SETTING NNP N
Medical NNP N
center NN N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
A NNP N
total NN N
of IN N
274 CD p
oocytes NNS p
obtained VBN p
from IN p
46 CD p
couples NNS p
undergoing JJ p
infertility NN p
treatment NN p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Metaphase NNP N
II NNP N
oocytes NNS N
were VBD N
divided VBN N
into IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
vitrified VBD i
with IN i
and CC i
without IN i
cumulus JJ i
cells NNS i
, , N
respectively RB N
. . N

MAIN NNP N
OUTCOMES NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Survival NNP o
rates NNS o
and CC o
maintenance NN o
of IN o
meiotic JJ o
spindle NN o
observed VBD o
immediately RB o
after IN o
warming VBG o
and CC o
3 CD o
hours NNS o
after IN o
incubation NN o
. . o

RESULT NNP N
( ( N
S NNP N
) ) N
No NNP N
statistically RB N
significant JJ N
difference NN N
was VBD N
detected VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
survival NN o
rate NN o
, , N
but CC N
a DT N
significantly RB N
higher JJR N
percentage NN N
of IN N
detectable JJ o
spindle NN o
was VBD N
observed VBN N
in IN N
group NN N
B NNP N
( ( N
completely RB N
denuded VBN N
oocytes NNS N
) ) N
, , N
either RB N
immediately RB N
after IN N
warming VBG N
or CC N
3 CD N
hours NNS N
after IN N
incubation NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Complete NNP N
denudation NN N
of IN N
oocytes NNS N
before IN N
slush JJ N
nitrogen NN N
vitrification NN N
does VBZ N
not RB N
influence VB N
survival JJ o
rates NNS o
but CC N
positively RB N
affects VBZ N
oocyte JJ N
meiotic JJ o
spindle NN o
competence NN o
. . o

These DT N
data NNS N
support NN N
the DT N
hypothesis NN N
that WDT N
cumulus VBZ N
cells NNS N
during IN N
vitrification NN N
represent VBP N
an DT N
obstacle NN N
to TO N
cryoprotectant VB N
penetration NN N
more JJR N
than IN N
having VBG N
a DT N
protective JJ N
role NN N
for IN N
the DT N
oocyte NN N
. . N

-DOCSTART- -20304413- O O

Efficacy NN N
and CC N
safety NN N
of IN N
a DT N
high JJ i
protein NN i
, , i
low JJ i
carbohydrate NN i
diet NN i
for IN N
weight JJ N
loss NN N
in IN N
severely JJ p
obese JJ p
adolescents NNS p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
a DT N
carbohydrate NN i
restricted VBN i
versus IN i
a DT i
low JJ i
fat NN i
diet NN i
on IN N
weight JJ o
loss NN o
, , o
metabolic JJ o
markers NNS o
, , o
body NN o
composition NN o
, , N
and CC N
cardiac JJ o
function NN o
tests NNS o
in IN N
severely RB p
obese JJ p
adolescents NNS p
. . p

STUDY NNP N
DESIGN NNP N
Subjects NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
diets NNS i
: : i
a DT i
high JJ i
protein NN i
, , i
low JJ i
carbohydrate NN i
( ( i
20 CD i
g/d NN i
) ) i
diet NN i
( ( i
high JJ i
protein NN i
, , i
low JJ i
carbohydrate NN i
, , i
HPLC NNP i
) ) i
or CC i
low JJ i
fat NN i
( ( i
30 CD i
% NN i
of IN i
calories NNS i
) ) i
regimen VBP i
for IN i
13 CD i
weeks NNS i
; : i
close JJ N
monitoring NN N
was VBD N
maintained VBN N
to TO N
evaluate VB N
safety NN N
. . N

After IN N
the DT N
intervention NN N
, , N
no DT N
clinical JJ N
contact NN N
was VBD N
made VBN N
until IN N
follow-up JJ N
measurements NNS N
were VBD N
obtained VBN N
at IN N
24 CD N
and CC N
36 CD N
weeks NNS N
from IN N
baseline NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
change NN o
in IN o
body NN o
mass NN o
index NN o
Z-score NNP o
for IN N
age NN N
and CC N
sex NN N
( ( o
BMI-Z NNP o
) ) o
at IN N
13 CD N
, , N
24 CD N
, , N
and CC N
36 CD N
weeks NNS N
. . N

RESULTS NNP N
Forty-six JJ p
subjects NNS p
( ( p
24 CD p
HPLC NNP p
, , p
22 CD p
in IN p
low JJ p
fat NN p
) ) p
initiated VBD p
and CC p
33 CD p
subjects NNS p
completed VBD p
the DT p
intervention NN p
; : p
follow-up JJ N
data NNS N
were VBD N
available JJ N
on IN N
approximately RB N
half NN N
of IN N
the DT N
subjects NNS N
. . N

Significant JJ N
reduction NN N
in IN N
( ( o
BMI-Z NNP o
) ) o
was VBD N
achieved VBN N
in IN N
both DT N
groups NNS N
during IN N
intervention NN N
and CC N
was VBD N
significantly RB N
greater JJR N
for IN N
the DT N
HPLC NNP N
group NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Both DT N
groups NNS N
maintained VBD N
significant JJ N
BMI-Z JJ o
reduction NN o
at IN N
follow-up NN N
; : N
changes NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

Loss NNP N
of IN N
lean JJ o
body NN o
mass NN o
was VBD N
not RB N
spared VBN N
in IN N
the DT N
HPLC NNP N
group NN N
. . N

No DT N
serious JJ o
adverse JJ o
effects NNS o
were VBD N
observed VBN N
related VBN N
to TO N
metabolic JJ o
profiles NNS o
, , o
cardiac JJ o
function NN o
, , N
or CC N
subjective JJ o
complaints NNS o
. . o

CONCLUSIONS VB N
The DT N
HPLC NNP i
diet NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
option NN N
for IN N
medically RB N
supervised VBN N
weight JJ N
loss NN N
in IN N
severely JJ p
obese JJ p
adolescents NNS p
. . p

-DOCSTART- -24938562- O O

Effect NN N
of IN N
selumetinib NN i
vs NN N
chemotherapy NN i
on IN N
progression-free JJ N
survival NN N
in IN N
uveal JJ p
melanoma NN p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
Uveal NNP N
melanoma NN N
is VBZ N
characterized VBN N
by IN N
mutations NNS N
in IN N
GNAQ NNP N
and CC N
GNA11 NNP N
, , N
resulting VBG N
in IN N
mitogen-activated JJ N
protein NN N
kinase VB N
pathway JJ N
activation NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
selumetinib NN i
, , N
a DT N
selective JJ N
, , N
non-adenosine JJ N
triphosphate NN N
competitive JJ N
inhibitor NN N
of IN N
MEK1 NNP N
and CC N
MEK2 NNP N
, , N
in IN N
uveal JJ p
melanoma NN p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Randomized NNP N
, , N
open-label NN N
, , N
phase NN N
2 CD N
clinical JJ N
trial NN N
comparing VBG N
selumetinib JJ i
vs NN N
chemotherapy NN i
conducted VBN N
from IN p
August NNP p
2010 CD p
through IN p
December NNP p
2013 CD p
among IN p
120 CD p
patients NNS p
with IN p
metastatic JJ p
uveal JJ p
melanoma NN p
at IN p
15 CD p
academic JJ p
oncology NN p
centers NNS p
in IN p
the DT p
United NNP p
States NNPS p
and CC p
Canada NNP p
. . p

INTERVENTIONS NNP N
One CD p
hundred VBD p
one CD p
patients NNS p
were VBD p
randomized VBN p
in IN p
a DT p
1:1 CD p
ratio NN p
to TO N
receive VB N
selumetinib NN i
, , N
75 CD N
mg NN N
orally RB N
twice RB N
daily RB N
on IN N
a DT N
continual JJ N
basis NN N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
, , N
or CC N
chemotherapy NN i
( ( i
temozolomide JJ i
, , i
150 CD i
mg/m2 NNS N
orally RB N
daily RB N
for IN N
5 CD N
of IN N
every DT N
28 CD N
days NNS N
, , N
or CC N
dacarbazine NN i
, , i
1000 CD i
mg/m2 NN N
intravenously RB N
every DT N
21 CD N
days NNS N
[ NNP N
investigator NN N
choice NN N
] NNP N
; : N
n CC N
= VB N
51 CD N
) ) N
until IN N
disease NN N
progression NN N
, , N
death NN N
, , N
intolerable JJ N
adverse JJ N
effects NNS N
, , N
or CC N
withdrawal NN N
of IN N
consent NN N
. . N

After IN N
primary JJ N
outcome NN N
analysis NN N
, , p
19 CD p
patients NNS p
were VBD p
registered VBN p
and CC p
18 CD p
treated VBN p
with IN p
selumetinib NN p
without IN p
randomization NN p
to TO p
complete VB p
the DT p
planned VBN p
120-patient JJ p
enrollment NN p
. . p

Patients NNS p
in IN i
the DT i
chemotherapy NN i
group NN i
could MD i
receive VB N
selumetinib NN i
at IN i
the DT i
time NN N
of IN N
radiographic JJ N
progression NN N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Progression-free NNP o
survival NN o
, , o
the DT o
primary JJ o
end NN N
point NN N
, , N
was VBD N
assessed VBN N
as IN N
of IN N
April NNP N
22 CD N
, , N
2013 CD N
. . N

Additional JJ N
end NN N
points NNS N
, , N
including VBG o
overall JJ o
survival NN o
, , o
response NN o
rate NN o
, , o
and CC o
safety/toxicity NN o
, , o
were VBD o
assessed VBN o
as IN N
of IN N
December NNP N
31 CD N
, , N
2013 CD N
. . N

RESULTS VB N
Median JJ N
progression-free JJ N
survival NN N
among IN N
patients NNS N
randomized VBN i
to TO i
chemotherapy VB i
was VBD i
7 CD i
weeks NNS i
( ( N
95 CD N
% NN N
CI NNP N
, , N
4.3-8.4 JJ N
weeks NNS N
; : N
median JJ N
treatment NN N
duration NN N
, , N
8 CD N
weeks NNS N
; : N
interquartile JJ N
range NN N
[ NNP N
IQR NNP N
] NNP N
, , N
4.3-16 JJ N
weeks NNS N
) ) N
and CC N
among IN N
those DT N
randomized VBN i
to TO i
selumetinib VB i
was VBD i
15.9 CD i
weeks NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
8.4-21.1 JJ N
weeks NNS N
; : N
median JJ N
treatment NN N
duration NN N
, , N
16.1 CD N
weeks NNS N
; : N
IQR NNP N
, , N
8.1-25.3 JJ N
weeks NNS N
) ) N
( ( N
hazard JJ N
ratio NN N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.30-0.71 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) o
. . o

Median JJ o
overall JJ o
survival NN o
time NN o
was VBD o
9.1 CD o
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
6.1-11.1 JJ N
months NNS N
) ) N
with IN N
chemotherapy NN N
and CC N
11.8 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
9.8-15.7 JJ N
months NNS N
) ) N
with IN N
selumetinib NN i
( ( N
hazard JJ N
ratio NN N
, , N
0.66 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.41-1.06 NNP N
; : N
P NNP N
= NNP N
.09 NNP N
) ) N
. . N

No DT N
objective JJ N
responses NNS N
were VBD N
observed VBN N
with IN i
chemotherapy NN i
. . i

Forty-nine JJ i
percent NN N
of IN N
patients NNS N
treated VBN N
with IN i
selumetinib NN i
achieved VBN o
tumor NN o
regression NN o
, , o
with IN o
14 CD N
% NN N
achieving VBG N
an DT N
objective JJ N
radiographic JJ N
response NN N
to TO N
therapy VB N
. . N

Treatment-related JJ N
adverse JJ N
events NNS N
were VBD N
observed VBN N
in IN N
97 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
selumetinib NN N
, , N
with IN N
37 CD N
% NN N
requiring VBG N
at IN N
least JJS N
1 CD N
dose JJ N
reduction NN N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
In IN N
this DT N
hypothesis-generating JJ p
study NN p
of IN p
patients NNS p
with IN p
advanced JJ p
uveal JJ p
melanoma NN p
, , p
selumetinib NN N
compared VBN i
with IN i
chemotherapy NN i
resulted VBN i
in IN N
a DT N
modestly RB N
improved VBN N
progression-free JJ N
survival NN N
and CC N
response NN N
rate NN N
; : N
however RB N
, , N
no DT N
improvement NN N
in IN N
overall JJ N
survival NN N
was VBD N
observed VBN N
. . N

Improvement NN N
in IN N
clinical JJ N
outcomes NNS N
was VBD N
accompanied VBN N
by IN N
a DT N
high JJ N
rate NN N
of IN N
adverse JJ N
events NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01143402 NN N
. . N

-DOCSTART- -22001391- O O

Multi-institutional JJ N
phase NN N
2 CD N
clinical JJ N
and CC N
pharmacogenomic JJ N
trial NN N
of IN N
tipifarnib JJ i
plus CC i
etoposide JJ i
for IN N
elderly JJ p
adults NNS p
with IN p
newly RB p
diagnosed VBN p
acute RB p
myelogenous JJ p
leukemia NN p
. . p

Tipifarnib NNP N
( ( N
T NNP N
) ) N
exhibits VBZ N
modest JJ N
activity NN N
in IN N
elderly JJ p
adults NNS p
with IN p
newly RB p
diagnosed VBN p
acute RB p
myelogenous JJ p
leukemia NN p
( ( p
AML NNP p
) ) p
. . p

Based VBN N
on IN N
preclinical JJ N
synergy NN N
, , N
a DT N
phase NN N
1 CD N
trial NN N
of IN N
T NNP N
plus CC N
etoposide NN N
( ( N
E NNP N
) ) N
yielded VBD N
25 CD N
% NN N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
. . N

We PRP N
selected VBD N
2 CD N
comparable JJ N
dose NN N
levels NNS N
for IN N
a DT N
randomized JJ N
phase NN N
2 CD N
trial NN N
in IN N
84 CD p
adults NNS p
( ( p
age NN p
range NN p
, , p
70-90 JJ p
years NNS p
; : p
median JJ p
, , p
76 CD p
years NNS p
) ) p
who WP p
were VBD p
not RB p
candidates NNS p
for IN p
conventional JJ p
chemotherapy NN p
. . p

Arm VB N
A NNP N
( ( N
T NNP N
600 CD N
mg NN N
twice RB N
a DT N
day NN N
? . N
14 CD N
days NNS N
, , N
E NNP N
100 CD N
mg NN N
days NNS N
1-3 CD N
and CC N
8-10 JJ N
) ) N
and CC N
arm NN N
B NNP N
( ( N
T NNP N
400 CD N
mg NN N
twice RB N
a DT N
day NN N
? . N
14 CD N
days NNS N
, , N
E NNP N
200 CD N
mg NN N
days NNS N
1-3 CD N
and CC N
8-10 CD N
) ) N
yielded VBD N
similar JJ N
CR NNP N
, , N
but CC N
arm NN N
B NNP N
had VBD N
greater JJR N
toxicity NN o
. . o

Total JJ o
CR NNP o
was VBD o
25 CD N
% NN N
, , N
day NN N
30 CD N
death NN N
rate NN N
7 CD N
% NN N
. . N

A DT N
2-gene JJ N
signature NN N
of IN N
high JJ N
RASGRP1 NNP N
and CC N
low JJ N
aprataxin NN N
( ( N
APTX NNP N
) ) N
expression NN N
previously RB N
predicted VBN N
for IN N
T NNP N
response NN o
. . o

Assays NNS N
using VBG N
blasts NNS N
from IN N
a DT N
subset NN N
of IN N
40 CD p
patients NNS p
treated VBN p
with IN N
T NNP N
plus CC N
E NNP N
on IN N
this DT N
study NN N
showed VBD N
that IN o
AMLs NNP o
with IN o
a DT o
RASGRP1/APTX NNP o
ratio NN o
of IN o
more JJR N
than IN N
5.2 CD N
had VBD N
a DT N
78 CD N
% NN N
CR NNP N
rate NN N
and CC N
negative JJ N
predictive JJ N
value NN N
87 CD N
% NN N
. . N

This DT N
ratio NN N
did VBD N
not RB N
correlate VB N
with IN N
outcome NN N
in IN N
41 CD N
patients NNS N
treated VBN N
with IN N
conventional JJ N
chemotherapies NNS N
. . N

The DT N
next JJ N
T-based JJ N
clinical JJ N
trials NNS N
will MD N
test VB N
the DT N
ability NN N
of IN N
the DT N
2-gene JJ N
signature NN N
to TO N
enrich VB N
for IN N
T NNP N
responders NNS N
prospectively RB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00602771 NNP N
. . N

-DOCSTART- -10093945- O O

A DT N
comparative JJ N
study NN N
of IN N
ofloxacin NN i
and CC N
cefixime NN i
for IN N
treatment NN N
of IN N
typhoid JJ p
fever NN p
in IN p
children NNS p
. . p

The DT N
Dong NNP p
Nai NNP p
Pediatric NNP p
Center NNP p
Typhoid NNP N
Study NNP N
Group NNP N
. . N

BACKGROUND NNP N
Despite IN N
concerns NNS N
about IN N
safety NN N
in IN N
children NNS N
, , N
fluoroquinolone NN i
antibiotics NNS i
have VBP N
become VBN N
the DT N
treatment NN N
of IN N
choice NN N
in IN N
patients NNS p
with IN p
multidrug-resistant JJ p
typhoid NN p
fever NN p
in IN p
Vietnam NNP p
. . p

However RB N
, , N
quinolone-resistant JJ N
strains NNS N
of IN N
Salmonella NNP N
typhi NN N
have VBP N
recently RB N
been VBN N
reported VBN N
from IN N
Vietnam NNP N
; : N
and CC N
if IN N
quinolone JJ N
resistance NN N
becomes NNS N
established VBN N
, , N
alternative JJ N
oral JJ N
treatment NN N
options NNS N
will MD N
be VB N
needed VBN N
. . N

OBJECTIVE NNP N
Cefixime NNP i
, , N
an DT N
orally RB N
administered VBN N
third JJ N
generation NN N
cephalosporin NN i
, , N
was VBD N
compared VBN N
with IN N
ofloxacin NN i
for IN N
the DT N
treatment NN N
of IN N
uncomplicated JJ N
typhoid NN N
fever NN N
in IN N
children NNS N
. . N

METHODS NNP N
In IN p
an DT p
open JJ p
trial NN p
children NNS p
with IN p
suspected JJ p
typhoid NN p
fever NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
ofloxacin NN i
( ( N
10 CD N
mg/kg/day NN N
in IN N
two CD N
divided JJ N
doses NNS N
) ) N
for IN N
5 CD N
days NNS N
or CC N
cefixime NN i
( ( N
20 CD N
mg/kg/day NN N
in IN N
two CD N
divided JJ N
doses NNS N
) ) N
for IN N
7 CD N
days NNS N
. . N

RESULTS NNP N
S. NNP N
typhi NN N
was VBD N
isolated VBN N
from IN N
82 CD p
patients NNS p
( ( p
44 CD p
in IN p
the DT p
cefixime NN i
group NN p
, , p
38 CD p
in IN p
the DT p
ofloxacin JJ i
group NN p
) ) p
and CC p
70 CD p
( ( p
85 CD p
% NN p
) ) p
of IN p
the DT p
isolates NNS p
were VBD p
multidrug-resistant JJ p
. . p

Median JJ N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
range NN N
) ) N
fever NN o
clearance NN o
times NNS o
were VBD N
4.4 CD N
( ( N
4 CD N
to TO N
5.2 CD N
, , N
0.2 CD N
to TO N
9.9 CD N
) ) N
days NNS N
for IN N
ofloxacin JJ i
recipients NNS N
and CC N
8.5 CD N
( ( N
4.2 CD N
to TO N
9 CD N
, , N
1.8 CD N
to TO N
15.2 CD N
) ) N
days NNS N
for IN N
cefixime-treated JJ i
patients NNS p
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

There EX N
were VBD N
11 CD N
treatment NN o
failures NNS o
( ( N
10 CD N
acute NN N
and CC N
one CD N
relapse NN N
) ) N
in IN N
the DT N
cefixime NN i
group NN N
and CC N
1 CD N
acute NN o
treatment NN o
failure NN o
in IN N
the DT N
ofloxacin NN i
group NN N
( ( N
mean JJ N
difference NN N
, , N
22 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
9 CD N
to TO N
36 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Short NNP N
course NN N
treatment NN N
with IN N
cefixime NN i
may MD N
provide VB N
a DT N
useful JJ N
alternative JJ N
treatment NN N
in IN N
cases NNS N
of IN N
uncomplicated JJ p
typhoid NN p
fever NN p
in IN p
children NNS p
, , N
but CC N
it PRP N
is VBZ N
less RBR N
effective JJ N
than IN N
short JJ N
course NN N
treatment NN N
with IN N
ofloxacin NN i
. . i

-DOCSTART- -21822764- O O

Using VBG N
the DT N
transporters NNS i
DVD NNP i
as IN N
a DT N
learning NN i
tool NN i
for IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Data NNS N
from IN N
two CD p
groups NNS p
of IN p
children NNS p
who WP N
were VBD N
randomly RB N
allocated VBN N
to TO N
those DT N
groups NNS N
showed VBD N
that IN N
the DT N
ability NN N
of IN N
children NNS p
with IN p
ASD NNP p
to TO N
identify VB o
and CC o
label VB o
basic JJ o
and CC o
complex JJ o
facial JJ o
expressions NNS o
following VBG N
a DT N
3-week JJ N
home NN i
based VBN i
DVD NNP i
intervention NN i
significantly RB N
improved VBN N
when WRB N
viewing VBG N
The DT i
Transporters NNPS i
DVD NNP i
. . i

Improvements NNS N
in IN N
emotion NN o
recognition NN o
appear RB N
related VBN N
to TO N
the DT N
content NN N
of IN N
the DT N
DVD NNP i
as IN N
participants NNS N
in IN N
a DT N
control NN N
group NN N
who WP N
observed VBD N
an DT N
alternate NN i
DVD NNP i
showed VBD N
no DT N
such JJ N
improvement NN N
. . N

Although IN N
social JJ o
behaviour NN o
improved VBD N
significantly RB N
as IN N
a DT N
result NN N
of IN N
watching VBG N
The DT N
Transporters NNPS N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
social JJ o
behaviour NN o
was VBD N
however RB N
, , N
also RB N
observed VBN N
in IN N
the DT N
Thomas NNP N
the DT N
Tank NNP N
Engine NNP N
condition NN N
suggesting VBG N
the DT N
unique JJ N
content NN N
of IN N
The DT N
Transporters NNP i
DVD NNP i
was VBD N
not RB N
pivotal JJ N
to TO N
the DT N
improvement NN N
of IN N
social JJ o
behaviour NN o
in IN N
general JJ N
. . N

-DOCSTART- -21154265- O O

Effect NN N
of IN N
L-arginine NNP i
or CC i
L-citrulline JJ i
oral JJ i
supplementation NN i
on IN N
blood NN o
pressure NN o
and CC o
right JJ o
ventricular NN o
function NN o
in IN N
heart NN p
failure NN p
patients NNS p
with IN p
preserved JJ p
ejection NN p
fraction NN p
. . p

BACKGROUND IN N
The DT N
effect NN N
of IN N
L-arginine NNP i
and CC i
L-citrulline NNP i
on IN N
blood NN o
pressure NN o
and CC o
right JJ o
ventricular NN o
function NN o
in IN N
heart NN p
failure NN p
patients NNS p
with IN p
preserved JJ p
ejection NN p
fraction NN p
( ( p
HFpEF NNP p
) ) p
is VBZ N
unknown JJ N
. . N

We PRP N
have VBP N
therefore RB N
evaluated VBN N
, , N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
the DT N
effect NN N
of IN N
these DT N
aminoacids NNS N
in IN N
chronic JJ p
outstanding JJ p
and CC p
stable JJ p
patients NNS p
with IN p
HFpEF NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
All NNP p
patients NNS p
underwent VBD p
an DT p
echocardiogram NN i
and CC i
radioisotopic NN i
ventriculography NN i
rest/exercise NN i
, , N
and CC N
were VBD N
randomized VBN N
in IN N
a DT N
consecutive JJ N
manner NN N
to TO N
the DT N
L-arginine NNP i
group NN i
( ( p
n JJ p
= VBZ p
15 CD p
; : p
8 CD p
g/day NN p
) ) p
; : p
and CC p
the DT p
citrulline NN i
malate NN i
group NN i
( ( p
n JJ p
= VBZ p
15 CD p
; : p
3 CD N
g/day NN N
) ) N
. . N

The DT N
duration NN N
of IN N
follow-up NN N
was VBD N
two CD N
months NNS N
. . N

The DT N
principal JJ N
echocardiographic JJ N
finding NN N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
pulmonary JJ o
artery NN o
pressure NN o
in IN N
the DT N
L-arginine NNP i
( ( N
56.3 CD N
? . N
10 CD N
vs NN N
44 CD N
? . N
16.5 CD N
mm NN N
Hg NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
the DT i
citrulline NN i
( ( i
56.67 CD N
? . N
7.96 CD N
vs NN N
47.67 CD N
? . N
8.59 CD N
mm NN N
Hg NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
groups NNS o
. . o

Duration NN o
on IN o
treadmill NN o
and CC o
right JJ o
ventricular NN o
ejection NN o
fraction NN o
post NN o
exercise NN o
increased VBD o
, , N
while IN o
diastolic JJ o
and CC o
systolic JJ o
artery NN o
pressure NN o
decreased VBN o
significantly RB N
in IN N
both DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
other JJ N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Administration NNP i
of IN i
L-arginine NNP i
and CC i
citrulline NN i
to TO i
patients NNS p
with IN p
HFpEF NNP p
improved VBD o
right JJ o
ventricular NN o
function NN o
by IN o
increasing VBG N
right JJ N
ventricular NN N
ejection NN N
fraction NN N
, , N
and CC N
probably RB N
decreasing VBG o
systolic JJ o
pulmonary JJ o
artery NN o
pressure NN o
. . o

-DOCSTART- -23621350- O O

Double-blind NNP N
, , N
placebo-controlled JJ i
, , N
dose-ranging JJ N
study NN N
of IN N
new JJ N
recombinant JJ i
hypoallergenic JJ i
Bet NNP i
v NN i
1 CD i
in IN N
an DT N
environmental JJ N
exposure NN N
chamber NN N
. . N

BACKGROUND NNP N
Recombinant NNP N
allergens VBZ N
offer VBP N
a DT N
tool NN N
for IN N
improving VBG N
specific JJ N
immunotherapy NN N
( ( N
SIT NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
find VB N
the DT N
optimal JJ N
dose NN N
of IN N
a DT N
new JJ N
hypoallergenic JJ N
folding NN N
variant NN N
of IN N
recombinant JJ i
Bet NNP i
v NN i
1 CD i
( ( i
rBet JJ i
v IN i
1-FV JJ i
) ) i
as IN N
SIT NNP N
for IN N
patients NNS p
with IN p
birch NN p
pollen NN p
allergy NN p
. . p

METHODS NNP N
Before IN N
SIT NNP N
, , N
thirty-seven JJ p
adult NN p
patients NNS p
were VBD p
exposed VBN p
for IN p
eight CD p
hours NNS p
in IN p
an DT p
environmental JJ i
exposure NN i
chamber NN i
( ( p
EEC NNP p
) ) p
to TO p
birch VB p
pollen NN p
at IN p
an DT p
average JJ p
concentration NN p
of IN p
3500 CD p
? . p
500 CD p
grains/m NN p
( ( p
3 CD p
) ) p
, , N
then RB N
randomized VBD N
to TO N
four CD N
maintenance NN N
dose NN N
groups NNS N
of IN i
rBet JJ i
v JJ i
1-FV JJ i
and CC N
one CD i
placebo NN i
group NN N
: : N
20 CD N
?g NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
80 CD N
?g NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
, , N
160 CD N
?g NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
320 CD N
?g NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
, , N
and CC N
placebo NN i
( ( i
n JJ i
= NNP i
7 CD N
) ) N
. . N

Patients NNS N
were VBD N
treated VBN N
for IN N
10 CD N
weeks NNS N
with IN N
weekly JJ N
injections NNS N
and CC N
then RB N
re-exposed JJ N
in IN N
the DT N
EEC NNP N
. . N

The DT N
optimal JJ N
dose NN N
for IN N
SIT NNP N
was VBD N
assessed VBN N
using VBG N
efficacy NN o
results NNS o
from IN o
the DT o
EEC NNP o
, , o
IgG NNP o
responses VBZ o
, , o
and CC o
tolerability NN o
. . o

RESULTS NNP o
Thirty-six JJ p
patients NNS p
were VBD p
evaluable JJ N
for IN N
efficacy NN N
assessment NN N
. . N

The DT N
total JJ o
symptom NN o
score NN o
significantly RB o
decreased VBN N
in IN N
all DT N
active JJ N
groups NNS N
compared VBN N
with IN N
placebo NN i
( ( i
-18.8 CD i
% NN N
for IN N
placebo NN N
patients NNS N
; : N
-71.9 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0022 CD N
for IN N
20 CD N
?g NN N
; : N
-75.6 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0007 CD N
for IN N
80 CD N
?g NN N
; : N
-81.8 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0009 CD N
for IN N
160 CD N
?g NN N
; : N
-78.3 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0003 CD N
for IN N
320 CD N
?g NN N
) ) N
. . N

IgG1 NNP o
increased VBD o
significantly RB N
in IN N
all DT N
active JJ N
groups NNS N
compared VBN N
to TO N
placebo VB N
. . N

All DT N
four CD N
active JJ N
doses NNS N
were VBD N
well RB N
tolerated VBN o
, , o
no DT o
serious JJ o
adverse JJ o
event NN o
occurred VBD o
; : N
two CD o
Grade NNP o
II NNP o
reactions NNS o
, , o
according VBG o
to TO N
EAACI NNP N
classification NN N
, , N
were VBD N
observed VBN N
, , N
one CD N
in IN N
each DT N
of IN N
the DT N
160- JJ N
and CC N
320-?g JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Considering NNP N
efficacy NN N
, , N
immunological JJ N
response NN N
, , N
and CC N
tolerability NN N
, , N
a DT N
maintenance NN N
dose NN N
of IN N
80 CD N
?g NN N
of IN i
rBet JJ i
v JJ i
1-FV JJ i
appears VBZ i
to TO N
be VB N
the DT N
ideal NN N
dose NN N
for IN N
allergen NN N
immunotherapy NN p
in IN p
birch NN p
pollen NN p
allergic JJ p
patients NNS p
. . p

-DOCSTART- -23414585- O O

Ganitumab NNP i
with IN N
either DT N
exemestane NN i
or CC N
fulvestrant NN i
for IN N
postmenopausal JJ p
women NNS p
with IN p
advanced JJ p
, , p
hormone-receptor-positive JJ p
breast NN p
cancer NN p
: : p
a DT N
randomised JJ N
, , N
controlled VBN N
, , N
double-blind NN N
, , N
phase NN N
2 CD N
trial NN N
. . N

BACKGROUND NNP N
Insulin-like JJ N
growth NN N
factors NNS N
( ( N
IGF-1 JJ N
and CC N
IGF-2 NNP N
) ) N
bind NN N
to TO N
the DT N
IGF-1 NNP N
receptor NN N
( ( N
IGF-1R NNP N
) ) N
, , N
increasing VBG N
cell NN o
proliferation NN o
and CC N
survival NN o
. . o

Ganitumab NNP i
is VBZ N
a DT N
monoclonal JJ N
IgG1 NNP N
antibody NN N
that WDT N
blocks VBZ N
IGF-1R NNP N
. . N

We PRP N
tested VBD N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
adding VBG N
ganitumab NN N
to TO N
endocrine VB N
treatment NN N
for IN N
patients NNS p
with IN p
hormone-receptor-positive JJ p
breast NN p
cancer NN p
. . p

METHODS NNP N
We PRP N
did VBD N
this DT N
phase NN N
2 CD N
trial NN N
in IN N
outpatient JJ p
clinics NNS p
and CC p
hospitals NNS p
. . p

We PRP p
enrolled VBD p
postmenopausal JJ p
women NNS p
with IN p
hormone-receptor-positive JJ p
, , p
locally RB p
advanced VBD p
or CC p
metastatic JJ p
breast NN p
cancer NN p
previously RB p
treated VBN p
with IN p
endocrine JJ p
treatment NN p
. . p

They PRP N
were VBD N
randomly RB N
assigned VBN N
( ( N
2:1 CD N
) ) N
with IN N
a DT N
central JJ N
randomisation NN N
schedule NN N
to TO N
receive VB N
intravenous JJ i
ganitumab NNS i
12 CD i
mg NNS i
per IN i
kg NN i
bodyweight NN i
or CC i
placebo NN i
in IN i
combination NN i
with IN i
open-label JJ i
intramuscular JJ i
fulvestrant NN i
( ( i
500 CD i
mg NN i
on IN i
day NN i
1 CD i
, , i
then RB i
250 CD i
mg NNS i
on IN i
days NNS i
15 CD i
, , i
29 CD i
, , i
and CC i
every DT i
28 CD i
days NNS i
) ) i
or CC i
oral JJ i
exemestane NN i
( ( i
25 CD i
mg NN i
once RB i
daily RB i
) ) i
on IN i
a DT i
28-day JJ i
cycle NN i
. . i

Patients NNS N
, , N
investigators NNS N
, , N
study NN N
monitors NNS N
, , N
and CC N
the DT N
sponsor JJ N
staff NN N
were VBD N
masked VBN N
to TO N
treatment NN N
allocation NN N
. . N

Response NNP i
was VBD i
assessed VBN i
every DT i
8 CD i
weeks NNS i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
median JJ o
progression-free JJ o
survival NN o
in IN N
the DT N
intention-to-treat JJ N
population NN N
. . N

We PRP N
analysed VBD N
overall JJ o
survival NN o
as IN N
one CD N
of IN N
our PRP$ N
secondary JJ N
endpoints NNS N
. . N

The DT N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00626106 NNP N
. . N

FINDINGS NNP N
We PRP p
screened VBD p
189 CD p
patients NNS p
and CC p
enrolled VBD p
156 CD p
( ( p
106 CD p
in IN p
the DT p
ganitumab NN i
group NN p
and CC p
50 CD p
in IN p
the DT p
placebo NN p
group NN p
) ) p
. . p

Median JJ o
progression-free JJ o
survival NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
ganitumab NN i
and CC N
placebo NN N
groups NNS N
( ( N
3?9 CD N
months NNS N
, , N
80 CD N
% NN N
CI NNP N
3?6-5?3 CD N
vs NN N
5?7 CD N
months NNS N
, , N
4?4-7?4 JJ N
; : N
hazard PRP$ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
1?17 CD N
, , N
80 CD N
% NN N
CI NNP N
0?91-1?50 CD N
; : N
p=0?44 NN N
) ) N
. . N

However RB N
, , N
overall JJ o
survival NN o
was VBD N
worse RBR N
in IN N
the DT N
the DT N
ganitumab NN i
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
HR NNP N
1?78 CD N
, , N
80 CD N
% NN N
CI NNP N
1?27-2?50 CD N
; : N
p=0?025 NN N
) ) N
. . N

With IN N
the DT N
exception NN N
of IN N
hyperglycaemia NN N
, , N
adverse JJ N
events NNS N
were VBD N
generally RB N
similar JJ N
between IN N
groups NNS N
. . N

The DT N
most RBS N
common JJ N
grade NN N
3 CD N
or CC N
higher JJR o
adverse JJ o
event NN o
was VBD o
neutropenia-reported JJ o
by IN N
six CD N
of IN N
106 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT i
ganitumab NN i
group NN N
and CC N
one CD N
of IN N
49 CD N
( ( N
2 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

Hyperglycaemia NNP o
was VBD o
reported VBN o
by IN N
12 CD N
of IN N
106 CD N
( ( N
11 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
ganitumab NN N
group NN N
( ( N
with IN N
six CD N
patients NNS N
having VBG N
grade JJ N
3 CD N
or CC N
4 CD N
hyperglycaemia NN N
) ) N
and CC N
none NN N
of IN N
49 CD N
in IN N
the DT N
placebo NN N
group NN N
. . N

Serious JJ o
adverse JJ o
events NNS o
were VBD o
reported VBN o
by IN N
27 CD N
of IN N
106 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
ganitumab NN N
group NN N
and CC N
nine CD N
of IN N
49 CD N
( ( N
18 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

INTERPRETATION NNP N
Addition NNP i
of IN i
ganitumab NN i
to TO N
endocrine VB N
treatment NN p
in IN p
women NNS p
with IN p
previously RB p
treated VBN p
hormone-receptor-positive JJ p
locally RB p
advanced VBD p
or CC p
metastatic JJ p
breast NN p
cancer NN p
did VBD N
not RB N
improve VB o
outcomes RB o
. . o

Our PRP$ o
results NNS N
do VBP N
not RB N
support VB N
further RBR N
study NN N
of IN N
ganitumab NN N
in IN N
this DT N
subgroup NN N
of IN N
patients NNS N
. . N

FUNDING NN N
Amgen NNP N
. . N

-DOCSTART- -3337028- O O

Iron NNP i
intake NN i
and CC i
iron NN i
nutritional JJ i
status NN i
of IN N
infants NNS p
fed VBN p
iron-fortified JJ i
beikost NN i
with IN i
meat NN i
. . i

We PRP N
compared VBN N
iron NNS N
intake NN N
and CC N
iron NN N
nutritional JJ N
status NN N
of IN N
two CD p
groups NNS p
of IN p
healthy JJ p
term NN p
infants NNS p
who WP p
received VBD p
meat-containing JJ i
baby NN i
foods NNS i
fortified VBN i
with IN i
ferrous JJ i
sulphate NN i
( ( p
2 CD p
mg NN p
Fe/100 NNP p
g NN p
) ) p
. . p

One CD N
group NN N
received VBD N
an DT N
Fe-fortified JJ i
formula NN i
( ( N
1.6 CD N
mg NN N
Fe/100 NNP N
kcal NN N
) ) N
and CC i
the DT i
other JJ i
a DT i
nonfortified JJ i
formula NN i
. . i

Fe NNP i
intake NN i
of IN N
the DT N
group NN N
fed VBD N
the DT N
nonfortified JJ N
formula NN N
was VBD N
significantly RB N
lower JJR N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

These DT N
infants NNS N
received VBD N
Fe NNP i
mainly RB i
from IN i
fortification NN i
Fe NNP i
with IN i
beikost NN i
( ( N
75-86 CD N
% NN N
) ) N
and CC N
less JJR N
than IN N
10 CD N
% NN N
met VBD N
the DT N
recommended JJ N
intake NN N
of IN N
1 CD N
mg.kg-1.d-1 NN N
; : N
whereas CC N
80-85 CD N
% NN N
of IN N
the DT N
infants NNS N
fed VBD N
the DT N
Fe-fortified NNP i
formula NN i
did VBD N
. . N

Hb NNP o
, , o
Hct NNP o
, , o
FEP NNP o
, , o
and CC o
ferritin NNS o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
with IN N
the DT N
exception NN N
of IN N
lower JJR N
ferritin NN N
values NNS N
at IN N
age NN N
365 CD N
d NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
in IN N
the DT N
group NN N
fed VBD N
the DT N
nonfortified JJ N
formula NN N
. . N

No DT N
infant NN N
had VBD N
hemoglobin NN o
less JJR N
than IN N
100 CD N
g/L NN N
. . N

We PRP N
conclude VBP N
that IN N
regular JJ N
consumption NN N
of IN N
commercially RB i
prepared JJ i
Fe-fortified JJ i
beikost NN i
with IN i
meat NN i
prevents NNS N
most RBS N
healthy JJ p
term NN p
infants NNS p
from IN N
Fe NNP N
deficiency NN N
even RB N
if IN N
Fe NNP N
intake NN N
is VBZ N
substantially RB N
below IN N
the DT N
recommended JJ N
intake NN N
. . N

-DOCSTART- -23233021- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
bumetanide NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
in IN p
children NNS p
. . p

Gamma NNP N
aminobutyric JJ N
acid NN N
( ( N
GABA NNP N
) ) N
-mediated VBD N
synapses NNS N
and CC N
the DT N
oscillations NNS N
they PRP N
orchestrate VBP N
are VBP N
altered VBN N
in IN N
autism NN N
. . N

GABA-acting JJ N
benzodiazepines NNS i
exert NN N
in IN N
some DT N
patients NNS N
with IN N
autism NN N
paradoxical JJ N
effects NNS o
, , N
raising VBG N
the DT N
possibility NN N
that IN N
like IN N
in IN N
epilepsies NNS N
, , N
GABA NNP N
excites VBZ N
neurons NNS N
because IN N
of IN N
elevated JJ N
intracellular JJ N
concentrations NNS N
of IN N
chloride NN N
. . N

Following VBG N
a DT N
successful JJ N
pilot NN N
study NN N
, , N
( ( N
1 CD N
) ) N
we PRP N
have VBP N
now RB N
performed VBN N
a DT N
double-blind JJ N
clinical JJ N
trial NN N
using VBG N
the DT N
diuretic JJ N
, , N
chloride-importer JJ N
antagonist NN N
bumetanide IN i
that DT N
reduces VBZ N
intracellular JJ N
chloride NN N
reinforcing VBG N
GABAergic NNP N
inhibition NN N
. . N

Sixty NNP p
children NNS p
with IN p
autism NN p
or CC p
Asperger NNP p
syndrome VBP p
( ( p
3-11 CD p
years NNS p
old JJ p
) ) p
received VBD N
for IN N
3 CD N
months NNS N
placebo NN i
or CC N
bumetanide NN i
( ( N
1 CD N
mg NNS N
daily RB N
) ) N
, , N
followed VBN N
by IN N
1-month JJ N
wash NN N
out IN N
. . N

Determination NN N
of IN N
the DT N
severity NN N
of IN N
autism NN N
was VBD N
made VBN N
with IN N
video JJ N
films NNS N
at IN N
day NN N
0 CD N
( ( N
D0 NNP N
) ) N
and CC N
D90 NNP N
by IN N
blind NN N
, , N
independent JJ N
evaluators NNS N
. . N

Bumetanide NNP i
reduced VBD N
significantly RB N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
CARS NNP o
) ) o
( ( N
D90-D0 NNP N
; : N
P NNP N
< VBD N
0.004 CD N
treated JJ N
vs NN N
placebo NN i
) ) i
, , N
Clinical JJ o
Global NNP o
Impressions NNP o
( ( N
P NNP N
< VBZ N
0.017 CD N
treated JJ N
vs NN N
placebo NN i
) ) i
and CC N
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
values NNS o
when WRB N
the DT N
most RBS N
severe JJ N
cases NNS N
( ( N
CARS NNPS N
values NNS N
above IN N
the DT N
mean NN N
? . N
s.d NN N
. . N

; : N
n=9 CC N
) ) N
were VBD N
removed VBN N
( ( N
Wilcoxon JJ N
test NN N
: : N
P-value=0.031 NN N
; : N
Student NNP N
's POS N
t-test NN N
: : N
P-value=0.017 NN N
) ) N
. . N

Side JJ o
effects NNS o
were VBD N
restricted VBN N
to TO N
an DT N
occasional JJ o
mild NN o
hypokalaemia NN o
( ( N
3.0-3.5 JJ N
mM NN N
l NN N
( ( N
-1 NNP N
) ) N
K NNP N
( ( N
+ NNP N
) ) N
) ) N
that WDT N
was VBD N
treated VBN N
with IN N
supplemental JJ N
potassium NN N
. . N

In IN N
a DT N
companion NN N
study NN N
, , N
chronic JJ N
bumetanide NN N
treatment NN N
significantly RB N
improved VBN o
accuracy NN o
in IN o
facial JJ o
emotional JJ o
labelling NN o
, , o
and CC o
increased VBD o
brain NN o
activation NN o
in IN o
areas NNS o
involved VBN o
in IN o
social JJ o
and CC o
emotional JJ o
perception NN o
( ( o
Hadjikhani NNP o
et RB N
al. RB N
, , N
submitted VBN N
) ) N
. . N

Therefore RB i
, , i
bumetanide NN i
is VBZ i
a DT N
promising JJ N
novel NN N
therapeutic JJ N
agent NN N
to TO N
treat VB N
autism NN N
. . N

Larger JJR N
trials NNS N
are VBP N
warranted VBN N
to TO N
better RBR N
determine VB N
the DT N
population NN N
best RB N
suited VBN N
for IN N
this DT N
treatment NN N
. . N

-DOCSTART- -12457629- O O

Pharmacokinetics NNS p
of IN p
azithromycin NN i
in IN p
lung NN p
tissue NN p
, , p
bronchial JJ p
washing NN p
, , p
and CC p
plasma NN p
in IN p
patients NNS p
given VBN p
multiple JJ p
oral JJ p
doses NNS p
of IN p
500 CD p
and CC p
1000 CD p
mg JJ p
daily RB p
. . p

The DT N
present JJ N
study NN N
compares VBZ N
the DT N
pharmacokinetics NNS p
of IN p
azithromycin NN i
in IN N
plasma NN N
, , N
lung NN N
tissue NN N
, , N
and CC N
bronchial JJ N
washing NN N
after IN N
oral JJ N
administration NN N
of IN N
500 CD N
mg NNS N
( ( N
standard JJ N
dose NN N
) ) N
versus NN N
1000 CD N
mg JJ N
daily JJ N
for IN N
3 CD N
days NNS N
. . N

Samples NNS N
were VBD N
taken VBN N
during IN N
surgery NN N
for IN N
lung NN N
resection NN N
at IN N
various JJ N
time NN N
points NNS N
up RB N
to TO N
204 CD N
h NN N
after IN N
the DT N
last JJ N
drug NN N
dose NN N
, , N
and CC N
azithromycin NN i
levels NNS N
were VBD N
analyzed VBN N
by IN N
HPLC NNP N
method NN N
. . N

Azithromycin NNP i
was VBD N
widely RB N
distributed VBN N
within IN N
the DT N
lower JJR N
respiratory NN N
tract NN N
; : N
sustained VBN o
concentrations NNS o
of IN o
the DT o
drug NN o
were VBD N
detectable JJ N
at IN N
the DT N
last JJ N
sampling JJ N
time NN N
( ( N
204 CD N
h NN N
) ) N
in IN N
lung NN N
tissue NN N
and CC N
bronchial JJ N
washing NN N
, , N
with IN N
long JJ N
terminal JJ N
half-lives NNS N
of IN N
132.86 CD N
and CC N
74.32 CD N
h NN N
at IN N
500 CD N
mg JJ N
daily JJ N
and CC N
133.32 CD N
and CC N
70.5 CD N
h NN N
at IN N
1000 CD N
mg JJ N
daily RB N
, , N
respectively RB N
. . N

Doubling VBG N
the DT N
drug NN N
dose NN N
resulted VBD N
in IN N
a DT N
remarkable JJ N
increase NN N
in IN N
lung JJ o
area NN o
under IN o
the DT o
curve NN o
( ( N
AUC NNP N
, , N
1318 CD N
hx NN N
microg NN N
g NN N
( ( N
-1 NNP N
) ) N
vs NN N
2502 CD N
hx NN N
microg NN N
g NN N
( ( N
-1 NNP N
) ) N
) ) N
and CC N
peak JJ N
tissue NN N
concentration NN N
( ( N
9.13+/-0.53 JJ N
microg NN N
g NN N
( ( N
-1 NNP N
) ) N
vs VBD N
17.85+/-2.4 JJ N
microg NN N
g NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

In IN N
addition NN N
to TO N
this DT N
, , N
enhanced VBD N
azithromycin JJ i
penetration NN N
from IN N
plasma NN N
into IN N
bronchial JJ N
secretion NN N
and CC N
lung NN N
tissue NN N
was VBD N
evidenced VBN N
by IN N
the DT N
increase NN N
in IN N
the DT N
ratio NN o
of IN o
AUC NNP o
( ( o
bronchial JJ o
washing NN o
) ) o
versus NN o
AUC NNP o
( ( o
plasma NN o
) ) o
( ( N
2.96 CD N
vs RB N
5.27 CD N
at IN N
500 CD N
and CC N
1000 CD N
mg NN N
, , N
respectively RB N
) ) N
and CC N
AUC NNP o
( ( o
lung NN o
) ) o
versus NN o
AUC NNP o
( ( o
plasma NN o
) ) o
( ( N
64.35 CD N
vs RB N
97.73 CD N
at IN N
500 CD N
and CC N
1000 CD N
mg NN N
, , N
respectively RB N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
exposure NN N
of IN N
lung NN N
and CC N
bronchial JJ N
washing NN N
to TO N
azithromycin VB i
is VBZ N
increased VBN N
by IN N
doubling VBG N
the DT N
dose NN N
, , N
which WDT N
results NNS N
in IN N
favorable JJ N
pharmacokinetic JJ o
profile NN o
of IN N
the DT N
drug NN N
in IN N
the DT N
lower JJR N
respiratory NN N
tract NN N
. . N

-DOCSTART- -18626761- O O

Engagement NN i
with IN i
electronic JJ i
screen JJ i
media NNS i
among IN N
students NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
four CD N
types NNS N
of IN N
electronic JJ i
screen JJ i
media NNS i
( ( i
ESM NNP i
) ) i
: : i
animated VBN i
video NN i
, , i
video NN i
of IN i
self NN i
, , i
video NN i
of IN i
a DT i
familiar JJ i
person NN i
engaged VBD i
with IN i
an DT i
immersive JJ i
virtual JJ i
reality NN i
( ( i
VR NNP i
) ) i
game NN i
, , i
and CC i
immersion NN i
of IN i
self NN i
in IN i
the DT i
VR NNP i
game NN i
. . i

Forty-two JJ p
students NNS p
with IN p
autism NN p
, , p
varying VBG p
in IN p
age NN p
and CC p
expressive JJ p
communication NN p
ability NN p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
experimental JJ p
conditions NNS p
. . p

Gaze NNP o
duration NN o
and CC o
vocalization NN o
served VBD N
as IN N
dependent JJ N
measures NNS N
of IN N
engagement NN N
. . N

The DT N
results NNS N
reveal VBP N
differential JJ N
responding NN N
across IN N
ESM NNP o
, , N
with IN N
some DT N
variation NN N
related VBN N
to TO N
the DT N
engagement NN N
metric JJ N
employed VBN N
. . N

Preferences NNS N
for IN N
seeing VBG o
themselves PRP o
on IN o
the DT o
screen NN o
, , o
as RB o
well RB o
as IN o
for IN o
viewing VBG o
the DT o
VR NNP o
scenarios NNS o
, , N
emerged VBD N
from IN N
the DT N
data NNS N
. . N

While IN N
the DT N
study NN N
did VBD N
not RB N
yield VB N
definitive JJ N
data NNS N
about IN N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
ESM NNP i
alternatives NNS N
, , N
it PRP N
does VBZ N
provide VB N
a DT N
foundation NN N
for IN N
future JJ N
research NN N
, , N
including VBG N
guidance NN N
related VBN N
to TO N
participant JJ N
profiles NNS N
, , N
stimulus NN N
characteristics NNS N
, , N
and CC N
data NNS N
coding NN N
challenges NNS N
. . N

-DOCSTART- -9437974- O O

The DT N
accuracy NN o
of IN N
clinical JJ o
neurosensory NN o
testing VBG o
for IN N
nerve JJ N
injury NN N
diagnosis NN N
. . N

PURPOSE VB N
The DT N
accuracy NN N
of IN N
the DT N
clinical JJ i
neurosensory JJ i
test NN i
to TO N
diagnose VB N
trigeminal JJ N
nerve NN N
injuries NNS N
has VBZ N
never RB N
been VBN N
statistically RB N
evaluated VBN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
statistical JJ o
efficacy NN o
of IN o
the DT o
clinical JJ o
neurosensory JJ o
test NN o
using VBG N
surgical JJ N
findings NNS N
as IN N
the DT N
gold JJ N
standard NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
a DT N
correlation NN N
existed VBN N
between IN N
the DT N
sensory JJ N
impairment NN N
score NN N
obtained VBN N
by IN N
preoperative JJ N
testing NN N
and CC N
the DT N
degree NN N
of IN N
nerve NN N
injury NN N
found VBD N
at IN N
surgery NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
multisite NN N
, , N
randomized VBN N
, , N
prospective JJ N
, , N
blinded VBD N
, , N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
130 CD p
patients NNS p
with IN p
inferior JJ p
alveolar JJ p
nerve NN p
( ( p
IAN NNP p
) ) p
and CC p
lingual JJ p
nerve NN p
( ( p
LN NNP p
) ) p
injuries NNS p
. . p

Preoperatively RB N
, , N
patients NNS i
were VBD i
provided VBN i
a DT i
sensory JJ i
impairment NN i
score NN i
using VBG i
a DT i
three-level JJ i
drop-out JJ i
clinical JJ i
neurosensory NN i
test NN i
( ( i
NST NNP i
) ) i
, , i
and CC i
blind IN i
comparisons NNS i
were VBD i
made VBN i
with IN i
the DT i
surgical JJ i
findings NNS i
postoperatively RB i
. . i

RESULTS VB N
The DT N
positive JJ o
predictive NN o
and CC o
negative JJ o
predictive NN o
values NNS o
for IN N
LN-injured JJ N
patients NNS N
were VBD N
95 CD N
% NN N
and CC N
100 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
positive JJ N
predictive NN N
and CC N
negative JJ N
predictive NN N
values NNS N
for IN N
IAN NNP p
patients NNS p
were VBD N
77 CD N
% NN N
and CC N
60 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
distribution NN N
of IN N
age NN N
, , N
duration NN N
of IN N
injury NN N
, , N
cause NN N
of IN N
injury NN N
, , N
presence NN N
of IN N
neuropathic JJ N
pain NN N
, , N
presence NN N
of IN N
trigger NN N
pain NN N
, , N
and CC N
degree NN N
of IN N
injury NN N
between IN N
the DT p
IAN NNP p
and CC p
LN NNP p
patient JJ p
populations NNS p
. . p

There EX N
was VBD N
a DT N
statistically RB o
significant JJ o
positive JJ o
relationship NN o
found VBD o
between IN o
the DT o
sensory JJ o
impairment NN o
score NN o
and CC o
the DT o
degree NN o
of IN o
nerve NN o
injury NN o
. . o

CONCLUSIONS VB N
The DT N
NST NNP i
is VBZ N
a DT N
clinically RB N
useful JJ N
method NN N
to TO N
diagnose VB N
IAN NNP N
and CC N
LN NNP N
injuries NNS N
. . N

However RB N
, , N
the DT N
NST NNP i
results NNS N
are VBP N
less RBR o
efficient JJ o
for IN N
IAN NNP N
injuries NNS N
than IN N
LN NNP N
injuries NNS N
, , N
and CC N
have VBP N
a DT N
high JJ o
incidence NN o
of IN o
false-positive JJ o
( ( N
23 CD N
% NN N
) ) N
and CC N
false-negative JJ o
( ( N
40 CD N
% NN N
) ) N
results NNS N
when WRB N
testing VBG N
patients NNS p
with IN p
IAN NNP p
injuries NNS p
. . p

The DT N
different JJ N
rates NNS N
of IN N
statistical JJ o
efficiency NN o
between IN N
the DT N
two CD N
groups NNS N
of IN N
patients NNS N
may MD N
be VB N
attributable JJ N
to TO N
differences NNS N
in IN N
prevalence NN N
and CC N
biologic NN N
covariates NNS N
. . N

-DOCSTART- -12121427- O O

Walking VBG N
trials NNS N
in IN N
postmenopausal JJ p
women NNS p
: : p
effect NN N
of IN N
one CD N
vs NN N
two CD N
daily JJ N
bouts NNS N
on IN N
aerobic JJ o
fitness NN o
. . o

We PRP N
compared VBN N
the DT N
effects NNS N
of IN N
one CD i
vs NN i
two CD i
daily JJ i
bouts NNS i
of IN i
walking VBG i
on IN N
aerobic JJ o
fitness NN o
and CC o
body NN o
composition NN o
in IN N
postmenopausal JJ p
women NNS p
. . p

One CD p
hundred CD p
and CC p
thirty-four JJ p
subjects NNS p
were VBD p
randomized VBN p
into IN p
exercise NN p
groups NNS p
or CC p
a DT p
control NN p
group NN p
and CC p
130 CD p
completed VBD p
the DT p
study NN p
. . p

The DT N
subjects NNS N
walked VBD i
5 CD i
d/week NN i
for IN i
15 CD i
weeks NNS i
at IN i
65 CD i
% NN i
of IN i
their PRP$ i
maximal NN i
aerobic JJ i
power NN i
expending VBG i
300 CD i
kcal JJ i
( ( i
1255 CD i
kJ NN i
) ) i
in IN i
exercise NN i
in IN i
one CD i
( ( i
Group NNP i
S1 NNP i
) ) i
or CC i
two CD i
daily JJ i
sessions NNS i
( ( i
Group NNP i
S2 NNP i
) ) i
. . i

VO NNP o
( ( o
2max CD o
) ) o
was VBD i
measured VBN i
in IN i
a DT i
direct JJ i
maximal NN i
treadmill NN i
test NN i
. . i

Body NNP o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
was VBD i
calculated VBN i
and CC i
the DT i
percentage NN i
of IN i
body NN i
fat NN i
( ( i
fat JJ i
% NN i
) ) i
estimated VBN i
using VBG i
skinfold JJ i
measurements NNS i
. . i

The DT N
net JJ N
change NN N
in IN N
the DT N
VO NNP o
( ( o
2max CD o
) ) o
was VBD N
2.5 CD N
mL NN N
min/kg NN N
( ( N
95 CD N
% NN N
CI NNP N
1.5 CD N
, , N
3.5 CD N
) ) N
( ( N
8.7 CD N
% NN N
) ) N
in IN N
Group NNP N
S1 NNP N
and CC N
2.5 CD N
mL NN N
min/kg NN N
( ( N
95 CD N
% NN N
CI NNP N
1.5 CD N
, , N
3.5 CD N
) ) N
( ( N
8.8 CD N
% NN N
) ) N
in IN N
Group NNP N
S2 NNP N
. . N

The DT N
net JJ o
change NN o
in IN o
body NN o
mass NN o
was VBD N
-1.2 JJ N
kg NN N
( ( N
95 CD N
% NN N
CI-1.9 NNP N
, , N
-0.5 NNP N
) ) N
in IN N
Group NNP N
S1 NNP N
and CC N
-1.1 NNP N
kg NNP N
( ( N
95 CD N
% NN N
CI NNP N
-1.8 NNP N
, , N
-0.4 NNP N
) ) N
in IN N
Group NNP N
S2 NNP N
. . N

The DT N
net JJ o
fat NN o
% NN o
change NN o
was VBD N
-2.1 JJ N
% NN N
( ( N
95 CD N
% NN N
CI-2.7 NNP N
, , N
-1.4 NNP N
) ) N
in IN N
Group NNP N
S1 NNP N
and CC N
-1.7 NNP N
% NN N
( ( N
95 CD N
% NN N
CI-2.3 NNP N
, , N
-1.0 NNP N
) ) N
in IN N
Group NNP N
S2 NNP N
. . N

Exercise NN N
improved VBD N
the DT N
maximal NN N
aerobic JJ N
power NN N
and CC N
body NN N
composition NN N
equally RB N
when WRB N
walking NN i
was VBD N
performed VBN N
in IN N
one CD N
or CC N
two CD N
daily JJ N
bouts NNS N
. . N

-DOCSTART- -23381958- O O

Drug-drug JJ N
interaction NN N
study NN N
of IN N
ACT-178882 NNP N
, , N
a DT N
new JJ N
renin NN N
inhibitor NN N
, , N
and CC N
diltiazem NN N
in IN N
healthy JJ p
subjects NNS p
. . p

BACKGROUND NNP N
AND CC N
OBJECTIVE NNP N
The DT N
cytochrome NN N
P450 NNP N
( ( N
CYP NNP N
) ) N
enzyme NN N
, , N
CYP3A4 NNP N
, , N
metabolizes VBZ N
ACT-178882 NNP N
, , N
a DT N
new JJ N
direct JJ N
renin NN N
inhibitor NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effect NN o
of IN N
diltiazem NN i
, , N
a DT N
moderate JJ N
inhibitor NN N
of IN N
CYP3A4 NNP N
, , N
on IN N
the DT N
single-dose JJ N
pharmacokinetics NNS N
of IN N
ACT-178882 NNP N
in IN N
healthy JJ p
subjects NNS p
. . p

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
two-way JJ N
crossover NN N
, , N
drug-drug JJ N
interaction NN N
study NN N
, , N
healthy JJ p
young JJ p
male JJ p
subjects NNS p
received VBD N
treatments NNS N
A NNP N
and CC N
B NNP N
in IN N
a DT N
randomized JJ N
fashion NN N
. . N

Treatment VB N
A NNP N
consisted NN N
of IN N
a DT N
single JJ i
dose NN i
of IN i
100 CD i
mg JJ i
ACT-178882 NNP i
and CC i
treatment NN i
B NNP i
of IN i
diltiazem NN i
300 CD i
mg NN i
once RB i
a DT i
day NN i
for IN i
13 CD i
days NNS i
and CC i
a DT i
single JJ i
dose NN i
of IN i
100 CD i
mg JJ i
ACT-178882 JJ i
on IN i
day NN i
4 CD i
. . i

Serial JJ N
blood NN N
samples NNS N
for IN N
the DT N
measurement NN N
of IN N
ACT-178882 NNP N
were VBD N
drawn VBN N
pre-dose NN N
and CC N
up RB N
to TO N
120 CD N
h JJ N
post-dose JJ N
during IN N
treatment NN N
A NNP N
and CC N
pre-dose JJ N
ACT-178882 NNP N
and CC N
up RB N
to TO N
240 CD N
h JJ N
post-dose JJ N
during IN N
treatment NN N
B. NNP N
Trough NNP N
blood NN o
samples NNS o
for IN o
the DT o
measurement NN N
of IN N
diltiazem NN N
were VBD N
taken VBN N
on IN N
days NNS N
1-5 CD N
of IN N
dosing VBG N
during IN N
treatment NN o
B NNP o
. . o

Safety NNP o
was VBD o
assessed VBN o
by IN o
recording VBG o
of IN o
vital JJ o
signs NNS o
and CC o
electrocardiogram NN o
, , o
clinical JJ o
laboratory NN o
tests NNS o
and CC o
adverse JJ o
event NN o
reporting NN o
. . o

RESULTS NNP o
Fourteen JJ p
subjects NNS p
were VBD p
enrolled VBN p
and CC p
completed VBN p
the DT p
study NN p
. . N

In IN N
the DT N
absence NN N
of IN N
diltiazem NN N
, , N
the DT N
mean NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
) ) N
maximum NN N
concentration NN N
( ( N
Cmax NNP N
) ) N
and CC N
area NN N
under IN N
the DT N
curve NN N
from IN N
time NN N
zero CD N
to TO N
infinity NN N
( ( N
AUC? NNP N
) ) N
were VBD N
26.8 CD N
( ( N
20.1-35.8 JJ N
) ) N
ng/mL NN N
and CC N
454 CD N
( ( N
351-587 CD N
) ) N
ng?h/mL NN N
, , N
respectively RB N
. . N

In IN N
the DT N
presence NN N
of IN N
diltiazem NN N
these DT N
values NNS N
were VBD N
43.5 CD N
( ( N
36.8-51.4 CD N
) ) N
ng/mL NN N
and CC N
918 CD N
( ( N
781-1078 CD N
) ) N
ng?h/mL NN N
, , N
respectively RB o
. . o

The DT o
median JJ o
time NN o
to TO o
Cmax NNP o
( ( o
tmax NN o
) ) o
for IN o
ACT-178882 NNP N
was VBD N
prolonged VBN N
from IN N
3.5 CD N
to TO N
5.0 CD N
h NN N
by IN N
diltiazem JJ N
whereas NNS N
its PRP$ N
apparent JJ o
terminal JJ o
half-life NN o
( ( o
t? NN o
) ) o
was VBD o
unaffected VBN o
by IN N
diltiazem NN N
, , N
22.9 CD N
and CC N
24.2 CD N
h NN N
for IN N
treatments NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
. . N

Using VBG N
treatment NN N
A NNP N
as IN N
reference NN N
, , N
the DT o
geometric JJ o
mean NN o
ratio NN o
( ( o
90 CD N
% NN N
CI NNP N
) ) N
was VBD N
1.62 CD N
( ( N
1.36-1.94 CD N
) ) N
for IN o
Cmax NNP o
and CC o
2.02 CD N
( ( N
1.75-2.34 CD N
) ) N
for IN N
AUC? NNP N
, , N
indicating VBG N
a DT N
significant JJ N
interaction NN N
between IN N
ACT-178882 NNP N
and CC N
diltiazem NN N
. . N

One CD N
( ( N
7.1 CD N
% NN N
) ) N
and CC N
3 CD N
( ( N
21.3 CD N
% NN N
) ) N
of IN N
14 CD N
subjects NNS N
reported VBD o
an DT o
adverse JJ o
event NN o
during IN N
treatment NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
, , N
with IN o
headache NN o
being VBG N
the DT N
most RBS N
frequently RB N
reported VBN N
, , N
with IN N
three CD N
events NNS N
. . N

There EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
effects NNS N
of IN N
treatments NNS N
on IN N
vital JJ N
signs NNS N
, , N
electrocardiogram NN N
or CC N
clinical JJ N
laboratory NN N
variables NNS N
. . N

CONCLUSION NNP N
Concomitant NNP N
administration NN N
of IN N
diltiazem NN N
doubled VBD N
the DT N
exposure NN N
to TO N
ACT-178882 NNP N
without IN N
affecting VBG N
t? NN N
. . N

The DT N
clinical JJ N
significance NN N
of IN N
this DT N
increase NN N
is VBZ N
at IN N
present JJ N
unknown JJ N
and CC N
will MD N
need VB N
to TO N
be VB N
investigated VBN N
in IN N
future JJ N
clinical JJ N
studies NNS N
. . N

Treatment NN N
with IN N
ACT-178882 NNP N
alone RB N
or CC N
in IN N
combination NN N
with IN N
diltiazem NN N
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -1996926- O O

Repeatability NN N
and CC N
protocol JJ N
comparability NN N
of IN N
presyncopal JJ i
symptom NN p
limited VBD i
lower JJR i
body NN i
negative JJ i
pressure NN i
exposures NNS p
. . p

Data NNS N
on IN N
repeatability NN N
and CC N
comparability NN N
of IN N
different JJ N
presyncopal JJ i
symptom-limited JJ i
lower JJR i
body NN i
negative JJ i
pressure NN i
( ( i
PSL-LBNP NNP i
) ) i
exposure NN i
protocols NNS i
, , N
while IN N
scarce NN N
, , N
are VBP N
critical JJ N
to TO N
the DT N
interpretation NN N
of IN N
studies NNS N
using VBG N
PSL-LBNP NNP i
methods NNS N
. . N

To TO N
investigate VB N
if IN N
PSL-LBNP JJ N
tolerance NN N
, , N
heart NN N
rate NN N
, , N
and CC N
blood NN N
pressure NN N
were VBD N
repeatable JJ N
, , N
11 CD p
subjects NNS p
were VBD p
exposed VBN p
to TO p
4 CD p
PSL-LBNP JJ i
tests NNS i
; : i
each DT N
test NN N
occurring VBG N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
, , N
separated VBN N
by IN N
at IN N
least JJS N
72 CD N
h NN N
, , N
and CC N
using VBG N
the DT N
same JJ N
protocol NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
either CC N
the DT N
heart NN o
rate NN o
or CC o
blood NN o
pressure NN o
responses VBZ o
to TO N
the DT N
PSL-LBNP NNP i
or CC N
the DT N
tolerance NN o
indices NNS o
( ( N
cumulative JJ N
stress NN N
index NN N
; : N
maximum JJ N
negative JJ N
pressure NN N
tolerated VBN N
; : N
and CC N
duration NN N
of IN N
negative JJ N
pressure NN N
exposure NN N
) ) N
. . N

To TO N
study VB N
the DT N
comparability NN N
of IN N
different JJ N
PSL-LBNP NNP i
protocols NNS N
, , N
nine CD p
subjects NNS p
were VBD N
exposed VBN N
randomly RB N
to TO N
five CD N
PSL-LBNP JJ i
tests NNS i
using VBG N
protocols NNS N
that WDT N
varied VBD N
in IN N
stage NN N
duration NN N
but CC N
not RB N
pressure NN N
profile NN N
. . N

The DT N
protocols NNS N
had VBD N
1- CD N
, , N
3- CD N
, , N
5- JJ N
, , N
7- JJ N
, , N
or CC N
9-min JJ N
stage NN N
durations NNS N
. . N

These DT N
PSL-LBNP JJ i
exposures NNS N
were VBD N
conducted VBN N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
and CC N
separated VBN N
by IN N
at IN N
least JJS N
72 CD N
h. NN N
While IN N
no DT N
differences NNS N
were VBD N
noted VBN N
in IN N
either CC N
the DT N
response NN N
pattern NN N
or CC N
magnitude NN N
of IN N
heart NN o
rate NN o
or CC o
blood NN o
pressure NN o
to TO N
the DT N
differing NN N
protocols NNS N
, , N
the DT N
cumulative JJ o
stress NN o
index NN o
and CC o
the DT o
duration NN o
of IN o
negative JJ o
pressure NN o
exposure NN o
varied VBD N
proportionally RB N
with IN N
the DT N
length NN N
of IN N
the DT N
stage NN N
durations NNS N
. . N

With IN N
the DT N
exception NN N
of IN N
the DT N
1-min JJ N
protocol NN N
, , N
the DT N
maximum JJ N
negative JJ N
pressure NN N
tolerated VBD N
did VBD N
not RB N
vary JJ N
regardless NN N
of IN N
the DT N
protocol NN N
used VBN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -20484002- O O

Efficacy NN N
of IN N
TeachTown NNP N
: : N
Basics NNS i
computer-assisted JJ i
intervention NN i
for IN N
the DT N
Intensive NNP N
Comprehensive NNP N
Autism NNP N
Program NNP N
in IN N
Los NNP N
Angeles NNP N
Unified NNP N
School NNP N
District NNP N
. . N

Computer NNP i
Assisted NNP i
Instruction NNP i
( ( i
CAI NNP i
) ) i
has VBZ N
shown VBN N
increased VBN N
popularity NN N
recently RB N
and CC N
there EX N
are VBP N
many JJ N
studies NNS N
showing VBG N
promise NN N
for IN N
this DT N
approach NN N
for IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

However RB N
, , N
there EX N
are VBP N
no DT N
between-subject JJ N
studies NNS N
to TO N
date NN N
assessing VBG N
the DT N
efficacy NN N
of IN N
CAI NNP i
with IN N
this DT N
population NN N
. . N

In IN N
this DT N
study NN N
, , N
47 CD p
preschool NN p
and CC p
K-1 JJ p
students NNS p
in IN p
ASD NNP p
classrooms NNS p
participated VBD p
from IN p
Los NNP p
Angeles NNP p
Unified NNP p
School NNP p
District NNP p
. . p

TeachTown NN i
: : i
Basics NNS i
, , i
a DT i
CAI NNP i
program NN i
which WDT i
also RB i
includes VBZ i
supplementary JJ i
off-computer NN i
activities NNS i
, , N
was VBD N
implemented VBN N
over IN N
3 CD N
months NNS N
for IN N
approximately RB N
20 CD N
minutes NNS N
per IN N
day NN N
on IN N
the DT N
computer NN i
and CC N
20 CD i
minutes NNS i
per IN i
day NN i
in IN i
supplementary JJ i
TeachTown NN i
: : i
Basics JJ i
activities NNS i
. . i

Compared VBN N
to TO N
the DT N
students NNS N
in IN N
the DT N
control NN N
group NN N
, , N
the DT N
TeachTown NNP N
: : N
Basics NNS N
students NNS N
showed VBD N
more RBR N
improvement NN N
overall JJ o
on IN o
language NN o
and CC o
cognitive JJ o
outcome NN o
measures NNS o
. . o

In IN N
addition NN N
, , N
students NNS N
who WP N
used VBD N
TeachTown NNP N
: : N
Basics NNS N
demonstrated VBD N
significant JJ N
progress NN o
overall NN o
in IN o
the DT o
software NN o
and CC N
those DT N
students NNS N
who WP N
used VBD N
the DT N
program NN N
for IN N
more JJR N
time NN N
demonstrated VBD o
larger JJR o
gains NNS o
within IN o
the DT o
software NN o
and CC o
in IN o
outcome JJ o
measures NNS o
. . o

Although IN N
not RB N
conclusive JJ N
, , N
these DT N
findings NNS N
offer VBP N
possibilities NNS N
for IN N
the DT N
use NN N
of IN N
CAI NNP i
for IN N
remediating VBG N
many JJ N
deficits NNS N
for IN N
children NNS p
with IN p
ASD NNP p
and CC p
other JJ p
special JJ p
needs NNS p
. . p

In IN N
addition NN N
, , N
CAI NNP i
may MD N
offer VB N
solutions NNS N
to TO N
schools NNS N
and CC N
parents NNS N
with IN N
insufficient JJ N
funds NNS N
for IN N
more RBR N
expensive JJ N
treatments NNS N
. . N

-DOCSTART- -18843564- O O

Physical JJ N
health NN N
-- : N
a DT N
cluster NN i
randomized VBN i
controlled VBN i
lifestyle JJ i
intervention NN i
among IN N
persons NNS p
with IN p
a DT p
psychiatric JJ p
disability NN p
and CC p
their PRP$ p
staff NN p
. . p

The DT N
objective NN N
was VBD N
to TO N
explore VB N
the DT N
impact NN N
on IN N
physical JJ N
health NN N
of IN N
a DT N
lifestyle JJ i
programme NN i
among IN N
persons NNS p
with IN p
psychiatric JJ p
disabilities NNS p
, , p
and CC p
their PRP$ p
caregivers NNS p
. . p

Their PRP$ N
satisfaction NN N
with IN N
the DT N
intervention NN N
was VBD N
also RB N
assessed VBN N
. . N

Somatic JJ N
comorbidity NN N
and CC N
an DT N
increased VBN N
mortality NN N
related VBN N
to TO N
the DT N
lifestyle NN N
among IN N
persons NNS p
with IN p
psychiatric JJ p
disabilities NNS p
are VBP N
well RB N
known VBN N
. . N

Few JJ N
randomized VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
aimed VBN N
specifically RB N
at IN N
lifestyle JJ N
issues NNS N
among IN N
persons NNS p
with IN p
a DT p
psychiatric JJ p
disability NN p
. . p

This DT N
trial NN N
includes VBZ N
clients NNS p
with IN p
psychiatric JJ p
disabilities NNS p
living VBG p
in IN p
supported JJ p
housing NN p
and CC p
their PRP$ p
staff NN p
. . p

Forty-one CD p
persons NNS p
with IN p
a DT p
DSM- NNP p
? . p
V NNP p
diagnosis NN p
of IN p
severe JJ p
mental JJ p
illness NN p
from IN p
psychiatric JJ p
disability NN p
from IN p
10 CD p
supported VBD p
housing NN p
facilities NNS p
and CC p
41 CD p
of IN p
their PRP$ p
caregivers NNS p
participated VBN p
in IN p
this DT p
12-month JJ p
study NN p
during IN p
2005-2006 JJ p
in IN p
Sweden NNP p
. . p

The DT N
supported JJ N
housing NN N
facilities NNS N
with IN N
residents NNS N
and CC N
staff NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
a DT N
health NN i
intervention NN i
programme NN i
or CC N
a DT N
control NN N
programme NN N
with IN N
an DT N
aesthetic JJ N
content NN N
. . N

The DT N
presence NN o
of IN o
metabolic JJ o
syndrome NN o
and CC o
changes NNS o
in IN o
the DT o
mean NN o
of IN o
physiological JJ o
parameters NNS o
such JJ o
as IN o
Hba1c NNP o
, , o
P-glucose NNP o
, , o
P-insulin NNP o
, , o
lipids NNS o
, , o
blood NN o
pressure NN o
, , o
physical JJ o
working NN o
capacity NN o
, , o
body NN o
mass NN o
index NN o
, , o
Heart NNP o
Score NNP o
were VBD o
investigated VBN o
and CC o
participants NNS o
' POS o
satisfaction NN o
assessed VBD N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
mean NN o
of IN o
metabolic JJ o
syndrome JJ o
criteria NNS o
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
at IN N
the DT N
follow-up NN N
. . N

The DT N
participants NNS N
expressed VBD N
satisfaction NN N
with IN N
the DT N
programme NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
health NN i
interventions NNS i
on IN N
lifestyle JJ N
issues NNS N
when WRB N
involving VBG N
carers NNS p
are VBP N
appreciated VBN N
, , N
feasible JJ N
and CC N
could MD N
be VB N
successful JJ N
in IN N
reducing VBG N
some DT N
health-related JJ o
risk NN o
factors NNS o
among IN N
persons NNS p
with IN p
psychiatric JJ p
disabilities NNS p
. . p

-DOCSTART- -21334061- O O

Comparison NNP N
of IN N
adaptive JJ i
pacing NN i
therapy NN i
, , i
cognitive JJ i
behaviour NN i
therapy NN i
, , i
graded VBD i
exercise NN i
therapy NN i
, , N
and CC N
specialist VB i
medical JJ i
care NN i
for IN N
chronic JJ p
fatigue NN p
syndrome NN p
( ( N
PACE NNP N
) ) N
: : N
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Trial NNP N
findings NNS N
show VBP N
cognitive JJ i
behaviour NN i
therapy NN i
( ( i
CBT NNP i
) ) i
and CC N
graded VBN i
exercise NN i
therapy NN i
( ( i
GET NNP i
) ) i
can MD N
be VB N
effective JJ N
treatments NNS N
for IN N
chronic JJ N
fatigue NN N
syndrome NN N
, , N
but CC N
patients NNS N
' POS N
organisations NNS N
have VBP N
reported VBN N
that IN N
these DT N
treatments NNS N
can MD N
be VB N
harmful JJ N
and CC N
favour JJ N
pacing NN i
and CC N
specialist NN i
health NN i
care NN i
. . i

We PRP N
aimed VBD N
to TO N
assess VB N
effectiveness NN o
and CC o
safety NN o
of IN N
all DT N
four CD N
treatments NNS N
. . N

METHODS NNP N
In IN N
our PRP$ N
parallel-group NN N
randomised VBN N
trial NN N
, , N
patients NNS p
meeting NN p
Oxford NNP p
criteria NN p
for IN p
chronic JJ p
fatigue NN p
syndrome NN p
were VBD p
recruited VBN p
from IN p
six CD i
secondary-care JJ i
clinics NNS i
in IN i
the DT i
UK NNP i
and CC i
randomly RB i
allocated VBN i
by IN i
computer-generated JJ i
sequence NN i
to TO i
receive VB i
specialist NN i
medical JJ i
care NN i
( ( i
SMC NNP i
) ) i
alone RB i
or CC i
with IN i
adaptive JJ i
pacing VBG i
therapy NN i
( ( i
APT NNP i
) ) i
, , i
CBT NNP i
, , i
or CC i
GET NNP i
. . i

Primary NNP N
outcomes NNS N
were VBD N
fatigue JJ o
( ( o
measured VBN o
by IN o
Chalder NNP o
fatigue NN o
questionnaire NN o
score NN o
) ) o
and CC o
physical JJ o
function NN o
( ( o
measured VBN o
by IN o
short JJ o
form-36 JJ o
subscale NN o
score NN o
) ) o
up IN N
to TO N
52 CD N
weeks NNS N
after IN N
randomisation NN N
, , N
and CC N
safety NN N
was VBD N
assessed VBN N
primarily RB N
by IN N
recording VBG N
all DT N
serious JJ o
adverse JJ o
events NNS o
, , N
including VBG N
serious JJ o
adverse JJ o
reactions NNS o
to TO N
trial NN N
treatments NNS N
. . N

Primary JJ N
outcomes NNS N
were VBD N
rated VBN N
by IN N
participants NNS N
, , N
who WP N
were VBD N
necessarily RB N
unmasked VBN N
to TO N
treatment NN N
assignment NN N
; : N
the DT N
statistician NN N
was VBD N
masked VBN N
to TO N
treatment NN N
assignment NN N
for IN N
the DT N
analysis NN N
of IN N
primary JJ N
outcomes NNS N
. . N

We PRP N
used VBD N
longitudinal JJ i
regression NN i
models NNS i
to TO i
compare VB i
SMC NNP i
alone RB i
with IN i
other JJ i
treatments NNS i
, , i
APT NNP i
with IN i
CBT NNP i
, , i
and CC i
APT NNP i
with IN i
GET NNP i
. . i

The DT N
final JJ N
analysis NN N
included VBD N
all DT N
participants NNS N
for IN N
whom WP N
we PRP N
had VBD N
data NNS N
for IN N
primary JJ N
outcomes NNS N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
at IN N
http NN N
: : N
//isrctn.org NN N
, , N
number NN N
ISRCTN54285094 NNP N
. . N

FINDINGS NNP N
We PRP N
recruited VBD N
641 CD p
eligible JJ p
patients NNS p
, , N
of IN N
whom WP N
160 CD N
were VBD N
assigned VBN N
to TO N
the DT N
APT NNP N
group NN N
, , N
161 CD N
to TO N
the DT N
CBT NNP N
group NN N
, , N
160 CD N
to TO N
the DT N
GET NNP N
group NN N
, , N
and CC N
160 CD N
to TO N
the DT N
SMC-alone NNP i
group NN N
. . N

Compared VBN N
with IN N
SMC NNP N
alone RB N
, , N
mean JJ o
fatigue NN o
scores NNS o
at IN N
52 CD N
weeks NNS N
were VBD N
3?4 CD N
( ( N
95 CD N
% NN N
CI NNP N
1?8 CD N
to TO N
5?0 CD N
) ) N
points NNS N
lower JJR N
for IN N
CBT NNP N
( ( N
p JJ N
= NNP N
0?0001 CD N
) ) N
and CC N
3?2 CD N
( ( N
1?7 CD N
to TO N
4?8 CD N
) ) N
points NNS N
lower JJR N
for IN N
GET NNP N
( ( N
p JJ N
= NNP N
0?0003 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
differ VB N
for IN N
APT NNP N
( ( N
0?7 CD N
[ RB N
-0?9 NN N
to TO N
2?3 CD N
] NN N
points NNS N
lower JJR N
; : N
p VB N
= $ N
0?38 CD N
) ) N
. . N

Compared VBN N
with IN N
SMC NNP N
alone RB N
, , N
mean JJ N
physical JJ o
function NN o
scores NNS o
were VBD N
7?1 CD N
( ( N
2?0 CD N
to TO N
12?1 CD N
) ) N
points NNS N
higher JJR N
for IN N
CBT NNP N
( ( N
p JJ N
= NNP N
0?0068 CD N
) ) N
and CC N
9?4 CD N
( ( N
4?4 CD N
to TO N
14?4 CD N
) ) N
points NNS N
higher JJR N
for IN N
GET NNP N
( ( N
p JJ N
= NNP N
0?0005 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
differ VB N
for IN N
APT NNP N
( ( N
3?4 CD N
[ RB N
-1?6 NN N
to TO N
8?4 CD N
] NN N
points NNS N
lower JJR N
; : N
p=0?18 NN N
) ) N
. . N

Compared VBN N
with IN N
APT NNP N
, , N
CBT NNP N
and CC N
GET NNP N
were VBD N
associated VBN N
with IN N
less JJR o
fatigue NN o
( ( o
CBT NNP o
p VBZ N
= JJ N
0?0027 CD N
; : N
GET NNP N
p VBP N
= NNP N
0?0059 CD N
) ) N
and CC N
better JJR o
physical JJ o
function NN o
( ( N
CBT NNP N
p=0?0002 NN N
; : N
GET NNP N
p VBP N
< NNP N
0?0001 CD N
) ) N
. . N

Subgroup NNP N
analysis NN N
of IN N
427 CD N
participants NNS N
meeting VBG N
international JJ N
criteria NNS p
for IN p
chronic JJ o
fatigue NN o
syndrome NN o
and CC p
329 CD N
participants NNS N
meeting VBG N
London NNP N
criteria NNS N
for IN N
myalgic JJ N
encephalomyelitis NN N
yielded VBN N
equivalent JJ N
results NNS N
. . N

Serious JJ N
adverse JJ o
reactions NNS o
were VBD N
recorded VBN N
in IN N
two CD N
( ( N
1 CD N
% NN N
) ) N
of IN N
159 CD N
participants NNS N
in IN N
the DT N
APT NNP N
group NN N
, , N
three CD N
( ( N
2 CD N
% NN N
) ) N
of IN N
161 CD N
in IN N
the DT N
CBT NNP N
group NN N
, , N
two CD N
( ( N
1 CD N
% NN N
) ) N
of IN N
160 CD N
in IN N
the DT N
GET NNP N
group NN N
, , N
and CC N
two CD N
( ( N
1 CD N
% NN N
) ) N
of IN N
160 CD N
in IN N
the DT N
SMC-alone NNP N
group NN N
. . N

INTERPRETATION NNP N
CBT NNP N
and CC N
GET NNP N
can MD N
safely RB N
be VB N
added VBN N
to TO N
SMC NNP N
to TO N
moderately RB N
improve VB N
outcomes NNS N
for IN N
chronic JJ N
fatigue NN o
syndrome NN o
, , N
but CC N
APT NNP N
is VBZ N
not RB N
an DT N
effective JJ N
addition NN N
. . N

FUNDING NN N
UK NNP N
Medical NNP N
Research NNP N
Council NNP N
, , N
Department NNP N
of IN N
Health NNP N
for IN N
England NNP N
, , N
Scottish NNP N
Chief NNP N
Scientist NNP N
Office NNP N
, , N
Department NNP N
for IN N
Work NNP N
and CC N
Pensions NNP N
. . N

-DOCSTART- -20362507- O O

Effect NN N
of IN N
zoledronic JJ i
acid NN i
on IN N
disseminated JJ N
tumour NN N
cells NNS N
in IN N
women NNS p
with IN p
locally RB p
advanced JJ p
breast NN p
cancer NN p
: : p
an DT N
open JJ N
label NN N
, , N
randomised VBN N
, , N
phase VB N
2 CD N
trial NN N
. . N

BACKGROUND NNP N
Treatment NNP N
with IN N
bisphosphonates NNS i
decreases NNS N
bone VBP N
loss NN N
and CC N
can MD N
increase VB N
disease-free JJ N
survival NN N
in IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
. . p

The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
zoledronic JJ i
acid NN i
on IN N
clearance NN N
of IN N
disseminated JJ o
tumour NN o
cells NNS o
( ( o
DTCs NNP o
) ) o
from IN N
the DT N
bone NN N
marrow NN N
in IN N
women NNS p
undergoing VBG p
neoadjuvant JJ p
chemotherapy NN p
for IN p
breast NN p
cancer NN p
. . p

METHODS NNP N
Patients NNPS N
were VBD N
recruited VBN N
for IN N
this DT N
open-label JJ p
, , p
phase VB p
2 CD p
randomised JJ p
trial NN p
between IN p
March NNP p
17 CD p
, , p
2003 CD p
, , p
and CC p
May NNP p
19 CD p
, , p
2006 CD p
, , p
at IN p
a DT p
single JJ p
centre NN p
. . p

Eligible JJ p
patients NNS p
had VBD p
clinical JJ p
stage NN p
II-III NNP p
( ( p
> CD p
or CC p
= VB p
T2 NNP p
and/or JJ p
> NN p
or CC p
= VB p
N1 NNP p
) ) p
newly RB p
diagnosed VBN p
breast NN p
cancer NN p
, , p
Eastern NNP p
Cooperative NNP p
Oncology NNP p
Group NNP p
performance NN p
status NN p
of IN p
0 CD p
or CC p
1 CD p
, , p
and CC p
normal JJ p
cardiac NN p
, , p
renal JJ p
, , p
and CC p
liver JJ p
function NN p
. . p

120 CD p
women NNS p
were VBD p
randomly RB p
assigned VBN p
, , N
using VBG N
allocation NN N
concealment NN N
, , N
to TO N
receive VB N
4 CD i
mg NN i
zoledronic JJ i
acid NN i
intravenously RB i
every DT i
3 CD N
weeks NNS N
( ( N
n=60 NN N
) ) N
, , N
or CC N
no DT i
zoledronic JJ i
acid NN i
( ( N
n=60 JJ N
) ) N
, , N
for IN N
1 CD N
year NN N
concomitant NN N
with IN N
four CD i
cycles NNS i
of IN i
neoadjuvant JJ i
epirubicin NN i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
plus CC i
docetaxel JJ i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
and CC i
two CD i
cycles NNS i
of IN i
adjuvant JJ i
epirubicin JJ i
plus CC i
docetaxel JJ i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
number NN N
of IN N
patients NNS N
with IN N
detectable JJ o
DTCs NNP o
at IN N
3 CD N
months NNS N
. . N

Final NNP N
analysis NN N
was VBD N
done VBN N
1 CD N
year NN N
after IN N
the DT N
last JJ N
patient NN N
was VBD N
enrolled VBN N
. . N

Analyses NNS N
were VBD N
done VBN N
for IN N
all DT N
patients NNS N
with IN N
available JJ N
data NNS N
at IN N
3 CD N
months NNS N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00242203 NNP N
. . N

FINDINGS NNP N
Of IN N
the DT N
120 CD p
patients NNS p
initially RB p
enrolled VBD p
, , p
one CD p
withdrew NN p
after IN p
signing VBG p
consent NN p
and CC p
one CD p
patient NN p
's POS p
baseline NN p
bone NN p
marrow NN p
was VBD p
not RB p
available JJ p
. . p

Both DT N
of IN N
these DT N
patients NNS N
were VBD N
in IN N
the DT N
control NN N
group NN N
. . N

At IN N
3 CD N
months NNS N
, , N
109 CD p
bone-marrow NN p
samples NNS p
were VBD p
available JJ p
for IN N
analysis NN N
. . N

In IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
, , N
bone NN N
marrow NN N
was VBD N
not RB N
collected VBN N
from IN N
one CD N
patient NN N
because IN N
of IN N
disease NN N
progression NN N
, , N
one CD N
patient NN N
was VBD N
taken VBN N
off RP N
study NN N
because IN N
of IN N
severe JJ N
diarrhoea NN N
, , N
and CC N
two CD N
patients NNS N
had VBD N
not RB N
consented VBN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
bone NN N
marrow NN N
was VBD N
not RB N
collected VBN N
from IN N
two CD N
patients NNS N
because IN N
of IN N
disease NN N
progression NN N
, , N
one CD N
patient NN N
withdrew VBD N
consent NN N
, , N
and CC N
three CD N
patients NNS N
were VBD N
not RB N
consented VBN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

At IN N
baseline NN N
, , N
DTCs NNP N
were VBD N
detected VBN N
in IN N
26 CD N
of IN N
60 CD N
patients NNS N
in IN N
the DT N
zoledronic JJ i
acid NN i
group NN N
and CC N
28 CD N
of IN N
58 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
. . N

At IN N
3 CD N
months NNS N
, , N
17 CD N
of IN N
56 CD N
patients NNS N
receiving VBG N
zoledronic JJ N
acid NN N
versus IN N
25 CD N
of IN N
53 CD N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
zoledronic JJ N
acid NN N
had VBD N
detectable JJ N
DTCs NNP N
( ( N
p=0.054 NN N
) ) N
. . N

The DT N
most RBS N
common JJ N
grade NN N
3-4 JJ N
toxicities NNS N
were VBD N
infection NN N
( ( N
five CD N
of IN N
60 CD N
patients NNS N
in IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
and CC N
six CD N
of IN N
59 CD N
in IN N
the DT N
control NN N
group NN N
) ) N
and CC N
thrombosis NN N
( ( N
five CD N
of IN N
60 CD N
in IN N
the DT N
zoledronic JJ N
acid NN N
and CC N
two CD N
of IN N
59 CD N
in IN N
the DT N
control NN N
group NN N
) ) N
. . N

There EX N
was VBD N
one CD N
documented JJ N
case NN N
of IN N
osteonecrosis NN o
in IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
. . N

INTERPRETATION NNP N
Zoledronic NNP i
acid NN i
administered VBD N
with IN N
chemotherapy NN N
resulted VBN N
in IN N
a DT N
decreased JJ N
proportion NN N
of IN N
patients NNS N
with IN N
DTCs NNP N
detected VBD N
in IN N
the DT N
bone NN N
marrow NN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

Our PRP$ N
study NN N
supports VBZ N
the DT N
hypothesis NN N
that IN N
the DT N
antimetastatic JJ N
effects NNS N
of IN N
zoledronic JJ i
acid NN i
may MD N
be VB N
through IN N
effects NNS N
on IN N
DTCs NNP N
. . N

FUNDING NN N
Novartis NN N
Pharmaceuticals NNP N
and CC N
Pfizer NNP N
Inc NNP N
. . N

-DOCSTART- -17961229- O O

How WRB N
well RB N
do VB N
blood NN o
folate VB o
concentrations NNS o
predict VBP N
dietary JJ i
folate NN i
intakes NNS i
in IN N
a DT N
sample NN N
of IN N
Canadian JJ p
lactating VBG p
women NNS p
exposed VBN p
to TO p
high JJ p
levels NNS p
of IN p
folate NN p
? . N
An DT N
observational JJ N
study NN N
. . N

BACKGROUND NNP N
In IN N
1998 CD N
, , N
mandatory JJ N
folic JJ N
acid JJ N
fortification NN N
of IN N
white JJ i
flour NN i
and CC i
select JJ i
cereal NN i
grain NN i
products NNS i
was VBD N
implemented VBN N
in IN N
Canada NNP p
with IN N
the DT N
intention NN N
to TO N
increase VB N
dietary JJ i
folate JJ i
intakes NNS i
of IN N
reproducing VBG p
women NNS p
. . p

Folic NNP N
acid JJ N
fortification NN N
has VBZ N
produced VBN N
a DT N
dramatic JJ N
increase NN N
in IN N
blood NN N
folate JJ N
concentrations NNS N
among IN N
reproductive JJ N
age NN N
women NNS N
, , N
and CC N
a DT N
reduction NN N
in IN N
neural JJ N
tube NN N
defect NN N
( ( N
NTD NNP N
) ) N
-affected VBD N
pregnancies NNS N
. . N

In IN N
response NN N
to TO N
improved VBN N
blood NN N
folate NN N
concentrations NNS N
, , N
many JJ N
health NN N
care NN N
professionals NNS N
are VBP N
asking VBG N
whether IN N
a DT N
folic JJ i
acid NN i
supplement NN i
is VBZ N
necessary JJ N
for IN N
NTD NNP N
prevention NN N
among IN N
women NNS p
with IN p
high JJ p
blood NN p
folate NN p
values NNS p
, , N
and CC N
how WRB N
reliably RB N
high JJ N
RBC NNP N
folate NN N
concentrations NNS N
predict VBP N
folate JJ N
intakes NNS N
shown VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
to TO N
be VB N
protective JJ N
against IN N
NTDs NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
how WRB N
predictive JJ N
blood NN o
folate NN o
concentrations NNS o
and CC o
folate NN o
intakes NNS o
are VBP N
of IN N
each DT N
other JJ N
in IN N
a DT N
sample NN N
of IN N
well-educated JJ p
lactating VBG p
Canadian JJ p
women NNS p
exposed VBN p
to TO p
high JJ p
levels NNS p
of IN p
synthetic JJ p
folate NN p
. . p

METHODS NNP N
The DT N
relationship NN N
between IN N
blood NN o
folate NN o
concentrations NNS o
and CC N
dietary JJ o
folate NN o
intakes NNS o
, , N
determined VBN N
by IN N
weighed VBN i
food NN i
records NNS i
, , N
were VBD N
assessed VBN N
in IN N
a DT N
sample NN p
of IN p
predominantly RB p
university-educated JJ p
lactating VBG p
women NNS p
( ( p
32 CD p
+/- JJ p
4 CD p
yr NN p
) ) p
at IN p
4- JJ p
( ( p
n JJ p
= NNP p
53 CD p
) ) p
and CC p
16-wk JJ p
postpartum NN p
( ( p
n JJ p
= NNP p
55 CD p
) ) p
. . p

RESULTS NNP N
Median JJ N
blood NN o
folate NN o
concentrations NNS o
of IN N
all DT N
participants NNS N
were VBD N
well RB N
above IN N
plasma NN N
and CC N
RBC NNP N
folate VBP N
cut-off NN N
levels NNS N
indicative CD N
of IN N
deficiency NN N
( ( N
6.7 CD N
and CC N
317 CD N
nmol/L NN N
, , N
respectively RB N
) ) N
and CC N
all DT N
, , N
except IN N
for IN N
2 CD N
subjects NNS N
, , N
were VBD N
above IN N
the DT N
cut-off NN N
for IN N
NTD-risk NNP N
reduction NN N
( ( N
> $ N
906 CD N
nmol/L NN N
) ) N
. . N

Only RB N
modest JJ N
associations NNS N
existed VBD N
between IN N
total JJ o
folate NN o
intakes NNS o
and CC N
plasma NN o
( ( N
r JJ N
= NN N
0.46 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
RBC NNP N
( ( N
r VB N
= RB N
0.36 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
folate NN o
concentrations NNS o
at IN N
16-wk JJ N
postpartum NN N
. . N

Plasma NNP o
and CC o
RBC NNP o
folate VBP o
values NNS o
at IN N
16-wk JJ N
postpartum NN N
correctly RB N
identified VBD N
the DT N
quartile NN N
of IN N
folate JJ N
intake NN N
of IN N
only RB N
26 CD N
of IN N
55 CD N
( ( N
47 CD N
% NN N
) ) N
and CC N
18 CD N
of IN N
55 CD N
( ( N
33 CD N
% NN N
) ) N
of IN N
subjects NNS N
, , N
respectively RB N
. . N

The DT N
mean JJ N
RBC NNP o
folate NN o
concentration NN o
of IN N
women NNS N
consuming VBG N
151-410 JJ N
microg/d NN N
of IN N
synthetic JJ N
folate NN N
( ( N
2nd CD N
quartile NN N
of IN N
intake NN N
) ) N
did VBD N
not RB N
differ VB N
from IN N
that DT N
of IN N
women NNS N
consuming VBG N
> JJ N
410 CD N
microg/d NN N
( ( N
3rd CD N
and CC N
4th CD N
quartile NN N
) ) N
. . N

CONCLUSION NNP N
Folate NNP o
intakes NNS o
, , N
estimated VBN N
by IN N
food NN N
composition NN N
tables NNS N
, , N
and CC N
blood NN o
folate NN o
concentrations NNS o
are VBP N
not RB N
predictive JJ N
of IN N
each DT N
other JJ N
in IN N
Canadian JJ N
lactating VBG N
women NNS N
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
folate NN o
. . o

Synthetic JJ N
intakes NNS N
> VBP N
151-410 JJ N
microg/d NN N
in IN N
these DT N
women NNS N
produced VBD N
little JJ N
additional JJ N
benefit NN N
in IN N
terms NNS N
of IN N
maximizing VBG N
RBC NNP N
content NN N
. . N

More JJR N
studies NNS N
are VBP N
needed VBN N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
blood NN o
folate NN o
concentration NN o
and CC N
NTD NNP N
risk NN N
. . N

Until IN N
data NNS N
from IN N
such JJ N
studies NNS N
are VBP N
available JJ N
, , N
women NNS N
planning VBG N
a DT N
pregnancy NN N
should MD N
continue VB N
to TO N
consume VB N
a DT N
daily JJ N
folic JJ i
acid JJ i
supplement NN i
of IN N
400 CD N
microg NN N
. . N

-DOCSTART- -22221670- O O

Randomised VBN N
controlled JJ N
trial NN N
of IN N
improvisational JJ i
music NN i
therapy NN i
's POS i
effectiveness NN o
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( N
TIME-A NNP N
) ) N
: : N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
Previous NNP N
research NN N
has VBZ N
suggested VBN N
that IN N
music NN i
therapy NN i
may MD N
facilitate VB N
skills NNS o
in IN N
areas NNS N
typically RB N
affected VBN N
by IN N
autism NN p
spectrum NN p
disorders NNS p
such JJ N
as IN N
social JJ o
interaction NN o
and CC o
communication NN o
. . o

However RB N
, , N
generalisability NN N
of IN N
previous JJ N
findings NNS N
has VBZ N
been VBN N
restricted VBN N
, , N
as IN N
studies NNS N
were VBD N
limited VBN N
in IN N
either DT N
methodological JJ N
accuracy NN N
or CC N
the DT N
clinical JJ N
relevance NN N
of IN N
their PRP$ N
approach NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
determine VB N
effects NNS N
of IN N
improvisational JJ i
music NN i
therapy NN i
on IN N
social JJ o
communication NN o
skills NNS o
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

An DT N
additional JJ N
aim NN N
of IN N
the DT N
study NN N
is VBZ N
to TO N
examine VB N
if IN N
variation NN N
in IN N
dose NN N
of IN N
treatment NN N
( ( N
i.e. FW N
, , N
number NN N
of IN N
music NN i
therapy NN i
sessions NNS N
per IN N
week NN N
) ) N
affects VBZ N
outcome NN o
of IN o
therapy NN o
, , N
and CC N
to TO N
determine VB N
cost-effectiveness NN o
. . o

METHODS/DESIGN NNP N
Children NNP p
aged VBD p
between IN p
4 CD p
; : p
0 CD p
and CC p
6 CD p
; : p
11 CD p
years NNS p
who WP p
are VBP p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorder NN p
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
. . N

Parents NNS p
of IN p
all DT p
participants NNS p
will MD N
receive VB N
three CD i
sessions NNS i
of IN i
parent NN i
counselling NN i
( ( N
at IN N
0 CD N
, , N
2 CD N
, , N
and CC N
5 CD N
months NNS N
) ) N
. . N

In IN N
addition NN N
, , N
children NNS N
randomised VBD N
to TO N
the DT N
two CD N
intervention NN N
groups NNS N
will MD N
be VB N
offered VBN N
individual JJ i
, , i
improvisational JJ i
music NN i
therapy NN i
over IN N
a DT N
period NN N
of IN N
five CD N
months NNS N
, , N
either RB N
one CD N
session NN N
( ( N
low-intensity NN N
) ) N
or CC N
three CD N
sessions NNS N
( ( N
high-intensity NN N
) ) N
per IN N
week NN N
. . N

Generalised JJ N
effects NNS N
of IN N
music NN i
therapy NN i
will MD N
be VB N
measured VBN N
using VBG N
standardised JJ o
scales NNS o
completed VBN N
by IN N
blinded JJ N
assessors NNS N
( ( o
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
, , o
ADOS NNP o
) ) o
and CC o
parents NNS o
( ( o
Social NNP o
Responsiveness NNP o
Scale NNP o
, , o
SRS NNP o
) ) o
before IN N
and CC N
2 CD N
, , N
5 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
randomisation NN N
. . N

Cost NNP o
effectiveness NN o
will MD N
be VB N
calculated VBN N
as IN N
man NN N
years NNS N
. . N

A DT N
group NN N
sequential JJ N
design NN N
with IN N
first JJ N
interim JJ N
look NN N
at IN N
N NNP N
= NNP N
235 CD N
will MD N
ensure VB N
both DT N
power NN N
and CC N
efficiency NN N
. . N

DISCUSSION NNP N
Responding VBG N
to TO N
the DT N
need NN N
for IN N
more RBR N
rigorously RB N
designed VBN N
trials NNS N
examining VBG N
the DT N
effectiveness NN N
of IN N
music NN i
therapy NN i
in IN N
autism NN p
spectrum NN p
disorders NNS p
, , N
this DT N
pragmatic JJ N
trial NN N
sets NNS N
out RP N
to TO N
generate VB N
findings NNS N
that WDT N
will MD N
be VB N
well RB N
generalisable JJ N
to TO N
clinical JJ N
practice NN N
. . N

Addressing VBG N
the DT N
issue NN N
of IN N
dose JJ N
variation NN N
, , N
this DT N
study NN N
's POS N
results NNS N
will MD N
also RB N
provide VB N
information NN N
on IN N
the DT N
relevance NN N
of IN N
session NN o
frequency NN o
for IN N
therapy NN o
outcome NN o
. . o

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN78923965 NNP N
. . N

-DOCSTART- -16508555- O O

Minimal NNP i
clinically RB i
important JJ i
change NN i
for IN N
pain NN o
intensity NN o
, , o
functional JJ o
status NN o
, , N
and CC N
general JJ N
health NN o
status NN o
in IN N
patients NNS p
with IN p
nonspecific JJ p
low JJ p
back RB p
pain NN p
. . p

STUDY NNP N
DESIGN NNP N
Cohort NNP N
study NN N
. . N

OBJECTIVES NNP N
To TO N
estimate VB N
the DT N
Minimal NNP o
Clinically NNP o
Important NNP o
Change NNP o
( ( o
MCIC NNP o
) ) o
of IN N
the DT N
pain NN o
intensity NN o
numerical JJ o
rating NN o
scale NN o
( ( o
PI-NRS NNP o
) ) o
, , N
the DT N
Quebec NNP o
Back NNP o
Pain NNP o
Disability NNP o
Scale NNP o
( ( o
QBPDS NNP o
) ) o
, , N
and CC N
the DT N
Euroqol NNP o
( ( o
EQ NNP o
) ) o
in IN N
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
. . p

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
MCIC NNP N
can MD N
provide VB N
valuable JJ N
information NN N
for IN N
researchers NNS N
, , N
healthcare NN N
providers NNS N
, , N
and CC N
policymakers NNS N
. . N

METHODS NNP N
Data NNP N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
with IN N
442 CD p
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
were VBD p
used VBN p
. . p

The DT N
MCIC NNP i
was VBD N
estimated VBN N
over IN N
a DT N
12-week JJ N
period NN N
, , N
and CC N
three CD N
different JJ N
methods NNS N
were VBD N
used VBN N
: : N
1 CD N
) ) N
mean NN N
change NN N
scores NNS N
, , N
2 CD N
) ) N
minimal NN N
detectable JJ N
change NN N
, , N
and CC N
3 CD N
) ) N
optimal VBD N
cutoff NN N
point NN N
in IN N
receiver NN N
operant JJ N
curves NNS N
. . N

The DT N
global JJ N
perceived JJ N
effect NN N
scale NN N
( ( N
GPE NNP N
) ) N
was VBD N
used VBN N
as IN N
an DT N
external JJ N
criterion NN N
. . N

The DT N
effect NN N
of IN N
initial JJ N
scores NNS N
on IN N
the DT N
MCIC NNP i
was VBD N
also RB N
assessed VBN N
. . N

RESULTS VB N
The DT N
MCIC NNP o
of IN N
the DT N
PI-NRS NNP N
ranged VBD N
from IN N
3.5 CD N
to TO N
4.7 CD N
points NNS N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
2.5 CD N
to TO N
4.5 CD N
points NNS N
in IN N
chronic JJ N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
. . N

The DT N
MCIC NNP o
of IN o
the DT o
QBPDS NNP o
was VBD N
estimated VBN N
between IN N
17.5 CD N
to TO N
32.9 CD N
points NNS N
and CC N
8.5 CD N
to TO N
24.6 CD N
points NNS N
for IN N
( ( p
sub NN p
) ) p
acute NN p
and CC p
chronic JJ p
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
. . p

The DT N
MCIC NNP o
for IN o
the DT o
EQ NNP o
ranged VBD N
from IN N
0.07 CD N
to TO N
0.58 CD N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
0.09 CD N
to TO N
0.28 CD N
in IN N
patients NNS N
with IN N
chronic JJ N
low JJ N
back RB N
pain NN N
. . N

CONCLUSION NNP N
Reporting VBG N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
have VBP N
made VBN N
a DT N
MCIC NNP i
adds VBZ N
to TO N
the DT N
interpretability NN N
of IN N
study NN N
results NNS N
. . N

We PRP N
present VBD N
a DT N
range NN N
of IN N
MCIC NNP i
values NNS N
and CC N
advocate VB N
the DT N
choice NN N
of IN N
a DT N
single JJ N
MCIC NNP i
value NN N
according VBG N
to TO N
the DT N
specific JJ N
context NN N
. . N

-DOCSTART- -19864187- O O

Enhancing VBG N
antiepileptic JJ i
drug NN i
adherence NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Suboptimal JJ N
adherence NN N
to TO N
antiepileptic JJ i
drug NN i
( ( i
AED NNP i
) ) i
treatment NN i
is VBZ N
commonplace NN N
, , N
and CC N
increases VBZ N
the DT N
risk NN N
of IN N
status NN N
epilepticus NN N
and CC N
sudden JJ N
unexplained JJ N
death NN N
in IN N
epilepsy NN N
. . N

This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
designed VBN N
to TO N
demonstrate VB N
whether IN N
an DT N
implementation NN i
intention NN i
intervention NN i
involving VBG N
the DT N
completion NN N
of IN N
a DT N
simple JJ N
self-administered JJ i
questionnaire NN i
linking VBG N
the DT N
intention NN i
of IN i
taking VBG i
medication NN i
with IN i
a DT i
particular JJ i
time NN i
, , i
place NN i
, , i
and CC i
other JJ i
activity NN i
can MD N
improve VB N
AED NNP i
treatment NN N
schedule NN N
adherence NN N
. . N

Of IN N
the DT N
81 CD p
patients NNS p
with IN p
epilepsy NN p
who WP N
were VBD N
randomized VBN N
, , N
69 CD p
completed VBD p
a DT p
1-month JJ p
monitoring NN p
period NN p
with IN N
an DT N
objective JJ N
measure NN N
of IN N
tablet NN N
taking NN N
( ( N
electronic JJ N
registration NN N
of IN N
pill NN N
bottle JJ N
openings NNS N
, , N
Medication NNP N
Event NNP N
Monitoring NNP N
System NNP N
[ NNP N
MEMS NNP N
] NNP N
) ) N
. . N

Intervention NN i
participants NNS N
showed VBD N
improved JJ o
adherence RB o
relative JJ o
to TO o
controls VB o
on IN N
all DT N
three CD N
outcomes NNS N
: : N
doses NNS o
taken VBN o
in IN o
total JJ o
( ( N
93.4 CD N
% NN N
vs. FW N
79.1 CD N
% NN N
) ) N
, , N
days NNS N
on IN N
which WDT N
correct VBP o
dose NN o
was VBD o
taken VBN o
( ( N
88.7 CD N
% NN N
vs. FW N
65.3 CD N
% NN N
) ) N
, , N
and CC N
doses VBZ o
taken VBN o
on IN o
schedule NN o
( ( N
78.8 CD N
% NN N
vs. FW N
55.3 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
implementation NN N
intention NN i
intervention NN i
may MD N
be VB N
an DT N
easy-to-administer JJ N
and CC N
effective JJ N
means NNS N
of IN N
promoting VBG N
AED NNP i
adherence NN N
. . N

-DOCSTART- -19122080- O O

Detection NN N
of IN N
traumatic JJ N
arthrotomy NN N
of IN N
the DT N
knee NN N
using VBG N
the DT N
saline JJ i
solution NN i
load NN i
test NN i
. . i

BACKGROUND IN N
The DT N
saline JJ i
solution NN i
load NN i
test NN i
helps VBZ N
to TO N
determine VB N
if IN N
a DT N
wound NN N
extends VBZ N
into IN N
the DT N
knee NN N
joint NN N
. . N

Little JJ N
is VBZ N
known VBN N
about IN N
the DT N
volume NN N
of IN N
injected JJ N
intra-articular JJ N
saline NN i
solution NN i
that WDT N
is VBZ N
needed VBN N
to TO N
effectively RB N
rule VB N
in IN N
or CC N
rule VB N
out IN N
a DT N
traumatic JJ N
arthrotomy NN N
of IN N
the DT N
knee NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
appropriate JJ o
volume NN o
and CC N
needle JJ o
location NN o
for IN N
the DT N
diagnosis NN N
of IN N
a DT N
traumatic JJ N
knee NN N
arthrotomy NN N
and CC N
to TO N
assess VB N
the DT N
effect NN o
of IN N
associated JJ o
variables NNS o
, , N
including VBG N
knee NN o
circumference NN o
, , o
body NN o
mass NN o
index NN o
, , o
and CC o
sex NN o
. . o

METHODS NNP N
Fifty-six NNP p
consecutive JJ p
patients NNS p
scheduled VBN p
for IN p
knee NN p
arthroscopy NN p
were VBD N
enrolled VBN N
. . N

A DT i
standard JJ i
inferolateral JJ i
arthroscopic NN i
portal NN i
was VBD i
made VBN i
with IN i
a DT i
single JJ i
stab NN i
incision NN i
with IN i
use NN i
of IN i
a DT i
number-11 JJ i
blade NN i
. . i

Injection NN N
sites NNS N
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
superomedial NN N
or CC N
inferomedial JJ N
location NN N
. . N

The DT N
injection NN i
of IN i
normal JJ i
saline JJ i
solution NN i
at IN i
a DT i
rate NN i
of IN i
5 CD i
mL/sec NNS i
through IN i
an DT i
18-gauge JJ i
needle NN i
was VBD N
continued VBN N
while IN N
the DT N
knee NN N
was VBD N
moved VBN N
through IN N
a DT N
range NN N
of IN N
motion NN N
until IN N
fluid NNS N
extravasated VBN N
from IN N
the DT N
iatrogenic JJ N
laceration NN N
. . N

The DT N
volume NN N
of IN N
injected JJ N
fluid NN N
was VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
study NN N
group NN N
included VBD N
thirty-one JJ p
female NN p
patients NNS p
and CC p
twenty-five JJ p
male NN p
patients NNS p
with IN p
a DT p
combined JJ p
average JJ p
age NN p
of IN p
fifty JJ p
years NNS p
and CC p
an DT p
average JJ o
body NN o
mass NN o
index NN o
of IN p
30.9 CD p
. . p

In IN N
order NN N
to TO N
effectively RB N
diagnose VB o
50 CD o
% NN o
of IN o
the DT o
arthrotomies NNS o
, , N
75 CD N
mL NN N
of IN N
injected JJ N
fluid NN N
was VBD N
needed VBN N
; : N
the DT N
volumes NNS o
that WDT o
were VBD o
needed VBN o
in IN o
order NN o
to TO o
effectively RB o
diagnose VB o
75 CD o
% NN o
, , N
90 CD N
% NN N
, , N
95 CD N
% NN N
, , N
and CC N
99 CD N
% NN N
of IN N
the DT N
arthrotomies NNS o
were VBD N
110 CD N
, , N
145 CD N
, , N
155 CD N
, , N
and CC N
175 CD N
mL NN N
, , N
respectively RB N
. . N

The DT N
mean JJ o
volumes NNS o
of IN o
injected JJ o
fluid NN o
needed VBN o
for IN o
a DT o
positive JJ o
result NN o
at IN o
the DT o
inferomedial JJ o
and CC o
superomedial JJ o
needle JJ o
locations NNS o
were VBD N
64.0 CD N
and CC N
95.2 CD N
mL NN N
, , N
respectively RB N
; : N
this DT N
difference NN N
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT o
correlation NN o
between IN o
necessary JJ o
injection NN o
volume NN o
and CC o
sex NN o
, , o
body NN o
mass NN o
index NN o
, , o
or CC o
knee VB o
circumference NN o
. . o

CONCLUSIONS NNP N
In IN N
order NN N
to TO N
detect VB N
95 CD N
% NN N
of IN N
1-cm JJ N
inferolateral JJ N
arthrotomies NNS N
of IN N
the DT N
knee NN N
with IN N
use NN N
of IN N
the DT N
saline JJ N
solution NN N
load NN N
test NN N
, , N
155 CD N
mL NN N
must MD N
be VB N
injected VBN N
. . N

An DT N
inferomedial JJ o
injection NN o
location NN o
requires VBZ N
significantly RB o
less JJR o
fluid NN o
than IN N
a DT N
superomedial JJ o
injection NN o
location NN o
does VBZ N
for IN N
the DT N
diagnosis NN N
of IN N
inferolateral JJ N
arthrotomies NNS N
of IN N
the DT N
knee NN N
. . N

-DOCSTART- -2067508- O O

Tracheal NNP N
soiling VBG N
with IN N
blood NN N
during IN N
intranasal NN i
surgery NN i
-- : i
comparison NN i
of IN N
two CD N
endotracheal JJ N
tubes NNS N
. . N

Sixty NNP p
adult NN p
patients NNS p
, , p
ASA NNP p
Classes NNP p
I PRP p
& CC p
II NNP p
, , N
were VBD N
involved VBN N
in IN N
a DT N
study NN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
Mallinckrodt NNP i
Hi-Lo-Evac NNP i
tube NN i
and CC i
Portex NNP i
blue JJ i
line NN i
tube NN i
in IN N
preventing VBG N
soiling NN N
of IN N
the DT N
lower JJR N
airways NNS N
during IN N
intranasal NN N
surgery NN N
. . N

The DT N
Hi-Lo-Evac JJ N
tube NN N
with IN N
and CC N
without IN N
pack NN N
was VBD N
significantly RB N
more RBR N
effective JJ o
than IN N
the DT N
Portex NNP N
tube NN N
with IN N
pharyngeal JJ N
pack NN N
( ( N
P NNP N
less JJR N
than IN N
0.002 CD N
) ) N
and CC N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
respectively RB N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
when WRB N
the DT N
Hi-Lo-Evac NNP N
tube NN N
was VBD N
used VBN N
with IN N
or CC N
without IN N
a DT N
pack NN N
( ( N
P NNP N
greater JJR N
than IN N
0.2 CD N
) ) N
. . N

The DT N
more RBR N
effective JJ o
protection NN o
of IN o
the DT o
lower JJR o
airways NNS o
by IN N
the DT N
Hi-Lo-Evac NNP N
tube NN N
is VBZ N
attributed VBN N
to TO N
the DT N
facility NN N
of IN N
subglottic JJ N
aspiration NN N
during IN N
surgery NN N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
the DT N
Hi-Lo-Evac NNP N
tube NN N
could MD N
be VB N
used VBN N
with IN N
safety NN o
during IN N
intranasal JJ N
surgery NN N
in IN N
order NN N
to TO N
reduce VB N
postoperative JJ o
morbidity NN o
associated VBN N
with IN N
the DT N
use NN N
of IN N
pharyngeal JJ N
pack NN N
. . N

-DOCSTART- -17201277- O O

[ IN N
The DT N
effects NNS N
of IN N
mexicor NN i
on IN N
thrombocyte JJ o
aggregation NN o
, , o
blood NN o
viscosity NN o
, , o
hemodynamics NNS o
, , N
and CC N
the DT N
clinical JJ N
course NN N
of IN N
coronary JJ p
artery NN p
disease NN p
] NNP p
. . N

The DT N
authors NNS N
analyze VBP N
their PRP$ N
experience NN N
in IN N
the DT N
application NN N
of IN N
mexicor NN i
, , i
a DT i
Russian JJ i
cytoprotector NN i
, , N
in IN N
50patients CD p
with IN p
chronic JJ p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
and CC p
51 CD p
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndrome NN p
. . p

In IN N
additional JJ N
to TO N
cytoprotective JJ N
action NN N
, , N
the DT N
use NN N
of IN N
mexidor NN i
in IN N
complex JJ N
therapy NN N
of IN N
CAD NNP N
lowers VBZ N
the DT N
functional JJ o
activity NN o
of IN o
thrombocytes NNS o
, , N
eliminates VBZ N
high JJ o
blood NN o
viscosity NN o
syndrome NN o
, , N
and CC N
lowers NNS N
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
level NN o
. . o

These DT N
favorable JJ N
changes NNS N
in IN N
hemorheological JJ N
parameters NNS N
improves VBZ N
myocardial JJ o
perfusion NN o
, , N
lowers VBZ N
the DT N
strength NN o
and CC o
frequency NN o
of IN o
coronary JJ o
pain NN o
attacks NNS o
, , N
retards NNS N
postinfarction NN o
left VBD o
ventricular JJ o
remodeling NN o
, , N
and CC N
increases VBZ N
the DT N
quality NN o
of IN o
life NN o
of IN o
patients NNS o
with IN p
various JJ p
CAD NNP p
forms NNS p
. . p

-DOCSTART- -23531317- O O

A DT N
randomized JJ N
cross-over NN N
study NN N
of IN N
inhalation NN N
of IN N
diesel NN N
exhaust NN N
, , N
hematological JJ N
indices NNS N
, , N
and CC N
endothelial JJ N
markers NNS N
in IN N
humans NNS N
. . N

BACKGROUND NNP N
Exposure NNP N
to TO N
traffic-related JJ N
air NN N
pollution NN N
( ( N
TRAP NNP N
) ) N
is VBZ N
considered VBN N
a DT N
trigger NN N
for IN N
acute JJ N
cardiovascular JJ N
events NNS N
. . N

Diesel NNP N
Exhaust NNP N
( ( N
DE NNP N
) ) N
is VBZ N
a DT N
major JJ N
contributor NN N
to TO N
TRAP NNP N
in IN N
the DT N
world NN N
. . N

We PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
DE NNP N
inhalation NN N
on IN N
circulating VBG N
blood NN N
cell NN N
populations NNS N
, , N
hematological JJ N
indices NNS N
, , N
and CC N
systemic JJ N
inflammatory NN N
cytokines NNS N
in IN N
humans NNS N
using VBG N
a DT N
specialized JJ N
facility NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
balanced VBD N
to TO N
order NN N
, , N
17 CD p
metabolic JJ p
syndrome NN p
( ( p
MetS NNP p
) ) p
and CC p
15 CD p
healthy JJ p
subjects NNS p
inhaled VBN i
filtered JJ i
air NN i
( ( i
FA NNP i
) ) i
or CC i
DE NNP i
exposure NN i
in IN p
two-hour JJ p
sessions NNS p
on IN p
different JJ p
days NNS p
with IN p
a DT p
minimum JJ p
2-week JJ p
washout NN p
period NN p
. . p

We PRP N
collected VBD N
blood NN N
pre-exposure NN N
, , N
7 CD N
, , N
and CC N
22 CD N
hours NNS N
after IN N
exposure NN N
initiation NN N
and CC N
measured VBD N
the DT N
complete JJ N
blood NN o
count NN o
and CC o
differential JJ o
. . o

We PRP N
performed VBD N
multiplex JJ N
cytokine NN N
assay NN N
to TO N
measure VB N
the DT N
changes NNS N
in IN N
the DT N
systemic JJ N
inflammatory NN N
cytokines NNS N
, , N
and CC N
endothelial JJ N
adhesion NN N
molecules NNS N
( ( N
n=15 NN N
) ) N
. . N

A DT N
paired JJ N
analysis NN N
compared VBN N
the DT N
effect NN N
of IN N
DE NNP N
and CC N
FA NNP N
exposures NNS N
for IN N
the DT N
change NN N
from IN N
pre-exposure NN N
to TO N
the DT N
subsequent JJ N
time NN N
points NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
increase NN o
in IN o
the DT o
hematocrit NN o
was VBD N
noted VBN N
7 CD N
hrs NNS N
after IN N
DE NNP N
[ FW N
1.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.9 CD N
to TO N
1.9 CD N
% NN N
) ) N
] NN N
compared VBN N
to TO N
FA NNP N
exposure NN N
[ VBZ N
0.5 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
-0.09 NN N
to TO N
1.0 CD N
% NN N
) ) N
; : N
p=0.008 NN N
. . N

The DT N
hemoglobin NN o
levels NNS o
increased VBD o
non-significantly RB N
at IN N
7 CD N
hrs JJ N
post NN N
DE NNP N
[ NNP N
0.3 CD N
gm/dL NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.2 CD N
to TO N
0.5 CD N
gm/dL NN N
) ) N
] VBZ N
versus JJ N
FA NNP N
exposure NN N
[ VBZ N
0.2 CD N
gm/dL NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0 CD N
to TO N
0.3 CD N
gm/dL NN N
) ) N
] NN N
; : N
p=0.06 NN N
. . N

Furthermore RB N
, , N
the DT N
platelet NN o
count NN o
increased VBD o
22 CD N
hrs NN N
after IN N
DE NNP N
exposure NN N
in IN N
healthy JJ N
, , N
but CC N
not RB N
in IN N
MetS NNP N
subjects NNS N
[ FW N
DE NNP N
: : N
16.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
10.2 CD N
to TO N
23 CD N
) ) N
thousand CD N
platelets/mL JJ N
versus NN N
[ NN N
FA NNP N
: : N
3.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
-9.5 NN N
to TO N
16.3 CD N
) ) N
thousand CD N
platelets/mL NN N
) ) N
] NN N
; : N
p=0.04 NN N
. . N

No DT N
DE NNP o
effect NN o
was VBD N
observed VBN N
for IN N
WBC NNP o
, , o
neutrophils RB o
, , o
lymphocytes VBZ o
or CC N
erythrocytes VBZ o
. . o

Using VBG N
the DT N
multiplex JJ N
assay NN N
, , N
small JJ N
borderline NN N
significant JJ N
increases NNS o
in IN o
matrix JJ o
metalloproteinase-9 NN o
, , o
interleukins NNS o
( ( o
IL NNP o
) ) o
-1 NNP o
beta NN o
, , o
6 CD o
and CC o
10 CD o
occurred VBD N
7 CD N
hrs NN N
post NN N
exposure NN N
initiation NN N
, , N
whereas IN N
E-selectin NNP o
, , o
intercellular JJ o
adhesion NN o
molecule-1 NN o
, , N
and CC N
vascular JJ o
cell NN o
adhesion NN o
molecule NN o
-1 NNP o
, , N
and CC N
myeloperoxidase VB o
22 CD o
hrs NN N
post NN N
exposure NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
short-term JJ N
DE NNP N
exposure NN N
results NNS N
in IN N
hemoconcentration NN o
and CC o
thrombocytosis NN o
, , N
which WDT N
are VBP N
important JJ N
determinants NNS N
of IN N
acute JJ N
cardiovascular JJ N
events NNS N
. . N

Multiplex NNP N
assay VBP N
showed VBD N
a DT N
non-significant JJ N
increase NN N
in IN N
IL-1? NNP N
and CC N
IL-6 NNP N
immediately RB N
post NN N
exposure NN N
followed VBN N
by IN N
myeloperoxidase NN N
and CC N
endothelial JJ N
activation NN N
molecules NNS N
. . N

Further NNP N
specific JJ N
assays NNS N
in IN N
a DT N
larger JJR N
population NN N
will MD N
improve VB N
our PRP$ N
understanding NN N
of IN N
the DT N
systemic JJ N
inflammatory JJ N
mechanisms NNS N
following VBG N
acute NN N
exposure NN N
to TO N
TRAP NNP N
. . N

-DOCSTART- -11595000- O O

Safety NN N
and CC N
efficacy NN N
of IN N
PNU-142633 NNP i
, , i
a DT i
selective JJ i
5-HT1D JJ i
agonist NN i
, , N
in IN N
patients NNS p
with IN p
acute JJ p
migraine NN p
. . p

In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
study NN N
, , N
patients NNS p
received VBD N
a DT N
single JJ N
50-mg JJ i
oral JJ i
dose NN i
of IN i
a DT i
5-HT JJ i
( ( i
1D CD i
) ) i
agonist NN i
, , i
PNU-142633 NNP i
( ( i
n JJ i
= NNP i
34 CD i
) ) i
, , i
or CC i
matching VBG i
placebo NN i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
during IN N
an DT N
acute JJ p
migraine NN p
attack NN p
. . p

No DT N
statistically RB N
significant JJ N
treatment NN N
effects NNS N
were VBD N
observed VBN N
at IN N
1 CD N
and CC N
2 CD N
h NN N
after IN N
dosing VBG N
, , N
even RB N
after IN N
stratifying VBG N
by IN N
baseline NN N
headache NN N
intensity NN N
. . N

At IN N
1 CD N
and CC N
2 CD N
h NN N
post-dose JJ N
, , N
8.8 CD N
% NN N
and CC N
29.4 CD N
% NN N
of IN N
the DT N
PNU-142633 NNP i
group NN N
, , N
respectively RB N
, , N
and CC N
8.6 CD N
% NN N
and CC N
40.0 CD N
% NN N
of IN N
the DT N
placebo NN i
group NN N
, , N
respectively RB N
, , N
experienced VBD N
headache NN o
relief NN o
; : o
2.9 CD N
% NN N
and CC N
8.8 CD N
% NN N
of IN N
the DT N
PNU-142633 NNP i
group NN N
and CC N
0 CD N
% NN N
and CC N
5.7 CD N
% NN N
of IN N
the DT N
placebo NN i
group NN N
were VBD N
free JJ o
of IN o
headache NN o
pain NN o
. . o

Adverse JJ o
events NNS o
associated VBN N
with IN N
PNU-142633 NNP i
treatment NN N
included VBD N
chest JJS o
pain NN o
( ( N
two CD N
patients NNS N
) ) N
and CC N
QTc NNP o
prolongation NN o
( ( N
three CD N
patients NNS N
) ) N
. . N

Results NNS N
from IN N
this DT N
study NN N
suggest VBP N
that IN N
anti-migraine JJ N
efficacy NN N
is VBZ N
not RB N
mediated VBN N
solely RB N
through IN N
the DT N
5-HT JJ i
( ( i
1D CD i
) ) i
receptor NN N
subtype NN N
, , N
although IN N
this DT N
receptor NN N
may MD N
contribute VB N
, , N
at IN N
least JJS N
in IN N
part NN N
, , N
to TO N
the DT N
adverse JJ N
cardiovascular JJ N
effects NNS N
observed VBN N
with IN N
5-HT JJ i
agonist JJ i
medications NNS N
. . N

-DOCSTART- -2755692- O O

An DT N
evaluation NN N
of IN N
sealing VBG o
ability NN o
of IN N
calcium NN i
hydroxide NN i
sealers NNS i
. . i

Solid NNP N
core NN N
filling VBG N
material NN N
such JJ N
as IN N
gutta-percha NN N
has VBZ N
been VBN N
used VBN N
to TO N
fill VB N
the DT N
root NN N
canal NN N
in IN N
conjunction NN N
with IN N
a DT N
sealer NN N
to TO N
prevent VB N
apical JJ N
leakage NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
apical JJ i
seal NN i
of IN N
five CD N
different JJ N
root NN i
canal JJ i
sealers NNS i
. . i

Sixty NNP p
roots NNS p
of IN p
maxillary JJ p
central JJ p
incisors NNS p
were VBD N
cleansed VBN N
and CC N
shaped VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
six CD N
groups NNS N
of IN N
ten JJ N
roots NNS N
each DT N
. . N

The DT N
root NN N
canals NNS N
were VBD N
obturated VBN N
with IN N
gutta-percha JJ i
and CC N
one CD N
of IN N
the DT N
sealers NNS i
by IN N
the DT N
lateral-vertical JJ N
condensation NN N
technique NN N
. . N

Groups NNP N
I PRP N
, , N
II NNP N
, , N
III NNP N
, , N
IV NNP N
, , N
and CC N
V NNP N
consisted VBD N
of IN N
roots NNS N
in IN N
which WDT N
the DT N
canal NN i
was VBD i
filled VBN i
with IN i
gutta-percha JJ i
along IN i
with IN i
either DT i
Roth NNP i
's POS i
sealer NN i
, , i
AH26 NNP i
, , i
Sealapex NNP i
, , i
CRCS NNP i
, , i
or CC i
Nogenol NNP i
sealer NN i
, , i
respectively RB i
. . i

Group NNP N
VI NNP N
was VBD N
filled VBN i
with IN i
gutta-percha JJ i
and CC i
without IN i
sealer NN i
to TO i
serve VB i
as IN i
a DT i
control NN i
. . i

The DT N
access NN N
opening NN N
was VBD N
filled VBN N
with IN N
amalgam NN i
. . i

Each DT p
tooth NN p
was VBD N
then RB N
placed VBN N
in IN N
a DT N
capped JJ N
vial NN N
containing VBG N
2 CD N
X JJ N
2 CD N
inch JJ N
gauze NN N
pads NNS N
saturated VBD N
with IN N
distilled JJ N
water NN N
, , N
and CC N
the DT N
sealer NN N
was VBD N
allowed VBN N
to TO N
set VB N
at IN N
37 CD N
degrees NNS N
C NNP N
in IN N
the DT N
humidor NN N
for IN N
48 CD N
hours NNS N
. . N

The DT N
roots NNS N
, , N
except IN N
for IN N
the DT N
apical JJ N
2 CD N
mm NN N
, , N
were VBD N
coated VBN N
with IN N
two CD N
layers NNS N
of IN N
nail JJ N
polish NN N
. . N

The DT N
roots NNS N
were VBD N
stained VBN N
with IN N
india JJ N
ink NN N
, , N
decalcified VBN N
, , N
dehydrated VBN N
, , N
and CC N
then RB N
placed VBN N
in IN N
methylsalicylate NN N
to TO N
make VB N
them PRP N
transparent NN N
. . N

The DT N
leakage NN N
was VBD N
measured VBN N
with IN N
a DT N
filar JJ N
micrometer NN N
eyepiece NN N
under IN N
a DT N
dissecting NN N
microscope NN N
. . N

The DT N
mean JJ o
apical JJ o
leakage NN o
of IN N
six CD N
groups NNS N
was VBD N
as IN N
follows VBZ N
: : N
I PRP N
= VBP N
0.45 CD N
mm NN N
, , N
II NNP N
= VBZ N
0.277 CD N
mm NN N
, , N
III NNP N
= VBZ N
0.343 CD N
mm NN N
, , N
IV NNP N
= VBZ N
0.263 CD N
mm NN N
, , N
V NNP N
= VBZ N
0.336 CD N
mm NN N
, , N
and CC N
VI NNP N
= NNP N
2.310 CD N
mm NN N
. . N

Results NNP N
showed VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
apical JJ N
seal NN N
produced VBN N
by IN N
gutta-percha NN N
and CC N
the DT N
tested JJ N
root NN N
canal JJ N
sealers NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -20068494- O O

Monitoring VBG N
acute JJ N
effects NNS N
on IN N
athletic JJ N
performance NN N
with IN N
mixed JJ N
linear JJ N
modeling NN N
. . N

UNLABELLED IN N
There EX N
is VBZ N
a DT N
need NN N
for IN N
a DT N
sophisticated JJ N
approach NN N
to TO N
track VB N
athletic JJ N
performance NN N
and CC N
to TO N
quantify VB N
factors NNS N
affecting VBG N
it PRP N
in IN N
practical JJ N
settings NNS N
. . N

PURPOSE NNP N
To TO N
demonstrate VB N
the DT N
application NN N
of IN N
mixed JJ N
linear JJ N
modeling VBG N
for IN N
monitoring VBG N
athletic JJ N
performance NN N
. . N

METHODS NNP N
Elite NNP p
sprint NN p
and CC p
middle-distance NN p
swimmers NNS p
( ( p
three CD p
females NNS p
and CC p
six CD p
males NNS p
; : p
aged VBN p
21-26 JJ p
yr NN p
) ) p
performed VBD p
6-13 JJ p
time NN p
trials NNS p
in IN p
training NN p
and CC p
competition NN p
in IN p
the DT p
9 CD p
wk NN p
before IN p
and CC p
including VBG p
Olympic-qualifying JJ p
trials NNS p
, , p
all DT p
in IN p
their PRP$ p
specialty NN p
event NN p
. . p

We PRP N
included VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
diet-controlled JJ i
crossover NN i
intervention NN i
, , N
in IN N
which WDT N
the DT N
swimmers NNS N
consumed VBN N
caffeine NN i
( ( N
5 CD N
mg NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
body NN N
mass NN N
) ) N
or CC N
placebo NN i
. . i

The DT N
swimmers NNS N
also RB N
knowingly RB N
consumed VBD N
varying VBG N
doses NNS N
of IN N
caffeine NN i
in IN N
some DT N
time NN N
trials NNS N
. . N

We PRP N
used VBD N
mixed JJ N
linear JJ N
modeling NN N
of IN N
log-transformed JJ N
swim JJ N
time NN N
to TO N
quantify VB N
effects NNS o
on IN o
performance NN o
in IN N
training VBG N
versus NN N
competition NN N
, , N
in IN N
morning NN N
versus NN N
evening NN N
swims NNS N
, , N
and CC N
with IN N
use NN N
of IN N
caffeine NN N
. . N

Predictor NN N
variables NNS N
were VBD N
coded VBN N
as IN N
0 CD N
or CC N
1 CD N
to TO N
represent VB N
absence NN N
or CC N
presence NN N
, , N
respectively RB N
, , N
of IN N
each DT N
condition NN N
and CC N
were VBD N
included VBN N
as IN N
fixed JJ N
effects NNS N
. . N

The DT N
date NN N
of IN N
each DT N
performance NN N
test NN N
was VBD N
included VBN N
as IN N
a DT N
continuous JJ N
linear JJ N
fixed VBN N
effect NN N
and CC N
interacted VBN N
with IN N
the DT N
random NN N
effect NN N
for IN N
the DT N
athlete NN N
to TO N
represent VB N
individual JJ N
differences NNS N
in IN N
linear JJ N
trends NNS N
in IN N
performance NN N
. . N

RESULTS NNP N
Most JJS N
effects NNS o
were VBD N
clear JJ N
, , N
owing VBG N
to TO N
the DT N
high JJ N
reliability NN N
of IN N
performance NN o
times NNS o
in IN o
training NN o
and CC o
competition NN o
( ( N
typical JJ N
errors NNS N
of IN N
0.9 CD N
% NN N
and CC N
0.8 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Performance NN o
time NN o
improved VBN N
linearly RB N
by IN N
0.8 CD N
% NN N
per IN N
4 CD N
wk NN N
. . N

The DT N
swimmers NNS N
performed VBD o
substantially RB o
better RBR o
in IN N
evenings NNS N
versus JJ N
mornings NNS N
and CC N
in IN N
competition NN N
versus IN N
training NN N
. . N

A DT N
100-mg JJ N
dose NN N
of IN N
caffeine NN N
enhanced VBN N
performance NN o
in IN o
training NN o
and CC o
competition NN o
by IN N
approximately RB N
1.3 CD N
% NN N
. . N

There EX N
were VBD N
substantial JJ N
but CC N
unclear JJ N
individual JJ N
responses NNS N
to TO N
training NN N
and CC N
caffeine NN N
( ( N
SD NNP N
of IN N
0.3 CD N
% NN N
and CC N
0.8 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Mixed NNP N
linear IN N
modeling VBG N
can MD N
be VB N
applied VBN N
successfully RB N
to TO N
monitor VB N
factors NNS N
affecting VBG N
performance NN N
in IN N
a DT N
squad NN N
of IN N
elite JJ p
athletes NNS p
. . p

-DOCSTART- -21142736- O O

Effects NNS N
of IN N
the DT N
810-nm JJ i
diode NN i
laser NN i
on IN N
hair NN N
and CC N
on IN N
the DT N
biophysical JJ N
properties NNS N
of IN N
skin NN N
. . N

INTRODUCTION NNP N
Laser NNP i
therapy NN i
is VBZ N
clinically RB N
effective JJ N
in IN N
hair NN N
removal NN N
; : N
however RB N
, , N
despite IN N
the DT N
development NN N
of IN N
various JJ N
strategies NNS N
, , N
laser NN N
procedures NNS N
still RB N
present VBP N
a DT N
risk NN N
of IN N
adverse JJ N
effects NNS N
due JJ N
to TO N
the DT N
overheating NN N
of IN N
the DT N
skin NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
810-nm JJ i
diode NN i
laser RBR i
treatment NN i
on IN N
hair NN N
and CC N
on IN N
the DT N
biophysical JJ N
properties NNS N
of IN N
skin NN N
by IN N
using VBG N
various JJ N
non-invasive JJ i
techniques NNS i
on IN N
various JJ N
parameters NNS N
, , N
including VBG N
hair NN N
analysis NN N
, , N
surface NN N
color NN N
changes NNS N
, , N
integrity NN N
of IN N
skin NN N
barrier NN N
, , N
sebum JJ N
production NN N
rate NN N
and CC N
pH NN N
level NN N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
right-left JJ N
comparison NN N
study NN N
, , N
35 CD p
women NNS p
with IN p
axillary JJ p
hair NN p
received VBD N
single-session JJ i
diode NN i
laser NN i
therapy NN i
. . i

Hair NNP N
analysis NN N
and CC N
biophysical JJ N
properties NNS N
of IN N
the DT N
skin NN N
were VBD N
assessed VBN N
before IN N
treatment NN N
and CC N
at IN N
weeks NNS N
2 CD N
, , N
4 CD N
and CC N
6 CD N
after IN N
the DT N
therapy NN N
. . N

RESULTS NNP N
Hair NNP o
density NN o
and CC o
thicknesses NNS o
statistically RB o
significantly RB o
decreased VBN o
after IN N
the DT N
first JJ N
post-treatment JJ N
evaluation NN N
. . N

Regarding VBG N
comparison NN N
of IN N
the DT N
biophysical JJ N
properties NNS N
of IN N
the DT N
skin NN N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
assessments NNS N
, , N
except IN N
for IN N
the DT N
increase NN N
determined VBD N
during IN N
the DT N
second JJ N
week NN N
in IN N
the DT N
erythema NN o
index NN o
in IN N
the DT N
laser-treated JJ N
areas NNS N
. . N

CONCLUSION VB N
The DT N
findings NNS N
of IN N
this DT N
study NN N
showed VBD N
that IN N
the DT N
diode NN i
laser NN i
can MD i
perform VB N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
hair NN o
amount NN o
without IN N
significant JJ N
epidermal JJ N
damage NN N
, , N
at IN N
least JJS N
for IN N
a DT N
short JJ N
period NN N
. . N

-DOCSTART- -7755996- O O

A DT N
prospective JJ N
comparison NN N
of IN N
the DT N
multiplane NN i
probe NN i
with IN N
the DT N
biplane NN i
probe NN i
in IN N
structure NN o
visualization NN o
and CC o
Doppler NNP o
examination NN o
during IN p
transesophageal JJ p
echocardiography NN p
. . p

To TO N
compare VB N
the DT N
imaging JJ o
capability NN o
of IN N
the DT N
multiplane NN i
probe NN i
with IN N
that DT N
of IN N
the DT N
biplane NN i
probe NN i
, , N
317 CD p
consecutive JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
undergo VB N
transesophageal JJ i
echocardiography NN i
with IN i
either DT i
probe NN i
. . i

Images NNS N
of IN N
24 CD N
cardiac JJ N
structures NNS N
and CC N
nine CD o
Doppler NNP o
signals NNS o
were VBD N
graded VBN N
prospectively RB N
on IN N
a DT N
three-grade JJ N
system NN N
. . N

Both DT N
multiplane NN i
and CC i
biplane NN i
probes NNS i
provided VBD N
excellent JJ o
visualization NN o
of IN o
cardiac JJ o
structures NNS o
and CC N
Doppler NNP o
signals NNS o
, , N
but CC N
the DT N
multiplane NN i
probe NN i
was VBD N
significantly RB N
superior JJ N
to TO N
the DT N
biplane NN N
probe NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
number NN o
of IN o
attempts NNS o
at IN o
esophageal JJ o
intubation NN o
, , o
the DT o
amount NN o
of IN o
sedation NN o
used VBN o
, , o
and CC o
the DT o
examination NN o
time NN o
. . o

The DT N
number NN o
of IN o
complications NNS o
was VBD o
similar JJ o
, , N
although IN N
all DT N
failed VBD o
intubations NNS o
occurred VBD N
with IN N
the DT N
multiplane NN i
probe NN i
. . i

-DOCSTART- -3957541- O O

An DT N
analysis NN N
of IN N
the DT N
mortality NN N
effect NN N
in IN N
a DT N
breast NN i
cancer NN i
screening VBG i
study NN N
. . N

In IN N
order NN N
to TO N
better JJR N
understand VB N
the DT N
effect NN N
of IN N
breast NN p
cancer NN p
screening VBG N
on IN N
mortality NN N
, , N
we PRP N
use VBP N
the DT N
theory NN N
of IN N
competing VBG N
risks NNS N
to TO N
analyse VB N
deaths NNS N
from IN N
the DT N
long-term JJ p
follow-up NN p
of IN p
the DT p
HIP NNP i
breast NN i
cancer NN i
screening VBG i
trial NN i
. . i

We PRP N
conclude VBP N
that IN N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
of IN N
the DT N
breast NN p
cancer NN p
cases NNS p
detected VBD N
early RB N
as IN N
a DT N
result NN N
of IN N
screening VBG i
realized VBN N
a DT N
benefit NN N
in IN N
terms NNS N
of IN N
elimination NN N
of IN N
the DT N
risk NN N
of IN N
breast NN o
cancer NN o
mortality NN o
. . o

Breast NNP i
cancer NN i
screening VBG i
appears VBZ N
not RB N
to TO N
affect VB N
the DT N
rate NN o
of IN o
mortality NN o
from IN N
causes NNS N
of IN N
death NN N
other JJ N
than IN N
breast JJ N
cancer NN N
. . N

Methodologically RB N
, , N
we PRP N
demonstrate VBP N
the DT N
importance NN N
of IN N
analysing VBG N
mortality NN N
separately RB N
for IN N
the DT N
breast NN p
cancer NN p
cases NNS N
as RB N
well RB N
as IN N
for IN N
the DT N
entire JJ p
population NN p
in IN N
a DT N
trial NN N
. . N

-DOCSTART- -15324531- O O

Oxaprozin NNP i
versus NN N
diclofenac NN i
in IN N
NSAID-refractory NNP N
periarthritis NN N
pain NN N
of IN N
the DT N
shoulder NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
oxaprozin NN i
in IN N
comparison NN N
with IN N
diclofenac NN i
in IN N
patients NNS p
with IN p
periarthritis NN p
pain NN p
of IN p
the DT p
shoulder NN p
previously RB p
unsuccessfully RB p
treated VBN p
with IN p
nonsteroidal JJ p
anti-inflammatory JJ p
drugs NNS p
other JJ p
than IN p
diclofenac NNS p
and CC p
oxaprozin NN p
. . p

METHODS NNP N
In IN N
this DT N
open JJ N
, , N
multicentre NN N
, , N
randomised VBN N
, , N
controlled VBN N
study NN N
, , N
eligible JJ p
patients NNS p
with IN p
periarthritis NN p
of IN p
the DT p
shoulder NN p
were VBD N
randomised VBN N
to TO N
receive VB i
either RB i
oxaprozin JJ i
1200 CD i
mg NN i
once RB i
daily JJ i
( ( i
n JJ i
= NNP i
49 CD i
) ) i
or CC i
diclofenac $ i
50 CD i
mg NN i
three CD i
times NNS i
daily RB i
( ( i
n JJ i
= NNP i
47 CD i
) ) i
. . i

The DT N
treatment NN N
period NN N
was VBD N
15 CD N
+/- JJ N
1 CD N
days NNS N
. . N

The DT N
study NN N
was VBD N
planned VBN N
on IN N
a DT N
hypothesis NN N
of IN N
equivalence NN N
between IN N
the DT N
two CD N
study NN N
drugs NNS N
. . N

The DT N
primary JJ N
study NN N
endpoint NN N
was VBD N
the DT N
change NN o
from IN o
baseline NN o
at IN o
day NN o
15 CD o
in IN o
the DT o
patient-assessed JJ o
shoulder NN o
pain NN o
score NN o
. . o

Secondary JJ N
efficacy NN N
variables NNS N
included VBD N
investigator-assessed JJ o
shoulder NN o
function NN o
, , o
patient-assessed JJ o
quality NN o
of IN o
life NN o
on IN o
the DT o
Short-Form-36 NNP o
( ( o
SF-36 NNP o
) ) o
Acute NNP o
Health NNP o
Survey NNP o
and CC o
both DT o
patients NNS o
' POS o
and CC o
investigators NNS o
' POS o
overall JJ o
assessment NN o
of IN o
efficacy NN o
. . o

RESULTS NNP N
At IN N
day NN N
15 CD N
, , N
the DT N
mean NN N
changes NNS N
in IN N
shoulder NN o
pain NN o
score NN o
from IN N
baseline NN N
in IN N
the DT N
oxaprozin NN i
and CC N
diclofenac NN i
groups NNS N
were VBD N
-5.85 JJ N
+/- JJ N
SD NNP N
4.62 CD N
and CC N
-5.54 JJ N
+/- JJ N
SD NNP N
4.41 CD N
, , N
respectively RB N
. . N

The DT N
difference NN o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
, , N
confirming VBG N
the DT N
hypothesis NN N
of IN N
the DT N
study NN N
that IN N
oxaprozin NN i
is VBZ N
as RB N
effective JJ N
as IN N
diclofenac NN i
. . i

Investigator-assessed JJ o
shoulder NN o
function NN o
improved VBN N
in IN N
both DT N
groups NNS N
but CC N
more JJR N
so RB N
in IN N
the DT N
oxaprozin NN N
group NN N
( ( N
p JJ N
= RB N
0.028 CD N
at IN N
day NN N
15 CD N
) ) N
. . N

Quality NN o
of IN o
life NN o
as IN o
measured VBN o
by IN o
SF-36 NNP o
total JJ o
score NN o
was VBD N
also RB N
improved VBN N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
with IN N
a DT N
trend NN N
toward IN N
greater JJR N
improvement NN N
in IN N
the DT N
oxaprozin NN i
group NN N
. . N

Furthermore RB N
, , N
a DT N
significantly RB N
more RBR N
favourable JJ N
effect NN o
on IN N
the DT N
SF-36 NNP o
'mental NNP o
health NN o
' '' o
item NN o
was VBD N
observed VBN N
in IN N
oxaprozin NN N
compared VBN N
with IN N
diclofenac-treated JJ N
patients NNS N
at IN N
day NN N
15 CD N
( ( N
p NN N
= RB N
0.0202 CD N
) ) N
. . N

As IN N
assessed VBN N
by IN N
investigators NNS N
, , N
the DT N
overall JJ N
efficacy NN N
of IN N
oxaprozin NN i
was VBD N
superior JJ N
to TO N
that DT N
for IN N
diclofenac NN i
at IN N
visit NN N
3 CD N
( ( N
8 CD N
+/- JJ N
1 CD N
days NNS N
) ) N
( ( N
p JJ N
= NNP N
0.0067 CD N
) ) N
. . N

Patients NNS p
also RB p
assessed VBD p
the DT p
overall JJ p
efficacy NN o
of IN p
oxaprozin NN i
as IN p
superior JJ p
to TO p
that DT p
of IN p
diclofenac NN i
at IN N
visits NNS N
3 CD N
( ( N
8 CD N
+/- JJ N
1 CD N
days NNS N
) ) N
( ( N
p JJ N
= NNP N
0.0235 CD N
) ) N
and CC N
4 CD N
( ( N
15 CD N
+/- JJ N
1 CD N
days NNS N
) ) N
( ( N
p JJ N
= NNP N
0.0272 CD N
) ) N
. . N

Only RB N
six CD N
adverse JJ o
events NNS o
, , N
all DT N
of IN N
which WDT N
were VBD N
mild NNS N
or CC N
moderate VB N
in IN N
intensity NN N
and CC N
occurred VBD N
in IN N
four CD N
diclofenac NN i
recipients NNS N
, , N
were VBD N
observed VBN N
in IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
As IN N
expected VBN N
, , N
once-daily JJ N
oxaprozin NN i
proved VBD N
to TO N
be VB N
as RB N
effective JJ N
as IN N
diclofenac NN i
three CD N
times NNS N
daily RB N
in IN N
reducing VBG N
the DT N
primary JJ N
efficacy NN N
variable NN N
of IN N
patient-assessed JJ o
shoulder NN o
pain NN o
score NN o
in IN N
patients NNS p
with IN p
periarthritis NN p
of IN p
the DT p
shoulder NN p
refractory NN p
to TO N
previous JJ N
treatments NNS N
with IN N
other JJ N
NSAIDs NNP N
. . N

Oxaprozin NNP i
was VBD N
shown VBN N
to TO N
be VB N
superior JJ N
to TO N
diclofenac VB i
in IN N
improving VBG N
shoulder NN o
function NN o
and CC N
was VBD N
considered VBN N
by IN N
investigators NNS N
and CC N
patients NNS N
to TO N
have VB N
greater JJR N
overall JJ N
efficacy NN N
than IN N
diclofenac NN i
. . i

In IN N
addition NN N
, , N
oxaprozin NN i
showed VBD N
a DT N
trend NN N
toward IN N
superior JJ N
results NNS N
in IN N
improving VBG N
patients NNS N
' POS N
quality NN o
of IN o
life NN o
compared VBN N
with IN N
diclofenac NN i
. . i

A DT N
trend NN N
towards VBZ N
better JJR N
tolerability NN o
results NNS o
for IN N
oxaprozin JJ i
compared VBN N
with IN N
diclofenac NN i
was VBD N
also RB N
noted VBN N
. . N

-DOCSTART- -10651597- O O

Effectiveness NN N
of IN N
manual JJ i
physical JJ i
therapy NN i
and CC i
exercise NN i
in IN N
osteoarthritis NN p
of IN p
the DT p
knee NN p
. . p

A DT N
randomized JJ N
, , N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Few JJ N
investigations NNS N
include VBP N
both DT N
subjective JJ N
and CC N
objective JJ N
measurements NNS N
of IN N
the DT N
effectiveness NN N
of IN N
treatments NNS N
for IN N
osteoarthritis NN p
of IN p
the DT p
knee NN p
. . p

Beneficial JJ N
interventions NNS N
may MD N
decrease VB N
the DT N
disability NN o
associated VBN N
with IN N
osteoarthritis NN N
and CC N
the DT N
need NN N
for IN N
more RBR N
invasive JJ N
treatments NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
physical JJ i
therapy NN i
for IN N
osteoarthritis NN N
of IN N
the DT N
knee NN N
, , N
applied VBN N
by IN N
experienced JJ N
physical JJ N
therapists NNS N
with IN N
formal JJ N
training NN N
in IN N
manual JJ N
therapy NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
Outpatient NNP p
physical JJ p
therapy NN p
department NN p
of IN p
a DT p
large JJ p
military JJ p
medical JJ p
center NN p
. . p

PATIENTS CC N
83 CD p
patients NNS p
with IN p
osteoarthritis NN p
of IN p
the DT p
knee NN p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
treatment NN i
( ( p
n JJ p
= VBZ p
42 CD p
; : p
15 CD p
men NNS p
and CC p
27 CD p
women NNS p
[ JJ p
mean JJ p
age NN p
, , p
60 CD p
+/- JJ p
11 CD p
years NNS p
] RB p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= VBZ p
41 CD p
; : p
19 CD p
men NNS p
and CC p
22 CD p
women NNS p
[ JJ p
mean JJ p
age NN p
, , p
62 CD p
+/- JJ p
10 CD p
years NNS p
] RB p
) ) p
. . p

INTERVENTION NNP N
The DT N
treatment NN p
group NN p
received VBD N
manual JJ i
therapy NN i
, , N
applied VBN N
to TO N
the DT N
knee NN N
as RB N
well RB N
as IN N
to TO N
the DT N
lumbar NN N
spine NN N
, , N
hip NN N
, , N
and CC N
ankle RB N
as IN N
required VBN N
, , N
and CC N
performed VBD N
a DT N
standardized JJ i
knee NN i
exercise NN i
program NN i
in IN N
the DT N
clinic NN N
and CC N
at IN N
home NN N
. . N

The DT N
placebo NN i
group NN p
had VBD N
subtherapeutic JJ i
ultrasound NN i
to TO N
the DT N
knee NN N
at IN N
an DT N
intensity NN N
of IN N
0.1 CD N
W/cm2 NNP N
with IN N
a DT N
10 CD N
% NN N
pulsed JJ N
mode NN N
. . N

Both DT N
groups NNS N
were VBD N
treated VBN N
at IN N
the DT N
clinic JJ N
twice JJ N
weekly NN N
for IN N
4 CD N
weeks NNS N
. . N

MEASUREMENTS NNP N
Distance NNP o
walked VBD o
in IN o
6 CD o
minutes NNS o
and CC o
sum NN o
of IN o
the DT o
function NN o
, , o
pain NN o
, , o
and CC o
stiffness JJ o
subscores NNS o
of IN o
the DT o
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
. . o

A DT N
tester NN N
who WP N
was VBD N
blinded VBN N
to TO N
group NN N
assignment NN N
made VBD N
group NN N
comparisons NNS N
at IN N
the DT N
initial JJ N
visit NN N
( ( N
before IN N
initiation NN N
of IN N
treatment NN N
) ) N
, , N
4 CD N
weeks NNS N
, , N
8 CD N
weeks NNS N
, , N
and CC N
1 CD N
year NN N
. . N

RESULTS NNP N
Clinically NNP N
and CC N
statistically RB N
significant JJ N
improvements NNS N
in IN N
6-minute JJ o
walk NN o
distance NN o
and CC o
WOMAC NNP o
score NN o
at IN N
4 CD N
weeks NNS N
and CC N
8 CD N
weeks NNS N
were VBD N
seen VBN N
in IN N
the DT N
treatment NN i
group NN N
but CC N
not RB N
the DT N
placebo NN i
group NN N
. . N

By IN N
8 CD N
weeks NNS N
, , N
average JJ N
6-minute JJ o
walk NN o
distances NNS o
had VBD N
improved VBN N
by IN N
13.1 CD N
% NN N
and CC N
WOMAC NNP o
scores NNS o
had VBD N
improved VBN N
by IN N
55.8 CD N
% NN N
over IN N
baseline NN N
values NNS N
in IN N
the DT N
treatment NN i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
controlling VBG N
for IN N
potential JJ N
confounding NN N
variables NNS N
, , N
the DT N
average JJ N
distance NN o
walked VBD o
in IN o
6 CD o
minutes NNS o
at IN N
8 CD N
weeks NNS N
among IN N
patients NNS N
in IN N
the DT N
treatment NN i
group NN N
was VBD N
170 CD N
m NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
71 CD N
to TO N
270 CD N
m NN N
) ) N
more JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN i
group NN N
and CC N
the DT N
average JJ N
WOMAC JJ o
scores NNS o
were VBD N
599 CD N
mm NN N
higher JJR N
( ( N
95 CD N
% NN N
CI NNP N
, , N
197 CD N
to TO N
1002 CD N
mm NN N
) ) N
. . N

At IN N
1 CD N
year NN N
, , N
patients NNS N
in IN N
the DT N
treatment NN i
group NN N
had VBD N
clinically RB N
and CC N
statistically RB N
significant JJ N
gains NNS N
over IN N
baseline JJ o
WOMAC NNP o
scores NNS o
and CC o
walking VBG o
distance NN o
; : o
20 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
and CC N
5 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
treatment NN i
group NN N
had VBD N
undergone JJ N
knee NN o
arthroplasty NN o
. . o

CONCLUSIONS VB N
A DT N
combination NN N
of IN N
manual JJ i
physical JJ i
therapy NN i
and CC i
supervised VBD i
exercise NN i
yields NNS N
functional JJ o
benefits NNS o
for IN N
patients NNS p
with IN p
osteoarthritis NN p
of IN p
the DT p
knee NN p
and CC N
may MD N
delay VB N
or CC N
prevent VB N
the DT N
need NN N
for IN N
surgical JJ o
intervention NN o
. . o

-DOCSTART- -20673857- O O

Clinical JJ i
massage NN i
and CC i
modified VBD i
Proprioceptive NNP i
Neuromuscular NNP i
Facilitation NNP i
stretching VBG i
in IN N
males NNS p
with IN p
latent JJ p
myofascial JJ p
trigger NN p
points NNS p
. . p

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
immediate JJ N
effects NNS N
of IN N
modified JJ i
Proprioceptive NNP i
Neuromuscular NNP i
Facilitation NNP i
( ( i
PNF NNP i
) ) i
stretching NN i
( ( N
group NN N
I PRP N
) ) N
versus VBP N
Myofascial JJ i
Trigger NNP i
Point NNP i
( ( i
MTrP NNP i
) ) i
therapy NN i
plus CC i
modified JJ i
PNF NNP i
stretching NN i
( ( N
group NN N
II NNP N
) ) N
in IN N
comparison NN N
to TO N
a DT N
control NN N
group NN N
receiving VBG N
no DT i
treatment NN i
. . i

DESIGN NNP N
Randomized NNP N
, , N
assessor-blind NN N
, , N
( ( N
3 CD N
x RB N
4 CD N
) ) N
mixed-model NN N
repeated VBN N
measures NNS N
. . N

SETTING NNP N
University NNP N
laboratory NN N
. . N

PARTICIPANTS NNP N
Thirty NNP p
physically RB p
active JJ p
males NNS p
with IN p
tight JJ p
hamstrings NNS p
and CC p
at IN p
least JJS p
one CD p
latent NN p
MTrP NNP p
on IN p
muscles NNS p
innervated VBN p
by IN p
the DT p
lumbosacral JJ p
, , p
sciatic JJ p
, , p
tibial JJ p
and CC p
common JJ p
peroneal JJ p
nerves NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Knee NNP o
range NN o
of IN o
motion NN o
( ( o
ROM NNP o
) ) o
, , o
stretch JJ o
perception NN o
, , o
pressure NN o
pain NN o
threshold NN o
( ( o
PPT NNP o
) ) o
and CC o
subjective JJ o
pain NN o
intensity NN o
. . o

Outcomes CC N
were VBD N
evaluated VBN N
at IN N
baseline NN N
, , N
immediately RB N
after IN N
treatment NN N
, , N
at IN N
10 CD N
and CC N
30 CD N
min NN N
. . N

RESULTS NNP N
Significant NNP N
changes VBZ N
over IN N
time NN N
occurred VBD N
for IN N
group NN N
II NNP N
in IN N
all DT N
outcomes NNS N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.001 CD N
) ) N
. . N

Group NNP N
II NNP N
also RB N
showed VBD N
lower JJR o
pain NN o
intensity NN o
scores NNS o
than IN N
group NN N
I PRP N
immediately RB N
post-treatment NN N
( ( N
p JJ N
= NNP N
0.045 CD N
) ) N
and CC N
a DT N
strong JJ N
clinical JJ o
effect NN o
over IN N
group NN N
I PRP N
in IN N
ROM NNP o
at IN N
all DT N
follow-ups NNS N
( ( N
effect NN N
sizes VBZ N
= JJ N
0.9-1.0 JJ N
, , N
p JJ N
< NN N
or CC N
= VB N
0.05 CD N
) ) N
. . N

Other JJ N
differences NNS N
were VBD N
found VBN N
between IN N
both DT N
stretching VBG N
groups NNS N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
indicate VBP N
immediate JJ N
pre- JJ N
to TO N
post-treatment JJ N
benefits NNS N
from IN N
MTrP NNP i
therapy NN i
combined VBN N
with IN N
modified JJ i
PNF NNP i
stretching NN i
in IN N
young JJ p
and CC p
physically RB p
active JJ p
males NNS p
with IN N
latent JJ N
MTrPs NNP N
. . N

-DOCSTART- -2868645- O O

Comparison NNP N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
esmolol NN i
, , N
a DT N
short-acting JJ N
beta NN N
blocker NN N
, , N
with IN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
supraventricular JJ p
tachyarrhythmias NN p
. . p

The DT N
Esmolol NNP i
vs NN i
Placebo NNP i
Multicenter NNP N
Study NNP N
Group NNP N
. . N

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
esmolol NN i
, , N
a DT N
short-acting JJ N
intravenous JJ N
beta-adrenergic-blocking JJ N
agent NN N
, , N
and CC N
placebo NN i
were VBD N
compared VBN N
in IN N
patients NNS p
with IN p
supraventricular JJ p
tachyarrhythmias NN p
( ( p
heart NN p
rate NN p
greater JJR p
than IN p
120 CD p
bpm NN p
) ) p
in IN N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
partial-crossover JJ N
study NN N
. . N

Seventy-one CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
esmolol NN i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
as IN N
initial JJ N
treatment NN N
. . N

Therapeutic JJ N
failures NNS N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
other JJ N
study NN N
medication NN N
. . N

Therapeutic JJ o
response NN o
was VBD N
defined VBN N
as IN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
20 CD N
% NN N
reduction NN N
in IN N
heart NN o
rate NN o
, , o
heart NN o
rate NN o
less JJR o
than IN o
100 CD o
bpm NN o
, , o
or CC o
conversion NN o
to TO o
normal JJ o
sinus NN o
rhythm NN o
. . o

The DT o
therapeutic JJ o
response NN o
to TO N
esmolol VB i
during IN N
the DT N
initial JJ N
treatment NN N
period NN N
( ( N
72 CD N
% NN N
) ) N
was VBD N
similar JJ N
to TO N
that DT N
obtained VBN N
when WRB N
esmolol NN N
was VBD N
given VBN N
as IN N
a DT N
second JJ N
agent NN N
. . N

The DT N
average JJ N
esmolol JJ N
dosage NN N
producing VBG N
a DT N
therapeutic JJ N
response NN N
was VBD N
97.5 CD N
micrograms/kg/min NN N
. . N

Four CD N
patients NNS N
( ( N
6 CD N
% NN N
) ) N
converted VBD N
to TO N
normal JJ o
sinus JJ o
rhythm NN o
during IN N
esmolol JJ N
infusion NN N
. . N

In IN N
the DT N
majority NN N
of IN N
patients NNS N
( ( N
80 CD N
% NN N
) ) N
, , N
therapeutic JJ o
response NN o
was VBD N
lost VBN N
within IN N
30 CD N
minutes NNS N
following VBG N
discontinuation NN N
of IN N
esmolol JJ i
infusion NN N
, , N
a DT N
finding JJ N
indicative NN N
of IN N
rapid JJ N
reversal NN N
of IN N
beta-adrenoceptor NN N
blockade NN N
. . N

The DT N
most RBS N
prevalent JJ N
adverse JJ o
effect NN o
during IN N
esmolol JJ i
infusion NN N
was VBD N
hypotension NN o
which WDT N
occurred VBD N
in IN N
eight CD N
patients NNS N
( ( N
12 CD N
% NN N
) ) N
. . N

Hypotension NN o
and CC o
associated VBN o
symptoms NNS o
resolved VBD N
within IN N
30 CD N
minutes NNS N
after IN N
discontinuation NN N
of IN N
esmolol JJ i
infusion NN N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
the DT N
short JJ N
duration NN N
of IN N
action NN N
of IN N
esmolol NN i
( ( N
elimination JJ N
half-life NN N
of IN N
9.2 CD N
minutes NNS N
) ) N
. . N

-DOCSTART- -8179563- O O

Ketorolac NNP i
versus NN i
fentanyl NN i
for IN N
gynaecological JJ p
day-case NN p
surgery NN p
. . p

The DT N
effectiveness NN N
of IN N
fentanyl NN i
and CC N
ketorolac NN i
in IN N
providing VBG N
analgesia NN N
for IN N
day-case JJ p
gynaecological JJ p
procedures NNS p
was VBD p
evaluated VBN p
in IN p
55 CD p
healthy JJ p
volunteers NNS p
in IN p
a DT p
single JJ p
blinded JJ p
fashion NN p
. . p

Fentanyl NNP i
( ( N
1 CD N
mcg/kg RB N
iv NN N
) ) N
and CC N
ketorolac NN i
( ( N
30 CD N
mg RB N
im NN N
) ) N
were VBD N
administered VBN N
immediately RB N
following VBG N
induction NN N
of IN N
anaesthesia NN N
. . N

Anaesthesia NNP N
was VBD N
standardized VBN N
with IN N
propofol NN i
, , i
nitrous JJ i
oxide NN i
and CC i
enflurane NN i
. . i

Outcome NNP N
variables NNS N
assessed VBN N
were VBD N
pain RB o
, , o
additional JJ o
analgesic NN o
requirements NNS o
, , o
and CC o
incidence NN o
of IN o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
. . o

All DT N
variables NNS N
were VBD N
recorded VBN N
at IN N
15 CD N
minutes NNS N
, , N
2 CD N
hours NNS N
and CC N
24 CD N
hours NNS N
postoperatively RB N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
with IN N
respect NN N
to TO N
any DT N
of IN N
the DT N
measured JJ N
variables NNS N
. . N

Both DT N
drugs NNS N
were VBD N
ineffective JJ o
as IN N
sole JJ o
analgesic JJ o
agents NNS o
in IN N
half NN N
of IN N
their PRP$ N
respective JJ N
groups NNS N
. . N

It PRP N
may MD N
be VB N
that IN N
a DT N
combination NN N
of IN N
these DT N
drugs NNS N
, , N
providing VBG N
a DT N
multireceptor NN N
approach NN N
to TO N
analgesia VB N
, , N
will MD N
prove VB N
to TO N
be VB N
more RBR N
effective JJ N
. . N

-DOCSTART- -24781567- O O

Sedation NNP o
depth NN o
during IN N
spinal JJ i
anesthesia NN i
and CC N
survival NN N
in IN N
elderly JJ p
patients NNS p
undergoing VBG p
hip JJ p
fracture NN p
repair NN p
. . p

Low JJ N
intraoperative JJ o
Bispectral NNP o
Index NNP o
( ( o
BIS NNP o
) ) o
values NNS o
may MD N
be VB N
associated VBN N
with IN N
increased JJ N
mortality NN N
. . N

In IN N
a DT N
previously RB N
reported VBN N
trial NN N
to TO N
prevent VB N
delirium NN N
, , N
we PRP N
randomized VBD N
patients NNS p
undergoing VBG p
hip JJ o
fracture NN o
repair NN o
under IN p
spinal JJ i
anesthesia NN i
to TO i
light NN i
( ( i
BIS NNP i
> NNP i
80 CD i
) ) i
or CC i
deep JJ i
( ( i
BIS NNP i
approximately RB i
50 CD i
) ) i
sedation NN i
. . i

We PRP N
analyzed VBD N
survival NN o
of IN N
patients NNS N
in IN N
the DT N
original JJ N
trial NN N
. . N

Among IN N
all DT N
patients NNS N
, , N
mortality NN o
was VBD N
equivalent JJ N
across IN N
sedation NN N
groups NNS N
. . N

However RB N
, , N
among IN N
patients NNS N
with IN N
serious JJ N
comorbidities NNS N
( ( N
Charlson NNP N
score RB N
> VBZ N
4 CD N
) ) N
, , N
1-year JJ o
mortality NN o
was VBD N
reduced VBN N
in IN N
the DT N
light NN i
( ( N
22.2 CD N
% NN N
) ) N
vs NN N
deep JJ i
( ( N
43.6 CD N
% NN N
) ) N
sedation NN i
group NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.43 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.19-0.97 JJ N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
during IN N
spinal JJ N
anesthesia NN N
. . N

Similarly RB N
, , N
among IN N
patients NNS N
with IN N
Charlson NNP N
score VBD N
> JJ N
6 CD N
, , N
1-year JJ o
mortality NN o
was VBD N
reduced VBN N
in IN N
the DT N
light NN i
( ( N
28.6 CD N
% NN N
) ) N
vs NN N
deep JJ i
( ( N
52.6 CD N
% NN N
) ) N
sedation NN i
group NN N
( ( N
HR NNP N
0.33 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.12-0.94 JJ N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
during IN N
spinal JJ i
anesthesia NN i
. . i

Further NNP N
research NN N
on IN N
reduced JJ o
mortality NN o
after IN o
light JJ o
sedation NN o
during IN o
spinal JJ o
anesthesia NN o
is VBZ N
needed VBN N
. . N

-DOCSTART- -14616279- O O

Vaginal JJ i
electrical JJ i
stimulation NN i
of IN i
the DT i
pelvic JJ i
floor NN i
: : i
a DT N
randomized JJ N
feasibility NN N
study NN N
in IN N
urinary JJ p
incontinent NN p
elderly JJ p
women NNS p
. . p

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN o
of IN N
intravaginal JJ i
electrical JJ i
stimulation NN i
( ( i
ES NNP i
) ) i
of IN N
the DT N
pelvic JJ N
floor NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ p
women NNS p
, , N
and CC N
to TO N
determine VB N
whether IN N
ES NNP i
of IN i
the DT i
pelvic JJ i
floor NN i
is VBZ N
a DT N
preferable JJ N
treatment NN N
for IN N
urinary JJ p
incontinence NN p
in IN p
elderly JJ p
women NNS p
. . p

METHODS NNP N
Postmenopausal NNP p
women NNS p
( ( p
age NN p
65 CD p
years NNS p
or CC p
older JJR p
) ) p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
and CC N
underwent JJ N
every-other-day JJ N
ES NNP i
of IN i
the DT i
pelvic JJ i
floor NN i
, , i
or CC i
a DT i
daily JJ i
Kegel NNP i
exercise NN i
( ( i
KE NNP i
) ) i
program NN i
. . i

Objective NNP N
outcome NN N
variables NNS N
were VBD N
: : N
( ( o
1 CD o
) ) o
Urinary JJ o
leakage NN o
( ( o
during IN o
a DT o
standardized JJ o
PAD NNP o
test NN o
) ) o
, , o
( ( o
2 CD o
) ) o
pelvic NN o
muscle NN o
strength NN o
( ( o
measured VBN o
by IN o
a DT o
perineometer NN o
) ) o
, , o
and CC o
( ( o
3 CD o
) ) o
detrusor NN o
instability NN o
( ( o
on IN o
ambulant NN o
urodynamic JJ o
registration NN o
) ) o
. . o

Subjective JJ N
outcome NN N
variables NNS N
were VBD N
women NNS o
's POS o
subjective JJ o
assessment NN o
of IN o
change NN o
in IN o
urinary JJ o
symptoms NNS o
based VBN o
on IN o
the DT o
PRAFAB NNP o
score NN o
. . o

Twenty-four JJ p
women NNS p
treated VBN p
with IN p
ES NNP i
and CC p
11 CD p
women NNS p
treated VBN p
with IN p
Kegel NNP i
exercises NNS i
completed VBD N
the DT N
8-week JJ N
study NN N
program NN N
. . N

The DT N
Chi-square JJ N
test NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
improvement NN N
in IN N
objective JJ N
outcome NN N
variables NNS N
was VBD N
observed VBN N
in IN N
the DT N
population NN N
treated VBD N
with IN N
ES NNP i
compared VBN N
with IN N
the DT N
population NN N
treated VBD N
with IN N
KE NNP i
( ( N
with IN N
29.2 CD N
% NN N
vs. FW N
36.4 CD N
% NN N
of IN N
the DT N
women NNS N
showing VBG N
objective JJ N
improvement NN N
in IN N
measured JJ o
urinary JJ o
leakage NN o
) ) o
. . N

Neither CC N
was VBD N
subjective JJ N
improvement NN N
significant JJ N
, , N
with IN N
29.2 CD N
% NN N
vs. FW N
27.3 CD N
% NN N
of IN N
the DT N
women NNS N
reporting VBG N
improvement NN N
in IN N
the DT N
amount NN o
of IN o
urinary JJ o
leakage NN o
. . o

CONCLUSIONS NNP N
Although IN N
the DT N
number NN N
of IN N
enrolled JJ N
women NNS N
was VBD N
very RB N
small JJ N
this DT N
study NN N
shows VBZ N
that IN N
: : N
1 CD N
. . N

Treating VBG N
elderly JJ p
women NNS p
with IN N
vaginal JJ N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
has VBZ N
a DT N
high JJ N
physical JJ N
and CC N
emotional JJ N
cost NN N
for IN N
the DT N
individual NN N
. . N

2 CD N
. . N

The DT N
effectiveness NN o
of IN N
ES NNP i
of IN N
the DT N
pelvic JJ N
floor NN N
in IN N
urinary JJ N
incontinent NN N
elderly JJ N
women NNS N
is VBZ N
low JJ N
. . N

3 CD N
. . N

There EX N
is VBZ N
no DT N
great JJ N
discrepancy NN N
between IN N
objective JJ N
amelioration NN N
( ( N
PAD NNP N
test NN N
) ) N
and CC N
subjective JJ N
amelioration NN N
( ( N
PRAFAB NNP N
score/quantity NN N
of IN N
urinary JJ N
leakage NN N
) ) N
, , N
if IN N
the DT N
objective JJ N
improvement NN N
is VBZ N
adequately RB N
defined VBN N
. . N

4 CD N
. . N

It PRP N
is VBZ N
not RB N
reasonable JJ N
to TO N
advise VB N
elderly JJ N
women NNS N
with IN N
urinary JJ N
incontinence NN N
to TO N
undertake VB N
this DT N
treatment NN N
procedure NN N
. . N

The DT N
effectiveness NN N
of IN N
treatment NN N
does VBZ N
not RB N
compensate VB N
for IN N
the DT N
long-lasting JJ N
and CC N
intense JJ N
treatment NN N
protocol NN N
. . N

5 CD N
. . N

We PRP N
terminated VBD N
this DT N
study NN N
because IN N
of IN N
the DT N
negative JJ N
outcome NN N
with IN N
ES NNP i
. . i

-DOCSTART- -9652561- O O

Randomised VBN N
placebo-controlled JJ i
trial NN N
of IN N
rhesus-human JJ i
reassortant JJ i
rotavirus NN i
vaccine NN i
for IN N
prevention NN N
of IN N
severe JJ o
rotavirus NN o
gastroenteritis NN o
. . o

BACKGROUND NNP N
Rotavirus NNP N
is VBZ N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
acute JJ N
childhood NN N
gastroenteritis NN N
. . N

Vaccination NN N
with IN N
live JJ N
oral JJ N
heterologous JJ N
rotavirus NN N
vaccines NNS N
may MD N
prevent VB N
rotavirus NN N
gastroenteritis NN N
. . N

We PRP N
assessed VBD N
the DT N
efficacy NN o
of IN N
rhesus-human JJ i
reassortant JJ i
rotavirus NN i
tetravalent NN i
vaccine NN i
( ( i
RRV-TV NNP i
) ) i
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
in IN N
Finnish JJ p
children NNS p
in IN N
a DT N
randomised JJ N
placebo-controlled JJ i
double-blind JJ N
trial NN N
. . N

METHODS NNP N
Placebo NNP i
or CC i
RRV-TV NNP i
( ( N
titre JJ N
4x10 CD N
( ( N
5 CD N
) ) N
plaque-forming JJ N
units NNS N
) ) N
was VBD N
given VBN N
to TO N
infants NNS p
at IN p
ages NNS p
2 CD p
, , p
3 CD p
, , p
and CC p
5 CD p
months NNS p
. . p

The DT N
children NNS N
were VBD N
followed VBN N
up RP N
for IN N
one CD N
or CC N
two CD N
rotavirus JJ N
epidemic JJ N
seasons NNS N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
protection NN o
against IN o
severe JJ o
rotavirus NN o
gastroenteritis NN o
( ( N
score JJ N
> NN N
or CC N
=11 NN N
on IN N
a DT N
20-point JJ N
severity NN N
scale NN N
) ) N
. . N

2398 CD p
children NNS p
were VBD p
enrolled VBN p
and CC N
received VBN N
at IN N
least JJS N
one CD N
dose NN N
of IN N
RRV-TV NNP N
( ( N
n=1191 NN N
) ) N
or CC N
placebo NN i
( ( N
n=1207 JJ N
) ) N
. . N

The DT N
primary JJ N
efficacy NN N
analysis NN N
was VBD N
based VBN N
on IN N
children NNS N
who WP N
received VBD N
three CD N
doses NNS N
of IN N
RRV-TV NNP N
( ( N
n=1128 NN N
) ) N
or CC N
placebo NN N
( ( N
n=1145 JJ N
) ) N
. . N

FINDINGS $ N
256 CD N
episodes NNS N
of IN N
rotavirus NN N
gastroenteritis NN N
occurred VBD N
at IN N
any DT N
time NN N
during IN N
the DT N
study NN N
; : N
65 CD N
were VBD N
among IN N
1191 CD N
RRV-TV JJ i
recipients NNS N
, , N
and CC N
191 CD N
among IN N
1207 CD N
placebo NN i
recipients NNS N
( ( N
vaccine JJ N
efficacy NN N
66 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
55-74 JJ N
] NN N
; : N
intention-to-treat JJ N
analysis NN N
) ) N
. . N

226 CD N
episodes NNS N
were VBD N
included VBN N
in IN N
the DT N
primary JJ N
efficacy NN o
analysis NN N
of IN N
fully RB N
vaccinated VBN N
children NNS N
( ( N
54 CD N
among IN N
1128 CD N
RRV-TV JJ N
recipients NNS N
, , N
172 CD N
among IN N
1145 CD N
placebo NN N
recipients NNS N
; : N
vaccine VB N
efficacy NN N
68 CD N
% NN N
[ JJ N
57-76 JJ N
] NN N
) ) N
. . N

100 CD N
episodes NNS N
were VBD N
severe JJ N
, , N
eight CD N
in IN N
RRV-TV NNP i
recipients NNS N
and CC N
92 CD N
in IN N
placebo NN N
recipients NNS N
( ( N
vaccine JJ N
efficacy NN N
91 CD N
% NN N
[ JJ N
82-96 JJ N
] NN N
) ) N
. . N

INTERPRETATION NNP N
RRV-TV NNP i
vaccine NN i
was VBD N
highly RB N
effective JJ N
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
in IN N
young JJ p
children NNS p
. . p

Incorporation NN N
of IN N
this DT N
vaccine NN N
into IN N
routine JJ N
immunisation NN N
schedules NNS N
of IN N
infants NNS N
could MD N
reduce VB N
severe JJ o
rotavirus NN o
gastroenteritis NN o
by IN N
90 CD N
% NN N
and CC N
severe JJ o
gastroenteritis NN o
of IN N
all DT N
causes NNS N
in IN N
young JJ N
children NNS N
by IN N
60 CD N
% NN N
. . N

-DOCSTART- -15602505- O O

A DT N
placebo NN N
controlled VBN N
crossover RB N
trial NN N
of IN N
liquid JJ i
fluoxetine NN i
on IN N
repetitive JJ o
behaviors NNS o
in IN p
childhood NN p
and CC p
adolescent JJ p
autism NN p
. . p

Repetitive JJ o
behaviors NNS o
are VBP N
a DT N
core NN N
symptom NN N
domain NN N
in IN N
autism NN N
that WDT N
has VBZ N
been VBN N
linked VBN N
to TO N
alterations NNS N
in IN N
the DT N
serotonin NN N
system NN N
. . N

While IN N
the DT N
selective JJ N
serotonin-receptive JJ i
inhibitor NN i
fluvoxamine NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
adults NNS N
with IN N
autism NN N
, , N
as IN N
yet RB N
no DT N
published VBN N
placebo NN i
controlled VBN N
trials NNS N
with IN N
these DT N
agents NNS N
document NN N
safety NN o
and CC N
efficacy NN o
in IN N
children NNS p
with IN p
autism NN p
. . p

This DT N
study NN N
examines VBZ N
the DT N
selective JJ N
serotonin NN i
reuptake NN i
inhibitor NN i
liquid JJ i
fluoxetine NN i
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ o
behaviors NNS o
in IN p
childhood NN p
and CC p
adolescent JJ p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
. . p

In IN N
total JJ N
, , N
45 CD p
child NN p
or CC p
adolescent JJ p
patients NNS p
with IN p
ASD NNP p
were VBD p
randomized VBN p
into IN p
two CD p
acute JJ p
8-week JJ p
phases NNS p
in IN p
a DT p
double-blind JJ p
placebo-controlled JJ p
crossover NN p
study NN p
of IN p
liquid JJ i
fluoxetine NN i
. . i

Study NNP N
design NN N
included VBD N
two CD N
randomized VBN N
8-week JJ N
fluoxetine NN i
and CC N
placebo NN i
phases NNS N
separated VBN N
by IN N
a DT N
4-week JJ N
washout NN N
phase NN N
. . N

Outcome NNP N
measures NNS N
included VBD N
measures NNS o
of IN o
repetitive JJ o
behaviors NNS o
and CC o
global JJ o
improvement NN o
. . o

Low-dose JJ N
liquid JJ i
fluoxetine NN i
( ( N
mean JJ N
final JJ N
dose NN N
: : N
9.9+/-4.35 JJ N
mg/day NN N
) ) N
was VBD N
superior JJ N
to TO N
placebo VB i
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ o
behaviors NNS o
by IN N
CY-BOCS NNP o
compulsion NN o
scale NN o
. . o

The DT N
effect NN o
size NN o
was VBD N
in IN N
the DT N
moderate NN N
to TO N
large JJ N
range NN N
, , N
and CC N
the DT N
doses NNS N
used VBN N
were VBD N
low JJ N
. . N

Liquid NNP i
fluoxetine NN i
was VBD N
only RB N
slightly RB N
, , N
and CC N
not RB N
significantly RB N
, , N
superior JJ N
to TO N
placebo VB N
on IN N
CGI NNP o
autism NN o
score NN o
partially RB N
due JJ N
to TO N
a DT N
phase NN o
order NN o
effect NN o
. . o

However RB N
, , N
fluoxetine NN i
was VBD N
marginally RB N
superior JJ N
to TO N
placebo VB i
on IN N
a DT N
composite JJ o
measure NN o
of IN o
global JJ o
effectiveness NN o
. . o

Liquid NNP N
fluoxetine NN N
did VBD N
not RB N
significantly RB N
differ VBP N
from IN N
placebo NN i
on IN N
treatment NN o
emergent JJ o
side NN o
effects NNS o
. . o

Liquid NNP i
fluoxetine NN i
in IN N
low JJ N
doses NNS N
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ o
behaviors NNS o
in IN N
childhood NN N
autism NN N
. . N

Limitations NNS N
include VBP N
small JJ N
sample JJ N
size NN N
and CC N
the DT N
crossover NN N
design NN N
of IN N
the DT N
study NN N
. . N

Further NNP N
replication NN N
and CC N
long-term JJ N
maintenance NN N
trials NNS N
are VBP N
needed VBN N
. . N

-DOCSTART- -12844138- O O

Effect NN N
of IN N
2 CD N
weeks NNS N
of IN N
theophylline NN N
on IN N
glucose JJ o
counterregulation NN o
in IN N
patients NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
and CC p
unawareness NN p
of IN p
hypoglycemia NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
A NNP N
single JJ N
dose NN N
of IN N
theophylline JJ N
improves NNS N
hypoglycemia NN N
unawareness NN N
in IN N
type NN p
1 CD p
diabetic JJ p
patients NNS p
. . p

Prolonged NNP N
theophylline NN N
use NN N
is VBZ N
, , N
however RB N
, , N
associated VBN N
with IN N
emergence NN N
of IN N
tolerance NN N
. . N

This DT N
study NN N
investigated VBD N
whether IN N
prolonged JJ N
use NN N
of IN N
theophylline NN N
retains NNS N
efficacy VBP N
for IN N
counterregulatory NN o
defects NNS o
in IN N
patients NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
and CC p
hypoglycemia NN p
unawareness NN p
. . p

METHODS JJ N
Experiments NNS N
were VBD N
performed VBN N
with IN N
12 CD p
subjects NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
and CC p
hypoglycemia NN p
unawareness NN p
. . p

All DT N
subjects NNS p
participated VBN N
in IN N
a DT N
crossover NN N
study NN N
of IN N
2 CD N
randomly NNS N
scheduled VBN N
15-day JJ i
study NN i
periods NNS i
during IN i
which WDT i
250 CD i
mg NN i
theophylline NN i
twice RB i
daily RB i
or CC i
matching VBG i
placebo NN i
was VBD i
used VBN i
. . i

On IN i
the DT i
final JJ i
day NN i
of IN i
each DT i
period NN i
, , i
hyperinsulinemic JJ i
( ( i
360 CD i
pmol NN i
x NNP i
m NN i
( ( i
-2 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
) ) i
hypoglycemic NN i
( ( i
5.0 CD i
, , i
3.5 CD i
, , i
2.5 CD i
mmol NN i
x NN i
L NNP i
( ( i
-1 NNP i
) ) i
) ) i
glucose VBP i
clamps NNS i
were VBD i
used VBN i
to TO i
assess VB i
counterregulatory NN o
and CC o
cardiovascular JJ o
responses NNS o
. . o

RESULTS NNP N
Under IN N
normoglycemic JJ N
conditions NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
theophylline NN N
and CC N
placebo NN N
. . N

Under IN N
hypoglycemic JJ N
conditions NNS N
, , N
theophylline NN N
enhanced VBD N
responses NNS N
of IN N
growth NN o
hormone NN o
, , o
symptoms NNS o
, , o
heart NN o
rate NN o
, , o
and CC o
pulse JJ o
pressure NN o
( ( N
all DT N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
induced VBD o
sweating VBG o
at IN o
higher JJR o
plasma NN o
glucose NN o
levels NNS o
( ( N
P NNP N
=.039 NNP N
) ) N
, , N
and CC N
reduced VBD o
exogenous JJ o
glucose NN o
requirements NNS o
( ( N
P NNP N
=.018 NNP N
) ) N
. . N

Hypoglycemia-induced JJ N
responses NNS N
of IN N
epinephrine NN N
, , N
norepinephrine NN N
, , N
and CC N
cortisol NNS N
were VBD N
not RB N
enhanced VBN N
by IN N
theophylline NN N
. . N

CONCLUSIONS NNP N
Prolonged NNP N
use NN N
of IN N
theophylline NN N
has VBZ N
a DT N
sustained VBN N
effect NN N
on IN N
cardiovascular NN o
, , o
metabolic NN o
, , o
and CC o
symptom JJ o
responses NNS o
to TO N
hypoglycemia VB N
in IN N
patients NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
and CC p
hypoglycemia NN p
unawareness NN p
. . p

Whether IN N
these DT N
results NNS N
translate VBP N
into IN N
clinical JJ N
benefit NN N
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

-DOCSTART- -21418212- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
Hanen NNP i
's POS i
'More JJR i
Than NNP i
Words NNP i
' POS i
in IN N
toddlers NNS p
with IN p
early JJ p
autism NN p
symptoms NNS p
. . p

BACKGROUND NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
compared VBN N
Hanen NNP i
's POS i
'More JJR i
than IN i
Words NNS i
' POS i
( ( i
HMTW NNP i
) ) i
, , i
a DT i
parent-implemented JJ i
intervention NN i
, , N
to TO N
a DT N
'business NN i
as IN i
usual JJ i
' POS i
control NN i
group NN N
. . N

METHODS NNP N
Sixty-two JJ p
children NNS p
( ( p
51 CD p
boys NNS p
and CC p
11 CD p
girls NNS p
; : p
M NNP p
age NN p
= VBD p
20 CD p
months NNS p
; : p
SD NNP p
= NNP p
2.6 CD p
) ) p
who WP p
met VBD p
criteria NNS p
for IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC p
their PRP$ p
parents NNS p
participated VBN p
in IN p
the DT p
study NN p
. . p

The DT N
HMTW NNP i
intervention NN i
was VBD N
provided VBN N
over IN N
3.5 CD N
months NNS N
. . N

There EX N
were VBD N
three CD N
measurement NN N
periods NNS N
: : N
prior RB i
to TO i
randomization NN i
( ( i
Time NNP i
1 CD i
) ) i
and CC i
at IN i
5 CD i
and CC i
9 CD i
months NNS i
post VBN i
enrollment NN i
( ( i
Times NNP i
2 CD i
and CC i
3 CD i
) ) i
. . i

Children NNP o
's POS o
communication NN o
and CC o
parental JJ o
responsivity NN o
were VBD i
measured VBN i
at IN i
each DT i
time NN i
point NN i
. . i

Children NNP o
's POS o
object JJ o
interest NN o
, , o
a DT o
putative JJ o
moderator NN o
, , i
was VBD i
measured VBN i
at IN i
Time NNP i
1 CD i
. . i

RESULTS VB N
There EX N
were VBD N
no DT N
main JJ N
effects NNS N
of IN N
the DT N
HMTW NNP i
intervention NN N
on IN N
either DT N
parental JJ o
responsivity NN o
or CC N
children NNS o
's POS o
communication NN o
. . o

However RB N
, , N
the DT N
effects NNS N
on IN N
residualized JJ N
gains NNS N
in IN N
parental JJ o
responsivity NN o
from IN N
Time NNP N
1 CD N
to TO N
both DT N
Times NNP N
2 CD N
and CC N
3 CD N
yielded VBN N
noteworthy JJ N
effect NN N
sizes NNS N
( ( N
Glass NNP N
's POS N
? . N
= JJ N
.71 NN N
, , N
.50 NNP N
respectively RB N
) ) N
. . N

In IN N
contrast NN N
, , N
there EX N
were VBD N
treatment NN N
effects NNS N
on IN o
child JJ o
communication NN o
gains NNS N
to TO N
Time VB N
3 CD N
that WDT N
were VBD N
moderated VBN N
by IN N
children NNS N
's POS N
Time NNP N
1 CD N
object JJ N
interest NN N
. . N

Children NNP N
with IN N
lower JJR N
levels NNS N
of IN N
Time NNP N
1 CD N
object JJ o
interest NN o
exhibited VBN N
facilitated JJ N
growth NN N
in IN o
communication NN o
; : o
children NNS N
with IN N
higher JJR N
levels NNS N
of IN o
object JJ o
interest NN o
exhibited VBD o
growth NN o
attenuation NN o
. . o

CONCLUSIONS VB N
The DT i
HMTW NNP i
intervention NN N
showed VBD N
differential JJ N
effects NNS N
on IN o
child NN o
communication NN o
depending VBG N
on IN N
a DT N
baseline NN N
child NN N
factor NN N
. . N

HMTW NNP i
facilitated VBD o
communication NN o
in IN N
children NNS N
with IN N
lower JJR N
levels NNS N
of IN N
Time NNP N
1 CD N
object JJ N
interest NN N
. . N

Parents NNS p
of IN p
children NNS p
who WP p
evidence NN p
higher JJR o
object JJ o
interest NN o
may MD N
require VB N
greater JJR N
support NN N
to TO N
implement VB N
the DT i
HMTW NNP i
strategies NNS N
, , N
or CC N
may MD N
require VB N
different JJ N
strategies NNS N
than IN N
those DT N
provided VBN N
by IN N
the DT i
HMTW NNP i
curriculum NN N
. . N

-DOCSTART- -7936339- O O

[ JJ N
Effect NNP N
of IN N
dopexamine NN i
in IN N
splanchnic JJ N
perfusion NN N
during IN N
surgery NN p
of IN p
the DT p
abdominal JJ p
aorta NN p
] NNP p
. . N

Abdominal NNP N
aortic JJ N
surgery NN N
has VBZ N
significant JJ N
effects NNS N
on IN N
cardiac NN N
and CC N
splanchnic JJ N
perfusion NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
dopexamine NN N
, , N
an DT N
inodilator JJ N
drug NN N
, , N
on IN N
hemodynamic JJ N
and CC N
splanchnic JJ N
perfusion NN N
with IN N
measurement NN N
of IN N
gastric JJ N
intramucosal NN N
pH NN N
, , N
by IN N
the DT N
method NN N
of IN N
gastric JJ N
tonometry NN N
, , N
during IN N
abdominal JJ N
aneurysm JJ N
resection NN N
. . N

Twenty-five JJ p
patients NNS p
undergoing VBG p
excision NN p
of IN p
an DT p
aortic JJ p
abdominal JJ p
aneurysm NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

During IN N
aortic JJ N
cross-clamping JJ N
Group NNP N
II NNP N
patients NNS N
received VBD N
dopexamine JJ i
infusion NN N
, , N
at IN N
a DT N
dose NN N
of IN N
1 CD N
microgram/kg/m NN N
, , N
and CC N
at IN N
a DT N
dose NN N
of IN N
0.5 CD N
micrograms/kg/m NN N
from IN N
declamping VBG N
to TO N
the DT N
end NN N
of IN N
the DT N
surgery NN N
. . N

Whereas NNP N
Group NNP N
I PRP N
patients NNS N
did VBD i
not RB i
receive VB i
a DT i
dopexamine JJ i
infusion NN i
. . i

During IN N
aortic JJ N
cross-clamping VBG N
the DT N
intramucosal NN o
pH VBZ o
value NN o
decreased VBN N
in IN N
Group NNP N
I PRP N
patients NNS N
, , N
but CC N
did VBD N
not RB N
change VB N
in IN N
Group NNP N
II NNP N
patients NNS N
. . N

Heart NNP o
rate NN o
, , o
cardiac JJ o
index NN o
, , o
and CC o
mixed JJ o
venous JJ o
oxygen NN o
saturation NN o
increased VBD N
significantly RB N
during IN N
dopexamine JJ N
infusion NN N
, , N
whereas JJ N
systemic JJ o
vascular NN o
resistance NN o
was VBD N
reduced VBN N
. . N

During IN N
aortic JJ N
cross-clamping JJ N
dopexamine NN i
was VBD N
a DT N
useful JJ N
agent NN N
in IN N
improving VBG N
splanchnic JJ o
blood NN o
flow NN o
, , o
cardiac JJ o
index NN o
venous JJ o
saturation NN o
. . o

Also RB N
, , N
since IN N
the DT N
drug NN N
produces VBZ N
dose RB N
related JJ N
hemodynamic JJ N
changes NNS N
of IN N
rapid JJ N
onset NN N
and CC N
reversibility NN N
, , N
it PRP N
is VBZ N
possible JJ N
to TO N
interrupt VB N
the DT N
infusion NN N
before IN N
aortic JJ N
declamping NN N
to TO N
avoid VB N
the DT N
decrease NN N
in IN N
the DT N
intramucosal NN N
pH VBZ N
value NN N
. . N

-DOCSTART- -12668582- O O

Pharmacokinetics NNS o
and CC o
tolerance NN o
of IN N
single- JJ N
and CC N
multiple-dose JJ N
oral JJ N
or CC N
intravenous JJ N
linezolid NNS i
, , N
an DT N
oxazolidinone NN N
antibiotic JJ N
, , N
in IN N
healthy JJ p
volunteers NNS p
. . p

AIMS NNP N
To TO N
determine VB N
the DT N
pharmacokinetics NNS N
and CC N
tolerance NN o
of IN N
oral JJ N
and CC N
intravenous JJ N
linezolid NN i
, , N
an DT N
oxazolidinone NN N
antibiotic JJ N
, , N
in IN N
healthy JJ p
volunteers NNS p
following VBG N
single- JJ N
and CC N
multiple-dose JJ N
administration NN N
. . N

METHODS NNP N
In IN N
two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
dose-escalating JJ N
trials NNS N
, , N
subjects NNS p
were VBD N
exposed VBN N
either RB N
to TO N
oral JJ N
( ( N
375 CD N
, , N
500 CD N
or CC N
625 CD N
mg NN N
) ) N
or CC N
intravenous JJ N
( ( N
500 CD N
or CC N
625 CD N
mg NN N
) ) N
linezolid VBD i
or CC i
placebo VB i
twice JJ N
daily RB N
. . N

Serial JJ o
blood NN o
and CC o
urine JJ o
samples NNS o
were VBD N
obtained VBN N
after IN N
the DT N
first- JJ N
and CC N
multiple-dose JJ N
administrations NNS N
for IN N
up IN N
to TO N
18 CD N
days NNS N
. . N

Non-compartmental JJ N
pharmacokinetic JJ o
analyses NNS o
were VBD N
used VBN N
to TO N
describe VB N
the DT N
disposition NN N
of IN N
linezolid JJ i
. . i

RESULTS NNP N
Plasma NNP o
linezolid JJ o
concentrations NNS o
and CC o
area NN o
under IN o
the DT o
concentration-time JJ o
curves NNS o
increased VBD N
proportionally RB N
with IN N
dose JJ N
irrespective NN N
of IN N
the DT N
route NN N
of IN N
administration NN N
. . N

Plasma NNP o
linezolid JJ o
concentrations NNS o
remained VBN N
above IN N
the DT N
MIC90 NNP N
for IN N
susceptible JJ N
target NN N
pathogens NNS N
( ( N
4.0 CD N
mg/L NN N
) ) N
for IN N
the DT N
majority NN N
of IN N
the DT N
12 CD N
h NN N
dosing VBG N
interval NN N
. . N

Mean JJ o
clearance NN o
, , o
half-life JJ o
and CC o
volume NN o
of IN o
distribution NN o
were VBD N
similar JJ N
irrespective NN N
of IN N
dose NN N
for IN N
both DT N
the DT N
oral JJ N
and CC N
intravenous JJ N
routes NNS N
. . N

Linezolid NNP i
was VBD N
well RB N
tolerated VBN o
and CC N
the DT N
frequency NN o
of IN o
drug-related JJ o
adverse JJ o
events NNS o
was VBD N
similar JJ N
between IN N
the DT N
linezolid JJ i
and CC N
placebo JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Oral NNP N
and CC N
intravenous JJ N
linezolid JJ i
exhibit NN N
linear JJ o
pharmacokinetics NNS o
, , N
with IN N
concentrations NNS N
remaining VBG N
above IN N
the DT N
target NN o
MIC90 NNP o
for IN N
most JJS N
of IN N
the DT N
dosing NN N
interval NN N
. . N

These DT N
results NNS N
support VBD N
a DT N
twice-daily JJ N
schedule NN N
for IN N
linezolid JJ N
and CC N
demonstrate VB N
the DT N
feasibility NN N
of IN N
converting VBG N
from IN N
intravenous JJ N
to TO N
oral JJ N
dosing NN N
without IN N
a DT N
dose JJ N
adjustment NN N
. . N

-DOCSTART- -20149953- O O

Helping VBG N
women NNS N
make VBP N
choices NNS N
about IN N
mammography NN N
screening NN N
: : N
an DT N
online NN N
randomized VBN N
trial NN N
of IN N
a DT N
decision NN N
aid NN N
for IN N
40-year-old JJ p
women NNS p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
decision NN i
aid NN i
( ( i
DA NNP i
) ) i
on IN N
women NNS N
's POS N
knowledge NN N
of IN N
the DT N
benefits NNS N
and CC N
harms NNS N
of IN N
screening VBG N
and CC N
on IN N
their PRP$ N
ability NN N
to TO N
make VB N
an DT N
informed JJ N
decision NN N
. . N

METHODS NNP N
An DT N
online NN N
randomized VBN N
controlled VBN N
trial NN N
among IN N
321 CD p
women NNS p
aged VBN p
38-45 CD p
years NNS p
was VBD p
conducted VBN p
. . p

Participants NNS N
were VBD N
randomized VBN N
to TO N
either DT N
immediate JJ i
or CC i
delayed JJ i
access NN i
to TO i
the DT i
online NN i
DA NNP i
which WDT N
( ( N
i NN N
) ) N
explained VBD N
the DT N
benefits NNS N
and CC N
harms NNS N
, , N
( ( N
ii NN N
) ) N
included VBD N
a DT N
values NNS N
clarification NN N
exercise NN N
and CC N
a DT N
worksheet NN N
to TO N
support VB N
decision NN N
making NN N
. . N

The DT N
primary JJ N
outcome NN N
, , N
knowledge NN o
of IN o
benefits NNS o
and CC o
harms NNS o
of IN o
screening NN o
, , o
and CC o
secondary JJ o
outcomes NNS o
, , o
informed VBN o
choice NN o
( ( o
composite JJ o
of IN o
knowledge NN o
, , o
values NNS o
and CC o
intention NN o
) ) o
, , o
anxiety NN o
and CC o
acceptability NN o
of IN o
the DT o
DA NNP o
were VBD N
measured VBN N
using VBG N
online JJ N
questionnaires NNS N
. . N

RESULTS NNP N
Women NNP p
in IN p
the DT p
intervention NN p
group NN p
were VBD N
more RBR N
knowledgeable JJ o
( ( N
mean VB N
score NN N
out IN N
of IN N
10 CD N
, , N
7.35 CD N
vs NN N
6.27 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
made VBN o
a DT o
decision NN o
( ( N
82 CD N
% NN N
vs JJ N
61 CD N
% NN N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Of IN N
those DT N
who WP N
made VBD N
a DT N
decision NN N
, , N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
were VBD N
less RBR N
likely JJ N
to TO N
start VB o
screening VBG o
now RB o
( ( N
52 CD N
% NN N
vs JJ N
65 CD N
% NN N
p=0.05 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
proportion NN o
of IN o
women NNS o
who WP o
made VBD o
an DT o
informed JJ o
choice NN o
( ( N
71 CD N
% NN N
intervention NN N
group NN N
vs VBD N
64 CD N
% NN N
control NN i
group NN N
, , N
p=0.24 NN N
) ) N
. . N

The DT N
DA NNP N
was VBD N
helpful JJ N
, , N
balanced JJ N
and CC N
clear JJ N
, , N
and CC N
did VBD N
not RB N
make VB N
women NNS N
anxious JJ o
. . o

CONCLUSIONS VB N
The DT N
DA NNP N
increased VBD N
knowledge NN o
and CC N
reduced JJ N
indecision NN o
, , N
without IN N
increasing VBG N
feelings NNS o
of IN o
anxiety NN o
. . o

PRACTICE NNP N
IMPLICATIONS NNP N
This DT N
decision NN N
aid NN N
is VBZ N
easy JJ N
to TO N
access NN N
online NN N
and CC N
could MD N
be VB N
an DT N
inexpensive JJ N
way NN N
of IN N
supporting VBG N
women NNS N
aged VBN N
40 CD N
who WP N
are VBP N
considering VBG N
whether IN N
to TO N
start VB N
screening VBG N
now RB N
, , N
or CC N
wait VBP N
until IN N
they PRP N
are VBP N
50 CD N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
demonstrate VB N
the DT N
potential NN N
of IN N
DAs NNP N
to TO N
help VB N
inform VB N
women NNS N
about IN N
both DT N
the DT N
benefits NNS N
and CC N
risks NNS N
of IN N
screening VBG N
at IN N
this DT N
age NN N
and CC N
to TO N
support VB N
women NNS N
and CC N
clinicians NNS N
in IN N
this DT N
decision NN N
making VBG N
process NN N
. . N

-DOCSTART- -15533466- O O

Botulinum NNP i
toxin NN i
a DT N
has VBZ N
antinociceptive JJ o
effects NNS o
in IN N
treating VBG N
interstitial JJ N
cystitis NN N
. . N

OBJECTIVES NNP N
To TO N
present VB N
clinical JJ N
evidence NN N
with IN N
botulinum NN i
toxin NN i
A NNP i
( ( i
BTX-A NNP i
) ) i
suggesting VBG N
an DT N
antinociceptive JJ o
role NN o
in IN N
patients NNS p
with IN p
interstitial JJ p
cystitis NN p
( ( p
IC NNP p
) ) p
. . p

Intriguing VBG N
evidence NN N
in IN N
a DT N
somatic JJ N
pain NN N
model NN N
has VBZ N
suggested VBN N
that IN N
BTX-A NNP i
injection NN i
may MD N
have VB N
an DT N
antinociceptive JJ o
effect NN o
on IN N
both DT N
acute NN N
and CC N
chronic NN N
( ( N
inflammatory NN N
) ) N
pain NN N
. . N

METHODS NNP N
Thirteen NNP p
female JJ p
patients NNS p
( ( p
6 CD p
in IN p
the DT p
United NNP p
States NNPS p
and CC p
7 CD p
in IN p
Poland NNP p
) ) p
with IN p
IC NNP p
according VBG p
to TO p
the DT p
criteria NNS p
of IN p
the DT p
National NNP p
Institute NNP p
of IN p
Diabetes NNP p
, , p
Digestive NNP p
and CC p
Kidney NNP p
Disease NNP p
were VBD p
included VBN p
. . p

Under IN N
short JJ N
general JJ N
anesthesia NN N
or CC N
sedation NN N
, , N
100 CD p
to TO p
200 CD p
U NNP p
of IN p
Dysport NNP i
( ( p
Polish JJ p
patients NNS p
) ) p
or CC p
Botox NNP i
( ( p
U.S. NNP p
patients NNS p
) ) p
was VBD N
injected VBN N
through IN N
a DT N
cystoscope NN N
into IN N
20 CD N
to TO N
30 CD N
sites NNS N
submucosally RB N
in IN N
the DT N
trigone NN N
and CC N
floor NN N
of IN N
the DT N
bladder NN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
with IN N
the DT N
O'Leary-Sant NNP o
validated VBD o
IC NNP o
questionnaire NN o
or CC o
with IN o
voiding JJ o
charts NNS o
and CC o
a DT o
visual JJ o
analog NN o
pain VBP o
scale JJ o
1 CD N
month NN N
postoperatively RB N
and CC N
at IN N
subsequent JJ N
3-month JJ N
intervals NNS N
. . N

The DT N
Polish JJ p
patients NNS p
also RB N
underwent JJ N
pretreatment NN N
and CC N
post-treatment JJ N
urodynamic JJ o
evaluations NNS o
. . o

RESULTS NNP N
Overall NNP N
, , N
9 CD N
( ( N
69 CD N
% NN N
) ) N
of IN N
13 CD N
patients NNS N
noted JJ N
subjective JJ o
improvement NN o
after IN N
BTX-A NNP i
treatment NN N
. . N

The DT N
Interstitial NNP o
Cystitis NNP o
Symptom NNP o
Index NNP o
and CC o
Interstitial NNP o
Cystitis NNP o
Problem NNP o
Index NNP o
mean NN o
scores NNS o
improved VBN N
by IN N
71 CD N
% NN N
and CC N
69 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Daytime NNP o
frequency NN o
, , o
nocturia NN o
, , o
and CC o
pain NN o
by IN o
visual JJ o
analog NN o
scale NN o
decreased VBN N
by IN N
44 CD N
% NN N
, , N
45 CD N
% NN N
, , N
and CC N
79 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
first JJ o
desire NN o
to TO o
void VB o
and CC o
maximal VB o
cystometric JJ o
capacity NN o
increased VBN N
by IN N
58 CD N
% NN N
and CC N
57 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
BTX-A NNP i
has VBZ N
an DT N
antinociceptive JJ o
effect NN o
on IN N
bladder NN N
afferent NN N
pathways NNS N
in IN N
patients NNS N
with IN N
IC NNP N
, , N
producing VBG N
both DT N
symptomatic JJ N
and CC N
functional JJ N
( ( N
ie JJ N
, , N
urodynamic JJ N
) ) N
improvements NNS N
. . N

-DOCSTART- -10188144- O O

Efficacy NN o
and CC o
safety NN o
of IN N
mizolastine JJ i
10 CD N
mg NN N
in IN N
a DT N
placebo-controlled JJ i
comparison NN N
with IN N
loratadine NN i
in IN N
chronic JJ p
idiopathic JJ p
urticaria NNS p
: : p
results NNS N
of IN N
the DT N
MILOR NNP N
Study NNP N
. . N

BACKGROUND NNP N
Mizolastine NNP i
is VBZ N
a DT N
novel JJ N
histamine NN N
H1-antagonist NN N
registered VBD N
in IN N
Europe NNP N
for IN N
the DT N
management NN N
of IN N
allergic JJ N
rhinitis NN N
and CC N
urticaria NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
clinical JJ N
efficacy NN o
and CC o
safety NN o
of IN N
mizolastine NN i
with IN i
loratadine NN i
and CC i
placebo NN i
in IN N
patients NNS p
with IN p
chronic JJ p
idiopathic JJ p
urticaria NN p
( ( p
CIU NNP p
) ) p
. . p

METHODS CC N
A DT N
multicentre NN N
, , N
double-blind NN N
, , N
parallel JJ N
group NN N
study NN N
was VBD N
designed VBN N
in IN N
which WDT N
247 CD p
patients NNS p
with IN p
CIU NNP p
were VBD N
randomised VBN N
after IN N
a DT N
1-week JJ N
placebo NN i
run-in JJ N
period NN N
to TO N
10 CD N
mg NNS N
daily JJ N
mizolastine NN i
( ( N
n JJ N
= NNP N
88 CD N
) ) N
, , N
10 CD N
mg JJ N
daily JJ N
loratadine NN i
( ( N
n JJ N
= NNP N
79 CD N
) ) N
, , N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
80 CD N
) ) N
for IN N
a DT N
4-week JJ N
treatment NN N
period NN N
. . N

RESULTS NNP N
Mizolastine NNP i
and CC N
loratadine VB i
both DT N
relieved JJ o
symptoms NNS o
of IN o
CIU NNP o
. . o

After IN N
2 CD N
weeks NNS N
' POS N
treatment NN N
, , N
the DT N
severity NN o
of IN o
pruritus NN o
( ( o
visual JJ o
analogue NN o
score NN o
( ( o
VAS NNP o
) ) o
assessed VBN o
by IN o
patients NNS o
) ) o
decreased VBD N
significantly RB N
in IN N
both CC N
the DT N
mizolastine NN i
and CC i
loratadine NN i
groups NNS N
compared VBN N
with IN N
placebo NN i
( ( i
mizolastine NN i
: : i
-36.7 NN N
mm NN N
, , N
P NNP N
= NNP N
0.0001 CD N
; : N
loratadine NN i
: : i
-29.8 NN N
, , N
P NNP N
= NNP N
0.0071 CD N
; : N
placebo NN i
: : i
-16.3 NN N
) ) N
; : N
this DT N
improvement NN N
with IN N
both DT N
active JJ N
treatments NNS N
was VBD N
maintained VBN N
throughout IN N
the DT N
treatment NN N
period NN N
, , N
the DT N
difference NN N
being VBG N
significant JJ N
only RB N
for IN N
the DT N
mizolastine NN N
group NN N
( ( N
P NNP N
= NNP N
0.0090 CD N
) ) N
. . N

Both DT N
active JJ N
treatments NNS N
were VBD N
also RB N
associated VBN N
with IN N
reduced JJ N
weekly JJ N
episodes NNS o
of IN o
urticaria NNS o
compared VBN N
with IN N
placebo NN i
, , N
which WDT N
was VBD N
significant JJ N
after IN N
2 CD N
weeks NNS N
' POS N
treatment NN N
( ( i
mizolastine NN i
: : i
7.9 CD N
episodes NNS N
, , N
P NNP N
= NNP N
0.0061 CD N
; : N
loratadine NN i
: : i
8.3 CD N
, , N
P NNP N
= NNP N
0.0221 CD N
; : N
placebo NN i
: : i
13.3 CD N
) ) N
. . N

Angioedema NNP o
was VBD N
improved VBN N
to TO N
a DT N
clinically RB N
significant JJ N
extent NN N
with IN N
mizolastine NN i
, , N
and CC N
loratadine NN i
compared VBN N
with IN N
placebo NN i
in IN N
those DT N
patients NNS p
who WP p
had VBD p
this DT p
symptom NN p
before IN p
treatment NN p
. . p

Overall JJ o
tolerability NN o
of IN N
both DT N
treatments NNS N
was VBD N
similar JJ N
to TO N
placebo VB i
, , N
and CC N
there EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
effects NNS o
on IN o
cardiac JJ o
repolarisation NN o
with IN N
either DT N
mizolastine NN i
or CC i
loratadine NN i
. . i

CONCLUSION NNP N
Mizolastine NNP i
( ( N
10 CD N
mg NNS N
daily RB N
) ) N
is VBZ N
confirmed VBN N
as IN N
an DT N
effective JJ o
and CC o
well RB o
tolerated JJ o
agent NN N
, , N
comparable JJ N
to TO N
loratadine VB N
and CC N
superior VB N
to TO N
placebo VB i
, , N
for IN N
the DT N
management NN N
of IN N
CIU NNP N
. . N

Mizolastine NNP i
acted VBD N
as RB N
rapidly RB N
as IN N
loratadine NN i
in IN N
improving VBG N
urticarial JJ o
symptoms NNS o
from IN N
the DT N
first JJ N
day NN N
of IN N
treatment NN N
. . N

-DOCSTART- -20413513- O O

The DT N
11-beta-hydroxysteroid JJ N
dehydrogenase NN N
type NN N
1 CD N
inhibitor NN N
INCB13739 NNP i
improves VBZ N
hyperglycemia NN o
in IN p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
inadequately RB p
controlled VBN p
by IN p
metformin NN p
monotherapy NN p
. . p

OBJECTIVE CC N
11-Beta-hydroxysteroid JJ N
dehydrogenase NN N
type NN N
1 CD N
( ( N
11betaHSD1 CD N
) ) N
converts NNS N
inactive JJ N
cortisone NN N
into IN N
active JJ N
cortisol NN N
, , N
thereby RB N
amplifying VBG N
intracellular JJ N
glucocorticoid JJ N
action NN N
. . N

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
the DT N
11betaHSD1 CD N
inhibitor NN N
INCB13739 NNP N
were VBD N
assessed VBN N
when WRB N
added VBN N
to TO N
ongoing VBG N
metformin NN N
monotherapy NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
exhibiting VBG p
inadequate JJ p
glycemic NNS p
control NN p
( ( p
A1C NNP p
7-11 CD p
% NN p
) ) p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
This DT N
double-blind JJ N
placebo-controlled JJ i
paralleled VBN N
study NN N
randomized VBD N
302 CD p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
( ( p
mean JJ p
A1C NNP p
8.3 CD p
% NN p
) ) p
on IN p
metformin NN i
monotherapy NN i
( ( p
mean JJ p
1.5 CD p
g/day NN p
) ) p
to TO N
receive VB N
one CD N
of IN N
five CD N
INCB13739 NNP i
doses NNS i
or CC i
placebo NN i
once RB N
daily JJ N
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
change NN o
in IN o
A1C NNP o
at IN o
study JJ o
end NN o
. . o

Other JJ N
end NN N
points NNS N
included VBD N
changes NNS o
in IN o
fasting VBG o
glucose NN o
, , o
lipids NNS o
, , o
weight NN o
, , o
adverse JJ o
events NNS o
, , o
and CC o
safety NN o
. . o

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
, , N
200 CD N
mg NN N
of IN N
INCB13739 NNP N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
A1C NNP o
( ( N
-0.6 NNP N
% NN N
) ) N
, , N
fasting VBG o
plasma NN o
glucose NN o
( ( N
-24 NNP N
mg/dl NN N
) ) N
, , N
and CC N
homeostasis NN o
model NN o
assessment-insulin JJ o
resistance NN o
( ( N
HOMA-IR NNP N
) ) N
( ( N
-24 CD N
% NN N
) ) N
compared VBN N
with IN N
placebo NN N
. . N

Total JJ o
cholesterol NN o
, , o
LDL NNP o
cholesterol NN o
, , o
and CC o
triglycerides NNS o
were VBD N
all DT N
significantly RB N
decreased VBN N
in IN N
hyperlipidemic JJ N
patients NNS N
. . N

Body NNP o
weight VBD o
decreased JJ N
relative NN N
to TO N
placebo VB N
after IN N
INCB13739 NNP N
therapy NN N
. . N

A DT N
reversible JJ N
dose-dependent JJ N
elevation NN N
in IN N
adrenocorticotrophic JJ o
hormone NN o
, , N
generally RB N
within IN N
the DT N
normal JJ N
reference NN N
range NN N
, , N
was VBD N
observed VBN N
. . N

Basal NNP o
cortisol JJ o
homeostasis NN o
, , o
testosterone NN o
in IN o
men NNS o
, , o
and CC o
free JJ o
androgen NN o
index NN o
in IN o
women NNS o
were VBD N
unchanged JJ N
by IN N
INCB13739 NNP N
. . N

Adverse JJ N
events NNS N
were VBD N
similar JJ N
across IN N
all DT N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
INCB13739 NNP N
added VBD N
to TO N
ongoing VBG N
metformin NN N
therapy NN N
was VBD N
efficacious JJ o
and CC N
well RB N
tolerated VBN o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
who WP p
had VBD p
inadequate JJ p
glycemic NNS p
control NN p
with IN p
metformin NN p
alone RB p
. . p

11BetaHSD1 CD N
inhibition NN N
offers NNS N
a DT N
new JJ N
potential JJ N
approach NN N
to TO N
control VB N
glucose JJ o
and CC o
cardiovascular JJ o
risk NN o
factors NNS o
in IN N
type NN p
2 CD p
diabetes NNS p
. . p

-DOCSTART- -9230829- O O

Mortality NN o
in IN N
patients NNS p
with IN p
small JJ p
choroidal NNS p
melanoma NN p
. . p

COMS NNP N
report NN N
no DT N
. . N

4 CD N
. . N

The DT N
Collaborative JJ N
Ocular NNP N
Melanoma NNP N
Study NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
describe VB N
the DT N
clinical JJ N
characteristics NNS N
and CC N
survival JJ N
experience NN N
of IN N
a DT N
prospectively RB N
followed VBN N
up RP N
group NN N
of IN N
patients NNS p
with IN p
small JJ p
choroidal NNS p
melanoma NN p
. . p

METHODS NNP N
The DT N
Collaborative NNP N
Ocular NNP N
Melanoma NNP N
Study NNP N
( ( N
COMS NNP N
) ) N
is VBZ N
a DT N
set NN N
of IN N
clinical JJ N
trials NNS N
designed VBN N
to TO N
compare VB N
the DT N
role NN N
of IN N
radiotherapy NN i
and CC N
enucleation NN i
in IN N
the DT N
treatment NN N
of IN N
medium NN N
and CC N
large-size JJ N
choroidal NN N
melanoma NN N
. . N

From IN p
December NNP p
1986 CD p
to TO p
August NNP p
1989 CD p
, , p
patients NNS p
with IN p
small JJ p
choroidal NN p
melanoma NN p
, , p
not RB p
large JJ p
enough RB p
to TO p
be VB p
eligible JJ p
for IN p
the DT p
COMS NNP p
clinical JJ p
trials NNS p
, , N
were VBD N
offered VBN N
participation NN N
in IN N
a DT N
nonrandomized JJ N
prospective JJ N
follow-up NN N
study NN N
. . N

Small NNP N
choroidal JJ N
melanomas NN N
were VBD N
defined VBN N
as IN N
1.0 CD N
to TO N
3.0 CD N
mm NNS N
in IN N
apical JJ N
height NN N
and CC N
at IN N
least JJS N
5.0 CD N
mm NN N
in IN N
basal NN N
diameter NN N
. . N

A DT p
total NN p
of IN p
204 CD p
patients NNS p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

Patients NNS N
were VBD N
followed VBN N
up RP N
annually RB N
through IN N
August NNP N
1989 CD N
. . N

Two CD N
additional JJ N
assessments NNS N
of IN N
treatment NN N
status NN N
and CC N
mortality NN o
were VBD N
conducted VBN N
in IN N
1993-1994 JJ N
and CC N
1995-1996 JJ N
. . N

The DT N
median JJ o
length NN o
of IN N
follow-up NN N
was VBD N
92 CD N
months NNS N
. . N

Eight NNP N
percent NN N
of IN N
patients NNS N
were VBD N
treated VBN N
at IN N
the DT N
time NN N
of IN N
study NN N
enrollment NN N
and CC N
an DT N
additional JJ N
33 CD N
% NN N
were VBD N
treated VBN N
during IN N
follow-up JJ N
. . N

RESULTS JJ N
Twenty-seven JJ N
patients NNS N
have VBP N
died VBN o
; : o
6 CD N
deaths NNS o
were VBD N
reported VBN N
by IN N
the DT N
clinical JJ N
center NN N
as IN N
due JJ N
to TO N
metastatic JJ o
melanoma NN o
. . o

The DT N
Kaplan-Meier NNP N
estimate NN N
of IN N
5-year JJ N
all-cause JJ N
mortality NN o
was VBD N
6.0 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
2.7 CD N
% NN N
-9.3 NNP N
% NN N
) ) N
and CC N
8-year JJ N
all-cause NN N
mortality NN o
was VBD N
14.9 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
9.6 CD N
% NN N
-20.2 NNP N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Otherwise NNP p
healthy JJ p
patients NNS p
, , p
average JJ p
age NN p
of IN p
60 CD p
years NNS p
, , p
without IN p
a DT p
previous JJ p
diagnosis NN p
of IN p
malignant JJ p
disease NN p
who WP p
have VBP p
small JJ p
choroidal JJ o
lesions NNS o
judged VBD p
to TO p
be VB p
melanoma VBN p
have VBP N
a DT N
low JJ N
risk NN N
of IN N
dying VBG N
within IN N
5 CD N
years NNS N
. . N

-DOCSTART- -7591314- O O

The DT N
European JJ p
Myocardial NNP N
Infarction NNP N
Project NNP N
: : N
an DT N
assessment NN N
of IN N
pre-hospital JJ p
thrombolysis NN p
. . p

The DT N
use NN N
of IN N
thrombolytic JJ i
agents NNS i
in IN N
patients NNS p
with IN p
suspected JJ p
myocardial JJ p
infarction NN p
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
early JJ N
and CC N
long-term JJ N
mortality NN N
by IN N
about IN N
20 CD N
% NN N
, , N
and CC N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
since IN N
time NN N
is VBZ N
an DT N
important JJ N
factor NN N
, , N
pre-hospital JJ N
treatment NN N
would MD N
give VB N
better JJR N
results NNS N
. . N

However RB N
, , N
health NN N
deciders NNS N
need VBP N
reliable JJ N
data NNS N
on IN N
which WDT N
to TO N
base VB N
future JJ N
policies NNS N
concerning VBG N
this DT N
. . N

The DT N
European JJ N
Myocardial NNP N
Infarction NNP N
Project NNP N
was VBD N
a DT N
European JJ N
Economic NNP N
Community-supported NNP N
double-blind NN N
study NN N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
pre-hospital JJ i
early JJ i
thrombolytic JJ i
treatment NN i
in IN N
patients NNS p
with IN p
suspected JJ p
myocardial JJ p
infarction NN p
compared VBN N
with IN N
the DT N
same JJ N
treatment NN N
given VBN N
later RB N
in IN N
a DT N
hospital NN N
setting NN N
. . N

A DT N
total NN p
of IN p
5469 CD p
patients NNS p
in IN p
16 CD p
countries NNS p
were VBD p
randomised VBN p
by IN p
198 CD p
mobile JJ p
emergency NN p
units NNS p
to TO p
receive VB p
either DT p
pre-hospital JJ i
treatment NN i
with IN p
anistreplase NN i
, , p
the DT p
thrombolytic JJ p
agent NN p
used VBN p
, , p
followed VBN i
by IN i
placebo NN i
after IN p
hospital JJ p
admission NN p
( ( p
pre-hospital JJ p
group NN p
; : p
2750 CD p
patients NNS p
) ) p
, , p
or CC p
placebo NN i
followed VBN i
by IN i
anistreplase NN i
( ( p
hospital JJ p
group NN p
; : p
2719 CD p
patients NNS p
) ) p
. . p

The DT N
median JJ o
time NN o
delay NN o
between IN N
the DT N
injections NNS N
was VBD N
55 CD N
min NN N
. . N

A DT N
non-significant JJ o
decrease NN o
in IN o
30-day JJ o
mortality NN o
was VBD o
observed VBN o
in IN o
favour NN o
of IN o
the DT o
pre-hospital JJ o
group NN o
( ( N
13 CD N
% NN N
: : N
P NNP N
= NNP N
0.08 CD N
) ) N
, , N
whereas IN N
the DT o
decrease NN o
in IN o
cardiac JJ o
death NN o
observed VBD o
, , N
also RB N
in IN N
favour NN N
of IN N
the DT N
pre-hospital JJ N
group NN N
, , N
was VBD N
on IN N
the DT N
borderline NN N
of IN N
significance NN N
( ( N
16 CD N
% NN N
; : N
P NNP N
= NNP N
0.049 CD N
) ) N
. . N

Although IN N
some DT o
complications NNS o
occurred VBD o
more RBR o
frequently RB o
in IN o
the DT o
pre-hospital JJ o
group NN o
in IN N
the DT N
pre-hospital JJ N
period NN N
, , N
the DT N
overall JJ o
incidence NN o
for IN o
serious JJ o
complications NNS o
was VBD o
similar JJ o
for IN o
both DT o
groups NNS o
. . o

These DT N
results NNS N
show VBP N
that IN N
the DT o
pre-hospital JJ o
thrombolytic JJ o
strategy NN o
in IN o
patients NNS o
with IN o
suspected JJ o
myocardial JJ o
infarction NN o
is VBZ o
both DT o
effective JJ o
and CC o
safe JJ o
when WRB o
performed VBN o
by IN o
well-equipped JJ o
well-staffed JJ o
mobile JJ o
emergency NN o
units NNS o
. . o

-DOCSTART- -16208798- O O

Single-use NNP N
plaque NN N
removal NN N
efficacy NN o
of IN N
three CD p
power NN i
toothbrushes NNS i
. . i

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
safety NN o
and CC o
plaque NN o
removal NN o
efficacy NN o
of IN N
two CD i
oscillating/rotating/pulsating VBG i
toothbrushes NNS i
( ( i
Oral-B NNP i
ProfessionalCare NNP i
7000 CD i
[ NNP i
PC NN i
7000 CD i
] NN i
and CC i
Oral-B JJ i
3D CD i
Excel NNP i
[ VBD i
3DE CD i
] NN i
) ) i
and CC i
a DT i
high-frequency NN i
toothbrush NN i
( ( i
Sonicare NNP i
Advance NNP i
, , i
Philips NNP i
Oral NNP i
Healthcare NNP i
; : i
SA NNP i
) ) i
in IN N
a DT N
single-use NN N
, , N
examiner-blind NN N
, , N
three CD N
period NN N
crossover NN N
study NN N
. . N

METHODS NNP N
After IN p
refraining VBG p
from IN p
all DT p
oral JJ p
hygiene NN p
procedures NNS p
for IN p
23-25 JJ p
hours NNS p
, , p
subjects NNS p
received VBD p
an DT p
oral JJ p
tissue NN p
examination NN p
and CC N
those DT N
with IN N
pre-brushing JJ N
whole JJ N
mouth NN N
mean JJ N
plaque NN N
scores NNS N
> VBP N
or CC N
= VBP N
0.6 CD N
based VBN N
on IN N
the DT N
Rustogi NNP N
et CC N
al NN N
. . N

Modified NNP N
Navy NNP N
Plaque NNP N
Index NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
sequence NN N
. . N

After IN N
brushing VBG N
with IN N
the DT N
assigned JJ N
toothbrush NN N
and CC N
a DT N
commercially RB N
available JJ N
dentifrice NN N
for IN N
2 CD N
minutes NNS N
, , N
oral JJ o
tissues NNS o
were VBD o
then RB o
re-examined JJ o
and CC o
post-brushing JJ o
plaque NN o
scores NNS o
recorded VBN o
. . o

Following VBG N
a DT N
brief JJ N
washout JJ N
period NN N
between IN N
two CD N
additional JJ N
visits NNS N
, , N
the DT N
above NN N
procedures NNS N
were VBD N
repeated VBN N
with IN N
the DT N
two CD N
alternate NN N
toothbrushes NNS N
. . N

One CD N
examiner NN N
, , N
blinded VBD N
to TO N
the DT N
treatment NN N
sequence NN N
, , N
performed VBD N
all DT N
clinical JJ N
measurements NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
79 CD p
subjects NNS p
( ( p
28 CD p
males NNS p
and CC p
51 CD p
females NNS p
) ) p
were VBD p
enrolled VBN p
and CC p
completed VBN p
the DT p
study NN p
. . p

Each DT N
toothbrush NN N
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC N
significantly RB N
reduced VBN N
plaque NN o
levels NNS o
after IN N
a DT N
single JJ N
brushing NN N
. . N

The DT N
PC NN N
7000 CD N
and CC N
3DE CD N
were VBD N
equally RB N
more RBR N
effective JJ N
in IN N
plaque NN o
removal NN o
than IN N
the DT N
SA NNP N
, , N
at IN N
all DT N
tooth DT N
areas NNS N
, , N
reducing VBG N
plaque NN o
by IN N
59.0 CD N
% NN N
, , N
59.7 CD N
% NN N
and CC N
51.8 CD N
% NN N
, , N
respectively RB N
on IN N
whole JJ N
mouth NN N
surfaces NNS N
, , N
and CC N
by IN N
67.5 CD N
% NN N
, , N
67.8 CD N
% NN N
and CC N
59.4 CD N
% NN N
, , N
respectively RB N
on IN N
approximal JJ N
surfaces NNS N
. . N

CONCLUSIONS VB N
The DT N
action NN N
of IN N
the DT N
oscillating/rotating/pulsating NN N
toothbrushes NNS N
( ( N
Oral-B NNP N
ProfessionalCare NNP N
7000 CD N
and CC N
Oral-B NNP N
3D CD N
Excel NNP N
) ) N
was VBD N
more RBR N
effective JJ N
in IN N
plaque NN N
removal NN N
than IN N
the DT N
high-frequency NN N
toothbrush NN N
( ( N
Sonicare NNP N
Advance NNP N
) ) N
. . N

-DOCSTART- -22727707- O O

Rosiglitazone NN i
and CC N
cognitive JJ N
function NN N
in IN N
clozapine-treated JJ i
patients NNS p
with IN p
schizophrenia NN p
: : p
a DT N
pilot NN N
study NN N
. . N

Studies NNS N
have VBP N
shown VBN N
that IN N
insulin NN N
resistance NN N
is VBZ N
associated VBN N
with IN N
cognitive JJ N
impairment NN N
. . N

Peroxisome VB i
proliferator-activated JJ i
receptor-? NN i
( ( i
PPAR-? NNP i
) ) i
agonists VBZ i
improve JJ N
insulin NN N
sensitivity NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT o
effect NN o
of IN o
rosiglitazone NN o
, , o
a DT N
PPAR-? JJ N
agonist NN N
, , N
on IN N
cognition NN N
in IN N
clozapine-treated JJ p
patients NNS p
with IN p
schizophrenia NN p
. . p

In IN p
an DT N
eight-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
pilot NN N
trial NN p
, , p
clozapine-treated JJ p
patients NNS p
with IN p
schizophrenia NN p
were VBD p
randomized VBN N
to TO N
receive VB i
rosiglitazone NN i
( ( i
4mg/day CD i
) ) i
or CC i
placebo NN i
. . i

A DT i
neuropsychological JJ N
battery NN N
including VBG o
the DT o
Digit NNP o
Span NNP o
subtest JJS o
from IN o
the DT o
Wechsler NNP o
Adult NNP o
Intelligence NNP o
Scale-III NNP o
( ( o
WAIS-III NNP o
) ) o
, , o
the DT o
verbal JJ o
fluency NN o
test NN o
, , o
the DT o
Hopkins NNP o
Verbal NNP o
Learning NNP o
Test NNP o
( ( o
HVLT NNP o
) ) o
, , o
the DT o
Trail-Making JJ o
Test NNP o
( ( o
TMT NNP o
) ) o
and CC o
the DT o
Wisconsin NNP o
Card NNP o
Sorting NNP o
Test NNP o
( ( o
WCST NNP o
) ) o
was VBD o
administered VBN N
at IN N
baseline NN N
and CC N
week NN N
eight CD p
. . p

Nineteen JJ p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

There EX p
were VBD N
no DT N
significant JJ N
differences NNS N
on IN N
any DT N
demographic JJ o
or CC o
general JJ o
clinical JJ o
variables NNS o
between IN o
the DT N
rosiglitazone NN i
group NN i
( ( p
n=9 CC p
) ) p
and CC p
the DT p
placebo NN i
group NN i
( ( p
n=10 RB p
) ) p
. . p

When WRB p
baseline NN N
scores NNS N
were VBD N
controlled VBN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
change NN N
scores NNS N
of IN N
cognitive JJ o
performance NN o
over IN o
eight CD N
weeks NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
this DT N
pilot NN N
study NN i
, , i
rosiglitazone NN i
had VBD i
no DT N
cognitive JJ o
benefit NN o
in IN o
clozapine-treated JJ p
patients NNS p
with IN p
schizophrenia NN p
. . p

Future JJ p
studies NNS N
with IN N
longer JJR N
treatment NN N
duration NN N
and CC N
larger JJR N
sample NN N
size NN N
are VBP N
needed VBN N
to TO N
further RBR N
explore VB N
the DT N
potential JJ N
role NN N
of IN N
rosiglitazone NN i
in IN i
improving VBG N
cognitive JJ N
function NN N
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

-DOCSTART- -20164800- O O

Relief NN N
of IN N
periorbital JJ N
pain NN N
after IN N
acute JJ N
angle JJ N
closure NN N
glaucoma NN N
attack NN N
by IN N
botulinum NN i
toxin NN i
type NN i
A NNP i
. . i

PURPOSE NNP N
To TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
botulinum NN i
toxin NN i
type NN i
A NNP i
( ( i
BoNT-A NNP i
) ) i
injection NN N
in IN N
patients NNS p
suffering VBG p
from IN p
intractable JJ p
periorbital NN p
pain NN p
after IN p
acute JJ p
angle JJ p
closure NN p
glaucoma NN p
( ( p
AACG NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
prospective JJ N
randomized VBN N
intervention NN N
study NN N
, , N
19 CD p
patients NNS p
suffering VBG p
from IN p
periorbital JJ p
pain NN p
after IN p
an DT p
AACG NNP p
attack NN p
were VBD N
injected VBN i
with IN i
BoNT-A NNP i
or CC i
placebo NN i
for IN N
pain NN N
relief NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
on IN N
days NNS N
1 CD N
, , N
2 CD N
, , N
7 CD N
, , N
14 CD N
, , N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
. . N

The DT N
main JJ N
outcomes NNS N
were VBD N
mean JJ N
change NN N
of IN N
visual JJ N
analog NN N
rating NN N
scale NN N
( ( N
VARS NNP N
) ) N
and CC N
index NN N
scores NNS N
measured VBN N
through IN N
a DT N
quality-of-life JJ N
questionnaire NN N
( ( N
EQ-5D NNP N
) ) N
, , N
and CC N
changes NNS N
in IN N
the DT N
visual JJ o
analog NN o
scale NN o
( ( N
VAS NNP N
) ) N
, , N
all DT N
of IN N
which WDT N
were VBD N
assessed VBN N
at IN N
each DT N
visit NN N
. . N

A DT N
secondary JJ N
outcome NN N
was VBD N
the DT N
frequency NN N
and CC N
nature NN N
of IN N
adverse JJ N
events NNS N
and CC N
the DT N
number NN N
of IN N
patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
study NN N
as IN N
a DT N
result NN N
. . N

RESULTS NN N
In IN N
the DT N
treatment NN N
group NN N
( ( N
n=10 NN N
) ) N
, , N
the DT N
mean JJ o
index NN o
score NN o
of IN o
EQ-5D NNP o
and CC o
VAS NNP o
changed VBD N
significantly RB N
from IN N
the DT N
placebo NN i
group NN N
( ( N
by IN N
0.299 CD N
and CC N
2.61 CD N
, , N
respectively RB N
) ) N
from IN N
day NN N
2 CD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
VARS NNP o
of IN o
EQ-5D NNP o
also RB N
disclosed VBD N
significant JJ N
changes NNS N
from IN N
day NN N
2 CD N
( ( N
17 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
addition NN N
, , N
efficacy NN o
was VBD N
maintained VBN N
mainly RB N
between IN N
days NNS N
2 CD N
and CC N
60 CD N
but CC N
declined VBD N
slightly RB N
by IN N
day NN N
90 CD N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
treatment-related JJ N
adverse JJ N
events NNS N
in IN N
the DT N
treatment NN N
and CC N
placebo NN N
groups NNS N
were VBD N
local JJ o
tenderness NN o
( ( N
21 CD N
% NN N
) ) N
, , N
subcutaneous JJ o
hemorrhage NN o
( ( N
10.5 CD N
% NN N
) ) N
, , N
and CC N
conjunctivitis NN o
( ( N
10.5 CD N
% NN N
) ) N
. . N

No UH N
severe JJ o
adverse JJ o
events NNS o
were VBD N
reported VBN N
during IN N
the DT N
study NN N
or CC N
follow-up JJ N
period NN N
. . N

CONCLUSIONS NNP N
BoNT-A NNP i
is VBZ N
effective JJ N
and CC N
well RB N
tolerated VBN N
for IN N
the DT N
treatment NN N
of IN N
periorbital JJ N
pain NN N
after IN N
an DT N
AACG NNP N
attack NN N
. . N

Its PRP$ N
effects NNS N
may MD N
be VB N
maintained VBN N
for IN N
3 CD N
months NNS N
. . N

-DOCSTART- -6363798- O O

A DT N
controlled VBN N
study NN N
of IN N
the DT N
effect NN o
of IN N
indomethacin NN i
in IN N
uremic JJ o
pericarditis NN o
. . o

To TO N
determine VB N
the DT N
impact NN N
of IN N
indomethacin NN i
on IN N
the DT N
course NN N
of IN N
uremic JJ N
pericarditis NN N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
double JJ N
blind NN N
study NN N
in IN N
which WDT N
24 CD p
patients NNS p
with IN p
endstage NN p
chronic JJ p
renal JJ p
failure NN p
and CC p
pericarditis NN p
randomly RB p
received VBD p
indomethacin JJ i
, , p
25 CD p
mg NN p
four CD p
times NNS p
daily RB p
, , p
( ( p
11 CD p
patients NNS p
) ) p
or CC p
a DT p
placebo NN i
( ( p
13 CD p
patients NNS p
) ) p
for IN N
a DT N
3-week JJ N
period NN N
. . N

All DT N
patients NNS p
received VBN p
peritoneal JJ p
or CC p
hemodialysis NN p
treatment NN p
concurrently RB p
with IN N
the DT N
study NN N
drug NN N
. . N

In IN N
contrast NN N
to TO N
the DT N
placebo NN i
, , i
indomethacin NN i
produced VBD N
an DT N
immediate JJ N
and CC N
sustained JJ N
reduction NN o
of IN o
fever NN o
in IN N
all DT N
but CC N
one CD N
patient NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
indomethacin NN i
had VBD N
no DT N
effect NN N
on IN N
the DT N
duration NN o
of IN o
chest NN o
pain NN o
( ( N
mean JJ N
days NNS N
+/- JJ N
SE NNP N
: : N
placebo NN i
1.4 CD N
+/- JJ N
0.6 CD N
, , N
indomethacin JJ i
5.5 CD N
+/- JJ N
3.3 CD N
) ) N
, , N
duration NN N
of IN N
pericardial JJ o
friction NN o
rub NN o
( ( N
placebo JJ N
10.3 CD N
+/- JJ N
1.7 CD N
, , N
indomethacin JJ i
16.0 CD N
+/- JJ N
3.8 CD N
) ) N
, , N
or CC N
on IN N
the DT N
amount NN N
of IN N
pericardial JJ o
effusion NN o
. . o

Further NNP N
, , N
indomethacin NN N
did VBD N
not RB N
diminish VB N
the DT N
need NN o
for IN o
invasive JJ o
surgical JJ o
procedures NNS o
for IN o
relief NN o
of IN o
tamponade NN o
( ( N
three CD N
of IN N
13 CD N
placebo NN N
patients NNS N
, , N
two CD N
of IN N
11 CD N
indomethacin JJ N
patients NNS N
) ) N
or CC N
result NN N
in IN N
decreased JJ N
mortality NN o
rate NN o
. . o

Death NNP o
( ( N
not RB N
due RB N
to TO N
pericarditis NN N
) ) N
occurred VBD N
in IN N
two CD N
patients NNS N
treated VBN N
with IN N
indomethacin NN N
and CC N
one CD N
patient NN N
who WP N
received VBD N
the DT N
placebo NN i
. . i

In IN N
our PRP$ N
patients NNS N
pericarditis VBP N
encompassed VBD N
a DT N
wide JJ N
spectrum NN N
ranging VBG N
from IN N
a DT N
mild JJ o
illness NN o
of IN o
several JJ o
days NNS o
duration NN o
to TO N
a DT N
painful JJ o
and CC o
debilitating JJ o
disease NN o
lasting JJ o
weeks NNS o
and CC N
requiring VBG N
surgical JJ o
intervention NN o
. . o

Although IN N
the DT N
size NN N
of IN N
our PRP$ N
population NN N
prohibits VBZ N
definitive JJ N
conclusions NNS N
, , N
it PRP N
would MD N
appear VB N
that IN N
, , N
except IN N
for IN N
fever NN N
, , N
the DT N
manifestations NNS N
and CC N
natural JJ N
history NN N
of IN N
this DT N
illness NN o
are VBP N
unaffected VBN N
by IN N
indomethacin NN i
. . i

-DOCSTART- -18837418- O O

The DT N
value NN o
of IN o
transbronchial JJ o
lung NN o
biopsy NN o
using VBG N
jumbo JJ N
forceps NNS N
via IN N
rigid JJ N
bronchoscope NN N
in IN N
diffuse NN p
lung NN p
disease NN p
. . p

BACKGROUND NNP N
Transbronchial NNP N
lung NN N
biopsy NN N
( ( N
TBLB NNP N
) ) N
is VBZ N
a DT N
valuable JJ N
procedure NN N
used VBN N
to TO N
obtain VB N
a DT N
parenchymal JJ o
specimen NNS o
in IN N
the DT N
evaluation NN N
of IN N
diffuse NN N
lung NN N
infiltrates NNS N
. . N

Large JJ N
forceps NNS N
are VBP N
expected VBN N
to TO N
result VB N
in IN N
larger JJR N
specimens NNS N
and CC N
improve VB N
diagnostic JJ N
yield NN N
. . N

AIM CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
diagnostic JJ N
yield NN N
of IN N
TBLB NNP N
using VBG N
large JJ N
modified VBN N
flexible JJ N
gastroenterological JJ N
forceps NNS N
( ( N
Jumbo NNP N
forceps NNS N
) ) N
compared VBN N
with IN N
'normal NNP N
' POS N
flexible JJ N
forceps NNS N
via IN N
rigid JJ N
bronchoscopy NN N
in IN N
patients NNS N
with IN N
diffuse NN p
parenchymal JJ p
lung NN p
disease NN p
( ( p
DPLD NNP p
) ) p
. . p

METHODS PDT N
The DT N
study NN N
was VBD N
a DT N
prospective JJ N
analysis NN N
of IN N
95 CD p
patients NNS p
who WP p
underwent VBP i
fluoroscopy NN i
guided VBD i
TBLB NNP i
over IN i
a DT i
two CD i
year NN i
period NN i
. . i

Patients NNS p
with IN p
a DT p
lung NN p
mass NN p
or CC p
solitary JJ p
lung NN p
nodule NN p
undergoing VBG p
TBLB NNP p
were VBD p
excluded VBN p
. . p

The DT N
larger JJR i
and CC i
small JJ i
forceps NNS i
were VBD N
used VBN N
in IN N
a DT N
random JJ N
sequence NN N
to TO N
avoid VB N
a DT N
reduction NN N
in IN N
diagnostic JJ N
yield NN N
of IN N
the DT N
second JJ N
series NN N
of IN N
biopsies NNS N
related VBN N
to TO N
possible JJ N
bleeding NN N
by IN N
first JJ N
series NN N
of IN N
biopsies NNS N
. . N

To TO N
minimize VB N
the DT N
consequence NN N
of IN N
haemorrhage NN N
, , N
we PRP N
performed VBD N
every DT N
rigid JJ N
bronchoscopy NN i
, , i
placing VBG i
a DT i
non NN i
inflated VBN i
Fogarty NNP i
balloon NN i
and CC i
a DT i
rigid JJ i
aspirator NN i
( ( i
diameter JJ i
4 CD i
mm NN i
) ) i
in IN i
lobar NN i
bronchus NN i
near IN i
the DT i
biopsy NN i
segment NN i
. . i

The DT i
Fogarty NNP i
balloon NN i
has VBZ i
been VBN i
inflated VBN i
in IN i
case NN i
of IN i
bleeding NN i
. . i

After IN N
the DT N
bleeding NN N
was VBD N
controlled VBN N
we PRP N
continued VBD N
to TO N
operate VB N
up RP N
to TO N
the DT N
biopsy NN N
segment NN N
. . N

RESULTS NNP N
Diagnostic JJ o
yield NN o
of IN N
TBLB NNP N
using VBG N
Jumbo NNP N
forceps NNS N
was VBD N
significantly RB N
higher JJR N
than IN N
using VBG N
normal JJ N
flexible JJ N
forceps NNS N
via IN N
rigid JJ N
bronchoscopy NN N
in IN N
patients NNS p
with IN p
DPLD NNP p
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

In IN N
74 CD p
out IN p
of IN p
95 CD p
patients NNS p
( ( p
78 CD p
% NN p
) ) p
the DT N
diagnosis NN N
was VBD N
placed VBN N
with IN N
Jumbo NNP p
forcep NN p
while IN p
the DT p
smaller JJR p
forcep NN p
was VBD p
diagnostic JJ p
in IN p
62 CD p
out IN p
of IN p
95 CD p
patients NNS p
( ( p
65 CD p
% NN p
) ) p
. . p

Large JJ N
forceps NNS N
obtained VBD N
significantly RB N
more RBR N
tissue NN o
than IN N
the DT N
small JJ N
forceps NNS N
; : N
the DT N
biopsy NN N
specimen NNS N
taken VBN N
with IN N
normal JJ N
forcep NNS N
measured VBN N
in IN N
average JJ N
1.4 CD N
x JJ N
1.0 CD N
mm NN N
and CC N
the DT N
larger JJR N
biopsy NN N
taken VBN N
with IN N
jumbo JJ N
forcep NNS N
measured VBN N
in IN N
average JJ N
2.5 CD N
x JJ N
1.9 CD N
mm NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
use NN N
of IN N
large JJ N
biopsy NN N
forceps NNS N
to TO N
perform VB N
TBLB NNP N
via IN N
rigid JJ N
bronchoscope NN N
can MD N
significantly RB N
increase VB N
diagnostic JJ N
yield NN N
in IN N
the DT N
pathological JJ N
diagnosis NN N
of IN N
diffuse NN p
infiltrative JJ p
lung NN p
disease NN p
. . p

-DOCSTART- -9413463- O O

Randomised VBN N
trial NN N
of IN N
efficacy NN o
and CC o
safety NN o
of IN N
oral JJ i
ganciclovir NN i
in IN N
the DT N
prevention NN N
of IN N
cytomegalovirus NN N
disease NN N
in IN N
liver-transplant JJ p
recipients NNS p
. . p

The DT N
Oral NNP N
Ganciclovir NNP i
International NNP N
Transplantation NNP N
Study NNP N
Group NNP N
[ NNP N
corrected VBD N
] NNP N
. . N

BACKGROUND NNP N
Cytomegalovirus NNP N
( ( N
CMV NNP N
) ) N
disease NN N
is VBZ N
a DT N
frequent JJ N
cause NN N
of IN N
serious JJ N
morbidity NN N
after IN N
solid-organ JJ N
transplantation NN N
. . N

The DT N
prophylactic JJ N
regimens NNS N
used VBN N
to TO N
prevent VB N
CMV NNP N
infection NN N
and CC N
disease NN N
have VBP N
shown VBN N
limited JJ N
benefit NN N
in IN N
seronegative JJ N
recipients NNS N
. . N

We PRP N
studied VBD N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
oral JJ i
ganciclovir NN i
in IN N
the DT N
prevention NN N
of IN N
CMV NNP N
disease NN N
following VBG N
orthotopic NN p
liver JJ p
transplantation NN p
. . p

METHODS NNP N
Between NNP p
December NNP p
, , p
1993 CD p
, , p
and CC p
April NNP p
, , p
1995 CD p
, , p
304 CD p
liver-transplant JJ p
recipients NNS p
were VBD N
randomised VBN N
to TO N
receive VB N
oral JJ i
ganciclovir NN i
1000 CD i
mg NN N
or CC N
matching VBG N
placebo NN i
three CD N
times NNS N
a DT N
day NN N
. . N

Seronegative JJ p
recipients NNS p
of IN p
seronegative JJ p
livers NNS p
were VBD N
excluded VBN N
. . N

Study NNP N
drug NN N
was VBD N
administered VBN N
as RB N
soon RB N
as IN N
the DT N
patient NN N
was VBD N
able JJ N
to TO N
take VB N
medication NN N
by IN N
mouth NN N
( ( N
no DT N
later RB N
than IN N
day NN N
10 CD N
) ) N
until IN N
the DT N
98th CD N
day NN N
after IN N
transplantation NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
specified VBN N
times NNS N
throughout IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
surgery NN N
for IN N
evidence NN N
of IN N
CMV NNP o
infection NN o
, , o
CMV NNP o
disease NN o
, , o
rejection NN o
, , o
opportunistic JJ o
infections NNS o
, , o
and CC o
possible JJ o
drug NN o
toxicity NN o
. . o

FINDINGS IN N
The DT N
Kaplan-Meier NNP N
estimate NN N
of IN N
the DT N
6-month JJ o
incidence NN o
of IN o
CMV NNP o
disease NN o
was VBD N
29 CD N
( ( N
18.9 CD N
% NN N
) ) N
of IN N
154 CD N
in IN N
the DT N
placebo NN N
group NN N
, , N
compared VBN N
with IN N
seven CD N
( ( N
4.8 CD N
% NN N
) ) N
of IN N
150 CD N
in IN N
the DT N
ganciclovir NN i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
the DT N
high-risk JJ N
group NN N
of IN N
seronegative JJ N
recipients NNS N
( ( N
R- NNP N
) ) N
of IN N
seropositive JJ N
livers NNS N
( ( N
D+ NNP N
) ) N
, , N
incidence NN o
of IN o
CMV NNP o
disease NN o
was VBD N
11 CD N
( ( N
44.0 CD N
% NN N
) ) N
of IN N
25 CD N
in IN N
the DT N
placebo NN i
group NN N
, , N
three CD N
( ( N
14.8 CD N
% NN N
) ) N
of IN N
21 CD N
in IN N
the DT N
ganciclovir NN i
group NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

Significant JJ N
benefit NN N
was VBD N
also RB N
observed VBN N
in IN N
those DT N
receiving VBG N
antibodies NNS N
to TO N
lymphocytes NNS N
, , N
where WRB N
the DT N
incidence NN N
of IN N
CMV NNP o
disease NN o
was VBD N
12 CD N
( ( N
32.9 CD N
% NN N
) ) N
of IN N
37 CD N
in IN N
the DT N
placebo NN i
group NN N
and CC N
two CD N
( ( N
4.6 CD N
% NN N
) ) N
of IN N
44 CD N
in IN N
the DT N
ganciclovir NN i
group NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

Oral JJ N
ganciclovir NN N
reduced VBD N
the DT N
incidence NN o
of IN o
CMV NNP o
infection NN o
( ( i
placebo JJ i
79 CD N
[ JJ N
51.5 CD N
% NN N
] NN N
of IN N
154 CD N
; : N
ganciclovir CC i
37 CD N
[ JJ N
24.5 CD N
% NN N
] NN N
of IN N
150 CD N
; : N
p NN N
< VBZ N
0.001 CD N
) ) N
and CC N
also RB N
reduced VBN N
symptomatic JJ o
herpes-simplex JJ o
infections NNS o
( ( N
Kaplan-Meier NNP N
estimates NNS N
: : N
placebo NN i
36 CD N
[ JJ N
23.5 CD N
% NN N
] NN N
of IN N
154 CD N
; : N
ganciclovir JJ N
five CD N
[ JJ N
3.5 CD N
% NN N
] NN N
of IN N
150 CD N
; : N
p NN N
< VBZ N
0.001 CD N
) ) N
. . N

INTERPRETATION NNP N
Oral NNP N
ganciclovir NN i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
method NN N
for IN N
the DT N
prevention NN N
of IN N
CMV NNP N
disease NN N
after IN N
orthotopic NN p
liver NN p
transplantation NN p
. . p

-DOCSTART- -18208642- O O

Comparison NNP N
of IN N
the DT N
therapeutic JJ N
effects NNS N
of IN N
epoetin NN i
zeta NN i
to TO i
epoetin VB i
alfa NN i
in IN N
the DT N
maintenance NN p
phase NN p
of IN p
renal JJ p
anaemia NN p
treatment NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
therapeutic JJ N
efficacy NN N
and CC N
safety NN N
of IN N
epoetin JJ i
zeta NN i
, , N
compared VBN N
with IN N
epoetin NN i
alfa NN i
, , N
in IN N
maintaining VBG N
target NN N
haemoglobin NN N
( ( N
Hb NNP N
) ) N
concentrations NNS N
in IN N
patients NNS p
with IN p
anaemia NN p
and CC p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
maintained VBD p
on IN p
haemodialysis NN p
. . p

METHODS NNP N
Patients NNPS N
received VBD N
epoetin JJ i
zeta NN i
or CC i
epoetin NN i
alfa NN i
intravenously RB N
, , N
1-3 JJ N
times/week NN N
for IN N
12 CD N
weeks NNS N
, , N
then RB N
the DT N
alternative JJ N
treatment NN N
for IN N
12 CD N
weeks NNS N
, , N
in IN N
this DT N
double-blind NN N
, , N
crossover NN N
, , N
phase NN N
III NNP N
trial NN N
. . N

Eligible JJ p
patients NNS p
were VBD p
18-75 CD p
years NNS p
old JJ p
with IN p
CKD NNP p
stage NN p
5 CD p
maintained VBN p
on IN p
haemodialysis NN p
. . p

Patients NNS N
had VBD N
received VBN N
epoetin NN i
for IN N
> NN N
or CC N
= $ N
3 CD N
months NNS N
upon IN N
study NN N
entry NN N
and CC N
had VBD N
achieved VBN N
a DT N
target NN N
Hb NNP N
level NN N
of IN N
10.5-12.5 JJ N
g/dL NN N
with IN N
a DT N
stable JJ N
epoetin NN i
dose NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
efficacy NN N
endpoints NNS N
were VBD N
intra-individual JJ N
differences NNS N
( ( N
test-reference NN N
) ) N
in IN N
mean JJ N
Hb NNP N
levels NNS N
and CC N
mean JJ N
weekly JJ N
dose/kg NN N
of IN N
body NN N
weight NN N
. . N

Safety NN N
endpoints NNS N
included VBD N
occurrence NN o
of IN o
neutralizing VBG o
anti-erythro JJ o
poietin NN o
antibodies NNS o
, , o
tolerability NN o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . N

RESULTS NNP N
In IN p
total JJ p
, , p
313 CD p
patients NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
epoetin NN i
zeta NN i
( ( N
n JJ N
= NNP N
155 CD N
) ) N
or CC N
epoetin JJ i
alfa NN i
( ( N
n JJ N
= NNP N
158 CD N
) ) N
; : N
146 CD N
and CC N
145 CD N
patients NNS N
( ( N
respectively RB N
) ) N
switched VBD N
treatment NN N
after IN N
12 CD N
weeks NNS N
. . N

Mean NNP o
( ( o
range NN o
) ) o
Hb NNP o
levels NNS o
were VBD N
11.35 CD N
( ( N
8.96-14.22 CD N
) ) N
g/dL NN N
and CC N
11.54 CD N
( ( N
8.74-13.84 CD N
) ) N
g/dL NN N
for IN N
patients NNS N
receiving VBG N
epoetin JJ N
zeta NN N
and CC N
epoetin NN N
alfa NN N
, , N
respectively RB N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
[ NNP N
test-reference NN N
] NN N
: : N
0.09-0.28 JJ N
g/dL NN N
, , N
within IN N
the DT N
predefined JJ N
equivalence NN N
range NN N
of IN N
+/-0.6 NNP N
g/dL NN N
) ) N
. . N

Mean NNP o
( ( o
range NN o
) ) o
weekly JJ o
doses NNS o
were VBD N
92.68 CD N
( ( N
12.74-398.41 JJ N
) ) N
IU/kg/wk NNP N
and CC N
92.58 CD N
( ( N
10.53-393.07 JJ N
) ) N
IU/kg/wk NNP N
for IN N
patients NNS N
receiving VBG N
epoetin JJ i
zeta NN i
and CC N
epoetin NN i
alfa NN i
, , N
respectively RB N
( ( N
95 CD N
% NN N
CI NNP N
[ NNP N
test-reference NN N
] NN N
: : N
-4.67 NN N
and CC N
4.29 CD N
IU/kg/wk NNP N
, , N
within IN N
the DT N
equivalence NN N
range NN N
of IN N
+/-45.00 NNP N
IU/kg/wk NNP N
) ) N
. . N

Patients NNPS N
underwent JJ N
minor JJ N
nominal JJ N
dose NN N
adjustments NNS N
during IN N
treatment NN N
crossover NN N
. . N

AE NNP N
profile NN N
was VBD N
similar JJ N
for IN N
both DT N
products NNS N
; : N
the DT N
most RBS N
commonly RB N
reported VBD N
AEs NNP N
were VBD N
infections NNS o
and CC o
infestations NNS o
( ( N
in IN N
26.5 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
epoetin JJ N
zeta NN N
and CC N
23.6 CD N
% NN N
receiving VBG N
epoetin JJ N
alfa NN N
) ) N
. . N

No UH N
patients NNS N
developed VBD N
neutralizing VBG o
anti-erythropoietin JJ o
antibodies NNS o
. . o

CONCLUSIONS NNP N
Epoetin NNP i
zeta NN i
is VBZ N
therapeutically RB N
equivalent JJ N
to TO N
epoetin VB N
alfa NN N
in IN N
the DT N
maintenance NN N
of IN N
target NN N
Hb NNP N
levels NNS N
in IN N
patients NNS p
with IN p
renal JJ p
anaemia NN p
. . p

No DT N
unexpected JJ N
AEs NNP N
were VBD N
seen VBN N
. . N

-DOCSTART- -10337847- O O

Problem-solving JJ i
counseling NN i
for IN N
caregivers NNS N
of IN N
the DT N
cognitively JJ N
impaired JJ N
: : N
effective JJ N
for IN N
whom WP N
? . N
BACKGROUND NNP N
Individualized VBD N
problem-solving JJ i
counseling NN i
for IN N
caregivers NNS N
of IN N
cognitively RB N
impaired JJ N
relatives NNS N
is VBZ N
thought VBN N
to TO N
help VB N
caregivers NNS N
cope VB N
with IN N
the DT N
stress NN N
and CC N
burden NN N
of IN N
caregiving VBG N
. . N

Few JJ N
studies NNS N
have VBP N
shown VBN N
the DT N
effectiveness NN N
of IN N
counseling VBG N
for IN N
these DT N
caregivers NNS N
. . N

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
individualized JJ i
problem-solving JJ i
counseling NN i
by IN i
nurses NNS i
for IN N
caregivers NNS N
and CC N
the DT N
expenditures NNS N
of IN N
health NN N
care NN N
utilization NN N
. . N

METHOD NNP N
Caregivers NNP p
( ( p
n JJ p
= NNP p
77 CD p
) ) p
of IN p
the DT p
cognitively RB p
impaired JJ p
living NN p
at IN p
home NN p
were VBD N
randomized VBN N
to TO N
receive VB N
nurse JJ i
counseling NN i
or CC i
not RB i
. . i

Psychosocial JJ N
adjustment NN N
to TO N
their PRP$ N
relative NN o
's POS o
illness NN o
, , o
psychological JJ o
distress NN o
, , o
burden NN o
, , o
coping VBG o
skills NNS o
, , o
and CC o
expenditures NNS o
were VBD N
measured VBN N
after IN N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
. . N

RESULTS NNP N
Although IN N
on IN N
average NN N
, , N
all DT N
caregivers NNS N
receiving VBG N
nurse JJ i
counseling NN i
indicated VBD N
no DT N
improvement NN o
in IN N
psychosocial JJ N
adjustment NN N
to TO N
their PRP$ N
relative NN o
's POS o
illness NN o
, , o
psychological JJ o
distress NN o
, , o
or CC o
caregiver RB o
burden NN o
, , N
they PRP N
found VBD N
counseling VBG N
very RB N
helpful JJ N
and CC N
it PRP N
was VBD N
effective JJ N
for IN N
a DT N
subgroup NN N
of IN N
caregivers NNS N
. . N

Those DT N
with IN N
poor JJ N
logical JJ N
analysis NN N
coping VBG N
skills NNS N
at IN N
baseline NN N
had VBD N
decreased VBN o
psychological JJ o
distress NN o
( ( N
F NNP N
( ( N
1,53 CD N
) ) N
= NN N
9.7 CD N
, , N
p NN N
= NNP N
.003 NNP N
) ) N
and CC N
improved VBN o
psychosocial JJ o
adjustment NN o
( ( N
F NNP N
( ( N
1,53 CD N
) ) N
= NN N
4.7 CD N
, , N
p NN N
= NNP N
.035 NNP N
) ) N
after IN N
1 CD N
year NN N
. . N

Caregivers NNS N
in IN N
control NN i
and CC N
counseling VBG i
groups NNS N
whose WP$ N
relatives NNS N
entered VBD N
a DT N
nursing NN N
home NN N
improved VBD N
their PRP$ N
psychosocial JJ o
adjustment NN o
23 CD N
% NN N
on IN N
average JJ N
whereas NNS N
those DT N
continuing VBG N
to TO N
live VB N
in IN N
the DT N
community NN N
decreased VBN N
by IN N
8 CD N
% NN N
. . N

Almost NNP N
half NN N
as IN N
many JJ N
relatives NNS N
entered VBD N
nursing VBG N
homes NNS N
in IN N
the DT N
counseling NN i
group NN N
( ( N
n JJ N
= $ N
9 CD N
vs. FW N
n JJ N
= NNP N
5 CD N
) ) N
but CC N
these DT N
compared VBN N
to TO N
control VB i
group NN N
relatives NNS N
had VBD N
greater JJR N
annualized VBN N
per IN N
person NN N
expenditures NNS N
for IN N
health NN o
and CC o
social JJ o
services NNS o
( ( N
Cdn NNP N
$ $ N
23,437 CD N
vs. FW N
Cdn NNP N
$ $ N
15,151 CD N
) ) N
. . N

CONCLUSIONS NNP N
Caregivers NNPS N
found VBD N
nurse RB i
counseling VBG i
most JJS N
helpful JJ N
. . N

Those DT N
indicating VBG N
infrequent JJ N
use NN N
of IN N
logical JJ N
analysis NN N
coping VBG N
skills NNS N
showed VBD N
benefits NNS N
. . N

-DOCSTART- -23482762- O O

Satisfactory JJ N
sampling NN N
in IN N
cytological JJ p
cervical JJ p
diagnosis NN p
: : p
comparison NN N
between IN N
a DT N
conventional JJ i
and CC i
a DT i
new JJ i
sampling NN i
device NN i
. . i

AIM NNP N
Inadequate NNP N
cervical JJ N
sampling NN N
is VBZ N
the DT N
most RBS N
frequent JJ N
cause NN N
of IN N
misdiagnosis NN N
in IN N
cervical JJ p
cancer NN p
screening NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
ability NN N
of IN N
PapCone? NNP i
versus IN i
the DT i
conventional JJ i
sampling NN i
method NN i
( ( i
Ayre NNP i
's POS i
spatula NN i
plus CC i
cytobrush NN i
) ) i
to TO N
collect VB N
ectocervical JJ N
and CC N
glandular JJ N
cells NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN p
18 CD p
healthy JJ p
women NNS p
, , p
two CD p
ecto-endocervical JJ p
samples NNS p
, , p
obtained VBN p
by IN p
two CD p
different JJ p
methods NNS p
, , p
were VBD p
obtained VBN p
at IN p
a DT p
three-month JJ p
interval NN p
. . p

Qualitative JJ N
and CC N
quantitative JJ N
parameters NNS N
were VBD N
evaluated VBN N
. . N

Ultrastructure NN o
features NNS o
of IN o
sampling VBG o
devices NNS o
were VBD N
analyzed VBN N
by IN N
scanning VBG N
electron NN N
microscopy NN N
( ( N
SEM NNP N
) ) N
before IN N
and CC N
after IN N
sampling VBG N
. . N

RESULTS VB N
The DT N
? . N
( ( N
2 CD N
) ) N
test NN N
revealed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
: : N
PapCone? NNP N
caused VBD N
less JJR o
cell NN o
overlap NN o
and CC o
sampled VBD N
less JJR o
white JJ o
blood NN o
cells NNS o
( ( o
p JJ o
< NNP N
0.05 CD N
) ) N
and CC N
more RBR o
metaplastic JJ o
cells NNS o
( ( o
p JJ o
< NNP N
0.01 CD N
) ) N
. . N

SEM NNP N
evaluation NN o
highlighted VBD o
the DT N
porous JJ N
and CC N
spongy JJ N
structure NN N
of IN N
PapCone? NNP N
that WDT N
was VBD N
responsible JJ N
for IN N
the DT N
large JJ N
number NN N
of IN N
glandular JJ N
cells NNS N
on IN N
its PRP$ N
surface NN N
. . N

CONCLUSION NNP N
Cervical NNP N
smears NNS N
performed VBN N
by IN N
PapCone? NNP N
were VBD N
adequate JJ N
and CC N
generally RB N
easier JJR N
to TO N
screen VB N
than IN N
conventionally RB N
performed VBN N
ones NNS N
. . N

-DOCSTART- -18391640- O O

The DT N
effects NNS N
of IN N
strength NN i
training NN i
on IN N
central JJ o
arterial JJ o
compliance NN o
in IN N
middle-aged JJ p
and CC p
older JJR p
adults NNS p
. . p

BACKGROUND NNP N
Contrary NNP N
to TO N
aerobic VB N
exercise NN N
, , N
strength NN i
training NN i
( ( i
ST NNP i
) ) i
is VBZ N
associated VBN N
with IN N
decreased JJ p
central JJ o
arterial JJ o
compliance NN o
in IN p
young JJ p
men NNS p
. . p

It PRP N
is VBZ N
unknown JJ N
whether IN N
ST NNP i
, , N
with IN N
or CC N
without IN N
concurrent JJ N
endurance NN N
training NN N
, , N
would MD N
have VB N
a DT N
similar JJ N
effect NN N
in IN N
older JJR p
adults NNS p
with IN p
reduced JJ p
baseline NN p
arterial JJ o
compliance NN o
. . o

OBJECTIVE CC N
The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
a DT N
ST NNP i
program NN N
on IN N
central JJ o
arterial JJ o
compliance NN o
in IN N
middle-aged JJ p
and CC p
older JJR p
adults NNS p
. . p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
intervention NN N
study NN N
in IN N
which WDT N
37 CD p
healthy JJ p
, , p
sedentary JJ p
men NNS p
and CC p
women NNS p
( ( p
52+/-2 JJ p
years NNS p
) ) p
performed VBD p
13 CD p
weeks NNS p
of IN p
ST NNP p
( ( p
n=13 NN p
) ) p
, , p
ST+aerobic NNP i
exercise NN i
( ( p
n=12 JJ p
) ) p
or CC i
stretching VBG i
exercises NNS i
as IN i
a DT i
control NN i
group NN i
( ( N
n=12 RB N
) ) N
. . N

METHODS JJ N
Participants NNS p
were VBD p
rigorously RB p
screened VBN p
for IN p
cardiovascular JJ p
disease NN p
and CC p
underwent JJ p
pre-post JJ p
testing NN p
for IN p
carotid JJ o
arterial JJ o
compliance NN o
( ( o
via IN o
simultaneous JJ o
ultrasound NN o
and CC o
applanation NN o
tonometry NN o
) ) o
, , o
carotid-femoral JJ o
pulse NN o
wave NN o
velocity NN o
, , o
plasma JJ o
endothelin-1 NN o
and CC o
angiotensin NN o
II NNP o
concentrations NNS o
and CC o
carotid JJ o
artery NN o
vasoreactivity NN o
( ( o
cold JJ o
pressor NN o
test NN o
) ) o
. . o

RESULTS NNP N
ST NNP N
performed VBD N
alone RB N
, , N
or CC N
in IN N
conjunction NN N
with IN N
aerobic JJ i
exercise NN i
, , N
improved VBN N
maximal JJ o
muscle NN o
strength NN o
and CC o
increased VBD o
total JJ o
lean JJ o
body NN o
mass NN o
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
carotid NN o
artery NN o
compliance NN o
or CC o
carotid-femoral JJ o
pulse JJ o
wave NN o
velocity NN o
following VBG o
ST NNP o
or CC o
ST+aerobic NNP o
exercise NN o
. . o

Carotid NNP o
artery JJ o
compliance NN o
increased VBD N
significantly RB N
( ( N
23 CD N
% NN N
) ) N
following VBG N
stretching VBG N
which WDT N
may MD N
be VB N
attributed VBN N
to TO N
a DT N
reduction NN N
in IN N
carotid NN N
pulse JJ N
pressure NN N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
plasma JJ o
vasoconstrictor NN o
hormones NNS o
or CC o
carotid VB o
artery JJ o
vasoreactivity NN o
following VBG N
the DT N
interventions NNS N
. . N

CONCLUSION NNP N
Thirteen NNP N
weeks NNS N
of IN N
moderate JJ N
ST NNP i
two CD N
or CC N
three CD N
times NNS N
per IN N
week NN N
does VBZ N
not RB N
reduce VB N
central JJ o
arterial JJ o
compliance NN o
in IN N
middle-aged JJ p
and CC p
older JJR p
adults NNS p
. . p

-DOCSTART- -7714229- O O

Effects NNS N
of IN N
the DT N
cholinomimetic JJ i
SDZ NNP i
ENS-163 NNP i
on IN N
scopolamine-induced JJ N
cognitive JJ o
impairment NN o
in IN N
humans NNS p
. . p

Scopolamine-induced JJ p
cognitive JJ p
impairment NN p
was VBD p
used VBN p
in IN p
healthy JJ p
men NNS p
to TO N
evaluate VB N
the DT N
central JJ N
nervous JJ N
system NN N
activity NN N
of IN N
the DT N
new JJ i
cholinomimetic JJ i
SDZ NNP i
ENS-163 NNP i
. . i

Eighteen JJ p
subjects NNS p
were VBD N
treated VBN N
in IN N
a DT N
crossover NN N
design NN N
with IN N
oral JJ i
placebo/intravenous JJ i
saline NN i
, , i
50 CD i
mg NN i
of IN i
oral JJ i
SDZ NNP i
ENS-163/intravenous JJ i
saline NN i
, , i
oral JJ i
placebo/0.4 NN i
mg NN i
of IN i
intravenous JJ i
scopolamine NN i
, , i
and CC i
50 CD i
mg NN i
of IN i
oral JJ i
SDZ NNP i
ENS-163/0.4 NNP i
mg NN i
of IN i
intravenous JJ i
scopolamine NN i
. . i

The DT N
administration NN N
of IN N
placebo NN N
with IN N
scopolamine NN N
caused VBN N
significant JJ o
cognitive JJ o
impairment NN o
, , N
as IN N
assessed VBN N
by IN N
the DT N
Computerized NNP o
Neuropsychological NNP o
Test NNP o
Battery NNP o
( ( o
CNTB NNP o
) ) o
, , N
and CC N
also RB N
decreased VBN o
salivation NN o
and CC o
heart NN o
rate NN o
. . o

In IN N
contrast NN N
, , N
SDZ NNP N
ENS-163 NNP N
with IN N
saline NN N
had VBD N
no DT N
effect NN o
on IN o
CNTB NNP o
scores NNS o
, , o
increased VBN o
salivation NN o
, , o
and CC o
increased VBD o
heart NN o
rate NN o
. . o

Despite IN N
the DT N
observed JJ N
cholinomimetic JJ o
effects NNS o
of IN N
SDZ NNP N
ENS-163 NNP N
when WRB N
administered VBN N
with IN N
saline NN N
, , N
the DT N
changes NNS o
in IN o
CNTB NNP o
scores NNS o
, , o
heart NN o
rate NN o
, , o
and CC o
salivation NN o
were VBD N
indistinguishable JJ N
between IN N
placebo/scopolamine NN N
and CC N
SDZ NNP N
ENS-163/scopolamine NNP N
. . N

Thus NNP N
, , N
50 CD N
mg NN N
of IN N
oral JJ N
SDZ NNP N
ENS-163 NNP N
has VBZ N
cholinomimetic JJ o
activity NN o
in IN N
normal JJ N
men NNS N
, , N
but CC N
this DT N
dose NN N
is VBZ N
insufficient JJ N
to TO N
reverse VB N
the DT N
muscarinic JJ o
effects NNS o
of IN N
0.4 CD N
mg NN N
of IN N
intravenous JJ N
scopolamine NN N
. . N

-DOCSTART- -1423955- O O

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
intravenous JJ N
diltiazem NNS i
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
or CC p
atrial JJ p
flutter NN p
. . p

BACKGROUND NNP N
Diltiazem NNP i
, , N
a DT N
calcium NN N
channel NN N
blocker NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
in IN p
atrial JJ p
fibrillation NN p
and/or IN p
atrial JJ p
flutter NN p
. . p

However RB N
, , N
there EX N
have VBP N
been VBN N
no DT N
pharmacokinetic/pharmacodynamic JJ N
studies NNS N
of IN N
diltiazem NN N
in IN N
these DT N
patients NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
intravenous JJ i
diltiazem NNS i
were VBD N
determined VBN N
in IN N
32 CD p
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
or CC p
atrial JJ p
flutter NN p
( ( p
mean JJ p
+/- NN p
SD NNP p
age NN p
, , p
66 CD p
+/- JJ p
7 CD p
years NNS p
; : p
mean VB p
baseline JJ p
heart NN p
rate NN p
, , p
131 CD p
+/- JJ p
10 CD p
beats NNS p
per IN p
minute NN p
) ) p
after IN p
20 CD p
mg NN p
or CC p
20 CD p
mg NN p
followed VBN p
by IN p
25-mg JJ p
bolus NN p
doses NNS p
and CC p
a DT p
10 CD p
and CC p
15 CD p
mg/hr NN p
infusion NN p
for IN p
24 CD p
hours NNS p
. . N

After IN N
the DT N
10 CD N
and CC N
15 CD N
mg/hr JJ N
infusions NNS N
of IN N
diltiazem NN i
, , N
mean JJ N
+/- JJ N
SD NNP N
elimination NN N
half-life NN N
was VBD N
6.8 CD N
+/- JJ N
1.8 CD N
and CC N
6.9 CD N
+/- JJ N
1.5 CD N
hours NNS N
, , N
volume NN N
of IN N
distribution NN N
was VBD N
411 CD N
+/- JJ N
151.8 CD N
and CC N
299 CD N
+/- JJ N
70.8 CD N
I PRP N
, , N
and CC N
systemic JJ N
clearance NN N
was VBD N
42 CD N
+/- JJ N
12.4 CD N
and CC N
31 CD N
+/- JJ N
8.3 CD N
l/hr NN N
, , N
respectively RB N
. . N

Percentages NNS o
of IN o
the DT o
plasma JJ o
concentrations NNS o
of IN o
the DT o
principal JJ o
metabolites NNS o
desacetyldiltiazem NNS o
and CC o
N-desmethyldiltiazem NNP o
to TO o
diltiazem VB o
were VBD N
< JJ N
15 CD N
% NN N
and CC N
< $ N
10 CD N
% NN N
, , N
respectively RB N
. . N

Thirty NNP p
of IN p
32 CD p
patients NNS p
maintained VBD N
response NN N
throughout IN N
the DT N
24-hour JJ N
infusion NN N
of IN N
diltiazem NN N
. . N

Using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
pharmacodynamic JJ N
model NN N
, , N
a DT N
strong JJ N
relation NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
r2 NN N
, , N
0.78 CD N
+/- JJ N
0.2 CD N
) ) N
was VBD N
observed VBN N
between IN N
plasma NN o
diltiazem NN o
concentration NN o
and CC o
percent JJ o
heart NN o
rate NN o
reduction NN o
. . o

Mean JJ o
+/- JJ o
SD NNP o
Emax NNP o
( ( N
maximum JJ N
percent NN N
reduction NN N
in IN N
heart NN N
rate NN N
from IN N
baseline NN N
) ) N
and CC N
EC50 NNP o
( ( N
plasma JJ N
diltiazem NN N
concentration NN N
that WDT N
achieves VBZ N
half DT N
Emax NNP N
) ) N
were VBD N
52 CD N
+/- JJ N
17 CD N
% NN N
and CC N
110 CD N
+/- JJ N
84 CD N
ng/ml NN N
, , N
respectively RB N
. . N

The DT N
model NN N
predicts VBZ N
that IN N
mean JJ N
plasma NN o
diltiazem NN o
concentration NN o
of IN N
79 CD N
, , N
172 CD N
, , N
and CC N
294 CD N
ng/ml NNS N
are VBP N
required VBN N
to TO N
produce VB N
a DT N
20 CD N
% NN N
, , N
30 CD N
% NN N
, , N
and CC N
40 CD N
% NN N
reduction NN N
in IN N
heart NN o
rate NN o
, , N
respectively RB N
. . N

A DT N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent NN N
change NN N
in IN N
systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
or CC o
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
from IN N
baseline NN N
was VBD N
not RB N
observed VBN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
r2 NN N
, , N
SBP/DBP NNP N
: : N
0.35 CD N
+/- JJ N
0.24/0.36 CD N
+/- JJ N
0.2 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
untoward JJ N
side NN N
effects NNS N
observed VBN N
. . N

CONCLUSIONS NNP N
First NNP N
, , N
the DT N
pharmacokinetics NNS N
of IN N
diltiazem NN i
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
or CC p
atrial JJ p
flutter NN p
is VBZ N
nonlinear JJ N
with IN N
an DT N
apparent JJ N
dose-dependent JJ N
decrease NN N
in IN N
systemic JJ N
clearance NN N
with IN N
increasing VBG N
infusion NN N
rate NN N
. . N

Second NNP N
, , N
using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
model NN N
, , N
there EX N
is VBZ N
a DT N
strong JJ N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent JJ N
heart NN N
rate NN N
reduction NN N
. . N

Third NNP N
, , N
the DT N
plasma JJ N
concentrations NNS N
of IN N
the DT N
principal JJ N
metabolites NNS N
desacetyldiltiazem NNS N
and CC N
N-desmethyldiltiazem NNP N
are VBP N
low JJ N
and CC N
are VBP N
not RB N
expected VBN N
to TO N
contribute VB N
significantly RB N
to TO N
the DT N
pharmacodynamics NNS N
of IN N
intravenous JJ N
diltiazem NNS N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -12233987- O O

Multimodal NNP N
evaluation NN N
of IN N
risperidone NN i
for IN N
destructive JJ N
behavior NN N
: : N
functional JJ o
analysis NN o
, , o
direct JJ o
observations NNS o
, , o
rating NN o
scales NNS o
, , o
and CC o
psychiatric JJ o
impressions NNS o
. . o

Risperidone NNP i
, , N
an DT N
atypical JJ N
neuroleptic NN N
, , N
has VBZ N
become VBN N
a DT N
popular JJ N
option NN N
for IN N
treating VBG N
destructive JJ N
behaviors NNS N
of IN N
persons NNS p
with IN p
developmental JJ p
disabilities NNS p
. . p

A DT N
few JJ N
studies NNS N
have VBP N
been VBN N
conducted VBN N
that IN N
evaluate VBP N
the DT N
effects NNS N
of IN N
risperidone NN i
on IN N
destructive JJ N
behavior NN N
; : N
however RB N
, , N
none NN N
of IN N
these DT N
studies NNS N
have VBP N
combined VBN N
objective JJ N
measures NNS N
with IN N
rating NN N
scales NNS N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
risperidone NN i
on IN N
destructive JJ N
behavior NN N
across IN N
home NN N
and CC N
clinical JJ N
settings NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
wide JJ N
range NN N
of IN N
effects NNS N
of IN N
risperidone NN i
on IN N
destructive JJ N
behavior NN N
of IN N
2 CD p
persons NNS p
with IN p
developmental JJ p
disabilities NNS p
using VBG N
weekly JJ N
functional JJ o
analysis NN o
sessions NNS o
, , o
daily JJ o
observations NNS o
, , o
hourly RB o
home NN o
data NNS o
, , o
weekly JJ o
rating NN o
scales NNS o
, , o
and CC o
monthly JJ o
psychiatric JJ o
impressions NNS o
. . o

Results NNS N
indicate VBP N
that IN N
risperidone NN N
does VBZ N
decrease VB N
destructive JJ o
behavior NN o
and CC N
that IN N
, , N
for IN N
the DT N
most JJS N
part NN N
, , N
all DT N
of IN N
the DT N
various JJ N
measures NNS N
yielded VBD N
similar JJ N
results NNS N
. . N

-DOCSTART- -8882257- O O

Injection NN o
pain NN o
with IN N
propofol NN i
. . i

Reduction NN N
with IN N
aspiration NN N
of IN N
blood NN N
. . N

A DT N
randomised JJ N
, , N
controlled VBN N
, , N
single-blind NN N
study NN N
was VBD N
performed VBN N
on IN N
100 CD p
patients NNS p
to TO N
investigate VB N
a DT N
new JJ N
method NN N
of IN N
reducing VBG N
pain NN o
on IN N
propofol NN i
injection NN N
. . N

Aspiration NNP N
of IN N
2 CD N
ml NN N
of IN N
the DT N
patient NN N
's POS N
blood NN N
into IN N
a DT N
syringe NN N
of IN N
propofol NN i
immediately RB N
before IN N
injection NN N
was VBD N
compared VBN N
with IN N
the DT N
addition NN N
of IN N
lignocaine NN i
20 CD i
mg NN i
or CC i
normal JJ i
saline JJ i
2 CD i
ml NN i
to TO i
the DT i
propofol NN i
before IN i
injection NN i
. . i

The DT N
addition NN N
of IN N
blood NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
in IN N
reducing VBG o
pain NN o
on IN o
injection NN o
than IN N
the DT N
addition NN N
of IN N
saline NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
was VBD N
not RB N
significantly RB N
more RBR N
effective JJ o
than IN N
the DT N
addition NN N
of IN N
lignocaine NN N
. . N

-DOCSTART- -2405107- O O

Randomized VBN N
study NN N
of IN N
continuous JJ i
infusion NN i
fluorouracil NN i
versus NN i
fluorouracil NN i
plus CC i
cisplatin NN i
in IN N
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

One CD p
hundred VBD p
twenty-two JJ p
chemotherapy-naive JJ p
patients NNS p
with IN p
histologically RB p
confirmed VBN p
colorectal JJ p
adenocarcinoma NN p
were VBD N
entered VBN N
into IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
infusional JJ i
fluorouracil NN i
( ( i
FU NNP i
) ) i
versus NN i
cisplatin NN i
( ( i
CDDP NNP i
) ) i
and CC i
FU NNP i
. . i

In IN p
both DT p
groups NNS p
, , p
patients NNS p
received VBD p
continuous JJ p
infusion NN p
FU NNP i
1,000 CD p
mg/m2/d NN p
for IN p
5 CD p
consecutive JJ p
days NNS p
every DT p
4 CD p
weeks NNS p
. . p

Patients NNS N
randomized VBD N
to TO N
CDDP/FU NNP i
also RB N
received VBD N
CDDP NNP i
20 CD N
mg/m2 NN N
intravenous JJ N
( ( N
IV NNP N
) ) N
bolus NN N
on IN N
days NNS N
1 CD N
to TO N
5 CD N
of IN N
each DT N
cycle NN N
. . N

Patients NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
age NN N
, , N
performance NN N
status NN N
, , N
baseline VB N
laboratory NN N
values NNS N
, , N
dominant JJ N
sites NNS N
of IN N
measurable JJ N
disease NN N
, , N
and CC N
percent NN N
of IN N
liver JJ N
involvement NN N
. . N

The DT N
partial JJ o
response NN o
rate NN o
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS N
who WP N
received VBD N
CDDP/FU NNP i
versus NN N
FU NNP i
alone RB N
( ( N
25 CD N
% NN N
v JJ N
3 CD N
% NN N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Patients NNPS N
who WP N
received VBD N
CDDP/FU NNP i
experienced VBD N
significantly RB N
greater JJR o
toxicity NN o
compared VBN N
with IN N
FU NNP i
alone RB N
: : N
grades NNS o
3 CD o
and CC o
4 CD o
hematologic JJ o
toxicity NN o
occurred VBD N
in IN N
22 CD N
% NN N
and CC N
0 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
; : N
grades VBZ N
2 CD N
to TO N
4 CD N
nausea NN o
and CC o
vomiting NN o
occurred VBD N
in IN N
80 CD N
% NN N
and CC N
15 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
either CC N
the DT N
duration NN o
of IN o
response NN o
( ( N
median JJ N
, , N
6 CD N
and CC N
4.7 CD N
months NNS N
for IN N
CDDP/FU NNP i
and CC N
FU NNP i
groups NNS N
, , N
respectively RB N
) ) N
or CC N
survival NN o
( ( N
median JJ N
10 CD N
, , N
and CC N
12 CD N
months NNS N
, , N
respectively RB N
) ) N
. . N

Compared VBN N
with IN N
infusional JJ N
FU NNP i
alone RB N
, , N
CDDP/FU NNP i
provided VBD N
a DT N
significantly RB N
greater JJR N
partial JJ o
response NN o
rate NN o
with IN N
increased JJ o
toxicity NN o
, , N
but CC N
it PRP N
did VBD N
not RB N
improve VB N
overall JJ o
survival NN o
in IN N
patients NNS p
with IN p
advanced JJ p
colorectal JJ p
carcinoma NN p
. . p

Therefore RB N
, , N
the DT N
use NN N
of IN N
CDDP/FU NNP i
as IN N
routine JJ N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
colorectal JJ N
carcinoma NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -14617595- O O

Remifentanil NNP N
with IN N
morphine JJ N
transitional JJ N
analgesia NN N
shortens VBZ N
neurological JJ o
recovery NN o
compared VBN N
to TO N
fentanyl VB N
for IN N
supratentorial JJ N
craniotomy NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
recovery NN o
profiles NNS o
, , o
efficacy NN o
and CC o
safety NN o
of IN N
remifentanil NN N
and CC N
morphine NN N
for IN N
transitional JJ N
analgesia NN N
with IN N
fentanyl NN N
in IN N
patients NNS p
undergoing VBG p
elective JJ p
craniotomy NN p
for IN p
supratentorial JJ p
mass NN p
lesions NNS p
. . p

METHODS NNP N
Ninety-one JJ p
patients NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicentre FW N
study NN N
. . N

Anesthesia NNP i
was VBD i
induced VBN i
with IN i
thiopental JJ i
and CC i
remifentanil NN i
( ( i
1.0 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
bolus NN i
and CC i
a DT i
1 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
infusion NN i
) ) i
or CC i
fentanyl NN i
( ( i
1 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
bolus NN i
and CC i
a DT i
1.0 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
infusion NN i
) ) i
. . i

The DT i
opioid JJ i
infusion NN i
continued VBD i
until IN i
the DT i
level NN i
of IN i
anesthesia NN i
was VBD i
deemed VBN i
appropriate JJ i
for IN i
intubation NN i
. . i

Anesthesia NNP i
was VBD i
maintained VBN i
with IN i
N NNP i
( ( i
2 CD i
) ) i
O/O NNP i
( ( i
2 CD i
) ) i
, , i
isoflurane $ i
0.5 CD i
MAC NNP i
and CC i
remifentanil VB i
0.2 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 JJ i
) ) i
or CC i
fentanyl $ i
0.04 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
. . i

At IN i
bone NN i
flap NN i
replacement NN i
, , i
either DT i
morphine NN i
0.08 CD i
mg NN i
x NN i
kg NN i
( ( i
-1 NN i
) ) i
( ( i
remifentanil JJ i
group NN i
) ) i
or CC i
saline NN i
( ( i
fentanyl JJ i
group NN i
) ) i
was VBD i
given VBN i
. . i

RESULTS NNP N
Systolic NNP o
blood NN o
pressure NN o
was VBD N
greater JJR N
in IN N
those DT N
receiving VBG N
fentanyl NN N
during IN N
induction NN N
( ( N
145.6 CD N
+/-17.5 JJ N
mmHg NN N
vs NN N
128.8 CD N
+/-18.3 JJ N
mmHg NN N
; : N
P NNP N
= NNP N
0.006 CD N
) ) N
and CC N
intubation NN N
( ( N
126.9 CD N
+/-17.1 JJ N
vs NN N
110.9 CD N
+/-16.5 JJ N
mmHg NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Median JJ o
time NN o
to TO o
tracheal VB o
extubation NN o
was VBD N
similar JJ N
but CC N
less RBR N
variable JJ N
in IN N
the DT N
remifentanil NN N
group NN N
( ( N
remifentanil JJ N
= $ N
8 CD N
min NN N
: : N
range NN N
= VBZ N
2-44 JJ N
min NN N
; : N
fentanyl CC N
= $ N
8 CD N
min NN N
: : N
range NN N
= VBZ N
1-732 JJ N
min NN N
) ) N
. . N

The DT N
fentanyl JJ N
patients NNS N
required VBD N
a DT N
longer JJR N
time NN o
to TO o
achieve VB o
the DT o
first JJ o
normal JJ o
neurological JJ o
score NN o
( ( N
fentanyl JJ N
= $ N
38.0 CD N
min NN N
; : N
remifentanil CC N
= $ N
26.0 CD N
min NN N
; : N
P NNP N
= NNP N
0.035 CD N
) ) N
. . N

Both CC N
the DT N
anesthesiologists NNS N
and CC N
the DT N
recovery NN N
room NN N
nurses NNS N
rated VBD N
remifentanil JJ N
better RBR N
with IN N
respect NN N
to TO N
level NN o
of IN o
consciousness NN o
. . o

Analgesics NNS o
were VBD N
required VBN N
earlier RBR N
in IN N
patients NNS N
receiving VBG N
remifentanil NN N
; : N
median JJ N
time NN N
0.5 CD N
vs NN N
1.08 CD N
hr NN N
, , N
P NNP N
< VBZ N
0.001 CD N
. . N

CONCLUSIONS NNP N
Remifentanil NNP N
is VBZ N
a DT N
suitable JJ N
alternative NN N
to TO N
fentanyl VB N
in IN N
supratentorial JJ N
craniotomy NN N
. . N

Time NN o
to TO o
preoperative VB o
neurological JJ o
recovery NN o
is VBZ N
faster RBR N
and CC N
morphine VB N
provides VBZ N
some DT N
transitional JJ o
analgesia NN o
without IN N
compromising VBG N
the DT N
quality NN o
of IN o
recovery NN o
. . o

-DOCSTART- -11849797- O O

Prophylactic JJ N
use NN N
of IN N
amifostine NN i
to TO N
prevent VB N
radiochemotherapy-induced JJ N
mucositis NN N
and CC N
xerostomia NN N
in IN N
head-and-neck JJ N
cancer NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
the DT N
prophylactic JJ N
properties NNS N
of IN N
amifostine NN i
against IN N
acute JJ N
and CC N
late JJ N
toxicities NNS N
from IN N
radiochemotherapy NN N
in IN N
patients NNS p
with IN p
head-and-neck JJ p
cancer NN p
. . p

METHODS NNP N
AND CC N
MATERIALS NNP N
Fifty NNP p
patients NNS p
were VBD p
randomized VBN p
to TO p
receive VB p
conventional JJ i
radiotherapy NN i
( ( p
RT NNP p
) ) p
( ( p
2-Gy JJ p
fractions NNS p
, , p
5 CD p
days NNS p
weekly RB p
, , p
to TO p
a DT p
total NN p
of IN p
60-74 JJ p
Gy NNP p
, , p
depending VBG p
on IN p
the DT p
tumor NN p
localization NN p
and CC p
TNM NNP p
classification NN p
) ) p
and CC p
carboplatin NN i
( ( p
90 CD p
mg/m NN p
( ( p
2 CD p
) ) p
infusion NN p
once RB p
per IN p
week NN p
before IN p
RT NNP p
) ) p
. . N

Amifostine NNP i
( ( N
300 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
was VBD N
administered VBN N
in IN N
the DT N
study NN N
group NN N
only RB N
15-30 JJ N
min NN N
before IN N
RT NNP N
for IN N
6-7.5 JJ N
weeks NNS N
. . N

The DT N
primary JJ N
study NN N
end NN N
point NN N
was VBD N
the DT N
grading NN o
of IN o
acute NN o
and CC o
late JJ o
nonhematologic NN o
toxicities NNS o
( ( o
mucositis NN o
, , o
dysphagia NN o
, , o
xerostomia NN o
) ) o
induced VBN N
by IN N
radiochemotherapy NN i
. . i

Secondary JJ N
end NN N
points NNS N
included VBD N
treatment NN o
duration NN o
, , o
hematologic JJ o
toxicity NN o
, , o
and CC o
clinical JJ o
outcome NN o
. . o

RESULTS VB N
The DT N
treatment NN o
duration NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
amifostine-treated JJ p
group NN p
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
, , N
because IN N
treatment NN N
interruptions NNS N
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
control NN N
group NN N
. . N

Acute NNP o
toxicities NNS o
( ( o
mucositis NN o
and CC o
dysphagia NN o
) ) o
were VBD N
less JJR N
severe JJ N
in IN N
the DT N
amifostine-treated JJ N
group NN N
. . N

By IN N
Week JJ N
3 CD N
, , N
all DT N
in IN N
the DT N
control NN N
group NN N
experienced VBD N
Grade NNP o
2 CD o
mucositis NN o
compared VBN N
with IN N
only RB N
9 CD N
% NN N
in IN N
the DT N
amifostine-treated JJ N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

By IN N
Week JJ N
5 CD N
, , N
52.2 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
control NN N
group NN N
experienced VBD N
Grade NNP o
4 CD o
mucositis NN o
compared VBN N
with IN N
4.5 CD N
% NN N
in IN N
the DT N
amifostine-treated JJ N
group NN N
( ( N
p JJ N
= NNP N
0.0006 CD N
) ) N
. . N

Similar JJ N
results NNS N
were VBD N
obtained VBN N
for IN N
dysphagia NN o
. . o

At IN N
3 CD N
months NNS N
of IN N
follow-up NN N
, , N
only RB N
27 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
study NN N
group NN N
experienced VBD N
Grade NNP o
2 CD o
xerostomia NN o
compared VBN N
with IN N
73.9 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

Eighteen JJ N
months NNS N
after IN N
cessation NN N
of IN N
therapy NN N
, , N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
Grade NNP o
2 CD o
xerostomia NN o
was VBD N
4.5 CD N
% NN N
vs. FW N
30.4 CD N
% NN N
for IN N
each DT N
respective JJ N
treatment NN N
group NN N
( ( N
p JJ N
= NNP N
0.047 CD N
) ) N
. . N

Cytoprotection NN i
with IN N
amifostine NN i
did VBD N
not RB N
affect VB N
treatment NN N
outcome NN N
, , N
with IN N
90.9 CD N
% NN N
complete JJ N
responses NNS N
in IN N
the DT N
amifostine-treated JJ N
group NN N
compared VBN N
with IN N
78.3 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.414 CD N
) ) N
. . N

CONCLUSION NNP N
Amifostine NNP i
was VBD N
effective JJ N
in IN N
reducing VBG N
mucositis NN N
and CC N
dysphagia NN N
resulting VBG N
from IN N
radiochemotherapy NN N
in IN N
patients NNS p
with IN p
head-and-neck JJ p
cancer NN p
. . p

Furthermore NNP N
, , N
amifostine NN i
reduced VBD N
the DT N
severity NN N
of IN N
late JJ N
xerostomia NN N
, , N
a DT N
side NN N
effect NN N
of IN N
RT NNP N
with IN N
long-lasting JJ N
consequences NNS N
. . N

Amifostine NNP i
treatment NN N
did VBD N
not RB N
affect VB N
the DT N
clinical JJ N
outcome NN N
. . N

-DOCSTART- -1631861- O O

Biochemical NNP N
and CC N
functional JJ N
effects NNS N
of IN N
creatine NN i
phosphate NN i
in IN N
cardioplegic JJ N
solution NN N
during IN N
aortic JJ p
valve NN p
surgery NN p
-- : p
a DT p
clinical JJ N
study NN N
. . N

During IN N
myocardial JJ N
ischemia NN N
there EX N
is VBZ N
a DT N
drop NN o
in IN o
high-energy JJ o
phosphates NNS o
in IN N
the DT N
myocardium NN N
. . N

Cold NNP N
potassium NN N
cardioplegia NN N
decreases NNS N
but CC N
does VBZ N
not RB N
altogether RB N
prevent VB N
this DT N
reduction NN N
. . N

Supplementation NN N
of IN N
cardioplegic JJ N
solutions NNS N
with IN N
the DT N
high-energy JJ N
compound NN N
creatine NN i
phosphate NN i
( ( N
10 CD N
mmol/L NN N
) ) N
compared VBN N
to TO N
plain VB i
cardioplegic JJ i
solutions NNS i
was VBD N
investigated VBN N
in IN N
this DT N
study NN N
. . N

Thirty NNP p
patients NNS p
scheduled VBN p
for IN p
aortic JJ p
valve NNS p
replacement NN p
were VBD p
included VBN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
group NN N
I PRP N
( ( i
creatine VB i
phosphate NN i
) ) i
or CC N
group NN N
II NNP N
( ( i
control NN i
) ) i
. . N

Postoperative JJ N
hemodynamic JJ o
evaluation NN o
revealed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

However RB N
, , N
group NN N
I PRP N
exhibited VBD N
a DT N
tendency NN N
toward IN N
a DT N
better JJR N
stroke-work NN o
index NN o
( ( N
135 CD N
+/- JJ N
18 CD N
% NN N
vs. FW N
102 CD N
+/- JJ N
5 CD N
% NN N
recovery NN N
15 CD N
minutes NNS N
after IN N
bypass NN N
and CC N
145 CD N
+/- JJ N
16 CD N
% NN N
vs. FW N
119 CD N
+/- JJ N
11 CD N
% NN N
recovery NN N
105 CD N
min NN N
after IN N
bypass NN N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
5/15 CD N
) ) N
needing VBG o
inotropic JJ o
support NN o
compared VBN N
to TO N
group NN N
II NNP N
( ( N
9/14 CD N
) ) N
. . N

The DT N
myocardial JJ o
content NN o
of IN o
ATP NNP o
and CC o
creatine NN o
phosphate NN o
showed VBD N
no DT N
significant JJ N
differences NNS N
during IN N
ischemia NN N
and CC N
reperfusion NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
myocardial JJ N
protection NN N
during IN N
ischemia NN N
was VBD N
sufficient JJ N
to TO N
prevent VB N
significant JJ N
reductions NNS N
of IN N
myocardial JJ o
ATP NNP o
and CC o
creatine VB o
phosphate JJ o
irrespective NN N
of IN N
supplementation NN N
with IN N
CP NNP N
. . N

-DOCSTART- -15241630- O O

Registration NNP N
accuracy NN N
of IN N
153Gd CD N
transmission NN N
images NNS N
of IN N
the DT N
brain NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
accuracy NN N
of IN N
non-rigid JJ N
nine-parameter JJ N
image NN N
registrations NNS N
based VBN N
on IN N
153Gd CD i
transmission NN i
computed VBN i
tomography NN i
( ( N
TCT NNP N
) ) N
images VBZ N
as IN N
compared VBN N
with IN N
those DT N
based VBN N
on IN N
99mTc-ethyl JJ i
cysteinate NN i
dimer NN i
( ( i
ECD NNP i
) ) i
images NNS i
and CC N
to TO N
assess VB N
whether IN N
normalised JJ N
mutual JJ N
information NN N
( ( N
NMI NNP N
) ) N
or CC N
count NN N
difference NN N
( ( N
CD NN N
) ) N
should MD N
be VB N
used VBN N
. . N

METHODS NNP N
TCT NNP N
and CC N
ECD NNP N
data NNS N
were VBD N
acquired VBN N
in IN N
25 CD p
randomly RB p
selected VBN p
patients NNS p
. . p

Emission NN N
images NNS N
were VBD N
registered VBN N
to TO N
an DT N
ECD NNP i
template NN N
with IN N
a DT N
CD NN N
cost NN N
function NN N
. . N

The DT N
same JJ N
registration NN N
parameters NNS N
were VBD N
applied VBN N
to TO N
the DT N
transmission NN N
images VBZ N
to TO N
create VB N
a DT N
TCT NNP N
template NN N
. . N

All DT N
TCT NNP N
images NNS N
were VBD N
registered VBN N
to TO N
the DT N
TCT NNP i
template NN N
and CC N
the DT N
same JJ N
registration NN N
parameters NNS N
were VBD N
applied VBN N
to TO N
the DT N
ECD NNP i
images NNS N
. . N

The DT N
procedure NN N
was VBD N
repeated VBN N
with IN N
NMI NNP N
as IN N
cost NN N
function NN N
. . N

Accuracy NN N
of IN N
both DT N
ECD-based JJ i
and CC N
TCT-based JJ i
registrations NNS N
was VBD N
assessed VBN N
by IN N
comparing VBG N
the DT N
normalisation NN N
parameter NN N
values NNS N
and CC N
regional JJ N
activities NNS N
in IN N
the DT N
spatially RB N
normalised JJ N
ECD NNP N
images NNS N
, , N
using VBG N
a DT N
mixed-model JJ N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
. . N

Scheffe NNP N
post NN N
hoc NN N
tests NNS N
were VBD N
performed VBN N
. . N

RESULTS NNP N
No NNP o
significant JJ o
differences NNS o
were VBD N
found VBN N
between IN N
ECD/CD NNP i
, , i
ECD/NMI NNP i
and CC N
TCT/CD NNP i
, , N
suggesting VBG N
that IN N
ECD NNP N
registration NN N
can MD N
be VB N
done VBN N
with IN N
either DT N
CD NN N
or CC N
NMI NNP N
, , N
and CC N
that IN N
TCT NNP N
registration NN N
using VBG N
CD NN N
is VBZ N
equally RB N
as RB N
accurate JJ N
as IN N
ECD NNP N
registration NN N
. . N

The DT N
accuracy NN o
of IN o
TCT NNP o
registration NN o
with IN N
NMI NNP N
was VBD N
lower JJR o
, , N
with IN N
discrepancies NNS N
occurring VBG N
in IN N
the DT N
frontal JJ N
inferior JJ N
region NN N
and CC N
the DT N
cerebellum NN N
. . N

The DT N
analysis NN N
of IN N
normalisation NN N
parameters NNS N
indicated VBD N
that IN N
z-scaling NN N
is VBZ N
underestimated JJ N
and CC N
yz-rotation NN N
overestimated VBN N
with IN N
TCT/NMI NNP N
registration NN N
. . N

CONCLUSION NNP N
We PRP N
conclude VBP N
that IN N
ECD NNP i
registrations NNS N
with IN N
CD NN i
or CC N
NMI NNP i
are VBP N
as RB N
accurate JJ N
as IN N
TCT NNP i
registrations NNS N
with IN N
CD NN N
and CC N
that DT N
TCT NNP i
registrations NNS N
with IN N
NMI NNP N
should MD N
be VB N
avoided VBN N
. . N

-DOCSTART- -19135077- O O

Face NNP i
composite JJ i
effects NNS N
reveal VBP N
abnormal JJ N
face NN N
processing NN N
in IN N
Autism NNP p
spectrum NN p
disorders NNS p
. . p

Although IN N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
individuals NNS p
with IN p
an DT p
Autism NNP p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
process NN N
faces VBZ N
less RBR N
holistically RB N
than IN N
typically RB N
developing VBG N
controls NNS N
, , N
there EX N
are VBP N
few JJ N
direct JJ N
investigations NNS N
of IN N
this DT N
hypothesis NN N
. . N

This DT N
question NN N
was VBD N
addressed VBN N
before IN N
using VBG N
the DT N
composite JJ N
paradigm NN N
( ( N
Teunisse NNP N
, , N
J. NNP N
P. NNP N
, , N
& CC N
de FW N
Gelder NNP N
, , N
B NNP N
. . N

( ( N
2003 CD N
) ) N
. . N

Face NN N
processing NN N
in IN N
adolescents NNS N
with IN N
autistic JJ N
disorder NN N
: : N
The DT N
inversion NN N
and CC N
composite JJ N
effects NNS N
. . N

Brain NNP N
Cognition NNP N
, , N
52 CD N
( ( N
3 CD N
) ) N
, , N
285-294. JJ N
) ) N
. . N

The DT N
results NNS N
had VBD N
revealed VBN N
that IN N
adolescents NNS p
with IN p
ASDs NNP p
were VBD N
less RBR N
sensitive JJ N
than IN N
controls NNS N
to TO N
the DT N
misalignment NN N
of IN N
face NN N
parts NNS N
and CC N
it PRP N
was VBD N
concluded VBN N
their PRP$ N
face NN N
processing NN N
was VBD N
less RBR N
holistic JJ N
. . N

However RB N
, , N
because IN N
of IN N
shortcomings NNS N
of IN N
the DT N
design NN N
, , N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
distinguish VB N
whether IN N
individuals NNS p
with IN p
Autism NNP p
processed VBD N
both DT N
aligned VBN N
and CC N
misaligned VBN N
composites NNS N
in IN N
a DT N
part-based JJ N
fashion NN N
, , N
or CC N
both DT N
in IN N
a DT N
holistic JJ N
fashion NN N
. . N

We PRP N
compared VBN N
adolescents NNS i
with IN i
ASDs NNP i
to TO p
controls VB i
matched VBN p
on IN p
sex NN p
, , p
age NN p
and CC p
IQ NNP p
on IN N
a DT N
more RBR N
complete JJ N
version NN N
of IN N
the DT N
composite JJ i
paradigm NN i
. . i

The DT o
results NNS o
indicate VBP o
that IN o
individuals NNS o
with IN o
ASDs NNP o
, , o
like IN o
controls NNS o
, , o
experience NN o
interference NN o
from IN o
facial JJ o
features NNS o
that IN o
they PRP o
are VBP o
told VBN o
to TO o
ignore VB o
. . o

However RB o
, , o
while IN o
such JJ o
interference NN o
is VBZ o
released VBN o
for IN o
controls NNS o
if IN o
parts NNS o
of IN o
face NN o
composites NNS o
are VBP o
misaligned VBN o
, , o
individuals NNS o
with IN o
ASDs NNP o
show VBP o
comparable JJ o
interference NN o
from IN o
irrelevant JJ o
parts NNS o
regardless RB o
of IN o
alignment NN o
. . o

Two CD o
different JJ o
interpretations NNS o
are VBP o
discussed VBN o
, , o
both DT o
compatible JJ o
with IN o
the DT o
idea NN o
that WDT o
perceptual JJ o
and CC o
or CC o
attentional JJ o
abnormalities NNS o
in IN o
ASDs NNP o
result NN o
in IN o
a DT o
diminished JJ o
level NN o
of IN o
expertise NN o
for IN o
faces VBZ o
. . o

-DOCSTART- -15154956- O O

ROMEO NN N
: : N
rethink NN N
organization NN N
to TO N
improve VB N
education NN N
and CC N
outcomes NNS N
. . N

AIMS NNP N
Scarcity NNP N
of IN N
resources NNS N
, , N
expertise NN N
and CC N
evidence-based JJ N
models NNS N
have VBP N
so RB N
far RB N
limited JJ N
delivery NN N
of IN N
patient-centred JJ N
diabetes NNS N
education NN N
. . N

We PRP N
have VBP N
developed VBN N
and CC N
validated VBD N
a DT N
group NN N
care NN N
approach NN N
that WDT N
is VBZ N
applicable JJ N
to TO N
everyday VB N
clinical JJ N
practice NN N
and CC N
cost-effective JJ N
in IN N
improving VBG N
metabolic JJ o
control NN o
, , o
knowledge NN o
of IN o
diabetes NNS o
, , o
health NN o
behaviours NNS o
, , N
and CC N
quality NN o
of IN o
life NN o
in IN N
Type NNP N
2 CD N
diabetes NNS N
. . N

A DT N
clinical JJ N
trial NN N
( ( N
ROMEO NNP N
) ) N
was VBD N
planned VBN N
to TO N
evaluate VB N
applicability NN N
and CC N
reproducibility NN N
of IN N
group NN N
care NN N
in IN N
other JJ N
outpatients NNS N
facilities NNS N
and CC N
assess VB N
its PRP$ N
impact NN N
on IN N
a DT N
larger JJR p
patient JJ p
population NN p
. . p

METHODS NNP N
Multicentre NNP N
, , N
randomized VBD N
, , N
controlled VBD N
clinical JJ N
trial NN N
of IN N
group NN i
vs. FW i
individual JJ i
care NN i
in IN N
the DT N
routine JJ N
management NN N
of IN N
Type NNP N
2 CD N
diabetes NNS N
. . N

Nine NNP p
hundred VBD p
patient JJ p
aged VBN p
< NN p
80 CD p
, , p
with IN p
diabetes NNS p
of IN p
> NN p
or CC p
=1 JJ p
year NN p
known VBN p
duration NN p
, , p
treated VBN p
by IN p
either DT p
diet JJ i
alone NN i
or CC i
diet JJ i
and CC i
oral JJ i
agents NNS i
, , p
will MD p
be VB p
recruited VBN p
in IN p
15 CD p
centres NNS p
and CC p
followed VBD p
for IN p
4 CD p
years NNS p
. . p

Training NN i
of IN i
physicians NNS i
, , i
nurses NNS i
and CC i
dietitians NNS i
included VBD i
preparation NN i
of IN i
operating VBG i
manual JJ i
and CC i
videos NNS i
, , i
interactive JJ i
sessions NNS i
, , i
and CC i
evaluation NN i
of IN i
local JJ i
facilities NNS i
and CC i
resources NNS i
. . i

RESULTS NNP N
PRIMARY NNP N
MEASUREMENTS NNP N
3-monthly JJ o
HbA1c NNP o
, , o
fasting VBG o
blood NN o
glucose NN o
, , o
body NN o
weight VBD o
, , o
waist-hip JJ o
ratio NN o
, , o
yearly RB o
blood NN o
lipids NNS o
, , o
and CC o
bi-yearly JJ o
assessment NN o
of IN o
knowledge NN o
of IN o
diabetes NNS o
, , o
health NN o
behaviours NNS o
and CC o
quality NN o
of IN o
life NN o
. . o

SECONDARY NNP N
OUTCOMES NNP N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
, , o
evaluation NN o
of IN o
ECG NNP o
for IN o
ischaemia NN o
and CC o
QT NNP o
interval NN o
, , o
hypoglycaemic JJ o
and CC o
anti-hypertensive JJ o
medication NN o
and CC o
cardiovascular JJ o
events NNS o
. . o

Analysis NN N
will MD N
be VB N
by IN N
intention-to-treat JJ N
. . N

DISCUSSION NNP N
If IN N
ROMEO NNP N
confirms VBZ N
that IN N
group NN N
care NN N
can MD N
be VB N
successfully RB N
implemented VBN N
in IN N
different JJ N
clinics NNS N
, , N
a DT N
novel JJ N
clinico-pedagogic JJ N
tool NN N
will MD N
have VB N
been VBN N
acquired VBN N
to TO N
support VB N
patient-centred JJ N
education NN N
, , N
improve VB o
lifestyle NN o
and CC N
outcomes NNS o
, , o
support NN o
team NN o
work NN o
, , o
enhance NN o
providers NNS o
' POS o
attitudes NNS o
and CC N
competencies NNS o
and CC N
ameliorate VB N
diabetes NNS N
care JJ N
organization NN N
. . N

-DOCSTART- -24164087- O O

Therapeutic JJ N
effect NN N
of IN N
inhaled JJ N
budesonide NN i
( ( i
Pulmicort? NNP i
Turbuhaler NNP i
) ) i
on IN N
the DT N
inflammatory JJ N
response NN N
to TO N
one-lung JJ N
ventilation NN N
. . N

This DT N
prospective JJ N
, , N
double-blind JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
inhaled JJ i
budesonide NN i
on IN o
lung NN o
function NN o
and CC o
the DT o
inflammatory JJ o
response NN o
to TO o
one-lung JJ o
ventilation NN o
. . o

One CD p
hundred VBD p
patients NNS p
scheduled VBN p
for IN p
lobectomy NN p
were VBD N
allocated VBN N
randomly RB N
to TO N
pre-operative JJ N
nebulised JJ i
budesonide NN i
or CC i
saline NN i
. . i

Bronchoalveolar JJ N
lavage NN N
fluid NN N
samples NNS N
were VBD N
collected VBN N
from IN N
either CC N
the DT N
collapsed JJ N
or CC N
the DT N
ventilated VBN N
lung NN N
both DT N
before IN N
one-lung JJ N
ventilation NN N
and CC N
30 CD N
min NN N
after IN N
re-expansion NN N
of IN N
the DT N
lung NN N
. . N

The DT o
concentrations NNS o
of IN o
serum NN o
and CC o
bronchoalveolar JJ o
lavage NN o
fluid NN o
cytokines NNS o
were VBD N
determined VBN N
. . N

Budesonide NNP i
treatment NN N
, , N
compared VBN N
with IN N
saline NN N
, , N
reduced VBD o
both DT o
peak NN o
( ( N
mean JJ N
( ( N
SD NNP N
) ) N
3.7 CD N
( ( N
0.4 CD N
) ) N
vs NN N
2.5 CD N
( ( N
0.2 CD N
) ) N
kPa NN N
) ) N
and CC o
plateau NN o
( ( N
mean JJ N
( ( N
SD NNP N
) ) N
3.1 CD N
( ( N
0.2 CD N
) ) N
vs NN N
2.2 CD N
( ( N
0.1 CD N
) ) N
kPa NN N
, , N
respectively RB N
, , N
p JJ N
< VBP N
0.001 CD N
for IN N
both DT o
) ) o
ventilatory NN o
pressures NNS o
. . o

Thirty NNP N
minutes NNS N
after IN N
re-expansion NN N
, , N
lung NN o
compliance NN o
increased VBD N
in IN N
the DT i
budesonide NN i
group NN N
compared VBN N
with IN N
saline NN N
( ( N
57.5 CD N
( ( N
4.1 CD N
) ) N
vs NN N
40.1 CD N
( ( N
3.5 CD N
) ) N
ml.cmH NN N
( ( N
2 CD N
) ) N
O NNP N
( ( N
-1 NNP N
) ) N
, , N
respectively RB N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Budesonide NNP i
also RB N
reduced VBD N
the DT o
concentrations NNS o
of IN o
tumour JJ o
necrosis NN o
factor-? NN o
, , o
interleukin-1? JJ o
, , o
interleukin-6 JJ o
and CC o
interleukin-8 JJ o
in IN o
bronchoalveolar JJ o
lavage NN o
fluid NN o
, , o
but CC o
increased VBD o
interleukin-10 JJ o
30 CD o
min NN N
after IN N
re-expansion NN N
( ( N
p JJ N
< VBP N
0.05 CD N
for IN N
all DT N
measures NNS N
) ) N
. . N

Pre-operative JJ N
nebulisation NN N
of IN N
budesonide NN i
may MD i
be VB N
effective JJ N
in IN N
improving VBG o
ventilatory NN o
mechanics NNS o
and CC o
reducing VBG o
the DT o
inflammatory JJ o
response NN o
to TO o
one-lung JJ N
ventilation NN N
during IN N
thoracic JJ N
surgery NN N
. . N

-DOCSTART- -10808042- O O

Increased VBN o
growth NN o
hormone NN o
response NN N
to TO N
sumatriptan VB i
challenge NN N
in IN N
adult NN p
autistic JJ p
disorders NNS p
. . p

Serotonergic NNP N
( ( N
5-HT JJ N
) ) N
abnormalities NNS N
have VBP N
been VBN N
documented VBN N
in IN N
autism NN N
. . N

To TO N
assess JJ N
sensitivity NN N
of IN N
the DT N
5-HT1d JJ N
receptor NN N
, , N
growth NN o
hormone NN o
response NN o
to TO N
the DT N
5-HT1d JJ i
receptor NN i
agonist NN i
sumatriptan NN i
was VBD N
studied VBN N
in IN N
adult NN p
autistic JJ p
patients NNS p
and CC p
matched VBD p
normal JJ p
controls NNS p
. . p

In IN N
this DT N
study NN N
, , N
11 CD p
adult NN p
patients NNS p
with IN p
autism NN p
or CC p
Asperger NNP p
's POS p
disorder NN p
were VBD p
compared VBN p
with IN p
nine CD p
matched JJ p
controls NNS p
. . p

All DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
single JJ i
dose JJ i
sumatriptan NN i
( ( i
6 CD i
mg RB i
SQ NNP i
) ) i
and CC i
placebo NN i
challenges NNS i
, , i
separated VBN i
by IN i
a DT i
1-week JJ i
interval NN i
, , i
and CC i
growth NN o
hormone NN o
was VBD i
measured VBN i
before IN i
and CC i
during IN i
the DT i
challenges NNS i
. . i

The DT N
results NNS N
showed VBD N
a DT N
highly RB N
significant JJ N
diagnosisxdrugxtime JJ o
interaction NN o
on IN N
repeated JJ N
measure NN N
analysis NN N
covaried VBD N
for IN N
baseline NN N
. . N

This DT N
suggests VBZ N
that IN N
autistic JJ p
patients NNS p
had VBD N
significantly RB N
greater JJR N
growth NN o
hormone NN o
response NN o
to TO N
sumatriptan VB i
than IN N
normal JJ N
controls NNS N
, , N
independent JJ N
of IN N
placebo JJ N
effects NNS N
. . N

Therefore RB N
, , N
abnormalities NNS N
in IN N
5-HT JJ N
regulation NN N
in IN N
autism NN N
may MD N
be VB N
related VBN N
to TO N
increased VBN N
sensitivity NN N
of IN N
the DT N
5-HT1d JJ N
inhibitory NN N
receptor NN N
in IN N
autism NN N
. . N

-DOCSTART- -10525558- O O

An DT N
empirical JJ N
comparison NN N
of IN N
the DT N
St NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
( ( N
SGRQ NNP N
) ) N
and CC N
the DT N
Chronic NNP N
Respiratory NNP N
Disease NNP N
Questionnaire NNP N
( ( N
CRQ NNP N
) ) N
in IN N
a DT N
clinical JJ N
trial NN N
setting NN N
. . N

BACKGROUND IN N
The DT N
Chronic NNP N
Respiratory NNP N
Questionnaire NNP N
( ( N
CRQ NNP N
) ) N
and CC N
the DT N
St NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
( ( N
SGRQ NNP N
) ) N
are VBP N
the DT N
two CD N
most JJS N
widely RB N
used VBN N
quality NN N
of IN N
life NN N
questionnaires NNS N
in IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( p
COPD NNP p
) ) p
. . p

A DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
directly RB N
the DT N
self-administered JJ N
version NN N
of IN N
the DT N
CRQ NNP N
and CC N
the DT N
SGRQ NNP N
with IN N
respect NN N
to TO N
feasibility NN N
, , N
internal JJ N
consistency NN N
, , N
validity NN N
, , N
and CC N
sensitivity NN N
to TO N
changes NNS N
resulting VBG N
from IN N
bronchodilator NN N
therapy NN N
. . N

METHODS NNP N
One CD p
hundred CD p
and CC p
forty VB p
four CD p
patients NNS p
with IN p
moderate JJ p
or CC p
severe JJ p
COPD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
three CD N
months NNS N
of IN N
treatment NN N
with IN N
either DT N
salmeterol NN i
, , i
salmeterol NN i
+ NNP i
ipratropium NN i
bromide NN i
, , i
or CC i
placebo NN i
. . i

Quality NN o
of IN o
life NN o
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

RESULTS VB N
The DT N
proportions NNS o
of IN o
missing VBG o
values NNS o
per IN N
patient NN N
were VBD N
low JJ N
for IN N
both DT N
questionnaires NNS N
( ( N
0.54 CD N
% NN N
for IN N
the DT N
CRQ NNP N
and CC N
2 CD N
% NN N
for IN N
the DT N
SGRQ NNP N
) ) N
. . N

The DT N
internal JJ o
consistency NN o
was VBD N
good JJ N
for IN N
both DT N
questionnaires NNS N
( ( N
Cronbach NNP N
's POS N
alpha NN N
coefficients NNS N
> VBP N
/= $ N
0.84 CD N
for IN N
the DT N
CRQ NNP N
and CC N
> NNP N
/= NNP N
0.76 CD N
for IN N
the DT N
SGRQ NNP N
) ) N
. . N

Factor NNP N
analysis NN N
confirmed VBD N
the DT N
original JJ N
domain NN N
structure NN N
of IN N
the DT N
CRQ NNP N
but CC N
not RB N
of IN N
the DT N
SGRQ NNP N
. . N

Correlations NNS N
with IN N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( o
FEV NNP o
( ( o
1 CD o
) ) o
) ) o
% NN o
predicted VBN N
and CC N
peak JJ o
expiratory NN o
flow NN o
rate NN o
( ( o
PEFR NNP o
) ) o
were VBD N
low JJ N
for IN N
both DT N
questionnaires NNS N
but CC N
better JJR N
for IN N
the DT N
SGRQ NNP N
than IN N
for IN N
the DT N
CRQ NNP N
. . N

The DT N
ability NN N
to TO N
discriminate VB N
between IN N
subjects NNS N
with IN N
different JJ N
levels NNS N
of IN N
FEV NNP o
( ( o
1 CD o
) ) o
was VBD N
somewhat RB N
better JJR N
for IN N
the DT N
SGRQ NNP N
. . N

The DT N
correlations NNS N
with IN N
symptom JJ N
scores NNS N
were VBD N
comparable JJ N
for IN N
both DT N
questionnaires NNS N
. . N

Cross NNP N
sectionally RB N
, , N
the DT N
scores NNS N
of IN N
the DT N
two CD N
questionnaires NNS N
were VBD N
moderately RB N
to TO N
highly RB N
correlated VBN N
( ( N
coefficients NNS N
ranged VBD N
from IN N
0.35 CD N
to TO N
0.72 CD N
) ) N
. . N

Longitudinally RB N
, , N
these DT N
correlations NNS N
were VBD N
lower JJR N
( ( N
coefficients NNS N
ranged VBD N
from IN N
0.17 CD N
to TO N
0.54 CD N
) ) N
but CC N
were VBD N
still RB N
significant JJ N
. . N

The DT N
CRQ NNP o
total NN o
and CC o
emotions NNS o
score NN o
and CC o
the DT o
SGRQ NNP o
symptoms NNS o
score NN o
were VBD N
the DT N
most RBS N
responsive JJ N
to TO N
change VB N
. . N

The DT N
SGRQ NNP o
symptoms NNS o
domain NN o
was VBD N
the DT N
only JJ N
domain NN N
where WRB N
the DT N
improvement NN N
in IN N
patients NNS p
receiving VBG p
combination NN p
treatment NN p
crossed VBD N
the DT N
threshold NN N
for IN N
clinical JJ N
relevance NN N
. . N

CONCLUSIONS NNP N
Since IN N
this DT N
analysis NN N
of IN N
reliability NN N
, , N
validity NN N
, , N
and CC N
responsiveness NN N
to TO N
change VB N
did VBD N
not RB N
clearly RB N
favour VBP N
one CD N
instrument NN N
above IN N
the DT N
other JJ N
, , N
the DT N
choice NN N
between IN N
the DT N
CRQ NNP N
and CC N
the DT N
SGRQ NNP N
can MD N
be VB N
based VBN N
on IN N
other JJ N
considerations NNS N
such JJ N
as IN N
the DT N
required JJ N
sample NN N
size NN N
or CC N
the DT N
availability NN N
of IN N
reference NN N
values NNS N
. . N

-DOCSTART- -20204689- O O

Promoting VBG i
social JJ i
skill NN i
development NN i
in IN N
children NNS p
with IN p
pervasive JJ p
developmental JJ p
disorders NNS p
: : p
a DT N
feasibility NN N
and CC N
efficacy NN N
study NN N
. . N

A DT N
randomized JJ N
controlled JJ N
design NN N
was VBD N
employed VBN N
to TO N
evaluate VB N
a DT N
social JJ i
skills NNS i
intervention NN i
for IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

Aims NNP N
included VBD N
evaluating VBG N
the DT N
acceptability NN N
of IN N
the DT N
program NN N
and CC N
gathering VBG N
preliminary JJ N
evidence NN N
on IN N
efficacy NN N
. . N

Forty-four JJ p
children NNS p
, , p
ages VBZ p
8-11 CD p
years NNS p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO p
treatment NN i
or CC p
wait JJ i
list NN i
. . i

Treatment NNP N
consisted VBD N
of IN N
a DT N
16-week JJ N
group NN i
intervention NN i
designed VBN i
to TO i
teach VB i
appropriate JJ i
social JJ i
behavior NN i
. . i

Between NNP N
group NN N
comparisons NNS N
showed VBD N
that IN N
children NNS N
in IN N
treatment NN N
were VBD N
rated VBN N
as IN N
improved VBN N
on IN N
the DT N
primary JJ o
outcome NN o
measure NN o
, , o
( ( o
unblinded JJ o
parent NN o
report NN o
) ) o
, , N
but CC N
not RB N
on IN N
the DT N
secondary JJ N
outcome NN N
measure NN N
, , N
a DT N
parent NN o
questionnaire NN o
. . o

Parents NNS p
reported VBD N
a DT N
high JJ N
level NN o
of IN o
satisfaction NN o
with IN N
the DT N
intervention NN N
. . N

The DT N
study NN N
supports VBZ N
the DT N
feasibility NN N
of IN N
this DT N
intervention NN N
to TO N
families NNS p
and CC N
highlights NNS N
challenges NNS N
for IN N
future JJ N
research NN N
in IN N
social JJ i
skills NNS i
intervention NN i
. . i

-DOCSTART- -3882217- O O

A DT N
randomized VBN N
, , N
prospective JJ N
trial NN N
of IN N
adjuvant JJ i
chemotherapy NN i
in IN N
adults NNS p
with IN p
soft JJ p
tissue NN p
sarcomas NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
, , p
breast NN p
, , p
and CC p
trunk NN p
. . p

Since IN p
1977 CD p
, , p
31 CD p
patients NNS p
were VBD p
entered VBN p
in IN p
a DT p
randomized JJ p
, , p
prospective JJ p
study NN p
testing VBG p
the DT p
efficacy NN p
of IN p
adjuvant JJ i
chemotherapy NN i
after IN p
aggressive JJ p
local JJ p
treatment NN p
of IN p
high-grade JJ p
sarcomas NN p
of IN p
the DT p
head NN p
, , p
neck NN p
, , p
breast NN p
, , p
and CC p
trunk NN p
( ( p
excluding VBG p
retroperitoneal VB p
sarcomas NN p
) ) p
. . p

All DT p
patients NNS p
had VBD p
complete JJ p
resection NN i
of IN i
gross JJ i
tumor NN i
and CC p
underwent JJ p
postoperative JJ i
radiotherapy NN i
( ( p
6000-6300 JJ p
rads NNS p
over IN p
7-8 JJ p
weeks NNS p
) ) p
. . p

Seventeen JJ p
patients NNS p
received VBD p
adjuvant JJ i
chemotherapy NN i
consisting NN i
of IN i
doxorubicin NN i
( ( i
less JJR i
than IN i
or CC i
equal JJ i
to TO i
550 CD i
mg/m2 NN i
) ) i
, , i
cyclophosphamide RB i
( ( i
less JJR i
than IN i
or CC i
equal JJ i
to TO i
5500 CD i
mg/m2 NN i
) ) i
, , i
and CC i
methotrexate NN i
( ( i
less JJR i
than IN i
or CC i
equal JJ i
to TO i
1000 CD i
mg/kg NN i
) ) i
. . N

Three-year JJ N
actuarial JJ o
disease-free JJ o
survival NN o
in IN N
the DT N
chemotherapy NN i
arm NN N
was VBD N
77 CD N
% NN N
, , N
compared VBN N
to TO N
49 CD N
% NN N
in IN N
the DT N
no-chemotherapy JJ i
arm NN N
( ( N
P NNP N
= NNP N
0.075 CD N
) ) N
. . N

Three-year JJ N
overall JJ o
actuarial JJ o
survivals NNS o
in IN N
the DT N
two CD N
treatment NN N
arms NNS N
, , N
however RB N
, , N
were VBD N
68 CD N
% NN N
and CC N
58 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.38 CD N
) ) N
. . N

Considering VBG N
only JJ N
patients NNS N
with IN N
tumors NNS N
of IN N
the DT N
trunk NN N
( ( N
22 CD N
patients NNS N
) ) N
, , N
3-year JJ N
actuarial JJ N
disease-free JJ N
survival NN N
in IN N
the DT N
chemotherapy NN N
arm NN N
was VBD N
92 CD N
% NN N
, , N
compared VBN N
to TO N
47 CD N
% NN N
in IN N
the DT N
no-chemotherapy JJ N
arm NN N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
. . N

Actuarial JJ N
3-year JJ N
overall JJ N
survival NN N
in IN N
the DT N
chemotherapy NN N
arm NN N
was VBD N
82 CD N
% NN N
, , N
compared VBN N
to TO N
61 CD N
% NN N
in IN N
the DT N
no-chemotherapy JJ N
arm NN N
( ( N
P NNP N
= NNP N
0.18 CD N
) ) N
. . N

An DT p
additional JJ p
26 CD p
patients NNS p
were VBD N
treated VBN N
in IN N
an DT N
identical JJ N
fashion NN N
, , N
but CC N
were VBD N
not RB N
part NN N
of IN N
the DT N
randomized VBN N
trial NN N
because IN N
of IN N
contraindications NNS N
to TO N
chemotherapy VB N
, , N
refusal NN N
to TO N
enter VB N
the DT N
randomized JJ N
trial NN N
, , N
or CC N
because IN N
they PRP N
were VBD N
treated VBN N
before IN N
1977 CD N
in IN N
a DT N
trial NN N
in IN N
which WDT N
all DT N
patients NNS N
received VBD N
chemotherapy NN N
. . N

Considering VBG N
the DT N
entire JJ p
group NN p
of IN p
57 CD p
patients NNS p
, , N
follow-up JJ N
ranged VBD N
from IN N
10 CD N
to TO N
86 CD N
months NNS N
( ( N
median JJ N
, , N
35 CD N
months NNS N
) ) N
. . N

Local JJ o
control NN o
was VBD N
achieved VBN N
in IN N
46 CD N
patients NNS N
( ( N
81 CD N
% NN N
) ) N
; : N
3-year JJ N
actuarial JJ o
disease-free NN o
and CC o
overall JJ o
survivals NNS o
were VBD N
67 CD N
% NN N
and CC N
77 CD N
% NN N
, , N
respectively RB N
. . N

A DT N
tendency NN N
toward IN N
improved JJ N
disease-free JJ o
survival NN o
was VBD N
apparent JJ N
among IN N
patients NNS N
treated VBN N
with IN N
chemotherapy NN N
( ( N
P NNP N
= NNP N
0.018 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
overall JJ o
actuarial JJ o
survival NN o
( ( N
P NNP N
= NNP N
0.46 CD N
) ) N
. . N

The DT p
subgroup NN p
of IN p
patients NNS p
with IN p
sarcomas NN p
of IN p
the DT p
trunk NN p
( ( p
39 CD p
patients NNS p
) ) p
demonstrated VBD N
the DT N
greatest JJS N
benefit NN N
from IN N
chemotherapy NN i
, , N
with IN N
regard NN N
to TO N
disease-free JJ o
survival NN o
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.001 CD N
) ) N
. . N

The DT N
most RBS N
significant JJ N
toxicity NN o
associated VBN N
with IN N
chemotherapy NN i
was VBD N
doxorubicin-induced JJ o
cardiomyopathy NN o
, , N
which WDT N
resulted VBD N
in IN N
clinically RB N
apparent JJ N
congestive JJ o
heart NN o
failure NN o
in IN N
five CD N
patients NNS N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
chemotherapy NN i
when WRB N
combined VBN N
with IN N
aggressive JJ N
local JJ N
measures NNS N
appears VBZ N
to TO N
improve VB N
disease-free JJ o
survival NN o
, , N
but CC N
additional JJ N
patients NNS N
and CC N
longer JJR N
follow-up NN N
are VBP N
necessary JJ N
to TO N
determine VB N
if IN N
improved VBN N
overall JJ o
survival NN o
will MD N
result VB N
. . N

-DOCSTART- -7742155- O O

The DT N
effect NN N
of IN N
fasting VBG i
on IN N
total JJ o
serum NN o
bilirubin NN o
concentrations NNS o
. . o

Thirty-seven NNP p
healthy JJ p
volunteers NNS p
, , p
19 CD p
of IN p
whom WP p
had VBD p
consistently RB p
elevated VBN p
total JJ o
serum NN o
bilirubin NN o
( ( o
TSB NNP o
) ) o
concentrations NNS o
, , p
took VBD p
part NN p
in IN N
an DT N
open JJ N
, , N
randomised VBD N
cross-over NN N
study NN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
fasting VBG i
on IN N
TSB NNP N
concentrations NNS N
. . N

The DT N
study NN N
comprised VBD N
of IN N
two CD N
treatments NNS N
. . N

During IN N
one CD N
treatment NN N
period NN N
volunteers NNS p
ate VBP i
a DT i
standard JJ i
supper NN i
but CC i
fasted VBD i
for IN i
24 CD i
h NN i
thereafter RB i
. . i

During IN N
the DT N
other JJ N
treatment NN N
period NN N
volunteers NNS p
ate VBP N
a DT N
standard JJ i
supper NN i
, , i
snacks NNS i
, , i
breakfast NN i
and CC i
lunch NN i
. . i

TSB NNP o
concentrations NNS o
were VBD N
measured VBN N
at IN N
regular JJ N
intervals NNS N
. . N

In IN N
both DT N
the DT N
normal JJ N
and CC N
high JJ N
bilirubin NN N
groups NNS N
, , N
minimum JJ o
TSB NNP o
values NNS o
were VBD N
recorded VBN N
4 CD N
h NN N
after IN N
the DT N
supper NN N
. . N

A DT N
24 CD N
h NN N
fast RB N
more RBR o
than IN o
doubled VBD o
TSB NNP o
concentration NN o
from IN N
baseline NN N
values NNS N
in IN N
both DT N
the DT N
normal JJ N
and CC N
high JJ N
bilirubin NN N
groups NNS N
. . N

A DT N
clinically RB N
relevant JJ N
rise NN o
in IN o
TSB NNP o
took VBD N
place NN N
after IN N
12 CD N
h NN N
into IN N
the DT N
fasting JJ N
period NN N
( ( N
TSB NNP N
of IN N
17.3 CD N
mumol JJ N
l-1 NN N
in IN N
the DT N
fasted JJ N
group NN N
vs VBD N
14.0 CD N
mumol JJ N
l-1 NN N
in IN N
the DT N
non-fasted JJ N
group NN N
) ) N
. . N

When WRB N
designing VBG N
a DT N
clinical JJ N
trial NN N
, , N
selecting VBG N
volunteers NNS p
, , N
or CC N
judging VBG N
the DT N
tolerance NN N
of IN N
a DT N
new JJ N
drug NN N
, , N
the DT N
rise NN N
in IN N
TSB NNP o
caused VBN N
by IN N
fasting VBG N
must MD N
therefore RB N
be VB N
taken VBN N
into IN N
account NN N
, , N
particularly RB N
in IN N
trials NNS N
where WRB N
volunteers NNS p
or CC N
patients NNS N
fast JJ N
before IN N
entering VBG N
the DT N
study NN N
. . N

-DOCSTART- -23160656- O O

Effect NN N
of IN N
whole-body JJ i
mild-cold JJ i
exposure NN i
on IN N
arterial JJ o
stiffness NN o
and CC o
central JJ o
haemodynamics NNS o
: : o
a DT N
randomised JJ N
, , N
cross-over JJ N
trial NN N
in IN N
healthy JJ p
men NNS p
and CC p
women NNS p
. . p

Aortic JJ o
pulse NN o
wave NN o
velocity NN o
( ( o
PWV NNP o
) ) o
and CC N
augmentation NN o
index NN o
( ( o
AIx NNP o
) ) o
are VBP N
independent JJ N
predictors NNS N
of IN N
cardiovascular JJ o
risk NN o
and CC o
mortality NN o
, , N
but CC N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effect NN N
of IN N
air NN N
temperature NN N
changes NNS N
on IN N
these DT N
variables NNS N
. . N

Our PRP$ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
exposure NN N
to TO N
whole-body JJ i
mild-cold JJ i
on IN N
measures NNS N
of IN N
arterial JJ o
stiffness NN o
( ( o
aortic JJ o
and CC o
brachial JJ o
PWV NNP o
) ) o
, , o
and CC o
on IN o
central JJ o
haemodynamics NNS o
[ VBP o
including VBG o
augmented VBN o
pressure NN o
( ( o
AP NNP o
) ) o
, , o
AIx NNP o
] NNP o
, , o
and CC o
aortic JJ o
reservoir NN o
components NNS o
[ VBP o
including VBG o
reservoir NN o
and CC o
excess JJ o
pressures NNS o
( ( o
P NNP o
ex NN o
) ) o
] NN o
. . o

Sixteen NNP p
healthy JJ p
volunteers NNS p
( ( p
10 CD p
men NNS p
, , p
age NN p
43 CD p
? . p
19 CD p
years NNS p
; : p
mean VB p
? . p
SD NNP p
) ) p
were VBD p
randomised VBN N
to TO N
be VB N
studied VBN N
under IN N
conditions NNS N
of IN N
12 CD i
?C NNS i
( ( i
mild-cold JJ i
) ) i
and CC i
21 CD i
?C NNP i
( ( i
control NN i
) ) i
on IN i
separate JJ N
days NNS N
. . o

Supine JJ o
resting VBG o
measures NNS o
were VBD o
taken VBN N
at IN N
baseline NN N
( ( N
ambient JJ N
temperature NN N
) ) N
and CC N
after IN N
10 CD N
, , N
30 CD N
, , N
and CC N
60 CD N
min NN N
exposure NN N
to TO N
each DT N
experimental JJ N
condition NN N
in IN N
a DT N
climate JJ N
chamber NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
change NN o
in IN o
brachial JJ o
blood NN o
pressure NN o
between IN o
mild-cold JJ i
and CC i
control JJ N
conditions NNS N
. . N

However RB N
, , N
compared VBN N
to TO N
control VB o
, , o
AP NNP o
[ NNP N
+2 NNP N
mmHg NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.36-4.36 NN N
; : N
p CC N
= $ N
0.01 CD N
] NN N
and CC N
AIx NNP o
( ( N
+6 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
1.24-10.1 CD N
; : N
p CC N
= VB N
0.02 CD N
) ) N
increased VBN N
, , N
and CC N
time NN o
to TO o
maximum VB o
P NNP o
ex FW o
( ( N
a DT N
component NN N
of IN N
reservoir NN N
function NN N
related VBN N
to TO N
timing NN N
of IN N
peak JJ N
aortic JJ N
in-flow NN N
) ) N
decreased VBD N
( ( N
-7 JJ N
ms NN N
, , N
95 CD N
% NN N
CI NNP N
-15.4 NNP N
to TO N
2.03 CD N
; : N
p NN N
= VBZ N
0.01 CD N
) ) N
compared VBN N
to TO N
control VB N
. . N

Yet CC N
there EX N
was VBD N
no DT N
significant JJ N
change NN o
in IN o
aortic JJ o
PWV NNP o
( ( N
+0.04 NNP N
m/s NN N
, , N
95 CD N
% NN N
CI NNP N
-0.47 NNP N
to TO N
0.55 CD N
; : N
p NN N
= VBZ N
0.87 CD N
) ) o
or CC o
brachial JJ o
PWV NNP o
( ( N
+0.36 NNP N
m/s NN N
; : N
-0.41 VBZ N
to TO N
1.12 CD N
; : N
p NN N
= VBZ N
0.35 CD N
) ) N
between IN N
conditions NNS N
. . N

We PRP N
conclude VBP N
that IN N
mild-cold JJ i
exposure NN i
increases VBZ o
central JJ o
haemodynamic JJ o
stress NN o
and CC o
alters NNS o
timing NN o
of IN o
peak JJ o
aortic JJ o
in-flow NN o
without IN o
differentially RB N
affecting VBG o
arterial JJ o
stiffness NN o
. . o

-DOCSTART- -17700649- O O

Should MD N
snacks NNS i
be VB N
recommended VBN N
in IN N
obesity NN p
treatment NN p
? . N
A DT N
1-year JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
to TO N
recommend VB N
no DT i
snacks NNS i
vs VBP i
three CD i
snacks NNS i
per IN N
day NN N
on IN N
1-year JJ N
weight JJ N
loss NN N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
it PRP N
is VBZ N
easier JJR N
to TO N
control VB N
energy NN N
intake NN N
and CC N
lose VB N
weight NN N
if IN N
snacks NNS N
in IN N
between IN N
meals NNS N
are VBP N
omitted VBN N
. . N

SUBJECTS/METHOD NNP N
In IN N
total JJ N
140 CD p
patients NNS p
( ( p
36 CD p
men NNS p
, , p
104 CD p
women NNS p
) ) p
, , p
aged VBN p
18-60 CD p
years NNS p
and CC p
body NN p
mass NN p
index NN p
> VBD p
30 CD p
kg/m NN p
( ( p
2 CD p
) ) p
were VBD p
randomized VBN p
and CC p
93 CD p
patients NNS p
( ( p
27 CD p
men NNS p
, , p
66 CD p
women NNS p
) ) p
completed VBD p
the DT p
study NN p
. . p

A DT N
1-year JJ N
randomized JJ N
intervention NN N
trial NN N
was VBD N
conducted VBN N
with IN N
two CD N
treatment NN N
arms NNS N
with IN N
different JJ N
eating VBG N
frequencies NNS N
; : N
3 CD i
meals/day NN i
( ( i
3M CD i
) ) i
or CC N
3 CD i
meals NNS i
and CC i
3 CD i
snacks/day NN i
( ( N
3+3M CD N
) ) N
. . N

The DT N
patients NNS N
received VBD N
regular JJ N
and CC N
individualized JJ N
counseling NN N
by IN N
dieticians NNS N
. . N

Information NN o
on IN o
eating NN o
patterns NNS o
, , o
dietary JJ o
intake NN o
, , o
weight NN o
and CC o
metabolic JJ o
variables NNS o
was VBD N
collected VBN N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
year NN N
. . N

RESULTS NNP N
Over IN N
1 CD N
year NN N
the DT N
3M CD i
group NN N
reported VBD N
a DT N
decrease NN N
in IN N
the DT N
number NN o
of IN o
snacks NNS o
whereas VBP N
the DT N
3+3M CD i
group NN N
reported VBD N
an DT N
increase NN N
( ( N
-1.1 JJ N
vs NN N
+0.4 NN N
snacks/day NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Both DT N
groups NNS N
decreased VBD N
energy NN o
intake NN o
and CC N
E NNP o
% NN o
( ( o
energy NN o
percent NN o
) ) o
fat NN o
and CC N
increased VBD N
E NNP o
% NN o
protein NN o
and CC o
fiber VB o
intake NN o
but CC N
there EX N
was VBD N
no DT N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Both DT N
groups NNS N
lost VBD o
weight NN o
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
weight JJ o
loss NN o
after IN N
1 CD N
year NN N
of IN N
treatment NN N
( ( i
3M CD i
vs RB N
3+3M=-4.1+/-6.1 JJ i
vs NN N
-5.9+/-9.4 NNP N
kg NN N
; : N
P=0.31 NNP N
) ) N
. . N

Changes NNS N
in IN N
metabolic JJ o
variables NNS o
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
, , N
except IN N
for IN N
high-density NN o
lipoprotein NN o
that WDT N
increased VBD N
in IN N
the DT N
3M CD i
group NN N
but CC N
not RB N
in IN N
3+3M CD i
group NN N
( ( N
P NNP N
< VBZ N
0.033 CD N
for IN N
group NN N
difference NN N
) ) N
. . N

CONCLUSION NNP N
Recommending VBG N
snacks NNS N
or CC N
not RB N
between IN N
meals NNS N
does VBZ N
not RB N
influence VB N
1-year JJ o
weight NN o
loss NN o
. . o

-DOCSTART- -7235205- O O

Theophylline NNP o
concentrations NNS o
in IN N
serum NN N
and CC N
saliva NN N
after IN N
oral JJ N
microcrystalline NN i
and CC N
sustained-release JJ i
preparations NNS i
in IN N
asthmatics NNS p
. . p

Theophylline NNP o
concentrations NNS o
in IN N
saliva NN N
have VBP N
been VBN N
compared VBN N
with IN N
those DT N
in IN N
serum NN N
in IN N
13 CD p
asthmatic JJ p
patients NNS p
after IN p
single JJ p
and CC p
multiple JJ p
oral JJ p
dosage NN p
of IN p
a DT p
microcrystalline JJ i
theophylline NN i
tablet NN i
( ( p
Nuelin NNP p
) ) p
and CC p
a DT p
sustained-release JJ i
preparation NN i
( ( p
Nuelin NNP p
Retard NNP p
) ) p
. . N

There EX N
was VBD N
wide JJ N
individual JJ N
variation NN N
in IN N
the DT N
ratio NN o
of IN o
serum NN o
to TO o
saliva VB o
concentrations NNS o
indicating VBG N
that IN N
, , N
even RB N
when WRB N
individual JJ N
serum NN N
to TO N
saliva VB N
ratios NNS N
have VBP N
been VBN N
established VBN N
, , N
the DT N
use NN N
of IN N
saliva JJ N
theophylline NN i
measurements NNS N
alone RB N
is VBZ N
unreliable JJ N
for IN N
the DT N
routine JJ N
monitoring NN N
of IN N
theophylline JJ i
therapy NN i
. . i

Both DT N
preparations NNS N
produced VBD N
mean JJ o
serum NN o
theophylline NN o
concentrations NNS o
within IN N
the DT N
10 CD N
-- : N
20 CD N
mcg/ml NN N
range NN N
, , N
the DT N
sustained-release JJ N
tablet NN N
giving VBG N
higher JJR N
monitoring NN N
through IN N
values NNS N
and CC N
smaller JJR N
through IN N
to TO N
peak VB o
variation NN o
. . o

The DT N
preparations NNS N
were VBD N
equally RB N
and CC N
highly RB N
bioavailable JJ N
. . N

Side JJ o
effects NNS o
were VBD N
reported VBN N
by IN N
three CD N
patients NNS N
, , N
which WDT N
were VBD N
the DT N
patients NNS N
with IN N
the DT N
highest JJS N
AUC NN N
. . N

The DT N
Nuelin NNP i
Retard NNP i
preparation NN N
appears VBZ N
to TO N
provide VB N
smooth RB N
, , N
sustained VBD N
serum JJ o
theophylline NN o
concentrations NNS o
within IN N
the DT N
therapeutic JJ N
range NN N
and CC N
the DT N
simple JJ N
, , N
twice-daily JJ N
dosage NN N
should MD N
result VB N
in IN N
improved JJ N
patient NN N
compliance NN N
. . N

-DOCSTART- -23642776- O O

Extra NNP i
virgin NN i
olive JJ i
oil NN i
( ( i
EVOO NNP i
) ) i
consumption NN N
and CC N
antioxidant JJ o
status NN o
in IN N
healthy JJ p
institutionalized VBN p
elderly JJ p
humans NNS p
. . p

Recent JJ N
studies NNS N
show VBP N
that IN N
the DT N
elderly JJ p
have VBP N
increased VBN N
oxidative JJ N
stress NN N
and CC N
impaired JJ N
antioxidant NN N
defense NN N
systems NNS N
. . N

Our PRP$ N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
daily JJ N
consumption NN N
of IN N
EVOO NNP i
in IN N
the DT N
healthy JJ p
institutionalized JJ p
elderly RB p
. . p

We PRP N
studied VBD N
anthropometric JJ o
, , o
biochemical JJ o
and CC o
antioxidant JJ o
parameters NNS o
in IN N
62 CD p
subjects NNS p
aged VBN p
65-96 CD p
years NNS p
after IN N
a DT N
6-week JJ N
daily JJ N
intake NN N
of IN N
polyphenol-rich JJ i
EVOO NNP i
with IN i
high JJ i
oleuropein NNS i
derivative JJ i
contents NNS i
. . i

Subjects NNS N
were VBD N
divided VBN N
into IN N
a DT N
control NN i
group NN i
( ( i
CG NNP i
) ) i
who WP N
maintained VBD i
their PRP$ i
dietary JJ i
habits NNS i
( ( N
n=39 NN N
) ) N
and CC N
an DT N
olive JJ i
group NN i
( ( i
OG NNP i
) ) i
who WP i
consumed VBD i
EVOO NNP i
as IN N
the DT N
only RB N
added JJ N
fat NN N
, , N
plus CC N
a DT N
daily JJ N
dose NN N
of IN N
50ml CD N
( ( N
n=23 NN N
) ) N
. . N

We PRP N
found VBD N
a DT N
significant JJ N
reduction NN N
of IN N
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
HDL NNP o
, , o
LDL NNP o
and CC o
TGs NNP o
in IN N
OG NNP N
subjects NNS N
and CC N
a DT N
significant JJ N
increase NN N
of IN N
HDL NNP N
levels NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
variation NN N
in IN N
the DT N
CG NNP N
parameters NNS N
. . N

In IN N
OG NNP N
the DT N
total JJ o
antioxidant JJ o
capacity NN o
( ( o
TAC NNP o
) ) o
in IN o
plasma NN o
increased VBN N
with IN N
significant JJ N
differences NNS N
over IN N
CG NNP N
. . N

Plasma NNP o
hydroxytyrosol NN o
( ( o
OH-Tyr NNP o
) ) o
concentration NN o
showed VBD N
a DT N
significant JJ N
increase NN N
after IN N
EVOO NNP i
intervention NN N
. . N

Daily JJ N
consumption NN N
of IN N
EVOO NNP i
was VBD N
found VBN N
to TO N
have VB N
positive JJ N
effects NNS N
on IN N
lipid JJ o
profiles NNS o
, , o
OH-Tyr NNP o
levels NNS o
and CC o
TAC NNP o
. . o

The DT N
results NNS N
also RB N
show VBP N
a DT N
significant JJ N
increase NN N
of IN N
catalase NN o
( ( o
CAT NNP o
) ) o
in IN N
erythrocytes NNS N
and CC N
a DT N
decrease NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
superoxide JJ o
dismutase NN o
( ( o
SOD NNP o
) ) o
and CC o
glutathione JJ o
peroxidase NN o
( ( o
GH-PX NNP o
) ) o
activity NN o
after IN N
EVOO NNP N
intake NN N
. . N

To TO N
our PRP$ N
knowledge NN N
, , N
no DT N
other JJ N
study NN N
has VBZ N
examined VBN N
the DT N
effects NNS N
of IN N
EVOO NNP i
consumption NN N
on IN N
biochemical JJ o
parameters NNS o
, , o
antioxidant JJ o
capacity NN o
and CC o
antioxidant JJ o
enzyme NN o
activity NN o
in IN N
healthy JJ p
elderly JJ p
subjects NNS p
. . p

In IN N
conclusion NN N
, , N
our PRP$ N
results NNS N
show VBP N
that IN N
nutritional JJ N
intervention NN N
with IN N
EVOO NNP i
improves VBZ N
antioxidant JJ N
status NN N
in IN N
healthy JJ p
elderly JJ p
people NNS p
. . p

-DOCSTART- -10826576- O O

Identifying VBG N
the DT N
indications NNS N
for IN N
laparoscopically RB i
assisted VBN i
vaginal JJ i
hysterectomy NN i
: : i
a DT N
prospective JJ N
, , N
randomised VBD N
comparison NN N
with IN N
abdominal JJ i
hysterectomy NN i
in IN p
patients NNS p
with IN p
symptomatic JJ p
uterine JJ p
fibroids NNS p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
laparoscopically RB i
assisted VBN i
vaginal JJ i
hysterectomy NN i
( ( i
LAVH NNP i
) ) i
and CC i
total JJ i
abdominal JJ i
hysterectomy NN i
( ( i
TAH NNP i
) ) i
in IN N
patients NNS p
with IN p
uterine JJ p
fibroids NNS p
. . p

DESIGN VB N
A DT N
prospective JJ N
randomised VBN N
study NN N
. . N

SETTING CC N
The DT p
San NNP p
Paolo NNP p
Hospital NNP p
, , p
Milan NNP p
. . p

POPULATION NNP N
Sixty-two JJ p
patients NNS p
, , p
who WP p
were VBD p
not RB p
suitable JJ p
for IN p
a DT p
vaginal JJ p
hysterectomy NN p
, , p
requiring VBG p
treatment NN p
for IN p
uterine JJ p
fibroids NNS p
. . p

METHODS NNP N
Randomisation NNP N
between IN N
LAVH NNP i
and CC i
TAH NNP i
. . i

Comparison NNP N
of IN N
outcomes NNS N
on IN N
the DT N
whole JJ N
series NN N
, , N
patients NNS N
with IN N
uteri JJ N
< NN N
or CC N
= $ N
500 CD N
g NN N
( ( N
Group NNP N
1 CD N
) ) N
and CC N
patients NNS N
with IN N
uteri JJ N
> $ N
500 CD N
g NN N
( ( N
Group NNP N
2 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
To TO N
establish VB N
operating NN o
time NN o
, , o
blood NN o
loss NN o
, , o
complications NNS o
, , o
febrile JJ o
morbidity NN o
, , o
analgesics NNS o
administration NN o
and CC o
hospital JJ o
stay NN o
for IN N
both DT N
treatment NN N
approaches NNS N
. . N

RESULTS NNP N
Median JJ o
uterine JJ o
weight NN o
was VBD N
400 CD N
g NN N
in IN N
both DT N
LAVH NNP i
and CC N
TAH NNP i
group NN N
. . N

Median JJ o
operating NN o
time NN o
was VBD N
longer RBR N
for IN N
LAVH NNP i
( ( N
135 CD N
min NNS N
compared VBN N
with IN N
120 CD N
min NNS N
for IN N
TAH NNP i
; : i
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
but CC N
patients NNS N
undergoing JJ N
LAVH NNP i
had VBD N
less RBR N
analgesics JJ o
administration NN o
( ( N
23 CD N
% NN N
compared VBN N
with IN N
77 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
shorter NN N
median JJ o
hospital NN o
stay NN o
( ( N
3.8 CD N
compared VBN N
with IN N
5.8 CD N
days NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

LAVH NNP i
, , N
when WRB N
compared VBN N
with IN N
TAH NNP i
in IN N
the DT N
two CD N
weight NN N
subgroups NNS N
, , N
required VBD N
a DT N
significantly RB N
longer RBR N
operating VBG o
time NN o
only RB N
in IN N
Group NNP N
2 CD N
, , N
significantly RB N
reduced VBN N
analgesics NNS o
administration NN o
only RB N
in IN N
Group NNP N
1 CD N
, , N
and CC N
significantly RB N
reduced VBN N
hospital NN o
stay NN o
in IN N
both DT N
groups NNS N
. . N

Conversions NNS N
of IN N
LAVH NNP N
to TO N
laparotomy VB N
were VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
Group NNP N
2 CD N
( ( N
3/11 CD N
) ) N
than IN N
in IN N
Group NNP N
1 CD N
( ( N
0/20 CD N
) ) N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
TAH NNP i
, , i
LAVH NNP i
has VBZ N
advantages NNS o
in IN N
removing VBG N
uteri JJ N
weighing VBG N
< NN N
or CC N
= $ N
500 CD N
g NN N
, , N
with IN N
comparable JJ N
operating NN o
time NN o
, , N
less JJR N
post-operative JJ o
pain NN o
and CC N
shorter JJR N
recovery NN o
. . o

Among IN N
uteri JJ N
weighing VBG N
> JJ N
500 CD N
g NN N
LAVH NNP i
showed VBD N
a DT N
shorter NN N
recovery NN N
, , N
but CC N
longer JJR N
operating NN N
time NN N
than IN N
TAH NNP i
and CC N
a DT N
27 CD N
% NN N
rate NN N
of IN N
conversion NN o
to TO o
laparotomy VB o
. . o

-DOCSTART- -24684867- O O

A DT N
prospective JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
of IN N
single-incision NN i
laparoscopic NN i
vs JJ i
conventional JJ i
3-port JJ i
laparoscopic NN i
appendectomy NN i
for IN N
treatment NN N
of IN N
acute JJ N
appendicitis NN N
. . N

BACKGROUND NNP N
Proponents NNPS N
of IN N
single-incision NN i
laparoscopic NN i
surgery NN i
( ( i
SILS NNP i
) ) i
claim NN N
patients NNS N
have VBP N
less JJR N
pain NN N
, , N
faster JJR N
recovery NN N
, , N
and CC N
better JJR N
long-term JJ N
cosmetic JJ N
results NNS N
than IN N
patients NNS N
who WP N
undergo VBP N
multiport NN i
laparoscopy NN i
. . i

However RB N
, , N
randomized JJ N
comparisons NNS N
are VBP N
lacking VBG N
. . N

This DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
SILS NNP i
or CC N
3-port JJ i
laparoscopic NN i
appendectomy NN i
. . i

STUDY NNP N
DESIGN NNP N
Adults NNP p
with IN p
uncomplicated JJ p
acute NN p
appendicitis NN p
were VBD N
randomized VBN N
1:1 CD N
to TO N
either DT N
SILS NNP i
or CC i
3-port JJ i
laparoscopic NN i
appendectomy NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
early JJ o
postoperative JJ o
pain NN o
( ( N
measured VBN N
by IN N
opiate JJ N
usage NN N
and CC N
pain NN N
score NN N
in IN N
the DT N
first JJ N
12 CD N
hours NNS N
) ) N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
operative JJ o
time NN o
, , o
complication NN o
rate NN o
( ( o
including VBG o
conversions NNS o
) ) o
, , o
and CC o
recovery NN o
time NN o
( ( o
days NNS o
of IN o
oral JJ o
opiate JJ o
usage NN o
and CC o
return NN o
to TO o
work VB o
) ) o
. . N

After IN N
6 CD N
months NNS N
, , N
body NN o
image NN o
and CC N
cosmetic JJ o
appearance NN o
were VBD N
assessed VBN N
using VBG N
a DT N
validated JJ N
survey NN N
. . N

RESULTS VB N
The DT p
trial NN p
was VBD p
planned VBN p
for IN p
150 CD p
patients NNS p
, , p
but CC p
was VBD p
halted VBN p
after IN p
75 CD p
patients NNS p
when WRB p
planned VBN p
interim NN p
analysis NN p
showed VBD p
that IN p
SILS NNP i
patients NNS p
had VBD p
more RBR p
postoperative JJ o
pain NN o
( ( N
pain NN N
score NN N
: : N
4.4 CD N
? . N
1.6 CD N
vs NN N
3.5 CD N
? . N
1.5 CD N
; : N
p NN N
= VBZ N
0.01 CD N
) ) N
and CC N
higher JJR o
inpatient NN o
opiate NN o
usage NN o
( ( o
hydromorphone NN N
use NN N
: : N
3.9 CD N
? . N
1.9 CD N
mg NN N
vs NN N
2.8 CD N
? . N
1.7 CD N
mg NN N
; : N
p CC N
= VB N
0.01 CD N
) ) N
than IN N
3-port JJ N
laparoscopy NN o
. . o

Operative JJ o
time NN o
for IN o
SILS NNP i
averaged VBD i
40 CD N
% NN N
longer JJR N
( ( N
54 CD N
? . N
17 CD N
minutes NNS N
vs RB N
38 CD N
? . N
11 CD N
minutes NNS N
; : N
p VB N
< $ N
0.01 CD N
) ) N
. . N

Only RB N
1 CD N
SILS NNP o
case NN o
was VBD N
converted VBN i
to TO i
3-port JJ i
. . i

There EX i
were VBD N
no DT N
significant JJ N
differences NNS o
in IN o
length NN o
of IN o
stay NN o
, , o
complications NNS o
, , o
oral JJ o
pain NN o
medication NN o
usage NN o
after IN o
discharge NN o
, , o
or CC o
return VB o
to TO o
work VB o
. . o

After IN N
6 CD N
months NNS N
, , N
body NN N
image NN N
and CC N
cosmetic JJ N
appearance NN N
were VBD N
excellent JJ N
for IN N
both DT N
groups NNS N
and CC N
indistinguishable JJ N
by IN N
most JJS N
measures NNS N
. . N

However RB i
, , i
3-port JJ i
patients NNS i
reported VBD N
better RBR N
physical JJ o
attractiveness NN o
( ( o
4.0 CD o
? . N
0.4 CD N
vs NN N
3.8 CD N
? . N
0.4 CD N
; : N
p NN N
= VBZ N
0.04 CD N
) ) N
and CC i
SILS NNP i
patients NNS i
reported VBD N
better JJR o
scars NNS o
( ( o
score VB N
18.4 CD N
? . N
2.7 CD N
vs NN N
16.4 CD N
? . N
3.0 CD N
; : N
p NN N
< VBZ N
0.01 CD N
) ) N
. . N

Results NNS N
are VBP N
reported VBN N
as IN N
mean NN N
? . N
SD NNP N
. . N

CONCLUSIONS NNP N
Single-incision NNP i
laparoscopic NN i
surgery NN i
appendectomy NN i
resulted VBD i
in IN i
more RBR o
pain NN o
and CC N
longer RB N
operative JJ o
times NNS o
without IN o
improving VBG N
short-term JJ N
recovery NN N
or CC N
complications NNS N
. . N

Long-term JJ N
body NN N
image NN N
and CC N
cosmetic JJ N
appearance NN N
were VBD N
excellent JJ N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -9581739- O O

Comparison NNP N
of IN N
single- JJ i
and CC i
dual-coil JJ i
active JJ i
pectoral JJ i
defibrillation NN i
lead NN i
systems NNS i
. . i

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
defibrillation NN N
thresholds NNS N
with IN N
lead JJ N
systems NNS N
consisting VBG N
of IN N
an DT N
active JJ N
left JJ N
pectoral JJ N
electrode NN N
and CC N
either DT N
single JJ i
or CC N
dual JJ i
transvenous JJ i
coils NNS i
. . i

BACKGROUND NNP N
Lead NNP N
systems NNS N
that WDT N
include VBP N
an DT N
active JJ N
pectoral JJ N
pulse NN N
generator NN N
reduce VB N
defibrillation NN N
thresholds NNS N
and CC N
permit VBP N
transvenous JJ N
defibrillation NN N
in IN N
nearly RB N
all DT N
patients NNS N
. . N

A DT N
further JJ N
improvement NN N
in IN N
defibrillation NN o
efficacy NN o
is VBZ N
desirable JJ N
to TO N
allow VB N
for IN N
smaller JJR N
pulse NN N
generators NNS N
with IN N
a DT N
reduced VBN N
maximal NN N
output NN N
. . N

METHODS NNP N
This DT N
prospective JJ N
study NN N
was VBD N
performed VBN N
in IN N
50 CD p
consecutive JJ p
patients NNS p
. . p

Each DT p
patient NN p
was VBD N
evaluated VBN N
with IN N
two CD N
lead JJ i
configurations NNS i
with IN N
the DT N
order NN N
of IN N
testing VBG N
randomized VBN N
. . N

Shocks NNS N
were VBD N
delivered VBN N
between IN N
the DT N
right JJ N
ventricular NN N
coil NN N
and CC N
either DT N
an DT N
active JJ N
can MD N
alone RB N
( ( i
single JJ i
coil NN i
) ) i
or CC N
an DT N
active JJ N
can MD N
with IN N
the DT N
proximal JJ N
atrial JJ N
coil NN N
( ( i
dual JJ i
coil NN i
) ) i
. . N

The DT N
right JJ N
ventricular NN N
coil NN N
was VBD N
the DT N
cathode NN N
for IN N
the DT N
first JJ N
phase NN N
of IN N
the DT N
biphasic JJ N
defibrillation NN N
waveform NN N
. . N

RESULTS NNP N
Delivered NNP o
energy NN o
at IN N
the DT N
defibrillation NN o
threshold NN o
was VBD N
10.1+/-5.0 JJ N
J NNP N
for IN N
the DT N
single-coil JJ i
configuration NN N
and CC N
8.7+/-4.0 JJ N
J NNP N
for IN N
the DT N
dual-coil JJ i
configuration NN N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

Moreover RB N
, , N
98 CD p
% NN p
of IN p
patients NNS p
had VBD p
low JJ p
( ( p
< JJ p
15 CD p
J NNP p
) ) p
thresholds VBZ o
with IN N
the DT N
dual-coil JJ i
lead NN p
system NN p
, , N
compared VBN N
with IN N
88 CD p
% NN p
of IN p
patients NNS p
with IN p
the DT p
single-coil JJ i
configuration NN p
( ( N
p=0.05 NN N
) ) N
. . N

Leading VBG o
edge NN o
voltage NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
shock NN o
impedance NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
were VBD N
also RB N
decreased VBN N
with IN N
the DT N
dual-coil NN i
configuration NN N
, , N
although IN N
peak JJ o
current JJ o
was VBD N
increased VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS VB N
A DT N
dual-coil NN i
, , N
active JJ N
pectoral JJ N
lead NN N
system NN N
reduces VBZ N
defibrillation NN o
energy NN o
requirements NNS o
compared VBN N
with IN N
a DT N
single-coil NN i
, , N
unipolar JJ N
configuration NN N
. . N

-DOCSTART- -11162323- O O

Counselor NNP N
and CC N
stimulus VB N
control NN N
enhancements NNS N
of IN N
a DT N
stage-matched JJ o
expert NN o
system NN o
intervention NN o
for IN o
smokers NNS o
in IN N
a DT N
managed VBN N
care NN N
setting VBG N
. . N

BACKGROUND NNP N
Previous NNP N
research NN N
has VBZ N
demonstrated VBN N
the DT N
efficacy NN o
of IN N
an DT N
interactive JJ i
expert NN i
system NN i
intervention NN i
for IN N
smoking VBG N
cessation NN N
for IN N
a DT N
general JJ p
population NN p
. . p

The DT N
intervention NN N
provides VBZ N
individualized JJ N
feedback NN N
that WDT N
guides VBZ N
participants NNS N
through IN N
the DT N
stages NNS N
of IN N
change NN N
for IN N
cessation NN N
. . N

Enhancing VBG N
the DT N
expert NN N
system NN N
by IN N
adding VBG N
proactive JJ N
telephone NN N
counseling NN N
or CC N
a DT N
stimulus NN N
control NN N
computer NN N
designed VBN N
to TO N
produce VB N
nicotine JJ N
fading NN N
could MD N
produce VB N
preventive JJ N
programs NNS N
with IN N
greater JJR N
population NN N
impacts NNS N
. . N

METHODS NNP N
Four CD N
interventions NNS N
were VBD N
compared VBN N
: : N
( ( N
a DT N
) ) N
the DT i
interactive JJ i
expert NN i
system NN i
intervention NN i
; : i
( ( N
b NN N
) ) N
the DT N
expert NN i
system NN i
intervention NN i
plus CC i
counselor NN i
calls VBZ i
; : i
( ( N
c NN N
) ) N
the DT i
expert NN i
system NN i
intervention NN i
plus CC i
the DT i
stimulus NN i
control NN i
computer NN i
; : i
and CC N
( ( N
d NN N
) ) N
an DT N
assessment NN i
only RB i
condition NN i
. . i

A DT N
4 CD N
( ( N
intervention NN N
) ) N
x VBZ N
4 CD N
( ( N
occasions NNS N
) ) N
( ( N
0,6,12 CD N
, , N
and CC N
18 CD N
months NNS N
) ) N
design NN N
was VBD N
used VBN N
. . N

Smokers NNS p
were VBD N
contacted VBN N
at IN N
home NN N
via IN N
telephone NN N
or CC N
mail NN N
. . N

The DT N
initial JJ p
subject JJ p
pool NN p
was VBD p
the DT p
24,178 JJ p
members NNS p
of IN p
a DT p
managed VBN p
care NN p
company NN p
. . p

Screening NN N
was VBD N
completed VBN N
for IN N
19,236 CD p
members NNS p
( ( p
79.6 CD p
% NN p
) ) p
, , p
of IN p
whom WP p
4,653 CD p
were VBD p
smokers NNS p
; : p
85.3 CD p
% NN p
of IN p
the DT p
smokers NNS p
were VBD p
enrolled VBN p
. . p

RESULTS NNP N
Thirty-eight JJ p
percent NN p
were VBD p
in IN p
the DT p
precontemplation NN p
stage NN p
, , p
45 CD p
% NN p
in IN p
the DT p
contemplation NN p
stage NN p
, , p
and CC p
only RB p
17 CD p
% NN p
in IN p
the DT p
preparation NN p
stage NN p
. . p

At IN N
18 CD N
months NNS N
, , N
the DT N
expert NN N
system NN N
resulted VBD N
in IN N
23.2 CD N
% NN N
point NN N
prevalence NN o
abstinence NN o
, , N
which WDT N
was VBD N
33 CD N
% NN N
greater JJR N
than IN N
that DT N
of IN N
assessment NN N
only RB N
. . N

The DT N
counselor NN N
enhancement NN N
produced VBD N
increased JJ N
cessation NN o
at IN N
12 CD N
months NNS N
but CC N
not RB N
at IN N
18 CD N
months NNS N
. . N

The DT N
stimulus NN N
control NN N
computer NN N
produced VBD N
no DT N
improvement NN o
, , N
resulting VBG N
in IN N
20 CD N
% NN N
worse JJR N
cessation NN o
rates NNS o
than IN N
the DT N
assessment NN N
only RB N
condition NN N
. . N

CONCLUSIONS VB N
The DT N
enhanced JJ N
conditions NNS N
failed VBD N
to TO N
outperform VB o
the DT N
expert NN o
system NN o
alone RB N
. . N

The DT N
study NN N
also RB N
demonstrated VBD N
the DT N
ability NN N
of IN N
the DT N
interactive JJ i
expert NN i
system NN i
to TO N
produce VB N
significantly RB N
greater JJR N
cessation NN o
in IN N
a DT N
population NN p
of IN p
smokers NNS p
than IN N
assessment JJ N
alone RB N
. . N

-DOCSTART- -653534- O O

Failure NN N
of IN N
pyridoxine NN N
to TO N
suppress VB N
raised VBN o
serum NN o
prolactin NN o
levels NNS o
. . o

Pyridoxine NNP N
has VBZ N
been VBN N
reported VBN N
as IN N
having VBG N
an DT N
antilactogenic JJ N
effect NN N
, , N
presumably RB N
by IN N
suppressing VBG N
prolactin JJ o
secretion NN o
. . o

We PRP N
have VBP N
measured VBN N
serum JJ o
prolactin NN o
levels NNS o
during IN N
pyridoxine JJ i
administration NN i
in IN N
two CD p
groups NNS p
of IN p
hyperprolactinaemic JJ i
subjects NNS i
. . i

In IN N
normal JJ p
postpartum JJ p
women NNS p
, , N
the DT N
postdelivery NN N
fall NN N
in IN N
serum NN o
prolactin NN o
levels NNS o
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
treated JJ N
and CC N
control JJ N
subjects NNS N
. . N

In IN N
patients NNS p
with IN p
chlorpromazine-induced JJ p
hyperprolactinaemia NN p
and CC p
galactorrhoea NN p
, , N
pyridoxine NN N
did VBD N
not RB N
reduce VB N
the DT N
elevated JJ N
levels NNS N
. . N

In IN p
neither DT p
group NN p
was VBD p
milk VBN o
production NN o
suppressed VBN p
. . p

-DOCSTART- -7516831- O O

Optimized VBN N
strategy NN N
for IN N
detection NN N
of IN N
early JJ p
stage NN p
, , p
curable JJ p
prostate NN p
cancer NN p
: : p
role NN N
of IN N
prescreening VBG N
with IN N
prostate-specific JJ N
antigen NN N
. . N

In IN p
1,002 CD p
men NNS p
aged VBN p
45-80 JJ p
y NN p
, , N
81 CD N
% NN N
of IN N
the DT N
cancers NNS N
detectable JJ N
by IN N
serum JJ o
prostate-specific JJ o
antigen NN o
( ( o
PSA NNP o
) ) o
, , o
digital JJ o
rectal JJ o
examination NN o
( ( o
DRE NNP o
) ) o
, , o
and CC o
transrectal JJ o
ultrasonography NN o
( ( o
TRUS NNP o
) ) o
were VBD N
present JJ N
in IN N
a DT N
subpopulation NN N
( ( N
19 CD N
% NN N
of IN N
total JJ N
) ) N
identified VBN N
by IN N
serum NN N
PSA NNP N
above IN N
the DT N
threshold JJ N
value NN N
of IN N
3.0 CD N
micrograms/L NN N
. . N

This DT N
study NN N
was VBD N
extended VBN N
to TO N
7,350 CD p
men NNS p
using VBG p
serum NN p
PSA NNP i
and CC p
DRE NNP i
as IN p
first JJ p
approach NN p
, , p
followed VBN p
by IN p
TRUS NNP i
only RB p
when WRB p
1 CD p
of IN p
these DT p
2 CD p
tests NNS p
was VBD p
abnormal JJ p
. . p

Because IN N
the DT N
aim NN N
of IN N
prostate NN N
cancer NN N
detection NN N
is VBZ N
to TO N
find VB N
cancers NNS N
at IN N
an DT N
early JJ N
, , N
potentially RB N
curable JJ N
stage NN N
, , N
it PRP N
is VBZ N
of IN N
major JJ N
interest NN N
that IN N
71.8 CD N
% NN N
of IN N
evaluable JJ N
cancers NNS N
were VBD N
clinical JJ N
stage NN N
B NNP N
; : N
8.4 CD N
% NN N
and CC N
10.7 CD N
% NN N
were VBD N
stages NNS N
C1 NNP N
and CC N
C2 NNP N
, , N
respectively RB N
; : N
only RB N
9.2 CD N
% NN N
were VBD N
stage JJ N
D NNP N
( ( N
metastatic JJ N
) ) N
at IN N
first JJ N
visit NN N
while IN N
none NN N
was VBD N
at IN N
stage NN N
D NNP N
at IN N
follow-up JJ N
visits NNS N
. . N

This DT N
study NN N
, , N
the DT N
first JJ N
performed VBN N
in IN N
an DT N
unselected JJ p
, , p
unscreened JJ p
population NN p
, , N
shows VBZ N
that IN N
serum NN o
PSA NNP o
is VBZ N
the DT N
most RBS N
sensitive JJ o
technique NN o
to TO N
identify VB N
men NNS N
at IN N
high JJ N
risk NN o
of IN o
having VBG o
prostate NN o
cancer NN o
and CC N
that IN N
12 CD N
% NN N
more JJR N
cancers NNS N
can MD N
be VB N
found VBN N
at IN N
first JJ N
visit NN N
by IN N
doing VBG N
DRE NNP i
in IN N
addition NN N
to TO N
PSA NNP i
. . i

Follow-ups NNS N
can MD N
be VB N
done VBN N
every DT N
second JJ N
year NN N
using VBG N
serum JJ o
PSA NNP o
alone RB o
, , N
as IN N
97 CD N
% NN N
of IN N
the DT N
cancers NNS N
detected VBD N
at IN N
annual JJ N
follow-up NN N
by IN N
DRE NNP i
+ NNP N
PSA NNP i
were VBD N
PSA+ NNP i
. . N

Cancers NNS N
are VBP N
discovered VBN N
by IN N
the DT N
present JJ N
approach NN N
at IN N
an DT N
estimated JJ o
cost NN o
of IN N
$ $ N
2,665 CD N
per IN N
cancer NN N
. . N

Such JJ N
cancers NNS N
are VBP N
potentially RB N
curable JJ o
in IN N
at IN N
least JJS N
80 CD N
% NN N
of IN N
cases NNS N
detected VBN N
at IN N
first JJ N
visit NN N
and CC N
in IN N
97 CD N
% NN N
of IN N
cases NNS N
at IN N
follow-up NN N
. . N

This DT N
strategy NN N
offers VBZ N
the DT N
possibility NN N
to TO N
improve VB N
markedly RB N
morbidity NN o
and CC o
mortality NN o
from IN o
prostate NN o
cancer NN o
, , N
presently RB N
the DT N
second JJ N
leading JJ N
cause NN N
of IN N
cancer NN N
death NN N
in IN N
North JJ N
American JJ N
men NNS N
. . N

-DOCSTART- -18337049- O O

Nurse NNP o
and CC o
patient JJ o
communication NN o
profiles NNS o
in IN N
a DT N
home-based JJ p
telehealth NN p
intervention NN p
for IN N
heart NN N
failure NN N
management NN N
. . N

OBJECTIVE VB N
This DT N
study NN N
compared VBN N
differences NNS N
in IN N
nurse JJ o
and CC o
patient JJ o
communication NN o
profiles NNS o
between IN N
two CD N
telehealth NN N
modes NNS N
: : N
telephone NN i
and CC N
videophone NN i
, , N
and CC N
evaluated VBD N
longitudinal JJ o
changes NNS o
in IN o
communication NN o
, , o
nurse JJ o
perceptions NNS o
, , o
and CC o
patient JJ o
satisfaction NN o
. . o

METHODS NNP N
Subjects NNPS p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized NN p
controlled VBD p
clinical JJ p
trial NN p
evaluating VBG N
a DT N
90-day JJ N
home-based JJ N
intervention NN N
for IN N
heart NN N
failure NN N
. . N

Telephone NNP i
( ( p
n=14 NN p
) ) p
and CC p
videophone NN i
( ( p
n=14 JJ p
) ) p
interactions NNS p
were VBD N
audio JJ N
taped VBN N
and CC N
analyzed VBN N
using VBG N
the DT N
Roter NNP o
Interaction NNP o
Analysis NNP o
System NNP o
. . o

RESULTS NNP N
Nurses NNPS p
were VBD N
more RBR N
likely JJ N
to TO N
use VB o
open-ended JJ o
questions NNS o
, , o
back-channel JJ o
responses NNS o
, , o
friendly JJ o
jokes NNS o
, , o
and CC o
checks NNS o
for IN o
understanding VBG o
on IN N
the DT N
telephone NN i
compared VBN N
to TO N
videophone VB i
. . i

Compliments NNS o
given VBN o
and CC o
partnership NN o
were VBD N
more JJR N
common JJ N
on IN N
the DT N
videophone NN N
. . N

Patients NNS p
were VBD N
more RBR N
likely JJ N
to TO N
give VB o
lifestyle JJ o
information NN o
and CC o
approval NN o
comments NNS o
on IN N
the DT N
telephone NN i
, , N
and CC N
used VBD N
more JJR N
closed-ended JJ o
questions NNS o
on IN N
the DT N
videophone NN i
. . i

Nurses CC o
perceptions NNS o
of IN o
the DT o
interactions NNS o
were VBD N
not RB N
different JJ N
between IN N
the DT N
telephone NN N
and CC N
videophone NN i
, , N
nor CC N
did VBD N
their PRP$ N
perceptions NNS o
change VBP N
significantly RB N
over IN N
the DT N
course NN N
of IN N
the DT N
intervention NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
patient JJ o
satisfaction NN o
between IN N
the DT N
telephone NN N
and CC N
videophone NN i
. . i

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
did VBD N
not RB N
support VB N
use NN N
of IN N
a DT N
videophone NN i
over IN N
the DT N
telephone NN i
. . i

PRACTICE NNP N
IMPLICATIONS NNP N
It PRP N
is VBZ N
critical JJ N
to TO N
match VB N
technologies NNS N
to TO N
patient VB N
needs NNS N
and CC N
use VB N
the DT N
least JJS N
complex JJ N
technology NN N
possible JJ N
. . N

When WRB N
considering VBG N
use VBP N
a DT N
videophone NN i
, , N
health NN N
care NN N
providers NNS N
should MD N
critically RB N
examine VB N
the DT N
trade-offs NNS N
between IN N
additional JJ N
complexities NNS N
with IN N
the DT N
added JJ N
value NN N
of IN N
the DT N
visual JJ N
interaction NN N
. . N

-DOCSTART- -19644973- O O

Randomized NNP N
clinical JJ N
trial NN N
comparing VBG N
laparoscopic NN i
and CC N
open JJ i
surgery NN i
in IN N
patients NNS p
with IN p
rectal JJ p
cancer NN p
. . p

BACKGROUND IN N
The DT N
laparoscopic NN i
treatment NN i
of IN N
rectal JJ N
cancer NN N
is VBZ N
controversial JJ N
. . N

This DT N
study NN N
compared VBN N
surgical JJ N
outcomes NNS N
after IN N
laparoscopic NN i
and CC N
open JJ N
approaches NNS N
for IN N
mid NN p
and CC p
low JJ p
rectal NN p
cancers NNS p
. . p

METHODS NNP N
Some DT p
204 CD p
patients NNS p
with IN p
mid NNS p
and CC p
low JJ p
rectal NN p
adenocarcinomas NN p
were VBD p
allocated VBN p
randomly RB p
to TO p
open VB i
( ( p
103 CD p
) ) p
or CC i
laparoscopic NN i
( ( i
101 CD i
) ) i
surgery NN i
. . i

The DT N
surgical JJ N
team NN N
was VBD N
the DT N
same JJ N
for IN N
both DT N
procedures NNS N
. . N

Most JJS p
patients NNS p
had VBD p
stage NN p
II NNP p
or CC p
III NNP p
disease NN p
, , N
and CC N
received VBD N
neoadjuvant JJ i
therapy NN i
with IN N
oral JJ i
capecitabine NN i
and CC i
50-54 JJ i
Gy NNP i
external JJ i
beam NN i
radiotherapy NN i
. . i

RESULTS NNP N
Sphincter-preserving JJ i
surgery NN i
was VBD N
performed VBN N
in IN N
78.6 CD N
and CC N
76.2 CD N
per IN N
cent NN N
of IN N
patients NNS N
in IN N
the DT N
open JJ i
and CC N
laparoscopic JJ N
groups NNS N
respectively RB N
. . N

Blood NNP o
loss NN o
was VBD N
significantly RB N
greater JJR N
for IN N
open JJ i
surgery NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
operating VBG o
time NN o
was VBD N
significantly RB N
greater JJR N
for IN N
laparoscopic NN i
surgery NN i
( ( N
P NNP N
= NNP N
0.020 CD N
) ) N
, , N
and CC N
return NN N
to TO N
diet VB N
and CC N
hospital VB o
stay NN o
were VBD N
longer JJR N
for IN N
open JJ i
surgery NN i
. . i

Complication NN o
rates NNS o
, , o
and CC o
involvement NN o
of IN o
circumferential JJ o
and CC o
radial JJ o
margins NNS o
were VBD N
similar JJ N
for IN N
both DT N
procedures NNS N
, , N
but CC N
the DT N
number NN N
of IN N
isolated JJ N
lymph NN N
nodes NNS N
was VBD N
greater JJR N
in IN N
the DT N
laparoscopic NN i
group NN N
( ( N
mean JJ N
13.63 CD N
versus NN N
11.57 CD N
; : N
P NNP N
= NNP N
0.026 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
local JJ o
recurrence NN o
, , o
disease-free JJ o
or CC o
overall JJ o
survival NN o
. . o

CONCLUSION NNP N
Laparoscopic NNP i
surgery NN i
for IN N
rectal JJ N
cancer NN N
has VBZ N
a DT N
similar JJ N
complication NN N
rate NN N
to TO N
open VB i
surgery NN i
, , N
with IN N
less JJR N
blood NN o
loss NN o
, , N
rapid JJ N
intestinal JJ o
recovery NN o
, , N
shorter JJR N
hospital NN o
stay NN o
, , N
and CC N
no DT N
compromise NN N
of IN N
oncological JJ o
outcomes NNS o
. . o

-DOCSTART- -12402011- O O

Preliminary JJ N
findings NNS N
from IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
two CD N
palatal JJ i
operations NNS i
for IN N
sleep-disordered JJ N
breathing NN N
. . N

OBJECTIVES IN N
We PRP N
compared VBN N
the DT N
efficacy NN o
of IN N
2 CD i
palatal JJ i
surgical JJ i
procedures NNS i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
mild JJ p
sleep-disordered JJ p
breathing NN p
( ( p
SDB NNP p
) ) p
. . p

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
crossover RB N
surgical JJ N
trial NN N
at IN N
a DT N
university NN N
hospital NN N
. . N

METHODS NNP N
Twenty NNP p
patients NNS p
with IN p
mild JJ p
SDB NNP p
for IN p
whom WP p
conservative JJ p
treatment NN p
failed VBD p
were VBD N
identified VBN N
and CC N
consecutively RB N
enrolled VBD N
into IN N
an DT N
institutional JJ N
review NN N
board-approved JJ N
surgical JJ N
protocol NN N
. . N

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
either DT N
radiofrequency NN i
ablation NN i
of IN i
the DT i
palate NN i
( ( i
RFAP NNP i
) ) i
for IN i
a DT i
planned JJ i
3-stage JJ i
treatment NN i
or CC i
laser-assisted JJ i
uvulopalatoplasty JJ i
( ( i
LAUP NNP i
) ) i
, , i
also RB i
for IN i
3 CD i
stages NNS i
of IN i
treatment NN i
, , i
using VBG i
a DT i
CO NNP i
( ( i
2 CD i
) ) i
laser NN i
. . i

Parameters NNS N
assessed VBD N
included JJ N
severity NN o
of IN o
SDB NNP o
( ( o
polysomnography NN o
) ) o
, , o
subjective JJ o
and CC o
objective JJ o
loudness NN o
of IN o
snoring VBG o
( ( o
visual JJ o
analog NN o
scale NN o
and CC o
SNAP NNP o
recording NN o
) ) o
, , o
sleepiness NN o
( ( o
Epworth NNP o
Sleepiness NNP o
Scale NNP o
) ) o
, , N
and CC N
anatomic JJ o
changes NNS o
( ( o
upper JJ o
airway RB o
endoscopy NN o
) ) o
, , N
as RB N
well RB N
as IN N
demographic JJ N
factors NNS N
. . N

Patients NNS N
not RB N
achieving VBG N
satisfactory JJ N
improvement NN N
in IN N
their PRP$ N
condition NN N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
alternative JJ i
surgical JJ i
therapy NN i
for IN i
attempted JJ i
salvage NN i
. . i

RESULTS NNP N
Seventeen NNP N
of IN N
the DT N
enrolled JJ N
patients NNS N
have VBP N
completed VBN N
the DT N
protocol NN N
. . N

Ten CD N
of IN N
these DT N
were VBD N
randomized VBN N
to TO N
the DT N
RFAP NNP i
group NN N
, , N
and CC N
7 CD N
to TO N
the DT N
LAUP NNP i
group NN N
. . N

Six CD N
of IN N
the DT N
RFAP NNP i
patients NNS N
( ( N
60 CD N
% NN N
) ) N
achieved VBD N
a DT N
satisfactory JJ N
resolution NN N
of IN N
their PRP$ N
snoring NN o
, , N
and CC N
4 CD N
failed VBD N
and CC N
were VBD N
salvaged VBN N
with IN N
LAUP NNP i
. . i

Six NNP N
of IN N
the DT N
LAUP NNP i
patients NNS N
( ( N
86 CD N
% NN N
) ) N
achieved VBD N
a DT N
satisfactory JJ N
resolution NN N
of IN N
their PRP$ N
snoring NN o
, , N
and CC N
1 CD N
patient NN N
failed VBD N
and CC N
was VBD N
salvaged VBN N
with IN N
nasal JJ i
surgery NN i
. . i

One CD N
patient NN N
who WP N
was VBD N
initially RB N
cured VBN N
had VBD N
a DT N
relapse NN N
after IN N
9 CD N
months NNS N
and CC N
was VBD N
successfully RB N
salvaged VBN N
with IN N
RFA NNP i
. . i

CONCLUSION NNP N
Prospective NNP N
, , N
randomized VBD N
trials NNS N
of IN N
surgery NN N
for IN N
SDB NNP N
are VBP N
possible JJ N
. . N

Preliminary JJ N
findings NNS N
from IN N
the DT N
current JJ N
protocol NN N
reveal NN N
a DT N
slight JJ N
advantage NN N
of IN N
LAUP NNP i
over IN N
RFAP NNP i
but CC N
with IN N
a DT N
greater JJR N
degree NN N
of IN N
discomfort NN N
postoperatively RB N
. . N

-DOCSTART- -11915576- O O

The DT N
impact NN N
of IN N
different JJ N
doses NNS N
of IN N
medroxyprogesterone NN i
acetate NN i
on IN N
mood NN o
symptoms NNS o
in IN N
sequential JJ i
hormonal JJ i
therapy NN i
. . i

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
adverse JJ N
mood NN o
effects NNS o
of IN N
two CD N
different JJ N
doses NNS N
of IN N
medroxyprogesterone NN i
acetate NN i
( ( i
MPA NNP i
) ) i
during IN N
postmenopausal NN p
hormone CD p
replacement NN p
therapy NN p
( ( p
HRT NNP p
) ) p
in IN p
women NNS p
with IN p
and CC p
without IN p
a DT p
history NN p
of IN p
premenstrual JJ p
syndrome NN p
( ( p
PMS NNP p
) ) p
. . p

The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
randomized JJ N
double-blind JJ N
cross-over NN N
study NN N
and CC N
included VBD N
36 CD p
postmenopausal JJ p
women NNS p
at IN p
three CD p
health NN p
care NN p
areas NNS p
in IN p
northern JJ p
Sweden NNP p
. . p

The DT N
women NNS N
received VBD N
2 CD i
mg NNS i
estradiol RB i
continuously RB N
during IN N
five CD N
28-day JJ N
cycles NNS N
and CC N
10 CD N
mg NN N
or CC N
20 CD N
mg NNS N
MPA NNP N
sequentially RB N
for IN N
12 CD N
days NNS N
during IN N
each DT N
cycle NN N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
mood NN o
and CC o
physical JJ o
symptoms NNS o
noted VBD o
on IN o
a DT o
daily JJ o
rating NN o
scale NN o
. . o

We PRP N
found VBD N
that IN N
physical JJ o
symptoms NNS o
did VBD N
not RB N
differ VB N
between IN N
10 CD N
and CC N
20 CD N
mg NN N
MPA NNP N
. . N

Both DT N
women NNS N
with IN N
a DT N
history NN N
of IN N
PMS NNP N
and CC N
women NNS N
without IN N
responded VBD N
with IN N
more RBR N
negative JJ N
mood NN o
symptoms NNS o
with IN N
the DT N
lower JJR N
dose NN N
of IN N
MPA NNP N
. . N

In IN N
women NNS N
with IN N
previous JJ N
PMS NNP N
the DT N
higher JJR N
dose NN N
of IN N
MPA NNP N
enhanced VBD N
positive JJ o
mood NN o
symptoms NNS o
. . o

With IN N
respect NN N
to TO N
mood NN o
and CC o
physical JJ o
symptoms NNS o
, , N
the DT N
aim NN N
to TO N
lower VB N
MPA NNP N
doses NNS N
in IN N
HRT NNP N
is VBZ N
unwarranted JJ N
. . N

-DOCSTART- -11074150- O O

Effects NNS N
of IN N
nicotine NN o
on IN N
regional JJ o
cerebral JJ o
glucose JJ o
metabolism NN o
in IN N
awake JJ p
resting NN p
tobacco NN p
smokers NNS p
. . p

Eleven NNP p
healthy JJ p
tobacco NN p
smoking VBG p
adult NN p
male NN p
volunteers NNS p
of IN p
mixed JJ p
race NN p
were VBD N
tobacco JJ i
abstinent JJ i
overnight NN N
for IN N
this DT N
study NN N
. . N

In IN N
each DT N
subject NN N
, , N
positron NN o
emission NN o
tomographic JJ o
images NNS o
of IN N
regional JJ N
cerebral JJ o
metabolism NN o
of IN o
glucose JJ o
with IN N
[ JJ o
18F CD o
] NNS o
fluorodeoxyglucose JJ o
were VBD N
obtained VBN N
in IN N
two CD N
conditions NNS N
in IN N
the DT N
morning NN N
on IN N
different JJ N
days NNS N
: : N
about IN N
3min CD N
after IN N
approximately RB i
1-2mg JJ i
of IN i
nasal JJ i
nicotine JJ i
spray NN i
and CC i
after IN i
an DT i
equivalent JJ i
volume NN i
of IN i
an DT i
active JJ i
placebo NN i
spray NN i
of IN i
oleoresin NN i
of IN i
pepper NN i
in IN N
a DT N
random NN N
counterbalanced VBD N
design NN N
. . N

A DT N
Siemens/CTI JJ N
931/08-12 JJ N
scanner NN N
with IN N
the DT N
capability NN N
of IN N
15 CD N
horizontal JJ N
brain NN N
slices NNS N
was VBD N
used VBN N
. . N

The DT N
images NNS N
were VBD N
further RB N
converted VBN N
into IN N
a DT N
standard JJ N
uniform NN N
brain NN N
format NN N
in IN N
which WDT N
the DT N
mean NN N
data NNS N
of IN N
all DT N
11 CD N
subjects NNS N
were VBD N
obtained VBN N
. . N

Images NNS N
were VBD N
analysed VBN N
in IN N
stereotactic JJ N
coordinates NNS N
using VBG N
pixel-wise JJ N
t NN N
statistics NNS N
and CC N
a DT N
smoothed JJ N
Gaussian JJ N
model NN N
. . N

Peak NNP o
plasma JJ o
nicotine NN o
levels NNS o
varied VBN N
three-fold JJ N
and CC N
the DT N
areas NNS N
under IN N
the DT N
curve NN N
( ( N
0-30min JJ N
) ) N
varied VBD N
seven-fold JJ N
among IN N
the DT N
individual JJ N
subjects NNS N
. . N

Nicotine NNP i
caused VBD N
a DT N
small JJ N
overall JJ N
reduction NN N
in IN N
global JJ o
cerebral JJ o
metabolism NN o
of IN o
glucose NN o
but CC N
, , N
when WRB N
the DT N
data NNS N
were VBD N
normalized VBN N
, , N
several JJ N
brain NN N
regions NNS N
showed VBD N
relative JJ N
increases NNS o
in IN o
activity NN o
. . o

Cerebral JJ N
structures NNS N
specifically RB N
activated VBN N
by IN N
nicotine NN i
( ( N
nicotine JJ N
minus NN N
pepper NN N
, , N
Z NNP N
score VBD N
> NNP N
4.0 CD N
) ) N
included VBD N
: : N
left VBN N
inferior JJ N
frontal JJ N
gyrus NN N
, , N
left VBD N
posterior JJ N
cingulate NN N
gyrus NN N
and CC N
right JJ N
thalamus NN N
. . N

The DT N
visual JJ N
cortex NN N
, , N
including VBG N
the DT N
right NN N
and CC N
left VBD N
cuneus NN N
and CC N
left VBD N
lateral JJ N
occipito-temporal JJ N
gyrus NN N
fusiformis NN N
, , N
also RB N
showed VBD N
an DT N
increase NN N
in IN N
regional JJ o
cerebral JJ o
metabolism NN o
of IN o
glucose NN o
with IN N
Z NNP N
scores NNS N
> VBD N
3 CD N
. . N

6 CD N
. . N

Structures NNS N
with IN N
a DT N
decrease NN o
in IN o
regional JJ o
cerebral JJ o
metabolism NN o
of IN o
glucose NN o
( ( o
pepper JJ o
minus FW N
nicotine NN o
) ) o
were VBD N
the DT N
left JJ N
insula NN N
and CC N
right JJ N
inferior JJ N
occipital JJ N
gyrus NN N
, , N
with IN N
Z NNP N
scores NNS N
> VBD N
3.5 CD N
. . N

Especially RB N
important JJ N
is VBZ N
the DT N
fact NN N
that IN N
the DT N
thalamus NN N
is VBZ N
activated VBN N
by IN N
nicotine NN i
. . i

This DT N
is VBZ N
consistent JJ N
with IN N
the DT N
high JJ N
density NN N
of IN N
nicotinic JJ N
cholinoceptors NNS N
in IN N
that DT N
brain NN N
region NN N
. . N

However RB N
, , N
not RB N
all DT N
brain NN N
regions NNS N
affected VBN N
by IN N
nicotine NN N
are VBP N
known VBN N
to TO N
have VB N
many JJ N
nicotinic JJ N
cholinoceptors NNS N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
relation NN N
to TO N
the DT N
cognitive JJ o
effects NNS o
of IN o
nicotine NN o
. . o

-DOCSTART- -3630589- O O

Gastric JJ o
contents NNS o
and CC N
pH NN N
after IN N
oral JJ N
premedication NN i
. . i

Forty NNP p
women NNS p
, , p
aged VBN p
26-40 CD p
years NNS p
, , N
were VBD N
investigated VBN N
with IN N
regard NN N
to TO N
gastric JJ p
contents NNS p
and CC p
pH NN p
before IN p
general JJ p
anaesthesia NN i
. . i

The DT N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
( ( N
20 CD N
in IN N
each DT N
) ) N
. . N

Group NNP N
100 CD N
received VBD N
0.3 CD N
mg JJ N
kg-1 JJ N
diazepam NN i
orally RB N
with IN N
100 CD N
ml NNS N
of IN N
water NN i
2 CD N
h NN N
before IN N
surgery NN N
. . N

Group NNP N
50 CD N
received VBD N
0.3 CD N
mg JJ N
kg-1 JJ N
diazepam NN i
with IN i
50 CD N
ml NNS N
of IN N
water NN i
2 CD N
h NN N
before IN N
surgery NN N
. . N

The DT N
amount NN o
of IN o
gastric JJ o
content NN o
was VBD N
significantly RB N
greater JJR N
in IN N
Group NNP N
100 CD N
than IN N
in IN N
Group NNP N
50 CD N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
pH NN o
values NNS o
between IN N
the DT N
groups NNS N
. . N

The DT N
number NN N
of IN N
patients NNS N
with IN N
both DT N
gastric JJ o
pH NN o
less JJR N
than IN N
2.5 CD N
and CC N
gastric JJ o
volume NN o
greater JJR N
than IN N
25 CD N
ml NN N
was VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
100 CD N
compared VBN N
to TO N
Group NNP N
50 CD N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

We PRP N
can MD N
not RB N
recommend VB N
the DT N
use NN N
of IN N
oral JJ N
premedication NN i
using VBG N
these DT N
amounts NNS N
of IN N
water NN N
, , N
considering VBG N
the DT N
increased VBN N
risk NN N
of IN N
aspiration NN N
of IN N
gastric JJ N
contents NNS N
. . N

-DOCSTART- -23727103- O O

Anxiolytics NNS i
in IN N
patients NNS p
suffering VBG p
a DT p
suspected JJ p
acute JJ p
coronary JJ p
syndrome NN p
: : p
multi-centre NN p
randomised VBD N
controlled VBN N
trial NN N
in IN N
Emergency NNP N
Medical NNP N
Service NNP N
. . N

BACKGROUND NNP N
The DT N
prehospital JJ N
treatment NN N
of IN N
pain NN p
and CC p
discomfort NN p
among IN p
patients NNS p
who WP p
suffer VBP p
from IN p
acute JJ p
coronary JJ p
syndrome NN p
( ( p
ACS NNP p
) ) p
needs VBZ N
a DT N
treatment NN N
strategy NN N
which WDT N
combines VBZ N
relief NN N
of IN N
pain NN N
with IN N
relief NN N
of IN N
anxiety NN N
. . N

AIM IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
on IN N
pain NN N
and CC N
anxiety NN N
of IN N
the DT N
combination NN N
of IN N
an DT N
anxiolytic JJ i
and CC N
an DT N
analgesic JJ N
as IN N
compared VBN N
with IN N
an DT N
analgesic JJ i
alone NN N
in IN N
the DT N
prehospital JJ N
setting NN N
of IN N
suspected JJ N
ACS NNP N
. . N

METHODS NNP N
A DT N
multi-centre NN p
randomised VBN N
controlled VBN N
trial NN N
compared VBN N
the DT N
combination NN N
of IN N
Midazolam NNP i
( ( i
Mi NNP i
) ) i
+Morphine NN i
( ( i
Mo NNP i
) ) i
and CC i
Mo NNP i
alone RB i
. . i

All DT N
measures NNS N
took VBD N
part NN N
: : N
Prior NNP N
to TO N
randomisation NN N
, , N
15 CD N
min NN N
thereafter RB N
and CC N
on IN N
admission NN N
to TO N
a DT N
hospital NN N
. . N

Inclusion NN N
criteria NNS N
were VBD N
: : N
1 CD N
) ) N
pain NN N
raising VBG N
suspicion NN N
of IN N
ACS NNP N
and CC N
2 CD N
) ) N
pain NN N
score NN N
?4 NN N
. . N

PRIMARY NNP N
ENDPOINT NNP N
Pain NNP N
score NN N
after IN N
15 CD N
min NN N
. . N

RESULTS NNP N
In IN N
all DT p
, , p
890 CD p
patients NNS p
were VBD p
randomised VBN p
to TO p
Mi+Mo NNP N
and CC N
873 CD N
to TO N
Mo NNP N
alone RB o
. . o

Pain NN o
was VBD o
reduced VBN N
from IN N
a DT N
median NN N
of IN N
6 CD N
to TO N
4 CD N
and CC N
finally RB N
to TO N
3 CD N
in IN N
both DT N
groups NNS N
. . N

The DT N
mean JJ N
dose NN N
of IN N
Mo NNP N
was VBD N
5.3 CD N
mg NN N
in IN N
Mi+Mo NNP i
and CC i
6.0 CD N
mg NN N
in IN N
Mo NNP i
alone RB i
( ( N
p JJ N
< NNP o
0.0001 CD o
) ) o
. . o

Anxiety NN o
was VBD o
reported VBN N
in IN N
66 CD N
% NN N
in IN N
Mi+Mo NNP N
and CC N
in IN N
64 CD N
% NN N
in IN N
Mo NNP N
alone RB N
at IN N
randomisation NN N
( ( N
NS NNP N
) ) N
; : N
15 CD N
min NN N
thereafter RB N
in IN N
31 CD N
% NN N
and CC N
39 CD N
% NN N
( ( N
p=0.002 NN N
) ) N
and CC N
finally RB N
in IN N
12 CD N
% NN N
and CC N
26 CD N
% NN N
respectively RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

On IN N
admission NN N
to TO N
a DT N
hospital NN o
nausea NN o
or CC o
vomiting NN o
was VBD o
reported VBN N
in IN N
9 CD N
% NN N
in IN N
Mi+Mo NNP i
and CC i
in IN N
13 CD N
% NN N
in IN N
Mo NNP N
alone RB N
( ( N
p=0.003 NN o
) ) o
. . o

Drowsiness NNP o
differed VBD o
; : N
15 CD N
% NN N
and CC N
14 CD N
% NN N
were VBD N
drowsy VBN N
in IN N
Mi+Mo NNP N
versus VBP N
2 CD N
% NN N
and CC N
3 CD N
% NN N
in IN N
Mo NNP N
alone RB N
respectively RB N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Despite IN N
the DT N
fact NN N
that IN N
the DT N
combination NN N
of IN N
anxiolytics NNS i
and CC i
analgesics NNS i
as IN i
compared VBN N
with IN N
analgesics NNS N
alone RB N
reduced VBN N
anxiety NN N
and CC N
the DT N
requirement NN N
of IN N
Morphine NNP N
in IN N
the DT N
prehospital JJ N
setting NN N
of IN N
acute JJ N
coronary JJ N
syndrome NN N
, , N
this DT N
strategy NN N
did VBD N
not RB N
reduce VB N
patients NNS N
' POS N
estimation NN N
of IN N
pain NN N
( ( N
primary JJ N
endpoint NN N
) ) N
. . N

More RBR N
effective JJ N
pain NN N
relief NN N
among IN N
these DT N
patients NNS N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -17046466- O O

Toxicity NN o
and CC o
efficacy NN o
of IN N
6-thioguanine JJ i
versus NN i
6-mercaptopurine JJ i
in IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
6-mercaptopurine JJ i
has VBZ N
been VBN N
a DT N
standard JJ N
component NN N
of IN N
long-term JJ N
continuing VBG N
treatment NN N
for IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
, , N
whereas JJ N
6-thioguanine NN i
has VBZ N
been VBN N
mainly RB N
used VBN N
for IN N
intensification NN N
courses NNS N
. . N

Since IN N
preliminary JJ N
data NNS N
have VBP N
shown VBN N
that IN N
6-thioguanine JJ i
is VBZ N
more RBR N
effective JJ N
than IN N
6-mercaptopurine JJ i
, , N
we PRP N
compared VBN N
the DT N
efficacy NN o
and CC o
toxicity NN o
of IN N
the DT N
two CD N
drugs NNS N
for IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
. . p

METHODS NNP N
Consecutive JJ p
children NNS p
with IN p
lymphoblastic JJ p
leukaemia NN p
diagnosed VBN p
in IN p
the DT p
UK NNP p
and CC p
Ireland NNP p
between IN p
April NNP p
, , p
1997 CD p
, , p
and CC p
June NNP p
, , p
2002 CD p
, , N
were VBD N
randomly RB N
assigned VBN N
either CC N
6-thioguanine JJ i
( ( i
750 CD i
patients NNS N
) ) N
or CC N
6-mercaptopurine JJ i
( ( N
748 CD N
patients NNS N
) ) N
during IN N
interim JJ N
maintenance NN N
and CC N
continuing VBG N
therapy NN N
. . N

All DT N
patients NNS N
received VBD N
6-thioguanine JJ i
during IN N
intensification NN N
courses NNS N
. . N

We PRP N
analysed VBD N
event-free JJ o
and CC o
overall JJ o
survival NN o
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

We PRP N
obtained VBD N
toxicity NN o
data NNS N
using VBG N
an DT N
adverse-event JJ N
reporting NN N
system NN N
, , N
with IN N
follow-up JJ N
questionnaires NNS N
to TO N
seek VB N
detailed JJ N
information NN N
for IN N
specific JJ N
toxicities NNS N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
the DT N
International NNP N
Standard NNP N
Randomised VBD N
Controlled NNP N
Number NNP N
26727615 CD N
with IN N
the DT N
name NN N
ALL97 NNP N
. . N

FINDINGS NNP N
After IN N
a DT N
median JJ N
follow NN N
up IN N
of IN N
6 CD N
years NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
event-free JJ o
or CC o
overall JJ o
survival NN o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Although IN N
6-thioguanine JJ i
conferred VBD N
a DT N
significantly RB N
lower JJR N
risk NN N
of IN N
isolated JJ N
CNS NNP o
relapse NN o
than IN N
did VBD N
6-mercaptopurine JJ i
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
0.53 CD N
, , N
95 CD N
% NN N
CI NNP N
0.30-0.92 CD N
, , N
p=0.02 NN N
) ) N
, , N
the DT N
benefit NN N
was VBD N
offset VBN N
by IN N
an DT N
increased VBN N
risk NN o
of IN o
death NN o
in IN N
remission NN N
( ( N
2.22 CD N
, , N
1.20-4.14 CD N
, , N
p=0.01 NN N
) ) N
, , N
mainly RB N
due JJ N
to TO N
infections NNS N
during IN N
continuing VBG N
therapy NN N
. . N

Additionally RB N
, , N
95 CD N
patients NNS N
developed VBD N
veno-occlusive JJ o
disease NN o
of IN o
the DT o
liver NN o
. . o

Of IN N
these DT N
, , N
82 CD N
were VBD N
randomly RB N
assigned VBN N
6-thioguanine JJ i
, , N
representing VBG N
11 CD N
% NN N
of IN N
all DT N
6-thioguanine JJ i
recipients NNS N
. . N

On IN N
long-term JJ N
follow-up NN N
, , N
about RB N
5 CD N
% NN N
of IN N
6-thioguanine JJ i
recipients NNS N
have VBP N
evidence NN N
of IN N
non-cirrhotic JJ o
portal JJ o
hypertension NN o
due JJ N
to TO N
periportal JJ N
liver JJ N
fibrosis NN N
or CC N
nodular JJ N
regenerative JJ N
hyperplasia NN N
. . N

INTERPRETATION NNP N
Compared VBD N
with IN N
6-mercaptopurine JJ i
, , i
6-thioguanine JJ i
causes NNS N
excess JJ N
toxicity NN o
without IN N
an DT N
overall JJ o
benefit NN o
. . o

6-mercaptopurine JJ i
should MD N
remain VB N
the DT N
thiopurine NN N
of IN N
choice NN N
for IN N
continuing VBG N
therapy NN N
of IN N
childhood NN N
lymphoblastic JJ N
leukaemia NN N
. . N

-DOCSTART- -19911168- O O

Dose-dependent JJ N
effects NNS o
of IN N
the DT N
CRF NNP i
( ( i
1 CD i
) ) i
receptor NN i
antagonist JJ i
R317573 NNP i
on IN N
regional JJ N
brain NN N
activity NN N
in IN N
healthy JJ p
male JJ p
subjects NNS p
. . p

BACKGROUND NNP N
Corticotropin-releasing NNP i
factor NN i
receptor NN i
type NN i
1 CD i
( ( i
CRF NNP i
( ( i
1 CD i
) ) i
) ) i
antagonists NNS N
have VBP N
been VBN N
proposed VBN N
as IN N
therapeutic JJ N
agents NNS N
in IN N
the DT N
treatment NN N
of IN N
mood NN N
and CC N
anxiety NN N
disorders NNS N
although IN N
clinical JJ N
evidence NN N
supporting VBG N
their PRP$ N
development NN N
and CC N
understanding NN N
of IN N
a DT N
dose-response JJ N
relationship NN N
has VBZ N
been VBN N
lacking VBG N
. . N

METHODS NNP N
We PRP N
tested VBD N
two CD N
doses NNS N
of IN N
the DT N
CRF NNP i
( ( i
1 CD i
) ) i
antagonist NN i
R317573 NNP i
for IN N
effects NNS N
on IN N
regional JJ o
cerebral JJ o
glucose NN o
metabolism NN o
( ( o
rCMglu NN o
) ) o
using VBG N
[ NNP i
( ( i
18 CD i
) ) i
F NNP i
] JJ i
fluoro-2-deoxy-D NN i
: : i
-glucose NN i
( ( i
FDG NNP i
) ) i
positron NN i
emission NN i
tomography NN i
( ( i
PET NNP i
) ) i
following VBG N
single-dose JJ N
challenges NNS N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
cross-over JJ N
design NN N
, , N
in IN N
12 CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

RESULTS NNP N
Single NNP N
30- JJ N
and CC N
200-mg JJ N
doses NNS N
of IN N
R317573 NNP i
resulted VBD N
in IN N
dose-related JJ N
changes NNS N
in IN N
rCMglu NN o
. . o

Relative JJ N
increases NNS N
in IN N
rCMglu NN o
were VBD N
observed VBN N
in IN N
frontal JJ N
cortical JJ N
regions NNS N
while IN N
relative JJ N
decreases NNS N
occurred VBD N
in IN N
the DT N
putamen NNS N
and CC N
right JJ N
amygdala NN N
after IN N
both DT N
doses NNS N
. . N

Relative JJ N
decreases NNS N
occurred VBD N
in IN N
cerebellum NN N
and CC N
right JJ N
parahippocampal NN N
gyrus NN N
following VBG N
the DT N
higher JJR N
dose NN N
. . N

CONCLUSIONS NNP N
R317573 NNP i
appears VBZ N
to TO N
produce VB N
acute JJ N
dose-dependent JJ N
changes NNS N
in IN N
rCMglu NN N
. . N

Effects NNS N
occurred VBD N
in IN N
regions NNS N
that WDT N
may MD N
be VB N
behaviorally RB N
relevant JJ N
to TO N
mood NN N
and CC N
anxiety NN N
disorders NNS N
. . N

In IN N
some DT N
regions NNS N
, , N
these DT N
effects NNS N
may MD N
be VB N
related VBN N
to TO N
the DT N
receptor NN N
( ( N
target NN N
) ) N
density NN N
. . N

Measuring VBG N
acute JJ N
effects NNS N
on IN N
rCMglu NN i
with IN N
FDG-PET NNP i
may MD N
offer VB N
a DT N
method NN N
for IN N
defining VBG N
pharmacologically RB N
active JJ N
doses NNS N
for IN N
central JJ N
nervous JJ N
system NN N
targets NNS N
for IN N
which WDT N
selective JJ N
radiotracers NNS N
are VBP N
lacking VBG N
. . N

-DOCSTART- -2990708- O O

Intensive JJ i
induction NN i
chemotherapy NN i
for IN N
small JJ N
cell NN N
anaplastic JJ N
carcinoma NN N
of IN N
the DT N
lung NN N
. . N

The DT N
role NN N
of IN N
intensive JJ i
induction NN i
chemotherapy NN i
in IN N
small JJ N
cell NN N
cancer NN N
of IN N
the DT N
lung NN N
remains VBZ N
unclear JJ N
. . N

Twenty-eight JJ p
newly RB p
diagnosed VBN p
patients NNS p
with IN p
small JJ p
cell NN p
lung NN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
high-dose JJ i
or CC i
standard-dose JJ i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
and CC i
semustine NN i
in IN N
a DT N
trial NN N
where WRB N
the DT N
dose NN N
of IN N
induction NN N
chemotherapy NN N
was VBD N
the DT N
sole JJ N
treatment NN N
variable JJ N
. . N

Complete JJ o
responses NNS o
( ( o
CR NNP o
) ) o
were VBD N
achieved VBN N
in IN N
57 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
high-dose JJ N
therapy NN N
as IN N
compared VBN N
to TO N
21 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
standard-dose JJ N
therapy NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
higher JJR N
rate NN N
of IN N
severe JJ o
toxicity NN o
in IN N
the DT N
high-dose JJ N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
overall JJ o
median JJ o
survival NN o
was VBD N
not RB N
improved VBN N
( ( N
36 CD N
weeks NNS N
for IN N
the DT N
high-dose JJ N
group NN N
vs VBD N
43 CD N
weeks NNS N
for IN N
the DT N
standard-dose JJ N
group NN N
) ) N
; : N
however RB N
, , N
the DT N
median JJ o
survival NN o
in IN N
patients NNS N
achieving VBG N
CR NNP N
was VBD N
prolonged VBN N
( ( N
92 CD N
weeks NNS N
for IN N
the DT N
high-dose JJ N
group NN N
vs VBD N
50 CD N
weeks NNS N
for IN N
the DT N
standard-dose JJ N
group NN N
) ) N
. . N

These DT N
effects NNS N
were VBD N
most RBS N
pronounced VBN N
in IN N
patients NNS p
with IN p
extensive JJ p
disease NN p
; : p
a DT N
CR NNP o
after IN N
induction NN N
was VBD N
achieved VBN N
in IN N
five CD N
of IN N
nine CD N
patients NNS N
treated VBN N
with IN N
high JJ N
doses NNS N
but CC N
not RB N
in IN N
any DT N
of IN N
those DT N
treated VBN N
with IN N
standard JJ N
doses NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

A NNP N
small JJ N
group NN N
of IN N
patients NNS N
appear VBP N
to TO N
benefit VB N
by IN N
achieving VBG N
a DT N
long-term JJ N
remission NN N
with IN N
intensive JJ N
induction NN N
chemotherapy NN N
, , N
but CC N
this DT N
effect NN N
may MD N
be VB N
offset VBN N
by IN N
increased JJ N
morbidity NN N
. . N

-DOCSTART- -16714498- O O

Confidential JJ i
registration NN i
in IN N
health NN N
services NNS N
: : N
randomised VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Human NNP N
rights NNS N
legislation NN N
safeguards VBZ N
the DT N
privacy NN N
and CC N
dignity NN N
of IN N
patients NNS p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
in IN N
terms NNS N
of IN N
patient NN N
assessed VBN N
privacy NN N
of IN N
confidential JJ i
registration NN i
. . i

DESIGN NNP N
Randomised VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Emergency NNP p
Department NNP p
, , p
University NNP p
Hospital NNP p
of IN p
Wales NNP p
. . p

PARTICIPANTS VB N
A DT p
total NN p
of IN p
302 CD p
patients NNS p
aged VBN p
over IN p
15 CD p
years NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Binary NNP i
choices NNS i
and CC N
ordinal JJ i
visual JJ i
analogue NN i
scores NNS N
from IN N
a DT N
validated JJ i
questionnaire NN i
on IN i
self NN i
reported VBN i
measures NNS i
: : i
patient NN o
ability NN o
and CC o
preference NN o
to TO o
speak VB o
to TO o
receptionists NNS o
and CC o
disclose VB o
confidential JJ o
information NN o
without IN o
being VBG o
overhead JJ o
and CC o
concern NN o
about IN o
disclosure NN o
of IN o
items NNS o
of IN o
confidential JJ o
personal JJ o
information NN o
. . o

RESULTS NNP N
Patients NNPS N
who WP N
registered VBD N
in IN N
a DT N
screened JJ i
area NN i
felt VBD N
significantly RB N
more RBR N
able JJ N
to TO N
tell VB o
receptionists NNS o
things NNS o
they PRP o
did VBD o
not RB o
want VB o
others NNS o
to TO o
hear VB o
. . o

Control NNP N
patients NNS N
were VBD N
significantly RB N
more RBR N
concerned JJ N
than IN N
intervention NN N
patients NNS N
that WDT N
others NNS o
heard VBP o
their PRP$ o
name NN o
, , o
address NN o
, , o
date NN o
of IN o
birth NN o
, , o
reason NN o
for IN o
emergency NN o
department NN o
attendance NN o
, , o
and CC o
telephone NN o
number NN o
, , o
but CC o
not RB o
their PRP$ o
marital JJ o
status NN o
. . o

Overall NNP N
, , N
intervention NN N
patients NNS N
were VBD N
less RBR N
concerned JJ N
about IN N
disclosure NN o
of IN o
information NN o
and CC N
that IN N
they PRP N
had VBD N
been VBN N
overheard RB N
. . N

CONCLUSIONS NNP N
Patients NNPS N
value NN N
privacy NN N
when WRB N
they PRP N
register VBP N
and CC N
are VBP N
concerned VBN N
if IN N
others NNS N
can MD N
hear VB N
them PRP N
tell VB N
receptionists NNS N
who WP N
they PRP N
are VBP N
, , N
how WRB N
to TO N
contact VB N
them PRP N
, , N
and CC N
why WRB N
they PRP N
are VBP N
there RB N
. . N

Confidential JJ i
registration NN i
should MD N
be VB N
instituted VBN N
in IN N
health NN N
services NNS N
. . N

Confidential JJ i
registration NN i
increased VBD N
patient JJ N
privacy NN N
and CC N
should MD N
be VB N
instituted VBN N
in IN N
health NN N
services NNS N
. . N

-DOCSTART- -12614412- O O

Ambulatory NNP i
phlebectomy NN i
versus NN N
compression NN i
sclerotherapy NN i
: : i
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
no DT N
randomized VBN N
controlled VBN N
trial NN N
has VBZ N
assessed VBN N
the DT N
effects NNS N
of IN N
either DT N
compression NN i
sclerotherapy NN i
or CC N
ambulatory JJ i
phlebectomy NN i
, , N
both DT N
techniques NNS N
are VBP N
used VBN N
to TO N
treat VB N
varicose JJ N
veins NNS N
worldwide RB N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
compare VB N
recurrence NN N
rates NNS N
of IN N
varicose JJ N
veins NNS N
and CC N
complications NNS N
after IN N
compression NN i
sclerotherapy NN i
and CC N
ambulatory JJ i
phlebectomy NN i
. . i

METHODS NNP N
From IN N
September NNP p
1996 CD p
to TO p
October NNP p
1998 CD p
, , p
we PRP p
randomly RB p
allocated VBD p
49 CD p
legs NNS p
to TO p
compression VB i
sclerotherapy NN i
and CC p
49 CD p
legs NNS p
to TO p
ambulatory JJ i
phlebectomy NN i
. . i

Our PRP$ N
primary JJ N
outcome NN N
parameters NNS N
were VBD N
as IN N
follows VBZ N
: : N
recurrence NN N
rates NNS N
at IN N
1 CD N
and CC N
2 CD N
years NNS N
and CC N
complications NNS N
related VBN N
to TO N
therapy VB N
. . N

Eighty-two JJ p
patients NNS p
were VBD p
included VBN p
, , p
of IN p
whom WP p
16 CD p
were VBD p
included VBN p
with IN p
both DT p
of IN p
their PRP$ p
legs NNS p
. . p

The DT p
number NN p
of IN p
treated JJ p
legs NN p
was VBD p
therefore RB p
98 CD p
, , N
but CC N
two CD p
patients NNS p
were VBD N
lost VBN N
to TO N
follow-up JJ N
. . N

RESULTS VB N
One CD o
year NN o
recurrence NN o
amounted VBD N
to TO N
1 CD N
out IN N
of IN N
48 CD N
for IN N
phlebectomy NN i
and CC N
12 CD N
out IN N
of IN N
48 CD N
for IN N
compression NN i
sclerotherapy NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
at IN N
2 CD N
years NNS N
, , N
six CD N
additional JJ N
recurrences NNS o
were VBD N
found VBN N
, , N
but CC N
then RB N
solely RB N
for IN N
compression NN i
sclerotherapy NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significant JJ N
differences NNS N
in IN N
complications NNS N
occurring VBG N
more RBR N
in IN N
phlebectomy NN N
than IN N
in IN N
compression NN i
sclerotherapy NN i
therapy NN N
were VBD N
blisters NNS o
, , o
teleangiectatic JJ o
matting NN o
, , o
scar NN o
formation NN o
, , o
and CC o
bruising VBG o
from IN o
bandaging VBG o
. . o

CONCLUSION NNP N
Our PRP$ N
results NNS N
show VBP N
that IN N
ambulatory JJ i
phlebectomy NN i
is VBZ N
an DT N
effective JJ N
therapy NN N
for IN N
varicose JJ N
veins NNS N
of IN N
the DT N
leg NN N
. . N

Recurrence NN N
rates NNS N
are VBP N
significantly RB N
lower JJR N
than IN N
for IN N
compression NN i
sclerotherapy NN i
therapy NN i
. . i

If IN N
varicose JJ N
veins NNS N
persist VBP N
4 CD N
weeks NNS N
after IN N
compression NN i
sclerotherapy NN i
, , N
it PRP N
can MD N
be VB N
argued VBN N
that IN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
future JJ N
recurrence NN N
ambulatory JJ i
phlebectomy NN i
should MD N
be VB N
considered VBN N
as IN N
the DT N
better JJR N
treatment NN N
option NN N
. . N

-DOCSTART- -8521712- O O

Differential JJ N
effects NNS N
on IN N
bone NN o
density NN o
of IN N
progestogen-only JJ i
methods NNS N
for IN N
contraception NN N
in IN N
premenopausal JJ p
women NNS p
. . p

The DT N
question NN N
of IN N
differential JJ N
effects NNS N
on IN N
bone NN N
density NN N
by IN N
two CD N
different JJ N
types NNS N
of IN N
progestogen-only JJ i
methods NNS N
for IN N
contraception NN N
in IN N
premenopausal JJ p
women NNS p
was VBD N
addressed VBN N
. . N

Data NNS N
from IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
among IN N
22 CD p
premenopausal JJ p
women NNS p
, , p
age NN p
32.6 CD p
( ( p
range JJ p
20-45 CD p
years NNS p
) ) p
, , N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
of IN N
two CD N
treatments NNS N
with IN N
continuous JJ i
progestogens NNS i
for IN i
contraception NN i
were VBD N
analyzed VBN N
; : N
depot-medroxyprogesterone JJ i
acetate NN i
( ( i
DMPA NNP i
) ) i
or CC N
continuous JJ i
levonorgestrel NN i
treatment NN i
with IN i
subdermal JJ i
implants NNS i
( ( N
Norplant NNP N
) ) N
, , N
respectively RB N
. . N

Forearm NNP o
bone NN o
density NN o
( ( o
BMDprox NNP o
) ) o
increased VBD N
with IN N
2.94 CD N
% NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
in IN N
women NNS N
who WP N
were VBD N
prescribed VBN N
levonorgestrel NN N
, , N
which WDT N
was VBD N
in IN N
contrast NN N
to TO N
stable JJ N
values NNS N
in IN N
those DT N
prescribed JJ N
depot-medroxy-progesterone JJ i
acetate NN i
; : i
group NN N
difference NN N
at IN N
6 CD N
months NNS N
for IN N
BMDprox NNP o
3.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
1.3 CD N
, , N
5.5 CD N
; : N
p NN N
= VBZ N
0.025 CD N
) ) N
and CC N
BMDdist $ o
4.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
- : N
1.3 CD N
, , N
9.6 CD N
; : N
p NN N
= VBZ N
0.077 CD N
) ) N
. . N

The DT N
changes NNS o
in IN o
bone NN o
density NN o
were VBD N
consistent JJ N
with IN N
the DT N
changes NNS N
in IN N
biochemical JJ o
indices NNS o
for IN o
bone NN o
metabolism NN o
; : o
DMPA NNP i
users NNS N
showed VBD N
signs NNS N
of IN N
increased VBN N
bone NN o
turnover NN o
and CC N
users NNS N
of IN N
levonorgestrel NN N
showed VBD N
increased JJ o
bone NN o
formation NN o
with IN N
increased JJ N
levels NNS N
of IN N
both DT N
alkaline JJ N
phosphatase NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
and CC N
osteocalcin $ N
( ( N
p JJ N
= NNP N
0.007 CD N
) ) N
. . N

The DT N
findings NNS N
suggest VBP N
an DT N
increase NN N
in IN N
bone JJ o
density NN o
during IN N
treatment NN N
with IN N
levonorgestrel NN i
and CC N
stable JJ N
values NNS N
during IN N
short-term JJ N
administration NN N
of IN N
DMPA NNP i
, , N
in IN N
standard JJ N
clinical JJ N
doses NNS N
for IN N
contraception NN N
. . N

-DOCSTART- -17073957- O O

Polydioxanone NNP i
sternal JJ i
sutures NNS i
for IN N
prevention NN N
of IN N
sternal JJ N
dehiscence NN N
. . N

BACKGROUND NNP N
Sternal NNP o
dehiscence NN o
and CC o
wound NN o
instability NN o
are VBP N
troublesome JJ N
complications NNS N
following VBG N
median JJ N
sternotomy NN N
. . N

Classic JJ N
sternal JJ N
approximation NN N
with IN N
stainless JJ N
steel NN N
wires NNS N
may MD N
not RB N
be VB N
the DT N
ideal JJ N
approach NN N
in IN N
patients NNS N
predisposed VBN N
to TO N
these DT N
complications NNS N
. . N

We PRP N
tested VBD N
the DT N
efficacy NN o
of IN N
polydioxanone NN i
( ( i
PDS NNP i
) ) i
suture NN i
in IN N
sternal JJ o
closure NN o
and CC N
in IN N
prevention NN N
of IN N
complications NNS o
in IN N
comparison NN N
to TO N
steel NN N
wires NNS N
in IN N
high-risk JJ p
individuals NNS p
. . p

METHODS NNP N
Three CD p
hundred VBD p
sixty-six JJ p
patients NNS p
undergoing VBG p
elective JJ p
cardiac JJ p
surgery NN p
with IN p
full JJ p
median JJ p
sternotomy NN p
and CC p
having VBG p
body NN p
surface JJ p
area NN p
( ( p
BSA NNP p
) ) p
less JJR p
than IN p
1.5 CD p
m NN p
( ( p
2 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
PDS NNP i
( ( N
n JJ N
= NNP N
181 CD N
) ) N
or CC N
stainless JJ i
steel NN i
( ( N
SS NNP N
, , N
n JJ N
= NNP N
185 CD N
) ) N
sternal JJ N
approximation NN N
. . N

The DT N
study NN N
was VBD N
focused VBN N
on IN N
aseptic JJ N
sternal JJ N
complications NNS N
, , N
namely RB N
bone JJ o
dehiscence NN o
and CC o
superficial JJ o
wound NN o
instability NN o
. . o

RESULTS NNP N
Both NNP N
bone VBD o
dehiscence NN o
and CC o
superficial JJ o
wound NN o
instability NN o
were VBD N
less JJR N
frequent JJ N
in IN N
the DT N
PDS NNP i
Group NNP N
( ( N
4 CD N
and CC N
3 CD N
cases NNS N
in IN N
the DT N
SS NNP N
Group NNP N
, , N
respectively RB N
, , N
vs. IN N
no DT N
cases NNS N
in IN N
the DT N
PDS NNP N
Group NNP N
) ) N
. . N

Cox NNP o
proportional JJ o
hazards NNS o
regression NN o
model NN N
in IN N
the DT N
whole NN N
study NN N
population NN N
identified VBN N
female JJ o
sex NN o
, , o
chronic JJ o
renal JJ o
insufficiency NN o
, , o
diabetes VBZ o
, , o
advanced JJ o
age NN o
, , o
lower JJR o
sternal JJ o
thickness NN o
, , o
osteoporosis NN o
, , o
corticosteroid JJ o
therapy NN o
, , o
and CC o
prolonged VBD o
CPB NNP o
or CC o
ventilation NN o
times NNS o
as IN N
predisposing VBG N
factors NNS N
to TO N
any DT N
of IN N
the DT N
two CD N
studied VBD N
sternal JJ N
complications NNS N
. . N

DISCUSSION NNP N
Data NNP N
suggest NN N
that IN N
PDS NNP i
suture NN N
can MD N
protect VB N
against IN N
development NN N
of IN N
aseptic JJ o
sternal JJ o
complications NNS o
following VBG p
median JJ p
sternotomy NN p
in IN p
high-risk JJ p
patients NNS p
with IN p
little JJ p
body NN p
mass NN p
. . p

The DT N
adoption NN N
of IN N
PDS NNP i
in IN N
other JJ N
subsets NNS N
of IN N
patients NNS N
, , N
i.e. FW N
, , N
obese JJ N
individuals NNS N
, , N
is VBZ N
to TO N
be VB N
questioned VBN N
. . N

-DOCSTART- -21054362- O O

Antimigraine NNP o
efficacy NN o
of IN N
telcagepant NN i
based VBN N
on IN N
patient NN p
's POS p
historical JJ p
triptan NN i
response NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
the DT N
same JJ N
or CC N
different JJ N
patients NNS p
respond NN o
to TO o
triptans NNS o
and CC i
telcagepant NN i
. . i

BACKGROUND NNP N
Telcagepant NNP i
is VBZ N
an DT N
oral JJ i
calcitonin NN i
gene-related JJ i
peptide NN i
receptor NN i
antagonist NN N
with IN N
acute JJ N
antimigraine NN o
efficacy NN o
comparable JJ N
to TO N
oral JJ i
triptans NNS i
. . i

It PRP N
is VBZ N
currently RB N
unknown JJ N
whether IN N
migraine NN p
patients NNS p
who WP p
can MD p
not RB p
be VB p
adequately RB p
helped VBN p
with IN p
triptans NNS i
might MD N
benefit VB N
from IN N
treatment NN N
with IN N
telcagepant NN i
. . i

METHODS NNP N
Post-hoc JJ N
analysis NN N
of IN N
data NNS N
from IN N
a DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
telcagepant NN i
( ( i
150 CD i
mg NN i
, , i
300 CD i
mg NN i
) ) i
zolmitriptan VBZ i
5 CD i
mg NN i
, , i
or CC i
placebo NN i
for IN N
a DT N
moderate/severe JJ N
migraine NN N
. . N

Responder VB N
rates NNS N
were VBD N
analyzed VBN N
according VBG N
to TO N
patients NNS p
' POS p
self-reported JJ o
historical JJ o
triptan NN o
response NN o
( ( o
HTR NNP o
) ) o
: : o
( ( p
1 CD p
) ) p
good JJ p
HTR NNP p
( ( p
N NNP p
= NNP p
660 CD p
) ) p
: : p
response NN p
in IN p
75-100 CD p
% NN p
of IN p
attacks NNS p
; : p
( ( p
2 CD p
) ) p
intermediate NN p
HTR NNP p
( ( p
N NNP p
= NNP p
248 CD p
) ) p
: : p
response NN p
in IN p
25-74 JJ p
% NN p
of IN p
attacks NNS p
; : p
( ( p
3 CD p
) ) p
poor JJ p
HTR/no NNP p
use NN p
( ( p
N NNP p
= NNP p
407 CD p
) ) p
: : p
response NN p
in IN p
< JJ p
25 CD p
% NN p
of IN p
attacks NNS p
, , p
or CC p
patient NN p
did VBD p
not RB p
take VB p
triptans NNS p
. . p

A DT N
limitation NN N
of IN N
the DT N
analysis NN N
is VBZ N
that IN N
the DT p
last JJ p
subgroup NN p
comprised VBD p
mainly RB p
( ( p
91 CD p
% NN p
) ) p
patients NNS p
who WP p
reported VBD p
that IN p
they PRP p
did VBD p
not RB p
take VB p
triptans NNS p
, , p
but CC p
it PRP p
was VBD p
not RB p
known VBN p
whether IN p
these DT p
patients NNS p
were VBD p
triptan-na?ve JJ p
or CC p
had VBD p
previously RB p
used VBN i
triptans NNS i
and CC p
stopped VBD p
taking VBG p
them PRP p
. . p

RESULTS VB N
For IN i
zolmitriptan JJ i
, , i
2-hour JJ o
pain NN o
relief NN o
rates NNS o
were VBD N
higher JJR N
in IN N
the DT N
good JJ N
HTR NNP N
subgroup NN N
( ( N
116/162 CD N
, , N
72 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
intermediate NN N
( ( N
29/62 CD N
, , N
47 CD N
% NN N
) ) N
and CC N
poor/no NN N
use NN N
( ( N
44/111 CD N
, , N
40 CD N
% NN N
) ) N
HTR NNP N
subgroups NNS N
. . N

The DT o
2-hour JJ o
pain NN o
relief NN o
rates NNS o
were VBD N
similar JJ N
across IN N
HTR NNP N
subgroups NNS N
for IN i
telcagepant JJ i
150 CD N
mg NN N
( ( N
48-58 CD N
% NN N
) ) N
, , N
300 CD N
mg NN N
( ( N
52-58 CD N
% NN N
) ) N
, , N
and CC i
placebo NN i
( ( N
26-31 CD N
% NN N
) ) N
. . N

In IN N
the DT N
poor/no NN N
use NN N
HTR NNP N
subgroup NN N
, , N
more JJR N
patients NNS N
receiving VBG i
telcagepant JJ i
300 CD N
mg NN N
( ( N
56/98 CD N
, , N
57.1 CD N
% NN N
) ) N
had VBD o
2-hour JJ o
pain NN o
relief NN o
than IN N
those DT N
receiving VBG i
zolmitriptan NN i
( ( N
44/111 CD N
, , N
39.6 CD N
% NN N
; : N
odds NNS N
ratio VBP N
= $ N
2.11 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
: : N
1.20,3.71 CD N
] NN N
, , N
P NNP N
= NNP N
.009 NNP N
) ) N
; : N
the DT N
percentage NN N
for IN i
telcagepant JJ i
150 CD N
mg NN N
( ( N
57/119 CD N
, , N
47.9 CD N
% NN N
) ) N
was VBD N
not RB N
significantly RB N
different JJ N
from IN i
zolmitriptan NN i
( ( N
odds NNS N
ratio VBP N
= $ N
1.41 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
: : N
0.82 CD N
, , N
2.40 CD N
] NN N
, , N
P NNP N
= NNP N
.211 NNP N
) ) N
. . N

CONCLUSIONS VB N
This DT N
suggests VBZ N
that IN N
different JJ N
patients NNS N
may MD N
respond VB N
to TO i
triptans NNS i
or CC i
telcagepant JJ i
300 CD N
mg NN N
. . N

Caution NN N
should MD N
be VB N
exercised VBN N
in IN N
interpreting VBG N
the DT N
results NNS N
because IN N
of IN N
the DT N
post-hoc JJ N
nature NN N
of IN N
the DT N
analysis NN N
( ( N
clinical JJ N
trial NN N
registry NN N
: : N
NCT00442936 NNP N
) ) N
. . N

-DOCSTART- -16232016- O O

Comparison NNP N
of IN N
methods NNS N
for IN N
intravenous JJ N
infusion NN i
of IN i
fat JJ i
emulsion NN i
during IN N
extracorporeal JJ N
membrane JJ N
oxygenation NN N
. . N

STUDY NNP N
OBJECTIVES NNP N
To TO N
characterize VB N
the DT N
effects NNS N
of IN N
infusing VBG N
fat JJ i
emulsion NN i
during IN N
neonatal JJ N
extracorporeal JJ N
membrane NN N
oxygenation NN N
( ( N
ECMO NNP N
) ) N
by IN N
comparing VBG N
results NNS N
from IN N
patients NNS N
receiving VBG N
fat JJ i
emulsion NN i
through IN N
the DT N
ECMO NNP N
circuit NN N
with IN N
those DT N
receiving VBG N
fat JJ N
emulsion NN N
through IN N
separate JJ N
intravenous JJ N
access NN N
. . N

A DT N
second JJ N
goal NN N
was VBD N
to TO N
identify VB N
the DT N
optimal JJ N
route NN N
for IN N
administration NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
open-label JJ N
trial NN N
. . N

SETTING NN N
Neonatal NNP p
intensive JJ p
care NN p
unit NN p
in IN p
a DT p
106-bed JJ p
quaternary JJ p
care NN p
pediatric JJ p
hospital NN p
. . p

SUBJECTS NNP N
Nine NNP p
neonates VBZ p
receiving VBG p
ECMO NNP p
who WP p
required VBD p
intravenous JJ p
nutrition NN i
. . i

Intervention NNP N
. . N

Patients NNS N
received VBD N
1-3 JJ i
g/kg/day NN i
of IN i
fat JJ i
emulsion NN i
into IN i
either CC i
the DT i
ecmo NN i
circuit NN i
or CC i
separate JJ i
intravenous JJ i
access NN i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
ECMO NNP N
circuit NN N
and CC N
samples NNS N
of IN N
blood NN N
were VBD N
evaluated VBN N
hourly RB N
for IN N
phase NN N
separation NN N
, , N
layering VBG N
out IN N
of IN N
the DT N
emulsion NN N
from IN N
blood NN N
, , N
agglutination NN N
, , N
and CC N
blood NN N
clots NNS N
. . N

After IN N
completion NN N
, , N
the DT N
oxygenators NNS N
were VBD N
dissected VBN N
and CC N
examined VBN N
. . N

Data NNS N
were VBD N
compared VBN N
with IN N
an DT N
unpaired JJ N
t NN N
test NN N
. . N

The DT N
characteristics NNS N
of IN N
the DT N
groups NNS N
were VBD N
similar JJ N
, , N
except IN N
for IN N
a DT N
higher JJR N
mean JJ N
weight NN o
in IN N
the DT N
ECMO NNP N
circuit NN N
group NN N
( ( N
3.6 CD N
+/- JJ N
0.3 CD N
kg NN N
vs NN N
2.8 CD N
+/- JJ N
0.4 CD N
kg NN N
, , N
p=0.03 NN N
) ) N
. . N

The DT N
mean JJ o
+/- JJ o
SD NNP o
triglyceride NN o
level NN o
during IN N
the DT N
study NN N
was VBD N
87 CD N
+/- JJ N
79 CD N
mg/dl NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Two CD N
patients NNS N
in IN N
each DT N
group NN N
had VBD N
elevated VBN N
triglyceride NN o
levels NNS o
. . o

No DT N
cases NNS N
of IN N
phase NN o
separation NN o
occurred VBD N
. . N

In IN N
the DT N
five CD N
patients NNS N
who WP N
received VBD N
fat JJ i
emulsion NN i
into IN N
the DT N
ECMO NNP N
circuit NN N
, , N
three CD N
had VBD N
layering VBG o
out IN o
of IN o
the DT o
emulsion NN o
and CC N
agglutination NN o
, , N
and CC N
all DT N
developed JJ N
clots NNS o
in IN N
the DT N
circuit NN N
despite IN N
adequate JJ N
anticoagulation NN N
. . N

Of IN N
the DT N
four CD N
patients NNS N
in IN N
the DT N
intravenous-access JJ N
group NN N
, , N
one CD N
had VBD N
layering NN N
and CC N
agglutination NN N
, , N
and CC N
two CD N
had VBD N
blood NN N
clots NNS N
. . N

CONCLUSIONS NNP N
Although IN N
both DT N
methods NNS N
were VBD N
associated VBN N
with IN N
layering VBG o
out RP o
, , o
agglutination NN o
, , o
and CC o
clot NN o
formation NN o
, , N
these DT N
effects NNS N
occurred VBD N
more RBR N
frequently RB N
with IN N
administration NN N
into IN N
the DT N
ECMO NNP N
circuit NN N
, , N
particularly RB N
in IN N
areas NNS N
of IN N
stasis NN N
. . N

This DT N
may MD N
result VB N
in IN N
disruption NN N
of IN N
normal JJ N
ECMO NNP N
blood NN N
flow NN N
and CC N
impaired JJ N
delivery NN N
of IN N
calories NNS N
. . N

Fat NNP i
emulsion NN i
should MD N
therefore RB N
be VB N
administered VBN N
through IN N
separate JJ N
intravenous JJ N
access NN N
during IN N
ECMO NNP N
whenever WRB N
possible JJ N
. . N

-DOCSTART- -20155309- O O

Pilot NNP N
randomized VBD N
controlled VBN N
trial NN N
of IN N
Reciprocal NNP i
Imitation NNP i
Training NNP i
for IN N
teaching VBG N
elicited VBN N
and CC N
spontaneous JJ o
imitation NN o
to TO N
children NNS p
with IN p
autism NN p
. . p

Children NNP p
with IN p
autism NN p
exhibit NN N
significant JJ N
deficits NNS N
in IN N
imitation NN o
skills NNS o
. . o

Reciprocal JJ i
Imitation NNP i
Training NNP i
( ( i
RIT NNP i
) ) i
, , N
a DT N
naturalistic JJ N
imitation NN N
intervention NN N
, , N
was VBD N
developed VBN N
to TO N
teach VB N
young JJ p
children NNS p
with IN p
autism NN p
to TO N
imitate VB N
during IN N
play NN N
. . N

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
RIT NNP N
on IN N
elicited VBN N
and CC N
spontaneous JJ N
imitation NN o
skills NNS o
in IN N
21 CD p
young JJ p
children NNS p
with IN p
autism NN p
. . p

Results NNP N
found VBD N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB o
more RBR o
gains NNS o
in IN N
elicited JJ o
and CC o
spontaneous JJ o
imitation NN o
, , N
replicating VBG N
previous JJ N
single-subject JJ N
design NN N
studies NNS N
. . N

Number NNP o
of IN o
spontaneous JJ o
play NN o
acts NNS o
at IN N
pre-treatment NN N
was VBD N
related VBN N
to TO N
improvements NNS N
in IN N
imitation NN o
during IN N
the DT N
intervention NN N
, , N
suggesting VBG N
that IN N
children NNS N
with IN N
a DT N
greater JJR N
play NN N
repertoire NN N
make VBP N
greater JJR N
gains NNS N
during IN N
RIT NNP N
. . N

-DOCSTART- -12925182- O O

Reduction NN N
of IN N
isoflurane NN N
MAC NNP N
by IN N
fentanyl NN i
or CC N
remifentanil NN i
in IN N
rats NNS p
. . p

OBJECTIVE IN N
The DT N
main JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
three CD N
different JJ N
infusion NN N
rates NNS N
of IN N
fentanyl NN i
and CC i
remifentanil NN i
on IN N
the DT N
minimum JJ N
alveolar JJ N
concentration NN N
( ( N
MAC NNP N
) ) N
of IN N
isoflurane NN N
in IN N
the DT N
rat NN p
. . p

A DT N
secondary JJ N
objective NN N
was VBD N
to TO N
assess VB N
the DT N
cardiovascular NN N
and CC N
respiratory JJ N
effects NNS N
of IN N
the DT N
two CD N
opioid JJ N
drugs NNS N
. . N

ANIMAL NNP N
POPULATION NNP N
Thirty-seven NNP p
male NN p
Wistar NNP p
rats NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
six CD N
treatment NN N
groups NNS N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
For IN N
all DT N
treatment NN N
groups NNS N
anaesthesia NN N
was VBD N
induced VBN N
with IN N
5 CD N
% NN N
isoflurane NN i
in IN i
oxygen NN i
using VBG N
an DT N
induction NN N
chamber NN N
. . N

A DT N
14-gauge JJ N
catheter NN N
was VBD N
used VBN N
for IN N
endotracheal JJ N
intubation NN N
, , N
and CC N
anaesthesia NN N
was VBD N
maintained VBN N
with IN N
isoflurane NN N
delivered VBN N
in IN N
oxygen NN N
via IN N
a DT N
T-piece NNP N
breathing NN N
system NN N
. . N

A DT N
baseline JJ N
determination NN N
of IN N
the DT N
minimum JJ N
alveolar JJ N
concentration NN N
of IN N
isoflurane NN N
( ( N
MACISO NNP N
) ) N
was VBD N
made VBN N
for IN N
each DT N
animal NN N
. . N

Fentanyl NNP i
( ( N
15 CD N
, , N
30 CD N
, , N
60 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
or CC N
remifentanil NN i
( ( N
60 CD N
, , N
120 CD N
, , N
240 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
were VBD N
infused VBN N
intravenously RB N
into IN N
a DT N
previously RB N
cannulated VBN N
tail NN N
vein NN N
. . N

Thirty NNP N
minutes NNS N
after IN N
the DT N
infusion NN N
started VBD N
, , N
a DT N
second JJ N
MACISO NNP N
( ( N
MACISO+drug NNP N
) ) N
was VBD N
determined VBN N
. . N

The DT N
carotid NN N
artery NN N
was VBD N
cannulated VBN N
to TO N
monitor VB N
the DT N
arterial JJ o
pressure NN o
and CC N
to TO N
take VB N
samples NNS N
for IN N
arterial JJ o
gas NN o
measurements NNS o
. . o

Cardiovascular NNP o
( ( o
heart NN o
rate NN o
and CC o
arterial JJ o
pressure NN o
) ) o
and CC o
respiratory NN o
( ( o
respiratory JJ o
rate NN o
and CC o
presence/absence NN o
of IN o
apnoea NN o
) ) o
effects NNS o
after IN N
opioid JJ N
infusion NN N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS NNP N
Fentanyl NNP i
( ( N
15 CD N
, , N
30 CD N
, , N
60 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
and CC N
remifentanil NN i
( ( N
60 CD N
, , N
120 CD N
, , N
240 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
similarly RB N
reduced VBN N
isoflurane NN N
MAC NNP N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
: : N
by IN N
10 CD N
% NN N
at IN N
lower JJR N
doses NNS N
, , N
25 CD N
% NN N
at IN N
medium NN N
doses NNS N
and CC N
by IN N
60 CD N
% NN N
at IN N
higher JJR N
doses NNS N
of IN N
both DT N
the DT N
drugs NNS N
. . N

Both DT N
opioids NNS N
reduced VBD N
the DT N
respiratory NN N
rate NN N
in IN N
a DT N
similar JJ N
way NN N
for IN N
all DT N
doses NNS N
tested VBN N
. . N

No DT N
episodes NNS N
of IN N
apnoea NN N
were VBD N
recorded VBN N
in IN N
the DT N
remifentanil NN i
groups NNS N
, , N
while IN N
administration NN N
of IN N
fentanyl NN N
resulted VBN N
in IN N
apnoea NN N
in IN N
three CD N
animals NNS N
( ( N
one CD N
at IN N
each DT N
dose JJ N
level NN N
) ) N
. . N

The DT N
effects NNS N
on IN N
the DT N
cardiovascular JJ N
system NN N
were VBD N
similar JJ N
with IN N
both DT N
drugs NNS N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
the DT N
intraoperative JJ N
use NN N
of IN N
remifentanil NN i
in IN N
the DT N
rat NN N
reduces VBZ N
the DT N
MAC NNP N
of IN N
isoflurane NN N
, , N
and CC N
that IN N
this DT N
anaesthetic JJ N
sparing NN N
effect NN N
is VBZ N
dose-dependent JJ N
and CC N
similar JJ N
to TO N
that DT N
produced VBN N
by IN N
fentanyl NN N
at IN N
the DT N
doses NNS N
tested VBN N
. . N

CLINICAL JJ N
RELEVANCE NNP N
The DT N
use NN N
of IN N
remifentanil NN i
during IN N
inhalant JJ N
anaesthesia NN N
in IN N
the DT N
rat NN N
can MD N
be VB N
considered VBN N
an DT N
intravenous JJ N
alternative NN N
to TO N
fentanyl VB i
, , N
providing VBG N
similar JJ N
reduction NN N
in IN N
isoflurane NN N
requirements NNS N
. . N

Due NNP N
to TO N
its PRP$ N
rapid JJ N
offset NN N
, , N
it PRP N
is VBZ N
recommended VBN N
that IN N
alternative JJ N
pain NN N
relief NN N
be VB N
instituted VBN N
before IN N
it PRP N
is VBZ N
discontinued VBN N
. . N

-DOCSTART- -15587240- O O

Scent NN N
and CC N
mood NN N
state NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
water NN i
, , i
lavender NN i
, , i
or CC i
rosemary JJ i
scent NN i
on IN N
physiology NN o
and CC o
mood NN o
state NN o
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

The DT p
nonsmoking JJ p
participants NNS p
, , p
ages VBZ p
18-30 CD p
years NNS p
, , p
included VBD p
42 CD p
women NNS p
and CC p
31 CD p
men NNS p
who WP p
reported VBD p
demographic JJ p
information NN p
and CC p
measures NNS p
of IN p
external JJ p
temperature NN p
and CC p
heart NN p
rate NN p
were VBD p
taken VBN p
prior RB p
to TO p
introduction NN p
of IN p
an DT p
anxiety-eliciting JJ i
task NN i
and CC p
exposure NN p
to TO p
lavender VB i
, , i
rosemary JJ i
, , i
or CC i
water NN i
scents NNS i
. . i

Following VBG N
the DT N
task NN N
, , N
participants NNS N
completed VBD N
the DT N
Profile NNP N
of IN N
Mood NNP N
States NNPS N
to TO N
assess VB N
mood NN o
, , o
and CC o
temperature NN o
and CC o
heart NN o
rate NN o
were VBD N
reassessed VBN N
. . N

Participants NNS N
rated VBD N
the DT N
pleasantness NN N
of IN N
the DT N
scent NN N
received VBD N
. . N

When WRB N
pleasantness JJ N
ratings NNS N
of IN N
scent NN N
were VBD N
covaried VBN N
, , N
physiological JJ o
changes NNS o
in IN o
temperature NN o
and CC o
heart NN o
rate NN o
did VBD N
not RB N
differ VB N
based VBN N
on IN N
scent NN N
exposure NN N
, , N
but CC N
mood VBD o
ratings NNS o
differed VBN N
by IN N
scent JJ N
condition NN N
. . N

Participants NNS N
in IN N
the DT N
rosemary JJ N
condition NN N
scored VBD N
higher JJR N
on IN N
measures NNS N
of IN N
tension-anxiety NN o
and CC o
confusion-bewilderment JJ o
relative NN N
to TO N
the DT N
lavender NN N
and CC N
control NN N
conditions NNS N
. . N

The DT N
lavender NN N
and CC N
control NN N
conditions NNS N
showed VBD N
higher JJR N
mean JJ o
vigor-activity NN o
ratings NNS o
relative VBP N
to TO N
the DT N
rosemary JJ N
group NN N
, , N
while IN N
both DT N
rosemary JJ N
and CC N
lavender JJ N
scents NNS N
were VBD N
associated VBN N
with IN N
lower JJR N
mean NN o
ratings NNS o
on IN o
the DT o
fatigue-inertia JJ o
subscale NN o
, , N
relative JJ N
to TO N
the DT N
control NN N
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
, , N
when WRB N
individual JJ N
perception NN N
of IN N
scent JJ N
pleasantness NN N
is VBZ N
controlled VBN N
, , N
scent NN N
has VBZ N
the DT N
potential JJ N
to TO N
moderate VB N
different JJ N
aspects NNS N
of IN N
mood NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

-DOCSTART- -22821273- O O

Different JJ N
cardiac JJ N
biomarkers NNS N
to TO N
detect VB N
peri-procedural JJ N
myocardial JJ N
infarction NN N
in IN N
contemporary JJ p
coronary JJ p
stent NN p
trials NNS p
: : p
impact NN N
on IN N
outcome NN N
reporting NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
differential JJ N
implications NNS N
of IN N
cardiac JJ N
biomarker NN N
type NN N
on IN N
peri-procedural JJ N
myocardial JJ N
infarction NN N
( ( N
PMI NNP N
) ) N
reporting NN N
. . N

SETTING CC N
The DT p
Resolute NNP p
'All-Comers NNS p
' POS p
stent JJ p
trial NN p
. . p

INTERVENTIONS NNP N
Blood NNP N
samples NNS N
for IN N
creatine NN N
kinase NN N
( ( N
CK NNP N
) ) N
, , N
CK-myoband NNP N
( ( N
CK-MB NNP N
) ) N
mass NN N
or CC N
cardiac JJ N
troponin NN N
( ( N
cTn NN N
) ) N
( ( N
optional JJ N
) ) N
were VBD N
collected VBN N
before RB N
and CC N
at IN N
6 CD N
, , N
12 CD N
and CC N
18 CD N
h NN N
after IN p
the DT p
assigned JJ p
percutaneous JJ i
coronary JJ i
intervention NN i
or CC p
at IN p
discharge NN p
. . p

PMIs NNP N
were VBD N
adjudicated VBN N
using VBG N
either CC N
the DT N
2007 CD N
universal JJ N
definition NN N
of IN N
MI NNP N
( ( N
type-4a JJ N
) ) N
or CC N
the DT N
extended JJ N
historical JJ N
definition NN N
of IN N
MI NNP N
. . N

PATIENTS NNP N
2121/2292 CD p
patients NNS p
( ( p
92.5 CD p
% NN p
) ) p
had VBD p
an DT p
analysable JJ p
dataset NN p
for IN p
either DT p
biomarker NN p
. . p

890/2121 CD p
patients NNS p
( ( N
42 CD N
% NN N
) ) N
presented VBN N
with IN N
an DT N
acute JJ N
coronary JJ N
syndrome NN N
( ( N
ACS NNP N
) ) N
. . N

267/890 CD p
patients NNS p
( ( N
30 CD N
% NN N
) ) N
were VBD N
within IN N
24 CD N
h NN N
of IN N
an DT N
ST-segment JJ N
elevation NN N
MI NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Type-4a NNP o
MI NNP o
was VBD N
diagnosed VBN N
in IN N
208/2121 CD N
patients NNS N
( ( N
9.8 CD N
% NN N
) ) N
when WRB N
cTn NN N
was VBD N
used VBN N
( ( N
CK-MB JJ N
mass NN N
if IN N
cTn NN N
not RB N
available JJ N
) ) N
, , N
and CC N
in IN N
93/2121 CD N
of IN N
patients NNS N
( ( N
4.4 CD N
% NN N
) ) N
when WRB N
CK-MB JJ N
mass NN N
was VBD N
used VBN N
( ( N
cTn JJ N
if IN N
CK-MB NNP N
mass NN N
not RB N
available JJ N
) ) N
. . N

With IN N
the DT N
extended JJ N
historical JJ N
CK-based JJ N
definition NN N
of IN N
MI NNP N
, , N
PMI NNP o
was VBD N
diagnosed VBN N
in IN N
65/2121 CD N
patients NNS N
( ( N
3.1 CD N
% NN N
) ) N
. . N

Adjudication NN N
of IN N
type-4a JJ o
MI NNP o
in IN N
patients NNS N
with IN N
an DT N
ACS NNP N
was VBD N
problematic JJ N
with IN N
< JJ N
10 CD N
% NN N
of IN N
the DT N
potential JJ N
type-4a NN N
MI NNP N
being VBG N
confirmed VBN N
as IN N
an DT N
event NN N
, , N
as IN N
compared VBN N
with IN N
approximately RB N
95 CD N
% NN N
in IN N
stable JJ N
patients NNS N
undergoing VBG N
elective JJ N
PCI NNP N
. . N

Type-4a NNP N
MI NNP N
was VBD N
not RB N
associated VBN N
with IN N
the DT N
subsequent JJ N
hazard NN N
for IN N
cardiac JJ o
mortality NN o
( ( N
p=0.6 NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
percentage NN N
of IN N
adjudicated JJ N
PMI NNP o
events NNS o
is VBZ N
driven VBN N
by IN N
the DT N
MI-definition NNP N
criteria NNS N
and CC N
biomarker NN N
type NN N
. . N

Type-4a JJ N
MI NNP N
may MD N
not RB N
be VB N
a DT N
reliable JJ N
component NN N
of IN N
the DT N
primary JJ N
composite JJ N
end NN N
point NN N
in IN N
coronary JJ N
stent NN N
investigations NNS N
which WDT N
recruit VBP N
patients NNS N
with IN N
ACS NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
http NN N
: : N
//www.ClinicalTrials.gov NN N
; : N
Unique NNP N
identifier NN N
: : N
NCT00617084 NNP N
. . N

-DOCSTART- -6108264- O O

A DT N
double JJ N
blind JJ N
trial NN N
of IN N
terfenadine NN i
and CC N
placebo NN i
in IN N
hay NN N
fever NN N
using VBG N
a DT N
substitution NN N
technique NN N
for IN N
non-responders NNS N
. . N

A DT N
double-blind JJ N
study NN N
of IN N
terfenadine NN i
and CC N
placebo NN i
in IN N
110 CD p
patients NNS p
suffering VBG p
from IN p
hay NN p
fever NN p
( ( p
confirmed VBN p
by IN p
skin NN p
tests NNS p
) ) p
was VBD N
conducted VBN N
. . N

A DT N
novel JJ N
technique NN N
was VBD N
applied VBN N
using VBG N
an DT N
escape NN N
envelope NN N
containing VBG N
a DT N
reference NN i
drug NN i
which WDT N
could MD N
be VB N
taken VBN N
under IN N
controlled JJ N
conditions NNS N
if IN N
, , N
after IN N
48 CD N
hours NNS N
, , N
the DT N
patient NN N
experienced VBD N
no DT N
relief NN o
. . o

Significantly RB N
more JJR N
patients NNS N
on IN N
placebo NN i
opened VBD o
the DT o
envelope NN o
than IN N
patients NNS N
taking VBG N
the DT N
active JJ N
drug NN N
. . N

Terfenadine NNP i
was VBD N
demonstrated VBN N
to TO N
be VB N
an DT N
effective JJ o
drug NN o
in IN N
hay NN N
fever NN N
and CC N
produced VBD N
no DT N
more RBR N
drowsiness NN o
than IN N
placebo NN N
. . N

-DOCSTART- -22752489- O O

Effectiveness NN N
and CC N
safety NN N
of IN N
donepezil NN i
in IN N
boys NNS p
with IN p
fragile JJ p
x JJ p
syndrome NN p
: : p
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
controlled VBN N
pilot NN N
study NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
pilot NN N
study NN N
to TO N
evaluate VB N
the DT N
effectiveness NN o
and CC o
safety NN o
of IN N
donepezil NN i
in IN N
boys NNS p
with IN p
fragile JJ p
X NNP p
syndrome NN p
. . p

Twenty NNP p
boys VBZ p
with IN p
fragile JJ p
X NNP p
syndrome NN p
were VBD N
randomized VBN N
to TO N
receive VB N
12 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
either DT N
placebo NN i
or CC i
donepezil NN i
( ( N
2.5 CD N
mg NNS N
daily RB N
for IN N
initial JJ N
4 CD N
weeks NNS N
followed VBN N
by IN N
5 CD N
mg NNS N
daily RB N
for IN N
next JJ N
8 CD N
weeks NNS N
) ) N
. . N

The DT N
outcome NN N
measures NNS N
included VBD N
change NN o
in IN o
intelligence NN o
quotient NN o
scores NNS o
on IN o
Stanford-Binet NNP o
Intelligence NNP o
Scale NNP o
( ( o
Hindi NNP o
adaptation NN o
by IN o
Kulshrestha NNP o
) ) o
, , o
change NN o
in IN o
behavioral JJ o
scores NNS o
by IN o
Conners NNS o
3 CD o
Parent NN o
Rating VBG o
Scale NNP o
( ( o
Short NNP o
) ) o
and CC o
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
, , o
safety NN o
, , o
and CC o
tolerability NN o
of IN o
donepezil NN o
. . o

The DT N
study NN N
failed VBD N
to TO N
show VB N
significant JJ N
difference NN N
in IN N
intelligence NN o
quotient NN o
and CC N
behavioral JJ o
scales NNS o
with IN N
donepezil JJ i
therapy NN N
over IN N
12 CD N
weeks NNS N
. . N

However RB N
, , N
donepezil RB i
appeared VBD N
to TO N
be VB N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -11816482- O O

[ JJ N
Intravesical NNP N
instillation NN N
of IN N
doxorubicin NN i
or CC N
epirubicin NN i
for IN N
chemoprophylaxis NN N
of IN N
superficial JJ N
bladder NN N
cancer NN N
-- : N
the DT N
fifth JJ N
study NN N
of IN N
the DT N
Japanese JJ N
Urological JJ N
Cancer NNP N
Research NNP N
Group NNP N
for IN N
Adriamycin/Farumorubicin NNP N
] NNP N
. . N

A NNP p
total NN p
of IN p
465 CD p
patients NNS p
with IN p
primary JJ p
and CC p
multiple JJ p
or CC p
recurrent NN p
, , p
stages VBZ p
Ta NNP p
and CC p
T1 NNP p
superficial JJ p
bladder NN p
cancer NN p
were VBD N
included VBN N
in IN N
this DT N
randomized JJ N
multicenter NN N
trial NN N
to TO N
compare VB N
the DT N
prophylactic JJ N
effect NN N
by IN N
17 CD N
times NNS N
instillation NN N
of IN N
40 CD i
mg NNS i
doxorubicin VBD i
or CC i
40 CD i
mg NNS i
epirubicin VBP i
with IN i
no DT i
instillation NN i
after IN i
transurethral JJ i
resection NN i
of IN i
tumor NN i
( ( i
s NN i
) ) i
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
first JJ o
recurrence NN o
after IN N
transurethral JJ N
resection NN N
. . N

Endoscopic NNP o
examination NN o
as RB N
well RB N
as IN N
urinary JJ o
cytology NN o
was VBD N
performed VBN N
in IN N
each DT N
case NN N
every DT N
three CD N
months NNS N
. . N

It PRP N
became VBD N
evident JJ N
that IN N
the DT N
recurrence NN o
rate NN o
in IN N
the DT N
doxorubicin NN i
or CC N
epirubicin JJ i
instillation NN N
arm NN N
was VBD N
lower JJR N
that IN N
in IN N
the DT N
no DT N
instillation NN N
arm NN N
. . N

Toxicity NN o
was VBD N
mainly RB N
restricted VBN N
to TO N
bladder VB o
irritation NN o
in IN N
about RB N
10 CD N
% NN N
of IN N
patients NNS N
in IN N
each DT N
instillation NN N
arm NN N
. . N

-DOCSTART- -23102530- O O

End-expiratory JJ p
lung NN p
volume NN p
recovers NNS N
more RBR N
slowly RB N
after IN N
closed JJ i
endotracheal NN o
suctioning VBG i
than IN N
after IN N
open JJ i
suctioning NN i
: : i
a DT N
randomized VBN N
crossover NN N
study NN N
. . N

PURPOSE NNP N
Endotracheal NNP N
suctioning VBG N
causes NNS N
significant JJ N
lung JJ N
derecruitment NN N
. . N

Closed VBN i
suction NN o
( ( i
CS NNP i
) ) i
minimizes VBZ N
lung JJ N
volume NN N
loss NN N
during IN N
suction NN N
, , N
and CC N
therefore RB N
, , N
volumes NNS N
are VBP N
presumed VBN N
to TO N
recover VB N
more RBR N
quickly RB N
postsuctioning VBG N
. . N

Conflicting VBG N
evidence NN N
exists VBZ N
regarding VBG N
this DT N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
open JJ i
suction NN i
( ( i
OS NNP i
) ) i
and CC i
CS NNP i
on IN N
lung NN o
volume NN o
loss NN N
during IN N
suctioning NN o
, , N
and CC N
recovery NN N
of IN N
end-expiratory JJ o
lung NN o
volume NN o
( ( o
EELV NNP o
) ) o
up RB N
to TO N
30 CD N
minutes NNS N
postsuction NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Randomized NNP N
crossover NN N
study NN N
examining VBG N
20 CD p
patients NNS p
postcardiac JJ o
surgery NN p
. . p

CS NNP o
and CC N
OS NNP o
were VBD N
performed VBN N
in IN N
random JJ N
order NN N
, , N
30 CD N
minutes NNS N
apart RB N
. . N

Lung NNP o
impedance NN o
was VBD N
measured VBN N
during IN N
suction NN N
, , N
and CC N
end-expiratory JJ N
lung NN N
impedance NN N
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
postsuctioning VBG N
using VBG N
electrical JJ N
impedance NN N
tomography NN N
. . N

Oximetry NNP o
, , o
partial JJ o
pressure NN o
of IN o
oxygen NN o
in IN o
the DT o
alveoli/fraction NN o
of IN o
inspired JJ o
oxygen NN o
ratio NN o
and CC o
compliance NN o
were VBD N
collected VBN N
. . N

RESULTS JJ N
Reductions NNPS N
in IN N
lung NN N
impedance NN o
during IN N
suctioning VBG N
were VBD N
less JJR N
for IN N
CS NNP i
than IN N
for IN N
OS NNP i
( ( N
mean JJ N
difference NN N
, , N
-905 JJ N
impedance NN N
units NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
-1234 NNP N
to TO N
-587 VB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

However RB N
, , N
at IN N
all DT N
points NNS N
postsuctioning VBG N
, , N
EELV NNP o
recovered VBD N
more RBR N
slowly RB N
after IN N
CS NNP i
than IN N
after IN N
OS NNP i
. . i

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
other JJ N
respiratory NN N
parameters NNS N
. . N

CONCLUSIONS NNP N
Closed VBD i
suctioning VBG i
minimized VBN N
lung NN N
volume NN N
loss NN N
during IN N
suctioning VBG N
but CC N
, , N
counterintuitively RB N
, , N
resulted VBD N
in IN N
slower JJR N
recovery NN N
of IN N
EELV NNP N
postsuction NN N
compared VBN N
with IN N
OS NNP i
. . i

Therefore NNP N
, , N
the DT N
use NN N
of IN N
CS NNP i
can MD N
not RB N
be VB N
assumed VBN N
to TO N
be VB N
protective JJ N
of IN N
lung NN N
volumes NNS N
postsuctioning VBG o
. . o

Consideration NN N
should MD N
be VB N
given VBN N
to TO N
restoring VBG N
EELV NNP N
after IN N
either DT N
suction NN N
method NN N
via IN N
a DT N
recruitment JJ N
maneuver NN N
. . N

-DOCSTART- -1440804- O O

The DT N
relationship NN N
between IN N
the DT N
response NN N
of IN N
Plasmodium NNP p
falciparum NN p
malaria NN p
to TO p
mefloquine VB i
in IN p
African JJ p
children NNS p
and CC N
its PRP$ N
sensitivity NN N
in IN N
vitro NN N
. . N

The DT N
clinical JJ N
efficacy NN N
of IN N
two CD N
doses NNS N
of IN N
mefloquine NN i
( ( N
15 CD N
and CC N
25 CD N
mg/kg NN N
body NN N
weight VBD N
) ) N
was VBD N
evaluated VBN N
in IN N
85 CD p
children NNS p
suffering VBG p
from IN p
acute JJ p
symptomatic JJ p
falciparum NN p
malaria NN p
. . p

The DT N
cure NN o
rate NN o
on IN N
day NN N
28 CD N
was VBD N
100 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
in IN N
the DT N
mean JJ o
parasite NN o
and CC o
fever NN o
clearance NN o
times NNS o
in IN N
both DT N
groups NNS N
( ( N
48.5 CD N
+/- JJ N
14.6 CD N
and CC N
32.0 CD N
+/- JJ N
12.7 CD N
h NN N
respectively RB N
for IN N
the DT N
25 CD N
mg/kg NN N
group NN N
and CC N
49.0 CD N
+/- JJ N
15.1 CD N
and CC N
30.0 CD N
+/- JJ N
13.3 CD N
h NN N
respectively RB N
for IN N
the DT N
15 CD N
mg/kg NNS N
group NN N
) ) N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
in IN N
these DT N
values NNS N
between IN N
children NNS p
with IN p
hyperparasitaemia NN p
( ( N
53.6 CD N
+/- JJ N
11.1 CD N
and CC N
36.0 CD N
+/- JJ N
17.0 CD N
h NN N
respectively RB N
) ) N
and CC N
those DT p
without IN p
hyperparasitaemia NN p
( ( N
49.1 CD N
+/- JJ N
13.6 CD N
and CC N
31.8 CD N
+/- JJ N
14.6 CD N
h NN N
respectively RB N
) ) N
. . N

Recurrence NN o
of IN o
parasitaemia NN o
was VBD N
observed VBN N
after IN N
day NN N
30 CD N
in IN N
2 CD N
patients NNS N
in IN N
the DT N
15 CD N
mg/kg NN N
group NN N
and CC N
in IN N
1 CD N
patient NN N
in IN N
the DT N
25 CD N
mg/kg NN N
group NN N
. . N

In IN N
vitro NN N
, , N
3 CD N
of IN N
21 CD N
isolates NNS N
showed VBD N
reduced JJ N
susceptibility NN o
to TO o
mefloquine VB o
, , N
with IN N
minimum JJ N
inhibitory JJ o
concentrations NNS o
( ( N
MIC NNP N
) ) N
> VBD N
67 CD N
nM/litre NN N
. . N

The DT N
MIC NNP N
and CC N
50 CD N
% NN N
, , N
90 CD N
% NN N
and CC N
99 CD N
% NN N
inhibitory JJ o
concentrations NNS o
were VBD N
200.8 CD N
, , N
6.27 CD N
, , N
31.7 CD N
and CC N
119.6 CD N
nM/litre NNS N
respectively RB N
. . N

Four CD N
of IN N
22 CD N
isolates NNS N
were VBD N
resistant JJ o
to TO N
chloroquine VB i
( ( N
MIC NNP N
> NNP N
108 CD N
nM/litre NN N
) ) N
. . N

Isolates VBZ N
that IN N
showed VBD N
low JJ N
sensitivity NN o
to TO N
mefloquine VB i
in IN N
vitro NN N
were VBD N
sensitive JJ o
to TO N
chloroquine VB N
in IN N
vitro NN N
, , N
and CC N
the DT N
4 CD N
that WDT N
were VBD N
resistant JJ o
to TO N
chloroquine VB N
were VBD N
sensitive JJ o
to TO N
mefloquine VB N
. . N

Irrespective NNP N
of IN N
MIC NNP N
and CC N
dose NN N
of IN N
mefloquine NN N
, , N
parasitaemia NN N
cleared VBN N
in IN N
all DT N
subjects NNS N
in IN N
96 CD N
h NN N
or CC N
less JJR N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -22608375- O O

Healthcare NN N
costs NNS N
around IN N
the DT N
time NN N
of IN N
smoking VBG N
cessation NN N
. . N

BACKGROUND IN N
The DT N
Affordable NNP N
Care NNP N
Act NNP N
mandates VBZ N
that IN N
new JJ N
insurance NN N
plans NNS N
cover VBP N
smoking-cessation NN i
therapy NN i
without IN N
cost-sharing NN N
. . N

Previous JJ N
cost NN N
difference NN N
estimates NNS N
, , N
which WDT N
show VBP N
a DT N
spike NN N
around IN N
the DT N
time NN N
of IN N
cessation NN N
, , N
suggest VBP N
premiums NNS N
might MD N
rise VB N
as IN N
a DT N
result NN N
of IN N
covering VBG N
these DT N
services NNS N
. . N

PURPOSE VB N
The DT N
goal NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
test VB N
( ( N
1 CD N
) ) N
whether IN N
individuals NNS p
in IN p
an DT p
RCT NNP p
of IN p
pharmacotherapy NN i
and CC p
counseling VBG i
for IN p
smoking VBG p
cessation NN p
differed VBN N
in IN N
their PRP$ N
healthcare NN N
costs VBZ N
around IN N
the DT N
cessation NN N
period NN N
, , N
and CC N
( ( N
2 CD N
) ) N
whether IN N
the DT N
healthcare NN N
costs NNS N
of IN N
those DT N
in IN N
the DT N
trial NN N
who WP N
successfully RB N
quit VBP N
were VBD N
different JJ N
from IN N
a DT N
matched JJ N
sample NN N
of IN N
smokers NNS N
in IN N
the DT N
community NN N
. . N

METHODS NNP N
Generalized NNP i
linear JJ i
regression NN i
models NNS i
were VBD i
used VBN i
to TO i
analyze VB i
healthcare NN o
cost NN o
data NNS o
on IN i
individuals NNS i
enrolled VBN i
in IN i
a DT i
comparative JJ i
effectiveness NN i
trial NN i
of IN i
cessation NN i
therapies NNS i
between IN p
October NNP p
2005 CD p
and CC p
May NNP p
2007 CD p
( ( p
1346 CD p
total NN p
participants NNS p
; : p
1338 CD p
with IN p
requisite JJ p
data NNS p
for IN p
further JJ p
analysis NN p
) ) p
. . p

Cost NN o
differences NNS o
for IN N
the DT N
period NN N
preceding NN N
and CC N
subsequent JJ N
to TO N
the DT N
cessation NN N
attempt NN N
were VBD N
assessed VBN N
by IN N
trial NN N
participants NNS N
' POS N
12-month JJ N
sustained VBD N
quit NN N
status NN N
. . N

Healthcare NNP o
cost NN o
differences NNS o
between IN N
sustained VBN N
quitters NNS N
and CC N
a DT N
sample NN N
of IN N
community-dwelling JJ N
smokers NNS N
, , N
matched VBD N
to TO N
these DT N
quitters NNS N
on IN N
the DT N
basis NN N
of IN N
health NN N
services NNS N
use VBP N
around IN N
the DT N
time NN N
trial NN N
participant NN N
enrolled VBN N
and CC N
by IN N
demographics NNS N
, , N
were VBD N
also RB N
examined VBN N
. . N

Data NNS N
were VBD N
analyzed VBN N
in IN N
2011 CD N
. . N

RESULTS VB N
All DT N
three CD N
groups NNS N
had VBD N
a DT N
spike NN N
in IN N
cost NN N
associated VBN N
with IN N
the DT N
index NN N
clinic JJ N
visit NN N
. . N

Regression NNP N
results NNS N
revealed VBD N
little JJ N
difference NN N
in IN N
healthcare NN o
costs NNS o
by IN N
quit NN N
status NN N
for IN N
trial NN N
participants NNS N
until IN N
the DT N
sixth JJ N
quarter NN N
post-quit NN N
. . N

By IN N
that DT N
quarter NN N
, , N
continuous JJ N
sustained VBD N
quitters NNS N
cost VBD o
$ $ N
541 CD N
( ( N
p NN N
< RB N
0.001 CD N
) ) N
less JJR N
than IN N
continuing VBG N
smokers NNS N
. . N

Continuous JJ N
sustained VBD N
quitters NNS N
cost NN o
less JJR N
than IN N
their PRP$ N
matched JJ N
community- JJ N
dwelling VBG N
smokers NNS N
in IN N
almost RB N
every DT N
quarter NN N
observed VBN N
. . N

The DT N
cost NN N
difference NN N
ranged VBD N
from IN N
$ $ N
270 CD N
( ( N
p=0.01 NN N
) ) N
during IN N
the DT N
quarter NN N
of IN N
quit NN N
, , N
to TO N
$ $ N
490 CD N
( ( N
p NN N
< RB N
0.01 CD N
) ) N
in IN N
the DT N
6th CD N
quarter NN N
after IN N
quitting VBG N
. . N

CONCLUSIONS VB N
The DT N
inclusion NN N
of IN N
smoking-cessation JJ i
therapy NN i
does VBZ N
not RB N
appear VB N
to TO N
raise VB N
short-term JJ o
healthcare NN o
costs NNS o
. . o

By IN N
the DT N
sixth JJ N
quarter NN N
post-quit NN N
, , N
sustained VBN N
quitters NNS N
were VBD N
less RBR N
costly JJ N
than IN N
trial NN N
participants NNS N
who WP N
continued VBD N
smoking NN N
. . N

-DOCSTART- -24402830- O O

A DT N
phase NN N
II NNP N
, , N
randomized VBD N
, , N
multicenter NN N
study NN N
evaluating VBG N
the DT N
combination NN N
of IN N
lapatinib NN N
and CC N
vinorelbine NN N
in IN N
women NNS p
with IN p
ErbB2 NNP p
overexpressing VBG p
metastatic JJ p
breast NN p
cancer NN p
. . p

Lapatinib NNP N
is VBZ N
approved VBN N
in IN N
combination NN N
with IN N
capecitabine NN N
for IN N
treatment NN N
of IN N
patients NNS p
with IN p
human JJ p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
2 CD p
( ( p
HER2 NNP p
) ) p
-positive VBP p
metastatic JJ p
breast NN p
cancer NN p
( ( p
MBC NNP p
) ) p
who WP N
have VBP N
progressed VBN N
on IN N
prior JJ N
trastuzumab NN N
in IN N
the DT N
metastatic JJ N
setting NN N
. . N

Vinorelbine NNP N
is VBZ N
an DT N
important JJ N
chemotherapy NN N
option NN N
for IN N
MBC NNP N
. . N

We PRP N
evaluated VBD N
efficacy NN N
and CC N
safety NN N
of IN N
lapatinib JJ N
plus CC N
vinorelbine JJ N
, , N
compared VBN N
with IN N
lapatinib JJ N
plus CC N
capecitabine JJ N
, , N
in IN N
women NNS p
with IN p
HER2-positive JJ p
MBC NNP p
. . p

In IN p
this DT p
open-label JJ p
, , p
multicenter NN p
, , p
phase NN p
II NNP p
study NN p
, , p
eligible JJ p
patients NNS p
( ( p
N NNP p
= NNP p
112 CD p
) ) p
were VBD N
randomized VBN N
2:1 CD N
to TO N
lapatinib VB i
plus JJ i
vinorelbine NN i
[ NNP i
( ( i
N NNP i
= NNP i
75 CD i
) ) i
1,250 CD i
mg NN i
orally RB i
once RB i
daily JJ i
( ( i
QD NNP i
) ) i
continuously RB i
plus CC i
20 CD i
mg/m NN i
( ( i
2 CD i
) ) i
/day NN i
intravenously RB i
] VBZ i
or CC i
lapatinib JJ i
plus CC i
capecitabine JJ i
[ NNP i
( ( i
N NNP i
= NNP i
37 CD i
) ) i
1,250 CD i
mg NN i
orally RB i
QD NNP i
continuously RB i
plus CC i
2,000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
/day NN i
orally RB i
, , i
2 CD i
doses NNS i
] RB i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

Other JJ N
endpoints NNS N
included VBD N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
and CC o
safety NN o
. . o

Patients NNS N
progressing VBG N
within IN N
the DT N
study NN N
were VBD N
given VBN N
the DT N
option NN N
of IN N
crossover NN N
to TO N
the DT N
other JJ N
treatment NN N
arm NN N
; : N
time NN N
to TO N
second JJ N
progression NN N
was VBD N
an DT N
exploratory JJ N
endpoint NN N
. . N

Patient JJ o
demographics NNS o
, , o
stratification NN o
, , o
and CC o
prognostic JJ o
factors NNS o
were VBD N
well RB N
balanced VBN N
between IN N
treatments NNS N
. . N

Median JJ o
PFS NNP o
in IN N
both DT N
arms NNS N
was VBD N
6.2 CD N
months NNS N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
4.2 CD N
, , N
8.8 CD N
( ( N
lapatinib JJ N
plus CC N
vinorelbine JJ N
) ) N
; : N
4.4 CD N
, , N
8.3 CD N
( ( N
lapatinib JJ N
plus CC N
capecitabine NN N
) ) N
] NN N
. . N

Median JJ o
OS NNP o
on IN N
lapatinib JJ N
plus CC N
vinorelbine NN N
was VBD N
24.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
16.4 CD N
, , N
NE NNP N
) ) N
and CC N
19.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
16.4 CD N
, , N
27.2 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
capecitabine NN N
. . N

In IN N
total JJ N
, , N
42 CD N
patients NNS N
opted VBN N
to TO N
cross VB N
over RP N
; : N
median JJ N
PFS NNP N
was VBD N
3.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
1.7 CD N
, , N
5.1 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
vinorelbine NN N
and CC N
4.0 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
2.1 CD N
, , N
5.8 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
capecitabine NN N
. . N

Lapatinib NNP N
plus CC N
vinorelbine NN N
offers NNS N
an DT N
effective JJ N
treatment NN N
option NN N
for IN N
patients NNS p
with IN p
HER2-overexpressing NNP p
MBC NNP p
, , N
having VBG N
displayed VBN N
comparable JJ N
efficacy NN N
and CC N
tolerability NN N
rates NNS N
to TO N
lapatinib VB N
plus JJ N
capecitabine NN N
. . N

-DOCSTART- -15025886- O O

Strength NN N
of IN N
vital JJ N
force NN N
in IN N
classical JJ N
homeopathy NN N
: : N
bio-psycho-social-spiritual JJ N
correlates NNS N
within IN N
a DT N
complex JJ N
systems NNS N
context NN N
. . N

OBJECTIVE UH N
To TO N
explore VB N
associations NNS N
between IN N
a DT N
global JJ N
rating NN N
for IN N
the DT N
classical JJ N
homeopathic JJ N
construct NN N
of IN N
vital JJ N
force NN N
and CC N
clinician JJ N
and CC N
patient JJ N
ratings NNS N
on IN N
previously RB N
validated VBN N
bio-psycho-social-spiritual JJ N
questionnaires NNS N
. . N

METHODS NNP N
Sixty-two NNP p
( ( p
62 CD p
) ) p
community-recruited JJ p
patients NNS p
with IN p
fibromyalgia NN p
( ( p
FM NNP p
) ) p
were VBD N
assessed VBN N
at IN N
baseline NN N
prior RB N
to TO N
a DT N
clinical JJ N
trial NN N
of IN N
individualized JJ N
homeopathy NN N
. . N

Two CD p
homeopaths NNS p
jointly RB p
performed VBD p
case-taking JJ i
interviews NNS i
. . i

A DT p
conventional JJ p
medical JJ p
provider NN p
independently RB p
evaluated VBD p
patients NNS p
with IN p
a DT p
standardized JJ p
history NN p
and CC p
physical JJ p
examination NN p
. . p

Homeopaths NNP N
rated VBD N
each DT N
patient NN N
's POS N
vital JJ N
force NN N
( ( N
five-point JJ N
Likert NNP N
scale NN N
, , N
with IN N
1 CD N
= JJ N
very RB N
weak JJ N
to TO N
5 CD N
= NNS N
very RB N
strong JJ N
) ) N
. . N

Homeopaths NNP N
and CC N
the DT N
conventional JJ N
medical JJ N
provider NN N
rated VBN N
their PRP$ N
Clinical JJ o
Global NNP o
Impression NNP o
( ( o
CGI NNP o
) ) o
of IN o
the DT o
severity NN o
of IN o
illness NN o
( ( N
1 CD N
= NNP N
normal JJ N
; : N
7 CD N
= NN N
among IN N
the DT N
most RBS N
extremely RB N
ill JJ N
) ) N
. . N

Patients NNS N
completed VBD N
self-rating JJ o
scales NNS o
on IN o
pain NN o
, , o
global JJ o
health NN o
, , o
mood NN o
, , o
quality NN o
of IN o
life NN o
, , o
coping VBG o
style NN o
, , o
health NN o
locus NN o
of IN o
control NN o
, , o
multidimensional JJ o
well-being NN o
, , o
spirituality NN o
, , o
sense NN o
of IN o
coherence NN o
, , o
positive JJ o
states NNS o
of IN o
mind NN o
, , o
and CC o
social JJ o
desirability NN o
. . o

RESULTS NNP N
Greater NNP N
vital JJ o
force NN o
ratings NNS o
( ( N
mean VB N
2.9 CD N
standard JJ N
deviation NN N
[ NNP N
SD NNP N
] NNP N
0.6 CD N
) ) N
correlated VBN N
moderately RB N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.005 CD N
) ) N
with IN N
less JJR N
severe JJ N
CGI NNP o
illness NN o
ratings NNS N
by IN N
the DT N
homeopaths NNS N
( ( N
r VB N
=-0.59 NN N
) ) N
, , N
decreased VBD N
patient-rated JJ o
mental JJ o
confusion NN o
( ( N
r VB N
=-0.43 NN N
) ) N
, , N
higher JJR N
vigor NN o
( ( N
r JJ N
= NNP N
0.38 CD N
) ) N
, , N
and CC N
greater JJR N
positive JJ o
states NNS o
of IN o
mind NN o
( ( N
r JJ N
= NNP N
0.36 CD N
) ) N
. . N

Vital NNP N
force NN N
also RB N
showed VBD N
correlations NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
lower JJR N
CGI NNP o
ratings NNS o
by IN N
the DT N
conventional JJ N
medical JJ N
provider NN N
( ( N
r VB N
=-0.32 NN N
) ) N
, , N
better RB N
selfrated VBN N
quality NN o
of IN o
life NN o
( ( N
r JJ N
= NNP N
0.33 CD N
) ) N
, , N
lesser JJR N
fatigue NN o
( ( N
r VB N
=-0.31 NN N
) ) N
, , N
better JJR o
global JJ o
health NN o
( ( N
r VB N
= RB N
0.29 CD N
) ) N
, , N
greater JJR o
sense NN o
of IN o
coherence NN o
( ( N
r JJ N
= NNP N
0.28 CD N
) ) N
, , N
powerful-others JJ o
health NN o
locus NN o
of IN o
control NN o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
increased VBD o
emotional JJ o
well-being NN o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
and CC N
higher JJR o
social JJ o
desirability NN o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
but CC N
not RB N
with IN N
age NN N
, , N
pain NN N
, , N
or CC N
illness JJ N
duration NN N
. . N

CONCLUSION NNP N
Homeopathic NNP N
vital JJ N
force NN N
ratings NNS N
reflect VBP N
better JJR N
perceived VBN N
mental JJ N
function NN N
, , N
energy NN N
, , N
and CC N
positive JJ N
dimensions NNS N
of IN N
the DT N
individual NN N
, , N
beyond IN N
absence NN N
of IN N
disease NN N
. . N

-DOCSTART- -3739807- O O

Abstinence NN i
or CC i
controlled VBN i
drinking NN i
in IN N
clinical JJ N
practice NN N
: : N
indications NNS N
at IN N
initial JJ N
assessment NN N
. . N

Previous JJ N
research NN N
has VBZ N
suggested VBN N
two CD N
leading JJ N
hypotheses NNS N
concerning VBG N
which WDT N
excessive JJ p
drinkers NNS p
can MD N
re-establish VB N
control NN N
: : N
one CD N
based VBN N
upon IN N
level NN N
of IN N
dependence NN N
, , N
the DT N
other JJ N
upon IN N
the DT N
client NN N
's POS N
personal JJ N
persuasion NN N
. . N

Using VBG N
initial JJ N
assessment NN N
data NNS N
from IN N
46 CD p
clients NNS p
of IN p
a DT p
clinical JJ p
psychology NN p
alcohol NN p
problems NNS p
service NN p
( ( p
30 CD p
men NNS p
, , p
16 CD p
women NNS p
) ) p
, , N
an DT N
attempt NN N
was VBD N
made VBN N
to TO N
operationalize VB N
the DT N
concepts NNS N
of IN N
dependence NN i
and CC N
personal JJ i
persuasion NN i
using VBG N
a DT N
variety NN N
of IN N
indicators NNS N
of IN N
each DT N
. . N

Although IN N
SADQ NNP o
scores NNS o
and CC o
Rand NNP o
definite VBP o
alcoholism NN o
were VBD N
in IN N
general JJ N
agreement NN N
, , N
there EX N
were VBD N
a DT N
number NN N
of IN N
borderline JJ N
instances NNS N
and CC N
cases NNS N
of IN N
disagreement NN N
, , N
and CC N
neither DT N
was VBD N
in IN N
good JJ N
agreement NN N
with IN N
estimates NNS N
of IN N
problem NN N
duration NN N
, , N
nor CC N
with IN N
reports NNS N
of IN N
recent JJ N
or CC N
earlier RBR N
attainment NN N
of IN N
abstinence NN i
or CC N
control NN i
. . i

Indicators NNS N
of IN N
personal JJ o
persuasion NN o
were VBD N
more RBR N
consistent JJ N
. . N

Those DT p
with IN p
dependence NN i
indicators NNS o
for IN o
abstinence NN o
tended VBD N
to TO N
prefer VB N
abstinence NN i
as IN N
a DT N
goal NN N
, , N
but CC N
there EX N
were VBD N
many JJ N
departures NNS N
from IN N
this DT N
pattern NN N
particularly RB N
for IN N
women NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
in IN N
clinical JJ N
practice NN N
it PRP N
will MD N
be VB N
very RB N
difficult JJ N
to TO N
make VB N
a DT N
clear JJ N
cut NN N
recommendation NN N
about IN N
treatment NN N
goal NN N
at IN N
initial JJ N
assessment NN N
except IN N
in IN N
a DT N
few JJ N
cases NNS N
. . N

-DOCSTART- -18157013- O O

Minimally RB N
invasive JJ N
treatment NN N
combined VBN N
with IN N
cytokine-induced JJ i
killer NN i
cells NNS i
therapy VBP i
lower JJR N
the DT N
short-term JJ N
recurrence NN N
rates NNS N
of IN N
hepatocellular JJ p
carcinomas NN p
. . p

The DT N
recurrence NN N
of IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
after IN N
minimally RB N
invasive JJ N
therapy NN N
is VBZ N
frequent JJ N
. . N

Adoptive JJ i
immunotherapy NN i
is VBZ N
thought VBN N
to TO N
be VB N
an DT N
effective JJ N
method NN N
to TO N
lower JJR N
recurrence NN N
and CC N
metastasis NN N
rates NNS N
of IN N
malignant JJ N
tumors NNS N
. . N

Therefore RB N
, , N
85 CD p
HCC NNP p
patients NNS p
after IN p
transcatheter JJ i
arterial JJ i
chemoembolization NN i
and CC p
radiofrequency NN i
ablation NN i
therapy NN i
were VBD p
randomized VBN p
to TO p
immunotherapy VB i
group NN p
and CC p
no DT i
adjuvant JJ i
therapy NN i
group NN p
. . p

Autologous JJ i
cytokine-induced JJ i
killer NN i
( ( i
CIK NNP i
) ) i
cells NNS i
were VBD i
transfused VBN i
via IN N
hepatic JJ N
artery NN N
to TO N
the DT N
patients NNS N
. . N

The DT N
alteration NN N
of IN N
levels NNS N
of IN N
lymphocyte JJ N
subsets NNS N
in IN N
peripheral JJ N
blood NN N
of IN N
patients NNS N
was VBD N
examined VBN N
by IN N
flow JJ N
cytometry NN N
. . N

All DT p
patients NNS p
were VBD p
screened VBN p
by IN p
computed JJ p
tomography NN p
every DT p
2 CD p
months NNS p
to TO p
observe VB p
the DT p
tumor NN p
recurrent NN p
conditions NNS p
. . p

After IN N
CIK NNP i
cell NN i
infusions NNS N
, , N
the DT N
percentages NNS o
of IN o
CD3+ NNP o
, , o
CD4+ NNP o
, , o
CD56+ NNP o
, , o
CD3+CD56+ NNP o
cells NNS o
, , o
and CC o
CD4+/CD8+ NNP o
ratio VBP o
increased VBN N
from IN N
68.6+/-11.0 CD N
% NN N
, , N
31.1+/-9.0 CD N
% NN N
, , N
15.6+/-7.9 CD N
% NN N
, , N
5.2+/-3.1 CD N
% NN N
, , N
and CC N
1.1+/-0.5 JJ N
to TO N
70.7+/-10.1 CD N
% NN N
, , N
33.5+/-8.0 CD N
% NN N
, , N
18.4+/-9.4 CD N
% NN N
, , N
5.9+/-2.8 CD N
% NN N
, , N
and CC N
1.3+/-0.7 JJ N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
whereas IN N
the DT N
percentage NN o
of IN o
CD8 NNP o
cells NNS o
decreased VBN N
from IN N
31.1+/-7.8 CD N
% NN N
to TO N
28.6+/-8.3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
1-year JJ o
and CC o
18-month JJ o
recurrence NN o
rates NNS o
of IN o
the DT o
study NN o
group NN o
were VBD N
8.9 CD N
% NN N
and CC N
15.6 CD N
% NN N
, , N
compared VBN N
with IN N
30.0 CD N
% NN N
and CC N
40.0 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
both DT N
P NNP N
value NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
data NN N
suggest NN N
that IN N
CIK NNP i
cell NN i
transfusion NN i
is VBZ N
an DT N
effective JJ N
treatment NN N
. . N

It PRP N
can MD N
boost VB N
the DT N
immunologic JJ N
function NN N
in IN N
HCC NNP p
patients NNS p
and CC N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
reducing VBG N
the DT N
recurrence NN N
rate NN N
of IN N
HCC NNP N
. . N

-DOCSTART- -8127293- O O

National NNP N
Surgical NNP N
Adjuvant NNP N
Breast NNP N
and CC N
Bowel NNP N
Project NNP N
's POS N
Breast NNP N
Cancer NNP N
Prevention NNP N
Trial NNP N
. . N

The DT N
Breast NNP N
Cancer NNP N
Prevention NNP N
Trial NNP N
is VBZ N
the DT N
largest JJS N
breast NN N
cancer NN N
prevention NN N
study NN N
ever RB N
undertaken RB N
. . N

Administered VBN N
by IN N
the DT N
National NNP N
Surgical NNP N
Adjuvant NNP N
Breast NNP N
and CC N
Bowel NNP N
Project NNP N
, , N
it PRP N
is VBZ N
the DT N
first JJ N
trial NN N
seeking VBG N
to TO N
demonstrate VB N
whether IN N
a DT N
drug NN N
, , N
tamoxifen NN i
, , N
can MD N
prevent VB p
breast NN p
cancer NN p
in IN p
high-risk JJ p
women NNS p
. . p

The DT N
objectives NNS N
of IN N
this DT N
trial NN N
are VBP N
to TO N
determine VB N
whether IN N
tamoxifen NN i
is VBZ N
effective JJ N
in IN N
1 CD N
) ) N
reducing VBG o
the DT o
incidence NN o
of IN o
invasive JJ o
breast NN o
cancer NN o
, , o
2 CD o
) ) o
reducing VBG o
breast NN o
cancer NN o
mortality NN o
, , o
3 CD o
) ) o
reducing VBG o
deaths NNS o
from IN o
cardiovascular JJ o
disease NN o
, , o
and CC o
4 CD o
) ) o
reducing VBG o
bone NN o
fractures NNS o
. . o

In IN N
addition NN N
, , N
the DT N
study NN N
will MD N
evaluate VB N
side NN o
effects NNS o
, , o
toxicity NN o
, , o
and CC o
the DT o
quality NN o
of IN o
life NN o
of IN N
all DT N
study NN N
participants NNS N
. . N

-DOCSTART- -2146875- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
intravenous JJ i
immunoglobulin NN i
therapy NN i
in IN N
patients NNS p
with IN p
chronic JJ p
fatigue NN p
syndrome NN p
. . p

PURPOSE VB N
The DT N
chronic JJ N
fatigue NN N
syndrome NN N
( ( N
CFS NNP N
) ) N
is VBZ N
characterized VBN N
by IN N
profound NN N
fatigue NN N
, , N
neuropsychiatric JJ N
dysfunction NN N
, , N
and CC N
frequent JJ N
abnormalities NNS N
in IN N
cell-mediated JJ N
immunity NN N
. . N

No DT N
effective JJ N
therapy NN N
is VBZ N
known VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty-nine NNP p
patients NNS p
( ( p
40 CD p
with IN p
abnormal JJ p
cell-mediated JJ p
immunity NN p
) ) p
participated VBD p
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
high-dose JJ N
intravenously RB i
administered VBN i
immunoglobulin NN i
G. NNP i
The DT N
patients NNS N
received VBD N
three CD N
intravenous JJ N
infusions NNS N
of IN N
a DT N
placebo JJ i
solution NN i
or CC i
immunoglobulin NN i
at IN N
a DT N
dose NN N
of IN N
2 CD N
g/kg/month NN N
. . N

Assessment NN N
of IN N
the DT N
severity NN N
of IN N
symptoms NNS N
and CC N
associated JJ N
disability NN N
, , N
both DT N
before IN N
and CC N
after IN N
treatment NN N
, , N
was VBD N
completed VBN N
at IN N
detailed JJ N
interviews NNS N
by IN N
a DT N
physician NN N
and CC N
psychiatrist NN N
, , N
who WP N
were VBD N
unaware NN N
of IN N
the DT N
treatment NN N
status NN N
. . N

In IN N
addition NN N
, , N
any DT N
change NN N
in IN N
physical JJ N
symptoms NNS N
and CC N
functional JJ N
capacity NN N
was VBD N
recorded VBN N
using VBG N
visual JJ N
analogue NN N
scales NNS N
, , N
while IN N
changes NNS N
in IN N
psychologic JJ N
morbidity NN N
were VBD N
assessed VBN N
using VBG N
patient-rated JJ N
indices NNS N
of IN N
depression NN N
. . N

Cell-mediated JJ N
immunity NN N
was VBD N
evaluated VBN N
by IN N
T-cell NNP N
subset NN N
analysis NN N
, , N
delayed-type JJ N
hypersensitivity NN N
skin NN N
testing NN N
, , N
and CC N
lymphocyte JJ N
transformation NN N
with IN N
phytohemagglutinin NN N
. . N

RESULTS NNP N
At IN N
the DT N
interview NN N
conducted VBN N
by IN N
the DT N
physician JJ N
3 CD N
months NNS N
after IN N
the DT N
final JJ N
infusion NN N
, , N
10 CD N
of IN N
23 CD N
( ( N
43 CD N
% NN N
) ) N
immunoglobulin NN N
recipients NNS N
and CC N
three CD N
of IN N
the DT N
26 CD N
( ( N
12 CD N
% NN N
) ) N
placebo NN N
recipients NNS N
were VBD N
assessed VBN N
as IN N
having VBG N
responded VBN N
with IN N
a DT N
substantial JJ o
reduction NN o
in IN o
their PRP$ o
symptoms NNS o
and CC o
recommencement NN o
of IN o
work NN o
, , o
leisure NN o
, , o
and CC o
social JJ o
activities NNS o
. . o

The DT N
patients NNS N
designated VBN N
as IN N
having VBG N
responded VBN N
had VBD N
improvement NN N
in IN N
physical JJ N
, , N
psychologic JJ N
, , N
and CC N
immunologic JJ N
measures NNS N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
for IN N
each DT N
) ) N
. . N

CONCLUSION NNP N
Immunomodulatory NNP i
treatment NN i
with IN N
immunoglobulin NN i
is VBZ N
effective JJ o
in IN o
a DT o
significant JJ o
number NN o
of IN o
patients NNS o
with IN o
CFS NNP o
, , N
a DT N
finding NN N
that WDT N
supports VBZ N
the DT N
concept NN N
that IN N
an DT N
immunologic JJ N
disturbance NN N
may MD N
be VB N
important JJ N
in IN N
the DT N
pathogenesis NN N
of IN N
this DT N
disorder NN N
. . N

-DOCSTART- -10172265- O O

Protocol NN N
for IN N
the DT N
Multicenter NNP N
Acute NNP N
Stroke NNP N
Trial NNP N
-- : N
thrombolysis NN N
study NN N
. . N

The DT N
rationale NN N
for IN N
the DT N
Multicenter NNP N
Acute NNP N
Stroke NNP N
Trial NNP N
( ( N
MAST NNP N
) ) N
is VBZ N
presented VBN N
in IN N
a DT N
companion NN N
article NN N
appearing VBG N
in IN N
this DT N
issue NN N
. . N

Acute NNP N
ischaemic JJ N
stroke NN N
is VBZ N
the DT N
third JJ N
major JJ N
cause NN N
of IN N
death NN o
in IN N
developed JJ N
countries NNS N
, , N
and CC N
a DT N
major JJ N
cause NN N
of IN N
disability NN o
. . o

Despite IN N
a DT N
very RB N
poor JJ N
prognosis NN N
, , N
no DT N
treatment NN N
has VBZ N
demonstrated VBN N
an DT N
efficacy NN N
in IN N
lowering VBG N
the DT N
mortality NN o
and CC o
disability NN o
resulting VBG N
from IN N
stroke NN N
events NNS N
. . N

Thrombolysis NN i
has VBZ N
been VBN N
proven VBN N
to TO N
reduce VB N
mortality NN o
in IN o
myocardial JJ o
infarction NN o
, , N
and CC N
it PRP N
has VBZ N
been VBN N
shown VBN N
able JJ N
to TO N
induce VB N
recanalisation NN o
when WRB N
administered VBN N
to TO N
acute VB p
stroke NN p
patients NNS p
. . p

A DT N
recent JJ N
meta NN N
analysis NN N
of IN N
small-sized JJ N
studies NNS N
suggests VBZ N
that IN N
thrombolysis NN i
could MD N
offer VB N
some DT N
benefit NN N
to TO N
stroke VB p
patients NNS p
, , N
by IN N
reducing VBG N
the DT N
mortality NN o
and CC o
severe JJ o
invalidity NN o
by IN N
56 CD N
% NN N
; : N
these DT N
results NNS N
need VBP N
to TO N
be VB N
confirmed VBN N
in IN N
adequately RB N
designed VBN N
and CC N
sized VBN N
studies NNS N
. . N

-DOCSTART- -24061784- O O

Baseline NNP N
factors NNS N
predicting VBG N
placebo NN i
response NN N
to TO N
treatment NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
multisite JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE VBZ N
The DT N
finding NN N
of IN N
factors NNS N
that WDT N
differentially RB N
predict VBP N
the DT N
likelihood NN N
of IN N
response NN N
to TO N
placebo VB N
over IN N
that DT N
of IN N
an DT N
active JJ N
drug NN N
could MD N
have VB N
a DT N
significant JJ N
impact NN N
on IN N
study NN N
design NN N
in IN N
this DT N
population NN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
possible JJ N
nonspecific NN N
, , N
baseline JJ N
predictors NNS N
of IN N
response NN o
to TO o
intervention NN o
in IN N
a DT N
large JJ N
randomized JJ N
clinical JJ N
trial NN N
of IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Randomized NNP N
clinical JJ N
trial NN N
of IN N
citalopram NN i
hydrobromide NN i
for IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
prominent JJ p
repetitive JJ p
behavior NN p
. . p

Baseline NNP N
data NN N
at IN N
study NN N
entry NN N
were VBD N
examined VBN N
with IN N
respect NN N
to TO N
final JJ N
outcome NN N
to TO N
determine VB N
if IN N
response NN N
predictors NNS N
could MD N
be VB N
identified VBN N
. . N

A DT N
total NN N
of IN N
149 CD p
children NNS p
and CC p
adolescents NNS p
5 CD p
to TO p
17 CD p
years NNS p
of IN p
age NN p
( ( p
mean JJ p
[ NNP p
SD NNP p
] NNP p
age NN p
, , p
9.4 CD p
[ NN p
3.1 CD p
] CD p
years NNS p
) ) p
from IN p
6 CD p
academic JJ p
centers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
citalopram VB i
( ( N
n JJ N
= NNP N
73 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
76 CD N
) ) N
. . N

Participants NNS p
had VBD p
autistic JJ p
disorder NN p
, , p
Asperger NNP p
syndrome NN p
, , p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
, , p
not RB p
otherwise RB p
specified VBN p
; : p
had VBD p
illness JJ p
severity NN p
ratings NNS p
that WDT p
were VBD p
moderate JJ p
or CC p
more JJR p
than IN p
moderate VB p
on IN p
the DT p
Clinical JJ p
Global NNP p
Impression-Severity NNP p
scale NN p
; : p
and CC p
scored VBD p
moderate JJ p
or CC p
more JJR p
than IN p
moderate VB p
on IN p
compulsive JJ p
behaviors NNS p
measured VBN p
with IN p
the DT p
modified JJ p
Children NNP p
's POS p
Yale-Brown JJ p
Obsessive-Compulsive JJ p
Scale NNP p
. . p

INTERVENTIONS NNP N
Twelve NNP N
weeks NNS N
of IN N
treatment NN N
with IN N
citalopram NN i
( ( N
10 CD N
mg/5 RB N
mL NN N
) ) N
or CC N
placebo NN i
. . i

The DT N
mean NN N
( ( N
SD NNP N
) ) N
maximum VBD N
dose NN N
of IN N
citalopram NN N
was VBD N
16.5 CD N
( ( N
6.5 CD N
) ) N
mg NN N
by IN N
mouth JJ N
daily JJ N
( ( N
maximum JJ N
dose NN N
, , N
20 CD N
mg/d NN N
) ) N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
A NNP N
positive JJ N
response NN N
was VBD N
defined VBN N
as IN N
having VBG N
a DT N
score NN N
of IN N
at IN N
least JJS N
much JJ N
improved VBN N
on IN N
the DT N
Clinical JJ o
Global NNP o
Impression-Improvement NNP o
scale NN o
at IN N
week NN N
12 CD N
. . N

Baseline NNP N
measures VBZ N
included VBN N
demographic JJ N
( ( N
sex NN N
, , N
age NN N
, , N
weight NN N
, , N
and CC N
pubertal JJ N
status NN N
) ) N
, , N
clinical JJ N
, , N
and CC N
family NN N
measures NNS N
. . N

Clinical JJ N
variables NNS N
included VBD N
baseline NN N
illness NN N
severity NN N
ratings NNS N
( ( o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , o
the DT o
Child NNP o
and CC o
Adolescent NNP o
Symptom NNP o
Inventory NNP o
, , o
the DT o
Vineland NNP o
Adaptive NNP o
Behavior NNP o
Scales NNP o
, , o
the DT o
Repetitive JJ o
Behavior NNP o
Scale-Revised JJ o
, , o
and CC o
the DT o
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive-Compulsive JJ o
Scale NNP o
) ) o
. . N

Family JJ N
measures NNS N
included VBD N
the DT N
Caregiver NNP o
Strain NNP o
Questionnaire NNP o
. . o

RESULTS NNP N
Several JJ N
baseline JJ N
predictors NNS N
of IN N
response NN N
were VBD N
identified VBN N
, , N
and CC N
a DT N
principal JJ N
component NN N
analysis NN N
yielded VBD N
3 CD N
composite JJ N
measures NNS N
( ( o
disruptive JJ o
behavior NN o
, , o
autism/mood NN o
, , o
and CC o
caregiver RB o
strain NN o
) ) o
that WDT N
significantly RB N
predicted VBD N
response NN N
at IN N
week NN N
12 CD N
. . N

Specifically RB N
, , N
participants NNS N
in IN N
the DT N
placebo NN N
group NN N
were VBD N
significantly RB N
less RBR N
likely JJ N
than IN N
participants NNS N
in IN N
the DT N
citalopram NN N
group NN N
to TO N
respond VB N
at IN N
week NN N
12 CD N
if IN N
they PRP N
entered VBD N
the DT N
study NN N
more RBR N
symptomatic JJ N
on IN N
each DT N
of IN N
the DT N
3 CD N
composite JJ N
measures NNS N
, , N
and CC N
they PRP N
were VBD N
at IN N
least JJS N
2 CD N
times NNS N
less RBR N
likely JJ N
to TO N
be VB N
responders NNS N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
This DT N
analysis NN N
suggests VBZ N
strategies NNS N
that WDT N
may MD N
be VB N
useful JJ N
in IN N
anticipating VBG N
and CC N
potentially RB N
mitigating VBG N
the DT N
nonspecific JJ N
response NN N
in IN N
randomized JJ N
clinical JJ N
trials NNS N
of IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00086645 NN N
. . N

-DOCSTART- -9553982- O O

Determinants NNS N
of IN N
total JJ N
and CC N
specific JJ N
IgE NNP N
in IN N
infants NNS p
with IN p
atopic JJ p
dermatitis NN p
. . p

ETAC NNP N
Study NNP N
Group NNP N
. . N

Early NNP N
Treatment NNP N
of IN N
the DT N
Atopic NNP p
Child NNP p
. . p

ETAC NNP p
( ( p
Early JJ p
Treatment NN p
of IN p
the DT p
Atopic NNP p
Child NNP p
) ) p
, , p
a DT p
multi-centre JJ p
predominantly RB p
European JJ p
study NN p
to TO p
investigate VB p
the DT p
potential NN p
for IN p
cetirizine NN i
to TO p
prevent VB p
the DT p
development NN p
of IN p
asthma NN p
in IN p
infants NNS p
with IN p
atopic NN p
dermatitis NN p
has VBZ N
completed VBN N
enrollment NN N
: : N
817 CD p
children NNS p
have VBP N
been VBN N
randomised VBN N
to TO N
18 CD N
months NNS N
' POS N
treatment NN N
with IN N
either DT N
active JJ i
or CC N
placebo NN i
and CC N
a DT N
subsequent JJ N
18 CD N
months NNS N
of IN N
post-treatment JJ N
follow-up NN N
. . N

Results NNS N
of IN N
the DT N
therapeutic JJ N
effects NNS N
will MD N
not RB N
be VB N
available JJ N
for IN N
some DT N
time NN N
, , N
but CC N
the DT N
study NN N
has VBZ N
provided VBN N
an DT N
opportunity NN N
to TO N
investigate VB N
influences NNS N
on IN N
sensitization NN o
to TO o
allergens NNS o
in IN N
a DT N
large JJ p
cohort NN p
of IN p
1-2 JJ p
years NNS p
olds VBZ p
with IN p
already RB p
established VBN p
atopic NN p
dermatitis NN p
, , p
resident NN p
in IN p
different JJ p
countries NNS p
and CC p
in IN p
different JJ p
environments NNS p
. . p

The DT N
study NN N
shows VBZ N
that IN N
in IN N
infants NNS p
with IN p
atopic NN p
dermatitis NN p
, , N
raised VBD N
serum JJ o
total NN o
IgE NNP o
has VBZ N
significantly RB N
different JJ N
determinants NNS N
from IN N
that IN N
a DT N
specific JJ o
allergen NN o
sensitization NN o
. . o

In IN N
infancy NN N
, , N
increased VBD N
total JJ o
IgE NNP o
is VBZ N
more RBR N
affected JJ N
by IN N
factors NNS N
increasing VBG N
risk NN N
of IN N
intercurrent JJ N
infection NN N
and CC N
non-specific JJ N
airway NN N
inflammation NN N
, , N
such JJ N
as IN N
environmental JJ N
tobacco NN N
smoke NN N
exposure NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
use NN N
of IN N
gas NN N
cookers NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

Specific JJ N
allergen NN o
sensitization NN o
as IN N
represented VBN N
by IN N
detectable JJ N
IgE NNP o
antibodies NNS o
is VBZ N
influenced VBN N
primarily RB N
by IN N
allergen NN N
exposure NN N
. . N

In IN N
Sweden NNP N
, , N
low JJ N
level NN N
exposure NN N
to TO N
allergens NNS N
is VBZ N
associated VBN N
with IN N
reduced VBN N
specific JJ o
allergen NN o
sensitization NN o
rates NNS N
even RB N
though IN N
the DT N
infants NNS p
already RB N
have VBP N
atopic VBN N
dermatitis NN N
. . N

-DOCSTART- -22838229- O O

In IN N
vitro JJ N
biocompatibility NN N
tests NNS N
of IN N
glass NN N
ionomer NN N
cements NNS N
impregnated VBN N
with IN N
collagen NN N
or CC N
bioactive JJ N
glass NN N
to TO N
fibroblasts NNS N
. . N

AIM NNP N
AND CC N
DESIGN NNP N
To TO N
evaluate VB N
the DT N
biocompatibility NN N
of IN N
glass NN p
ionomer NN p
cement NN p
( ( N
GIC NNP N
) ) N
impregnated VBD N
with IN N
collagen NN N
or CC N
bioactive JJ N
glass NN N
to TO N
BHK-21 NNP N
fibroblasts NNS N
in IN N
vitro NN N
. . N

Mineral NNP N
Trioxide NNP N
Aggregate NNP N
was VBD N
used VBN N
as IN N
the DT N
standard NN N
for IN N
comparison NN N
. . N

Human NNP p
maxillary JJ p
central JJ p
incisors NNS p
( ( p
n JJ p
= NNP p
70 CD p
) ) p
were VBD N
instrumented VBN N
with IN N
a DT N
rotary JJ N
NiTi NNP N
system NN N
and CC N
filled VBN N
. . N

Following VBG N
resection NN N
of IN N
the DT N
apical JJ N
3mm CD N
, , N
root JJ p
end NN p
cavities NNS p
were VBD N
prepared JJ N
and CC N
restored VBN N
with IN N
conventional JJ i
GIC NNP i
( ( i
group NN i
1 CD i
) ) i
or CC i
GIC NNP i
with IN i
0.01 CD i
% NN i
, , i
0.1 CD i
% NN i
or CC i
1 CD i
% NN i
collagen NN i
( ( i
groups NNS i
2 CD i
, , i
3 CD i
, , i
4 CD i
respectively RB i
) ) i
or CC i
, , i
10 CD i
% NN i
, , i
30 CD i
% NN i
or CC i
50 CD i
% NN i
bioactive JJ i
glass NN i
( ( i
groups NNS i
5 CD i
, , i
6 CD i
, , i
7 CD i
respectively RB i
) ) i
, , i
or CC i
Mineral NNP i
Trioxide NNP i
Aggregate NNP i
( ( i
group NN i
8 CD i
) ) i
. . i

The DT N
root NN p
slices NNS p
were VBD N
incubated VBN N
in IN N
tissue NN N
culture NN N
plates VBZ N
with IN N
BHK-21 NNP N
fibroblast NN N
cell NN N
line NN N
. . N

Phase NNP N
contrast NN N
and CC N
scanning VBG N
electron NN N
microscopes NNS N
were VBD N
used VBN N
to TO N
score VB o
cell NN o
quantity NN o
, , o
morphology NN o
and CC o
cell NN o
attachment NN o
. . o

The DT N
data NNS N
were VBD N
statistically RB o
analyzed VBN o
by IN N
one CD N
way NN N
ANOVA NNP o
with IN o
Post NNP o
Hoc NNP o
Tukey NNP o
HSD NNP o
test NN o
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
AND NNP N
CONCLUSIONS NNP N
Group NNP N
5 CD N
showed VBD N
the DT N
highest JJS N
scores NNS N
which WDT N
was VBD N
significantly RB N
higher JJR N
than IN N
all DT N
other JJ N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
except IN N
group NN N
8 CD N
, , N
with IN N
which WDT N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Glass NNP N
ionomer JJ N
cement NN N
with IN N
10 CD N
% NN N
bioactive JJ N
glass NN N
showed VBD N
better JJR o
adhesion NN o
and CC o
spreading NN o
of IN o
cells NNS o
than IN N
glass NN N
ionomer NN N
cement NN N
with IN N
0.01 CD N
% NN N
collagen NN N
. . N

The DT N
biocompatibility NN o
of IN o
collagen NN o
and CC o
bioactive JJ o
glass NN o
was VBD N
concentration NN N
dependent NN N
. . N

The DT N
addition NN N
of IN N
bioactive JJ N
glass NN N
improved VBD o
the DT o
biocompatibility NN o
of IN o
glass NN o
ionomer NN o
cement NN o
to TO N
fibroblasts NNS N
better JJR N
than IN N
addition NN N
of IN N
collagen NN N
. . N

-DOCSTART- -23475835- O O

Parenting VBG o
stress NN o
in IN p
the DT p
infant JJ p
aphakia NN p
treatment NN p
study NN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
parenting VBG p
stress NN p
following VBG p
infants NNS p
' POS p
cataract NN i
extraction NN i
surgery NN i
, , N
and CC N
to TO N
determine VB N
if IN N
levels NNS N
of IN N
stress NN N
differ NN N
between IN N
2 CD N
treatments NNS N
for IN N
unilateral JJ o
congenital JJ o
cataract NN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
At IN N
surgery NN N
, , N
an DT N
intraocular JJ i
lens NNS i
( ( i
IOL NNP i
) ) i
was VBD i
implanted VBN i
or CC N
children NNS N
were VBD N
left VBN i
aphakic NN i
, , i
treated VBD i
with IN i
contact NN i
lens NNS i
( ( i
CL NNP i
) ) i
. . i

Stress JJ N
measures NNS N
were VBD N
administered VBN N
3 CD N
months NNS N
after IN N
surgery NN N
and CC N
at IN N
the DT N
first JJ N
visit NN N
after IN N
the DT N
visual JJ N
acuity NN N
( ( N
VA NNP N
) ) N
assessment NN N
done VBN N
at IN N
12 CD N
months NNS N
of IN N
age NN N
. . N

RESULTS NNP N
Caregivers NNPS p
in IN N
the DT N
IOL NNP i
group NN N
reported VBD N
higher JJR N
levels NNS N
of IN N
stress NN o
than IN N
those DT N
in IN N
the DT N
CL NNP i
group NN N
3 CD N
months NNS N
after IN N
surgery NN N
, , N
but CC N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
in IN N
stress NN o
scores NNS o
at IN N
the DT N
post-VA JJ o
assessment NN o
. . o

Stress NNP o
scores NNS o
did VBD N
not RB N
change VB N
differentially RB N
for IN N
participants NNS N
assigned VBN N
to TO N
IOL NNP i
versus NN N
CL NNP i
treatments NNS N
. . N

CONCLUSIONS NNP N
Treatment NNP N
assignment NN N
did VBD N
not RB N
have VB N
a DT N
significant JJ N
impact NN N
on IN N
caregiver NN o
stress NN o
during IN p
infancy NN p
or CC N
on IN N
the DT N
change NN N
in IN N
stress NN N
during IN N
the DT N
child NN N
's POS N
first JJ N
2 CD N
years NNS N
of IN N
life NN N
. . N

-DOCSTART- -7650233- O O

Does NNP N
tetanus CC i
immune VB i
globulin NN i
interfere RB N
with IN N
the DT N
immune JJ o
response NN o
to TO N
simultaneous JJ N
administration NN N
of IN N
tetanus-diphtheria JJ i
vaccine NN i
? . N
A DT N
comparative JJ N
clinical JJ N
trial NN p
in IN p
adults NNS p
. . p

In IN N
the DT N
management NN N
of IN N
wounds NNS N
, , N
sometimes RB N
it PRP N
is VBZ N
recommended VBN N
to TO N
give VB N
an DT N
adult-type JJ N
tetanus-diphtheria NN i
( ( i
Td NNP i
) ) i
vaccine NN i
dose JJ N
plus CC N
tetanus JJ i
immune JJ i
globulin NN i
( ( i
TIG NNP i
) ) i
. . i

Sixty NNP p
and CC p
59 CD p
healthy JJ p
young JJ p
adults NNS p
previously RB p
immunized VBN p
against IN p
tetanus NN p
( ( p
T NNP p
) ) p
and CC p
diphtheria NN p
( ( p
D NNP p
) ) p
were VBD p
randomized VBN p
to TO p
receive VB i
intramuscularly RB i
either DT i
Td NNP i
vaccine NN i
alone RB i
( ( i
group NN i
1 CD i
) ) i
or CC i
Td NNP i
vaccine NN i
plus CC i
500 CD i
IU NNP i
of IN i
TIG NNP i
( ( i
group NN i
2 CD i
) ) i
simultaneously RB i
. . i

Antitoxin NNP o
response NN o
was VBD i
assessed VBN i
after IN i
4 CD i
weeks NNS i
and CC i
4 CD i
months NNS i
. . i

Circulating VBG o
antibodies NNS o
were VBD o
measured VBN o
by IN o
enzyme-linked JJ o
immunosorbent NN o
assay NN o
( ( o
ELISA NNP o
) ) o
. . o

The DT N
cutoff NN N
of IN N
these DT N
tests NNS N
was VBD N
0.1 CD N
IU/mL NNP N
. . N

Titers NNS N
of IN N
0.1 CD N
IU/mL NNP N
or CC N
greater JJR N
were VBD N
considered VBN N
protective JJ N
. . N

For IN N
geometric JJ N
mean NN N
titers NNS N
( ( N
GMT NNP N
) ) N
, , N
antibody NN o
titers NNS o
below IN N
the DT N
cutoff NN N
of IN N
the DT N
assay NN N
were VBD N
given VBN N
, , N
arbitrarily RB N
, , N
0.05 CD N
IU/mL NNP N
. . N

At IN N
4 CD N
weeks NNS N
, , N
98 CD N
% NN N
or CC N
more JJR N
of IN N
the DT N
subjects NNS N
in IN N
group NN N
1 CD N
had VBD N
circulating NN o
T NNP o
and CC o
D NNP o
antitoxin NN o
levels NNS o
of IN N
0.1 CD N
IU/mL NNP N
or CC N
higher JJR N
; : N
in IN N
group NN N
2 CD N
, , N
95 CD N
% NN N
and CC N
90 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
titers NNS N
above IN N
this DT N
limit NN N
for IN N
T NNP N
and CC N
D NNP N
, , N
respectively RB N
. . N

At IN N
4 CD N
months NNS N
, , N
these DT N
percentages NNS N
were VBD N
98 CD N
% NN N
and CC N
95 CD N
% NN N
for IN N
T NNP o
antitoxin NN o
levels NNS o
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
; : N
whereas CC N
96 CD N
% NN N
and CC N
88 CD N
% NN N
of IN N
the DT N
subjects NNS N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
had VBD N
D NNP o
antitoxin NN o
levels NNS o
of IN N
0.1 CD N
IU/mL NNP N
or CC N
higher JJR N
, , N
respectively RB N
. . N

Significantly NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
higher JJR N
GMTs NNP N
were VBD N
seen VBN N
at IN N
the DT N
4-week JJ N
assessment NN N
( ( N
but CC N
not RB N
at IN N
4 CD N
months NNS N
) ) N
in IN N
group NN N
1 CD N
, , N
as IN N
compared VBN N
with IN N
group NN N
2 CD N
, , N
in IN N
both DT N
T NNP N
and CC N
D NNP N
antitoxin NN N
levels NNS N
( ( N
9.91 CD N
IU/mL NNP N
versus NN N
5.60 CD N
IU/mL NNP N
for IN N
T NNP N
antitoxin NN N
, , N
and CC N
2.86 CD N
IU/mL NNP N
versus NN N
1.45 CD N
IU/mL NNP N
for IN N
D NNP N
antitoxin NN N
) ) N
. . N

This DT N
finding NN N
resulted VBD N
from IN N
those DT N
participants NNS N
with IN N
low JJ N
( ( N
< JJ N
0.1 CD N
IU/mL NNP N
) ) N
prevaccination NN N
antibody NN N
titers NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -10097996- O O

The DT N
TOM NNP i
test NN i
: : i
a DT N
new JJ N
instrument NN N
for IN N
assessing VBG p
theory NN p
of IN p
mind NN p
in IN p
normal JJ p
children NNS p
and CC p
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

This DT N
article NN N
describes VBZ N
a DT N
first JJ N
attempt NN N
to TO N
investigate VB N
the DT N
reliability NN N
and CC N
validity NN N
of IN N
the DT N
TOM NNP o
test NN o
, , N
a DT N
new JJ N
instrument NN N
for IN N
assessing VBG N
theory NN N
of IN N
mind NN N
ability NN N
in IN N
normal JJ p
children NNS p
and CC p
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
( ( p
PDDs NNP p
) ) p
. . p

In IN N
Study NNP N
1 CD N
, , N
TOM NNP i
test NN i
scores NNS N
of IN N
normal JJ p
children NNS p
( ( p
n JJ p
= NNP p
70 CD p
) ) p
correlated VBD N
positively RB N
with IN N
their PRP$ N
performance NN N
on IN N
other JJ N
theory NN N
of IN N
mind NN N
tasks NNS N
. . N

Furthermore NNP N
, , N
young JJ p
children NNS p
only RB N
succeeded VBD N
on IN N
TOM NNP N
items NNS N
that WDT N
tap VBP N
the DT N
basic JJ N
domains NNS N
of IN N
theory NN N
of IN N
mind NN N
( ( N
e.g. JJ N
, , N
emotion JJ N
recognition NN N
) ) N
, , N
whereas JJ N
older JJR p
children NNS p
also RB N
passed VBD N
items NNS N
that WDT N
measure VBP N
the DT N
more JJR N
mature JJ N
areas NNS N
of IN N
theory NN N
of IN N
mind NN N
( ( N
e.g. JJ N
, , N
understanding NN N
of IN N
humor NN N
, , N
understanding VBG N
of IN N
second-order JJ N
beliefs NNS N
) ) N
. . N

Taken VBN N
together RB N
, , N
the DT N
findings NNS N
of IN N
Study NNP N
1 CD N
suggest NN N
that IN N
the DT N
TOM NNP o
test NN o
is VBZ N
a DT N
valid JJ N
measure NN N
. . N

Study NNP N
2 CD N
showed VBD N
for IN N
a DT N
separate JJ N
sample NN N
of IN N
normal JJ p
children NNS p
( ( p
n JJ p
= NNP p
12 CD p
) ) p
that IN N
the DT N
TOM NNP o
test NN o
possesses VBZ N
sufficient JJ N
test-retest JJ N
stability NN N
. . N

Study NNP N
3 CD N
demonstrated VBD N
for IN N
a DT N
sample NN p
of IN p
children NNS p
with IN p
PDDs NNP p
( ( p
n JJ p
= NNP p
10 CD p
) ) p
that IN N
the DT N
interrater NN o
reliability NN o
of IN N
the DT N
TOM NNP o
test NN o
is VBZ N
good JJ N
. . N

Study VB N
4 CD N
found NN N
that IN N
children NNS p
with IN p
PDDs NNP p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
had VBD N
significantly RB N
lower JJR N
TOM NNP o
test NN o
scores NNS o
than IN N
children NNS p
with IN p
other JJ p
psychiatric JJ p
disorders NNS p
( ( p
e.g. NN p
, , N
children NNS p
with IN p
Attention-deficit NNP p
Hyperactivity NNP p
Disorder NNP p
; : p
n CC p
= VB p
32 CD p
) ) p
, , N
a DT N
finding NN N
that WDT N
underlines VBZ N
the DT N
discriminant JJ N
validity NN N
of IN N
the DT N
TOM NNP i
test NN i
. . i

Furthermore RB N
, , N
Study NNP N
4 CD N
showed VBD N
that DT N
intelligence NN o
as IN N
indexed VBN N
by IN N
the DT N
Wechsler NNP o
Intelligence NNP o
Scale NNP o
for IN o
Children NNP o
was VBD N
positively RB N
associated VBN N
with IN N
TOM NNP o
test NN o
scores NNS o
. . o

Finally RB N
, , N
in IN N
all DT N
studies NNS N
, , N
the DT N
TOM NNP o
test NN o
was VBD N
found VBN N
to TO N
be VB N
reliable JJ N
in IN N
terms NNS N
of IN N
internal JJ N
consistency NN N
. . N

Altogether RB N
, , N
results NNS N
indicate VBP N
that IN N
the DT N
TOM NNP i
test NN i
is VBZ N
a DT N
reliable JJ N
and CC N
valid JJ N
instrument NN N
that WDT N
can MD N
be VB N
employed VBN N
to TO N
measure VB N
various JJ N
aspects NNS N
of IN N
theory NN N
of IN N
mind NN N
. . N

-DOCSTART- -3306431- O O

Alpha NNP i
interferon NN i
clinical JJ N
trial NN N
for IN N
multiple JJ p
sclerosis NN p
: : p
design NN N
considerations NNS N
. . N

The DT N
design NN N
and CC N
course NN N
of IN N
a DT N
placebo-controlled JJ i
alpha-2 JJ i
interferon NN i
trial NN N
in IN N
MS NNP p
patients NNS p
are VBP N
described VBN N
. . N

No DT o
beneficial JJ o
effect NN o
of IN N
the DT N
interferon NN o
on IN N
the DT N
course NN N
of IN N
MS NNP N
could MD N
be VB N
shown VBN N
. . N

-DOCSTART- -6516935- O O

Rational-emotive JJ i
therapy NN i
and CC N
the DT N
reduction NN N
of IN N
interpersonal JJ o
anxiety NN o
in IN N
junior JJ p
high JJ p
school NN p
students NNS p
. . p

This DT N
study NN N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
rational-emotive JJ i
therapy NN i
and CC i
rational-emotive JJ i
imagery NN i
. . i

Fifty-nine JJ p
junior JJ p
high JJ p
school NN p
students NNS p
who WP p
volunteered VBD p
to TO p
participate VB p
in IN p
treatment NN p
for IN p
interpersonal JJ o
anxiety NN o
were VBD N
randomly RB N
assigned VBN N
to TO N
rational-emotive JJ i
therapy NN i
without IN i
imagery NN i
( ( i
RET NNP i
) ) i
, , i
rational-emotive JJ i
therapy NN i
with IN i
imagery NN i
( ( i
REI NNP i
) ) i
, , i
relationship-oriented JJ i
counseling NN i
( ( i
ROC NNP i
) ) i
, , i
and CC i
waiting-list JJ i
control NN i
( ( i
WLC NNP i
) ) i
groups NNS i
. . i

Groups NNP N
met VBD N
for IN N
seven CD N
50-minute JJ N
treatment NN N
sessions NNS N
during IN N
a DT N
three-week JJ N
period NN N
. . N

Assessments NNS N
were VBD N
conducted VBN N
at IN N
pretreatment NN N
, , N
posttreatment NN N
, , N
and CC N
three-week JJ N
follow-up NN N
. . N

Both DT N
self-report JJ o
and CC o
sociometric JJ o
measures NNS o
were VBD N
used VBN N
to TO N
evaluate VB N
treatment NN N
outcome NN N
. . N

At IN N
postassessment NN N
, , N
both CC N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
were VBD N
rated VBN N
on IN N
sociometric JJ o
measures NNS o
as IN N
significantly RB o
less RBR o
interpersonally RB o
anxious JJ o
than IN N
the DT N
WLC NNP N
group NN N
. . N

Mean NNP o
scores VBZ o
favored VBD N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
, , N
but CC N
no DT N
significant JJ N
differences NNS N
between IN N
these DT N
groups NNS N
and CC N
the DT N
ROC NNP N
group NN N
were VBD N
obtained VBN N
. . N

The DT N
self-report JJ o
measure NN o
did VBD N
not RB N
significantly RB N
differentiate VBP N
between IN N
groups NNS N
, , N
but CC N
the DT N
REI NNP N
group NN N
demonstrated VBD N
significant JJ N
pre- JJ N
to TO N
follow-up JJ N
changes NNS N
. . N

Both CC N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
yielded VBD N
greater JJR N
reductions NNS o
in IN o
irrational JJ o
thinking NN o
than IN N
did VBD N
the DT N
ROC NNP N
and CC N
WLC NNP N
groups NNS N
. . N

In IN N
addition NN N
, , N
the DT N
pattern NN N
of IN N
the DT N
results NNS N
supported VBD N
the DT N
use NN N
of IN N
rational-emotive JJ i
imagery NN i
as IN N
a DT N
component NN N
of IN N
rational-emotive JJ i
therapy NN i
. . i

The DT N
practical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -1919850- O O

Effects NNS N
of IN N
propranolol NN i
on IN N
bone NN o
metabolism NN o
in IN N
the DT N
rat NN p
. . p

Propranolol NNP i
, , N
a DT N
nonspecific JJ N
beta-blocker NN N
has VBZ N
many JJ N
physiologic JJ N
effects NNS N
. . N

Its PRP$ N
effects NNS N
on IN N
bone NN o
in IN N
vivo NN N
are VBP N
unknown JJ N
, , N
although IN N
beta NN N
receptor NN N
sites NNS N
have VBP N
been VBN N
found VBN N
on IN N
osteoblasts NNS N
. . N

In IN N
this DT N
study NN N
, , N
the DT N
hypothesis NN N
tested VBD N
was VBD N
that IN N
low JJ N
doses NNS N
of IN N
propranolol NN i
could MD N
alter VB N
bone NN o
properties NNS o
and CC N
enhance NN N
orthotopic RB o
endochondral JJ o
bone NN o
formation NN o
. . o

In IN N
a DT N
group NN N
of IN N
nonsurgical JJ p
rats NNS p
, , N
propranolol JJ i
treatment NN N
increased VBD N
femoral JJ o
torsional JJ o
strength NN o
on IN N
biomechanical JJ N
testing NN N
. . N

In IN N
the DT N
rat NN p
surgical JJ p
model NN p
used VBN N
, , N
right JJ N
femora NNS N
were VBD N
fixed VBN N
to TO N
a DT N
polyethylene NN N
plate NN N
and CC N
then RB N
defects NNS N
were VBD N
created VBN N
mid-diaphysis NN N
and CC N
subsequently RB N
filled VBN N
with IN N
demineralized JJ N
bone NN N
matrix NN N
. . N

These DT N
rats NNS p
( ( p
defect JJ p
rats NNS p
) ) p
were VBD N
randomly RB N
divided VBN N
into IN N
groups NNS N
that WDT N
were VBD N
given VBN N
propranolol NNS i
or CC N
a DT N
saline NN i
carrier NN N
for IN N
19 CD N
consecutive JJ N
days NNS N
. . N

In IN N
the DT N
defect NN p
rats NNS p
, , N
increased VBD N
trabecular JJ o
femoral JJ o
metaphyseal JJ o
mineral JJ o
apposition NN o
rates NNS o
were VBD N
observed VBN N
in IN N
propranolol-treated JJ N
groups NNS N
. . N

Densitometry NNP N
and CC N
roentgenographic JJ N
scoring NN N
of IN N
callus NN N
formation NN N
after IN N
12 CD N
weeks NNS N
in IN N
propranolol-treated JJ N
rats NNS N
revealed VBD N
increased JJ N
callus NN o
and CC o
bone NN o
union NN o
. . o

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
propranolol NN i
treatment NN N
can MD N
significantly RB N
affect VB N
bone NN o
properties NNS o
. . o

-DOCSTART- -7410734- O O

Scaling VBG N
clinical JJ N
judgments NNS N
of IN N
symptom JJ N
pathology NN N
by IN N
means NNS N
of IN N
the DT N
psychophysiological JJ N
method NN N
of IN N
magnitude NN N
estimation NN N
. . N

Summing VBG N
scores NNS N
across IN N
heterogeneous JJ N
symptom NN N
items NNS N
without IN N
consideration NN N
of IN N
their PRP$ N
differing JJ N
psychopathological JJ N
significance NN N
has VBZ N
been VBN N
criticized VBN N
as IN N
producing VBG N
an DT N
inadequate JJ N
picture NN N
of IN N
an DT N
individual NN N
's POS N
clinical JJ N
status NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
derive JJ N
symptom JJ N
item NN N
weights NNS N
representing VBG N
clinically RB N
judged VBN N
seriousness NN N
of IN N
each DT N
symptom NN N
through IN N
the DT N
application NN N
of IN N
Steven NNP i
's POS i
psychophysical JJ i
method NN i
of IN i
magnitude NN i
estimation NN i
. . i

A DT N
nationwide JJ N
sample NN N
of IN N
129 CD p
clinicians NNS p
rated VBD N
the DT N
pathological JJ N
significance NN N
of IN N
221 CD N
symptom JJ N
items NNS N
in IN N
a DT N
design NN N
such JJ N
that IN N
every DT N
rater NN N
rated VBD N
121 CD N
items NNS N
, , N
21 CD N
of IN N
which WDT N
were VBD N
rated VBN N
by IN N
all DT N
raters NNS N
and CC N
100 CD N
of IN N
which WDT N
were VBD N
rated VBN N
only RB N
by IN N
the DT N
A NNP N
or CC N
B NNP N
subgroup NN N
to TO N
which WDT N
each DT N
rater NN N
was VBD N
randomly RB N
assigned VBN N
. . N

Each DT N
item NN N
was VBD N
rated VBN N
as IN N
to TO N
the DT N
seriousness NN N
of IN N
the DT N
pathology NN N
it PRP N
would MD N
represent VB N
if IN N
manifested VBN N
by IN N
either CC N
a DT N
boy NN N
child NN N
, , N
girl JJ N
child NN N
, , N
boy JJ N
adolescent NN N
, , N
or CC N
girl JJ N
adolescent NN N
, , N
with IN N
one-fourth NN N
of IN N
the DT N
raters NNS N
assigned VBD N
to TO N
each DT N
condition NN N
. . N

The DT N
results NNS N
of IN N
211 CD N
two-way JJ i
analyses NNS i
of IN i
variance NN i
revealed VBD N
that IN N
age NN N
and CC N
age NN o
and CC o
sex NN o
in IN N
interaction NN N
, , N
but CC N
not RB N
sex VB N
alone RB N
, , N
significantly RB N
influenced VBD N
the DT N
clinical JJ N
ratings NNS N
. . N

The DT N
resulting VBG N
magnitude JJ o
estimation NN o
ratings NNS o
of IN o
symptom JJ o
pathology NN o
ranged VBD N
from IN N
1.0 CD N
to TO N
9.9 CD N
. . N

They PRP N
were VBD N
demonstrated VBN N
to TO N
have VB N
satisfactoy VBN N
reliability NN N
and CC N
convergent NN N
validity NN N
and CC N
to TO N
have VB N
the DT N
psychophysical JJ N
characteristics NNS N
of IN N
a DT N
prothetic JJ N
continuum NN N
. . N

-DOCSTART- -16472720- O O

Brain NNP N
mechanisms NNS N
of IN N
expectation NN N
associated VBN N
with IN N
insula NN p
and CC p
amygdala JJ p
response NN N
to TO N
aversive JJ N
taste NN N
: : N
implications NNS N
for IN N
placebo NN i
. . i

The DT N
experience NN N
of IN N
aversion NN N
is VBZ N
shaped VBN N
by IN N
multiple JJ N
physiological JJ N
and CC N
psychological JJ N
factors NNS N
including VBG N
one CD N
's POS N
expectations NNS N
. . N

Recent JJ N
work NN N
has VBZ N
shown VBN N
that IN N
expectancy NN N
manipulation NN N
can MD N
alter VB N
perceptions NNS N
of IN N
aversive JJ N
events NNS N
and CC N
concomitant JJ N
brain NN N
activation NN N
. . N

Accruing VBG N
evidence NN N
indicates VBZ N
a DT N
primary JJ N
role NN N
of IN N
altered JJ N
expectancies NNS N
in IN N
the DT N
placebo NN i
effect NN N
. . N

Here RB N
, , N
we PRP N
probed VBD N
the DT N
mechanism NN N
by IN N
which WDT N
expectation NN N
attenuates VBZ N
sensory JJ N
taste NN N
transmission NN N
by IN N
examining VBG N
how WRB N
brain NN p
areas NNS p
activated VBN p
by IN p
misleading VBG i
information NN i
during IN p
an DT p
expectancy NN p
period NN p
modulate NN N
insula NN N
and CC N
amygdala JJ N
activation NN N
to TO N
a DT N
highly RB i
aversive JJ i
bitter NN i
taste NN i
. . i

In IN N
a DT N
rapid JJ N
event-related JJ N
fMRI NN i
design NN i
, , N
we PRP N
showed VBD N
that IN N
activations NNS N
in IN N
the DT N
rostral JJ p
anterior JJ p
cingulate NN p
cortex NN p
( ( p
rACC NN p
) ) p
, , p
orbitofrontal JJ p
cortex NN p
( ( p
OFC NNP p
) ) p
, , p
and CC p
dorsolateral JJ p
prefrontal NN p
cortex NN p
to TO N
a DT N
misleading NN N
cue NN N
that IN N
the DT N
taste NN N
would MD N
be VB N
mildly RB N
aversive JJ N
predicted VBN N
decreases NNS N
in IN N
insula NN o
and CC o
amygdala JJ o
activation NN o
to TO N
the DT N
highly RB N
aversive JJ N
taste NN N
. . N

OFC NNP N
and CC N
rACC VB N
activation NN N
to TO N
the DT N
misleading NN i
cue NN i
were VBD N
also RB N
associated VBN N
with IN N
less RBR N
aversive JJ o
ratings NNS o
of IN o
that DT o
taste NN o
. . o

Additional JJ N
analyses NNS N
revealed VBD N
consistent JJ N
results NNS N
demonstrating VBG N
functional JJ N
connectivity NN N
among IN N
the DT N
OFC NNP N
, , N
rACC NN N
, , N
and CC N
insula NN N
. . N

Altering VBG N
expectancies NNS N
of IN N
upcoming VBG N
aversive JJ N
events NNS N
are VBP N
shown VBN N
here RB N
to TO N
depend VB N
on IN N
robust JJ N
functional JJ N
associations NNS N
among IN N
brain NN N
regions NNS N
implicated VBN N
in IN N
prior JJ N
work NN N
on IN N
the DT N
placebo NN N
effect NN N
. . N

-DOCSTART- -8305277- O O

MR NNP N
imaging NN N
of IN N
pituitary JJ p
region NN p
lesions NNS p
with IN N
gadodiamide JJ i
injection NN N
. . N

Twelve CD p
patients NNS p
with IN p
known VBN p
or CC p
suspected VBN p
pituitary JJ p
lesions NNS p
underwent JJ N
MR NNP i
imaging VBG i
with IN N
gadodiamide JJ i
injection NN i
at IN N
a DT N
dose NN N
of IN N
0.1 CD N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
0.3 CD N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
mM/kg NN N
. . N

Six CD p
of IN p
the DT p
patients NNS p
were VBD N
also RB N
studied VBN N
with IN N
0.1 CD i
mM/kg NNS i
gadopentetate JJ i
dimeglumine NN i
. . i

Consistent JJ N
with IN N
previous JJ N
reports NNS N
gadodiamide NN i
injection NN N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ o
and CC o
effective JJ o
contrast NN N
medium NN N
for IN N
MR NNP N
imaging NN N
of IN N
the DT N
pituitary JJ N
region NN N
. . N

No DT N
additional JJ N
diagnostic JJ N
information NN N
was VBD N
obtained VBN N
using VBG N
0.3 CD N
mM/kg JJ N
gadodiamide NN i
injection NN N
compared VBN N
to TO N
0.1 CD N
mM/kg NNS N
gadopentate JJ N
dimeglumine NN N
in IN N
the DT N
same JJ N
patients NNS N
. . N

The DT N
high JJ N
dose NN N
( ( N
0.3 CD N
mM/kg NN N
) ) N
gadodiamide NN i
injection NN N
in IN N
7 CD N
patients NNS N
did VBD N
not RB N
shorten VB o
the DT o
T2 NNP o
value NN o
sufficiently RB o
to TO N
overwhelm VB N
the DT N
T1 NNP o
shortening NN o
and CC o
leave VBP o
pathologic JJ o
lesions NNS o
hypointense VBP o
compared VBN N
to TO N
precontrast VB N
studies NNS N
. . N

With IN N
the DT N
comparable JJ N
relaxivities NNS N
of IN N
gadodiamide JJ i
injection NN N
and CC N
gadopentetate NN i
dimeglumine NN i
, , N
similarities NNS N
in IN N
results NNS N
have VBP N
to TO N
be VB N
expected VBN N
when WRB N
using VBG N
these DT N
media NNS N
for IN N
MR NNP N
image NN N
enhancement NN N
. . N

-DOCSTART- -20535539- O O

Melatonin NNP i
versus NN i
placebo NN i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
conditions NNS p
and CC p
severe JJ p
sleep NN p
problems NNS p
not RB p
amenable JJ p
to TO p
behaviour VB p
management NN p
strategies NNS p
: : p
a DT N
randomised JJ N
controlled VBN N
crossover NN N
trial NN N
. . N

Twenty-two JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
who WP p
had VBD p
not RB p
responded VBN p
to TO p
supported VB p
behaviour JJ p
management NN p
strategies NNS p
for IN p
severe JJ p
dysomnias NN p
entered VBD N
a DT N
double JJ N
blind NN N
, , N
randomised VBN N
, , N
controlled VBD N
crossover RB N
trial NN N
involving VBG N
3 CD N
months NNS N
of IN N
placebo NN i
versus IN N
3 CD N
months NNS N
of IN N
melatonin NN i
to TO N
a DT N
maximum JJ N
dose NN N
of IN N
10 CD N
mg. NNS N
17 CD p
children NNS p
completed VBD p
the DT p
study NN p
. . p

There EX N
were VBD N
no DT o
significant JJ o
differences NNS o
between IN N
sleep JJ o
variables NNS o
at IN N
baseline NN N
. . N

Melatonin NNP i
significantly RB N
improved VBD o
sleep JJ o
latency NN o
( ( N
by IN N
an DT N
average NN N
of IN N
47 CD N
min NN N
) ) N
and CC N
total JJ o
sleep NN o
( ( N
by IN N
an DT N
average NN N
of IN N
52 CD N
min NN N
) ) N
compared VBN N
to TO N
placebo VB i
, , N
but CC N
not RB N
number NN N
of IN N
night NN N
wakenings NNS N
. . N

The DT N
side NN o
effect NN o
profile NN o
was VBD N
low JJ o
and CC o
not RB o
significantly RB o
different JJ o
between IN N
the DT N
two CD N
arms NNS N
. . N

-DOCSTART- -21860188- O O

Effect NN N
of IN N
prophylactic JJ i
amiodarone NN i
in IN N
patients NNS p
with IN p
rheumatic JJ p
valve NNS p
disease NN p
undergoing VBG p
valve JJ p
replacement NN p
surgery NN p
. . p

The DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prophylactic JJ N
single-dose JJ N
intravenous JJ N
amiodarone NN i
in IN N
patients NNS p
undergoing VBG p
valve JJ p
replacement NN p
surgery NN p
. . p

Maintenance NN N
of IN N
sinus NN N
rhythm NN N
is VBZ N
better JJR N
than IN N
maintenance NN N
of IN N
fixed JJ N
ventricular JJ N
rate NN N
in IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
especially RB N
in IN N
the DT N
presence NN N
of IN N
irritable JJ N
left NN N
or CC N
right JJ N
atrium NN N
because IN N
of IN N
enlargement NN N
. . N

Fifty-six JJ p
patients NNS p
with IN p
valvular JJ p
heart NN p
disease NN p
with IN p
or CC p
without IN p
AF NNP p
were VBD p
randomly RB p
divided VBN p
into IN N
two CD N
groups NNS N
. . N

Group NNP N
I PRP N
or CC N
the DT N
amiodarone NN i
group NN i
( ( N
n=28 NN N
) ) N
received VBD N
amiodarone NN i
( ( N
3 CD N
mg/kg NN N
in IN N
100 CD N
ml NNS N
normal JJ N
saline NN N
) ) N
and CC N
group NN N
II NNP N
or CC N
the DT N
control NN i
group NN N
received VBD N
same JJ N
volume NN N
of IN N
normal JJ i
saline NN i
. . i

The DT N
standardized JJ N
protocol NN N
for IN N
cardiopulmonary JJ N
bypass NN N
was VBD N
maintained VBN N
for IN N
all PDT N
the DT N
patients NNS N
. . N

AF NNP o
occurred VBD N
in IN N
7.14 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
, , N
and CC N
in IN N
group NN N
II NNP N
, , N
28.57 CD N
% NN N
( ( N
P=0.035 NNP N
) ) N
; : N
ventricular JJ o
tachycardia/fibrillation NN o
was VBD N
observed VBN N
in IN N
21.43 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
and CC N
46.43 CD N
% NN N
patients NNS N
in IN N
group NN N
II NNP N
( ( N
P=0.089 NNP N
) ) N
after IN N
release NN N
of IN N
aortic JJ N
clamp NN N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
92.86 CD N
% NN N
) ) N
maintained VBD N
sinus JJ o
rhythm NN o
without IN o
cardioversion NN o
or CC o
defibrillation NN o
after IN N
release NN N
of IN N
aortic JJ N
cross NN N
clamp NN N
( ( N
P=0.002 NNP N
) ) N
. . N

Defibrillation NN o
or CC o
cardio NN o
version NN o
was VBD N
needed VBN N
in IN N
7.14 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
and CC N
28.57 CD N
% NN N
patients NNS N
in IN N
group NN N
II NNP N
( ( N
P=0.078 NNP N
) ) N
. . N

A DT N
single JJ N
prophylactic JJ N
intraoperative NN N
dose NN N
of IN N
intravenous JJ N
amiodarone NN i
decreased VBD N
post NN o
bypass NN o
arrhythmia NN o
in IN N
this DT N
study NN N
in IN N
comparison NN N
to TO N
the DT N
control NN N
group NN N
. . N

Single NNP N
dose NN N
of IN N
intraoperative JJ N
amiodarone NN i
may MD N
be VB N
used VBN N
to TO N
decrease VB N
postoperative JJ N
arrhythmia NN N
in IN N
open JJ N
heart NN N
surgery NN N
. . N

-DOCSTART- -14616872- O O

Presentation NN N
of IN N
allergen NN N
in IN N
different JJ N
food NN N
preparations NNS N
affects VBZ N
the DT N
nature NN N
of IN N
the DT N
allergic JJ p
reaction NN p
-- : p
a DT p
case NN p
series NN p
. . p

BACKGROUND NNP N
Characterization NNP N
of IN N
fatal JJ N
and CC N
non-fatal JJ N
reactions NNS N
to TO N
food NN N
indicates NNS N
that IN N
the DT N
majority NN N
of IN N
reactions NNS N
are VBP N
due JJ N
to TO N
the DT N
ingestion NN N
of IN N
prepared JJ N
foods NNS N
rather RB N
than IN N
the DT N
non-processed JJ N
allergen NN N
. . N

In IN N
an DT N
ongoing JJ N
study NN N
that WDT N
used VBD N
a DT N
double-blind JJ N
placebo-controlled JJ i
food NN N
challenge NN N
to TO N
investigate VB N
peanut NN N
allergy NN N
and CC N
clinical JJ N
symptoms NNS N
, , N
the DT N
observed JJ N
reaction NN N
severity NN N
in IN N
four CD N
of IN N
the DT N
first JJ p
six CD p
subjects NNS p
was VBD N
greater JJR N
than IN N
anticipated VBN N
. . N

We PRP N
hypothesized VBD N
that IN N
this DT N
was VBD N
due JJ N
to TO N
differences NNS N
in IN N
the DT N
composition NN N
of IN N
the DT N
challenge NN N
vehicle NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
severity NN N
of IN N
observed JJ N
challenge NN N
reactions NNS N
would MD N
be VB N
repeated VBN N
on IN N
re-challenge NN N
with IN N
a DT N
lower JJR i
fat JJ i
challenge NN i
vehicle NN i
. . i

METHODS NNP N
Peanut-allergic JJ p
subjects NNS p
were VBD N
re-challenged JJ N
with IN N
a DT N
lower JJR i
fat NN i
recipe NN i
after IN N
reacting VBG N
more RBR N
severely RB N
than IN N
was VBD N
anticipated VBN N
to TO N
an DT N
initial JJ N
peanut NN i
challenge NN N
. . N

Similar JJ N
challenge NN N
vehicle NN N
recipes NNS N
were VBD N
used VBN N
, , N
the DT N
only JJ N
difference NN N
being VBG N
the DT N
lower JJR N
fat JJ N
content NN N
( ( N
22.9 CD N
% NN N
compared VBN N
with IN N
31.5 CD N
% NN N
) ) N
. . N

The DT N
peanut NN N
content NN N
of IN N
the DT N
two CD N
recipes NNS N
was VBD N
analysed VBN N
using VBG N
RAST NNP N
inhibition NN N
studies NNS N
and CC N
ELISA NNP N
tests NNS N
. . N

RESULTS NNP N
Three CD N
of IN N
four CD N
subjects NNS N
reacted VBD N
to TO N
much JJ N
smaller JJR N
doses NNS o
of IN o
peanut NN o
protein NN o
on IN o
re-challenge NN o
( ( N
mean JJ N
dose NN N
equivalence NN N
- : N
23 CD N
times NNS N
less RBR N
peanut NN N
) ) N
with IN N
the DT N
lower JJR N
fat JJ N
recipe NN N
. . N

RAST NNP o
inhibition NN o
showed VBD N
that IN N
neither CC N
recipe VB N
altered VBN N
epitope DT o
recognition NN o
. . o

The DT N
higher JJR N
fat JJ N
recipe NN N
required VBN N
twice RB N
as RB N
much JJ N
peanut NN N
to TO N
cause VB N
50 CD o
% NN o
inhibition NN o
. . o

ELISA NNP N
detected VBD N
far RB N
lower JJR N
levels NNS N
of IN N
peanut NN N
in IN N
the DT N
higher JJR N
fat JJ N
recipe NN N
( ( N
220 CD N
000 CD N
parts NNS N
per IN N
million CD N
( ( N
p.p.m NN N
. . N

) ) N
) ) N
than IN N
in IN N
the DT N
lower JJR N
fat NN N
recipe NN N
( ( N
990 CD N
000 CD N
p.p.m. NN N
) ) N
. . N

CONCLUSION VB N
The DT N
fat JJ N
content NN N
of IN N
a DT N
challenge NN N
vehicle NN N
has VBZ N
a DT N
profound JJ N
effect NN N
on IN N
the DT N
reaction NN N
experienced VBD N
after IN N
allergen NN N
ingestion NN N
. . N

This DT N
is VBZ N
another DT N
factor NN N
to TO N
be VB N
considered VBN N
in IN N
assessing VBG N
the DT N
risk NN N
of IN N
certain JJ N
foods NNS N
to TO N
food-allergic JJ p
consumers NNS p
and CC N
adds VBZ N
another DT N
dimension NN N
to TO N
clinical JJ N
, , N
research NN N
and CC N
regulatory JJ N
practice NN N
. . N

-DOCSTART- -17984242- O O

Effects NNS N
of IN N
resistance NN i
versus NN i
endurance NN i
training NN i
on IN N
serum NN o
adiponectin NN o
and CC o
insulin NN o
resistance NN o
index NN o
. . o

PURPOSE VB N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
resistance NN i
and CC i
endurance NN i
training NN i
on IN N
serum NN o
adiponectin NN o
and CC o
insulin NN o
resistance NN o
index NN o
( ( o
SI NNP o
) ) o
in IN N
healthy JJ p
men NNS p
. . p

METHODS NNP N
Twenty-four CD p
healthy JJ p
males NNS p
( ( p
age NN p
, , p
35-48 CD p
years NNS p
) ) p
participated VBD p
in IN p
the DT p
study NN p
. . p

The DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
endurance NN i
training NN i
group NN i
( ( i
n=8 NN i
) ) i
, , i
resistance NN i
training NN i
group NN i
( ( i
n=8 CC i
) ) i
and CC i
control NN i
group NN i
( ( i
n=8 RB i
) ) i
. . i

Blood NN o
samples NNS o
were VBD i
taken VBN i
in IN i
fasting VBG i
state NN i
from IN i
all DT i
subjects NNS i
. . i

The DT i
experimental JJ i
groups NNS i
performed VBD i
either CC i
endurance NN i
or CC i
resistance NN i
training NN i
3 CD i
days NNS i
a DT i
week NN i
for IN i
12 CD i
weeks NNS i
. . i

The DT i
endurance NN i
training NN i
programme NN i
included VBD i
continuous JJ i
running VBG i
at IN i
an DT i
intensity NN i
corresponding VBG i
to TO i
75-85 CD i
% NN i
of IN i
maximal JJ i
heart NN i
rate NN i
, , i
while IN i
resistance NN i
training NN i
consisted VBD i
of IN i
four CD i
sets NNS i
of IN i
circuit NN i
weight NN i
training NN i
for IN i
11 CD i
stations NNS i
and CC i
at IN i
an DT i
intensity NN i
corresponding VBG i
to TO i
50-60 CD i
% NN i
of IN i
one-repetition JJ i
maximum NN i
. . i

The DT N
maximum JJ N
numbers NNS N
of IN N
repetitions NNS N
in IN N
each DT N
station NN N
was VBD N
12 CD N
. . N

RESULTS VB N
There EX N
were VBD N
significant JJ N
negative JJ N
correlations NNS N
between IN N
serum NN o
adiponectin NN o
and CC o
body NN o
fat JJ o
percentage NN o
, , o
waist-to-hip JJ o
ratio NN o
, , o
body NN o
mass NN o
index NN o
and CC o
the DT o
insulin NN o
resistance NN o
index NN o
at IN o
baseline NN o
, , N
whereas JJ N
changes NNS N
in IN N
response NN N
to TO N
training NN N
were VBD N
not RB N
significantly RB N
correlated VBN N
. . N

Both DT N
endurance NN N
and CC N
resistance NN N
training NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
SI NNP o
in IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
serum JJ o
adiponectin NN o
did VBD N
not RB N
change VB N
significantly RB N
in IN N
response NN N
to TO N
resistance NN N
and CC N
endurance NN N
training NN N
. . N

CONCLUSION NNP N
Endurance NNP N
and CC N
resistance NN N
training NN N
caused VBD N
an DT N
improvement NN N
in IN N
insulin NN N
resistance NN N
in IN N
healthy JJ p
men NNS p
, , N
but CC N
this DT N
improvement NN N
was VBD N
not RB N
accompanied VBN N
by IN N
increased JJ N
adiponectin NN N
levels NNS N
. . N

-DOCSTART- -15264973- O O

The DT N
effect NN N
of IN N
reinforcement NN i
or CC i
stimulus NN i
control NN i
to TO N
reduce VB N
sedentary JJ o
behavior NN o
in IN N
the DT N
treatment NN N
of IN N
pediatric JJ p
obesity NN p
. . p

Obese JJ p
children NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
family-based JJ i
behavioral JJ i
treatment NN i
that WDT i
included VBD i
either DT i
stimulus NN i
control NN i
or CC i
reinforcement NN i
to TO N
reduce VB N
sedentary JJ N
behaviors NNS N
. . N

Significant NNP N
and CC N
equivalent JJ N
decreases NNS N
in IN N
sedentary JJ o
behavior NN o
and CC o
high JJ o
energy NN o
density NN o
foods NNS o
, , N
increases NNS N
in IN N
physical JJ o
activity NN o
and CC o
fruits NNS o
and CC o
vegetables NNS o
, , N
and CC N
decreases NNS N
in IN N
standardized JJ N
body NN o
mass NN o
index NN o
( ( o
z-BMI NN o
) ) o
were VBD N
observed VBN N
. . N

Children NNP N
who WP N
substituted VBD N
active JJ N
for IN N
sedentary JJ o
behaviors NNS o
had VBD N
significantly RB N
greater JJR N
z-BMI JJ o
changes NNS o
at IN N
6 CD N
( ( N
-1.21 NNP N
vs. IN N
-0.76 NNP N
) ) N
and CC N
12 CD N
( ( N
-1.05 NNP N
vs. IN N
-0.51 NNP N
) ) N
months NNS N
, , N
respectively RB N
. . N

Substitution NN N
of IN N
physically RB N
active JJ N
for IN N
sedentary JJ o
behaviors NNS o
and CC N
changes NNS o
in IN o
activity NN o
level NN o
predicted VBD N
6- CD N
and CC N
12-month JJ N
z-BMI NN o
changes NNS o
. . o

Results NNS N
suggest VBP N
stimulus JJ i
control NN i
and CC i
reinforcing VBG i
reduced VBN N
sedentary JJ o
behaviors NNS o
are VBP N
equivalent JJ N
ways NNS N
to TO N
decrease VB N
sedentary JJ o
behaviors NNS o
, , N
and CC N
behavioral JJ o
economic JJ o
relationships NNS o
in IN o
eating NN o
and CC o
activity NN o
may MD N
mediate VB N
the DT N
effects NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -16691061- O O

Safety NN N
and CC N
acceptability NN N
of IN N
cellulose JJ i
sulfate NN i
as IN N
a DT N
vaginal JJ N
microbicide NN N
in IN N
HIV-infected JJ p
women NNS p
. . p

OBJECTIVES NNP N
Few JJ N
studies NNS N
of IN N
topical JJ N
microbicides NNS N
have VBP N
assessed VBN N
their PRP$ N
safety NN o
in IN o
HIV-infected JJ o
women NNS o
. . o

We PRP N
conducted VBD N
this DT N
study NN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
acceptability NN o
of IN N
6 CD N
% NN N
cellulose JJ i
sulfate NN i
( ( i
CS NNP i
) ) i
gel NN N
as IN N
a DT N
vaginal JJ N
microbicide NN N
in IN p
sexually RB p
abstinent JJ p
and CC p
active JJ p
HIV-infected JJ p
women NNS p
. . p

METHODS NNP N
Fifty-nine JJ p
HIV-infected JJ p
women NNS p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ i
study NN N
comparing VBG N
6 CD N
% NN N
CS NNP i
to TO i
placebo VB i
gel NNS i
used VBN N
for IN N
14 CD N
days NNS N
. . N

Sexually NNP p
abstinent JJ p
women NNS p
applied VBD N
gel JJ N
once RB N
or CC N
twice JJ N
daily JJ N
and CC N
sexually RB N
active JJ N
women NNS N
used VBN N
gel JJ N
once RB N
daily JJ N
. . N

RESULTS NNP N
CS NNP N
gel NN N
was VBD N
safe JJ N
with IN N
no DT N
reported VBN N
severe RB o
or CC o
life-threatening JJ o
adverse JJ o
events NNS o
( ( o
AE NNP o
) ) o
. . o

Thirty-nine NNP N
( ( N
66 CD N
% NN N
) ) N
of IN N
the DT N
participants NNS N
experienced VBD N
urogenital JJ o
AE NNP o
judged VBD N
as IN N
probably RB N
or CC N
possibly RB N
related VBN N
to TO N
gel VB N
. . N

The DT N
majority NN N
( ( N
51 CD N
% NN N
) ) N
of IN N
these DT N
participants NNS N
reported VBD N
only RB N
mild JJ o
events NNS o
. . o

Fewer JJR N
women NNS N
( ( N
62 CD N
% NN N
) ) N
who WP N
used VBD N
CS NNP N
experienced VBD N
urogenital JJ o
AE NNP o
than IN N
those DT N
assigned VBN N
to TO N
placebo VB i
gel NN N
( ( N
70 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.59 CD N
) ) N
. . N

Eleven NNP N
( ( N
19 CD N
% NN N
) ) N
women NNS N
experienced VBD N
intermenstrual JJ o
bleeding NN o
judged VBD N
to TO N
be VB N
probably RB N
or CC N
possibly RB N
related VBN N
to TO N
gel VB N
use NN N
( ( N
four CD N
in IN N
the DT N
CS NNP N
and CC N
seven CD N
in IN N
the DT N
placebo NN N
gel NN N
group NN N
) ) N
. . N

There EX N
was VBD N
no DT N
increase NN N
in IN N
AE NNP o
by IN N
frequency NN N
of IN N
gel NN N
use NN N
or CC N
sexual JJ N
activity NN N
with IN N
the DT N
exception NN N
of IN N
abdominal/pelvic NN o
pain NN o
which WDT N
was VBD N
noted VBN N
more RBR N
frequently RB N
with IN N
twice RB N
daily JJ N
use NN N
among IN N
sexually RB N
abstinent JJ N
women NNS N
. . N

Women NNS N
and CC N
men NNS N
found VBD N
the DT N
gel NN N
highly RB N
acceptable JJ N
. . N

CONCLUSIONS VB N
This DT N
Phase NNP N
I PRP N
study VBP N
demonstrated VBD N
that IN N
CS NNP i
vaginal JJ i
gel NN i
was VBD N
safe JJ o
, , o
well RB o
tolerated VBN o
and CC o
acceptable JJ o
by IN N
HIV-infected JJ p
women NNS p
and CC p
their PRP$ p
male JJ p
partners NNS p
. . p

Thus RB N
, , N
further JJ N
development NN N
of IN N
CS NNP N
is VBZ N
warranted VBN N
as IN N
a DT N
potential JJ N
method NN N
to TO N
prevent VB N
HIV NNP o
transmission NN o
and CC o
acquisition NN o
. . o

-DOCSTART- -24517028- O O

Effects NNS N
of IN N
iron NN i
on IN N
the DT N
pharmacokinetics NNS o
of IN o
paracetamol NN o
in IN o
saliva NN o
. . o

Paracetamol NNP i
has VBZ N
been VBN N
reported VBN N
to TO N
chelate VB N
with IN N
iron NN i
. . i

It PRP N
was VBD N
found VBN N
that IN N
no DT N
in IN o
vitro JJ o
reaction NN o
between IN N
ferrous JJ N
ion NN N
and CC N
paracetamol NN N
. . N

Other JJ N
studies NNS N
found VBD N
that IN N
there EX N
is VBZ N
an DT N
aerobic JJ N
( ( N
in IN N
the DT N
gastrointestinal JJ N
tract NN N
) ) N
oxidation NN N
of IN N
ferrous JJ N
ion NN N
to TO N
ferric VB N
ion NN N
caused VBN N
in IN N
iron-paracetamol NN N
in IN N
vivo JJ N
reactions NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
iron NN N
interacts NNS N
with IN N
paracetamol NN N
and CC N
reduces NNS N
paracetamol JJ o
absorption NN o
. . o

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
study NN N
design NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
in IN o
vivo JJ o
interaction NN o
of IN o
paracetamol NN o
and CC o
ferrous JJ o
ion NN o
. . o

Paracetamol NNP i
( ( N
1.0 CD N
g NN N
) ) N
was VBD N
co-ignested JJ N
alone RB i
or CC i
with IN N
( ( i
300 CD i
mg NN i
) ) i
ferrous JJ i
sulphate NN i
by IN N
ten JJ p
healthy JJ p
male NN p
volunteers NNS p
, , N
using VBG N
saliva JJ N
drug NN N
levels NNS N
as IN N
a DT N
parameter NN N
. . N

Concomitant NNP N
administration NN N
of IN N
ferrous JJ i
sulphate NN i
and CC i
paracetamol NN i
, , N
decreased VBN N
AUC8 NNP o
from IN N
42.88 CD N
+/- JJ N
3.8-34.25 JJ N
+/- JJ N
2.8 CD N
microg NN N
h NN N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
and CC N
Cmax NNP o
from IN N
18.75 CD N
+/- JJ N
1.9 CD N
to TO N
15.9 CD N
+/- JJ N
1.7 CD N
microg NN N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
while IN N
no DT N
change NN N
in IN N
tmax NN N
( ( N
p JJ N
= NNP N
0.5 CD N
) ) N
was VBD N
originated VBN N
. . N

A DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
paracetamol NN o
pharmacokinetic JJ o
parameter NN o
oral JJ o
clearance NN o
( ( o
C1/F NNP o
) ) o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
and CC N
slightly RB N
increased VBN N
in IN N
volume NN o
of IN o
distribution NN o
( ( N
V NNP N
( ( N
d NN N
) ) N
/F NN N
) ) N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
. . N

Co-administration NN N
of IN N
iron NN i
and CC i
paracetamol JJ i
results NNS N
in IN N
decreased JJ o
paracetamol NN o
absorption NN o
due JJ N
to TO N
an DT N
interaction NN N
between IN N
iron NN N
and CC N
paracetamol NN N
. . N

-DOCSTART- -22066973- O O

Comparison NNP N
of IN N
epidural JJ i
tramadol-ropivacaine JJ i
and CC i
fentanyl-ropivacaine JJ i
for IN N
labor NN p
analgesia NN p
: : p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
5 CD N
mg/mL NN N
tramadol NN i
is VBZ N
superior JJ N
to TO N
3 CD N
? . N
g/mL NN N
fentanyl NN i
when WRB N
combined VBN N
with IN N
0.125 CD N
% NN N
ropivacaine NN i
in IN N
parturients NNS p
undergoing VBG p
labor NN p
during IN p
epidural JJ p
analgesia NN p
. . p

METHODS NNP N
Sixty-one JJ p
parturients NNS p
undergoing VBG p
labor NN p
selected VBN p
for IN p
delivery NN p
with IN p
epidural JJ p
analgesia NNS p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
Group NNP N
tramadol VBD i
( ( i
0.125 CD i
% NN i
ropivacaine NN i
plus CC i
tramadol JJ i
5 CD i
mg/mL NN i
) ) i
and CC N
Group NNP N
fentanyl NNP i
( ( i
0.125 CD i
% NN i
ropivacaine NN i
plus CC i
fentanyl JJ i
3 CD i
ug/mL NN i
) ) i
. . N

Hemodynamics NNS o
, , o
rate NN o
of IN o
cesarean JJ o
delivery NN o
, , o
sensory JJ o
block NN o
level NN o
, , o
Bromage NNP o
motor NN o
scale NN o
scores NNS o
, , o
instrument-assisted JJ o
delivery NN o
, , o
oxytocin NN o
use NN o
, , o
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
scores VBZ o
, , o
Apgar NNP o
scores VBZ o
, , o
umbilical JJ o
cord NN o
artery NN o
gas NN N
analysis NN o
, , o
and CC o
maternal JJ o
side-effects NNS o
including VBG o
nausea NN o
, , o
vomiting VBG o
, , o
pruritus NN o
, , o
urinary JJ o
retention NN o
, , o
shivering VBG o
, , o
hypotension NN o
, , o
and CC o
respiratory JJ o
depression NN o
were VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
two CD N
groups NNS N
had VBD N
no DT N
significant JJ N
differences NNS N
with IN N
respect NN N
to TO N
maternal JJ o
hemodynamics NNS o
, , o
neonatal JJ o
heart NN o
rate NN o
, , o
VAS NNP o
scores VBZ o
, , o
rate NN o
of IN o
cesarean JJ o
delivery NN o
, , o
sensory JJ o
block NN o
level NN o
, , o
Bromage NNP o
motor NN o
scale NN o
scores NNS o
, , o
instrument-assisted JJ o
delivery NN o
, , o
oxytocin NN o
use NN o
, , o
hypotension NN o
, , o
nausea NN o
, , o
vomiting NN o
, , o
and CC o
respiratory JJ o
depression NN o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
pruritus NN o
, , o
shivering NN o
, , o
and CC o
urinary JJ o
retention NN o
were VBD N
more JJR N
commonly RB N
observed VBN N
in IN N
Group NNP N
fentanyl VBD N
despite IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Umbilical JJ o
artery NN o
pH NN o
was VBD N
significantly RB N
lower JJR N
while IN N
PCO NNP N
( ( N
2 CD N
) ) N
was VBD N
higher RBR N
in IN N
Group NNP N
fentanyl VBD i
than IN N
Group NNP N
tramadol NN i
( ( N
p JJ N
= NN N
0.003 CD N
and CC N
p VB N
= JJ N
0.026 CD N
, , N
respectively RB N
) ) N
. . N

Birth-weight NNP o
, , o
umbilical JJ o
artery NN o
PO NNP o
( ( o
2 CD o
) ) o
and CC o
base NN o
deficit NN o
, , o
and CC o
Apgar NNP o
scores NNS o
at IN N
1 CD N
and CC N
5 CD N
min NNS N
were VBD N
comparable JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
Our PRP$ N
observations NNS N
suggest VBP N
that IN N
tramadol NN i
seems VBZ N
to TO N
be VB N
a DT N
safe JJ N
alternative NN N
to TO N
fentanyl VB i
for IN N
labor NN N
analgesia NNS N
due JJ N
to TO N
its PRP$ N
similar JJ N
analgesic JJ N
efficacy NN N
. . N

-DOCSTART- -12044624- O O

A DT N
single JJ N
infusion NN N
of IN N
intravenous JJ N
ketamine NN i
improves VBZ N
pain VBP N
relief NN N
in IN N
patients NNS p
with IN p
critical JJ p
limb NN p
ischaemia NN p
: : p
results NNS N
of IN N
a DT N
double JJ N
blind NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

We PRP N
report VBP N
the DT N
first JJ N
double JJ N
blind NN N
randomised VBD N
controlled JJ N
trial NN N
of IN N
regular JJ N
opioids NNS i
and CC N
an DT N
infusion NN N
of IN N
low JJ N
dose NN N
( ( N
0.6 CD N
mg/kg NN N
) ) N
intravenous JJ N
ketamine NN i
compared VBN N
with IN N
opioids NNS i
and CC N
placebo NN i
in IN N
patients NNS p
with IN p
allodynia NN p
, , p
hyperalgesia NN p
and CC p
hyperpathia NN p
secondary JJ p
to TO p
critical JJ p
limb NN p
ischaemia NN p
. . p

Thirty-five JJ p
patients NNS p
completed VBD p
the DT p
study NN p
, , p
18 CD p
received VBD N
regular JJ N
opioids NNS i
plus CC i
ketamine NN i
, , N
while IN N
17 CD p
received VBD N
regular JJ i
opioids NNS i
plus CC i
placebo NN i
. . i

Using VBG N
the DT N
Brief NNP o
Pain NNP o
Inventory NNP o
, , o
the DT o
% NN o
pain NN o
relief NN o
that IN N
the DT N
patients NNS N
in IN N
the DT N
ketamine NN N
group NN N
attributed VBD N
to TO N
their PRP$ N
medication NN N
improved VBN N
significantly RB N
from IN N
50 CD N
% NN N
immediately RB N
pre-infusion NN N
to TO N
65 CD N
% NN N
24 CD N
h JJ N
post-infusion NN N
and CC N
69 CD N
% NN N
5 CD N
days NNS N
post VBN N
infusion NN N
. . N

Over IN N
the DT N
same JJ N
period NN N
, , N
the DT N
pain NN o
relief NN o
achieved VBN o
by IN N
the DT N
placebo NN N
group NN N
rose VBD N
from IN N
58 CD N
% NN N
pre-infusion NN N
to TO N
56 CD N
% NN N
24 CD N
h NN N
post NN N
infusion NN N
and CC N
then RB N
50 CD N
% NN N
relief NN N
5 CD N
days NNS N
later RB N
. . N

This DT N
was VBD N
statistically RB o
significant JJ o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
using VBG N
both DT N
the DT N
t-test NN o
and CC o
the DT o
Wilcoxon NNP o
Rank NNP o
Sum NNP o
test NN o
. . o

The DT N
ketamine NN N
group NN N
also RB N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
24 CD N
h NN N
post NN N
infusion NN N
of IN N
the DT N
effect NN N
of IN N
pain NN o
on IN N
their PRP$ N
general JJ N
activity NN N
( ( N
P=0.03 NNP N
) ) N
and CC N
on IN N
their PRP$ N
enjoyment NN N
of IN N
life NN N
( ( N
P=0.004 NNP N
) ) N
. . N

This DT N
study NN N
shows VBZ N
that IN N
combining VBG N
a DT N
single JJ N
infusion NN N
of IN N
low JJ N
dose JJ N
ketamine NN N
with IN N
regular JJ N
opioid JJ i
analgesia NN i
can MD N
result VB N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
pain NN o
relief NN o
for IN N
this DT N
patient NN N
group NN N
. . N

-DOCSTART- -404962- O O

Comparative JJ N
trial NN N
of IN N
carbenicillin NN i
and CC N
ampicillin NN i
therapy NN N
for IN N
purulent NN p
meningitis NN p
. . p

A DT N
randomized JJ N
therapeutic JJ N
trial NN N
of IN N
carbenicillin NN i
( ( i
CB NNP i
) ) i
or CC i
ampicillin NN i
( ( i
AMP NNP i
) ) i
in IN N
purulent NN N
meningitis NN N
was VBD N
performed VBN N
in IN N
86 CD p
pediatric JJ p
and CC p
adult NN p
patients NNS p
( ( p
41 CD p
Haemophilus NNP p
influenzae NN p
, , p
22 CD p
Streptococcus NNP p
pneumoniae NN p
, , p
13 CD p
Neisseria NNP p
meningitidis NN p
, , p
and CC p
10 CD p
of IN p
unknown JJ p
etiology NN p
) ) p
. . p

All DT N
isolates NNS N
, , N
incuding VBG N
H. NNP N
influenzae NN N
, , N
were VBD N
susceptible JJ N
to TO N
CB NNP N
and CC N
AMP NNP N
. . N

Median JJ N
cerebrospinal JJ o
fluid NN o
( ( o
CSF NNP o
) ) o
antibiotic JJ o
concentrations NNS o
were VBD N
0.85 CD N
and CC N
1.60 CD N
mug/ml NN N
for IN N
CB NNP N
and CC N
AMP NNP N
, , N
respectively RB N
, , N
during IN N
administration NN N
of IN N
daily JJ N
doses NNS N
of IN N
400 CD N
mg/kg NNS N
and CC N
0.65 CD N
and CC N
0.45 CD N
mug/ml NN N
, , N
respectively RB N
, , N
on IN N
daily JJ N
doses NNS N
of IN N
200 CD N
mg/kg NN N
. . N

Higher JJR o
CSF NNP o
concentrations NNS o
, , N
up RB N
to TO N
a DT N
median JJ N
concentration NN N
of IN N
4.5 CD N
mug/ml NNS N
, , N
were VBD N
observed VBN N
in IN N
patients NNS N
with IN N
CSF NNP N
protein NN N
concentrations NNS N
> VBP N
/=75 JJ N
mg/100 NN N
ml NN N
. . N

Clinical JJ o
responses NNS o
were VBD N
equivalent JJ N
on IN N
either CC N
antibiotic JJ N
regimen NNS N
. . N

Among IN N
AMP JJ i
patients NNS N
( ( N
45 CD N
) ) N
, , N
8 CD N
had VBD o
significant JJ o
residua NN o
and CC N
3 CD N
died VBD o
; : o
among IN N
CB NNP i
patients NNS N
( ( N
41 CD N
) ) N
, , N
5 CD N
had VBD o
residua NN o
and CC N
none NN o
died VBD o
. . o

However RB N
, , N
38 CD N
% NN N
of IN N
H. NNP p
influenzae NN p
patients NNS p
treated VBN N
with IN N
CB NNP i
had VBD N
positive JJ o
CSF NNP o
cultures NNS o
on IN N
day NN N
1 CD N
follow-up JJ N
lumbar NN N
punctures NNS N
, , N
compared VBN N
with IN N
only RB N
5.8 CD N
% NN N
of IN N
AMP NNP N
patients NNS p
with IN p
H. NNP p
influenzae NN p
. . p

The DT N
significance NN N
of IN N
a DT N
delay NN o
of IN o
CSF NNP o
sterilization NN o
among IN N
CB-treated JJ N
patients NNS N
is VBZ N
unknown JJ N
, , N
since IN N
there EX N
was VBD N
no DT N
correlation NN N
between IN N
persistence NN N
of IN N
hemophilus JJ N
organisms NNS N
and CC N
the DT N
frequency NN N
of IN N
adverse JJ N
outcome NN N
. . N

AMP NNP i
and CC N
CB NNP i
are VBP N
equivalent JJ N
for IN N
the DT N
treatment NN N
of IN N
bacterial JJ N
meningitis NN N
due JJ N
to TO N
susceptible JJ N
organisms NNS N
. . N

-DOCSTART- -9672054- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
risperidone NN i
in IN N
adults NNS p
with IN p
autistic JJ p
disorder NN p
and CC p
other JJ p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

BACKGROUND NNP N
Neurobiological NNP N
research NN N
has VBZ N
implicated VBN N
the DT N
dopamine NN N
and CC N
serotonin JJ N
systems NNS N
in IN N
the DT N
pathogenesis NN N
of IN N
autism NN p
. . p

Open-label JJ N
reports NNS N
suggest VBP N
that IN N
the DT N
serotonin2A-dopamine JJ i
D2 NNP i
antagonist NN i
risperidone NN i
may MD N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
reducing VBG N
the DT N
interfering NN N
symptoms NNS N
of IN N
patients NNS p
with IN p
autism NN p
. . p

METHODS NNP N
Thirty-one CD p
adults NNS p
( ( p
age NN p
[ VBZ p
mean+/-SD JJ p
] NNP p
, , p
28.1+/-7.3 JJ p
years NNS p
) ) p
with IN p
autistic JJ p
disorder NN p
( ( p
n=17 JJ p
) ) p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
not RB p
otherwise RB p
specified VBN p
( ( p
n=14 JJ p
) ) p
participated VBD p
in IN p
a DT p
12-week JJ p
double-blind NN p
, , p
placebo-controlled JJ i
trial NN p
of IN p
risperidone NN i
. . i

Patients NNS N
treated VBD N
with IN N
placebo NN N
subsequently RB N
received VBD N
a DT N
12-week JJ N
open-label JJ N
trial NN N
of IN N
risperidone NN i
. . i

RESULTS NNP N
For IN N
persons NNS N
completing VBG N
the DT N
study NN N
, , N
8 CD N
( ( N
57 CD N
% NN N
) ) N
of IN N
14 CD N
patients NNS N
treated VBN N
with IN N
risperidone NN i
were VBD N
categorized VBN N
as IN N
responders NNS N
( ( N
daily JJ N
dose VB N
[ JJ N
mean+/-SD JJ N
] NN N
, , N
2.9+/-1.4 JJ N
mg NN N
) ) N
compared VBN N
with IN N
none NN N
of IN N
16 CD N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
. . N

Risperidone NN i
was VBD N
superior JJ N
to TO N
placebo VB i
in IN N
reducing VBG N
repetitive JJ o
behavior NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
aggression NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
anxiety NN o
or CC o
nervousness NN o
( ( o
P NNP o
< NNP o
.02 NNP o
) ) o
, , o
depression NN o
( ( o
P NNP o
< NNP o
.03 NNP o
) ) o
, , o
irritability NN o
( ( o
P NNP o
< NNP o
.01 NNP o
) ) o
, , N
and CC N
the DT N
overall JJ o
behavioral JJ o
symptoms NNS o
of IN o
autism NN o
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Objective NNP N
, , N
measurable JJ N
change NN N
in IN N
social JJ o
behavior NN o
and CC o
language NN o
did VBD N
not RB N
occur VB N
. . N

Nine NNP N
( ( N
60 CD N
% NN N
) ) N
of IN N
15 CD N
patients NNS N
who WP N
received VBD N
treatment NN N
with IN N
open-label JJ N
risperidone NN N
following VBG N
the DT N
double-blind JJ N
placebo NN i
phase NN N
responded VBD N
. . N

Other JJ N
than IN N
mild JJ o
, , o
transient JJ o
sedation NN o
, , N
risperidone NN N
was VBD N
well RB N
tolerated VBN o
, , N
with IN N
no DT N
evidence NN N
of IN N
extrapyramidal JJ o
effects NNS o
, , o
cardiac JJ o
events NNS o
, , o
or CC o
seizures NNS o
. . o

CONCLUSION NNP N
Risperidone NNP i
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
symptoms NNS N
of IN N
autism NN p
in IN p
adults NNS p
. . p

-DOCSTART- -10832772- O O

Secretin NNP N
and CC N
autism NN N
: : N
a DT N
two-part JJ N
clinical JJ N
investigation NN N
. . N

Recent JJ N
anecdotal JJ N
reports NNS N
have VBP N
touted VBN N
the DT N
gastrointestinal NN N
( ( N
GI NNP N
) ) N
hormone NN N
secretin NN i
as IN N
a DT N
treatment NN N
modality NN N
for IN N
autism NN N
, , N
though IN N
there EX N
is VBZ N
little JJ N
clinical JJ N
evidence NN N
or CC N
literature NN N
to TO N
support VB N
its PRP$ N
viability NN N
. . N

We PRP N
undertook VBD N
a DT N
two-part JJ N
clinical JJ N
trial NN N
to TO N
investigate VB N
these DT N
claims NNS N
. . N

Fifty-six JJ p
patients NNS p
( ( p
49 CD p
boys NNS p
, , p
7 CD p
girls NNS p
, , p
mean JJ p
age NN p
= VBD p
6.4 CD p
years NNS p
, , p
SD NNP p
= NNP p
2.7 CD p
) ) p
enrolled VBN p
in IN p
an DT p
open-label JJ p
trial NN p
of IN p
secretin NN i
, , p
during IN p
which WDT p
they PRP p
received VBD p
one CD p
injection NN p
of IN p
the DT p
hormone NN p
( ( p
2 CD p
IU/kg NNP p
) ) p
. . p

All DT N
subjects NNS N
were VBD N
evaluated VBN N
by IN N
their PRP$ N
parents NNS N
at IN N
baseline NN N
and CC N
follow-up JJ N
visits NNS N
( ( N
3-6 JJ N
weeks NNS N
later RB N
, , N
M NNP N
= NNP N
3.7 CD N
, , N
SD NNP N
= VBZ N
1.4 CD N
weeks NNS N
) ) N
with IN N
Childhood NNP o
Autism NNP o
Rating NNP o
Scales NNP o
( ( o
CARS NNP o
) ) o
. . N

Thirty-four JJ p
patients NNS p
were VBD p
labeled VBN p
with IN p
Pervasive NNP p
Developmental NNP p
Disorder NNP p
Not RB p
Otherwise NNP p
Specified NNP p
, , p
and CC p
22 CD p
met VBD p
diagnostic JJ p
criteria NNS p
for IN p
Autistic JJ p
Disorder NNP p
. . p

Forty-five JJ p
patients NNS p
were VBD p
concurrently RB p
on IN p
other JJ p
drug NN p
treatments NNS p
. . p

At IN N
follow-up NN N
, , N
some DT N
reported VBD N
minimal JJ N
but CC N
potentially RB N
significant JJ N
improvements NNS N
including VBG N
changes NNS o
in IN o
GI NNP o
symptoms NNS o
, , o
expressive JJ o
and/or NN o
receptive JJ o
language NN o
function NN o
, , o
and CC o
improved JJ o
awareness NN o
and CC o
social JJ o
interactions NNS o
. . o

No DT N
adverse JJ o
effects NNS o
were VBD N
reported VBN N
or CC N
observed VBN N
. . N

Subsequently NNP N
, , N
17 CD N
of IN N
the DT N
most RBS N
responsive JJ N
patients NNS N
from IN N
Study NNP N
1 CD N
began VBD N
a DT N
double-blind JJ N
trial NN N
that WDT N
also RB N
included VBD N
8 CD N
newly RB N
enrolled VBN N
patients NNS N
. . N

Patients NNS N
in IN N
this DT N
second JJ N
study NN N
were VBD N
alternatively RB N
entered VBN N
into IN N
one CD N
of IN N
two CD N
groups NNS N
and CC N
received VBD N
injections NNS N
of IN N
secretin NN i
or CC i
placebo NN i
with IN N
crossover NN N
at IN N
4 CD N
weeks NNS N
. . N

Patients NNS p
from IN p
Study NNP p
1 CD p
entered VBD p
into IN p
Study NNP p
2 CD p
at IN p
an DT p
average NN p
of IN p
6.5 CD p
( ( p
SD NNP p
= NNP p
0.8 CD p
) ) p
weeks NNS p
after IN p
beginning VBG p
Study NNP p
1 CD p
. . p

Results NNS N
of IN N
both DT N
inquiries NNS N
indicate VBP N
that IN N
although IN N
treatment NN N
with IN N
secretin NN i
was VBD N
reported VBN N
to TO N
cause VB N
transient JJ o
changes NNS o
in IN o
speech NN o
and CC o
behavior NN o
in IN N
some DT N
children NNS N
, , N
overall JJ N
it PRP N
produced VBD N
few JJ N
clinically RB N
meaningful JJ N
changes NNS N
when WRB N
compared VBN N
to TO N
children NNS N
given VBN N
placebo JJ i
injections NNS N
. . N

-DOCSTART- -16920077- O O

Omega-3 JJ i
fatty JJ i
acids NNS i
supplementation NN i
in IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
double-blind JJ N
randomized NN N
, , N
placebo-controlled JJ i
pilot NN N
study NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
increasing VBG N
evidence NN N
that IN N
fatty JJ N
acid JJ N
deficiencies NNS N
or CC N
imbalances NNS N
may MD N
contribute VB N
to TO N
childhood VB p
neurodevelopmental JJ p
disorders NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
6-week JJ N
pilot NN N
trial NN N
investigating VBG N
the DT N
effects NNS N
of IN N
1.5 CD i
g/d NN i
of IN i
omega-3 JJ i
fatty JJ i
acids NNS i
( ( i
.84 JJ i
g/d NN i
eicosapentaenoic NN i
acid NN i
, , i
.7 NNP i
g/d NN i
docosahexaenoic NN i
acid NN i
) ) i
supplementation NN i
in IN N
13 CD p
children NNS p
( ( p
aged VBN p
5 CD p
to TO p
17 CD p
years NNS p
) ) p
with IN p
autistic JJ p
disorders NNS p
accompanied VBN p
by IN p
severe JJ p
tantrums NNS p
, , p
aggression NN p
, , p
or CC p
self-injurious JJ p
behavior NN p
. . p

The DT N
outcome NN N
measure NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
at IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
We PRP N
observed VBD N
an DT N
advantage NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
compared VBN N
with IN N
placebo NN i
for IN N
hyperactivity NN o
and CC o
stereotypy NN o
, , N
each DT N
with IN N
a DT N
large JJ N
effect NN N
size NN N
. . N

Repeated-measures NNS N
ANOVA NNP N
indicated VBD N
a DT N
trend NN N
toward IN N
superiority NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
over IN N
placebo NN N
for IN N
hyperactivity NN o
. . o

No DT N
clinically RB N
relevant JJ N
adverse JJ o
effects NNS o
were VBD N
elicited VBN N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS VBZ N
The DT N
results NNS N
of IN N
this DT N
study NN N
provide VBP N
preliminary JJ N
evidence NN N
that IN N
omega-3 JJ i
fatty JJ i
acids NNS i
may MD N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -10554799- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
itraconazole JJ i
versus NN i
fluconazole NN i
for IN N
the DT N
prevention NN o
of IN o
fungal JJ o
infections NNS o
in IN p
patients NNS p
with IN p
haematological JJ p
malignancies NNS p
. . p

U.K. NNP N
Multicentre NNP N
Antifungal NNP N
Prophylaxis NNP N
Study NNP N
Group NNP N
. . N

Fluconazole NNP i
is VBZ N
widely RB N
used VBN N
as IN N
antifungal JJ o
prophylaxis NN o
but CC N
it PRP N
is VBZ N
ineffective JJ N
against IN N
Aspergillus NNP N
. . N

Itraconazole NNP i
has VBZ N
a DT N
broader JJR N
spectrum NN N
of IN N
activity NN N
but CC N
the DT N
capsules NNS N
give VBP N
erratic JJ N
bioavailability NN N
in IN N
neutropenic JJ N
patients NNS N
. . N

We PRP N
compared VBN N
itraconazole JJ i
oral JJ i
solution NN i
( ( N
which WDT N
has VBZ N
an DT N
improved VBN N
pharmacokinetic JJ N
profile NN N
) ) N
with IN N
fluconazole NN i
for IN N
antifungal JJ N
prophylaxis NN N
. . N

Adults NNS p
with IN p
haematological JJ p
malignancies NNS p
receiving VBG p
chemotherapy NN p
or CC p
bone NN p
marrow NN p
transplants NNS p
were VBD N
randomly RB N
allocated VBN N
5 CD N
mg/kg/d JJ N
itraconazole NN i
( ( i
itra JJ i
) ) i
solution NN N
( ( N
288 CD N
episodes NNS N
) ) N
or CC N
100 CD N
mg JJ N
fluconazole JJ i
suspension NN i
( ( i
flu NN i
) ) i
( ( N
293 CD N
episodes NNS N
) ) N
from IN N
before IN N
the DT N
onset NN N
of IN N
neutropenia NN N
until IN N
neutrophil JJ N
recovery NN N
or CC N
suspected VBN N
fungal JJ N
infection NN N
. . N

Outcomes CC N
were VBD N
assessed VBN N
by IN N
independent JJ N
reviewers NNS N
unaware NN N
of IN N
the DT N
prophylaxis JJ N
allocation NN N
. . N

More JJR N
proven JJ o
systemic JJ o
fungal JJ o
infections NNS o
occurred VBD N
in IN N
flu NN N
( ( N
Aspergillus NNP N
four CD N
, , N
Candida NNP N
tropicalis VBZ N
one CD N
, , N
C. NNP N
krusei NNP N
one NN N
) ) N
than IN N
itra NN N
( ( N
C. NNP N
albicans VBZ N
one CD N
) ) N
and CC N
more JJR N
of IN N
these DT N
were VBD N
fatal JJ N
( ( N
four CD N
versus NN N
nil NN N
) ) N
. . N

This DT N
difference NN N
reached VBD N
statistical JJ N
significance NN N
when WRB N
first RB N
study VB N
episodes NNS N
were VBD N
considered VBN N
separately RB N
( ( N
six CD N
flu NN N
versus NN N
nil JJ N
itra NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Significantly RB N
more RBR N
deaths NNS o
of IN o
presumed JJ o
fungal JJ o
origin NN o
occurred VBD N
in IN N
flu NN N
than IN N
itra JJ N
( ( N
seven CD N
versus NN N
nil NN N
, , N
P NNP N
= NNP N
0.024 CD N
) ) N
. . N

There EX N
were VBD N
significantly RB N
more JJR N
cases NNS N
of IN N
proven JJ N
aspergillosis NN o
in IN N
flu NN N
than IN N
itra JJ N
( ( N
six CD N
versus NN N
nil NN N
, , N
P NNP N
= NNP N
0.038 CD N
, , N
5/6 CD N
cases NNS N
were VBD N
fatal JJ N
) ) N
if IN N
those DT N
occurring VBG N
outside IN N
the DT N
study NN N
period NN N
are VBP N
included VBN N
. . N

Significantly RB N
more RBR p
patients NNS p
receiving VBG p
flu NN p
required VBN p
amphotericin NN i
B NNP p
( ( N
58 CD N
v NN N
39 CD N
, , N
P NNP N
= NNP N
0.043 CD N
) ) N
but CC N
this DT N
may MD N
have VB N
been VBN N
affected VBN N
by IN N
the DT N
fact NN N
that IN N
the DT N
study NN N
was VBD N
not RB N
blinded VBN N
. . N

There EX N
were VBD N
11 CD N
proven JJ N
mucosal NN o
candidal JJ o
infections NNS o
in IN N
flu NN N
and CC N
four CD N
in IN N
itra NN N
. . N

Itraconazole NNP i
solution NN i
and CC N
fluconazole JJ i
provide NN N
effective JJ N
prophylaxis NN N
against IN N
Candida NNP N
but CC N
itraconazole JJ N
affords NNS N
greater JJR N
protection NN N
against IN N
fatal JJ N
aspergillosis NN o
. . o

-DOCSTART- -1342306- O O

Long-term JJ N
anticoagulant NN i
treatment NN i
after IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

The DT N
Warfarin NNP N
Re-Infarction NNP N
Study NNP N
. . N

High NNP N
levels NNS N
of IN N
fibrinogen NN N
and CC N
clotting VBG N
factor NN N
VII NNP N
are VBP N
associated VBN N
with IN N
an DT N
increased VBN o
risk NN o
for IN N
subsequent JJ o
death NN o
and CC N
cardiovascular JJ o
disease NN o
in IN N
apparently RB p
healthy JJ p
individuals NNS p
. . p

Furthermore RB N
, , N
pathoanatomic JJ N
studies NNS N
and CC N
coronary JJ N
angiography NN N
have VBP N
confirmed VBN N
a DT N
relationship NN o
between IN o
coronary JJ o
thrombus NN o
formation NN o
and CC o
acute JJ o
Q-wave NNP o
infarction NN o
. . o

Effective JJ N
antithrombotic JJ N
agents NNS N
may MD N
prevent VB N
or CC N
limit VB N
thrombus JJ o
formation NN o
and CC N
events NNS o
related VBN o
to TO o
thrombosis NN o
. . o

The DT N
Warfarin NNP N
Re-Infarction NNP N
Study NNP N
( ( N
WARIS NNP N
) ) N
studied VBD N
the DT N
effect NN N
of IN N
warfarin NN i
in IN N
survivors NNS p
of IN p
acute JJ p
myocardial JJ p
infarction NN p
. . p

Patients NNS p
aged VBD p
75 CD p
years NNS p
or CC p
less JJR p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
to TO N
test VB N
whether IN N
long-term JJ N
treatment NN N
with IN N
warfarin JJ i
reduces NNS N
the DT N
risk NN o
of IN N
death NN o
, , o
reinfarction NN o
, , N
and CC N
thromboembolic JJ o
morbidity NN o
. . o

A DT p
total NN p
of IN p
1918 CD p
patients NNS p
were VBD p
screened VBN p
for IN p
participation NN p
; : p
1214 CD p
were VBD p
recruited VBN p
. . p

The DT N
mean JJ N
follow-up NN N
was VBD N
37 CD N
months NNS N
. . N

Analyzed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
, , N
123 CD N
( ( N
20 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
died VBD o
, , N
versus FW N
94 CD N
( ( N
15 CD N
% NN N
) ) N
in IN N
the DT N
warfarin NN i
group NN N
, , N
a DT N
risk NN o
reduction NN o
of IN N
24 CD N
% NN N
( ( N
P NNP N
= NNP N
0.026 CD N
) ) N
. . N

Considering VBG N
patients NNS N
on IN N
treatment NN N
or CC N
within IN N
28 CD N
days NNS N
after IN N
discontinuing VBG N
the DT N
test NN N
medication NN N
, , N
92 CD N
in IN N
the DT N
placebo NN N
group NN N
died VBD o
, , N
as IN N
compared VBN N
with IN N
60 CD N
of IN N
the DT N
warfarin-treated JJ i
patients NNS N
, , N
a DT N
risk NN o
reduction NN o
of IN N
35 CD N
% NN N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

Relapsing VBG o
myocardial JJ o
infarction NN o
( ( o
fatal JJ o
and CC o
nonfatal JJ o
) ) o
was VBD N
reduced VBN N
by IN N
43 CD N
% NN N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
cerebrovascular JJ o
attacks NNS o
was VBD N
lower RBR N
in IN N
the DT N
warfarin NN i
group NN N
( ( N
16 CD N
patients NNS N
) ) N
than IN N
the DT N
placebo NN i
group NN N
( ( N
41 CD N
patients NNS N
) ) N
, , N
a DT N
highly RB N
significant JJ N
reduction NN N
of IN N
61 CD N
% NN N
( ( N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

Serious JJ o
bleeding NN o
occurred VBD N
in IN N
11 CD N
patients NNS N
taking VBG N
warfarin NN i
, , N
an DT N
incidence NN N
of IN N
0.6 CD N
% NN N
per IN N
year NN N
. . N

In IN N
conclusion NN N
, , N
long-term JJ N
anticoagulant JJ i
therapy NN i
may MD N
be VB N
recommended VBN N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -14567804- O O

GnRH NNP i
agonist NN i
treatment NN i
before IN N
total JJ N
laparoscopic NN N
hysterectomy NN N
for IN N
large JJ N
uteri NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
whether IN N
uterine JJ N
shrinkage NN N
induced VBN N
by IN N
gonadotropin-releasing VBG i
hormone NN i
( ( i
GnRH NNP i
) ) i
agonists VBZ i
in IN N
women NNS p
with IN p
a DT p
large JJ p
uterus NN p
( ( p
> JJ p
14 CD p
wks NNS p
) ) p
may MD N
facilitate VB N
total JJ N
laparoscopic JJ N
hysterectomy NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
prospective JJ N
study NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
. . N

SETTING CC N
University-affiliated JJ N
hospital NN N
. . N

PATIENTS VB N
Sixty-two JJ p
women NNS p
with IN p
symptomatic JJ p
uterine JJ p
myomas NN p
( ( p
size NN p
16-20 CD p
wks NN p
) ) p
. . p

INTERVENTIONS NNP N
Total NNP i
laparoscopic NN i
hysterectomy NN i
for IN i
benign JJ i
pathology NN i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Before IN N
surgery NN N
, , N
women NNS N
were VBD N
assigned VBN N
, , N
at IN N
a DT N
ratio NN N
of IN N
1:1 CD N
by IN N
random NN N
selection NN N
, , N
to TO N
receive VB N
injections NNS N
of IN N
triptorelin NN i
depot NN i
11.25 CD N
mg NN N
3 CD N
months NNS N
before IN N
surgery NN N
( ( N
group NN N
A NNP N
) ) N
or CC N
no DT N
treatment NN N
( ( N
group NN N
B NNP N
) ) N
. . N

Uterine JJ o
volume NN o
, , o
mean VB o
operating NN o
time NN o
, , o
uterine JJ o
weight NN o
, , o
drop NN o
in IN o
hemoglobin NN o
, , o
intraoperative JJ o
complications NNS o
, , o
conversions NNS o
to TO o
laparotomy VB o
, , o
and CC o
hospital NN o
stay NN o
were VBD N
recorded VBN N
. . N

Triptorelin NNP N
decreased VBD N
uterine JJ o
volume NN o
, , N
calculated VBN N
by IN N
ultrasonography NN N
, , N
by IN N
26.5 CD N
% NN N
in IN N
group NN N
A NNP N
, , N
whereas IN N
the DT N
volume NN N
remained VBD N
unchanged JJ N
in IN N
group NN N
B NNP N
. . N

Statistical JJ N
differences NNS N
were VBD N
found VBN N
between IN N
groups NNS N
concerning VBG N
uterine JJ o
weight NN o
, , o
operating VBG o
time NN o
, , o
and CC o
drop NN o
in IN o
hemoglobin JJ o
level NN o
. . o

Three CD N
patients NNS N
in IN N
group NN N
B NNP N
were VBD N
converted VBN N
to TO N
laparotomy VB N
because IN N
of IN N
uterine JJ N
size NN N
. . N

CONCLUSION NNP N
In IN N
women NNS p
with IN p
a DT p
large JJ p
uterus NN p
, , N
a DT N
3-month JJ N
preoperative JJ N
course NN N
of IN N
GnRH NNP i
may MD N
facilitate VB N
laparoscopic NN N
hysterectomy NN N
, , N
decreasing VBG N
uterine JJ N
size NN N
, , N
operating VBG N
time NN N
, , N
and CC N
blood NN N
loss NN N
. . N

-DOCSTART- -9196141- O O

Dose-response JJ N
relationship NN N
of IN N
complementary JJ i
radiotherapy NN i
following VBG N
four CD N
cycles NNS N
of IN N
combination NN i
chemotherapy NN i
in IN N
intermediate-stage JJ N
Hodgkin NNP p
's POS p
disease NN p
. . p

PURPOSE NNP N
To TO N
determine VB N
the DT N
appropriate JJ N
irradiation NN N
dose NN N
after IN N
four CD N
cycles NNS N
of IN N
modern JJ i
combination NN i
chemotherapy NN i
in IN p
nonbulky JJ p
involved JJ p
field NN p
( ( p
IF/BF NNP p
) ) p
and CC p
noninvolved VBN p
extended-field NN p
( ( p
EF/IF NNP p
) ) p
sites VBZ p
in IN p
patients NNS p
with IN p
intermediate-stage JJ p
Hodgkin NNP p
's POS p
disease NN p
( ( p
HD NNP p
) ) p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
HD NNP p
patients NNS p
in IN p
stage NN p
I PRP p
to TO p
IIIA NNP p
with IN p
a DT p
large JJ p
mediastinal JJ p
mass NN p
, , p
E NNP p
stage NN p
, , p
or CC p
massive JJ p
spleen JJ p
involvement NN p
were VBD N
treated VBN N
with IN N
two CD N
double JJ N
cycles NNS i
of IN i
alternating VBG i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
COPP NNP i
) ) i
plus CC i
doxorubicin JJ i
, , i
bleomycin NN i
, , i
vinblastine NN i
, , i
and CC i
dacarbazine NN i
( ( i
ABVD NNP i
) ) i
followed VBN i
by IN i
EF NNP i
irradiation NN i
in IN N
two CD N
successive JJ N
trials NNS N
( ( N
HD1 NNP N
and CC N
HD5 NNP N
) ) N
. . N

In IN N
the DT N
HD1 NNP N
trial NN N
( ( N
1983 CD N
to TO N
1988 CD N
) ) N
, , N
146 CD p
patients NNS p
who WP p
responded VBD p
to TO p
chemotherapy VB p
were VBD p
randomized VBN p
to TO p
receive VB p
20 CD p
Gy NNP p
( ( p
70 CD p
patients NNS p
) ) p
or CC p
40 CD p
Gy NNP p
( ( p
76 CD p
patients NNS p
) ) p
of IN p
EF NNP p
irradiation NN p
in IN p
all DT p
fields NNS p
outside IN p
bulky JJ p
disease NN p
sites NNS p
. . p

A DT p
cohort NN p
of IN p
111 CD p
patients NNS p
who WP p
fulfilled VBD p
the DT p
same JJ p
inclusion NN p
criteria NNS p
in IN p
the DT p
subsequent JJ p
trial NN p
HD5 NNP p
( ( p
1988 CD p
to TO p
1993 CD p
) ) p
were VBD p
treated VBN p
with IN p
30 CD p
Gy NNP p
. . p

Bulky NNP N
disease NN N
always RB N
received VBD N
40 CD N
Gy NNP N
. . N

RESULTS NNP N
Freedom-from-treatment-failure NNP o
( ( o
FFTF NNP o
) ) o
and CC o
survival NN o
( ( o
SV NNP o
) ) o
curves VBZ o
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
20- JJ N
, , N
30- JJ N
, , N
and CC N
40-Gy JJ N
groups NNS N
. . N

However RB N
, , N
acute JJ o
toxicities NNS o
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
40-Gy JJ N
arm NN N
. . N

Analysis NN o
of IN o
relapse NN o
patterns NNS o
showed VBD N
that IN N
18 CD N
of IN N
26 CD N
relapsing VBG N
patients NNS N
either CC N
failed VBD N
to TO N
respond VB N
in IN N
initial JJ N
bulky NN N
sites NNS N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
had VBD N
an DT N
extranodal JJ N
relapse NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
or CC N
both DT N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
. . N

After IN N
5 CD N
years NNS N
, , N
the DT N
cumulative JJ N
risk NN o
for IN o
relapse NN o
in IN N
bulky NN N
sites NNS N
is VBZ N
10 CD N
% NN N
, , N
despite IN N
40 CD N
Gy NNP N
of IN N
radiation NN i
. . i

CONCLUSION NNP N
Our PRP$ N
results NNS N
strongly RB N
suggest VBP N
that IN N
there EX N
is VBZ N
no DT N
relevant JJ N
radiotherapy NN o
dose JJ o
effect NN o
in IN N
the DT N
range NN N
between IN N
20 CD N
Gy NNP N
and CC N
40 CD N
Gy NNP N
in IN N
IF/BF NNP N
and CC N
EF/IF NNP N
after IN N
4 CD N
months NNS N
of IN N
modern JJ p
polychemotherapy NN i
in IN p
patients NNS p
with IN p
intermediate-stage JJ p
HD NNP p
. . p

Relapse NNP N
patterns VBZ N
indicate VB N
that IN N
patients NNS N
destined VBD N
to TO N
relapse VB N
need VB N
more JJR N
systemic JJ N
, , N
rather RB N
than IN N
local JJ N
, , N
treatment NN N
. . N

Based VBN N
on IN N
our PRP$ N
data NNS N
, , N
we PRP N
conclude VBP N
that IN N
20 CD N
Gy NNP N
is VBZ N
sufficient JJ N
in IN N
EF/IF NNP N
of IN N
intermediate-stage JJ N
HD NNP N
following VBG N
four CD N
cycles NNS N
of IN N
modern JJ N
polychemotherapy NN i
. . i

-DOCSTART- -2679258- O O

Prospective JJ N
trial NN N
of IN N
timing NN N
of IN N
bacillus NN i
Calmette-Gu?rin NNP i
vaccination NN i
in IN p
Canadian JJ p
Cree NNP p
infants NNS p
. . p

We PRP N
studied VBD p
184 CD p
Cree NNP p
Indian JJ p
infants NNS p
in IN N
randomized VBN N
, , N
prospective JJ N
fashion NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
age NN N
on IN o
lymphocyte JJ o
sensitization NN o
to TO N
purified VB N
protein JJ N
derivative JJ N
( ( N
PPD NNP N
) ) N
before IN N
and CC N
after IN N
and CC N
without IN i
bacillus JJ i
Calmette-Gu?rin NNP i
( ( i
BCG NNP i
) ) i
vaccination NN o
. . o

Lymphocyte JJ o
responses NNS o
to TO o
PPD NNP N
, , N
Candida NNP N
, , N
and CC N
streptokinase NN N
were VBD N
measured VBN N
at IN N
birth NN N
and CC N
at IN N
intervals NNS N
later RB N
. . N

The DT N
mean JJ N
response NN N
of IN N
paired JJ N
values NNS N
from IN p
26 CD p
infants NNS p
without IN p
BCG NNP p
vaccination NN p
rose VBD p
for IN p
the DT N
PPD NNP N
stimulation NN N
index NN N
( ( N
SI NNP N
) ) N
from IN N
2.7 CD N
at IN N
birth NN N
to TO N
3.9 CD N
before IN N
2 CD N
yr NN N
of IN N
age NN N
. . N

The DT N
SI NNP N
for IN N
both DT N
Candida NNP N
and CC N
streptokinase VB N
for IN N
this DT N
group NN N
of IN N
infants NNS N
rose VBD N
significantly RB N
in IN N
the DT N
first JJ N
2 CD N
yr NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

In IN N
66 CD p
infants NNS p
who WP p
received VBD i
BCG NNP i
in IN i
the DT p
first JJ p
7 CD p
days NNS p
of IN p
life NN p
, , p
the DT o
PPD-SI NNP o
rose VBD o
from IN N
3.1 CD N
to TO N
35.3 CD N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

In IN N
17 CD N
infants NNS N
who WP N
received VBD N
the DT N
vaccine NN N
later RB N
but CC N
before IN N
9 CD N
months NNS N
, , N
it PRP N
rose VBD N
from IN N
3.1 CD N
at IN N
birth NN N
to TO N
24.9 CD N
, , N
and CC N
in IN N
14 CD N
who WP N
received VBD N
it PRP N
between IN N
9 CD N
months NNS N
and CC N
2 CD N
yr NN N
, , N
it PRP N
rose VBD N
from IN N
2.2 CD N
to TO N
52.9 CD N
. . N

The DT o
lymphocyte JJ o
responses NNS o
to TO o
PPD NNP N
after IN i
BCG NNP i
in IN i
these DT N
two CD N
groups NNS N
were VBD N
significantly RB N
different JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
evidence NN N
in IN N
the DT N
older JJR N
infants NNS N
that IN N
a DT N
raised VBN o
PPD-SI NN o
before IN o
BCG NNP N
vaccination NN N
affected VBD o
lymphocyte JJ o
sensitization NN o
by IN o
the DT N
vaccine NN N
. . N

We PRP N
conclude VBP N
that IN N
increasing VBG N
the DT N
age NN N
at IN N
vaccination NN N
with IN i
BCG NNP i
from IN i
birth NN N
to TO N
more JJR N
than IN N
9 CD N
months NNS N
enhances NNS o
immunologic JJ o
sensitization NN o
to TO o
PPD NNP N
significantly RB N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -10352397- O O

Low-dose JJ i
growth NN i
hormone NN i
treatment NN i
with IN i
diet JJ i
restriction NN i
accelerates VBZ o
body JJ o
fat JJ o
loss NN o
, , o
exerts VBZ o
anabolic JJ o
effect NN o
and CC o
improves VBZ o
growth NN o
hormone NN o
secretory NN o
dysfunction NN o
in IN N
obese JJ p
adults NNS p
. . p

Growth NNP i
hormone NN i
( ( N
GH NNP N
) ) N
can MD N
induce VB N
an DT N
accelerated JJ o
lipolysis NN o
. . o

Impaired NNP N
secretion NN N
of IN N
GH NNP N
in IN N
obesity NN N
results NNS N
in IN N
the DT N
consequent JJ N
loss NN N
of IN N
the DT N
lipolytic JJ o
effect NN o
of IN o
GH NNP o
. . o

Dietary NNP N
restriction NN N
as IN N
a DT N
basic JJ N
treatment NN N
for IN N
obesity NN N
is VBZ N
complicated VBN N
by IN N
poor JJ N
compliance NN N
, , N
protein NN N
catabolism NN N
, , N
and CC N
slow VB N
rates NNS N
or CC N
weight JJ N
loss NN N
. . N

GH NNP N
has VBZ N
an DT N
anabolic JJ N
effect NN N
by IN N
increasing VBG o
insulin-like JJ o
growth NN o
factor NN o
( ( o
IGF NNP o
) ) o
-I NN o
. . o

We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
GH NNP N
treatment NN N
and CC N
dietary JJ N
restriction NN N
on IN N
lipolytic JJ o
and CC o
anabolic JJ o
actions NNS o
, , o
as RB o
well RB o
as IN o
the DT o
consequent NN o
changes NNS o
in IN o
insulin NN o
and CC o
GH NNP o
secretion NN o
in IN o
obesity NN o
. . o

24 CD p
obese JJ p
subjects NNS p
( ( p
22 CD p
women NNS p
and CC p
2 CD p
men NNS p
; : p
22-46 CD p
years NNS p
old JJ p
) ) p
were VBD N
fed VBN N
a DT N
diet NN i
of IN N
25 CD N
kcal/kg NNS N
ideal JJ N
body NN N
weight NN N
( ( N
IBW NNP N
) ) N
with IN N
1.2 CD N
g NNS N
protein/kg JJ N
IBW NNP N
daily RB N
and CC N
were VBD N
treated VBN N
with IN N
recombinant JJ i
human JJ i
GH NNP i
( ( N
n JJ N
= NN N
12 CD N
, , N
0.18 CD N
U/kg NNP N
IBW/week NNP N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NN N
12 CD N
, , N
vehicle NN N
injection NN N
) ) N
in IN N
a DT N
12-week JJ N
randomized NN N
, , N
double-blind JJ N
and CC N
placebo-controlled JJ N
trial NN N
. . N

GH NNP i
treatment NN N
caused VBD N
a DT N
1.6-fold JJ N
increase NN N
in IN N
the DT N
fraction NN o
of IN o
body NN o
weight NN o
lost VBD o
as IN o
fat NN o
and CC o
a DT o
greater JJR o
loss NN o
of IN o
visceral JJ o
fat JJ o
area NN o
than IN N
placebo NN N
treatment NN N
( ( N
35.3 CD N
vs. FW N
28.5 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
there EX N
was VBD N
a DT N
loss NN N
in IN N
lean JJ o
body NN o
mass NN o
( ( N
-2.62 JJ N
+/- JJ N
1.51 CD N
kg NN N
) ) N
and CC N
a DT N
negative JJ o
nitrogen NN o
balance NN o
( ( N
-4.52 JJ N
+/- JJ N
3.51 CD N
g/day NN N
) ) N
. . N

By IN N
contrast NN N
, , N
the DT N
GH NNP i
group NN N
increased VBD N
in IN N
lean JJ o
body NN o
mass NN o
( ( N
1.13 CD N
+/- JJ N
1.04 CD N
kg NN N
) ) N
and CC N
had VBD N
a DT N
positive JJ o
nitrogen NN o
balance NN o
( ( N
1.81 CD N
+/- JJ N
2.06 CD N
g/day NN N
) ) N
. . N

GH NNP i
injections NNS i
caused VBD N
a DT N
1.6-fold JJ N
increase NN o
in IN o
IGF-I NNP o
, , N
despite IN N
caloric JJ N
restriction NN N
. . N

GH NNP o
response NN o
to TO o
L-dopa NNP o
stimulation NN o
was VBD N
blunted VBN o
in IN N
all DT N
subjects NNS N
and CC N
it PRP N
was VBD N
increased VBN N
after IN N
treatment NN N
in IN N
both DT N
groups NNS N
. . N

GH NNP i
treatment NN N
did VBD N
not RB N
induce VB N
a DT N
further JJ N
increase NN N
in IN N
insulin JJ o
levels NNS o
during IN N
an DT N
oral JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
but CC N
significantly RB N
decreased VBD N
free JJ o
fatty JJ o
acid NN o
( ( o
FFA NNP o
) ) o
levels NNS o
during IN N
OGTT NNP N
. . N

The DT N
decrease NN N
in IN N
FFA NNP o
area NN o
under IN N
the DT N
curve NN N
during IN N
OGTT NNP N
was VBD N
positively RB N
correlated VBN N
with IN N
visceral JJ o
fat JJ o
loss NN o
. . o

This DT N
study NN N
demonstrates VBZ N
that IN N
in IN N
obese JJ p
subjects NNS p
given VBN N
a DT N
hypocaloric JJ N
diet NN N
, , N
GH NNP N
accelerates VBZ N
body NN o
fat JJ o
loss NN o
, , o
exerts VBZ o
anabolic JJ o
effects NNS o
and CC o
improves NNS o
GH NNP o
secretion NN o
. . o

These DT N
findings NNS N
suggest VBP N
a DT N
possible JJ N
therapeutic JJ N
role NN N
of IN N
low-dose JJ N
GH NNP i
with IN N
caloric JJ N
restriction NN N
for IN N
obesity NN N
. . N

-DOCSTART- -16948927- O O

Risperidone NN i
in IN N
children NNS p
with IN p
autism NN p
: : p
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
study NN N
. . N

Some DT N
open-label JJ N
studies NNS N
suggest VBP N
that IN N
risperidone NN i
can MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
certain JJ N
target NN N
symptoms NNS N
in IN N
children NNS p
with IN p
autism NN p
. . p

We PRP N
aimed VBD N
to TO N
study VB N
whether IN N
the DT N
use NN N
of IN N
risperidone NN i
in IN N
comparison NN N
with IN N
placebo NN i
improved VBN N
functioning NN N
in IN N
children NNS p
with IN p
autism NN p
with IN N
regard NN N
to TO N
behavior VB N
( ( N
aggressiveness NN N
, , N
hyperactivity NN N
, , N
irritability NN N
) ) N
, , N
social JJ N
and CC N
emotional JJ N
responsiveness NN N
, , N
and CC N
communication NN N
skills NNS N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
with IN N
40 CD p
consecutive JJ p
children NNS p
with IN p
autism NN p
, , p
whose WP$ p
ages NNS p
ranged VBD p
from IN p
2 CD p
to TO p
9 CD p
years NNS p
, , p
who WP p
were VBD p
receiving VBG p
either CC p
risperidone NN i
or CC i
placebo VB i
given VBN p
orally RB p
at IN p
a DT p
dose NN p
of IN p
1 CD p
mg/day NN p
for IN p
6 CD p
months NNS p
. . p

Autism NN N
symptoms NNS N
were VBD N
monitored VBN N
periodically RB N
. . N

The DT N
outcome NN N
variables NNS N
were VBD N
total JJ N
scores NNS N
on IN N
the DT N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
CARS NNP N
) ) N
and CC N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
( ( N
CGAS NNP N
) ) N
after IN N
6 CD N
months NNS N
. . N

Of IN N
the DT N
40 CD p
children NNS p
enrolled VBD p
, , N
39 CD N
completed VBD N
the DT N
trial NN N
over IN N
a DT N
period NN N
of IN N
18 CD N
months NNS N
; : N
19 CD N
received VBD N
risperidone NN i
, , N
and CC N
20 CD N
received VBD N
placebo NN i
. . i

In IN N
the DT N
risperidone NN i
group NN N
, , N
12 CD N
of IN N
19 CD N
children NNS N
showed VBD N
improvement NN N
in IN N
the DT N
total JJ o
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
score NN o
and CC N
17 CD N
of IN N
19 CD N
children NNS N
in IN N
the DT N
Children NNP o
's POS o
Global NNP o
Assessment NNP o
Scale NNP o
score NN o
compared VBN N
with IN N
0 CD N
of IN N
20 CD N
children NNS N
for IN N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
score NN o
and CC N
2 CD N
of IN N
20 CD N
children NNS N
for IN N
the DT N
Children NNP o
's POS o
Global NNP o
Assessment NNP o
Scale NNP o
score NN o
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
and CC N
P NNP N
= NNP N
.035 NNP N
, , N
respectively RB N
) ) N
. . N

Risperidone NNP i
also RB N
improved VBD N
social JJ o
responsiveness NN o
and CC o
nonverbal JJ o
communication NN o
and CC N
reduced VBD N
the DT N
symptoms NNS o
of IN o
hyperactivity NN o
and CC o
aggression NN o
. . o

Risperidone NN i
was VBD N
associated VBN N
with IN N
increased VBN N
appetite NN o
and CC o
a DT o
mild JJ o
weight NN o
gain NN o
, , o
mild JJ o
sedation NN o
in IN o
20 CD o
% NN o
, , o
and CC o
transient NN o
dyskinesias NN o
in IN N
three CD N
children NNS N
. . N

Risperidone NN i
improved VBD N
global JJ o
functioning NN o
and CC o
social JJ o
responsiveness NN o
while IN N
reducing VBG o
hyperactivity NN o
and CC o
aggression NN o
in IN N
children NNS p
with IN p
autism NN p
and CC N
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -17974096- O O

Sivelestat NNP i
sodium NN i
hydrate NN i
improves VBZ N
septic JJ p
acute NN p
lung NN p
injury NN p
by IN N
reducing VBG N
alveolar JJ N
dysfunction NN N
. . N

Sivelestat NNP i
sodium NN i
hydrate NN i
( ( i
sivelestat NN i
) ) i
is VBZ N
a DT N
selective JJ N
inhibitor NN N
of IN N
polymorphonuclear JJ N
leukocyte JJ N
elastase NN N
( ( N
PMN-E NNP N
) ) N
. . N

We PRP N
administered VBD N
sivelestat NNS i
to TO N
patients NNS p
with IN p
septic JJ p
acute NN p
lung NN p
injury NN p
( ( p
ALI NNP p
) ) p
to TO N
examine VB N
its PRP$ N
usefulness NN N
. . N

The DT N
primary JJ N
endpoints NNS N
in IN N
the DT N
study NN N
were VBD N
the DT N
duration NN o
of IN o
artificial JJ o
ventilation NN o
and CC o
pulmonary JJ o
oxygenation NN o
ability NN o
, , N
and CC N
the DT N
secondary JJ N
endpoints NNS N
were VBD N
mortality NN o
and CC o
the DT o
concentrations NNS o
of IN o
PMN-E NNP o
, , o
SP-D NNP o
, , o
TNF-alpha NNP o
and CC o
IL-8 NNP o
in IN o
blood NN o
. . o

In IN N
the DT N
sivelestat NN i
group NN N
, , N
the DT N
duration NN o
of IN o
artificial JJ o
ventilation NN o
, , o
pulmonary JJ o
oxygenation NN o
ability NN o
, , o
and CC o
the DT o
blood NN o
PMN-E NNP o
, , o
SP-D NNP o
, , o
TNF-alpha NNP o
and CC o
IL-8 NNP o
concentrations NNS o
decreased VBD N
significantly RB N
. . N

Administration NNP N
of IN N
sivelestat NN i
was VBD N
found VBN N
to TO N
reduce VB N
alveolar JJ o
dysfunction NN o
and CC N
improve VB N
respiratory NN o
function NN o
, , N
and CC N
it PRP N
was VBD N
suggested VBN N
that IN N
early JJ N
administration NN N
might MD N
be VB N
useful JJ N
. . N

-DOCSTART- -9935005- O O

The DT N
influence NN N
of IN N
ventricular JJ N
fibrillation NN N
duration NN N
on IN N
defibrillation NN o
efficacy NN o
using VBG N
biphasic JJ N
waveforms NNS N
in IN N
humans NNS N
. . N

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
prospectively RB N
investigate VB N
the DT N
influence NN N
of IN N
ventricular JJ N
fibrillation NN N
( ( N
VF NNP N
) ) N
durations NNS N
of IN N
5 CD N
, , N
10 CD N
and CC N
20 CD N
s NN N
on IN N
the DT N
defibrillation NN o
threshold NN o
( ( o
DFT NNP o
) ) o
during IN N
implantable JJ N
cardioverter-defibrillator NN N
( ( N
ICD NNP N
) ) N
implantation NN N
. . N

BACKGROUND NNP N
Although IN N
the DT N
DFT NNP o
using VBG o
monophasic JJ o
waveforms NNS o
has VBZ N
been VBN N
shown VBN N
to TO N
increase VB N
with IN N
VF NNP N
duration NN N
in IN N
humans NNS N
, , N
the DT N
effect NN N
of IN N
VF NNP N
duration NN N
on IN N
defibrillation NN N
efficacy NN N
using VBG N
biphasic JJ N
waveforms NNS N
in IN N
humans NNS N
is VBZ N
not RB N
known VBN N
. . N

METHODS NNP N
Thirty NNP p
patients NNS p
undergoing VBG p
primary JJ p
ICD NNP p
implantation NN p
or CC p
pulse JJ p
generator NN p
replacement NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
the DT N
DFT NNP i
determined VBD i
using VBG i
biphasic JJ i
shocks NNS i
at IN N
two CD N
durations NNS N
of IN N
VF NNP i
each DT N
( ( N
5 CD N
and CC N
10 CD N
s NN N
, , N
10 CD N
and CC N
20 CD N
s NN N
or CC N
5 CD N
and CC N
20 CD N
s NN N
) ) N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
mean JJ o
DFT NNP o
comparing VBG N
VF NNP N
durations NNS N
of IN N
5 CD N
s NNS N
( ( N
9.5+/-6.0 CD N
J NNP N
) ) N
and CC N
10 CD N
s NN N
( ( N
10.8+/-7.0 JJ N
J NNP N
) ) N
( ( N
p=0.4 NN N
) ) N
. . N

The DT N
mean JJ o
DFT NNP o
significantly RB N
increased VBD N
from IN N
10.9+/-6.1 JJ N
J NNP N
at IN N
10 CD N
s NN N
of IN N
VF NNP N
to TO N
12.6+/-5.6 JJ N
J NNP N
( ( N
p=0.03 NN N
) ) N
at IN N
20 CD N
s NN N
of IN N
VF NNP N
, , N
and CC N
from IN N
7.0+/-3.5 JJ N
J NNP N
at IN N
5 CD N
s NN N
of IN N
VF NNP N
to TO N
10.5+/-6.3 JJ N
J NNP N
( ( N
p=0.04 NN N
) ) N
at IN N
20 CD N
s NN N
of IN N
VF NNP N
. . N

An DT N
increase NN N
in IN N
the DT N
DFT NNP o
was VBD N
observed VBN N
in IN N
14 CD p
patients NNS p
as IN N
VF NNP N
duration NN N
increased VBD N
. . N

There EX N
were VBD N
no DT N
clinical JJ N
characteristics NNS N
that WDT N
differentiated VBD N
patients NNS N
with IN N
and CC N
without IN N
an DT N
increase NN N
in IN N
the DT N
DFT NNP o
. . o

CONCLUSIONS NNP N
Defibrillation NNP o
efficacy NN o
decreases VBZ N
with IN N
increasing VBG N
VF NNP N
duration NN N
using VBG N
biphasic JJ N
waveforms NNS N
in IN N
humans NNS N
. . N

Ventricular JJ N
fibrillation NN N
durations NNS N
greater JJR N
than IN N
10 CD N
s NN N
may MD N
negatively RB N
affect VB N
the DT N
effectiveness NN o
of IN o
ICD NNP o
therapy NN o
. . o

-DOCSTART- -23361064- O O

Temporal JJ N
expectation NN N
in IN N
focal JJ p
hand NN p
dystonia NN p
. . p

Patients NNS p
with IN p
writer NN p
's POS p
cramp NN p
present JJ N
sensory NN N
and CC N
representational JJ N
abnormalities NNS N
relevant VBP N
to TO N
motor VB N
control NN N
, , N
such JJ N
as IN N
impairment NN N
in IN N
the DT N
temporal JJ N
discrimination NN N
between IN N
tactile JJ N
stimuli NNS N
and CC N
in IN N
pure JJ N
motor NN N
imagery NN N
tasks NNS N
, , N
like IN N
the DT N
mental JJ N
rotation NN N
of IN N
corporeal NN N
and CC N
inanimate JJ N
objects NNS N
. . N

However RB N
, , N
only RB N
limited JJ N
information NN N
is VBZ N
available JJ N
on IN N
the DT N
ability NN N
of IN N
patients NNS p
with IN p
dystonia NN p
to TO N
process VB N
the DT N
time-dependent JJ N
features NNS N
( ( N
e.g NN N
. . N

speed NN N
) ) N
of IN N
movement NN N
in IN N
real JJ N
time NN N
. . N

The DT N
processing NN N
of IN N
time-dependent JJ N
features NNS N
of IN N
movement NN N
has VBZ N
a DT N
crucial JJ N
role NN N
in IN N
predicting VBG N
whether IN N
the DT N
outcome NN N
of IN N
a DT N
complex JJ N
motor NN N
sequence NN N
, , N
such JJ N
as IN N
handwriting NN N
or CC N
playing VBG N
a DT N
musical JJ N
passage NN N
, , N
will MD N
be VB N
consistent JJ N
with IN N
its PRP$ N
ultimate JJ N
goal NN N
, , N
or CC N
results NNS N
instead RB N
in IN N
an DT N
execution NN N
error NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
implicit JJ N
ability NN N
to TO N
perceive VB N
the DT N
temporal JJ i
outcome NN i
of IN N
different JJ N
movements NNS N
in IN N
a DT N
group NN N
of IN N
patients NNS p
with IN p
writer NN p
's POS p
cramp NN p
. . p

Fourteen JJ p
patients NNS p
affected VBN p
by IN p
writer NN p
's POS p
cramp NN p
in IN p
the DT p
right JJ p
hand NN p
and CC p
17 CD p
age- JJ p
and CC p
gender-matched JJ p
healthy JJ p
subjects NNS p
were VBD p
recruited VBN p
for IN p
the DT p
study NN p
. . p

Subjects NNS N
were VBD N
asked VBN N
to TO N
perform VB N
a DT N
temporal JJ i
expectation NN i
task NN i
by IN N
predicting VBG N
the DT N
end NN N
of IN N
visually RB N
perceived VBN N
human JJ N
body NN N
motion NN N
( ( N
handwriting VBG N
, , N
i.e NN N
. . N

the DT N
action NN N
performed VBN N
by IN N
the DT N
human JJ N
body NN N
segment NN N
specifically RB N
affected VBN N
by IN N
writer NN N
's POS N
cramp NN N
) ) N
or CC N
inanimate JJ N
object JJ N
motion NN N
( ( N
a DT N
moving VBG N
circle NN N
reaching VBG N
a DT N
spatial JJ N
target NN N
) ) N
. . N

Videos NNP i
representing VBG i
movements NNS i
were VBD N
shown VBN N
in IN N
full JJ N
before IN N
experimental JJ N
trials NNS N
; : N
the DT N
actual JJ N
tasks NNS N
consisted VBN N
of IN N
watching VBG N
the DT N
same JJ N
videos NN N
, , N
but CC N
interrupted VBD N
after IN N
a DT N
variable JJ N
interval NN N
( ( N
'pre-dark NNP N
' POS N
) ) N
from IN N
its PRP$ N
onset VBN N
by IN N
a DT N
dark JJ N
interval NN N
of IN N
variable JJ N
duration NN N
. . N

During IN N
the DT N
'dark NNP N
' POS N
interval NN N
, , N
subjects NNS N
were VBD N
asked VBN N
to TO N
indicate VB N
when WRB N
the DT N
movement NN N
represented VBN N
in IN N
the DT N
video NN N
reached VBD N
its PRP$ N
end NN N
by IN N
clicking VBG N
on IN N
the DT N
space NN N
bar NN N
of IN N
the DT N
keyboard NN N
. . N

We PRP N
also RB N
included VBD N
a DT N
visual JJ o
working JJ o
memory NN o
task NN o
. . o

Performance NN N
on IN N
the DT N
timing NN N
task NN N
was VBD N
analysed VBN N
measuring VBG N
the DT N
absolute JJ N
value NN N
of IN N
timing VBG N
error NN N
, , N
the DT N
coefficient NN N
of IN N
variability NN N
and CC N
the DT N
percentage NN N
of IN N
anticipation NN N
responses NNS N
. . N

Patients NNS p
with IN p
writer NN p
's POS p
cramp NN p
exhibited VBD N
greater JJR N
absolute JJ N
timing NN N
error NN N
compared VBN N
with IN N
control NN N
subjects NNS N
in IN N
the DT N
human JJ N
body NN N
motion NN N
task NN N
( ( N
whereas IN N
no DT N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
inanimate NN N
object JJ N
motion NN N
task NN N
) ) N
. . N

No DT N
effect NN N
of IN N
group NN N
was VBD N
documented VBN N
on IN N
the DT N
visual JJ N
working JJ N
memory NN N
tasks NNS N
. . N

Absolute NNP o
timing VBG o
error NN o
on IN N
the DT N
human JJ N
body NN N
motion NN N
task NN N
did VBD N
not RB N
significantly RB N
correlate VB N
with IN N
symptom JJ N
severity NN N
, , N
disease VB N
duration NN N
or CC N
writing VBG N
speed NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
an DT N
alteration NN N
of IN N
the DT N
writing VBG N
movement NN N
representation NN N
at IN N
a DT N
central JJ N
level NN N
and CC N
are VBP N
consistent JJ N
with IN N
the DT N
view NN N
that IN N
dystonia NN N
is VBZ N
not RB N
a DT N
purely RB N
motor NN N
disorder NN N
, , N
but CC N
it PRP N
also RB N
involves VBZ N
non-motor NN N
( ( N
sensory JJ N
, , N
cognitive JJ N
) ) N
aspects NNS N
related VBN N
to TO N
movement NN N
processing NN N
and CC N
planning NN N
. . N

-DOCSTART- -10094243- O O

Epinephrine-induced JJ N
panic NN N
attacks NNS N
and CC N
hyperventilation NN N
. . N

To TO N
assess VB N
the DT N
effects NNS N
of IN N
epinephrine NN i
on IN N
ventilation NN N
in IN N
patients NNS p
with IN p
panic JJ p
disorder NN p
and CC p
in IN p
social JJ p
phobics NNS p
, , N
analyses NNS N
were VBD N
performed VBN N
on IN N
pooled VBN N
data NNS N
from IN N
two CD N
previous JJ N
infusion NN N
studies NNS N
. . N

Throughout IN N
the DT N
infusion NN N
, , N
changes NNS o
in IN o
transcutaneous JJ o
PCO2 NNP o
( ( o
tcPCO2 NN o
) ) o
, , o
subjective JJ o
anxiety NN o
, , o
heart NN o
rate NN o
and CC o
blood NN o
pressure NN o
were VBD N
recorded VBN N
continuously RB N
. . N

Twenty-nine JJ p
patients NNS p
received VBD p
epinephrine JJ i
, , p
ten JJ p
patients NNS p
received VBD p
placebo NN i
. . i

Thirteen JJ N
patients NNS N
( ( N
45 CD N
% NN N
) ) N
had VBD N
a DT N
panic JJ N
attack NN N
during IN N
epinephrine NN i
. . i

The DT N
fall NN o
in IN o
tcPCO2 NN o
and CC o
the DT o
cardiovascular JJ o
response NN o
was VBD N
greater JJR N
in IN N
panicking VBG N
patients NNS N
than IN N
patients NNS N
who WP N
did VBD N
not RB N
panic JJ N
. . N

Although IN N
the DT N
fall NN N
in IN N
tcPCO2 NN o
associated VBN N
with IN N
panic NN N
was VBD N
not RB N
substantial JJ N
and CC N
did VBD N
not RB N
indicate VB N
clinically RB N
significant JJ N
acute JJ o
hyperventilation NN o
, , N
it PRP N
appears VBZ N
to TO N
be VB N
a DT N
sensitive JJ N
index NN N
for IN N
epinephrine-induced JJ N
panic NN N
. . N

The DT N
fall NN o
in IN o
tcPCO2 NN o
was VBD N
predicted VBN N
rather RB N
by IN N
the DT N
frequency NN N
of IN N
occurrence NN o
of IN o
anxiety-related JJ o
somatic NN o
symptoms NNS o
than IN N
by IN N
the DT N
fear NN N
of IN N
these DT N
symptoms NNS N
. . N

These DT N
findings NNS N
further RB N
reduce VB N
a DT N
role NN N
for IN N
fear NN N
of IN N
bodily JJ N
sensations NNS N
in IN N
epinephrine-induced JJ i
panic NN N
attacks NNS N
and CC N
favor VBP N
a DT N
biological JJ N
sensitivity NN N
to TO N
sympathetic JJ N
stimulation NN N
. . N

-DOCSTART- -10902449- O O

[ RB N
Comparative NNP N
study NN N
between IN N
5 CD i
% NN i
prilocaine NN i
and CC N
2 CD i
% NN i
mepivacaine NN i
by IN N
the DT N
subarachnoid JJ N
route NN N
in IN N
transurethral JJ p
resections NNS p
] VBP p
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
duration NN o
of IN N
spinal JJ N
block NN N
with IN N
5 CD i
% NN i
prilocaine NN i
and CC i
2 CD i
% NN i
mepivacaine NN i
in IN N
short JJ p
procedures NNS p
for IN p
transurethral JJ p
resection NN p
and CC N
to TO N
assess VB o
possible JJ o
complications NNS o
in IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifty-seven NNP p
patients NNS p
scheduled VBN p
for IN p
transurethral JJ p
resection NN p
of IN p
the DT p
prostate NN p
or CC p
a DT p
vesical JJ p
tumor NN p
. . p

Patients NNS p
were VBD p
ASA NNP p
I-III NNP p
, , p
over IN p
55 CD p
years NNS p
of IN p
age NN p
and CC N
randomly RB N
assigned VBN N
to TO N
two CD i
groups NNS i
to TO i
receive VB i
5 CD i
% NN i
prilocaine NN i
( ( i
1 CD i
mg/kg NN i
, , i
n JJ i
= NNP i
27 CD i
) ) i
or CC i
2 CD i
% NN i
mepivacaine NN i
( ( i
0.8 CD i
mg/kg NN i
, , i
n JJ i
= NNP i
30 CD i
) ) i
. . N

We PRP i
collected VBD i
data NNS i
on IN i
anesthetic JJ o
technique NN o
, , o
levels NNS o
of IN o
extension NN o
of IN o
motor NN o
and CC o
sensory JJ o
blockades NNS o
, , o
duration NN o
of IN o
blockades NNS o
and CC o
complications NNS o
within IN o
the DT o
first JJ o
24 CD o
hours NNS o
after IN i
surgery NN i
. . i

RESULTS NNP N
Demographic NNP N
data NNS N
, , N
ASA NNP N
classification NN N
and CC N
duration NN N
of IN N
surgery NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

We PRP N
found VBD N
statistically RB N
significant JJ N
differences NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
duration NN o
of IN o
sensory JJ o
blockade NN o
( ( N
120.92 CD N
+/- JJ N
36.21 CD N
min NN N
with IN N
prilocaine NN i
and CC N
145.83 CD N
+/- JJ N
35.81 CD N
min NN N
with IN N
mepivacaine NN i
) ) i
and CC N
in IN N
motor NN o
blockade NN o
( ( N
106.29 CD N
+/- JJ N
38.16 CD N
min NN N
with IN N
prilocaine NN N
and CC N
133.16 CD N
+/- JJ N
42.21 CD N
min NN N
with IN N
mepivacaine NN N
) ) N
. . N

Five JJ N
cases NNS N
of IN N
hypotension NN o
and CC N
4 CD N
of IN N
bradycardia NN o
occurred VBN N
in IN N
each DT N
group NN N
and CC N
one CD N
patient NN N
in IN N
the DT N
mepivacaine NN N
group NN N
suffered VBD N
slight JJ N
postoperative JJ N
cephalea NN N
. . N

CONCLUSIONS NNP N
Both NNP N
local JJ N
anesthetics NNS N
offer VBP N
good JJ N
surgical JJ o
conditions NNS o
with IN N
hemodynamic JJ N
stability NN N
and CC N
few JJ N
complications NNS o
. . o

The DT N
duration NN N
of IN N
sensory NN o
and CC o
motor NN o
blockade NN o
is VBZ N
shorter JJR N
with IN N
prilocaine NN N
than IN N
with IN N
mepivacaine NN N
, , N
making VBG N
prilocaine NN N
more JJR N
appropriate JJ N
for IN N
short JJ N
interventions NNS N
. . N

-DOCSTART- -11545629- O O

Penetration NN N
of IN N
ofloxacin NN i
and CC i
ciprofloxacin NN i
into IN N
the DT N
aqueous JJ N
humor NN N
of IN N
eyes NNS p
with IN p
functioning VBG p
filtering VBG p
blebs NN p
: : p
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
concentrations NNS N
of IN N
ofloxacin NN N
and CC N
ciprofloxacin NN N
hydrochloride NN N
in IN N
aqueous JJ N
humor NN N
after IN N
topical JJ N
or CC N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
in IN N
eyes NNS p
with IN p
filtering VBG p
blebs NN p
. . p

DESIGN VB N
A DT N
prospective JJ N
, , N
investigator-masked JJ N
, , N
randomized VBN N
, , N
controlled VBD N
comparative JJ N
study NN N
involving VBG N
36 CD p
eyes NNS p
of IN p
34 CD p
patients NNS p
with IN p
functioning VBG p
filtering VBG p
blebs NNS p
who WP p
were VBD p
to TO p
undergo VB p
cataract NN p
surgery NN p
. . p

Treatment NN N
groups NNS N
received VBD N
either RB N
topical JJ i
ofloxacin NN i
or CC i
topical JJ i
ciprofloxacin NN i
( ( N
instillation NN N
of IN N
0.3 CD N
% NN N
ophthalmic JJ N
solution NN N
every DT N
30 CD N
minutes NNS N
for IN N
4 CD N
hours NNS N
before IN N
surgery NN i
) ) i
, , N
or CC N
a DT N
combined JJ N
topical JJ N
plus CC N
oral JJ N
regimen NNS N
( ( i
ciprofloxacin JJ i
hydrochloride NN i
, , i
four CD i
100-mg JJ i
tablets NNS i
, , i
or CC i
ofloxacin RB i
, , i
one CD i
400-mg JJ i
tablet NN i
, , N
administered VBN N
24-26 JJ N
, , N
12-14 JJ N
, , N
and CC N
2 CD N
hours NNS N
preceding VBG N
surgery NN i
) ) i
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
antibiotic JJ o
concentration NN o
measured VBN N
by IN N
chromatographic JJ N
separation NN N
and CC N
mass NN N
spectrometry NN N
of IN N
aqueous JJ N
samples NNS N
obtained VBN N
during IN N
surgery NN N
. . N

RESULTS NNP N
Topical NNP N
antibiotic JJ N
treatment NN N
yielded VBN N
mean JJ N
concentrations NNS o
of IN o
ofloxacin NN o
, , N
0.75 CD N
microg/mL NN N
, , N
and CC N
ciprofloxacin NN i
, , N
0.21 CD N
microg/mL NN N
, , N
in IN N
aqueous JJ N
. . N

With IN N
combined JJ N
topical JJ N
and CC N
oral JJ N
therapy NN N
, , N
significantly RB N
more JJR N
ofloxacin NN N
was VBD N
measured VBN N
than IN N
ciprofloxacin NN N
( ( N
3.84 CD N
microg/mL NN N
vs NN N
0.35 CD N
microg/mL NN N
[ NNP N
P NNP N
< NNP N
.001 NNP N
] NNP N
) ) N
. . N

The DT N
combination NN N
regimen NNS N
produced VBD N
significantly RB N
greater JJR o
ofloxacin NN o
levels NNS o
than IN N
did VBD N
topical JJ N
therapy NN N
alone RB N
( ( N
P NNP N
=.007 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Ofloxacin NNP N
penetrates VBZ N
better JJR N
than IN N
ciprofloxacin NN o
into IN N
the DT N
aqueous JJ N
of IN N
eyes NNS N
with IN N
filtering VBG N
blebs NNS N
, , N
particularly RB N
after IN N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
, , N
by IN N
which WDT N
ofloxacin NN N
reaches VBZ N
more JJR N
than IN N
a DT N
10-fold JJ N
greater JJR N
concentration NN N
than IN N
does VBZ N
ciprofloxacin VB N
. . N

Combined VBN N
topical JJ i
and CC i
oral JJ i
therapy NN i
with IN i
ofloxacin NN i
may MD N
be VB N
beneficial JJ N
in IN N
the DT N
treatment NN N
of IN N
bleb-associated JJ N
infections NNS N
. . N

-DOCSTART- -14656280- O O

Intraperitoneal NNP i
cisplatin NN i
versus NN N
no DT N
further JJ N
treatment NN N
: : N
8-year JJ N
results NNS N
of IN N
EORTC NNP N
55875 CD N
, , N
a DT N
randomized JJ N
phase NN N
III NNP N
study NN N
in IN N
ovarian JJ p
cancer NN p
patients NNS p
with IN p
a DT p
pathologically RB p
complete JJ p
remission NN p
after IN p
platinum-based JJ i
intravenous JJ i
chemotherapy NN i
. . i

First-line NNP i
intravenous JJ i
chemotherapy NN i
( ( N
CT NNP N
) ) N
following VBG N
debulking VBG N
surgery NN N
is VBZ N
associated VBN N
with IN N
prolonged JJ o
survival NN o
, , N
in IN N
particular JJ N
in IN N
patients NNS p
who WP p
achieve VBP p
a DT p
pathological JJ p
complete JJ p
remission NN p
( ( p
pCR NN p
) ) p
at IN p
second-look NN p
surgery NN p
but CC p
in IN p
whom WP p
a DT p
high JJ p
rate NN p
of IN p
relapses NNS p
still RB p
occurs VBZ p
. . p

Between JJ p
1988 CD p
and CC p
1997 CD p
, , p
153 CD p
patients NNS p
in IN p
pCR JJ p
following VBG p
platinum-based JJ i
intravenous JJ i
CT NNP i
were VBD N
randomized VBN N
between IN N
four CD i
courses NNS i
of IN i
intraperitoneal NN i
cisplatin NN i
( ( i
P NNP i
) ) i
( ( i
90 CD i
mg/m2 NN i
every DT i
3 CD i
weeks NNS i
) ) i
or CC i
observation NN i
. . i

Overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
was VBD N
the DT N
primary JJ N
endpoint NN N
, , N
while IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
was VBD N
a DT N
secondary JJ N
endpoint NN N
. . N

This DT N
intent-to-treat JJ N
analysis NN N
includes VBZ p
16 CD p
patients NNS p
who WP p
were VBD p
not RB p
eligible JJ p
and CC p
17 CD p
patients NNS p
who WP p
had VBD p
protocol NN p
violations NNS p
. . p

The DT N
two CD p
groups NNS p
were VBD p
well RB p
balanced VBN p
in IN p
terms NNS p
of IN p
age NN p
( ( p
median JJ p
= VBZ p
55 CD p
years NNS p
) ) p
, , p
performance NN p
status NN p
( ( p
78 CD p
% NN p
P.S NNP p
. . p

O NNP p
) ) p
, , p
FIGO NNP p
stage NN p
( ( p
96 CD p
% NN p
stage NN p
III NNP p
) ) p
, , p
histology NN p
( ( p
serous JJ p
in IN p
66 CD p
% NN p
) ) p
, , p
grade VBD p
( ( p
2 CD p
or CC p
3 CD p
in IN p
80 CD p
% NN p
) ) p
, , p
and CC p
residuum NN p
before RB p
intravenous JJ p
CT NNP p
( ( p
> $ p
1 CD p
cm NN p
in IN p
40 CD p
% NN p
) ) p
. . p

Intraperitoneal NNP i
CT NNP i
was VBD N
delivered VBN N
mainly RB N
through IN N
intraperitoneal JJ N
catheters NNS N
( ( N
Port-a-Cath JJ N
61 CD N
% NN N
and CC N
Tenckhoff NNP N
25 CD N
% NN N
) ) N
. . N

Side JJ N
effects NNS N
of IN N
intraperitoneal NN i
cisplatin NN i
included VBD N
vomiting VBG o
[ NNP N
> NNP N
or CC N
=grade VB N
2 CD N
( ( N
82 CD N
% NN N
) ) N
] NN N
, , N
rise NN o
in IN o
serum JJ o
creatinine NN o
[ NNP N
> NNP N
or CC N
=grade VB N
2 CD N
( ( N
14 CD N
% NN N
) ) N
] NN N
, , N
abdominal JJ o
pain NN o
[ JJ N
grade NN N
1-2 JJ N
( ( N
38 CD N
% NN N
) ) N
] NN N
, , N
and CC N
neurotoxicity NN o
[ NNP N
grade VBD N
2-3 CD N
( ( N
15 CD N
% NN N
) ) N
] NN N
. . N

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
8 CD N
years NNS N
, , N
80 CD N
patients NNS N
( ( N
52 CD N
% NN N
) ) N
have VBP N
progressed VBN N
with IN N
no DT N
difference NN N
in IN N
the DT N
pattern NN o
of IN o
relapse NN o
between IN N
the DT N
two CD N
groups NNS N
and CC N
75 CD N
patients NNS N
( ( N
49 CD N
% NN N
) ) N
have VBP N
died VBN o
; : o
the DT N
respective JJ N
hazard NN N
ratios NNS N
for IN N
PFS NNP N
and CC N
OS NNP N
with IN N
95 CD N
% NN N
CI NNP N
are VBP N
0.89 CD N
( ( N
0.59-1.33 NN N
) ) N
and CC N
0.82 CD N
( ( N
0.52-1.29 NN N
) ) N
. . N

These DT N
results NNS N
are VBP N
suggestive JJ N
of IN N
a DT N
treatment NN N
benefit NN N
but CC N
do VBP N
not RB N
support VB N
a DT N
change NN N
in IN N
clinical JJ N
practice NN N
. . N

Other JJ N
randomized JJ N
clinical JJ N
trials NNS N
of IN N
intraperitoneal JJ i
CT NNP i
are VBP N
reviewed VBN N
and CC N
briefly NN N
discussed VBN N
. . N

-DOCSTART- -937075- O O

Maximal NNP o
bioavailability NN o
of IN p
digoxin NN i
from IN p
tablets NNS p
and CC p
oral JJ p
solution NN p
in IN p
steady JJ p
state NN p
. . p

Comparison NNP N
has VBZ N
been VBN N
made VBN N
between IN N
the DT N
absorption NN o
of IN o
digoxin NN o
from IN N
Lanoxin NNP i
tablets NNS N
and CC N
the DT N
absorption NN N
of IN N
international JJ N
chemical NN N
reference NN N
substance NN N
digoxin NN o
from IN i
an DT i
oral JJ i
solution NN i
. . i

Plasma NNP o
levels NNS o
, , o
areas NNS o
under IN o
24-hour JJ o
plasma NN o
concentration NN o
curves NNS o
and CC o
urinary JJ o
excretion NN o
were VBD N
similar JJ N
by IN N
both DT N
formulations NNS N
in IN N
steady JJ N
state NN N
. . N

78 CD N
% NN N
of IN N
the DT N
digoxin NN o
administered VBD N
was VBD N
absorbed VBN N
from IN N
the DT N
tablets NNS N
and CC N
76 CD N
% NN N
from IN N
the DT N
solution NN N
. . N

Rapid JJ N
dissolution NN N
in IN N
the DT N
intestinal JJ N
fluids NNS N
accounts NNS N
for IN N
the DT N
high JJ N
digoxin NN o
bioavailability NN o
of IN N
the DT N
tablets NNS N
. . N

-DOCSTART- -7712308- O O

Effects NNS N
of IN N
ursodeoxycholic JJ i
acid NN i
on IN N
serum NN o
liver NN o
enzymes NNS o
in IN N
patients NNS p
with IN p
hepatitis JJ p
C NNP p
virus-related JJ p
chronic JJ p
liver NN p
disease NN p
. . p

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
ursodeoxycholic JJ i
acid NN i
( ( i
UDCA NNP i
) ) i
on IN N
serum NN o
liver NN o
enzyme NN o
levels NNS o
[ VBP o
alanine JJ o
aminotransferase NN o
( ( o
ALT NNP o
) ) o
and CC o
gamma-glutamyl JJ o
transferase NN o
( ( o
GGT NNP o
) ) o
] VBP o
in IN N
101 CD p
patients NNS p
with IN p
hepatitis JJ p
C NNP p
virus-related JJ p
chronic JJ p
liver NN p
disease NN p
. . p

METHODS NNP N
Forty-nine JJ p
patients NNS p
were VBD p
assigned VBN p
to TO p
receive VB p
UDCA NNP i
( ( p
450 CD p
mg/day NN p
) ) p
over IN p
a DT p
period NN p
of IN p
6 CD p
months NNS p
and CC p
52 CD p
to TO p
receive VB p
no DT i
treatment NN i
. . i

RESULTS NNP N
In IN N
the DT N
UDCA NNP i
group NN N
, , N
serum NN o
ALT NNP o
and CC o
GGT NNP o
levels NNS o
significantly RB N
improved VBN N
. . N

ALT NNP o
values NNS o
decreased VBN N
from IN N
pre-treatment JJ N
levels NNS N
of IN N
157.0 CD N
+/- JJ N
62.6 CD N
IU/l NNP N
to TO N
82.5 CD N
+/- JJ N
46.4 CD N
IU/l NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
GGT NNP N
fell VBD N
from IN N
141.3 CD N
+/- JJ N
86.2 CD N
IU/l NNP N
to TO N
66.0 CD N
+/- JJ N
49.5 CD N
IU/l NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
change NN N
occurred VBD N
in IN N
the DT N
mean JJ o
ALT NNP o
and CC o
GGT NNP o
levels NNS o
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
Although IN N
our PRP$ N
encouraging JJ N
preliminary JJ N
results NNS N
must MD N
be VB N
validated VBN N
by IN N
double-blind JJ N
histological JJ N
trials NNS N
, , N
UDCA NNP i
may MD N
be VB N
an DT N
alternative JJ N
treatment NN N
for IN N
patients NNS p
who WP p
fail VBP p
to TO p
respond VB p
to TO p
interferon VB i
therapy NN i
. . i

-DOCSTART- -9648960- O O

Bronchodilator NNP N
response NN N
to TO N
salbutamol VB i
after IN N
spontaneous JJ N
recovery NN N
from IN N
nonspecific JJ N
bronchial JJ N
provocation NN N
tests NNS N
in IN N
asthma NN p
. . p

Assessment NN N
of IN N
airway NN N
responsiveness NN N
by IN N
bronchoprovocation NN N
and CC N
bronchodilatation NN N
tests NNS N
is VBZ N
important JJ N
in IN N
the DT N
diagnostic JJ N
work-up JJ N
protocol NN N
of IN N
bronchial JJ p
asthma NN p
and CC N
it PRP N
would MD N
be VB N
convenient JJ N
to TO N
undertake VB N
both DT N
tests NNS N
on IN N
the DT N
same JJ N
occasion NN N
. . N

However RB N
, , N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
this DT N
can MD N
be VB N
done VBN N
accurately RB N
. . N

Therefore RB N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
a DT N
prior JJ N
bronchial JJ N
provocation NN N
test NN N
on IN N
the DT N
bronchodilator NN N
response NN N
to TO N
salbutamol VB i
after IN N
spontaneous JJ N
recovery NN N
of IN N
the DT N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( o
FEV1 NNP o
) ) o
in IN N
a DT p
group NN p
of IN p
asthmatic JJ p
subjects NNS p
. . p

On IN N
two CD N
separate JJ N
occasions NNS N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
, , N
concentration-response JJ N
studies NNS N
with IN N
inhaled JJ N
histamine NN i
or CC i
methacholine NN i
, , i
or CC i
a DT i
sham JJ i
challenge NN i
with IN i
normal JJ i
saline NN i
were VBD N
carried VBN N
out RP N
in IN N
a DT N
blinded JJ N
, , N
randomized JJ N
manner NN N
. . N

Changes NNS N
in IN N
airway NN N
calibre NN N
were VBD N
followed VBN N
as IN N
FEV1 NNP o
and CC N
agonist JJ N
responsiveness NN N
expressed VBN N
as IN N
the DT N
provocative JJ N
concentration NN N
causing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV1 NNP o
( ( N
PC20 NNP N
) ) N
. . N

After IN N
either DT N
spontaneous JJ N
recovery NN N
or CC N
a DT N
fixed-duration JJ N
wait NN N
of IN N
45 CD N
min NNS N
( ( N
when WRB N
appropriate NN N
) ) N
, , N
the DT N
subjects NNS N
received VBD N
2x100 CD N
microg NN N
of IN N
salbutamol NN i
from IN N
a DT N
metered VBN N
dose NN N
inhaler NN N
with IN N
a DT N
spacer NN N
. . N

The DT N
bronchodilator NN N
response NN N
to TO N
salbutamol VB N
was VBD N
expressed VBN N
as IN N
a DT N
percentage NN N
of IN N
initial JJ o
FEV1 NNP o
( ( N
deltaFEV1 CD N
% NN N
init NN N
) ) N
. . N

Bronchial JJ N
challenge NN N
with IN N
both DT N
agonists NNS N
failed VBD N
to TO N
alter VB N
significantly RB N
the DT N
airway NN o
response NN o
to TO N
salbutamol VB N
, , N
with IN N
the DT N
deltaFEV1 NN o
% NN o
init JJ o
mean JJ o
value NN o
( ( N
range NN N
) ) N
being VBG N
16.9 CD N
% NN N
( ( N
9.0-31.9 CD N
) ) N
and CC N
17.5 CD N
% NN N
( ( N
11.6-31.2 JJ N
) ) N
on IN N
the DT N
sham NN N
and CC N
histamine/methacholine JJ N
challenge NN N
day NN N
respectively RB N
. . N

It PRP N
was VBD N
shown VBN N
that IN N
the DT N
degree NN N
of IN N
bronchodilatation NN N
achieved VBN N
after IN N
salbutamol JJ N
200 CD N
microg NN N
is VBZ N
not RB N
affected VBN N
by IN N
prior JJ N
bronchoprovocation NN N
testing VBG N
when WRB N
enough JJ N
time NN N
is VBZ N
allowed VBN N
for IN N
the DT N
airways NNS N
to TO N
recover VB N
spontaneously RB N
to TO N
baseline VB N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
. . N

Thus NNP N
evaluation NN N
of IN N
airway NN N
responsiveness NN N
by IN N
both DT N
bronchial JJ N
provocation NN N
tests NNS N
and CC N
bronchodilator NN N
testing NN N
can MD N
be VB N
assessed VBN N
reliably RB N
within IN N
a DT N
few JJ N
hours NNS N
in IN N
asthmatic JJ p
patients NNS p
. . p

-DOCSTART- -22214113- O O

Pilot NNP N
study NN N
of IN N
the DT N
effectiveness NN N
of IN N
weighted JJ i
vests NNS i
. . i

OBJECTIVE NN N
In IN N
this DT N
pilot NN N
study NN N
, , N
we PRP N
determined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
weighted JJ i
vest NN i
on IN N
attention NN N
to TO N
task VB N
for IN N
second-grade JJ p
general JJ p
education NN p
students NNS p
with IN p
difficulty NN p
attending VBG p
. . p

METHOD NNP N
We PRP N
used VBD N
an DT N
intervention NN i
and CC N
a DT N
control NN i
group NN N
and CC N
an DT N
ABA NNP N
design NN N
to TO N
compare VB N
participants NNS N
' POS N
percentage NN N
of IN N
time NN N
on IN N
task NN N
with IN i
and CC i
without IN i
a DT i
vest NN i
. . i

Ten CD p
participants NNS p
from IN p
nine CD p
elementary JJ p
schools NNS p
in IN p
a DT p
suburban JJ p
Texas NNP p
school NN p
district NN p
were VBD p
randomly RB p
assigned VBN p
to TO N
an DT N
intervention NN i
or CC N
a DT N
control NN i
group NN N
. . N

Control NNP N
group NN N
participants NNS N
wore VBD N
a DT N
nonweighted JJ i
vest NN i
. . i

Participants NNS N
, , N
classroom NN N
teachers NNS N
, , N
and CC N
research NN N
assistants NNS N
who WP N
coded VBD N
the DT N
data NNS N
were VBD N
blind RB N
as IN N
to TO N
the DT N
group NN N
to TO N
which WDT N
the DT N
participants NNS N
were VBD N
assigned VBN N
. . N

RESULTS VB N
A NNP N
repeated JJ N
measures NNS N
analysis NN N
of IN N
variance NN N
indicated VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
or CC N
between IN N
baseline NN N
, , N
intervention NN N
, , N
and CC N
withdrawal NN N
conditions NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicated VBD N
that IN N
the DT N
weighted JJ i
vests NNS i
were VBD N
not RB N
effective JJ N
in IN N
increasing VBG N
time NN o
on IN o
task NN o
. . o

These DT N
results NNS N
should MD N
be VB N
generalized VBN N
cautiously RB N
owing VBG N
to TO N
the DT N
small JJ N
sample NN N
size NN N
and CC N
participant JJ N
selection NN N
process NN N
. . N

-DOCSTART- -6425480- O O

Short-term JJ N
pulmonary JJ N
effects NNS N
of IN N
total JJ i
parenteral JJ i
nutrition NN i
in IN N
children NNS p
with IN p
cystic JJ p
fibrosis NN p
. . p

Indices NNS N
of IN N
respiratory JJ N
muscle NN N
strength NN N
, , N
pulmonary JJ N
function NN N
, , N
and CC N
pulmonary JJ N
diffusing NN N
capacity NN N
were VBD N
measured VBN N
in IN N
11 CD p
malnourished JJ p
children NNS p
( ( p
age NN p
10 CD p
to TO p
17 CD p
years NNS p
) ) p
with IN p
cystic JJ p
fibrosis NN p
, , p
before IN p
and CC p
after IN p
improvement NN p
of IN p
nutritional JJ p
status NN p
with IN p
supplemental JJ i
parenteral JJ i
nutrients NNS i
for IN p
1 CD p
month NN p
. . p

During IN N
this DT N
time NN N
, , N
the DT N
children NNS N
received VBD N
120 CD N
% NN N
of IN N
estimated VBN N
energy NN N
requirements NNS N
( ( N
either CC N
3.75 CD N
% NN N
or CC N
22.5 CD N
% NN N
as IN N
lipid NN i
) ) i
and CC N
amino JJ i
acids NNS i
2.5 CD N
gm/120 JJ N
kcal JJ N
by IN N
central JJ N
venous JJ N
catheter NN N
, , N
plus CC N
as IN N
much JJ N
of IN N
their PRP$ N
usual JJ N
diet NN N
as IN N
desired VBN N
. . N

With IN N
nutritional JJ o
supplementation NN o
, , o
body NN o
weight NN o
, , o
triceps NNS o
skinfold VBD o
thickness NN o
, , o
and CC o
mid-arm JJ o
muscle NN o
circumference NN o
increased VBD N
( ( N
mean JJ N
15 CD N
% NN N
, , N
62 CD N
% NN N
, , N
and CC N
95 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Maximum JJ o
inspiratory JJ o
airway NN o
pressure NN o
also RB N
increased VBD N
( ( N
mean JJ N
29 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
suggesting VBG N
improvement NN N
in IN N
respiratory JJ o
muscle NN o
strength NN o
. . o

However RB N
, , N
none NN N
of IN N
the DT N
indices NNS o
of IN o
pulmonary JJ o
function NN o
improved VBN N
. . N

Pulmonary JJ o
diffusing VBG o
capacity NN o
did VBD N
not RB N
change VB N
during IN N
parenteral JJ N
nutrition NN N
regardless NN N
of IN N
the DT N
amount NN N
of IN N
parenteral JJ o
energy NN o
intake NN o
supplied VBN N
by IN N
lipid JJ N
, , N
but CC N
arterial JJ o
oxygen NN o
saturation NN o
decreased VBN N
( ( N
mean NN N
of IN N
93.5 CD N
% NN N
to TO N
91.5 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
0.005 CD N
) ) N
. . N

During IN N
the DT N
month NN N
following VBG N
parenteral JJ N
nutrition NN N
, , N
weight NN N
, , N
skinfold JJ N
thickness NN N
, , N
and CC N
mid-arm JJ N
muscle NN N
circumference NN N
, , N
but CC N
not RB N
MIP NNP N
, , N
decreased VBD N
and CC N
arterial JJ N
oxygen NN N
saturation NN N
returned VBD N
to TO N
the DT N
initial JJ N
value NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

-DOCSTART- -7820060- O O

Interferon NNP i
treatment NN i
for IN N
hairy NN o
cell NN o
leukemia NN o
. . o

An DT N
update NN N
on IN N
a DT N
cohort NN p
of IN p
69 CD p
patients NNS p
treated VBN p
from IN p
1983 CD p
to TO p
1986 CD p
. . p

We PRP N
report VBP N
follow-up JJ N
information NN N
on IN N
69 CD p
hairy NN o
cell NN o
leukemia NN o
( ( o
HCL NNP o
) ) o
patients NNS p
treated VBN p
with IN p
interferon JJ i
alfa-2b NN i
( ( i
IFN NNP i
) ) i
as IN p
primary JJ p
treatment NN p
from IN p
1983 CD p
to TO p
1986 CD p
. . p

Follow-up NNP N
through IN N
April NNP N
, , N
1993 CD N
shows VBZ N
that IN N
only RB N
14 CD N
patients NNS N
have VBP N
expired VBN N
. . N

Forty-seven CD N
of IN N
the DT N
61 CD N
patients NNS N
completing VBG N
the DT N
intended JJ N
12 CD N
or CC N
more JJR N
months NNS N
of IN N
initial JJ N
IFN NNP i
treatment NN N
were VBD N
eventually RB N
considered VBN N
IFN NNP i
failures NNS N
. . N

Forty-three CD N
required JJ N
re-treatment NN N
( ( N
41 CD N
received VBD N
a DT N
second JJ N
course NN N
of IN N
IFN NNP i
and CC N
2 CD N
received VBD N
pentostatin NN i
) ) i
. . N

Four CD N
patients NNS N
died VBD N
without IN N
further JJ N
therapy NN N
for IN N
HCL NNP o
. . o

The DT N
median JJ N
time NN N
to TO N
interferon VB i
failure NN N
was VBD N
31.3 CD N
months NNS N
. . N

Fourteen JJ N
patients NNS N
are VBP N
alive JJ N
and CC N
have VBP N
not RB N
required VBN N
further RBR N
treatment NN N
after IN N
completing VBG N
their PRP$ N
initial JJ N
12 CD N
or CC N
more JJR N
months NNS N
of IN N
interferon NN i
. . i

Fifteen JJ N
patients NNS N
underwent VBD N
a DT N
third JJ N
course NN N
of IN N
interferon NN i
therapy NN N
at IN N
a DT N
median JJ N
time NN N
after IN N
completion NN N
of IN N
a DT N
second JJ N
course NN N
of IN N
IFN NNP i
of IN N
1.0 CD N
year NN N
. . N

Eighteen JJ N
patients NNS N
were VBD N
eventually RB N
treated VBN N
with IN N
pentostatin NN i
and CC N
ten VB N
with IN N
2-chlorodeoxyadenosine JJ i
( ( i
2-CdA JJ i
) ) i
. . i

Thirteen JJ N
patients NNS N
developed VBD N
a DT N
second JJ o
malignancy NN o
; : o
six CD N
of IN N
these DT N
patients NNS N
developed VBD N
a DT N
hematologic JJ o
malignancy NN o
between IN N
44.6 CD N
months NNS N
and CC N
99.1 CD N
months NNS N
after IN N
initiation NN N
of IN N
interferon NN i
therapy NN N
. . N

We PRP N
conclude VBP N
that IN N
although IN N
interferon NN i
provides VBZ N
excellent JJ o
palliation NN o
, , N
that IN N
most JJS N
patients NNS N
will MD N
eventually RB N
require VB N
further JJ N
treatment NN N
with IN N
interferon NN o
or CC N
chemotherapy NN o
. . o

Future JJ N
trials NNS N
in IN N
HCL NNP N
must MD N
be VB N
aware JJ N
of IN N
the DT N
risk NN N
of IN N
second JJ o
malignancies NNS o
. . o

-DOCSTART- -23118720- O O

Clinical JJ N
trial NN N
: : N
marine NN i
lipid JJ i
suppositories NNS i
as IN N
laxatives NNS N
. . N

UNLABELLED JJ N
Cod-liver JJ N
oil NN N
and CC N
other JJ N
marine NN N
products NNS N
containing VBG N
polyunsaturated JJ N
fatty JJ N
acids NNS N
have VBP N
anti-inflammatory JJ N
, , N
anti-bacterial JJ N
and CC N
anti-viral JJ N
effects NNS N
and CC N
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
various JJ N
inflammatory NN N
and CC N
infectious JJ N
diseases NNS N
. . N

We PRP N
developed VBD N
suppositories NNS i
and CC i
ointment NN i
with IN i
30 CD i
% NN i
free JJ i
fatty JJ i
acid NN i
( ( i
FFA NNP i
) ) i
extract NN i
from IN i
omega-3 JJ i
fish JJ i
oil NN i
. . i

Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN o
of IN N
marine JJ N
lipid JJ N
suppositories NNS N
and CC N
ointment NN N
in IN N
healthy JJ p
volunteers NNS p
and CC N
to TO N
explore VB N
the DT N
laxative JJ o
effect NN o
of IN N
the DT N
suppositories NNS N
. . N

Thirty NNP p
healthy JJ p
volunteers NNS p
were VBD N
randomized VBN N
either RB N
to TO N
a DT N
study NN N
group NN N
administrating VBG N
30 CD N
% NN N
FFA NNP i
suppositories NNS i
and CC N
applying VBG N
30 CD N
% NN N
FFA NNP i
ointment NN i
to TO N
the DT N
perianal JJ N
region NN N
twice RB N
per IN N
day NN N
for IN N
two CD N
weeks NNS N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
using VBG N
placebo NN i
suppositories NNS i
and CC N
ointment NN N
in IN N
a DT N
double JJ N
blinded JJ N
manner NN N
. . N

RESULTS NNP N
No NNP N
serious JJ o
toxic NN o
effects NNS o
or CC o
irritation NN o
were VBD N
observed VBN N
. . N

In IN N
the DT N
study NN N
group NN N
93 CD N
% NN N
felt VBD N
the DT N
urge NN o
to TO o
defecate VB o
after IN N
administration NN N
of IN N
the DT N
suppositories NNS N
as IN N
compared VBN N
to TO N
37 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Subsequently RB N
90 CD N
% NN N
in IN N
the DT N
study NN N
group NN N
defecated VBD o
, , N
compared VBN N
to TO N
33 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
marine JJ N
lipid JJ N
suppositories NNS N
and CC N
ointment NN N
were VBD N
well RB N
tolerated VBN N
with IN N
no DT N
significant JJ N
toxic JJ o
side NN o
effects NNS o
observed VBD N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
suppositories NNS N
have VBP N
a DT N
distinct JJ N
laxative JJ o
effect NN o
and CC N
we PRP N
aim VBP N
to TO N
explore VB N
this DT N
effect NN N
in IN N
further JJ N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -17443855- O O

Long-term JJ N
results NNS N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
Shouldice NNP i
, , i
Lichtenstein NNP i
and CC i
transabdominal JJ i
preperitoneal NN i
hernia NN i
repairs NNS i
. . i

INTRODUCTION NNP N
There EX N
is VBZ N
an DT N
ongoing JJ N
debate NN N
about IN N
the DT N
preferred JJ N
technique NN N
for IN N
inguinal JJ N
hernia NN N
repair NN N
. . N

In IN N
this DT N
randomized VBN N
study NN N
the DT N
long-term JJ N
results NNS N
of IN N
Shouldice NNP i
, , i
Lichtenstein NNP i
and CC N
transabdominal JJ i
preperitoneal NN i
( ( i
TAPP NNP i
) ) i
hernia NN i
repair NN i
were VBD N
compared VBN N
. . N

METHODS NNP N
Some DT p
280 CD p
men NNS p
with IN p
a DT p
primary JJ p
hernia NN p
were VBD p
randomized VBN p
prospectively RB N
to TO N
undergo VB N
Shouldice NNP i
, , i
tension-free JJ i
Lichtenstein NNP i
or CC i
laparoscopic JJ i
TAPP NNP i
repair NN i
. . i

Patients NNS N
were VBD N
examined VBN N
after IN N
52 CD N
months NNS N
to TO N
assess VB N
hernia NN o
recurrence NN o
, , o
nerve NN o
damage NN o
, , o
testicular JJ o
atrophy NN o
and CC o
patient JJ o
satisfaction NN o
. . o

RESULTS NNP N
Hernia NNP o
recurrence NN o
occurred VBD N
in IN N
six CD N
patients NNS N
after IN N
Shouldice NNP N
repair NN N
, , N
and CC N
in IN N
one CD N
patient NN N
each DT N
after IN N
Lichtenstein NNP N
and CC N
TAPP NNP N
repairs NNS N
. . N

All DT N
recurrences NNS o
after IN o
tension-free JJ o
repairs NNS o
were VBD N
diagnosed VBN N
within IN N
the DT N
first JJ N
year NN N
after IN N
surgery NN N
. . N

Nerve CC o
injuries NNS o
were VBD N
significantly RB N
more RBR N
frequent JJ N
after IN N
open JJ N
Shouldice NNP N
and CC N
Lichtenstein NNP N
repairs NNS N
. . N

Patient JJ o
satisfaction NN o
was VBD N
greatest JJS N
after IN N
laparoscopic JJ N
TAPP NNP N
repair NN N
. . N

CONCLUSION NNP N
Tension-free NNP N
repair NN N
was VBD N
superior JJ N
to TO N
the DT N
non-mesh JJ N
Shouldice NNP N
technique NN N
. . N

The DT N
open JJ N
anterior JJ N
approach NN N
to TO N
the DT N
groin NN N
was VBD N
associated VBN N
with IN N
demonstrable JJ N
nerve NN o
injury NN o
, , N
and CC N
laparoscopic JJ N
TAPP NNP N
repair NN N
was VBD N
the DT N
most RBS N
effective JJ N
approach NN N
in IN N
the DT N
hands NNS N
of IN N
an DT N
experienced JJ N
surgeon NN N
. . N

-DOCSTART- -23753523- O O

Effect NN p
of IN p
resistance NN i
exercise NN i
contraction NN i
mode NN i
and CC p
protein JJ i
supplementation NN i
on IN p
members NNS p
of IN p
the DT p
STARS NNP p
signalling VBG p
pathway RB p
. . p

The DT N
striated JJ N
muscle NN N
activator NN N
of IN N
Rho NNP N
signalling VBG N
( ( N
STARS NNP N
) ) N
pathway NN N
is VBZ N
suggested VBN N
to TO N
provide VB N
a DT N
link NN N
between IN N
external JJ N
stress NN N
responses NNS N
and CC N
transcriptional JJ N
regulation NN N
in IN N
muscle NN N
. . N

However RB N
, , N
the DT N
sensitivity NN N
of IN N
STARS NNP N
signalling VBG N
to TO N
different JJ N
mechanical JJ N
stresses NNS N
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

In IN N
a DT N
comparative JJ N
study NN N
, , N
we PRP N
examined VBD N
the DT N
regulation NN N
of IN N
the DT N
STARS NNP N
signalling VBG N
pathway RB N
in IN N
response NN N
to TO N
unilateral JJ N
resistance NN i
exercise NN i
performed VBN N
as IN N
either DT N
eccentric JJ i
( ( i
ECC NNP i
) ) i
or CC i
concentric JJ i
( ( i
CONC NNP i
) ) i
contractions NNS i
as RB N
well RB N
as IN N
prolonged JJ i
training NN i
; : i
with IN p
and CC p
without IN p
whey JJ i
protein NN i
supplementation NN i
. . i

Skeletal JJ N
muscle NN N
STARS NNP N
, , N
myocardian-related JJ N
transcription NN N
factor-A NN N
( ( N
MRTF-A NNP N
) ) N
and CC N
serum JJ N
response NN N
factor NN N
( ( N
SRF NNP N
) ) N
mRNA NN N
and CC N
protein NN N
, , N
as RB N
well RB N
as IN N
muscle NN N
cross-sectional JJ N
area NN N
and CC N
maximal JJ N
voluntary JJ N
contraction NN N
, , N
were VBD N
measured VBN N
. . N

A DT N
single-bout NN N
of IN N
exercise NN i
produced VBN N
increases NNS N
in IN N
STARS NNP o
and CC o
SRF NNP o
mRNA NN o
and CC o
decreases NNS o
in IN o
MRTF-A NNP o
mRNA NN o
with IN o
both DT o
ECC NNP o
and CC o
CONC NNP o
exercise NN o
, , N
but CC N
with IN N
an DT N
enhanced JJ N
response NN N
occurring VBG N
following VBG N
ECC NNP i
exercise NN i
. . i

A DT N
31 CD N
% NN N
increase NN N
in IN N
STARS NNP o
protein NN o
was VBD N
observed VBN N
exclusively RB N
after IN N
CONC NNP i
exercise NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
while IN N
pSRF JJ o
protein NN N
levels NNS N
increased VBD N
similarly RB N
by IN N
48 CD N
% NN N
with IN N
both DT N
CONC NNP N
and CC N
ECC NNP N
exercise NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Prolonged VBN N
ECC NNP N
and CC N
CONC NNP N
training VBG N
equally RB N
stimulated VBN N
muscle NN N
hypertrophy NN N
and CC N
produced VBD N
increases NNS N
in IN N
MRTF-A NNP o
protein NN o
of IN N
125 CD N
% NN N
and CC N
99 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No UH N
changes NNS N
occurred VBD N
for IN N
total JJ o
SRF NNP o
protein NN o
. . o

There EX N
was VBD N
no DT N
effect NN N
of IN N
whey NN o
protein NN o
supplementation NN o
. . o

These DT N
results NNS N
show VBP N
that IN N
resistance NN N
exercise NN N
provides VBZ N
an DT N
acute JJ o
stimulation NN o
of IN o
the DT o
STARS NNP o
pathway NN o
that WDT N
is VBZ N
contraction JJ N
mode NN N
dependent NN N
. . N

The DT N
responses NNS N
to TO N
acute VB i
exercise NN i
were VBD N
more RBR N
pronounced JJ N
than IN N
responses NNS N
to TO N
accumulated JJ i
training NN i
, , N
suggesting VBG N
that IN N
STARS NNP N
signalling VBG N
is VBZ N
primarily RB N
involved VBN N
in IN N
the DT N
initial JJ N
phase NN N
of IN N
exercise-induced JJ N
muscle NN N
adaptations NNS N
. . N

-DOCSTART- -8580292- O O

[ NN p
Evaluating VBG p
an DT p
interactive JJ i
, , i
multi-media JJ i
learning NN i
system NN i
for IN p
the DT p
study NN p
of IN p
primary JJ p
open JJ p
angle NN p
glaucoma NN p
] NNP p
. . N

Using VBG N
the DT N
interactive JJ i
multimedia NN i
learning NN i
system NN i
for IN N
studying VBG N
open-angle JJ p
glaucoma NN p
[ $ N
3 CD N
] CC N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
case-controlled JJ N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
value NN N
of IN N
this DT N
new JJ N
form NN N
of IN N
learning VBG N
in IN N
terms NNS N
of IN N
acceptance NN o
and CC o
the DT o
imparting NN o
of IN o
knowledge NN o
. . o

This DT N
article NN N
describes VBZ N
details NNS N
of IN N
the DT N
study NN N
and CC N
presents NNS N
their PRP$ N
results NNS N
. . N

Results NNS N
were VBD N
established VBN N
on IN N
the DT N
basis NN N
of IN N
targeted JJ N
questions NNS N
asked VBD N
prior JJ N
to TO N
and CC N
after IN N
the DT N
learning NN N
phase NN N
, , N
followed VBN N
by IN N
an DT N
analysis NN N
of IN N
frequencies NNS N
and CC N
significance NN N
testing NN N
by IN N
the DT N
Chi NNP N
squared VBD N
method NN N
. . N

It PRP N
was VBD N
shown VBN N
that IN N
the DT N
imparting NN o
of IN o
knowledge NN o
is VBZ N
significantly RB N
improved VBN N
when WRB N
this DT N
learning NN i
system NN i
is VBZ N
employed VBN N
. . N

In IN N
addition NN N
, , N
after IN N
its PRP$ N
first JJ N
use NN N
, , N
acceptance NN o
of IN o
this DT o
new JJ o
medium NN o
rose VBD N
dramatically RB N
. . N

-DOCSTART- -21672315- O O

A DT N
randomized VBN N
crossover NN N
study NN N
comparing VBG N
patient JJ N
preference NN N
for IN N
tamsulosin NN i
and CC i
silodosin NN i
in IN N
patients NNS p
with IN p
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
associated VBN p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
. . p

Patient JJ p
preference NN p
for IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
treatment NN p
with IN p
the DT p
? . i
( ( i
1 CD i
) ) i
-blockers NNS i
, , i
tamsulosin NN i
or CC i
silodosin NN i
, , i
was VBD N
compared VBN N
using VBG N
patient-reported JJ N
outcomes NNS N
. . N

Japanese JJ p
patients NNS p
with IN p
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
associated VBN p
with IN p
BPH NNP p
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
the DT i
T-S NNP i
group NN i
( ( i
tamsulosin $ i
0.2 CD i
mg NN i
orally RB i
once RB i
daily JJ i
for IN i
4 CD i
weeks NNS i
then RB i
silodosin VBD i
4 CD i
mg NNS i
orally RB i
twice RB i
daily RB i
for IN i
4 CD i
weeks NNS i
) ) i
or CC i
the DT i
S-T JJ i
group NN i
( ( i
silodosin $ i
4 CD i
mg NN i
orally RB i
twice JJ i
daily RB i
for IN i
4 CD i
weeks NNS i
then RB i
tamsulosin VBD i
0.2 CD i
mg NNS i
orally RB i
once RB i
daily JJ i
for IN i
4 CD i
weeks NNS i
) ) i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT o
preferred JJ o
drug NN o
for IN o
treatment NN o
continuation NN o
at IN o
8 CD o
weeks NNS o
, , o
determined VBN o
by IN o
a DT o
patient-reported JJ o
questionnaire NN o
. . o

In IN N
total JJ N
, , N
102 CD p
patients NNS p
( ( p
mean JJ p
age NN p
70.3 CD p
years NNS p
) ) p
were VBD p
enrolled VBN p
and CC p
84 CD p
( ( p
n JJ p
= $ p
42 CD p
per IN p
group NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

A DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
preferred VBD i
tamsulosin NN i
( ( N
59/84 CD N
patients NNS N
; : N
70.2 CD N
% NN N
) ) N
and CC N
those DT N
who WP N
preferred VBD i
silodosin NN i
( ( N
18/84 CD N
patients NNS N
; : N
21.4 CD N
% NN N
) ) N
. . N

A DT N
major JJ N
reason NN N
for IN N
preference NN N
of IN N
either DT N
drug NN N
was VBD N
'good VBN o
efficacy NN o
' '' o
. . o

Incidence NN o
of IN o
adverse JJ o
effects NNS o
was VBD N
significantly RB N
lower JJR N
with IN i
tamsulosin NN i
( ( N
3/91 CD N
patients NNS N
; : N
3.3 CD N
% NN N
) ) N
than IN N
with IN i
silodosin NN i
( ( N
25/88 CD N
patients NNS N
; : N
28.4 CD N
% NN N
) ) N
. . N

These DT N
findings NNS N
indicate VBP N
that IN i
tamsulosin NN i
is VBZ N
very RB N
effective JJ N
for IN N
BPH NNP N
, , N
has VBZ N
few JJ N
adverse JJ N
effects NNS N
and CC N
that IN p
patients NNS p
want VBP N
to TO N
continue VB N
to TO N
use VB N
it PRP N
. . N

-DOCSTART- -16480401- O O

CDP571 NNP i
, , N
a DT N
humanized JJ N
monoclonal JJ N
antibody NN N
to TO N
tumour VB N
necrosis NN N
factor-alpha NN N
, , N
for IN N
steroid-dependent JJ N
Crohn NNP N
's POS N
disease NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

BACKGROUND NNP N
More JJR p
than IN p
50 CD p
% NN p
of IN p
patients NNS p
with IN p
Crohn NNP p
's POS p
disease NN p
become NN N
either CC N
steroid JJ N
resistant NN N
or CC N
dependent NN N
. . N

Accordingly RB N
, , N
development NN N
of IN N
new JJ N
treatments NNS N
for IN N
steroid-dependent JJ N
Crohn NNP N
's POS N
disease NN N
is VBZ N
a DT N
research NN N
priority NN N
. . N

AIM NNP N
To TO N
evaluate VB N
CDP571 NNP i
, , N
a DT N
humanized VBN N
antibody NN N
to TO N
tumour VB N
necrosis NN N
factor-alpha NN N
, , N
for IN N
the DT N
treatment NN N
of IN N
steroid-dependent JJ N
Crohn NNP N
's POS N
disease NN N
. . N

METHODS NNP N
Patients NNPS p
with IN p
steroid-dependent JJ p
Crohn NNP p
's POS p
disease NN p
( ( p
n JJ p
= NNP p
271 CD p
) ) p
were VBD p
enrolled VBN p
in IN N
a DT N
36-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

Steroid JJ p
dependence NN p
was VBD p
defined VBN p
as IN p
use NN p
of IN p
prednisolone NN p
or CC p
prednisone NN i
( ( p
15-40 JJ p
mg/day NN p
) ) p
or CC p
budesonide NN p
( ( p
9 CD p
mg/day NN p
) ) p
for IN p
> NN p
or CC p
=8 JJ p
weeks NNS p
, , p
a DT p
previous JJ p
failed JJ p
attempt NN p
to TO p
decrease VB p
or CC p
discontinue VB p
steroids NNS p
within IN p
8 CD p
weeks NNS p
of IN p
screening NN p
, , p
and CC p
a DT p
Crohn NNP p
's POS p
Disease NNP p
Activity NNP p
Index NNP p
score NN p
of IN p
< NN p
or CC p
=150 JJ p
points NNS p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
intravenous JJ i
CDP571 NNP i
10 CD i
mg/kg NN i
or CC i
placebo NN i
8-weekly RB N
through IN N
to TO N
week NN N
32 CD N
. . N

Steroids NNS N
were VBD N
then RB N
tapered VBN N
using VBG N
a DT N
defined JJ N
schedule NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
percentage NN o
of IN o
patients NNS o
with IN o
steroid JJ o
sparing NN o
, , o
defined VBD o
as IN o
discontinuation NN o
of IN o
steroid JJ o
therapy NN o
without IN o
a DT o
disease NN o
flare NN o
( ( o
Crohn NNP o
's POS o
Disease NNP o
Activity NNP o
Index NNP o
score VBD o
> NNP o
or CC o
=220 NNP o
points NNS o
) ) o
at IN N
week NN N
36 CD N
. . N

RESULTS NNP N
Steroid NNP o
sparing VBG o
occurred VBD N
in IN N
53 CD N
of IN N
181 CD N
( ( N
29.3 CD N
% NN N
) ) N
CDP571 NNP i
patients NNS N
and CC N
33 CD N
of IN N
90 CD N
( ( N
36.7 CD N
% NN N
) ) N
placebo NN i
patients NNS N
( ( N
P NNP N
= NNP N
0.24 CD N
) ) N
. . N

Adverse JJ o
events NNS o
occurred VBD N
at IN N
similar JJ N
frequencies NNS N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
CDP571 NNP i
was VBD N
ineffective JJ N
for IN N
sparing VBG o
steroids NNS o
in IN N
patients NNS p
with IN p
steroid-dependent JJ p
Crohn NNP p
's POS p
disease NN p
. . p

CDP571 NNP i
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -11331049- O O

A DT N
randomized VBN N
controlled VBN N
trial NN N
assessing VBG N
the DT N
health NN o
economics NNS o
of IN o
realtime NN o
teledermatology NN o
compared VBN i
with IN i
conventional JJ i
care NN i
: : i
an DT N
urban JJ p
versus NN p
rural JJ p
perspective NN p
. . p

A DT N
randomized JJ N
controlled JJ N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
measure VB N
the DT N
cost-effectiveness NN o
of IN o
realtime NN o
teledermatology NN o
compared VBN N
with IN N
conventional JJ i
outpatient NN i
dermatology NN i
care NN i
for IN N
patients NNS p
from IN p
urban JJ p
and CC p
rural JJ p
areas NNS p
. . p

One CD N
urban NN N
and CC N
one CD N
rural JJ N
health NN N
centre NNS N
were VBD N
linked VBN N
to TO N
a DT N
regional JJ N
hospital NN N
in IN N
Northern NNP N
Ireland NNP N
by IN N
ISDN NNP N
at IN N
128 CD N
kbit/s NN N
. . N

Over IN p
two CD p
years NNS p
, , p
274 CD p
patients NNS p
required VBD p
a DT p
hospital JJ p
outpatient NN p
dermatology NN p
referral JJ p
-- : p
126 CD p
patients NNS p
( ( p
46 CD p
% NN p
) ) p
were VBD N
randomized VBN N
to TO N
a DT N
telemedicine JJ i
consultation NN i
and CC N
148 CD N
( ( N
54 CD N
% NN N
) ) N
to TO N
a DT N
conventional JJ i
hospital NN i
outpatient JJ i
consultation NN i
. . i

Of IN N
those DT N
seen VBN N
by IN N
telemedicine NN i
, , N
61 CD N
% NN N
were VBD N
registered VBN N
with IN N
an DT N
urban JJ N
practice NN N
, , N
compared VBN N
with IN N
71 CD N
% NN N
of IN N
those DT N
seen VBN N
conventionally RB i
. . i

The DT N
clinical JJ o
outcomes NNS o
of IN N
the DT N
two CD N
types NNS N
of IN N
consultation NN o
were VBD N
similar JJ o
-- : o
almost RB o
half PDT N
the DT N
patients NNS N
were VBD N
managed VBN N
after IN N
a DT N
single JJ N
consultation NN N
with IN N
the DT N
dermatologist NN N
. . N

The DT N
observed JJ o
marginal JJ o
cost NN o
per IN o
patient NN o
of IN N
the DT N
initial JJ N
realtime NN i
teledermatology NN i
consultation NN i
was VBD N
52.85 CD N
Pounds NNS N
for IN N
those DT N
in IN N
urban JJ N
areas NNS N
and CC N
59.93 CD N
Pounds NNS N
per IN N
patient NN N
for IN N
those DT N
from IN N
rural JJ N
areas NNS N
. . N

The DT N
observed JJ o
marginal JJ o
cost NN o
of IN N
the DT N
initial JJ N
conventional JJ i
consultation NN i
was VBD N
47.13 CD N
Pounds NNS N
for IN N
urban JJ p
patients NNS p
and CC N
48.77 CD N
Pounds NNS N
for IN N
rural JJ p
patients NNS p
. . p

The DT N
total JJ o
observed JJ o
costs NNS o
of IN N
teledermatology NN o
were VBD N
higher JJR N
than IN N
the DT N
costs NNS N
of IN N
conventional JJ i
care NN i
in IN N
both DT N
urban JJ N
and CC N
rural JJ N
areas NNS N
, , N
mainly RB N
because IN N
of IN N
the DT N
fixed JJ N
equipment NN N
costs NNS N
. . N

Sensitivity NNP N
analysis NN N
using VBG N
a DT N
real-world NN N
scenario NN N
showed VBD N
that IN N
in IN p
urban JJ p
areas NNS p
the DT N
average JJ o
costs NNS o
of IN N
the DT N
telemedicine NN i
and CC N
conventional JJ i
consultations NNS i
were VBD N
about RB N
equal JJ N
, , N
while IN N
in IN p
rural JJ p
areas NNS p
the DT N
average JJ N
cost NN N
of IN N
the DT N
telemedicine NN i
consultation NN i
was VBD N
less JJR N
than IN N
that DT N
of IN N
the DT N
conventional JJ i
consultation NN i
. . i

-DOCSTART- -15979021- O O

The DT N
effect NN N
of IN N
venlafaxine NN i
on IN N
ongoing VBG N
and CC N
experimentally RB N
induced JJ N
pain NN N
in IN N
neuropathic JJ p
pain NN p
patients NNS p
: : p
a DT N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIM NNP N
The DT N
aim NN N
of IN N
this DT N
randomized VBN N
double JJ N
blind NN N
placebo NN i
controlled VBD N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effectiveness NN N
and CC N
the DT N
safety NN N
of IN N
venlafaxine JJ i
XR NNP i
75 CD i
and CC i
150 CD i
mg NN i
on IN N
ongoing VBG N
pain NN N
and CC N
on IN N
quantitative JJ N
sensory NN N
tests NNS N
in IN N
60 CD p
patients NNS p
with IN p
neuropathic JJ p
pain NN p
for IN p
8 CD p
weeks NNS p
. . p

METHODS NNP N
Evaluation NNP N
parameters NNS N
consisted VBD N
of IN N
ongoing VBG N
pain NN N
intensity NN N
( ( N
VAS NNP N
) ) N
, , N
patient JJ N
satisfaction NN N
, , N
side NN N
effects NNS N
, , N
global JJ N
efficacy NN N
and CC N
tolerance NN N
. . N

Quantitative JJ N
sensory NN N
measurements NNS N
taken VBN N
from IN N
the DT N
affected JJ N
area NN N
before IN N
and CC N
after IN N
the DT N
drug NN N
treatment NN N
included VBD N
pin-prick JJ N
hyperalgesia NN N
, , N
allodynia NN N
, , N
detection NN N
and CC N
pain NN N
thresholds NNS N
to TO N
electrical JJ N
and CC N
heat NN N
stimuli NNS N
, , N
temporal JJ N
summation NN N
of IN N
repetitive JJ N
electrical JJ N
and CC N
heat NN N
stimuli NNS N
. . N

RESULTS VB p
A DT p
total NN p
of IN p
55 CD p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

VAS NNP o
scores NNS o
decreased VBD N
significantly RB N
compared VBN N
to TO N
the DT N
baseline NN N
measurements NNS N
in IN N
all DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS p
regarding VBG p
pain NN o
intensity NN o
and CC o
escape NN o
medication NN o
. . o

The DT N
areas NNS o
of IN o
allodynia NN o
and CC o
pin-prick JJ o
hyperalgesia NN o
decreased VBN N
significantly RB N
in IN N
venlafaxine NN N
groups NNS N
compared VBN N
to TO N
the DT N
placebo NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
regarding VBG N
the DT N
detection NN N
thresholds NNS N
( ( N
electrical JJ N
and CC N
heat NN N
) ) N
. . N

The DT N
pain NN o
threshold NN o
and CC o
the DT o
summation NN o
threshold NN o
to TO o
electrical JJ o
stimuli NNS o
and CC o
the DT o
summation NN o
threshold NN o
to TO o
heat VB o
stimuli NNS o
increased VBN N
significantly RB N
following VBG N
treatment NN N
in IN N
both DT N
venlafaxine JJ i
groups NNS N
. . N

In IN N
addition NN N
, , N
the DT N
degree NN o
of IN o
the DT o
temporal JJ o
summation NN o
to TO o
electrical JJ o
and CC o
heat NN o
stimuli NNS o
decreased VBN N
significantly RB N
following VBG N
treatment NN N
in IN N
both DT N
venlafaxine NN i
groups NNS N
compared VBN N
to TO N
the DT N
placebo NN N
. . N

CONCLUSION VB N
The DT N
study NN N
showed VBD N
significant JJ N
effect NN N
of IN N
venlafaxine NN i
in IN N
the DT N
manifestations NNS N
of IN N
hyperalgesia NN N
and CC N
temporal JJ N
summation NN N
, , N
but CC N
not RB N
on IN N
the DT N
ongoing JJ N
pain NN N
intensity NN N
. . N

Furthermore RB N
, , N
the DT N
quantitative JJ N
sensory NN N
tests NNS N
provided VBD N
complementing VBG N
information NN N
to TO N
the DT N
clinical JJ N
measures NNS N
. . N

-DOCSTART- -9950438- O O

Active NNP i
specific JJ i
immunotherapy NN i
for IN N
stage NN p
II NNP p
and CC p
stage NN p
III NNP p
human JJ p
colon NN p
cancer NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Colon NNP N
cancer NN N
is VBZ N
curable JJ N
by IN N
surgery NN N
, , N
but CC N
cure NN N
rate NN N
depends VBZ N
on IN N
the DT N
extent NN N
of IN N
disease NN N
. . N

We PRP N
investigated VBD N
whether IN N
adjuvant JJ N
active JJ i
specific JJ i
immunotherapy NN i
( ( N
ASI NNP N
) ) N
with IN N
an DT N
autologous JJ N
tumour JJ N
cell-BCG JJ N
vaccine NN N
with IN N
surgical JJ N
resection NN N
was VBD N
more RBR N
beneficial JJ N
than IN N
resection NN N
alone RB N
in IN N
stage NN N
II NNP N
and CC N
III NNP N
colon NN N
cancer NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
, , N
254 CD p
patients NNS p
with IN p
colon NN p
cancer NN p
were VBD p
randomly RB p
assigned VBN p
postoperative JJ i
ASI NNP i
or CC i
no DT i
adjuvant JJ i
treatment NN i
. . i

ASI NNP N
was VBD N
three CD N
weekly JJ N
vaccinations NNS N
starting VBG N
4 CD N
weeks NNS N
after IN N
surgery NN N
, , N
with IN N
a DT N
booster NN N
vaccination NN N
at IN N
6 CD N
months NNS N
with IN N
10 CD N
( ( N
7 CD N
) ) N
irradiated VBN N
autologous JJ i
tumour NN i
cells NNS i
. . i

The DT N
first JJ N
vaccinations NNS N
contained VBN N
10 CD N
( ( N
7 CD N
) ) N
BCG NNP N
organisms UH N
. . N

We PRP N
followed VBD N
up RP N
patients NNS N
for IN N
time NN N
to TO N
recurrence VB N
, , N
and CC N
recurrence-free JJ N
and CC N
overall JJ N
survival NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
The DT N
5.3 CD N
year NN N
median JJ N
follow-up NN N
( ( N
range VB N
8 CD N
months NNS N
to TO N
8 CD N
years NNS N
11 CD N
months NNS N
) ) N
showed VBD N
44 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
7-66 CD N
) ) N
risk NN N
reduction NN N
for IN N
recurrence NN N
in IN N
the DT N
recurrence-free JJ N
period NN N
in IN N
all DT N
patients NNS N
receiving VBG N
ASI NNP i
( ( N
p=0.023 NN N
) ) N
. . N

Overall JJ N
, , N
there EX N
were VBD N
40 CD N
recurrences NNS N
in IN N
the DT N
control NN N
group NN N
and CC N
25 CD N
in IN N
the DT N
ASI NNP N
group NN N
. . N

Analysis NN N
by IN N
stage NN N
showed VBD N
no DT N
significant JJ N
benefit NN N
of IN N
ASI NNP o
in IN N
stage NN N
III NNP N
disease NN N
. . N

The DT N
major JJ N
impact NN N
of IN N
ASI NNP N
was VBD N
seen VBN N
in IN N
patients NNS p
with IN p
stage NN p
II NNP p
disease NN p
, , N
with IN N
a DT N
significantly RB N
longer RBR N
recurrence-free JJ o
period NN o
( ( N
p=0.011 NN N
) ) N
and CC N
61 CD N
% NN N
( ( N
18-81 JJ N
) ) N
risk NN o
reduction NN o
for IN o
recurrences NNS o
. . o

Recurrence-free JJ o
survival NN o
was VBD N
significantly RB N
longer RBR N
with IN N
ASI NNP N
( ( N
42 CD N
% NN N
risk NN N
reduction NN N
for IN N
recurrence NN N
or CC N
death NN N
[ JJ N
0-68 JJ N
] NN N
, , N
p=0.032 NN N
) ) N
and CC N
there EX N
was VBD N
a DT N
trend NN N
towards VBZ N
improved VBN N
overall JJ o
survival NN o
. . o

INTERPRETATION NNP N
ASI NNP N
gave VBD N
significant JJ N
clinical JJ N
benefit NN N
in IN N
surgically RB N
resected VBN N
patients NNS N
with IN N
stage NN p
II NNP p
colon NN p
cancer NN p
. . p

ASI NNP N
has VBZ N
minimal JJ N
adverse JJ N
reactions NNS N
and CC N
should MD N
be VB N
considered VBN N
in IN N
the DT N
management NN N
of IN N
stage NN N
II NNP N
colon NN N
cancer NN N
. . N

-DOCSTART- -1860302- O O

Effect NN N
of IN N
ranitidine NN i
on IN N
the DT N
disposition NN o
of IN N
orally RB N
and CC N
intravenously RB N
administered VBN N
triazolam NN N
. . N

The DT N
effect NN N
of IN N
orally RB N
administered VBN N
ranitidine NN i
on IN N
the DT N
pharmacokinetic JJ o
properties NNS o
of IN N
orally RB N
and CC N
intravenously RB N
administered VBD N
triazolam NN i
was VBD N
determined VBN N
. . N

Twelve NNP p
healthy JJ p
males NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
35 CD p
years NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
four-way NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
. . N

Each DT N
subject NN N
received VBD N
a DT N
total NN N
of IN N
four CD N
treatments NNS N
, , N
each DT N
separated VBN N
by IN N
one CD N
week NN N
. . N

The DT N
treatments NNS N
consisted VBN N
of IN N
( ( N
1 CD N
) ) N
one CD N
orally RB N
administered VBN N
0.25-mg JJ i
triazolam NN i
tablet NN i
after IN i
treatment NN i
with IN i
ranitidine NN i
; : i
( ( N
2 CD N
) ) N
one CD N
orally RB N
administered VBN N
0.25-mg JJ i
triazolam NN i
tablet NN i
, , i
with IN i
no DT i
ranitidine JJ i
pretreatment NN i
; : i
( ( N
3 CD N
) ) N
a DT N
0.25-mg JJ i
intravenous JJ i
dose NN i
of IN i
triazolam NN i
after IN i
treatment NN i
with IN i
ranitidine NN i
; : i
and CC N
( ( N
4 CD N
) ) N
a DT N
0.25-mg JJ i
intravenous JJ i
dose NN i
of IN i
triazolam NN i
, , i
with IN i
no DT i
ranitidine NN i
pretreatment NN i
. . i

Ranitidine NNP i
pretreatment NN N
consisted VBD N
of IN N
five CD N
150-mg JJ N
oral JJ N
doses NNS N
( ( N
as IN N
the DT N
hydrochloride NN N
salt NN N
) ) N
given VBN N
every DT N
12 CD N
hours NNS N
; : N
the DT N
last JJ N
dose NN N
was VBD N
given VBN N
two CD N
hours NNS N
before IN N
triazolam NN i
was VBD N
administered VBN N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
at IN N
intervals NNS N
up RB N
to TO N
12 CD N
hours NNS N
after IN N
triazolam JJ N
treatment NN N
. . N

Serum NNP o
triazolam JJ o
concentrations NNS o
were VBD N
measured VBN N
by IN N
modified JJ N
high-performance NN N
liquid NN N
chromatography NN N
, , N
and CC N
pharmacokinetic JJ o
values NNS o
were VBD N
calculated VBN N
. . N

Pretreatment NN N
with IN N
ranitidine NN i
had VBD N
no DT N
effect NN N
on IN N
the DT N
disposition NN o
of IN o
intravenously RB o
administered VBN o
triazolam NN o
but CC N
significantly RB N
increased VBD N
the DT N
area NN o
under IN o
the DT o
serum JJ o
drug NN o
concentration-time JJ o
curve NN o
of IN o
oral JJ o
triazolam NN o
. . o

Ranitidine NNP i
pretreatment NN N
had VBD N
no DT N
effect NN N
on IN N
triazolam NN o
's POS o
terminal JJ o
elimination NN o
rate NN o
constant JJ o
or CC N
on IN N
the DT N
time NN o
to TO o
reach VB o
maximum JJ o
serum JJ o
triazolam NN o
concentration NN o
. . o

Ranitidine JJ i
pretreatment NN N
increased VBD N
the DT N
systemic JJ o
availability NN o
of IN o
triazolam NN o
by IN N
increasing VBG N
its PRP$ N
absorption NN o
. . o

-DOCSTART- -17979862- O O

Exploring VBG N
effects NNS N
of IN N
different JJ N
treadmill NN i
interventions NNS i
on IN N
walking VBG o
onset NN o
and CC N
gait NN o
patterns NNS o
in IN N
infants NNS p
with IN p
Down NNP p
syndrome NN p
. . p

Two CD N
cohorts NNS N
of IN N
participants NNS N
were VBD N
included VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
different JJ N
treadmill NN i
interventions NNS i
on IN N
walking VBG o
onset NN o
and CC N
gait NN o
patterns NNS o
in IN N
infants NNS p
with IN p
Down NNP p
syndrome NN p
( ( p
DS NNP p
) ) p
. . p

The DT p
first JJ p
cohort NN p
included VBD p
30 CD p
infants NNS p
with IN p
DS NNP p
( ( p
17 CD p
males NNS p
, , p
13 CD p
females NNS p
; : p
mean JJ p
age NN p
10 CD p
mo NN p
[ NNP p
SD NNP p
1.9 CD p
mo NN p
] NN p
) ) p
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
lower-intensity-generalized JJ i
( ( i
LG NNP i
) ) i
training VBG i
group NN i
, , i
or CC i
a DT i
higher-intensity-individualized JJ i
( ( i
HI NNP i
) ) i
training VBG i
group NN i
. . i

A DT p
control NN i
( ( i
C NNP i
) ) i
group NN p
from IN p
another DT p
study NN p
, , p
who WP p
did VBD p
not RB i
receive VB i
treadmill NN i
training NN i
, , p
served VBD p
as IN p
the DT p
control NN p
( ( p
eight CD p
males NNS p
, , p
seven CD p
females NNS p
; : p
mean JJ p
age NN p
10.4 CD p
mo NN p
[ NNP p
SD NNP p
2.2 CD p
mo NN p
] NN p
) ) p
. . p

Mean JJ o
age NN o
at IN o
walking VBG o
onset NN o
was VBD N
19.2 CD N
, , N
21.4 CD N
, , N
and CC N
23.9 CD N
months NNS N
for IN N
the DT N
HI NNP N
, , N
LG NNP N
, , N
and CC N
C NNP N
groups NNS N
respectively RB N
. . N

At IN N
walking VBG o
onset RP o
the DT N
HI NNP N
group NN N
was VBD N
significantly RB N
younger JJR N
than IN N
the DT N
C NNP N
group NN N
( ( N
p=0.011 NN N
) ) N
. . N

At IN N
the DT N
gait NN N
follow-up NN N
that WDT N
was VBD N
conducted VBN N
between IN N
1 CD N
and CC N
3 CD N
months NNS N
after IN N
walking VBG N
onset NN N
, , N
three CD N
groups NNS N
significantly RB N
different JJ N
in IN N
overall JJ N
gait NN N
patterns NNS N
( ( N
p=0.037 NN N
) ) N
were VBD N
examined VBN N
by IN N
six CD N
basic JJ N
gait NN N
parameters NNS N
including VBG N
average JJ o
velocity NN o
, , o
stride JJ o
length NN o
, , o
step NN o
width NN o
, , o
stride JJ o
time NN o
, , o
stance NN o
time NN o
, , o
and CC o
dynamic JJ o
base NN o
. . o

Post-hoc JJ N
analyses NNS N
demonstrated VBD N
that IN N
stride JJ o
length NN o
was VBD N
the DT N
gait NN N
parameter NN N
largely RB N
contributing VBG N
to TO N
this DT N
overall JJ N
group NN N
difference NN N
( ( N
p=0.033 NN N
) ) N
, , N
and CC N
the DT N
HI NNP N
group NN N
produced VBD N
a DT N
significantly RB N
longer RBR N
stride JJ o
length NN o
than IN N
the DT N
C NNP N
group NN N
( ( N
p=0.030 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
HI NNP N
treadmill NN N
intervention NN N
significantly RB N
promoted VBN N
earlier RBR N
walking JJ o
onset NN o
and CC N
elicited VBD N
more RBR N
advanced JJ N
gait NN o
patterns NNS o
( ( N
particularly RB N
in IN N
stride JJ N
length NN N
) ) N
in IN N
infants NNS p
with IN p
DS NNP p
. . p

-DOCSTART- -15536093- O O

Syncope NNP p
Evaluation NNP N
in IN N
the DT N
Emergency NNP N
Department NNP N
Study NNP N
( ( N
SEEDS NNP N
) ) N
: : N
a DT N
multidisciplinary JJ N
approach NN N
to TO N
syncope VB p
management NN N
. . N

BACKGROUND VB N
The DT N
primary JJ N
aim NN N
and CC N
central JJ N
hypothesis NN N
of IN N
the DT N
study NN N
are VBP N
that IN N
a DT N
designated VBN N
syncope NN N
unit NN N
in IN N
the DT N
emergency NN N
department NN N
improves VBZ N
diagnostic JJ N
yield NN N
and CC N
reduces NNS N
hospital JJ N
admission NN N
for IN N
patients NNS p
with IN p
syncope NN p
who WP p
are VBP p
at IN p
intermediate JJ p
risk NN p
for IN p
an DT p
adverse JJ p
cardiovascular JJ p
outcome NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
single-center JJ p
study NN p
, , p
patients NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
2 CD N
treatment NN N
arms NNS N
: : N
syncope NN i
unit NN i
evaluation NN i
and CC i
standard NN i
care NN i
. . i

The DT N
2 CD N
groups NNS N
were VBD N
compared VBN N
with IN N
chi2 JJ N
test NN N
for IN N
independence NN N
of IN N
categorical JJ N
variables NNS N
. . N

Wilcoxon NNP N
rank VBD N
sum JJ N
test NN N
was VBD N
used VBN N
for IN N
continuous JJ N
variables NNS N
. . N

Survival NNP o
was VBD N
estimated VBN N
with IN N
the DT N
Kaplan-Meier NNP N
method NN N
. . N

One CD p
hundred VBD p
three CD p
consecutive JJ p
patients NNS p
( ( p
53 CD p
women NNS p
; : p
mean JJ p
age NN p
64+/-17 CD p
years NNS p
) ) p
entered VBD p
the DT p
study NN p
. . p

Fifty-one CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
syncope NN N
unit NN N
. . N

For IN N
the DT N
syncope NN N
unit NN N
and CC N
standard JJ N
care NN N
patients NNS N
, , N
the DT N
presumptive JJ o
diagnosis NN o
was VBD N
established VBN N
in IN N
34 CD N
( ( N
67 CD N
% NN N
) ) N
and CC N
5 CD N
( ( N
10 CD N
% NN N
) ) N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
respectively RB N
, , N
hospital JJ o
admission NN o
was VBD N
required VBN N
for IN N
22 CD N
( ( N
43 CD N
% NN N
) ) N
and CC N
51 CD N
( ( N
98 CD N
% NN N
) ) N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
total JJ o
patient-hospital JJ o
days NNS o
were VBD N
reduced VBN N
from IN N
140 CD N
to TO N
64 CD N
. . N

Actuarial JJ o
survival NN o
was VBD N
97 CD N
% NN N
and CC N
90 CD N
% NN N
( ( N
P=0.30 NNP N
) ) N
, , N
and CC N
survival JJ o
free JJ o
from IN o
recurrent JJ o
syncope NN o
was VBD N
88 CD N
% NN N
and CC N
89 CD N
% NN N
( ( N
P=0.72 NNP N
) ) N
at IN N
2 CD N
years NNS N
for IN N
the DT N
syncope NN N
unit NN N
and CC N
standard JJ N
care NN N
groups NNS N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
The DT N
novel JJ N
syncope NN N
unit NN N
designed VBN N
for IN N
this DT N
study NN N
significantly RB N
improved VBN N
diagnostic JJ o
yield NN o
in IN N
the DT N
emergency NN N
department NN N
and CC N
reduced JJ N
hospital NN o
admission NN o
and CC N
total JJ o
length NN o
of IN o
hospital NN o
stay NN o
without IN N
affecting VBG N
recurrent NN N
syncope NN N
and CC N
all-cause JJ N
mortality NN o
among IN N
intermediate-risk JJ p
patients NNS p
. . p

Observations NNS N
from IN N
the DT N
present JJ N
study NN N
provide VBP N
benchmark NN N
data NNS N
for IN N
improving VBG N
patient NN N
care NN N
and CC N
effectively RB N
utilizing JJ N
healthcare JJ N
resources NNS N
. . N

-DOCSTART- -18322606- O O

[ JJ N
Effects NNS N
of IN N
Kang NNP i
Gang NNP i
Qian NNP i
Granule NNP i
( ( i
KGQG NNP i
) ) i
on IN N
clinical JJ o
and CC o
pathological JJ o
features NNS o
in IN N
chronic JJ p
hepatitis NN p
B NNP p
patients NNS p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
efficacy NN N
of IN N
KGQG NNP i
and CC N
its PRP$ N
therapeutic JJ N
mechanisms NNS N
in IN N
chronic JJ p
hepatitis NN p
B NNP p
patients NNS p
with IN p
liver JJ p
fibrosis NN p
. . p

METHODS NNP N
57 CD p
chronic NN p
hepatitis NN p
B NNP p
patients NNS p
with IN p
liver JJ p
fibrosis NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
45 CD N
cases NNS N
in IN N
KGQG NNP i
group NN N
were VBD N
treated VBN N
by IN N
KGQG NNP i
and CC i
routine JJ i
medications NNS i
; : i
12 CD N
cases NNS N
in IN N
control NN N
group NN N
were VBD N
treated VBN N
by IN N
routine JJ N
medications NNS N
only RB N
. . N

Serum NNP o
liver NN o
function NN o
test NN o
results NNS o
, , o
PCIII NNP o
, , o
CIV NNP o
, , o
HA NNP o
and CC o
liver RB o
biopsy JJ o
results NNS o
of IN N
these DT N
57 CD N
patients NNS N
were VBD N
simultaneously RB N
collected VBN N
and CC N
analyzed VBN N
before IN N
and CC N
after IN N
this DT N
intervention NN N
. . N

RESULTS NNP N
KGQG NNP i
group NN N
showed VBD N
better JJR N
efficacy NN o
over IN N
control NN N
group NN N
in IN N
liver NN o
function NN o
recovery NN o
, , N
decrease NN N
of IN N
serum NN o
PCIII NNP o
, , o
CIV NNP o
, , o
HA NNP o
levels NNS o
and CC o
liver NN o
pathologic NN o
grades NNS o
( ( N
P NNP N
0.05 CD N
or CC N
0.01 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
KGQG NNP i
could MD N
effectively RB N
ameliorate VB N
liver NN N
function NN N
and CC N
facilitate VB N
the DT N
inhibition NN N
and CC N
degradation NN N
of IN N
liver JJ p
fibrosis NN p
in IN p
chronic JJ p
hepatitis NN p
B NNP p
patients NNS p
, , N
which WDT N
may MD N
be VB N
developed VBN N
as IN N
a DT N
novel JJ N
therapeusis NN N
to TO N
treat VB N
this DT N
hard-to-cure JJ N
disease NN N
. . N

-DOCSTART- -6342928- O O

Caries NNS o
preventive JJ o
effects NNS o
of IN N
toothpastes NNS N
containing VBG N
monofluorophosphate NN i
and CC N
trimetaphosphate NN i
: : i
a DT N
3-year JJ N
clinical JJ N
trial NN N
. . N

The DT N
caries-preventive JJ o
effects NNS o
of IN N
two CD N
toothpastes NNS N
were VBD N
tested VBN N
in IN N
a DT N
3-year JJ N
clinical JJ N
trial NN N
involving VBG N
1319 CD p
children NNS p
aged VBN p
11-13 CD p
years NNS p
. . p

The DT N
test NN N
toothpastes NNS N
were VBD N
: : N
1 CD N
) ) N
a DT i
low JJ i
abrasion NN i
paste NN i
containing VBG i
0.8 CD i
% NN i
sodium NN i
monofluorophosphate NN i
( ( i
MFP NNP i
) ) i
, , N
and CC N
2 CD N
) ) N
a DT i
paste NN i
containing VBG i
3 CD i
% NN i
sodium NN i
trimetaphosphate NN i
( ( i
TMP NNP i
) ) i
. . i

The DT N
control NN N
toothpaste NN N
was VBD N
a DT N
conventional JJ i
, , i
moderately RB i
abrasive JJ i
paste NN i
containing VBG i
0.8 CD i
% NN i
sodium NN i
monofluorophosphate NN i
. . i

The DT N
children NNS p
were VBD N
examined VBN N
clinically RB N
and CC N
radiologically RB N
each DT N
year NN N
. . N

Toothpaste NN N
was VBD N
supplied VBN N
to TO N
the DT N
children NNS N
's POS N
homes NNS N
, , N
and CC N
its PRP$ N
use NN N
was VBD N
unsupervised JJ N
. . N

Caries NNS o
increments NNS o
after IN N
3 CD N
years NNS N
, , N
in IN N
terms NNS N
of IN N
DMF NNP N
teeth NNS N
and CC N
DMF NNP N
surfaces NNS N
, , N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT p
MFP NNP i
test NN i
group NN p
( ( p
444 CD p
children NNS p
) ) p
and CC p
the DT p
MFP NNP i
control NN i
group NN p
( ( p
450 CD p
children NNS p
) ) p
. . N

However RB N
, , N
the DT N
TMP NNP i
test NN p
group NN p
( ( p
425 CD p
children NNS p
) ) p
had VBD N
significantly RB N
higher JJR N
caries NNS o
increments NNS o
than IN N
the DT N
MFP NNP i
control NN i
group NN N
. . N

All DT N
three CD p
groups NNS p
of IN p
children NNS p
showed VBD N
some DT N
improvement NN N
in IN N
oral JJ o
hygiene NN o
and CC o
in IN o
gingival JJ o
health NN o
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

-DOCSTART- -11343038- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
single-dose JJ N
intravenous JJ N
secretin NN i
as IN N
treatment NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
a DT N
single JJ N
injection NN N
of IN N
intravenous JJ N
secretin NN i
results NNS N
in IN N
measurable JJ N
improvements NNS N
in IN N
socialization NN N
and/or NN N
communication NN N
skills NNS N
in IN N
children NNS p
with IN p
autism NN p
. . p

STUDY NNP N
DESIGN NNP N
Sixty NNP p
subjects VBZ p
with IN p
autism NN p
were VBD N
randomly RB N
selected VBN N
and CC N
assigned VBN N
to TO N
either DT N
treatment NN N
or CC N
placebo NN i
group NN N
. . N

Subjects VBZ N
in IN N
the DT N
treatment NN N
group NN N
received VBD N
2.0 CD i
clinical JJ i
units NNS i
of IN i
secretin NN i
per IN i
kilogram NN i
of IN i
body NN i
weight NN i
as IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
. . N

Subjects NNS N
in IN N
the DT N
placebo NN i
group NN N
received VBD N
normal JJ i
saline JJ i
solution NN i
. . i

Neurodevelopmental NNP N
and CC N
behavioral JJ N
assessments NNS N
were VBD N
performed VBN N
for IN N
all DT N
subjects NNS N
before IN N
injection NN N
and CC N
at IN N
3 CD N
and CC N
6 CD N
weeks NNS N
after IN N
injection NN N
. . N

RESULTS NNP N
Assessment NNP o
of IN o
language NN o
skills NNS o
and CC o
parents NNS o
' POS o
behavioral JJ o
assessments NNS o
revealed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
and CC N
placebo NN N
groups NNS N
. . N

Raters NNS o
' POS o
assessments NNS o
of IN o
severity NN o
of IN o
autistic JJ o
symptoms NNS o
did VBD N
not RB N
differ VB N
for IN N
the DT N
2 CD N
groups NNS N
at IN N
6 CD N
weeks NNS N
after IN N
injection NN N
. . N

A DT N
marginally RB N
statistically RB N
significant JJ N
improvement NN N
in IN N
autistic JJ N
behaviors NNS N
was VBD N
seen VBN N
in IN N
the DT N
treatment NN N
group NN N
at IN N
3 CD N
weeks NNS N
after IN N
injection NN N
( ( N
P NNP N
=.051 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
single JJ N
dose NN N
of IN N
intravenous JJ N
secretin NN i
does VBZ N
not RB N
appear VB N
to TO N
have VB N
significant JJ N
effects NNS N
on IN N
either DT N
parents NNS N
' POS N
perception NN N
of IN N
autistic JJ N
behaviors NNS N
or CC N
language NN N
skills NNS N
at IN N
6 CD N
weeks NNS N
after IN N
injection NN N
. . N

Transient NNP N
, , N
marginally RB N
significant JJ N
improvements NNS N
in IN N
autistic JJ N
behaviors NNS N
may MD N
occur VB N
in IN N
some DT N
children NNS N
. . N

-DOCSTART- -21295919- O O

Using VBG N
personalized VBN i
feedback NN i
to TO N
reduce VB N
alcohol NN N
use NN N
among IN N
hazardous JJ p
drinking VBG p
college NN p
students NNS p
: : p
the DT N
moderating VBG N
effect NN N
of IN N
alcohol-related JJ N
negative JJ N
consequences NNS N
. . N

UNLABELLED JJ N
Web-based JJ i
screening NN i
and CC i
brief JJ i
interventions NNS i
that WDT N
include VBP N
personalized VBN N
feedback NN N
about IN N
their PRP$ N
alcohol NN N
use NN N
have VBP N
proven VBN N
to TO N
be VB N
particularly RB N
promising VBG N
for IN N
reducing VBG N
hazardous JJ p
drinking NN p
among IN p
university JJ p
students NNS p
. . p

Despite IN N
the DT N
increasing VBG N
use NN N
of IN N
these DT N
approaches NNS N
, , N
there EX N
is VBZ N
still RB N
relatively RB N
little JJ N
known VBN N
about IN N
how WRB N
the DT N
content NN N
of IN N
these DT N
interventions NNS N
may MD N
influence VB N
outcomes NNS N
and CC N
who WP N
may MD N
benefit VB N
most JJS N
from IN N
these DT N
approaches NNS N
. . N

The DT N
current JJ N
study NN N
sought VBD N
to TO N
address VB N
these DT N
issues NNS N
by IN N
examining VBG N
how WRB N
individual JJ N
differences NNS N
in IN N
alcohol NN N
consequences NNS N
influence NN N
outcomes NNS N
of IN N
a DT N
laboratory-based JJ i
computerized JJ i
intervention NN i
. . i

METHODS NNP N
One-hundred JJ p
and CC p
nineteen JJ p
introductory NN p
psychology NN p
students NNS p
who WP p
either DT p
had VBD p
two CD p
episodes NNS p
of IN p
heavy JJ p
episodic JJ p
drinking NN p
in IN p
the DT p
past JJ p
month NN p
or CC p
scored VBN p
?8 NNS p
on IN p
the DT p
AUDIT NNP p
participated VBD p
in IN p
this DT p
randomized VBN p
controlled VBD p
trial NN p
for IN p
course NN p
credit NN p
. . p

Participants NNS N
were VBD N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
conditions NNS N
in IN N
this DT N
2 CD N
Intervention NNP i
( ( i
Alcohol NNP i
Feedback NNP i
vs. IN i
Control NNP i
) ) i
?2 FW i
Assessment NNP i
( ( i
Motivational NNP i
Assessment NNP i
vs. IN i
No NNP i
Motivational NNP i
Assessment NNP i
) ) i
between-subjects NNS i
design NN o
. . o

Quantity NN o
of IN o
alcohol NN o
consumed VBN o
per IN o
week NN o
and CC o
heavy JJ o
episodic JJ o
drinking VBG o
one CD o
month NN o
later RBR o
were VBD o
the DT N
primary JJ N
dependent JJ N
variables NNS N
. . N

RESULTS NNP N
Controlling VBG N
for IN N
corresponding VBG N
baseline NN o
alcohol NN o
measures NNS o
, , o
hierarchical JJ o
linear JJ N
regression NN N
analyses NNS N
showed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
intervention NN N
condition NN N
and CC N
baseline VB N
alcohol-related JJ N
consequences NNS N
. . N

For IN N
those DT N
who WP N
reported VBD N
more JJR N
alcohol NN N
consequences NNS N
at IN N
baseline NN N
, , N
the DT N
alcohol NN N
intervention NN N
resulted VBD N
in IN N
significantly RB N
less JJR o
alcohol NN o
use NN o
and CC o
fewer JJR o
heavy JJ o
drinking NN o
episodes NNS o
at IN o
follow-up JJ N
, , N
while IN N
no DT N
difference NN N
was VBD N
observed VBN N
between IN N
intervention NN N
conditions NNS N
for IN N
those DT N
with IN N
few JJ N
baseline NN N
consequences NNS N
. . N

Assessment NN N
did VBD N
not RB N
moderate VB N
intervention NN N
effects NNS N
. . N

DISCUSSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN i
a DT i
feedback-based JJ i
computerized JJ i
intervention NN i
that WDT i
includes VBZ N
normative JJ N
information NN N
about IN o
alcohol NN o
use NN o
and CC o
consequences NNS N
may MD N
be VB N
more RBR N
effective JJ N
for IN N
hazardous JJ p
drinking NN p
students NNS p
who WP p
are VBP p
experiencing VBG p
higher JJR p
levels NNS p
of IN p
alcohol-related JJ p
consequences NNS p
. . p

-DOCSTART- -12358251- O O

Tegaserod NNP i
, , i
a DT i
5-hydroxytryptamine JJ i
type NN i
4 CD i
receptor NN i
partial JJ i
agonist NN i
, , N
is VBZ N
devoid JJ N
of IN N
electrocardiographic JJ o
effects NNS o
. . o

OBJECTIVES NNP N
Certain NNP N
GI NNP i
prokinetic JJ i
agents NNS i
have VBP N
been VBN N
shown VBN N
to TO N
affect VB N
cardiac JJ N
repolarization NN N
, , N
which WDT N
may MD N
be VB N
associated VBN N
with IN N
life-threatening JJ N
arrhythmias NNS N
. . N

The DT N
selective JJ i
5-hydroxytryptamine JJ i
type NN i
4 CD i
receptor NN i
partial JJ i
agonist NN i
tegaserod NN i
is VBZ N
a DT N
novel JJ N
promotile NN N
agent NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
functional JJ N
motility NN N
disorders NNS N
such JJ N
as IN N
irritable JJ N
bowel NN N
syndrome NN N
( ( N
IBS NNP N
) ) N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
cardiac JJ o
safety NN o
profile NN o
of IN N
tegaserod NN i
through IN N
analysis NN N
of IN N
electrocardiographic JJ N
data NNS N
from IN N
clinical JJ N
studies NNS N
conducted VBN N
in IN N
patients NNS p
with IN p
IBS NNP p
and CC p
a DT p
study NN p
conducted VBN p
in IN p
healthy JJ p
male JJ p
subjects NNS p
. . p

METHODS NNP N
In IN N
three CD N
randomized NNS N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
clinical JJ N
studies NNS N
, , N
2516 CD p
IBS NNP p
patients NNS p
with IN p
symptoms NNS p
of IN p
abdominal JJ p
pain NN p
and CC p
constipation NN p
received VBD N
tegaserod JJ i
2 CD N
or CC N
6 CD N
mg JJ N
b.i.d NN N
. . N

( ( N
n JJ N
= NN N
1679 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
837 CD N
) ) N
for IN N
12 CD N
wk NN N
. . N

In IN p
an DT p
additional JJ p
study NN p
, , p
36 CD p
healthy JJ p
male NN p
subjects NNS p
received VBD p
iv NN p
. . p

single JJ p
doses NNS p
of IN p
tegaserod NN i
( ( p
0.8 CD p
mg NN p
to TO p
20 CD p
mg NN p
) ) p
or CC i
placebo NN i
. . i

Standard NNP N
12-lead JJ N
electrocardiograms NNS N
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
during IN N
treatment NN N
. . N

Baseline NNP N
values NNS N
were VBD N
compared VBN N
with IN N
data NNS N
collected VBN N
during IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS VB N
The DT N
proportion NN N
of IN N
patients NNS N
with IN N
prolongation NN o
of IN o
the DT o
QTc NNP o
interval NN o
was VBD N
the DT N
same JJ N
for IN N
placebo NN N
and CC N
tegaserod NN N
, , N
as IN N
was VBD N
the DT N
frequency NN o
of IN o
overall JJ o
electrocardiographic JJ o
abnormalities NNS o
. . o

No DT N
ventricular NN o
or CC o
supraventricular JJ o
tachycardia NN o
was VBD N
observed VBN N
. . N

Comparable JJ N
electrocardiographic JJ o
results NNS o
were VBD N
obtained VBN N
during IN N
placebo NN N
and CC N
tegaserod NN N
treatment NN N
. . N

In IN N
healthy JJ p
volunteers NNS p
, , N
tegaserod NN N
at IN N
i.v NN N
. . N

doses NNS N
resulting VBG N
in IN N
plasma NN o
concentrations NNS o
up IN N
to TO N
100 CD N
times NNS N
those DT N
measured VBN N
after IN N
therapeutic JJ N
doses NNS N
( ( N
6 CD N
mg NN N
b.i.d NN N
. . N

) ) N
did VBD N
not RB N
influence VB N
electrocardiographic JJ N
parameters NNS N
. . N

CONCLUSIONS NNP N
Tegaserod NNP N
is VBZ N
devoid JJ N
of IN N
electrocardiographic JJ o
effects NNS o
and CC N
is VBZ N
not RB N
expected VBN N
to TO N
adversely RB N
influence VB N
cardiac JJ o
function NN o
. . o

These DT N
data NNS N
confirm VBP N
preclinical JJ N
findings NNS N
. . N

-DOCSTART- -10871578- O O

Plasma NNP N
antioxidant NN N
status NN N
after IN N
high-dose JJ i
chemotherapy NN i
: : i
a DT N
randomized JJ N
trial NN N
of IN N
parenteral JJ N
nutrition NN N
in IN N
bone NN p
marrow NN p
transplantation NN p
patients NNS p
. . p

BACKGROUND NNP N
Chemotherapy NNP i
and CC i
radiation NN i
therapy NN i
result NN N
in IN N
increased JJ N
free JJ N
radical JJ N
formation NN N
and CC N
depletion NN N
of IN N
tissue NN N
antioxidants NNS N
. . N

It PRP N
is VBZ N
not RB N
known VBN N
whether IN N
parenteral JJ i
nutrition NN i
( ( i
PN NNP i
) ) i
administered VBD N
during IN N
bone NN i
marrow NN i
transplantation NN i
( ( i
BMT NNP i
) ) i
supports VBZ N
systemic JJ N
antioxidant NN N
status NN N
. . N

OBJECTIVE CC N
The DT N
aims NNS N
of IN N
the DT N
study NN N
were VBD N
to TO N
determine VB N
1 CD N
) ) N
whether IN N
high-dose JJ i
chemotherapy NN i
decreases VBZ N
concentrations NNS N
of IN N
major JJ N
circulating VBG N
antioxidants NNS N
in IN N
patients NNS p
undergoing VBG p
BMT NNP i
and CC N
2 CD N
) ) N
whether IN N
administration NN N
of IN N
standard JJ N
PN NNP i
maintains VBZ N
systemic JJ N
antioxidant JJ N
concentrations NNS N
compared VBN N
with IN N
PN NNP i
containing VBG N
micronutrients NNS N
and CC N
minimal JJ N
lipids NNS N
alone RB N
. . N

DESIGN NNP N
Twenty-four JJ p
BMT NNP i
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
standard JJ i
PN NNP i
containing VBG i
conventional JJ i
amounts NNS i
of IN i
dextrose NN i
, , i
amino JJ i
acids NNS i
, , i
micronutrients NNS i
, , i
and CC i
lipid JJ i
( ( N
120 CD N
kJ/d NN N
) ) N
or CC N
a DT N
solution NN i
containing VBG i
only JJ i
micronutrients NNS i
( ( N
identical JJ N
to TO N
those DT N
in IN N
standard JJ N
PN NNP N
) ) N
and CC N
a DT N
small JJ N
amount NN N
of IN N
lipid JJ N
( ( N
12 CD N
kJ/d NN N
) ) N
. . N

Plasma NNP o
antioxidant JJ o
status NN o
was VBD N
measured VBN N
before IN N
conditioning VBG N
therapy NN N
and CC N
serially RB N
at IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
10 CD N
, , N
and CC N
14 CD N
after IN N
BMT NNP N
. . N

RESULTS NNP N
Plasma NNP o
glutathione NN o
( ( o
GSH NNP o
) ) o
and CC o
alpha- JJ o
and CC o
gamma-tocopherol JJ o
concentrations NNS o
decreased VBN N
and CC N
the DT N
GSH NNP o
redox NN o
state NN o
became VBD N
more RBR N
oxidized JJ N
after IN N
conditioning VBG N
chemotherapy NN N
. . N

Plasma NNP o
cysteine JJ o
concentrations NNS o
were VBD N
unchanged JJ N
, , N
whereas JJ N
cystine NN N
concentrations NNS N
increased VBD N
. . N

Plasma NNP o
vitamin JJ o
C NNP o
and CC o
zinc NNP o
concentrations NNS o
and CC o
GSH NNP o
peroxidase NN o
activity NN o
increased VBD N
over IN N
time NN N
. . N

Plasma VB o
alpha-tocopherol JJ o
concentrations NNS o
were VBD N
lower JJR N
in IN N
patients NNS N
given VBN N
standard JJ N
PN NNP N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
other JJ N
plasma JJ o
antioxidants NNS o
between IN N
groups NNS N
. . N

CONCLUSIONS VB N
A DT N
significant JJ N
decline NN N
in IN N
GSH-glutathione NNP o
disulfide NN o
, , o
cysteine-cystine NN o
, , o
and CC o
vitamin FW o
E NNP o
status NN o
occurs VBZ N
after IN N
chemotherapy NN i
and CC i
BMT NNP i
. . i

Standard NNP N
PN NNP N
does VBZ N
not RB N
improve VB N
antioxidant NN N
status NN N
compared VBN N
with IN N
administration NN N
of IN N
micronutrients NNS N
alone RB N
. . N

Further JJ N
evaluation NN N
of IN N
PN NNP N
formulations NNS N
to TO N
support VB N
patients NNS p
undergoing VBG p
high-dose JJ i
chemotherapy NN i
and CC N
BMT NNP i
are VBP N
needed VBN N
. . N

-DOCSTART- -15816106- O O

The DT N
influence NN N
of IN N
epidermal JJ i
growth NN i
factor NN i
receptor NN i
and CC N
tumor NN N
differentiation NN N
on IN N
the DT N
response NN N
to TO N
accelerated VBN N
radiotherapy NN N
of IN N
squamous JJ p
cell NN p
carcinomas NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
in IN N
the DT N
randomized JJ N
DAHANCA NNP N
6 CD N
and CC N
7 CD N
study NN N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Reduction NNP N
of IN N
the DT N
overall JJ N
treatment NN N
time NN N
of IN N
radiotherapy NN N
has VBZ N
increased VBN N
locoregional JJ o
control NN o
and CC N
disease NN o
specific JJ o
survival NN o
in IN N
squamous JJ p
cell NN p
carcinomas NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
( ( p
HNSCC NNP p
) ) p
, , N
but CC N
the DT N
response NN N
is VBZ N
heterogeneous JJ N
. . N

EGFr NNP N
is VBZ N
often RB N
overexpressed VBN N
in IN N
HNSCC NNP N
and CC N
has VBZ N
been VBN N
related VBN N
to TO N
the DT N
repopulation NN N
taking VBG N
place NN N
during IN N
radiotherapy NN N
. . N

The DT N
aim NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
address VB N
the DT N
influence NN o
of IN o
EGFr NNP o
and CC N
histopathological JJ o
differentiation NN o
when WRB N
the DT N
overall JJ o
treatment NN o
time NN o
of IN o
radiotherapy NN o
was VBD N
moderately RB N
reduced VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Eight NNP p
hundred VBD p
and CC p
three CD p
patients NNS p
with IN p
representative JJ p
pretreatment NN p
tissue NN p
samples NNS p
from IN p
the DT p
randomized VBN p
DAHANCA NNP p
6 CD p
and CC p
7 CD p
study NN p
of IN p
5 CD p
vs. FW p
6 CD p
fx/wk NN p
of IN p
radiotherapy NN i
. . i

EGFr NNP N
was VBD N
visualized VBN N
using VBG N
immunohistochemistry NN N
and CC N
separated VBN N
into IN N
high JJ N
and CC N
low JJ N
expression NN N
before IN N
correlation NN N
with IN N
clinical JJ N
data NNS N
. . N

RESULTS NNP N
Tumors NNPS N
with IN N
high JJ N
EGFr NNP N
( ( N
84 CD N
% NN N
) ) N
responded VBD o
better RBR N
to TO N
moderately RB N
accelerated JJ N
radiotherapy NN N
, , N
than IN N
carcinomas NNS N
with IN N
low JJ N
EGFr NNP N
, , N
using VBG N
locoregional JJ N
control NN N
as IN N
endpoint NN N
and CC N
a DT N
similar JJ N
pattern NN N
was VBD N
seen VBN N
, , N
stratifying VBG N
by IN N
well/moderate NN N
vs. FW N
poor JJ N
tumor NN o
differentiation NN o
. . o

Therefore RB N
, , N
a DT N
combined JJ N
parameter NN N
was VBD N
constructed VBN N
showing VBG N
a DT N
more RBR N
prominent JJ o
separation NN o
of IN o
response NN o
: : o
tumors NNS N
with IN N
high JJ N
EGFr NNP N
and CC N
well/moderate JJ N
differentiation NN o
did VBD N
benefit VB N
from IN N
moderate JJ N
acceleration NN N
of IN N
treatment NN N
regarding VBG N
locoregional JJ N
control NN N
, , N
HR NNP N
0.54 CD N
( ( N
0.37-0.78 NN N
) ) N
, , N
whereas NNS N
such JJ N
an DT N
effect NN N
was VBD N
not RB N
seen VBN N
in IN N
tumors NNS N
with IN N
low JJ N
EGFr NNP N
and/or NN N
poor JJ N
differentiation NN N
, , N
HR NNP N
0.8 CD N
( ( N
0.51-1.25 NN N
) ) N
. . N

These DT N
results NNS N
reflected VBD N
the DT N
disease NN o
specific JJ o
survival NN o
as IN N
well RB N
and CC N
were VBD N
confirmed VBN N
in IN N
multivariable JJ N
analyses NNS N
. . N

CONCLUSIONS NNP N
Moderately RB N
accelerated JJ N
fractionation NN N
is VBZ N
superior JJ o
to TO o
conventional JJ o
treatment NN o
in IN N
HNSCC NNP N
but CC N
the DT N
response NN o
is VBZ N
heterogeneous JJ N
and CC N
may MD N
be VB N
predicted VBN N
by IN N
high JJ N
expression NN o
of IN o
EGFr NNP o
and CC N
well/moderate JJ N
tumor NN o
differentiation NN o
. . o

-DOCSTART- -23046525- O O

Dalteparin NNP i
low JJ N
molecular JJ N
weight NN N
heparin NN i
( ( N
LMWH NNP N
) ) N
in IN N
ovarian JJ p
cancer NN p
: : p
a DT N
phase NN N
II NNP N
randomized VBD N
study NN N
. . N

OBJECTIVE NNP N
Low NNP N
molecular JJ N
weight NN N
heparin NN N
reduces VBZ N
the DT N
risk NN N
of IN N
venous JJ N
thromboembolism NN N
( ( N
VTE NNP N
) ) N
and CC N
may MD N
have VB N
antineoplastic JJ N
effects NNS N
by IN N
interfering VBG N
with IN N
angiogenesis NN N
and CC N
with IN N
tumor NN N
growth NN N
and CC N
metastasis NN N
. . N

A DT N
multicentre JJ N
phase NN N
II NNP N
randomized VBD N
trial NN N
was VBD N
done VBN N
to TO N
evaluate VB N
the DT N
antineoplastic JJ N
potential NN N
of IN N
dalteparin NN i
in IN N
ovarian JJ N
cancer NN N
( ( N
OC NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Women NNP p
with IN p
newly-diagnosed JJ p
epithelial JJ p
OC NNP p
were VBD N
randomized VBN N
to TO N
receive VB N
standard JJ i
chemotherapy NN i
( ( i
CT NNP i
) ) i
and CC N
one CD N
of IN N
3 CD N
doses NNS N
of IN N
dalteparin NN i
( ( N
50 CD N
IU/kg NNP N
, , N
100 CD N
IU/kg NNP N
, , N
or CC N
150 CD N
IU/kg NNP N
) ) N
subcutaneously RB N
once RB N
daily JJ N
during IN N
the DT N
first JJ N
3 CD N
of IN N
6 CD N
cycles NNS N
of IN N
3-weekly JJ N
CT NNP N
. . N

Blood NNP N
was VBD N
drawn VBN N
on IN N
day NN N
1 CD N
of IN N
each DT N
cycle NN N
for IN N
CA125 NNP N
and CC N
, , N
in IN N
a DT N
substudy NN N
of IN N
randomized JJ N
patients NNS N
, , N
for IN N
markers NNS N
of IN N
coagulation NN N
activation NN N
and CC N
angiogenesis NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
tumor JJ o
response NN o
defined VBN o
by IN o
? . o
50 CD o
% NN o
reduction NN o
in IN o
serum NN o
CA125 NNP o
from IN o
baseline NN o
sustained VBN o
for IN o
at IN o
least JJS o
28 CD o
days NNS o
. . o

Patients NNS N
were VBD N
followed VBN N
until IN N
the DT N
end NN N
of IN N
CT NNP N
. . N

RESULTS VB N
The DT N
study NN N
was VBD N
terminated VBN N
early RB N
due JJ N
to TO N
poor JJ N
recruitment NN p
. . p

Seventy-seven JJ p
women NNS p
were VBD p
evaluable JJ p
for IN p
the DT p
primary JJ p
outcome NN p
. . p

A DT N
50 CD N
% NN N
drop NN N
in IN N
CA125 NNP o
at IN o
the DT N
end NN N
of IN N
cycle NN N
3 CD N
was VBD N
seen VBN N
in IN N
85 CD N
% NN N
of IN N
the DT N
50 CD N
IU/kg NNP N
group NN N
, , N
92 CD N
% NN N
of IN N
the DT N
100 CD N
IU/kg NNP N
group NN N
, , N
and CC N
85 CD N
% NN N
of IN N
the DT N
150 CD N
IU/kg NNP N
group NN N
. . N

There EX N
were VBD N
no DT N
symptomatic JJ o
VTE NNP o
or CC o
major JJ o
bleeding VBG o
events NNS o
while IN o
on IN N
dalteparin NN N
. . N

Two CD N
patients NNS N
experienced VBD o
VTE NNP o
several JJ o
days NNS N
after IN N
discontinuing VBG N
study JJ N
drug NN N
. . N

Women NNS N
on IN N
dalteparin NN N
had VBD N
lower JJR N
levels NNS N
of IN N
D-dimer NNP o
and CC o
thrombin-antithrombin NN o
, , o
and CC o
higher JJR o
levels NNS o
of IN o
tissue NN o
factor NN o
pathway NN o
inhibitor NN o
, , o
relative JJ N
to TO N
baseline VB N
. . N

CONCLUSION NNP i
Dalteparin NNP i
is VBZ i
safe JJ o
and CC o
well RB o
tolerated VBN o
in IN o
women NNS p
receiving VBG p
CT NNP p
for IN p
newly-diagnosed JJ p
epithelial JJ p
OC NNP p
. . p

A DT N
dose-response JJ N
effect NN N
was VBD N
not RB N
identified VBN N
. . N

The DT N
lack NN N
of IN N
control NN N
group NN N
precluded VBD N
any DT N
inference NN N
on IN N
the DT N
antineoplastic JJ N
effect NN N
of IN N
dalteparin NN i
. . i

-DOCSTART- -24323035- O O

Randomized VBN N
, , N
placebo-controlled JJ N
, , N
phase JJ N
III NNP N
trial NN N
of IN N
sunitinib JJ N
plus CC N
prednisone JJ N
versus NN N
prednisone NN N
alone RB N
in IN N
progressive JJ p
, , p
metastatic JJ p
, , p
castration-resistant JJ p
prostate NN p
cancer NN p
. . p

PURPOSE NNP N
We PRP N
evaluated VBD N
angiogenesis-targeted JJ o
sunitinib NN o
therapy NN o
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
of IN N
metastatic JJ p
castration-resistant JJ p
prostate NN p
cancer NN p
( ( p
mCRPC NN p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Men NNP p
with IN p
progressive JJ p
mCRPC NN p
after IN p
docetaxel-based JJ p
chemotherapy NN p
were VBD N
randomly RB N
assigned VBN N
2:1 CD N
to TO N
receive VB N
sunitinib NN i
37.5 CD i
mg/d NN i
continuously RB i
or CC i
placebo VB i
. . i

Patients NNS N
also RB N
received VBD N
oral JJ i
prednisone NN i
5 CD i
mg NN i
twice RB i
daily RB i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ o
survival NN o
( ( N
OS NNP N
) ) N
; : N
secondary JJ N
end NN N
points NNS N
included VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . N

Two CD N
interim JJ N
analyses NNS N
were VBD N
planned VBN N
. . N

RESULTS NNP N
Overall NNP N
, , N
873 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
receive VB N
sunitinib NN N
( ( N
n JJ N
= NNP N
584 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
289 CD N
) ) N
. . N

The DT N
independent JJ N
data NNS N
monitoring VBG N
committee NN N
stopped VBD N
the DT N
study NN N
for IN N
futility NN N
after IN N
the DT N
second JJ N
interim JJ N
analysis NN N
. . N

After IN N
a DT N
median JJ N
overall JJ N
follow-up NN N
of IN N
8.7 CD N
months NNS N
, , N
median JJ o
OS NNP o
was VBD N
13.1 CD N
months NNS N
and CC N
11.8 CD N
months NNS N
for IN N
sunitinib NN N
and CC N
placebo NN N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.914 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.762 CD N
to TO N
1.097 CD N
; : N
stratified VBN N
log-rank JJ N
test NN N
, , N
P NNP N
= NNP N
.168 NNP N
) ) N
. . N

PFS NNP o
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
sunitinib NN N
arm NN N
( ( N
median JJ N
5.6 CD N
v JJ N
4.1 CD N
months NNS N
; : N
HR NNP N
, , N
0.725 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.591 CD N
to TO N
0.890 CD N
; : N
stratified VBN N
log-rank JJ N
test NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Toxicity NN o
and CC o
rates NNS o
of IN o
discontinuations NNS o
because IN o
of IN o
adverse JJ o
events NNS o
( ( N
AEs NNP N
; : N
27 CD N
% NN N
v JJ N
7 CD N
% NN N
) ) N
were VBD N
greater JJR N
with IN N
sunitinib JJR N
than IN N
placebo NN N
. . N

The DT N
most RBS N
common JJ N
treatment-related JJ N
grade NN N
3/4 CD N
AEs NNP N
were VBD N
fatigue JJ o
( ( N
9 CD N
% NN N
v JJ N
1 CD N
% NN N
) ) N
, , N
asthenia RB o
( ( N
8 CD N
% NN N
v JJ N
2 CD N
% NN N
) ) N
, , N
and CC N
hand-foot JJ o
syndrome NN o
( ( N
7 CD N
% NN N
v JJ N
0 CD N
% NN N
) ) N
. . N

Frequent JJ N
treatment-emergent JJ N
grade NN N
3/4 CD N
hematologic JJ o
abnormalities NNS o
were VBD N
lymphopenia JJ o
( ( N
20 CD N
% NN N
v JJ N
11 CD N
% NN N
) ) N
, , N
anemia NN o
( ( N
9 CD N
% NN N
v JJ N
8 CD N
% NN N
) ) N
, , N
and CC N
neutropenia NN o
( ( N
6 CD N
% NN N
v NN N
< CD N
1 CD N
% NN N
) ) N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
sunitinib NN N
to TO N
prednisone VB N
did VBD N
not RB N
improve VB N
OS NNP o
compared VBN N
with IN N
placebo NN N
in IN N
docetaxel-refractory JJ N
mCRPC NN N
. . N

The DT N
role NN N
of IN N
antiangiogenic JJ N
therapy NN N
in IN N
mCRPC NN N
remains VBZ N
investigational JJ N
. . N

-DOCSTART- -24317552- O O

Activation NN N
and CC N
intermuscular JJ N
coherence NN N
of IN N
distal JJ N
arm NN N
muscles NNS N
during IN N
proximal JJ N
muscle NN N
contraction NN N
. . N

In IN N
the DT N
human JJ N
upper JJ N
extremity NN N
( ( N
UE NNP N
) ) N
, , N
unintended JJ N
effects NNS N
of IN N
proximal JJ N
muscle NN N
activation NN N
on IN N
muscles NNS N
controlling VBG N
the DT N
hand NN N
could MD N
be VB N
an DT N
important JJ N
aspect NN N
of IN N
motor NN N
control NN N
due JJ N
to TO N
the DT N
necessary JJ N
coordination NN N
of IN N
distal NN N
and CC N
proximal JJ N
segments NNS N
during IN N
functional JJ N
activities NNS N
. . N

This DT N
study NN N
aimed VBD N
to TO N
elucidate VB N
the DT N
effects NNS N
of IN N
concurrent JJ N
activation NN N
of IN N
elbow NN N
muscles NNS N
on IN N
the DT N
coordination NN N
between IN N
hand NN N
muscles NNS N
performing VBG N
a DT N
grip NN N
task NN N
. . N

Eleven NNP p
healthy JJ p
subjects NNS p
performed VBN N
precision NN i
grip NN i
tasks NNS i
while IN i
a DT i
constant JJ i
extension NN i
or CC i
flexion NN i
moment NN i
was VBD i
applied VBN i
to TO i
their PRP$ i
elbow NN i
joints NNS i
, , N
inducing VBG N
a DT N
sustained VBN N
submaximal JJ N
contraction NN N
of IN N
elbow NN N
muscles NNS N
to TO N
counter VB N
the DT N
applied JJ N
torque NN N
. . N

Activation NNP N
of IN N
four CD N
hand NN N
muscles NNS N
was VBD N
measured VBN N
during IN N
each DT N
task NN N
condition NN N
using VBG N
surface NN i
electromyography NN i
( ( i
EMG NNP i
) ) i
. . i

When WRB N
concurrent JJ N
activation NN N
of IN N
elbow NN N
muscles NNS N
was VBD N
induced VBN N
, , N
significant JJ N
changes NNS N
in IN N
the DT N
activation NN o
levels NNS o
of IN o
the DT o
hand NN o
muscles NNS o
were VBD N
observed VBN N
, , N
with IN N
greater JJR N
effects NNS N
on IN N
the DT N
extrinsic JJ N
finger NN N
extensor NN N
( ( N
23.2 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
extensor NN N
activation NN N
; : N
p CC N
= VB N
0.003 CD N
) ) N
than IN N
extrinsic JJ N
finger NN N
flexor NN N
( ( N
14.2 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
flexor JJ N
activation NN N
; : N
p CC N
= VB N
0.130 CD N
) ) N
. . N

Elbow NNP o
muscle NN o
activation NN o
also RB N
induced VBD N
involuntary JJ N
changes NNS N
in IN N
the DT N
intrinsic JJ o
thumb NN o
flexor NN o
activation NN o
( ( N
44.6 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
extensor NN N
activation NN N
; : N
p CC N
= VB N
0.005 CD N
) ) N
. . N

EMG-EMG JJ N
coherence NN N
analyses NNS N
revealed VBD N
that IN N
elbow JJ o
muscle NN o
activation NN o
significantly RB N
reduced VBD N
intermuscular JJ o
coherence NN o
between IN o
distal JJ o
muscle NN o
pairs NNS o
, , N
with IN N
its PRP$ N
greatest JJS N
effects NNS N
on IN N
coherence NN N
in IN N
the DT N
?-band NN N
( ( N
13-25 JJ N
Hz NNP N
) ) N
( ( N
average NN N
of IN N
17 CD N
% NN N
decrease NN N
under IN N
30 CD N
% NN N
elbow NN N
flexor JJ N
activation NN N
) ) N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
provide VBP N
evidence NN N
for IN N
involuntary JJ N
, , N
muscle-specific JJ N
interactions NNS N
between IN N
distal NN N
and CC N
proximal JJ N
UE NNP N
muscles NNS N
, , N
which WDT N
may MD N
contribute VB N
to TO N
UE NNP N
motor NN N
performance NN N
in IN N
health NN N
and CC N
disease NN N
. . N

-DOCSTART- -9301391- O O

Plasma NNP o
dilution NN o
and CC N
the DT N
rate NN N
of IN N
infusion NN N
of IN N
Ringer NNP i
's POS i
solution NN i
. . i

Changes NNS N
in IN N
the DT N
volume NN N
of IN N
the DT N
fluid JJ N
space NN N
expanded VBN N
by IN N
i.v NN N
. . N

infusion NN N
of IN N
Ringer NNP i
's POS i
acetate JJ i
solution NN i
have VBP N
been VBN N
analysed VBN N
recently RB N
using VBG N
mathematical JJ N
models NNS N
. . N

Data NNS N
obtained VBN N
by IN N
such JJ N
analyses NNS N
allow VBP N
simulation NN N
of IN N
the DT N
dilution NN N
of IN N
the DT N
plasma NN o
volume NN o
during IN N
infusion NN o
of IN N
the DT N
solution NN N
at IN N
different JJ N
rates NNS N
. . N

To TO N
obtain VB N
basic JJ N
kinetic JJ N
data NNS N
for IN N
such JJ N
simulations NNS N
, , N
the DT N
plasma JJ o
dilution-time JJ o
curves NNS o
were VBD N
measured VBN N
during IN N
and CC N
after IN N
i.v NN i
. . i

infusion NN i
of IN i
Ringer NNP i
's POS i
solution NN i
25 CD N
ml NN N
kg-1 NN N
over IN N
30 CD N
min NNS N
in IN N
15 CD p
healthy JJ p
male NN p
volunteers NNS p
( ( p
mean JJ p
age NN p
31 CD p
yr NN p
) ) p
and CC p
over IN p
30 CD p
, , p
45 CD p
and CC p
80 CD p
min NN p
in IN p
six CD p
females NNS p
( ( p
mean JJ p
age NN p
32 CD p
yr NN p
) ) p
. . p

Based VBN N
on IN N
these DT N
experiments NNS N
, , N
nomograms NNS N
were VBD N
constructed VBN N
from IN N
which WDT N
the DT N
rate NN N
of IN N
infusion NN N
of IN N
Ringer NNP i
's POS i
solution NN i
and CC N
the DT N
infusion NN N
time NN N
required VBN N
to TO N
obtain VB N
a DT N
defined JJ N
plasma NN N
dilution NN N
in IN N
both DT N
males NNS N
and CC N
females NNS N
can MD N
be VB N
estimated VBN N
together RB N
with IN N
the DT N
infusion NN N
rate NN N
needed VBN N
to TO N
maintain VB N
the DT N
dilution NN N
at IN N
the DT N
level NN N
reached VBD N
. . N

-DOCSTART- -9772108- O O

Functional JJ N
modification NN p
of IN p
agonist-antagonist JJ p
electromyographic JJ p
activity NN p
for IN p
rapid JJ p
movement NN p
inhibition NN p
. . p

Subjects NNS p
made VBD p
a DT p
fast JJ p
elbow NN p
extension NN p
movement NN p
to TO p
designated VBN p
target NN p
in IN p
response NN p
to TO p
a DT p
go JJ i
signal NN i
. . i

In IN N
45 CD N
% NN N
of IN N
trials NNS N
a DT N
stop JJ N
signal NN N
was VBD N
presented VBN N
after IN N
the DT N
go JJ N
signal NN N
, , N
to TO N
which WDT N
subjects NNS N
were VBD N
asked VBN N
to TO N
stop VB N
the DT N
movement NN N
as RB N
rapidly RB N
as IN N
possible JJ N
. . N

The DT i
interstimulus JJ i
interval NN i
( ( i
ISI NNP i
) ) i
, , i
or CC i
time NN i
interval NN i
between IN i
the DT i
go NN i
and CC i
stop NN i
signals NNS i
, , N
was VBD N
randomly RB N
varied VBN N
between IN N
0 CD N
and CC N
200 CD N
ms. NN N
Electromyographic NNP o
( ( o
EMG NNP o
) ) o
activity NN o
was VBD i
recorded VBN i
from IN i
biceps NNS i
brachii NNS i
and CC i
triceps NNS i
brachii NN i
. . i

Subjects NNS N
could MD N
sometimes RB N
completely RB N
inhibit JJ N
initiation NN N
of IN N
the DT N
movements NNS N
when WRB N
the DT N
ISI NNP N
was VBD N
0 CD N
ms NN N
, , N
but CC N
could MD N
rarely RB N
do VB N
so RB N
when WRB N
the DT N
ISI NNP N
exceeded VBD N
100 CD N
ms. NN N
For IN N
responses NNS N
that WDT N
were VBD N
initiated VBN N
but CC N
stopped VBN N
on IN N
the DT N
way NN N
, , N
the DT N
amplitude NN o
of IN o
the DT o
movement NN o
decreased VBD N
linearly RB N
as IN N
the DT N
time NN N
interval NN N
( ( N
=modification JJ N
time NN N
) ) N
from IN N
the DT N
stop JJ N
signal NN N
to TO N
EMG NNP N
onset NN N
increased VBD N
. . N

The DT N
peak JJ o
velocity NN o
increased VBD N
linearly RB N
as IN N
the DT N
movement NN N
amplitude NN N
increased VBD N
. . N

This DT N
tendency NN N
was VBD N
similar JJ N
to TO N
those DT N
previously RB N
reported VBN N
in IN N
step-tracking JJ N
movements NNS N
with IN N
various JJ N
amplitudes NNS N
. . N

In IN N
spite NN N
of IN N
the DT N
similarity NN N
in IN N
the DT N
kinematics NNS N
of IN N
the DT N
movement NN N
, , N
the DT N
EMG NNP o
pattern NN o
was VBD N
different JJ N
from IN N
that DT N
of IN N
step-tracking JJ o
movement NN o
. . o

While IN N
the DT N
initial JJ o
agonist NN o
burst NN o
( ( o
AG1 NNP o
) ) o
decreased VBD N
linearly RB N
after IN N
the DT N
modification NN N
time NN N
exceeded VBD N
100 CD N
ms NN N
, , N
the DT N
antagonist NN o
burst NN o
( ( o
ANT NNP o
) ) o
increased VBD N
compared VBN N
with IN N
the DT N
go JJ N
trial NN N
for IN N
the DT N
modification NN N
time NN N
from IN N
0 CD N
to TO N
200 CD N
ms NNS N
and CC N
decreased VBN N
after IN N
the DT N
modification NN N
time NN N
exceeded VBD N
300 CD N
ms NN N
. . N

This DT N
change NN N
of IN N
activation NN N
is VBZ N
analogous JJ N
to TO N
functional JJ N
modification NN N
of IN N
middle-latency NN N
reflex NN N
EMG NNP o
response NN o
to TO N
load VB N
, , N
or CC N
cutaneous JJ N
perturbation NN N
. . N

In IN N
conclusion NN N
, , N
it PRP N
is VBZ N
suggested VBN N
that IN N
adaptive JJ N
mechanisms NNS N
, , N
which WDT N
would MD N
functionally RB N
modify VB N
the DT N
reflex NN N
responses NNS N
, , N
are VBP N
also RB N
continuously RB N
working VBG N
during IN N
voluntary JJ N
movements NNS N
in IN N
response NN N
to TO N
sudden JJ N
changes NNS N
in IN N
environmental JJ N
information NN N
. . N

-DOCSTART- -21598839- O O

The DT N
effects NNS N
of IN N
encoding VBG N
in IN N
hypnosis NN N
and CC N
post-hypnotic JJ N
suggestion NN N
on IN N
academic JJ N
performance NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
relationship NN N
between IN N
proactive JJ p
learning NN p
in IN p
hypnosis NN i
, , i
post-hypnotic JJ i
suggestion NN i
, , p
and CC p
academic JJ p
performance NN p
. . p

Participants NNS p
( ( p
N NNP p
= NNP p
56 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
control NN i
group NN p
or CC N
a DT N
treatment NN i
group NN p
. . p

The DT N
treatment NN N
group NN N
was VBD N
hypnotized VBN i
and CC i
read VB i
a DT i
passage NN i
while IN i
in IN i
hypnosis NN i
. . i

Concurrently RB N
, , N
they PRP N
were VBD N
given VBN N
a DT N
post-hypnotic JJ i
suggestion NN i
, , N
which WDT N
attempted VBD N
to TO N
aid VB N
recognition NN N
and CC N
performance NN N
on IN N
a DT N
test NN N
immediately RB N
following VBG N
the DT N
hypnosis NN N
session NN N
. . N

Both DT N
groups NNS N
completed VBD N
a DT N
multiple-choice JJ N
test NN N
based VBN N
on IN N
the DT N
aforementioned JJ N
passage NN N
. . N

An DT N
analysis NN N
of IN N
covariance NN N
discerned VBD N
the DT N
effect NN o
of IN o
proactive JJ o
learning NN o
and CC N
post-hypnotic JJ o
suggestion NN o
on IN N
test NN o
performance NN o
, , N
while IN N
controlling VBG N
for IN N
the DT N
variance NN N
introduced VBN N
by IN N
scholastic JJ o
aptitude NN o
as IN N
measured VBN N
by IN N
the DT N
ACT NNP N
. . N

Results NNP N
indicated VBD N
that IN N
the DT N
hypnosis NN i
sessions NNS N
predicted VBD N
significantly RB N
impaired JJ o
test NN o
performance NN o
. . o

-DOCSTART- -21600592- O O

Standardized NNP N
preoperative JJ N
corticosteroid NN i
treatment NN N
in IN N
neonates NNS p
undergoing VBG p
cardiac JJ p
surgery NN p
: : p
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE CC N
A DT N
heightened JJ N
inflammatory NN N
response NN N
occurs VBZ N
after IN N
cardiac JJ N
surgery NN N
. . N

The DT N
perioperative JJ N
use NN N
of IN N
glucocorticoids NNS N
has VBZ N
been VBN N
advocated VBN N
as IN N
a DT N
method NN N
to TO N
improve VB N
postoperative JJ N
outcomes NNS N
. . N

Randomized VBN N
prospective JJ N
studies NNS N
to TO N
quantify VB N
the DT N
effect NN N
of IN N
methylprednisolone NN i
on IN N
perioperative JJ N
outcomes NNS N
in IN N
neonatal JJ p
cardiac NN p
surgery NN p
have VBP N
not RB N
been VBN N
performed VBN N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
preoperative JJ N
methylprednisolone NN N
would MD N
improve VB N
postoperative JJ N
recovery NN N
in IN N
neonates NNS N
requiring VBG N
cardiac JJ N
surgery NN N
. . N

METHODS NNP N
Neonates NNP p
scheduled VBD p
for IN p
cardiac JJ p
surgery NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
either DT N
2-dose JJ N
( ( N
8 CD N
hours NNS N
preoperatively RB N
and CC N
operatively RB N
, , N
n JJ p
= NNP p
39 CD p
) ) p
or CC p
single-dose JJ N
( ( N
operatively RB p
, , p
n JJ p
= NNP i
37 CD i
) ) i
methylprednisolone NN i
( ( i
30 CD i
mg/kg NN N
per IN N
dose NN N
) ) N
in IN N
a DT N
prospective JJ N
double-blind JJ N
trial NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
incidence NN o
of IN o
low JJ o
cardiac JJ o
output NN o
syndrome NN o
( ( o
standardized VBN o
score NN N
) ) N
or CC N
death NN N
36 CD N
hours NNS N
postoperatively RB N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
death NN o
at IN o
30 CD o
days NNS o
, , o
interleukin-6 JJ o
levels NNS o
, , o
inotropic NN o
score NN o
, , o
fluid NN o
balance NN o
, , o
serum JJ o
creatinine NN o
, , o
and CC o
intensive JJ o
care NN o
unit NN o
and CC o
hospital NN o
stay NN o
. . o

RESULTS NNP o
Preoperative NNP o
plasma NN o
levels NNS o
of IN o
the DT N
inflammatory JJ o
cytokine JJ o
interleukin-6 NN o
were VBD o
reduced VBN N
by IN N
2-fold JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
2-dose JJ N
methylprednisolone NN N
group NN N
, , N
consistent NN N
with IN N
the DT N
anti-inflammatory JJ N
effects NNS N
of IN N
methylprednisolone NN N
. . N

However RB N
, , N
the DT N
incidence NN o
of IN o
low JJ o
cardiac JJ o
output NN o
syndrome NN o
was VBD o
46 CD o
% NN N
( ( N
17/37 CD N
) ) N
in IN N
the DT N
single-dose JJ N
and CC N
38 CD N
% NN N
( ( N
15/39 CD N
) ) N
in IN N
the DT N
2-dose JJ N
methylprednisolone NN N
groups NNS N
( ( N
P NNP N
= NNP N
.51 NNP N
) ) N
. . N

Two-dose JJ N
methylprednisolone NN N
was VBD N
associated VBN o
with IN o
a DT o
higher JJR o
serum NN o
creatinine NN o
( ( o
0.61 CD o
? . o
0.18 CD N
mg/dL NN N
vs NN N
0.53 CD N
? . N
0.12 CD N
mg/dL NN N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC o
poorer $ o
postoperative JJ o
diuresis NN o
( ( o
-96 VB o
? . N
49 CD N
mL NN N
, , N
P NNP N
= NNP N
.05 NNP N
) ) N
. . N

Inotropic NNP o
requirement NN o
, , o
duration NN o
of IN o
mechanical JJ o
ventilation NN o
, , o
intensive JJ o
care NN o
unit NN o
, , o
and CC o
hospital JJ o
stay NN o
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Combined NNP N
preoperative NN N
and CC N
intraoperative JJ N
use NN N
of IN N
glucocorticoids NNS N
in IN N
neonatal JJ N
cardiac JJ N
surgery NN N
does VBZ N
not RB N
favorably RB N
affect VBP N
early JJ N
clinical JJ N
outcomes NNS N
and CC N
may MD N
exacerbate VB N
perioperative JJ N
renal JJ N
dysfunction NN N
. . N

-DOCSTART- -12663340- O O

Dose-response JJ N
characteristics NNS N
during IN N
long-term JJ N
inhalation NN N
of IN N
nitric JJ i
oxide NN i
in IN N
patients NNS p
with IN p
severe JJ p
acute JJ p
respiratory NN p
distress JJ p
syndrome NN p
: : p
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
. . N

Inhaled VBN N
nitric JJ i
oxide NN i
( ( i
NO NNP i
) ) i
improves VBZ N
systemic JJ N
oxygenation NN N
( ( N
PaO2/FIO2 NNP N
) ) N
in IN N
adult NN p
patients NNS p
with IN p
acute JJ p
respiratory NN p
distress NN p
syndrome NN p
( ( p
ARDS NNP p
) ) p
. . p

However RB N
, , N
individual JJ N
response NN N
varies NNS N
, , N
and CC N
previous JJ N
trials NNS N
demonstrated VBD N
no DT N
outcome NN N
benefit NN N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
in IN N
40 CD p
ARDS NNP p
patients NNS p
analyzed VBD N
dose-response JJ o
( ( o
DR NNP o
) ) o
characteristics NNS o
during IN N
long-term JJ N
inhaled JJ N
NO NNP i
. . i

Patients NNS p
were VBD p
randomized VBN i
for IN i
conventional JJ i
therapy NN i
( ( i
control NN i
) ) i
or CC i
continuous JJ i
treatment NN i
with IN i
10 CD i
parts NNS i
per IN i
million CD i
( ( i
ppm NN i
) ) i
inhaled VBD i
NO NNP i
until IN i
weaning VBG i
was VBD i
initiated VBN i
. . i

We PRP N
measured VBD N
DR NNP o
curves NNS o
of IN o
PaO2/FIO2 NNP o
versus IN o
the DT o
inhaled JJ o
NO NNP o
dose NN o
at IN N
regular JJ N
intervals NNS N
. . N

Before IN N
treatment NN N
( ( N
Day NNP N
0 CD N
) ) N
, , N
peak JJ N
improvement NN N
in IN N
PaO2/FIO2 NNP o
was VBD N
achieved VBN N
at IN N
10 CD N
ppm NN N
for IN N
both DT N
control NN N
and CC N
NO-treated JJ i
patients NNS N
. . N

After IN N
4 CD N
days NNS N
, , N
the DT N
DR NNP o
curve NN o
of IN o
the DT o
NO-treated JJ o
patients NNS o
was VBD N
left VBN N
shifted VBN N
with IN N
a DT N
peak JJ N
response NN N
at IN N
1 CD N
ppm NN N
. . N

At IN N
higher JJR N
doses NNS N
( ( N
10 CD N
and CC N
100 CD N
ppm NN N
) ) N
, , N
oxygenation NN o
deteriorated VBD o
, , N
and CC N
the DT N
response NN N
to TO N
inhaled VB N
NO RB N
disappeared VBN N
in IN N
several JJ N
patients NNS N
. . N

This DT N
effect NN N
was VBD N
not RB N
observed VBN N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
of IN N
inhaled JJ N
NO NNP N
on IN N
duration NN N
of IN N
mechanical JJ o
ventilation NN o
or CC o
stay VB o
at IN o
the DT o
intensive JJ o
care NN o
unit NN o
. . o

In IN N
conclusion NN N
, , N
long-term JJ N
inhaled VBD N
NO NNP N
with IN N
constant JJ N
doses NNS N
of IN N
10 CD N
ppm NNS N
leads VBZ N
to TO N
enhanced VB N
sensitivity NN N
after IN N
several JJ N
days NNS N
and CC N
does VBZ N
do VB N
not RB N
allow VB N
reduction NN N
of IN N
ventilation NN N
parameters NNS N
. . N

Hence NNP N
, , N
previous JJ N
trials NNS N
on IN N
therapy NN N
with IN N
inhaled JJ N
NO NNP N
in IN N
ARDS NNP N
should MD N
be VB N
carefully RB N
interpreted VBN N
, , N
as IN N
they PRP N
used VBD N
constant JJ N
NO NNP N
concentrations NNS N
, , N
which WDT N
may MD N
have VB N
become VBN N
overdoses NNS N
leading VBG N
to TO N
deterioration NN N
of IN N
oxygenation NN o
after IN N
several JJ N
days NNS N
. . N

-DOCSTART- -16099893- O O

Effect NN N
of IN N
exercise NN i
, , i
training NN i
, , N
and CC N
glycogen NN i
availability NN i
on IN N
IL-6 NNP N
receptor NN N
expression NN N
in IN N
human JJ p
skeletal JJ p
muscle NN p
. . p

The DT N
cytokine JJ N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
exerts VBZ N
it PRP N
actions NNS N
via IN N
the DT N
IL-6 NNP N
receptor NN N
( ( N
IL-6R NNP N
) ) N
in IN N
conjunction NN N
with IN N
the DT N
ubiquitously RB N
expressed VBN N
gp130 NN N
receptor NN N
. . N

IL-6 NNP N
is VBZ N
tightly RB N
regulated VBN N
in IN N
response NN N
to TO N
exercise NN i
, , N
being VBG N
affected VBN N
by IN N
factors NNS N
such JJ N
as IN N
exercise NN N
intensity NN N
and CC N
duration NN N
, , N
as RB N
well RB N
as IN N
energy NN N
availability NN N
. . N

Although IN N
the DT N
IL-6 NNP N
response NN N
to TO N
exercise NN N
has VBZ N
been VBN N
extensively RB N
studied VBN N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
regulation NN N
of IN N
the DT N
IL-6R NNP N
response NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
exercise NN i
, , i
training NN i
, , i
and CC i
glycogen NN i
availability NN i
, , N
factors NNS N
known VBN N
to TO N
affect VB N
IL-6 NNP N
, , N
on IN N
the DT N
regulation NN N
of IN N
gene NN N
expression NN N
of IN N
the DT N
IL-6R NNP N
in IN N
human JJ N
skeletal JJ N
muscle NN N
. . N

Human NNP p
subjects VBZ p
performed VBD N
either CC N
10 CD i
wk NN i
of IN i
training VBG i
with IN i
an DT i
acute JJ i
exercise NN i
bout NN i
before IN i
and CC i
after IN i
the DT i
training NN i
period NN i
, , i
or CC i
a DT i
low-glycogen JJ i
vs. NN i
normal-glycogen JJ i
acute NN i
exercise NN i
trial NN i
. . i

The DT N
IL-6R JJ o
mRNA NN o
response NN o
was VBD N
evaluated VBN N
in IN N
both DT N
trials NNS N
. . N

In IN N
response NN N
to TO N
acute VB N
exercise NN N
, , N
an DT N
increase NN N
in IN N
IL-6R NNP o
mRNA NN o
levels NNS o
was VBD N
observed VBN N
. . N

Neither CC N
training VBG N
nor CC N
intramuscular JJ N
glycogen NN N
levels NNS N
had VBD N
an DT N
effect NN N
on IN N
the DT N
IL-6R NNP o
mRNA NN o
response NN o
to TO N
exercise NN N
. . N

However RB N
, , N
after IN N
10 CD N
wk NN N
of IN N
training NN N
, , N
the DT N
skeletal JJ N
muscle NN N
expressed VBD N
a DT N
higher JJR N
mRNA JJ o
level NN o
of IN o
IL-6R NNP o
compared VBN N
with IN N
before RB N
training VBG N
. . N

The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
the DT N
IL-6R NNP o
gene NN o
expression NN o
levels NNS o
in IN N
skeletal JJ N
muscle NN N
are VBP N
increased VBN N
in IN N
response NN N
to TO N
acute VB N
exercise NN N
, , N
a DT N
response NN N
that WDT N
is VBZ N
very RB N
well RB N
conserved VBN N
, , N
being VBG N
affected VBN N
by IN N
neither DT N
training NN o
status NN o
nor CC N
intramuscular JJ o
glycogen NN o
levels NNS o
, , N
as IN N
opposed VBN N
to TO N
IL-6 NNP N
. . N

However RB N
, , N
after IN N
the DT N
training NN N
period NN N
, , N
IL-6R JJ o
mRNA NN o
production NN o
was VBD N
increased VBN N
in IN N
skeletal JJ N
muscle NN N
, , N
suggesting VBG N
a DT N
sensitization NN N
of IN N
skeletal JJ N
muscle NN N
to TO N
IL-6 NNP N
at IN N
rest NN N
. . N

-DOCSTART- -24156287- O O

Effect NN N
of IN N
clinical JJ N
context NN N
on IN N
simulator-based JJ N
assessment NN N
of IN N
blood NN o
pressure NN o
taking VBG p
- : N
a DT N
pilot NN N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Blood NNP N
pressure NN N
measurement NN N
is VBZ N
an DT N
essential JJ N
clinical JJ N
skill NN N
that WDT N
can MD N
readily RB N
be VB N
assessed VBN N
in IN N
objective JJ N
structured JJ N
clinical JJ N
examination NN N
( ( N
OSCE NNP N
) ) N
. . N

While IN N
the DT N
use NN N
of IN N
simulators NNS i
can MD N
enhance VB N
test NN N
validity NN N
and CC N
reliability NN N
, , N
the DT N
given VBN N
clinical JJ N
context NN N
may MD N
also RB N
affect VB N
student NN N
performance NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
variations NNS N
in IN N
clinical JJ N
context NN N
on IN N
blood NN N
pressure NN N
measurement NN N
in IN N
a DT N
simulator-based JJ i
OSCE NNP i
. . i

METHOD NNP N
We PRP N
randomized VBD p
162 CD p
first-year JJ p
medical JJ p
students NNS p
into IN p
four CD p
groups NNS p
that WDT p
received VBD p
different JJ p
lead-in JJ p
statements NNS p
before IN p
measuring VBG p
blood NN o
pressure NN o
on IN p
a DT p
manikin JJ i
simulator NN i
. . i

These DT N
statements NNS N
described VBD N
hypothetical JJ N
patients NNS N
with IN N
different JJ N
likelihoods NNS N
of IN N
having VBG N
systemic JJ o
hypertension NN o
. . o

RESULTS VB N
The DT N
lead-in JJ N
that WDT N
described VBD N
the DT N
highest JJS N
likelihood NN o
of IN o
hypertension NN o
was VBD N
associated VBN N
with IN N
significantly RB N
higher JJR N
reported VBD o
readings NNS o
and CC o
lower JJR o
accuracy NN o
. . o

The DT N
lead-in NN N
that WDT N
suggested VBD N
normality NN N
yielded VBN N
the DT N
best JJS N
performance NN N
. . N

CONCLUSION NNP N
Student NNP p
performance NN N
in IN N
simulator-based JJ i
OSCE NNP i
may MD N
be VB N
affected VBN N
by IN N
the DT N
clinical JJ N
context NN N
provided VBN N
. . N

However RB N
, , N
we PRP N
argue VBP N
that IN N
construct NN N
validity NN N
should MD N
be VB N
viewed VBN N
in IN N
light NN N
of IN N
the DT N
application NN N
of IN N
a DT N
test NN N
, , N
in IN N
that DT N
patients NNS N
may MD N
also RB N
present VB N
with IN N
different JJ N
cues NNS N
and CC N
likelihoods NNS N
of IN N
having VBG N
hypertension NN N
. . N

Variations NNS N
in IN N
construct NN N
design NN N
should MD N
be VB N
further RB N
explored VBN N
to TO N
enhance VB N
the DT N
training NN N
and CC N
assessment NN N
of IN N
clinical JJ N
competence NN N
that WDT N
reflects VBZ N
the DT N
unpredictability NN N
encountered VBN N
in IN N
daily JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -8162628- O O

Influence NN N
of IN N
glyceryl NN i
trinitrate NN i
on IN N
venous JJ N
and CC N
arterial JJ N
effects NNS N
of IN N
chronic NN N
, , N
asymmetric JJ N
isosorbide NN i
dinitrate NN i
treatment NN i
in IN N
patients NNS p
with IN p
ischemic JJ p
heart NN p
disease NN p
. . p

Asymmetric JJ N
dosage NN N
regimes NNS N
have VBP N
been VBN N
introduced VBN N
to TO N
circumvent VB N
development NN N
of IN N
nitrate JJ N
tolerance NN N
. . N

This DT N
study NN N
assessed VBD N
invasively RB N
the DT N
hemodynamics NNS N
during IN N
supine JJ N
rest NN N
and CC N
exercise NN N
before RB N
and CC N
after IN N
4 CD N
weeks NNS N
treatment NN N
with IN N
30 CD i
mg NNS i
isosorbide JJ i
dinitrate NN i
( ( i
ISDN NNP i
) ) i
or CC i
placebo VB i
asymmetrically RB N
b.i.d JJ N
. . N

in IN N
14 CD p
randomized JJ p
patients NNS p
with IN p
stable JJ p
ischemic JJ p
heart NN p
disease NN p
in IN N
a DT N
double-blinded JJ N
study NN N
. . N

An DT N
intravenous JJ i
infusion NN i
of IN i
glyceryl NN i
trinitrate NN i
( ( i
GTN NNP i
) ) i
was VBD N
used VBN N
to TO N
assess VB N
possible JJ N
nitrate JJ N
tolerance NN N
. . N

During IN N
the DT N
initial JJ N
, , N
medication-free JJ N
exercise NN N
all DT N
patients NNS N
had VBD N
increased VBN N
pulmonary JJ o
arterial JJ o
wedge NN o
pressure NN o
( ( o
PAWP NNP o
) ) o
31.4 CD N
+/- JJ N
5.56 CD N
mmHg NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
, , N
showing VBG N
impaired JJ N
left VBD N
ventricular JJ N
function NN N
, , N
while IN N
mean JJ o
arterial JJ o
pressures NNS o
( ( o
MAP NNP o
) ) o
rose VBD N
from IN N
112 CD N
+/- JJ N
16.3 CD N
mmHg NN N
at IN N
rest NN N
to TO N
141 CD N
+/- JJ N
15.9 CD N
mmHg NN N
during IN N
exercise NN N
. . N

After IN N
4 CD N
weeks NNS N
ISDN NNP i
treatment NN N
, , N
mean JJ o
exercise NN o
PAWP NNP o
and CC o
MAP NNP o
, , N
3 CD N
h NN N
after IN N
morning NN N
dose NN N
, , N
were VBD N
reduced VBN N
to TO N
22.4 CD N
+/- JJ N
7.09 CD N
mmHg NN N
and CC N
127 CD N
+/- JJ N
18.2 CD N
mmHg NN N
, , N
respectively RB N
. . N

Before IN N
the DT N
ISDN NNP i
treatment NN i
, , i
GTN NNP i
reduced VBD N
exercise NN N
PAWP NNP o
to TO N
13.9 CD N
+/- JJ N
5.27 CD N
mmHg NN N
and CC N
MAP NNP N
to TO N
119 CD N
+/- JJ N
11.2 CD N
mmHg NN N
, , N
whereas NNS N
after IN N
4 CD N
weeks NNS N
ISDN NNP i
treatment NN N
, , N
the DT N
addition NN N
of IN N
GTN NNP N
did VBD N
not RB N
reduce VB N
exercise NN N
PAWP NNP o
and CC o
MAP NNP o
to TO N
the DT N
same JJ N
low JJ N
levels NNS N
. . N

Thus RB N
, , N
the DT N
applied JJ N
ISDN NNP i
regimen NNS N
improved VBD N
the DT N
hemodynamics NNS N
, , N
but CC N
induced VBD N
a DT N
definite NN N
, , N
partial JJ N
nitrate NN N
tolerance NN N
. . N

-DOCSTART- -9407259- O O

Effects NNS N
of IN N
creatine JJ i
supplementation NN i
on IN N
repetitive JJ N
sprint NN N
performance NN N
and CC N
body NN N
composition NN N
in IN N
competitive JJ p
swimmers NNS p
. . p

In IN N
a DT N
double-blind NN N
and CC N
randomized JJ N
manner NN N
, , N
18 CD p
male NN p
and CC p
female JJ p
junior JJ p
competitive JJ p
swimmers NNS p
supplemented VBD N
their PRP$ N
diets NNS N
with IN N
21 CD N
g.day-1 NN N
of IN N
creatine NN i
monohydrate NN i
( ( i
Cr NNP i
) ) i
or CC N
a DT N
maltodextrin JJ i
placebo NN i
( ( i
P NNP i
) ) i
for IN N
9 CD p
days NNS p
during IN p
training NN p
. . p

Prior NNP N
to TO N
and CC N
following VBG N
supplementation NN N
, , N
subjects NNS N
performed VBD N
three CD N
100-m JJ N
freestyle JJ N
sprint NN N
swims NNS N
( ( N
long JJ N
course NN N
) ) N
with IN N
60 CD N
s JJ N
rest/recovery NN N
between IN N
heats NNS N
. . N

In IN N
addition NN N
, , N
subjects NNS N
performed VBD N
three CD N
20-s JJ N
arm NN N
ergometer NN N
maximal-effort JJ N
sprint NN N
tests NNS N
in IN N
the DT N
prone NN N
position NN N
with IN N
60 CD N
s JJ N
rest/recovery NN N
between IN N
sprint NN N
tests NNS N
. . N

Significant JJ N
differences NNS N
were VBD N
observed VBN N
among IN N
swim JJ o
times NNS o
, , N
with IN N
Cr NNP N
subjects NNS N
swimming VBG N
significantly RB N
faster RBR N
than IN N
P NNP N
subjects NNS N
following VBG N
supplementation NN N
in IN N
Heat NNP N
1 CD N
and CC N
significantly RB N
decreasing VBG N
swim JJ o
time NN o
in IN N
the DT N
second JJ N
100-m JJ N
sprint NN N
. . N

There EX N
was VBD N
also RB N
some DT N
evidence NN N
that IN N
cumulative JJ o
time NN o
to TO o
perform VB o
the DT o
three CD o
100-m JJ o
swims NNS o
was VBD N
decreased VBN N
in IN N
the DT N
Cr NNP N
group NN N
. . N

Results NNP N
indicate VBP N
that IN N
9 CD N
days NNS N
of IN N
Cr NNP i
supplementation NN N
during IN N
swim JJ N
training NN N
may MD N
provide VB N
some DT N
ergogenic JJ N
value NN N
to TO N
competitive JJ N
junior JJ N
swimmers NNS N
during IN N
repetitive JJ N
sprint NN N
performance NN N
. . N

-DOCSTART- -9932558- O O

Videotaped NNP i
training NN i
in IN i
alcohol NN i
counseling NN i
for IN N
obstetric JJ p
care NN p
practitioners NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
feasibility NN N
of IN N
videotaped JJ i
training NN i
for IN i
obstetric JJ i
care NN i
practitioners NNS i
in IN i
motivational JJ i
interviewing NN i
skills NNS i
that WDT N
could MD N
be VB N
used VBN N
in IN N
brief JJ N
patient JJ N
consultations NNS N
on IN N
problem NN N
drinking NN N
. . N

METHODS NNP N
Thirty NNP p
health NN p
care NN p
practitioners NNS p
participated VBD N
in IN N
a DT N
clinical JJ N
trial NN N
using VBG N
a DT N
20-minute JJ i
videotape NN i
to TO N
instruct VB N
them PRP N
in IN N
motivational JJ N
interviewing NN N
. . N

Participants NNS N
engaged VBN N
in IN N
a DT N
pretest JJ N
roleplay NN N
with IN N
an DT N
actress NN N
playing VBG N
a DT N
drinking NN N
pregnant JJ N
woman NN N
. . N

Those DT N
randomly RB N
assigned VBN N
to TO N
the DT N
experimental JJ N
condition NN N
watched VBD N
the DT N
motivational JJ i
interviewing NN i
videotape NN i
. . i

Control NNP i
condition NN N
participants NNS N
watched VBD N
a DT N
20-minute JJ i
docudrama NN i
of IN N
a DT N
pregnant JJ N
problem NN N
drinker NN N
. . N

Both DT N
groups NNS N
then RB N
engaged VBD N
in IN N
a DT N
post-test JJ N
roleplay NN N
similar JJ N
to TO N
the DT N
pretest NN N
. . N

Behavioral JJ o
ratings NNS o
of IN o
the DT o
roleplays NNS o
and CC o
participant JJ o
evaluations NNS o
of IN o
the DT o
motivational JJ o
interviewing NN o
video NN o
constituted VBD o
the DT o
outcome NN o
measures NNS o
. . o

RESULTS NNP N
Participant NNP N
evaluations NNS N
indicated VBD N
that IN N
the DT N
training NN i
video NN i
was VBD N
clear JJ N
in IN N
explaining VBG N
and CC N
demonstrating VBG N
the DT N
principles NNS N
and CC N
skills NNS N
of IN N
motivational JJ N
interviewing NN N
. . N

Change NN N
in IN N
behavioral JJ N
ratings NNS N
from IN N
pretest NN N
to TO N
post-test NN N
showed VBD N
significant JJ N
differences NNS N
in IN N
motivational JJ N
interviewing NN N
skills NNS N
between IN N
the DT N
experimental JJ N
and CC N
control NN N
groups NNS N
. . N

Obstetric NNP p
care NN p
practitioners NNS p
who WP N
viewed VBD N
the DT N
training NN N
video NN N
were VBD N
rated VBN N
as IN N
showing VBG N
greater JJR N
empathy NN o
, , N
minimizing VBG N
patient JJ o
defensiveness NN o
, , N
and CC N
supporting VBG o
women NNS o
's POS o
beliefs NNS o
in IN o
their PRP$ o
ability NN o
to TO o
change VB o
. . o

CONCLUSION NNP N
Obstetric NNP N
care NN N
practitioners NNS N
can MD N
improve VB N
their PRP$ N
alcohol NN N
intervention NN N
skills NNS N
through IN N
the DT N
use NN N
of IN N
a DT N
20-minute JJ N
videotaped JJ i
instruction NN i
in IN i
motivational JJ i
interviewing NN i
. . i

Clinicians NNPS N
who WP N
improve VBP N
their PRP$ N
skills NNS N
in IN N
motivational JJ N
interviewing NN N
can MD N
intervene VB N
more RBR N
effectively RB N
with IN N
their PRP$ N
drinking NN N
pregnant JJ N
patients NNS N
. . N

Using VBG N
motivational JJ i
interviewing NN i
with IN N
this DT N
population NN N
holds VBZ N
promise RB N
for IN N
helping VBG N
prevent JJ N
alcohol-related JJ N
health NN N
problems NNS N
. . N

-DOCSTART- -7655889- O O

Movement-related JJ i
potentials NNS i
in IN N
Parkinson NNP p
's POS p
disease NN p
. . p

Presence NNP N
and CC N
predictability NN N
of IN N
temporal JJ i
and CC i
spatial JJ i
cues NNS i
. . i

Activity NN N
of IN N
the DT N
supplementary JJ N
motor NN N
area NN N
may MD N
be VB N
inferred VBN N
from IN N
movement-related JJ i
potentials NNS i
( ( i
MRPs NNP i
) ) i
which WDT N
are VBP N
associated VBN N
with IN N
the DT N
preparation NN N
and CC N
execution NN N
of IN N
voluntary JJ N
, , N
or CC N
internally RB N
determined JJ N
movements NNS N
. . N

Supplementary NNP N
motor NN N
area NN N
activity NN N
may MD N
be VB N
abnormal JJ N
in IN N
Parkinson NNP p
's POS p
disease NN p
since IN N
its PRP$ N
major JJ N
input NN N
from IN N
the DT N
basal NN N
ganglia NN N
is VBZ N
disrupted VBN N
. . N

Investigation NN N
of IN N
the DT N
abnormalities NNS N
in IN N
supplementary JJ N
motor NN N
area NN N
activity NN N
associated VBN N
with IN N
movement NN N
deficits NNS N
in IN N
Parkinson NNP N
's POS N
disease NN N
may MD N
therefore VB N
reveal JJ N
functions NNS N
of IN N
the DT N
basal NN N
ganglia NN N
and CC N
the DT N
supplementary JJ N
motor NN N
area NN N
. . N

Movement-related JJ i
potentials NNS i
associated VBN i
with IN i
sequential JJ i
movements NNS i
were VBD i
investigated VBN i
under IN i
various JJ i
cueing VBG i
conditions NNS i
in IN N
Parkinson NNP p
's POS p
disease NN p
subjects NNS p
and CC p
age-matched JJ p
controls NNS i
. . i

In IN N
controls NNS N
, , N
MRPs NNP N
revealed VBD N
involvement NN N
of IN N
the DT N
supplementary JJ N
motor NN N
area NN N
in IN N
movements NNS N
which WDT N
can MD N
be VB N
internally RB N
determined VBN N
( ( i
non-cued JJ i
and CC N
externally RB i
cued VBN i
, , i
predictable JJ i
movements NNS N
, , N
but CC N
not RB i
unpredictable JJ i
movements NNS N
) ) N
. . N

In IN N
Parkinson NNP N
's POS N
disease NN N
, , N
however RB N
, , N
the DT N
supplementary JJ N
motor NN N
area NN N
was VBD N
only RB N
involved VBN N
in IN N
movements NNS N
which WDT N
must MD N
be VB N
internally RB N
determined VBN N
( ( i
non-cued JJ i
movements NNS N
, , N
but CC N
not RB i
externally RB i
cued VBN i
movements NNS N
) ) N
; : N
therefore RB N
impaired VBD N
internal JJ N
control NN N
mechanisms NNS N
, , N
operating VBG N
via IN N
the DT N
supplementary JJ N
motor NN N
area NN N
, , N
are VBP N
bypassed VBN N
when WRB N
external JJ i
cues NNS i
are VBP i
given VBN i
. . i

As IN N
a DT N
result NN N
, , N
Parkinson NNP p
's POS p
disease NN p
patients NNS p
are VBP N
more RBR N
reliant JJ N
on IN N
external JJ i
cues NNS i
and CC N
are VBP N
unable JJ N
to TO N
use VB N
predictive JJ N
models NNS N
to TO N
internally RB N
guide VB N
movement NN N
. . N

Supplementary NNP N
motor NN N
area NN N
involvement NN N
also RB N
relied VBD N
on IN N
the DT N
predictability NN N
( ( N
in IN N
controls NNS N
) ) N
or CC N
presence NN N
( ( N
in IN N
Parkinson NNP N
's POS N
disease NN N
) ) N
of IN N
timing VBG i
cues NNS i
and CC N
not RB i
spatial JJ i
cues NNS i
, , N
indicating VBG N
a DT N
role NN N
of IN N
the DT N
supplementary JJ N
motor NN N
area NN N
and CC N
basal NN N
ganglia NNS N
in IN N
the DT N
temporal JJ N
organizations NNS N
of IN N
sequential JJ N
movement NN N
rather RB N
than IN N
the DT N
programming NN N
of IN N
specific JJ N
movements NNS N
. . N

For IN N
non-cued JJ i
movements NNS N
, , N
abnormalities NNS N
in IN N
MRPs NNP N
for IN N
Parkinson NNP N
's POS N
disease NN N
subjects VBZ N
consisted VBN N
of IN N
delayed JJ o
MRP NNP o
onset NN o
and CC o
peak NN o
times NNS o
, , N
and CC N
prolonged VBD N
cortical JJ N
activity NN N
following VBG N
movement NN N
. . N

These DT N
observations NNS N
led VBD N
to TO N
a DT N
proposed VBN N
model NN N
of IN N
the DT N
interaction NN N
between IN N
the DT N
basal NN N
ganglia NN N
and CC N
the DT N
supplementary JJ N
motor NN N
area NN N
, , N
involving VBG N
the DT N
temporal JJ N
organization NN N
of IN N
voluntary JJ N
and CC N
internally RB N
determined VBD N
sequential JJ N
movements NNS N
. . N

-DOCSTART- -11550726- O O

Is VBZ N
psychotherapy VBN i
more RBR N
effective JJ N
when WRB N
therapists NNS p
disclose VB N
information NN N
about IN N
themselves PRP N
? . N
Theorists NNS N
have VBP N
long RB N
debated VBN N
the DT N
wisdom NN N
of IN N
therapists NNS p
disclosing VBG o
personal JJ o
information NN o
during IN p
psychotherapy NN i
. . i

Some DT N
observers NNS N
have VBP N
argued VBN N
that IN N
such JJ N
therapist JJ N
self-disclosure NN N
impedes NNS N
treatment NN N
, , N
whereas IN N
others NNS N
have VBP N
suggested VBN N
that IN N
it PRP N
enhances VBZ N
the DT N
effectiveness NN o
of IN o
therapy NN o
. . o

To TO N
test VB N
these DT N
competing VBG N
positions NNS N
, , N
therapists NNS p
at IN p
a DT p
university NN p
counseling NN p
center NN p
were VBD N
instructed VBN N
to TO N
increase VB i
the DT i
number NN i
of IN i
self-disclosures NNS i
they PRP N
made VBD N
during IN N
treatment NN i
of IN N
one CD p
client NN p
and CC N
refrain NN i
from IN i
making VBG i
self-disclosures NNS i
during IN i
treatment NN i
of IN N
another DT p
client NN p
. . p

Analyses NNS N
revealed VBD N
that IN N
clients NNS N
receiving VBG N
psychotherapy NN i
under IN N
conditions NNS N
of IN N
heightened VBN N
therapist NN i
disclosure NN i
not RB N
only RB N
reported VBD N
lower JJR o
levels NNS o
of IN o
symptom NN o
distress NN o
but CC N
also RB N
liked VBD o
their PRP$ o
therapist NN o
more RBR o
. . o

Such JJ N
findings NNS N
suggest VBP N
that IN N
self-disclosure NN N
by IN N
the DT N
therapist NN N
may MD N
improve VB N
both PDT N
the DT N
quality NN o
of IN o
the DT o
therapeutic JJ o
relationship NN o
and CC o
the DT o
outcome NN o
of IN o
treatment NN o
. . o

-DOCSTART- -23483320- O O

Effect NN N
of IN N
perioperative JJ N
parecoxib NN i
on IN N
postoperative JJ o
pain NN o
and CC o
local JJ o
inflammation NN o
factors NNS N
PGE2 NNP N
and CC N
IL-6 NNP N
for IN N
total JJ N
knee NN N
arthroplasty NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

To TO N
assess VB N
the DT N
efficacy NN o
of IN N
postoperative JJ N
pain NN N
management NN N
and CC N
the DT N
concentration NN N
change NN N
of IN N
PGE-2 NNP N
and CC N
IL-6 NNP N
of IN N
joint JJ N
fluid NN N
with IN N
parecoxib NN i
after IN N
postoperative JJ N
total JJ N
knee NN N
arthroplasty NN N
. . N

In IN N
the DT N
study NN N
, , N
100 CD p
patients NNS p
experiencing VBG p
primary JJ p
TKA NNP p
were VBD N
randomly RB N
divided VBN N
into IN N
study NN N
group NN N
, , N
receiving VBG N
parecoxib NN i
sodium NN i
( ( N
40 CD N
mg NN N
) ) N
intravenously RB N
( ( N
IV NNP N
) ) N
at IN N
the DT N
completion NN N
of IN N
surgery NN N
and CC N
once RB N
every DT N
12 CD N
h NN N
for IN N
totally RB N
6 CD N
times NNS N
postoperatively RB N
, , N
and CC i
placebo NN i
group NN i
, , N
receiving VBG i
normal JJ i
saline JJ i
2 CD i
mL NN N
IV NNP N
at IN N
the DT N
same JJ N
time NN N
points NNS o
. . o

Efficacy NN o
was VBD o
assessed VBN N
by IN N
total JJ o
amount NN o
of IN o
morphine NN o
consumed VBN o
, , o
pain VBP o
intensity NN o
, , o
range NN o
of IN o
motion NN o
( ( o
ROM NNP o
) ) o
, , o
the DT o
concentration NN o
change NN o
of IN o
PGE-2 NNP o
and CC o
IL-6 NNP o
of IN o
joint JJ o
fluid NN o
, , o
and CC o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
( ( o
PONV NNP o
) ) o
postoperatively RB o
. . N

Patients NNS N
in IN N
study NN N
group NN N
consumed VBD N
significantly RB N
less JJR o
morphine NN o
, , o
experienced VBD o
significant JJ N
less JJR o
pain NN o
scores NNS o
, , o
and CC o
obtained VBD N
significantly RB N
more RBR o
ROM NNP o
( ( o
P NNP o
< NNP N
0.01 CD N
) ) N
compared VBN N
with IN N
that DT N
in IN N
placebo NN N
group NN N
during IN N
3 CD N
days NNS N
postoperatively RB o
. . o

The DT o
concentration NN o
of IN o
PGE-2 NNP o
and CC o
IL-6 NNP o
of IN o
joint JJ o
fluid NN o
in IN N
study NN N
group NN N
are VBP N
significantly RB N
lower JJR N
than IN N
that DT N
in IN i
placebo NN i
group NN i
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
during IN N
24 CD N
h NNS N
postoperatively RB o
. . o

The DT o
overall JJ o
incidence NN o
of IN o
PONV NNP o
was VBD N
low JJ N
and CC N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
the DT N
perioperative JJ N
administration NN i
of IN i
parecoxib NN i
after IN i
primary JJ i
TKA NNP N
resulted VBD N
in IN N
significantly RB N
improved VBN N
postoperative JJ o
analgesic JJ o
management NN o
as IN o
defined VBN o
by IN N
reduction NN N
in IN N
opioid JJ N
requirement NN o
, , o
lower JJR o
pain NN o
scores NNS o
and CC o
ROM NNP o
, , o
and CC N
significantly RB o
lowered VBD o
local JJ o
inflammation NN o
factors NNS o
PGE2 NNP o
and CC o
IL-6 NNP o
. . N

-DOCSTART- -8419816- O O

Effect NN N
of IN N
ranitidine NN i
and CC i
amoxicillin JJ i
plus CC i
metronidazole JJ i
on IN N
the DT N
eradication NN N
of IN N
Helicobacter NNP o
pylori NN o
and CC o
the DT o
recurrence NN o
of IN o
duodenal JJ o
ulcer NN o
. . o

BACKGROUND NNP N
Persistent NNP N
infection NN N
with IN N
Helicobacter NNP N
pylori NN N
is VBZ N
associated VBN N
with IN N
the DT N
recurrence NN N
of IN N
duodenal JJ N
ulcer NN N
. . N

Whether IN N
the DT N
efficacy NN N
of IN N
bismuth NN N
therapy NN N
in IN N
reducing VBG N
the DT N
rate NN N
of IN N
recurrence NN N
of IN N
duodenal JJ N
ulcer NN N
is VBZ N
due JJ N
to TO N
its PRP$ N
antimicrobial JJ N
effects NNS N
on IN N
H. NNP o
pylori NN o
or CC N
to TO N
a DT N
direct JJ N
protective JJ N
action NN N
on IN N
the DT N
mucosa NN N
is VBZ N
still RB N
a DT N
matter NN N
of IN N
debate NN N
. . N

METHODS NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
the DT N
eradication NN N
of IN N
H. NNP N
pylori NN o
on IN N
the DT N
recurrence NN N
of IN N
duodenal JJ N
ulcer NN N
, , N
we PRP N
treated VBD N
104 CD p
patients NNS p
with IN p
H. NNP p
pylori FW p
infection NN p
and CC p
recurrent JJ p
duodenal JJ p
ulcer NN p
with IN N
either DT N
amoxicillin NN i
( ( N
750 CD N
mg NN N
three CD N
times NNS N
daily RB N
) ) N
plus CC N
metronidazole JJ i
( ( N
500 CD N
mg NN N
three CD N
times NNS N
daily RB N
) ) N
or CC N
identical-appearing JJ i
placebos NN i
, , N
given VBN N
orally RB N
for IN N
12 CD N
days NNS N
. . N

All DT N
patients NNS N
also RB N
received VBD N
ranitidine NN i
( ( N
300 CD N
mg RB N
each DT N
night NN N
) ) N
for IN N
6 CD N
or CC N
10 CD N
weeks NNS N
. . N

Endoscopy NNP N
was VBD N
performed VBN N
before IN N
treatment NN N
and CC N
periodically RB N
during IN N
follow-up NN N
for IN N
up IN N
to TO N
12 CD N
months NNS N
after IN N
healing VBG N
. . N

RESULTS NNP N
Among IN N
the DT N
52 CD p
patients NNS p
given VBN p
antibiotics NNS i
, , N
H. NNP o
pylori NN o
was VBD N
eradicated VBN o
in IN N
46 CD N
, , N
as IN N
compared VBN N
with IN N
1 CD N
of IN N
the DT N
52 CD N
given VBN N
placebo NN i
( ( N
89 CD N
percent NN N
vs. FW N
2 CD N
percent NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

After IN N
six CD N
weeks NNS N
, , N
the DT N
ulcers NNS o
were VBD N
healed VBN o
in IN N
48 CD N
patients NNS N
given VBN N
antibiotics NNS i
and CC N
39 CD N
given VBN N
placebo NN i
( ( N
92 CD N
percent NN N
vs. FW N
75 CD N
percent NN N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

Side JJ N
effects NNS N
, , N
mainly RB N
diarrhea NN o
, , N
occurred VBD N
in IN N
15 CD N
percent NN N
of IN N
the DT N
patients NNS N
given VBN N
antibiotics NNS i
. . i

Among IN N
the DT N
patients NNS N
followed VBD N
up RP N
for IN N
12 CD N
months NNS N
, , N
duodenal JJ o
ulcers NNS o
recurred VBD o
in IN N
4 CD N
of IN N
50 CD N
patients NNS N
given VBN N
antibiotics NNS i
and CC N
42 CD N
of IN N
49 CD N
given VBN N
placebo NN i
( ( N
8 CD N
percent NN N
vs. FW N
86 CD N
percent NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Ulcers NNS o
recurred VBD o
in IN N
1 CD N
of IN N
46 CD N
patients NNS N
in IN N
whom WP N
H. NNP N
pylori NN N
had VBD N
been VBN N
eradicated VBN N
, , N
as IN N
compared VBN N
with IN N
45 CD N
of IN N
53 CD N
in IN N
whom WP N
H. NNP o
pylori NN o
persisted VBD N
( ( N
2 CD N
percent NN N
vs. FW N
85 CD N
percent NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
recurrent JJ p
duodenal JJ p
ulcer NN p
, , N
eradication NN o
of IN o
H. NNP o
pylori NN o
by IN N
a DT N
regimen NNS N
that WDT N
does VBZ N
not RB N
have VB N
any DT N
direct JJ N
action NN N
on IN N
the DT N
mucosa NN N
is VBZ N
followed VBN N
by IN N
a DT N
marked JJ N
reduction NN N
in IN N
the DT N
rate NN N
of IN N
recurrence NN N
, , N
suggesting VBG N
a DT N
causal JJ N
role NN N
for IN N
H. NNP N
pylori NN N
in IN N
recurrent JJ N
duodenal JJ N
ulcer NN N
. . N

-DOCSTART- -12830748- O O

Clinic JJ N
visit NN N
and CC N
waiting NN N
: : N
patient JJ o
education NN o
and CC o
satisfaction NN o
. . o

Patients NNS i
who WP i
were VBD i
taught VBN i
about IN i
their PRP$ i
health NN i
problems NNS i
while IN i
waiting VBG i
in IN i
the DT i
clinic NN i
( ( p
n JJ p
= NNP p
104 CD p
) ) p
were VBD N
significantly RB N
more RBR N
satisfied JJ o
with IN o
the DT o
education NN o
received VBD N
during IN N
that DT N
visit NN N
than IN N
the DT N
control NN i
group NN i
( ( p
n JJ p
= NNP p
101 CD p
) ) p
. . p

The DT N
longer JJR N
patients NNS N
waited VBD N
in IN N
the DT N
clinic NN N
to TO N
see VB N
their PRP$ N
providers NNS N
, , N
the DT N
less JJR N
satisfied JJ o
they PRP N
were VBD N
with IN N
the DT N
clinic JJ N
visit NN N
. . N

-DOCSTART- -20367417- O O

Teriparatide NNP N
improves VBZ N
early JJ o
callus NN o
formation NN o
in IN N
distal JJ p
radial JJ p
fractures NNS p
. . p

BACKGROUND NNP N
Teriparatide NNP N
( ( N
parathyreoid JJ N
hormone NN N
; : N
PTH NNP N
1-34 CD N
) ) N
increases VBZ N
skeletal JJ N
mass NN N
in IN N
humans NNS N
and CC N
improves VBZ N
fracture NN N
healing VBG N
in IN N
animals NNS N
. . N

A DT N
recent JJ N
randomized JJ N
multicenter NN N
trial NN N
of IN N
nonoperated JJ p
distal JJ p
radial NN p
fractures NNS p
showed VBD N
a DT N
moderate JJ N
shortening NN N
of IN N
the DT N
time NN N
to TO N
restoration NN N
of IN N
cortical JJ N
continuity NN N
by IN N
treatment NN N
with IN N
20 CD i
microg NNS i
( ( i
low-dose JJ i
) ) i
teriparatide NN i
per IN i
day NN i
, , i
but CC i
not RB i
with IN i
40 CD i
microg NNS i
( ( i
high-dose JJ i
) ) i
. . N

As IN N
radiographic JJ N
cortical JJ N
continuity NN N
appears VBZ N
late RB N
in IN N
the DT N
healing NN N
process NN N
, , N
perhaps RB N
too RB N
late JJ N
for IN N
clinical JJ N
relevance NN N
, , N
we PRP N
studied VBD N
the DT N
qualitative JJ N
appearance NN N
of IN N
the DT N
callus JJ N
5 CD N
weeks NNS N
after IN N
fracture NN N
. . N

METHODS NNP N
One CD p
third NN p
of IN p
the DT p
patients NNS p
of IN p
the DT p
international JJ p
trial NN p
were VBD p
treated VBN p
at IN p
Link?ping NNP p
University NNP p
Hospital NNP p
. . p

The DT N
multicenter NN N
trial NN N
did VBD N
not RB N
evaluate VB N
early JJ N
callus NN N
formation NN N
. . N

We PRP N
therefore RB N
made VBD N
a DT N
blinded JJ N
qualitative JJ N
scoring NN N
of IN N
the DT N
callus NN N
at IN N
5 CD N
weeks NNS N
in IN N
our PRP$ p
27 CD p
patients NNS p
. . p

Callus NNP N
formation NN N
was VBD N
arbitrarily RB N
classified VBN N
as IN N
rich JJ N
, , N
intermediate JJ N
, , N
or CC N
poor JJ N
. . N

RESULTS NNP N
9 CD N
patients NNS N
were VBD N
classified VBN N
as IN o
rich JJ o
( ( N
none NN N
had VBD N
received VBN N
placebo RB N
, , N
3 CD N
low-dose JJ N
teriparatide NN N
, , N
and CC N
6 CD N
high-dose JJ N
teriparatide NN N
) ) N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN o
intermediate NN o
( ( N
1 CD N
had VBD N
received VBN N
placebo RB N
, , N
5 CD N
low-dose JJ N
, , N
and CC N
3 CD N
high-dose JJ N
) ) N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN o
poor JJ o
( ( N
7 CD N
had VBD N
received VBN N
placebo RB N
, , N
1 CD N
low-dose JJ N
, , N
and CC N
1 CD N
high-dose NN N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

INTERPRETATION NN N
This DT N
is VBZ N
a DT N
post NN N
hoc NN N
subgroup NN N
analysis NN N
of IN N
an DT N
outcome NN N
variable NN N
, , N
which WDT N
was VBD N
not RB N
in IN N
the DT N
official JJ N
protocol NN N
. . N

The DT N
results NNS N
must MD N
therefore RB N
be VB N
interpreted VBN N
with IN N
caution NN N
. . N

However RB N
, , N
in IN N
combination NN N
with IN N
the DT N
results NNS N
of IN N
the DT N
larger JJR N
trial NN N
, , N
the DT N
data NN N
suggest NN N
that IN N
radiographic JJ N
quality NN N
at IN N
an DT N
early JJ N
time NN N
point NN N
might MD N
be VB N
a DT N
sensitive JJ N
variable NN N
, , N
perhaps RB N
better JJR N
than IN N
time NN N
to TO N
cortical JJ N
continuity NN N
. . N

Moreover RB N
, , N
teriparatide RB i
appeared VBD N
to TO N
improve VB o
early JJ o
callus NN o
formation NN o
in IN p
distal JJ p
radial JJ p
fractures NNS p
. . p

-DOCSTART- -2653041- O O

Treatments NNS N
of IN N
preterm JJ p
premature JJ p
rupture NN p
of IN p
the DT p
membranes NNS p
: : p
a DT N
meta-analysis NN N
. . N

The DT N
objective NN N
of IN N
this DT N
overview NN N
was VBD N
to TO N
critically RB N
evaluate VB N
published VBN N
randomized JJ N
controlled VBN N
trials NNS N
on IN N
treatments NNS N
in IN N
preterm JJ p
premature JJ p
rupture NN p
of IN p
the DT p
membranes NNS p
. . p

The DT N
Oxford NNP N
data NN N
base NN N
on IN N
perinatal JJ N
trials NNS N
, , N
MEDLINE NNP N
, , N
Excerpta NNP N
Medica NNP N
, , N
and CC N
Index NNP N
Medicus NNP N
were VBD N
searched VBN N
. . N

Through IN N
primary JJ N
and CC N
secondary JJ N
review NN N
with IN N
preset JJ N
inclusion NN N
criteria NNS N
, , N
two CD N
independent JJ N
judges NNS N
identified VBD N
27 CD p
randomized VBN p
controlled VBN p
trials NNS p
, , p
of IN p
which WDT p
13 CD p
met VBD p
inclusion NN p
criteria NNS p
. . p

The DT N
quality NN N
of IN N
these DT N
randomized VBN N
controlled VBD N
trials NNS N
was VBD N
scored VBN N
. . N

Five CD p
randomized VBN p
controlled VBN N
trials NNS N
regarding VBG N
antenatal JJ N
use NN N
of IN N
corticosteroids NNS i
to TO N
prevent VB N
respiratory JJ o
distress JJ o
syndrome NN o
could MD N
be VB N
combined VBN N
meta-analytically RB N
and CC N
showed VBD N
a DT N
reduction NN N
in IN N
respiratory NN o
distress NN o
syndrome NN o
in IN N
the DT N
treatment NN N
group NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
no DT N
significant JJ N
reduction NN N
in IN N
respiratory NN o
distress NN o
syndrome NN o
( ( N
p JJ N
= NNP N
0.286 CD N
) ) N
was VBD N
found VBN N
after IN N
one CD N
study NN N
, , N
with IN N
the DT N
lowest JJS N
quality NN N
score NN N
, , N
was VBD N
excluded VBN N
. . N

A DT N
significant JJ N
increase NN N
in IN N
endometritis NN o
and CC N
a DT N
trend NN N
toward IN N
an DT N
increase NN N
in IN N
neonatal JJ o
infections NNS o
and CC o
cesarean JJ o
section NN o
rates NNS o
were VBD N
noted VBN N
with IN N
treatment NN N
. . N

Tocolysis NN i
, , i
prophylactic JJ i
antibiotics NNS i
, , N
and CC N
other JJ N
interventions NNS N
studied VBN N
were VBD N
not RB N
found VBN N
to TO N
be VB N
of IN N
proved JJ N
benefit NN N
and CC N
therefore RB N
should MD N
not RB N
be VB N
used VBN N
outside IN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

-DOCSTART- -125133- O O

Anabolic JJ i
steroids NNS i
in IN N
athelics NNS N
: : N
crossover RB N
double-blind VBP N
trial NN N
on IN N
weightlifters NNS p
. . p

Thirteen NNP p
experienced VBD p
male JJ p
weightlifters NNS p
taking VBG p
high-protein JJ p
diets NNS p
and CC p
regular JJ p
exercise NN p
took VBD N
part NN N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
of IN N
methandienone NN i
10 CD N
or CC N
25 CD N
mg/day NN N
to TO N
seeif VB N
the DT N
drug NN N
improved VBD N
athletic JJ o
performance NN o
. . o

Their PRP$ N
improvemments NNS N
were VBD N
significantly RB N
greater JJR o
on IN N
methandienone NN i
than IN N
on IN N
placebo NN i
; : i
their PRP$ N
body NN o
weights NNS o
rose VBD o
( ( N
though IN N
this DT N
seemed VBD N
to TO N
be VB N
associated VBN N
with IN N
water NN N
retention NN N
) ) N
; : N
and CC N
systolic JJ o
blood NN o
pressure NN o
rose VBD o
significantly RB N
. . N

Methandienone NNP i
caused VBD N
many JJ N
side NN o
effects NNS o
, , N
and CC N
three CD N
men NNS N
had VBD N
to TO N
withdraw VB N
because IN N
of IN N
them PRP N
. . N

All DT N
side NN o
effects NNS o
disappeared VBD N
after IN N
the DT N
drug NN N
was VBD N
stopped VBN N
. . N

Anabolic JJ i
steroids NNS i
are VBP N
effective JJ N
only RB N
when WRB N
given VBN N
combination NN N
with IN N
exercise NN N
and CC N
high-protein JJ N
diet NN N
. . N

We PRP N
deprecate VBP N
their PRP$ N
use NN N
in IN N
athletics NNS N
but CC N
can MD N
suggest VB N
no DT N
way NN N
of IN N
stopping VBG N
it PRP N
. . N

-DOCSTART- -19243606- O O

Randomised VBN N
Phase NNP N
I/II NNP N
trial NN N
assessing VBG N
the DT N
safety NN o
and CC N
efficacy NN o
of IN N
radiolabelled JJ i
anti-carcinoembryonic JJ i
antigen NN i
I PRP i
( ( i
131 CD i
) ) i
KAb201 NNP i
antibodies NNS N
given VBN N
intra-arterially RB N
or CC N
intravenously RB N
in IN N
patients NNS p
with IN p
unresectable JJ p
pancreatic JJ p
adenocarcinoma NN p
. . p

BACKGROUND NNP N
Advanced NNP p
pancreatic JJ p
cancer NN p
has VBZ N
a DT N
poor JJ N
prognosis NN N
, , N
and CC N
the DT N
current JJ N
standard NN N
of IN N
care NN N
( ( i
gemcitabine NN i
based VBN i
chemotherapy NN i
) ) i
provides VBZ N
a DT N
small JJ N
survival NN N
advantage NN N
. . N

However RB N
the DT N
drawback NN N
is VBZ N
the DT N
accompanying VBG N
systemic JJ N
toxicity NN N
, , N
which WDT N
targeted VBD N
treatments NNS N
may MD N
overcome VB N
. . N

This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
safety NN o
and CC N
tolerability NN o
of IN N
KAb201 NNP i
, , N
an DT N
anti-carcinoembryonic JJ N
antigen NN N
monoclonal JJ N
antibody NN N
, , N
labelled VBD N
with IN N
I PRP N
( ( N
131 CD N
) ) N
in IN N
pancreatic JJ N
cancer NN N
( ( N
ISRCTN NNP N
16857581 CD N
) ) N
. . N

METHODS JJ N
Patients NNS p
with IN p
histological/cytological JJ p
proven NN p
inoperable JJ p
adenocarcinoma NN p
of IN p
the DT p
head NN p
of IN p
pancreas NNS p
were VBD p
randomised VBN p
to TO p
receive VB p
KAb NNP i
201 CD i
via IN N
either CC N
the DT N
intra-arterial JJ N
or CC N
intravenous JJ N
delivery NN N
route NN N
. . N

The DT N
dose JJ o
limiting NN o
toxicities NNS o
within IN N
each DT N
group NN N
were VBD N
determined VBN N
. . N

Patients NNS N
were VBD N
assessed VBN N
for IN N
safety NN o
and CC o
efficacy NN o
and CC N
followed VBD N
up RP N
until IN N
death NN N
. . N

RESULTS NNP N
Between NNP p
February NNP p
2003 CD p
and CC p
July NNP p
2005 CD p
, , p
25 CD p
patients NNS p
were VBD p
enrolled VBN p
. . p

Nineteen JJ p
patients NNS p
were VBD p
randomised VBN p
, , p
9 CD p
to TO p
the DT p
intravenous JJ p
and CC p
10 CD p
to TO p
the DT p
intra-arterial JJ p
arms NNS p
. . p

In IN N
the DT N
intra-arterial JJ N
arm NN N
, , N
dose VB N
limiting VBG N
toxicity NN o
was VBD N
seen VBN N
in IN N
2/6 CD N
( ( N
33 CD N
% NN N
) ) N
patients NNS N
at IN N
50 CD N
mCi NNS N
whereas RB N
in IN N
the DT N
intravenous JJ N
arm NN N
, , N
dose VB N
limiting VBG N
toxicity NN o
was VBD N
noted VBN N
in IN N
1/6 CD N
patients NNS N
at IN N
50 CD N
mCi NN N
, , N
but CC N
did VBD N
not RB N
occur VB N
at IN N
75 CD N
mCi NN N
( ( N
0/3 CD N
) ) N
.The CD N
overall JJ N
response NN o
rate NN o
was VBD N
6 CD N
% NN N
( ( N
1/18 CD N
) ) N
. . N

Median JJ o
overall JJ o
survival NN o
was VBD N
5.2 CD N
months NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
= VBD N
3.3 CD N
to TO N
9 CD N
months NNS N
) ) N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
intravenous JJ N
and CC N
intra-arterial JJ N
arms NNS N
( ( N
log JJ N
rank NN N
test NN N
p NN N
= NNP N
0.79 CD N
) ) N
. . N

One CD N
patient NN N
was VBD N
still RB N
alive JJ N
at IN N
the DT N
time NN N
of IN N
this DT N
analysis NN N
. . N

CONCLUSION NNP N
Dose NNP o
limiting VBG o
toxicity NN o
for IN N
KAb201 NNP i
with IN N
I PRP N
( ( N
131 CD N
) ) N
by IN N
the DT N
intra-arterial JJ N
route NN N
was VBD N
50 CD N
mCi NNS N
, , N
while IN N
dose JJ o
limiting VBG o
toxicity NN o
was VBD N
not RB N
reached VBN N
in IN N
the DT N
intravenous JJ N
arm NN N
. . N

-DOCSTART- -15616772- O O

Efficiency NN o
of IN i
adjuvant JJ i
immunochemotherapy NN i
following VBG N
curative JJ N
resection NN N
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
gastric JJ p
cancer NN p
. . p

BACKGROUND NNP N
Despite IN N
curative JJ N
resection NN N
, , N
50 CD N
% NN N
-90 CD N
% NN N
of IN N
gastric JJ p
cancer NN p
patients NNS p
die VBP N
of IN N
disease NN o
relapse NN o
. . o

Although IN N
some DT N
clinical JJ N
trials NNS N
have VBP N
indicated VBN N
that IN N
chemotherapy NN N
and CC N
immunochemotherapy NN N
may MD N
be VB N
effective JJ N
modalities NNS N
, , N
more RBR N
recent JJ N
studies NNS N
have VBP N
not RB N
been VBN N
able JJ N
to TO N
define VB N
the DT N
standard JJ N
treatment NN N
for IN N
advanced JJ p
gastric JJ p
cancer NN p
. . p

The DT N
present JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ i
immunochemotherapy NN i
with IN i
the DT i
use NN i
of IN i
BCG NNP i
( ( i
bacille IN i
Calmette-Guerin NNP i
) ) i
and CC i
FAM NNP i
( ( i
5-fluorouracil JJ i
, , i
adriamycin JJ i
, , i
mitomycin JJ i
C NNP i
) ) i
chemotherapy NN i
on IN N
the DT N
survival NN o
of IN o
patients NNS o
with IN p
locally RB p
advanced VBN p
resectable JJ p
gastric JJ p
cancer NN p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
156 CD p
patients NNS p
with IN p
stage NN p
III NNP p
or CC p
IV NNP p
gastric JJ p
cancer NN p
who WP p
had VBD p
undergone JJ p
curative JJ p
resection NN p
were VBD N
randomly RB i
assigned VBN i
to TO i
three CD i
treatment NN i
groups NNS i
: : i
BCG NNP i
+ NNP i
FAM NNP i
( ( i
immunochemotherapy NN i
) ) i
, , i
FAM NNP i
( ( i
chemotherapy NN i
) ) i
, , i
and CC i
control NN i
( ( i
surgery NN i
only RB i
) ) i
. . i

Treatment NN i
was VBD i
continued VBN i
for IN i
2 CD i
years NNS i
or CC i
until IN i
death NN i
. . i

Further NNP i
postsurgical JJ i
follow VBP i
up RP i
was VBD i
carried VBN i
on IN i
for IN i
up IN i
to TO i
10 CD i
years NNS i
. . i

RESULTS VB N
Overall JJ N
10-year JJ o
survival NN o
was VBD N
47.1 CD N
% NN N
for IN N
the DT N
immunochemotherapy NN N
group NN N
( ( N
P NNP N
< VBZ N
0.037 CD N
vs NN N
FAM NNP i
and CC N
P NNP N
< NNP N
0.0006 CD N
vs NNS N
control NN N
) ) N
, , N
30 CD N
% NN N
for IN N
the DT N
chemotherapy NN i
group NN N
( ( N
vs FW N
control NN N
, , N
NS NNP N
) ) N
, , N
and CC N
15.2 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
. . N

In IN N
patients NNS p
with IN p
pT2/T3 JJ p
primary JJ p
tumors NNS p
, , N
10-year JJ o
survival NN o
was VBD N
55.3 CD N
% NN N
for IN N
BCG NNP i
+ NNP i
FAM NNP i
vs VBD N
28.2 CD N
% NN N
for IN N
FAM NNP N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
14.6 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.00018 CD N
) ) N
. . N

BCG NNP i
+ NNP i
FAM NNP i
significantly RB N
improved VBD N
the DT N
survival NN o
of IN o
patients NNS o
with IN p
intestinal-type JJ p
but CC p
not RB p
diffuse-type JJ p
cancer NN p
. . p

Immunochemotherapy NNP i
was VBD N
well RB N
tolerated VBN N
. . N

CONCLUSION VB N
This DT N
study NN N
, , N
based VBN N
on IN N
a DT N
limited JJ p
number NN p
of IN p
patients NNS p
, , N
indicates VBZ N
that IN N
adjuvant JJ N
immunochemotherapy NN N
( ( N
BCG NNP N
+ NNP N
FAM NNP N
) ) N
may MD N
prolong VB N
the DT N
survival NN o
of IN N
gastric JJ p
cancer NN p
patients NNS p
after IN p
curative JJ p
gastrectomy NN p
; : p
in IN p
particular JJ p
, , p
in IN p
patients NNS p
with IN p
pT2/T3 JJ p
tumors NNS p
and CC p
intestinal-type JJ p
primary JJ p
tumors NNS p
. . p

There EX N
was VBD N
no DT N
survival JJ o
benefit NN o
from IN N
FAM NNP i
adjuvant JJ i
chemotherapy NN i
. . i

-DOCSTART- -12193353- O O

Local JJ N
warming NN N
and CC N
insertion NN N
of IN N
peripheral JJ N
venous JJ N
cannulas NNS N
: : N
single JJ N
blinded VBD N
prospective JJ N
randomised VBN N
controlled VBN N
trial NN N
and CC N
single JJ N
blinded VBD N
randomised VBN N
crossover RB N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
local JJ N
warming NN N
of IN N
the DT N
lower JJR N
arm NN N
and CC N
hand NN N
facilitates NNS N
peripheral VBP o
venous JJ o
cannulation NN o
. . o

DESIGN NNP N
Single NNP N
blinded VBD N
prospective JJ N
randomised VBN N
controlled VBN N
trial NN N
and CC N
single JJ N
blinded VBD N
randomised VBN N
crossover RB N
trial NN N
. . N

SETTING NNP N
Neurosurgical JJ p
unit NN p
and CC p
haematology NN p
ward NN p
of IN p
university NN p
hospital NN p
. . p

PARTICIPANTS CC N
100 CD p
neurosurgical JJ p
patients NNS p
and CC p
40 CD p
patients NNS p
with IN p
leukaemia NNS p
who WP p
required VBD p
chemotherapy NN p
. . p

INTERVENTIONS NNP N
Neurosurgical JJ N
patients NNS N
' POS N
hands NNS i
and CC i
forearms NNS i
were VBD i
covered VBN i
for IN i
15 CD i
minutes NNS i
with IN i
a DT i
carbon NN i
fibre NN i
heating VBG i
mitt NN i
. . i

Patients NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
active JJ i
warming NN i
at IN i
52 CD i
degrees NNS i
C NNP i
or CC i
passive JJ i
insulation NN i
( ( N
heater NN N
not RB N
activated VBN N
) ) N
. . N

The DT N
same JJ N
warming NN N
system NN N
was VBD N
used VBN N
for IN N
10 CD N
minutes NNS N
in IN N
patients NNS N
with IN N
leukaemia NN N
. . N

They PRP N
were VBD N
assigned VBN N
randomly RB N
to TO N
active JJ N
warming NN N
or CC N
passive JJ N
insulation NN N
on IN N
day NN N
1 CD N
and CC N
given VBN N
alternative JJ N
treatment NN N
during IN N
the DT N
subsequent JJ N
visit NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
PRIMARY NNP N
: : N
success NN o
rate NN o
for IN o
insertion NN o
of IN o
18 CD o
gauge NN o
cannula NN o
into IN o
vein NN o
on IN o
back NN o
of IN o
hand NN o
. . o

SECONDARY NN N
: : N
time NN o
required VBN o
for IN o
successful JJ o
cannulation NN o
. . o

RESULTS NNP N
In IN N
neurosurgical JJ N
patients NNS N
, , N
it PRP N
took VBD N
36 CD N
seconds NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
31 CD N
to TO N
40 CD N
seconds NNS N
) ) N
to TO N
insert VB o
a DT o
cannula NN o
in IN N
the DT N
active JJ N
warming NN N
group NN N
and CC N
62 CD N
( ( N
50 CD N
to TO N
74 CD N
) ) N
seconds NNS N
in IN N
the DT N
passive JJ N
insulation NN N
group NN N
( ( N
P=0.002 NNP N
) ) N
. . N

Three NNP N
( ( N
6 CD N
% NN N
) ) N
first RB N
attempts VBZ N
failed VBN o
in IN N
the DT N
active JJ N
warming VBG N
group NN N
compared VBN N
with IN N
14 CD N
( ( N
28 CD N
% NN N
) ) N
in IN N
the DT N
passive JJ N
insulation NN N
group NN N
( ( N
P=0.008 NNP N
) ) N
. . N

The DT N
crossover NN N
study NN N
in IN N
patients NNS N
with IN N
leukaemia NN N
showed VBD N
that IN N
insertion NN o
time NN o
was VBD N
reduced VBN N
by IN N
20 CD N
seconds NNS N
( ( N
8 CD N
to TO N
32 CD N
, , N
P=0.013 NNP N
) ) N
with IN N
active JJ N
warming NN N
and CC N
that IN N
failure NN o
rates NNS o
at IN o
first JJ o
attempt NN o
were VBD N
6 CD N
% NN N
with IN N
warming VBG N
and CC N
30 CD N
% NN N
with IN N
passive JJ N
insulation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Local NNP N
warming VBG N
facilitates VBZ N
the DT N
insertion NN o
of IN o
peripheral JJ o
venous JJ o
cannulas NNS o
, , N
reducing VBG N
both DT N
time NN o
and CC o
number NN o
of IN o
attempts NNS o
required VBN o
. . o

This DT N
may MD N
decrease VB N
the DT N
time NN o
staff NN N
spend VBP N
inserting VBG o
cannulas NN o
, , N
reduce VB N
supply NN o
costs NNS o
, , N
and CC N
improve VB N
patient JJ N
satisfaction NN N
. . N

-DOCSTART- -15889546- O O

Automatic JJ p
detection NN p
of IN p
red JJ p
lesions NNS p
in IN p
digital JJ p
color NN p
fundus NN p
photographs NN p
. . p

The DT N
robust JJ N
detection NN i
of IN i
red JJ o
lesions NNS o
in IN i
digital JJ i
color NN i
fundus NN i
photographs NN i
is VBZ N
a DT N
critical JJ N
step NN N
in IN N
the DT N
development NN N
of IN N
automated JJ N
screening VBG N
systems NNS N
for IN N
diabetic JJ p
retinopathy NN p
. . p

In IN N
this DT N
paper NN N
, , N
a DT N
novel NN i
red JJ i
lesion NN i
detection NN i
method NN i
is VBZ N
presented VBN N
based VBN N
on IN N
a DT N
hybrid JJ N
approach NN N
, , N
combining VBG N
prior JJ N
works NNS N
by IN N
Spencer NNP N
et CC N
al NN N
. . N

( ( N
1996 CD N
) ) N
and CC N
Frame NNP N
et NNP N
al NN N
. . N

( ( N
1998 CD N
) ) N
with IN N
two CD N
important JJ N
new JJ N
contributions NNS N
. . N

The DT N
first JJ N
contribution NN N
is VBZ N
a DT N
new JJ N
red JJ i
lesion NN i
candidate NN i
detection NN i
system NN i
based VBN N
on IN N
pixel JJ N
classification NN N
. . N

Using VBG N
this DT N
technique NN N
, , N
vasculature NN o
and CC o
red JJ o
lesions NNS o
are VBP N
separated VBN N
from IN N
the DT N
background NN N
of IN N
the DT N
image NN N
. . N

After IN N
removal NN N
of IN N
the DT N
connected JJ N
vasculature NN N
the DT N
remaining VBG N
objects NNS N
are VBP N
considered VBN N
possible JJ N
red JJ N
lesions NNS N
. . N

Second NNP N
, , N
an DT N
extensive JJ N
number NN N
of IN N
new JJ N
features NNS N
are VBP N
added VBN N
to TO N
those DT N
proposed VBN N
by IN N
Spencer-Frame NNP N
. . N

The DT N
detected JJ N
candidate NN N
objects NNS N
are VBP N
classified VBN N
using VBG N
all DT N
features NNS N
and CC N
a DT N
k-nearest JJ N
neighbor NN N
classifier NN N
. . N

An DT N
extensive JJ N
evaluation NN N
was VBD N
performed VBN N
on IN N
a DT N
test NN N
set NN N
composed VBN N
of IN N
images NNS N
representative NN N
of IN N
those DT N
normally RB N
found VBN N
in IN N
a DT N
screening NN N
set NN N
. . N

When WRB N
determining VBG N
whether IN N
an DT N
image NN N
contains VBZ N
red JJ o
lesions NNS o
the DT N
system NN N
achieves VBZ N
a DT N
sensitivity NN o
of IN N
100 CD N
% NN N
at IN N
a DT N
specificity NN N
of IN N
87 CD N
% NN N
. . N

The DT N
method NN N
is VBZ N
compared VBN N
with IN N
several JJ N
different JJ N
automatic JJ N
systems NNS N
and CC N
is VBZ N
shown VBN N
to TO N
outperform VB N
them PRP N
all DT N
. . N

Performance NNP o
is VBZ N
close RB N
to TO N
that DT N
of IN N
a DT N
human JJ N
expert NN N
examining VBG N
the DT N
images NNS N
for IN N
the DT N
presence NN N
of IN N
red JJ N
lesions NNS N
. . N

-DOCSTART- -14670288- O O

The DT N
efficacy NN N
of IN N
sublingual JJ i
immunotherapy NN i
for IN N
respiratory NN N
allergy NN N
is VBZ N
not RB N
affected VBN N
by IN N
different JJ N
dosage NN N
regimens NNS N
in IN N
the DT N
induction NN N
phase NN N
. . N

BACKGROUND NNP N
Sublingual NNP i
administration NN i
of IN i
allergens NNS i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
alternative NN N
to TO N
subcutaneous JJ N
immunotherapy NN N
in IN N
patients NNS p
with IN p
respiratory JJ p
allergies NNS p
. . p

A DT N
drawback NN N
to TO N
this DT N
therapeutic JJ N
approach NN N
is VBZ N
the DT N
relatively RB N
long JJ N
and CC N
complex JJ N
management NN N
of IN N
the DT N
induction NN N
phase NN N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
determine VB N
whether IN N
different JJ N
induction NN N
regimens NNS N
affect VBP N
the DT N
outcome NN N
of IN N
sublingual JJ i
immunotherapy NN i
. . i

METHODS NNP N
AND CC N
RESULTS NNP N
Adult NNP p
and CC p
pediatric JJ p
patients NNS p
with IN p
allergic JJ p
rhinoconjunctivitis NN p
and/or NN p
asthma NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Ten CD p
subjects VBZ p
served VBN N
as IN N
controls NNS N
and CC N
received VBN N
symptomatic JJ i
treatments NNS i
. . i

Forty-three JJ p
subjects NNS p
were VBD N
allocated VBN N
to TO N
sublingual JJ i
immunotherapy NN i
, , i
with IN i
three CD i
different JJ i
induction NN i
protocols NNS i
( ( i
8- CD i
, , i
15- CD i
and CC i
20-day JJ i
, , i
respectively RB i
) ) i
. . N

Symptom NNP o
and CC o
medication NN o
scores NNS o
, , o
skin JJ o
test NN o
results NNS o
and CC o
( ( o
in IN o
asthmatic JJ o
patients NNS o
) ) o
FEV1 NNP o
values NNS o
were VBD N
monitored VBN N
for IN N
two CD N
years NNS N
. . N

Adverse JJ o
effects NNS o
were VBD N
recorded VBN N
. . N

All DT N
induction NN N
regimens NNS N
produced VBD N
a DT N
significant JJ o
improvement NN o
in IN o
symptom NN o
and CC o
medication NN o
usage NN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
; : N
skin JJ o
test NN o
scores NNS o
decreased VBN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC N
FEV1 NNP o
improved VBD o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
symptom NN o
and CC o
skin JJ o
test NN o
scores NNS o
did VBD o
not RB o
significantly RB N
change VBP o
in IN N
controls NNS N
. . N

No DT o
relevant JJ N
adverse JJ o
effects NNS o
were VBD N
observed VBN N
with IN N
any DT N
of IN N
the DT N
induction NN N
regimens VBZ N
. . N

CONCLUSIONS NNP N
For IN N
patients NNS p
with IN p
respiratory JJ p
allergies NNS p
, , N
sublingual JJ i
immunotherapy NN i
with IN N
an DT N
8-day JJ N
induction NN N
protocol NN N
is VBZ N
safe JJ N
and CC N
effective JJ N
. . N

Our PRP$ N
results NNS N
encourage VB N
the DT N
usage NN N
of IN N
shorter JJR N
induction NN N
regimens NNS N
, , N
which WDT N
produce VBP N
better JJR N
compliance NN N
with IN N
this DT N
therapy NN N
. . N

-DOCSTART- -11191952- O O

[ JJ N
Diphtheria NNP N
antitoxin NN N
level NN N
2 CD N
years NNS N
after IN N
booster NN i
vaccination NN i
] NNP i
. . N

In IN N
a DT N
prospective JJ N
, , N
controlled VBN N
, , N
randomized VBN N
, , N
multicenter RBR N
study VBP N
the DT N
immunogenicity NN N
of IN N
a DT N
single JJ N
( ( N
day NN N
0 CD N
) ) N
and CC N
two CD N
( ( N
day NN N
0 CD N
, , N
28 CD N
) ) N
booster NN i
vaccination NN i
against IN i
diphtheria NN i
were VBD N
compared VBN N
in IN N
subjects NNS p
who WP p
had VBD p
received VBN p
their PRP$ p
last JJ p
diphtheria NN i
vaccination NN i
more JJR p
than IN p
10 CD p
years NNS p
ago RB p
. . p

Both DT N
short-term JJ N
and CC N
long-term JJ N
immunogenicity NN N
was VBD N
assessed VBN N
by IN N
determining VBG N
diphtheria NN o
antitoxin NN o
levels NNS o
four CD N
weeks NNS N
after IN N
vaccination NN i
and CC N
after IN N
one CD N
and CC N
two CD N
years NNS N
. . N

102 CD p
subjects NNS p
received VBD p
the DT p
first JJ i
booster NN i
vaccination NN i
, , i
and CC i
83 CD i
were VBD i
vaccinated VBN i
twice RB i
. . i

Prior NNP N
to TO N
the DT N
first JJ N
vaccination NN N
27 CD p
% NN p
of IN p
the DT p
subjects NNS p
had VBD N
a DT N
diphtheria NN o
antitoxin NN o
level NN o
below IN N
0.01 CD N
I.U./ml NNP N
; : N
after IN N
the DT N
first JJ N
booster NN N
only RB N
5 CD N
% NN N
were VBD N
unprotected VBN N
. . N

The DT N
second JJ N
booster NN i
did VBD N
not RB N
show VB N
a DT N
significant JJ N
effect NN N
, , N
however RB N
, , N
in IN N
1 CD N
of IN N
the DT N
5 CD N
subjects NNS N
who WP N
were VBD N
still RB N
unprotected VBN N
after IN N
the DT N
first JJ N
booster NN N
the DT N
second JJ N
elicited VBD N
an DT N
antitoxin JJ o
level NN o
of IN N
more JJR N
than IN N
0.01 CD N
I.U./ml NNP N
. . N

After IN N
one CD N
and CC N
two CD N
years NNS N
7 CD p
% NN p
and CC p
8 CD p
% NN p
of IN p
the DT p
subjects NNS p
had VBD N
diphtheria VBN o
antitoxin JJ o
level NN o
below IN N
0.01 CD N
I.U./ml NNP N
. . N

A NNP N
serological JJ N
effect NN N
of IN N
a DT N
second JJ N
booster NN i
vaccination NN i
four CD N
weeks NNS N
after IN N
the DT N
first JJ N
one NN N
could MD N
not RB N
be VB N
demonstrated VBN N
neither RB N
after IN N
one CD N
nor CC N
after IN N
two CD N
years NNS N
. . N

-DOCSTART- -12437457- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
to TO N
assess VB N
5 CD N
% NN N
imiquimod JJ i
cream NN i
for IN N
the DT N
treatment NN N
of IN p
multiple JJ o
actinic JJ o
keratoses NNS o
. . o

BACKGROUND NNP N
Actinic NNP o
keratoses NNS o
( ( o
AKs NNP o
) ) o
are VBP N
precancerous JJ N
epidermal JJ N
lesions NNS N
found VBD N
most JJS N
frequently RB N
on IN N
areas NNS N
of IN N
the DT N
skin NN N
exposed VBD N
to TO N
the DT N
sun NN N
. . N

Several JJ N
case NN N
studies NNS N
published VBN N
recently RB N
have VBP N
indicated VBN N
that IN N
5 CD N
% NN N
imiquimod JJ i
cream NN N
, , N
currently RB N
licensed VBN N
for IN N
the DT N
treatment NN N
of IN N
genital JJ N
warts NNS N
, , N
may MD N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
AK NNP N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
imiquimod NN N
for IN N
the DT N
treatment NN N
of IN N
AK NNP o
. . o

DESIGN NNP N
Patients NNPS N
in IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
applied VBD N
5 CD i
% NN i
imiquimod JJ i
cream NN i
or CC i
vehicle NN i
to TO i
AK NNP o
lesions NNS o
3 CD i
times NNS i
per IN i
week NN i
for IN i
a DT i
maximum NN i
of IN i
12 CD i
weeks NNS i
or CC i
until IN i
lesions NNS i
had VBD i
resolved VBN i
. . i

In IN N
the DT N
event NN N
of IN N
an DT N
adverse JJ N
reaction NN N
, , N
application NN N
of IN N
imiquimod NN i
was VBD N
reduced VBN N
to TO N
1 CD N
or CC N
2 CD N
times NNS N
per IN N
week NN N
. . N

Rest JJS N
periods NNS N
were VBD N
also RB N
allowed VBN N
if IN N
necessary JJ N
. . N

SETTING VB N
A DT p
specialized JJ p
outpatient NN p
dermatology NN p
clinic NN p
within IN p
a DT p
state-funded JJ p
hospital NN p
in IN p
Germany NNP p
. . p

PATIENTS VB p
The DT p
study NN p
population NN p
was VBD p
aged VBN p
45 CD p
to TO p
85 CD p
years NNS p
. . p

Of IN p
52 CD p
patients NNS p
screened VBD p
, , p
36 CD p
men NNS p
and CC p
women NNS p
with IN p
AK NNP p
confirmed VBN p
by IN p
histological JJ p
diagnosis NN p
were VBD p
enrolled VBN p
. . p

Patients NNS p
were VBD p
excluded VBN p
from IN p
the DT p
study NN p
if IN p
they PRP p
did VBD p
not RB p
have VB p
a DT p
histological JJ p
diagnosis NN p
for IN p
AK NNP p
, , p
if IN p
they PRP p
were VBD p
older JJR p
than IN p
85 CD p
years NNS p
, , p
or CC p
if IN p
they PRP p
did VBD p
not RB p
comply VB p
with IN p
the DT p
protocol NN p
. . p

All DT p
patients NNS p
had VBD p
responded VBN p
to TO p
a DT p
notice NN p
asking VBG p
for IN p
volunteers NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
number NN o
and CC o
appearance NN o
of IN o
lesions NNS o
were VBD N
evaluated VBN N
before RB N
, , N
during IN N
, , N
and CC N
after IN N
treatment NN N
. . N

All DT N
adverse JJ o
effects NNS o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Lesions NNP N
treated VBD N
with IN N
5 CD N
% NN N
imiquimod JJ i
cream NN i
were VBD N
clinically RB o
cleared VBN o
in IN N
21 CD N
( ( N
84 CD N
% NN N
) ) N
of IN N
25 CD N
patients NNS N
and CC N
partially RB o
cleared VBN o
in IN N
2 CD N
( ( N
8 CD N
% NN N
) ) N
. . N

Clearance NN o
was VBD N
histologically RB N
confirmed VBN N
2 CD N
weeks NNS N
after IN N
the DT N
last JJ N
application NN N
of IN N
imiquimod NN i
in IN N
all DT N
patients NNS N
clinically RB N
diagnosed VBN N
as IN N
lesion NN N
free NN N
. . N

Only RB N
10 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
imiquimod NN i
were VBD N
clinically RB N
diagnosed VBN N
with IN N
recurrence NN N
1 CD N
year NN N
after IN N
treatment NN N
. . N

No DT N
reduction NN o
in IN o
the DT o
size NN o
or CC o
number NN o
of IN o
AK NNP o
lesions NNS o
was VBD N
observed VBN N
in IN N
vehicle-treated JJ N
patients NNS N
. . N

Adverse JJ N
effects NNS N
reported VBN N
by IN p
patients NNS p
treated VBN p
with IN p
imiquimod NN i
included VBD N
erythema NN o
, , o
edema NN o
, , o
induration NN o
, , o
vesicles NNS o
, , o
erosion NN o
, , o
ulceration NN o
, , o
excoriation NN o
, , o
and CC o
scabbing VBG o
. . o

However RB N
, , N
imiquimod NN i
was VBD N
well RB N
tolerated VBN o
since IN N
all DT N
patients NNS N
completed VBD N
the DT N
12-week JJ N
treatment NN N
. . N

Only RB N
a DT N
few JJ N
, , N
mild JJ N
adverse JJ N
reactions NNS N
to TO N
the DT N
vehicle NN N
cream NN N
were VBD N
reported VBN N
. . N

CONCLUSION NNP N
Application NNP N
of IN N
5 CD N
% NN N
imiquimod JJ i
cream NN i
for IN N
12 CD N
weeks NNS N
is VBZ N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
AK NNP o
. . o

-DOCSTART- -15217131- O O

[ JJ N
Comparison NNP N
of IN N
two CD N
methods NNS N
of IN N
local JJ i
anaesthesia NN i
prior RB N
to TO N
transrectal VB N
ultrasound-guided JJ N
prostate NN N
biopsies NNS N
] VBP N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
rectal JJ N
administration NN N
of IN N
Lidoca?ne NNP i
gel NN i
with IN i
Lidoca?ne NNP i
periprostatic JJ i
infiltration NN i
prior RB i
to TO N
transrectal VB N
ultrasound-guided JJ N
prostate NN N
biopsies NNS N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP p
Between NNP p
July NNP p
2002 CD p
and CC p
July NNP p
2003 CD p
, , p
candidates NNS p
to TO p
prostate VB p
biopsies NNS p
were VBD p
randomised VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
group NN N
1 CD N
, , N
15 CD i
ml VBD i
2 CD i
% NN i
Lidoca?ne NNP i
gel NN i
was VBD i
administered VBN i
intra-rectally RB N
10 CD N
minutes NNS N
prior RB N
to TO N
biopsies NNS N
and CC N
patients NNS N
included VBD N
in IN N
group NN N
2 CD N
received VBD N
10 CD N
ml NN N
of IN N
1 CD i
% NN i
Lidoca?ne NNP i
in IN i
two CD i
p?riprostatique JJ i
equivalent JJ i
injections NNS i
, , i
4 CD i
minutes NNS i
prior RB N
to TO N
prostate VB N
biopsies NNS N
. . N

Pain NN N
was VBD N
assessed VBN N
with IN N
a DT o
Visual JJ o
Analog NNP o
Scale NNP o
, , o
during IN o
anaesthesia NN N
( ( N
VAS NNP N
1 CD N
) ) N
, , N
during IN N
the DT N
biopsies NNS N
procedure NN N
( ( N
VAS NNP N
2 CD N
) ) N
and CC N
30 CD N
minutes NNS N
after IN N
them PRP N
( ( N
VAS NNP N
3 CD N
) ) N
. . N

RESULTS $ p
308 CD p
patients NNS p
were VBD p
included VBN p
in IN p
this DT p
trial NN p
with IN p
156 CD p
patients NNS p
in IN p
group NN p
1 CD p
and CC p
152 CD p
in IN p
group NN p
2 CD p
. . p

Group NNP p
1 CD N
experienced VBD N
statistically RB N
less JJR N
pain NN N
for IN o
VAS NNP o
1 CD o
( ( o
0.1 CD o
versus NN N
1.4 CD N
, , N
p NN N
< NNP N
0.0001 CD o
) ) o
and CC o
VAS $ o
3 CD o
( ( o
0.8 CD o
versus NN N
1.4 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
but CC N
no DT N
significative JJ N
difference NN N
could MD N
be VB N
demonstrated VBN o
for IN o
VAS NNP o
2 CD o
( ( o
1.8 CD o
versus IN N
2.0 CD N
) ) N
. . N

No DT o
major JJ o
complication NN o
was VBD o
noted VBN N
. . N

CONCLUSION NNP N
Rectal NNP N
administration NN i
of IN i
Lidoca?ne NNP i
gel NN i
and CC i
infiltration NN i
of IN i
Lidoca?ne NNP i
lead NN i
to TO i
a DT N
comparable JJ N
level NN N
of IN N
anaesthesia NN N
during IN N
prostatic JJ N
biopsies NNS N
procedure NN N
. . N

However RB N
, , i
the DT i
Lidoca?ne NNP i
gel NN i
, , i
being VBG i
both DT N
safe JJ N
and CC N
simple JJ N
, , N
tends VBZ N
to TO N
maintain VB N
a DT N
better JJR N
comfort NN N
of IN N
the DT N
patient NN N
30 CD N
minutes NNS N
after IN N
the DT N
end NN N
of IN N
the DT N
biopsies NNS N
. . N

-DOCSTART- -23410851- O O

Family RB i
economic JJ i
empowerment NN i
and CC N
mental JJ N
health NN N
among IN N
AIDS-affected JJ p
children NNS p
living VBG p
in IN p
AIDS-impacted JJ p
communities NNS p
: : p
evidence NN N
from IN N
a DT N
randomised JJ N
evaluation NN N
in IN N
southwestern JJ p
Uganda NNP p
. . p

OBJECTIVE CC N
The DT N
authors NNS N
examine VBP N
whether IN N
an DT N
innovative JJ N
family NN i
economic JJ i
empowerment NN i
intervention NN N
addresses VBZ N
mental JJ N
health NN N
functioning NN N
of IN N
AIDS-affected JJ p
children NNS p
in IN p
communities NNS p
heavily RB p
impacted VBN p
by IN p
HIV/AIDS NNP p
in IN p
Uganda NNP p
. . p

METHODS NNP N
A NNP N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
consisting VBG N
of IN N
two CD N
study NN N
arms NNS N
, , N
a DT p
treatment NN i
condition NN i
( ( p
n=179 JJ p
) ) p
and CC p
a DT p
control NN i
condition NN i
( ( p
n=118 JJ p
) ) p
, , N
was VBD N
used VBN N
to TO N
examine VB N
the DT N
impact NN N
of IN N
the DT N
family NN i
economic JJ i
empowerment NN i
intervention NN i
on IN N
children NNS N
's POS N
levels NNS N
of IN N
hopelessness NN N
and CC N
depression NN N
. . N

The DT N
intervention NN N
comprised VBD N
matched JJ i
children NNS i
savings NNS i
accounts NNS i
, , i
financial JJ i
management NN i
workshops NNS i
and CC i
mentorship NN i
. . i

Data NNS N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
12 CD N
months NNS N
post-intervention NN N
. . N

RESULTS NNP N
Using VBG N
multivariate JJ N
analysis NN N
with IN N
several JJ N
socioeconomic JJ N
controls NNS N
, , N
the DT N
authors NNS N
find VBP N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
condition NN N
( ( N
receiving VBG N
the DT N
intervention NN N
) ) N
report NN N
significant JJ N
improvement NN N
in IN N
their PRP$ N
mental JJ o
health NN o
functioning NN o
. . o

Specifically RB N
, , N
the DT N
intervention NN N
reduces VBZ N
hopelessness NN o
and CC o
depression NN o
levels NNS o
. . o

On IN N
the DT N
other JJ N
hand NN N
, , N
children NNS N
in IN N
the DT N
control NN i
condition NN N
( ( N
not RB N
receiving VBG N
the DT N
intervention NN N
) ) N
report NN N
no DT N
changes NNS N
on IN N
both DT N
measures NNS N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
indicate VBP N
that IN N
children NNS p
with IN p
poor JJ p
mental JJ p
health NN p
functioning VBG p
living NN p
in IN p
communities NNS p
affected VBN p
by IN p
HIV/AIDS NNP p
may MD N
benefit VB N
from IN N
innovative JJ N
family NN N
economic JJ N
empowerment NN N
interventions NNS N
. . N

As IN N
measures NNS N
of IN N
mental JJ N
health NN N
functioning NN N
, , N
both DT N
hopelessness NN o
and CC o
depression NN o
have VBP N
long-term JJ N
negative JJ N
psychosocial NN N
and CC N
developmental JJ N
impacts NNS N
on IN N
children NNS N
. . N

These DT N
findings NNS N
have VBP N
implications NNS N
for IN N
public JJ N
health NN N
programmes NNS N
intended VBN N
for IN N
long-term JJ N
care NN N
and CC N
support NN N
of IN N
children NNS p
living VBG p
in IN p
resource JJ p
poor JJ p
AIDS-impacted JJ p
communities NNS p
. . p

-DOCSTART- -11701672- O O

Acute NNP N
effect NN N
of IN N
pegvisomant NN i
on IN N
cardiovascular JJ N
risk NN N
markers NNS N
in IN N
healthy JJ p
men NNS p
: : p
implications NNS N
for IN N
the DT N
pathogenesis NN N
of IN N
atherosclerosis NN N
in IN N
GH NNP N
deficiency NN N
. . N

Cardiovascular JJ N
risk NN N
is VBZ N
increased VBN N
in IN N
GH NNP N
deficiency NN N
( ( N
GHD NNP N
) ) N
. . N

GHD NNP p
adults NNS p
are VBP N
frequently RB N
abdominally RB N
obese JJ N
and CC N
display JJ N
features NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

Otherwise NNP N
healthy JJ N
abdominally RB N
obese JJ N
subjects NNS N
have VBP N
low JJ N
GH NNP N
levels NNS N
and CC N
show NN N
features NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
as RB N
well RB N
. . N

We PRP N
investigated VBD N
in IN N
healthy JJ p
nonobese JJ p
males NNS p
the DT N
effect NN N
of IN N
the DT N
GH NNP N
receptor NN N
antagonist NN N
pegvisomant NN i
in IN N
different JJ N
metabolic JJ N
conditions NNS N
. . N

This DT N
is VBZ N
a DT N
model NN N
for IN N
acute JJ N
GHD NNP N
without IN N
the DT N
alterations NNS N
in IN N
body NN N
composition NN N
associated VBN N
with IN N
GHD NNP N
. . N

We PRP N
compared VBN N
the DT N
effect NN N
of IN N
pegvisomant NN i
with IN N
that DT N
of IN N
placebo NN i
before IN N
and CC N
after IN N
3 CD N
d NN N
of IN N
fasting VBG N
. . N

In IN N
addition NN N
, , N
we PRP N
investigated VBD N
the DT N
effect NN N
of IN N
pegvisomant JJ i
under IN N
normal JJ N
, , N
i.e JJ N
. . N

fed VBN N
, , N
conditions NNS N
. . N

Three CD N
days NNS N
of IN N
fasting NN N
as RB N
well RB N
as IN N
pegvisomant JJ N
alone NN N
decreased VBD N
serum JJ o
free JJ o
IGF-I NN o
levels NNS o
( ( N
1.0 CD N
+/- JJ N
0.15 CD N
vs. FW N
0.31 CD N
+/- JJ N
0.05 CD N
ng/ml NN N
and CC N
0.86 CD N
+/- JJ N
0.23 CD N
vs. FW N
0.46 CD N
+/- JJ N
0.23 CD N
ng/ml NN N
, , N
respectively RB N
) ) N
. . N

Fasting VBG N
in IN N
combination NN N
with IN N
pegvisomant NN N
also RB N
decreased VBD N
serum JJ o
free JJ o
IGF-I NN o
levels NNS o
( ( N
1.0 CD N
+/- JJ N
0.15 CD N
vs. FW N
0.31 CD N
+/- JJ N
0.07 CD N
ng/ml NN N
) ) N
. . N

Treatment NN N
with IN N
pegvisomant NN i
had VBD N
no DT N
additional JJ N
influence NN N
on IN N
the DT N
decline NN N
of IN N
free JJ o
IGF-I NNP o
induced VBN N
by IN N
fasting VBG N
. . N

Pegvisomant VB N
alone RB N
had VBD N
no DT N
influence NN N
on IN N
insulin NN o
sensitivity NN o
. . o

The DT N
increase NN N
in IN N
insulin JJ o
sensitivity NN o
induced VBN N
by IN N
fasting VBG N
was VBD N
comparable JJ N
to TO N
the DT N
increase NN N
in IN N
insulin JJ o
sensitivity NN o
induced VBN N
by IN N
fasting VBG N
combined VBN N
with IN N
pegvisomant JJ N
. . N

Among IN N
serum JJ o
lipid JJ o
concentrations NNS o
, , N
only RB N
serum JJ o
triglycerides NNS o
increased VBD N
significantly RB N
as IN N
a DT N
result NN N
of IN N
pegvisomant NN N
alone NN N
( ( N
1.0 CD N
+/- JJ N
0.2 CD N
vs. FW N
1.6 CD N
+/- JJ N
0.4 CD N
mmol/liter NN N
) ) N
. . N

The DT N
changes NNS o
in IN o
lipid JJ o
concentrations NNS o
induced VBN N
by IN N
fasting VBG N
alone RB N
or CC N
pegvisomant VB N
were VBD N
not RB N
different JJ N
from IN N
those DT N
induced VBN N
by IN N
pegvisomant JJ N
alone NN N
. . N

von JJ o
Willebrand NNP o
factor NN o
antigen NN o
levels NNS o
declined VBD N
significantly RB N
under IN N
the DT N
influence NN N
of IN N
pegvisomant NN N
alone NN N
( ( N
1.1 CD N
+/- JJ N
0.07 CD N
vs. FW N
0.8 CD N
+/- JJ N
0.06 CD N
U/ml NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
in IN N
different JJ N
metabolic JJ N
conditions NNS N
the DT N
GH NNP N
receptor NN N
antagonist NN N
pegvisomant NN N
induces VBZ N
no DT N
significant JJ N
acute NN N
changes NNS N
in IN N
the DT N
major JJ N
risk NN o
markers NNS o
for IN o
cardiovascular JJ o
disease NN o
. . o

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
secondary JJ N
metabolic NN N
changes NNS N
, , N
e.g NN N
. . N

abdominal JJ o
obesity NN o
or CC o
inflammatory JJ o
factors NNS o
, , N
that WDT N
develop VBZ N
as IN N
a DT N
result NN N
of IN N
long-standing JJ N
GHD NNP N
are VBP N
of IN N
primary JJ N
importance NN N
in IN N
the DT N
pathogenesis NN N
of IN N
atherosclerosis NN N
in IN N
patients NNS N
with IN N
GHD NNP N
. . N

-DOCSTART- -15383046- O O

Atrial NNP o
remodeling NN o
after IN N
mitral JJ i
valve NN i
surgery NN i
in IN N
patients NNS p
with IN p
permanent JJ p
atrial JJ p
fibrillation NN p
. . p

BACKGROUND NNP N
Mitral NNP N
valve NNP N
pathology NN N
is VBZ N
frequently RB N
associated VBN N
with IN N
auricular JJ N
dilatation NN N
and CC N
atrial JJ N
fibrillation NN N
. . N

Mitral JJ i
surgery NN i
allows VBZ N
an DT N
immediate JJ N
surgical JJ N
auricular NN N
remodeling NN N
and CC N
besides NNS N
in IN N
those DT N
cases NNS N
in IN N
which WDT N
sinus NN N
rhythm NN N
is VBZ N
reached VBN N
, , N
it PRP N
is VBZ N
followed VBN N
by IN N
a DT N
late JJ N
remodeling NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
process NN N
of IN N
postoperative JJ N
auricular JJ N
remodeling VBG N
in IN N
patients NNS p
with IN p
permanent JJ p
atrial JJ p
fibrillation NN p
undergoing VBG p
mitral JJ i
surgery NN i
. . i

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
, , N
50 CD p
patients NNS p
with IN p
permanent JJ p
atrial JJ p
fibrillation NN p
and CC p
dilated VBD p
left JJ p
atrium NN p
, , p
submitted VBN p
to TO p
surgical JJ p
mitral JJ p
repair NN p
, , N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
Group NNP i
I PRP i
contained VBD i
25 CD i
patients NNS i
with IN i
left JJ i
auricular JJ i
reduction NN i
and CC i
mitral JJ i
surgery NN i
, , i
and CC i
Group NNP i
II NNP i
contained VBD i
25 CD i
patients NNS i
with IN i
isolated JJ i
valve NN i
surgery NN i
. . i

Both DT N
groups NNS N
were VBD N
considered VBN N
homogeneous JJ N
in IN N
the DT N
preoperative JJ N
assessment NN N
. . N

RESULTS NNP N
After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
31 CD N
months NNS N
, , N
46 CD N
% NN N
of IN N
patients NNS N
included VBN N
in IN N
Group NNP N
I PRP N
versus VBP N
18 CD N
% NN N
of IN N
patients NNS N
included VBN N
in IN N
Group NNP N
II NNP N
restarted VBD N
sinus JJ o
rhythm NN o
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

An DT N
auricular JJ o
remodeling NN o
with IN o
size NN o
regression NN o
occurred VBD N
in IN N
those DT N
patients NNS N
who WP N
recovered VBD N
from IN N
sinus NN N
rhythm NN N
, , N
worthy NN N
of IN N
remark NN N
in IN N
Group NNP N
II NNP N
( ( N
-10.8 CD N
% NN N
of IN N
left JJ N
auricular JJ N
volume NN N
reduction NN N
in IN N
Group NNP N
I PRP N
compared VBN N
to TO N
-21.5 VB N
% NN N
in IN N
Group NNP N
II NNP N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

A DT N
new JJ o
atrial JJ o
enlargement NN o
took VBD N
place NN N
in IN N
those DT N
patients NNS N
who WP N
remained VBD N
with IN N
atrial JJ N
fibrillation NN N
( ( N
+16.8 CD N
% NN N
left VBD N
auricular JJ N
volume NN N
in IN N
Group NNP N
I PRP N
vs. VBP N
+8.4 CD N
% NN N
in IN N
Group NNP N
II NNP N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Mitral NNP N
surgery NN N
produces VBZ N
an DT N
atrial JJ N
postoperative NN N
volume NN N
that IN N
decrease NN N
especially RB N
when WRB N
reduction NN N
techniques NNS N
are VBP N
employed VBN N
. . N

Late JJ N
left VBD N
atrial JJ N
remodeling VBG N
depended VBN N
on IN N
the DT N
type NN N
of IN N
atrial JJ o
rhythm NN o
and CC N
postoperative JJ o
surgical JJ o
volume NN o
. . o

-DOCSTART- -20587582- O O

Abnormal JJ N
cardiac JJ N
contractility NN N
in IN N
long-term JJ i
exogenous JJ i
subclinical JJ i
hyperthyroid NN i
patients NNS p
as IN N
demonstrated VBN N
by IN N
two-dimensional JJ N
echocardiography NN N
speckle NN N
tracking VBG N
imaging VBG N
. . N

BACKGROUND NNP N
Subclinical NNP N
hyperthyroidism NN N
is VBZ N
associated VBN N
with IN N
cardiovascular JJ o
morbidity NN o
. . o

Recent JJ N
advances NNS N
in IN N
echocardiography NN N
imaging NN N
have VBP N
allowed VBN N
sophisticated JJ N
evaluation NN N
of IN N
myocardial JJ o
tissue NN N
properties NNS N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
myocardial JJ N
effects NNS N
of IN N
long-term JJ N
exogenous JJ i
subclinical JJ i
hyperthyroidism NN i
using VBG N
two-dimensional JJ i
speckle NN i
tracking VBG i
echocardiography NN i
imaging NN i
( ( i
2D-STE JJ i
) ) i
. . N

DESIGN NNP N
Prospective NNP N
, , N
single-blinded JJ N
, , N
placebo-controlled JJ N
randomized JJ N
trial NN N
of IN N
6 CD N
months NNS N
duration NN N
with IN N
two CD N
parallel JJ N
groups NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Totally NNP p
25 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
differentiated JJ p
thyroid JJ p
carcinoma NN p
on IN p
long-term JJ p
TSH-suppressive JJ p
levothyroxine NN p
( ( p
l-T JJ p
( ( p
4 CD p
) ) p
) ) p
substitution NN p
were VBD N
randomized VBN N
to TO N
persistent JJ N
TSH-suppressive JJ i
l-T NN i
( ( i
4 CD i
) ) i
substitution NN i
( ( N
low-TSH JJ N
group NN N
) ) N
or CC N
restoration NN i
of IN i
euthyroidism NN i
. . i

Additionally RB p
40 CD p
euthyroid JJ p
controls NNS p
were VBD p
studied VBN p
. . p

RESULTS NNP N
( ( N
PROPOSAL NNP N
) ) N
: : N
At IN N
baseline NN N
, , N
the DT N
group NN N
of IN N
patients NNS N
showed VBD N
normal JJ o
left JJ o
ventricular NN o
( ( o
LV NNP o
) ) o
systolic JJ o
function NN o
but CC N
impaired JJ o
diastolic JJ o
function NN o
as IN N
assessed VBN N
with IN N
conventional JJ N
echocardiographic JJ N
parameters NNS N
. . N

Importantly RB N
, , N
2D-STE JJ N
analysis NN N
demonstrated VBD N
the DT N
presence NN N
of IN N
subclinical JJ o
LV NNP o
systolic NN o
and CC o
diastolic JJ o
dysfunction NN o
with IN N
impaired JJ o
circumferential NN o
and CC o
longitudinal JJ o
strain NN o
and CC o
strain NN o
rate NN o
at IN N
the DT N
isovolumic JJ N
relaxation NN N
time NN N
. . N

After IN N
restoration NN N
of IN N
euthyroidism NN N
, , N
a DT N
significant JJ N
improvement NN o
in IN o
LV NNP o
systolic NN o
and CC o
diastolic JJ o
function NN o
as IN N
assessed VBN N
with IN N
2D-STE JJ N
strain NN N
was VBD N
observed VBN N
. . N

CONCLUSION NNP N
Prolonged NNP i
subclinical JJ i
hyperthyroidism NN i
leads VBZ N
to TO N
systolic VB o
and CC o
diastolic JJ o
dysfunction NN o
, , N
which WDT N
is VBZ N
reversible JJ N
after IN N
restoration NN N
of IN N
euthyroidism NN N
. . N

2D-STE JJ N
is VBZ N
a DT N
more RBR N
sensitive JJ N
technique NN N
to TO N
evaluate VB N
subtle JJ N
changes NNS N
in IN N
LV NNP N
performance NN N
of IN N
these DT N
patients NNS N
. . N

-DOCSTART- -3112261- O O

Postoperative JJ o
pain NN o
control NN o
for IN N
outpatient JJ p
oral JJ p
surgery NN p
. . p

16 CD p
healthy JJ p
patients NNS p
requiring VBG p
removal NN p
of IN p
bilateral JJ p
symmetrically-impacted JJ p
mandibular JJ p
third JJ p
molars NNS p
participated VBD N
in IN N
a DT N
double-blind NN N
randomised VBN N
crossover RB N
trial NN N
to TO N
test VB N
the DT N
effectiveness NN o
of IN o
postoperative JJ o
pain NN o
control NN o
using VBG N
a DT N
long-acting JJ N
anti-inflammatory JJ N
agent NN N
( ( i
diflunisal NN i
) ) i
in IN N
combination NN N
with IN N
a DT N
long-acting JJ N
local JJ N
anaesthetic JJ N
agent NN N
( ( i
bupivacaine NN i
) ) i
. . N

Results NNS N
were VBD N
compared VBN N
to TO N
the DT N
more RBR N
traditional JJ N
method NN N
of IN N
using VBG N
an DT N
oral JJ N
analgesic NN N
with IN N
shorter JJR N
duration NN N
of IN N
action NN N
( ( i
paracetamol NN i
with IN i
codeine NN i
) ) i
with IN N
lignocaine NN i
as IN N
the DT N
local JJ N
anaesthetic NN N
. . N

Using VBG N
a DT N
visual JJ o
analogue NN o
pain NN o
scale NN o
, , N
patients NNS N
reported VBD N
that IN N
significantly RB N
reduced VBN N
pain NN o
was VBD N
experienced VBN N
over IN N
the DT N
first JJ N
4 CD N
days NNS N
postoperatively RB N
with IN N
the DT N
diflunisal/bupivacaine NN i
treatment NN i
and CC N
patient JJ o
preference NN o
for IN N
this DT N
treatment NN N
was VBD N
highly RB N
significant JJ N
. . N

This DT N
report NN N
represents VBZ N
the DT N
first JJ N
such JJ N
study NN N
of IN N
diflunisal NN i
used VBN N
for IN N
an DT N
extended JJ N
course NN N
in IN N
oral JJ N
surgery NN N
with IN N
pain NN o
assessment NN N
over IN N
the DT N
same JJ N
period NN N
. . N

No DT N
significant JJ N
side-effects NNS o
or CC o
adverse JJ o
reactions NNS o
were VBD N
encountered VBN N
. . N

-DOCSTART- -19779715- O O

Phase NNP N
III NNP N
, , N
randomised VBD N
, , N
multicentre JJ N
trial NN N
of IN N
maintenance NN N
immunotherapy NN i
with IN N
low-dose JJ N
interleukin-2 JJ i
and CC i
interferon-alpha JJ i
for IN N
metastatic JJ p
renal NN p
cell NN p
cancer NN p
. . p

This DT N
is VBZ N
the DT N
first JJ N
phase NN N
III NNP N
randomised VBD N
trial NN N
to TO N
evaluate VB N
maintenance NN N
immunotherapy NN N
in IN N
metastatic JJ p
renal NN p
cell NN p
cancer NN p
( ( N
mRCC NN N
) ) N
. . N

Patients NNS p
were VBD N
randomised VBN N
to TO N
receive VB N
treatment NN N
with IN N
a DT N
4-week JJ N
cycle NN N
of IN N
subcutaneous JJ i
low JJ i
doses NNS i
IL-2 NNP i
+ NNP i
IFN NNP i
in IN N
months NNS N
1 CD N
, , N
3 CD N
and CC N
5 CD N
, , N
and CC N
then RB N
every DT N
3 CD N
months NNS N
until IN N
the DT N
first JJ N
documented JJ N
disease NN N
progression NN N
( ( N
arm NN N
A NNP N
, , N
suspension NN N
) ) N
, , N
or CC N
the DT N
same JJ N
regimen NNS N
, , N
with IN N
chronic JJ N
maintenance NN N
of IN N
immunotherapy NN N
, , N
regardless RB N
of IN N
tumour JJ N
response NN N
, , N
until IN N
death NN N
or CC N
intolerable JJ N
toxicity NN N
( ( N
arm NN N
B NNP N
, , N
maintenance NN N
) ) N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
; : o
secondary JJ N
endpoints NNS N
were VBD N
time NN o
from IN o
first JJ o
progression NN o
to TO o
death NN o
( ( o
TFPTD NNP o
) ) o
and CC o
tolerability NN o
. . o

One CD p
hundred CD p
and CC p
eighty-three JJ p
patients NNS p
were VBD p
enrolled VBN p
between IN p
January NNP p
1998 CD p
and CC p
November NNP p
2003 CD p
. . p

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
53.9 CD N
months NNS N
, , N
response NN o
rate NN o
, , o
median JJ o
OS NNP o
and CC o
median JJ o
TFPTD NNP o
were VBD N
14.7 CD N
% NN N
( ( N
6.3 CD N
% NN N
CR NNP N
) ) N
versus VBP N
11.3 CD N
% NN N
( ( N
5.5 CD N
% NN N
CR NNP N
) ) N
, , N
14 CD N
versus NN N
14 CD N
months NNS N
, , N
6 CD N
versus NN N
5 CD N
months NNS N
, , N
in IN N
arms NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Cox NNP N
regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
use NN N
of IN N
chemotherapy NN i
after IN N
first JJ N
progression NN N
( ( N
HR NNP N
0.54 CD N
; : N
95 CD N
% NN N
CI NNP N
0.35-0.86 CD N
; : N
p CC N
= VB N
0.008 CD N
) ) N
, , N
PS NNP N
= VBZ N
0 CD N
( ( N
HR NNP N
0.53 CD N
; : N
95 CD N
% NN N
CI NNP N
0.35-0.81 CD N
; : N
p CC N
= VB N
0.001 CD N
) ) N
and CC N
female JJ N
gender NN N
( ( N
HR NNP N
0.63 CD N
; : N
95 CD N
% NN N
CI NNP N
0.41-0.98 CD N
; : N
p CC N
= VB N
0.038 CD N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
a DT N
longer RBR N
TFPTD NNP o
; : o
treatment NN N
arm NN N
was VBD N
not RB N
significant JJ N
( ( N
HR NNP N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
0.60-1.31 CD N
; : N
p CC N
= VB N
0.54 CD N
) ) N
. . N

Toxicity NN o
was VBD N
mainly RB N
limited JJ N
to TO N
WHO NNP N
grades VBZ N
1 CD N
or CC N
2 CD N
. . N

Chronic JJ i
maintenance NN i
immunotherapy NN i
after IN N
disease NN N
progression NN N
is VBZ N
feasible JJ N
, , N
but CC N
does VBZ N
not RB N
significantly RB N
increase VB N
OS NNP o
or CC N
the DT N
TFPTD NNP o
. . o

-DOCSTART- -6343259- O O

A DT N
comparison NN N
of IN N
once RB N
and CC N
twice RB N
daily JJ N
atenolol NN i
for IN N
angina JJ p
pectoris NN p
. . p

We PRP N
have VBP N
studied VBN N
the DT N
effects NNS N
of IN N
four CD N
doses NNS N
of IN N
atenolol NN i
in IN N
11 CD p
patients NNS p
with IN p
stable JJ p
angina NNS p
pectoris VBP p
using VBG N
a DT N
symptom-limited JJ N
exercise NN N
test NN N
and CC N
angina NN N
diaries NNS N
. . N

The DT N
doses NNS N
100 CD N
mg JJ N
twice RB N
daily RB N
and CC N
50 CD N
mg NN N
, , N
100 CD N
mg NN N
and CC N
200 CD N
mg NN N
once RB N
daily JJ N
were VBD N
given VBN N
double-blind NNS N
and CC N
randomised VBD N
within IN N
patients NNS N
following VBG N
run-in NN N
on IN N
placebo NN i
. . i

Measurements NNS N
were VBD N
made VBN N
12 CD N
hours NNS N
after IN N
the DT N
last JJ N
twice JJ N
daily RB N
dose JJ N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
last JJ N
once JJ N
daily JJ N
dose NN N
. . N

Exercise NN o
tolerance NN o
was VBD N
improved VBN N
by IN N
40-74 JJ N
% NN N
and CC N
exercise NN o
duration NN o
before IN o
the DT o
onset NN o
of IN o
angina NN o
by IN N
61-94 JJ N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Maximal JJ o
heart NN o
rate NN o
was VBD N
reduced VBN N
further RB N
by IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
200 CD N
mg NNS N
than IN N
by IN N
lower JJR N
doses NNS N
, , N
but CC N
no DT N
extra JJ N
benefit NN N
was VBD N
derived VBN N
by IN N
giving VBG N
the DT N
drug NN N
twice RB N
daily RB N
. . N

The DT N
largest JJS N
increase NN N
in IN N
exercise NN o
tolerance NN o
was VBD N
obtained VBN N
during IN N
treatment NN N
with IN N
50 CD N
mg NNS N
once RB N
daily RB N
. . N

Atenolol NNP i
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ N
anti-anginal JJ N
agent NN N
when WRB N
given VBN N
once RB N
daily JJ N
, , N
and CC N
there EX N
were VBD N
no DT N
major JJ N
differences NNS N
between IN N
the DT N
doses NNS N
studied VBN N
. . N

-DOCSTART- -15573541- O O

Not RB N
Now RB N
! . N
Supporting VBG N
interruption NN N
management NN N
by IN N
indicating VBG N
the DT N
modality NN N
and CC N
urgency NN N
of IN N
pending VBG N
tasks NNS N
. . N

Operators NNS p
in IN p
complex JJ p
event-driven JJ p
domains NNS p
must MD N
coordinate VB N
competing VBG N
attentional JJ N
demands NNS N
in IN N
the DT N
form NN N
of IN N
multiple JJ N
tasks NNS N
and CC N
interactions NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
extent NN N
to TO N
which WDT N
this DT N
requirement NN N
can MD N
be VB N
supported VBN N
more RBR N
effectively RB N
through IN N
informative JJ N
interruption NN N
cueing NN N
( ( N
in IN N
this DT N
case NN N
, , N
partial JJ N
information NN N
about IN N
the DT N
nature NN N
of IN N
pending VBG N
tasks NNS N
) ) N
. . N

The DT N
48 CD p
participants NNS p
performed VBD p
a DT p
visually RB i
demanding VBG i
air NN i
traffic NN i
control NN i
( ( i
ATC NNP i
) ) i
task NN i
. . i

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
experimental JJ N
groups NNS N
that WDT N
differed VBD N
in IN N
the DT N
availability NN i
of IN i
information NN i
( ( i
not RB i
available JJ i
, , i
available JJ i
upon IN i
request NN i
, , i
available JJ i
automatically RB i
) ) i
about IN N
the DT N
urgency NN N
and CC N
modality NN N
of IN N
pending VBG N
interruption NN N
tasks NNS N
. . N

Within-subject JJ N
variables NNS N
included VBD N
ATC-related JJ o
workload NN o
and CC o
the DT o
modality NN o
, , o
frequency NN o
, , o
and CC o
priority NN o
of IN o
interruption NN o
tasks NNS o
. . o

The DT N
results NNS N
show VBP N
that IN N
advance NN N
knowledge NN N
about IN N
the DT N
nature NN N
of IN N
pending VBG N
tasks NNS N
led VBD N
participants NNS N
to TO N
delay VB N
visual JJ N
interruption NN N
tasks VBZ N
the DT N
longest JJS N
, , N
which WDT N
allowed VBD N
them PRP N
to TO N
avoid VB N
intramodal JJ N
interference NN N
and CC N
scanning NN N
costs NNS N
associated VBN N
with IN N
performing VBG N
these DT N
tasks NNS N
concurrently RB N
with IN N
ATC NNP N
tasks NNS N
. . N

The DT N
3 CD N
experimental JJ N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
their PRP$ N
interruption NN o
task NN o
performance NN o
; : o
however RB N
, , N
the DT N
group NN N
that WDT N
automatically RB N
received VBD N
task-related JJ N
information NN N
showed VBD N
better JJR N
ATC NNP N
performance NN N
, , N
thus RB N
experiencing VBG N
a DT N
net JJ N
performance NN N
gain NN N
. . N

Actual NNP N
or CC N
potential JJ N
applications NNS N
of IN N
this DT N
research NN N
include VBP N
the DT N
design NN N
of IN N
interfaces NNS N
in IN N
support NN N
of IN N
attention NN N
and CC N
interruption NN N
management NN N
in IN N
a DT N
wide JJ N
range NN N
of IN N
event-driven JJ N
environments NNS N
. . N

-DOCSTART- -17845737- O O

Expectancies NNS N
, , N
not RB N
aroma RB N
, , N
explain JJ N
impact NN N
of IN N
lavender NN i
aromatherapy NN i
on IN N
psychophysiological JJ N
indices NNS N
of IN N
relaxation NN N
in IN N
young JJ p
healthy JJ p
women NNS p
. . p

OBJECTIVES NNP N
In IN N
aromatherapy NN i
, , i
lavender JJR i
aroma NN i
is VBZ N
reputed VBN N
to TO N
assist VB N
with IN N
relaxation NN N
. . N

However RB N
, , N
while IN N
there EX N
is VBZ N
much JJ N
anecdotal JJ N
evidence NN N
to TO N
that DT N
effect NN N
, , N
the DT N
empirical JJ N
literature NN N
is VBZ N
very RB N
inconsistent JJ N
. . N

Failure NN N
to TO N
employ VB N
adequate JJ N
placebos NNS i
, , N
proper JJ N
blinding NN N
, , N
objective JJ N
measures NNS N
, , N
or CC N
screening NN N
of IN N
prior JJ N
beliefs NNS N
about IN N
aromatherapy NN N
means NNS N
that IN N
many JJ N
previous JJ N
findings NNS N
could MD N
have VB N
been VBN N
influenced VBN N
by IN N
expectancy NN N
biases NNS N
. . N

The DT N
present JJ N
study NN N
sought VBD N
to TO N
establish VB N
whether IN N
lavender NN i
aroma NN i
and/or JJ N
expectancies NNS N
affect VBP N
post-stress JJ N
relaxation NN N
. . N

DESIGN VB N
A DT N
double-blind NN N
, , N
3 CD N
( ( N
aroma NN N
) ) N
x VBZ N
3 CD N
( ( N
instruction NN N
) ) N
x VBZ N
10 CD N
( ( N
time NN N
in IN N
minutes NNS N
) ) N
mixed-factorial JJ i
placebo-controlled JJ i
trial NN N
. . N

METHOD NNP N
In IN N
a DT N
laboratory NN N
, , N
96 CD p
healthy JJ p
undergraduate JJ p
women NNS p
were VBD N
exposed VBN i
to TO i
lavender VB i
, , i
placebo NN i
, , i
or CC i
no DT i
aroma NN i
during IN N
physiologically RB N
assessed VBN N
relaxation NN N
after IN N
an DT N
arousing VBG N
cognitive JJ i
task NN i
. . i

Where WRB N
an DT N
aroma NN N
was VBD N
presented VBN N
, , N
an DT N
instructional JJ N
priming NN N
procedure NN N
was VBD N
used VBN N
to TO N
manipulate VB N
participants NNS N
' POS N
expectancies NNS N
about IN N
the DT N
aroma NN N
's POS N
likely JJ N
impact NN N
on IN N
their PRP$ N
ability NN N
to TO N
relax VB N
. . N

RESULTS NNP N
Results NNP N
showed VBD N
no DT N
effect NN N
of IN N
aroma NN o
on IN o
galvanic JJ o
skin NN o
response NN o
during IN N
relaxation NN N
. . N

However RB N
, , N
the DT N
nature NN N
of IN N
instructional JJ N
prime NN N
was VBD N
associated VBN N
with IN N
relaxation NN o
patterns NNS o
: : o
when WRB N
expecting VBG N
the DT N
aroma NN N
to TO N
inhibit VB N
them PRP N
, , N
participants NNS N
relaxed VBD o
more RBR N
; : N
when WRB N
expecting VBG N
facilitation NN N
, , N
participants NNS N
relaxed VBD o
less RBR N
. . N

The DT N
effect NN N
was VBD N
not RB N
seen VBN N
with IN N
regard NN N
to TO N
self-reported JJ o
relaxation NN o
( ( N
as IN N
represented VBN N
by IN N
changes NNS N
in IN N
state NN N
anxiety NN N
) ) N
and CC N
was VBD N
independent JJ N
of IN N
ratings NNS N
of IN N
attitudes NNS o
towards NNS N
aromatherapy NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
imply VBP N
that IN N
the DT N
previous JJ N
associations NNS N
of IN N
lavender NN i
aroma NN i
with IN N
assisted JJ N
relaxation NN N
may MD N
have VB N
been VBN N
influenced VBN N
by IN N
expectancy NN N
biases NNS N
, , N
and CC N
that IN N
the DT N
relevant JJ N
expectancies NNS N
are VBP N
easily RB N
manipulable JJ N
. . N

-DOCSTART- -1282182- O O

Prevention NN N
of IN N
coronary JJ p
spasm NN p
by IN N
nicorandil NNS i
: : i
comparison NN N
with IN N
nifedipine NN i
. . i

The DT N
efficacy NN N
of IN N
nicorandil NN i
was VBD N
compared VBN N
with IN N
that DT N
of IN N
nifedipine NN i
in IN N
13 CD p
patients NNS p
with IN p
vasospastic JJ p
angina NNS p
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

All DT p
patients NNS p
had VBD p
a DT p
coronary JJ p
spasm NN p
during IN p
coronary JJ p
arteriography NN p
, , p
either CC p
spontaneously RB p
or CC p
ergometrine-induced JJ p
. . p

During IN N
two CD N
consecutive JJ N
periods NNS N
of IN N
2 CD N
days NNS N
, , N
patients NNS N
received VBD N
active JJ i
drugs NNS i
or CC N
placebo NN i
in IN N
a DT N
randomized JJ N
order NN N
. . N

Each DT N
patient NN N
received VBD N
single JJ N
oral JJ N
doses NNS N
of IN N
30 CD N
mg NN N
nicorandil NN i
, , N
10 CD N
mg NN N
nifedipine NN i
, , N
and CC N
, , N
on IN N
2 CD N
days NNS N
, , N
a DT N
placebo NN i
. . i

One CD N
hour NN N
after IN N
drug NN N
intake NN N
, , N
patients NNS N
underwent VBD N
an DT N
ergometrine JJ N
test NN N
with IN N
increasing VBG N
doses NNS N
of IN N
Methergin NNP i
( ( i
ergometrine NN i
) ) i
( ( N
0.05 CD N
, , N
0.10 CD N
, , N
0.20 CD N
, , N
and CC N
0.40 CD N
mg NN N
every DT N
5 CD N
min NN N
) ) N
. . N

After IN N
placebo NN i
, , N
the DT N
tests NNS N
always RB N
were VBD N
positive JJ N
, , N
and CC N
the DT N
ECG NNP o
changes NNS o
occurred VBD N
at IN N
the DT N
same JJ N
+/- JJ N
1 CD N
dose NN N
of IN N
ergometrine NN i
in IN N
10 CD N
cases NNS N
, , N
showing VBG N
good JJ o
reproducibility NN o
. . o

After IN N
nicorandil NN i
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
nine CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
lower JJR N
dose NN N
of IN N
ergometrine NN i
in IN N
three CD N
and CC N
one CD N
patient NN N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0034 CD N
vs. FW N
placebo NN i
) ) i
. . N

After IN N
nifedipine NN i
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
five CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
the DT N
same JJ N
dose NN N
of IN N
ergometrine NN i
in IN N
four CD N
and CC N
four CD N
patients NNS N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0039 CD N
vs. FW N
placebo NN i
) ) i
. . N

Nifedipine NNP i
( ( N
10 CD N
mg NN N
) ) N
and CC N
nicorandil $ N
( ( N
30 CD N
mg NN N
) ) N
were VBD N
equally RB N
effective JJ N
in IN N
eight CD N
patients NNS N
; : N
in IN N
the DT N
remaining VBG N
five CD N
patients NNS N
, , N
nicorandil NNS i
had VBD N
better JJR N
results NNS N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Nicorandil NNP i
( ( N
30 CD N
mg NN N
) ) N
prevents VBZ N
ergometrine-induced JJ o
coronary JJ o
spasm NN o
. . o

This DT N
compound NN N
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS p
with IN p
vasospastic JJ o
angina NN o
. . o

-DOCSTART- -20726255- O O

[ NN N
Study NNP N
on IN N
safety NN N
and CC N
immunogenicity NN N
of IN N
oral JJ i
poliomyelitis NN i
attenuated VBD i
live JJ i
vaccine NN i
( ( N
human JJ N
diploid NN N
cell NN N
) ) N
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN o
and CC N
Immunogenicity NNP o
of IN N
the DT N
Poliomyelitis NNP i
vaccine NN i
( ( N
Human NNP N
Diploid NNP N
Cell NNP N
) ) N
in IN N
> NN N
or CC N
=2 VB p
month-old JJ p
children NNS p
. . p

METHODS NNP N
A NNP N
random NN N
, , N
blind NN N
and CC N
control NN N
trial NN N
, , N
1200 CD p
healthy JJ p
children NNS p
of IN p
2-5 JJ p
months NNS p
old JJ p
in IN p
Jiangsu NNP p
province NN p
were VBD p
administered VBN p
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
and CC i
control NN i
vaccines NNS i
. . i

The DT N
antibody NN N
was VBD N
tested VBN N
by IN N
neutralization NN N
test NN N
. . N

RESULTS NNP N
After IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
, , N
the DT N
systemic JJ o
reactions NNS o
were VBD N
mild JJ N
. . N

After IN N
1 CD N
month NN N
of IN N
vaccination NN N
with IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
, , N
the DT N
immune JJ o
success NN o
rates NNS o
of IN o
I PRP o
, , o
II NNP o
, , o
III NNP o
type NN o
were VBD N
98.28 CD N
% NN N
, , N
99.45 CD N
% NN N
, , N
and CC N
95.71 CD N
% NN N
respectively RB N
, , N
the DT N
GMTs NNP o
of IN o
I PRP o
, , o
II NNP o
, , o
III NNP o
type NN o
in IN N
susceptible JJ N
children NNS N
were VBD N
1:1243.72 CD N
, , N
1:234.38 CD N
and CC N
1:273.10 CD N
respectively RB N
. . N

CONCLUSIONS VB N
The DT N
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
was VBD N
safe JJ N
and CC N
immunogenicity NN N
for IN N
the DT p
children NNS p
> VBP p
or CC p
=2 JJ p
months NNS p
old JJ p
. . p

-DOCSTART- -9809262- O O

Treatment NN N
of IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
a DT N
caregiver-based JJ i
intervention NN i
program NN i
in IN N
community NN p
day-care NN p
centers NNS p
. . p

This DT N
study NN N
reports VBZ N
on IN N
the DT N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
that WDT N
evaluated VBD N
a DT N
caregiver-based JJ i
intervention NN i
program NN i
for IN N
children NNS p
with IN p
autism NN p
in IN p
community NN p
day-care NN p
centers NNS p
. . p

Thirty-five JJ p
preschool NN p
children NNS p
with IN p
a DT p
DSM NNP p
III-R NNP p
diagnosis NN p
of IN p
autism NN p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
were VBD N
randomized VBN N
to TO N
an DT N
experimental JJ N
or CC N
control NN N
group NN N
. . N

Children NNP N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
enrolled VBN N
in IN N
day NN N
care NN N
and CC N
their PRP$ N
parents NNS i
and CC i
child NN i
care NN i
workers NNS i
received VBD i
a DT i
12-week JJ i
intervention NN i
consisting NN i
of IN i
lectures NNS i
and CC i
on-site JJ i
consultations NNS i
to TO i
day-care JJ i
centers NNS i
. . i

In IN N
addition NN N
, , N
supportive JJ N
work NN N
was VBD N
undertaken VBN N
with IN N
families NNS N
. . N

Control NNP N
subjects VBZ N
received VBN N
day NN i
care VB i
alone RB i
. . i

In IN N
the DT N
experimental JJ N
group NN N
, , N
there EX N
were VBD N
greater JJR N
gains NNS N
in IN N
language NN o
abilities NNS o
, , N
significant JJ N
increases NNS N
in IN N
caregivers NNS o
' POS o
knowledge NN o
about IN o
autism NN o
, , N
greater JJR N
perception NN o
of IN o
control NN o
on IN o
the DT o
part NN o
of IN o
mothers NNS o
, , N
and CC N
greater JJR N
parent NN o
satisfaction NN o
. . o

We PRP N
conclude VBP N
that IN N
this DT N
research NN N
design NN N
demonstrated VBD N
that IN N
the DT N
intervention NN N
was VBD N
significantly RB N
superior JJ N
to TO N
day NN N
care VB N
alone RB N
. . N

-DOCSTART- -14685645- O O

Prediction NN N
of IN N
the DT N
response NN N
to TO N
citalopram VB i
and CC i
reboxetine VB i
in IN N
post-stroke NN p
depressed JJ p
patients NNS p
. . p

RATIONALE NNP N
AND NNP N
OBJECTIVE NNP N
Depression NNP N
is VBZ N
a DT N
significant JJ N
complication NN N
of IN N
stroke NN N
. . N

The DT N
effectiveness NN N
of IN N
antidepressant JJ N
drugs NNS N
in IN N
the DT N
management NN N
of IN N
post-stroke JJ N
depression NN N
( ( N
PSD NNP N
) ) N
has VBZ N
been VBN N
widely RB N
investigated VBN N
. . N

However RB N
, , N
the DT N
choice NN N
of IN N
antidepressant JJ N
drug NN N
is VBZ N
critically RB N
influenced VBN N
by IN N
its PRP$ N
safety NN o
and CC N
tolerability NN o
and CC N
by IN N
its PRP$ N
effect NN N
on IN N
concurrent NN N
pathologies NNS N
. . N

Here RB N
we PRP N
investigate VBP N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
a DT N
selective JJ N
serotonin NN i
reuptake NN i
inhibitor NN i
( ( i
SSRI NNP i
) ) i
, , i
citalopram NN i
, , i
and CC i
a DT i
noradrenaline JJ i
reuptake NN i
inhibitor NN i
( ( i
NARI NNP i
) ) i
, , i
reboxetine NN i
, , N
in IN N
post-stroke JJ p
patients NNS p
affected VBN p
by IN p
anxious JJ p
depression NN p
or CC p
retarded VBN p
depression NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
double-blind NN N
study NN N
. . N

Seventy-four JJ p
post-stroke NN p
depressed JJ p
patients NNS p
were VBD N
diagnosed VBN N
as IN N
affected VBN N
by IN N
anxious JJ N
or CC N
retarded VBN N
depression NN N
by IN N
using VBG N
a DT N
synoptic JJ N
table NN N
. . N

Randomisation NN N
was VBD N
planned VBN N
so RB N
that IN N
50 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
each DT N
subgroup NN N
were VBD N
assigned VBN N
for IN N
16 CD N
weeks NNS N
to TO N
treatment NN N
with IN N
citalopram NN i
and CC N
the DT N
remaining VBG N
50 CD N
% NN N
were VBD N
assigned VBN N
to TO N
treatment NN N
with IN N
reboxetine NN i
. . i

The DT N
Beck NNP o
Depression NNP o
Inventory NNP o
( ( o
BDI NNP o
) ) o
, , o
the DT o
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
( ( o
HDRS NNP o
) ) o
and CC N
a DT N
synoptic JJ N
table NN N
were VBD N
used VBN N
to TO N
score VB N
depressive JJ o
symptoms NNS o
. . o

RESULTS NNP N
Both NNP N
citalopram NN i
and CC N
reboxetine NN i
showed VBD N
good JJ N
safety NN o
and CC o
tolerability NN o
. . o

Citalopram NNP N
exhibited VBD N
greater JJR o
efficacy NN o
in IN N
anxious JJ N
depressed JJ N
patients NNS p
, , N
while IN N
reboxetine NN i
was VBD N
more RBR N
effective JJ o
in IN N
retarded JJ N
depressed JJ N
patients NNS N
. . N

CONCLUSIONS NNP N
Citalopram NNP i
or CC N
other JJ N
SSRIs NNP N
and CC N
reboxetine NN i
may MD N
be VB N
of IN N
first JJ N
choice NN N
treatment NN N
in IN N
PSD NNP N
because IN N
of IN N
their PRP$ N
good JJ N
efficacy NN o
and CC o
lack NN o
of IN o
severe JJ o
side NN o
effects NNS o
. . o

In IN N
addition NN N
, , N
PSD NNP p
patients NNS p
should MD N
be VB N
classified VBN N
according VBG N
to TO N
their PRP$ N
clinical JJ N
profile NN N
( ( N
similarly RB N
to TO N
patients NNS N
affected VBN N
by IN N
primary JJ N
depression NN N
) ) N
for IN N
the DT N
selection NN N
of IN N
SSRIs NNP N
or CC N
reboxetine VB N
as IN N
drugs NNS N
of IN N
choice NN N
in IN N
particular JJ N
subgroups NNS N
of IN N
patients NNS N
. . N

-DOCSTART- -24007198- O O

Network NNP N
coordination NN N
following VBG N
discharge NN N
from IN N
psychiatric JJ i
inpatient JJ i
treatment NN i
: : i
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
Inadequate NNP N
discharge NN N
planning VBG N
following VBG N
inpatient NN N
stays NNS N
is VBZ N
a DT N
major JJ N
issue NN N
in IN N
the DT N
provision NN N
of IN N
a DT N
high JJ o
standard NN o
of IN o
care NN o
for IN N
patients NNS p
who WP p
receive VBP p
psychiatric JJ i
treatment NN i
. . i

Studies NNS N
have VBP N
shown VBN N
that IN N
half NN N
of IN N
patients NNS p
who WP p
had VBD p
no DT p
pre-discharge JJ p
contact NN p
with IN p
outpatient NN p
services NNS p
do VBP N
not RB N
keep VB N
their PRP$ N
first JJ N
outpatient JJ N
appointment NN N
. . N

Additionally RB N
, , N
discharged VBD p
patients NNS p
who WP p
are VBP p
not RB p
well RB p
linked VBN p
to TO p
their PRP$ p
outpatient NN p
care NN p
networks NNS p
are VBP N
at IN N
twice RB N
the DT N
risk NN N
of IN N
re-hospitalization NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
if IN N
the DT N
Post-Discharge NNP o
Network NNP o
Coordination NNP o
Program NNP o
at IN N
ipw NN N
has VBZ N
a DT N
demonstrably RB N
significant JJ N
impact NN N
on IN N
the DT N
frequency NN o
and CC o
duration NN o
of IN o
patient JJ o
re-hospitalization NN o
. . o

Subjects NNS N
are VBP N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
treatment NN N
group NN N
or CC N
to TO N
the DT N
control NN N
group NN N
. . N

The DT N
treatment NN N
group NN N
participates VBZ N
in IN N
the DT N
Post-Discharge NNP o
Network NNP o
Coordination NNP o
Program NNP o
. . o

The DT N
control NN N
group NN N
receives VBZ N
treatment NN i
as IN i
usual JJ i
with IN N
no DT N
additional JJ N
social JJ N
support NN N
. . N

Further CC N
outcome JJ N
variables NNS N
include VBP N
: : N
social JJ o
support NN o
, , o
change NN o
in IN o
psychiatric JJ o
symptoms NNS o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
independence NN o
in IN o
daily JJ o
functioning NN o
. . o

METHODS/DESIGN NNP N
The DT N
study NN N
is VBZ N
conducted VBN N
as IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Subjects NNS N
are VBP N
randomly RB N
assigned VBN N
to TO N
either VB N
the DT N
control NN i
group NN N
or CC N
to TO N
the DT N
treatment NN i
group NN N
. . N

Computer NNP i
generated VBD i
block NN i
randomization NN i
is VBZ N
used VBN N
to TO N
assure VB N
both DT N
groups NNS N
have VBP N
the DT N
same JJ N
number NN N
of IN N
subjects NNS N
. . N

Stratified NNP i
block NN i
randomization NN i
is VBZ N
used VBN N
for IN N
the DT N
psychiatric JJ N
diagnosis NN N
of IN N
ICD-10 NNP N
, , N
F1 NNP N
. . N

Approximately RB p
160 CD p
patients NNS p
are VBP p
recruited VBN p
in IN p
two CD p
care NN p
units NNS p
at IN p
Psychiatrie-Zentrum NNP p
Hard NNP p
Embrach NNP p
and CC p
two CD p
care NN p
units NNS p
at IN p
Klinik NNP p
Schlosstal NNP p
Winterthur NNP p
. . p

DISCUSSION NNP N
The DT N
proposed VBN N
post-discharge NN o
network NN o
coordination NN o
program NN o
intervenes NNS N
during IN N
the DT N
critical JJ N
post-discharge NN N
period NN N
. . N

It PRP N
focuses VBZ N
primarily RB N
on IN N
promoting VBG N
the DT N
integration NN o
of IN o
the DT o
patients NNS o
into IN o
their PRP$ o
social JJ o
networks NNS o
, , N
and CC N
additionally RB N
to TO N
coordinating VBG o
outpatient JJ o
care NN o
and CC N
addressing VBG o
concerns NNS o
of IN o
daily JJ o
life NN o
. . o

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
ISRCTN58280620 NNP N
. . N

-DOCSTART- -16495253- O O

Pharmacokinetic JJ N
and CC N
safety NN N
evaluation NN N
of IN N
high-dose JJ N
combinations NNS N
of IN N
fosamprenavir NN N
and CC N
ritonavir NN N
. . N

High-dose JJ N
combinations NNS N
of IN N
fosamprenavir NN i
( ( i
FPV NNP i
) ) i
and CC i
ritonavir NN i
( ( i
RTV NNP i
) ) i
were VBD N
evaluated VBN N
in IN N
healthy JJ p
adult NN p
subjects NNS p
in IN N
order NN N
to TO N
select VB N
doses NNS N
for IN N
further JJ N
study NN N
in IN N
multiple JJ p
protease NN p
inhibitor NN p
( ( p
PI NNP p
) ) p
-experienced VBD p
patients NNS p
infected VBN p
with IN p
human JJ p
immunodeficiency NN p
virus NN p
type NN p
1 CD p
. . p

Two CD N
high-dose JJ N
regimens NNS N
, , N
FPV NNP i
1,400 CD N
mg NN N
twice RB N
a DT N
day NN N
( ( N
BID NNP N
) ) N
plus CC N
RTV $ i
100 CD N
mg NN N
BID NNP N
and CC N
FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
200 CD N
mg NN N
BID NNP N
, , N
were VBD N
planned VBN N
to TO N
be VB N
compared VBN N
to TO N
the DT N
approved JJ N
regimen NNS N
, , N
FPV NNP i
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
100 CD N
mg NN N
BID NNP N
, , N
in IN N
a DT N
randomized JJ N
three-period NN N
crossover NN N
study NN N
. . N

Forty-two NNP p
healthy JJ p
adult NN p
subjects NNS p
were VBD p
enrolled VBN p
, , N
and CC N
39 CD N
subjects NNS N
completed VBN N
period NN N
1 CD N
. . N

Due JJ N
to TO N
marked VB N
hepatic JJ N
transaminase NN N
elevations NNS N
, , N
predominantly RB N
with IN N
FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
200 CD N
mg NN N
BID NNP N
, , N
the DT N
study NN N
was VBD N
terminated VBN N
prematurely RB N
. . N

For IN N
FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
100 CD N
mg NN N
BID NNP N
, , N
the DT N
values NNS o
for IN o
plasma NN o
amprenavir NN o
( ( o
APV NNP o
) ) o
area NN o
under IN o
the DT o
concentration-time JJ o
profile NN o
over IN o
the DT o
dosing VBG o
interval NN o
( ( o
tau NN o
) ) o
at IN o
steady JJ o
state NN o
[ NNS N
AUC NNP N
( ( N
0-tau JJ N
) ) N
] NN N
, , N
maximum JJ o
concentration NN o
of IN o
drug NN o
in IN o
plasma NN o
( ( o
C NNP o
( ( o
max NN o
) ) o
) ) o
, , o
and CC o
plasma JJ o
concentration NN o
at IN o
the DT o
end NN o
of IN o
tau NN o
at IN o
steady JJ o
state NN o
( ( o
C NNP o
( ( o
tau NN o
) ) o
) ) o
were VBD N
54 CD N
, , N
81 CD N
, , N
and CC N
26 CD N
% NN N
higher JJR N
, , N
respectively RB N
, , N
and CC N
the DT N
values NNS o
for IN o
plasma NN o
RTV NNP o
AUC NNP o
( ( o
0-tau JJ o
) ) o
, , o
C NNP o
( ( o
max NN o
) ) o
, , o
and CC o
C NNP o
( ( o
tau NN o
) ) o
were VBD N
49 CD N
% NN N
higher JJR N
, , N
71 CD N
% NN N
higher JJR N
, , N
and CC N
11 CD N
% NN N
lower JJR N
, , N
respectively RB N
, , N
than IN N
those DT N
for IN N
FPV NNP i
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP N
100 CD N
mg NN N
BID NNP N
. . N

For IN N
FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP N
200 CD N
mg NN N
BID NNP N
, , N
the DT N
values NNS o
for IN o
plasma NN o
APV NNP o
AUC NNP o
( ( o
0-tau JJ o
) ) o
, , o
C NNP o
( ( o
max NN o
) ) o
, , o
and CC o
C NNP o
( ( o
tau NN o
) ) o
were VBD N
26 CD N
, , N
48 CD N
, , N
and CC N
32 CD N
% NN N
higher JJR N
, , N
respectively RB N
, , N
and CC N
the DT N
values NNS N
for IN N
plasma NN o
RTV NNP o
AUC NNP o
( ( o
0-tau JJ o
) ) o
, , o
C NNP o
( ( o
max NN o
) ) o
, , o
and CC o
C NNP o
( ( o
tau NN o
) ) o
increased VBD N
4.15-fold JJ N
, , N
4.17-fold JJ N
, , N
and CC N
3.99-fold JJ N
, , N
respectively RB N
, , N
compared VBN N
to TO N
those DT N
for IN N
FPV NNP i
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
100 CD N
mg NN N
BID NNP N
. . N

FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
200 CD N
mg NN N
BID NNP N
is VBZ N
not RB N
recommended VBN N
due JJ N
to TO N
an DT N
increased VBN N
rate NN o
of IN o
marked VBN o
hepatic JJ o
transaminase NN o
elevations NNS o
and CC N
lack NN o
of IN o
pharmacokinetic JJ o
advantage NN o
. . o

FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
100 CD N
mg NN N
BID NNP N
is VBZ N
currently RB N
under IN N
clinical JJ N
evaluation NN N
in IN N
multiple JJ N
PI-experienced JJ N
patients NNS N
. . N

-DOCSTART- -10997806- O O

Paclitaxel NNP i
( ( N
175 CD N
mg/m2 NN N
) ) N
plus CC i
carboplatin NN i
( ( N
6 CD N
AUC NNP N
) ) N
versus NN i
paclitaxel NN i
( ( N
225 CD N
mg/m2 NN N
) ) N
plus CC i
carboplatin NN i
( ( N
6 CD N
AUC NNP N
) ) N
in IN N
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
: : p
a DT N
multicenter NN N
randomized VBN N
trial NN N
. . N

Hellenic NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
HeCOG NNP N
) ) N
. . N

PURPOSE VB N
The DT N
combination NN N
of IN N
paclitaxel NN i
and CC i
carboplatin NN i
has VBZ N
become VBN N
a DT N
widely RB N
used VBN N
regimen NNS N
in IN N
NSCLC NNP N
due JJ N
to TO N
phase VB N
II NNP N
reports NNS N
of IN N
moderate JJ N
toxicity NN N
, , N
reasonable JJ N
activity NN N
and CC N
easy JJ N
outpatient JJ N
administration NN N
. . N

Purpose NNP N
of IN N
our PRP$ N
present JJ N
prospective JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
dose JJ o
response NN o
relationship NN N
of IN N
paclitaxel NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Since IN p
July NNP p
1996 CD p
, , p
198 CD p
patients NNS p
with IN p
non-operable JJ p
NSCLC NNP p
and CC p
measurable JJ p
disease NN p
without IN p
previous JJ p
chemotherapy NN i
entered VBD p
the DT p
trial NN p
. . p

Ninety NNP p
nine CD p
patients NNS p
( ( p
group NN p
A DT p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
paclitaxel NN i
175 CD N
mg/m2 NN N
in IN N
three-hour JJ N
infusion NN N
plus CC i
carboplatin NN i
dosed VBD N
to TO N
an DT N
area NN N
under IN N
the DT N
concentration-time JJ N
curve NN N
of IN N
6 CD N
every DT N
3 CD N
weeks NNS N
and CC N
99 CD N
( ( N
group NN N
B NNP N
) ) N
to TO N
receive VB N
the DT N
same JJ N
regimen NN N
with IN N
paclitaxel NN i
increased VBN N
to TO N
225 CD N
mg/m2 NN N
. . N

Eligibility NNP N
criteria NNS N
included VBD N
WHO NNP N
performance NN N
status NN N
0-2 CD N
, , N
documented VBN N
inoperable JJ N
stage NN N
IIIA NNP N
and CC N
IIIB NNP N
, , N
IV NNP N
, , N
no DT N
brain NN N
metastasis NN N
, , N
no DT N
prior JJ N
chemotherapy NN i
and CC N
adequate JJ N
renal NN N
and CC N
hepatic JJ N
function NN N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
were VBD N
well-matched JJ N
with IN N
baseline JJ N
disease NN N
characteristics NNS N
. . N

RESULTS NNP N
In IN N
group NN N
A NNP N
with IN N
90 CD N
evaluable JJ N
patients NNS N
, , N
the DT N
response NN o
rate NN o
was VBD N
25.6 CD N
% NN N
( ( N
6 CD N
CR NNP N
, , N
17 CD N
PR NNP N
) ) N
whereas VBP N
in IN N
group NN N
B NNP N
with IN N
88 CD N
evaluable JJ N
patients NNS N
, , N
the DT N
response NN o
rate NN o
was VBD N
31.8 CD N
% NN N
( ( N
3 CD N
CR NNP N
, , N
25 CD N
PR NNP N
) ) N
, , N
P NNP N
= VBZ N
0.733 CD N
. . N

Median JJ o
time NN o
to TO o
progression NN o
favored VBD N
the DT N
high-dose JJ N
paclitaxel NN N
( ( N
4.3 CD N
vs. FW N
6.4 CD N
months NNS N
, , N
P NNP N
= NNP N
0.044 CD N
) ) N
. . N

The DT N
median JJ o
survival NN o
was VBD N
9.5 CD N
months NNS N
for IN N
group NN N
A NNP N
versus NN N
11.4 CD N
months NNS N
for IN N
group NN N
B NNP N
( ( N
P NNP N
= NNP N
0.16 CD N
) ) N
. . N

The DT N
one-year JJ o
survival NN o
was VBD N
37 CD N
% NN N
for IN N
group NN N
A NNP N
and CC N
44 CD N
% NN N
for IN N
group NN N
B NNP N
( ( N
P NNP N
= NNP N
0.35 CD N
) ) N
. . N

The DT N
best JJS N
prognostic JJ N
factor NN N
for IN N
one-year JJ o
survival NN o
was VBD N
the DT N
response NN o
rate NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

With IN N
a DT N
relative JJ N
dose JJ N
intensity NN N
of IN N
paclitaxel NN i
0.94 CD N
in IN N
both DT N
groups NNS N
, , N
neurotoxicity NN o
( ( N
P NNP N
= NNP N
0.025 CD N
) ) N
and CC N
leucopenia $ o
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
were VBD N
more RBR N
pronounced JJ N
in IN N
group NN N
B NNP N
patients NNS N
. . N

No DT N
toxic JJ o
death NN o
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Higher NNP N
dose VBD N
paclitaxel JJ i
prolongs NNS N
the DT N
median JJ N
time NN N
to TO N
progression NN N
but CC N
causes VBZ N
more JJR N
neurotoxicity NN N
and CC N
leucopenia NN N
. . N

The DT N
better JJR N
response NN N
rate NN N
, , N
the DT N
longer JJR N
overall JJ N
and CC N
better JJR N
one-year JJ N
survival NN N
seen VBN N
with IN N
the DT N
higher JJR N
dose NN N
of IN N
paclitaxel NNS i
are VBP N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -22728026- O O

Phase NNP N
II NNP N
trial NN N
of IN N
nab-paclitaxel JJ N
compared VBN N
with IN N
docetaxel NN i
as IN N
first-line JJ N
chemotherapy NN N
in IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
: : p
final JJ N
analysis NN N
of IN N
overall JJ N
survival NN N
. . N

BACKGROUND VB N
A DT N
randomized JJ N
phase NN N
II NNP N
study NN N
in IN N
first-line JJ N
MBC NNP N
demonstrated VBD N
superior JJ N
efficacy NN o
and CC N
safety NN o
of IN N
weekly JJ N
nab-paclitaxel NNS N
compared VBN N
with IN N
docetaxel NN i
. . i

Final NNP N
survival NN o
analyses NNS o
and CC N
updated JJ N
safety NN o
results NNS N
are VBP N
reported VBN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Three NNP p
hundred VBD p
two CD p
patients NNS p
with IN p
no DT p
previous JJ p
chemotherapy NN p
for IN p
MBC NNP p
were VBD N
randomized VBN i
to TO i
receive VB i
nab-paclitaxel JJ i
300 CD i
mg/m NN i
( ( i
2 CD i
) ) i
q3w NN i
, , i
nab-paclitaxel JJ i
100 CD i
mg/m NN i
( ( i
2 CD i
) ) i
or CC i
150 CD i
mg/m NN i
( ( i
2 CD i
) ) i
the DT i
first JJ i
3 CD i
of IN i
4 CD i
weeks NNS i
( ( i
qw VB i
3/4 CD i
) ) i
, , i
or CC i
docetaxel VB i
100 CD i
mg/m NN i
( ( i
2 CD i
) ) i
q3w NN i
. . i

The DT N
trial NN N
was VBD N
powered VBN N
for IN N
analyses NNS N
of IN N
antitumor NN o
activity NN o
and CC N
safety NN o
. . o

RESULTS NNP N
Treatment NNP N
with IN N
nab-paclitaxel JJ N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
resulted VBD N
in IN N
a DT N
median JJ N
overall JJ N
survival NN o
( ( N
OS NNP N
) ) N
of IN N
33.8 CD N
months NNS N
compared VBN N
with IN N
22.2 CD N
, , N
27.7 CD N
, , N
and CC N
26.6 CD N
months NNS N
for IN N
nab-paclitaxel JJ N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
, , N
nab-paclitaxel JJ N
300 CD N
mg/m NN N
( ( N
2 CD N
) ) N
q3w NN N
, , N
and CC N
docetaxel NN i
, , N
respectively RB N
( ( N
overall JJ N
P NNP N
= NNP N
.047 NNP N
) ) N
. . N

Patients NNPS N
receiving VBG N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel NN N
had VBD N
prolonged VBN N
median JJ o
OS NNP o
compared VBN N
with IN N
those DT N
in IN N
the DT N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel JJ N
arm NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.575 CD N
; : N
P NNP N
= NNP N
.008 NNP N
) ) N
. . N

A DT N
trend NN N
toward IN N
a DT N
longer JJR N
OS NNP o
was VBD N
noted VBN N
in IN N
the DT N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel JJ N
arm NN N
versus NN N
docetaxel NN i
arm NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.688 CD N
) ) N
. . N

Grade $ o
3 CD o
or CC o
4 CD o
fatigue NN o
, , o
neutropenia NN o
, , o
and CC o
febrile JJ o
neutropenia NN o
were VBD N
less JJR N
frequent JJ N
in IN N
all DT N
nab-paclitaxel JJ N
arms NNS N
compared VBN N
with IN N
docetaxel NN i
. . i

CONCLUSIONS NNP N
Consistent NNP N
with IN N
previously RB N
published VBN N
efficacy NN N
results NNS N
, , N
these DT N
data NNS N
suggest VBP N
that IN N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
may MD N
represent VB N
the DT N
most RBS N
clinically RB N
efficacious JJ N
nab-paclitaxel JJ N
dosing VBG N
regimen NNS N
for IN N
patients NNS p
with IN p
no DT p
previous JJ p
chemotherapy NN p
for IN p
MBC NNP p
. . p

A DT N
phase NN N
III NNP N
trial NN N
confirming VBG N
these DT N
results NNS N
would MD N
be VB N
necessary JJ N
and CC N
prudent JJ N
before RB N
widespread JJ N
adoption NN N
of IN N
the DT N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
dose NN N
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -12660676- O O

Sustained VBN N
ventricular JJ N
arrhythmias NNS N
and CC N
mortality NN N
among IN N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
: : p
results NNS N
from IN N
the DT N
GUSTO-III NNP N
trial NN N
. . N

BACKGROUND NNP N
In IN N
many JJ N
patients NNS N
, , N
ventricular JJ N
arrhythmias NN N
will MD N
develop VB N
early JJ N
after IN N
acute JJ p
myocardial JJ p
infarction NN p
. . p

We PRP N
studied VBD N
the DT N
incidence NN N
, , N
timing NN N
, , N
and CC N
outcomes NNS N
of IN N
such JJ N
arrhythmias NNS N
in IN N
the DT N
international JJ N
Global NNP N
Utilization NNP N
of IN N
Streptokinase NNP N
and CC N
TPA NNP N
( ( N
alteplase NN N
) ) N
for IN N
Occluded NNP N
Coronary NNP N
Arteries NNP N
( ( N
GUSTO NNP N
) ) N
-III VBP N
trial NN N
. . N

METHODS NNP N
We PRP i
identified VBD i
independent JJ i
predictors NNS i
of IN i
inhospital JJ i
ventricular JJ i
fibrillation NN i
( ( i
VF NNP i
) ) i
and CC i
ventricular JJ i
tachycardia NN i
( ( i
VT NNP i
) ) i
and CC i
compared VBN i
30-day JJ i
and CC i
1-year JJ i
mortality NN i
rates NNS i
of IN i
patients NNS i
who WP i
did VBD i
( ( i
n VB i
= NNP i
1121 CD i
) ) i
and CC i
did VBD i
not RB i
( ( i
n JJ i
= NNP i
13,921 CD i
) ) i
have VBP i
these DT i
arrhythmias NNS i
during IN i
the DT i
index NN i
hospitalization NN i
. . i

RESULTS NNP N
Significant NNP N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
VF NNP N
were VBD N
higher JJR N
Killip NNP o
class NN o
, , o
lower JJR o
baseline NN o
systolic JJ o
pressure NN o
, , o
intravenous JJ o
preenrollment NN o
lidocaine NN o
use NN o
, , N
shorter JJR N
time NN N
to TO N
thrombolysis VB o
, , N
and CC N
beta-blocker NN i
use NN i
< VBZ N
2 CD N
weeks NNS N
before IN N
enrollment NN N
; : N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
VT NNP N
were VBD N
lower JJR N
baseline NN o
systolic JJ o
pressure NN o
, , o
intravenous JJ o
lidocaine NN o
use NN N
before IN N
enrollment NN N
, , N
higher JJR N
Killip NNP N
class NN N
, , N
faster JJR N
baseline JJ o
heart NN o
rate NN o
, , N
and CC N
advanced JJ N
age NN N
. . N

The DT N
30-day JJ o
mortality NN o
rate NN o
was VBD N
31 CD N
% NN N
in IN N
patients NNS N
with IN N
VF NNP N
, , N
24 CD N
% NN N
in IN N
those DT N
with IN N
VT NNP N
, , N
44 CD N
% NN N
in IN N
those DT N
with IN N
both DT N
, , N
and CC N
6 CD N
% NN N
in IN N
those DT N
with IN N
neither DT N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
corresponding JJ N
1-year JJ o
mortality NN o
rates NNS o
were VBD N
34 CD N
% NN N
, , N
29 CD N
% NN N
, , N
49 CD N
% NN N
, , N
and CC N
9 CD N
% NN N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
30-day JJ o
and CC o
1-year JJ o
mortality NN o
rates NNS o
were VBD N
higher JJR N
for IN N
patients NNS N
with IN N
late JJ N
( ( N
> JJ N
48 CD N
hours NNS N
after IN N
enrollment NN N
) ) N
versus FW N
early JJ N
arrhythmias NN N
( ( N
< CD N
or CC N
=48 VB N
hours NNS N
after IN N
enrollment NN N
) ) N
. . N

CONCLUSIONS NNP N
Despite IN N
thrombolysis NN N
, , N
inhospital JJ N
ventricular NN N
arrhythmias NNS N
are VBP N
associated VBN N
with IN N
higher JJR N
30-day JJ N
and CC N
1-year JJ N
mortality NN o
rates NNS o
after IN N
acute JJ p
myocardial JJ p
infarction NN p
, , N
particularly RB N
when WRB N
occurring VBG N
later RB N
during IN N
the DT N
initial JJ N
hospitalization NN N
. . N

Better JJR N
therapies NNS N
are VBP N
needed VBN N
to TO N
improve VB N
outcomes NNS N
of IN N
these DT N
arrhythmias NNS N
. . N

-DOCSTART- -15978926- O O

Endovascular JJ N
aneurysm NN N
repair NN N
and CC N
outcome NN N
in IN N
patients NNS p
unfit JJ p
for IN p
open JJ p
repair NN p
of IN p
abdominal JJ p
aortic JJ p
aneurysm NN p
( ( p
EVAR NNP p
trial NN p
2 CD p
) ) p
: : p
randomised VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Endovascular NNP i
aneurysm NN i
repair NN i
( ( i
EVAR NNP i
) ) i
to TO N
exclude VB N
abdominal JJ N
aortic JJ N
aneurysm NN N
( ( N
AAA NNP N
) ) N
was VBD N
introduced VBN N
for IN N
patients NNS p
of IN p
poor JJ p
health NN p
status NN p
considered VBN p
unfit NN p
for IN p
major JJ p
surgery NN p
. . p

We PRP N
instigated VBD N
EVAR NNP N
trial NN N
2 CD N
to TO N
identify VB N
whether IN N
EVAR NNP N
improves VBZ N
survival JJ o
compared VBN N
with IN N
no DT N
intervention NN N
in IN N
patients NNS p
unfit JJ p
for IN p
open JJ p
repair NN p
of IN p
aortic JJ p
aneurysm NN p
. . p

METHODS NNP N
We PRP N
did VBD N
a DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
338 CD p
patients NNS p
aged VBN p
60 CD p
years NNS p
or CC p
older JJR p
who WP p
had VBD p
aneurysms NNS p
of IN p
at IN p
least JJS p
5.5 CD p
cm NN p
in IN p
diameter NN p
and CC p
who WP p
had VBD p
been VBN p
referred VBN p
to TO p
one CD p
of IN p
31 CD p
hospitals NNS p
in IN p
the DT p
UK NNP p
. . p

We PRP N
assigned VBD N
patients NNS N
to TO N
receive VB N
either DT N
EVAR NNP i
( ( N
n=166 NN N
) ) N
or CC i
no DT i
intervention NN i
( ( N
n=172 JJ N
) ) N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
all-cause JJ o
mortality NN o
, , N
with IN N
secondary JJ N
endpoints NNS N
of IN N
aneurysm-related JJ o
mortality NN o
, , o
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQL NNP o
) ) o
, , o
postoperative JJ o
complications NNS o
, , o
and CC o
hospital NN o
costs NNS o
. . o

Analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
197 CD p
patients NNS p
underwent JJ N
aneurysm JJ i
repair NN i
( ( N
47 CD N
assigned VBN N
no DT N
intervention NN N
) ) N
and CC N
80 CD N
% NN N
of IN N
patients NNS N
adhered VBN N
to TO N
protocol VB N
. . N

The DT N
30-day JJ o
operative JJ o
mortality NN o
in IN o
the DT o
EVAR NNP o
group NN o
was VBD N
9 CD N
% NN N
( ( N
13 CD N
of IN N
150 CD N
, , N
95 CD N
% NN N
CI NNP N
5-15 CD N
) ) N
and CC N
the DT N
no DT N
intervention NN N
group NN N
had VBD N
a DT N
rupture NN N
rate NN N
of IN N
9.0 CD N
per IN N
100 CD N
person NN N
years NNS N
( ( N
95 CD N
% NN N
CI NNP N
6.0-13.5 CD N
) ) N
. . N

By IN N
end NN N
of IN N
follow JJ N
up IN N
142 CD N
patients NNS N
had VBD N
died VBN o
, , N
42 CD N
of IN N
aneurysm-related JJ N
factors NNS N
; : N
overall JJ o
mortality NN o
after IN N
4 CD N
years NNS N
was VBD N
64 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
EVAR NNP N
group NN N
and CC N
the DT N
no DT N
intervention NN N
group NN N
for IN N
all-cause JJ o
mortality NN o
( ( N
hazard JJ N
ratio NN N
1.21 CD N
, , N
95 CD N
% NN N
CI NNP N
0.87-1.69 CD N
, , N
p=0.25 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
aneurysm-related JJ o
mortality NN o
. . o

The DT N
mean JJ o
hospital NN o
costs NNS o
per IN o
patient NN o
over IN o
4 CD o
years NNS o
were VBD N
UK NNP N
pound NN N
sterling NN N
13,632 CD N
in IN N
the DT N
EVAR NNP N
group NN N
and CC N
pound NN N
sterling NN N
4983 CD N
in IN N
the DT N
no DT N
intervention NN N
group NN N
( ( N
mean JJ N
difference NN N
pound NN N
sterling NN N
8649 CD N
, , N
SE NNP N
1248 CD N
) ) N
, , N
with IN N
no DT N
difference NN N
in IN N
HRQL NNP N
scores NNS N
. . N

INTERPRETATION NNP N
EVAR NNP N
had VBD N
a DT N
considerable JJ N
30-day JJ o
operative JJ o
mortality NN o
in IN N
patients NNS N
already RB N
unfit JJ N
for IN N
open JJ N
repair NN N
of IN N
their PRP$ N
aneurysm NN N
. . N

EVAR NNP i
did VBD N
not RB N
improve VB N
survival NN N
over IN N
no DT N
intervention NN N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
need NN N
for IN N
continued JJ N
surveillance NN N
and CC N
reinterventions NNS N
, , N
at IN N
substantially RB N
increased VBN N
cost NN N
. . N

Ongoing VBG N
follow-up NN N
and CC N
improved JJ N
fitness NN N
of IN N
these DT N
patients NNS N
is VBZ N
a DT N
priority NN N
. . N

-DOCSTART- -7488285- O O

Corticosteroids NNP i
plus CC i
pulse JJ i
cyclophosphamide NN i
and CC i
plasma NN i
exchanges NNS i
versus VBP N
corticosteroids NNS i
plus CC i
pulse JJ i
cyclophosphamide NN i
alone RB i
in IN N
the DT N
treatment NN N
of IN N
polyarteritis NN p
nodosa NN p
and CC p
Churg-Strauss NNP p
syndrome NN p
patients NNS p
with IN p
factors NNS p
predicting VBG p
poor JJ p
prognosis NN p
. . p

A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
in IN N
sixty-two JJ p
patients NNS p
. . p

OBJECTIVE NNP N
To TO N
define VB N
the DT N
most RBS N
effective JJ N
treatment NN N
for IN N
severe JJ p
polyarteritis NN p
nodosa NN p
( ( p
PAN NNP p
) ) p
and CC p
Churg-Strauss JJ p
syndrome NN p
( ( p
CSS NNP p
) ) p
and CC N
to TO N
investigate VB N
the DT N
indication NN N
for IN N
plasma JJ N
exchange NN N
treatment NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
in IN N
which WDT N
62 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
either DT p
prednisone NN i
plus CC i
cyclophosphamide NN i
( ( i
intravenous JJ i
bolus NN i
) ) i
( ( i
group NN i
A NNP i
; : i
n JJ i
= NNP i
28 CD i
) ) i
or CC i
prednisone JJ i
plus CC i
cyclophosphamide JJ i
( ( i
intravenous JJ i
bolus NN i
) ) i
plus CC i
plasma JJ i
exchanges NNS i
( ( p
group NN p
B NNP p
; : p
n CC p
= VB p
34 CD p
) ) p
as IN p
first-line JJ p
treatment NN p
for IN p
severe JJ p
PAN NNP p
or CC p
CSS NNP p
. . p

Factors NNS N
predicting VBG N
poor JJ N
prognosis NN N
were VBD N
renal JJ N
symptoms NNS N
, , N
gastrointestinal JJ N
tract NN N
involvement NN N
, , N
cardiomyopathy NN N
, , N
central JJ N
nervous JJ N
system NN N
involvement NN N
, , N
weight JJ N
loss NN N
> VBZ N
10 CD N
% NN N
of IN N
body NN N
weight NN N
, , N
and CC N
age NN N
> VBP N
50 CD N
years NNS N
old JJ N
. . N

Patients NNS N
with IN N
hepatitis NN N
B NNP N
virus-related JJ N
PAN NNP N
were VBD N
not RB N
included VBN N
in IN N
this DT N
study NN N
. . N

The DT N
end NN N
point NN N
of IN N
the DT N
study NN N
was VBD N
control NN N
of IN N
the DT N
disease NN N
( ( N
recovery NN N
or CC N
remission NN N
) ) N
or CC N
death NN N
. . N

RESULTS NNP N
Clinical NNP N
symptoms NNS N
and CC N
laboratory JJ N
findings NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
the DT N
2 CD N
groups NNS N
. . N

Initial NNP N
control NN N
of IN N
the DT N
disease NN N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Relapse NNP o
after IN N
initial JJ N
control NN N
of IN N
the DT N
disease NN N
was VBD N
observed VBN N
in IN N
7 CD N
patients NNS N
( ( N
4 CD N
in IN N
group NN N
A NNP N
and CC N
3 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

The DT N
mean JJ o
+/- JJ o
SD NNP o
followup NN o
period NN N
was VBD N
31.1 CD N
+/- JJ N
20 CD N
months NNS N
for IN N
group NN N
A NNP N
and CC N
35.9 CD N
+/- JJ N
16.8 CD N
months NNS N
for IN N
group NN N
B NNP N
. . N

At IN N
5 CD N
years NNS N
of IN N
followup NN N
, , N
38 CD N
patients NNS N
( ( N
61.3 CD N
% NN N
) ) N
were VBD N
cured VBN o
( ( N
16 CD N
in IN N
group NN N
A NNP N
and CC N
22 CD N
in IN N
group NN N
B NNP N
) ) N
, , N
and CC N
5 CD N
( ( N
8.1 CD N
% NN N
) ) N
were VBD N
in IN N
remission NN N
without IN N
treatment NN N
but CC N
had VBD N
not RB N
yet RB N
completed VBN N
the DT N
cure-defining JJ N
period NN N
of IN N
18 CD N
months NNS N
( ( N
3 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

Eight NNP N
( ( N
12.9 CD N
% NN N
) ) N
( ( N
2 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
were VBD N
considered VBN N
to TO N
be VB N
in IN N
clinical JJ o
remission NN o
and CC N
required VBD N
a DT N
maintenance NN o
regimen NN o
of IN o
low-dose JJ o
corticosteroids NNS o
. . o

Eleven JJ N
patients NNS N
died VBD o
during IN N
the DT N
study NN N
period NN N
( ( N
7 CD N
in IN N
group NN N
A NNP N
[ RB N
25 CD N
% NN N
] NN N
, , N
4 CD N
in IN N
group NN N
B NNP N
[ VBZ N
11.8 CD N
% NN N
] NN N
) ) N
. . N

Uncontrolled VBN N
vasculitis NN N
was VBD N
responsible JJ N
for IN N
4 CD N
deaths NNS o
( ( N
2 CD N
in IN N
each DT N
group NN N
) ) N
, , N
and CC N
treatment NN o
side NN o
effects NNS o
caused VBD N
the DT N
death NN o
of IN N
1 CD N
patient NN N
in IN N
group NN N
A NNP N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
5-year JJ o
cumulative JJ o
survival NN o
rates NNS o
of IN N
the DT N
2 CD N
groups NNS N
( ( N
75 CD N
% NN N
and CC N
88 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
our PRP$ N
data NNS N
, , N
combined VBN N
treatment NN N
with IN N
prednisone NN i
, , i
cyclophosphamide NN i
, , N
and CC N
plasma NN i
exchanges NNS i
is VBZ N
not RB N
superior JJ N
to TO N
treatment NN N
with IN N
prednisone NN i
and CC N
cyclophosphamide VB i
alone RB N
, , N
and CC N
plasma JJ N
exchanges NNS N
should MD N
not RB N
be VB N
systematically RB N
proposed VBN N
for IN N
initial JJ N
treatment NN N
of IN N
severe JJ N
PAN NNP N
or CC N
CSS NNP N
. . N

-DOCSTART- -21396848- O O

Noninfiltrative JJ i
anesthesia NN i
for IN N
transrectal JJ i
prostate NN i
biopsy NN i
: : i
a DT N
randomized JJ N
prospective JJ N
study NN N
comparing VBG N
lidocaine-prilocaine JJ i
cream NN i
and CC N
lidocaine-ketorolac JJ i
gel NN i
. . i

OBJECTIVES NNP N
Periprostatic NNP N
nerve NN N
block NN N
( ( N
PPNB NNP N
) ) N
is VBZ N
the DT N
standard JJ N
anesthesia NN i
for IN N
ultrasound NN N
( ( N
US NNP N
) ) N
guided VBD N
transrectal JJ p
prostate NN p
biopsy NN p
( ( p
TPB NNP p
) ) p
, , N
but CC N
periprostatic JJ N
infiltration NN N
itself PRP N
constitutes VBZ N
a DT N
major JJ N
, , N
though RB N
often RB N
neglected VBN N
, , N
source NN N
of IN N
discomfort NN N
even RB N
in IN N
patients NNS p
receiving VBG p
perianal-intrarectal JJ i
lidocaine-prilocaine NN i
( ( i
PILP NNP i
) ) i
cream NN i
before IN p
PPNB NNP p
. . p

Noninfiltrative NNP i
anesthesia NN i
therefore NN N
represents VBZ N
an DT N
attractive JJ N
alternative NN N
to TO N
periprostatic JJ N
infiltration NN N
. . N

With IN N
this DT N
in IN N
mind NN N
, , N
we PRP N
aimed VBD N
to TO N
determine VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
perianal-intrarectal JJ i
( ( i
PI NNP i
) ) i
lidocaine NN i
gel NN i
, , i
lidocaine-ketorolac JJ i
gel NN i
, , N
and CC N
lidocaine-prilocaine JJ i
cream NN i
in IN N
relieving VBG o
pain NN o
during IN N
TPB NNP N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Three NNP p
hundred VBD p
consecutive JJ p
patients NNS p
scheduled VBN p
for IN p
US-guided JJ p
TPB NNP p
were VBD N
randomized VBN N
1:1:1 CD N
to TO N
receive VB N
PI NNP i
administration NN N
of IN N
5 CD N
g JJ N
2.5 CD N
% NN N
lidocaine JJ i
gel NN i
10 CD N
minutes NNS N
before IN N
TPB NNP N
( ( N
Group NNP N
1 CD N
) ) N
, , N
or CC N
a DT N
mixture NN N
of IN N
5 CD i
g JJ i
2.5 CD i
% NN i
lidocaine JJ i
gel NN i
and CC i
0.3 CD i
% NN i
ketorolac NN i
tromethamine JJ i
solution NN i
1 CD i
hour NN i
before IN i
TPB NNP i
( ( N
Group NNP N
2 CD N
) ) N
, , N
or CC N
5 CD i
g JJ i
2.5 CD i
% NN i
lidocaine NN i
and CC i
2.5 CD i
% NN i
prilocaine NN i
cream NN i
20 CD i
minutes NNS i
before IN i
TPB NNP i
( ( N
Group NNP N
3 CD N
) ) N
. . N

The DT N
0-to-10 JJ o
points NNS o
visual JJ o
analogue JJ o
scale NN o
( ( o
VAS NNP o
) ) o
was VBD N
used VBN N
for IN N
assessing VBG N
pain NN N
at IN N
probe NN N
insertion NN N
and CC N
movements NNS N
( ( N
VAS-1 NNP N
) ) N
, , N
at IN N
prostate NN N
sampling NN N
( ( N
VAS-2 NNP N
) ) N
, , N
and CC N
maximal JJ N
procedural JJ N
pain NN N
( ( N
MPP NNP N
) ) N
. . N

Complications NNS N
occurring VBG N
up RB N
to TO N
20 CD N
days NNS N
after IN N
the DT N
procedure NN N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
Four NNP N
( ( N
1.3 CD N
% NN N
) ) N
patients NNS N
were VBD N
excluded VBN N
because IN N
of IN N
unbearable JJ o
pain NN o
during IN N
the DT N
procedure NN N
, , N
leaving VBG N
Group NNP N
1 CD N
with IN N
98 CD N
patients NNS N
, , N
Group NNP N
2 CD N
with IN N
99 CD N
, , N
and CC N
Group NNP N
3 CD N
with IN N
99 CD N
; : N
the DT N
3 CD N
groups NNS N
were VBD N
comparable JJ N
for IN N
patients NNS N
' POS N
age NN N
, , N
serum NN o
PSA NNP o
, , o
prostate NN o
volume NN o
, , o
and CC o
cancer NN o
detection NN o
rate NN o
. . o

The DT N
addition NN N
of IN N
either DT N
ketorolac NN i
or CC N
prilocaine NN i
to TO i
lidocaine VB i
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
reduced VBD N
probe-related JJ N
, , N
sampling-related JJ N
, , N
and CC N
maximal JJ N
procedural JJ o
pain NN o
. . o

Compared VBN N
with IN N
lidocaine-prilocaine JJ i
, , i
lidocaine-ketorolac JJ i
was VBD N
less RBR N
effective JJ N
in IN N
relieving VBG N
probe-related JJ o
pain NN o
( ( N
mean JJ N
VAS-1 NNP N
: : N
1.47 CD N
? . N
1.30 CD N
vs. IN N
0.39 CD N
? . N
0.65 CD N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
but CC N
more RBR N
effective JJ N
in IN N
relieving VBG o
sampling-related JJ o
pain NN o
( ( o
mean JJ N
VAS-2 NNP N
: : N
0.76 CD N
? . N
0.94 CD N
vs. IN N
1.54 CD N
? . N
1.02 CD N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
; : N
there EX N
was VBD N
no DT N
difference NN N
in IN N
MPP NNP N
( ( N
mean VB N
1.82 CD N
? . N
1.21 CD N
vs. IN N
1.67 CD N
? . N
0.95 CD N
) ) N
, , N
probably RB N
due JJ N
to TO N
such JJ N
different JJ N
efficacy NN N
on IN N
the DT N
two CD o
pain NN o
sources NNS o
. . o

Complications NNS o
were VBD N
similar JJ N
in IN N
the DT N
3 CD N
groups NNS N
. . N

CONCLUSIONS NNP i
Lidocaine-prilocaine JJ i
cream NN i
was VBD N
most RBS N
effective JJ N
on IN N
probe-related JJ o
pain NN o
, , o
whereas IN i
lidocaine-ketorolac JJ i
gel NN i
was VBD i
most RBS N
effective JJ N
on IN N
sampling-related JJ N
pain NN N
. . N

These DT N
noninfiltrative JJ N
anesthetics NNS N
were VBD N
safe JJ N
, , N
easy JJ N
to TO N
administer VB N
, , N
and CC N
well RB N
accepted VBN N
by IN N
patients NNS N
; : N
the DT N
possibility NN N
to TO N
combine VB N
them PRP N
to TO N
further JJ N
improve VB o
pain NN o
control NN o
during IN o
TPB NNP N
deserves VBZ N
further JJ N
well-designed JJ N
studies NNS N
. . N

-DOCSTART- -15453848- O O

Position NN N
of IN N
anterior JJ N
capsulorhexis NN N
and CC N
posterior JJ N
capsule NN N
opacification NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
whether IN N
the DT N
position NN N
of IN N
the DT N
anterior JJ N
continuous JJ N
curvilinear NN N
capsulorhexis NN N
influences VBZ N
the DT N
rate NN o
of IN o
posterior JJ o
capsule NN o
opacification NN o
( ( o
PCO NNP o
) ) o
. . o

METHODS CC N
A DT p
total NN p
of IN p
119 CD p
patients NNS p
, , p
aged VBN p
61-86 CD p
years NNS p
, , p
underwent JJ p
cataract NN p
surgery NN p
with IN p
phacoemulsification NN p
performed VBN p
by IN p
a DT p
single JJ p
surgeon NN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
implantation NN N
with IN N
either CC N
a DT N
silicone NN i
intraocular NN i
lens NNS i
( ( i
IOL NNP i
) ) i
( ( i
SI40NB NNP i
, , i
Allergan NNP i
) ) i
or CC i
an DT i
AcrySof NNP i
IOL NNP i
( ( N
MA60BM NNP N
, , N
Alcon NNP N
) ) N
. . N

Three CD N
years NNS N
after IN N
surgery NN N
, , N
the DT N
rate NN o
of IN o
PCO NNP o
was VBD N
analysed VBN N
using VBG N
the DT N
evaluation NN N
of IN N
posterior JJ N
capsule NN N
opacification NN N
computer NN N
software NN N
( ( N
EPCO NNP N
) ) N
. . N

The DT N
results NNS N
were VBD N
related VBN N
to TO N
the DT N
capsulorhexis NN N
position NN N
, , N
which WDT N
was VBD N
assessed VBN N
with IN N
a DT N
retroillumination NN N
photograph NN N
. . N

RESULTS VB N
If IN N
the DT N
capsulorhexis NN o
was VBD N
located VBN N
partially RB N
or CC N
completely RB N
off IN N
the DT N
optics NNS o
of IN o
the DT o
IOL NNP o
, , N
compared VBN N
to TO N
totally RB o
on IN o
the DT o
IOL NNP o
, , N
significantly RB N
more JJR N
PCO NNP o
was VBD N
found VBN N
( ( N
p JJ N
= NNP N
0.0014 CD N
) ) N
. . N

When WRB N
comparing VBG N
within IN N
each DT N
IOL NNP N
type NN N
, , N
patients NNS N
with IN N
AcrySof NNP N
IOLs NNP N
were VBD N
found VBN N
to TO N
have VB N
significantly RB N
less JJR N
PCO NNP o
when WRB N
the DT N
capsulorhexis NN N
was VBD N
totally RB N
on IN N
the DT N
optic JJ N
( ( N
p JJ N
= NNP N
0.0048 CD N
) ) N
. . N

This DT N
difference NN N
was VBD N
also RB N
significant JJ N
in IN N
the DT N
silicone NN N
group NN N
( ( N
p JJ N
= NNP N
0.041 CD N
) ) N
. . N

CONCLUSION VB N
A NNP N
relatively RB N
small JJ N
and CC N
central JJ N
capsulorhexis NN N
allowing VBG N
for IN N
the DT N
complete JJ N
covering NN N
of IN N
the DT N
IOL NNP i
optics NNS i
by IN N
the DT N
rhexis NN N
edges VBZ N
seems VBZ N
to TO N
protect VB N
against IN N
PCO NNP o
in IN N
cataract NN N
surgery NN N
, , N
with IN N
both DT N
round-edged JJ N
silicone NN N
IOLs NNP N
and CC N
sharp-edged JJ N
hydrophobic JJ N
acrylic JJ i
IOLs NNP i
. . i

-DOCSTART- -11710599- O O

Absence NN o
of IN o
cervical JJ o
radiation NN o
myelitis NN o
after IN N
hyperfractionated VBN i
radiation NN i
therapy NN i
with IN N
and CC N
without IN N
concurrent JJ i
chemotherapy NN i
for IN N
locally RB p
advanced JJ p
, , p
unresectable JJ p
, , p
nonmetastatic JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
. . p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
risk NN o
of IN o
developing VBG o
radiation NN o
myelitis NN o
after IN N
a DT N
cervical JJ N
spinal NN N
cord NN N
dose NN N
of IN N
50.6 CD N
Gy NNP i
given VBN N
via IN N
1.1 CD N
Gy NNP N
b.i.d NN N
. . N

fractionation NN N
during IN N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
of IN N
hyperfractionated JJ i
radiation NN i
therapy NN i
( ( i
HFX NNP i
RT NNP i
) ) i
to TO N
a DT N
total JJ N
dose NN N
of IN N
77 CD N
Gy NNP i
given VBN N
in IN N
70 CD N
fractions NNS N
of IN N
1.1 CD N
Gy NNP N
b.i.d. NN N
, , N
with IN N
and CC N
without IN N
concurrent JJ N
low-dose JJ N
, , N
daily JJ N
cisplatin NN i
( ( i
CDDP NNP i
) ) i
for IN N
head NN p
and CC p
neck NN p
cancer NN p
. . p

METHODS NNP N
Of IN N
130 CD p
patients NNS p
with IN p
locally RB p
advanced VBN p
, , p
unresectable JJ p
, , p
nonmetastatic JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
( ( p
SCC NNP p
H NNP p
& CC p
N NNP p
) ) p
who WP N
entered VBD N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
, , N
101 CD N
patients NNS N
received VBD N
50.6 CD i
Gy NNP i
to TO i
a DT N
portion NN N
of IN N
their PRP$ N
spinal JJ N
cord NN N
and CC N
survived VBD N
> NNS N
1 CD N
year NN N
following VBG N
the DT N
beginning NN N
of IN N
therapy NN N
. . N

Forty-five JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
HFX NNP i
RT NNP i
alone RB N
and CC N
fifty-six JJ N
patients NNS N
also RB N
received VBD N
CDDP NNP i
. . i

RESULTS NNP N
None NN N
of IN N
these DT N
101 CD N
patients NNS N
developed VBD N
cervical JJ o
radiation NN o
myelitis NN o
. . o

Therefore RB N
, , N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
potentially RB o
contributing VBG o
factors NNS o
on IN N
the DT N
occurrence NN o
of IN o
radiation NN o
myelitis NN o
, , N
such JJ N
as IN N
interfraction NN o
interval NN o
, , o
cord NN o
length NN o
, , o
and CC o
administration NN o
of IN o
concurrent JJ o
CDDP NNP o
. . o

CONCLUSIONS NNP N
Given NNP N
the DT N
increasing VBG N
number NN N
of IN N
studies NNS N
with IN N
both DT N
altered VBN N
fractionated VBN N
regimens NNS N
and CC N
concurrent JJ N
radio-chemotherapy NN i
in IN N
SCC NNP N
H NNP N
& CC N
N NNP N
, , N
new JJ N
studies NNS N
with IN N
more JJR N
patients NNS N
are VBP N
needed VBN N
to TO N
gain VB N
better JJR N
insight NN N
into IN N
the DT N
risks NNS o
of IN o
developing VBG o
cervical JJ o
radiation NN o
myelitis NN o
. . o

-DOCSTART- -12666946- O O

Comparative JJ N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
metronidazole JJ i
application NN N
in IN N
adult NN p
periodontitis NN p
; : p
12-months JJ N
results NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
application NN N
of IN N
25 CD N
% NN N
metronidazole JJ i
dental JJ i
gel NN i
as IN N
an DT N
adjunct NN N
to TO N
scaling NN i
and CC i
root NN i
planing NN i
( ( i
SRP NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
adult NN p
periodontitis NN p
. . p

Eighty NNP p
teeth VBZ p
in IN p
18 CD p
patients NNS p
were VBD N
evaluated VBN N
using VBG N
a DT N
split NN N
mouth NN N
design NN N
. . N

The DT N
test NN N
teeth NN N
received VBD N
SRP NNP i
and CC N
a DT N
25 CD N
% NN N
metronidazole JJ i
gel NN i
applied VBN N
subgingivally RB N
on IN N
days NNS N
0 CD N
and CC N
7 CD N
. . N

The DT N
control NN N
teeth VBZ N
received VBN N
SRP NNP i
only RB i
. . i

Clinical JJ N
and CC N
microbiological JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
treatment NN N
and CC N
on IN N
weeks NNS N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
13 CD N
, , N
26 CD N
, , N
38 CD N
and CC N
52 CD N
of IN N
the DT N
experimental JJ N
period NN N
. . N

Colony NNP N
forming VBG N
units NNS N
of IN N
Porphyromonas NNP N
gingivalis NN N
and CC N
Prevotella NNP N
intermedia VBP N
/ NNP N
Prevotella NNP N
nigrescens NNS N
were VBD N
determined VBN N
. . N

Both DT N
treatments NNS N
provided VBD N
significant JJ N
improvements NNS N
in IN N
all PDT N
the DT N
clinical JJ o
and CC o
microbiological JJ o
parameters NNS o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
none NN N
of IN N
the DT N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
were VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

As IN N
a DT N
conclusion NN N
, , N
the DT N
present JJ N
study NN N
does VBZ o
not RB o
provide VB o
evidence NN o
in IN o
favour NN o
of IN o
the DT o
routine JJ o
use NN o
of IN o
adjunctive JJ o
metronidazole JJ o
dental NN o
gel NN o
in IN N
the DT N
treatment NN N
of IN N
adult NN o
periodontitis NN o
. . o

-DOCSTART- -6123810- O O

Clobazam NNP i
in IN N
catamenial JJ p
epilepsy NN p
. . p

A DT N
model NN N
for IN N
evaluating VBG N
anticonvulsants NNS N
. . N

The DT N
cyclical JJ N
exacerbations NNS N
of IN N
epilepsy NN N
( ( N
catamenial JJ N
epilepsy NN N
) ) N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
antiepileptic JJ N
effect NN N
of IN N
a DT N
benzodiazepine NN i
, , i
clobazam NN i
. . i

Doses NNS N
of IN N
20 CD N
mg NN N
, , N
and CC N
in IN N
some DT N
cases NNS N
30 CD N
mg NN N
, , N
per IN N
day NN N
were VBD N
compared VBN N
with IN N
placebo NN i
over IN N
predetermined JJ N
ten-day JJ N
periods NNS N
in IN N
a DT N
double-blind JJ N
cross-over NN N
study NN N
. . N

The DT N
results NNS N
were VBD N
evaluated VBN N
by IN N
preference NN N
in IN N
a DT N
sequential JJ N
procedure NN N
. . N

In IN N
14 CD p
of IN p
18 CD p
patients NNS p
who WP p
received VBD p
both DT p
treatments NNS p
clobazam NN i
was VBD N
superior JJ N
to TO N
placebo VB i
, , N
and CC N
in IN N
4 CD N
patients NNS N
no DT N
preference NN N
was VBD N
established VBN N
. . N

Clobazam NNP i
completely RB N
prevented VBD N
seizures NNS o
in IN N
most JJS N
of IN N
the DT N
patients NNS N
, , N
and CC N
toxic JJ N
effects NNS N
were VBD N
of IN N
low JJ N
frequency NN o
and CC o
severity NN o
. . o

-DOCSTART- -11159256- O O

The DT N
response NN N
of IN N
neuropathic JJ o
pain NN o
and CC o
pain NN o
in IN o
complex JJ o
regional JJ o
pain NN o
syndrome NN o
I PRP p
to TO N
carbamazepine VB i
and CC N
sustained-release JJ i
morphine NN i
in IN N
patients NNS p
pretreated VBN p
with IN p
spinal JJ i
cord NN i
stimulation NN i
: : i
a DT N
double-blinded JJ N
randomized NN N
study NN N
. . N

Forty-three JJ p
patients NNS p
with IN p
peripheral JJ p
neuropathic JJ p
pain NN p
, , p
exclusively RB p
pain NN p
reduced VBN p
by IN p
spinal JJ i
cord NN i
stimulation NN i
( ( i
SCS NNP i
) ) i
, , p
were VBD p
switched VBN p
into IN p
a DT p
painful JJ p
state NN p
after IN p
SCS NNP i
inactivation NN p
. . p

This DT N
mode NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
pain-relieving JJ N
effect NN N
of IN N
carbamazepine NN i
( ( i
CMZ NNP i
) ) i
and CC N
opioids NNS i
in IN N
a DT N
double-blinded JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

In IN N
Phase NNP N
1 CD N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
CMZ NNP i
( ( i
600 CD i
mg/d NN i
) ) i
or CC i
placebo NN i
during IN N
an DT N
SCS-free JJ N
period NN N
of IN N
8 CD N
days NNS N
. . N

In IN N
Phase NNP N
2 CD N
, , N
after IN N
a DT N
CMZ NNP i
elimination NN N
interval NN N
of IN N
7 CD N
days NNS N
, , N
38 CD N
patients NNS N
received VBD N
either RB N
sustained-release JJ i
morphine NN i
( ( i
90 CD i
mg/d NN i
) ) i
or CC i
placebo NN i
for IN N
8 CD N
days NNS N
. . N

In IN N
cases NNS N
of IN N
intolerable JJ o
pain NN o
, , N
the DT N
patients NNS N
were VBD N
authorized VBN N
to TO N
reactivate VB N
their PRP$ N
SCS NNP i
. . i

The DT N
pain NN o
intensity NN o
was VBD N
rated VBN N
on IN N
a DT N
numeric JJ o
analog NN o
scale NN o
. . o

In IN N
38 CD N
patients NNS N
who WP N
completed VBD N
Phase NNP N
1 CD N
, , N
significant JJ N
delay NN o
in IN o
pain JJ o
increase NN o
was VBD N
observed VBN N
in IN N
the DT N
CMZ NNP i
group NN N
as IN N
compared VBN N
with IN N
placebo NN i
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

In IN N
Phase NNP N
2 CD N
, , N
the DT N
trend NN N
observed VBD N
with IN N
morphine NN i
was VBD N
insignificant JJ N
( ( N
P NNP N
= NNP N
0.41 CD N
) ) N
. . N

Two CD N
CMZ JJ i
patients NNS N
and CC N
one CD N
morphine NN i
patient NN N
showed VBD N
complete JJ o
pain NN o
relief NN o
and CC N
preferred VBN N
to TO N
continue VB N
the DT N
medication NN N
. . N

Thirty-five JJ N
patients NNS N
returned VBN N
to TO N
SCS NNP i
. . i

We PRP N
conclude VBP N
that DT N
CMZ NNP i
is VBZ N
effective JJ N
in IN N
peripheral JJ N
neuropathic JJ o
pain NN o
. . o

Morphine NNP i
obviously RB N
requires VBZ N
larger JJR N
individually RB N
titrated VBD N
dosages NNS N
than IN N
those DT N
used VBN N
in IN N
this DT N
study NN N
for IN N
results NNS N
to TO N
be VB N
adequately RB N
interpreted VBN N
. . N

-DOCSTART- -18855271- O O

The DT N
effect NN N
of IN N
trandolapril NN i
and CC N
its PRP$ N
fixed-dose JJ N
combination NN N
with IN N
verapamil NN i
on IN N
circulating VBG N
adhesion NN N
molecules NNS N
levels NNS N
in IN N
hypertensive JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

BACKGROUND NNP N
AND NNP N
AIM NNP N
Endothelial NNP N
dysfunction NN N
in IN N
hypertensive JJ p
type-2 JJ p
diabetic JJ p
patients NNS p
is VBZ N
associated VBN N
with IN N
increased JJ N
levels NNS N
of IN N
circulating VBG N
soluble JJ o
adhesion NN o
molecules NNS o
( ( o
SAM NNP o
) ) o
. . o

SAM NNP N
participate VB N
in IN N
the DT N
development NN N
of IN N
diabetic JJ N
macroangiopathy NN N
and CC N
microangiopathy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
trandolapril NN i
( ( i
T NNP i
) ) i
and CC N
its PRP$ N
fixed-dose JJ N
combination NN N
with IN N
verapamil NN i
( ( i
FDTV NNP i
) ) i
on IN N
SAM NNP N
levels NNS N
in IN N
hypertensive JJ p
type-2 JJ p
diabetic JJ p
patients NNS p
. . p

METHODS NNP N
Forty NNP p
type-2 JJ p
diabetic JJ p
patients NNS p
with IN p
never-treated JJ p
hypertension NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
. . N

One CD N
group NN N
( ( i
FDTV NNP i
) ) i
received VBD N
2/180 CD N
mg NN N
once RB N
a DT N
day NN N
; : N
the DT N
other JJ N
group NN N
received VBD N
T NNP i
2 CD N
mg NN N
once RB N
a DT N
day NN N
. . N

Study NNP N
drugs NNS N
were VBD N
administered VBN N
for IN N
three CD N
months NNS N
in IN N
both DT N
groups NNS N
. . N

VCAM-1 NNP o
, , o
ICAM NNP o
, , o
and CC o
E-selectin NNP o
were VBD N
measured VBN N
by IN N
ELISA NNP N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
monthly RB N
for IN N
blood NN N
pressure NN N
, , N
fasting VBG N
serum NN N
glucose NN N
, , N
and CC N
adverse JJ N
events NNS N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
with IN N
ANOVA NNP N
. . N

RESULTS NNP N
Both NNP N
therapeutics NNS N
regimens NNS N
reduced VBD N
significantly RB N
the DT N
levels NNS o
of IN o
the DT o
SAM NNP o
tested VBD o
. . o

When WRB N
both DT N
groups NNS N
were VBD N
compared VBN N
, , N
we PRP N
did VBD N
not RB N
find VB N
a DT N
significant JJ N
difference NN N
in IN N
ICAM NNP o
and CC o
E-selectin NNP o
reduction NN o
. . o

However RB N
, , N
VCAM-1 NNP o
presented VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
( ( N
p JJ N
= NNP N
0.022 CD N
) ) N
in IN N
the DT N
trandolapril-verapamil JJ i
group NN N
. . N

No DT N
patient NN N
suffered VBD N
adverse JJ o
events NNS o
. . o

CONCLUSION NNP N
Our PRP$ N
results NNS N
show VBP N
that IN N
FDTV NNP N
produces VBZ N
a DT N
greater JJR N
reduction NN N
of IN N
VCAM-1 NNP N
circulating NN N
levels NNS N
than IN N
trandolapril NN N
alone RB N
. . N

This DT N
may MD N
explain VB N
some DT N
of IN N
the DT N
beneficial JJ N
effects NNS N
of IN N
this DT N
fixed VBN N
dosed JJ N
combination NN N
that WDT N
are VBP N
non-related JJ N
to TO N
its PRP$ N
antihypertensive JJ N
effects NNS N
. . N

-DOCSTART- -16900709- O O

The DT N
efficacy NN N
of IN N
conventional JJ i
PCNL NNP i
and CC i
two CD i
modifications NNS i
to TO i
standard JJ i
procedure NN i
. . i

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
conventional JJ i
Percutaneous JJ i
Nephrolithotomy NNP i
( ( i
PCNL NNP i
) ) i
with IN N
two CD N
of IN N
its PRP$ N
modified JJ N
procedures NNS N
. . N

METHODS NNP N
A NNP N
randomized VBD N
controlled VBN N
trial NN N
, , N
was VBD N
performed VBN N
on IN N
60 CD p
patients NNS p
undergoing JJ p
PCNL NNP i
. . i

Cases NNS p
of IN p
renal JJ p
stone NN p
regardless NN p
of IN p
stone NN p
size NN p
and CC p
configuration NN p
, , p
having VBG p
pre-operative JJ p
negative JJ p
urine JJ p
culture NN p
, , p
no DT p
coagulopathy NN p
, , p
and CC p
no DT p
visible JJ p
residual JJ p
stone NN p
in IN p
intra-operative JJ p
fluoroscopy NN p
, , p
were VBD p
included VBN p
. . p

They PRP N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
of IN N
20 CD N
cases NNS N
each DT N
with IN N
nephrostomy JJ i
tube NN i
( ( i
NT NNP i
) ) i
and CC i
temporary JJ i
ureteral JJ i
catheter NN i
( ( i
TU NNP i
) ) i
in IN N
group NN N
A NNP N
, , N
only RB i
TU NNP i
in IN N
group NN N
B NNP N
and CC N
only RB i
indwelling VBG i
ureteral JJ i
catheter NN i
( ( i
IU NNP i
) ) i
in IN N
group NN N
C. NNP N
Mean NNP p
age NN p
of IN p
cases NNS p
were VBD p
43.2 CD p
( ( p
25-70 JJ p
) ) p
, , p
40.1 CD p
( ( p
25-73 JJ p
) ) p
, , p
and CC p
44 CD p
( ( p
25-70 JJ p
) ) p
years NNS p
in IN p
groups NNS p
A NNP p
, , p
B NNP p
and CC p
C NNP p
, , p
respectively RB p
( ( N
P NNP N
= NNP N
0.6 CD N
) ) N
. . N

Procedures NNS N
were VBD N
performed VBN N
under IN N
general JJ N
anaesthesia NN N
, , N
using VBG N
standard JJ N
techniques NNS N
for IN N
access NN N
and CC N
lithotomy NN N
. . N

Forty-eight JJ N
hours NNS N
, , N
2 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
after IN N
PCNL NNP i
, , N
plain VBP N
X-ray JJ N
abdomen NNS N
, , N
ultrasonography NN N
and CC N
IVP NNP N
were VBD N
performed VBN N
for IN N
each DT N
case NN N
. . N

RESULTS NNP N
Only RB N
one CD N
case NN N
in IN N
group NN N
A NNP N
had VBD N
urinary JJ o
leakage NN o
after IN N
removal NN N
of IN N
nephrostomy JJ N
tube NN N
. . N

No DT N
cases NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
encountered VBD N
this DT N
problem NN N
. . N

There EX N
was VBD N
no DT N
haemorrhagic JJ o
episode NN o
. . o

Ultrasonic JJ N
evaluation NN N
showed VBD N
mild JJ o
residue NNS o
in IN N
3 CD N
, , N
1 CD N
and CC N
1 CD N
cases NNS N
of IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.2 CD N
) ) N
. . N

No UH N
collective JJ o
fluid NN o
was VBD N
found VBN N
in IN N
these DT N
groups NNS N
. . N

IVP NNP N
showed VBD N
dilatation NN o
without IN o
obstruction NN o
in IN N
3 CD N
subjects NNS N
of IN N
group NN N
A NNP N
and CC N
none NN N
in IN N
group NN N
B NNP N
or CC N
C NNP N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSION NNP N
Tubeless NNP i
PCNL NNP i
seems VBZ N
to TO N
be VB N
accompanied VBN N
by IN N
better JJR N
outcome NN N
. . N

So RB N
, , N
further JJ N
evaluation NN N
on IN N
more JJR N
patients NNS N
seems VBZ N
necessary JJ N
. . N

-DOCSTART- -18051010- O O

Effect NN N
of IN N
a DT N
ferrule NN i
and CC N
increased VBD N
clinical JJ N
crown NN N
length NN N
on IN N
the DT N
in IN N
vitro JJ N
fracture NN N
resistance NN N
of IN N
premolars NNS p
restored VBN p
using VBG p
two CD p
dowel-and-core JJ p
systems NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
a DT N
crown-lengthening JJ i
ferrule NN i
on IN N
the DT N
fracture NN N
resistance NN N
of IN N
endodontically-treated JJ p
teeth NNS p
restored VBN p
with IN p
two CD p
dowel-core JJ p
systems NNS p
. . p

Thirty-two NNP p
extracted VBD p
mandibular JJ p
first JJ p
premolars NNS p
were VBD N
sectioned VBN N
perpendicular JJ N
to TO N
the DT N
long JJ N
axis NN N
at IN N
a DT N
point NN N
1.0 CD N
mm NN N
occlusal NN N
to TO N
the DT N
buccal JJ N
cementoenamel NN N
junction NN N
. . N

Following VBG N
endodontic JJ N
treatment NN N
, , N
the DT N
teeth NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
: : N
cast VBN i
Ni-Cr JJ i
alloy NN i
dowel-core NN i
with IN i
no DT i
ferrule NN i
( ( i
Group NNP i
A1 NNP i
) ) i
, , i
cast VBD i
Ni-Cr JJ i
alloy NN i
dowel-core NN i
with IN i
2.0 CD i
mm NNS i
ferrule NN i
( ( i
Group NNP i
A2 NNP i
) ) i
, , i
prefabricated VBN i
carbon NN i
fiber-reinforced JJ i
dowel-resin NN i
core NN i
with IN i
no DT i
ferrule NN i
( ( i
Group NNP i
B1 NNP i
) ) i
and CC N
carbon JJ i
fiber-reinforced JJ i
dowel-resin NN i
core NN i
with IN i
2.0 CD i
mm NNS i
ferrule NN i
( ( N
Group NNP N
B2 NNP N
) ) N
. . N

Each DT N
specimen NN N
was VBD N
embedded VBN N
in IN N
a DT N
self-cured JJ N
acrylic JJ N
resin NN N
block NN N
from IN N
2.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
margins NNS N
of IN N
a DT N
cast JJ N
Ni-Cr JJ N
alloy NN N
crown NN N
, , N
then RB N
loaded VBD N
at IN N
150 CD N
degrees NNS N
from IN N
the DT N
long JJ N
axis NN N
in IN N
a DT N
universal JJ N
testing VBG N
machine NN N
at IN N
a DT N
crosshead JJ N
speed NN N
of IN N
1.0 CD N
mm/minute NN N
until IN N
fracture NN N
. . N

The DT N
data NNS N
were VBD N
recorded VBN N
and CC N
analyzed VBN N
using VBG N
ANOVA NNP o
and CC o
Fisher NNP o
's POS o
exact NN o
tests NNS o
, , N
with IN N
alpha JJ N
= $ N
0.05 CD N
. . N

Mean JJ o
failure NN o
loads NNS o
( ( o
kN NN o
) ) o
for IN N
the DT N
A1 NNP N
, , N
A2 NNP N
, , N
B1 NNP N
and CC N
B2 NNP N
Groups NNP N
were VBD N
: : N
1.46 CD N
( ( N
S.D NNP N
. . N

0.45 CD N
) ) N
, , N
1.07 CD N
( ( N
0.21 CD N
) ) N
, , N
1.13 CD N
( ( N
0.30 CD N
) ) N
and CC N
1.02 CD N
( ( N
0.27 CD N
) ) N
. . N

The DT N
teeth NNS N
restored VBD N
with IN N
cast JJ i
Ni-Cr JJ i
dowel-cores NNS i
and CC i
2.0 CD i
mm NN i
ferrules NNS i
demonstrated VBD N
significantly RB N
lower JJR N
fracture NN o
strengths NNS o
, , N
p VBP N
= JJ N
0.04 CD N
. . N

There EX N
were VBD N
significant JJ N
differences NNS N
in IN N
the DT N
root NN o
fracture NN o
patterns VBZ o
between IN N
the DT N
two CD N
dowel NN N
systems NNS N
, , N
with IN N
the DT N
carbon NN i
fiber-reinforced JJ i
dowel-resin NN i
core NN i
system NN i
, , N
being VBG N
the DT N
less JJS N
severe JJ N
p NN N
< VBD N
0.05 CD N
. . N

Crown NNP i
lengthening VBG i
with IN N
a DT N
2.0 CD i
mm NN i
apical JJ i
extended VBD i
ferrule NN i
resulted VBD N
in IN N
reduced JJ N
fracture NN o
strengths NNS o
for IN N
endodontically-treated JJ N
teeth NNS N
restored VBN N
using VBG N
two CD N
dowel-core JJ N
systems NNS N
and CC N
cast JJ N
metal NN N
crowns NNS N
. . N

The DT N
carbon NN N
fiber-reinforced JJ N
dowel-resin NN N
core NN N
system NN N
reduced VBD N
the DT N
severity NN N
of IN N
the DT N
root NN p
fractures NNS p
. . p

-DOCSTART- -18184678- O O

Impact NN N
of IN N
a DT N
controlled VBN i
heated VBN i
breathing VBG i
tube NN i
humidifier NN i
on IN N
sleep JJ o
quality NN o
during IN N
CPAP NNP i
therapy NN i
in IN p
a DT p
cool JJ p
sleeping NN p
environment NN p
. . p

There EX N
are VBP N
conflicting VBG N
data NNS N
on IN N
the DT N
effect NN N
of IN N
adding VBG N
a DT N
heated VBN i
humidifier NN i
to TO N
nasal RB N
continuous JJ i
positive JJ i
airway NN i
pressure NN i
( ( i
CPAP NNP i
) ) i
therapy NN i
for IN N
patients NNS p
with IN p
obstructive JJ p
sleep JJ p
apnoea NN p
syndrome NN p
( ( p
OSAS NNP p
) ) p
. . p

The DT N
effects NNS N
of IN N
heated JJ N
humidification NN N
on IN N
sleep JJ o
quality NN o
and CC o
treatment NN o
side-effects NNS o
for IN N
patients NNS N
who WP N
prefer VBP N
a DT N
cold JJ N
bedroom NN N
environment NN N
have VBP N
not RB N
been VBN N
studied VBN N
. . N

A DT N
randomised JJ N
, , N
controlled VBD N
crossover RB N
trial NN N
involving VBG N
19 CD p
patients NNS p
with IN p
a DT p
first-ever JJ p
diagnosis NN p
of IN p
OSAS NNP p
measured VBD N
the DT N
effect NN N
of IN N
conventional JJ i
heated JJ i
humidification NN i
added VBD i
to TO i
CPAP NNP i
compared VBN N
with IN N
a DT N
controlled VBN i
heated VBN i
breathing VBG i
tube NN i
humidifier NN i
( ( i
ThermoSmart NNP i
( ( i
R NNP i
) ) i
; : i
Fisher NNP N
and CC N
Paykel NNP N
Healthcare NNP N
, , N
Auckland NNP N
, , N
New NNP N
Zealand NNP N
) ) N
on IN N
sleep JJ o
quality NN o
. . o

During IN N
the DT N
night NN N
in IN N
the DT N
sleep JJ N
laboratory NN N
at IN N
a DT N
mean JJ N
room NN N
temperature NN N
of IN N
14 CD N
degrees NNS N
C NNP N
, , N
less JJR N
condensation NN o
formed VBN N
with IN N
the DT N
controlled VBN i
heated VBD i
breathing VBG i
tube NN i
humidifier NN i
( ( N
1.9 CD N
mL NN N
versus NN N
35.3 CD N
mL NN N
) ) N
in IN N
the DT N
delivery NN N
system NN N
. . N

In IN N
addition NN N
, , N
the DT N
total JJ o
sleep JJ o
time NN o
, , o
time NN o
spent VBN o
in IN o
sleep JJ o
stages NNS o
3 CD o
and CC o
4 CD o
, , o
and CC o
rapid JJ o
eye NN o
movement NN o
sleep JJ o
phases NNS o
were VBD N
significantly RB N
longer RBR N
and CC N
the DT N
overall JJ o
side-effect JJ o
score NN o
was VBD N
lower JJR N
than IN N
with IN N
conventional JJ N
heated JJ N
humidification NN N
. . N

Patients NNS N
on IN N
nasal JJ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
desiring VBG N
a DT N
cool JJ N
bedroom NN N
temperature NN N
could MD N
benefit VB N
from IN N
controlled VBN i
heated VBN i
breathing VBG i
tube JJ i
humidification NN i
technology NN i
( ( N
with IN N
inputs NNS N
from IN N
ambient JJ N
temperature NN N
, , N
set VBN N
pressure NN N
and CC N
flow NN N
) ) N
. . N

-DOCSTART- -8707361- O O

Comparison NNP N
of IN N
regimens NNS N
of IN N
amphotericin NN i
B NNP i
deoxycholate NN i
in IN N
kala-azar NN p
. . p

A DT N
total NN N
of IN N
288 CD p
parasitologically RB p
proved JJ p
patients NNS p
of IN p
kala-azar NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
treatment NN N
groups NNS N
. . N

Patients NNS N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
received VBD N
amphotericin JJ i
B NNP i
( ( i
AMB NNP i
) ) i
in IN N
a DT N
dose NN N
of IN N
1 CD N
mg/kg NNS N
body NN N
weight NN N
( ( N
bw NN N
) ) N
/day NN N
, , N
0.75 CD N
mg/kg NN N
bw/day NN N
and CC N
0.5 CD N
mg/kg NNS N
bw/day NN N
for IN N
20 CD N
days NNS N
respectively RB N
. . N

Apparent JJ o
cure NN o
( ( N
afebrile NN N
at IN N
the DT N
end NN N
of IN N
therapy NN N
) ) N
occurred VBD N
in IN N
all DT N
patients NNS N
and CC N
parasitological JJ o
cure NN o
in IN N
96 CD N
( ( N
100 CD N
% NN N
) ) N
, , N
92 CD N
( ( N
96 CD N
% NN N
) ) N
and CC N
84 CD N
( ( N
88 CD N
% NN N
) ) N
patients NNS N
respectively RB N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C. NNP N
Ultimate NNP o
cure NN o
( ( N
no DT N
relapse NN N
in IN N
six CD N
months NNS N
of IN N
follow VBP N
up RP N
) ) N
occurred VBD N
in IN N
95 CD N
( ( N
99 CD N
% NN N
) ) N
, , N
87 CD N
( ( N
91 CD N
% NN N
) ) N
and CC N
79 CD N
( ( N
82 CD N
% NN N
) ) N
patients NNS N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
respectively RB N
. . N

The DT N
difference NN N
between IN N
the DT N
ultimate JJ o
cure NN o
in IN N
the DT N
three CD N
groups NNS N
was VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
adverse JJ o
events NNS o
( ( o
rise NN o
in IN o
serum JJ o
creatinine NN o
and CC o
fall NN o
in IN o
serum JJ o
potassium NN o
, , o
loss NN o
of IN o
appetite NN o
and CC o
shivering NN o
, , o
rigor NN o
and CC o
fever NN o
during IN o
infusion NN o
indicative NN o
of IN o
renal JJ o
, , o
GIT NNP o
and CC o
infusion NN o
related JJ o
toxicities NNS o
respectively RB o
) ) o
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

This DT N
study NN N
showed VBD N
that IN N
amphotericin NN i
B NNP i
should MD N
be VB N
given VBN N
at IN N
a DT N
dosage NN N
of IN N
1 CD N
mg/kg NNS N
bw/day NN N
for IN N
20 CD N
days NNS N
for IN N
Indian JJ p
kala-azar JJ p
patients NNS p
to TO N
minimise VB N
relapses NNS o
and CC N
prevent NN N
development NN o
of IN N
drug NN o
unresponsiveness NN o
. . o

-DOCSTART- -1884668- O O

Levels NNS N
of IN N
opioid JJ p
physical JJ p
dependence NN p
in IN p
heroin NN p
addicts NNS p
. . p

The DT N
levels NNS N
of IN N
opioid JJ N
physical JJ N
dependence NN N
in IN N
a DT N
group NN N
of IN N
long-term JJ p
heroin NN p
addicts NNS p
were VBD N
ascertained VBN N
by IN N
measuring VBG N
the DT N
severity NN N
of IN N
the DT N
opioid JJ o
withdrawal NN o
syndrome NN o
before IN N
and CC N
after IN N
pharmacological JJ N
challenge NN N
with IN N
either DT N
0.4 CD N
mg NN N
naloxone NN i
or CC N
placebo NN i
. . i

Prior NNP N
to TO N
challenge VB N
, , N
patients NNS N
manifested VBD N
some DT N
subjective JJ o
symptoms NNS o
but CC N
few JJ N
objective JJ N
signs NNS N
of IN N
opioid JJ N
withdrawal NN N
. . N

Patients NNS p
who WP p
received VBD p
placebo NN i
( ( p
n JJ p
= NNP p
18 CD p
) ) p
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
mean NN N
score NN N
on IN N
one CD N
of IN N
three CD N
rating NN N
scales NNS N
used VBN N
to TO N
assess VB N
opioid JJ N
withdrawal NN N
. . N

Patients NNS p
who WP p
received VBD p
naloxone NN i
( ( p
n JJ p
= NNP p
58 CD p
) ) p
showed VBD N
significant JJ N
increases NNS N
in IN N
mean JJ N
scores NNS N
on IN N
all DT N
three CD N
rating NN N
scales NNS N
, , N
but CC N
this DT N
was VBD N
due JJ N
primarily RB N
to TO N
increases NNS N
observed VBN N
in IN N
a DT N
minority NN N
of IN N
patients NNS N
. . N

Sixty-one CD N
percent NN N
of IN N
patients NNS N
failed VBD N
to TO N
manifest VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
subjective NN o
symptoms NNS o
, , N
and CC N
74 CD N
% NN N
of IN N
patients NNS N
failed VBD N
to TO N
manifest VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
objective JJ o
signs NNS o
of IN o
opioid JJ o
withdrawal NN o
following VBG N
naloxone JJ i
administration NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
a DT N
substantial JJ N
subgroup NN N
of IN N
heroin NN N
addicts NNS N
are VBP N
able JJ N
to TO N
use VB N
opioids NNS N
regularly RB N
while IN N
maintaining VBG N
relatively RB N
low JJ N
levels NNS N
of IN N
physical JJ N
dependence NN N
. . N

-DOCSTART- -12036809- O O

Do VB N
colonic JJ N
short-chain NN N
fatty JJ N
acids NNS N
contribute NN N
to TO N
the DT N
long-term JJ o
adaptation NN o
of IN o
blood NN o
lipids NNS o
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
consuming VBG p
a DT p
high-fiber JJ i
diet NN i
? . N
BACKGROUND NNP N
We PRP N
recently RB N
obtained VBD N
evidence NN N
of IN N
long-term JJ o
adaptation NN o
of IN o
blood NN o
lipids NNS o
to TO N
changes NNS N
in IN N
intakes NNS N
of IN N
carbohydrate NN i
and CC i
fiber NN i
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
effect NN N
of IN N
increased JJ i
carbohydrate NN i
and CC i
fiber NN i
intakes NNS i
on IN N
serum JJ o
short-chain JJ o
fatty JJ o
acids NNS o
( ( o
SCFAs NNP o
) ) o
and CC N
the DT N
relation NN o
between IN o
changes NNS o
in IN o
serum NN o
acetate NN o
and CC o
changes NNS o
in IN o
blood NN o
lipids NNS o
. . o

DESIGN NNP N
Subjects VBZ p
with IN p
type NN p
2 CD p
diabetes NNS p
( ( p
n JJ p
= NNP p
62 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
approximately RB N
10 CD N
% NN N
of IN N
energy NN i
from IN i
low-fiber JJ i
breakfast NN i
cereal NN i
( ( i
LF NNP i
diet NN i
) ) i
, , i
high-fiber JJ i
breakfast NN i
cereal NN i
( ( i
HF NNP i
diet NN i
) ) i
, , i
or CC i
monounsaturated VBN i
fatty JJ i
acids NNS i
( ( i
MUFA NNP i
diet NN i
) ) i
for IN N
6 CD N
mo NNS N
. . N

RESULTS NNP N
Carbohydrate NNP o
intakes NNS o
were VBD N
higher JJR N
in IN N
the DT N
LF NNP N
and CC N
HF NNP N
groups NNS N
than IN N
in IN N
the DT N
MUFA NNP N
group NN N
( ( N
54 CD N
% NN N
compared VBN N
with IN N
43 CD N
% NN N
) ) N
, , N
and CC N
more JJR N
fiber NN N
was VBD N
consumed VBN N
by IN N
the DT N
HF NNP N
group NN N
( ( N
approximately RB N
50 CD N
g/d NNS N
) ) N
than IN N
by IN N
the DT N
LF NNP N
or CC N
MUFA NNP N
group NN N
( ( N
approximately RB N
23 CD N
g/d NN N
) ) N
. . N

Fasting VBG o
serum JJ o
SCFAs NNP o
did VBD N
not RB N
change VB N
significantly RB N
over IN N
the DT N
first JJ N
3 CD N
mo NN N
. . N

Between CC N
3 CD N
and CC N
6 CD N
mo NN N
, , N
serum JJ o
acetate NN o
tended VBD N
( ( N
NS NNP N
) ) N
to TO N
decrease VB N
in IN N
the DT N
LF NNP N
group NN N
( ( N
from IN N
69 CD N
+/- JJ N
4 CD N
to TO N
59 CD N
+/- JJ N
5 CD N
micromol/L NN N
) ) N
and CC N
increase VB N
in IN N
the DT N
HF NNP N
group NN N
( ( N
from IN N
100 CD N
+/- JJ N
18 CD N
to TO N
107 CD N
+/- JJ N
17 CD N
micromol/L NN N
) ) N
, , N
with IN N
no DT N
significant JJ N
change NN N
in IN N
the DT N
MUFA NNP N
group NN N
. . N

Serum NNP o
butyrate NN o
did VBD N
not RB N
change VB N
significantly RB N
in IN N
the DT N
LF NNP N
or CC N
MUFA NNP N
group NN N
but CC N
increased VBD N
in IN N
the DT N
HF NNP N
group NN N
( ( N
from IN N
2.5 CD N
+/- JJ N
0.5 CD N
to TO N
3.1 CD N
+/- JJ N
0.6 CD N
micromol/L NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Changes NNS o
in IN o
serum NN o
acetate NN o
from IN N
0 CD N
to TO N
3 CD N
mo NNS N
were VBD N
not RB N
related VBN N
to TO N
changes NNS o
in IN o
lipids NNS o
. . o

However RB N
, , N
changes NNS o
in IN o
serum NN o
acetate NN o
from IN N
3 CD N
to TO N
6 CD N
mo NNS N
were VBD N
positively RB N
related VBN N
to TO N
changes NNS o
in IN o
the DT o
ratio NN o
of IN o
total JJ o
to TO o
HDL NNP o
cholesterol NN o
( ( N
P NNP N
= NNP N
0.041 CD N
) ) N
and CC N
in IN N
fasting NN N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
and CC N
postprandial JJ o
( ( o
P NNP o
= NNP o
0.016 CD o
) ) o
triacylglycerols NNS o
. . o

CONCLUSIONS NNP N
In IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
, , N
changes NNS N
in IN N
serum NN o
SCFAs NNP o
in IN N
response NN N
to TO N
changes NNS N
in IN N
carbohydrate NN o
and CC o
fiber NN o
intakes NNS o
took VBD N
many JJ N
months NNS N
to TO N
occur VB N
, , N
and CC N
the DT N
changes NNS N
in IN N
serum NN o
acetate NN o
were VBD N
significantly RB N
related VBN N
to TO N
the DT N
long-term JJ o
adaptive JJ o
changes NNS o
in IN o
blood NN o
lipids NNS o
. . o

-DOCSTART- -18781287- O O

Efficacy NN o
of IN N
topical JJ N
azithromycin NN i
ophthalmic JJ N
solution NN N
1 CD N
% NN N
in IN N
the DT N
treatment NN N
of IN N
posterior JJ p
blepharitis NN p
. . p

INTRODUCTION NNP N
Azithromycin NNP i
, , N
a DT N
broad-spectrum JJ N
antibiotic JJ N
with IN N
potent JJ N
anti-inflammatory JJ N
activities NNS N
, , N
has VBZ N
the DT N
potential JJ N
to TO N
effectively RB N
treat VB N
blepharitis NN o
, , p
an DT p
inflammatory JJ p
disease NN p
of IN p
the DT p
eyelid JJ p
with IN p
abnormal JJ p
eyelid JJ p
flora NN p
as IN p
an DT p
etiologic JJ p
determinant NN p
. . p

The DT N
present JJ N
study NN N
compared VBN N
the DT N
efficacy NN o
of IN N
topical JJ N
azithromycin NN i
ophthalmic JJ N
solution NN N
1 CD N
% NN N
( ( N
AzaSite NNP N
; : N
Inspire NNP N
Pharmaceuticals NNP N
, , N
Inc NNP N
, , N
NC NNP N
, , N
USA NNP N
) ) N
combined VBD N
with IN N
warm JJ N
compresses NNS N
( ( N
azithromycin JJ N
group NN N
) ) N
to TO N
warm JJ N
compresses NNS N
alone RB N
( ( N
compress JJ N
group NN N
) ) N
in IN N
patients NNS N
with IN N
posterior JJ N
blepharitis NN N
. . N

METHODS NNP N
Twenty-one CD p
patients NNS p
diagnosed VBN p
with IN p
posterior JJ p
blepharitis NN p
were VBD N
randomized VBN N
in IN N
an DT N
open-label JJ N
study NN N
to TO N
receive VB N
either DT N
azithromycin NN i
plus CC i
warm JJ i
compresses NNS i
( ( N
10 CD N
patients NNS N
) ) N
, , N
or CC N
compresses VBZ N
alone RB N
( ( N
11 CD N
patients NNS N
) ) N
. . N

All DT N
patients NNS N
were VBD N
instructed VBN N
to TO N
apply VB N
compresses NNS N
to TO N
each DT N
eye NN N
for IN N
5-10 JJ N
minutes NNS N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Each DT N
eye NN N
in IN N
the DT N
azithromycin NN i
group NN N
also RB N
received VBD N
azithromycin JJ N
solution NN N
( ( N
1 CD N
drop NN N
) ) N
twice RB N
daily RB N
for IN N
the DT N
first JJ N
2 CD N
days NNS N
followed VBN N
by IN N
once RB N
daily JJ N
for IN N
the DT N
next JJ N
12 CD N
days NNS N
. . N

Patients NNS N
were VBD N
evaluated VBN N
at IN N
study NN N
initiation NN N
( ( N
visit IN N
1 CD N
) ) N
and CC N
at IN N
end NN N
of IN N
treatment NN N
( ( N
visit IN N
2 CD N
) ) N
for IN N
the DT N
severity NN N
of IN N
five CD N
clinical JJ N
signs NNS N
: : N
eyelid JJ o
debris NN o
, , o
eyelid JJ o
redness NN o
, , o
eyelid JJ o
swelling NN o
, , o
meibomian JJ o
gland NN o
( ( o
MG NNP o
) ) o
plugging NN o
, , o
and CC o
the DT o
quality NN o
of IN o
MG NNP o
secretion NN o
. . o

At IN N
visit NN N
2 CD N
, , N
patients NNS N
also RB N
rated VBD N
their PRP$ N
degree NN N
of IN N
overall JJ o
symptomatic JJ o
relief NN o
. . o

RESULTS NNP N
Twenty NNP p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

At IN N
visit NN N
2 CD N
, , N
patients NNS N
in IN N
the DT N
azithromycin NN i
group NN N
demonstrated VBD N
significant JJ o
improvements NNS o
in IN N
MG NNP o
plugging NN o
, , o
MG NNP o
secretions NNS o
, , o
and CC o
eyelid JJ o
redness NN o
as IN N
compared VBN N
with IN N
the DT N
compress NN N
group NN N
. . N

In IN N
the DT N
azithromycin NN i
group NN N
, , N
MG NNP o
plugging VBG o
resolved VBN N
completely RB N
in IN N
three CD N
patients NNS N
and CC N
MG NNP o
secretion NN o
returned VBD o
to TO o
normal JJ o
in IN N
two CD N
patients NNS N
; : N
no DT N
such JJ N
results NNS N
were VBD N
seen VBN N
in IN N
the DT N
compress NN N
group NN N
. . N

Furthermore RB N
, , N
a DT N
higher JJR N
percentage NN N
of IN N
patients NNS N
in IN N
the DT N
azithromycin NN N
group NN N
rated VBD N
overall JJ o
symptomatic JJ o
relief NN o
as IN N
excellent NN N
or CC N
good JJ N
. . N

Visual JJ o
acuity NN o
measurements NNS o
and CC o
biomicroscopic JJ o
evaluation NN o
revealed VBD N
no DT o
ocular JJ o
safety NN o
issues NNS o
. . o

CONCLUSION NNP N
Azithromycin NNP i
ophthalmic JJ N
solution NN N
in IN N
combination NN N
with IN N
warm JJ N
compresses NNS N
provided VBD N
a DT N
significantly RB o
greater JJR o
clinical JJ o
benefit NN o
than IN N
warm JJ N
compresses NNS N
alone RB N
in IN N
treating VBG N
the DT N
signs NNS o
and CC o
symptoms NNS o
of IN o
posterior JJ o
blepharitis NN o
. . o

-DOCSTART- -8921775- O O

Effect NN N
of IN N
supplementary JJ i
antioxidant JJ i
vitamin NNS i
intake VBP N
on IN N
carotid NNS o
arterial JJ o
wall JJ o
intima-media JJ o
thickness NN o
in IN N
a DT N
controlled JJ N
clinical JJ N
trial NN N
of IN N
cholesterol NN N
lowering VBG N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
accumulating VBG N
experimental JJ N
, , N
epidemiological JJ N
, , N
and CC N
clinical JJ N
evidence NN N
of IN N
an DT N
association NN N
between IN N
anti-oxidant JJ i
vitamin NNS i
intake NN N
and CC N
reduced JJ N
risk NN N
of IN N
coronary JJ N
heart NN N
disease NN N
. . N

Using VBG N
data NNS N
from IN N
the DT N
Cholesterol NNP N
Lowering NNP N
Atherosclerosis NNP N
Study NNP N
( ( N
CLAS NNP N
) ) N
, , N
we PRP N
explored VBD N
the DT N
association NN N
of IN N
self-selected JJ N
supplementary JJ N
antioxidant NN i
vitamin NNS i
intake VBP N
on IN N
the DT N
rate NN N
of IN N
progression NN N
of IN N
early JJ p
preintrusive JJ p
atherosclerosis NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
CLAS NNP N
was VBD N
an DT N
arterial JJ N
imaging NN N
trial NN N
in IN N
which WDT N
nonsmoking VBG p
40- JJ p
to TO p
59-year-old JJ p
men NNS p
with IN p
previous JJ p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
were VBD N
randomized VBN N
to TO N
colestipol/niacin VB i
plus JJ i
diet JJ i
or CC N
placebo JJ i
plus CC i
diet JJ i
. . i

The DT N
rate NN o
of IN o
progression NN o
of IN o
early JJ o
preintrusive JJ o
atherosclerosis NN o
was VBD N
determined VBN N
in IN N
146 CD p
subjects NNS p
using VBG N
high-resolution JJ N
B-mode NNP N
ultrasound JJ N
quantification NN N
of IN N
the DT N
distal JJ N
common JJ N
carotid NN N
artery NN N
far RB N
wall JJ N
intima-media JJ N
thickness NN N
( ( N
IMT NNP N
) ) N
. . N

From IN N
the DT N
nutritional JJ N
supplement NN N
database NN N
, , N
22 CD N
subjects NNS N
had VBD N
an DT N
on-trial JJ N
average JJ N
supplementary JJ N
vitamin NN i
E NNP i
intake NN N
of IN N
> NN N
or CC N
= $ N
100 CD N
IU NNP N
per IN N
day NN N
( ( N
high JJ N
users NNS N
) ) N
and CC N
29 CD N
subjects NNS N
had VBD N
an DT N
average JJ N
on-trial JJ N
supplementary JJ N
vitamin NN i
C NNP i
intake NN N
of IN N
> NN N
or CC N
= $ N
250 CD N
mg JJ N
per IN N
day NN N
( ( N
high JJ N
users NNS N
) ) N
. . N

Within IN N
the DT N
placebo NN i
group NN N
, , N
less JJR o
carotid JJ o
IMT NNP o
progression NN o
was VBD N
found VBN N
for IN N
high JJ N
supplementary JJ N
vitamin NN i
E NNP i
users NNS N
when WRB N
compared VBN N
with IN N
low JJ N
vitamin NNS i
E NN i
users NNS N
( ( N
0.008 CD N
versus NN N
0.023 CD N
mm/y NN N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

No DT N
effect NN N
of IN N
vitamin NN o
E NNP i
within IN N
the DT N
drug NN N
group NN N
was VBD N
found VBN N
. . N

No DT N
effect NN N
of IN N
vitamin NN i
C NNP i
within IN N
the DT N
drug NN N
or CC N
placebo NN i
group NN N
was VBD N
found VBN N
. . N

CONCLUSIONS NNP N
Supplementary NNP i
vitamin NN i
E NNP i
intake NN N
appears VBZ N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG o
the DT N
progression NN o
of IN o
atherosclerosis NN o
in IN N
subjects NNS p
not RB p
treated VBN p
with IN p
lipid-lowering JJ i
drugs NNS i
while IN N
the DT N
process NN N
is VBZ N
still RB N
confined VBN N
to TO N
the DT N
arterial JJ N
wall NN N
( ( N
early JJ N
preintrusive JJ N
atherosclerosis NN N
) ) N
. . N

-DOCSTART- -23463854- O O

Developing VBG N
the DT N
Ho'ouna NNP i
Pono NNP i
substance NN i
use NN i
prevention NN i
curriculum NN i
: : i
collaborating NN N
with IN N
Hawaiian JJ p
youth NN p
and CC p
communities NNS p
. . p

This DT N
article NN N
briefly NN N
outlines VBZ N
a DT N
collaboration NN N
among IN N
communities NNS p
on IN p
Hawai'i NNP p
Island NNP p
and CC N
a DT N
university-based JJ p
research NN p
team NN p
to TO N
develop VB o
, , o
implement NN o
, , o
and CC o
evaluate VB o
a DT o
school-based JJ o
substance NN o
use NN o
prevention NN o
curriculum NN o
called VBN i
Ho'ouna NNP i
Pono NNP i
. . i

In IN N
addition NN N
to TO N
providing VBG N
a DT N
rationale NN N
for IN N
the DT N
project NN N
, , N
the DT N
goal NN N
of IN N
this DT N
paper NN N
is VBZ N
fourfold JJ N
. . N

First NNP N
, , N
an DT N
overview NN N
of IN N
the DT N
Ho'ouna NNP i
Pono NNP i
research NN N
results NNS N
to TO N
date NN N
( ( N
2007-2013 JJ N
) ) N
is VBZ N
provided VBN N
. . N

Second JJ N
, , N
within IN N
this DT N
overview NN N
, , N
the DT N
ways NNS N
in IN N
which WDT N
selected VBD N
results NNS N
informed JJ N
program NN N
development NN N
are VBP N
highlighted VBN N
. . N

Third NNP N
, , N
the DT N
curriculum NN N
is VBZ N
briefly JJ N
described VBN N
, , N
and CC N
finally RB N
, , N
the DT N
role NN N
of IN N
the DT N
students NNS p
and CC p
community NN p
in IN N
the DT N
video NN N
production NN N
is VBZ N
described VBN N
. . N

-DOCSTART- -16846734- O O

Gemcitabine NNP i
and CC N
split-dose JJ N
paclitaxel NN i
or CC N
docetaxel NN i
in IN N
metastatic JJ N
breast NN N
cancer NN N
: : N
a DT N
randomised JJ N
phase NN N
II NNP N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
activity NN o
and CC o
toxicity NN o
of IN N
split-dose JJ i
paclitaxel NN i
or CC i
docetaxel NN i
in IN i
combination NN i
with IN i
gemcitabine NN i
in IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
( ( p
MBC NNP p
) ) p
who WP p
had VBD p
previously RB p
received VBN p
anthracyclines NNS p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
total NN p
of IN p
210 CD p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
arms NNS N
: : N
gemcitabine NN i
1,250 CD i
mg/m NN i
( ( i
2 CD i
) ) i
Days VBZ i
1 CD i
and CC i
8 CD i
and CC i
paclitaxel VB i
175 CD i
mg/m NN i
( ( i
2 CD i
) ) i
as IN i
a DT i
3-h JJ i
infusion NN i
on IN i
Day NNP i
1 CD i
( ( i
GP1 NNP i
) ) i
; : i
gemcitabine $ i
1,000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
Days VBZ i
1 CD i
and CC i
8 CD i
and CC i
paclitaxel VB i
100 CD i
mg/m NN i
( ( i
2 CD i
) ) i
as IN i
a DT i
1-h JJ i
infusion NN i
on IN i
Days NNP i
1 CD i
and CC i
8 CD i
( ( i
GP2 NNP i
) ) i
; : i
gemcitabine $ i
1,000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
Days VBZ i
1 CD i
and CC i
8 CD i
and CC i
docetaxel VB i
40 CD i
mg/m NN i
( ( i
2 CD i
) ) i
as IN i
a DT i
1-h JJ i
infusion NN i
on IN i
Days NNP i
1 CD i
and CC i
8 CD i
( ( i
GD NNP i
) ) i
. . N

Cycles NNS N
were VBD N
repeated VBN N
every DT N
3 CD N
weeks NNS N
. . N

RESULTS NNP N
For IN N
the DT N
204 CD p
patients NNS p
evaluable JJ p
for IN p
response NN p
assessment NN p
, , p
the DT p
response NN o
rates NNS o
were VBD p
48.6 CD p
% NN p
for IN p
GP1 NNP p
, , p
52.2 CD p
% NN p
for IN p
GP2 NNP p
, , p
and CC p
52.3 CD p
% NN p
for IN p
GD NNP p
. . p

Median JJ o
response NN o
duration NN o
, , o
time NN o
to TO o
treatment NN o
failure NN o
, , o
and CC o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
were VBD N
similar JJ N
in IN N
each DT N
arm NN N
. . N

Median JJ o
TTP NNP o
for IN N
GP1 NNP N
, , N
GP2 NNP N
and CC N
GD NNP N
was VBD N
7.5 CD N
, , N
7.0 CD N
and CC N
7.4 CD N
months NNS N
, , N
respectively RB N
. . N

For IN N
the DT N
208 CD p
patients NNS p
evaluable JJ p
for IN p
safety NN o
, , N
the DT N
most RBS N
common JJ N
grade NN N
3/4 CD N
toxicity NN o
for IN N
each DT N
regimen NN N
was VBD N
neutropaenia RB o
, , N
with IN N
64 CD N
% NN N
, , N
57 CD N
% NN N
, , N
and CC N
68 CD N
% NN N
for IN N
GP1 NNP N
, , N
GP2 NNP N
, , N
and CC N
GD NNP N
, , N
respectively RB N
. . N

Grade VB N
4 CD N
neutropaenia NN o
, , N
grade VBD N
3/4 CD N
anaemia NN o
, , o
febrile JJ o
neutropaenia NN o
, , o
and CC o
diarrhoea NNS o
were VBD N
more JJR N
common JJ N
in IN N
the DT N
docetaxel NN N
arm NN N
, , N
as IN N
was VBD N
the DT N
use NN N
of IN N
intravenous JJ N
antibiotics NNS N
and CC N
blood NN N
transfusions NNS N
. . N

CONCLUSION VB N
The DT N
study NN N
confirmed VBD N
the DT N
high JJ N
activity NN N
of IN N
gemcitabine-taxane JJ i
combinations NNS i
in IN N
MBC NNP N
. . N

Split-dose JJ N
paclitaxel NN i
had VBD N
similar JJ N
activity NN o
and CC N
toxicity NN o
to TO N
the DT N
3-weekly JJ N
administration NN N
. . N

The DT N
split-dose JJ N
docetaxel NN i
regimen NNS N
had VBD N
similar JJ N
activity NN o
to TO N
the DT N
paclitaxel NN i
combinations NNS i
though IN N
associated VBN N
with IN N
higher JJR N
toxicity NN o
. . o

-DOCSTART- -20822543- O O

A DT N
cluster NN N
randomised VBN N
trial NN N
to TO N
evaluate VB N
a DT N
physical JJ i
activity NN i
intervention NN i
among IN N
3-5 JJ p
year NN p
old JJ p
children NNS p
attending VBG p
long RB p
day NN p
care NN p
services NNS p
: : p
study NN N
protocol NN N
. . N

BACKGROUND NNP N
Young NNP p
children NNS p
are VBP N
not RB N
participating VBG N
in IN N
recommended JJ N
levels NNS N
of IN N
physical JJ N
activity NN N
and CC N
exhibit NN N
high JJ N
levels NNS N
of IN N
sedentary JJ N
behaviour NN N
. . N

Childcare NNP N
services NNS N
provide RB N
access NN N
to TO N
large JJ N
numbers NNS N
of IN N
young JJ p
children NNS p
for IN N
prolonged JJ N
periods NNS N
, , N
yet RB N
there EX N
is VBZ N
limited JJ N
experimental JJ N
evidence NN N
regarding VBG N
the DT N
effectiveness NN N
of IN N
physical JJ N
activity NN N
interventions NNS N
implemented VBN N
in IN N
this DT N
setting NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
effectiveness NN N
and CC N
acceptability NN N
of IN N
a DT N
multi-component JJ N
physical JJ i
activity NN i
intervention NN i
, , N
delivered VBN N
by IN N
childcare NN N
service NN N
staff NN N
, , N
in IN N
increasing VBG N
the DT N
physical JJ N
activity NN N
levels NNS N
of IN N
children NNS p
attending VBG p
long RB p
day NN p
care NN p
services NNS p
. . p

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
employ VB N
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
design NN N
. . N

Three CD p
hundred VBD p
children NNS p
aged VBN p
between IN p
3-5 CD p
years NNS p
from IN p
twenty NN p
randomly RB p
selected VBN p
long RB p
day NN p
care NN p
services NNS p
in IN p
the DT p
Hunter NNP p
Region NNP p
of IN p
New NNP p
South NNP p
Wales NNP p
, , p
Australia NNP p
will MD N
be VB N
invited VBN N
to TO N
participate VB N
in IN N
the DT N
trial NN N
. . N

Ten CD N
of IN N
the DT N
20 CD N
long JJ N
day NN N
care NN N
services NNS N
will MD N
be VB N
randomly RB N
allocated VBN N
to TO N
deliver VB N
the DT N
intervention NN N
with IN N
the DT N
remaining VBG N
ten NN N
services NNS N
allocated VBN N
to TO N
a DT N
wait JJ i
list NN i
control NN i
group NN N
. . N

The DT N
physical JJ i
activity NN i
intervention NN i
will MD i
consist VB i
of IN i
a DT i
number NN i
of IN i
strategies NNS i
including VBG i
: : i
delivering NN i
structured VBD i
fundamental JJ i
movement NN i
skill NN i
activities NNS i
, , i
increasing VBG i
physical JJ i
activity NN i
opportunities NNS i
, , i
increasing VBG i
staff NN i
role NN i
modelling NN i
, , i
providing VBG i
children NNS i
with IN i
a DT i
physical JJ i
activity NN i
promoting VBG i
indoor NN i
and CC i
outdoor JJ i
environment NN i
and CC i
limiting VBG i
children NNS i
's POS i
small JJ i
screen JJ i
recreation NN i
and CC i
sedentary JJ i
behaviours NNS i
. . i

Intervention NNP N
effectiveness NN N
will MD N
be VB N
measured VBN N
via IN N
child JJ o
physical JJ o
activity NN o
levels NNS o
during IN o
attendance NN o
at IN o
long RB o
day NN o
care NN o
. . o

The DT N
study NN N
also RB N
seeks VBZ N
to TO N
determine VB N
the DT N
acceptability NN o
and CC o
extent NN o
of IN o
implementation NN o
of IN o
the DT o
intervention NN o
by IN o
services NNS o
and CC N
their PRP$ N
staff NN N
participating VBG N
in IN N
the DT N
study NN N
. . N

DISCUSSION NNP N
The DT N
trial NN N
will MD N
address VB N
current JJ N
gaps NNS N
in IN N
the DT N
research NN N
evidence NN N
base NN N
and CC N
contribute NN N
to TO N
the DT N
design NN N
and CC N
delivery NN N
of IN N
future JJ N
interventions NNS N
promoting VBG N
physical JJ N
activity NN N
for IN N
young JJ p
children NNS p
in IN p
long JJ p
day NN p
care NN p
settings NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
Australian NNP p
New NNP p
Zealand NNP p
Clinical NNP p
Trials NNP p
Registry NNP p
ACTRN12610000087055 NNP N
. . N

-DOCSTART- -21616612- O O

Effectiveness NN N
of IN N
a DT N
short-term JJ N
treatment NN N
with IN N
progesterone NN i
injections NNS N
on IN N
synchrony NN N
of IN N
lambing NN N
and CC N
fertility NN N
in IN N
tropical JJ p
hair NN p
sheep NN p
. . p

The DT N
efficacy NN N
of IN N
using VBG N
a DT N
low JJ N
cost NN N
system NN N
for IN N
delivering VBG N
progesterone NN i
as IN N
part NN N
of IN N
an DT N
estrous JJ N
synchronization NN N
protocol NN N
in IN N
sheep NN p
was VBD N
evaluated VBN N
. . N

In IN N
experiment JJ N
1 CD N
, , N
Barbados NNP p
Black NNP p
Belly NNP p
ewes FW p
( ( p
n=34 NN p
) ) p
and CC p
ewe JJ p
lambs NN p
( ( p
n=35 JJ p
; : p
37.5?0.9 CD p
kg NN p
) ) p
were VBD i
assigned VBN i
to TO i
be VB i
untreated JJ i
, , i
control NN i
animals NNS i
( ( i
C NNP i
) ) i
, , i
or CC i
to TO i
receive VB i
PGF NNP i
( ( i
2? CD i
) ) i
on IN i
d0 NN i
( ( i
PG NNP i
) ) i
, , i
or CC i
receive VB i
two CD i
injections NNS i
of IN i
progesterone NN i
( ( i
200mg CD i
, , i
i.m NN i
. . i

each DT i
) ) i
on IN i
D NNP i
-5 NNP i
and CC i
on IN i
D NNP i
-2.5 NNP i
, , i
prior RB i
to TO i
PGF NNP i
( ( i
2? CD i
) ) i
, , i
on IN i
D NNP i
0 CD i
( ( i
2PPG CD i
) ) i
. . i

Treatment NN i
with IN N
2PPG CD N
increased VBD N
the DT N
proportion NN o
of IN o
animals NNS o
lambing VBG o
to TO o
the DT N
first JJ N
service NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
an DT N
effect NN N
that WDT N
was VBD N
greater JJR N
in IN N
ewe NN p
lambs NNS p
than IN p
ewes NN p
( ( p
treatment NN p
? . N
parity NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
interval NN N
from IN N
ram JJ N
introduction NN o
to TO o
lambing NN o
and CC o
the DT o
mean JJ o
lambing NN o
day NN o
was VBD N
less JJR N
( ( N
P=0.04 NNP N
) ) N
in IN N
the DT N
2PPG-treated JJ N
animals NNS N
compared VBN N
to TO N
control VB N
animals NNS p
. . p

In IN p
Experiment JJ p
2 CD p
, , p
lactating VBG p
ewes NN p
from IN p
experiment JJ p
1 CD p
( ( p
n=61 NN p
) ) p
60-85 JJ p
days NNS p
postpartum NN p
were VBD p
assigned VBN N
within IN N
parity NN N
and CC N
number NN N
of IN N
lambs NNS N
reared VBN N
to TO N
remain VB N
nursing NN N
( ( N
S NNP N
; : N
n=29 CC N
) ) N
or CC N
weaned VBN N
( ( N
W NNP N
; : N
n=32 CC N
) ) N
3 CD N
weeks NNS N
prior RB N
to TO N
treatment NN N
with IN N
the DT N
2PPG CD N
protocol NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
of IN N
treatment NN N
on IN N
the DT N
proportion NN o
of IN o
animals NNS o
lambing VBG o
to TO o
the DT o
first JJ o
service NN o
or CC o
overall JJ o
, , o
interval NN o
from IN N
ram JJ N
introduction NN N
to TO N
lambing NN N
and CC N
lambing VBG N
interval NN N
. . N

An DT N
8-month JJ o
lambing NN o
interval NN o
was VBD o
observed VBN p
in IN p
ewes NN p
in IN p
which WDT N
estrus NN N
was VBD N
synchronized VBN N
regardless RB N
of IN N
physiological JJ N
state NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
two-progesterone JJ N
injection NN N
synchronization NN N
protocol NN N
may MD N
be VB N
used VBN N
as IN N
a DT N
practical JJ N
low JJ N
cost NN N
and CC N
efficient JJ N
method NN N
of IN N
synchronizing VBG N
estrus NN N
to TO N
reduce VB N
the DT N
lambing NN N
interval NN N
and CC N
maximize VB N
productivity NN p
in IN p
tropical JJ p
breeds NNS p
of IN p
sheep NN p
. . p

-DOCSTART- -15606733- O O

5 CD N
% NN N
imiquimod JJ i
cream NN N
and CC N
reflectance-mode JJ i
confocal JJ i
microscopy NN i
as IN N
adjunct JJ N
modalities NNS N
to TO N
Mohs NNP i
micrographic JJ i
surgery NN i
for IN N
treatment NN N
of IN N
basal NN p
cell NN p
carcinoma NN p
. . p

BACKGROUND NNP N
Imiquimod NNP i
is VBZ N
an DT N
immune JJ N
response NN N
modifier NN N
that IN N
up-regulates JJ N
cytokines NNS N
and CC N
has VBZ N
been VBN N
shown VBN N
in IN N
clinical JJ N
studies NNS N
to TO N
reduce VB N
or CC N
clear VB N
basal NN p
cell NN p
carcinoma NN p
tumors NNS N
when WRB N
applied VBN N
topically RB N
. . N

OBJECTIVE CC N
The DT N
objectives NNS N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
5 CD N
% NN N
imiquimod JJ i
cream NN N
in IN N
treating VBG N
basal NN N
cell NN N
carcinoma NN N
preceding VBG N
excision NN N
by IN N
Mohs NNP N
micrographic JJ N
surgery NN N
and CC N
to TO N
determine VB N
if IN N
reflectance-mode JJ i
confocal JJ i
microscopy NN i
is VBZ N
useful JJ N
to TO N
establish VB N
the DT N
need NN N
for IN N
surgical JJ N
intervention NN N
after IN N
imiquimod JJ i
treatment NN N
. . N

METHODS NNP N
Subjects NNP p
applied VBD p
study NN p
cream NN p
to TO p
one CD p
biopsy-confirmed JJ p
basal NN p
cell NN p
carcinoma NN p
tumor NN p
5 CD N
x/week NN N
for IN N
2 CD N
, , N
4 CD N
, , N
or CC N
6 CD N
weeks NNS N
in IN N
this DT N
vehicle-controlled JJ p
, , p
double-blind JJ p
study NN p
. . p

Confocal NNP i
microscopy NN i
was VBD N
used VBN N
for IN N
the DT N
6-week JJ N
treatment NN N
group NN N
to TO N
examine VB N
the DT N
target NN N
tumor NN N
area NN N
at IN N
each DT N
interval JJ N
visit NN N
and CC N
immediately RB N
before IN N
Mohs NNP i
micrographic JJ i
surgery NN i
. . i

After IN N
the DT N
Mohs NNP i
micrographic JJ i
surgery NN i
excision NN i
, , N
the DT N
tissue NN N
was VBD N
evaluated VBN N
histologically RB N
, , N
and CC N
the DT N
excision NN N
area NN N
was VBD N
measured VBN N
. . N

Confocal JJ i
microscopy NN i
readings NNS N
were VBD N
correlated VBN N
to TO N
the DT N
histologic JJ N
diagnosis NN N
. . N

RESULTS NNP N
Tumors NNPS o
cleared VBD o
or CC o
the DT o
target NN o
tumor NN o
area NN o
was VBD N
reduced VBN N
in IN N
subjects NNS N
in IN N
the DT N
4- JJ N
and CC N
6-week JJ N
dosing NN N
regimens NNS N
. . N

Confocal JJ o
microscopy NN o
assessments NNS o
correlated VBN N
well RB N
with IN N
the DT N
histologic JJ N
diagnosis NN N
. . N

CONCLUSION NNP N
Imiquimod NNP i
improved VBD N
excision NN o
results NNS o
relative JJ N
to TO N
vehicle NN N
when WRB N
used VBN N
for IN N
treating VBG N
basal NN p
cell NN p
carcinoma NN p
before IN p
Mohs NNP i
micrographic JJ i
surgery NN i
. . i

Confocal JJ N
microscopy NN N
assessments NNS N
correlated VBN N
well RB N
with IN N
tumor NN N
response NN N
to TO N
therapy VB N
, , N
suggesting VBG N
that IN N
confocal JJ N
microscopy NN N
may MD N
help VB N
determine VB N
the DT N
need NN N
for IN N
surgery NN N
. . N

-DOCSTART- -21126245- O O

Intervention NN i
targeting VBG N
development NN N
of IN N
socially RB N
synchronous JJ N
engagement NN N
in IN N
toddlers NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Social NNP N
and CC N
communication NN N
impairments NNS N
are VBP N
core JJ N
deficits NNS N
and CC N
prognostic JJ N
indicators NNS N
of IN N
autism NN N
. . N

We PRP N
evaluated VBD N
the DT N
impact NN N
of IN N
supplementing VBG N
a DT N
comprehensive JJ i
intervention NN i
with IN N
a DT N
curriculum NN N
targeting VBG N
socially RB N
synchronous JJ N
behavior NN N
on IN N
social JJ N
outcomes NNS N
of IN N
toddlers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

METHODS NNP N
Fifty NNP p
toddlers NNS p
with IN p
ASD NNP p
, , p
ages VBZ p
21 CD p
to TO p
33 CD p
months NNS p
, , N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
six-month JJ N
interventions NNS N
: : N
Interpersonal NNP i
Synchrony NNP i
or CC N
Non-Interpersonal JJ i
Synchrony NNP i
. . i

The DT N
interventions NNS N
provided VBD N
identical JJ N
intensity NN N
( ( N
10 CD N
hours NNS N
per IN N
week NN N
in IN N
classroom NN N
) ) N
, , N
student-to-teacher JJ N
ratio NN N
, , N
schedule NN N
, , N
home-based JJ N
parent NN N
training NN N
( ( N
1.5 CD N
hours NNS N
per IN N
month NN N
) ) N
, , N
parent JJ N
education NN N
( ( N
38 CD N
hours NNS N
) ) N
, , N
and CC N
instructional JJ N
strategies NNS N
, , N
except IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
condition NN N
provided VBD N
a DT N
supplementary JJ N
curriculum NN N
targeting VBG N
socially RB N
engaged VBN N
imitation NN N
, , N
joint JJ N
attention NN N
, , N
and CC N
affect JJ N
sharing NN N
; : N
measures NNS N
of IN N
these DT N
were VBD N
primary JJ N
outcomes NNS N
. . N

Assessments NNS N
were VBD N
conducted VBN N
pre-intervention NN N
, , N
immediately RB N
post-intervention NN N
, , N
and CC N
, , N
to TO N
assess VB N
maintenance NN N
, , N
at IN N
six-month JJ N
follow-up NN N
. . N

Random NNP N
effects NNS N
models NNS N
were VBD N
used VBN N
to TO N
examine VB N
differences NNS N
between IN N
groups NNS N
over IN N
time NN N
. . N

Secondary JJ N
analyses NNS N
examined VBD N
gains NNS o
in IN o
expressive JJ o
language NN o
and CC o
nonverbal JJ o
cognition NN o
, , N
and CC N
time NN o
effects NNS o
during IN N
the DT N
intervention NN N
and CC N
follow-up JJ N
periods NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
treatment NN N
effect NN N
was VBD N
found VBN N
for IN N
socially RB N
engaged VBN N
imitation NN N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
, , N
with IN N
more JJR N
than IN N
doubling VBG N
( ( N
17 CD N
% NN N
to TO N
42 CD N
% NN N
) ) N
of IN N
imitated JJ N
acts NNS N
paired VBN N
with IN N
eye NN N
contact NN N
in IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
group NN N
after IN N
the DT N
intervention NN N
. . N

This DT N
skill NN N
was VBD N
generalized VBN N
to TO N
unfamiliar VB N
contexts NN N
and CC N
maintained VBD N
through IN N
follow-up NN N
. . N

Similar JJ N
gains NNS N
were VBD N
observed VBN N
for IN N
initiation NN N
of IN N
joint JJ o
attention NN o
and CC N
shared VBD N
positive JJ N
affect NN N
, , N
but CC N
between-group JJ N
differences NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

A DT N
significant JJ N
time NN N
effect NN N
was VBD N
found VBN N
for IN N
all DT N
outcomes NNS N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
; : N
greatest JJS N
change NN N
occurred VBD N
during IN N
the DT N
intervention NN N
period NN N
, , N
particularly RB N
in IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
group NN N
. . N

CONCLUSIONS NNP N
This DT N
is VBZ N
the DT N
first JJ N
ASD NNP N
randomized VBN N
trial NN N
involving VBG N
toddlers NNS p
to TO N
identify VB N
an DT N
active JJ N
ingredient NN N
for IN N
enhancing VBG N
socially RB N
engaged VBN N
imitation NN N
. . N

Adding VBG N
social JJ N
engagement JJ N
targets NNS N
to TO N
intervention VB N
improves NNS N
short-term JJ N
outcome NN N
at IN N
no DT N
additional JJ N
cost NN N
to TO N
the DT N
intervention NN N
. . N

The DT N
social JJ N
, , N
language NN N
, , N
and CC N
cognitive JJ N
gains NNS N
in IN N
our PRP$ N
participants NNS N
provide VBP N
evidence NN N
for IN N
plasticity NN N
of IN N
these DT N
developmental JJ N
systems NNS N
in IN N
toddlers NNS p
with IN p
ASD NNP p
. . p

http NN N
: : N
//www.clinicaltrials.gov/ct2/show/NCT00106210 NN N
? . N
term NN N
= NNP N
landa NN N
& CC N
rank NN N
= NN N
3 CD N
. . N

-DOCSTART- -21690083- O O

A DT N
pilot NN N
randomized VBN N
controlled JJ N
trial NN N
of IN N
DIR/Floortime? NNP i
parent NN i
training NN i
intervention NN i
for IN i
pre-school JJ p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

This DT N
pilot NN N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
adding VBG i
home-based JJ i
Developmental NNP i
, , i
Individual-Difference NNP i
, , i
Relationship-Based JJ i
( ( i
DIR NNP i
) ) i
/Floortime? VBZ i
intervention NN i
to TO i
the DT N
routine JJ N
care NN N
of IN p
preschool NN p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorder NN p
. . p

Measures NNS p
of IN N
functional JJ N
emotional JJ N
development NN N
and CC N
symptom JJ N
severity NN N
were VBD N
taken VBN N
. . N

It PRP N
was VBD N
found VBN N
that IN N
after IN N
the DT N
parents NNS N
added VBD i
home-based JJ i
DIR/Floortime? NNP i
intervention NN i
at IN i
an DT i
average NN N
of IN N
15.2 CD N
hours/week NN N
for IN N
three CD N
months NNS N
, , N
the DT N
intervention NN N
group NN N
made VBD N
significantly RB N
greater JJR N
gains NNS N
in IN N
all DT N
three CD N
measures NNS N
employed VBN N
in IN N
the DT N
study NN N
: : N
Functional NNP o
Emotional NNP o
Assessment NNP o
Scale NNP o
( ( o
FEAS NNP o
) ) o
( ( o
F NNP o
= NNP o
5.1 CD N
, , N
p NN N
= NNP N
.031 NNP N
) ) N
, , N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( N
F NNP N
= NNP N
2.1 CD N
, , N
p NN N
= NNP N
.002 NNP N
) ) N
, , N
and CC N
the DT o
Functional NNP o
Emotional NNP o
Questionnaires NNP o
( ( o
F NNP o
= NNP o
6.8 CD N
, , N
p NN N
= NNP N
.006 NNP N
) ) N
. . N

This DT N
study NN N
confirms VBZ N
the DT N
positive JJ N
results NNS N
obtained VBN N
by IN N
a DT N
previous JJ N
DIR NNP N
pilot NN N
study NN N
( ( N
Solomon NNP N
et RB N
al. RB N
, , N
2007 CD N
) ) N
. . N

-DOCSTART- -8435382- O O

Torasemide NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
cirrhosis NN p
and CC p
ascites NNS p
. . p

The DT N
effects NNS N
of IN N
torasemide NN i
( ( i
20 CD i
mg/day NN i
) ) i
and CC N
furosemide JJ i
( ( i
50 CD i
mg/day NN i
) ) i
, , N
each DT N
given VBN N
over IN N
4 CD N
days NNS N
, , N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
and CC N
crossover NN N
study NN N
carried VBD N
out RP N
in IN N
seven CD p
patients NNS p
with IN p
cirrhosis NN p
and CC p
tense NN p
ascites NNS p
. . p

Patients NNS p
also RB N
received VBD N
a DT N
low-sodium NN i
( ( i
40 CD i
mmol/day NN i
) ) i
diet NN i
and CC i
the DT i
aldosterone NN i
antagonist NN i
, , i
potassium NN i
canrenoate NN i
( ( N
100 CD N
mg RB N
b.i.d. NN N
) ) N
. . N

Torasemide NNP i
induced VBD N
a DT N
remarkably RB N
higher RBR N
natriuretic JJ o
( ( N
120 CD N
+/- JJ N
15 CD N
vs. FW N
33 CD N
+/- JJ N
6 CD N
mmol/day NN N
, , N
p NN N
< NNP N
0.02 CD N
) ) N
and CC N
diuretic JJ o
( ( N
1450 CD N
+/- NN N
63 CD N
vs. IN N
900 CD N
+/- JJ N
58 CD N
ml NN N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
effect NN N
than IN N
furosemide NN i
. . i

Body NNP o
weight JJ o
loss NN o
was VBD N
also RB N
significantly RB N
higher JJR N
( ( N
2.5 CD N
+/- JJ N
1.6 CD N
vs. FW N
0.2 CD N
+/- JJ N
1.3 CD N
kg NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
during IN N
the DT N
torasemide JJ i
period NN N
. . N

Kaliuresis NNP o
was VBD N
similar JJ N
during IN N
the DT N
two CD N
treatment NN N
periods NNS N
, , N
despite IN N
the DT N
striking JJ N
differences NNS N
observed VBN N
in IN N
natriuresis NN N
. . N

Neither CC N
torasemide JJ i
nor CC N
furosemide JJ i
induced VBD N
any DT N
significant JJ N
change NN N
in IN N
serum NN o
electrolyte NN o
or CC o
creatinine NN o
concentrations NNS o
, , o
or CC o
in IN o
ammonia JJ o
levels NNS o
. . o

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
torasemide NN i
is VBZ N
suitable JJ N
for IN N
the DT N
treatment NN N
of IN N
sodium NN N
retention NN N
in IN N
patients NNS p
with IN p
cirrhosis NN p
and CC p
ascites NNS p
. . p

-DOCSTART- -3287999- O O

Transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
after IN N
thoracotomy NN N
. . N

Pain NNP o
relief NN o
and CC N
peak JJ o
expiratory NN o
flow NN o
rate NN o
-- : o
a DT o
trial NN N
of IN N
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
. . i

Forty NNP p
patients NNS p
scheduled VBN p
to TO p
undergo VB p
thoracotomy NN p
were VBD N
randomly RB i
allocated VBN i
to TO i
receive VB i
either RB i
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
with IN i
intramuscular JJ i
papaveretum NN i
( ( i
20 CD i
patients NNS i
) ) i
or CC i
intramuscular JJ i
papaveretum NN i
alone RB i
( ( i
20 CD i
patients NNS i
) ) i
for IN i
postoperative JJ i
pain NN i
relief NN i
. . i

Total JJ o
intramuscular JJ o
analgesic NN o
requirements NNS o
in IN o
the DT o
first JJ o
24 CD o
hours NNS o
, , o
time NN o
to TO o
satisfactory VB o
transfer NN o
to TO o
oral JJ o
analgesia NN o
, , o
antiemetic JJ o
requirements NNS o
and CC o
length NN o
of IN o
stay NN o
in IN o
hospital NN o
postoperatively RB o
were VBD N
noted VBN N
. . N

Peak NNP o
expiratory JJ o
flow NN o
rate NN o
was VBD o
compared VBN o
pre- JJ o
and CC o
postoperatively RB o
in IN N
the DT N
two CD N
groups NNS N
. . N

Use NNP N
of IN N
nerve NN N
stimulation NN N
did VBD N
not RB N
significantly RB N
alter VB N
the DT N
requirements NNS N
for IN N
analgesia JJ N
although IN N
there EX N
was VBD N
a DT N
reduction NN N
in IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
in IN N
the DT N
nerve NN N
stimulation NN N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
changes NNS N
in IN N
peak NN o
expiratory NN o
flow NN o
rate NN o
. . o

-DOCSTART- -7789678- O O

Randomized VBN N
, , N
controlled VBD N
study NN N
of IN N
various JJ N
agents NNS N
for IN N
endoscopic NN N
injection NN N
sclerotherapy NN N
of IN N
bleeding VBG N
canine NN N
gastric JJ N
varices NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
relative JJ o
efficacy NN o
and CC o
technical JJ o
ease NN o
of IN o
use NN o
of IN N
eight CD N
different JJ N
agents NNS N
for IN N
endoscopic JJ N
hemostasis NN N
and CC N
obliteration NN N
of IN N
bleeding VBG N
gastric JJ N
varices NNS N
in IN N
a DT N
canine NN N
model NN N
, , N
as IN N
no DT N
comparative JJ N
data NNS N
are VBP N
available JJ N
on IN N
gastric JJ N
variceal NN N
sclerotherapy NN N
. . N

Large JJ N
bleeding VBG N
gastric JJ N
varices NNS N
in IN N
20 CD p
heparinized JJ p
dogs NNS p
were VBD N
randomized VBN i
to TO i
endoscopic VB i
injection NN i
treatment NN i
with IN i
one CD i
of IN i
the DT i
following JJ i
agents NNS i
: : i
cyanoacrylate NN i
; : i
a DT i
1:1:1 CD i
mixture NN i
of IN i
sodium NN i
tetradecyl NN i
sulfate VBP i
3 CD i
% NN i
, , i
ethanol RB i
98 CD i
% NN i
, , i
and CC i
normal JJ i
saline JJ i
solution NN i
; : i
ethanolamine VB i
oleate VBP i
5 CD i
% NN i
; : i
sodium NN i
morrhuate VBP i
5 CD i
% NN i
; : i
sodium NN i
tetradecyl NN i
sulfate VBP i
1.5 CD i
% NN i
; : i
polidocanol CC i
1 CD i
% NN i
; : i
normal JJ i
saline JJ i
solution NN i
with IN i
epinephrine JJ i
1:10,000 CD i
; : i
or CC i
normal JJ i
saline JJ i
solution NN i
( ( i
control NN i
) ) i
. . i

The DT N
number NN N
and CC N
volume NN N
of IN N
injections NNS N
and CC N
the DT N
time NN N
required VBN N
to TO N
achieve VB N
complete JJ N
hemostasis NN N
were VBD N
evaluated VBN N
; : N
follow-up JJ N
endoscopy NN N
was VBD N
performed VBN N
at IN N
1 CD N
month NN N
to TO N
assess VB N
gastric JJ N
variceal NN N
obliteration NN N
. . N

Cyanoacrylate NNP N
was VBD N
the DT N
best JJS N
agent NN N
overall JJ N
in IN N
terms NNS N
of IN N
immediate JJ o
efficacy NN o
, , o
low JJ o
volume NN o
requirement NN o
, , o
time NN o
required VBN o
for IN o
initial JJ o
hemostasis NN o
, , o
and CC o
reduction NN o
of IN o
gastric JJ o
variceal NN o
size NN o
. . o

Cyanoacrylate NNP o
, , o
tetradecyl NN o
sulfate NN o
, , o
and CC o
polidocanol NN o
were VBD N
the DT N
most RBS N
effective JJ N
agents NNS N
for IN N
reducing VBG N
gastric JJ N
variceal NN N
size NN N
. . N

Epinephrine NNP N
was VBD N
effective JJ N
for IN N
controlling VBG N
induced JJ o
or CC o
secondary JJ o
bleeding NN o
caused VBN N
by IN N
puncture NN N
of IN N
the DT N
gastric JJ N
varices NNS N
with IN N
the DT N
sclerotherapy NN N
needle NN N
during IN N
intravariceal JJ N
injections NNS N
. . N

Ongoing VBG N
studies NNS N
are VBP N
evaluating VBG N
combinations NNS N
of IN N
agents NNS N
with IN N
different JJ N
mechanisms NNS N
of IN N
action NN N
, , N
such JJ N
as IN N
epinephrine NN N
( ( N
for IN N
vasoconstriction NN N
to TO N
minimize VB N
secondary JJ N
bleeding NN N
) ) N
plus CC N
alcohol NN N
, , N
and/or JJ N
tetradecyl NN N
sulfate NN N
( ( N
for IN N
variceal NN N
thrombosis NN N
and CC N
sclerosis NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -7259216- O O

Topical JJ i
treatment NN i
of IN N
alopecia NN N
areata NN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
previously RB N
that IN N
alopecia JJ N
areata NNS N
can MD N
be VB N
treated VBN N
with IN N
dinitrochlorobenzene NN i
( ( i
DNCB NNP i
) ) i
and CC N
other JJ N
contact NN i
allergens NNS i
. . i

Whether IN N
these DT N
agents NNS N
work NN N
by IN N
inducing VBG N
immunologic JJ N
stimulation NN N
or CC N
simply RB N
a DT N
nonspecific JJ N
inflammatory NN N
reaction NN N
has VBZ N
not RB N
been VBN N
definitively RB N
demonstrated VBN N
. . N

To TO N
test VB N
the DT N
relative JJ N
importance NN N
of IN N
these DT N
two CD N
mechanisms NNS N
, , N
we PRP N
have VBP N
randomly RB N
studied VBN N
22 CD p
patients NNS p
with IN p
alopecia JJ p
areata NNS p
to TO p
whom WP p
either DT p
DNCB NNP i
or CC i
croton VB i
oil NN i
was VBD p
applied VBN p
topically RB p
. . p

Sixty-three JJ N
percent NN N
of IN N
patients NNS N
without IN N
spontaneous JJ N
regrowth NN o
of IN o
hair NN o
regrew NNS o
hair NN o
after IN N
DNCB NNP N
application NN N
. . N

None NN o
of IN N
those DT N
treated VBN N
with IN N
croton NN i
oil NN i
regrew VBD o
hair NN o
when WRB N
treated VBN N
later RB N
with IN N
DNCB NNP i
. . i

Therefore NNP N
, , N
a DT N
proved JJ N
contact NN N
allergen NN N
was VBD N
shown VBN N
to TO N
be VB N
required VBN N
for IN N
therapeutic JJ N
success NN N
. . N

Patient JJ o
acceptance NN o
of IN N
the DT N
induced JJ N
contact NN N
dermatitis NN N
was VBD N
excellent JJ N
. . N

In IN N
light NN N
of IN N
recent JJ N
data NNS N
on IN N
the DT N
mutagenicity NN N
of IN N
DNCB NNP i
to TO N
bacteria NNS N
, , N
other JJ N
contact NN N
allergens NNS N
for IN N
topical JJ N
immunotherapy NN N
are VBP N
being VBG N
sought VBN N
. . N

-DOCSTART- -21669583- O O

A DT N
simple JJ N
meal NN i
plan NN i
of IN i
'eating VBG i
vegetables NNS i
before IN i
carbohydrate NN i
' '' i
was VBD N
more RBR N
effective JJ N
for IN N
achieving VBG N
glycemic JJ o
control NN o
than IN N
an DT N
exchange-based JJ i
meal NN i
plan NN i
in IN N
Japanese JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
whether IN N
educating VBG N
diabetic JJ N
patients NNS N
to TO N
'eat VB i
vegetables NNS i
before IN i
carbohydrate NN i
' '' i
was VBD N
as IN N
effective JJ N
on IN N
long-term JJ o
glycemic JJ o
control NN o
as IN N
a DT N
traditional JJ N
exchange-based JJ N
meal NN N
plan NN N
. . N

To TO N
test VB N
this DT N
hypothesis NN N
, , N
we PRP N
carried VBD N
out RP N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
that IN N
compared VBN N
changes NNS o
in IN o
HbA1c NNP o
as IN N
the DT N
primary JJ N
outcome NN N
. . N

A DT p
total NN p
of IN p
101 CD p
patients NNS p
were VBD p
stratified VBN p
according VBG p
to TO p
sex NN p
, , p
age NN p
, , p
BMI NNP p
, , p
duration NN p
of IN p
diabetes NNS p
, , p
and CC p
HbA1c NNP p
, , N
and CC N
then RB N
randomized VBN N
to TO N
receive VB N
instructions NNS N
to TO N
eat VB N
either DT N
vegetables NNS i
before IN i
carbohydrate NN i
( ( N
VBC NNP N
, , N
n=69 NN N
) ) N
or CC N
an DT N
exchange-based JJ i
meal NN i
plan NN i
( ( N
EXB NNP N
, , N
n=32 NN N
) ) N
. . N

The DT N
impact NN o
of IN o
the DT o
two CD o
plans NNS o
on IN o
glycemic JJ o
control NN o
was VBD N
compared VBN N
over IN N
24 CD N
months NNS N
of IN N
follow-up NN N
. . N

Significant JJ N
improvements NNS o
in IN o
HbA1c NNP o
over IN N
24 CD N
months NNS N
were VBD N
observed VBN N
in IN N
both DT N
groups NNS N
( ( N
VBC NNP N
, , N
8.3 CD N
to TO N
6.8 CD N
% NN N
vs NN N
EXB NNP N
, , N
8.2 CD N
to TO N
7.3 CD N
% NN N
) ) N
. . N

HbA1c NNP o
levels NNS o
were VBD o
significantly RB o
lower JJR o
in IN N
the DT N
VBC NNP N
group NN N
than IN N
in IN N
the DT N
EXB NNP N
group NN N
after IN N
6 CD N
, , N
9 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

Both DT N
groups NNS N
exhibited VBD N
similar JJ o
improvements NNS o
in IN o
dietary JJ o
practices NNS o
with IN N
respect NN N
to TO N
intake VB N
of IN N
carbohydrate NN N
, , N
fats NNS N
and CC N
sweets NNS N
, , N
while IN N
the DT N
VBC NNP N
group NN N
had VBD N
a DT N
significant JJ N
increase NN o
in IN N
consumption NN o
of IN o
green JJ o
vegetables NNS o
and CC N
a DT N
significant JJ N
decrease NN o
in IN o
fruit NN o
consumption NN o
. . o

A DT N
simple JJ N
meal NN i
plan NN i
of IN i
'eating VBG i
vegetables NNS i
before IN i
carbohydrate NN i
' '' i
achieved VBN N
better RBR o
glycemic JJ o
control NN o
than IN N
an DT N
exchange-based JJ N
meal NN N
plan NN N
in IN N
Japanese JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
over IN N
a DT N
24-month JJ N
period NN N
. . N

-DOCSTART- -2741888- O O

A DT N
comparison NN N
of IN N
high JJ i
and CC i
low JJ i
fat NN i
meals NNS i
on IN N
postprandial JJ p
esophageal JJ p
acid NN p
exposure NN p
. . p

Fatty NNP N
foods NNS N
have VBP N
been VBN N
identified VBN N
as IN N
precipitating VBG N
factors NNS N
in IN N
symptomatic JJ N
gastroesophageal NN p
reflux NN p
( ( p
GER NNP p
) ) p
. . p

A DT N
fat JJ N
meal NN N
has VBZ N
also RB N
been VBN N
found VBN N
to TO N
decrease VB N
lower JJR N
esophageal NN o
sphincter NN o
pressure NN o
( ( o
LESP NNP o
) ) o
in IN N
normal JJ N
subjects NNS N
. . N

We PRP N
used VBD N
the DT N
ambulatory JJ N
24-h JJ N
pH NN N
monitor NN N
to TO N
assess VB N
esophageal JJ N
acid NN N
exposure NN N
in IN N
10 CD p
normal JJ p
subjects NNS p
and CC p
10 CD p
GER NNP p
patients NNS p
following VBG p
low JJ i
and CC i
high JJ i
fat NN i
meals NNS i
eaten VBP i
in IN i
two CD i
body NN i
positions NNS i
. . i

The DT N
meals NNS N
had VBD N
nearly RB N
identical JJ N
protein NN N
content NN N
, , N
volumes NNS N
, , N
and CC N
calories NNS N
. . N

On IN N
successive JJ N
days NNS N
, , N
patients NNS N
ingested VBD N
one CD N
of IN N
the DT N
meals NNS i
twice RB N
, , N
followed VBN N
by IN N
random JJ N
assignment NN N
to TO N
3 CD N
h NN N
upright JJ i
and CC i
3 CD N
h NN N
recumbent JJ i
position NN i
. . i

Acid NNP o
exposure NN o
for IN o
each DT o
hour NN o
over IN N
a DT N
3-h JJ N
postprandial NN N
( ( N
PP NNP N
) ) N
period NN N
was VBD N
assessed VBN N
as IN N
the DT N
percent NN N
time NN N
pH NN N
less JJR N
than IN N
4.0 CD N
. . N

Increased VBN N
upright JJ o
acid NN o
exposure NN o
occurred VBD N
in IN N
normals NNS N
after IN N
the DT N
high JJ N
fat NN N
( ( N
6.2 CD N
+/- JJ N
2.1 CD N
% NN N
; : N
mean JJ N
+/- JJ N
SE NNP N
) ) N
compared VBN N
with IN N
the DT N
low JJ N
fat JJ N
meal NN N
( ( N
1.5 CD N
+/- JJ N
0.5 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

GER NNP N
patients NNS N
had VBD N
greater JJR N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
acid NN o
exposure NN o
than IN N
normals NNS N
in IN N
all DT N
study NN N
periods NNS N
, , N
but CC N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
low JJ N
and CC N
high JJ N
fat NN N
meals NNS N
in IN N
either DT N
study NN N
position NN N
. . N

High JJ N
fat JJ N
meals NNS N
induce VBP N
upright JJ o
GER NNP o
in IN N
normals NNS N
, , N
but CC N
do VBP N
not RB N
significantly RB N
affect VBP N
the DT N
abnormal JJ N
amount NN N
of IN N
GER NNP N
in IN N
patients NNS N
. . N

In IN N
addition NN N
, , N
progressive JJ N
increases NNS N
in IN N
acid JJ o
exposure NN o
were VBD N
found VBN N
over IN N
the DT N
3 CD N
postprandial JJ N
hours NNS N
in IN N
GER NNP N
patients NNS N
in IN N
a DT N
recumbent JJ N
position NN N
. . N

The DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
prior JJ N
data NNS N
showing VBG N
decreased JJ N
LESP NNP o
with IN N
a DT N
fat JJ N
meal NN N
in IN N
normals NNS N
. . N

-DOCSTART- -1682643- O O

Specific JJ i
immunoglobulin NN i
for IN N
treatment NN N
of IN N
whooping JJ p
cough NN p
. . p

Immunoglobulin NNP i
treatment NN N
for IN N
whooping JJ N
cough NN N
( ( N
pertussis NN N
) ) N
is VBZ N
widely RB N
believed VBN N
to TO N
be VB N
ineffective JJ o
although IN N
there EX N
are VBP N
sound JJ N
reasons NNS N
for IN N
regarding VBG N
the DT N
condition NN N
as IN N
a DT N
toxin-induced JJ N
disease NN N
. . N

We PRP N
wondered VBD N
whether IN N
the DT N
lack NN o
of IN o
success NN o
with IN N
pertussis NN N
immunoglobulins NNS i
might MD N
be VB N
attributable JJ N
to TO N
inadequate VB N
dose NN N
, , N
so IN N
we PRP N
designed VBD N
a DT N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
two CD N
immunoglobulin JJ N
preparations NNS N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
at IN N
three CD p
Swedish JJ p
hospitals NNS p
. . p

We PRP N
enrolled VBD N
73 CD p
children NNS p
aged VBD p
less JJR p
than IN p
36 CD p
months NNS p
who WP p
were VBD p
admitted VBN p
with IN p
a DT p
clinical JJ p
diagnosis NN p
of IN p
whooping JJ p
cough NN p
. . p

On IN N
admission NN N
they PRP N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
( ( N
a DT N
) ) N
monocomponent NN i
pertussis NN i
toxoid JJ i
vaccine NN i
; : i
( ( i
b NN i
) ) i
two-component NN i
acellular JJ i
vaccine NN i
also RB i
containing VBG i
filamentous JJ i
haemagglutinin NN i
; : i
or CC i
( ( i
c NN i
) ) i
20 CD i
% NN i
albumin JJ i
solution NN i
( ( i
placebo NN i
) ) i
. . i

The DT N
immunoglobulins NNS i
had VBD N
a DT N
high JJ N
antitoxin NN N
content NN N
and CC N
had VBD N
been VBN N
raised VBN N
with IN N
acellular JJ N
pertussis NN N
vaccines NNS N
. . N

Diagnosis NN N
of IN N
pertussis NN N
was VBD N
confirmed VBN N
by IN N
laboratory NN N
tests NNS N
and CC N
the DT N
follow-up NN N
was VBD N
completed VBN N
in IN N
67 CD N
children NNS N
. . N

The DT N
main JJ N
study NN N
group NN N
consisted VBD N
of IN N
47 CD p
children NNS p
with IN p
less JJR p
than IN p
or CC p
equal JJ p
to TO p
14 CD p
days NNS p
of IN p
disease NN p
before IN p
therapy NN p
. . p

Duration NN o
of IN o
whoops JJ o
post-treatment NN o
was VBD N
8.7 CD N
days NNS N
( ( N
95 CD N
% NN N
Cl NNP N
4.8 CD N
, , N
12.6 CD N
) ) N
in IN N
the DT N
33 CD N
children NNS N
receiving VBG N
immunoglobulin NN i
vs NN N
20.6 CD N
( ( N
95 CD N
% NN N
Cl NNP N
11.9 CD N
, , N
29.3 CD N
) ) N
in IN N
the DT N
14 CD N
receiving NN N
placebo NN i
( ( N
p JJ N
= NNP N
0.0041 CD N
) ) N
. . N

Mean JJ o
number NN o
of IN o
whoops NNS o
during IN N
the DT N
first JJ N
week NN N
of IN N
follow-up NN N
was VBD N
also RB N
significantly RB N
reduced VBN N
( ( N
p JJ N
= NNP N
0.0196 CD N
) ) N
. . N

We PRP N
found VBD N
that IN N
early JJ N
treatment NN N
was VBD N
important JJ N
, , N
since IN N
the DT N
effect NN N
on IN N
duration NN o
of IN o
whoops NNS o
was VBD N
most RBS N
pronounced JJ N
when WRB N
disease NN N
duration NN N
before IN N
treatment NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
7 CD N
days NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS o
between IN N
the DT N
two CD N
immunoglobulin NN N
preparations NNS N
. . N

High-dose JJ N
specific JJ N
pertussis NN N
immunoglobulin NN i
with IN N
a DT N
high JJ N
antitoxin NN N
concentration NN N
has VBZ N
a DT N
beneficial JJ o
effect NN o
in IN N
the DT N
treatment NN N
of IN N
whooping JJ N
cough NN N
. . N

-DOCSTART- -10986219- O O

Effect NN N
of IN N
L-ornithine-L-aspartate NNP i
on IN N
patients NNS p
with IN p
and CC p
without IN p
TIPS NNP p
undergoing VBG p
glutamine JJ p
challenge NN p
: : p
a DT N
double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
An DT N
oral JJ N
glutamine NN N
load NN N
in IN N
cirrhotic JJ p
patients NNS p
awaiting VBG p
liver JJ p
transplantation NN p
was VBD N
shown VBN N
to TO N
cause VB N
a DT N
rise NN N
in IN N
blood NN o
ammonia NN o
and CC o
psychometric NN o
abnormalities NNS o
which WDT N
were VBD N
reversed VBN N
by IN N
hepatic JJ N
transplantation NN N
. . N

L-Ornithine-L-aspartate NNP i
( ( i
LOLA NNP i
) ) i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
ammonia NN o
and CC o
improve VB o
psychometric JJ o
function NN o
in IN N
patients NNS p
with IN p
hepatic JJ p
encephalopathy NN p
. . p

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
LOLA NNP i
in IN N
healthy JJ p
patients NNS p
with IN p
cirrhosis NN p
and CC p
no DT p
evidence NN p
of IN p
clinical JJ p
encephalopathy NN p
after IN N
challenging VBG N
the DT N
central JJ N
nervous JJ N
system NN N
by IN N
administration NN N
of IN N
oral JJ N
glutamine NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Eight NNP p
cirrhotics NNS p
( ( p
Child NNP p
's POS p
B NNP p
or CC p
C NNP p
) ) p
without IN p
transjugular JJ p
intrahepatic JJ p
portosystemic JJ p
shunts NNS p
( ( p
TIPS NNP p
) ) p
and CC p
seven CD p
with IN p
TIPS NNP p
underwent JJ N
two CD N
oral JJ i
glutamine NN i
( ( i
20 CD i
g NN i
) ) i
challenges VBZ i
, , i
receiving VBG i
LOLA NNP i
( ( i
5 CD i
g RB i
intravenously RB i
) ) i
on IN N
one CD N
occasion NN N
and CC N
placebo NN i
on IN N
the DT N
other JJ N
in IN N
random JJ N
order NN N
. . N

Psychometric JJ N
tests NNS N
, , N
including VBG N
choice NN N
reaction NN N
time NN N
( ( N
CRT NNP N
) ) N
and CC N
number NN N
connection NN N
test NN N
, , N
were VBD N
performed VBN N
before IN N
and CC N
after IN N
glutamine NN N
, , N
together RB N
with IN N
electroencephalography NN N
and CC N
blood NN N
ammonia NN N
. . N

RESULTS NNP N
Mean NNP o
basal NN o
ammonia NN o
was VBD N
27 CD N
( ( N
SEM NNP N
5 CD N
) ) N
micromol/l NN N
in IN N
non-TIPS JJ N
and CC N
76 CD N
( ( N
10 CD N
) ) N
micromol/l NN N
in IN N
TIPS NNP N
patients NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Basal NNP o
CRT NNP o
2 CD o
was VBD N
0.643 CD N
( ( N
0.033 CD N
) ) N
s NN N
in IN N
non-TIPS JJ N
and CC N
0.825 CD N
( ( N
0.076 CD N
) ) N
s NN N
in IN N
TIPS NNP N
patients NNS N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

In IN N
non-TIPS JJ N
patients NNS N
, , N
ammonia NNS o
increased VBD N
to TO N
36 CD N
( ( N
10 CD N
) ) N
micromol/l NN N
when WRB N
LOLA NNP i
was VBD N
administered VBN N
and CC N
to TO N
62 CD N
( ( N
13 CD N
) ) N
micromol/l NN N
with IN N
placebo NN N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
alteration NN N
in IN N
psychometric JJ o
function NN o
in IN N
non-TIPS JJ N
patients NNS N
after IN N
glutamine NN N
when WRB N
LOLA NNP i
was VBD N
given VBN N
but CC N
when WRB N
placebo NN i
was VBD N
given VBN N
, , N
glutamine NN N
caused VBN N
prolongation NN N
of IN N
CRT NNP o
( ( N
p=0.02 NN N
) ) N
. . N

Glutamine NNP N
did VBD N
not RB N
affect VB N
psychometric JJ o
function NN o
in IN N
TIPS NNP N
patients NNS N
with IN N
or CC N
without IN N
LOLA NNP N
. . N

CONCLUSION NNP N
This DT N
study NN N
showed VBD N
that IN N
LOLA NNP i
ameliorated VBD N
the DT N
deleterious JJ N
psychometric JJ o
effects NNS o
of IN N
glutamine NN N
in IN N
Child NNP N
's POS N
grade NN N
B NNP N
and CC N
C NNP N
patients NNS p
with IN p
cirrhosis NN p
without IN p
TIPS NNP p
and CC N
supports VBZ N
its PRP$ N
use NN N
in IN N
clinical JJ N
practice NN N
in IN N
hepatic JJ N
encephalopathy NN N
. . N

-DOCSTART- -3543069- O O

Untoward NNP N
effects NNS N
of IN N
fenfluramine NN i
in IN N
autistic JJ p
children NNS p
. . p

Several JJ N
recent JJ N
studies NNS N
have VBP N
described VBN N
the DT N
benefits NNS N
of IN N
fenfluramine NN i
for IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
infantile JJ p
autism NN p
. . p

No DT N
large JJ N
surveys NNS N
of IN N
side JJ N
effects NNS N
of IN N
this DT N
drug NN N
have VBP N
been VBN N
reported VBN N
in IN N
autistic JJ p
children NNS p
. . p

To TO N
evaluate VB N
the DT N
untoward JJ N
effects NNS N
of IN N
fenfluramine NN i
in IN N
children NNS p
with IN p
autism NN p
, , p
12 CD p
subjects NNS p
were VBD N
systematically RB N
studied VBN N
. . N

Medication NNP N
was VBD N
administered VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
cross-over NN N
study NN N
. . N

Parents NNS N
were VBD N
trained VBN N
in IN N
monitoring VBG N
untoward JJ N
effects NNS N
. . N

These DT N
observations NNS N
were VBD N
compiled VBN N
in IN N
detailed JJ N
daily JJ N
notes NNS N
. . N

In IN p
addition NN p
, , p
four CD p
cases NNS p
describing VBG p
unusual JJ p
effects NNS p
found VBN p
in IN p
a DT p
sample NN p
of IN p
170 CD p
patients NNS p
treated VBN p
with IN p
fenfluramine NN i
are VBP p
also RB p
reported VBN p
. . p

In IN N
the DT N
initial JJ N
2 CD N
weeks NNS N
of IN N
active JJ N
drug NN N
listlessness NN N
, , N
food NN o
refusal NN o
, , o
and CC o
stomach NN o
upset NN o
were VBD N
frequently RB N
seen VBN N
. . N

A DT N
different JJ N
pattern NN N
of IN N
untoward JJ o
effects NNS o
was VBD N
seen VBN N
in IN N
the DT N
final JJ N
14 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Irritability NNP o
, , o
agitation NN o
, , o
and CC o
crying VBG o
along RB o
with IN o
continued VBN o
food NN o
refusal NN o
were VBD N
noted VBN N
. . N

The DT N
subjects NNS N
lost VBD N
2.1 CD N
% NN N
of IN N
body NN o
weight NN o
during IN N
active JJ N
drug NN N
phase NN N
, , N
but CC N
there RB N
was VBD N
a DT N
rebound NN o
weight NN o
gain NN o
during IN N
the DT N
subsequent JJ N
placebo NN i
phase NN N
. . N

A DT N
thorough JJ N
understanding NN N
of IN N
fenfluramine NN i
's POS i
side NN N
effects NNS N
and CC N
adverse JJ N
reactions NNS N
is VBZ N
necessary JJ N
so RB N
as IN N
to TO N
differentiate VB N
them PRP N
from IN N
the DT N
multiple NN N
symptoms NNS N
inherent NN N
in IN N
the DT N
syndrome NN N
of IN N
autism NN p
. . p

-DOCSTART- -12739123- O O

The DT N
utility NN N
of IN N
laparoscopy NN N
in IN N
the DT N
diagnosis NN N
of IN N
acute JJ p
appendicitis NN p
in IN p
women NNS p
of IN p
reproductive JJ p
age NN p
. . p

AIM NNP N
To TO N
see VB N
whether IN N
laparoscopy NN i
improves VBZ N
the DT N
accuracy NN N
of IN N
a DT N
clinical JJ N
diagnosis NN N
of IN N
acute JJ p
appendicitis NN p
in IN p
women NNS p
of IN p
reproductive JJ p
age NN p
, , N
and CC N
to TO N
determine VB N
what WP N
the DT N
long-term JJ N
sequelae NN N
are VBP N
of IN N
not RB N
removing VBG N
an DT N
appendix NN N
deemed VBN N
at IN N
laparoscopy NN N
to TO N
be VB N
normal JJ N
. . N

METHOD NNP N
The DT N
initial JJ N
part NN N
of IN N
the DT N
study NN N
was VBD N
undertaken VBN N
during IN N
1991-1992 JJ p
. . p

Female JJ p
patients NNS p
between IN p
16 CD p
and CC p
45 CD p
years NNS p
were VBD N
eligible JJ N
for IN N
inclusion NN N
once RB N
a DT N
clinical JJ N
decision NN N
had VBD N
been VBN N
made VBN N
to TO N
perform VB N
an DT N
appendicectomy NN N
for IN N
suspected JJ p
acute JJ p
appendicitis NN p
. . p

Following VBG N
consent NN N
, , N
patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
. . N

One CD N
group NN N
had VBD N
open JJ i
appendicectomy NN i
, , N
as IN N
planned VBN N
. . N

The DT N
other JJ N
group NN N
had VBD N
laparoscopy VBN i
, , i
followed VBN i
by IN i
open JJ i
appendicectomy NN i
only RB N
if IN N
the DT N
appendix NN N
was VBD N
seen VBN N
to TO N
be VB N
inflamed VBN N
or CC N
was VBD N
not RB N
visualized VBN N
. . N

The DT N
end NN N
points NNS N
for IN N
the DT N
study NN N
were VBD N
the DT N
clinical JJ N
outcomes NNS N
of IN N
all DT N
patients NNS N
, , N
and CC N
the DT N
results NNS N
of IN N
histology NN o
, , N
where WRB N
appropriate NN N
. . N

An DT N
attempt NN N
was VBD N
made VBN N
to TO N
contact VB N
all DT N
patients NNS N
at IN N
10 CD N
years NNS N
to TO N
determine VB N
whether IN N
they PRP N
had VBD N
had VBN N
a DT N
subsequent JJ N
appendicectomy NN N
, , N
or CC N
had VBD N
been VBN N
diagnosed VBN N
with IN N
another DT N
abdominal JJ N
condition NN N
that WDT N
might MD N
be VB N
relevant JJ N
to TO N
the DT N
initial JJ N
presentation NN N
in IN N
1991-1992 JJ N
. . N

RESULTS NNP N
Laparoscopic NNP N
assessment NN N
was VBD N
correct JJ N
in IN N
all DT N
cases NNS N
in IN N
which WDT N
the DT N
appendix NN N
was VBD N
visualized VBN N
. . N

Diagnostic JJ o
accuracy NN o
was VBD N
improved VBN N
from IN N
75 CD N
% NN N
to TO N
97 CD N
% NN N
. . N

Laparoscopy NNP N
was VBD N
associated VBN N
with IN N
no DT o
added JJ o
complications NNS o
, , o
no DT o
increase NN o
in IN o
hospital JJ o
stay NN o
in IN N
patients NNS N
who WP N
went VBD N
on IN N
to TO N
appendicectomy VB N
, , N
and CC N
a DT N
reduction NN o
in IN o
hospital NN o
stay NN o
for IN N
those DT N
who WP N
underwent JJ N
laparoscopy NN N
alone RB N
. . N

No UH N
patients NNS N
developed VBD N
a DT N
problem NN N
over IN N
the DT N
10-year JJ N
follow-up JJ N
period NN N
from IN N
having VBG N
a DT N
normal-looking JJ N
appendix NN N
not RB N
removed VBN N
at IN N
laparoscopy NN N
. . N

CONCLUSION NNP N
Laparoscopic NNP N
assessment NN N
of IN N
the DT N
appendix NN N
is VBZ N
reliable JJ N
, , N
and CC N
to TO N
leave VB N
a DT N
normal-looking JJ N
appendix NN N
at IN N
laparoscopy NN N
does VBZ N
not RB N
appear VB N
to TO N
cause VB N
any DT N
long-term JJ N
problems NNS N
. . N

-DOCSTART- -19886920- O O

Sustained JJ N
effect NN N
of IN N
SQ-standardized NNP N
grass NN N
allergy NN N
immunotherapy NN i
tablet NN i
on IN N
rhinoconjunctivitis NN N
quality NN N
of IN N
life NN N
. . N

BACKGROUND IN N
The DT N
prevalence NN N
of IN N
allergic JJ N
rhinoconjunctivitis NN N
has VBZ N
increased VBN N
significantly RB N
over IN N
the DT N
past JJ N
decades NNS N
with IN N
grass NN N
pollen NN N
being VBG N
a DT N
common JJ N
trigger NN N
. . N

The DT N
impact NN N
of IN N
allergy NN N
on IN N
patient NN N
's POS N
quality NN N
of IN N
life NN N
is VBZ N
substantial JJ N
. . N

AIM NNP N
To TO N
investigate VB N
the DT N
sustained JJ N
effect NN N
on IN N
quality NN N
of IN N
life NN N
during IN N
the DT N
grass NN N
pollen NN N
season NN N
1 CD N
year NN N
after IN N
3 CD N
years NNS N
of IN N
treatment NN N
with IN N
the DT N
SQ-standardized JJ N
grass NN i
allergy NN i
immunotherapy NN i
tablet NN i
( ( i
AIT NNP i
) ) i
, , N
Graza NNP N
( ( N
Phleum NNP N
pratense VBZ N
75,000 CD N
SQ-T/2800 JJ N
BAU NNP N
; : N
ALK NNP N
, , N
Denmark NNP N
) ) N
. . N

METHODS PDT N
The DT N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
in IN N
adult NN p
subjects NNS p
with IN p
a DT p
history NN p
of IN p
moderate-severe JJ p
grass NN p
pollen NN p
induced VBD p
rhinoconjunctivitis NN p
inadequately RB p
controlled VBN p
by IN p
symptomatic JJ p
medications NNS p
. . p

Subjects NNS p
received VBD N
3 CD N
years NNS N
of IN N
grass NN i
AIT NNP i
( ( N
n JJ N
= NNP N
157 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
126 CD N
) ) N
, , N
followed VBN N
by IN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

Quality NN o
of IN o
life NN o
assessments NNS N
were VBD N
based VBN N
on IN N
the DT N
standardized JJ o
rhinoconjunctivitis NN o
quality NN o
of IN o
life NN o
questionnaire NN o
( ( o
RQLQ NNP o
( ( o
S NNP o
) ) o
) ) o
; : o
completed VBN N
weekly JJ N
during IN N
the DT N
entire JJ N
grass NN N
pollen NN N
season NN N
. . N

RESULTS NNP N
During IN N
follow-up JJ N
, , N
the DT N
overall JJ N
RQLQ NNP o
( ( o
S NNP o
) ) o
score NN o
for IN N
the DT N
entire JJ N
grass NN N
pollen NN N
season NN N
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
active JJ N
group NN N
( ( N
relative JJ N
difference NN N
to TO N
placebo VB i
: : i
23 CD N
% NN N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
improvement NN N
was VBD N
higher JJR N
during IN N
the DT N
peak NN N
pollen NN N
season NN N
( ( N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
treatment NN N
effect NN N
of IN N
grass NN N
AIT NNP N
during IN N
the DT N
follow-up JJ N
year NN N
and CC N
the DT N
previous JJ N
three CD N
treatment NN N
years NNS N
was VBD N
similar JJ N
. . N

Improvements NNS N
were VBD N
found VBN N
in IN N
all DT N
seven CD N
RQLQ NNP o
( ( o
S NNP o
) ) o
domains VBZ o
. . o

The DT N
RQLQ NNP o
( ( o
S NNP o
) ) o
as IN N
a DT N
function NN N
of IN N
the DT N
weekly JJ N
average NN N
pollen NN N
counts VBZ N
showed VBD N
a DT N
clear JJ N
separation NN N
between IN N
the DT N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
subjects NNS N
inadequately RB N
controlled VBN N
by IN N
symptomatic JJ N
medications NNS N
, , N
grass NN N
AIT NNP i
provided VBD N
sustained VBN N
and CC N
clinically RB N
relevant JJ N
improvements NNS N
in IN N
rhinoconjunctivitis NN o
quality NN o
of IN o
life NN o
compared VBN N
to TO N
placebo VB i
. . i

The DT N
effect NN N
increased VBD o
with IN N
increasing VBG N
grass NN N
pollen NN N
exposure NN N
. . N

-DOCSTART- -22631032- O O

Evaluation NN o
of IN N
the DT N
pharmacodynamics NNS N
of IN N
acetylsalicylic JJ N
acid NN N
81 CD N
mg NN N
with IN N
or CC N
without IN N
esomeprazole JJ N
20 CD N
mg NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

BACKGROUND IN N
The DT N
absence NN N
of IN N
a DT N
pharmacokinetic JJ o
interaction NN o
between IN N
the DT N
proton NN N
pump NN N
inhibitor NN N
esomeprazole NN N
( ( N
40 CD N
mg NN N
) ) N
and CC N
acetylsalicylic JJ N
acid NN N
( ( N
aspirin JJ N
, , N
ASA NNP N
; : N
325 CD N
mg NN N
) ) N
has VBZ N
previously RB N
been VBN N
established VBN N
. . N

OBJECTIVE VB N
This DT N
study NN N
set VBD N
out RP N
to TO N
investigate VB N
the DT N
potential NN N
for IN N
pharmacodynamic JJ o
interaction NN o
between IN N
low-dose JJ N
ASA NNP N
and CC N
esomeprazole VB N
in IN N
healthy JJ p
volunteers NNS p
, , N
by IN N
measuring VBG N
ASA NNP N
antiplatelet NN o
activity NN o
. . o

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
single-center JJ N
, , N
open-label JJ N
, , N
two-period JJ N
, , N
randomized VBN N
crossover NN N
study NN N
. . N

PARTICIPANTS NNP N
Healthy NNP p
male NN p
and CC p
female JJ p
volunteers NNS p
aged VBN p
18-75 CD p
years NNS p
were VBD p
included VBN p
. . p

All DT i
volunteers NNS i
received VBD i
ASA NNP i
81 CD i
mg NN i
once RB i
daily JJ i
for IN i
5 CD i
days NNS i
prior RB i
to TO i
the DT i
study NN i
( ( i
pre-screen JJ i
) ) i
. . i

Subjects NNS p
were VBD p
eligible JJ p
for IN p
inclusion NN p
if IN p
they PRP p
had VBD p
aspirin VBN o
reactivity NN o
units NNS o
( ( o
ARU NNP o
, , o
as IN o
measured VBN o
by IN o
the DT o
VerifyNow NNP o
ASA NNP o
assay VBP o
) ) o
of IN p
< $ p
550 CD p
on IN p
Day NNP p
6 CD p
. . p

INTERVENTION NN N
After IN i
pre-screening NN i
and CC i
a DT i
washout JJ i
period NN i
of IN i
at IN i
least JJS i
14 CD i
days NNS i
, , i
eligible JJ i
volunteers NNS i
received VBD i
ASA NNP i
81 CD i
mg NN i
with IN i
or CC i
without IN i
esomeprazole JJ i
20 CD i
mg NN i
once RB i
daily JJ i
for IN i
5 CD i
days NNS i
in IN i
randomized JJ i
order NN i
, , i
with IN i
a DT i
14-day JJ i
washout NN i
between IN i
treatments NNS i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
antiplatelet NN o
activity NN o
of IN o
ASA NNP o
, , o
as IN o
assessed VBN o
by IN o
ARU NNP o
ratio NN o
relative NN o
to TO o
baseline VB o
in IN o
the DT o
VerifyNow NNP o
ASA NNP o
assay VBP o
; : o
suppression NN o
of IN o
serum NN o
thromboxane NN o
B NNP o
( ( o
2 CD o
) ) o
( ( o
TXB NNP o
( ( o
2 CD o
) ) o
) ) o
was VBD N
a DT N
secondary JJ N
endpoint NN N
. . N

Statistical JJ N
comparisons NNS N
were VBD N
made VBN N
using VBG N
linear JJ N
mixed JJ N
models NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
29 CD p
volunteers NNS p
( ( p
19 CD p
aged VBN p
?50 CD p
years NNS p
; : p
8 CD p
women NNS p
; : p
21 CD p
men NNS p
) ) p
were VBD p
evaluable JJ p
for IN p
pharmacodynamic JJ N
analysis NN N
( ( N
per IN N
protocol NN N
) ) N
. . N

All DT N
volunteers NNS N
on IN N
both DT N
treatments NNS N
achieved VBN o
ARU NNP o
< $ o
550 CD N
at IN N
Day NNP N
6 CD N
. . N

The DT N
geometric JJ N
mean NN N
ratio NN N
of IN N
Day NNP N
6 CD N
to TO N
Day NNP N
1 CD N
( ( N
baseline NN o
) ) o
platelet NN o
aggregation NN o
was VBD o
0.70 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
0.68 CD N
, , N
0.72 CD N
) ) N
with IN N
ASA NNP N
alone RB N
and CC N
0.71 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.69 CD N
, , N
0.74 CD N
) ) N
with IN N
ASA NNP N
+ NNP N
esomeprazole NN N
. . N

The DT N
ratio NN N
of IN N
platelet NN o
aggregation NN o
( ( o
ASA NNP N
+ NNP N
esomeprazole/ASA NN N
) ) N
was VBD N
1.02 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.99 CD N
, , N
1.05 CD N
) ) N
. . N

ASA NNP N
administered VBD N
alone RB N
or CC N
with IN N
esomeprazole JJ N
reduced VBN o
serum NN o
TXB NNP o
( ( o
2 CD o
) ) o
by IN o
more JJR N
than IN N
99.5 CD N
% NN N
. . N

The DT N
ratio NN N
of IN N
suppression NN N
of IN N
serum NN o
TXB NNP o
( ( o
2 CD o
) ) o
levels NNS o
( ( o
ASA NNP N
+ NNP N
esomeprazole/ASA NN N
) ) N
was VBD N
1.06 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.88 CD N
, , N
1.29 CD N
) ) N
. . N

The DT N
combination NN N
of IN N
ASA NNP N
and CC N
esomeprazole NN N
was VBD N
well RB o
tolerated VBN o
. . o

CONCLUSION NNP N
No NNP N
pharmacodynamic JJ o
interaction NN o
between IN o
low-dose JJ N
ASA NNP N
and CC N
esomeprazole NN N
was VBD N
found VBN N
with IN N
regard NN N
to TO N
platelet VB o
function NN o
. . o

TRIAL NNP N
REGISTRATION NNP N
Registered NNP N
at IN N
ClinicalTrials NNP N
. . N

gov NN N
as IN N
NCT01199328 NNP N
. . N

-DOCSTART- -17958625- O O

Oral NNP N
amoxicillin NN i
vs. FW N
oral JJ N
erythromycin NN i
in IN N
the DT N
treatment NN o
of IN o
pyoderma NN o
in IN p
Bamako NNP p
, , p
Mali NNP p
: : p
an DT N
open JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Pyoderma NNP p
( ( p
bacterial JJ p
superficial NN p
skin NN p
infection NN p
) ) p
is VBZ N
an DT N
extremely RB N
common JJ N
disorder NN N
in IN N
tropical JJ p
developing VBG p
countries NNS p
. . p

In IN N
these DT N
settings NNS N
, , N
Streptococcus NNP N
pyogenes NNS N
is VBZ N
considered VBN N
to TO N
be VB N
the DT N
main JJ N
etiological JJ N
agent NN N
. . N

Apart RB N
from IN N
epidemics NNS N
of IN N
poststreptococcal JJ N
glomerulonephritis NN N
where WRB N
mass NN N
treatment NN N
with IN N
intramuscular JJ N
benzathine-penicillin NN i
is VBZ N
recommended VBN N
, , N
no DT N
recommendation NN N
exists VBZ N
for IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
this DT N
setting NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
oral JJ N
amoxicillin NN i
in IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
Mali NNP N
, , N
by IN N
comparison NN N
with IN N
oral JJ N
erythromycin NN i
. . i

METHODS NNP N
In IN p
Bamako NNP p
, , p
132 CD p
patients NNS p
with IN p
pyoderma NN p
, , p
diagnosed VBN p
and CC p
graded VBN p
as IN p
severe JJ p
on IN p
clinical JJ p
grounds NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
oral JJ N
treatment NN N
by IN N
either DT N
amoxicillin NN i
( ( N
50 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
or CC N
erythromycin $ i
; : i
infections NNS N
of IN N
the DT N
follicular JJ N
appendage NN N
were VBD N
excluded VBN N
. . N

Both DT N
drugs NNS N
were VBD N
associated VBN N
with IN N
the DT N
topical JJ N
application NN N
of IN N
povidone NN N
iodine NN N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
openly RB N
at IN N
the DT N
seventh JJ N
day NN N
of IN N
treatment NN N
for IN N
cure NN N
or CC N
marked JJ N
improvement NN N
of IN N
the DT N
clinical JJ o
features NNS o
, , N
indicating VBG N
successful JJ o
treatment NN o
. . o

RESULTS NNP N
Three CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up JJ N
. . N

Treatment NN o
was VBD o
successful JJ o
in IN N
57 CD N
of IN N
64 CD N
patients NNS N
treated VBN N
with IN N
amoxicillin NN N
vs. FW N
58 CD N
of IN N
65 CD N
patients NNS N
treated VBN N
with IN N
erythromycin NN N
( ( N
P NNP N
= NNP N
0.00 CD N
) ) N
. . N

CONCLUSIONS NNP N
Amoxicillin NNP o
was VBD o
as RB o
efficacious JJ o
as IN N
erythromycin NN N
in IN N
the DT N
treatment NN o
of IN o
severe JJ o
pyoderma NN o
in IN p
Mali NNP p
. . p

Owing VBG N
to TO N
its PRP$ N
efficacy NN N
, , N
added VBD N
to TO N
high JJ N
availability NN N
and CC N
low JJ N
cost NN N
, , N
this DT N
compound NN N
should MD N
be VB N
considered VBN N
a DT N
first-line JJ N
treatment NN N
of IN N
this DT N
disorder NN N
in IN N
this DT N
country NN N
, , N
and CC N
perhaps RB N
in IN N
other JJ N
countries NNS N
where WRB N
this DT N
condition NN N
presents VBZ N
in IN N
a DT N
similar JJ N
way NN N
. . N

-DOCSTART- -8957368- O O

Thoracoscopic NNP i
talc NN i
insufflation NN i
versus IN N
talc NN i
slurry NN i
for IN N
symptomatic JJ p
malignant JJ p
pleural JJ p
effusion NN p
. . p

BACKGROUND NNP N
Talc NNP N
has VBZ N
been VBN N
generally RB N
accepted VBN N
to TO N
be VB N
the DT N
most RBS N
effective JJ N
sclerosant NN N
for IN N
chemical NN N
pleurodesis NN N
, , N
although IN N
the DT N
optimal JJ N
route NN N
of IN N
administration NN N
remains VBZ N
unclear JJ N
. . N

METHODS NNP N
We PRP N
designed VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
to TO N
compare VB N
video-assisted JJ i
thoracoscopic NN i
talc NN i
insufflation NN i
with IN i
bedside JJ i
talc NN i
slurry NN i
in IN i
the DT N
treatment NN N
of IN N
malignant JJ p
pleural JJ p
effusion NN p
. . p

From IN p
September NNP p
1993 CD p
to TO p
November NNP p
1995 CD p
, , p
57 CD p
patients NNS p
were VBD N
recruited VBN N
and CC N
randomized VBN N
to TO N
either DT N
video-assisted JJ i
thoracoscopic NN i
talc NN i
insufflation NN i
under IN N
general JJ i
anesthesia NN i
( ( N
n JJ N
= NNP N
28 CD N
) ) N
or CC N
talc JJ N
slurry NN N
by IN N
the DT N
bedside NN N
( ( N
n JJ N
= NNP N
29 CD N
) ) N
. . N

Patients NNS p
with IN p
poor JJ p
general JJ p
condition NN p
( ( p
Karnofsky NNP p
score RB p
less JJR p
than IN p
30 CD p
% NN p
) ) p
, , p
poor JJ p
pulmonary JJ p
function NN p
( ( p
forced JJ p
expiratory NN p
volume NN p
in IN p
1 CD p
second NN p
less JJR p
than IN p
0.5 CD p
L NNP p
) ) p
, , p
or CC p
trapped VBN p
lungs NNS p
were VBD p
excluded VBN p
from IN p
this DT p
study NN p
. . p

Five CD N
grams NNS N
of IN N
purified JJ N
talc NN N
was VBD N
used VBN N
for IN N
either DT N
video-assisted JJ N
thoracoscopic NN N
talc NN N
insufflation NN N
or CC N
talc NN N
slurry NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ o
difference NN o
between IN o
the DT o
two CD o
groups NNS o
of IN o
patients NNS o
with IN o
respect NN o
to TO o
age NN o
, , o
sex NN o
ratio NN o
, , o
chest JJS o
drainage NN o
duration NN o
, , o
postprocedural JJ o
hospital NN o
stay NN o
, , o
parenteral JJ o
narcotics NNS o
requirement NN o
, , o
complications NNS o
, , o
or CC o
procedure NN o
failure NN o
( ( o
ie NN o
, , o
recurrence NN o
) ) o
. . o

CONCLUSIONS NNP N
Video-assisted JJ N
thoracoscopic NN N
talc NN N
insufflation NN N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
a DT N
superior JJ N
approach NN N
compared VBN N
with IN N
talc NN N
slurry NN N
in IN N
our PRP$ N
study NN N
. . N

Because IN N
the DT N
former JJ N
demands NNS N
more RBR N
resources NNS N
, , N
we PRP N
advocate VBP N
that IN N
talc NN N
slurry NN N
should MD N
be VB N
considered VBN N
as IN N
the DT N
procedure NN N
of IN N
choice NN N
in IN N
the DT N
treatment NN N
of IN N
symptomatic JJ N
malignant JJ N
pleural JJ N
effusion NN N
in IN N
patients NNS p
who WP p
do VBP p
not RB p
have VB p
trapped VBN p
lungs NNS p
. . p

-DOCSTART- -23735703- O O

A DT N
randomised JJ N
trial NN N
comparing VBG N
preoperative JJ i
to TO i
perioperative JJ i
chemotherapy NN i
in IN N
early-stage JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
IFCT NNP p
0002 CD p
trial NN p
) ) p
. . p

HYPOTHESIS NNP N
There EX N
will MD N
be VB N
a DT N
detectable JJ N
increase NN N
in IN N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
using VBG N
preoperative JJ i
( ( i
PRE NNP i
) ) i
as IN i
opposed VBN i
to TO i
perioperative VB i
( ( i
PERI NNP i
) ) i
chemotherapy NN i
in IN N
resectable JJ p
StageI-II JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
. . p

METHODS NNP N
This DT N
multicenter NN N
, , N
open-label JJ N
, , N
randomised JJ N
trial NN N
with IN N
a DT N
2?2 CD N
factorial JJ N
design NN N
first RB N
compared VBN N
two CD N
chemotherapy NN N
strategies NNS N
( ( N
PRE NNP N
versus NNP N
PERI NNP N
) ) N
, , N
then RB N
two CD i
chemotherapy NN i
regimens NNS i
( ( i
gemcitabine-cisplatin JJ i
[ NNP i
GP NNP i
] NNP i
versus IN i
paclitaxel-carboplatin JJ i
[ NNP i
TC NNP i
] NNP i
) ) i
. . i

The DT i
PRE NNP i
group NN N
received VBD N
two CD N
preoperative JJ N
cycles NNS N
followed VBN N
by IN N
two CD N
additional JJ N
preoperative NN N
cycles NNS N
, , N
while IN N
the DT i
PERI NNP i
group NN N
underwent VBD N
two CD N
preoperative JJ N
cycles NNS N
followed VBN N
by IN N
two CD N
postoperative JJ N
cycles NNS N
, , N
the DT N
3rd CD N
and CC N
4th CD N
cycles NNS N
being VBG N
given VBN N
only RB N
to TO N
responders NNS N
in IN N
both DT N
cases NNS N
. . N

RESULTS VB p
A DT p
total NN p
of IN p
528 CD p
patients NNS p
were VBD N
randomised VBN N
, , N
267 CD N
of IN N
which WDT N
were VBD N
assigned VBN N
to TO N
the DT N
PRE NNP N
group NN N
and CC N
261 CD N
to TO N
the DT N
PERI NNP N
group NN N
. . N

Three-year JJ o
OS NNP o
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
( ( N
67.4 CD N
% NN N
and CC N
67.7 CD N
% NN N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
=1.01 VBP N
[ JJ N
0.79-1.30 JJ N
] NN N
, , N
p=0.92 NN N
) ) N
, , N
nor CC N
did VBD o
3-year JJ o
disease-free JJ o
survival NN o
, , o
response NN o
rates NNS o
, , o
toxicity NN o
, , o
or CC o
postoperative JJ o
mortality NN o
. . o

Pathological NNP o
complete JJ o
response NN o
was VBD N
observed VBN N
in IN N
22 CD N
( ( N
8.2 CD N
% NN N
) ) N
and CC N
16 CD N
patients NNS N
( ( N
6.1 CD N
% NN N
) ) N
, , N
respectively RB N
. . N

Although IN o
quality NN o
of IN o
life NN o
did VBD N
not RB N
differ VB N
significantly RB N
, , N
chemotherapy NN o
compliance NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
PRE NNP N
group NN N
. . N

The DT N
proportion NN N
of IN N
responders NNS N
who WP N
received VBD N
Cycles NNP N
3 CD N
and CC N
4 CD N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
PRE NNP N
group NN N
( ( N
90.4 CD N
% NN N
versus IN N
75.2 CD N
% NN N
, , N
p=0.001 NN N
) ) N
. . N

In IN N
responders NNS N
, , N
the DT N
dose JJ N
intensity NN N
of IN N
Cycles NNP N
3 CD N
and CC N
4 CD N
was VBD N
higher RBR N
in IN N
the DT N
PRE NNP N
group NN N
than IN N
in IN N
the DT N
PERI NNP N
group NN N
( ( N
mean JJ N
relative VBP N
dose JJ N
intensity NN N
of IN N
90.4 CD N
% NN N
versus IN N
82.6 CD N
% NN N
, , N
respectively RB N
; : N
p=0.0007 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN o
GP NNP o
and CC o
TC NNP o
in IN N
3-year JJ o
OS NNP o
( ( N
HR=0.97 NNP N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
0.76-1.25 JJ N
] NN N
, , N
p=0.80 NN N
) ) N
or CC o
response NN o
rates NNS o
. . o

However RB N
, , N
the DT N
regimens NNS o
' POS o
toxicity NN o
profiles NNS N
differed VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
failed VBD N
to TO N
demonstrate VB N
any DT N
difference NN N
in IN o
survival NN o
between IN N
patients NNS N
receiving VBG i
preoperative JJ i
and CC i
perioperative JJ i
chemotherapy NN i
in IN p
early-stage JJ p
NSCLC NNP p
. . p

The DT N
increase NN N
from IN N
two CD N
to TO N
four CD N
preoperative JJ N
chemotherapy NN N
cycles NNS N
did VBD N
not RB N
increase VB N
the DT o
pathological JJ o
response NN o
rate NN N
. . N

-DOCSTART- -11319711- O O

Physiologic NNP N
modeling NN N
of IN N
the DT N
intravenous JJ o
glucose JJ o
tolerance NN o
test NN o
in IN N
type NN p
2 CD p
diabetes NNS p
: : p
a DT N
new JJ N
approach NN N
to TO N
the DT N
insulin NN N
compartment NN N
. . N

The DT N
minimal JJ N
model NN N
of IN N
Bergman NNP N
et FW N
al NN N
has VBZ N
been VBN N
used VBN N
to TO N
yield VB N
estimates NNS N
of IN N
insulin NN o
sensitivity NN o
( ( o
Si NNP o
) ) o
and CC o
glucose JJ o
effectiveness NN o
( ( o
Sg NNP o
) ) o
in IN N
type NN N
2 CD N
diabetes NNS N
by IN N
incorporating VBG N
exogenous JJ i
insulin NN i
protocols NNS i
into IN N
the DT N
regular JJ N
intravenous JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
IVGTT NNP N
) ) N
. . N

These DT N
estimates NNS N
, , N
however RB N
, , N
are VBP N
influenced VBN N
by IN N
the DT N
degree NN N
to TO N
which WDT N
the DT N
dose NN N
of IN N
exogenous JJ i
insulin NN i
is VBZ N
greater JJR N
than IN N
the DT N
physiologic JJ N
response NN N
to TO N
a DT N
glucose JJ N
load NN N
. . N

Moreover RB N
, , N
most JJS N
studies NNS N
have VBP N
related VBN N
to TO N
type VB p
2 CD p
diabetes NNS p
subjects NNS p
whose WP$ N
diabetes NNS N
was VBD N
relatively RB N
mild JJ N
in IN N
terms NNS N
of IN N
therapeutic JJ N
requirements NNS N
. . N

To TO N
develop VB N
a DT N
minimal JJ N
disturbance NN N
approach NN N
in IN N
estimating VBG N
Si NNP o
and CC o
Sg NNP o
in IN N
type NN N
2 CD N
diabetes NNS N
, , N
we PRP N
have VBP N
used VBN N
a DT N
reduced JJ i
glucose JJ i
load NN i
( ( N
200 CD N
mg/kg NN N
) ) N
and CC i
a DT i
physiologic JJ i
insulin NN i
infusion NN i
throughout IN N
the DT N
IVGTT NNP N
in IN N
a DT N
series NN N
of IN N
8 CD p
patients NNS p
, , p
5 CD p
of IN p
whom WP p
were VBD p
insulin-requiring JJ p
. . p

Data NNS N
from IN N
this DT N
approach NN N
were VBD N
analyzed VBN N
using VBG N
the DT N
modelling VBG N
program NN N
CONSAM NNP N
to TO N
apply VB N
the DT N
Bergman NNP N
model NN N
, , N
either RB N
unmodified JJ N
( ( N
BMM NNP N
) ) N
, , N
or CC N
incorporating VBG N
an DT N
additional JJ N
delay NN N
element NN N
between IN N
the DT N
plasma NN N
and CC N
remote JJ N
insulin NN N
compartments NNS N
( ( N
MMD NNP N
) ) N
. . N

Application NN N
of IN N
the DT N
MMD NNP N
and CC N
extension NN N
of IN N
the DT N
IVGTT NNP N
from IN N
3 CD N
to TO N
5 CD N
hours NNS N
improved VBN N
successful JJ N
resolution NN o
of IN o
Si NNP o
and CC o
Sg NNP o
from IN N
37.5 CD N
% NN N
( ( N
BMM NNP N
, , N
3-hour JJ N
IVGTT NNP N
) ) N
to TO N
100 CD N
% NN N
( ( N
MMD NNP N
, , N
5-hour JJ N
IVGTT NNP N
) ) N
. . N

Si NNP o
was VBD N
reduced VBN N
in IN N
these DT N
type NN N
2 CD N
diabetes VBZ N
patients NNS N
compared VBN N
with IN N
normal JJ N
subjects NNS N
( ( N
1.86 CD N
+/- JJ N
0.60 CD N
v. JJ N
8.65 CD N
+/- JJ N
2.27 CD N
min NN N
( ( N
-1 NNP N
) ) N
x VBP N
microU NN N
( ( N
-1 NNP N
) ) N
x VBP N
mL JJ N
x $ N
10 CD N
( ( N
4 CD N
) ) N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

The DT N
results NNS N
were VBD N
validated VBN N
in IN N
the DT N
type NN p
2 CD p
diabetes NNS p
group NN p
using VBG N
a DT N
2-stage JJ N
euglycemic JJ N
clamp NN N
( ( N
( ( N
Si NNP N
) ) N
CLAMP NNP N
= $ N
2.02 CD N
+/- JJ N
0.42 CD N
min NN N
( ( N
-1 NNP N
) ) N
x VBP N
microU NN N
( ( N
-1 NNP N
) ) N
x VBP N
mL JJ N
x $ N
10 CD N
( ( N
4 CD N
) ) N
P NNP N
> NNP N
.4 NNP N
) ) N
. . N

Sg NNP o
was VBD N
not RB N
significantly RB N
reduced VBN N
( ( N
2.00 CD N
+/- JJ N
0.25 CD N
type NN N
2 CD N
diabetes NNS N
v. JJ N
1.55 CD N
+/- JJ N
0.26 CD N
normal JJ N
min NN N
( ( N
-1 NNP N
) ) N
x VBZ N
10 CD N
( ( N
2 CD N
) ) N
) ) N
. . N

Data NNS N
from IN N
a DT N
group NN N
of IN N
normal JJ p
nondiabetic JJ p
subjects NNS p
was VBD N
then RB N
analyzed VBN N
using VBG N
the DT N
MMD NNP N
, , N
but CC N
this DT N
approach NN N
did VBD N
not RB N
enhance VB N
the DT N
fit NN N
of IN N
the DT N
model NN N
compared VBN N
with IN N
the DT N
BMM NNP N
. . N

This DT N
result NN N
indicates VBZ N
that IN N
the DT N
delay NN N
in IN N
insulin JJ N
action NN N
in IN N
type NN N
2 CD N
diabetes VBZ N
represents VBZ N
an DT N
abnormality NN N
whereby WRB N
the DT N
onset NN N
of IN N
insulin JJ N
action NN N
can MD N
not RB N
be VB N
described VBN N
as IN N
a DT N
single JJ N
phase NN N
in IN N
the DT N
transfer NN N
of IN N
insulin NN N
from IN N
plasma NN N
to TO N
the DT N
remote JJ N
compartment NN N
. . N

It PRP N
is VBZ N
postulated VBN N
that IN N
the DT N
physiologic JJ N
basis NN N
for IN N
this DT N
delayed JJ N
action NN N
may MD N
relate VB N
to TO N
transcapillary JJ N
endothelial JJ N
transfer NN N
of IN N
insulin NN N
, , N
this DT N
process NN N
limiting VBG N
the DT N
rate NN N
of IN N
onset NN N
of IN N
insulin JJ N
action NN N
. . N

-DOCSTART- -21996342- O O

Epicutaneous JJ N
allergen-specific JJ i
immunotherapy NN i
ameliorates VBZ N
grass JJ N
pollen-induced JJ N
rhinoconjunctivitis NN N
: : N
A DT N
double-blind NN N
, , N
placebo-controlled JJ N
dose NN N
escalation NN N
study NN N
. . N

BACKGROUND NNP N
Epicutaneous NNP i
allergen NN i
administration NN N
using VBG N
a DT N
patch NN N
may MD N
be VB N
an DT N
alternative JJ N
to TO N
subcutaneous JJ N
or CC N
sublingual JJ N
immunotherapy NN N
. . N

OBJECTIVE UH N
To TO N
optimize VB N
treatment NN N
dose NN N
and CC N
to TO N
demonstrate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
epicutaneous JJ N
immunotherapy NN N
. . N

METHODS NNP N
This DT N
monocentric JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
included VBD p
132 CD p
patients NNS p
with IN p
grass JJ p
pollen-induced JJ p
rhinoconjunctivitis NN p
. . p

In IN N
February NNP N
2008 CD N
, , N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB i
placebo NN i
or CC i
3 CD i
different JJ i
doses NNS i
of IN i
allergen NN i
. . i

Before IN N
and CC N
during IN N
the DT N
pollen NN N
season NN N
2008 CD N
, , N
patients NNS p
received VBD p
6 CD p
weekly JJ p
patches NNS p
. . p

Efficacy NN N
was VBD N
assessed VBN N
4 CD N
to TO N
5 CD N
months NNS N
later RB N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
and CC N
during IN N
the DT N
pollen NN N
season NN N
of IN N
the DT N
treatment-free JJ N
follow-up JJ N
year NN N
in IN N
2009 CD N
( ( N
n JJ N
= NNP N
93 CD N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
was VBD o
patient-reported JJ o
changes NNS o
in IN o
hay NN o
fever NN o
symptoms NNS o
assessed VBN o
by IN o
a DT o
visual JJ o
analog NN o
scale NN o
. . o

Secondary JJ N
outcome NN N
measures NNS N
were VBD o
weekly JJ o
visual JJ o
analog NN o
scale JJ o
symptom NN o
scores NNS o
during IN o
pollen NN o
season NN o
, , o
use NN o
of IN o
rescue NN o
medication NN o
, , o
changes NNS o
in IN o
conjunctival NN o
and CC o
skin NN o
reactivity NN o
, , o
as RB o
well RB o
as IN o
safety NN o
. . o

RESULTS NNP o
Hay NNP o
fever NN o
symptoms NNS o
during IN o
the DT o
pollen NN o
season NN o
were VBD N
reduced VBN N
by IN N
more JJR N
than IN N
30 CD N
% NN N
in IN N
2008 CD N
and CC N
by IN N
24 CD N
% NN N
in IN N
2009 CD N
in IN N
the DT N
high-dose JJ N
group NN N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
the DT N
alleviation NN N
of IN N
symptoms NNS N
in IN N
the DT N
follow-up JJ N
year NN N
was VBD N
dependent JJ N
on IN N
the DT N
treatment NN N
dose NN N
. . N

Higher JJR N
allergen NN N
doses NNS N
were VBD N
associated VBN N
with IN o
drug-related JJ o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
, , o
predominantly RB N
manifested VBN N
by IN o
pruritus NN o
, , o
erythema NN o
, , o
wheal NN o
, , o
or CC o
eczema NN o
. . o

Eleven NNP N
systemic JJ o
AEs NNP o
of IN N
grades NNS N
1 CD N
to TO N
2 CD N
required VBN N
treatment NN N
and CC N
led VBD N
to TO N
study VB N
exclusion NN N
. . N

The DT o
dropout NN o
rate NN o
due JJ N
to TO o
AEs NNP o
was VBD N
8.3 CD N
% NN N
. . N

No DT N
drug-related JJ N
serious JJ o
AE NNP o
was VBD N
recorded VBN N
. . N

CONCLUSION NNP N
Epicutaneous NNP i
immunotherapy NN i
is VBZ N
safe JJ N
and CC N
efficacious JJ N
in IN N
a DT N
dose-dependent JJ N
manner NN N
after IN N
6 CD N
patches NNS N
only RB N
. . N

-DOCSTART- -19470807- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
balance-based JJ N
torso NN i
weighting VBG i
for IN N
improving VBG N
upright JJ o
mobility NN o
in IN N
people NNS p
with IN p
multiple JJ p
sclerosis NN p
. . p

BACKGROUND NNP N
Torso NNP N
weighting NN N
has VBZ N
sometimes RB N
been VBN N
effective JJ N
for IN N
improving VBG N
upright JJ o
mobility NN o
in IN N
people NNS p
with IN p
multiple JJ p
sclerosis NN p
, , N
but CC N
parameters NNS o
for IN o
weighting VBG o
have VBP N
been VBN N
inconsistent JJ N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
balance-based JJ i
torso NN i
weighting NN i
( ( i
BBTW NNP i
) ) i
has VBZ N
immediate JJ N
effects NNS N
on IN N
upright JJ N
mobility NN N
in IN N
people NNS N
with IN N
multiple JJ p
sclerosis NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
2-phase JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

In IN p
phase NN p
1 CD p
, , p
36 CD p
participants NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
experimental VB p
and CC p
control VB p
groups NNS p
. . p

In IN N
phase NN p
2 CD p
, , p
the DT p
control NN p
group NN p
was VBD N
subsequently RB N
randomized VBN N
into IN N
2 CD N
groups NNS N
with IN N
alternate JJ N
weight-placement JJ N
. . N

Tests NNS N
of IN N
upright JJ o
mobility NN o
included VBD N
: : N
timed VBN o
up RP o
and CC o
go VB o
( ( o
TUG NNP o
) ) o
, , o
sharpened VBD o
Romberg NNP o
, , o
360-degree JJ o
turns NNS o
, , o
25-foot JJ o
walk NN o
, , o
and CC o
computerized JJ o
platform NN o
posturography NN o
. . o

Participants NNS N
were VBD N
tested VBN N
at IN N
baseline NN N
and CC N
again RB N
with IN N
weights NNS N
placed VBN N
according VBG N
to TO N
group NN N
membership NN N
. . N

In IN N
both DT N
phases NNS N
, , N
a DT N
physical JJ N
therapist NN N
assessed VBD N
balance NN N
for IN N
the DT N
BBTW NNP N
group NN N
and CC N
then RB N
placed VBD N
weights NNS N
to TO N
decrease VB N
balance NN o
loss NN o
. . o

In IN N
phase NN N
1 CD N
, , N
the DT N
control NN N
group NN N
had VBD N
no DT N
weights NNS N
placed VBN N
. . N

In IN N
phase NN N
2 CD N
, , N
the DT N
alternate NN N
treatment NN N
group NN N
received VBD N
standard JJ N
weight JJ N
placement NN N
of IN N
1.5 CD N
% NN N
body NN N
weight NN N
. . N

RESULTS JJ N
People NNS N
with IN N
BBTW NNP i
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
25-foot JJ o
walk NN o
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
over IN N
those DT N
with IN N
no DT N
weight NN N
, , N
and CC N
the DT N
TUG NNP o
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
over IN N
those DT N
with IN N
standard JJ N
weight NN N
placement NN N
. . N

BBTW NNP N
participants NNS N
received VBD N
an DT N
average NN N
of IN N
0.5 CD N
kg NNS o
, , N
less JJR N
than IN N
1.5 CD N
% NN N
of IN N
any DT N
participant NN N
's POS N
body NN N
weight NN N
. . N

CONCLUSION NNP N
BBTW NNP i
can MD N
have VB N
immediate JJ N
advantages NNS N
over IN N
a DT N
nonweighted JJ N
condition NN N
for IN N
gait NN o
velocity NN o
and CC N
over IN N
a DT N
standardized JJ N
weighted JJ N
condition NN N
for IN N
a DT N
functional JJ o
activity NN o
in IN N
people NNS p
with IN p
multiple JJ p
sclerosis NN p
( ( p
MS NNP p
) ) p
who WP N
are VBP N
ambulatory JJ N
but CC N
have VBP N
balance NN N
and CC N
mobility NN N
abnormalities NNS N
. . N

-DOCSTART- -10757579- O O

Ropivacaine-clonidine JJ i
combination NN i
for IN N
caudal NN p
blockade NN p
in IN p
children NNS p
. . p

BACKGROUND NNP N
Adding NNP N
clonidine NN i
to TO N
weak JJ i
ropivacaine JJ i
solutions NNS i
( ( N
< VB N
0.2 CD N
% NN N
) ) N
could MD N
potentially RB N
enhance VB o
analgesia NN o
as RB N
well RB N
as IN N
further JJ N
reduce VB o
the DT o
risk NN o
for IN o
unwanted JJ o
motor NN o
blockade NN o
. . o

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
postoperative JJ N
pain-relieving JJ o
quality NN o
of IN N
a DT N
ropivacaine JJ i
0.1 CD i
% NN i
-clonidine JJ i
mixture NN i
to TO N
that DT N
of IN N
plain NN i
ropivacaine VBP i
0.2 CD N
% NN N
following VBG N
caudal JJ p
administration NN p
in IN p
children NNS p
. . p

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
observer-blinded JJ N
fashion NN N
, , N
40 CD p
ASA NNP p
1 CD p
paediatric JJ p
patients NNS p
undergoing VBG p
subumbilical JJ p
surgery NN p
were VBD N
randomly RB i
allocated VBN i
to TO i
receive VB i
a DT i
caudal JJ i
injection NN i
of IN i
either DT i
plain NN i
ropivacaine VBP i
0.2 CD i
% NN i
( ( i
1 CD i
ml/kg NN i
) ) i
( ( i
R0.2 NNP i
) ) i
or CC i
a DT i
mixture NN i
of IN i
ropivacaine JJ i
0.1 CD i
% NN i
with IN i
clonidine JJ i
2 CD i
microg/kg NN i
( ( i
1 CD i
ml/kg NN i
) ) i
( ( i
R0.1C NNP i
) ) i
. . N

Objective JJ o
pain NN o
scale NN o
score NN o
and CC o
need NN o
for IN o
supplemental JJ o
analgesia NN o
were VBD i
used VBN i
to TO i
evaluate VB i
analgesia NN i
during IN i
the DT i
first JJ i
24 CD i
h NN i
postoperatively RB i
. . i

Residual JJ o
postoperative JJ o
sedation NN o
was VBD i
also RB i
assessed VBN i
. . i

RESULTS VB N
A DT N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
in IN N
the DT N
R0.1C NNP N
group NN N
( ( N
18/20 CD N
) ) N
could MD N
be VB N
managed VBN N
without IN N
supplemental JJ o
analgesia NN o
during IN N
the DT N
first JJ N
24 CD N
h NN N
postoperatively RB N
compared VBN N
to TO N
the DT N
R0.2 NNP N
group NN N
( ( N
11/20 CD N
) ) N
( ( N
P=0.034 NNP N
) ) N
. . N

Both CC N
the DT N
degree NN o
and CC o
the DT o
duration NN o
of IN o
postoperative JJ o
sedation NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

No DT N
signs NNS N
of IN N
postoperative JJ o
motor NN o
blockade NN o
were VBD N
observed VBN N
. . N

CONCLUSIONS VB N
The DT N
combination NN N
of IN N
clonidine NN i
( ( i
2 CD i
microg/kg NN i
) ) i
and CC i
ropivacaine VB i
0.1 CD i
% NN i
is VBZ N
associated VBN N
with IN N
an DT N
improved JJ o
quality NN o
of IN o
postoperative JJ o
analgesia NN o
compared VBN N
to TO N
plain VB i
0.2 CD i
% NN i
ropivacaine NN i
. . i

The DT N
improved JJ o
analgesic JJ o
quality NN o
of IN N
the DT N
clonidine-ropivacaine JJ N
mixture NN N
is VBZ N
achieved VBN N
without IN N
causing VBG N
any DT N
significant JJ N
degree NN N
of IN N
postoperative JJ N
sedation NN N
. . N

-DOCSTART- -8709689- O O

Removing VBG i
bee JJ i
stings NNS i
. . i

BACKGROUND NNP N
Conventional NNP N
advice NN N
on IN N
immediate JJ N
treatment NN N
of IN N
honey-bee JJ N
stings NNS N
has VBZ N
emphasised VBN N
that IN N
the DT N
sting NN N
should MD N
be VB N
scraped VBN N
off RP N
, , N
never RB N
pinched VBN N
. . N

The DT N
morphology NN N
of IN N
the DT N
sting NN N
suggested VBD N
little JJ N
basis NN N
for IN N
this DT N
advice NN N
, , N
which WDT N
is VBZ N
likely JJ N
to TO N
slow VB N
down RP N
removal NN N
of IN N
the DT N
sting NN N
. . N

METHODS NNP N
The DT N
response NN N
to TO N
honey-bee JJ p
stings NNS p
was VBD N
assayed VBN N
with IN N
a DT N
measurement NN N
of IN N
the DT N
size NN N
of IN N
the DT N
resulting VBG N
weal NN N
. . N

Injection NN N
of IN N
known JJ N
quantities NNS N
of IN N
venom NN i
showed VBD N
that IN N
this DT N
measurement NN N
is VBZ N
a DT N
good JJ N
indicator NN N
of IN N
envenomisation NN N
. . N

FINDINGS NNP N
Weal NNP o
size NN o
, , N
and CC N
thus RB N
envenomisation NN N
, , N
increased VBD N
as IN N
the DT N
time NN o
from IN o
stinging VBG o
to TO o
removal NN o
of IN o
the DT o
sting NN o
increased VBD N
, , N
even RB N
within IN N
a DT N
few JJ N
seconds NNS N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
response NN N
between IN N
stings NNS o
scraped VBD o
or CC o
pinched VBD o
off RP o
after IN N
2 CD N
s. JJ N
INTERPRETATION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
advice NN N
to TO N
patients NNS p
on IN p
the DT p
immediate JJ p
treatment NN p
of IN p
bee JJ o
stings NNS o
should MD N
emphasise VB N
quick JJ i
removal NN i
, , N
without IN N
concern NN N
for IN N
the DT N
method NN N
of IN N
removal NN N
. . N

-DOCSTART- -15894964- O O

Cigarette NNP N
smoking NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
circulating VBG N
proinflammatory NN N
and CC N
procoagulant JJ N
markers NNS N
in IN N
patients NNS p
with IN p
chronic JJ p
coronary JJ p
artery NN p
disease NN p
: : p
effects NNS N
of IN N
aspirin JJ i
treatment NN N
. . N

BACKGROUND NNP N
Smoking NNP N
is VBZ N
associated VBN N
with IN N
endothelial JJ N
dysfunction NN N
. . N

Cytokines NNS N
released VBN N
by IN N
injured JJ N
endothelium NN N
promote NN N
vascular JJ N
interactions NNS N
with IN N
leukocytes NNS N
and CC N
platelets NNS N
. . N

We PRP N
investigated VBD N
whether IN N
( ( N
a DT N
) ) N
cigarette NN N
smoking NN N
is VBZ N
linked VBN N
to TO N
increased VBN N
cytokine NN N
production NN N
, , N
which WDT N
may MD N
mediate VB N
platelet NN N
activation NN N
and CC N
thrombin JJ N
generation NN N
in IN N
chronic JJ N
coronary JJ N
artery NN N
disease NN N
( ( N
CAD NNP N
) ) N
, , N
and CC N
( ( N
b NN N
) ) N
aspirin NN N
treatment NN N
inhibits VBZ N
smoking-related JJ N
changes NNS N
on IN N
cytokines NNS N
, , N
platelets NNS N
, , N
and CC N
thrombin NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Plasma NNP N
macrophage-colony-stimulating JJ N
factor NN N
( ( N
M-CSF NNP N
) ) N
and CC N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
were VBD N
measured VBN N
in IN N
100 CD p
patients NNS p
with IN p
chronic JJ p
CAD NNP p
, , p
60 CD p
of IN p
whom WP p
were VBD p
chronic JJ p
smokers NNS p
. . p

Prothrombin NNP N
fragments VBZ N
1+2 CD N
and CC N
urinary JJ N
11-dehydro-thromboxane JJ N
B2 NNP N
( ( N
TXB2 NNP N
) ) N
were VBD N
additionally RB N
measured VBN N
in IN N
60 CD p
of IN p
100 CD p
patients NNS p
( ( p
30 CD p
of IN p
whom WP p
were VBD p
smokers NNS p
) ) p
and CC p
in IN p
24 CD p
healthy JJ p
controls NNS p
. . p

Smokers NNS p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
matched VBN p
for IN p
age NN p
, , p
myocardial JJ p
ischemia NN p
, , p
and CC p
other JJ p
risk NN p
factors NNS p
with IN p
20 CD p
nonsmokers NNS p
entered VBD N
a DT N
double-blind JJ N
crossover NN N
trial NN N
of IN N
aspirin NN i
( ( N
300 CD N
mg/d NN N
for IN N
3 CD N
weeks NNS N
) ) N
versus VBP N
placebo NN i
. . i

Blood NNP N
and CC N
urine JJ N
measurements NNS N
were VBD N
repeated VBN N
after IN N
each DT N
treatment NN N
. . N

Compared VBN N
with IN N
nonsmokers NNS N
, , N
smokers NNS N
had VBD N
3-fold JJ o
median JJ o
M-CSF NNP o
( ( N
1499 CD N
vs NN N
476 CD N
pg/mL NN N
) ) N
, , N
2-fold JJ o
CRP NNP o
( ( N
1.5 CD N
vs RB N
0.8 CD N
mg/L NN N
) ) N
, , N
and CC N
higher JJR N
11-dehydro-TXB JJ o
2 CD N
( ( N
3.6 CD N
vs RB N
2.1 CD N
ng/mg JJ N
creatinine NN N
, , N
P NNP N
< NNP N
.01 NNP N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

After IN N
aspirin JJ N
treatment NN N
, , N
M-CSF NNP o
, , o
CRP NNP o
, , o
11-dehydro-TXB JJ o
2 CD o
, , o
and CC o
prothrombin NN o
fragments NNS o
1+2 CD o
remained VBD o
higher JJR o
in IN N
smokers NNS N
compared VBN N
with IN N
nonsmokers NNS N
despite IN N
a DT N
significant JJ N
reduction NN N
of IN N
these DT N
markers NNS N
by IN N
aspirin NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

M-CSF NNP N
remained VBD N
related JJ N
to TO N
11-dehydro-TXB JJ N
2 CD N
excretion NN N
during IN N
both DT N
treatment NN N
phases NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
suggesting VBG N
that IN N
cytokine-mediated JJ N
thromboxane NN N
A DT N
2 CD N
production NN N
was VBD N
not RB N
altered VBN N
by IN N
aspirin NN N
. . N

CONCLUSIONS NNP N
Smoking NNP N
is VBZ N
associated VBN N
with IN N
increased JJ N
M-CSF NNP N
, , N
CRP NNP N
, , N
and CC N
platelet NN N
activity NN N
. . N

Although IN N
aspirin JJ i
treatment NN N
reduces VBZ N
the DT N
proinflammatory NN N
and CC N
procoagulant JJ N
markers NNS N
in IN N
smokers NNS N
, , N
it PRP N
does VBZ N
not RB N
abolish VB N
the DT N
proinflammatory NN N
effects NNS N
of IN N
smoking NN N
in IN N
patients NNS p
with IN p
chronic JJ p
CAD NNP p
. . p

-DOCSTART- -1751266- O O

Propofol NNP i
and CC i
midazolam NNP i
act NN N
synergistically RB N
in IN N
combination NN N
. . N

We PRP N
have VBP N
studied VBN N
interactions NNS N
between IN N
i.v NN i
. . i

propofol NN i
and CC i
midazolam NN i
for IN N
induction NN p
of IN p
anaesthesia NN p
in IN p
200 CD p
unpremedicated JJ p
female NN p
patients NNS p
undergoing VBG p
elective JJ p
gynaecological JJ p
surgery NN p
. . p

Using VBG N
end-points NNS N
of IN N
hypnosis NN o
( ( o
loss NN o
of IN o
response NN o
to TO o
verbal JJ o
command NN o
) ) o
and CC N
anaesthesia $ o
( ( o
loss NN o
of IN o
response NN o
to TO o
a DT o
5-s JJ o
transcutaneous JJ o
tetanic JJ o
stimulus NN o
) ) o
, , N
we PRP N
determined VBD N
dose-response JJ N
curves NNS N
for IN N
propofol NN i
and CC i
midazolam VB i
alone RB i
and CC i
in IN i
combination NN i
. . i

For IN N
hypnosis NN o
, , o
synergistic JJ o
interaction NN o
was VBD N
found VBN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
the DT N
combination NN N
having VBG N
1.44 CD N
times NNS N
the DT N
potency NN N
of IN N
the DT N
individual JJ N
agents NNS N
. . N

Although IN N
midazolam NN i
failed VBD N
to TO N
produce VB N
anaesthesia NN o
in IN N
the DT N
dose NN N
range NN N
used VBN N
, , N
the DT N
dose NN N
of IN N
propofol NN i
required VBN o
to TO o
produce VB o
anaesthesia NN o
was VBD N
reduced VBN N
by IN N
52 CD N
% NN N
in IN N
the DT N
presence NN N
of IN N
midazolam NN i
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
arterial JJ o
pressure NN o
at IN o
induction NN o
was VBD N
the DT N
same JJ N
for IN N
the DT N
combination NN N
as IN N
for IN N
the DT N
individual JJ N
agents NNS N
. . N

The DT N
cause NN N
of IN N
the DT N
synergism NN N
was VBD N
not RB N
clear JJ N
, , N
but CC N
may MD N
have VB N
been VBN N
interaction NN N
at IN N
CNS NNP N
GABAA NNP N
receptors NNS N
. . N

-DOCSTART- -10754477- O O

The DT N
GH NNP N
response NN N
to TO N
low-dose JJ i
bolus JJ i
growth NN i
hormone-releasing VBG i
hormone NN i
( ( i
GHRH NNP i
( ( i
1-29 JJ i
) ) i
NH2 NNP i
) ) i
is VBZ N
attenuated VBN N
in IN N
patients NNS p
with IN p
longstanding JJ p
post-irradiation NN p
GH NNP p
insufficiency NN p
. . p

OBJECTIVE NNP N
Previous JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
post-irradiation NN N
GH NNP N
insufficiency NN N
results NNS N
from IN N
a DT N
loss NN N
of IN N
GHRH NNP N
secretion NN N
, , N
since IN N
many JJ N
patients NNS N
were VBD N
able JJ N
to TO N
release VB N
GH NNP N
following VBG N
exogenous JJ N
GHRH NNP N
stimulation NN N
. . N

However RB N
, , N
supramaximal JJ i
doses NNS i
of IN i
GHRH NNP i
were VBD N
used VBN N
and CC N
the DT N
response NN N
may MD N
decline VB N
with IN N
time NN N
after IN N
radiotherapy NN i
. . i

We PRP N
re-evaluated VBD N
the DT N
GHRH NNP i
dose-response JJ N
curve NN N
in IN N
patients NNS p
post VBP p
cranial JJ p
irradiation NN p
and CC p
in IN p
controls NNS p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
study NN N
. . N

METHODS NNP N
Five CD p
adult NN p
male NN p
long-term JJ p
survivors NNS p
of IN p
childhood NN p
brain NN p
tumours NNS p
( ( p
median JJ p
age NN p
21.8 CD p
years NNS p
( ( p
18.4-26.7 JJ p
) ) p
; : p
13.7 CD p
years NNS p
( ( p
11.4-15.7 JJ p
) ) p
post-radiotherapy NN p
, , p
> NNP p
30Gy CD p
) ) p
and CC p
five CD p
matched VBN p
controls NNS p
were VBD p
studied VBN p
. . p

An DT N
intravenous JJ N
bolus NN N
of IN N
GHRH NNP i
( ( i
1-29 JJ i
) ) i
NH NNP i
( ( i
2 CD i
) ) i
was VBD N
administered VBN N
in IN N
doses NNS N
at IN N
the DT N
lower JJR N
( ( N
0.05 CD N
microg/kg NN N
) ) N
and CC N
upper JJ N
( ( N
0.15 CD N
microg/kg NN N
) ) N
range NN N
of IN N
the DT N
dose-response JJ N
curves NNS N
for IN N
young JJ p
males NNS p
, , N
as RB N
well RB N
as IN N
the DT N
standard NN N
supramaximal NN N
dose NN N
( ( N
1 CD N
. . N

0 CD N
microg/kg NN N
) ) N
. . N

GH NNP o
was VBD N
measured VBN N
before IN N
stimulation NN N
, , N
every DT N
2min CD N
for IN N
the DT N
first JJ N
hour NN N
and CC N
every DT N
5min CD N
for IN N
the DT N
second JJ N
hour NN N
. . N

All DT N
studies NNS N
were VBD N
conducted VBN N
in IN N
a DT N
random JJ N
fashion NN N
. . N

RESULTS NNP N
Significantly NNP o
lower JJR o
peak NN o
and CC o
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC NNP o
) ) o
GH NNP o
concentrations NNS o
occurred VBD N
in IN N
the DT N
irradiated JJ N
group NN N
using VBG N
0.15 CD N
microg/kg NN N
( ( N
median JJ N
peak NN N
Irradiated NNP N
, , N
4 CD N
. . N

5mU/l CD N
vs NN N
median NN N
Controls NNP N
, , N
37.4mU/l CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
1.0 CD N
microg/kg NN N
( ( N
median JJ N
peak NN N
Irradiated NNP N
, , N
4.8mU/l CD N
vs NN N
median NN N
Controls NNP N
, , N
15.2mU/l CD N
; : N
P NNP N
< VBD N
0 CD N
. . N

05 CD N
) ) N
GHRH NNP N
( ( N
1-29 JJ N
) ) N
NH NNP N
( ( N
2 CD N
) ) N
. . N

In IN N
irradiated JJ N
subjects NNS N
there EX N
was VBD N
an DT N
incremental JJ N
rise NN o
in IN o
GH NNP o
output NN o
with IN N
increasing VBG N
doses NNS N
of IN N
GHRH NNP i
( ( i
1-29 JJ i
) ) i
NH NNP i
( ( i
2 CD i
) ) i
( ( i
median JJ i
AUC NNP N
: : N
122mU/l.min CD N
vs NN N
179mU/l.min CD N
vs NN N
268mU/l.min CD N
; : N
P=0.007 NNP N
) ) N
reflecting VBG N
altered VBN N
pituitary JJ o
sensitivity NN o
and CC o
reduced JJ o
responsiveness NN o
. . o

CONCLUSION VB N
The DT N
GH NNP N
response NN N
to TO N
bolus VB N
GHRH NNP i
( ( i
1-29 JJ i
) ) i
NH NNP i
( ( i
2 CD i
) ) i
is VBZ N
attenuated VBN N
in IN N
adult JJ p
long-term JJ p
survivors NNS p
of IN p
childhood NN p
brain NN p
tumours NN p
. . p

This DT N
may MD N
reflect VB N
direct JJ N
pituitary JJ N
damage NN N
and/or VBD N
the DT N
loss NN N
of IN N
the DT N
tropic NN N
effects NNS N
of IN N
chronic JJ N
GHRH NNP N
deficiency NN N
. . N

-DOCSTART- -19232615- O O

Intensive JJ i
insulin NN i
therapy NN i
on IN N
infection NN N
rate NN N
, , N
days NNS N
in IN N
NICU NNP N
, , N
in-hospital JJ o
mortality NN o
and CC o
neurological JJ o
outcome NN o
in IN N
severe JJ p
traumatic JJ p
brain NN p
injury NN p
patients NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVES NNP N
Evaluate NNP N
the DT N
impact NN N
of IN N
an DT N
intensive JJ i
insulin NN i
therapy NN i
and CC N
conventional JJ i
glucose NN i
control NN i
protocol NN i
during IN N
staying VBG N
in IN N
neurological JJ N
intensive JJ N
care NN N
unit NN N
( ( N
NICU NNP N
) ) N
on IN N
infection NN o
rate NN o
, , o
days NNS o
in IN o
NICU NNP o
, , o
in-hospital JJ o
mortality NN o
and CC o
long-term JJ o
neurological JJ o
outcome NN o
in IN N
severe JJ p
traumatic JJ p
brain NN p
injury NN p
( ( p
TBI NNP p
) ) p
patients NNS p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
240 CD p
patients NNS p
with IN p
severe JJ p
TBI NNP p
( ( p
GCS NNP p
score RB p
3-8 JJ p
) ) p
admitted VBD p
to TO p
NICU NNP p
were VBD N
prospectively RB N
enrolled VBN N
and CC N
randomly RB N
assigned VBD N
either DT N
to TO N
conventional JJ i
insulin NN i
therapy NN i
or CC N
to TO N
intensive JJ i
insulin NN i
therapy NN i
. . i

Patients NNS N
in IN N
intensive JJ i
glucose NNS i
control NN i
group NN i
( ( N
n=121 NN N
) ) N
received VBD N
continuous JJ i
insulin NN i
infusion NN i
to TO N
maintain VB N
glucose JJ N
levels NNS N
between IN N
4.4 CD N
m NNS N
mol/l NN N
( ( N
80 CD N
mg/dl NN N
) ) N
and CC N
6.1 CD N
m NN N
mol/l NN N
( ( N
110 CD N
mg/dl NN N
) ) N
. . N

Patients NNS N
in IN N
the DT N
conventional JJ i
treatment NN i
group NN i
( ( N
n=119 RB N
) ) N
were VBD N
not RB N
given VBN N
insulin NN i
unless IN N
glucose JJ o
levels NNS o
were VBD N
greater JJR N
than IN N
11.1 CD N
m JJ N
mol/l NN N
( ( N
200mg/dl CD N
) ) N
. . N

Both DT N
groups NNS N
were VBD N
treated VBN N
with IN N
insulin JJ i
infusion NN N
to TO N
maintain VB N
normoglycemia RB N
after IN N
leaving VBG N
NICU NNP N
. . N

Comparison NNP N
was VBD N
made VBN N
against IN N
conventional JJ i
insulin NN i
therapy NN i
using VBG N
a DT N
randomized JJ N
trial NN N
design NN N
. . N

The DT N
primary JJ N
outcomes NNS N
is VBZ N
the DT N
mortality NN o
rate NN o
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

The DT N
second JJ N
outcomes NNS N
including VBG N
ICU NNP o
infection NN o
rate NN o
, , o
duration NN o
of IN o
ICU NNP o
stay NN o
, , o
in-hospital JJ o
mortality NN o
rate NN o
and CC o
neurologic JJ o
outcome NN o
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
gender NN p
( ( p
66 CD p
% NN p
vs. FW p
67 CD p
% NN p
male NN p
) ) p
, , p
age NN p
( ( p
46+/-11 CD p
years NNS p
vs. IN p
45+/-10 CD p
years NNS p
) ) p
, , p
APACHE NNP p
II NNP p
score NN p
( ( p
30 CD p
vs. FW p
29 CD p
) ) p
, , p
TISS-28 NNP o
score NN o
( ( p
47 CD p
vs. FW p
46 CD p
) ) p
, , p
and CC p
Glasgow NNP o
Coma NNP o
Score NNP o
( ( p
GCS NNP p
, , p
5.3 CD p
vs. FW p
5.3 CD p
) ) p
between IN N
the DT N
two CD N
groups NNS N
. . N

Overall JJ o
mortality NN o
rates NNS o
at IN N
6 CD N
months NNS N
follow-up JJ N
were VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
61 CD N
of IN N
117 CD N
, , N
52.1 CD N
% NN N
vs. FW N
62 CD N
of IN N
116 CD N
, , N
53.4 CD N
% NN N
; : N
P=0.8 NNP N
) ) N
. . N

The DT N
infection NN o
rate NN o
during IN N
the DT N
study NN N
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS N
who WP N
received VBD N
conventional JJ i
insulin NN i
therapy NN i
than IN N
that DT N
in IN N
patients NNS N
who WP N
received VBD N
intensive JJ i
insulin NN i
therapy NN i
( ( N
46.2 CD N
% NN N
vs. FW N
31.4 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
days NNS o
stay VBP o
in IN o
NICU NNP o
was VBD N
shorter RBR N
in IN N
intensive JJ i
insulin NN i
control NN i
group NN i
than IN N
that DT N
in IN N
conventional JJ i
therapy NN i
group NN i
[ VBD N
4.2 CD N
days NNS N
vs. FW N
5.6 CD N
days NNS N
( ( N
medians NNS N
) ) N
P NNP N
< $ N
0.05 CD N
] NNP N
. . N

The DT N
in-hospital JJ o
mortality NN o
during IN N
the DT N
study NN N
was VBD N
similar JJ N
in IN N
conventional JJ i
and CC i
intensive JJ i
therapy NN i
groups NNS i
( ( N
34 CD N
of IN N
119 CD N
, , N
28.6 CD N
% NN N
vs. FW N
35 CD N
of IN N
121 CD N
, , N
28.9 CD N
% NN N
in IN N
the DT N
conventional JJ i
and CC i
intensive JJ i
insulin NN i
therapy NN i
groups NNS N
; : N
P=0.85 NNP N
) ) N
. . N

The DT N
neurologic JJ o
outcome NN o
according VBG N
to TO N
Glasgow NNP o
Outcome NNP o
Score NNP o
( ( o
GOS NNP o
) ) o
at IN N
6 CD N
months NNS N
( ( N
GOS NNP N
5 CD N
and CC N
4 CD N
) ) N
was VBD N
better RBR N
in IN N
the DT N
intensive JJ i
insulin NN i
therapy NN i
group NN N
( ( N
34 CD N
of IN N
117 CD N
, , N
29.1 CD N
% NN N
) ) N
than IN N
that DT N
in IN N
the DT N
conventional JJ i
therapy NN i
group NN N
( ( N
26 CD N
of IN N
116 CD N
, , N
22.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Mortality NNP o
rates NNS o
at IN N
6 CD N
months NNS N
follow-up NNS N
are VBP N
not RB N
affected VBN N
by IN N
intensive JJ N
glucose NNS N
control NN N
in IN N
patients NNS p
with IN p
severe JJ p
TBI NNP p
. . p

Intensive JJ i
insulin NN i
therapy NN i
decreases VBZ N
infection NN o
rate NN o
and CC o
days NNS o
in IN o
NICU NNP o
and CC N
improves VBZ o
the DT o
neurological JJ o
outcome NN o
at IN N
6 CD N
months NNS N
follow-up RB N
, , N
while IN N
has VBZ N
no DT N
obvious JJ N
influence NN N
on IN N
in-hospital JJ o
mortality NN o
of IN N
severe JJ p
TBI NNP p
patients NNS p
. . p

-DOCSTART- -11292273- O O

Clinical JJ N
implications NNS N
of IN N
a DT N
reduction NN N
in IN N
psychological JJ N
distress NN N
on IN N
cardiac JJ N
prognosis NN N
in IN N
patients NNS p
participating VBG p
in IN p
a DT p
psychosocial JJ i
intervention NN i
program NN i
. . i

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
secondary JJ N
analysis NN N
was VBD N
to TO N
examine VB N
the DT N
relationships NNS N
between IN N
a DT N
reduction NN N
in IN N
psychological JJ N
distress NN N
and CC N
long-term JJ N
cardiac NN N
and CC N
psychological JJ N
outcomes NNS N
in IN N
post-myocardial JJ p
infarction NN p
patients NNS p
who WP p
participated VBD p
in IN p
a DT p
randomized JJ p
trial NN p
of IN p
home-based JJ p
psychosocial JJ p
nursing NN p
interventions NNS p
( ( p
the DT p
Montreal NNP p
Heart NNP p
Attack NNP p
Readjustment NNP p
Trial NNP p
[ NNP p
M-HART NNP p
] NNP p
) ) p
. . p

Gender VB N
differences NNS N
were VBD N
considered VBN N
. . N

METHODS NNP N
We PRP N
studied VBD i
433 CD i
patients NNS i
( ( i
36.0 CD i
% NN i
women NNS i
) ) i
from IN i
the DT i
M-HART NNP i
treatment NN i
group NN i
who WP i
received VBD i
two CD i
home NN i
visits NNS i
after IN i
achieving VBG i
a DT i
high JJ i
psychological JJ i
distress NN i
score NN i
( ( i
ie JJ i
, , i
> JJ i
or CC i
=5 NN i
) ) i
on IN i
the DT i
General NNP i
Health NNP i
Questionnaire NNP i
( ( i
GHQ NNP i
) ) i
. . i

Short-term JJ N
GHQ NNP o
success NN o
was VBD N
determined VBN N
by IN N
a DT N
return NN N
to TO N
a DT N
normal JJ N
GHQ NNP o
score NN o
( ( N
< JJ N
5 CD N
) ) N
or CC N
a DT N
reduction NN N
of IN N
> NN N
or CC N
=50 CD N
% NN N
after IN N
the DT N
two CD N
visits NNS N
. . N

Patients NNS N
with IN N
short-term JJ N
successful JJ N
and CC N
unsuccessful JJ N
GHQ NNP N
outcomes NNS N
were VBD N
compared VBN N
for IN N
mid-term JJ N
maintenance NN N
of IN N
success NN N
, , N
1-year JJ N
death NN N
and CC N
readmission NN N
rates NNS N
, , N
and CC N
1-year JJ N
depression NN N
and CC N
anxiety NN N
symptoms NNS N
. . N

RESULTS JJ N
Patients NNS N
with IN N
short-term JJ N
GHQ NNP N
success NN N
were VBD N
more RBR N
likely JJ N
to TO N
show VB N
mid-term JJ o
GHQ NNP o
success NN o
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
, , N
marginally RB N
less RBR N
likely JJ N
to TO N
die VB o
of IN o
any DT o
causes NNS o
( ( N
p JJ N
= NNP N
.087 NNP N
) ) N
, , N
less RBR N
likely JJ N
to TO N
die VB o
of IN o
cardiac JJ o
causes NNS o
( ( N
p JJ N
= NNP N
.043 NNP N
) ) N
, , N
less RBR N
likely JJ N
to TO N
be VB N
readmitted VBN o
for IN N
any DT N
reason NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
and CC N
for IN N
cardiac JJ N
reasons NNS N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
less RBR N
likely JJ N
to TO N
have VB N
high JJ o
depression NN o
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
and CC N
anxiety NN o
( ( N
p JJ N
< NNP N
.001 NN N
) ) N
at IN N
1-year JJ N
than IN N
patients NNS N
with IN N
short-term JJ N
unsuccessful JJ N
GHQ NNP o
outcomes NNS o
. . o

Results NNS N
held VBD N
for IN N
men NNS p
and CC p
women NNS p
and CC N
were VBD N
not RB N
altered VBN N
by IN N
controlling VBG N
for IN N
potential JJ N
confounders NNS N
. . N

However RB N
, , N
the DT N
number NN N
of IN N
deaths NNS o
prevented VBN N
analysis NN N
with IN N
statistical JJ N
controls NNS N
. . N

CONCLUSIONS NNP N
Post-myocardial JJ N
infarction NN N
interventions NNS N
that WDT N
reduce VB N
psychological JJ N
distress NN N
have VBP N
the DT N
potential NN N
to TO N
improve VB N
long-term JJ o
prognosis NN o
and CC N
psychological JJ o
status NN o
for IN N
both DT N
men NNS p
and CC p
women NNS p
. . p

-DOCSTART- -10340153- O O

Gender NNP p
differences NNS p
in IN N
response NN N
to TO N
nicotine VB i
replacement NN i
therapy NN i
: : i
objective JJ N
and CC N
subjective JJ N
indexes NNS N
of IN N
tobacco NN p
withdrawal NN p
. . p

K. NNP N
A. NN N
Perkins NNP N
( ( N
1996 CD N
) ) N
recently RB N
proposed VBD N
that IN N
nicotine JJ i
reinforcement NN i
controls NNS p
smoking VBG p
to TO p
a DT p
greater JJR p
degree NN p
among IN p
men NNS p
than IN p
women NNS p
and CC N
that DT N
consequently RB N
, , N
nicotine JJ i
replacement NN i
therapy NN i
( ( i
NRT NNP i
) ) i
during IN N
smoking VBG N
cessation NN N
should MD N
benefit VB N
men NNS N
more JJR N
than IN N
women NNS N
. . N

The DT N
authors NNS N
tested VBD N
this DT N
hypothesis NN N
. . N

Polysomnographic JJ N
measures NNS N
of IN N
sleep NN o
and CC o
self-report NN o
indexes NNS o
of IN N
tobacco NN N
withdrawal NN N
were VBD N
collected VBN N
pre- JJ N
and CC N
postcessation NN N
from IN N
an DT N
active JJ p
nicotine NN i
patch NN i
group NN p
and CC p
a DT p
placebo NN i
patch NN i
group NN p
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
( ( p
N NNP p
= NNP p
34 CD p
) ) p
. . p

Objective JJ N
sleep JJ N
parameters NNS N
supported VBD N
Perkins NNP N
's POS N
hypothesis NN N
and CC N
indicated VBD N
that IN N
among IN N
women NNS N
, , N
NRT NNP i
may MD N
be VB N
less RBR N
effective JJ N
at IN N
suppressing VBG o
certain JJ o
withdrawal NN o
responses NNS o
compared VBN N
with IN N
men NNS N
and CC N
may MD o
produce VB o
some DT o
iatrogenic JJ o
effects NNS o
. . o

Valid NNP N
and CC N
reliable JJ N
self-report JJ N
measures NNS N
of IN N
withdrawal NN o
did VBD o
not RB o
reveal VB o
gender NN o
differences NNS o
in IN o
response NN o
to TO o
NRT NNP o
. . o

-DOCSTART- -23518801- O O

Effect NN N
of IN N
phenylephrine NN i
on IN N
the DT N
haemodynamic JJ o
state NN o
and CC o
cerebral JJ o
oxygen NN o
saturation NN o
during IN N
anaesthesia NN N
in IN N
the DT N
upright JJ N
position NN N
. . N

BACKGROUND IN N
The DT N
upright JJ N
sitting NN N
or CC N
beachchair NN N
position NN N
is VBZ N
associated VBN N
with IN N
hypotension NN o
, , o
risk NN o
of IN o
cerebral JJ o
hypoperfusion NN o
, , o
and CC o
cerebral JJ o
injury NN o
. . o

We PRP N
hypothesized VBD N
that IN N
by IN N
increasing VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine JJ i
administration NN N
, , N
cerebral JJ o
perfusion NN o
, , N
and CC N
postoperative JJ o
recovery NN o
would MD N
be VB N
improved VBN N
. . N

METHODS NNP N
Thirty-four JJ p
patients NNS p
undergoing VBG p
elective JJ p
shoulder NN p
surgery NN p
were VBD p
randomized VBN p
to TO N
receive VB N
either DT N
saline NN i
or CC i
phenylephrine NN i
infusion NN i
( ( i
PE NNP i
) ) i
5 CD N
min NN N
before IN N
being VBG N
placed VBN N
in IN N
the DT N
upright JJ N
position NN N
. . N

Simultaneous JJ N
measurements NNS N
of IN N
mean JJ o
arterial JJ o
pressure NN o
, , o
cerebral JJ o
oxygen NN o
saturation NN o
, , o
middle JJ o
cerebral JJ o
artery NN o
velocity NN o
, , o
and CC o
cardiac JJ o
function NN o
using VBG o
transthoracic JJ o
echocardiography NN o
were VBD N
made VBN N
. . N

Postoperative JJ N
neurocognitive JJ o
function NN o
was VBD N
assessed VBN N
. . N

RESULTS NNP N
At IN N
the DT N
commencement NN N
of IN N
PE NNP N
, , N
mean NN o
( ( o
SD NNP o
) ) o
cerebral JJ o
oxygen NN o
saturation NN o
significantly RB N
decreased VBN N
from IN N
77 CD N
( ( N
10 CD N
) ) N
to TO N
67 CD N
( ( N
13 CD N
) ) N
% NN N
( ( N
P=0.02 NNP N
) ) N
, , N
and CC N
further RB N
to TO N
59 CD N
( ( N
11 CD N
) ) N
% NN N
on IN N
upright JJ N
positioning NN N
. . N

The DT N
level NN o
of IN o
cerebral JJ o
saturation NN o
upright NN o
was VBD N
not RB N
significantly RB N
different JJ N
to TO N
patients NNS N
receiving VBG N
saline NN N
( ( N
P=0.07 NNP N
) ) N
, , N
with IN N
values NNS N
remaining VBG N
at IN N
room-air JJ N
levels NNS N
. . N

Middle NNP o
cerebral JJ o
artery RB o
blood NN o
velocity NN o
increased VBN N
by IN N
20 CD N
% NN N
( ( N
P=0.04 NNP N
) ) N
. . N

Phenylephrine NNP N
prevented VBD N
hypotension NN o
in IN N
the DT N
upright JJ N
position NN N
primarily RB N
by IN N
maintaining VBG N
preload NN N
and CC N
increasing VBG N
systemic JJ o
vascular NN o
resistance NN o
( ( N
P=0.01 NNP N
) ) N
, , N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
cardiac JJ o
output NN o
. . o

No DT N
postoperative JJ o
neurocognitive JJ o
dysfunction NN o
was VBD N
identified VBN N
. . N

CONCLUSIONS NNP N
Despite IN N
maintaining VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine NN i
, , N
cerebral JJ o
desaturation NN o
occurred VBD N
with IN N
upright JJ N
positioning VBG N
. . N

Cerebral NNP o
oxygen IN o
saturation NN o
can MD N
provide VB N
a DT N
valuable JJ N
endpoint NN N
when WRB N
evaluating VBG N
the DT N
effect NN N
of IN N
vasopressor NN N
therapy NN N
on IN N
cerebral JJ N
perfusion NN N
. . N

-DOCSTART- -24437202- O O

[ JJ N
Rehabilitation NNP N
of IN N
the DT N
patients NNS p
presenting VBG p
with IN p
combined JJ p
pathology NN p
: : p
dyscirculatory NN p
encephalopathy NN p
and CC p
climacteric JJ p
syndrome NN p
] NN p
. . p

The DT N
present JJ N
paper NN N
reports VBZ N
the DT N
data NNS N
on IN N
rehabilitation NN p
of IN p
women NNS p
presenting VBG p
with IN p
combined JJ p
pathology NN p
: : p
dyscirculatory NN p
encephalopathy NN p
and CC p
climacteric JJ p
syndrome NN p
. . p

It PRP N
is VBZ N
shown VBN N
that IN N
the DT N
introduction NN N
of IN N
ozonotherapy NN i
and CC i
klimadynon NN i
, , N
a DT N
herbal JJ N
medicine NN N
possessed VBN N
of IN N
the DT N
estrogen-like JJ N
action NN N
, , N
into IN N
combined VBN N
rehabilitative JJ N
treatment NN N
ensures VBZ N
the DT N
significant JJ N
improvement NN N
of IN N
the DT N
parameters NNS N
of IN N
interest NN N
, , N
such JJ N
as IN N
climacteric NN o
symptoms NNS o
, , o
short-term JJ o
memory NN o
, , o
lipid JJ o
profile NN o
, , o
endothelial JJ o
function NN o
, , o
cerebral JJ o
circulation NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -10441604- O O

Phenobarbital JJ i
compared VBN N
with IN N
phenytoin NN i
for IN N
the DT N
treatment NN N
of IN N
neonatal JJ p
seizures NNS p
. . p

BACKGROUND NNP N
Seizures NNP N
occur VBP N
in IN N
1 CD N
to TO N
2 CD N
percent NN N
of IN N
neonates NNS p
admitted VBN p
to TO p
an DT p
intensive JJ p
care NN p
unit NN p
. . p

The DT N
treatment NN N
is VBZ N
usually RB N
with IN N
either DT N
phenobarbital NN i
or CC N
phenytoin NN i
, , N
but CC N
the DT N
efficacy NN o
of IN N
the DT N
two CD N
drugs NNS N
has VBZ N
not RB N
been VBN N
compared VBN N
directly RB N
. . N

METHODS NNP N
From IN N
1990 CD N
to TO N
1995 CD N
, , N
we PRP N
studied VBD N
59 CD p
neonates NNS p
with IN p
seizures NNS p
that WDT p
were VBD p
confirmed VBN p
by IN p
electroencephalography NN p
. . p

The DT N
neonates NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
phenobarbital NN i
or CC N
phenytoin NN i
intravenously RB N
, , N
at IN N
doses NNS N
sufficient JJ N
to TO N
achieve VB N
free JJ N
plasma NN N
concentrations NNS N
of IN N
25 CD N
microg NNS N
per IN N
milliliter NN N
for IN N
phenobarbital NN N
and CC N
3 CD N
microg NNS N
per IN N
milliliter NN N
for IN N
phenytoin NN N
. . N

Neonates NNS N
whose WP$ N
seizures NNS N
were VBD N
not RB N
controlled VBN N
by IN N
the DT N
assigned JJ N
drug NN N
were VBD N
then RB N
treated VBN N
with IN N
both DT N
drugs NNS N
. . N

Seizure NN o
control NN o
was VBD N
assessed VBN N
by IN N
electroencephalographic JJ N
criteria NNS N
. . N

RESULTS NNP N
Seizures NNPS o
were VBD N
controlled VBN N
in IN N
13 CD N
of IN N
the DT N
30 CD p
neonates NNS p
assigned VBN p
to TO p
receive VB p
phenobarbital NN p
( ( N
43 CD N
percent NN N
) ) N
and CC N
13 CD N
of IN N
the DT N
29 CD p
neonates NNS p
assigned VBN p
to TO p
receive VB p
phenytoin NN p
( ( N
45 CD N
percent NN N
; : N
P=1.00 NNP N
) ) N
. . N

When WRB N
combined JJ N
treatment NN N
is VBZ N
considered VBN N
, , N
seizure NN o
control NN o
was VBD N
achieved VBN N
in IN N
17 CD N
( ( N
57 CD N
percent NN N
) ) N
of IN N
the DT N
neonates NNS N
assigned VBD N
to TO N
receive VB N
phenobarbital NN N
first RB N
and CC N
18 CD N
( ( N
62 CD N
percent NN N
) ) N
of IN N
those DT N
assigned VBN N
to TO N
receive VB N
phenytoin NN N
first RB N
( ( N
P=0.67 NNP N
) ) N
. . N

The DT N
severity NN o
of IN o
the DT o
seizures NNS o
was VBD N
a DT N
stronger JJR N
predictor NN N
of IN N
the DT N
success NN N
of IN N
treatment NN N
than IN N
was VBD N
the DT N
assigned JJ N
agent NN N
. . N

Neonates VBZ N
with IN N
mild JJ o
seizures NNS o
or CC N
with IN N
seizures NNS o
that WDT N
were VBD N
decreasing VBG N
in IN N
severity NN o
before IN N
treatment NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
their PRP$ N
seizures NNS o
end VBP o
, , N
regardless RB N
of IN N
the DT N
treatment NN N
assignment NN N
. . N

CONCLUSIONS NNP N
Phenobarbital NNP i
and CC N
phenytoin NN i
are VBP N
equally RB N
but CC N
incompletely RB N
effective JJ N
as IN N
anticonvulsants NNS o
in IN N
neonates NNS p
. . p

With IN N
either DT N
drug NN N
given VBN N
alone RB N
, , N
the DT N
seizures NNS o
were VBD N
controlled VBN o
in IN N
fewer JJR N
than IN N
half NN N
of IN N
the DT N
neonates NNS N
. . N

-DOCSTART- -9531360- O O

Impact NN N
of IN N
surgical JJ i
staging NN i
in IN N
evaluating VBG N
the DT N
radiotherapeutic JJ N
outcome NN N
in IN N
RTOG NNP N
# # N
77-06 NNP N
, , N
a DT N
phase NN N
III NNP N
study NN N
for IN N
T1BN0M0 NNP N
( ( N
A2 NNP N
) ) N
and CC N
T2N0M0 NNP N
( ( N
B NNP N
) ) N
prostate NN N
carcinoma NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
survival NN N
and CC N
time NN N
to TO N
metastatic JJ N
disease NN N
in IN N
patients NNS p
treated VBN p
for IN p
localized JJ p
prostatic JJ p
carcinoma NN p
in IN p
a DT p
Phase NNP i
III NNP i
radiotherapy NN i
( ( p
RT NNP p
) ) p
protocol NN p
, , p
Radiation NNP i
Therapy NNP i
Oncology NNP i
Group NNP i
( ( p
RTOG NNP p
) ) p
77-06 NN p
. . p

Patients NNS p
with IN p
T18N0M0 NNP p
( ( p
A2 NNP p
) ) p
or CC p
T2N0M0 NNP p
( ( p
B NNP p
) ) p
disease NN p
after IN p
lymphangiogram NN p
( ( p
LAG NNP p
) ) p
or CC p
staging VBG p
laparotomy NN p
( ( p
SL NNP p
) ) p
were VBD p
randomized VBN p
between IN p
prophylactic JJ p
radiation NN p
to TO p
the DT p
pelvic JJ p
lymph NN p
nodes NNS p
and CC p
prostatic JJ p
bed NN p
vs. FW p
prostatic JJ p
bed NN p
alone RB p
. . p

The DT N
outcome NN N
of IN N
both DT N
treatment NN N
arms NNS N
, , N
as RB N
well RB N
as IN N
a DT N
comparison NN N
of IN N
the DT N
LAG NNP N
group NN N
, , N
to TO N
that DT N
of IN N
the DT N
SL NNP N
group NN N
, , N
are VBP N
updated VBN N
. . N

METHODS NNP N
AND NNP N
MATERIALS NNP N
A NNP p
total NN p
of IN p
449 CD p
eligible JJ p
males NNS p
were VBD p
entered VBN p
into IN p
RTOG NNP p
protocol NN p
7706 CD p
between IN p
1978 CD p
and CC p
1983 CD p
. . p

Lymph NNP N
node IN N
staging VBG N
was VBD N
mandatory JJ N
but CC N
at IN N
the DT N
physician NN N
's POS N
discretion NN N
; : N
117 CD p
( ( p
26 CD p
% NN p
) ) p
patients NNS p
had VBD p
SL NNP p
, , p
while IN p
332 CD p
( ( p
74 CD p
% NN p
) ) p
had VBD p
LAG NNP p
. . p

Follow-up NNP N
was VBD N
a DT N
median NN N
of IN N
12 CD N
years NNS N
and CC N
a DT N
maximum NN N
of IN N
16 CD N
years NNS N
. . N

For IN N
those DT N
randomized VBN N
to TO N
receive VB N
prophylactic JJ N
pelvic NNS N
lymph VBP N
nodal JJ N
irradiation NN N
, , N
45 CD N
Gy NNP N
of IN N
megavoltage NN N
RT NNP N
was VBD N
delivered VBN N
via IN N
multiple JJ N
portals NNS N
in IN N
4.5-5 JJ N
weeks NNS N
, , N
while IN N
all DT N
patients NNS N
received VBD N
65 CD N
Gy NNP N
in IN N
6.5-8 JJ N
weeks NNS N
to TO N
the DT N
prostatic JJ N
bed NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
survival JJ o
whether IN N
treatment NN N
was VBD N
administered VBN N
to TO N
the DT N
prostate NN N
or CC N
prostate NN N
and CC N
pelvic JJ N
lymph NN N
nodes NNS N
. . N

The DT N
SL NNP N
group NN N
had VBD N
greater JJR N
12-year JJ o
survival NN o
than IN N
the DT N
LAG NNP N
group NN N
( ( N
48 CD N
% NN N
vs. FW N
38 CD N
% NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

Disease-free JJ o
survival NN o
was VBD N
statistically RB N
significant JJ N
, , N
with IN N
38 CD N
% NN N
for IN N
the DT N
SL NNP N
group NN N
vs. FW N
26 CD N
% NN N
for IN N
the DT N
LAG NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Bone NNP o
metastasis NN o
was VBD N
less JJR N
common JJ N
in IN N
the DT N
SL NNP N
group NN N
( ( N
14 CD N
% NN N
) ) N
than IN N
the DT N
LAG NNP N
group NN N
( ( N
27 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSION NN N
At IN N
12-year JJ N
median JJ N
follow-up NN N
, , N
there EX N
still RB N
was VBD N
no DT N
survival JJ N
difference NN N
in IN N
those DT N
patients NNS N
treated VBD N
prophylactically RB N
to TO N
the DT N
pelvic JJ N
nodes NNS N
and CC N
prostatic JJ N
bed NN N
vs. IN N
the DT N
prostatic JJ N
bed NN N
alone RB N
. . N

Those DT N
patients NNS N
not RB N
surgically RB N
staged VBN N
with IN N
only RB N
LAG NNP N
for IN N
lymph JJ N
node JJ N
evaluation NN N
were VBD N
less RBR N
accurately RB N
staged VBN N
, , N
as IN N
reflected VBN N
by IN N
a DT N
statistically RB N
significant JJ N
reduced VBN N
survival NN N
and CC N
earlier JJR N
metastases NNS N
. . N

-DOCSTART- -9278836- O O

Active JJ o
warming NN o
, , o
not RB o
passive JJ o
heat NN o
retention NN o
, , N
maintains VBZ N
normothermia JJ o
during IN N
combined JJ N
epidural-general JJ N
anesthesia NN N
for IN N
hip NN p
and CC p
knee NN p
arthroplasty NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
to TO N
compare VB N
passive JJ N
heat NN N
retention NN N
by IN N
low-flow JJ N
anesthesia NN N
, , N
alone RB N
and CC N
with IN N
additional JJ N
thermal JJ N
insulation NN N
by IN N
reflective JJ N
blankets NNS N
, , N
with IN N
forced-air JJ N
warming VBG N
preventing VBG N
intraoperative JJ N
hypothermia NN N
during IN N
combined JJ N
epidural-general JJ N
anesthesia NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
study NN N
. . N

SETTING NNP N
Inpatient NNP p
anesthesia NN p
at IN p
a DT p
university NN p
department NN p
of IN p
orthopedic JJ p
surgery NN p
. . p

PATIENTS CC p
30 CD p
ASA NNP p
physical JJ p
status NN p
I PRP p
and CC p
II NNP p
patients NNS p
, , p
who WP p
were VBD p
scheduled VBN p
for IN p
elective JJ p
hip NN p
or CC p
knee VB p
arthroplasty JJ p
and CC p
were VBD p
free JJ p
from IN p
systemic JJ p
disease NN p
. . p

INTERVENTIONS JJ N
Patients NNPS N
received VBD N
epidural JJ N
block NN N
up RB N
to TO N
T10 NNP N
by IN N
alkalinized JJ i
lidocaine JJ i
2 CD i
% NN i
, , N
and CC N
then RB N
were VBD N
administered VBN N
standard JJ i
general JJ i
anesthesia NN i
by IN i
means NNS i
of IN i
low-flow JJ i
rebreathing NN i
system NN i
( ( N
fresh JJ N
gas NN N
flow NN N
= VBD N
1 CD N
L/min NNP N
) ) N
. . N

All DT N
procedures NNS N
started VBD N
between IN N
8 CD N
and CC N
10 CD N
AM NNP N
, , N
and CC N
operating NN N
room NN N
( ( N
OR NNP N
) ) N
temperature NN N
was VBD N
maintained VBN N
between IN N
21 CD N
degrees NNS N
and CC N
23 CD N
degrees NNS N
C NNP N
, , N
with IN N
relative JJ N
humidity NN N
ranging VBG N
between IN N
40 CD N
% NN N
and CC N
45 CD N
% NN N
. . N

For IN N
heat NN N
retention NN N
or CC N
warming VBG N
therapy NN N
, , N
patients NNS N
received VBD N
either RB N
low-flow JJ i
anesthesia NN i
only RB i
( ( N
control NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
low-flow JJ i
anesthesia NN i
with IN i
additional JJ i
reflective JJ i
blankets NNS i
( ( N
blanket NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
or CC N
low-flow JJ i
anesthesia NN i
with IN i
active JJ i
forced-air JJ i
warming NN i
( ( N
forced-air JJ N
, , N
n JJ N
= NNP N
10 CD N
) ) N
. . N

Tympanic JJ o
temperature NN o
was VBD N
measured VBN N
at IN N
OR NNP N
arrival NN N
( ( N
baseline NN N
) ) N
; : N
immediately RB N
following VBG N
general JJ N
anesthesia JJ N
induction NN N
; : N
30 CD N
, , N
60 CD N
, , N
90 CD N
, , N
and CC N
120 CD N
minutes NNS N
from IN N
general JJ N
anesthesia NN N
induction NN N
; : N
and CC N
at IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Duration NNP o
of IN o
anesthesia NN o
, , o
invasiveness NN o
of IN o
surgery NN o
, , o
and CC o
baseline NN o
core NN o
temperature NN o
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

Core NNP o
temperature NN o
decreased VBN N
in IN N
all PDT N
the DT N
three CD N
groups NNS N
30 CD N
minutes NNS N
after IN N
general JJ N
anesthesia NN N
induction NN N
compared VBN N
with IN N
baseline NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
; : N
afterwards NNS N
, , N
it PRP N
progressively RB N
decreased VBD N
in IN N
the DT N
control NN N
and CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
, , N
with IN N
a DT N
reduction NN o
from IN o
baseline NN o
values NNS o
measured VBN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
of IN N
2.0 CD N
degrees NNS N
C NNP N
and CC N
1.6 CD N
degrees NNS N
C NNP N
, , N
respectively RB N
. . N

In IN N
the DT N
forced-air JJ N
group NN N
, , N
after IN N
the DT N
initial JJ N
significant JJ N
decrease NN N
( ( N
p JJ N
= $ N
0.01 CD N
vs. FW N
baseline NN N
) ) N
, , N
core JJ o
temperature NN o
progressively RB N
increased VBD N
to TO N
35.8 CD N
+/- JJ N
0.6 CD N
degrees NNS N
C NNP N
, , N
which WDT N
was VBD N
similar JJ N
to TO N
preoperative VB N
values NNS N
and CC N
significantly RB N
higher JJR N
than IN N
either CC N
the DT N
control NN N
or CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

CONCLUSIONS NNP N
During IN N
combined VBN N
epidural-general JJ N
anesthesia NN N
for IN N
elective JJ p
hip NN p
and CC p
knee NN p
arthroplasty NN p
, , N
passive JJ N
heat NN N
retention NN N
by IN N
means NNS N
of IN N
low-flow JJ i
anesthesia NN i
alone RB i
and CC i
in IN i
combination NN i
with IN i
reflective JJ i
blankets NNS i
is VBZ N
ineffective JJ N
in IN N
maintaining VBG o
intraoperative JJ o
normothermia NN o
and CC N
definitely RB N
inferior JJ N
to TO N
active JJ N
forced-air JJ N
warning NN N
. . N

-DOCSTART- -10489959- O O

Assessment NN p
of IN p
the DT p
pain NN p
of IN p
blood-sugar JJ p
testing NN p
: : p
a DT p
randomised JJ p
controlled VBN p
trial NN p
. . p

Lancet NNP i
puncture NN i
to TO i
the DT i
side NN i
of IN i
the DT i
thumb NN i
resulted VBD N
in IN N
less JJR o
pain NN o
than IN N
lancet JJ i
puncture NN i
to TO i
the DT i
finger NN i
or CC i
venepuncture NN i
at IN i
the DT i
elbow NN i
. . i

Success JJ N
rates NNS N
were VBD N
the DT N
same JJ N
. . N

-DOCSTART- -6653648- O O

Diazoxide NNP i
and CC i
labetalol NN i
in IN N
acute JJ p
hypertension NN o
during IN N
haemodialysis NN N
. . N

The DT N
antihypertensive JJ N
effect NN N
of IN N
the DT N
peripheral JJ i
vasodilator NN i
diazoxide NN i
in IN N
13 CD p
patients NNS p
and CC p
the DT p
alpha-beta JJ i
adrenoceptor NN i
blocking VBG i
agent JJ i
labetalol NN i
in IN p
12 CD p
patients NNS p
were VBD p
compared VBN p
in IN p
46 CD p
severe JJ p
acute NN p
hypertensive JJ o
episodes NNS p
during IN p
haemodialysis NN p
. . p

A DT N
single JJ N
dose NN N
of IN N
diazoxide JJ i
150 CD i
mg NN i
or CC i
labetalol $ i
50 CD i
mg NN i
was VBD N
effective JJ N
in IN N
74 CD N
% NN N
and CC N
70 CD N
% NN N
of IN N
the DT N
hypertensive JJ o
episodes NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
diazoxide-treated JJ i
patients NNS p
blood NN o
pressure NN o
fell VBD N
from IN N
192 CD N
+/- JJ N
3/115 CD N
+/- JJ N
4 CD N
mmHg NN N
to TO N
141 CD N
+/- JJ N
8/85 CD N
+/- JJ N
4 CD N
mmHg NN N
2 CD N
h NN N
after IN N
injection NN N
. . N

In IN N
7 CD N
hypertensive JJ o
episodes NNS N
a DT N
second JJ N
dose NN N
of IN N
diazoxide JJ i
150 CD N
mg NN N
was VBD N
given VBN N
60 CD N
+/- JJ N
11 CD N
min NN N
after IN N
the DT N
first JJ N
injection NN N
. . N

The DT N
reduction NN N
in IN N
mean JJ o
arterial JJ o
blood NN o
pressure NN o
at IN N
the DT N
end NN N
of IN N
haemodialysis NN N
was VBD N
21.5 CD N
+/- JJ N
2.6 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
single JJ N
dose NN N
and CC N
24.8 CD N
+/- JJ N
3.5 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
the DT N
repeated VBN N
dose NN N
of IN N
diazoxide NN i
. . i

In IN N
the DT N
labetalol-treated JJ i
patients NNS p
blood NN o
pressure NN o
in IN N
17 CD N
instances NNS N
fell VBD N
from IN N
198 CD N
+/- JJ N
5/104 CD N
+/- JJ N
4 CD N
mmHg NN N
to TO N
143 CD N
+/- JJ N
7/89 CD N
+/- JJ N
5 CD N
mmHg NN N
180 CD N
min NN N
following VBG N
injection NN N
of IN N
labetalol $ i
50 CD N
mg NN N
. . N

In IN N
6 CD N
episodes NNS N
a DT N
second JJ N
dose NN N
labetalol VBD i
50 CD N
mg NN N
was VBD N
given VBN N
41 CD N
+/- JJ N
9 CD N
min NN N
after IN N
the DT N
first JJ N
injection NN N
. . N

At IN N
the DT N
end NN N
of IN N
haemodialysis NN N
the DT N
decrease NN N
in IN N
mean JJ o
arterial JJ o
blood NN o
pressure NN o
was VBD N
17.2 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
single JJ N
dose NN N
and CC N
18 CD N
+/- JJ N
5 CD N
% NN N
in IN N
patients NNS N
given VBN N
the DT N
repeated VBN N
dose NN N
of IN N
labetalol NN i
. . i

The DT N
reduction NN N
in IN N
blood NN o
pressure NN o
caused VBN N
by IN N
diazoxide NN i
was VBD N
slightly RB N
greater JJR N
than IN N
that DT N
due JJ N
to TO N
labetalol VB N
. . N

At IN N
the DT N
end NN N
of IN N
haemodialysis NN N
the DT N
percentage NN N
reduction NN N
in IN N
mean JJ N
arterial JJ N
blood NN N
pressure NN N
was VBD N
23 CD N
+/- JJ N
2 CD N
% NN N
in IN N
the DT N
diazoxide-treated JJ N
group NN N
and CC N
17 CD N
+/- JJ N
2 CD N
% NN N
after IN N
labetalol NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -15914128- O O

Effects NNS N
of IN N
two CD N
combined JJ N
oral JJ i
contraceptives NNS i
containing VBG N
ethinyl NN i
estradiol $ i
20 CD N
microg NN N
combined VBN N
with IN N
either DT N
drospirenone NN i
or CC i
desogestrel NN i
on IN N
lipids NNS N
, , N
hemostatic JJ N
parameters NNS N
and CC N
carbohydrate JJ N
metabolism NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
ethinyl NN i
estradiol NN i
20 CD i
microg/drospirenone NN i
3 CD i
mg NN i
( ( N
EE NNP N
20 CD N
microg/DRSP NN N
3 CD N
mg NN N
) ) N
administered VBD N
according VBG N
to TO N
a DT N
24/4 JJ N
regimen NN N
with IN N
ethinyl JJ i
estradiol NN i
20 CD i
microg/desogestrel NN i
150 CD N
microg NN N
( ( N
EE NNP N
20 CD N
microg/DSG NN N
150 CD N
microg NN N
) ) N
administered VBD N
according VBG N
to TO N
the DT N
conventional JJ N
21/7 CD N
regimen NNS N
on IN N
lipid JJ N
, , N
carbohydrate NN N
and CC N
hemostatic JJ N
parameters NNS N
. . N

STUDY NNP N
DESIGN NNP N
In IN N
this DT N
open-label JJ N
study NN N
, , N
healthy JJ p
women NNS p
were VBD p
randomized VBN p
to TO p
EE VB p
20 CD p
microg/DRSP NN p
3 CD p
mg NN p
or CC p
EE NNP p
20 CD p
microg/DSG NN p
150 CD p
microg NN p
for IN p
seven CD p
cycles NNS p
. . p

Mean JJ N
differences NNS N
in IN N
high-density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
- : o
and CC o
low-density JJ o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
-cholesterol NN o
levels NNS o
at IN N
cycle NN N
7 CD N
compared VBN N
to TO N
baseline VB N
were VBD N
assessed VBN N
. . N

Secondary JJ N
variables NNS N
included VBD N
changes NNS N
in IN N
other JJ o
lipid JJ o
, , o
hemostatic JJ o
and CC o
carbohydrate JJ o
parameters NNS o
. . o

RESULTS NNP N
Both NNP N
treatments NNS N
increased VBD N
HDL-cholesterol NNP o
, , N
but CC N
decreased VBD N
LDL-cholesterol NNP o
by IN N
a DT N
comparable JJ N
extent NN N
. . N

Although IN N
slightly RB N
elevated VBN N
in IN N
both DT N
groups NNS N
, , N
blood NN o
glucose NN o
and CC o
C-peptide JJ o
levels NNS o
measured VBN N
during IN N
oral JJ N
glucose JJ N
tolerance NN N
tests NNS N
were VBD N
within IN N
normal JJ N
reference NN N
ranges VBZ N
at IN N
cycle NN N
7 CD N
. . N

Overall JJ N
, , N
the DT N
differences NNS N
in IN N
lipid JJ o
, , o
hemostatic JJ o
or CC o
carbohydrate JJ o
parameters NNS o
were VBD N
not RB N
significant JJ N
between IN N
the DT N
two CD N
treatments NNS N
. . N

CONCLUSION NNP N
EE NNP N
20 CD N
microg/DRSP NN N
3 CD N
mg NN N
has VBZ N
a DT N
good JJ N
safety NN N
profile NN N
comparable JJ N
with IN N
EE NNP N
20 CD N
microg/DSG NN N
150 CD N
microg NN N
. . N

-DOCSTART- -23101741- O O

Early JJ N
behavioral JJ N
intervention NN N
is VBZ N
associated VBN N
with IN N
normalized JJ N
brain NN o
activity NN o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

OBJECTIVE CC N
A DT N
previously RB N
published VBN N
randomized JJ N
clinical JJ N
trial NN N
indicated VBD N
that IN N
a DT N
developmental JJ N
behavioral JJ i
intervention NN i
, , N
the DT N
Early JJ N
Start NNP N
Denver NNP N
Model NNP N
( ( N
ESDM NNP N
) ) N
, , N
resulted VBD N
in IN N
gains NNS N
in IN N
IQ NNP N
, , N
language NN N
, , N
and CC N
adaptive JJ N
behavior NN N
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

This DT N
report NN N
describes VBZ N
a DT N
secondary JJ N
outcome NN N
measurement NN N
from IN N
this DT N
trial NN N
, , N
EEG NNP o
activity NN o
. . o

METHOD NNP N
Forty-eight JJ p
18- JJ p
to TO p
30-month-old JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
were VBD N
randomized VBN N
to TO N
receive VB i
the DT i
ESDM NNP i
or CC i
referral JJ i
to TO i
community NN i
intervention NN i
for IN i
2 CD i
years NNS i
. . i

After IN N
the DT N
intervention NN N
( ( N
age NN N
48 CD N
to TO N
77 CD N
months NNS N
) ) N
, , N
EEG NNP o
activity NN o
( ( o
event-related JJ o
potentials NNS o
and CC o
spectral JJ o
power NN o
) ) o
was VBD i
measured VBN i
during IN i
the DT i
presentation NN i
of IN i
faces VBZ i
versus JJ i
objects NNS i
. . i

Age-matched JJ p
typical JJ p
children NNS p
were VBD N
also RB N
assessed VBN N
. . N

RESULTS VB N
The DT N
ESDM NNP i
group NN N
exhibited VBD N
greater JJR N
improvements NNS N
in IN N
autism NN o
symptoms NNS o
, , o
IQ NNP o
, , o
language NN o
, , o
and CC o
adaptive JJ o
and CC o
social JJ o
behaviors NNS o
than IN N
the DT N
community NN N
intervention NN N
group NN N
. . N

The DT N
ESDM NNP N
group NN N
and CC N
typical JJ N
children NNS N
showed VBD N
a DT N
shorter NN o
Nc NNP o
latency NN o
and CC o
increased VBD o
cortical JJ o
activation NN o
( ( o
decreased VBN o
? . o
power NN o
and CC o
increased VBD o
? . o
power NN o
) ) o
when WRB o
viewing VBG N
faces VBZ N
, , N
whereas IN N
the DT N
community NN N
intervention NN N
group NN N
showed VBD N
the DT N
opposite JJ N
pattern NN N
( ( N
shorter JJ o
latency NN o
event-related JJ o
potential JJ o
[ NN o
ERP NNP o
] NNP o
and CC o
greater JJR o
cortical JJ o
activation NN o
when WRB o
viewing VBG N
objects NNS o
) ) o
. . o

Greater NNP o
cortical JJ o
activation NN o
while IN o
viewing VBG N
faces VBZ N
was VBD N
associated VBN N
with IN o
improved VBN o
social JJ o
behavior NN o
. . o

CONCLUSIONS VB N
This DT N
was VBD N
the DT N
first JJ N
trial NN N
to TO N
demonstrate VB N
that DT N
early JJ N
behavioral JJ N
intervention NN N
is VBZ N
associated VBN N
with IN o
normalized JJ o
patterns NNS o
of IN o
brain NN o
activity NN o
, , o
which WDT N
is VBZ N
associated VBN N
with IN o
improvements NNS o
in IN o
social JJ o
behavior NN o
, , o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

-DOCSTART- -12629094- O O

Final NNP o
height NN o
in IN o
girls NNS o
with IN p
turner NN p
syndrome NN p
after IN N
long-term JJ N
growth NN i
hormone NN i
treatment NN i
in IN N
three CD N
dosages NNS N
and CC N
low JJ N
dose NN N
estrogens NNS i
. . i

Although IN N
GH NNP i
treatment NN i
for IN N
short JJ N
stature NN N
in IN N
Turner NNP N
syndrome NN N
is VBZ N
an DT N
accepted JJ N
treatment NN N
in IN N
many JJ N
countries NNS N
, , N
which WDT N
GH NNP N
dosage NN N
to TO N
use VB N
and CC N
which WDT N
age NN N
to TO N
start VB N
puberty JJ N
induction NN N
are VBP N
issues NNS N
of IN N
debate NN N
. . N

This DT N
study NN N
shows VBZ N
final JJ o
height NN o
( ( o
FH NNP o
) ) o
in IN N
60 CD p
girls NNS p
with IN p
Turner NNP p
syndrome NN p
treated VBD p
in IN p
a DT p
randomized JJ p
dose-response JJ p
trial NN p
, , N
combining VBG i
GH NNP i
treatment NN i
with IN i
low JJ i
dose NN i
estrogens NNS i
at IN N
a DT N
relatively RB N
young JJ N
age NN N
. . N

Girls NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
group NN N
A NNP N
( ( N
4 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
approximately RB N
0.045 CD N
mg/kg/d NN N
) ) N
, , N
group NN N
B NNP N
( ( N
first JJ N
year NN N
, , N
4 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
thereafter RB N
6 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
) ) N
, , N
or CC N
group NN N
C NNP N
( ( N
first JJ N
year NN N
, , N
4 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
second JJ N
year NN N
, , N
6 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
thereafter RB N
, , N
8 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
) ) N
. . N

After IN N
a DT N
minimum NN N
of IN N
4 CD N
yr NN N
of IN N
GH NNP i
treatment NN i
, , N
at IN N
a DT N
mean JJ N
age NN N
of IN N
12.7 CD N
+/- JJ N
0.7 CD N
yr NNS N
, , N
low JJ N
dose RB N
micronized VBN i
17beta-estradiol CD i
was VBD N
given VBN N
orally RB N
. . N

After IN N
a DT N
mean JJ N
duration NN o
of IN o
GH NNP o
treatment NN o
of IN N
8.6 CD N
+/- JJ N
1.9 CD N
yr NN N
, , N
FH NNP N
was VBD N
reached VBN N
at IN N
a DT N
mean JJ N
age NN N
of IN N
15.8 CD N
+/- JJ N
0.9 CD N
yr. NN N
FH NNP o
, , N
expressed VBD N
in IN N
centimeters NNS N
or CC N
SD NNP N
score NN N
, , N
was VBD N
157.6 CD N
+/- JJ N
6.5 CD N
or CC N
-1.6 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
A NNP N
, , N
162.9 CD N
+/- JJ N
6.1 CD N
or CC N
-0.7 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
B NNP N
, , N
and CC N
163.6 CD N
+/- JJ N
6.0 CD N
or CC N
-0.6 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
C. NNP N
The DT N
difference NN N
in IN N
FH NNP o
in IN o
centimeters NNS o
, , N
corrected VBN N
for IN N
height NN N
SD NNP N
score NN N
and CC N
age NN N
at IN N
start NN N
of IN N
treatment NN N
, , N
was VBD N
significant JJ N
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
[ NNP N
regression NN N
coefficient NN N
, , N
4.1 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.4 CD N
, , N
6.9 CD N
; : N
P NNP N
< VBD N
0.01 CD N
] NN N
, , N
and CC N
groups NNS N
A NNP N
and CC N
C NNP N
( ( N
coefficient NN N
, , N
5.0 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
2.3 CD N
, , N
7.7 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
between IN N
groups NNS N
B NNP N
and CC N
C NNP N
( ( N
coefficient NN N
, , N
0.9 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
-1.8 NNP N
, , N
3.6 CD N
) ) N
. . N

Fifty NNP p
of IN p
the DT p
60 CD p
girls NNS p
( ( p
83 CD p
% NN p
) ) p
had VBD p
reached VBN p
a DT p
normal JJ o
FH NNP o
( ( p
FH NNP p
SD NNP p
score NN p
, , p
more JJR p
than IN p
-2 NN p
) ) p
. . N

After IN N
starting VBG N
estrogen NN i
treatment NN N
, , N
the DT N
decrease NN o
in IN o
height JJ o
velocity NN o
( ( o
HV NNP o
) ) o
changed VBD o
significantly RB o
to TO o
a DT o
stable JJ o
HV NNP o
, , N
without IN N
affecting VBG N
bone NN o
maturation NN o
( ( N
change NN N
in IN N
bone NN N
age/change NN N
in IN N
chronological JJ N
age NN N
) ) N
. . N

The DT N
following JJ N
variables NNS N
contributed VBD N
significantly RB N
to TO N
predicting VBG N
FH NNP o
SD NNP o
score NN o
: : o
GH NNP o
dose NN o
, , o
height VBD o
SD NNP o
score NN o
( ( N
ref JJ N
. . N

normal JJ N
girls NNS N
) ) N
, , N
chronological JJ o
age NN o
at IN o
start NN o
of IN o
treatment NN o
, , N
and CC N
HV NNP o
in IN N
the DT N
first JJ N
year NN N
of IN N
GH NNP N
treatment NN N
. . N

GH NNP i
treatment NN N
was VBD N
well RB o
tolerated VBN o
. . o

In IN N
conclusion NN N
, , N
GH NNP i
treatment NN N
leads VBZ N
to TO N
a DT N
normalization NN N
of IN N
FH NNP o
in IN N
most JJS N
girls NNS N
, , N
even RB N
when WRB N
puberty NN N
is VBZ N
induced VBN N
at IN N
a DT N
normal JJ N
pubertal JJ N
age NN N
. . N

The DT N
optimal JJ N
GH NNP i
dosage NN N
depends VBZ N
on IN N
height NN N
and CC N
age NN N
at IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
first JJ N
year NN N
HV NNP N
. . N

-DOCSTART- -14650571- O O

Can MD N
acupuncture VB i
ease VB N
the DT N
symptoms NNS o
of IN o
menopause NN o
? . N
In IN N
a DT N
randomized JJ N
, , N
2-group JJ N
clinical JJ N
study NN N
, , N
acupuncture NN i
was VBD N
used VBN N
for IN N
the DT N
relief NN N
of IN N
menopausal NN o
hot JJ o
flushes NNS o
, , o
sleep JJ o
disturbances NNS o
, , o
and CC o
mood NN o
changes NNS o
. . o

The DT N
experimental JJ N
acupuncture NN i
treatment NN N
consisted VBD N
of IN N
specific JJ N
acupuncture NN i
body NN N
points NNS N
related VBN N
to TO N
menopausal VB o
symptoms NNS o
. . N

The DT N
comparison JJ N
acupuncture NN i
treatment NN N
consisted VBN N
of IN N
a DT N
treatment NN N
designated VBN N
as IN N
a DT N
general JJ N
tonic NN N
specifically RB N
designed VBN N
to TO N
benefit VB N
the DT N
flow NN N
of IN N
Ch'i NNP N
( ( N
energy NN N
) ) N
. . N

Results NNS N
from IN N
the DT N
experimental JJ p
acupuncture NN i
treatment NN p
group NN p
showed VBD N
a DT N
decrease NN N
in IN N
mean JJ o
monthly JJ o
hot JJ o
flush NN o
severity NN o
for IN N
site-specific JJ N
acupuncture NN N
. . N

The DT N
comparison JJ N
acupuncture NN i
treatment NN p
group NN p
had VBD N
no DT N
significant JJ N
change NN o
in IN o
severity NN o
from IN N
baseline NN N
over IN N
the DT N
treatment NN N
phase NN N
. . N

Sleep JJ o
disturbances NNS o
in IN N
the DT N
experimental JJ p
acupuncture NN i
treatment NN p
group NN p
declined VBD N
over IN N
the DT N
study NN N
. . N

Mood NNP o
changes NNS o
in IN N
both DT N
the DT N
experimental JJ p
acupuncture NN i
treatment NN p
group NN p
and CC p
the DT p
comparison NN p
acupuncture NN p
treatment NN p
group NN p
showed VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
baseline NN N
and CC N
the DT N
third JJ N
month NN N
of IN N
the DT N
study NN N
. . N

Acupuncture NNP i
using VBG N
menopausal-specific JJ N
sites NNS N
holds VBZ N
promise NN N
for IN N
nonhormonal JJ N
relief NN o
of IN o
hot JJ o
flushes NNS o
and CC o
sleep JJ o
disturbances NNS o
. . o

-DOCSTART- -24065423- O O

The DT N
effect NN N
of IN N
leukocyte NN i
reduction NN i
filters NNS i
on IN N
inflammatory NN N
mediator NN N
release NN N
during IN N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
. . N

BACKGROUND NNP N
Extracorporeal NNP N
circulation NN N
used VBN N
during IN N
coronary JJ N
artery NN N
bypass NN N
grafting VBG N
triggers NNS N
systemic JJ N
inflammatory JJ N
response NN N
with IN N
neutrophil JJ N
activation NN N
which WDT N
adversely RB N
affects VBZ N
ischaemic/reperfused JJ N
myocardium NN N
. . N

One CD N
method NN N
of IN N
myocardial JJ N
protection NN N
during IN N
cardiac JJ N
surgery NN N
is VBZ N
the DT N
use NN N
of IN N
blood NN N
cardioplegia NN N
. . N

Its PRP$ N
protective JJ N
effect NN N
is VBZ N
related VBN N
to TO N
cardiac VB N
cooling NN N
and CC N
metabolism NN N
reduction NN N
, , N
oxygen VBP N
supply NN N
from IN N
erythrocytes NNS N
, , N
and CC N
reactive JJ N
oxygen NN N
species NNS N
scavenging VBG N
. . N

However RB N
, , N
blood NN N
cardioplegia NN N
is VBZ N
also RB N
associated VBN N
with IN N
myocardial JJ N
damage NN N
induced VBN N
by IN N
undesirable JJ N
morphotic JJ N
blood NN N
elements NNS N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
use NN N
of IN N
leukocyte JJ i
reduction NN i
filters NNS i
on IN N
the DT N
activity NN N
of IN N
polymorphonuclear NN N
neutrophils NNS N
( ( N
PMN NNP N
) ) N
in IN N
patients NNS p
undergoing VBG p
surgical JJ p
myocardial JJ p
revascularisation NN p
. . p

PMN NNP N
activity NN N
was VBD N
evaluated VBN N
based VBN N
on IN N
measurements NNS N
of IN N
plasma JJ N
activity NN N
of IN N
granulocyte NN N
enzymes NNS N
, , N
lysozyme NN N
and CC N
beta-glucuronidase NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
40 CD p
patients NNS p
who WP p
underwent VBP p
myocardial JJ p
revascularisation NN p
using VBG p
extracorporeal JJ i
circulation NN i
. . i

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
equal JJ N
groups NNS N
: : N
in IN N
Group NNP N
I PRP N
, , N
blood VBD i
cardioplegia NN i
was VBD i
administered VBN i
using VBG i
leukocyte JJ i
reduction NN i
filters NNS i
, , N
and CC N
in IN N
Group NNP N
II NNP N
, , N
leukocyte JJ i
reduction NN i
filters NNS i
were VBD i
not RB i
used VBN i
for IN i
blood NN i
cardioplegia NN i
. . i

Measurements NNS N
were VBD N
performed VBN N
in IN N
plasma NN N
of IN N
arterial JJ N
and CC N
coronary JJ N
sinus NN N
blood NN N
samples NNS N
collected VBD N
before IN N
aortic JJ N
clamping NN N
, , N
immediately RB N
after IN N
unclamping VBG N
, , N
and CC N
after IN N
25 CD N
min NN N
of IN N
reperfusion NN N
. . N

In IN N
addition NN N
, , N
blood NN N
cardioplegic JJ N
solution NN N
samples NNS N
were VBD N
collected VBN N
in IN N
Group NNP N
I PRP N
from IN N
the DT N
lines NNS N
proximal NN N
and CC N
distal NN N
to TO N
the DT N
filter NN N
during IN N
first JJ N
and CC N
last JJ N
administration NN N
. . N

Plasma NNP o
levels NNS o
of IN o
lysozyme NN o
and CC o
beta-glucuronidase NN o
were VBD N
determined VBN N
using VBG N
previously RB N
described VBN N
methods NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
a DT N
significant JJ N
decrease NN N
in IN N
PMN NNP o
count NN o
in IN N
filtered JJ N
blood NN o
cardioplegic JJ o
solution NN o
during IN N
its PRP$ N
first JJ N
administration NN N
( ( N
0.27 CD N
? . N
0.07 CD N
G/L NNP N
) ) N
compared VBN N
to TO N
samples NNS N
collected VBN N
before IN N
filter JJ N
passage NN N
( ( N
1.73 CD N
? . N
0.049 CD N
G/L NNP N
) ) N
. . N

Also RB N
during IN N
last JJ N
administration NN o
, , o
PMN NNP o
count NN o
in IN o
filtered JJ o
blood NN o
cardioplegic JJ o
solution NN o
was VBD o
decreased VBN N
compared VBN N
to TO N
samples NNS N
collected VBN N
before IN N
filter JJ N
passage NN N
( ( N
0.66 CD N
? . N
0.35 CD N
G/L NNP N
vs. FW N
3.64 CD N
? . N
1.14 CD N
G/L NNP N
, , N
respectively RB N
) ) N
. . N

Significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) o
plasma VB o
beta-glucuronidase JJ o
levels NNS o
were VBD o
found VBN N
in IN N
arterial JJ N
blood NN N
samples NNS N
in IN N
Group NNP N
I PRP N
compared VBN N
to TO N
Group NNP N
II NNP N
( ( N
5.59 CD N
? . N
1.63 CD N
?g/mL NN N
immediately RB N
after IN N
aortic JJ N
unclamping NN N
and CC N
6.59 CD N
? . N
1.98 CD N
?g/mL NN N
after IN N
25 CD N
min NN N
of IN N
reperfusion NN N
in IN N
Group NNP N
I PRP N
vs. VBP N
10.19 CD N
? . N
2.66 CD N
and CC N
12.83 CD N
? . N
1.88 CD N
?g/mL NN N
, , N
respectively RB N
, , N
in IN N
Group NNP N
II NNP N
) ) N
. . N

Beta-glucuronidase JJ o
levels NNS o
in IN o
coronary JJ o
sinus NN o
blood NN o
samples NNS o
collected VBN o
after IN N
aortic JJ N
unclamping NN N
and CC N
at IN N
the DT N
end NN N
of IN N
reperfusion NN N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
II NNP N
compared VBN N
to TO N
Group NNP N
I PRP N
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
. . N

In IN N
Group NNP N
I PRP N
, , N
plasma FW o
lysozyme NN o
levels NNS o
in IN o
arterial JJ N
and CC N
venous JJ N
blood NN N
samples NNS N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
during IN N
the DT N
surgery NN N
. . N

In IN N
contrast NN N
, , o
plasma VBP o
lysozyme JJ o
level NN o
in IN o
coronary JJ o
sinus NN N
blood NN N
samples NNS N
at IN N
the DT N
end NN N
of IN N
reperfusion NN N
in IN N
Group NNP N
II NNP N
was VBD N
significantly RB N
higher JJR N
compared VBN N
to TO N
that DT N
in IN N
pre-clamping JJ N
samples NNS N
( ( N
p JJ N
< NNP N
0.014 CD N
) ) N
. . N

CONCLUSIONS NN N
With IN N
the DT N
use NN N
of IN N
leukocyte JJ i
reduction NN i
filters NNS i
, , i
we PRP i
found VBD N
significantly RB N
lower JJR N
beta-glucuronidase NN N
levels NNS N
in IN N
arterial JJ N
and CC N
coronary JJ N
sinus NN N
blood NN N
samples NNS N
. . N

These DT N
findings NNS N
seem VBP N
to TO N
confirm VB N
reduced VBN N
PMN NNP N
activation NN N
and/or NN N
reduced VBD N
myocardial JJ N
infiltration NN N
by IN N
activated JJ N
PMN NNP N
. . N

Plasma NNP N
levels NNS N
of IN N
lysozyme NN N
, , N
a DT N
characteristic JJ N
product NN N
of IN N
PMN NNP N
degranulation NN N
, , N
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
. . N

-DOCSTART- -22129897- O O

A DT N
clinical JJ N
trial NN N
of IN N
glutathione NN N
supplementation NN N
in IN N
autism NN p
spectrum NN p
disorders NNS p
. . p

BACKGROUND NNP N
Recent NNP N
evidence NN N
shows VBZ N
that IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
have VBP N
significantly RB N
lower JJR N
levels NNS N
of IN N
glutathione NN N
than IN N
typically RB N
developing VBG N
children NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
use NN N
of IN N
two CD N
commonly NNS N
used VBD N
glutathione NN N
supplements NNS N
in IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
to TO N
determine VB N
their PRP$ N
efficacy NN N
in IN N
increasing VBG N
blood NN o
glutathione NN o
levels NNS o
in IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
. . p

MATERIAL/METHODS NNP N
The DT N
study NN N
was VBD N
an DT N
eight-week JJ N
, , N
open-label JJ N
trial NN p
using VBG p
oral JJ i
lipoceutical JJ i
glutathione NN i
( ( i
n=13 JJ i
) ) i
or CC i
transdermal JJ i
glutathione NN i
( ( i
n=13 JJ i
) ) i
in IN p
children NNS p
, , p
3-13 CD p
years NNS p
of IN p
age NN p
, , p
with IN p
a DT p
diagnosis NN p
of IN p
an DT p
ASD NNP p
. . p

Subjects NNPS p
underwent JJ p
pre- JJ p
and CC p
post-treatment JJ p
lab NN p
testing VBG p
to TO N
evaluate VB N
plasma NN o
reduced VBN o
glutathione NN o
, , o
oxidized VBD o
glutathione NN o
, , o
cysteine NN o
, , o
taurine NN o
, , o
free JJ o
and CC o
total JJ o
sulfate NN o
, , o
and CC o
whole-blood JJ o
glutathione NN o
levels NNS o
. . o

RESULTS VB N
The DT N
oral JJ N
treatment NN N
group NN N
showed VBD N
significant JJ N
increases NNS N
in IN N
plasma NN o
reduced VBD o
glutathione NN o
, , o
but CC o
not RB o
whole-blood JJ o
glutathione NN o
levels NNS o
following VBG N
supplementation NN N
. . N

Both CC N
the DT N
oral JJ p
and CC p
transdermal JJ p
treatment NN p
groups NNS p
showed VBD N
significant JJ N
increases NNS N
in IN N
plasma NN o
sulfate NN o
, , o
cysteine NN o
, , o
and CC o
taurine NN o
following VBG N
supplementation NN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
oral JJ N
and CC N
transdermal JJ N
glutathione NN N
supplementation NN N
may MD N
have VB N
some DT N
benefit NN N
in IN N
improving VBG N
some DT N
of IN N
the DT N
transsulfuration NN N
metabolites VBZ N
. . N

Future JJ N
studies NNS N
among IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
should MD N
further RB N
explore VB N
the DT N
pharmacokinetics NNS N
of IN N
glutathione NN N
supplementation NN N
and CC N
evaluate VB N
the DT N
potential JJ N
effects NNS N
of IN N
glutathione NN N
supplementation NN N
upon IN N
clinical JJ N
symptoms NNS N
. . N

-DOCSTART- -22434360- O O

Pemetrexed NNP i
in IN i
combination NN i
with IN i
cisplatin JJ i
versus NN i
cisplatin NN i
monotherapy NN i
in IN N
patients NNS p
with IN p
recurrent NN p
or CC p
metastatic JJ p
head NN p
and CC p
neck NN p
cancer NN p
: : p
final JJ N
results NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
phase VB N
3 CD N
study NN N
. . N

BACKGROUND NNP N
Recurrent NNP p
or CC p
metastatic JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
( ( p
SCCHN NNP p
) ) p
is VBZ N
associated VBN N
with IN N
poor JJ N
survival NN N
. . N

Platinum-based JJ i
chemotherapy NN i
is VBZ N
often RB N
a DT N
first-line JJ N
treatment NN N
. . N

Pemetrexed NNP i
has VBZ N
shown VBN N
single-agent JJ N
activity NN N
in IN N
SCCHN NNP N
and CC N
in IN N
combination NN N
with IN N
cisplatin NN N
for IN N
other JJ N
tumors NNS N
. . N

This DT N
trial NN N
examined VBD N
the DT N
efficacy NN N
of IN N
pemetrexed-cisplatin NN i
for IN N
SCCHN NNP N
. . N

METHODS NNP N
In IN N
a DT N
double-blind JJ N
phase NN N
3 CD N
trial NN N
, , N
patients NNS p
with IN p
recurrent NN p
or CC p
metastatic JJ p
SCCHN NNP p
and CC p
no DT p
prior JJ p
systemic JJ p
therapy NN p
for IN p
metastatic JJ p
disease NN p
were VBD p
randomized VBN p
to TO p
pemetrexed VB i
( ( p
500 CD p
mg/m NN p
( ( p
2 CD p
) ) p
) ) p
plus CC i
cisplatin NN i
( ( p
75 CD p
mg/m NN p
( ( p
2 CD p
) ) p
; : p
n CC p
= VB p
398 CD p
) ) p
or CC p
placebo JJ i
plus CC i
cisplatin NN i
( ( p
75 CD p
mg/m NN p
( ( p
2 CD p
) ) p
; : p
n CC p
= VB p
397 CD p
) ) p
to TO N
assess VB N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
and CC N
secondary JJ N
endpoints NNS N
. . N

RESULTS NNP N
Median JJ o
OS NNP o
was VBD N
7.3 CD N
months NNS N
in IN N
the DT N
pemetrexed-cisplatin JJ i
arm NN N
and CC N
6.3 CD N
months NNS N
in IN N
the DT N
placebo-cisplatin JJ i
arm NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.75-1.02 NNP N
; : N
P NNP N
= NNP N
.082 NNP N
) ) N
. . N

Median JJ o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
, , o
months NNS o
) ) o
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
arms NNS N
( ( i
pemetrexed-cisplatin NN i
, , N
3.6 CD N
; : N
placebo-cisplatin NN i
, , N
2.8 CD N
; : N
HR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.76-1.03 NNP N
; : N
P NNP N
= NNP N
.166 NNP N
) ) N
. . N

Among IN N
patients NNS N
with IN N
performance NN N
status NN N
0 CD N
or CC N
1 CD N
, , N
pemetrexed-cisplatin NN i
( ( N
n JJ N
= NNP N
347 CD N
) ) N
led VBD N
to TO N
longer JJR o
OS NNP o
and CC o
PFS NNP o
than IN N
placebo-cisplatin NN i
( ( N
n JJ N
= VBZ N
343 CD N
; : N
8.4 CD N
vs IN N
6.7 CD N
months NNS N
; : N
HR NNP N
, , N
0.83 CD N
; : N
P NNP N
= NNP N
.026 NNP N
; : N
4.0 CD N
vs IN N
3.0 CD N
months NNS N
; : N
HR NNP N
, , N
0.84 CD N
; : N
P NNP N
= NNP N
.044 NNP N
, , N
respectively RB N
) ) N
. . N

Among IN N
patients NNS p
with IN p
oropharyngeal JJ p
cancers NNS p
, , N
pemetrexed-cisplatin NN i
( ( N
n JJ N
= NNP N
86 CD N
) ) N
resulted VBD N
in IN N
longer JJR N
OS NNP o
and CC o
PFS NNP o
than IN N
placebo-cisplatin NN i
( ( N
n JJ N
= VBZ N
106 CD N
; : N
9.9 CD N
vs IN N
6.1 CD N
months NNS N
; : N
HR NNP N
, , N
0.59 CD N
; : N
P NNP N
= NNP N
.002 NNP N
; : N
4.0 CD N
vs IN N
3.4 CD N
months NNS N
; : N
HR NNP N
, , N
0.73 CD N
; : N
P NNP N
= NNP N
.047 NNP N
, , N
respectively RB N
) ) N
. . N

Pemetrexed-cisplatin JJ o
toxicity NN o
was VBD N
consistent JJ N
with IN N
studies NNS N
in IN N
other JJ N
tumors NNS N
. . N

CONCLUSIONS NNP N
Pemetrexed-cisplatin NNP i
compared VBN N
with IN N
placebo-cisplatin NN N
did VBD N
not RB N
significantly RB N
improve VB N
survival NN o
for IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

However RB N
, , N
in IN N
a DT N
prespecified JJ N
subgroup NN N
analysis NN N
, , N
pemetrexed-cisplatin NN i
showed VBD N
OS NNP o
and CC o
PFS NNP o
advantage NN o
for IN N
patients NNS N
with IN N
performance NN N
status NN N
0 CD N
or CC N
1 CD N
or CC N
oropharyngeal JJ N
cancers NNS N
. . N

-DOCSTART- -9105062- O O

The DT N
effect NN N
of IN N
inhaled JJ N
leukotriene NN i
D4 NNP i
and CC N
methacholine VB i
on IN N
sputum NN o
cell NN o
differentials NNS o
in IN N
asthma NN p
. . p

The DT N
cysteinyl JJ i
leukotriene NN i
LTE4 NNP i
has VBZ N
been VBN N
shown VBN N
to TO N
induce VB N
airway RP o
eosinophilia NNS o
in IN N
asthmatics NNS N
in IN N
vivo NN N
. . N

This DT N
phenomenon NN N
has VBZ N
not RB N
yet RB N
been VBN N
reported VBN N
for IN N
LTD4 NNP N
. . N

Hence NNP N
, , N
we PRP N
examined VBD N
the DT N
effect NN N
of IN N
inhaled JJ N
LTD4 NNP i
and CC N
a DT N
control NN N
bronchoconstrictor NN N
agent NN N
, , N
methacholine NN N
, , N
on IN N
cell NN o
differentials NNS o
in IN N
hypertonic JJ N
saline-induced JJ N
whole JJ N
sputum NN N
samples NNS N
of IN N
12 CD p
nonsmoking VBG p
atopic NN p
asthmatic JJ p
subjects NNS p
( ( p
three CD p
women NNS p
, , p
nine CD p
men NNS p
; : p
21 CD p
to TO p
29 CD p
yr NN p
of IN p
age NN p
; : p
FEV1 NNP p
, , p
74 CD p
to TO p
120 CD p
% NN p
pred VBD p
; : p
PC20FEV1 NNP p
methacholine VBP p
< $ p
9.6 CD p
mg/ml NN p
) ) p
. . N

The DT N
study NN N
had VBD N
a DT N
cross-over JJ N
, , N
placebo-controlled JJ N
design NN N
consisting NN N
of IN N
4 CD N
d NN N
separated VBN N
by IN N
> NN N
or CC N
= $ N
1 CD N
wk NN N
. . N

On IN N
each DT N
randomized VBN N
study NN N
day NN N
, , N
the DT N
subjects NNS N
inhaled VBD N
five CD N
serial JJ N
doses NNS N
of IN N
either DT N
LTD4 NNP i
( ( N
mean JJ N
cumulative JJ N
concentration NN N
: : N
95.7 CD N
microM NN N
) ) N
or CC N
methacholine NN i
( ( N
mean JJ N
cumulative JJ N
concentration NN N
: : N
542 CD N
mM NN N
) ) N
or CC N
five CD N
doses NNS N
of IN N
their PRP$ N
respective JJ N
diluents NNS N
( ( i
PBS/ethanol NNP i
or CC N
PBS NNP N
) ) N
. . N

The DT N
airway JJ o
response NN o
was VBD N
measured VBN N
by IN N
FEV1 NNP N
, , N
followed VBN N
by IN N
sputum JJ N
induction NN N
with IN N
4.5 CD N
% NN N
NaCl NNP N
, , N
4 CD N
h NN N
postchallenge NN N
. . N

Inflammatory NNP N
cells NNS N
( ( N
> CD N
or CC N
= VB N
250 CD N
) ) N
were VBD N
counted VBN N
twice RB N
on IN N
coded JJ N
cytospins NNS N
and CC N
expressed VBD N
as IN N
percentages NNS N
of IN N
nonsquamous JJ N
cells NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
maximal JJ o
percent NN o
fall NN o
in IN o
FEV1 NNP o
from IN o
baseline NN o
between IN N
LTD4 NNP N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
, , N
49.5 CD N
+/- JJ N
4.4 CD N
% NN N
fall NN N
) ) N
and CC N
methacholine NN N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
, , N
55.9 CD N
+/- JJ N
3.4 CD N
% NN N
fall NN N
) ) N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
. . N

LTD4 NNP N
induced VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
percentage NN o
of IN o
sputum NN o
eosinophils NNS o
as IN N
compared VBN N
with IN N
its PRP$ N
diluent NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
26.6 CD N
+/- JJ N
21.3 CD N
% NN N
and CC N
10.2 CD N
+/- JJ N
8.8 CD N
% NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.025 CD N
) ) N
, , N
whereas VBZ N
a DT N
similar JJ N
trend NN N
for IN N
methacholine NN N
failed VBD N
to TO N
reach VB N
significance NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
19.1 CD N
+/- JJ N
22.9 CD N
% NN N
and CC N
7.8 CD N
+/- JJ N
5.8 CD N
% NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.11 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
changes NNS N
in IN N
the DT N
percentage NN o
of IN o
sputum NN o
eosinophils NNS o
between IN o
LTD4 NNP o
and CC o
methacholine NN o
( ( N
mean JJ N
difference NN N
+/- JJ N
SD NNP N
, , N
7.5 CD N
+/- JJ N
12.5 CD N
% NN N
eosinophils NNS N
; : N
p VB N
= $ N
0.09 CD N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
LTD4 NNP N
induces NNS N
eosinophilia VBP o
in IN o
sputum NN o
of IN N
asthmatic JJ N
subjects NNS N
4 CD N
h NN N
after IN N
inhalation NN N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
LTD4 NNP N
recruits VBZ N
eosinophils NNS o
into IN N
the DT N
airways NNS N
of IN N
asthmatics NNS N
in IN N
vivo NN N
, , N
possibly RB N
by IN N
virtue NN N
of IN N
direct JJ N
or CC N
indirect JJ N
chemotactic JJ N
properties NNS N
, , N
whereas IN N
an DT N
additional JJ N
effect NN N
of IN N
vigourous JJ o
airway NN o
narrowing VBG o
per IN N
se NN N
can MD N
not RB N
be VB N
excluded VBN N
. . N

-DOCSTART- -1827602- O O

Chronology NN N
of IN N
panic NN N
and CC N
avoidance NN N
, , N
age NN p
of IN p
onset NN p
in IN p
panic JJ p
disorder NN p
, , N
and CC N
prediction NN N
of IN N
treatment NN N
response NN N
. . N

A DT N
report NN N
from IN N
the DT N
Cross-National JJ N
Collaborative NNP N
Panic NNP N
Study NNP N
. . N

The DT N
relevance NN N
of IN N
the DT N
chronology NN N
between IN N
panic JJ N
disorder NN N
and CC N
avoidance NN N
behavior NN N
and CC N
of IN N
an DT N
early JJ N
, , N
medium NN N
or CC N
late JJ N
onset NN N
of IN N
panic JJ N
disorder NN N
was VBD N
tested VBN N
. . N

Groups NNP p
from IN N
the DT p
sample NN p
of IN p
the DT p
cross-national JJ i
collaborative NN i
panic NN i
study NN i
( ( p
CNCPS NNP p
) ) p
were VBD N
compared VBN N
for IN N
differences NNS N
in IN N
basic JJ N
characteristics NNS N
and CC N
for IN N
the DT N
ability NN N
to TO N
predict VB N
treatment NN N
response NN N
. . N

Patients NNS p
who WP p
developed VBD p
avoidance NN o
behavior NN o
before IN p
the DT p
full JJ p
syndrome NN p
of IN p
panic JJ o
disorder NN o
had VBD N
less RBR N
often RB N
a DT N
full JJ N
agoraphobia NN o
but CC N
were VBD N
not RB N
different JJ N
in IN N
their PRP$ N
response NN N
to TO N
treatment NN i
. . i

Patients NNS p
with IN N
an DT N
early JJ o
onset NN o
of IN o
panic JJ o
disorder NN o
suffered VBD N
more RBR N
often RB N
from IN N
agoraphobia NNS o
. . o

The DT N
treatment NN o
response NN o
was VBD N
similar JJ o
in IN N
the DT N
groups NNS N
with IN N
early JJ o
, , o
medium NN o
or CC o
late JJ o
onset NN o
of IN o
panic JJ o
disorder NN o
. . o

Neither CC N
the DT N
chronology NN N
between IN N
panic JJ o
disorder NN o
and CC o
avoidance NN o
behavior NN o
nor CC N
the DT N
age NN o
of IN o
onset NN o
of IN o
panic JJ o
disorder NN o
predicted VBD N
outcome NN N
in IN N
short-term JJ i
treatment NN i
with IN i
alprazolam NN i
or CC i
imipramine NN i
. . i

-DOCSTART- -15940774- O O

Efficacy NN N
of IN N
rofecoxib NN i
, , i
celecoxib NN i
, , N
and CC N
acetaminophen NN i
in IN N
patients NNS p
with IN p
osteoarthritis NN p
of IN p
the DT p
knee NN p
. . p

A DT N
combined JJ N
analysis NN N
of IN N
the DT N
VACT NNP N
studies NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
efficacy NN N
among IN N
1578 CD p
patients NNS p
with IN p
osteoarthritis JJ p
randomized VBN N
to TO N
take VB N
acetaminophen NN i
4000 CD N
mg NN N
( ( N
n=269 JJ N
) ) N
, , N
celecoxib $ i
200 CD N
mg NN N
( ( N
n=523 JJ N
) ) N
, , N
rofecoxib VBZ i
12.5 CD N
mg NN N
( ( N
n=259 JJ N
) ) N
, , N
or CC N
rofecoxib VB i
25 CD N
mg NN N
( ( N
n=527 JJ N
) ) N
in IN N
a DT N
double JJ N
blind NN N
trial NN N
[ NNP i
Vioxx NNP i
, , i
Acetaminophen NNP i
, , i
Celecoxib NNP i
Trial NNP N
( ( N
VACT2 NNP N
) ) N
] NN N
. . N

Results NNS N
were VBD N
also RB N
pooled VBN N
with IN N
the DT N
similarly RB N
designed VBN N
VACT1 NNP N
trial NN N
. . N

METHODS NNP N
Patients NNPS N
evaluated VBD N
over IN N
Days NNP N
1 CD N
to TO N
6 CD N
and CC N
6 CD N
weeks NNS N
with IN N
Patient NNP o
Global NNP o
Assessment NNP o
of IN o
Response NNP o
to TO o
Therapy NNP o
( ( o
PGART NNP o
) ) o
and CC o
Western JJ o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
( ( o
WOMAC NNP o
) ) o
Osteoarthritis NNP o
Index NNP o
. . o

RESULTS NNP N
For IN N
VACT2 NNP N
, , N
median JJ o
time NN o
to TO o
good JJ o
or CC o
excellent JJ o
PGART NNP o
response NN o
was VBD N
6 CD N
, , N
5 CD N
, , N
4 CD N
, , N
and CC N
3 CD N
days NNS N
for IN N
acetaminophen NN i
, , i
celecoxib NN i
, , i
rofecoxib VBZ i
12.5 CD N
mg NN N
, , N
and CC N
rofecoxib VBZ i
25 CD N
mg NN N
( ( N
COX-2 JJ N
inhibitors NNS N
vs VBP N
acetaminophen NN i
, , N
p NN N
< NNP N
or=0.035 NN N
; : N
rofecoxib CC i
25 CD N
mg NN N
vs NN N
celecoxib NN i
, , N
p=0.01 NN N
) ) N
. . N

WOMAC NNP o
response NN o
over IN N
the DT N
first JJ N
6 CD N
days NNS N
was VBD N
greater JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
both DT N
rofecoxib NN i
doses VBZ N
than IN N
acetaminophen NN N
and CC N
celecoxib NN N
. . N

At IN N
Week JJ N
6 CD N
, , N
all DT N
COX-2 NNP N
inhibitors NNS N
provided VBD N
significantly RB N
greater JJR o
efficacy NN o
than IN N
acetaminophen NN N
. . N

Good JJ N
or CC N
excellent JJ N
PGART NNP o
was VBD N
numerically RB N
, , N
but CC N
not RB N
significantly RB N
, , N
greater JJR N
with IN N
rofecoxib NN i
25 CD N
mg NN N
( ( N
55.4 CD N
% NN N
) ) N
than IN N
celecoxib NN i
( ( N
50.6 CD N
% NN N
) ) N
at IN N
Week NNP N
6 CD N
; : N
a DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
at IN N
Weeks NNP N
2 CD N
( ( N
6.9 CD N
, , N
p=0.022 NN N
) ) N
and CC N
4 CD N
( ( N
6.7 CD N
, , N
p=0.027 NN N
) ) N
and CC N
over IN N
6 CD N
weeks NNS N
with IN N
analysis NN N
of IN N
all DT N
5 CD N
PGART NNP o
categories NNS N
of IN N
response NN N
( ( N
p=0.035 NN N
) ) N
. . N

Rofecoxib $ i
25 CD N
mg NN N
provided VBD N
greater JJR N
response NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
than IN N
celecoxib NN i
on IN N
WOMAC NNP o
subscales NNS o
. . o

Pooled VBD N
analysis NN N
of IN N
VACT1/VACT2 NNP N
demonstrated VBD N
greater JJR o
PGART NNP o
( ( N
p=0.023 NN N
) ) N
with IN N
rofecoxib NN i
25 CD N
mg NN N
( ( N
56.1 CD N
% NN N
) ) N
than IN N
celecoxib NN i
( ( N
49.8 CD N
% NN N
) ) N
at IN N
6 CD N
weeks NNS N
and CC N
greater JJR o
response NN o
to TO o
all DT o
other JJ o
PGART NNP o
and CC o
WOMAC NNP o
endpoints NNS o
, , N
and CC N
confirmed VBD N
superiority NN N
of IN N
COX-2 NNP N
inhibitors NNS N
to TO N
acetaminophen VB i
. . i

Overall NNP N
, , N
tolerability NN o
of IN N
the DT N
study NN N
medications NNS N
was VBD N
generally RB N
good JJ o
and CC o
similar JJ o
. . o

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
experienced VBD N
a DT N
clinical JJ o
adverse JJ o
experience NN o
( ( o
AE NNP o
) ) o
. . o

The DT N
incidence NN N
of IN N
discontinuations NNS o
due JJ o
to TO o
an DT o
AE NNP o
was VBD N
significantly RB N
lower JJR N
with IN N
celecoxib NN i
( ( N
2.5 CD N
% NN N
) ) N
compared VBN N
to TO N
rofecoxib VB i
25 CD N
mg NN N
( ( N
6.3 CD N
% NN N
, , N
p=0.004 NN N
) ) N
or CC N
acetaminophen NN i
( ( N
7.8 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
did VBD N
not RB N
differ VB N
significantly RB N
from IN N
rofecoxib JJ N
12.5 CD N
mg NN N
( ( N
4.6 CD N
% NN N
) ) N
. . N

Discontinuation NN o
rates NNS o
due JJ N
to TO N
edema VB o
and CC o
hypertension NN o
related VBN o
AE NNP o
were VBD N
similar JJ N
among IN N
all DT N
COX-2 NNP N
inhibitors NNS N
. . N

CONCLUSION NNP N
Rofecoxib NNP i
and CC N
celecoxib NN i
provided VBD N
superior JJ N
efficacy NN o
to TO N
acetaminophen VB i
. . i

There EX N
was VBD N
a DT N
more RBR N
rapid JJ N
and CC N
greater JJR N
response NN o
with IN N
rofecoxib JJ N
25 CD N
mg NN N
than IN N
celecoxib $ i
200 CD N
mg. NN N
Rofecoxib NNP i
12.5 CD N
mg NN N
demonstrated VBD N
greater JJR N
efficacy NN o
than IN N
celecoxib $ i
200 CD N
mg NN N
over IN N
the DT N
first JJ N
6 CD N
days NNS N
, , N
and CC N
was VBD N
similar JJ N
over IN N
6 CD N
weeks NNS N
. . N

All DT N
study NN N
medications NNS N
were VBD N
generally RB N
well RB o
tolerated VBN o
. . o

-DOCSTART- -3304622- O O

Dexamethasone NNP i
therapy NN i
and CC N
cortisol JJ N
excretion NN N
in IN N
severe JJ p
pediatric JJ p
head NN p
injury NN p
. . p

Glucocorticoids NNS i
are VBP N
used VBN N
in IN N
an DT N
attempt NN N
to TO N
reduce VB N
brain NN N
edema NN N
secondary JJ N
to TO N
head VB N
injury NN N
. . N

Nevertheless RB N
, , N
their PRP$ N
usefulness JJ N
remains NNS N
uncertain JJ N
and CC N
contradictory NN N
. . N

In IN N
a DT N
randomized JJ N
study NN N
of IN N
24 CD p
children NNS p
with IN p
severe JJ p
head NN p
injury NN p
, , p
urinary JJ p
free JJ p
cortisol NN p
was VBD N
measured VBN N
by IN N
radioimmunoassay NN i
. . i

Twelve CD p
patients NNS p
( ( N
group NN N
1 CD N
) ) N
received VBD N
dexamethasone NN i
and CC N
12 CD p
( ( p
group NN p
2 CD p
) ) p
did VBD N
not RB N
. . N

All DT N
patients NNS N
were VBD N
treated VBN N
with IN N
a DT N
standardized JJ N
regimen NN N
. . N

In IN N
group NN N
1 CD N
there EX N
was VBD N
complete JJ N
suppression NN o
of IN o
endogenous JJ o
cortisol NN o
production NN o
. . o

In IN N
group NN N
2 CD N
free JJ N
cortisol NN N
was VBD N
up RB N
to TO N
20-fold CD N
higher JJR N
than IN N
under IN N
basal JJ N
conditions NNS N
and CC N
reached VBN N
maximum JJ N
values NNS N
on IN N
days NNS N
1-3 RB N
. . N

Since IN N
the DT N
excretion NN o
of IN o
cortisol NN o
in IN o
urine JJ o
reflects VBZ N
the DT N
production NN N
rate NN N
closely RB N
and CC N
is VBZ N
not RB N
influenced VBN N
by IN N
liver NN N
function NN N
and CC N
barbiturates NNS N
, , N
the DT N
results NNS N
in IN N
group NN N
2 CD N
show NN N
that IN N
the DT N
endogenous JJ N
production NN N
of IN N
steroids NNS N
is VBZ N
an DT N
adequate JJ N
reaction NN N
to TO N
severe VB N
head JJ N
injury NN N
. . N

Exogenous JJ N
glucocorticoids NNS i
are VBP N
thus RB N
unlikely JJ N
to TO N
have VB N
any DT N
more JJR N
beneficial JJ N
effects NNS N
than IN N
endogenous JJ N
cortisol NN i
. . i

-DOCSTART- -3116609- O O

[ JJ i
Bupivacaine-CO2 NNP i
and CC i
bupivacaine-HCl NN i
at IN N
various JJ N
injection NN N
temperatures NNS N
in IN N
peridural JJ i
anesthesia NN i
for IN N
extracorporeal NN N
shock NN N
wave VBP N
lithotripsy VBN N
] NNP N
. . N

INTRODUCTION NNP N
The DT N
effect NN N
of IN N
different JJ N
injection NN N
temperatures NNS N
on IN N
carbonated JJ i
anesthetics NNS i
has VBZ N
been VBN N
controversial JJ N
since IN N
1965 CD N
. . N

The DT N
current JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
onset JJ o
times NNS o
of IN o
sensory NN o
and CC o
motor NN o
blockade NN o
after IN N
epidural JJ i
anesthesia NN i
with IN N
0.5 CD N
% NN N
bupivacaine-CO2 JJ i
and CC N
0.5 CD N
% NN N
bupivacaine-HCl NN i
at IN N
various JJ N
injection NN N
temperatures NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
was VBD N
performed VBN N
on IN N
90 CD p
ASA NNP p
class NN p
I-II NNP p
urologic JJ p
patients NNS p
during IN p
extracorporeal JJ i
shock NN i
wave NN i
lithotripsy NN i
. . i

The DT N
patients NNS N
were VBD N
randomized VBN N
in IN N
six CD N
groups NNS N
to TO N
receive VB N
either RB N
0.5 CD N
% NN N
bupivacaine-CO2 NN i
or CC N
0.5 CD N
% NN N
bupivacaine-HCl NN i
at IN N
temperatures NNS N
of IN N
4 CD N
degrees NNS N
, , N
20 CD N
degrees NNS N
, , N
or CC N
36 CD N
degrees NNS N
C. NNP N
The DT N
six CD p
groups NNS p
were VBD N
comparable JJ N
in IN N
age NN N
, , N
height NN N
, , N
and CC N
weight NN N
. . N

Epidural JJ i
anesthesia NN i
was VBD N
performed VBN N
at IN N
the DT N
L2-3 NNP N
interspace NN N
with IN N
an DT N
18-gauge JJ i
Tuohy NNP i
needle MD N
using VBG N
loss NN N
of IN N
resistance NN N
. . N

A DT N
catheter NN N
was VBD N
advanced JJ N
4 CD N
cm NN N
in IN N
the DT N
epidural JJ N
space NN N
and CC N
4 CD N
ml NNS N
0.5 CD N
% NN N
bupivacaine NN i
with IN i
adrenaline JJ i
1:200,000 CD N
was VBD N
given VBN N
as IN N
a DT N
test NN N
dose NN N
. . N

After IN N
4 CD N
min VBD N
the DT N
full JJ N
anesthetic JJ N
dose NN N
, , N
based VBN N
on IN N
body NN N
size NN N
, , N
was VBD N
injected VBN N
with IN N
the DT N
patient JJ N
supine NN N
. . N

Sensory NNP o
blockade NN o
was VBD N
determined VBN N
by IN N
the DT N
pinprick NN N
method NN N
and CC N
motor NN o
blockade NN o
by IN N
the DT N
Bromage NNP N
method NN N
at IN N
2-min JJ N
intervals NNS N
for IN N
the DT N
first JJ N
20 CD N
min NN N
, , N
at IN N
5-min JJ N
intervals NNS N
for IN N
the DT N
next JJ N
10 CD N
min NN N
, , N
and CC N
then RB N
every DT N
15 CD N
min NN N
to TO N
a DT N
total NN N
of IN N
240 CD N
min NN N
. . N

Statistical JJ N
analysis NN N
was VBD N
done VBN N
by IN N
the DT N
Mann-Whitney NNP N
test NN N
, , N
with IN N
P NNP N
less JJR N
than IN N
0.05 CD N
considered VBN N
significant JJ N
. . N

RESULTS NNP N
Spread NNP o
of IN o
sensory NN o
blockade NN o
was VBD N
significantly RB N
faster RBR N
with IN N
bupivacaine-CO2 JJ i
and CC N
-HCl NN i
at IN N
a DT N
temperature NN N
of IN N
36 CD N
degrees NNS N
C NNP N
as IN N
compared VBN N
to TO N
4 CD N
degrees NNS N
or CC N
20 CD N
degrees NNS N
C NNP N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
( ( N
Figs NNP N
. . N

1 CD N
, , N
2 CD N
and CC N
Table NNP N
2 CD N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -8872499- O O

Relationship NN N
of IN N
the DT N
dose NN N
of IN N
intravenous JJ N
gammaglobulin NN i
to TO N
the DT N
prevention NN N
of IN N
infections NNS N
in IN N
adults NNS p
with IN p
common JJ p
variable JJ p
immunodeficiency NN p
. . p

The DT N
objective NN N
was VBD N
to TO N
assess VB N
clinical JJ N
efficacy NN N
of IN N
3 CD N
dosages NNS N
of IN N
intravenous JJ i
gammaglobulins NNS i
to TO N
prevent VB N
infectious JJ N
episodes NNS N
in IN N
adult NN N
common JJ N
variable JJ N
immunodeficiency NN N
. . N

We PRP N
designed VBD N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
dose-assessing JJ N
study NN N
. . N

The DT p
setting NN p
was VBD p
at IN p
University NNP p
Hospital NNP p
, , p
Out-patient NNP p
Clinic NNP p
. . p

Our PRP$ N
patients NNS p
were VBD p
twenty-one JJ p
adult NN p
patients NNS p
with IN p
common JJ p
variable JJ p
immunodeficiency NN p
. . p

The DT N
measurements NNS N
were VBD N
comparative JJ N
study NN N
of IN N
the DT N
number NN o
and CC o
severity NN o
of IN o
infections NNS o
using VBG N
3 CD N
various JJ N
dosages NNS N
of IN N
intravenous JJ N
gammaglobulins NNS i
, , N
each DT N
given VBN N
monthly RB N
for IN N
M NNP N
least JJS N
6 CD N
months NNS N
. . N

Results NNS N
indicated VBD N
four CD N
hundred CD N
and CC N
eighty-four JJ N
infectious JJ o
episodes NNS o
occurred VBD N
while IN N
giving VBG N
305 CD i
infusions NNS i
of IN i
IVIG NNP i
200 CD i
mg/kg NN i
; : i
205 CD N
infectious JJ N
episodes NNS N
while IN N
giving VBG N
170 CD i
infusions NNS i
of IN i
400 CD i
mg/kg NNS i
and CC N
436 CD N
infectious JJ N
episodes NNS N
while IN N
giving VBG N
247 CD i
infusions NNS i
of IN i
600 CD i
mg/kg NN i
. . i

The DT N
morbidity NN o
scores NNS o
( ( o
infection/infusion NN o
) ) o
were VBD N
1.59 CD N
, , N
1.21 CD N
and CC N
1.77 CD N
respectively RB N
( ( N
p JJ N
- : N
N/S NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
severity NN o
of IN o
infections NNS o
on IN N
the DT N
above JJ N
3 CD N
dosages NNS N
, , N
and CC N
no DT N
difference NN N
in IN N
the DT N
duration NN o
of IN o
infection-free JJ o
intervals NNS o
. . o

The DT N
conclusions NNS N
resulted VBD N
in IN N
no DT N
significant JJ N
differences NNS N
in IN N
morbidity NN o
in IN N
adult NN N
patients NNS N
with IN N
common JJ N
variable JJ N
immunodeficiency NN N
treated VBN N
in IN N
cross-over JJ N
pattern NN N
with IN N
IVIG NNP N
200 CD N
mg/kg NN N
, , N
400 CD N
mg/kg NN N
and CC N
600 CD N
mg/kg NN N
. . N

Thus NNP N
, , N
high JJ N
dosages NNS N
of IN N
IVIG NNP N
are VBP N
not RB N
conferring VBG N
better JJR N
protection NN N
against IN N
infections NNS N
in IN N
such JJ N
patients NNS N
. . N

-DOCSTART- -6984358- O O

Tolfenamic NNP i
acid NN i
and CC i
caffeine NN i
: : i
a DT N
useful JJ N
combination NN N
in IN N
migraine NN o
. . o

Tolfenamic NNP i
acid NN i
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
prostaglandin JJ N
biosynthesis NN N
, , N
which WDT N
has VBZ N
been VBN N
proved VBN N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
acute JJ o
migraine NN o
attacks NNS o
. . o

The DT N
usefulness NN N
of IN N
caffeine NN i
, , i
metoclopramide NN i
and CC i
pyridoxine NN i
as IN N
adjuncts NNS N
to TO N
tolfenamic VB i
acid NN i
was VBD N
tested VBN N
in IN N
acute JJ o
migraine NN o
attacks NNS o
in IN p
ten JJ p
patients NNS p
. . p

A DT N
combination NN N
of IN N
tolfenamic JJ i
acid NN i
( ( N
200 CD N
mg NN N
) ) N
with IN N
either DT i
caffeine NN i
( ( N
100 CD N
mg NN N
) ) N
, , N
metoclopramide RB i
( ( N
10 CD N
mg NN N
) ) N
or CC i
pyridoxine NN i
( ( N
300 CD N
mg NN N
) ) N
was VBD N
given VBN N
twice RB N
to TO N
each DT N
patient NN N
in IN N
random JJ N
order NN N
. . N

Thus RB N
60 CD p
attacks NNS p
were VBD N
treated VBN N
. . N

The DT N
tolfenamic JJ i
acid-caffeine JJ i
combination NN i
proved VBD N
the DT N
most RBS N
effective JJ N
as IN N
judged VBN N
by IN N
duration NN o
and CC o
intensity NN o
of IN o
attacks NNS o
, , o
working VBG o
ability NN o
, , o
vigilance NN o
, , o
and CC o
overall JJ o
evaluation NN o
of IN o
the DT o
drugs NNS o
by IN N
the DT N
patients NNS N
. . N

Metoclopramide NNP i
was VBD N
somewhat RB N
better JJR N
than IN N
pyridoxine NN i
as IN N
an DT N
additive NN N
. . N

-DOCSTART- -22721929- O O

Effect NN N
of IN N
chelation NN i
therapy NN i
on IN N
progressive JJ N
diabetic JJ N
nephropathy NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
and CC p
high-normal JJ p
body NN p
lead JJ p
burdens NNS p
. . p

BACKGROUND VB N
A DT N
previous JJ N
study NN N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN N
high-normal JJ N
body NN N
lead NN N
burdens VBZ N
showed VBD N
that IN N
EDTA NNP i
chelation NN i
therapy NN i
for IN N
3 CD N
months NNS N
slows VBZ N
progressive JJ N
diabetic JJ N
nephropathy NN N
during IN N
a DT N
12-month JJ N
follow-up NN N
. . N

The DT N
effect NN N
of IN N
a DT N
longer JJR N
course NN N
of IN N
therapy NN N
on IN N
kidney NN N
function NN N
decrease NN N
over IN N
a DT N
longer JJR N
follow-up NN N
is VBZ N
not RB N
known VBN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
12-month JJ N
run-in JJ N
phase NN N
, , N
then RB N
a DT N
randomized VBN N
single-blind NN N
study NN N
with IN N
a DT N
27-month JJ N
intervention NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP N
University NNP p
medical JJ p
center NN p
; : p
50 CD p
patients NNS p
( ( p
serum JJ p
creatinine NN p
, , p
1.5-3.9 JJ p
mg/dL NN p
) ) p
with IN p
high-normal JJ p
body NN p
lead JJ p
burden NN p
( ( p
?80- JJ p
< NN p
600 CD p
?g NN p
) ) p
were VBD p
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN i
and CC i
control NN i
groups NNS i
. . i

INTERVENTION NNP i
The DT N
treatment NN N
group NN N
received VBD N
weekly JJ i
chelation NN i
therapy NN i
for IN i
3 CD N
months NNS N
to TO N
reduce VB N
their PRP$ N
body NN N
lead JJ N
burden NN N
to TO N
< VB N
60 CD N
?g NNS N
and CC N
then RB N
as IN N
needed VBN N
for IN N
24 CD N
months NNS N
to TO N
maintain VB N
this DT N
level NN N
. . N

The DT N
control NN N
group NN N
received VBD i
placebo NN i
for IN i
3 CD N
months NNS N
and CC N
then RB N
weekly VB N
for IN N
5 CD N
weeks NNS N
at IN N
6-month JJ N
intervals NNS N
for IN N
24 CD N
months NNS N
. . N

OUTCOMES IN o
The DT o
primary JJ o
end NN o
point NN o
was VBD o
change NN o
in IN o
estimated VBN o
glomerular JJ o
filtration NN o
rate NN o
( ( o
eGFR NN o
) ) o
over IN o
time NN o
. . o

A DT o
secondary JJ N
end NN N
point NN N
was VBD N
a DT o
2-fold JJ o
increase NN o
in IN o
baseline JJ o
serum NN o
creatinine NN o
level NN o
or CC o
the DT o
requirement NN o
for IN o
renal JJ o
replacement NN o
therapy NN o
. . o

MEASUREMENTS NNP o
Body NNP N
lead JJ N
burdens NNS N
were VBD N
assessed VBN N
by IN N
EDTA NNP N
mobilization NN N
tests NNS N
and CC N
eGFR NN N
was VBD N
calculated VBN N
using VBG N
the DT N
equation NN N
for IN N
Chinese JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

RESULTS NNP o
Mean NNP o
baseline NN o
eGFRs NN o
in IN o
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
were VBD N
similar JJ N
. . N

After IN N
3 CD N
months NNS N
of IN N
chelation NN N
therapy NN N
, , N
the DT N
change NN o
in IN o
eGFR NN o
in IN o
the DT N
treatment NN N
group NN N
( ( N
+1.0 NNP N
? . N
4.8 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
) ) N
differed VBN N
significantly RB N
from IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
-1.5 NNP N
? . N
4.8 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

In IN N
the DT N
subsequent JJ N
24-month JJ N
intervention NN N
, , N
the DT N
yearly JJ N
rate NN o
of IN o
decrease NN o
in IN o
eGFR NN o
( ( N
5.6 CD N
? . N
5.0 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
per IN N
year NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
slower JJR N
than IN N
that DT N
( ( N
9.2 CD N
? . N
3.6 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
per IN N
year NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
control NN N
group NN p
. . p

17 CD p
( ( p
68 CD p
% NN p
) ) N
control-group NN p
patients NNS p
and CC p
9 CD p
( ( p
36 CD p
% NN p
) ) p
treatment-group NN p
patients NNS p
achieved VBD p
the DT N
secondary JJ N
end NN N
point NN N
. . N

LIMITATIONS NNP N
Small NNP N
sample NN N
size NN N
, , N
not RB N
double JJ N
blind NN N
. . N

CONCLUSIONS VB N
A DT N
27-month JJ N
course NN N
of IN N
EDTA NNP N
chelation NN N
therapy NN N
retards VBZ N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN p
in IN p
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN p
high-normal JJ p
body NN p
lead JJ p
burdens NNS p
. . N

-DOCSTART- -10588965- O O

Lack NN N
of IN N
benefit NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
and CC p
pervasive JJ p
developmental JJ p
disorder NN p
. . p

BACKGROUND NNP N
Secretin NNP i
is VBZ N
a DT N
peptide JJ N
hormone NN N
that WDT N
stimulates VBZ N
pancreatic JJ N
secretion NN N
. . N

After IN N
recent JJ N
publicity NN N
about IN N
a DT N
child NN N
with IN N
autism NN N
whose WP$ N
condition NN N
markedly RB N
improved VBN N
after IN N
a DT N
single JJ N
dose NN N
of IN N
secretin NN i
, , N
thousands NNS p
of IN p
children NNS p
with IN p
autistic JJ p
disorders NNS p
may MD N
have VB N
received VBN N
secretin JJ i
injections NNS i
. . i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
in IN N
60 CD p
children NNS p
( ( p
age NN p
, , p
3 CD p
to TO p
14 CD p
years NNS p
) ) p
with IN p
autism NN p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
. . p

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
( ( N
0.4 CD N
microg NN N
per IN N
kilogram NN N
of IN N
body NN N
weight NN N
) ) N
or CC N
saline JJ i
placebo NN i
. . i

We PRP N
used VBD N
standardized JJ N
behavioral JJ N
measures NNS N
of IN N
the DT N
primary JJ N
and CC N
secondary JJ N
features NNS N
of IN N
autism NN N
, , N
including VBG N
the DT N
Autism NNP N
Behavior NNP N
Checklist NNP N
, , N
to TO N
assess VB N
the DT N
degree NN N
of IN N
impairment NN N
at IN N
base NN N
line NN N
and CC N
over IN N
the DT N
course NN N
of IN N
a DT N
four-week JJ N
period NN N
after IN N
treatment NN N
. . N

RESULTS NNP N
Of IN N
the DT N
60 CD p
children NNS p
, , p
4 CD p
could MD p
not RB p
be VB p
evaluated VBN p
- : N
2 CD N
received VBD N
secretin NN i
outside IN N
the DT N
study NN N
, , N
and CC N
2 CD N
did VBD N
not RB N
return VB N
for IN N
follow-up JJ N
. . N

Thus NNP N
, , N
56 CD p
children NNS p
( ( p
28 CD p
in IN p
each DT p
group NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

As IN N
compared VBN N
with IN N
placebo NN i
, , i
secretin FW i
treatment NN N
was VBD N
not RB N
associated VBN N
with IN N
significant JJ o
improvements NNS o
in IN o
any DT o
of IN o
the DT o
outcome NN o
measures NNS o
. . o

Among IN N
the DT N
children NNS N
in IN N
the DT N
secretin NN i
group NN N
, , N
the DT N
mean JJ o
total NN o
score NN o
on IN o
the DT o
Autism NNP o
Behavior NNP o
Checklist NNP o
at IN N
base NN N
line NN N
was VBD N
59.0 CD N
( ( N
range NN N
of IN N
possible JJ N
values NNS N
, , N
0 CD N
to TO N
158 CD N
, , N
with IN N
a DT N
larger JJR N
value NN N
corresponding VBG N
to TO N
greater JJR N
impairment NN N
) ) N
, , N
and CC N
among IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
it PRP N
was VBD N
63.2 CD N
. . N

The DT N
mean JJ o
decreases NNS o
in IN o
scores NNS o
over IN N
the DT N
four-week JJ N
period NN N
were VBD N
8.9 CD N
in IN N
the DT N
secretin NN i
group NN N
and CC N
17.8 CD N
in IN N
the DT N
placebo NN i
group NN N
( ( N
mean JJ N
difference NN N
, , N
-8.9 NNP N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
-19.4 VBP N
to TO N
1.6 CD N
; : N
P=0.11 NNP N
) ) N
. . N

None NN N
of IN N
the DT N
children NNS p
had VBD N
treatment-limiting JJ o
adverse JJ o
effects NNS o
. . o

After IN N
they PRP N
were VBD N
told VBN N
the DT N
results NNS N
, , N
69 CD N
percent NN N
of IN N
the DT N
parents NNS N
of IN N
the DT N
children NNS N
in IN N
this DT N
study NN N
said VBD N
they PRP N
remained VBD N
interested JJ N
in IN N
secretin NN i
as IN N
a DT N
treatment NN N
for IN N
their PRP$ N
children NNS N
. . N

CONCLUSIONS VB N
A DT N
single JJ N
dose NN N
of IN N
synthetic JJ N
human JJ i
secretin NN i
is VBZ N
not RB o
an DT o
effective JJ o
treatment NN o
for IN N
autism NN N
or CC N
pervasive JJ N
developmental JJ N
disorder NN N
. . N

-DOCSTART- -8624384- O O

Antibiotic JJ i
strategy NN i
after IN N
the DT N
empiric JJ N
phase NN N
in IN N
patients NNS p
treated VBN p
for IN p
a DT p
hematological JJ p
malignancy NN p
. . p

Empiric JJ i
broad-spectrum JJ i
antibiotic JJ i
therapy NN i
has VBZ N
become VBN N
a DT N
generally RB N
accepted VBN N
strategy NN N
in IN N
the DT N
treatment NN N
of IN N
febrile JJ p
neutropenic JJ p
patients NNS p
. . p

Particularly NNP N
in IN N
patients NNS p
with IN p
prolonged JJ p
neutropenia NN p
, , N
subsequent JJ N
adaptation NN N
of IN N
such JJ N
a DT N
regimen NNS N
will MD N
be VB N
the DT N
rule NN N
rather RB N
than IN N
exception NN N
. . N

Since IN N
there EX N
are VBP N
no DT N
uniformly RB N
accepted VBN N
guidelines NNS N
for IN N
the DT N
modification NN N
of IN N
antibiotic JJ i
therapy NN i
during IN N
the DT N
post-empiric JJ N
phase NN N
, , N
we PRP N
assessed VBD N
the DT N
impact NN i
of IN i
a DT i
set NN i
of IN i
rules NNS i
that WDT i
evolved VBD i
during IN i
the DT i
first JJ i
randomized JJ i
trials NNS i
. . i

Evaluation NN i
of IN i
the DT i
clinician NN i
's POS i
compliance NN i
with IN i
these DT i
rules NNS i
in IN i
1951 CD i
febrile NN i
neutropenic JJ i
episodes NNS i
was VBD i
the DT i
subject NN i
of IN i
the DT i
present JJ i
analysis NN i
. . i

Treatment NNP i
was VBD i
modified VBN i
in IN N
761 CD N
( ( N
39 CD N
% NN N
) ) N
cases NNS N
, , N
and CC N
these DT N
changes NNS N
were VBD N
made VBN N
according VBG N
to TO N
the DT N
rules NNS N
in IN N
76 CD N
% NN N
. . N

For IN N
75 CD N
% NN N
of IN N
the DT N
alterations NNS N
in IN N
treatment NN N
during IN N
the DT N
evening NN N
and CC N
night NN N
shifts NNS N
, , N
no DT N
reasonable JJ N
explanation NN N
was VBD N
established VBN N
, , N
while IN N
93 CD N
% NN N
of IN N
the DT N
modifications NNS N
during IN N
the DT N
normal JJ N
working JJ N
hours NNS N
were VBD N
made VBN N
for IN N
objective JJ N
reasons NNS N
. . N

The DT N
empiric JJ N
regimen NN N
was VBD N
more RBR N
frequently RB N
changed VBN N
in IN N
patients NNS N
with IN N
a DT N
clinical JJ N
focus NN N
of IN N
infection NN N
at IN N
the DT N
onset NN N
of IN N
fever NN N
than IN N
in IN N
patients NNS N
who WP N
showed VBD N
fever RB N
as IN N
the DT N
only JJ N
symptom NN N
of IN N
a DT N
possible JJ N
infection NN N
. . N

The DT N
perceived JJ N
need NN N
for IN N
modification NN N
amounted VBD N
to TO N
69 CD N
% NN N
in IN N
pulmonary JJ N
infections NNS N
, , N
to TO N
51 CD N
% NN N
in IN N
skin NN N
and CC N
soft-tissue NN N
infections NNS N
, , N
to TO N
44 CD N
% NN N
in IN N
patients NNS N
with IN N
abdominal JJ N
complaints NNS N
, , N
and CC N
to TO N
37 CD N
% NN N
in IN N
upper JJ N
respiratory NN N
tract NN N
infections NNS N
. . N

Glycopeptides NNP N
constituted VBD N
22 CD N
% NN N
of IN N
modifications NNS N
, , N
particularly RB N
in IN N
patients NNS N
with IN N
a DT N
central JJ N
venous JJ N
catheter NN N
, , N
and CC N
systemically RB N
active JJ N
antifungals NNS N
were VBD N
administered VBN N
in IN N
16 CD N
% NN N
of IN N
cases NNS N
. . N

Especially RB N
inexperienced JJ N
clinicians NNS N
tend VBP N
to TO N
adjust VB N
antibiotic JJ i
therapy NN i
, , N
in IN N
spite NN N
of IN N
the DT N
fact NN N
that IN N
persistence NN N
of IN N
fever NN N
alone RB N
seldom JJ N
reflects VBZ N
inadequate JJ N
treatment NN N
when WRB N
the DT N
clinical JJ N
condition NN N
of IN N
the DT N
patient NN N
is VBZ N
stable JJ N
or CC N
improving VBG N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
development NN N
of IN N
subsequent JJ N
infectious JJ N
events NNS N
emphasizes VBZ N
that IN N
a DT N
genuine JJ N
need NN N
for IN N
modification NN N
does VBZ N
frequently RB N
exist VB N
. . N

-DOCSTART- -10759619- O O

Pharmacokinetic JJ N
interaction NN N
between IN N
proton NN i
pump NN i
inhibitors NNS i
and CC i
roxithromycin NN i
in IN N
volunteers NNS p
. . p

BACKGROUND NNP N
Triple NNP N
therapy NN N
including VBG N
two CD N
antibiotics NNS N
and CC N
a DT N
proton NN N
pump NN N
inhibitor NN N
is VBZ N
a DT N
rational JJ N
approach NN N
to TO N
the DT N
treatment NN N
of IN N
Helicobacter NNP N
pylori NN N
induced VBD N
peptic JJ N
ulcer JJ N
disease NN N
. . N

The DT N
interaction NN N
of IN N
antimicrobial JJ N
therapy NN N
and CC N
acid JJ N
suppression NN N
is VBZ N
not RB N
yet RB N
well RB N
elucidated VBN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
proton NN i
pump NN i
inhibitors NNS i
on IN N
roxithromycin NN i
levels NNS N
in IN N
plasma NN N
and CC N
gastric JJ N
tissue NN N
under IN N
steady-state JJ p
conditions NNS p
in IN p
volunteers NNS p
. . p

METHODS NNP N
In IN N
two CD N
crossover NN N
studies NNS N
omeprazole VBP i
20 CD i
mg NN i
b.d. NN i
, , N
lansoprazole JJ i
30 CD i
mg NN i
b.d. NN i
, , N
roxithromycin VBZ i
300 CD i
mg NN i
b.d. NN i
, , N
and CC i
the DT i
combination NN i
of IN i
roxithromycin NN i
with IN i
either DT i
omeprazole NN i
or CC i
lansoprazole NN i
were VBD N
administered VBN N
to TO N
12 CD p
healthy JJ p
volunteers NNS p
over IN p
6 CD p
days NNS p
. . p

Blood NNP o
plasma NN o
levels NNS o
of IN N
the DT N
drugs NNS N
were VBD N
measured VBN N
. . N

In IN N
addition NN N
, , N
roxithromycin JJ o
concentrations NNS o
were VBD N
also RB N
determined VBN N
in IN N
gastric JJ N
juice NN N
and CC N
gastric JJ N
tissue NN N
obtained VBN N
during IN N
endoscopy NN N
. . N

RESULTS VB N
The DT N
proton NN i
pump NN i
inhibitors NNS i
and CC i
roxithromycin NN i
did VBD N
not RB N
alter VB N
the DT N
blood NN o
plasma NN o
pharmacokinetics NNS o
of IN N
each DT N
other JJ N
. . N

When WRB N
compared VBN N
to TO N
roxithromycin VB i
administered JJ N
alone RB N
, , N
its PRP$ N
combination NN N
with IN N
a DT N
proton NN i
pump NN i
inhibitor NN i
significantly RB N
increased VBD N
the DT N
roxithromycin NN o
concentrations NNS o
in IN o
gastric JJ o
juice NN o
( ( N
3.0-5.0 JJ N
microg/mL NN N
vs. IN N
0.3-0.4 NNP N
microg/mL NN N
) ) N
and CC N
gastric JJ o
tissue NN o
( ( N
antrum NN N
: : N
3.8-4.0 JJ N
vs. FW N
2.8 CD N
microg/g NN N
, , N
fundus NN N
: : N
5.9-7.4 JJ N
vs. IN N
4.2-4.4 JJ N
microg/g NN N
) ) N
. . N

CONCLUSIONS NNP N
Proton NNP i
pump NN i
inhibitors NNS i
and CC N
roxithromycin VB i
do VBP N
not RB N
alter VB N
the DT N
systemic JJ N
bioavailability NN N
of IN N
each DT N
other JJ N
. . N

However RB N
, , N
proton VBP i
pump NN i
inhibitors NNS i
increase VBP N
the DT N
local JJ N
concentration NN o
of IN o
roxithromycin NN o
in IN N
the DT N
stomach NN N
which WDT N
may MD N
contribute VB N
to TO N
the DT N
clinically RB N
proven JJ N
synergic JJ N
beneficial JJ N
action NN N
in IN N
eradication NN N
therapy NN N
of IN N
H. NNP N
pylori NN N
. . N

-DOCSTART- -23361389- O O

Effects NNS N
of IN N
a DT N
dietetic JJ i
treatment NN i
in IN N
older JJR p
, , p
undernourished JJ p
, , p
community-dwelling JJ p
individuals NNS p
in IN p
primary JJ p
care NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
Undernutrition NNP N
is VBZ N
a DT N
prevalent NN N
problem NN N
in IN N
older JJR p
, , p
community-dwelling JJ p
individuals NNS p
. . p

Aim NNP N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
a DT N
dietetic JJ i
treatment NN i
in IN N
older JJR p
, , p
undernourished JJ p
, , p
community-dwelling JJ p
individuals NNS p
. . p

METHODS NNP N
A NNP N
parallel JJ N
randomized VBN N
controlled JJ N
trial NN N
was VBD N
performed VBN N
in IN N
146 CD p
non-institutionalized JJ p
, , p
undernourished JJ p
individuals NNS p
aged VBN p
?65 CD p
years NNS p
in IN p
primary JJ p
care NN p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT i
intervention NN i
( ( i
referral JJ i
to TO i
and CC i
treatment NN i
by IN i
a DT i
trained JJ i
dietitian NN i
) ) i
or CC i
control VB i
group NN i
( ( i
no DT i
referral NN o
) ) o
. . o

Body NNP o
weight VBD o
, , o
physical JJ o
performance NN o
, , o
handgrip JJ o
strength NN o
, , o
energy NN o
intake NN o
, , o
protein JJ o
intake NN o
and CC o
fat-free JJ o
mass NN o
were VBD o
assessed VBN N
at IN N
baseline NN N
, , N
after IN N
3 CD N
months NNS N
and CC N
after IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
All NNP N
randomized VBD N
participants NNS N
( ( N
n JJ N
= NNP N
146 CD N
) ) N
were VBD N
included VBN N
in IN N
the DT N
intention-to-treat JJ N
generalized JJ N
estimating NN N
equations NNS N
analysis NN N
( ( N
72 CD N
in IN N
intervention NN N
and CC N
74 CD N
in IN N
control NN N
group NN N
) ) N
. . N

No DT N
treatment NN N
effect NN N
was VBD N
found VBN N
on IN N
the DT N
primary JJ N
outcomes NNS o
body NN o
weight NN o
( ( o
? . N
= $ N
0.49 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.15-1.12 NN o
) ) o
, , o
physical JJ o
performance NN o
( ( o
? . o
= RB N
0.15 CD N
points NNS N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.33-0.64 NN N
) ) N
and CC N
handgrip JJ o
strength NN o
( ( o
? . o
= $ N
0.49 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.62-1.60 NN N
) ) N
. . N

Furthermore NNP N
, , N
no DT N
treatment NN N
effect NN N
was VBD N
found VBN N
for IN N
the DT N
secondary JJ N
outcomes NNS N
. . N

Predefined VBN N
subgroup NN N
analyses VBZ N
showed VBD N
a DT N
treatment NN N
effect NN o
on IN o
body NN o
weight NN o
in IN o
physically RB o
active JJ N
participants NNS N
( ( N
? . N
= $ N
1.25 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.70-2.11 NN N
) ) N
and CC N
not RB N
in IN N
inactive JJ N
participants NNS N
( ( N
? . N
= '' N
-0.20 JJ N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-1.16-0.75 NN N
) ) N
. . N

CONCLUSIONS NNP N
After IN N
6 CD N
months NNS N
, , N
a DT i
dietetic JJ i
treatment NN i
by IN i
trained JJ i
dietitians NNS i
does VBZ i
not RB i
lead VB N
to TO N
increases NNS N
in IN N
body NN N
weight NN N
and CC N
physical JJ N
functioning NN p
in IN p
older JJR p
, , p
undernourished JJ p
, , p
community-dwelling JJ p
individuals NNS p
. . p

-DOCSTART- -9647338- O O

Effect NN N
of IN N
aldose JJ i
reductase NN i
inhibition NN N
on IN N
cardiovascular JJ o
reflex NN o
tests NNS o
in IN N
patients NNS p
with IN p
definite JJ p
diabetic JJ p
autonomic JJ p
neuropathy NN p
over IN p
a DT p
period NN p
of IN p
2 CD p
years NNS p
. . p

The DT N
potential NN N
of IN N
the DT N
aldose JJ N
reductase NN N
inhibitor NN N
tolrestat NN i
to TO N
ameliorate VB N
definite JJ N
diabetic JJ N
autonomic NN N
neuropathy NN N
( ( N
DAN NNP N
) ) N
, , N
as IN N
defined VBN N
by IN N
standard JJ N
cardiovascular JJ N
autonomic JJ N
function NN N
tests NNS N
, , N
was VBD N
evaluated VBN N
in IN N
35 CD p
patients NNS p
over IN N
a DT N
period NN N
of IN N
2 CD N
years NNS N
, , N
with IN N
repeated VBN N
measurements NNS N
at IN N
3-month JJ N
intervals NNS N
. . N

The DT N
effect NN N
of IN N
tolrestat NN i
( ( N
200 CD N
mg NN N
a DT N
day NN N
) ) N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
placebo NN i
on IN N
35 CD p
controls NNS p
with IN p
diabetes NNS p
mellitus NNS p
, , p
of IN p
similar JJ p
age NN p
, , p
gender NN p
, , p
and CC p
glycemic JJ p
control NN p
. . p

In IN N
the DT N
placebo NN i
group NN N
, , N
a DT N
significant JJ N
deterioration NN N
of IN N
the DT N
indices NNS N
, , N
with IN N
the DT N
exception NN N
of IN N
Valsalva NNP o
ratio NN o
, , N
was VBD N
recorded VBN N
, , N
while IN N
tolrestat NN i
induced VBD N
a DT N
significant JJ N
beneficial JJ N
change NN N
in IN N
the DT N
values NNS o
of IN o
most JJS o
standard JJ o
cardiovascular JJ o
reflex NN o
tests NNS o
, , N
in IN N
comparison NN N
to TO N
baseline VB N
and CC N
placebo VB N
. . N

The DT N
deep JJ o
breathing NN o
tests NNS o
( ( o
expiration-inspiration NN o
ratio NN o
, , o
standard JJ o
deviation NN o
, , o
and CC o
mean VB o
circular JJ o
resultant NN o
of IN o
R-R NNP o
intervals NNS o
) ) o
, , o
postural JJ o
index NN o
, , o
and CC o
postural JJ o
hypotension NN o
were VBD N
favorably RB N
affected VBN N
. . N

Three CD N
of IN N
35 CD N
patients NNS N
on IN N
tolrestat NN i
( ( N
8.6 CD N
% NN N
) ) N
developed VBD N
high JJ o
transaminases NNS o
levels NNS o
( ( N
more JJR N
than IN N
threefold VB N
the DT N
upper JJ N
normal JJ N
limit NN N
) ) N
and CC N
were VBD N
withdrawn VBN N
from IN N
the DT N
study NN N
. . N

In IN N
conclusion NN N
, , N
tolrestat NN i
improved VBD N
autonomic RB o
nervous JJ o
system NN o
function NN o
in IN N
patients NNS p
with IN p
definite JJ p
DAN NNP p
, , N
in IN N
comparison NN N
to TO N
baseline VB N
and CC N
placebo VB N
. . N

The DT N
clinical JJ N
importance NN N
of IN N
this DT N
finding NN N
needs VBZ N
further JJ N
investigation NN N
. . N

-DOCSTART- -8741469- O O

[ RB N
Intraoperative NNP N
continuous JJ N
epidural JJ N
block NN N
influences NNS N
postoperative JJ N
changes NNS N
in IN N
breathing VBG N
pattern NN N
and CC N
thoracoabdominal JJ N
movement NN N
associated VBN N
with IN N
upper JJ N
abdominal JJ N
surgery NN N
] NN N
. . N

We PRP N
have VBP N
examined VBN N
the DT N
changes NNS N
in IN N
breathing VBG N
pattern NN N
and CC N
thoracoabdominal JJ N
movement NN N
associated VBN N
with IN N
upper JJ N
abdominal JJ N
surgery NN N
in IN N
order NN N
to TO N
evaluate VB N
the DT N
possible JJ N
influences NNS N
of IN N
nociceptive JJ N
input NN N
on IN N
respiration NN N
. . N

Sixteen JJ p
patients NNS p
scheduled VBN p
for IN p
gastrectomy NN p
were VBD p
studied VBN p
. . p

Continuous JJ i
epidural JJ i
block NN i
was VBD i
instituted VBN i
prior RB i
to TO i
the DT i
induction NN i
of IN i
anesthesia NN i
and CC i
maintained VBD i
throughout IN i
the DT i
surgery NN i
in IN i
8 CD i
of IN i
16 CD i
patients NNS i
( ( i
Group NNP i
1 CD i
) ) i
while IN i
it PRP i
was VBD i
instituted VBN i
upon IN i
the DT i
peritoneal JJ i
closure NN i
and CC i
maintained VBD i
thereafter RB i
in IN i
the DT i
remaining VBG i
8 CD i
patients NNS i
( ( i
Group NNP i
2 CD i
) ) i
. . N

Breathing VBG o
pattern NN o
and CC o
thoracoabdominal JJ o
motion NN o
were VBD N
determined VBN N
before IN N
and CC N
after IN N
surgery NN N
while IN N
the DT N
patients NNS N
awake VBP N
by IN N
respiratory NN i
inductance NN i
plethysmography NN i
( ( i
Respisomnography NNP i
, , i
Chest NNP i
MI NNP i
) ) i
. . i

Breathing NNP o
frequency NN o
and CC o
minute JJ o
ventilation NN o
increased VBD N
significantly RB N
while IN N
tidal JJ N
volume NN N
was VBD N
unchanged JJ N
after IN N
the DT N
operation NN N
regardless NN N
of IN N
the DT N
intraoperative JJ N
epidural JJ N
block NN N
. . N

Furthermore RB N
, , N
there EX N
were VBD N
identical JJ N
shortening NN N
of IN N
inspiratory JJ o
time NN o
and CC o
prolongation NN o
of IN o
duty NN o
ratio NN o
( ( N
inspiratory JJ N
time/duration NN N
of IN N
a DT N
breath NN N
) ) N
in IN N
the DT N
two CD N
groups NNS N
. . N

Contribution NN o
of IN o
rib JJ o
cage NN o
movement NN o
on IN o
tidal JJ o
volume NN o
increased VBD N
significantly RB N
postoperatively RB N
in IN N
all PDT N
the DT N
patients NNS N
. . N

However RB N
, , N
the DT N
changes NNS N
were VBD N
significantly RB N
smaller JJR N
in IN N
patients NNS p
receiving VBG p
intraoperative JJ p
epidural JJ p
block NN p
. . p

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
causes NNS N
of IN N
tachypnea NN N
and CC N
increased VBD N
minute NN N
ventilation NN N
are VBP N
different JJ N
from IN N
the DT N
mechanism NN N
responsible JJ N
for IN N
the DT N
alteration NN N
of IN N
thoracoabdominal JJ N
partitioning NN N
of IN N
ventilation NN N
after IN N
upper JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
former JJ N
may MD N
be VB N
related VBN N
to TO N
the DT N
metabolic JJ N
changes NNS N
and CC N
, , N
conceivably RB N
, , N
unaffected VBN N
by IN N
continuous JJ N
epidural JJ N
block NN N
. . N

While IN N
the DT N
latter NN N
may MD N
be VB N
the DT N
consequence NN N
of IN N
the DT N
reflex JJ N
inhibition NN N
of IN N
the DT N
diaphragmatic JJ N
function NN N
that WDT N
can MD N
be VB N
, , N
at IN N
least JJS N
partially RB N
, , N
modified VBN N
by IN N
continuous JJ N
epidural JJ N
block NN N
. . N

-DOCSTART- -14714361- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
effect NN o
of IN N
fuzheng NN i
yiliu NN i
granule NN i
on IN N
cell NN N
cycle NN N
and CC N
nuclear JJ N
transcription NN N
factor-kappa NN N
B NNP N
in IN N
tissue NN N
of IN N
esophageal-gastric JJ N
carcinoma NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
effect NN o
of IN N
Fuzheng NNP i
Yiliu NNP i
Granule NNP i
( ( i
FZYLG NNP i
) ) i
on IN N
cell NN N
cycle NN N
and CC N
nuclear JJ N
transcription NN N
factor-kappa NN N
B NNP N
( ( N
NF-kappa NNP N
B NNP N
) ) N
in IN N
tissue NN N
of IN N
esophageal-gastric JJ N
carcinoma NN N
. . N

METHODS NNP N
Seventy-six JJ p
patients NNS p
with IN p
esophageal JJ p
gastric JJ p
carcinoma NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
FZYLG NNP i
group NN p
and CC N
the DT N
control NN i
group NN i
. . i

FZYLG NNP i
was VBD N
given VBN N
to TO N
the DT N
former JJ N
for IN N
15 CD N
days NNS N
. . N

The DT N
tumor NN N
tissue NN N
in IN N
both DT N
groups NNS N
was VBD N
resected VBN N
and CC N
cell JJ o
cycle NN o
and CC N
apoptosis NN o
rate NN o
as RB N
well RB N
as IN N
NF-kappa NNP N
B NNP N
were VBD N
determined VBN N
by IN N
flowcytometry NN N
. . N

RESULTS NNP N
Level NNP o
of IN o
NF-kappa NNP o
B NNP o
in IN N
the DT N
treated JJ N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
treated JJ N
group NN N
, , N
the DT N
percentage NN o
of IN o
G0/G1 NNP o
stage NN o
cells NNS o
were VBD N
significantly RB N
increased VBN N
and CC N
that IN N
of IN N
S NNP o
stage NN o
significantly RB N
decreased VBN N
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
same JJ N
time NN N
, , N
obvious JJ N
cell NN o
apoptosis NN o
was VBD N
found VBN N
in IN N
the DT N
treated JJ N
group NN N
, , N
the DT N
apoptosis NN o
rate NN o
of IN N
which WDT N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
FZYLG NNP i
can MD N
increase VB N
the DT N
NF-kappa NNP N
B NNP N
expression NN N
, , N
block VB N
the DT N
proliferation NN N
to TO N
promote VB N
the DT N
apoptosis NN o
of IN N
tumor NN N
cells NNS N
. . N

-DOCSTART- -8255984- O O

A DT N
preliminary JJ N
trial NN N
of IN N
ascorbic JJ i
acid NN i
as IN N
supplemental JJ N
therapy NN N
for IN N
autism NN p
. . p

1 CD N
. . N

This DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
30-week JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
exploring VBG N
the DT N
effectiveness NN N
of IN N
ascorbic JJ i
acid NN i
( ( N
8g/70kg/day CD N
) ) N
as IN N
a DT N
supplemental JJ N
pharmacological JJ N
treatment NN N
for IN N
autistic JJ p
children NNS p
in IN p
residential JJ p
treatment NN p
. . p

2 CD N
. . N

Residential JJ p
school NN p
children NNS p
( ( p
N NNP p
= NNP p
18 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
ascorbate-ascorbate-placebo JJ i
treatment NN i
order NN i
group NN i
or CC i
ascorbate-placebo-ascorbate JJ i
treatment NN i
order NN i
group NN N
. . N

Each DT N
treatment NN N
phase NN N
lasted VBD N
10 CD N
weeks NNS N
and CC N
behaviors NNS N
were VBD N
rated VBN N
weekly JJ N
using VBG N
the DT N
Ritvo-Freeman NNP N
scale NN N
. . N

3 CD N
. . N

Significant JJ N
group NN N
by IN N
phase NN N
interactions NNS N
were VBD N
found VBN N
for IN N
total JJ o
scores NNS o
and CC N
also RB N
sensory JJ o
motor NN o
scores NNS o
indicating VBG N
a DT N
reduction NN N
in IN N
symptom JJ o
severity NN o
associated VBN N
with IN N
the DT N
ascorbic JJ i
acid NN i
treatment NN i
. . i

4 CD N
. . N

These DT N
results NNS N
were VBD N
consistent JJ N
with IN N
a DT N
hypothesized VBN N
dopaminergic NN N
mechanism NN N
of IN N
action NN N
of IN N
ascorbic JJ i
acid NN i
. . i

-DOCSTART- -15673098- O O

Skeletal JJ N
muscle NN N
total JJ N
creatine NN N
content NN N
and CC N
creatine NN N
transporter NN N
gene NN N
expression NN N
in IN N
vegetarians NNS p
prior JJ N
to TO N
and CC N
following VBG N
creatine JJ i
supplementation NN i
. . i

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
vegetarianism NN N
on IN N
skeletal JJ o
muscle NN o
total JJ o
creatine NN o
( ( o
TCr NNP o
) ) o
content NN o
and CC N
creatine NN o
transporter NN o
( ( o
CreaT NNP o
) ) o
gene NN o
expression NN o
, , N
prior RB N
to TO N
and CC N
during IN N
5 CD N
d NN N
of IN N
Cr NNP i
supplementation NN i
( ( i
CrS NNP i
) ) i
. . N

In IN N
a DT N
double-blind NN N
, , N
crossover NN N
design NN N
, , N
7 CD p
vegetarians NNS p
( ( p
VEG NNP p
) ) p
and CC p
nonvegetarians NNS p
( ( p
NVEG NNP p
) ) p
were VBD N
assigned VBN N
Cr NNP i
or CC i
placebo NN i
supplements NNS i
for IN N
5 CD N
d NN N
and CC N
after IN N
5 CD N
wk NN N
, , N
received VBD N
the DT N
alternative JJ i
treatment NN i
. . i

Muscle NNP i
sampling VBG i
occurred VBD N
before IN N
, , N
and CC N
after IN N
1 CD N
and CC N
5 CD N
d NN N
of IN N
treatment NN N
ingestion NN N
. . N

Basal NNP o
muscle NN o
TCr NNP o
content NN N
was VBD N
lower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
VEG NNP N
compared VBN N
with IN N
NVEG NNP N
. . N

Muscle NNP o
TCr NNP o
increased VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
throughout IN N
the DT N
Cr NNP i
trial NN N
in IN N
both DT N
groups NNS N
but CC N
was VBD N
greater JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
VEG NNP N
compared VBN N
with IN N
NVEG NNP N
, , N
at IN N
days NNS N
1 CD N
and CC N
5 CD N
. . N

CreaT NNP o
gene NN o
expression NN o
was VBD N
not RB N
different JJ N
between IN N
VEG NNP N
and CC N
NVEG NNP N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
VEG NNP N
have VBP N
a DT N
lower JJR N
muscle NN o
TCr NNP o
content NN o
and CC N
an DT N
increased VBN N
capacity NN o
to TO N
load VB N
Cr NNP i
into IN N
muscle NN N
following VBG N
CrS NNP i
. . i

Muscle NNP o
CreaT NNP o
gene NN o
expression NN o
does VBZ N
not RB N
appear VB N
to TO N
be VB N
affected VBN N
by IN N
vegetarianism NN p
. . p

-DOCSTART- -15509083- O O

Sustained VBN N
oral JJ o
health NN o
improvement NN o
and CC N
use NN N
of IN N
toothbrushes NNS i
and CC i
dentifrice NN i
by IN N
previous JJ p
users NNS p
of IN p
traditional JJ p
materials NNS p
in IN p
a DT p
rural JJ p
population NN p
in IN p
Andhra NNP p
Pradesh NNP p
, , p
India NNP p
. . p

AIM NNP N
To TO N
follow-up NN N
, , N
one CD N
year NN N
later RB N
, , N
a DT N
double-blind NN N
, , N
randomised VBN N
study NN N
, , N
which WDT N
investigated VBD N
the DT N
effect NN o
of IN N
regular JJ i
brushing NN i
with IN i
dentifrices NNS i
on IN N
the DT N
oral JJ p
health NN p
of IN p
an DT p
economically RB p
disadvantaged JJ p
rural JJ p
population NN p
in IN p
Andhra NNP p
Pradesh NNP p
, , p
India NNP p
who WP p
were VBD p
primarily RB p
users NNS p
of IN p
traditional JJ p
materials NNS p
. . p

SUBJECTS NNP N
150 CD p
of IN p
the DT p
original JJ p
study NN p
population NN p
. . p

METHOD NNP N
Examination NNP N
to TO N
determine VB N
whether IN N
the DT N
improvements NNS o
in IN o
oral JJ o
health NN o
status NN o
and CC o
oral JJ o
health NN o
behaviour NN o
( ( N
use NN N
of IN N
toothbrush NN i
and CC i
dentifrice NN i
) ) i
, , N
being VBG N
unsupported JJ N
, , N
had VBD N
been VBN N
sustained VBN N
since IN N
completion NN N
of IN N
the DT N
original JJ N
study NN N
. . N

RESULTS NNP N
Data NNP N
analysis NN N
showed VBD N
sustained VBN N
, , N
statistically RB o
significant JJ o
improvements NNS o
in IN o
gingival JJ o
health NN o
as IN o
measured VBN o
by IN o
gingival NN o
bleeding NN o
and CC o
plaque NN o
indices NNS o
( ( o
GBI NNP o
and CC o
PI NNP o
) ) o
comparing VBG N
users NNS N
and CC N
non-users NNS N
of IN N
toothbrushes NNS N
and CC N
dentifrice NN N
in IN N
the DT N
original JJ N
study NN N
( ( N
PI NNP N
: : N
p NN N
= VBZ N
0.04 CD N
; : N
GBI NNP N
: : N
p NN N
= VBZ N
0.03 CD N
) ) N
and CC N
sustained VBN o
use NN o
of IN o
toothbrushes NNS o
and CC o
dentifrice NN o
by IN N
60 CD N
% NN N
of IN N
the DT N
subjects NNS N
at IN N
follow-up JJ N
one CD N
year NN N
later RB N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
a DT N
beneficial JJ o
effect NN o
on IN o
oral JJ o
hygiene NN o
indices NNS N
following VBG N
the DT N
introduction NN i
of IN i
toothbrushes NNS i
and CC i
dentifrices NNS i
to TO N
a DT N
community NN N
using VBG N
traditional JJ N
oral JJ N
hygiene NN N
materials NNS N
and CC N
sustainability NN N
of IN N
use NN N
of IN N
these DT N
materials NNS N
with IN N
motivation NN N
and CC N
support NN N
. . N

It PRP N
may MD N
therefore RB N
be VB N
concluded VBN N
that IN N
it PRP N
is VBZ N
feasible JJ N
to TO N
achieve VB N
significant JJ N
use NN N
of IN N
conventional JJ N
toothbrushes NNS N
and CC N
toothpastes NNS N
, , N
with IN N
consequent JJ N
major JJ N
and CC N
sustained JJ N
improvements NNS N
in IN N
plaque NN N
control NN N
and CC N
gingival JJ N
health NN N
in IN N
a DT N
disadvantaged JJ N
population NN N
hitherto NN N
often RB N
considered VBN N
as IN N
not RB N
amenable JJ N
to TO N
conventional JJ N
oral JJ N
hygiene NN N
for IN N
cultural JJ N
or CC N
economic JJ N
reasons NNS N
. . N

-DOCSTART- -18330493- O O

Allopurinol NNP i
improves VBZ N
endothelial JJ N
function NN N
and CC N
reduces VBZ N
oxidant-inflammatory JJ N
enzyme NN N
of IN N
myeloperoxidase NN N
in IN N
metabolic JJ p
syndrome NN p
. . p

OBJECTIVE NN N
In IN N
this DT N
study NN N
, , N
we PRP N
tested VBD N
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome VBP p
whether IN N
allopurinol NNS N
through IN N
decreasing VBG N
oxidative JJ N
stress NN N
improves VBZ N
endothelial JJ N
function NN N
, , N
and CC N
ameliorates VBZ N
inflammatory JJ N
state NN N
represented VBN N
by IN N
markers NNS N
of IN N
myeloperoxidase NN N
, , N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
and CC N
fibrinogen NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
fashion NN N
; : N
subjects NNS p
with IN p
metabolic JJ p
syndrome NN p
were VBD p
treated VBN p
with IN p
allopurinol NN i
( ( p
n JJ p
= NNP p
28 CD p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= NNP p
22 CD p
) ) p
for IN p
one CD p
month NN p
. . p

Before IN N
and CC N
after IN N
treatment NN N
, , N
blood NN i
samples NNS i
were VBD N
collected VBN N
and CC N
the DT N
flow-mediated JJ o
dilation NN o
( ( o
FMD NNP o
) ) o
and CC N
isosorbide JJ o
dinitrate NN o
( ( o
ISDN NNP o
) ) o
-mediated VBD o
dilation NN o
of IN N
the DT N
brachial JJ N
artery NN N
were VBD N
performed VBN N
. . N

RESULTS NNP N
Baseline NNP N
clinical JJ N
characteristics NNS N
of IN N
the DT N
allopurinol NN i
and CC N
placebo NN i
groups NNS N
demonstrated VBD N
no DT N
differences NNS N
in IN N
terms NNS N
of IN N
clinical JJ o
characteristics NNS o
, , o
endothelial JJ o
function NN o
and CC N
inflammatory JJ o
markers NNS o
. . o

After IN N
the DT N
treatment NN N
with IN N
allopurinol NN N
, , N
FMD NNP o
was VBD N
increased VBN N
from IN N
8.0 CD N
+/- JJ N
0.5 CD N
% NN N
to TO N
11.8 CD N
+/- JJ N
0.6 CD N
% NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
there EX N
were VBD N
no DT N
change NN N
in IN N
the DT N
placebo NN N
group NN N
. . N

In IN N
both DT N
groups NNS N
, , N
ISDN-mediated JJ o
dilation NN o
is VBZ N
unaffected VBN N
by IN N
the DT N
treatment NN N
. . N

As IN N
a DT N
marker NN N
of IN N
oxidative JJ N
stress NN N
, , N
allopurinol VBP N
significantly RB N
reduced VBN o
malondialdehyde NN o
. . o

Moreover RB N
, , N
myeloperoxidase NN o
levels NNS o
were VBD N
reduced VBN N
by IN N
the DT N
treatment NN N
with IN N
allopurinol NN N
( ( N
56.1 CD N
+/- JJ N
3.4 CD N
ng/ml JJ N
vs. FW N
44.4 CD N
+/- JJ N
2.4 CD N
ng/ml NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
but CC N
there EX N
were VBD N
no DT N
change NN N
in IN N
the DT N
placebo NN N
group NN N
. . N

Surprisingly RB N
, , N
neither DT N
CRP NNP o
nor CC o
fibrinogen NN o
levels NNS o
were VBD N
affected VBN N
by IN N
the DT N
treatment NN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Xanthine NNP N
oxidoreductase NN N
inhibition NN N
by IN N
allopurinol NN N
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome NN p
reduces NNS N
oxidative JJ o
stress NN o
, , o
improves VBZ o
endothelial JJ o
function NN o
, , o
ameliorates VBZ o
myeloperoxidase NN o
levels NNS o
and CC N
does VBZ N
not RB N
have VB N
any DT N
effect NN N
on IN N
CRP NNP N
and CC N
fibrinogen NN N
levels NNS N
. . N

-DOCSTART- -6428372- O O

Cognitive JJ N
effects NNS N
of IN N
lithium NN i
carbonate NN i
and CC i
haloperidol NN i
in IN N
treatment-resistant JJ p
aggressive JJ p
children NNS p
. . p

The DT N
effects NNS N
of IN N
lithium NN i
carbonate NN i
and CC i
haloperidol NN i
on IN N
cognition NN N
were VBD N
examined VBN N
in IN N
a DT N
placebo-controlled JJ i
, , N
double-blind JJ N
study NN N
of IN N
61 CD p
treatment-resistant JJ p
, , p
hospitalized VBN p
school-aged JJ p
children NNS p
. . p

They PRP N
all DT N
had VBD N
a DT N
DSM-III JJ N
diagnosis NN N
of IN N
conduct NN N
disorder NN N
-- : N
undersocialized JJ p
, , p
aggressive JJ p
, , p
with IN p
a DT p
profile NN p
of IN p
highly RB p
explosive JJ p
and CC p
aggressive JJ p
behavior NN p
. . p

Children NNP p
were VBD p
assessed VBN p
at IN p
the DT p
end NN p
of IN p
a DT p
two-week JJ p
placebo-baseline JJ i
period NN p
and CC p
again RB p
after IN p
four CD p
weeks NNS p
of IN p
treatment NN p
. . p

Drug NNP N
effects NNS N
on IN N
cognition NN N
were VBD N
mild JJ N
. . N

Haloperidol NNP i
( ( N
mean JJ N
dose NN N
, , N
2.95 CD N
mg/day NN N
) ) N
caused VBD N
significant JJ N
decreases NNS N
in IN N
Porteus NNP o
Maze NNP o
test NN o
quotient NN o
scores NNS o
and CC N
a DT N
slowing NN o
of IN o
reaction NN o
time NN o
( ( o
RT NNP o
) ) o
on IN N
a DT N
simple JJ N
RT NNP N
task NN N
. . N

Lithium JJ i
carbonate NN i
( ( N
mean JJ N
dose NN N
, , N
1,166 CD N
mg/day NN N
) ) N
adversely RB N
affected JJ N
qualitative JJ o
scores NNS o
on IN o
the DT o
Porteus NNP o
Maze NNP o
test NN o
. . o

No DT N
significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
the DT N
Matching NNP o
Familiar NNP o
Figures NNP o
Test NNP o
, , o
short-term JJ o
recognition NN o
memory NN o
and CC o
concept NN o
attainment NN o
tasks NNS o
, , o
or CC o
the DT o
Stroop NNP o
Test NNP o
. . o

-DOCSTART- -18166533- O O

Impact NN N
of IN N
a DT N
16-community JJ p
trial NN p
to TO p
promote VB p
judicious JJ p
antibiotic JJ p
use NN p
in IN p
Massachusetts NNP p
. . p

OBJECTIVES NNP N
Reducing VBG N
unnecessary JJ N
antibiotic JJ N
use NN N
, , N
particularly RB N
among IN N
children NNS N
, , N
continues VBZ N
to TO N
be VB N
a DT N
public JJ N
health NN N
priority NN N
. . N

Previous JJ N
intervention NN N
studies NNS N
have VBP N
been VBN N
limited VBN N
by IN N
size NN N
or CC N
design NN N
and CC N
have VBP N
shown VBN N
mixed JJ N
results NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
a DT N
multifaceted VBN i
, , i
community-wide JJ i
intervention NN i
on IN i
overall JJ i
antibiotic JJ i
use NN i
for IN N
young JJ p
children NNS p
and CC N
on IN N
use NN N
of IN N
broad-spectrum JJ N
agents NNS N
. . N

In IN N
addition NN N
, , N
we PRP N
sought VBD N
to TO N
compare VB N
the DT N
intervention NN N
's POS N
impact NN N
on IN N
commercially RB p
and CC p
Medicaid-insured JJ p
children NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
community-level JJ p
, , p
cluster-randomized JJ p
trial NN p
in IN p
16 CD p
nonoverlapping VBG p
Massachusetts NNP p
communities NNS p
, , p
studied VBN p
from IN p
1998 CD p
to TO p
2003 CD p
. . p

During IN N
3 CD N
years NNS N
, , N
we PRP N
implemented VBD N
a DT N
physician JJ i
behavior-change NN i
strategy NN i
that WDT i
included VBD i
guideline JJ i
dissemination NN i
, , i
small-group JJ i
education NN i
, , i
frequent JJ i
updates NNS i
and CC i
educational JJ i
materials NNS i
, , i
and CC i
prescribing VBG i
feedback NN i
. . i

Parents NNS i
received VBD i
educational JJ i
materials NNS i
by IN i
mail NN i
and CC i
in IN i
primary JJ i
care NN i
practices NNS i
, , i
pharmacies NNS i
, , i
and CC i
child NN i
care NN i
settings NNS i
. . i

Using VBG N
health-plan JJ i
data NNS i
, , N
we PRP N
measured VBD N
changes NNS N
in IN N
antibiotics NNS N
dispensed VBN N
per IN N
person-year NN N
of IN N
observation NN N
among IN N
children NNS p
who WP p
were VBD p
aged VBN p
3 CD p
to TO p
< VB p
72 CD p
months NNS p
, , p
resided VBN p
in IN p
study NN p
communities NNS p
, , p
and CC p
were VBD p
insured VBN p
by IN p
a DT p
participating VBG p
commercial JJ p
health NN p
plan NN p
or CC p
Medicaid NNP p
. . p

RESULTS VB N
The DT N
data NNS N
include VBP N
223,135 CD p
person-years NNS p
of IN p
observation NN p
. . p

Antibiotic-use JJ o
rates NNS o
at IN N
baseline NN N
were VBD N
2.8 CD N
, , N
1.7 CD N
, , N
and CC N
1.4 CD N
antibiotics NNS N
per IN N
person-year NN N
among IN N
those DT N
aged VBN N
3 CD N
to TO N
< VB N
24 CD N
, , N
24 CD N
to TO N
< VB N
48 CD N
, , N
and CC N
48 CD N
to TO N
< VB N
72 CD N
months NNS N
, , N
respectively RB N
. . N

We PRP N
observed VBD N
a DT N
substantial JJ N
downward JJ N
trend NN N
in IN N
antibiotic JJ o
prescribing NN o
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
intervention NN N
. . N

The DT N
intervention NN N
had VBD N
no DT N
additional JJ N
effect NN N
among IN N
children NNS N
aged VBD N
3 CD N
to TO N
< VB N
24 CD N
months NNS N
but CC N
was VBD N
responsible JJ N
for IN N
a DT N
4.2 CD N
% NN N
decrease NN N
among IN N
those DT N
aged VBN N
24 CD N
to TO N
< VB N
48 CD N
months NNS N
and CC N
a DT N
6.7 CD N
% NN N
decrease NN N
among IN N
those DT N
aged VBN N
48 CD N
to TO N
< VB N
72 CD N
months NNS N
. . N

The DT N
intervention NN N
effect NN N
was VBD N
greater JJR N
among IN N
Medicaid-insured JJ N
children NNS N
and CC N
for IN N
broad-spectrum JJ N
agents NNS N
. . N

CONCLUSIONS VB N
A DT N
sustained JJ N
, , N
multifaceted VBN N
, , N
community-level JJ N
intervention NN N
was VBD N
only RB N
modestly RB N
successful JJ N
at IN N
decreasing VBG N
overall JJ o
antibiotic JJ o
use NN o
beyond IN N
substantial JJ N
secular JJ N
trends NNS N
. . N

The DT N
more RBR N
robust JJ N
impact NN N
among IN N
Medicaid-insured JJ p
children NNS p
and CC N
for IN N
specific JJ N
medication NN N
classes NNS N
provides VBZ N
an DT N
argument NN N
for IN N
specific JJ N
targeting NN N
of IN N
resources NNS N
for IN N
patient NN N
and CC N
physician JJ N
behavior NN N
change NN N
. . N

-DOCSTART- -19702485- O O

Randomized VBN N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
of IN N
methylphenidate NN i
for IN N
attention-deficit/hyperactivity NN N
disorder NN N
symptoms NNS N
in IN p
preschoolers NNS p
with IN p
developmental JJ p
disorders NNS p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
efficacy NN o
and CC N
safety NN N
of IN N
methylphenidate NN i
( ( i
MPH NNP i
) ) i
to TO N
treat VB N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
symptoms NNS N
in IN N
an DT N
understudied JJ p
population NN p
of IN p
preschoolers NNS p
with IN p
pervasive JJ p
developmental JJ p
disorder NN p
( ( p
PDD NNP p
) ) p
or CC p
intellectual JJ p
disability NN p
( ( p
ID NNP p
) ) p
. . p

METHODS NNP N
Fourteen NNP p
preschoolers NNS p
with IN p
developmental JJ p
disorders NNS p
( ( p
DD NNP p
, , p
n JJ p
= VBP p
14 CD p
; : p
PDD NNP p
, , p
n JJ p
= VBP p
12 CD p
; : p
ID NNP p
, , p
n JJ p
= NNP p
2 CD p
) ) p
underwent NN N
MPH NNP i
titration NN i
in IN N
a DT N
single-blind JJ N
manner NN N
followed VBN N
by IN N
a DT N
4-week JJ N
double-blind NN N
crossover NN N
phase NN N
. . N

Each DT N
child NN N
was VBD N
administered VBN N
placebo NN i
for IN N
2 CD N
weeks NNS N
and CC N
optimal JJ i
dose NN i
for IN N
2 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Diagnostic NNP o
and CC o
Statistical NNP o
Manual NNP o
of IN o
Mental NNP o
Disorders NNP o
, , o
4 CD o
( ( o
th NN o
) ) o
edition NN o
( ( o
DSM-IV NNP o
) ) o
ADHD NNP o
subscale NN o
of IN o
the DT o
Conners NNP o
' POS o
Parent NN o
Rating VBG o
Scale-Revised JJ o
( ( N
CPRS-R-DSM-IV-ADHD NNP N
) ) N
. . N

RESULTS NNP N
MPH NNP i
improved VBD N
parent-rated JJ o
ADHD NNP o
symptoms NNS o
of IN N
the DT N
preschoolers NNS N
; : N
50 CD N
% NN N
were VBD N
rated VBN N
as IN N
responders NNS N
. . N

The DT N
CPRS-R-DSM-IV-ADHD JJ o
subscale NN o
was VBD N
significant JJ N
for IN N
the DT N
PDD NNP p
subgroup NN p
( ( N
p JJ N
= NN N
0.005 CD N
, , N
Cohen NNP N
d VBZ N
= NNP N
0.97 CD N
) ) N
and CC N
marginally RB N
significant JJ N
for IN N
the DT N
entire JJ N
DD NNP N
sample NN N
( ( N
p JJ N
= NN N
0.08 CD N
, , N
Cohen NNP N
d VBZ N
= NNP N
0.50 CD N
) ) N
. . N

Half NN N
of IN N
the DT N
preschoolers NNS p
experienced VBD N
side JJ o
effects NNS o
with IN N
MPH NNP i
, , N
including VBG N
reports NNS N
of IN N
increased VBN N
stereotypic NN o
behavior NN o
, , o
upset JJ o
stomach NN o
, , o
sleep-related JJ o
difficulties NNS o
, , o
and CC o
emotional JJ o
lability NN o
. . o

One CD N
child NN N
discontinued VBN N
during IN N
titration NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

CONCLUSION VB N
The DT N
predominant JJ N
direction NN N
of IN N
response NN N
in IN N
these DT N
preschoolers NNS p
with IN p
both DT p
ADHD NNP p
and CC p
PDD/ID NNP p
favored VBD N
MPH NNP i
, , N
even RB N
though IN N
the DT N
response NN N
was VBD N
more RBR N
subtle JJ N
and CC N
variable JJ N
than IN N
in IN N
older JJR N
and CC N
typically RB N
developing VBG N
children NNS N
. . N

Due NNP N
to TO N
high JJ N
rates NNS N
of IN N
adverse JJ N
effects NNS N
, , N
preschoolers NNS N
should MD N
be VB N
monitored VBN N
closely RB N
. . N

-DOCSTART- -12422941- O O

An DT N
exploratory NN N
study NN N
: : N
the DT N
use NN N
of IN N
paroxetine NN i
for IN N
methamphetamine NN o
craving NN o
. . o

Methamphetamine NNP i
abuse NN N
and CC N
dependence NN N
are VBP N
growing VBG N
problems NNS N
nationally RB N
and CC N
worldwide RB N
. . N

There EX N
are VBP N
currently RB N
no DT N
effective JJ N
pharmocologic NN N
treatments NNS N
. . N

Animal NNP N
studies NNS N
with IN N
SSRI NNP N
's POS N
suggest JJS N
that IN N
serotonergic JJ N
modulation NN N
alters NNS N
methamphetamine VBP i
's POS i
behavioral JJ o
effects NNS o
. . o

This DT N
exploratory NN N
study NN N
is VBZ N
a DT N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
the DT N
SSRI NNP i
paroxetine NN i
versus NN i
placebo NN i
( ( N
in IN N
a DT N
double JJ N
blind NN N
design NN N
) ) N
on IN N
craving NN N
and CC N
use NN N
in IN N
a DT N
population NN p
of IN p
methamphetamine NN i
users NNS p
. . p

Many JJ N
subjects NNS N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
, , N
but CC N
those DT N
in IN N
active JJ N
treatment NN N
who WP N
completed VBD N
the DT N
eight CD N
week NN N
trial NN N
had VBD N
a DT N
decrease NN N
in IN N
methamphetamine NN o
craving NN o
compared VBN N
to TO N
the DT N
placebo NN N
treatment NN N
as IN N
measured VBN N
by IN N
the DT N
OCDS NNP N
modified VBD N
for IN N
use NN N
in IN N
this DT N
population NN N
. . N

Statistical JJ N
analyses NNS N
were VBD N
not RB N
performed VBN N
due JJ N
to TO N
the DT N
low JJ N
number NN N
of IN N
subjects NNS N
. . N

The DT N
preliminary JJ N
data NNS N
suggest VBP N
that IN N
serotonergic JJ N
agents NNS N
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
effective JJ N
treatment NN N
of IN N
methamphetamine NN o
abuse NN o
and CC o
dependence NN o
within IN N
the DT N
context NN N
of IN N
other JJ N
effective JJ N
behavioral JJ N
interventions NNS N
. . N

-DOCSTART- -12653872- O O

Multiple NNP i
risk NN i
factor NN i
intervention NN i
reduces VBZ N
cardiovascular JJ N
risk NN N
in IN N
hypertensive JJ p
patients NNS p
with IN p
echolucent JJ p
plaques NNS p
in IN p
the DT p
carotid NN p
artery NN p
. . p

OBJECTIVE NNP N
In IN N
a DT N
previously RB N
published VBN N
randomized VBN N
6-year JJ N
study NN N
we PRP N
observed VBD N
that IN N
multiple JJ i
risk NN i
factor NN i
intervention NN i
reduced VBD N
cardiovascular JJ N
risk NN N
in IN N
high-risk JJ p
hypertensive JJ p
men NNS p
, , N
and CC N
that IN N
this DT N
effect NN N
was VBD N
confined VBN N
to TO N
patients NNS p
with IN p
carotid JJ p
artery NN p
plaques NNS p
. . p

Hypothetically RB N
, , N
the DT N
underlying VBG N
mechanism NN N
might MD N
have VB N
been VBN N
a DT N
stabilization NN N
of IN N
echolucent NN N
, , N
instable JJ N
, , N
rupture-prone JJ N
plaques NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
plaque NN o
characteristics NNS o
by IN N
B-mode NNP i
ultrasound NN i
in IN N
the DT N
previous JJ N
intervention NN N
study NN N
, , N
and CC N
also RB N
to TO N
investigate VB N
the DT N
relationship NN N
between IN N
plaque NN o
characteristics NNS o
at IN N
baseline NN N
and CC N
cardiovascular JJ o
events NNS o
during IN N
the DT N
6-year JJ N
follow-up NN N
in IN N
the DT N
two CD N
randomization NN N
groups NNS N
. . N

METHODS NNP N
High NNP i
resolution NN i
B-mode NNP i
ultrasound NN i
was VBD N
used VBN N
to TO N
characterize VB o
plaque JJ o
echogenicity NN o
in IN N
four CD N
subgroups NNS N
- : N
dominantly RB N
echolucent NN N
, , N
substantially RB N
echolucent JJ N
, , N
dominantly RB N
echogenic JJ N
, , N
and CC N
uniformly RB N
echogenic JJ N
. . N

RESULTS NNP N
In IN N
the DT N
usual JJ i
care NN i
group NN i
17 CD p
of IN p
32 CD p
( ( p
53 CD p
% NN p
) ) p
patients NNS p
with IN p
echolucent JJ o
plaques NNS o
at IN p
baseline NN p
suffered VBN N
from IN N
a DT N
combined VBN N
end-point NN N
( ( N
any DT N
death NN o
or CC o
nonfatal JJ o
myocardial JJ o
infarction NN o
or CC o
nonfatal JJ o
stroke NN o
) ) o
during IN N
follow-up JJ N
compared VBN N
with IN N
seven CD N
of IN N
28 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
intervention NN i
group NN i
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

The DT N
corresponding JJ o
numbers NNS o
in IN N
patients NNS N
with IN N
echogenic JJ o
plaques NNS o
were VBD N
n JJ N
= JJ N
4/13 CD N
( ( N
31 CD N
% NN N
) ) N
and CC N
n JJ N
= NN N
4/17 CD N
( ( N
24 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
NS NNP N
) ) N
. . N

In IN N
the DT N
usual JJ i
care NN i
group NN i
11 CD N
of IN N
33 CD N
( ( N
33 CD N
% NN N
) ) N
patients NNS N
with IN N
no DT N
plaques NNS N
suffered VBD N
from IN N
a DT N
combined JJ N
end-point NN N
during IN N
follow-up JJ N
compared VBN N
with IN N
11 CD N
of IN N
30 CD N
( ( N
37 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN i
group NN i
. . i

CONCLUSION NNP N
Our PRP$ N
data NNS N
indicate VBP N
that IN N
the DT N
beneficial JJ o
effect NN o
of IN N
the DT N
multiple NN i
risk NN i
intervention NN i
programme NN i
was VBD N
confined VBN N
to TO N
those DT N
patients NNS N
with IN N
echolucent JJ N
plaques NNS N
. . N

The DT N
data NNS N
have VBP N
to TO N
be VB N
confirmed VBN N
with IN N
a DT N
large-scale JJ N
trial NN N
. . N

-DOCSTART- -1715416- O O

[ VB N
A DT N
randomized JJ N
trial NN N
of IN N
PVB NNP i
, , i
VAB-6 NNP i
, , i
BVP NNP i
regimen VBP i
versus NN i
PEB NNP i
chemotherapy NN i
in IN N
patients NNS p
with IN p
disseminated JJ p
testicular JJ p
tumors NNS p
] VBP p
. . N

During IN N
2 CD N
years NNS N
and CC N
7 CD N
months NNS N
from IN N
June NNP N
, , N
1985 CD N
to TO N
December NNP N
, , N
1987 CD N
, , N
a DT N
randomized JJ N
multi-center JJ N
trial NN N
of IN N
PVB NNP i
, , i
VAB-6 NNP i
, , i
BVP NNP i
regimen NNS i
( ( N
group NN N
A DT N
) ) N
without IN i
etoposide JJ i
versus NN i
PEB NNP i
chemotherapy NN i
( ( i
bleomycin NN i
, , i
etoposide RB i
and CC i
cisplatinum NN i
) ) i
( ( N
group NN N
B NNP N
) ) N
was VBD N
given VBN N
to TO N
patients NNS p
with IN p
disseminated JJ p
testicular JJ p
tumors NNS p
. . p

Of IN p
34 CD p
patients NNS p
registered VBD p
, , p
10 CD p
patients NNS p
were VBD p
with IN p
minimal JJ p
disease NN p
in IN p
stages NNS p
IIA NNP p
, , p
IIIO NNP p
and CC p
IIIA NNP p
and CC p
24 CD p
with IN p
extensive JJ p
disease NN p
in IN p
IIB NNP p
, , p
IIIB2 NNP p
and CC p
IIIC NNP p
. . p

Seminomas NNP p
were VBD p
found VBN p
in IN p
10 CD p
patients NNS p
, , p
while IN p
non-seminomatous JJ p
tumors NNS p
in IN p
24 CD p
. . p

Among IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
clinicopathological JJ N
profiles NNS N
. . N

A DT N
group NN N
patients NNS N
were VBD N
given VBN N
either RB N
PVB NNP N
, , N
VAB-6 NNP N
or CC N
BVP NNP N
according VBG N
to TO N
the DT N
physician NN N
's POS N
discretion NN N
. . N

In IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
35 CD N
% NN N
and CC N
43 CD N
% NN N
of IN N
the DT N
patients NNS N
achieved VBD N
complete JJ o
response NN o
, , N
and CC N
45 CD N
% NN N
and CC N
50 CD N
% NN N
achieved VBN N
partial JJ o
response NN o
, , N
respectively RB N
. . N

The DT N
difference NN N
in IN N
CR NNP o
rates NNS o
among IN N
both DT N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
even RB N
when WRB N
calculated VBN N
according VBG N
to TO N
the DT N
stage NN N
or CC N
histologic JJ N
grouping NN N
. . N

Salvage NN N
treatments NNS N
mainly RB N
with IN N
surgical JJ N
resection NN N
of IN N
residual JJ N
tumors NNS N
after IN N
the DT N
chemotherapy NN N
, , N
however RB N
, , N
were VBD N
more RBR N
successful JJ N
in IN N
group NN N
B NNP N
( ( N
88 CD N
% NN N
) ) N
than IN N
group NN N
A NNP N
( ( N
61 CD N
% NN N
) ) N
. . N

It PRP N
appears VBZ N
likely JJ N
that IN N
the DT N
higher JJR N
response NN N
of IN N
induction NN N
chemotherapy NN i
in IN N
patients NNS N
with IN N
extensive JJ N
disease NN N
made VBD N
the DT N
salvage NN N
surgery NN i
more RBR N
successful JJ N
in IN N
group NN N
B NNP N
than IN N
in IN N
group NN N
A NNP N
. . N

The DT N
3 CD o
year NN o
survival NN o
rate NN o
was VBD N
100 CD N
% NN N
in IN N
group NN N
B NNP N
, , N
whereas IN N
it PRP N
was VBD N
76 CD N
% NN N
in IN N
group NN N
A NNP N
. . N

Although IN N
the DT N
incidence NN o
of IN o
myelosuppression NN o
and CC o
alopecia NN o
was VBD N
significantly RB N
higher JJR N
in IN N
group NN N
B NNP N
, , N
neuropathy NN o
was VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
group NN N
A NNP N
. . N

From IN N
the DT N
above JJ N
results NNS N
, , N
PEB NNP N
seems VBZ N
to TO N
be VB N
a DT N
better JJR N
induction NN N
chemotherapy NN N
than IN N
the DT N
conventional JJ N
one NN N
for IN N
advanced JJ N
testicular JJ N
tumors NNS N
. . N

-DOCSTART- -3516395- O O

Randomized VBN N
trial NN N
of IN N
high-dose JJ N
cytarabine NN i
versus NN i
amsacrine NN i
in IN N
acute JJ p
myelogenous JJ p
leukemia NN p
in IN p
relapse NN p
: : p
a DT p
Leukemia NNP p
Intergroup NNP p
Study NNP p
. . p

Patients NNS p
with IN p
acute JJ p
myelogenous JJ p
leukemia NN p
in IN p
relapse NN p
who WP p
were VBD p
ineligible JJ p
for IN p
further JJ p
anthracycline NN i
therapy NN i
either CC p
because IN p
they PRP p
were VBD p
judged VBN p
to TO p
be VB p
anthracycline JJ i
resistant NN p
or CC p
had VBD p
received VBN p
the DT p
maximum JJ p
doses NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
high-dose JJ N
cytarabine NN i
( ( N
3 CD N
g/m2 NN N
every DT N
12 CD N
hours NNS N
for IN N
6 CD N
days NNS N
) ) N
or CC N
amsacrine NN i
( ( N
75 CD N
mg/m2 NNS N
daily RB N
for IN N
7 CD N
days NNS N
) ) N
. . N

The DT N
response NN o
rates NNS o
in IN o
both DT N
groups NNS N
were VBD N
similar JJ N
: : N
three CD p
of IN p
25 CD p
patients NNS p
given VBN p
high-dose JJ p
cytarabine NN i
and CC p
three CD p
of IN p
23 CD p
given VBN p
amsacrine NN i
obtained VBN N
complete JJ o
remissions NNS o
. . o

-DOCSTART- -17082978- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
cognitive JJ i
behavioural JJ i
intervention NN i
for IN N
anger JJ N
management NN N
in IN N
children NNS p
diagnosed VBN p
with IN p
Asperger NNP p
syndrome NN p
. . p

The DT N
purpose NN N
of IN N
the DT N
study NN N
described VBD N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive JJ N
behavioural JJ N
intervention NN N
for IN N
anger JJ N
management NN N
with IN N
children NNS p
diagnosed VBN p
with IN p
Asperger NNP p
syndrome NN p
. . p

Forty-five JJ p
children NNS p
and CC p
their PRP$ p
parents NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
intervention NN i
or CC N
wait-list JJ i
control NN i
conditions NNS i
. . i

Children NNP N
in IN N
the DT N
intervention NN N
participated VBD N
in IN N
six CD i
2-h JJ i
weekly JJ i
sessions NNS i
while IN N
parents NNS N
participated VBN N
in IN N
a DT N
larger JJR N
parent NN N
group NN N
. . N

Parent NN N
reports NNS N
indicated VBD N
a DT N
significant JJ N
decrease NN N
in IN N
episodes NNS o
of IN o
anger NN o
following VBG N
intervention NN N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
their PRP$ N
own JJ N
confidence NN o
in IN N
managing VBG o
anger NN o
in IN o
their PRP$ o
child NN o
. . o

Qualitative JJ N
information NN N
gathered VBN N
from IN N
parents NNS N
and CC N
teachers NNS N
indicated VBD N
some DT N
generalization NN N
of IN N
strategies NNS N
learned VBN N
in IN N
the DT N
clinic JJ N
setting NN N
to TO N
both DT N
home NN N
and CC N
school NN N
settings NNS N
. . N

Limitations NNS N
of IN N
the DT N
study NN N
and CC N
suggestions NNS N
for IN N
future JJ N
research NN N
are VBP N
also RB N
discussed VBN N
. . N

-DOCSTART- -18794865- O O

A DT N
randomized JJ N
trial NN N
of IN N
etoposide NN N
and CC N
G-CSF NNP N
with IN N
or CC N
without IN N
rituximab NN i
for IN N
PBSC NNP N
mobilization NN N
in IN N
B-cell NNP p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

Some DT N
reports NNS N
have VBP N
suggested VBN N
that IN N
rituximab JJ N
administration NN N
before IN N
PBSC NNP N
mobilization NN N
may MD N
adversely RB N
affect VB N
PBSC NNP N
yield NN N
. . N

We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
PBSC NNP N
mobilization NN N
using VBG N
etoposide JJ i
and CC i
G-CSF JJ i
with IN i
or CC i
without IN i
rituximab NN i
to TO N
determine VB N
whether IN N
its PRP$ N
addition NN N
would MD N
adversely RB N
affect VB N
CD34+ NNP o
cell NN o
yield NN o
in IN N
patients NNS p
with IN p
non-Hodgkin JJ p
's POS p
lymphoma NN p
. . p

Twenty NNP p
seven CD p
patients NNS p
were VBD p
mobilized VBN p
with IN N
etoposide JJ i
and CC N
G-CSF NNP N
and CC N
28 CD N
with IN N
etoposide NN i
, , i
G-CSF NNP i
and CC i
rituximab NN i
. . i

There EX N
were VBD N
no DT N
adverse JJ N
consequences NNS N
of IN N
rituximab NN N
on IN N
CD34+ NNP o
cell NN o
yield NN o
, , o
or CC o
hematopoietic JJ o
recovery NN o
or CC o
immunoglobulin NN o
levels NNS o
after IN N
transplantation NN N
. . N

-DOCSTART- -2895910- O O

Multicenter NNP N
trial NN N
of IN N
cryotherapy NN i
for IN N
retinopathy NN p
of IN p
prematurity NN p
: : p
preliminary JJ N
results NNS N
. . N

Cryotherapy NNP i
for IN N
Retinopathy NNP N
of IN N
Prematurity NNP N
Cooperative NNP N
Group NNP N
. . N

We PRP N
report VBP N
the DT N
preliminary JJ N
3-month JJ N
outcome NN N
of IN N
a DT N
multicenter NN N
randomized VBN N
trial NN N
of IN N
cryotherapy NN i
for IN i
treatment NN i
of IN i
retinopathy NN i
of IN i
prematurity NN i
( ( N
ROP NNP N
) ) N
. . N

Transscleral JJ i
cryotherapy NN i
to TO N
the DT N
avascular JJ N
retina NN N
was VBD N
applied VBN N
to TO N
one CD p
randomly NN p
selected VBN p
eye NN p
when WRB N
there EX N
was VBD N
threshold JJ N
disease NN N
( ( N
defined VBN N
as IN N
five CD N
or CC N
more JJR N
contiguous JJ N
or CC N
eight CD N
cumulative JJ N
30 CD N
degree JJ N
sectors NNS N
[ VBP N
clock NN N
hours NNS N
] CD N
of IN N
stage NN N
3 CD N
ROP NNP N
in IN N
zone CD N
1 CD N
or CC N
2 CD N
in IN N
the DT N
presence NN N
of IN N
plus JJ N
disease NN N
) ) N
. . N

An DT N
unfavorable JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
posterior JJ o
retinal JJ o
detachment NN o
, , o
retinal JJ o
fold NN o
involving VBG o
the DT o
macula NN o
, , o
or CC o
retrolental JJ o
tissue NN o
. . o

At IN N
this DT N
writing NN N
, , N
172 CD p
infants NNS p
had VBD p
been VBN p
examined VBN p
3 CD p
months NNS p
after IN p
randomization NN p
. . p

An DT N
unfavorable JJ o
outcome NN o
was VBD N
significantly RB N
less JJR N
frequent JJ N
in IN N
the DT N
eyes NNS N
undergoing VBG N
cryotherapy NN i
( ( N
21.8 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
untreated JJ N
eyes NNS N
( ( N
43 CD N
% NN N
) ) N
. . N

While IN N
the DT N
surgery NN N
was VBD N
stressful JJ N
, , N
no DT N
unexpected JJ o
complications NNS o
occurred VBD N
during IN N
or CC N
following VBG N
treatment NN N
. . N

These DT N
data NNS N
support NN N
the DT N
efficacy NN o
of IN N
cryotherapy NN i
in IN N
reducing VBG N
by IN N
approximately RB N
one CD N
half PDT N
the DT N
risk NN N
of IN N
unfavorable JJ N
retinal JJ N
outcome NN N
from IN N
threshold JJ N
ROP NNP N
. . N

-DOCSTART- -21946197- O O

[ JJ N
Impact NNP N
of IN N
heparin NN i
on IN N
coagulation NN o
index NN o
during IN N
the DT N
therapy NN N
of IN N
molecular JJ N
adsorbent NN N
recirculating VBG N
system NN N
in IN N
patients NNS p
with IN p
liver JJ p
failure NN p
] NNP p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
coagulative JJ N
parameters NNS N
on IN N
different JJ o
anticoagulation NN o
systems NNS o
in IN N
molecular JJ N
adsorbent NN N
recirculating VBG N
system NN N
( ( N
MARS NNP N
) ) N
in IN N
subjects NNS p
with IN p
liver JJ p
failure NN p
, , N
and CC N
to TO N
evaluate VB N
the DT N
safety NN N
of IN N
different JJ N
anticoagulation NN o
methods NNS N
. . N

METHODS NNP N
A NNP N
prospective JJ N
experimental JJ N
observation NN N
was VBD N
designed VBN N
. . N

According VBG N
to TO N
anticoagulation NN N
Methods NNP N
, , N
174 CD p
MARS NNP i
treatment NN p
sessions NNS p
for IN p
146 CD p
patients NNS p
with IN p
liver JJ p
failure NN p
and CC p
prothrombin JJ p
time NN p
activity NN p
percentage NN p
( ( p
PTA NNP p
) ) p
? . p
40 CD p
% NN p
were VBD p
randomly RB p
divided VBN p
into IN p
2 CD p
groups NNS p
: : p
92 CD p
MARS NNP i
treatment NN i
sessions NNS i
in IN i
the DT i
heparin-free JJ i
group NN i
and CC i
82 CD p
in IN p
the DT i
low-dose JJ i
heparin NN i
group NN i
. . p

Time NNP N
points NNS N
of IN N
0 CD N
, , N
0.5 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
and CC N
6 CD N
h NNS N
were VBD N
selected VBN N
to TO N
observe VB N
the DT N
coagulation NN o
changes NNS o
of IN o
prothrombin NN o
time NN o
( ( o
PT NNP o
) ) o
, , o
PTA NNP o
, , o
thrombin JJ o
time NN o
( ( o
TT NNP o
) ) o
, , o
activated VBN o
partial JJ o
thromboplastin NN o
time NN o
( ( o
APTT NNP o
) ) o
and CC o
international JJ o
normalized VBN o
ratio NN o
( ( o
INR NNP o
) ) o
dynamically RB o
. . o

Adverse JJ N
events NNS N
such JJ N
as IN N
line NN o
/ VBP o
filter NN o
coagulation NN o
, , o
rupture NN o
and CC o
bleeding NN o
were VBD o
also RB N
investigated VBN N
and CC N
compared VBN N
due JJ N
to TO N
frequency NN N
and CC N
severity NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
PT NNP o
, , o
PTA NNP o
, , o
INR NNP o
between IN o
the DT N
2 CD N
groups NNS N
, , N
but CC N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
APTT NNP o
and CC o
TT NNP o
and CC o
fibrinogen NN o
( ( o
Fbg NNP o
) ) o
. . o

APTT NNP o
and CC o
TT NNP o
levels NNS o
in IN o
the DT i
low-dose JJ i
heparin NN i
group NN i
was VBD N
increased VBN N
rapidly RB N
after IN N
the DT N
first JJ N
given VBN N
dose NN N
of IN N
anticoagulant JJ i
heparin NN i
and CC i
reached VBD N
the DT N
peak NN N
within IN N
30 CD N
min.The NN N
levels NNS N
at IN N
each DT N
time NN N
point NN N
was VBD N
statistically RB N
different JJ N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

A DT N
significant JJ N
difference NN N
in IN N
the DT o
Fbg NNP o
level NN o
was VBD o
obtained VBN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
the DT i
low-dose JJ i
heparin NN i
group NN i
it PRP N
was VBD N
stabilized VBN N
and CC N
increased VBN N
slightly RB N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
. . N

While IN N
in IN N
the DT i
heparin-free JJ i
group NN i
it PRP N
was VBD N
decreased VBN N
gradually RB N
and CC N
reached VBD N
a DT N
ravine NN N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
. . N

A DT N
curve NN o
was VBD o
observed VBN o
after IN o
2.5 CD N
h NN N
treatment NN N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
P=0.001 NNP N
) ) N
. . N

There EX N
were VBD N
2 CD N
cases NNS N
of IN N
severe JJ o
bleeding NN o
after IN o
MARS NNP i
was VBD i
finished VBN N
in IN N
the DT N
heparin NN N
group NN N
, , N
and CC N
1 CD N
was VBD o
terminated VBN o
because IN o
of IN N
degree JJ o
III NNP o
clotting NN o
in IN o
the DT i
heparin-free JJ i
group NN i
. . N

CONCLUSION NNP N
Fibrinogen NNP N
should MD N
be VB N
adsorbed VBN N
while IN N
the DT N
blood NN N
touches VBZ N
the DT i
MARS NNP i
circuit NN i
path NN N
and CC N
anticoagulants NNS N
can MD N
prevent VB N
it PRP N
. . N

Comprehensive JJ N
analysis NN N
of IN N
blood NN o
platelet NN o
count NN o
( ( o
BPC NNP o
) ) o
, , o
fibrin JJ o
degradation NN o
products NNS o
( ( o
FDP NNP o
) ) o
, , o
D-dimer NNP o
and CC o
clinical JJ o
symptoms NNS o
is VBZ o
critical JJ N
and CC N
required VBN N
to TO N
determine VB N
the DT N
coagulation NN N
status NN N
to TO N
select VB N
an DT N
anticoagulation NN N
system NN N
before IN i
MARS NNP i
. . i

The DT N
use NN N
of IN N
low JJ i
dose JJ i
heparin NN i
in IN i
MARS NNP i
improves VBZ i
the DT o
disorder NN o
of IN o
hypercoagulable JJ o
state NN o
during IN o
the DT N
high JJ N
coaguation NN N
period NN N
, , N
while IN i
heparin-free JJ i
during IN i
low JJ N
coagulation NN N
period NN N
can MD N
effectively RB N
prevent VB N
the DT N
occurrence NN N
of IN N
bleeding NN N
and CC N
improve VB N
the DT N
mechanism NN N
of IN N
blood NN o
coagulation NN o
by IN o
reducing VBG N
heparin-like JJ N
substance NN N
in IN N
the DT N
blood NN N
. . N

-DOCSTART- -3430295- O O

Comparison NNP N
of IN N
ketoconazole NN i
and CC N
griseofulvin NN i
in IN N
the DT N
treatment NN N
of IN N
tinea NN p
pedis NN p
. . p

Twenty-nine JJ p
patients NNS p
with IN p
mycologically RB p
proven VBN p
tinea NN p
pedis NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
oral JJ N
treatment NN N
with IN N
either DT N
ketoconazole JJ i
200 CD i
mg JJ i
daily JJ i
or CC i
griseofulvin JJ i
1 CD i
g JJ i
daily RB N
for IN N
a DT N
period NN N
of IN N
up IN N
to TO N
8 CD N
weeks NNS N
. . N

Mycological JJ o
cure NN o
rate NN o
at IN N
4 CD N
weeks NNS N
was VBD N
33 CD N
% NN N
for IN N
ketoconazole NN i
and CC N
29 CD N
% NN N
for IN N
griseofulvin NN i
, , N
and CC N
at IN N
8 CD N
weeks NNS N
was VBD N
53 CD N
% NN N
and CC N
57 CD N
% NN N
respectively RB N
. . N

The DT N
efficacy NN o
of IN N
both DT N
drugs NNS N
in IN N
the DT N
treatment NN N
of IN N
interdigital JJ N
tinea NN N
pedis NN N
is VBZ N
similar JJ N
, , N
and CC N
is VBZ N
considerably RB N
lower JJR N
than IN N
that DT N
found VBD N
with IN N
topical JJ N
imidazole NN N
preparations NNS N
where WRB N
cure NN o
rates NNS o
of IN N
over IN N
70 CD N
% NN N
are VBP N
generally RB N
expected VBN N
. . N

-DOCSTART- -7557852- O O

Antipyrine NNP o
clearance NN o
and CC o
response NN o
to TO o
interferon VB o
treatment NN o
in IN N
patients NNS p
with IN p
chronic JJ p
active JJ p
hepatitis NN p
C. NNP p
To TO N
determine VB N
whether IN N
hepatic JJ N
metabolic JJ N
function NN N
affects VBZ N
the DT N
response NN o
to TO o
interferon VB o
treatment NN o
, , N
we PRP N
measured VBD N
antipyrine JJ o
clearance NN o
( ( o
APC NNP o
) ) o
in IN N
85 CD p
patients NNS p
with IN p
chronic JJ p
active JJ p
hepatitis NN p
C NNP p
and CC N
compared VBN N
the DT N
results NNS N
with IN N
treatment NN o
outcome NN o
. . o

Among IN N
55 CD p
patients NNS p
who WP p
responded VBD p
to TO p
interferon VB i
by IN p
normalization NN p
of IN p
alanine JJ p
transaminase NN p
( ( p
ALT NNP p
) ) p
, , p
median JJ p
APC NNP p
before IN p
treatment NN p
was VBD p
0.47 CD p
( ( p
range NN p
, , p
0.12 CD p
to TO p
0.98 CD p
; : p
normal JJ p
range NN p
, , p
0.34 CD p
to TO p
1.02 CD p
mL/min/kg NNS p
body NN p
wt NN p
) ) p
, , p
a DT p
value NN p
that WDT p
was VBD p
significantly RB p
greater JJR p
than IN p
in IN p
30 CD p
nonresponders NNS p
( ( p
0.23 CD p
; : p
0.08 CD p
to TO p
0.67 CD p
mL/min/kg NNS p
body NN p
wt NN p
, , p
P NNP p
< NNP p
.001 NNP p
) ) p
. . N

APC NNP N
was VBD N
closely RB N
associated VBN N
with IN N
response NN o
to TO o
interferon VB o
. . o

The DT N
response NN o
rate NN o
among IN N
cases NNS N
with IN N
values NNS N
> VBP N
0.25 CD N
mL/min/kg NN N
body NN N
weight NN N
was VBD N
79 CD N
% NN N
, , N
the DT N
same JJ N
as IN N
in IN N
cases NNS N
without IN N
cirrhosis NN N
. . N

Cases NNS N
without IN N
cirrhosis NN N
and CC N
with IN N
APC NNP N
of IN N
> NNP N
0.25 CD N
mL/min/kg NN N
body NN N
weight NN N
had VBD N
an DT N
85 CD N
% NN N
chance NN N
of IN N
responding VBG o
to TO o
interferon VB o
; : o
this DT N
was VBD N
unlikely JJ N
a DT N
simple JJ N
reflection NN N
of IN N
histological JJ N
activity NN N
, , N
because IN N
the DT N
correlation NN N
with IN N
Scheuer NNP o
score NN o
was VBD N
poor JJ N
in IN N
this DT N
subgroup NN N
( ( N
r JJ N
= NNP N
-.31 NNP N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

A DT p
second JJ p
, , p
independent JJ p
group NN p
of IN p
43 CD p
patients NNS p
was VBD N
used VBN N
to TO N
test VB N
the DT N
predictive JJ o
value NN o
of IN o
APC NNP o
( ( N
using VBG N
0.25 CD N
mL/min/kg NN N
body NN N
wt VBD N
as IN N
a DT N
cut-off NN N
) ) N
for IN N
response NN N
to TO N
interferon VB i
treatment NN N
. . N

In IN N
this DT N
group NN N
, , N
APC NNP N
correctly RB N
predicted VBD N
positive JJ o
response NN o
to TO o
interferon VB o
in IN N
75 CD N
% NN N
of IN N
cases NNS N
. . N

APC NNP N
was VBD N
also RB N
used VBN N
to TO N
measure VB N
the DT N
effects NNS N
of IN N
treatment NN N
on IN N
hepatic JJ o
metabolic JJ o
function NN o
. . o

Regardless NNP N
of IN N
outcome NN N
, , N
there EX N
was VBD N
no DT N
change NN N
in IN N
APC NNP o
at IN N
the DT N
end NN N
of IN N
a DT N
6-month JJ N
course NN N
of IN N
interferon NN i
treatment NN N
. . N

Six CD N
months NNS N
later RB N
, , N
however RB N
, , N
improvement NN N
in IN N
APC NNP N
( ( N
14 CD N
% NN N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
was VBD N
evident JJ N
among IN N
responders NNS N
but CC N
not RB N
in IN N
those DT N
who WP N
had VBD N
failed VBN N
to TO N
respond VB N
to TO N
interferon VB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -2232625- O O

The DT N
influence NN N
of IN N
penbutolol NN i
and CC N
placebo NN i
on IN N
blood NN N
sugar NN N
levels NNS N
and CC N
insulin NN N
consumption NN N
in IN N
the DT N
glucose-controlled JJ N
insulin NN N
infusion NN N
system NN N
( ( N
artificial JJ N
endocrine NN N
pancreas NNS N
) ) N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
40 CD N
mg NN N
of IN N
the DT N
beta-blocker NN N
penbutolol NN i
( ( N
Betapressin NNP N
TM NNP N
; : N
Hoechst NNP N
Ltd. NNP N
, , N
Frankfurt/Main NNP N
) ) N
in IN N
comparison NN N
to TO N
placebo VB i
on IN N
the DT N
insulin NN N
consumption NN N
on IN N
the DT N
blood NN N
sugar NN N
profile NN N
in IN N
twelve JJ p
insulin-dependent JJ p
diabetes NNS p
( ( p
IDDM NNP p
) ) p
patients NNS p
. . p

The DT N
patients NNS N
were VBD N
treated VBN i
with IN i
penbutolol NN i
and CC i
placebo NN i
for IN i
a DT i
period NN i
of IN i
three CD i
days NNS i
, , i
and CC i
then RB i
were VBD i
examined VBN i
with IN i
the DT i
help NN i
of IN i
the DT i
glucose-controlled JJ i
insulin NN i
infusion NN i
system NN i
. . i

The DT N
blood NN o
sugar NN o
profile NN o
and CC o
insulin NN o
consumption NN o
over IN N
a DT N
24 CD N
hour NN N
period NN N
was VBD N
not RB N
affected VBN N
by IN N
either DT N
penbutolol NN N
or CC N
placebo NN N
, , N
nor CC N
could MD N
any DT N
changes NNS N
be VB N
measured VBN N
in IN N
these DT N
parameters NNS N
when WRB N
measured VBN N
after IN N
food NN N
intake NN N
. . N

After IN N
a DT N
submaximal JJ N
exercise NN N
load NN N
on IN N
the DT N
bicycle NN N
ergometer NN N
( ( N
1 CD N
watt NN N
per IN N
kg NN N
body NN N
weight VBD N
) ) N
following VBG N
an DT N
evening JJ N
meal NN N
, , N
no DT N
difference NN N
could MD N
be VB N
observed VBN N
between IN N
penbutolol NN N
and CC N
placebo NN N
in IN N
the DT N
above-mentioned JJ N
parameters NNS N
. . N

The DT N
same JJ N
was VBD N
also RB N
true JJ N
for IN N
hormonal JJ N
parameters NNS N
as IN N
STH NNP o
, , o
ACTH NNP o
, , o
cortisol NN o
, , o
and CC o
catecholamines NNS o
. . o

These DT N
findings NNS N
demonstrated VBD N
that IN N
medication NN N
of IN N
penbutolol NN N
over IN N
a DT N
three-day JJ N
period NN N
has VBZ N
no DT N
influence NN N
on IN N
the DT N
baseline NN N
blood NN N
sugar NN N
profile NN N
and CC N
insulin NN N
consumption NN N
or CC N
on IN N
insulin NN N
consumption NN N
after IN N
food NN N
intake NN N
during IN N
rest NN N
and CC N
physical JJ N
exercise NN N
. . N

-DOCSTART- -8383874- O O

Sodium-potassium JJ i
pump NN i
activity NN i
in IN N
white JJ N
blood NN N
cells NNS N
from IN N
children NNS p
with IN p
an DT p
increased VBN p
risk NN p
of IN p
developing VBG p
hypertension NN p
-- : p
The DT p
Odense NNP N
Schoolchild NNP N
Study NNP N
. . N

We PRP N
have VBP N
measured VBN N
the DT N
capacity NN N
of IN N
the DT N
sodium-potassium JJ i
pump NN i
, , N
as IN N
assessed VBN N
by IN N
86rubidium CD N
uptake NN N
and CC N
the DT N
number NN N
of IN N
[ $ N
3H CD N
] NNP N
-ouabain NN N
binding VBG N
sites NNS N
on IN N
white JJ N
blood NN N
cells NNS N
, , N
in IN N
children NNS p
aged VBN p
9-11 CD p
years NNS p
, , p
partly RB p
cross-sectionally RB p
and CC p
partly RB p
longitudinally RB p
after IN p
a DT p
physical JJ i
training NN i
programme NN i
. . i

Children NNP p
from IN p
a DT p
hypertensive JJ p
subgroup NN p
comprising VBG p
the DT p
upper JJ p
5 CD p
% NN p
of IN p
the DT p
blood NN p
pressure NN p
distribution NN p
and CC p
children NNS p
from IN p
a DT p
randomly RB p
selected VBN p
normotensive JJ p
subgroup NN p
were VBD p
eligible JJ p
for IN p
the DT p
study NN p
. . p

In IN p
the DT p
cross-sectional JJ p
study NN p
40 CD p
children NNS p
from IN p
the DT p
hypertensive JJ p
subgroup NN p
and CC p
40 CD p
children NNS p
from IN p
the DT p
normotensive JJ p
subgroup NN p
were VBD p
evaluated VBN p
. . p

A DT N
significant JJ N
increase NN N
in IN N
86rubidium CD o
uptake NN o
was VBD N
present JJ N
in IN N
boys NN N
as IN N
compared VBN N
to TO N
girls NNS N
. . N

After IN N
adjustment NN N
for IN N
differences NNS N
in IN N
sexual JJ N
maturation NN N
the DT N
observed JJ N
significant JJ N
difference NN N
disappeared VBD N
. . N

Important NNP N
correlates NNS N
of IN N
pump NN i
activity NN i
were VBD N
height VBN N
, , N
plasma FW N
glucose NN N
, , N
and CC N
physical JJ N
fitness NN N
. . N

In IN N
the DT N
training NN N
study NN N
10 CD p
boys NNS p
from IN p
the DT p
hypertensive JJ p
subgroup NN p
and CC p
10 CD p
boys NNS p
from IN p
the DT p
normotensive JJ p
subgroup NN p
were VBD N
also RB N
evaluated VBN N
after IN N
eight CD N
months NNS N
of IN N
physical JJ N
training NN N
. . N

A DT N
significant JJ N
fall NN N
in IN N
86rubidium CD o
uptake NN o
was VBD N
observed VBN N
. . N

No DT N
control NN N
group NN N
was VBD N
examined VBN N
and CC N
probably RB N
the DT N
changes NNS N
reflect VBP N
some DT N
effects NNS N
of IN N
sexual JJ o
maturation NN o
on IN o
cation NN o
handling NN o
of IN o
cells NNS o
. . o

These DT N
results NNS N
indicate VBP N
a DT N
significant JJ N
effect NN N
of IN N
sexual JJ o
maturation NN o
in IN o
capacity NN o
of IN o
sodium-potassium JJ o
pump NN o
in IN N
children NNS p
. . p

-DOCSTART- -8852235- O O

An DT N
occupation NN i
based VBN i
physical JJ i
activity NN i
intervention NN i
program NN i
: : i
improving NN o
fitness NN o
and CC o
decreasing VBG o
obesity NN o
. . o

The DT N
purpose NN N
of IN N
this DT N
quasi-experimental JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
an DT N
occupation NN i
based VBN i
health NN i
and CC i
fitness NN i
program NN i
. . i

Subjects NNS p
were VBD p
1,504 CD p
police NNS p
trainees NNS p
( ( p
85 CD p
% NN p
male NN p
, , p
15 CD p
% NN p
female NN p
) ) p
with IN p
an DT p
ethnic JJ p
distribution NN p
of IN p
82 CD p
% NN p
white JJ p
, , p
16 CD p
% NN p
African JJ p
American NNP p
, , p
and CC p
2 CD p
% NN p
other JJ p
. . p

Data NNS p
were VBD p
collected VBN p
at IN p
25 CD p
sites NNS p
across IN p
the DT p
state NN p
of IN p
North NNP p
Carolina NNP p
. . p

The DT N
sites NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
( ( i
implemented VBN i
the DT i
intervention NN i
) ) i
or CC N
the DT N
control NN N
group NN N
( ( i
continued VBN i
usual JJ i
training NN i
) ) i
. . N

As IN N
compared VBN N
with IN N
controls NNS N
, , N
subjects NNS N
at IN N
the DT N
experimental JJ N
sites NNS N
improved VBN N
significantly RB N
in IN N
cardiovascular JJ o
fitness NN o
( ( o
aerobic JJ o
power NN o
) ) o
, , o
general JJ o
muscular JJ o
strength NN o
( ( o
number NN o
of IN o
sit NN o
ups NNS o
per IN o
minute NN o
) ) o
, , o
and CC o
flexibility NN o
, , o
and CC o
lowered VBD o
their PRP$ o
body NN o
fat NN o
. . o

The DT N
intervention NN N
required VBN N
minimal JJ N
equipment NN N
and CC N
was VBD N
taught VBN N
primarily RB N
by IN N
peers NNS N
who WP N
received VBD N
a DT N
1 CD N
week NN N
training NN N
program NN N
. . N

This DT N
occupational JJ i
approach NN i
to TO N
improving VBG N
health NN N
could MD N
be VB N
particularly RB N
useful JJ N
in IN N
occupations NNS N
with IN N
many JJ N
workers NNS N
who WP N
seldom VBP N
engage VB N
in IN N
leisure NN N
time NN N
physical JJ N
activity NN N
. . N

-DOCSTART- -11429349- O O

The DT N
clinical JJ N
and CC N
biochemical JJ N
effects NNS N
of IN N
propofol JJ i
infusion NN N
with IN i
and CC i
without IN i
EDTA NNP i
for IN N
maintenance NN N
anesthesia NN N
in IN N
healthy JJ p
children NNS p
undergoing VBG p
ambulatory NN p
surgery NN p
. . p

UNLABELLED IN N
We PRP N
conducted VBD N
this DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
comparative JJ N
, , N
parallel-group JJ N
study NN N
to TO N
determine VB N
whether IN N
adding VBG N
EDTA NNP i
to TO i
propofol VB i
would MD N
affect VB N
the DT N
clinical JJ N
profile NN N
, , N
calcium NN N
and CC N
magnesium NN N
homeostasis NN N
, , N
or CC N
renal JJ N
function NN N
in IN N
healthy JJ p
children NNS p
. . p

After IN N
the DT N
induction NN i
of IN i
anesthesia NN i
with IN i
halothane NN i
, , N
69 CD p
ambulatory JJ p
surgical JJ p
patients NNS p
( ( p
1 CD p
mo NN p
to TO p
< VB p
17 CD p
yr NNP p
old JJ p
) ) p
, , N
received VBD i
propofol NN i
without IN i
EDTA NNP i
( ( i
n JJ i
= NNP i
33 CD i
) ) i
or CC i
propofol NN i
with IN i
EDTA NNP i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
. . N

Blood NN o
samples NNS o
were VBD N
obtained VBN N
for IN N
the DT N
measurement NN o
of IN o
ionized JJ o
calcium NN o
, , o
ionized JJ o
magnesium NN o
, , o
and CC o
laboratory JJ o
indicators NNS o
of IN o
renal JJ o
function NN o
. . o

Hemodynamic NNP o
measurements NNS o
, , o
recovery NN o
, , N
and CC N
adverse JJ o
events NNS o
were VBD N
recorded VBN N
. . N

Propofol NNP i
with IN i
EDTA NNP i
produced VBD N
no DT N
significant JJ N
effects NNS N
on IN N
clinical JJ o
efficacy NN o
or CC o
renal JJ o
function NN o
. . o

Propofol NNP i
and CC i
propofol JJ i
EDTA NNP i
produced VBD N
a DT N
statistically RB N
significant JJ N
decrease NN o
from IN o
baseline NN o
in IN o
serum JJ o
concentrations NNS o
of IN o
ionized JJ o
calcium NN o
and CC o
magnesium NN o
during IN o
infusion NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
. . N

Hemodynamic NNP o
measurements NNS o
generally RB N
remained VBD N
stable JJ N
and CC N
were VBD N
similar JJ N
for IN N
both DT N
groups NNS N
. . N

Statistically NNP N
significant JJ N
changes NNS N
in IN N
systolic JJ o
blood NN o
pressure NN o
, , o
mean JJ o
arterial JJ o
pressure NN o
, , o
and CC o
heart NN o
rate NN o
were VBD N
not RB N
considered VBN N
clinically RB N
significant JJ N
. . N

Adverse JJ N
events NNS N
were VBD N
mild JJ N
or CC N
moderate JJ N
. . N

The DT N
addition NN N
of IN N
EDTA NNP i
does VBZ N
not RB N
alter VB N
the DT N
clinical JJ N
profile NN N
of IN N
propofol NN N
in IN N
pediatric JJ p
ambulatory JJ p
surgical JJ p
patients NNS p
. . p

With IN N
or CC N
without IN N
EDTA NNP i
, , i
propofol NN i
is VBZ N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
ionized JJ o
calcium NN o
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
. . N

IMPLICATIONS VBZ N
The DT N
addition NN N
of IN N
EDTA NNP N
does VBZ N
not RB N
alter VB N
the DT N
clinical JJ N
profile NN N
of IN N
propofol NN N
in IN N
pediatric JJ p
ambulatory JJ p
surgical JJ p
patients NNS p
. . p

With IN N
or CC N
without IN N
EDTA NNP N
, , N
propofol NN N
is VBZ N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
ionized JJ o
calcium NN o
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
. . N

-DOCSTART- -9951491- O O

A DT N
randomized JJ N
, , N
double-masked JJ N
, , N
placebo-controlled JJ N
parallel NN N
study NN N
of IN N
loteprednol JJ i
etabonate JJ i
0.2 CD N
% NN N
in IN N
patients NNS p
with IN p
seasonal JJ p
allergic JJ p
conjunctivitis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
loteprednol JJ i
etabonate NN i
( ( i
LE NNP i
) ) i
0.2 CD N
% NN N
in IN N
reducing VBG N
the DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
seasonal JJ o
allergic JJ o
conjunctivitis NN o
. . o

DESIGN NNP N
Randomized NNP N
, , N
double-masked JJ N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
group NN N
multicenter RBR N
study NN N
of IN N
6 CD N
weeks NNS N
duration NN N
. . N

PARTICIPANTS VB N
A DT p
total NN p
of IN p
135 CD p
patients NNS p
with IN p
signs NNS p
and CC p
symptoms NNS p
of IN p
seasonal JJ p
allergic JJ p
conjunctivitis NN p
participated VBD p
. . p

INTERVENTION NNP N
All NNP N
patients NNS N
received VBD N
either RB N
LE NNP i
0.2 CD i
% NN i
or CC i
placebo NN i
( ( N
vehicle NN N
) ) N
four CD N
times NNS N
a DT N
day NN N
in IN N
both DT N
eyes NNS N
for IN N
42 CD N
days NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Bulbar NNP o
conjunctival NN o
injection NN o
( ( o
primary JJ o
sign NN o
) ) o
and CC o
itching VBG o
( ( o
primary JJ o
symptom NN o
) ) o
over IN N
the DT N
first JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
was VBD N
measured VBN N
. . N

RESULTS VB N
A DT N
reduction NN o
in IN o
severity NN o
was VBD N
seen VBN N
in IN N
both DT N
LE NNP N
and CC N
placebo NN N
groups NNS N
for IN N
bulbar NN o
conjunctival NN o
injection NN o
( ( N
1.5 CD N
vs. FW N
1.0 CD N
units NNS N
on IN N
a DT N
0-3 JJ N
scale NN N
) ) N
and CC N
itching VBG N
( ( N
3.4 CD N
vs. FW N
3.0 CD N
units NNS N
on IN N
a DT N
0-4 JJ N
scale NN N
) ) N
over IN N
the DT N
first JJ N
2 CD N
weeks NNS N
. . N

The DT N
treatment NN N
effect NN N
by IN N
these DT N
measures NNS N
was VBD N
-0.5 NNP N
and CC N
-0.4 NNP N
units NNS N
in IN N
favor NN N
of IN N
LE NNP N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.008 CD N
) ) N
. . N

Resolution NNP N
( ( N
i.e. NN N
, , N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
signs NNS o
or CC o
symptoms VBZ o
no DT o
longer RBR o
present JJ o
) ) o
at IN N
day NN N
14 CD N
strongly RB N
favored VBN N
LE-treated JJ N
patients NNS N
( ( N
36 CD N
% NN N
and CC N
15 CD N
% NN N
; : N
58 CD N
% NN N
and CC N
38 CD N
% NN N
, , N
for IN N
injection NN N
and CC N
itching NN N
, , N
respectively RB N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN o
. . o

One CD N
patient NN N
in IN N
each DT N
treatment NN N
group NN N
( ( N
1 CD N
of IN N
67 CD N
and CC N
1 CD N
of IN N
68 CD N
, , N
respectively RB N
) ) N
had VBD N
an DT N
elevation NN o
of IN o
intraocular JJ o
pressure NN o
of IN N
10 CD N
mmHg NN N
or CC N
greater JJR N
during IN N
the DT N
6 CD N
weeks NNS N
of IN N
treatment NN N
. . N

CONCLUSIONS NNP N
Loteprednol NNP N
etabonate VB N
0.2 CD N
% NN N
was VBD N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ N
allergic JJ N
conjunctivitis NN N
. . N

Loteprednol NNP N
etabonate VBP N
0.2 CD N
% NN N
had VBD N
a DT N
safety NN N
profile NN N
comparable JJ N
to TO N
placebo VB N
. . N

-DOCSTART- -8570879- O O

Lung NNP N
function NN N
measurement NN N
in IN N
general JJ N
practice NN N
: : N
a DT N
comparison NN N
of IN N
the DT N
Escort NNP i
spirometer NN i
with IN N
the DT N
Micromed NNP i
turbine NN i
spirometer NN i
and CC N
the DT N
mini-Wright JJ i
peak NN i
flow NN i
meter NN i
. . i

It PRP N
is VBZ N
important JJ N
that IN N
new JJ N
types NNS N
of IN N
spirometer NN i
for IN N
widespread JJ N
clinical JJ N
use NN N
are VBP N
pragmatically RB N
evaluated VBN N
in IN N
primary JJ N
care NN N
. . N

This DT N
study NN N
compared VBN N
measurements NNS N
taken VBN N
by IN N
a DT N
new JJ i
portable JJ i
Fleisch NNP i
pneumotachograph NN i
spirometer NN i
( ( i
known VBN i
as IN i
the DT i
Escort NNP i
) ) i
with IN N
those DT N
of IN N
the DT N
commonly NN N
used VBN N
mini-Wright JJ i
peak NN i
flow NN i
meter NN i
and CC N
the DT N
Micromed NNP i
Pocket NNP i
turbine NN i
spirometer NN i
. . i

A NNP N
pragmatic JJ N
study NN N
was VBD N
conducted VBN N
in IN N
two CD N
phases NNS N
during IN p
routine JJ p
surgeries NNS p
at IN N
Aldermoor NNP N
Health NNP N
Centre NNP N
, , N
Southampton NNP N
. . N

Phase NNP N
I PRP N
compared VBN N
the DT N
new JJ i
spirometer NN i
with IN N
the DT N
mini-Wright JJ i
peak NN i
flow NN i
meter NN i
and CC N
Phase NNP N
2 CD N
compared VBN N
the DT N
new JJ i
spirometer NN i
and CC N
the DT N
turbine NN i
spirometer NN i
. . i

One CD p
hundred VBD p
patients NNS p
aged VBN p
5-88 CD p
years NNS p
( ( p
56 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
chronic JJ p
respiratory NN p
complaints NNS p
and CC p
44 CD p
patients NNS p
without IN p
) ) p
entered VBD p
Phase NNP p
1 CD p
, , p
and CC p
100 CD p
patients NNS p
aged VBN p
6-82 JJ p
years NNS p
( ( p
62 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
chronic JJ p
respiratory NN p
complaints NNS p
and CC p
38 CD p
patients NNS p
without IN p
) ) p
entered VBD p
Phase NNP p
2 CD p
. . p

Each DT N
patient NN N
contributed VBD N
only RB N
once RB N
to TO N
each DT N
phase NN N
, , N
but CC N
some DT N
entered VBD N
both DT N
phases NNS N
on IN N
separate JJ N
occasions NNS N
. . N

Ninety-five JJ N
percent NN N
limits NNS N
of IN N
agreement NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
were VBD N
wide JJ N
for IN N
all DT N
comparisons NNS N
. . N

Graphical JJ o
plots NNS o
revealed VBD N
trends NNS N
towards IN N
higher JJR N
Escort NN o
values NNS o
as IN N
mean NN N
values NNS N
rose VBD N
compared VBN N
with IN N
both DT N
mini-Wright JJ i
and CC N
turbine JJ i
readings NNS N
for IN N
peak JJ o
expiratory JJ o
flow NN o
rate NN o
and CC o
forced VBD o
expiratory JJ o
volume NN o
in IN o
one CD o
second NN o
. . o

Possible JJ N
over-reading NN N
of IN N
peak JJ o
expiratory JJ o
flow NN o
rate NN o
with IN N
the DT N
mini-Wright JJ i
meter NN i
at IN N
low JJ N
mean NN N
values NNS N
was VBD N
also RB N
seen VBN N
. . N

Readings NNS N
taken VBN N
with IN N
these DT N
different JJ N
types NNS N
of IN N
meter NN N
can MD N
not RB N
be VB N
interchanged VBN N
with IN N
confidence NN N
in IN N
clinical JJ N
practice NN N
. . N

The DT N
clinical JJ N
significance NN N
of IN N
the DT N
theoretically RB N
more RBR N
accurate JJ N
measures NNS o
of IN o
lung NN o
function NN o
produced VBN N
with IN N
the DT N
new JJ i
meter NN i
, , N
and CC N
indeed RB N
of IN N
spirometry NN N
itself PRP N
, , N
needs VBZ N
further JJ N
investigation NN N
. . N

-DOCSTART- -15746480- O O

The DT N
overt JJ i
aggression NN i
scale NN i
for IN i
rating NN i
aggression NN i
in IN N
outpatient JJ p
youth NN p
with IN p
autistic JJ p
disorder NN p
: : p
preliminary JJ N
findings NNS N
. . N

Aggression NNP N
is VBZ N
a DT N
common JJ N
and CC N
costly JJ N
problem NN N
in IN N
youth NN p
with IN p
developmental JJ p
disabilities NNS p
. . p

Rating VBG N
scales NNS N
that WDT N
accurately RB N
capture NN N
and CC N
measure NN N
subtypes NNS N
of IN N
aggression NN N
phenomenology NN N
, , N
frequency NN N
and CC N
severity NN N
are VBP N
urgently RB N
needed VBN N
, , N
in IN N
both DT N
clinical JJ N
practice NN N
and CC N
research NN N
. . N

The DT N
authors NNS N
studied VBD N
the DT N
Overt NNP o
Aggression NNP o
Scale NNP o
( ( o
OAS NNP o
) ) o
in IN N
a DT N
preliminary JJ N
sample NN N
of IN N
eight CD p
outpatients NNS p
who WP p
participated VBD p
in IN p
an DT p
ongoing JJ p
placebo-controlled JJ i
study NN p
of IN p
valproate NN i
for IN p
aggression NN p
in IN p
autism NN p
. . p

Subjects NNS N
' POS N
OAS NNP o
aggression NN o
scores NNS o
showed VBD N
significant JJ N
correlation NN N
with IN N
the DT N
already RB N
validated VBN N
retrospectively RB N
rated VBN N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Community NNP o
Scale NNP o
irritability NN o
subscale NN o
. . o

Further NNP N
study NN N
of IN N
the DT N
OAS NNP o
in IN N
outpatients NNS N
with IN N
aggression NN N
and CC N
developmental JJ N
disabilities NNS N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -17579182- O O

Use NNP N
of IN N
a DT N
DNAemia NNP i
cut-off NN i
for IN N
monitoring VBG N
human JJ N
cytomegalovirus NN N
infection NN N
reduces VBZ N
the DT N
number NN o
of IN o
preemptively RB o
treated VBN o
children NNS o
and CC p
young JJ p
adults NNS p
receiving VBG p
hematopoietic JJ p
stem-cell JJ p
transplantation NN p
compared VBN N
with IN N
qualitative JJ i
pp65 NN i
antigenemia NN i
. . i

We PRP N
performed VBD N
a DT N
randomized JJ N
trial NN N
comparing VBG N
the DT N
use NN N
of IN N
quantitative JJ i
DNAemia NNP i
versus NN i
positive JJ i
antigenemia NN i
for IN N
starting VBG N
preemptive JJ N
antihuman NN N
cytomegalovirus NN N
( ( N
HCMV NNP N
) ) N
therapy NN N
in IN N
hematopoietic JJ p
stem-cell JJ p
transplantation NN p
( ( p
HSCT NNP p
) ) p
recipients NNS p
. . p

In IN N
the DT N
DNAemia NNP i
arm NN N
, , N
antiviral JJ i
therapy NN i
was VBD N
initiated VBN N
on IN N
reaching VBG N
a DT N
DNAemia NNP i
cut-off NN i
of IN N
10 CD N
000 CD N
DNA NNP N
copies/mL NN N
of IN N
whole JJ N
blood NN N
, , N
whereas NNS N
in IN N
the DT N
antigenemia NN N
arm NN N
, , N
therapy NN N
was VBD N
started VBN N
in IN N
the DT N
presence NN N
of IN N
a DT N
positive JJ i
antigenemia NN i
. . i

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
number NN N
of IN N
patients NNS N
treated VBN N
in IN N
the DT N
2 CD N
arms NNS N
. . N

On IN N
the DT N
whole NN N
, , N
178 CD p
patients NNS p
( ( p
89 CD p
in IN p
each DT p
arm NN p
) ) p
, , p
receiving VBG p
unmanipulated JJ i
HSCT NNP i
from IN p
either CC p
a DT p
relative NN p
or CC p
an DT p
unrelated JJ p
donor NN p
, , N
completed VBD N
the DT N
study NN N
. . N

Although IN N
the DT N
incidence NN N
of IN N
HCMV NNP o
infection NN o
was VBD N
comparable JJ N
in IN N
DNAemia NNP N
and CC N
antigenemia NN N
arms NNS N
( ( N
34 CD N
% NN N
vs JJ N
42 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
.259 NNP N
) ) N
, , N
the DT N
number NN o
of IN o
patients NNS o
treated VBN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
DNAemia NNP i
arm NN N
( ( N
18 CD N
% NN N
vs JJ N
31 CD N
% NN N
, , N
P NNP N
= NNP N
.026 NNP N
) ) N
. . N

No DT N
patient NN N
developed VBD N
HCMV NNP o
disease NN o
. . o

The DT N
use NN N
of IN N
a DT N
DNAemia NNP i
cut-off NN i
avoids NNS N
unnecessary JJ N
antiviral JJ i
treatment NN i
. . i

-DOCSTART- -22092536- O O

Paracetamol NNP i
and CC N
opioid JJ N
pathways NNS N
: : N
a DT N
pilot NN N
randomized VBN N
clinical JJ N
trial NN N
. . N

Previous JJ N
studies NNS N
suggest VBP N
that IN N
the DT N
antinociceptive JJ N
action NN N
of IN N
paracetamol NN i
( ( i
acetaminophen NN i
, , i
APAP NNP i
) ) i
might MD N
involve VB N
descending VBG N
inhibitory JJ N
pain NN N
pathways NNS N
and CC N
the DT N
opioidergic JJ N
system NN N
: : N
this DT N
study NN N
explores VBZ N
this DT N
issue NN N
in IN p
humans NNS p
with IN p
naloxone NN i
, , i
the DT i
opioid JJ i
antagonist NN i
. . i

After IN N
ethical JJ N
approval NN N
, , N
12 CD p
healthy JJ p
male NN p
volunteers NNS p
were VBD p
included VBN p
in IN N
this DT N
randomized VBN N
, , N
controlled VBN N
, , N
double-blind NN N
, , N
crossover NN N
, , N
four-arm JJ N
study NN N
. . N

They PRP N
were VBD N
administered VBN N
intravenous JJ i
paracetamol NN i
( ( i
APAP NNP i
1 CD i
g NN i
) ) i
or CC i
saline NN i
( ( i
placebo NN i
, , i
pl NN i
) ) i
followed VBD N
at IN N
100 CD N
min NN N
with IN N
IV NNP i
naloxone NN i
( ( i
Nal NNP i
8 CD i
mg NN i
) ) i
or CC i
saline NN i
, , N
every DT N
week NN N
for IN N
4 CD N
weeks NNS N
. . N

The DT N
amplitude NN o
of IN o
cerebral JJ o
potentials NNS o
evoked VBN o
by IN N
thermal/painful JJ N
stimuli NNS N
applied VBN N
on IN N
the DT N
arm NN N
was VBD N
recorded VBN N
nine CD N
times NNS N
over IN N
150 CD N
min NNS N
, , N
witnessing VBG N
of IN N
pain NN N
integration NN N
at IN N
central JJ N
level NN N
. . N

Amplitude NNP o
changes NNS o
as RB o
well RB o
as IN o
areas NNS o
under IN o
the DT o
curve NN o
( ( o
AUCs NNP o
) ) o
over IN N
150 CD N
min NNS N
were VBD N
compared VBN N
for IN N
the DT N
four CD N
treatments NNS N
by IN N
repeated JJ N
measures NNS N
ANOVA NNP N
( ( N
significance NN N
0.05 CD N
) ) N
. . N

Amplitude NNP o
changes NNS o
were VBD N
significant JJ N
for IN N
APAP/pl NNP i
vs. FW N
pl/pl NN N
at IN N
t150 NN N
: : N
-44 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-58 NNP N
to TO N
-30 VB N
) ) N
vs. FW N
-27 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-37 NNP N
to TO N
-17 VB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
but CC N
not RB N
vs. IN N
APAP/Nal NNP i
. . i

AUC NNP o
( ( N
0-150 JJ N
) ) N
of IN N
APAP/pl NNP N
is VBZ N
significantly RB N
different JJ N
from IN N
pl/pl NN N
( ( N
-3452 CD N
% NN N
.min NNP N
( ( N
95 CD N
% NN N
CI NNP N
-4705 NNP N
to TO N
-2199 VB N
) ) N
vs. FW N
-933 CD N
% NN N
min NN N
( ( N
95 CD N
% NN N
CI NNP N
-2273 NNP N
to TO N
407 CD N
; : N
P NNP N
= NNP N
0.015 CD N
) ) N
but CC N
not RB N
from IN N
APAP/Nal NNP i
( ( N
-1731 CD N
% NN N
min NN N
( ( N
95 CD N
% NN N
CI NNP N
-3676 NNP N
to TO N
214 CD N
; : N
P NNP N
= NNP N
0.08 CD N
) ) N
and CC N
other JJ N
treatments NNS N
. . N

AUC NNP o
( ( N
90-150 CD N
) ) N
is VBZ N
not RB N
significantly RB N
different JJ N
. . N

This DT N
pilot NN N
study NN N
shows VBZ N
for IN N
the DT N
first JJ N
time NN N
in IN N
human JJ p
volunteers NNS p
that WDT N
naloxone RB i
does VBZ N
not RB N
inhibit VB o
paracetamol JJ o
antinociception NN o
, , N
suggesting VBG N
no DT N
significant JJ N
implication NN N
of IN N
the DT N
opioid NN N
system NN N
in IN N
paracetamol JJ i
mechanism NN N
of IN N
action NN N
: : N
this DT N
needs VBZ N
be VB N
confirmed VBN N
on IN N
a DT N
larger JJR N
number NN N
of IN N
subjects NNS N
. . N

-DOCSTART- -8411891- O O

[ JJ N
Comparison NNP N
of IN N
complications NNS o
after IN N
intra- JJ i
and CC i
extracapsular JJ i
cataract NN i
extraction NN i
with IN i
lens JJ i
implantation NN i
. . i

Results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
clinical JJ N
study NN N
] NNP N
. . N

BACKGROUND NNP N
The DT N
postoperative JJ o
complications NNS o
of IN N
ICCE NNP i
with IN i
ACL NNP i
implantation NN i
are VBP N
compared VBN N
with IN N
those DT N
of IN N
ECCE NNP i
and CC i
PCL NNP i
. . i

Our PRP$ N
clinical JJ N
experience NN N
with IN N
ICCE NNP i
and CC i
ACL NNP i
implantation NN i
can MD N
not RB N
confirm VB N
the DT N
widespread JJ N
rejection NN N
of IN N
this DT N
method NN N
. . N

PATIENTS NNP N
AND CC N
METHOD NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
, , N
clinical JJ N
study NN N
with IN N
participation NN p
of IN p
medical JJ p
statisticians NNS p
was VBD N
performed VBN N
. . N

A DT p
total NN p
of IN p
190 CD p
patients NNS p
with IN p
ICCE NNP i
and CC i
ACL NNP i
and CC p
170 CD p
patients NNS p
with IN p
ECCE NNP i
and CC i
PCL NNP i
were VBD p
followed VBN p
up RP p
for IN p
2 CD p
years NNS p
. . p

The DT N
follow-up JJ N
examinations NNS N
were VBD N
performed VBN N
upon IN N
dismission NN N
from IN N
the DT N
hospital NN N
, , N
after IN N
6 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
. . N

The DT N
data NNS N
were VBD N
compiled VBN N
in IN N
a DT N
computer NN N
program NN N
designed VBN N
for IN N
this DT N
study NN N
and CC N
evaluated VBN N
by IN N
the DT N
statisticians NNS N
. . N

The DT N
surgical JJ N
procedures NNS N
and CC N
the DT N
surgeons NNS N
were VBD N
defined VBN N
prior RB N
to TO N
the DT N
beginning NN N
of IN N
patient JJ N
recruitment NN N
. . N

RESULTS NNP N
ICCE NNP i
with IN i
ACL NNP i
shows NNS N
much RB N
less RBR N
postoperative JJ o
complications NNS o
as IN N
usually RB N
emphasized VBN N
. . N

There EX N
were VBD N
only RB N
2 CD N
( ( N
1.2 CD N
% NN N
) ) N
of IN N
retinal JJ o
detachment NN o
and CC N
no DT N
case NN N
of IN N
corneal NN o
decompensation NN o
. . o

Cystoid NNP o
macular JJ o
edema NN o
8 CD N
( ( N
4.7 CD N
% NN N
) ) N
, , N
postoperative JJ o
vitreous JJ o
prolaps NNS o
into IN o
the DT o
anterior JJ o
chamber NN o
4 CD N
( ( N
2.3 CD N
% NN N
) ) N
and CC N
spontaneous JJ o
complaints NNS o
of IN o
pain NN o
16 CD N
( ( N
9.4 CD N
% NN N
) ) N
occurred VBD N
in IN N
a DT N
low JJ N
percentage NN N
after IN N
ICCE NNP i
with IN i
ACL NNP i
. . i

These DT N
complications NNS N
did VBD N
not RB N
occur VB N
after IN N
ECCE NNP i
with IN i
PCL NNP i
. . i

The DT N
patients NNS N
with IN N
ECCE NNP i
and CC i
PCL NNP i
showed VBD N
capsular JJ o
fibrosis NN o
in IN N
48 CD N
( ( N
28 CD N
% NN N
) ) N
making VBG N
it PRP N
the DT N
most RBS N
frequent JJ N
complication NN N
of IN N
the DT N
whole JJ N
study NN N
. . N

33 CD N
% NN N
of IN N
these DT N
patients NNS N
required VBD N
YAG-laser NNP i
capsulotomy NN i
. . i

Since IN N
retinal JJ N
detachment NN N
occurs VBZ N
in IN N
2.5 CD N
% NN N
after IN N
YAG-laser NNP i
capsulotomy NN i
we PRP N
can MD N
not RB N
regard VB N
capsular JJ N
fibrosis NN N
as IN N
a DT N
totally RB N
harmless JJ N
complication NN N
. . N

It PRP N
is VBZ N
noteworthy JJ N
that IN N
visual JJ o
acuity NN o
is VBZ N
almost RB N
identical JJ N
1 CD N
year NN N
after IN N
surgery NN N
in IN N
both DT N
methods NNS N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
the DT N
evaluation NN N
of IN N
ICCE NNP i
with IN i
ACL NNP i
is VBZ N
too RB N
negative JJ N
. . N

The DT N
elimination NN N
of IN N
postoperative JJ N
complications NNS N
in IN N
this DT N
method NN N
is VBZ N
more RBR N
difficult JJ N
. . N

ECCE VB i
with IN i
PCL NNP i
is VBZ N
burdened VBN N
by IN N
frequent JJ o
capsular JJ o
fibrosis NN o
. . o

Visual JJ N
acuity NN N
is VBZ N
almost RB N
the DT N
same JJ N
in IN N
both DT N
methods NNS N
1 CD N
years NNS N
after IN N
the DT N
operation NN N
. . N

ACL-implantation NN i
remains VBZ N
our PRP$ N
method NN N
of IN N
choice NN N
for IN N
secondary JJ N
implantation NN N
in IN N
patients NNS p
with IN p
an DT p
intact JJ p
iris JJ p
diaphragm NN p
. . p

-DOCSTART- -6753091- O O

A DT N
randomized JJ N
trial NN N
of IN N
intranasal NN N
beclomethasone NN i
dipropionate NN i
after IN N
polypectomy NN N
. . N

Beneficial JJ N
effects NNS N
of IN N
intranasal NN i
beclomethasone NN i
dipropionate NN i
( ( i
Bdp NNP i
) ) i
in IN N
patients NNS p
with IN p
nasal JJ p
polyposis NN p
have VBP N
been VBN N
reported VBN N
earlier RBR N
. . N

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
investigate VB N
whether IN N
long-term JJ N
treatment NN N
with IN N
Bdp NNP i
after IN N
polypectomy NN N
could MD N
prevent VB N
formation NN N
of IN N
new JJ N
polyps NNS N
and CC N
reduce VB N
the DT N
number NN N
of IN N
surgical JJ N
removals NNS N
. . N

Forty NNP p
consecutive JJ p
patients NNS p
without IN p
laboratory NN p
or CC p
other JJ p
clinical JJ p
signs NNS p
of IN p
allergy NN p
but CC p
with IN p
severe JJ p
nasal JJ p
polyposis NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Twenty CD p
patients NNS p
were VBD p
treated VBN p
with IN p
intranasal JJ i
Bdp NNP i
and CC p
twenty JJ p
patients NNS p
received VBD p
no DT p
treatment NN p
after IN p
polypectomy NN i
. . i

All DT N
patients NNS p
were VBD p
followed VBN p
for IN p
at IN p
least JJS p
2.5 CD p
years NNS p
. . p

The DT N
size NN o
of IN o
the DT o
polyps NNS o
that WDT o
recurred VBD o
was VBD N
estimated VBN N
at IN N
different JJ N
time-intervals NNS N
by IN N
the DT N
examining VBG N
doctor NN N
. . N

After IN N
six CD N
months NNS N
there RB N
was VBD N
already RB N
a DT N
significant JJ o
difference NN o
in IN N
favour NN N
of IN N
the DT N
group NN N
treated VBD N
with IN N
intranasal JJ N
Bdp NNP i
. . i

Further NNP N
results NNS N
of IN N
the DT N
study NN N
and CC N
the DT N
clinical JJ N
implications NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -8656171- O O

Effectiveness NN N
of IN N
erythromycin NN i
in IN N
the DT N
treatment NN N
of IN N
acute JJ p
bronchitis NN p
. . p

BACKGROUND NNP N
Clinical NNP N
trials NNS N
have VBP N
not RB N
shown VBN N
a DT N
consistent JJ N
benefit NN N
of IN N
treating VBG N
bronchitis NN N
with IN N
antibiotics NNS N
. . N

Many JJ N
physicians NNS N
, , N
however RB N
, , N
treat VB N
acute JJ N
bronchitis NN N
with IN N
antibiotics NNS N
because IN N
of IN N
the DT N
possibility NN N
of IN N
Mycoplasma NNP N
pneumoniae NN N
or CC N
other JJ N
pathogens NNS N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
erythromycin JJ i
treatment NN N
in IN N
patients NNS p
with IN p
acute JJ p
bronchitis NN p
and CC N
to TO N
determine VB N
whether IN N
a DT N
newly RB N
developed VBN N
rapid JJ N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
is VBZ N
useful JJ N
in IN N
predicting VBG N
which WDT N
patients NNS N
will MD N
respond VB N
to TO N
therapy VB N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
at IN N
three CD p
primary JJ p
care NN p
centers NNS p
in IN p
North NNP p
Carolina NNP p
. . p

A DT N
convenience NN N
sample NN N
of IN N
140 CD p
patients NNS p
presenting VBG p
with IN p
acute JJ p
bronchitis NN p
were VBD p
tested VBN p
for IN p
M NNP p
pneumoniae NN p
, , p
91 CD p
of IN p
whom WP p
were VBD p
treated VBN p
with IN N
either DT N
erythromycin JJ i
250 CD i
mg RB i
four CD i
times NNS i
daily RB i
for IN i
10 CD i
days NNS i
or CC i
an DT i
identical-appearing JJ i
placebo NN i
. . i

RESULTS JJ N
Patients NNS N
treated VBN N
with IN N
erythromycin NN i
missed VBD N
an DT N
average NN N
of IN N
only JJ N
0.81 CD N
+/- JJ N
1.1 CD N
days NNS o
of IN o
work NN o
compared VBN N
with IN N
2.16 CD N
+/- JJ N
3.2 CD N
days NNS N
for IN N
placebo-treated JJ i
patients NNS N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
cough NN o
, , o
use NN o
of IN o
cough JJ o
medicine NN o
, , o
general JJ o
feeling NN o
of IN o
well-being NN o
, , o
or CC o
chest JJS o
congestion NN o
between IN N
the DT N
erythromycin NN i
and CC N
placebo NN i
groups NNS N
. . N

Twenty-five JJ N
percent NN N
of IN N
the DT N
patients NNS N
tested VBD N
positive JJ N
for IN N
M NNP N
pneumoniae NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
response NN N
to TO N
erythromycin VB i
based VBN N
on IN N
whether IN N
the DT N
patient NN N
had VBD N
a DT N
positive JJ N
test NN N
for IN N
M NNP N
pneumoniae NN N
. . N

CONCLUSIONS NNP N
Erythromycin NNP i
is VBZ N
effective JJ N
in IN N
significantly RB N
reducing VBG N
lost VBN N
time NN N
from IN N
work NN N
, , N
but CC N
it PRP N
is VBZ N
not RB N
effective JJ N
in IN N
reducing VBG N
cough NN N
or CC N
other JJ N
symptoms NNS N
in IN N
patients NNS p
with IN p
acute JJ p
bronchitis NN p
, , N
regardless RB N
of IN N
the DT N
outcome NN N
of IN N
the DT N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
. . N

-DOCSTART- -21793626- O O

Effect NN N
of IN N
ginseng NN i
extract JJ i
supplementation NN i
on IN N
testicular JJ o
functions NNS o
in IN N
diabetic JJ p
rats NNS p
. . p

OBJECTIVE IN N
It PRP N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
standardized JJ N
ginseng NN i
extract NN i
on IN N
fertility NN o
parameters NNS o
in IN N
diabetic JJ p
rats NNS p
. . p

METHODS NNP N
Thirty NNP p
male NN p
rats NNS p
were VBD N
randomly RB N
allocated VBN N
into IN N
three CD N
groups NNS N
of IN N
10 CD N
rats NNS N
each DT N
: : N
1. CD N
controls NNS N
, , N
2. CD N
diabetes NNS N
( ( N
D NNP N
) ) N
and CC N
3. CD N
diabetes NNS N
+ JJ N
ginseng NN N
( ( N
DG NNP N
) ) N
. . N

The DT N
latter JJ N
two CD N
groups NNS N
were VBD N
rendered VBN N
diabetic JJ N
by IN N
i.p NN N
. . N

injection NN N
of IN N
streptozotocin NN i
( ( N
STZ NNP N
; : N
50 CD N
mg/kg NN N
) ) N
. . N

Standardized VBN i
ginseng NN i
extract NN i
( ( N
Dansk NNP N
Droge NNP N
A/S NNP N
, , N
Copenhagen NNP N
, , N
Denmark NNP N
) ) N
was VBD N
administered VBN N
per IN N
os NN N
( ( N
100 CD N
mg/kg RB N
BW NNP N
) ) N
by IN N
stomach NN N
tube NN N
daily RB N
for IN N
90 CD N
days NNS N
starting VBG N
one CD N
week NN N
after IN N
STZ NNP N
. . N

Ninety NNP N
days NNS N
post NN N
STZ VBP N
the DT N
rats NNS N
were VBD N
sacrificed VBN N
, , N
and CC N
testis NN o
, , o
epididymis NN o
, , o
prostate NN o
, , o
and CC o
seminal JJ o
vesicles NNS o
were VBD o
weighed VBN o
and CC o
subjected VBN o
to TO o
histological JJ o
examination NN o
. . o

In IN N
addition NN N
, , N
spermiogram NN o
, , o
testicular JJ o
enzyme NN o
markers NNS o
, , o
intratesticular JJ o
steroid JJ o
hormonal NN o
profile NN o
and CC o
testicular JJ o
antioxidant NN o
status NN o
were VBD N
estimated VBN N
. . N

RESULTS VB N
The DT N
administration NN N
of IN N
ginseng JJ i
extract NN i
resulted VBD N
in IN N
a DT N
significant JJ N
improvement NN N
of IN N
fertility NN o
parameters NNS o
and CC o
testicular JJ o
antioxidants NNS o
together RB o
with IN N
a DT N
decrease NN o
in IN o
malondialdehyde NN o
and CC o
testicular JJ o
pathological JJ o
signs NNS o
including VBG o
degenerative JJ o
changes NNS o
of IN o
the DT o
seminiferous JJ o
tubules NNS o
. . o

CONCLUSION NNP N
Ginseng NNP i
extract NN i
may MD N
be VB N
a DT N
beneficial JJ N
adjuvant NN N
therapy NN N
for IN N
diabetics NNS N
suffering VBG N
from IN N
infertility NN o
as IN N
a DT N
complication NN N
. . N

-DOCSTART- -9757955- O O

Compliance NN N
with IN N
depot NN i
medroxyprogesterone NN i
acetate NN i
: : i
a DT N
randomized NN N
, , N
controlled VBD N
trial NN N
of IN N
intensive JJ N
reminders NNS N
. . N

We PRP N
enrolled VBD N
women NNS p
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
to TO N
determine VB N
whether IN N
an DT N
intensive JJ N
reminder NN N
system NN N
would MD N
improve VB N
compliance NN N
in IN N
women NNS p
receiving VBG p
depot NN i
medroxyprogesterone NN i
injections NNS p
. . p

Women NNP N
selecting VBG N
this DT N
treatment NN N
were VBD N
assigned VBN N
to TO N
a DT N
group NN N
that WDT N
received VBD N
both DT N
mail NN i
and CC i
telephone NN i
reminders NNS i
or CC N
to TO N
a DT N
second JJ N
group NN N
that WDT N
received VBD N
only RB i
a DT i
scheduled JJ i
appointment NN i
at IN i
the DT i
time NN i
of IN i
the DT i
previous JJ i
injection NN i
. . i

The DT N
rate NN o
of IN o
continuation NN o
and CC N
the DT N
rate NN o
of IN o
on-time JJ o
injections NNS o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

Women NNS N
who WP N
had VBD N
prolonged VBN o
bleeding NN o
were VBD N
more RBR N
likely JJ N
to TO N
discontinue VB N
depot VB N
medroxyprogesterone JJ N
injections NNS N
. . N

-DOCSTART- -10223244- O O

Allelic JJ o
imbalance NN o
in IN N
the DT N
clonal JJ N
evolution NN N
of IN N
prostate NN p
carcinoma NN p
. . p

BACKGROUND NNP N
To TO N
understand VB N
better JJR N
the DT N
genetic JJ N
basis NN N
of IN N
the DT N
clonal JJ N
evolution NN N
of IN N
prostate NN N
carcinoma NN N
, , N
the DT N
authors NNS N
analyzed VBD N
the DT N
pattern NN N
of IN N
allelic JJ o
loss NN o
in IN N
25 CD p
matched JJ p
primary NN p
and CC p
metastatic JJ p
prostate NN p
tumors NNS p
. . p

METHODS NNP N
Twenty-five JJ p
cases NNS p
were VBD p
selected VBN p
from IN p
the DT p
surgical JJ p
pathology NN p
files NNS p
of IN p
the DT p
Mayo NNP p
Clinic NNP p
from IN p
patients NNS p
who WP p
had VBD p
undergone JJ p
radical JJ i
retropubic NN i
prostatectomy NN i
and CC p
bilateral JJ i
lymphadenectomy NN i
between IN p
1987-1991 JJ p
. . p

All DT p
patients NNS p
had VBD p
regional JJ p
lymph NN p
node NN p
metastases NNS p
at IN p
the DT p
time NN p
of IN p
surgery NN p
. . p

DNA NN N
samples NNS N
for IN N
the DT N
analysis NN N
of IN N
allelic JJ o
loss NN o
pattern NN N
were VBD N
prepared VBN N
from IN N
primary JJ N
tumors NNS N
and CC N
matched VBD N
synchronous JJ N
lymph NN N
node NN N
metastases NNS N
by IN N
tissue NN N
microdissection NN N
. . N

The DT N
oligonucleotide JJ N
primer NN N
pairs NNS N
for IN N
the DT N
microsatellite JJ N
DNA NN N
markers NNS N
were VBD N
D8S133 NNP N
, , N
D8S136 NNP N
, , N
D8S137 NNP N
, , N
ANK1 NNP N
on IN N
chromosome NN N
8p12-21 CD N
, , N
LPLTET NNP N
on IN N
chromosome NN N
8p22 CD N
, , N
and CC N
D17S855 NNP N
( ( N
intragenic JJ N
to TO N
the DT N
BRCA1 NNP N
gene NN N
) ) N
on IN N
chromosome NN N
17q21 CD N
. . N

One CD N
case NN N
was VBD N
not RB N
informative JJ N
at IN N
any DT N
of IN N
the DT N
loci NN N
tested VBD N
and CC N
was VBD N
excluded VBN N
from IN N
further JJ N
analysis NN N
. . N

RESULTS VB N
The DT N
overall JJ o
frequency NN o
of IN o
allelic JJ o
imbalance NN o
was VBD N
79 CD N
% NN N
in IN N
primary JJ N
tumors NNS N
and CC N
88 CD N
% NN N
in IN N
paired JJ N
metastases NNS N
. . N

Of IN N
24 CD p
informative JJ p
cases NNS p
, , N
14 CD N
patients NNS N
( ( N
58 CD N
% NN N
) ) N
showed VBD N
the DT N
same JJ N
pattern NN N
of IN N
allelic JJ o
loss NN o
or CC o
retention NN o
in IN N
matched JJ N
primary NN N
and CC N
metastatic JJ N
tumors NNS N
at IN N
all DT N
marker NN N
locus NN N
; : N
discordant JJ N
allelic JJ o
loss NN o
was VBD N
observed VBN N
in IN N
the DT N
remaining VBG N
10 CD N
patients NNS N
( ( N
42 CD N
% NN N
) ) N
. . N

Four CD N
patients NNS N
showed VBD N
loss NN N
of IN N
the DT N
same JJ N
allele NN o
at IN N
one CD N
or CC N
more JJR N
marker NN N
loci NN N
in IN N
both DT N
primary JJ N
and CC N
metastatic JJ N
tumors NNS N
, , N
but CC N
discordant JJ N
allelic JJ o
loss NN o
was VBD N
observed VBN N
at IN N
other JJ N
marker NN N
loci NN N
. . N

Five CD N
patients NNS N
showed VBD N
allelic JJ o
loss NN o
in IN N
at IN N
least JJS N
one CD N
genetic JJ N
marker NN N
in IN N
the DT N
metastatic JJ N
tumor NN N
but CC N
not RB N
in IN N
its PRP$ N
matched JJ N
primary JJ N
tumor NN N
. . N

Five CD N
patients NNS N
displayed JJ N
loss NN o
of IN o
one CD o
allele NN o
at IN o
one CD o
or CC N
more JJR N
marker NN N
loci NN N
in IN N
a DT N
primary JJ N
tumor NN N
but CC N
not RB N
in IN N
the DT N
matched JJ N
metastases NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
frequency NN o
of IN o
allelic JJ o
imbalance NN o
between IN N
primary JJ N
and CC N
metastatic JJ N
tumors NNS N
at IN N
any DT N
marker NN N
analyzed VBN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
different JJ N
patterns NNS N
of IN N
allelic JJ o
deletion NN o
may MD N
be VB N
acquired VBN N
during IN N
cancer NN N
progression NN N
to TO N
metastases NNS N
. . N

The DT N
differences NNS N
in IN N
genetic JJ N
composition NN N
between IN N
primary JJ N
prostate NN N
carcinoma NN N
and CC N
its PRP$ N
metastases NNS N
may MD N
be VB N
related VBN N
to TO N
intrinsic JJ N
cancer NN N
heterogeneity NN N
, , N
overall JJ N
genetic JJ N
instability NN N
, , N
and CC N
clonal JJ N
divergence NN N
. . N

-DOCSTART- -11029345- O O

Tromethamine NNP i
buffer NN i
modifies VBZ N
the DT N
depressant JJ o
effect NN o
of IN N
permissive JJ N
hypercapnia NN N
on IN N
myocardial JJ N
contractility NN N
in IN N
patients NNS p
with IN p
acute JJ p
respiratory NN p
distress NN p
syndrome NN p
. . p

In IN N
patients NNS p
with IN p
acute JJ p
respiratory NN p
distress NN p
syndrome NN p
( ( p
ARDS NNP p
) ) p
, , N
permissive JJ N
hypercapnia NN N
is VBZ N
a DT N
strategy NN N
to TO N
decrease VB N
airway RB N
pressures NNS N
to TO N
prevent VB N
ventilator-induced JJ N
lung NN N
damage NN N
by IN N
lowering VBG N
tidal JJ N
volumes NNS N
and CC N
tolerating VBG N
higher JJR N
arterial JJ N
carbon NN N
dioxide NN N
tension NN N
. . N

However RB N
, , N
in IN N
experimental JJ N
studies NNS N
hypercapnia VBP N
impairs JJ N
myocardial JJ N
contractility NN N
and CC N
hemodynamic JJ N
function NN N
. . N

We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
short-term JJ N
permissive JJ N
hypercapnia NN N
on IN N
myocardial JJ N
contractility NN N
and CC N
hemodynamics NNS N
in IN N
patients NNS p
with IN p
ARDS NNP p
. . p

We PRP N
hypothesized VBD N
that IN N
the DT N
administration NN N
of IN N
tromethamine NN i
( ( i
THAM NNP i
) ) i
, , N
a DT N
buffer NN N
which WDT N
does VBZ N
not RB N
increase VB N
carbon NN N
dioxide NN N
production NN N
, , N
would MD N
modify VB N
these DT N
changes NNS N
. . N

In IN N
12 CD p
patients NNS p
with IN p
ARDS NNP p
, , N
permissive JJ N
hypercapnia NN N
was VBD N
implemented VBN N
for IN N
2 CD N
h NN N
with IN N
a DT N
target NN N
Pa NNP N
( ( N
CO NNP N
( ( N
2 CD N
) ) N
) ) N
of IN N
80 CD N
mm NN N
Hg NNP N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
have VB N
respiratory JJ N
acidosis NN N
corrected VBN N
by IN N
THAM NNP i
( ( N
pH-corrected JJ N
group NN N
) ) N
, , N
or CC N
not RB N
corrected VBN N
( ( N
pH-uncorrected JJ N
group NN N
) ) N
. . N

Hemodynamic JJ o
responses NNS o
were VBD N
measured VBN N
, , N
and CC N
transesophageal JJ N
echocardiography NN N
( ( N
TEE NNP N
) ) N
was VBD N
used VBN N
to TO N
determine VB N
myocardial JJ N
contractility NN N
. . N

Permissive NNP N
hypercapnia NN N
resulted VBD N
in IN N
significant JJ N
decreases NNS N
in IN N
systemic JJ o
vascular JJ o
resistance NN o
( ( o
SVR NNP o
) ) o
and CC o
increases VBZ o
in IN o
cardiac JJ o
output NN o
( ( o
Q NNP o
) ) o
. . o

Myocardial JJ o
contractility NN o
decreased VBN N
in IN N
both DT N
groups NNS N
but CC N
significantly RB N
less RBR N
in IN N
the DT N
pH-corrected JJ N
group NN N
( ( N
approximately RB N
10 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
pH-uncorrected JJ N
group NN N
( ( N
approximately RB N
18 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

Mean JJ o
arterial JJ o
pressure NN o
decreased VBN N
and CC N
mean JJ o
pulmonary JJ o
arterial JJ o
pressure NN o
increased VBD N
significantly RB N
only RB N
in IN N
the DT N
pH-uncorrected JJ N
group NN N
. . N

All DT N
values NNS N
returned VBN N
to TO N
baseline VB N
conditions NNS N
1 CD N
h NN N
after IN N
permissive JJ N
hypercapnia NN N
was VBD N
terminated VBN N
. . N

Our PRP$ N
study NN N
demonstrates VBZ N
a DT N
reversible JJ N
depression NN N
of IN N
myocardial JJ o
contractility NN o
and CC o
hemodynamic JJ o
alterations NNS o
during IN N
rapid JJ N
permissive JJ N
hypercapnia NN N
which WDT N
were VBD N
attenuated VBN N
by IN N
buffering VBG N
with IN N
THAM NNP i
. . i

This DT N
may MD N
have VB N
applicability NN N
to TO N
the DT N
clinical JJ N
strategy NN N
of IN N
permissive JJ N
hypercapnia NN N
and CC N
allow VB N
the DT N
benefit NN N
of IN N
decreased JJ N
airway NN o
pressures NNS o
to TO N
be VB N
realized VBN N
while IN N
minimizing VBG N
the DT N
adverse JJ N
hemodynamic JJ N
effects NNS N
of IN N
hypercapnic JJ N
acidosis NN N
. . N

-DOCSTART- -18339093- O O

Teaching VBG N
picture-to-object JJ N
relations NNS N
in IN N
picture-based JJ N
requesting NN N
by IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
comparison NN o
between IN N
error NN i
prevention NN i
and CC N
error NN i
correction NN i
teaching NN i
procedures NNS i
. . i

BACKGROUND NNP N
Children NNP p
who WP p
have VBP p
a DT p
combination NN p
of IN p
language NN p
and CC p
developmental JJ p
disabilities NNS p
with IN p
autism NN p
often RB N
experience JJ N
major JJ N
difficulties NNS N
in IN N
learning VBG N
relations NNS N
between IN N
objects NNS N
and CC N
their PRP$ N
graphic JJ N
representations NNS N
. . N

Therefore RB N
, , N
they PRP N
would MD N
benefit VB N
from IN N
teaching VBG i
procedures NNS i
that WDT N
minimize VBP N
their PRP$ N
difficulties NNS N
in IN N
acquiring VBG N
these DT N
relations NNS N
. . N

This DT N
study NN N
compared VBN N
two CD N
teaching NN i
procedures NNS i
, , i
an DT i
error NN i
prevention NN i
procedure NN i
and CC i
an DT i
error NN i
correction NN i
procedure NN i
, , i
for IN i
teaching VBG i
relations NNS i
between IN i
objects NNS i
and CC i
pictures NNS i
. . i

METHOD JJ N
Participants NNS p
were VBD p
two CD p
groups NNS p
of IN p
children NNS p
with IN p
autism NN p
, , p
aged VBD p
between IN p
3 CD p
and CC p
7 CD p
years NNS p
. . p

In IN N
the DT N
context NN N
of IN N
picture-to-object JJ N
requesting NN N
, , N
one CD N
group NN N
was VBD N
taught VBN N
using VBG N
an DT i
error NN i
correction NN i
method NN i
and CC N
the DT N
other JJ N
group NN N
with IN N
an DT i
error NN i
prevention NN i
method NN i
. . i

The DT N
measures NNS N
for IN N
each DT N
child NN N
were VBD N
accuracy NN o
of IN o
correspondences NNS o
between IN o
taught JJ o
picture NN o
and CC o
object JJ o
pairs NNS o
and CC o
accuracy NN o
of IN o
delayed JJ o
correspondences NNS o
in IN o
learning VBG o
outcome JJ o
tests NNS o
with IN o
all DT o
combinations NNS o
of IN o
object NN o
and CC o
picture NN o
pairs NNS o
presented VBN o
to TO N
them PRP N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
The DT N
group NN N
receiving VBG N
the DT N
error NN N
prevention-based JJ i
teaching NN i
made VBN N
significantly RB N
fewer JJR N
errors NNS o
during IN N
the DT N
teaching NN N
phases NNS N
and CC N
in IN N
their PRP$ N
learning NN N
outcome NN N
test NN N
for IN N
correspondences NNS N
between IN N
all DT N
combinations NNS N
of IN N
pictures NNS N
and CC N
objects NNS N
. . N

CONCLUSIONS VB N
The DT N
error NN N
prevention NN i
teaching NN i
procedure NN i
would MD N
seem VB N
to TO N
provide VB N
a DT N
more RBR N
efficient JJ N
and CC N
ecologically RB N
valid JJ N
method NN N
than IN N
the DT N
error NN N
correction NN N
procedure NN N
for IN N
teaching VBG N
relations NNS N
between IN N
objects NNS N
and CC N
their PRP$ N
graphic-based JJ N
referents NNS N
. . N

Improvements NNS N
in IN N
the DT N
methodology NN N
were VBD N
suggested VBN N
for IN N
providing VBG N
a DT N
stronger JJR N
basis NN N
for IN N
comparison NN N
between IN N
error NN N
correction NN N
and CC N
error NN N
prevention NN N
teaching VBG N
methods NNS N
. . N

-DOCSTART- -16739368- O O

[ JJ o
Rapidity NNP o
of IN o
pain NN o
relief NN o
, , o
medication NN o
requirement NN o
and CC o
patient JJ o
satisfaction NN o
with IN p
reflux JJ p
treatment NN p
in IN N
the DT N
physician NN N
's POS N
office NN N
] NN N
. . N

Treatment NN N
of IN N
gastroesophageal NN o
reflux NN o
disease NN o
( ( o
GERD NNP o
) ) o
with IN N
proton NN o
pump NN o
inhibitors NNS o
was VBD N
investigated VBN N
in IN N
three CD N
controlled VBD N
prospective JJ N
, , N
randomized JJ N
open JJ N
studies NNS N
. . N

Lansoprazole NNP i
, , i
omeprazole JJ i
MUPS NNP i
and CC i
esomeprazole NN i
were VBD N
compared VBN N
under IN N
doctor NN N
's POS N
office NN N
conditions NNS N
. . N

The DT N
outcomes NNS N
of IN N
interest NN N
were VBD N
the DT N
rapidity NN o
of IN o
pain NN o
relief NN o
achieved VBN N
with IN N
a DT N
single JJ o
dose NN o
, , o
effectiveness NN o
and CC o
patient JJ o
satisfaction NN o
with IN N
on IN N
demand NN N
therapy NN N
. . N

In IN N
the DT N
first JJ N
study NN N
, , N
180 CD p
patients NNS p
with IN p
chronic JJ p
and CC p
prolonged JJ p
episodes NNS p
of IN p
reflux NN p
were VBD p
investigated VBN p
. . p

Time NN N
to TO N
pain VB o
relief NN o
following VBG N
a DT N
single JJ N
dose NN N
was VBD N
1.1 CD N
+/- JJ N
0.8 CD N
hours NNS N
with IN N
30 CD N
mg NNS N
lansoprazole JJ i
, , N
3.0 CD N
+/- JJ N
2.5 CD N
hours NNS N
with IN N
20 CD N
mgomeprazole JJ i
MUPS NNP N
and CC N
2.1 CD N
+/- JJ N
1.2 CD N
hours NNS N
with IN N
40 CD N
mg NNS N
esomeprazole JJ i
. . i

Studies NNS N
2 CD N
and CC N
3 CD N
were VBD N
designed VBN N
as IN N
cross-over NN N
studies NNS N
intended VBN N
to TO N
investigate VB N
drug NN o
consumption NN o
. . o

In IN N
study NN N
2 CD N
, , N
the DT N
amount NN o
of IN o
lansoprazole NN o
consumed VBN o
was VBD N
approximately RB N
50 CD N
% NN N
less JJR N
than IN N
that DT N
of IN N
omeprazole NN i
, , N
and CC N
this DT N
translated VBN N
to TO N
81 CD N
% NN N
patient JJ o
satisfaction NN o
with IN N
lansoprazole JJ i
compared VBN N
with IN N
only RB N
9.5 CD N
% NN N
for IN N
omeprazole NN i
. . i

In IN N
study NN N
3 CD N
comparing VBG N
lansoprazole NN N
and CC N
esomeprazole NN i
, , N
consumption NN o
of IN N
the DT N
former JJ N
was VBD N
85 CD N
% NN N
that WDT N
of IN N
the DT N
latter NN N
. . N

58 CD N
% NN N
of IN N
the DT N
patients NNS N
opted VBD N
to TO N
continuetreatment VB o
with IN N
lansoprazole NN i
, , N
compared VBN N
with IN N
only RB N
25 CD N
% NN N
in IN N
the DT N
case NN N
of IN N
esomeprazole NN i
. . N

The DT N
appreciably RB N
greater JJR N
patient JJ o
satisfaction NN o
with IN N
lansoprazole NN i
was VBD N
due JJ N
tothe NN N
faster RBR o
pain NN o
relief NN o
achieved VBN N
with IN N
this DT N
drug NN N
. . N

-DOCSTART- -24229362- O O

Study NNP N
protocol NN N
: : N
Rehabilitation NN i
including VBG i
Social NNP i
and CC i
Physical NNP i
activity NN i
and CC i
Education NN i
in IN N
Children NNP p
and CC p
Teenagers NNP p
with IN p
Cancer NNP p
( ( N
RESPECT NNP N
) ) N
. . N

BACKGROUND NNP N
During IN N
cancer NN N
treatment NN N
children NNS p
have VBP p
reduced VBN p
contact NN p
with IN p
their PRP$ p
social JJ p
network NN p
of IN p
friends NNS p
, , p
and CC p
have VBP p
limited VBN p
participation NN p
in IN p
education NN p
, , p
sports NNS p
, , p
and CC p
leisure NN p
activities NNS p
. . p

During IN N
and CC N
following VBG N
cancer NN N
treatment NN N
, , N
children NNS p
describe VBP N
school NN N
related VBN N
problems NNS N
, , N
reduced VBD N
physical JJ N
fitness NN N
, , N
and CC N
problems NNS N
related VBN N
to TO N
interaction NN N
with IN N
peers NNS N
. . N

METHODS/DESIGN NNP N
The DT N
RESPECT NNP N
study NN N
is VBZ N
a DT N
nationwide JJ p
population-based JJ N
prospective NN N
, , N
controlled VBN N
, , N
mixed-methods NNS N
intervention NN N
study NN N
looking VBG N
at IN N
children NNS p
aged VBN p
6-18 CD p
years NNS p
newly RB p
diagnosed VBN p
with IN p
cancer NN p
in IN p
eastern JJ p
Denmark NNP p
( ( p
n=120 NN p
) ) p
and CC p
a DT p
matched JJ p
control NN p
group NN p
in IN p
western JJ p
Denmark NNP p
( ( p
n=120 NN p
) ) p
. . p

RESPECT NNP N
includes VBZ p
Danish-speaking NNP p
children NNS p
diagnosed VBD p
with IN p
cancer NN p
and CC p
treated VBN p
at IN p
pediatric JJ p
oncology NN p
units NNS p
in IN p
Denmark NNP p
. . p

Primary JJ N
endpoints NNS N
are VBP N
the DT N
level NN o
of IN o
educational JJ o
achievement NN o
one CD o
year NN o
after IN o
the DT o
cessation NN o
of IN o
first-line JJ o
cancer NN o
therapy NN o
, , o
and CC o
the DT o
value NN o
of IN o
VO2max NNP o
one CD o
year NN o
after IN o
the DT o
cessation NN o
of IN o
first-line JJ o
cancer NN o
therapy NN o
. . o

Secondary JJ N
endpoints NNS N
are VBP N
quality NN o
of IN o
life NN o
measured VBN o
by IN o
validated JJ o
questionnaires NNS o
and CC o
interviews NNS o
, , o
and CC o
physical JJ o
performance NN o
. . o

RESPECT NNP N
includes VBZ N
a DT N
multimodal JJ i
intervention NN i
program NN i
, , i
including VBG i
ambassador-facilitated JJ i
educational JJ i
, , i
physical JJ i
, , i
and CC i
social JJ i
interventions NNS i
. . i

The DT N
educational JJ i
intervention NN i
includes VBZ N
an DT N
educational JJ i
program NN i
aimed VBN N
at IN N
the DT N
child NN p
with IN p
cancer NN p
, , N
the DT N
child NN N
's POS N
schoolteachers NNS N
and CC N
classmates NNS N
, , N
and CC N
the DT N
child NN N
's POS N
parents NNS N
. . N

Children NNP p
with IN p
cancer NN p
will MD N
each DT N
have VB N
two CD N
ambassadors NNS N
assigned VBD N
from IN N
their PRP$ N
class NN N
. . N

The DT N
ambassadors NNS N
visit VBP i
the DT i
child NN i
with IN i
cancer NN i
at IN N
the DT N
hospital NN N
at IN N
alternating VBG N
2-week JJ N
intervals NNS N
and CC i
participate VB i
in IN i
the DT i
intervention NN i
program NN i
. . i

The DT N
physical JJ i
and CC i
social JJ i
intervention NN i
examines VBZ N
the DT N
effect NN N
of IN N
early JJ N
, , N
structured VBN N
, , N
individualized VBN N
, , N
and CC N
continuous JJ N
physical JJ N
activity NN N
from IN N
diagnosis NN N
throughout IN N
the DT N
treatment NN N
period NN N
. . N

The DT N
patients NNS p
are VBP N
tested VBN N
at IN N
diagnosis NN N
, , N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
diagnosis NN N
, , N
and CC N
one CD N
year NN N
after IN N
the DT N
cessation NN N
of IN N
treatment NN N
. . N

The DT N
study NN N
is VBZ N
powered VBN N
to TO N
quantify VB N
the DT N
impact NN N
of IN N
the DT N
combined JJ N
educational JJ i
, , i
physical JJ i
, , i
and CC i
social JJ i
intervention NN i
programs NNS i
. . i

DISCUSSION NNP N
RESPECT NNP N
is VBZ N
the DT N
first JJ N
population-based JJ N
study NN N
to TO N
examine VB N
the DT N
effect NN N
of IN N
early JJ N
rehabilitation NN N
for IN N
children NNS N
with IN N
cancer NN N
, , N
and CC N
to TO N
use VB N
healthy JJ N
classmates NNS i
as IN i
ambassadors NNS i
to TO N
facilitate VB N
the DT N
normalization NN N
of IN N
social JJ N
life NN N
in IN N
the DT N
hospital NN N
. . N

For IN N
children NNS p
with IN p
cancer NN p
, , N
RESPECT NNP N
contributes VBZ N
to TO N
expanding VBG N
knowledge NN N
on IN N
rehabilitation NN N
that WDT N
can MD N
also RB N
facilitate VB N
rehabilitation NN N
of IN N
other JJ N
children NNS N
undergoing VBG N
hospitalization NN N
for IN N
long-term JJ N
illness NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials.gov NNP N
: : N
file NN N
. . N

NCT01772849 NNP N
and CC N
NCT01772862 NNP N
. . N

-DOCSTART- -19705924- O O

Pharmacokinetic-pharmacodynamic JJ o
modelling NN o
of IN N
the DT N
antihistaminic NN p
( ( p
H1 NNP p
) ) p
effect NN p
of IN p
bilastine NN i
. . i

OBJECTIVE UH N
To TO N
model VB N
the DT N
pharmacokinetic JJ o
and CC o
pharmacodynamic JJ o
relationship NN N
of IN N
bilastine NN i
, , N
a DT N
new JJ N
histamine NN N
H NNP N
( ( N
1 CD N
) ) N
receptor NN N
antagonist NN N
, , N
from IN N
single- JJ N
and CC N
multiple-dose JJ N
studies NNS p
in IN p
healthy JJ p
adult NN p
subjects NNS p
. . p

METHODS NNP N
The DT N
pharmacokinetic JJ N
model NN N
was VBD N
developed VBN N
from IN N
different JJ N
single-dose JJ N
and CC N
multiple-dose JJ N
studies NNS N
. . N

In IN p
the DT p
single-dose JJ p
studies NNS p
, , p
a DT p
total NN p
of IN p
183 CD p
subjects NNS p
received VBD p
oral JJ p
doses NNS p
of IN p
bilastine NN i
2.5 CD N
, , N
5 CD N
, , N
10 CD N
, , N
20 CD N
, , N
50 CD N
, , N
100 CD N
, , N
120 CD N
, , N
160 CD N
, , N
200 CD N
and CC N
220 CD N
mg NN N
. . N

In IN p
the DT p
multiple-dose JJ p
studies NNS p
, , p
127 CD p
healthy JJ p
subjects NNS p
received VBD p
bilastine JJ i
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
50 CD N
, , N
80 CD N
, , N
100 CD N
, , N
140 CD N
or CC N
200 CD N
mg/day NN N
as IN N
multiple JJ N
doses NNS N
during IN N
a DT N
4- JJ N
, , N
7- JJ N
or CC N
14-day JJ N
period NN N
. . N

The DT N
pharmacokinetic JJ o
profile NN o
of IN N
bilastine NN N
was VBD N
investigated VBN N
using VBG N
a DT N
simultaneous JJ N
analysis NN N
of IN N
all DT N
concentration-time JJ o
data NNS o
by IN N
means NNS N
of IN N
nonlinear JJ N
mixed-effects NNS N
modelling VBG N
population NN N
pharmacokinetic JJ N
software NN N
NONMEM NNP N
version NN N
6.1 CD N
. . N

Plasma JJ o
concentrations NNS o
were VBD N
modelled VBN N
according VBG N
to TO N
a DT N
two-compartment JJ N
open JJ N
model NN N
with IN N
first-order JJ N
absorption NN N
and CC N
elimination NN N
. . N

For IN N
the DT N
pharmacodynamic JJ N
analysis NN N
, , N
the DT N
inhibitory JJ N
effect NN N
of IN N
bilastine NN i
( ( N
inhibition NN N
of IN N
histamine-induced JJ N
wheal NN N
and CC N
flare NN N
) ) N
was VBD N
assessed VBN N
on IN N
a DT N
preselected JJ N
time NN N
schedule NN N
, , N
and CC N
the DT N
predicted JJ N
typical JJ o
pharmacokinetic JJ o
profile NN o
( ( N
based VBN N
on IN N
the DT N
pharmacokinetic JJ N
model NN N
previously RB N
developed VBN N
) ) N
was VBD N
used VBN N
. . N

An DT N
indirect JJ N
response NN N
model NN N
was VBD N
developed VBN N
to TO N
describe VB N
the DT N
pharmacodynamic JJ o
relationships NNS o
between IN N
flare NN N
or CC N
wheal JJ N
areas NNS N
and CC N
bilastine NN o
plasma NN o
concentrations NNS o
. . o

Finally RB N
, , N
once RB N
values NNS N
of IN N
the DT N
concentration NN o
that WDT o
produced VBD o
50 CD o
% NN o
inhibition NN o
( ( o
IC NNP o
( ( o
50 CD o
) ) o
) ) o
had VBD N
been VBN N
estimated VBN N
for IN N
wheal NN N
and CC N
flare NN N
effects NNS N
, , N
simulations NNS N
were VBD N
carried VBN N
out IN N
to TO N
predict VB N
plasma JJ o
concentrations NNS o
for IN N
the DT N
doses NNS N
of IN N
bilastine NN i
5 CD N
, , N
10 CD N
and CC N
20 CD N
mg NN N
at IN N
steady JJ N
state NN N
( ( N
72-96 JJ N
hours NNS N
) ) N
. . N

RESULTS VB N
A DT N
non-compartmental JJ N
analysis NN N
resulted VBD N
in IN N
linear JJ N
kinetics NNS N
of IN N
bilastine NN i
in IN N
the DT N
dose JJ N
range NN N
studied VBN N
. . N

Bilastine NNP N
was VBD N
characterized VBN N
by IN N
two-compartmental JJ N
kinetics NNS N
with IN N
a DT N
rapid-absorption NN N
phase NN N
( ( N
first-order JJ N
absorption NN N
rate NN N
constant JJ N
= NN N
1.50 CD N
h NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
plasma JJ o
peak NN o
concentrations NNS o
were VBD N
observed VBN N
at IN N
1 CD N
hour NN N
following VBG N
administration NN N
and CC N
the DT N
maximal JJ o
response NN o
was VBD N
observed VBN N
at IN N
approximately RB N
4 CD N
hours NNS N
or CC N
later RB N
. . N

Concerning VBG N
the DT N
selected VBN N
pharmacodynamic JJ N
model NN N
to TO N
fit VB N
the DT N
data NN N
( ( N
type NN N
I PRP N
indirect VBP N
response NN N
model NN N
) ) N
, , N
this DT N
selection NN N
is VBZ N
attributable JJ N
to TO N
the DT N
presence NN N
of IN N
inhibitory JJ o
bilastine NN o
plasma NN o
concentrations NNS o
that WDT N
decrease VBP N
the DT N
input NN o
response NN o
function NN o
, , N
i.e NN N
. . N

the DT N
production NN N
of IN N
the DT N
skin JJ N
reaction NN N
. . N

This DT N
model NN N
resulted VBD N
in IN N
the DT N
best JJS N
fit NN N
of IN N
wheal NN N
and CC N
flare NN N
data NNS N
. . N

The DT N
estimates NNS N
( ( N
with IN N
relative JJ N
standard JJ N
errors NNS N
expressed VBD N
in IN N
percentages NNS N
in IN N
parentheses NNS N
) ) N
of IN N
the DT N
apparent JJ o
zero-order NN o
rate NN o
constant NN o
for IN o
flare NN o
or CC o
wheal NN o
spontaneous JJ o
appearance NN o
( ( N
k NN N
( ( N
in IN N
) ) N
) ) N
, , N
the DT N
first-order JJ o
rate NN o
constant NN o
for IN o
flare NN o
or CC o
wheal JJ o
disappearance NN o
( ( N
k NN N
( ( N
out IN N
) ) N
) ) N
and CC N
bilastine JJ o
IC NNP o
( ( o
50 CD o
) ) o
values NNS o
were VBD N
0.44 CD N
ng/mL/h NNS N
( ( N
14.60 CD N
% NN N
) ) N
, , N
1.09 CD N
h NN N
( ( N
-1 NN N
) ) N
( ( N
15.14 CD N
% NN N
) ) N
and CC N
5.15 CD N
ng/mL NN N
( ( N
16.16 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
for IN N
wheal JJ N
inhibition NN N
, , N
and CC N
11.10 CD N
ng/mL/h NN N
( ( N
8.48 CD N
% NN N
) ) N
, , N
1.03 CD N
h NN N
( ( N
-1 NN N
) ) N
( ( N
8.35 CD N
% NN N
) ) N
and CC N
1.25 CD N
ng/mL NN N
( ( N
14.56 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
for IN N
flare JJ N
inhibition NN N
. . N

The DT N
simulation NN N
results NNS N
revealed VBD N
that IN N
bilastine NN o
plasma NN o
concentrations NNS o
do VBP N
not RB N
remain VB N
over IN N
the DT N
IC NNP N
( ( N
50 CD N
) ) N
value NN N
throughout IN N
the DT N
inter-dose JJ N
period NN N
for IN N
doses NNS N
of IN N
5 CD N
and CC N
10 CD N
mg NN N
. . N

However RB N
, , N
with IN N
a DT N
dose NN N
of IN N
20 CD N
mg NN N
of IN N
bilastine NN i
administered VBN N
every DT N
24 CD N
hours NNS N
, , N
plasma JJ o
concentrations NNS o
remained VBD N
over IN N
the DT N
IC NNP N
( ( N
50 CD N
) ) N
value NN N
during IN N
the DT N
considered JJ N
period NN N
for IN N
the DT N
flare NN N
effect NN N
, , N
and CC N
up RB N
to TO N
20 CD N
hours NNS N
for IN N
the DT N
wheal JJ N
effect NN N
. . N

CONCLUSION NNP N
Pharmacokinetic NNP N
and CC N
pharmacodynamic JJ N
relationships NNS N
of IN N
bilastine NN N
were VBD N
reliably RB N
described VBN N
with IN N
the DT N
use NN N
of IN N
an DT N
indirect JJ N
response NN N
pharmacodynamic JJ N
model NN N
; : N
this DT N
led VBD N
to TO N
an DT N
accurate JJ N
prediction NN N
of IN N
the DT N
pharmacodynamic JJ N
activity NN N
of IN N
bilastine NN N
. . N

-DOCSTART- -14649341- O O

Intraperitoneal NNP N
application NN N
of IN N
bupivacaine NN i
plus CC N
morphine NN i
for IN N
pain NN o
relief NN o
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Intraperitoneal NNP N
administration NN N
of IN N
a DT N
local JJ N
anaesthetic NN N
in IN N
combination NN N
with IN N
an DT N
opioid NN i
, , N
for IN N
the DT N
relief NN N
of IN N
postoperative JJ o
pain NN o
, , N
has VBZ N
already RB N
been VBN N
reported VBN N
except IN N
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

This DT N
study NN N
was VBD N
aimed VBN N
at IN N
assessing VBG N
the DT N
analgesic JJ N
effect NN N
of IN N
the DT N
intraperitoneal JJ N
administration NN N
of IN N
bupivacaine NN i
and CC i
morphine NN i
in IN N
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
. . p

METHODS NNP N
At IN N
the DT N
end NN N
of IN N
laparoscopic JJ N
cholecystectomy NN N
, , N
in IN N
a DT N
double-blind NN N
, , N
randomized JJ N
manner NN N
, , N
one CD N
of IN N
the DT N
following JJ N
injections NNS N
was VBD N
given VBN N
intraperitoneally RB N
. . N

There EX N
were VBD N
30 CD p
patients NNS p
in IN p
each DT p
group NN p
: : p
Group NNP N
1 CD N
, , N
physiological JJ i
saline NN i
30 CD N
mL NN N
; : N
Group NNP N
2 CD N
, , N
bupivacaine VBP i
0.25 CD N
% NN N
30 CD N
mL NN N
; : N
Group NNP N
3 CD N
, , N
bupivacaine VBP i
0.25 CD N
% NN N
30 CD N
mL NN N
plus CC i
morphine JJ i
2 CD N
mg NN N
. . N

In IN N
addition NN N
, , N
Group NNP N
2 CD N
received VBD N
2 CD N
mg NNS N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
morphine NN i
in IN N
2 CD N
mL NNS N
saline NN i
, , N
and CC N
Groups NNP N
1 CD N
and CC N
3 CD N
, , N
2 CD N
mL NN N
saline NN i
intravenously RB N
. . N

Patients NNS N
' POS N
postoperative JJ o
pain NN o
was VBD N
evaluated VBN N
using VBG N
a DT N
visual JJ o
analogue NN o
scale NN o
and CC N
a DT N
verbal JJ o
rating NN o
score NN o
. . o

The DT N
postoperative JJ N
analgesic JJ N
requirement NN N
was VBD N
assessed VBN N
by IN N
the DT N
total JJ N
dose NN N
of IN N
metamizol NN o
administered VBN N
by IN N
an DT N
i.v NN N
. . N

patient-controlled JJ o
analgesia NN o
( ( o
PCA NNP o
) ) o
device NN N
. . N

Pain NNP o
, , o
vital JJ o
signs NNS o
, , o
supplemental JJ o
analgesic JJ o
consumption NN o
and CC o
side-effects NNS o
were VBD N
recorded VBN N
for IN N
all DT N
patients NNS N
for IN N
24 CD N
h. JJ N
RESULTS NNP N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
regarding VBG N
pain NN o
scores NNS o
( ( N
at IN N
rest NN N
and CC N
coughing VBG N
) ) N
during IN N
the DT N
study NN N
except IN N
in IN N
the DT N
first JJ N
2 CD N
h NN N
, , N
when WRB N
scores NNS N
were VBD N
lower JJR N
for IN N
patients NNS N
receiving VBG N
intraperitoneal JJ N
bupivacaine NN i
plus CC N
i.v NN N
. . N

morphine NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Supplemental JJ o
consumption NN o
of IN o
metamizol NN o
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
Group NNP N
3 CD N
than IN N
in IN N
Group NNP N
1 CD N
during IN N
the DT N
first JJ N
6 CD N
h NN N
after IN N
surgery NN N
. . N

However RB N
, , N
the DT N
cumulative JJ o
doses NNS o
of IN N
metamizol NN N
were VBD N
also RB N
lower JJR N
in IN N
Group NNP N
2 CD N
than IN N
in IN N
Groups NNP N
1 CD N
and CC N
3 CD N
over IN N
the DT N
entire JJ N
study NN N
( ( N
2025 CD N
+/- NN N
1044 CD N
mg NN N
vs. FW N
4925 CD N
+/- JJ N
1238 CD N
and CC N
4125 CD N
+/- JJ N
1276mg CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
, , N
the DT N
intraperitoneal JJ N
administration NN N
of IN N
morphine JJ i
plus CC N
bupivacaine JJ i
0.25 CD N
% NN N
reduced VBD N
the DT N
analgesic JJ o
requirements NNS o
during IN N
the DT N
first JJ N
6 CD N
postoperative JJ N
hours NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
the DT N
combination NN N
of IN N
intraperitoneal JJ N
bupivacaine JJ i
0.25 CD N
% NN N
and CC N
i.v NN N
. . N

morphine NN i
was VBD N
more RBR N
effective JJ N
for IN N
treatment NN N
of IN N
pain NN o
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

-DOCSTART- -22795327- O O

Selected VBN N
polymorphisms NNS N
of IN N
GSTP1 NNP N
and CC N
TERT NNP N
were VBD N
associated VBN N
with IN N
glioma NN p
risk NN p
in IN p
Han NNP p
Chinese NNP p
. . p

BACKGROUND NNP N
Current NNP N
evidence NN N
suggests VBZ N
that IN N
a DT N
majority NN N
of IN N
the DT N
inherited JJ N
risks NNS N
play VBP N
a DT N
major JJ N
role NN N
in IN N
glioma JJ p
susceptibility NN p
, , N
and CC N
glioma NN N
is VBZ N
due JJ N
to TO N
the DT N
co-inheritance NN N
of IN N
multiple JJ N
low-risk JJ N
variants NNS N
. . N

These DT N
variants NNS N
can MD N
be VB N
identified VBN N
through IN N
association NN N
studies NNS N
including VBG N
such JJ N
as IN N
genome-wide JJ N
association NN N
studies NNS N
( ( N
GWAS NNP N
) ) N
, , N
which WDT N
has VBZ N
led VBN N
the DT N
glioma NN N
epidemiology NN N
researchers NNS N
to TO N
focus VB N
on IN N
identifying VBG N
potential JJ N
disease-causing JJ N
factors NNS N
. . N

METHODS NNP N
We PRP N
evaluated VBD N
and CC N
validated VBD N
10 CD p
tag NN p
single JJ p
nucleotide JJ p
polymorphisms NN p
( ( p
tSNPs NN p
) ) p
in IN p
seven CD p
genes NNS p
associated VBN p
with IN p
glioma NN p
susceptibility NN p
in IN p
a DT p
Han NNP p
Chinese NNP p
population NN p
, , p
including VBG p
301 CD p
glioma NN p
cases NNS p
and CC p
302 CD p
controls NNS p
, , p
using VBG p
a DT p
multiplexed JJ i
single JJ i
nucleotide NN i
polymorphism NN i
( ( i
SNP NNP i
) ) i
MassEXTEND NNP i
assay NN i
. . i

We PRP N
ascertained VBD N
the DT N
genotypic NN N
frequencies NNS N
for IN N
each DT N
tSNP NN N
in IN N
control NN N
subjects NNS N
were VBD N
within IN N
Hardy-Weinberg NNP N
equilibrium NN N
( ( N
HWE NNP N
) ) N
using VBG N
an DT N
exact JJ N
test NN N
, , N
and CC N
then RB N
compared VBN N
the DT N
genotype NN N
and CC N
allele JJ N
frequencies NNS N
of IN N
glioma NN N
patients NNS N
and CC N
control NN N
subjects NNS N
using VBG N
the DT N
?2 JJ N
test NN N
. . N

We PRP N
then RB N
applied VBD N
three CD N
genetic JJ N
models NNS N
( ( N
dominant JJ N
, , N
recessive JJ N
, , N
and CC N
additive JJ N
) ) N
using VBG N
PLINK NNP N
software NN N
to TO N
assess VB N
the DT N
association NN N
of IN N
each DT N
tSNP NN N
with IN N
glioma NN N
risk NN N
. . N

RESULTS NNP N
We PRP N
identified VBD N
two CD N
tSNPs NN N
to TO N
be VB N
associated VBN N
with IN o
glioma NN o
susceptibility NN o
( ( N
rs1695 NN N
, , N
GSTP1 NNP N
, , N
P NNP N
= NNP N
0.019 CD N
; : N
rs2853676 NN N
, , N
TERT NNP N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
which WDT N
we PRP N
confirmed VBD N
using VBG N
dominant NN N
and CC N
additive JJ N
model NN N
analyses NNS N
. . N

The DT N
genotype NN N
& CC N
ldquo NN N
; : N
GA NNP N
& CC N
rdquo NN N
; : N
for IN N
rs1695 NN N
was VBD N
recognized VBN N
to TO N
be VB N
a DT N
protective JJ N
genotype NN N
for IN o
glioma NN o
( ( N
OR NNP N
, , N
0.67 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.47-0.96 NNP N
; : N
P NNP N
= NNP N
0.027 CD N
) ) N
, , N
while IN N
the DT N
genotype NN N
& CC N
ldquo NN N
; : N
AG NNP N
& CC N
rdquo NN N
; : N
for IN N
rs2853676 NN N
was VBD N
shown VBN N
to TO N
be VB N
a DT N
risk NN N
genotype NN N
for IN o
glioma NN o
( ( N
OR NNP N
, , N
1.50 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.05-2.15 JJ N
; : N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
, , N
and CC N
those DT N
from IN N
previous JJ N
studies NNS N
, , N
suggest VBP N
potential JJ N
genetic JJ N
contributes NNS N
for IN N
GSTP1 NNP N
and CC N
TERT NNP N
in IN N
glioma NN N
development NN N
. . N

-DOCSTART- -18989547- O O

Comparison NNP N
between IN N
intermittent JJ i
mandatory JJ i
ventilation NN i
and CC N
synchronized JJ i
intermittent NN i
mandatory JJ i
ventilation NN i
with IN N
pressure NN i
support NN i
in IN p
children NNS p
. . p

OBJECTIVE NN N
To TO N
compare VB N
intermittent JJ i
mandatory JJ i
ventilation NN i
( ( i
IMV NNP i
) ) i
with IN N
synchronized JJ i
intermittent JJ i
mandatory NN i
ventilation NN i
plus CC i
pressure NN i
support NN i
( ( i
SIMV+PS NNP i
) ) i
in IN N
terms NNS N
of IN N
time NN o
on IN o
mechanical JJ o
ventilation NN o
, , o
duration NN o
of IN o
weaning VBG o
and CC o
length NN o
of IN o
stay NN o
in IN o
a DT o
pediatric JJ o
intensive JJ o
care NN o
unit NN o
( ( p
PICU NNP p
) ) p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
clinical JJ N
trial NN N
that WDT N
enrolled VBD p
children NNS p
aged VBN p
28 CD p
days NNS p
to TO p
4 CD p
years NNS p
who WP p
were VBD p
admitted VBN p
to TO p
a DT p
PICU NNP p
between IN p
October NNP p
of IN p
2005 CD p
and CC p
June NNP p
of IN p
2007 CD p
and CC p
put VB p
on IN p
mechanical JJ i
ventilation NN i
( ( i
MV NNP i
) ) i
for IN p
more JJR p
than IN p
48 CD p
hours NNS p
. . p

These DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
by IN N
drawing VBG N
lots NNS N
: : N
IMV NNP i
group NN N
( ( i
IMVG NNP i
; : i
n CC N
= VB N
35 CD N
) ) N
and CC N
SIMV+PS NNP i
group NN N
( ( i
SIMVG NNP i
; : i
n CC N
= VB N
35 CD N
) ) N
. . N

Children NNP p
were VBD p
excluded VBN p
if IN p
they PRP p
had VBD p
undergone JJ p
tracheotomy NN p
or CC p
had VBD p
chronic JJ p
respiratory NN p
diseases NNS p
. . p

Data NNS N
on IN N
oxygenation NN o
and CC o
ventilation NN o
were VBD N
recorded VBN N
at IN N
admission NN N
and CC N
at IN N
the DT N
start NN N
of IN N
weaning VBG N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
terms NNS N
of IN N
age NN o
, , o
sex NN o
, , o
indication NN o
for IN o
MV NNP o
, , o
PRISM NNP o
score NN o
, , o
Comfort NNP o
scale NN o
, , o
use NN o
of IN o
sedatives NNS o
or CC o
ventilation NN o
and CC o
oxygenation NN o
parameters NNS o
. . o

The DT N
median JJ o
time NN o
on IN o
MV NNP o
was VBD N
5 CD N
days NNS N
for IN N
both DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.120 CD N
) ) N
. . N

There EX N
were VBD N
also RB N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
for IN N
duration NN o
of IN o
weaning VBG o
[ JJ i
IMVG NNP i
: : i
1 CD N
day NN N
( ( N
1-6 JJ N
) ) N
vs. FW N
SIMVG NNP i
: : i
1 CD N
day NN N
( ( N
1-6 JJ N
) ) N
; : N
p CC N
= $ N
0.262 CD N
] NN N
or CC N
length NN o
of IN o
hospital NN o
stay NN o
[ JJ i
IMVG NNP i
: : i
8 CD N
days NNS N
( ( N
2-22 JJ N
) ) N
vs. FW N
SIMVG NNP i
: : i
6 CD N
days NNS N
( ( N
3-20 JJ N
) ) N
; : N
p CC N
= $ N
0.113 CD N
] NNP N
. . N

CONCLUSION NNP N
Among IN N
the DT N
children NNS p
studied VBN p
here RB p
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
IMV NNP i
and CC N
SIMV+PS NNP i
in IN N
terms NNS N
of IN N
time NN N
on IN N
MV NNP o
, , o
duration NN o
of IN o
weaning VBG o
or CC o
time NN o
spent VBN o
in IN o
the DT o
PICU NNP o
. . o

ClinicalTrials.govID NN N
: : N
NCT00549809 NNP N
. . N

-DOCSTART- -16909273- O O

A DT N
comparative JJ o
study NN o
of IN o
the DT o
pharmacokinetics NNS o
of IN N
ibuprofen JJ i
arginate NN i
versus NN i
dexibuprofen NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

OBJECTIVE NNP N
Ibuprofen NNP i
arginate NN i
is VBZ N
a DT N
salt JJ N
formulation NN N
of IN N
ibuprofen NN i
designed VBN N
to TO N
reach VB N
target NN N
concentrations NNS N
rapidly RB N
. . N

The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
12-h JJ N
pharmacokinetic JJ o
profile NN o
of IN N
S NNP i
( ( i
+ NNP i
) ) i
-ibuprofen VBD i
following VBG N
administration NN N
of IN N
single JJ N
doses NNS N
of IN N
ibuprofen JJ i
arginate NN i
( ( N
600 CD N
mg NN N
) ) N
and CC N
dexibuprofen NN i
( ( N
400 CD N
mg NN N
) ) N
in IN N
healthy JJ p
volunteers NNS p
. . p

METHODS NNP N
Twenty-four JJ p
volunteers NNS p
were VBD p
recruited VBN p
into IN p
an DT p
open-label JJ p
, , p
randomised JJ p
, , p
two-period JJ p
, , p
single-centre JJ p
study NN p
with IN N
crossover NN N
design NN N
. . N

RESULTS NNP N
Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
. . N

Ibuprofen NNP i
arginate NN i
and CC N
dexibuprofen NN i
showed VBD N
similar JJ N
bioavailability NN o
for IN o
S NNP o
( ( o
+ NNP o
) ) o
-ibuprofen NN o
. . o

Compared VBN N
with IN N
dexibuprofen NN i
, , i
ibuprofen JJ i
arginate NN i
demonstrated VBD N
a DT N
45 CD N
% NN N
higher JJR N
maximum JJ o
concentration NN o
( ( o
C NNP o
( ( o
max NN o
) ) o
) ) o
, , N
and CC N
a DT N
time NN o
to TO o
peak VB o
concentration NN o
( ( o
T NNP o
( ( o
max NN o
) ) o
) ) o
2 CD N
h NN N
sooner NN N
. . N

CONCLUSION NNP N
Ibuprofen NNP i
arginate NN i
approaches NNS N
maximum JJ N
concentrations NNS N
of IN N
S NNP N
( ( N
+ NNP N
) ) N
-ibuprofen VBP N
faster RBR N
and CC N
higher JJR N
than IN N
dexibuprofen NN i
. . i

-DOCSTART- -6352035- O O

A DT N
comparative JJ N
study NN N
of IN N
netilmicin-cefoxitin JJ i
and CC N
gentamicin-cefoxitin JJ i
in IN N
surgical JJ p
patients NNS p
with IN p
serious JJ p
systemic JJ p
infection NN p
. . p

A DT N
double-blind NN N
, , N
randomized VBN N
study NN N
of IN N
gentamicin NN i
and CC N
netilmicin NN i
, , N
each DT N
in IN N
combination NN N
with IN N
cefoxitin NN i
, , N
was VBD N
done VBN N
to TO N
compare VB N
their PRP$ N
respective JJ N
efficacy NN o
and CC o
toxicity NN o
in IN N
patients NNS p
with IN p
serious JJ p
systemic JJ p
infection NN p
. . p

Thirty-seven JJ p
surgical JJ p
patients NNS p
were VBD p
evaluated VBN p
for IN p
efficacy NN o
and CC p
46 CD p
patients NNS p
were VBD p
evaluated VBN p
for IN p
toxicity NN p
. . p

The DT N
most RBS N
frequently RB N
cultured VBN N
organisms NNS N
were VBD N
Escherichia NNP N
coli NNS N
( ( N
15 CD N
) ) N
, , N
Klebsiella NNP N
sp NN N
( ( N
9 CD N
) ) N
, , N
Proteus NNP N
sp NN N
( ( N
6 CD N
) ) N
, , N
and CC N
Bacteroides NNP N
sp NN N
( ( N
4 CD N
) ) N
. . N

For IN N
23 CD N
patients NNS N
treated VBN N
with IN N
gentamicin-cefoxitin JJ i
( ( N
G-C NNP N
) ) N
, , N
the DT N
clinical JJ o
response NN o
was VBD N
favorable JJ N
in IN N
20/21 CD N
( ( N
95.2 CD N
% NN N
) ) N
evaluable JJ N
cases NNS N
, , N
and CC N
elimination NN N
or CC N
marked VBN N
reduction NN N
of IN N
33/34 CD N
( ( N
97.1 CD N
% NN N
) ) N
organisms NN N
was VBD N
achieved VBN N
. . N

For IN N
14 CD N
patients NNS N
treated VBN N
with IN N
netilmicin-cefoxitin JJ i
( ( N
N-C NNP N
) ) N
, , N
the DT N
clinical JJ o
response NN o
was VBD N
favorable JJ N
in IN N
13/13 CD N
( ( N
100 CD N
% NN N
) ) N
evaluable JJ N
cases NNS N
, , N
and CC N
19/20 CD N
( ( N
95 CD N
% NN N
) ) N
organisms WDT N
were VBD N
eliminated VBN N
or CC N
markedly RB N
reduced VBN N
. . N

Nephrotoxicity NNP o
was VBD N
defined VBN N
as IN N
an DT N
increase NN N
in IN N
serum JJ o
creatinine NN o
to TO N
greater JJR N
than IN N
25 CD N
% NN N
over IN N
baseline NN N
with IN N
an DT N
absolute JJ N
rise NN N
of IN N
at IN N
least JJS N
0.5 CD N
mg/100 JJ N
ml NN N
to TO N
a DT N
value NN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
1.3 CD N
mg/100 NN N
ml NN N
. . N

Based VBN N
on IN N
these DT N
criteria NNS N
, , N
nephrotoxicity NN o
was VBD N
seen VBN N
in IN N
2/27 CD N
( ( N
7.4 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
G-C NNP N
and CC N
in IN N
3/19 CD N
( ( N
15.8 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
N-C. NNP N
Ototoxicity NNP o
was VBD N
defined VBN N
as IN N
a DT N
greater JJR N
than IN N
20 CD N
dB JJ N
loss NN N
at IN N
any DT N
frequency NN N
. . N

Based VBN N
on IN N
these DT N
criteria NNS N
, , N
ototoxicity NN o
was VBD N
seen VBN N
in IN N
5/27 CD N
( ( N
18.5 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
G-C NNP N
and CC N
2/19 CD N
( ( N
10.5 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
N-C NNP N
. . N

The DT N
data NN N
show NN N
no DT N
significant JJ N
difference NN N
in IN N
toxicity NN o
and CC N
suggest VBP N
that IN N
netilmicin NN N
and CC N
gentamicin NN N
are VBP N
both DT N
highly RB N
effective JJ N
in IN N
combination NN N
with IN N
cefoxitin NN N
in IN N
patients NNS p
who WP p
have VBP p
serious JJ p
infections NNS p
after IN p
surgery NN p
. . p

-DOCSTART- -20220293- O O

Efficacy NN N
and CC N
safety NN N
of IN N
two CD i
different JJ i
testosterone NN i
undecanoate JJ i
formulations NNS i
in IN N
hypogonadal JJ p
men NNS p
with IN p
metabolic JJ p
syndrome NN p
. . p

AIM NNP N
To TO N
investigate VB N
efficacy NN N
and CC N
safety NN N
of IN N
two CD i
different JJ i
preparations NNS i
of IN i
testosterone NN i
undecanoate NN i
( ( i
TU NNP i
) ) i
in IN N
52 CD p
hypogonadal JJ p
men NNS p
[ VBP p
mean JJ p
age NN p
57 CD p
yr NN p
and CC p
mean VB p
testosterone NN p
( ( p
T NNP p
) ) p
< VBD p
320 CD p
ng/dl JJ p
] NN p
with IN p
metabolic JJ p
syndrome NN p
( ( p
MS NNP p
) ) p
. . p

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
double-dummy JJ N
study NN N
with IN N
three CD N
parallel JJ N
treatment NN N
arms NNS N
[ VBP N
oral JJ N
TU NNP N
; : N
transdermal JJ i
placebo NN i
gel NN i
( ( N
P NNP N
) ) N
; : N
im JJ N
TU NNP i
] NNP i
administration NN N
for IN N
12 CD N
months NNS N
( ( N
mo NN N
) ) N
. . N

Each DT N
subject NN N
was VBD N
randomized VBN N
( ( N
1:1:3 CD N
) ) N
to TO N
receive VB N
either DT N
oral JJ i
TU NNP i
( ( N
2 CD N
capsules NNS N
of IN N
40 CD N
mg/twice NNS N
per IN N
day NN N
at IN N
breakfast NN N
and CC N
dinner NN N
, , N
equalling VBG N
a DT N
total JJ N
dose NN N
of IN N
160 CD N
mg/day NN N
; : N
no.=10 CC N
) ) N
for IN N
6 CD N
mo NN N
and CC N
continued VBN N
with IN N
im JJ N
TU NNP N
for IN N
further JJ N
6 CD N
mo NN N
, , N
or CC N
P NNP i
( ( N
3-4 JJ N
g/day NN N
; : N
no.=10 CC N
) ) N
and CC N
im JJ i
TU NNP i
( ( N
1000 CD N
mg/12 NN N
weeks NNS N
from IN N
week NN N
6 CD N
; : N
no.=32 NNS N
) ) N
for IN N
12 CD N
mo NNS N
. . N

RESULTS NNP N
After IN N
6 CD N
mo NN N
, , N
im JJ N
TU NNP i
increased VBD N
T NNP o
and CC o
free- JJ o
T NNP o
levels NNS o
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
, , N
and CC N
improved VBN N
metabolic JJ o
parameters NNS o
[ VBP N
reduction NN N
in IN N
Homeostasis NNP o
Model NNP o
Assessment NNP o
( ( o
HOMA NNP o
) ) o
index NN o
, , N
p NN N
< VBD N
0.0001 CD N
; : N
waist JJ o
circumference NN o
and CC o
fat JJ o
mass NN o
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
] JJ N
, , N
in IN N
International NNP o
Index NNP o
of IN o
Erectile NNP o
Function-5 NNP o
and CC o
Aging NNP o
Males NNP o
' POS o
Symptoms NNP o
scores NNS o
( ( N
p VB N
< RB N
0.01 CD N
, , N
respectively RB N
) ) N
. . N

After IN N
12 CD N
months NNS N
, , N
im JJ i
TU NNP i
produced VBD N
further JJ N
increases NNS N
in IN N
T NNP o
and CC o
free- JJ o
T NNP o
levels NNS o
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
and CC N
metabolic JJ o
parameters NNS o
( ( N
reduction NN N
in IN N
HOMA-index NNP o
, , N
p NN N
< VBD N
0.0001 CD N
; : N
waist JJ o
circumference NN o
p NN N
< VBZ N
0.0001 CD N
; : N
fat JJ o
mass NN o
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
major JJ N
adverse JJ N
event NN N
due JJ N
to TO N
T NNP N
treatment NN N
occurred VBD N
. . N

CONCLUSIONS NNP N
Clinical NNP N
efficacy NN N
of IN N
T NNP N
replacement NN N
therapy NN N
in IN N
hypogonadal JJ p
men NNS p
with IN p
MS NNP p
is VBZ N
reached VBN N
when WRB N
its PRP$ N
plasmatic JJ N
levels NNS N
approach VBP N
into IN N
the DT N
medium-high JJ N
range NN N
of IN N
normality NN N
( ( N
> JJ N
5 CD N
ng/ml NN N
) ) N
, , N
although IN N
subjective JJ N
threshold JJ N
values NNS N
may MD N
be VB N
different JJ N
. . N

Administration NN N
of IN N
im JJ N
TU NNP i
was VBD N
more RBR N
effective JJ N
than IN N
oral JJ N
TU NNP N
to TO N
reach VB N
the DT N
target NN N
for IN N
T NNP o
levels NNS o
and CC N
to TO N
improve VB N
MS NNP N
parameters NNS N
. . N

TU NNP N
was VBD N
safe JJ N
over IN N
12 CD N
months NNS N
and CC N
discontinuation NN N
rates NNS N
were VBD N
similar JJ N
to TO N
placebo VB i
. . i

-DOCSTART- -15088136- O O

Bisphosphonate JJ i
infusions NNS i
: : i
patient NN o
preference NN o
, , o
safety NN o
and CC o
clinic JJ o
use NN o
. . o

GOALS NNP N
OF NNP N
WORK NNP N
We PRP N
set VBD N
out RP N
to TO N
assess VB N
the DT N
preference NN N
of IN N
patients NNS p
with IN p
common JJ p
cancers NNS p
involving VBG p
bone NN p
receiving VBG p
intravenous JJ p
bisphosphonate NN i
therapy NN i
for IN N
either DT N
pamidronate NN i
( ( i
P NNP i
) ) i
or CC i
zoledronic JJ i
acid NN i
( ( i
Z NNP i
) ) i
and CC N
their PRP$ N
preference NN N
for IN N
the DT N
location NN N
of IN N
the DT N
infusion NN N
( ( N
clinic JJ N
or CC N
home NN N
) ) N
. . N

We PRP N
also RB N
aimed VBD N
to TO N
monitor VB N
these DT N
patients NNS N
' POS N
renal JJ o
safety NN o
, , N
and CC N
to TO N
compare VB N
their PRP$ N
time NN N
in IN N
clinic NN N
to TO N
receive VB N
P NNP i
and CC i
Z NNP i
infusions NNS i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Enrolled NNP p
in IN p
the DT p
study NN p
were VBD p
184 CD p
patients NNS p
, , N
and CC N
all DT N
received VBD N
initial JJ N
infusions NNS i
of IN i
Z NNP i
( ( N
so RB N
any DT N
first JJ N
infusion NN N
reactions NNS N
did VBD N
not RB N
confound VB N
preferences NNS N
for IN N
P NNP N
) ) N
. . N

For IN N
their PRP$ N
second JJ N
and CC N
third JJ N
infusions NNS N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
Z NNP i
then RB i
P NNP i
or CC i
P NNP i
then RB i
Z NNP i
, , N
and CC N
questioned VBD N
on IN N
their PRP$ N
preferences NNS N
. . N

For IN N
up IN N
to TO N
1 CD N
year NN N
they PRP N
continued VBD N
on IN N
Z NNP i
infusions NNS i
every DT N
3-4 JJ N
weeks NNS N
, , N
while IN N
their PRP$ N
renal JJ N
safety NN N
was VBD N
monitored VBN N
. . N

Where NNP N
practical JJ N
, , N
later JJ N
infusions NNS N
were VBD N
given VBN N
at IN N
home NN N
( ( N
rather RB N
than IN N
in IN N
the DT N
clinic NN N
) ) N
and CC N
patients NNS N
questioned VBN N
on IN N
their PRP$ N
preferred JJ N
infusion NN N
location NN N
. . N

In IN N
a DT N
convenience NN N
subset NN N
of IN N
43 CD N
patients NNS N
, , N
clinic JJ N
use NN N
for IN N
Z NNP i
and CC i
P NNP i
infusions NNS i
was VBD N
also RB N
measured VBN N
by IN N
timing VBG N
infusions NNS N
and CC N
other JJ N
procedures NNS N
. . N

MAIN NNP N
RESULTS NNP N
Of IN N
144 CD N
patients NNS N
who WP N
received VBD N
a DT N
third JJ N
infusion NN N
, , N
138 CD N
responded VBD N
to TO N
questions NNS N
on IN N
bisphosphonate NN N
preference NN N
, , N
and CC N
of IN N
these DT N
138 CD N
, , N
92 CD N
% NN N
( ( N
127 CD N
) ) N
preferred VBD N
Z NNP i
to TO i
P VB i
, , N
because IN N
shorter JJR N
infusions NNS N
caused VBD N
less JJR N
disruption NN o
to TO o
their PRP$ o
day NN o
. . o

Only RB N
12 CD p
% NN p
of IN p
eligible JJ p
patients NNS p
( ( p
16/138 CD p
) ) p
received VBD N
home NN N
infusions NNS N
, , N
but CC N
13/14 CD N
questioned VBD N
preferred VBN N
this DT N
location NN N
. . N

Among IN N
184 CD N
patients NNS N
, , N
19 CD N
episodes NNS N
of IN N
renal JJ o
impairment NN o
were VBD N
noted VBN N
, , N
mostly RB N
owing VBG N
to TO N
disease VB o
progression NN o
( ( N
e.g JJ N
. . N

obstructive JJ N
uropathy JJ N
) ) N
, , N
with IN N
none NN N
linked VBN N
to TO N
Z NNP N
therapy NN N
. . N

The DT N
mean JJ o
clinic JJ o
time NN o
taken VBN o
to TO o
receive VB o
Z NNP o
and CC o
any DT o
concomitant JJ o
therapy NN o
was VBD N
about IN N
half PDT N
that DT N
for IN N
P NNP N
( ( N
78 CD N
vs RB N
161 CD N
min NN N
) ) N
. . N

CONCLUSIONS NNP N
Cancer NNP p
patients NNS p
prefer VBP N
shorter JJR N
bisphosphonate JJ o
infusions-and NN o
at IN N
home NN N
, , N
where WRB N
practical JJ N
. . N

Regular JJ N
Z NNP i
4 CD i
mg NN i
infusions NNS i
appear VBP N
to TO N
be VB N
safe JJ o
in IN N
these DT N
patients NNS N
, , N
with IN N
routine JJ N
monitoring NN N
of IN N
serum JJ N
creatinine NN N
. . N

Using VBG N
Z NNP i
rather RB i
than IN i
P NNP i
could MD N
save VB N
busy JJ N
cancer NN N
centres NNS N
time NN N
and CC N
improve VB N
patient JJ o
satisfaction NN o
. . o

-DOCSTART- -21097567- O O

A DT N
pilot NN N
study NN N
of IN N
the DT N
Tele-Airway NNP i
Management NNP i
System NNP i
in IN N
a DT N
hospital NN p
emergency NN p
department NN p
. . p

We PRP N
developed VBD N
a DT N
telemedicine NN N
system NN N
for IN N
remote JJ N
guidance NN N
of IN N
emergency NN N
airway NN N
management NN N
called VBD N
the DT N
Tele-Airway NNP i
Management NNP i
System NNP i
( ( N
TAMS NNP N
) ) N
. . N

In IN N
a DT N
pilot NN N
study NN N
we PRP N
examined VBD N
the DT N
usefulness NN N
of IN N
the DT N
TAMS NNP i
for IN N
intubations NNS N
of IN N
actual JJ N
patients NNS p
in IN p
a DT p
hospital NN p
emergency NN p
department NN p
. . p

Twenty-five JJ p
patients NNS p
were VBD p
allocated VBN p
randomly RB p
either DT p
to TO p
a DT p
TAMS NNP i
group NN i
or CC p
to TO p
an DT p
on-scene JJ i
directed NN i
( ( i
OSD NNP i
) ) i
group NN i
. . i

A DT N
total NN N
of IN N
12 CD p
were VBD p
intubated VBN p
using VBG N
the DT N
TAMS NNP i
. . i

The DT N
mean JJ o
time NN o
to TO o
intubation NN o
( ( i
TAMS NNP i
62 CD N
s NN N
vs. FW N
OSD NNP i
56 CD N
s NN N
) ) N
and CC N
the DT N
success NN o
rate NN o
was VBD N
not RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
two CD N
oesophageal JJ o
intubations NNS o
in IN N
the DT N
TAMS NNP i
group NN N
and CC N
four CD N
in IN N
the DT N
OSD NNP i
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
P NNP N
= NNP N
0.36 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
mechanical JJ o
or CC o
technical JJ o
errors NNS o
such JJ o
as IN o
disconnection NN o
during IN N
use NN N
of IN N
the DT N
TAMS NNP i
. . i

The DT N
pilot NN N
study NN N
demonstrated VBD N
the DT N
feasibility NN o
of IN N
the DT N
TAMS NNP N
as IN N
an DT N
alternative NN N
to TO N
OSD NNP i
. . i

However RB N
, , N
a DT N
larger JJR N
study NN N
will MD N
be VB N
required VBN N
to TO N
determine VB N
non-superiority NN N
or CC N
equivalence NN N
. . N

-DOCSTART- -24534270- O O

Accumulated VBN i
brisk JJ i
walking NN i
reduces NNS N
arterial JJ N
stiffness NN N
in IN p
overweight JJ p
adults NNS p
: : p
evidence NN N
from IN N
a DT N
randomized VBN N
control NN N
trial NN N
. . N

Arterial JJ N
stiffness NN N
is VBZ N
a DT N
major JJ N
contributor NN N
to TO N
the DT N
development NN N
of IN N
atherosclerosis NN N
and CC N
consequently RB N
cardiovascular JJ N
disease NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
examine VB N
whether IN N
6 CD N
months NNS N
of IN N
accumulated VBN N
( ( N
3 CD N
? . N
10 CD N
minutes NNS N
, , N
5 CD N
days/week NN i
) ) i
brisk NN i
walking NN i
was VBD N
sufficient JJ N
to TO N
reduce VB N
arterial JJ N
stiffness NN p
in IN p
sedentary JJ p
, , p
overweight JJ p
individuals NNS p
. . p

Seventy-seven JJ p
individuals NNS p
( ( p
19 CD p
men NNS p
, , p
58 CD p
women NNS p
; : p
age NN p
, , p
30-55 CD p
years NNS p
) ) p
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS p
; : p
two CD p
groups NNS p
completed VBD i
30 CD i
minutes NNS i
of IN i
accumulated JJ i
walking VBG i
with IN i
either DT i
monthly JJ i
or CC i
weekly JJ i
telephone NN i
support NN i
; : i
the DT p
third JJ i
group NN i
( ( i
control NN i
) ) i
performed VBD i
stretching VBG i
exercises NNS i
. . i

The DT p
walking VBG p
groups NNS p
were VBD N
combined VBN N
and CC N
telephone NN N
support NN N
included VBD N
as IN N
a DT N
covariate NN N
. . N

Anthropometry NNP o
, , o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , o
blood NN o
lipids NNS o
, , o
pulse RB o
wave VBP o
velocity NN o
( ( o
PWV NNP o
) ) o
, , o
and CC o
NOx NNP o
( ( o
surrogate JJ o
marker NN o
for IN o
nitric JJ o
oxide NN o
) ) o
were VBD N
measured VBN N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
4 CD N
months NNS N
post-intervention NN N
. . N

No CC N
changes NNS N
were VBD N
observed VBN N
for IN o
anthropometry NN o
, , o
BP NNP o
, , o
or CC o
lipids NNS o
. . o

However RB N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
, , N
there EX N
was VBD N
a DT N
decrease NN N
in IN o
PWV NNP o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
accompanied VBN N
by IN N
an DT N
increase NN N
in IN o
NOx NNP o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
with IN N
changes NNS N
maintained VBD N
4 CD N
months NNS N
post-intervention NN N
. . N

A NNP N
strong JJ N
negative JJ N
correlation NN N
between IN o
PWV NNP o
and CC o
NOx NNP o
was VBD N
also RB N
observed VBN N
( ( N
P NNP N
< NNP N
.001 NNP N
; : N
r NN N
= NNP N
-0.65 NNP N
) ) N
. . N

A DT N
lifestyle JJ N
approach NN N
to TO N
meeting VBG N
current JJ i
physical JJ i
activity NN i
guidelines NNS N
results NNS N
in IN N
favorable JJ N
alterations NNS N
in IN N
arterial JJ N
function NN N
in IN p
overweight JJ p
individuals NNS p
. . p

-DOCSTART- -9497116- O O

The DT N
importance NN N
of IN N
the DT N
dual-switch JJ i
valve NN i
for IN N
the DT N
treatment NN N
of IN N
adult NN p
normotensive JJ p
or CC p
hypertensive JJ p
hydrocephalus NN p
. . p

Since IN N
the DT N
beginning NN N
of IN N
1995 CD N
the DT N
new JJ p
hydrostatic JJ i
dual-switch NN i
valve NN i
( ( i
DSV NNP i
) ) i
was VBD p
implanted VBN p
in IN p
35 CD p
adult NN p
patients NNS p
with IN p
hydrocephalus NN p
of IN p
different JJ p
etiology NN p
. . p

26 CD p
patients NNS p
suffered VBD p
from IN p
normotensive JJ p
hydrocephalus NN p
( ( p
10 CD p
idiopathic NN p
and CC p
16 CD p
symptomatic JJ p
) ) p
, , p
and CC p
9 CD p
patients NNS p
from IN p
hypertensive JJ p
hydrocephalus NN p
of IN p
various JJ p
origin NN p
. . p

The DT N
first JJ N
21 CD N
cases NNS N
of IN N
this DT N
cohort NN N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
study NN N
with IN N
a DT N
comparable JJ N
group NN N
of IN N
21 CD N
hydrocephalic JJ N
patients NNS N
who WP N
received VBD N
a DT N
conventional JJ i
differential-pressure NN i
( ( i
DP- NNP i
) ) i
valve NN i
. . i

The DT N
clinical JJ N
status NN N
and CC N
CT NNP N
were VBD N
assessed VBN N
prior RB N
to TO N
shunting VBG N
, , N
14 CD N
days NNS N
and CC N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
the DT N
operation NN N
. . N

The DT N
reduction NN N
of IN N
ventricular JJ o
size NN o
was VBD N
evaluated VBN N
by IN N
the DT N
measurement NN N
of IN N
the DT N
Evans NNP N
Index NNP N
. . N

The DT N
CT NNP N
follow-up NN N
in IN N
the DT N
DSV NNP i
group NN N
was VBD N
characterized VBN N
by IN N
an DT N
only JJ N
minimal NN N
( ( N
14 CD N
) ) N
or CC N
only RB N
slight JJ N
( ( N
16 CD N
) ) N
reduction NN N
of IN N
ventricular JJ N
size NN N
in IN N
the DT N
vast JJ N
majority NN N
of IN N
cases NNS N
. . N

A DT N
comparison NN N
of IN N
21 CD p
patients NNS p
with IN N
a DT N
DSV NNP i
and CC N
the DT N
patients NNS N
with IN N
DP NNP i
valves NNS i
, , N
evaluated VBN N
by IN N
measuring VBG N
the DT N
reduction NN N
of IN N
the DT N
Evans NNP o
Index NNP o
, , N
revealed VBD N
a DT N
distinctly RB N
higher JJR N
percentage NN N
of IN N
significant JJ N
regressions NNS N
in IN N
the DT N
DP NNP i
valve NN i
collective NN N
, , N
without IN N
doubt NN N
due JJ N
to TO N
chronic JJ N
overdrainage NN N
. . N

The DT N
overall JJ N
clinical JJ N
result NN N
of IN N
our PRP$ N
35 CD p
patients NNS p
with IN N
a DT N
DSV NNP i
was VBD N
excellent JJ N
and CC N
good JJ N
in IN N
31 CD N
patients NNS N
, , N
but CC N
the DT N
outcome NN N
seems VBZ N
to TO N
be VB N
more RBR N
dependent JJ N
on IN N
the DT N
preshunt NN o
damage NN o
of IN o
the DT o
brain NN o
than IN N
on IN N
hydrocephalic JJ o
aspects NNS o
. . o

A DT N
neglegible JJ N
incidence NN N
of IN N
subdural JJ o
effusions NNS o
in IN N
the DT N
DSV NNP i
group NN N
compared VBN N
to TO N
11 CD N
cases NNS N
in IN N
the DT N
DP NNP i
valve FW i
collective JJ N
reflects VBZ N
the DT N
ability NN N
of IN N
the DT N
DSV NNP i
to TO N
prevent VB N
overdrainage NN o
. . o

The DT N
capability NN N
of IN N
the DT N
DSV NNP i
to TO N
maintain VB N
the DT N
IVP NNP o
within IN N
physiological JJ N
limits NNS N
after IN N
shunting VBG N
, , N
especially RB N
in IN N
the DT N
upright JJ N
position NN N
, , N
is VBZ N
documented VBN N
by IN N
a DT N
comparison NN N
with IN N
possible JJ o
unphysiological JJ o
IVP NNP o
variations NNS o
in IN N
other JJ N
valve NN N
constructions NNS N
, , N
which WDT N
depend VBP N
on IN N
the DT N
level NN o
of IN o
implantation NN o
, , o
subcutaneous JJ o
pressure NN o
or CC o
CSF NNP o
flow VBP o
through IN o
the DT o
valve NN o
. . o

-DOCSTART- -23385110- O O

Wheelchair NNP i
skills VBZ i
training NN i
to TO N
improve VB N
confidence NN o
with IN N
using VBG N
a DT N
manual JJ N
wheelchair NN N
among IN N
older JJR p
adults NNS p
: : p
a DT N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
wheelchair NN i
skills NNS i
training VBG i
on IN N
confidence NN o
in IN N
older JJR p
adults NNS p
who WP p
are VBP p
inexperienced VBN p
wheelchair JJ p
users NNS p
. . p

DESIGN NNP N
Parallel NNP N
group NN N
, , N
single-blind JJ N
randomized VBD N
controlled JJ N
trial NN N
. . N

SETTING NNP N
Research NNP N
laboratory NN N
in IN N
a DT N
rehabilitation NN N
hospital NN N
. . N

PARTICIPANTS JJ N
Participants NNS p
( ( p
N=20 NNP p
) ) p
who WP p
were VBD p
community-living JJ p
older JJR p
adults NNS p
at IN p
least JJS p
65 CD p
years NNS p
old JJ p
( ( p
mean JJ p
age NN p
, , p
70y CD p
) ) p
, , p
50 CD p
% NN p
women NNS p
, , p
and CC p
who WP p
had VBD p
no DT p
experience NN p
of IN p
using VBG p
a DT p
wheelchair NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
an DT N
intervention NN N
( ( N
n=10 JJ N
) ) N
or CC N
control NN N
( ( N
n=10 JJ N
) ) N
group NN N
. . N

INTERVENTIONS VBZ N
The DT N
intervention NN N
group NN N
received VBD N
two CD i
1-hour JJ i
training NN i
sessions NNS i
that WDT i
followed VBD i
the DT i
Wheelchair NNP i
Skills NNP i
Training NNP i
Program NNP i
( ( i
WSTP NNP i
) ) i
protocol NN i
. . i

The DT N
control NN N
group NN N
received VBD N
a DT N
single JJ i
socialization NN i
contact NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
Wheelchair NNP o
Use NNP o
Confidence NNP o
Scale-Manual JJ o
( ( o
WheelCon-M NNP o
) ) o
was VBD N
used VBN N
to TO N
evaluate VB o
confidence NN o
with IN N
using VBG N
a DT N
manual JJ N
wheelchair NN N
. . N

The DT N
WheelCon-M NNP N
is VBZ N
a DT N
self-report JJ N
questionnaire NN N
that WDT N
comprises VBZ N
65 CD N
items NNS N
in IN N
6 CD N
conceptual JJ N
areas NNS N
. . N

RESULTS VB N
A DT N
1-way JJ N
between-groups JJ N
analysis NN N
of IN N
covariance NN N
revealed VBD N
a DT N
significant JJ o
difference NN o
in IN N
postintervention NN o
WheelCon-M JJ o
scores NNS o
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
( ( N
F1,17=10.9 NNP N
, , N
P=.004 NNP N
) ) N
after IN N
controlling VBG N
for IN N
baseline JJ N
WheelCon-M JJ N
scores NNS N
. . N

A DT N
large JJ N
effect NN o
size NN o
was VBD N
also RB N
observed VBN N
( ( N
partial JJ N
? . N
( ( N
2 CD N
) ) N
=.39 NN N
) ) N
. . N

Secondary JJ N
analyses NNS N
revealed VBD N
that IN N
the DT N
WSTP NNP N
had VBD N
greater JJR o
effects NNS o
on IN o
confidence NN o
in IN o
areas NNS o
related VBN o
to TO o
maneuvering VBG o
around IN o
the DT o
physical JJ o
environment NN o
, , o
knowledge NN o
and CC o
problem NN o
solving NN o
, , o
advocacy NN o
, , o
and CC o
managing VBG o
emotions NNS o
than IN o
in IN o
areas NNS o
related VBN o
to TO o
performing VBG o
activities NNS o
and CC o
behaving VBG o
in IN o
social JJ o
situations NNS o
. . o

CONCLUSION NNP N
Two CD N
1-hour JJ N
WSTP NNP N
sessions NNS N
improve VBP o
confidence NN o
with IN o
using VBG o
a DT o
manual JJ o
wheelchair NN o
among IN p
older JJR p
adults NNS p
who WP p
are VBP p
inexperienced VBN p
wheelchair JJ p
users NNS p
. . p

-DOCSTART- -12088604- O O

Improving VBG N
patient JJ i
involvement NN i
in IN N
chronic JJ N
disease NN N
management NN N
: : N
the DT N
views NNS N
of IN N
patients NNS N
, , N
GPs NNP N
and CC N
specialists NNS N
on IN N
a DT N
guidebook NN N
for IN N
ulcerative JJ N
colitis NN N
. . N

Patient JJ N
information NN N
, , N
shared VBN N
care NN N
and CC N
decision-making NN N
are VBP N
recognised VBN N
as IN N
beneficial JJ N
to TO N
chronic VB N
disease NN N
management NN N
. . N

As IN N
part NN N
of IN N
an DT N
RCT NNP N
, , N
opinions NNS N
of IN N
ulcerative JJ p
colitis NN p
patients NNS p
and CC p
their PRP$ p
doctors NNS p
were VBD N
sought VBN N
on IN N
a DT N
guidebook NN N
designed VBN N
to TO N
support VB i
self-care NN i
and CC N
mediate VB i
doctor/patient JJ i
interaction NN i
during IN N
consultations NNS N
. . N

Semi-structured JJ i
interviews NNS i
were VBD N
conducted VBN N
with IN N
6 CD p
specialists NNS p
and CC p
16 CD p
GPs NNP p
. . p

Patients NNS p
' POS p
views NNS p
were VBD p
obtained VBN p
from IN p
written VBN p
responses NNS p
to TO p
a DT p
postal JJ i
questionnaire NN i
( ( p
136 CD p
replies NNS p
) ) p
. . p

Inclusion NN N
of IN N
lay NN N
knowledge NN N
and CC N
clarification NN N
of IN N
treatment NN N
decision NN N
processes NNS N
increased VBD N
patients NNS N
' POS N
perception NN N
of IN N
involvement NN N
in IN N
disease NN N
management NN N
through IN N
increased VBN N
identification NN N
and CC N
awareness NN N
of IN N
others NNS N
' POS N
self-management JJ N
experiences NNS N
. . N

Doctors NNS N
focused VBD N
on IN N
the DT N
importance NN N
of IN N
improving VBG N
patients NNS N
' POS N
compliance NN N
and CC N
use NN N
of IN N
services NNS N
. . N

However RB N
, , N
the DT N
guidebook NN N
was VBD N
seldom RB N
used VBN N
as IN N
it PRP N
had VBD N
been VBN N
intended VBN N
during IN N
consultations NNS N
. . N

Patients NNS N
felt VBD N
constrained VBN N
by IN N
time NN N
limits NNS N
and CC N
consultants NNS N
did VBD N
not RB N
actively RB N
encourage VB N
guidebook NN N
use NN N
. . N

Based VBN N
on IN N
the DT N
findings NNS N
, , N
we PRP N
suggest VBP N
an DT N
approach NN N
utilising VBG o
the DT o
guidebook NN o
to TO N
improve VB N
patient JJ o
participation NN o
in IN N
disease NN N
management NN N
. . N

-DOCSTART- -6148163- O O

Thyroid NNP i
stimulating VBG i
antibodies NNS i
: : i
an DT N
aid NN N
to TO N
the DT N
strategy NN N
of IN N
treatment NN N
of IN N
Graves NNP p
' POS p
disease NN p
? . N
In IN N
1976 CD N
we PRP N
initiated VBD N
a DT N
prospective JJ N
study NN N
to TO N
specify VB N
the DT N
usefulness NN N
of IN N
thyroid JJ i
stimulating VBG i
antibody NN i
( ( i
TSAb NNP i
) ) i
determinations NNS N
in IN N
predicting VBG N
the DT N
outcome NN N
of IN N
post-antithyroid JJ i
drug NN i
treatment NN i
for IN N
Graves NNP N
' POS N
disease NN N
. . N

This DT p
study NN p
was VBD p
carried VBN p
out RP p
on IN p
55 CD p
patients NNS p
, , p
who WP p
were VBD p
either RB p
treated VBN p
for IN p
six CD p
( ( p
n JJ p
= NNP p
16 CD p
) ) p
or CC p
18 CD p
months NNS p
( ( p
n JJ p
= NNP p
39 CD p
) ) p
and CC p
followed VBD p
up RP p
for IN p
an DT p
additional JJ p
two-year JJ p
period NN p
. . p

TSAb NNP o
was VBD p
determined VBN p
on IN p
whole JJ p
serum NN p
in IN p
29 CD p
patients NNS p
before IN p
and CC p
at IN p
the DT p
end NN p
of IN p
treatment NN p
, , p
and CC p
in IN p
26 CD p
patients NNS p
at IN p
the DT p
end NN p
of IN p
treatment NN p
only RB p
. . p

These DT N
determinations NNS N
were VBD N
carried VBN N
out RP N
using VBG N
a DT N
sensitive JJ N
and CC N
reproducible JJ N
microassay NNS N
based VBN N
on IN N
cAMP JJ N
accumulation NN N
in IN N
human JJ N
thyroid NN N
cell NN N
cultures NNS N
. . N

Before IN N
treatment NN N
, , N
TSAb NNP o
ranging VBG N
from IN N
170 CD N
to TO N
1529 CD N
% NN N
was VBD N
present JJ N
in IN N
28/29 CD N
patients NNS N
and CC N
reached VBN N
significantly RB N
low JJ N
levels NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
whatever WDT N
its PRP$ N
duration NN N
. . N

TSAb NNP o
was VBD N
undetectable JJ N
in IN N
24/55 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

8/16 CD N
'short-treated JJ N
' POS N
and CC N
18/39 CD N
'long-treated JJ N
' POS N
patients NNS N
remained VBD N
in IN N
remission NN o
. . o

As IN N
expected VBN N
, , N
initial JJ o
TSAb NNP o
levels NNS o
had VBD N
no DT N
predictive JJ N
value NN N
. . N

End-treatment JJ o
TSAb NNP o
values NNS o
, , N
when WRB N
low JJ N
( ( N
less JJR N
than IN N
350 CD N
% NN N
) ) N
or CC N
negative JJ N
did VBD N
not RB N
correlate VB N
with IN N
later JJ N
evolution NN N
: : N
in IN N
these DT N
39 CD N
patients NNS N
, , N
relapse NN o
rate NN o
was VBD N
41 CD N
% NN N
. . N

In IN N
contrast NN N
, , N
13/16 CD N
patients NNS N
with IN N
end-treatment JJ o
TSAb NNP o
greater JJR N
than IN N
350 CD N
% NN N
relapsed VBN N
. . N

Relapses NNS o
tended VBD N
to TO N
occur VB N
earlier RBR N
in IN N
patients NNS N
with IN N
the DT N
highest JJS N
TSAb NN o
levels NNS o
. . o

TSAb NNP o
determined VBD p
again RB p
during IN p
follow-up NN p
was VBD p
negative JJ p
in IN p
each DT p
of IN p
the DT p
18 CD p
patients NNS p
in IN p
remission NN p
, , p
and CC p
positive JJ p
in IN p
8/10 CD p
patients NNS p
at IN p
the DT p
time NN p
of IN p
relapse NN p
, , p
whatever WDT p
its PRP$ p
level NN p
at IN p
the DT p
end NN p
of IN p
the DT p
drug NN p
course NN p
. . p

This DT N
study NN N
confirms VBZ N
that IN N
only RB N
end-treatment JJ N
TSAb NNP N
levels NNS N
are VBP N
predictive JJ N
of IN N
relapse NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -10568568- O O

Effect NN N
of IN N
nitric-oxide-generating JJ i
system NN i
on IN N
microcirculatory NN o
blood NN o
flow NN o
in IN N
skin NN N
of IN N
patients NNS p
with IN p
severe JJ p
Raynaud NNP p
's POS p
syndrome NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Patients NNPS p
with IN p
Raynaud NNP p
's POS p
syndrome NN p
have VBP N
abnormal JJ N
digital JJ N
vasoconstriction NN N
, , N
which WDT N
may MD N
be VB N
secondary JJ N
to TO N
impaired JJ N
synthesis NN N
of IN N
, , N
or CC N
impaired JJ N
sensitivity NN N
to TO N
, , N
nitric JJ N
oxide NN N
. . N

We PRP N
studied VBD N
the DT N
effect NN N
on IN N
microcirculation NN N
of IN N
a DT N
nitric-oxide-generating JJ i
system NN i
applied VBN N
topically RB N
to TO N
the DT N
finger NN N
and CC N
forearm NN N
of IN N
healthy JJ p
volunteers NNS p
and CC p
patients NNS p
with IN p
primary JJ p
Raynaud NNP p
's POS p
syndrome NN p
. . p

METHODS NNP N
We PRP N
did VBD N
a DT N
single-blind NN N
, , N
randomised VBN N
, , N
placebo NN N
controlled VBD N
, , N
cross-over NN N
study NN N
of IN N
the DT N
microcirculatory NN o
response NN o
to TO N
topical JJ N
application NN N
of IN N
a DT N
nitric-oxidegenerating JJ i
gel NN i
in IN N
20 CD p
patients NNS p
with IN p
severe JJ p
Raynaud NNP p
's POS p
syndrome NN p
, , p
and CC p
ten RB p
healthy JJ p
volunteers NNS p
. . p

We PRP i
prepared VBD i
the DT i
nitric-oxide-generating JJ i
system NN i
by IN i
mixing VBG i
a DT i
solution NN i
of IN i
KY NNP i
jelly RB i
and CC i
sodium JJ i
nitrite NN i
( ( i
5 CD i
% NN i
weight/volume NN i
) ) i
, , i
with IN i
a DT i
solution NN i
of IN i
KY NNP i
jelly RB i
and CC i
ascorbic JJ i
acid NN i
( ( i
5 CD i
% NN i
weight/volume NN i
) ) i
. . N

About IN i
0.5 CD i
mL NNS i
of IN i
each DT i
solution NN i
was VBD i
separately RB i
applied VBN i
to TO i
the DT i
skin NN i
of IN i
the DT i
forearm NN i
( ( i
3 CD i
cm2 NN i
) ) i
, , i
and CC i
then RB i
mixed JJ i
with IN i
a DT i
sterile JJ i
cotton NN i
bud NN i
. . i

A DT i
similar JJ i
procedure NN i
was VBD i
done VBN i
simultaneously RB i
on IN i
the DT i
other JJ i
arm NN i
with IN i
KY NNP i
jelly RB i
only RB i
( ( i
placebo NN i
) ) i
. . N

The DT N
procedure NN N
was VBD N
then RB N
repeated VBN N
on IN N
the DT N
finger NN N
pulps VBZ N
. . N

Changes NNS o
in IN o
skin JJ o
microcirculatory NN o
volume NN o
and CC o
flux NN o
were VBD N
measured VBN N
bilaterally RB N
by IN N
infrared JJ N
photoplethysmography NN N
and CC N
laser NN N
doppler NN N
fluxmetry NN N
, , N
respectively RB N
. . N

FINDINGS NNP N
In IN N
the DT N
forearm NN N
, , N
blood NN o
flow NN o
increased VBD N
significantly RB N
after IN N
application NN N
of IN N
the DT N
active JJ N
gel NN N
both DT N
in IN N
patients NNS N
with IN N
Raynaud NNP N
's POS N
syndrome NN N
( ( N
microcirculatory JJ N
volume NN N
from IN N
mean JJ N
area NN N
under IN N
the DT N
curve NN N
98 CD N
[ NNP N
SE NNP N
14 CD N
] NN N
to TO N
1024 CD N
[ NN N
130 CD N
] NN N
; : N
microcirculatory JJ N
flux NN N
from IN N
5060 CD N
[ $ N
462 CD N
] NN N
to TO N
74,800 CD N
[ NN N
3940 CD N
] NN N
) ) N
and CC N
in IN N
healthy JJ N
controls NNS N
( ( N
volume NN N
from IN N
85 CD N
[ $ N
19 CD N
] NN N
to TO N
1020 CD N
[ NN N
60 CD N
] NN N
; : N
flux NN N
from IN N
4420 CD N
[ $ N
435 CD N
] NN N
to TO N
84,500 CD N
[ NN N
7000 CD N
] NN N
) ) N
. . N

In IN N
the DT N
fingers NNS N
, , N
although IN N
baseline NN o
blood NN o
flow NN o
was VBD N
lower JJR N
in IN N
patients NNS N
than IN N
in IN N
controls NNS N
, , N
both DT N
groups NNS N
showed VBD N
increases NNS N
with IN N
application NN N
of IN N
active JJ N
gel NN N
( ( N
volume NN N
from IN N
1100 CD N
[ $ N
194 CD N
] NN N
to TO N
3280 CD N
[ NN N
672 CD N
] NN N
and CC N
2380 CD N
[ NN N
441 CD N
] NN N
to TO N
6160 CD N
[ NN N
1160 CD N
] NN N
, , N
respectively RB N
; : N
flux NN o
from IN N
33,400 CD N
[ JJ N
4200 CD N
] NN N
to TO N
108,000 CD N
[ NNS N
13,600 CD N
] NNS N
and CC N
52,000 CD N
[ NN N
8950 CD N
] NN N
to TO N
185,000 CD N
[ NNS N
19,500 CD N
] NN N
) ) N
. . N

Increases VBZ N
in IN N
blood NN o
flow NN o
with IN N
placebo JJ N
gel NNS N
were VBD N
not RB N
significant JJ N
. . N

No DT N
adverse JJ N
effects NNS N
were VBD N
reported VBN N
. . N

INTERPRETATION NNP N
In IN N
primary JJ p
Raynaud NNP p
's POS p
syndrome NN p
, , N
topical JJ N
application NN N
of IN N
a DT N
nitric-oxide-generating JJ i
system NN i
can MD N
stimulate VB N
an DT N
increase NN N
in IN N
both DT N
microcirculatory JJ o
volume NN o
and CC o
flux NN o
. . o

-DOCSTART- -11064610- O O

Comparison NNP N
of IN N
alfentanil NN i
, , i
fentanyl NN i
and CC N
sufentanil NN i
for IN N
total JJ N
intravenous JJ N
anaesthesia NN N
with IN N
propofol NN i
in IN N
patients NNS p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
surgery NN p
. . p

We PRP N
have VBP N
studied VBN N
the DT N
pharmacokinetics NNS o
and CC o
pharmacodynamics NNS o
of IN N
alfentanil NN i
, , i
fentanyl NN i
and CC N
sufentanil VB i
together RB N
with IN N
propofol NN i
in IN N
patients NNS p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
( ( p
CABG NNP p
) ) p
. . p

Sixty JJ p
patients NNS p
( ( p
age NN p
40-73 CD p
yr NN p
, , p
56 CD p
male NN p
) ) p
were VBD p
assigned VBN p
randomly RB p
to TO p
receive VB p
alfentanil NN i
, , i
fentanyl NN i
or CC i
sufentanil NN i
and CC i
propofol NN i
. . i

Plasma NNP o
concentrations NNS o
of IN N
these DT N
drugs NNS N
and CC N
times NNS o
for IN o
the DT o
plasma NN o
concentration NN o
to TO o
decrease VB o
by IN o
50 CD o
% NN o
( ( N
t50 NN N
) ) N
and CC N
80 CD N
% NN N
( ( N
t80 NN N
) ) N
after IN N
cessation NN N
of IN N
the DT N
infusion NN N
were VBD N
determined VBN N
. . N

Times NNS o
were VBD N
recorded VBN N
to TO N
awakening VBG N
and CC N
tracheal JJ N
extubation NN N
. . N

Total JJ o
dose NN o
and CC o
plasma JJ o
concentrations NNS o
of IN N
propofol NN N
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

Mean NNP o
total JJ o
doses NNS o
of IN N
alfentanil NN i
, , i
fentanyl NN i
and CC i
sufentanil NN i
were VBD N
443 CD N
, , N
45 CD N
and CC N
4.4 CD N
micrograms NNS N
kg-1 JJ N
, , N
respectively RB N
. . N

Time NN o
to TO o
awakening VBG o
did VBD N
not RB N
differ VB N
significantly RB N
. . N

In IN N
patients NNS N
receiving VBG N
fentanyl NN i
, , N
the DT N
trachea NN o
was VBD N
extubated VBN o
on IN N
average JJ N
2 CD N
h NN N
later RB N
than IN N
in IN N
those DT N
receiving VBG N
sufentanil NN i
and CC N
3 CD N
h NN N
later RB N
than IN N
in IN N
those DT N
receiving VBG N
alfentanil NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
t80 NN o
of IN N
fentanyl NN i
was VBD N
longer JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
that DT N
of IN N
alfentanil NN i
or CC N
sufentanil NN i
, , N
and CC N
there RB N
was VBD N
a DT N
linear JJ N
correlation NN N
between IN N
the DT N
t80 NN o
of IN N
the DT N
opioid NN N
and CC N
the DT N
time NN o
to TO o
tracheal VB o
extubation NN o
( ( N
r JJ N
= VBZ N
0.51 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

However RB N
, , N
the DT N
t50 NN o
values NNS o
for IN N
these DT N
opioids NNS N
were VBD N
similar JJ N
and CC N
did VBD N
not RB N
correlate VB N
with IN N
recovery NN o
time NN o
. . o

In IN N
conclusion NN N
, , N
patients NNS p
undergoing VBG p
CABG NNP p
and CC N
who WP N
were VBD N
anaesthetized VBN N
with IN N
fentanyl NN i
and CC N
propofol NN i
needed VBN N
mechanical JJ o
ventilatory NN o
support NN o
for IN N
a DT N
significantly RB N
longer JJR N
time NN N
than IN N
those DT N
receiving VBG N
alfentanil NN i
or CC N
sufentanil NN i
and CC N
propofol NN i
. . i

On IN N
the DT N
basis NN N
of IN N
the DT N
interindividual JJ N
variation NN N
observed VBD N
, , N
the DT N
time NN o
to TO o
tracheal VB o
extubation NN o
was VBD N
most RBS N
predictable JJ N
in IN N
patients NNS N
receiving VBG N
alfentanil NN i
and CC N
most RBS N
variable JJ N
in IN N
patients NNS N
receiving VBG N
fentanyl NN i
, , N
a DT N
finding NN N
which WDT N
may MD N
be VB N
important JJ N
if IN N
the DT N
patients NNS N
are VBP N
transferred VBN N
to TO N
a DT N
step-down JJ N
unit NN N
on IN N
the DT N
evening NN N
of IN N
the DT N
operation NN N
. . N

-DOCSTART- -1797999- O O

Home NNP i
blood NN o
pressure NN o
monitoring NN i
: : i
advantages NNS N
and CC N
limitations NNS N
. . N

Home NNP i
blood NN i
pressure NN i
monitoring NN i
is VBZ N
a DT N
useful JJ N
tool NN N
for IN N
clinical JJ o
management NN o
of IN N
patients NNS p
with IN p
hypertension NN p
. . p

Its PRP$ N
major JJ N
advantages NNS N
are VBP N
the DT N
ease NN N
with IN N
which WDT N
the DT N
techniques NNS N
can MD N
be VB N
learned VBN N
, , N
reproducibility NN N
of IN N
values NNS N
, , N
sensitivity NN N
of IN N
measurement NN N
and CC N
availability NN N
of IN N
normotensive JJ N
data NNS N
. . N

In IN N
spite NN N
of IN N
the DT N
ability NN N
to TO N
tell VB N
whether IN N
a DT N
subject NN N
has VBZ N
normal JJ N
or CC N
abnormal JJ N
values NNS N
, , N
because IN N
of IN N
the DT N
lack NN N
of IN N
prospective JJ N
mortality/morbidity NN N
data NNS N
, , N
home NN i
blood NN i
pressure NN i
monitoring NN i
can MD N
not RB N
be VB N
used VBN N
to TO N
decide VB N
whether IN N
treatment NN N
is VBZ N
indicated VBN N
. . N

The DT N
treatment NN N
decision NN N
must MD N
be VB N
based VBN N
on IN N
repeated VBN N
clinic JJ o
blood NN o
pressure NN o
readings NNS o
. . o

After IN N
that IN N
the DT N
home NN i
blood NN o
pressure NN o
monitoring NN i
can MD N
be VB N
used VBN N
to TO N
exclude VB N
individuals NNS N
who WP N
are VBP N
at IN N
risk NN N
for IN N
side NN N
effects NNS N
due JJ N
to TO N
low JJ N
out-of-office JJ N
blood NN o
pressure NN o
readings NNS N
and CC N
to TO N
precisely RB N
monitor VB N
the DT N
blood NN o
pressure NN o
response NN o
to TO N
therapy NN N
. . N

Home NNP i
blood NN i
pressure NN i
monitoring NN i
is VBZ N
frequently RB N
used VBN N
to TO N
find VB N
subjects NNS N
with IN N
'white-coat NNP o
' POS o
hypertension NN o
. . o

In IN N
our PRP$ N
study NN N
of IN N
borderline JJ p
hypertension NN p
in IN p
Tecumseh NNP p
, , N
white-coat JJ N
hypertension NN N
is VBZ N
present JJ N
in IN N
7.1 CD N
% NN N
of IN N
the DT N
whole JJ N
population NN N
and CC N
in IN N
58 CD N
% NN N
of IN N
all DT N
subjects NNS N
with IN N
elevated JJ N
blood NN o
pressures NNS o
in IN N
the DT N
clinic NN N
. . N

Subjects NNS N
with IN N
white-coat JJ N
hypertension NN N
in IN N
Tecumseh NNP N
appear VBP N
to TO N
be VB N
at IN N
an DT N
increased VBN N
risk NN N
for IN N
coronary JJ o
heart NN o
disease NN o
: : o
they PRP N
show VBP N
repeated VBN N
elevated JJ N
clinic NN o
readings NNS o
throughout IN N
their PRP$ N
life NN N
time NN N
, , N
their PRP$ N
parents NNS N
have VBP N
higher JJR N
blood NN o
pressure NN o
, , N
their PRP$ N
high-density NN o
lipoprotein NN o
is VBZ N
decreased VBN N
and CC N
insulin NN o
, , o
cholesterol NN o
and CC o
triglycerides NNS o
are VBP N
elevated VBN N
. . N

Whereas JJ N
subjects NNS N
with IN N
white-coat JJ N
hypertension NN N
should MD N
not RB N
be VB N
treated VBN N
with IN N
antihypertensive JJ N
agents NNS N
, , N
they PRP N
must MD N
be VB N
followed VBN N
and CC N
managed VBN N
through IN N
non-pharmacologic JJ i
means NNS i
. . i

-DOCSTART- -17069543- O O

A DT N
double-blind JJ N
placebo-controlled JJ i
pilot NN N
study NN N
of IN N
olanzapine NN i
in IN N
childhood/adolescent JJ p
pervasive JJ p
developmental NN p
disorder NN p
. . p

Atypical JJ N
antipsychotics NNS N
have VBP N
been VBN N
shown VBN N
to TO N
improve VB N
disruptive NN o
and CC o
repetitive JJ o
behaviors NNS o
in IN N
pervasive JJ N
developmental NN N
disorders NNS N
( ( N
PDDs NNP N
) ) N
, , N
but CC N
they PRP N
require VBP N
assessment NN N
of IN N
potential JJ N
side NN o
effects NNS o
. . o

This DT N
is VBZ N
the DT N
first JJ N
placebo-controlled JJ i
trial NN N
of IN N
olanzapine NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS N
and CC N
adolescents NNS N
with IN N
PDD NNP N
. . N

Eleven NNP p
patients NNS p
with IN p
a DT p
diagnosis NN p
of IN p
either DT p
autism NN p
, , p
Asperger NNP p
's POS p
syndrome NN p
, , p
or CC p
PDD NNP p
not RB p
otherwise RB p
specified VBN p
( ( p
PDD-NOS NNP p
) ) p
and CC p
aged VBN p
6-14 CD p
years NNS p
were VBD N
randomized VBN N
into IN N
an DT N
8-week JJ N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
treatment NN N
study NN N
with IN N
olanzapine NN i
. . i

There EX N
was VBD N
a DT N
significant JJ N
linear JJ N
trend NN N
x NNP N
group NN N
interaction NN N
on IN N
the DT N
Clinical JJ o
Global NNP o
Impressions- NNP o
Improvement NNP o
( ( o
CGI-I NNP o
) ) o
and CC N
50 CD N
% NN N
on IN N
olanzapine JJ N
versus NN N
20 CD N
% NN N
on IN N
placebo NN N
were VBD N
responders NNS N
. . N

Olanzapine NNP N
was VBD N
associated VBN N
with IN N
significant JJ o
weight JJ o
gain NN o
( ( N
7.5 CD N
+/- JJ N
4.8 CD N
lbs NN N
vs. FW N
1.5 CD N
+/- JJ N
1.5 CD N
lbs NN N
on IN N
placebo NN N
) ) N
. . N

Olanzapine NN N
may MD N
be VB N
a DT N
promising JJ N
treatment NN N
for IN N
improving VBG N
global JJ o
functioning NN o
of IN o
PDDs NNP o
, , N
but CC N
the DT N
risk NN N
of IN N
significant JJ N
weight JJ o
gain NN o
remains VBZ N
a DT N
concern NN N
. . N

Additional JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
olanzapine NN N
in IN N
the DT N
treatment NN N
of IN N
children NNS N
with IN N
PDD NNP N
. . N

-DOCSTART- -15673999- O O

Pilot NNP N
study NN N
of IN N
a DT N
moderate JJ i
dose JJ i
multivitamin/mineral JJ i
supplement NN i
for IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorder NN p
. . p

OBJECTIVE NNP N
Determine NNP N
the DT N
effect NN N
of IN N
a DT N
moderate JJ N
dose JJ N
multivitamin/mineral JJ i
supplement NN i
on IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorder NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ i
3-month JJ N
study NN N
. . N

SUBJECTS NNP N
Twenty NNP p
( ( p
20 CD p
) ) p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorder NN p
, , p
ages VBZ p
3-8 CD p
years NNS p
. . p

RESULTS VB N
A DT N
Global JJ N
Impressions NNP N
parental NN N
questionnaire NN N
found VBD N
that IN N
the DT N
supplement NN N
group NN N
reported VBD N
statistically RB o
significant JJ o
improvements NNS o
in IN N
sleep NN o
and CC o
gastrointestinal JJ o
problems NNS o
compared VBN N
to TO N
the DT N
placebo NN i
group NN N
. . N

An DT N
evaluation NN N
of IN N
vitamin NN o
B NNP o
( ( o
6 CD o
) ) o
levels NNS o
prior RB N
to TO N
the DT N
study NN N
found VBD N
that IN N
the DT N
autistic JJ p
children NNS p
had VBD N
substantially RB o
elevated VBN o
levels NNS o
of IN o
B6 NNP o
compared VBN N
to TO N
a DT N
control NN N
group NN N
of IN N
typical JJ N
children NNS N
( ( N
75 CD N
% NN N
higher JJR N
, , N
p JJ N
< NNP N
0.0000001 CD N
) ) N
. . N

Vitamin NNP o
C NNP o
levels NNS o
were VBD N
measured VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
and CC N
the DT N
placebo NN N
group NN N
had VBD N
levels NNS N
that WDT N
were VBD N
significantly RB o
below JJ o
average NN o
for IN N
typical JJ N
children NNS N
, , N
whereas IN N
the DT N
supplement NN N
group NN N
had VBD N
near-average JJ N
levels NNS N
. . N

DISCUSSION VB N
The DT N
finding NN N
of IN N
high JJ o
vitamin NN o
B NNP o
( ( o
6 CD o
) ) o
levels NNS o
is VBZ N
consistent JJ N
with IN N
recent JJ N
reports NNS N
of IN N
low JJ N
levels NNS o
of IN o
pyridoxal-5-phosphate NN o
and CC N
low JJ N
activity NN o
of IN o
pyridoxal NN o
kinase NN o
( ( N
i.e. FW N
, , N
pyridoxal NN N
is VBZ N
only RB N
poorly RB N
converted VBN N
to TO N
pyridoxal-5-phosphate NN N
, , N
the DT N
enzymatically RB N
active JJ N
form NN N
) ) N
. . N

This DT N
may MD N
explain VB N
the DT N
functional JJ N
need NN N
for IN N
high-dose JJ N
vitamin NN i
B NNP i
( ( i
6 CD i
) ) i
supplementation NN i
in IN N
many JJ N
children NNS N
and CC N
adults NNS N
with IN N
autism NN N
. . N

-DOCSTART- -16864164- O O

Long-term JJ N
follow-up NN N
of IN N
the DT N
Stockholm NNP N
randomized VBD N
trials NNS N
of IN N
postoperative JJ i
radiation NN i
therapy NN i
versus NN i
adjuvant JJ i
chemotherapy NN i
among IN N
'high JJ p
risk NN p
' POS p
pre- NN p
and CC p
postmenopausal NN p
breast NN p
cancer NN p
patients NNS p
. . p

For IN N
many JJ N
years NNS N
, , N
loco-regional JJ N
radiotherapy NN N
was VBD N
the DT N
standard JJ N
postoperative JJ N
treatment NN N
for IN N
node JJ p
positive JJ p
breast NN p
cancer NN p
patients NNS p
in IN p
Sweden NNP p
. . p

Because IN N
of IN N
encouraging VBG N
results NNS N
from IN N
trials NNS N
of IN N
adjuvant JJ i
chemotherapy NN i
in IN N
the DT N
mid NN N
1970s CD N
, , N
the DT p
Stockholm NNP p
Breast NNP p
Cancer NNP p
Study NNP p
Group NNP p
decided VBD N
to TO N
directly RB N
compare VB N
postoperative JJ i
radiation NN i
( ( i
RT NNP i
) ) i
with IN i
adjuvant JJ i
CMF-type JJ i
chemotherapy NN i
( ( i
CT NNP i
) ) i
. . i

Long-term JJ N
results NNS N
are VBP N
presented VBN N
from IN N
two CD N
randomized JJ N
trials NNS N
of IN N
RT NNP i
versus NN N
CT NNP i
in IN N
pre- NN p
( ( p
n JJ p
= NNP p
547 CD p
) ) p
and CC p
postmenopausal NN p
( ( p
n JJ p
= NNP p
679 CD p
) ) p
patients NNS p
, , p
respectively RB p
, , p
with IN p
node JJ p
positive JJ p
disease NN p
or CC p
a DT p
tumour JJ p
diameter NN p
> VBD p
30 CD p
mm NN p
. . p

RT NNP N
substantially RB N
reduced VBD N
loco-regional JJ o
recurrences NNS o
among IN N
both DT N
pre- JJ N
and CC N
postmenopausal JJ N
patients NNS N
( ( N
relative JJ N
hazard NN N
RT NNP N
versus NN N
CT NNP N
: : N
0.67 CD N
and CC N
0.43 CD N
, , N
respectively RB N
) ) N
. . N

Among IN N
premenopausal JJ N
patients NNS N
distant JJ o
metastases NNS o
occurred VBD N
less RBR N
frequently RB N
in IN N
the DT N
CT NNP N
group NN N
( ( N
relative JJ N
hazard NN N
: : N
1.68 CD N
, , N
p NN N
> NNP N
0.001 CD N
) ) N
resulting VBG N
in IN N
an DT N
improved JJ N
recurrence-free JJ o
survival NN o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

Overall JJ o
survival NN o
was VBD N
also RB N
better RB N
with IN N
CT NNP N
( ( N
cumulative JJ N
survival NN N
at IN N
15 CD N
years NNS N
: : N
50 CD N
% NN N
and CC N
44 CD N
% NN N
in IN N
the DT N
CT NNP N
and CC N
RT NNP N
groups NNS N
, , N
respectively RB N
) ) N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Among IN N
the DT N
postmenopausal NN N
patients NNS N
there EX N
were VBD N
no DT N
substantial JJ N
differences NNS N
in IN N
terms NNS N
of IN N
recurrence-free NN o
or CC o
overall JJ o
survival NN o
between IN N
the DT N
treatment NN N
groups NNS N
. . N

The DT N
risk NN o
of IN o
a DT o
second JJ o
primary JJ o
malignancy NN o
, , N
however RB N
, , N
was VBD N
doubled VBN N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
> NNP N
0.01 CD N
) ) N
. . N

The DT N
most RBS N
pronounced JJ N
excess NN N
concerned JJ N
second JJ o
lung NN o
cancers NNS o
occurring VBG N
after IN N
10 CD N
years NNS N
. . N

The DT N
cumulative JJ o
incidence NN o
at IN o
20 CD o
years NNS o
was VBD N
estimated VBN N
at IN N
0.3 CD N
% NN N
and CC N
3.7 CD N
% NN N
in IN N
the DT N
CT NNP N
and CC N
RT NNP N
groups NNS N
, , N
respectively RB N
. . N

The DT N
trials NNS N
illustrate VBP N
the DT N
role NN N
of IN N
radiotherapy NN N
in IN N
preventing VBG N
loco-regional JJ o
recurrences NNS o
among IN N
high-risk JJ N
patients NNS N
, , N
as RB N
well RB N
as IN N
the DT N
need NN N
for IN N
systemic JJ N
treatment NN N
to TO N
control VB N
the DT N
disease NN N
systemically RB N
. . N

-DOCSTART- -16116013- O O

Cervical JJ N
spine NN N
motion NN N
: : N
a DT N
fluoroscopic NN N
comparison NN N
during IN N
intubation NN p
with IN N
lighted JJ N
stylet NN N
, , N
GlideScope NNP N
, , N
and CC N
Macintosh NNP N
laryngoscope NN N
. . N

The DT N
question NN N
of IN N
which WDT N
is VBZ N
the DT N
optimum JJ N
technique NN N
to TO N
intubate VB N
the DT N
trachea NN N
in IN N
a DT N
patient NN p
who WP p
may MD p
have VB p
a DT p
cervical JJ p
( ( p
C NNP p
) ) p
-spine VBP p
injury NN p
remains VBZ N
unresolved JJ N
. . N

We PRP N
compared VBN N
, , N
using VBG N
fluoroscopic JJ N
video NN N
, , N
C-spine JJ o
motion NN o
during IN N
intubation NN N
for IN N
Macintosh NNP N
3 CD N
blade NN N
, , N
GlideScope NNP N
, , N
and CC N
Intubating NNP N
Lighted NNP N
Stylet NNP N
, , N
popularly RB N
known VBN N
as IN N
the DT N
Lightwand NNP N
or CC N
Trachlight NNP N
. . N

Thirty-six NNP p
healthy JJ p
patients NNS p
were VBD p
randomized VBN p
to TO p
participate VB p
in IN p
a DT p
crossover JJ p
trial NN p
of IN N
either DT N
Lightwand NNP i
or CC i
GlideScope NNP i
to TO i
Macintosh NNP i
laryngoscopy NN i
, , i
with IN i
in-line JJ i
stabilization NN i
. . i

C-spine JJ o
motion NN o
was VBD N
examined VBN N
at IN N
the DT N
Occiput-C1 NNP N
junction NN N
, , N
C1-2 NNP N
junction NN N
, , N
C2-5 NNP N
motion NN N
segment NN N
, , N
and CC N
C5-thoracic NNP N
motion NN N
segment NN N
during IN N
manual JJ i
ventilation NN i
via IN i
bag-mask NN i
, , i
laryngoscopy NN i
, , i
and CC i
intubation NN i
. . i

Time NN o
to TO N
intubate VB N
was VBD N
also RB N
measured VBN N
. . N

C-spine JJ o
motion NN o
during IN o
bag-mask JJ o
ventilation NN o
was VBD N
82 CD N
% NN N
less JJR N
at IN N
the DT N
four CD N
motion NN N
segments NNS N
studied VBD N
than IN N
during IN N
Macintosh NNP N
laryngoscopy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

C-spine JJ o
motion NN o
using VBG o
the DT o
Lightwand NNP o
was VBD N
less JJR N
than IN N
during IN N
Macintosh NNP N
laryngoscopy NN N
, , N
averaging VBG N
57 CD N
% NN N
less JJR N
at IN N
the DT N
four CD N
motion NN N
segments NNS N
studied VBN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
time NN o
to TO o
intubate VB o
between IN N
the DT N
Lightwand NNP N
and CC N
the DT N
Macintosh NNP N
blade NN N
. . N

C-spine JJ o
motion NN o
was VBD N
reduced VBN N
50 CD N
% NN N
at IN N
the DT N
C2-5 NNP N
segment NN N
using VBG N
the DT N
GlideScope NNP N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
but CC N
unchanged JJ N
at IN N
the DT N
other JJ N
segments NNS N
. . N

Laryngoscopy NNP N
with IN N
GlideScope NNP N
took VBD N
62 CD N
% NN N
longer JJR o
than IN N
with IN N
the DT N
Macintosh NNP N
blade NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Thus RB N
, , N
the DT N
Lightwand NNP N
( ( N
Intubating NNP N
Lighted NNP N
Stylet NNP N
) ) N
is VBZ N
associated VBN N
with IN N
reduced JJ N
C-spine JJ o
movement NN o
during IN N
endotracheal JJ N
intubation NN N
compared VBN N
with IN N
the DT N
Macintosh NNP N
laryngoscope NN N
. . N

-DOCSTART- -21610189- O O

Do VB N
sheltered VBD i
workshops NNS i
enhance VB N
employment NN o
outcomes NNS o
for IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
? . N
This DT N
study NN N
investigated VBD N
whether IN N
sheltered VBN i
workshops NNS i
help VBP N
prepare VB N
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
for IN N
competitive JJ o
employment NN o
within IN N
the DT N
community NN N
. . N

Two CD N
groups NNS N
of IN N
individuals NNS N
were VBD N
compared VBN N
: : N
( ( p
a DT p
) ) p
215 CD p
supported VBN p
employees NNS p
who WP p
were VBD p
in IN p
sheltered JJ i
workshops NNS i
prior RB p
to TO p
entering VBG p
supported JJ p
employment NN p
and CC p
( ( p
b NN p
) ) p
215 CD p
supported VBN p
employees NNS p
who WP p
were VBD p
not RB i
in IN i
sheltered JJ i
workshops NNS i
. . i

Individuals NNS N
from IN N
both DT N
groups NNS N
were VBD N
matched VBN N
based VBN N
on IN N
their PRP$ N
primary JJ N
diagnosis NN N
, , N
secondary JJ N
diagnosis NN N
( ( N
if IN N
present NN N
) ) N
, , N
and CC N
gender NN N
. . N

Results NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
rates NNS o
of IN o
employment NN o
between IN N
these DT N
two CD N
groups NNS N
. . N

However RB N
, , N
individuals NNS N
who WP N
participated VBD N
in IN N
sheltered JJ i
workshops NNS i
earned VBD o
significantly RB o
less JJR o
( ( N
US NNP N
$ $ N
129.36 CD N
versus NN N
US NNP N
$ $ N
191.42 CD N
per IN N
week NN N
) ) N
, , N
and CC N
cost NN o
significantly RB o
more RBR o
to TO N
serve VB N
( ( N
US NNP N
$ $ N
6,065.08 CD N
versus NN N
US NNP N
$ $ N
2,440.60 CD N
) ) N
, , N
than IN N
their PRP$ N
non-sheltered JJ i
workshop NN i
peers NNS N
. . N

Results NNS N
presented VBD N
here RB N
suggest VBP N
that IN N
individuals NNS p
with IN p
ASD NNP p
achieve VBP N
better RBR o
vocational JJ o
outcomes NNS o
if IN N
they PRP N
do VBP N
not RB N
participate VB N
in IN N
sheltered JJ N
workshops NNS N
prior RB N
to TO N
enrolling VBG N
in IN N
supported JJ N
employment NN N
. . N

-DOCSTART- -24201696- O O

Do VB N
ACE NNP N
inhibitors NNS N
improve VBP N
the DT N
response NN o
to TO N
exercise VB o
training NN o
in IN N
functionally RB p
impaired JJ p
older JJR p
adults NNS p
? . N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Loss NNP o
of IN o
muscle NN o
mass NN o
and CC o
strength NN o
with IN N
ageing NN N
is VBZ N
a DT N
major JJ N
cause NN N
for IN N
falls NNS o
, , o
disability NN o
, , o
and CC o
morbidity NN o
in IN N
older JJR p
people NNS p
. . p

Previous JJ N
studies NNS N
have VBP N
found VBN N
that IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
( ( N
ACEi NNP N
) ) N
may MD N
improve VB N
physical JJ o
function NN o
in IN N
older JJR N
people NNS N
. . N

It PRP N
is VBZ N
unclear JJ N
whether IN N
ACEi NNP N
provide VBP N
additional JJ N
benefit NN N
when WRB N
added VBD N
to TO N
a DT N
standard JJ N
exercise NN N
training NN N
program NN N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
ACEi NNP N
therapy NN N
on IN N
physical JJ o
function NN o
in IN N
older JJR N
people NNS N
undergoing VBG N
exercise NN N
training NN N
. . N

METHODS NNP N
Community-dwelling JJ p
people NNS p
aged VBN p
? . p
65 CD p
years NNS p
with IN p
functional JJ p
impairment NN p
were VBD p
recruited VBN N
through IN N
general JJ N
( ( N
family NN N
) ) N
practices NNS N
. . N

All DT N
participants NNS N
received VBD i
progressive JJ i
exercise NN i
training NN i
. . i

Participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB i
4 CD i
mg NNS i
perindopril NN i
or CC i
matching VBG i
placebo JJ i
daily JJ i
for IN N
20 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD o
between-group JJ o
change NN o
in IN o
6-minute JJ o
walk NN o
distance NN o
from IN o
baseline NN N
to TO N
20 CD N
weeks NNS N
. . N

Secondary JJ N
outcomes NNS N
included VBD o
changes NNS o
in IN o
Short NNP o
Physical NNP o
Performance NNP o
Battery NNP o
, , o
handgrip NN o
and CC o
quadriceps JJ o
strength NN o
, , o
self-reported JJ o
quality NN o
of IN o
life NN o
using VBG o
the DT o
EQ-5D NNP o
, , o
and CC o
functional JJ o
impairment NN o
measured VBD o
using VBG o
the DT o
Functional NNP o
Limitations NNP o
Profile NNP o
. . o

RESULTS VB p
A DT p
total NN p
of IN p
170 CD p
participants NNS p
( ( p
n JJ p
= $ p
86 CD p
perindopril NN i
, , i
n JJ p
= FW p
84 CD p
placebo NN p
) ) p
were VBD p
randomized VBN p
. . p

Mean JJ p
age NN p
was VBD p
75.7 CD p
( ( p
standard JJ p
deviation NN p
[ NNP p
SD NNP p
] NNP p
6.8 CD p
) ) p
years NNS p
. . p

Baseline NNP o
6-minute JJ o
walk NN o
distance NN o
was VBD o
306 CD N
m NN N
( ( N
SD NNP N
99 CD N
) ) N
. . N

Both DT N
groups NNS N
increased VBD N
their PRP$ o
walk NN o
distance NN o
( ( o
by IN N
29.6 CD N
m NNS N
perindopril NN N
, , N
36.4 CD N
m NN N
placebo NN N
group NN N
) ) N
at IN N
20 CD N
weeks NNS N
, , N
but CC N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
treatment NN N
effect NN N
between IN N
groups NNS N
( ( N
-8.6m JJ N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
-30.1 NN N
, , N
12.9 CD N
] NN N
, , N
p NN N
= NNP N
.43 NNP N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
treatment NN N
effects NNS N
were VBD N
observed VBN N
between IN N
groups NNS N
for IN N
the DT N
secondary JJ N
outcomes NNS N
. . N

Adverse JJ N
events NNS N
leading VBG N
to TO N
withdrawal VB N
were VBD N
few JJ N
( ( N
n JJ N
= $ N
0 CD N
perindopril NN N
, , N
n JJ N
= FW N
4 CD N
placebo NN N
) ) N
. . N

INTERPRETATION NNP N
ACE NNP N
inhibitors NNS N
did VBD N
not RB N
enhance VB N
the DT N
effect NN N
of IN N
exercise NN o
training NN o
on IN o
physical JJ o
function NN o
in IN o
functionally RB p
impaired JJ p
older JJR p
people NNS p
. . p

-DOCSTART- -12704402- O O

Effect NN N
of IN N
a DT N
high-protein JJ i
, , i
energy-restricted JJ i
diet NN i
on IN N
weight JJ o
loss NN o
and CC o
energy NN o
expenditure NN o
after IN N
weight JJ N
stabilization NN N
in IN N
hyperinsulinemic JJ p
subjects NNS p
. . p

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effect NN N
of IN N
replacing VBG N
some DT N
dietary JJ N
carbohydrate NN N
with IN N
protein NN N
, , N
during IN N
energy NN N
restriction NN N
, , N
on IN N
weight JJ o
loss NN o
, , o
total JJ o
energy NN o
expenditure NN o
( ( o
TEE NNP o
) ) o
, , o
resting VBG o
energy NN o
expenditure NN o
( ( o
REE NNP o
) ) o
, , o
respiratory JJ o
quotient NN o
( ( o
RQ NNP o
) ) o
, , o
and CC o
the DT o
thermic JJ o
effect NN o
of IN o
feeding NN o
( ( o
TEF NNP o
) ) o
in IN N
subjects NNS p
with IN p
hyperinsulinemia NN p
. . p

DESIGN NNP N
Parallel NNP N
, , N
clinical JJ N
intervention NN N
study NN N
of IN N
12 CD N
weeks NNS N
energy NN i
restriction NN i
( ( N
6.5 CD N
MJ/day NNP N
) ) N
and CC N
4 CD N
weeks NNS N
energy NN i
balance NN i
( ( N
8.2 CD N
MJ/day NNP N
) ) N
in IN N
two CD N
groups NNS N
of IN N
subjects NNS N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
high-protein NN i
( ( i
HP NNP i
) ) i
diet NN i
( ( N
27 CD N
% NN N
of IN N
energy NN N
( ( N
% NN N
E NNP N
) ) N
as IN N
protein NN N
, , N
45 CD N
% NN N
E NNP N
as IN N
carbohydrate NN N
) ) N
or CC N
a DT N
lower-protein JJ i
( ( i
LP NNP i
) ) i
diet NN i
( ( N
16 CD N
% NN N
E NNP N
as IN N
protein NN N
, , N
57 CD N
% NN N
E NNP N
as IN N
carbohydrate NN N
) ) N
. . N

SUBJECTS VB N
A DT p
total NN p
of IN p
36 CD p
obese JJ p
nondiabetic JJ p
volunteers NNS p
with IN p
hyperinsulinemia NN p
( ( p
10 CD p
males/26 NN p
females NNS p
, , p
aged VBD p
34-65 JJ p
y NN p
, , p
BMI NNP p
28-43 CD p
kg/m NN p
( ( p
2 CD p
) ) p
, , p
fasting VBG p
insulin JJ p
12-45 JJ p
mU/l NN p
) ) p
. . p

MEASUREMENTS NNP N
Body NNP o
weight VBD o
and CC o
composition NN o
, , o
TEE NNP o
, , o
REE NNP o
, , o
and CC o
RQ NNP o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
at IN N
week NN N
16 CD N
. . N

In IN N
addition NN N
, , N
the DT N
TEF NNP o
to TO N
an DT N
HP NNP i
or CC N
LP NNP i
meal NN N
was VBD N
determined VBN N
for IN N
3 CD N
h NN N
, , N
at IN N
baseline NN N
and CC N
at IN N
week NN N
16 CD N
. . N

RESULTS NN N
After IN N
16 CD N
weeks NNS N
, , N
weight JJ o
loss NN o
was VBD N
similar JJ N
in IN N
response NN N
to TO N
each DT N
diet NN N
; : N
the DT N
overall JJ N
decrease NN N
was VBD N
7.9+/-0.6 JJ N
kg NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
of IN N
which WDT N
6.8+/-0.5 JJ N
kg NN N
was VBD N
fat JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

REE NNP o
fell VBD N
similarly RB N
with IN N
each DT N
diet NN N
; : N
the DT N
overall JJ N
decrease NN N
was VBD N
719+/-106 JJ N
kJ/day NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
TEF NNP o
was VBD N
2 CD N
% NN N
greater JJR N
after IN N
the DT N
HP NNP i
than IN N
after IN N
the DT N
LP NNP i
meal NN N
at IN N
baseline NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
0.8 CD N
% NN N
greater JJR N
at IN N
week NN N
16 CD N
( ( N
P=0.35 NNP N
) ) N
. . N

After IN N
16 CD N
weeks NNS N
, , N
the DT N
TEF NNP o
was VBD N
not RB N
reduced VBN N
in IN N
either DT N
dietary JJ N
group NN N
. . N

There EX N
was VBD N
no DT N
change NN N
in IN N
TEE NNP o
after IN N
16 CD N
weeks NNS N
. . N

CONCLUSION NNP N
In IN N
subjects NNS p
with IN p
hyperinsulinemia PDT p
an DT N
energy-restrictive JJ N
diet NN N
containing VBG N
an DT N
increased VBN N
protein-to-carbohydrate NN o
ratio NN o
does VBZ N
not RB N
enhance VB N
weight JJ o
loss NN o
or CC o
significantly RB o
affect JJ o
energy NN o
expenditure NN o
. . o

Caloric NNP N
restriction NN N
, , N
rather RB N
than IN N
the DT N
macronutrient JJ N
composition NN N
of IN N
the DT N
diet NN N
, , N
is VBZ N
the DT N
most RBS N
important JJ N
determinant NN N
of IN N
weight JJ N
loss NN N
. . N

-DOCSTART- -6751144- O O

Epidural JJ i
morphine NN i
in IN N
the DT p
elderly JJ p
. . p

A DT N
controlled JJ N
trial NN N
after IN p
upper JJ p
abdominal JJ p
surgery NN p
. . p

The DT N
effectiveness NN N
of IN N
epidurally RB i
administered VBN i
morphine NN i
in IN N
the DT N
relief NN o
of IN o
pain NN o
after IN N
upper JJ N
abdominal JJ N
surgery NN N
was VBD N
assessed VBN N
in IN N
a DT N
controlled VBN N
study NN N
involving VBG N
20 CD p
patients NNS p
aged VBD p
61 CD p
to TO p
78 CD p
years NNS p
. . p

Analgesia NNP o
provided VBN N
by IN N
epidural JJ i
morphine NN i
was VBD N
comparable JJ N
to TO N
that DT N
obtained VBN N
in IN N
matched JJ N
patients NNS N
given VBN N
an DT N
intramuscular JJ i
regime NN i
. . i

The DT N
total JJ N
dose NN N
required VBN N
by IN N
the DT N
epidural JJ N
route NN N
was VBD N
less JJR N
than IN N
one-fifth JJ N
that IN N
required VBD N
intramuscularly RB N
, , N
and CC N
sedation NN N
was VBD N
correspondingly RB N
reduced VBN N
. . N

Postoperative JJ o
respiratory NN o
mechanics NNS o
, , N
however RB N
, , N
were VBD N
not RB N
significantly RB N
improved VBN N
and CC N
delayed VBN o
respiratory NN o
depression NN o
was VBD N
observed VBN N
in IN N
one CD N
patient NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
in IN N
elderly JJ p
patients NNS p
undergoing VBG p
upper JJ p
abdominal JJ p
surgery NN p
the DT N
risks NNS N
related VBN N
to TO N
the DT N
use NN N
of IN N
morphine NN i
by IN N
the DT N
epidural JJ N
route NN N
outweigh VBP N
the DT N
marginal JJ N
advantages NNS N
it PRP N
may MD N
offer VB N
over IN N
conventional JJ N
analgesic JJ N
techniques NNS N
. . N

-DOCSTART- -9474454- O O

Twice-a-day JJ N
versus NN N
four-times-a-day JJ N
ofloxacin JJ N
treatment NN N
of IN N
external JJ N
ocular JJ N
infection NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacies NNS o
of IN N
0.3 CD N
% NN N
ofloxacin JJ N
eyedrops NNS N
, , N
when WRB N
given VBN N
twice-a-day JJ N
( ( N
BID NNP N
) ) N
versus IN N
four-times-a-day JJ N
( ( N
QID NNP N
) ) N
, , N
for IN N
the DT N
treatment NN N
of IN N
external JJ N
ocular JJ N
disease NN N
. . N

METHOD NNP N
Fifty NNP p
patients NNS p
with IN p
blepharitis NN p
, , p
conjuctivitis NN p
, , p
or CC p
blepharoconjunctivitis NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN i
with IN i
0.3 CD i
% NN i
ofloxacin JJ i
eyedrops NNS i
, , i
BID NNP i
or CC i
QID NNP i
, , i
for IN i
10 CD i
days NNS i
. . i

Signs NNP N
, , N
symptoms NNS N
, , N
and CC N
cultures NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS VB N
The DT N
clinical JJ N
outcome NN N
was VBD N
virtually RB N
identical JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
clinical JJ o
scores NNS o
in IN N
the DT N
BID NNP N
and CC N
QID NNP N
groups NNS N
by IN N
days NNS N
3 CD N
to TO N
5 CD N
( ( N
2.6-3.0 JJ N
points NNS N
) ) N
and CC N
a DT N
further JJ N
decrease NN N
by IN N
day NN N
11 CD N
( ( N
4.3-5.0 JJ N
points NNS N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
at IN N
any DT N
time NN N
interval NN N
. . N

Microbiologic NNP N
studies NNS N
showed VBD N
a DT N
reduction NN N
in IN N
colony-forming JJ o
units NNS o
in IN N
87 CD N
% NN N
of IN N
the DT N
BID NNP N
group NN N
and CC N
in IN N
80 CD N
% NN N
of IN N
the DT N
QID NNP N
group NN N
. . N

CONCLUSION NNP N
The DT N
treatment NN N
of IN N
external JJ o
ocular JJ o
disease NN o
with IN N
0.3 CD N
% NN N
ofloxacin JJ o
eyedrops NN o
was VBD o
equally RB o
effective JJ o
when WRB o
given VBN o
BID NNP o
or CC o
QID NNP o
. . o

-DOCSTART- -18681363- O O

[ JJ o
Intra-uterine JJ o
insemination NN o
with IN i
controlled JJ i
ovarian JJ o
hyperstimulation NN o
compared VBN i
to TO i
an DT i
expectant JJ o
management NN o
in IN N
couples NNS p
with IN p
unexplained JJ p
subfertility NN o
and CC p
an DT p
intermediate JJ p
prognosis NN p
: : p
a DT N
randomised JJ N
study NN N
] NNP N
. . N

OBJECTIVE NNP N
Intrauterine NNP o
insemination NN o
( ( o
IUI NNP o
) ) o
with IN i
controlled JJ o
ovarian JJ o
hyperstimulation NN o
( ( o
COH NNP o
) ) o
is VBZ N
commonly RB N
used VBN N
as IN N
treatment NN N
of IN N
first JJ N
choice NN N
in IN N
couples NNS p
with IN p
unexplained JJ o
subfertility NN o
. . o

This DT N
treatment NN N
should MD N
only RB N
be VB N
applied VBN N
when WRB N
there EX N
is VBZ N
a DT N
realistic JJ N
increase NN o
in IN o
chance NN o
of IN o
pregnancy NN o
, , N
particularly RB N
because IN N
it PRP N
carries VBZ N
the DT N
increased VBN N
risk NN N
of IN N
multiple JJ N
pregnancies NNS N
. . N

We PRP N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
IUI NNP o
with IN i
COH NNP o
relative VBP N
to TO N
expectant VB o
management NN o
in IN N
couples NNS p
with IN p
unexplained JJ o
subfertility NN o
and CC N
an DT N
intermediate JJ N
prognosis NN N
of IN N
a DT N
spontaneous JJ o
ongoing JJ o
pregnancy NN o
. . o

DESIGN NNP N
Multicentre NNP N
randomised VBD N
clinical JJ N
study NN N
. . N

METHOD NNP N
253 CD p
couples NNS p
with IN p
unexplained JJ o
subfertility NN o
and CC p
a DT p
probability NN p
of IN p
a DT p
spontaneous JJ o
ongoing JJ o
pregnancy NN o
of IN p
30 CD p
% NN p
to TO p
40 CD p
% NN p
within IN p
12 CD p
months NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
IUI NNP o
with IN i
COH NNP o
for IN N
6 CD N
months NNS N
or CC N
expectant JJ i
management NN i
for IN N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
endpoint NN N
of IN N
our PRP$ N
study NN N
was VBD N
ongoing JJ o
pregnancy NN o
within IN o
6 CD o
months NNS o
. . o

Analysis NN N
was VBD N
carried VBN N
out RP N
according VBG N
to TO N
the DT N
intention NN N
to TO N
treat VB N
principle NN N
. . N

This DT N
study NN N
was VBD N
registered VBN N
with IN N
the DT N
Dutch JJ N
Trial NNP N
Register NNP N
and CC N
has VBZ N
the DT N
International NNP N
Standard NNP N
Randomised VBD N
Clinical JJ N
Trial NNP N
number NN N
ISRCTN72675518 NNP N
. . N

RESULTS NNP N
Of IN N
the DT N
253 CD N
couples NNS N
included VBD N
, , N
127 CD N
couples NNS N
were VBD N
allocated VBN N
to TO N
IUI NNP o
with IN i
COH NNP o
and CC N
126 CD N
to TO N
expectant VB o
management NN o
. . o

In IN N
the DT N
intervention NN N
group NN N
, , N
42 CD N
women NNS N
( ( N
33 CD N
% NN N
) ) N
conceived VBD N
, , N
of IN N
which WDT N
29 CD N
pregnancies NNS N
were VBD N
ongoing VBG N
( ( N
23 CD N
% NN N
) ) N
. . N

In IN N
the DT N
expectant JJ N
management NN N
group NN N
, , N
40 CD N
women NNS N
( ( N
32 CD N
% NN N
) ) N
conceived VBD o
, , N
of IN N
which WDT N
34 CD N
pregnancies NNS N
were VBD N
ongoing VBG o
( ( N
27 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
: : N
0.85 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.63-1.1 NN N
) ) N
. . N

In IN N
the DT N
expectant JJ i
management NN i
group NN N
one CD N
twin NN o
pregnancy NN o
occurred VBD N
and CC N
in IN N
the DT N
intervention NN N
group NN N
one CD N
woman NN N
conceived VBD N
twins NNS o
and CC o
one CD o
a DT o
triplet NN o
. . o

CONCLUSION VB N
A DT N
substantial JJ N
beneficial JJ N
effect NN N
of IN N
IUI NNP o
with IN o
COH NNP o
in IN N
couples NNS N
with IN N
unexplained JJ o
subfertility NN o
and CC N
an DT N
intermediate JJ N
prognosis NN N
can MD N
be VB N
excluded VBN N
. . N

Expectant JJ o
management NN o
for IN N
a DT N
period NN N
of IN N
6 CD N
months NNS N
therefore RB N
appears VBZ N
justified JJ N
in IN N
these DT N
couples NNS N
. . N

-DOCSTART- -22349989- O O

ApoA-I JJ i
induction NN N
as IN N
a DT N
potential JJ N
cardioprotective JJ N
strategy NN N
: : N
rationale NN N
for IN N
the DT N
SUSTAIN NNP N
and CC N
ASSURE NNP N
studies NNS N
. . N

BACKGROUND NNP N
Considerable JJ N
interest NN N
has VBZ N
focused VBN N
on IN N
the DT N
development NN N
of IN N
therapies NNS N
that WDT N
target VBP N
the DT N
functionality NN N
of IN N
high-density NN N
lipoproteins NNS N
( ( N
HDL NNP N
) ) N
. . N

Upregulation NN N
of IN N
endogenous JJ N
synthesis NN N
of IN N
the DT N
major JJ N
protein NN N
on IN N
HDL NNP N
particles NNS N
, , N
apolipoprotein RB i
A-I NNP i
( ( N
apoA-I NN N
) ) N
, , N
represents VBZ N
a DT N
novel JJ N
approach NN N
to TO N
generation NN N
of IN N
new JJ N
HDL NNP N
particles NNS N
. . N

The DT N
Study NNP N
of IN N
Quantitative NNP N
Serial NNP N
Trends NNP N
in IN N
Lipids NNP N
with IN N
Apolipoprotein NNP i
A-I NNP i
Stimulation NNP i
( ( N
SUSTAIN NNP N
, , N
NCT01423188 NNP N
) ) N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
lipid JJ o
efficacy NN o
, , o
safety NN o
and CC N
tolerability NN o
of IN N
an DT N
apoA-I JJ i
inducer NN i
( ( i
RVX-208 NNP i
) ) i
. . N

The DT N
ApoA-I JJ N
Synthesis NNP N
Stimulation NNP N
and CC N
Intravascular NNP i
Ultrasound NNP i
for IN N
Coronary NNP N
Atheroma NNP N
Regression NNP N
Evaluation NNP N
( ( N
ASSURE NNP N
, , N
NCT01067820 NNP N
) ) N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
RVX-208 NNP N
on IN N
plaque NN N
burden NN N
. . N

METHODS NNP N
In IN p
SUSTAIN NNP p
, , p
172 CD p
patients NNS p
with IN p
low JJ p
levels NNS p
of IN p
HDL-C NNP p
will MD p
be VB p
randomized VBN p
to TO N
receive VB N
RVX-208 NNP i
100 CD N
mg NN N
bid NN N
or CC N
placebo NN i
for IN N
24 CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
parameter NN N
will MD N
be VB N
the DT N
percentage NN o
change NN o
in IN o
HDL-C NNP o
levels NNS o
. . o

In IN p
ASSURE NNP p
, , p
310 CD p
patients NNS p
with IN p
angiographic JJ p
coronary JJ p
artery NN p
disease NN p
and CC p
low JJ p
HDL-C NNP p
levels NNS p
will MD p
be VB p
randomized VBN p
to TO N
receive VB N
RVX-208 NNP i
100 CD N
mg NN N
bid NN N
or CC N
placebo NN i
for IN N
26 CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
parameter NN N
will MD N
be VB N
the DT N
nominal JJ N
change NN N
in IN N
percent NN o
atheroma NN o
volume NN o
( ( o
PAV NNP o
) ) o
, , N
determined VBN N
by IN N
analysis NN N
of IN N
intravascular JJ N
ultrasound NN N
( ( N
IVUS NNP N
) ) N
images NNS N
of IN N
matched JJ N
coronary JJ N
artery NN N
segments NNS N
acquired VBD N
at IN N
baseline NN N
and CC N
at IN N
26-week JJ N
follow-up NN N
. . N

The DT N
effect NN N
of IN N
RVX-208 NNP i
on IN N
other JJ N
lipid JJ o
and CC o
inflammatory JJ o
markers NNS o
, , o
safety NN o
and CC o
tolerability NN o
will MD N
also RB N
be VB N
assessed VBN N
in IN N
both DT N
studies NNS N
. . N

CONCLUSION NNP N
ApoA-I NNP i
induction NN N
represents VBZ N
a DT N
potential JJ N
novel NN N
strategy NN N
to TO N
reduce VB N
cardiovascular JJ o
risk NN o
, , N
by IN N
generating VBG N
nascent JJ N
HDL NNP N
particles NNS N
. . N

These DT N
studies NNS N
will MD N
provide VB N
early JJ N
evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
RVX-208 NNP i
on IN N
lipids NNS N
and CC N
atherosclerotic JJ N
plaque NN N
. . N

-DOCSTART- -2199180- O O

[ JJ N
Treatment NNP N
of IN N
primary JJ N
osteoporosis NN N
with IN N
calcium NN i
and CC i
salmon JJ i
calcitonin NN i
] NN i
. . N

Fifty-nine JJ p
consecutive JJ p
patients NNS p
( ( p
19 CD p
men NNS p
, , p
40 CD p
women NNS p
, , p
mean JJ p
age NN p
60.8 CD p
[ JJ p
27-80 JJ p
] NNP p
years NNS p
) ) p
with IN p
primary JJ p
osteoporosis NN p
were VBD N
studied VBN N
to TO N
see VB N
if IN N
there EX N
was VBD N
any DT N
significant JJ N
gain NN N
in IN N
bone NN N
mass NN N
after IN N
treatment NN N
with IN N
salmon JJ i
calcitonin NN i
. . i

All PDT N
the DT N
patients NNS N
were VBD N
given VBN N
1 CD N
g JJ N
calcium NN i
by IN N
mouth NN N
every DT N
morning NN N
. . N

Group NNP N
1 CD N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
received VBN N
no DT N
other JJ N
specific JJ N
medication NN N
while IN N
group NN N
2 CD N
( ( N
n JJ N
= NNP N
19 CD N
) ) N
were VBD N
given VBN N
100 CD i
I.U NNP i
. . i

calcitonin NN i
subcutaneously RB i
every DT i
second JJ i
evening NN i
and CC i
group NN i
3 CD i
( ( i
n JJ i
= NNP i
20 CD i
) ) i
received VBD i
the DT i
same JJ i
dose NN i
every DT i
evening NN i
. . i

The DT N
pain NN o
reported VBN N
by IN N
the DT N
patients NNS N
was VBD N
subdivided VBN N
into IN N
four CD N
severity NN N
grades NNS N
, , N
and CC N
analgesic JJ o
consumption NN o
was VBD N
recorded VBN N
. . N

In IN N
group NN N
1 CD N
there EX N
was VBD N
a DT N
nonsignificant JJ N
decrease NN N
in IN N
pain NN o
, , N
but CC N
in IN N
groups NNS N
2 CD N
and CC N
3 CD N
there EX N
was VBD N
a DT N
highly RB N
significant JJ N
diminution NN N
in IN N
pain NN o
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
) ) N
and CC N
in IN N
analgesic JJ o
intake NN o
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Measurements NNS N
of IN N
bone NN o
density NN o
carried VBD N
out RP N
by IN N
photon NN N
absorption NN N
at IN N
the DT N
end NN N
of IN N
12 CD N
months NNS N
showed VBD N
a DT N
5.5 CD N
% NN N
increase NN N
in IN N
the DT N
distal JJ o
radius NN o
in IN N
group NN N
2 CD N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
and CC N
a DT N
7.1 CD N
% NN N
increase NN N
in IN N
group NN N
3 CD N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
, , N
while IN N
in IN N
group NN N
1 CD N
mineral NN N
content NN N
had VBD N
decreased VBN N
by IN N
4.3 CD N
% NN N
( ( N
nonsignificant JJ N
) ) N
. . N

These DT N
results NNS N
show VBP N
that IN N
a DT N
significant JJ N
gain NN N
in IN N
bone NN o
mass NN o
can MD N
be VB N
achieved VBN N
by IN N
administration NN N
of IN N
calcitonin NN N
, , N
either CC N
daily RB N
or CC N
on IN N
alternate JJ N
days NNS N
. . N

The DT N
incidence NN N
of IN N
extravertebral JJ N
fractures NNS N
and CC N
of IN N
new JJ N
or CC N
progressive JJ N
vertebral JJ N
deformity NN N
tended VBD N
to TO N
be VB N
lower JJR N
in IN N
groups NNS N
2 CD N
and CC N
3 CD N
than IN N
in IN N
group NN N
1 CD N
. . N

-DOCSTART- -20484550- O O

Biomarkers NNS N
of IN N
dietary JJ i
exposure NN i
are VBP N
associated VBN N
with IN N
lower JJR N
risk NN N
of IN N
breast NN p
fibroadenomas NN p
in IN p
Chinese JJ p
women NNS p
. . p

Fibroadenomas NNP N
are VBP N
the DT N
most RBS N
common JJ N
benign NN N
breast JJ N
condition NN N
among IN N
women NNS N
and CC N
account NN N
for IN N
up IN N
to TO N
50 CD N
% NN N
of IN N
all DT N
breast NN N
biopsies NNS N
being VBG N
performed VBN N
. . N

Although IN N
considered VBN N
a DT N
benign JJ N
condition NN N
, , N
fibroadenomas JJ N
utilize VBP N
substantial JJ N
resources NNS N
for IN N
management NN N
and CC N
treatment NN N
to TO N
rule VB N
out RP N
potential JJ N
malignancies NNS N
. . N

Dietary JJ i
factors NNS i
may MD N
influence VB N
benign JJ N
fibrocystic JJ N
breast NN N
conditions NNS N
, , N
but CC N
little JJ N
is VBZ N
known VBN N
of IN N
their PRP$ N
association NN N
with IN N
fibroadenomas NN N
. . N

We PRP N
examined VBD N
possible JJ N
associations NNS N
between IN N
a DT N
broad JJ N
spectrum NN N
of IN N
circulating VBG N
biomarkers NNS o
of IN o
dietary JJ o
intake NN o
and CC N
risk NN N
of IN N
fibroadenomas NN N
. . N

Participants NNS p
were VBD p
women NNS p
in IN p
a DT p
breast NN i
self-examination NN i
trial NN p
in IN p
Shanghai NNP p
, , p
China NNP p
who WP p
were VBD p
diagnosed VBN p
with IN p
fibroadenomas NN p
( ( p
n JJ p
= NNP p
258 CD p
) ) p
and CC p
1035 CD p
controls NNS p
. . p

Conditional NNP o
logistic JJ o
regression NN o
was VBD N
used VBN N
to TO N
estimate VB o
adjusted VBN o
odds NNS o
ratios NNS o
( ( o
OR NNP o
) ) o
and CC N
95 CD o
% NN o
CI NNP o
. . o

Isoflavone NNP o
concentrations NNS o
were VBD N
inversely RB N
associated VBN N
with IN N
risk NN o
of IN o
fibroadenomas NN o
. . o

Adjusted VBN o
OR NNP o
( ( o
95 CD o
% NN o
CI NNP o
) ) o
for IN N
the DT N
highest JJS N
versus NN N
the DT N
lowest JJS N
quartile NN N
of IN N
plasma JJ N
concentration NN N
were VBD N
0.36 CD N
( ( N
0.16-0.79 CD N
; : N
P-trend NNP N
< NNP N
0.001 CD N
) ) N
for IN N
daidzein NN i
and CC N
0.39 CD N
( ( N
0.19-0.84 CD N
; : N
P-trend NNP N
= NNP N
0.010 CD N
) ) N
for IN N
genistein NN i
. . i

We PRP N
also RB N
observed VBD N
inverse JJ o
associations NNS o
between IN N
higher JJR N
percentages NNS o
of IN o
the DT o
RBC NNP o
( ( o
n-3 JJ o
) ) o
fatty JJ o
acids NNS o
, , o
eicosapentaenoic JJ o
acid NN o
( ( o
EPA NNP o
) ) o
( ( N
[ $ N
0.38 CD N
( ( N
0.19-0.77 JJ N
) ) N
; : N
P-trend JJ N
= NN N
0.007 CD N
] NN N
and CC N
docosapentaenoic NN o
acid NN o
( ( o
DPA NNP o
) ) o
[ VBZ N
0.32 CD N
( ( N
0.15-0.70 JJ N
) ) N
; : N
P-trend JJ N
= NN N
0.024 CD N
] NN N
, , N
and CC N
fibroadenoma NN N
risk NN N
. . N

Circulating VBG N
concentrations NNS N
of IN N
carotenoids NNS o
, , o
vitamin FW o
C NNP o
, , o
retinol NN o
, , o
and CC o
ferritin NNS o
were VBD N
not RB N
associated VBN N
with IN N
fibroadenoma NN N
risk NN N
. . N

The DT N
inverse JJ o
associations NNS o
between IN N
plasma NN o
isoflavone NN o
concentrations NNS o
and CC N
RBC NNP o
EPA NNP o
and CC o
DPA NNP o
and CC N
fibroadenoma NN o
risk NN o
suggest VBP N
that IN N
higher JJR N
intakes NNS N
of IN N
soy JJ i
foods NNS i
and CC i
fatty JJ i
fish NN i
may MD N
lower VB N
the DT N
risk NN o
of IN o
fibroadenomas NN o
. . o

-DOCSTART- -23084254- O O

The DT N
effects NNS N
of IN N
a DT N
six-week JJ N
supervised JJ N
multimodal NN i
exercise NN i
intervention NN i
during IN N
chemotherapy NN i
on IN N
cancer-related JJ o
fatigue NN o
. . o

PURPOSE NNP N
Cancer NNP o
related VBN o
fatigue NN o
( ( o
CRF NNP o
) ) o
is VBZ N
a DT N
common JJ N
problem NN N
for IN N
cancer NN p
patients NNS p
across IN p
diagnoses NNS p
during IN p
chemotherapy NN i
and CC N
is VBZ N
associated VBN N
with IN N
physical JJ N
inactivity NN N
, , N
lower JJR N
functional JJ N
level NN N
and CC N
lack NN N
of IN N
energy NN N
. . N

Few JJ N
RCT NNP N
exercise NN i
intervention NN i
studies NNS N
have VBP N
included VBN N
cancer NN p
patients NNS p
undergoing VBG p
chemotherapy NN p
. . p

The DT N
objective NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
whether IN N
a DT N
six-week JJ N
supervised JJ i
multimodal NN i
exercise NN i
intervention NN i
, , i
adjunct JJ i
to TO i
chemotherapy VB i
and CC i
standard VB i
care NN i
, , N
can MD N
reduce VB N
the DT N
patient NN N
's POS N
CRF NNP o
level NN o
. . o

METHODS NNP N
Data NNP N
is VBZ N
based VBN N
on IN N
analyses NNS N
of IN N
a DT N
prospective JJ N
randomised VBN N
controlled VBN N
trial NN N
'The NNP N
Body NNP N
& CC N
Cancer NNP N
Trial NNP N
' POS N
. . N

213 CD p
cancer NN p
patients NNS p
with IN p
different JJ p
diagnoses NNS p
were VBD N
randomised VBN N
into IN p
an DT N
intervention NN i
group NN i
or CC N
wait-list JJ i
control NN i
group NN i
. . i

The DT N
primary JJ N
outcome NN N
, , N
Fatigue NNP o
score NN o
( ( o
CRF NNP o
) ) o
, , N
was VBD N
evaluated VBN N
by IN N
the DT N
Functional NNP o
Assessment NNP o
of IN o
Cancer NNP o
Therapy-Anaemia NNP o
Questionnaire NNP o
( ( o
FACT-An- NNP o
) ) o
( ( o
FACT-G NNP o
score NN o
& CC o
FACT-An NNP o
Anemia NNP o
subscale NN o
) ) o
. . o

INTERVENTION NNP N
Supervised VBD i
exercise NN i
, , i
comprising VBG i
high-intensity NN i
cardiovascular NN i
and CC i
heavy JJ i
resistance NN i
training NN i
, , i
relaxation- JJ i
and CC i
body NN i
awareness JJ i
training NN i
and CC i
massage NN i
, , N
9 CD N
h JJ N
weekly JJ N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
CRF NNP o
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
intervention NN N
group NN N
, , N
corresponding VBG N
to TO N
a DT N
Fatigue NNP o
score NN o
reduction NN o
of IN N
3.04 CD N
( ( N
effect NN N
size NN N
of IN N
0.44 CD N
, , N
95 CD N
% NN N
CI NNP N
0.17-0.72 NN N
) ) N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
, , N
the DT N
FACT-An NNP o
score NN o
by IN N
5.40 CD N
( ( N
P NNP N
= NNP N
.015 NNP N
) ) N
, , N
the DT N
FACT-An NNP o
Toi NNP o
score NN N
by IN N
5.22 CD N
( ( N
P NNP N
= NNP N
.009 NNP N
) ) N
and CC N
the DT N
Anaemia-ANS JJ o
by IN N
3.76 CD N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
effect NN N
on IN N
the DT N
General NNP o
Quality NNP o
of IN o
Life NNP o
score NN o
( ( N
FACT-G NNP N
) ) N
or CC N
on IN N
any DT N
of IN N
the DT N
individual JJ o
wellbeing NN o
scores NNS o
; : o
Physical NNP o
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
, , N
Emotional NNP o
( ( N
P NNP N
= NNP N
.87 NNP N
) ) N
, , N
Social NNP o
( ( N
P NNP N
= NNP N
.83 NNP N
) ) N
and CC N
Functional NNP o
( ( N
P NNP N
= NNP N
.26 NNP N
) ) N
. . N

CONCLUSION NNP N
In IN N
summary JJ N
, , N
this DT N
six-week JJ N
supervised JJ i
multimodal NN i
exercise NN i
intervention NN i
can MD N
lead VB N
to TO N
significant JJ N
reduction NN N
in IN N
self-reported JJ o
CRF NNP o
in IN p
cancer NN p
patients NNS p
undergoing VBG p
chemotherapy NN p
. . p

-DOCSTART- -8639070- O O

The DT N
effects NNS N
of IN N
amantadine NN i
and CC N
pemoline NN i
on IN N
cognitive JJ p
functioning NN p
in IN N
multiple JJ N
sclerosis NN N
. . N

BACKGROUND NNP N
Amantadine NNP i
hydrochloride NN i
and CC N
pemoline NN i
, , N
both DT N
frequently RB N
used VBN N
to TO N
treat VB N
the DT N
fatigue NN N
of IN N
multiple JJ N
sclerosis NN N
( ( N
MS NNP N
) ) N
, , N
may MD N
also RB N
improve VB N
attention NN N
and CC N
other JJ N
cognitive JJ N
functions NNS N
in IN N
MS. NNP N
To TO N
our PRP$ N
knowledge NN N
, , N
these DT N
agents NNS N
have VBP N
never RB N
been VBN N
compared VBN N
in IN N
a DT N
placebo-controlled JJ N
trial NN N
of IN N
patients NNS p
with IN p
MS NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
amantadine NN i
and CC i
pemoline NN i
on IN N
cognitive JJ N
functioning NN N
in IN N
MS. NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
45 CD p
ambulatory JJ p
patients NNS p
with IN p
MS NNP p
and CC p
severe JJ p
fatigue NN p
were VBD N
treated VBN N
for IN N
6 CD N
weeks NNS N
with IN N
amantadine NN i
, , i
pemoline NN i
, , i
or CC i
placebo NN i
using VBG N
a DT N
parallel JJ N
group NN N
design NN N
. . N

They PRP N
underwent VBD N
comprehensive JJ N
neuropsychological JJ N
testing NN N
to TO N
determine VB N
treatment NN N
effects NNS N
on IN N
cognitive JJ N
functioning NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
tests NNS N
of IN N
attention NN N
( ( o
Digit NNP o
Span NNP o
, , o
Trail NNP o
Making NNP o
Test NNP o
, , o
and CC o
Symbol NNP o
Digit NNP o
Modalities NNP o
Test NNP o
) ) o
, , o
verbal JJ o
memory NN o
( ( o
Selective JJ o
Reminding NNP o
Test NNP o
) ) o
, , o
nonverbal JJ o
memory NN o
( ( o
Benton NNP o
Visual NNP o
Retention NNP o
Test NNP o
) ) o
, , o
and CC o
motor NN o
speed NN o
( ( o
Finger NNP o
Tapping NNP o
Test NNP o
) ) o
. . N

RESULTS NNP N
Fatigue NNP o
did VBD N
not RB N
significantly RB N
correlate VB N
with IN N
any DT N
of IN N
the DT N
neuropsychological JJ N
outcome NN N
measures NNS N
at IN N
baseline NN N
or CC N
after IN N
treatment NN N
. . N

All DT N
three CD N
treatment NN N
groups NNS N
improved VBN N
on IN N
tests NNS o
of IN o
attention NN o
( ( N
P NNP N
< NNP N
.003 NNP N
) ) N
, , N
verbal JJ o
memory NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
motor NN o
speed NN o
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
amantadine NN N
, , N
pemoline NN N
, , N
and CC N
placebo NN N
. . N

CONCLUSIONS NNP N
Cognitive NNP N
functioning NN N
in IN N
MS NNP N
is VBZ N
independent JJ N
of IN N
fatigue NN N
. . N

Neither CC N
amantadine JJ i
nor CC N
pemoline JJ i
enhances NNS N
cognitive JJ N
performance NN N
in IN N
MS NNP N
compared VBN N
with IN N
placebo NN i
. . i

-DOCSTART- -9839765- O O

Concurrent JJ N
administration NN N
of IN N
donepezil JJ i
HCl NNP i
and CC i
digoxin NN i
: : i
assessment NN N
of IN N
pharmacokinetic JJ N
changes NNS N
. . N

AIM VBP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
pharmacokinetics NNS N
of IN N
donepezil NN i
HCl NNP i
and CC i
digoxin NN i
separately RB i
, , i
and CC i
in IN i
combination NN i
, , N
following VBG N
administration NN N
of IN N
single JJ N
oral JJ N
doses NNS N
. . N

Changes NNS N
in IN N
cardiac JJ N
conduction NN N
parameters NNS N
following VBG N
drug NN N
administration NN N
were VBD N
also RB N
assessed VBN N
. . N

METHODS NNP N
This DT N
was VBD N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
three-period JJ N
crossover NN N
study NN N
in IN N
healthy JJ p
male NN p
volunteers NNS p
( ( p
n=12 NN p
) ) p
. . p

During IN N
each DT N
treatment NN N
period NN N
, , N
subjects VBZ p
received VBN p
a DT p
single JJ p
dose NN p
of IN p
either CC p
donepezil JJ i
HCl NNP i
( ( i
5 CD i
mg NN i
) ) i
, , i
digoxin NN i
( ( i
0.25 CD i
mg NN i
) ) i
, , i
or CC i
a DT i
combination NN i
of IN i
both DT i
drugs NNS i
. . i

Each DT N
treatment NN N
period NN N
was VBD N
followed VBN N
by IN N
a DT N
2-week JJ N
, , N
drug-free JJ N
washout NN N
period NN N
. . N

RESULTS NNP N
All DT N
12 CD p
volunteers NNS p
completed VBD N
the DT N
study NN N
without IN N
incident NN N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
donepezil NN o
pharmacokinetics NNS o
( ( o
Cmax NNP o
, , o
tmax NN o
, , o
AUC NNP o
( ( o
0-120 JJ o
) ) o
, , o
AUC NNP o
( ( o
0-infinity NN o
) ) o
or CC N
t1/2 NN N
) ) N
were VBD N
observed VBN N
when WRB N
donepezil NN i
administered VBD i
alone RB i
was VBD N
compared VBN N
with IN N
donepezil NN i
administered VBN i
in IN i
combination NN i
with IN i
digoxin NN i
. . i

Similarly RB N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
digoxin NN i
pharmacokinetics NNS N
were VBD N
observed VBN N
when WRB N
digoxin NN i
was VBD N
administered VBN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
donepezil NN i
. . i

No DT N
clinically RB N
relevant JJ N
changes NNS N
in IN N
cardiac JJ o
conduction NN o
( ( N
lead JJ N
II NNP N
ECG NNP N
) ) N
were VBD N
observed VBN N
in IN N
any DT N
subject NN N
during IN N
any DT N
treatment NN N
period NN N
. . N

CONCLUSIONS NNP N
Co-administration NN N
of IN N
single JJ N
doses NNS N
of IN N
donepezil NN i
HCl NNP i
( ( N
5 CD N
mg NN N
) ) N
and CC N
digoxin NN i
( ( N
0.25 CD N
mg NN N
) ) N
produced VBD N
no DT N
changes NNS N
in IN N
the DT N
pharmacokinetic JJ N
profile NN N
of IN N
either DT N
drug NN N
. . N

In IN N
addition NN N
, , N
co-administration NN N
produced VBD N
no DT N
changes NNS N
in IN N
cardiac JJ N
conduction NN N
parameters NNS N
during IN N
the DT N
24 CD N
h NN N
of IN N
telemetry NN N
monitoring NN N
following VBG N
drug NN N
administration NN N
. . N

-DOCSTART- -17366257- O O

Providing VBG N
live JJ i
supervision NN i
via IN i
teleconferencing VBG i
improves JJ N
acquisition NN o
of IN o
motivational JJ o
interviewing NN o
skills NNS o
after IN N
workshop NN N
attendance NN N
. . N

Teleconferencing VBG i
Supervision NNP i
is VBZ N
a DT N
method NN N
for IN N
training VBG N
community-based JJ p
substance NN p
abuse NN p
clinicians NNS p
in IN N
Motivational NNP i
Interviewing NNP i
( ( i
MI NNP i
) ) i
. . i

Following VBG N
a DT N
2-day JJ N
workshop NN N
, , N
13 CD p
clinicians NNS p
received VBD p
live JJ i
supervision NN i
via IN i
telephone NN i
during IN p
5 CD p
counseling VBG p
sessions NNS p
conducted VBN p
at IN p
their PRP$ p
community NN p
treatment NN p
facilities NNS p
. . p

Clinicians NNPS N
were VBD N
assessed VBN N
for IN N
skill JJ o
level NN o
at IN o
post-workshop NN o
, , N
at IN N
post-training NN N
, , N
and CC N
3 CD N
months NNS N
later RB N
; : N
learning VBG N
was VBD N
assessed VBN N
using VBG N
the DT N
MI NNP N
Treatment NNP N
Integrity NNP N
instrument NN N
. . N

All DT N
summary JJ o
scores NNS o
and CC N
therapist JJ o
behavior NN o
frequency NN o
counts NNS o
improved VBN N
by IN N
post-training NN N
or CC N
by IN N
the DT N
3 CD N
month NN N
follow-up RB N
, , N
although IN N
some DT N
gains NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Teleconferencing VBG i
Supervision NN i
may MD N
help VB N
facilitate VB N
the DT N
proficient NN N
use NN N
of IN N
MI NNP p
community NN p
clinicians NNS p
following VBG N
workshop NN N
instruction NN N
. . N

-DOCSTART- -2208619- O O

[ JJ N
Clinical NNP N
observations NNS N
on IN N
the DT N
treatment NN N
of IN N
hookworm NN p
, , p
Ascaris NNP p
and CC p
Trichuris NNP p
infection NN p
with IN N
oxibendazole JJ i
] NN i
. . N

340 CD p
cases NNS p
of IN p
hookworm NN p
infection NN p
, , p
196 CD p
cases NNS p
of IN p
ascariasis NN p
and CC p
178 CD p
cases NNS p
of IN p
trichuriasis NN p
were VBD p
treated VBN p
with IN p
an DT i
anthelmintic JJ i
, , i
oxibendazole JJ i
, , i
15mg/kg.d CD i
x JJ i
3d CD i
; : i
102 CD i
, , i
70 CD i
and CC i
66 CD i
cases NNS i
of IN i
respective JJ i
infections NNS i
were VBD i
treated VBN i
with IN i
pyrantel NN i
10mg/kg.d CD i
x NN i
3d CD i
and CC i
108 CD i
, , i
74 CD i
and CC i
63 CD i
cases NNS i
took VBD i
placebo NN i
for IN i
comparison NN i
and CC i
as IN i
control NN i
under IN i
double-blind JJ i
observations NNS i
. . i

Re-examinations NNS N
of IN N
the DT N
stool NN N
were VBD N
performed VBN N
after IN N
the DT N
treatment NN N
. . N

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
oxibendazole NN N
, , N
the DT N
egg NN o
negative JJ o
conversion NN o
rates NNS o
of IN o
hookworm NN o
, , o
Ascaris NNP o
and CC o
Trichuris NNP o
were VBD N
70.3-80.6 CD N
% NN N
, , N
92.5-97.8 CD N
and CC N
67.0-71.0 CD N
% NN N
respectively RB N
. . N

The DT N
egg NN o
reduction NN o
rates NNS o
of IN o
hookworm NN o
were VBD N
98.1-98.6 CD N
% NN N
. . N

The DT N
larval JJ o
negative JJ o
conversion NN o
rates NNS o
of IN o
Ancylostoma NNP o
duodenale NN o
and CC o
Necator NNP o
americanus VBP o
were VBD N
77.7 CD N
and CC N
83.2 CD N
% NN N
respectively RB N
. . N

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
pyrantel NN N
, , N
the DT N
egg NN o
negative JJ o
conversion NN o
rates NNS o
of IN N
the DT N
three CD N
above IN N
mentioned VBN N
parasites NNS N
were VBD N
73.5 CD N
, , N
90.0 CD N
and CC N
28.8 CD N
% NN N
respectively RB N
. . N

The DT N
egg NN o
reduction NN o
rate NN o
of IN o
hookworm NN o
was VBD N
98.8 CD N
% NN N
. . N

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
placebo NN N
, , N
the DT N
egg NN o
negative JJ o
conversion NN o
rates NNS o
of IN N
the DT N
three CD N
above IN N
mentioned VBN N
parasites NNS N
were VBD N
6.5 CD N
, , N
29.7 CD N
and CC N
7.9 CD N
% NN N
. . N

No CC N
marked JJ N
adverse JJ N
reactions NNS N
were VBD N
observed VBN N
by IN N
clinical JJ N
and CC N
laboratory JJ N
examinations NNS N
. . N

-DOCSTART- -20206437- O O

A DT N
prospective JJ N
multicenter NN N
randomized VBD N
comparative JJ N
study NN N
between IN N
the DT N
U- NNP i
and CC i
H-type NNP i
methods NNS i
of IN i
the DT i
TVT NNP i
SECUR NNP i
procedure NN i
for IN N
the DT N
treatment NN N
of IN N
female JJ p
stress NN p
urinary JJ p
incontinence NN p
: : p
1-year JJ N
follow-up NN N
. . N

BACKGROUND NNP N
No NNP N
studies NNS N
have VBP N
been VBN N
published VBN N
comparing VBG N
the DT N
U- JJ i
and CC i
H-type JJ i
methods NNS i
of IN i
the DT i
TVT NNP i
SECUR NNP i
( ( i
TVT-S NNP i
) ) i
procedure NN i
. . i

OBJECTIVE CC N
Our PRP$ N
aim NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
the DT N
two CD i
types NNS i
of IN i
TVT-S NNP i
for IN N
female JJ p
stress NN p
urinary JJ p
incontinence NN p
( ( p
SUI NNP p
) ) p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Women NNP p
with IN p
urodynamic JJ p
SUI NNP p
were VBD p
enrolled VBN p
in IN N
this DT N
12-mo JJ N
multicenter NN N
randomized VBN N
study NN N
. . N

INTERVENTION NNP N
Subjects NNPS p
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
the DT N
U- JJ i
or CC i
H-type JJ i
method NN i
of IN i
TVT-S. JJ i
MEASUREMENTS NNP N
Pre- NNP N
and CC N
postoperative JJ N
evaluations NNS N
included VBD N
a DT N
standing VBG o
stress NN o
test NN o
, , N
the DT N
Sandvik NNP o
questionnaire NN o
, , N
the DT N
Incontinence NNP o
Quality NNP o
of IN o
Life NNP o
( ( o
I-QOL NNP o
) ) o
questionnaire NN o
, , N
and CC N
the DT N
International NNP o
Consultation NNP o
on IN o
Incontinence NNP o
Questionnaire-Female NNP o
Lower NNP o
Urinary NNP o
Tract NNP o
Symptoms NNP o
( ( o
ICIQ-FLUTS NNP o
) ) o
. . o

Patients NNS N
' POS N
satisfaction NN o
and CC N
complications NNS o
were VBD N
evaluated VBN N
. . N

Objective NNP N
and CC N
subjective JJ N
cures NNS N
were VBD N
defined VBN N
as IN N
no DT N
leakage NN N
on IN N
the DT N
stress JJ o
test NN o
and CC N
responses NNS N
on IN N
the DT N
Sandvik NNP o
questionnaire NN o
, , N
respectively RB N
. . N

We PRP N
compared VBN N
the DT N
surgical JJ o
outcomes NNS o
between IN N
the DT N
two CD N
methods NNS N
. . N

RESULTS NNP N
AND NNP N
LIMITATIONS NNP N
Of IN p
285 CD p
women NNS p
, , p
144 CD p
had VBD p
the DT p
U-type JJ p
method NN p
and CC p
141 CD p
had VBD p
the DT p
H-type JJ p
method NN p
. . p

Objective JJ o
cure NN o
rates NNS o
were VBD N
87.5 CD N
% NN N
for IN N
the DT N
U-type JJ N
method NN N
and CC N
80.1 CD N
% NN N
for IN N
the DT N
H-type NNP N
method NN N
( ( N
p=0.091 NN N
) ) N
. . N

Subjective JJ o
cure NN o
rates NNS o
were VBD N
77.1 CD N
% NN N
for IN N
the DT N
U-type JJ N
method NN N
and CC N
75.7 CD N
% NN N
for IN N
the DT N
H-type NNP N
method NN N
( ( N
p=0.786 NN N
) ) N
. . N

Improvement NN N
in IN N
I-QOL NNP o
and CC o
domain NN o
scores NNS o
of IN o
the DT o
ICIQ-FLUTS NNP o
( ( o
filling VBG o
and CC o
incontinence NN o
sum NN o
, , o
QOL NNP o
score NN o
) ) o
, , N
and CC N
patients NNS o
' POS o
satisfaction NN o
favored VBD N
the DT N
U-type JJ N
method NN N
. . N

There EX N
were VBD N
three CD N
cases NNS N
of IN N
intraoperative JJ o
vaginal JJ o
wall NN o
perforation NN o
, , N
one CD N
case NN N
of IN N
increased VBN o
bleeding NN o
, , N
and CC N
three CD N
cases NNS N
of IN N
temporary JJ o
postoperative JJ o
retention NN o
. . o

A DT N
power NN N
calculation NN N
was VBD N
not RB N
performed VBN N
, , N
and CC N
some DT N
baseline NN N
characteristics NNS N
were VBD N
not RB N
balanced VBN N
between IN N
the DT N
two CD N
methods NNS N
. . N

CONCLUSIONS NNP N
Both NNP N
methods NNS i
of IN i
TVT-S NNP i
provided VBD N
comparable JJ N
cure NN o
rates NNS o
for IN N
female JJ p
SUI NNP p
. . p

However RB N
, , N
QOL NNP o
and CC N
treatment NN o
satisfaction NN o
favored VBD N
the DT N
U-type JJ i
method NN i
. . i

TRIAL NNP N
REGISTRATION NNP N
The DT N
protocol NN N
of IN N
this DT N
study NN N
was VBD N
not RB N
registered VBN N
. . N

-DOCSTART- -8770026- O O

Effects NNS N
of IN N
glucocorticoids NNS i
on IN N
energy NN o
metabolism NN o
and CC N
food NN o
intake NN o
in IN N
humans NNS p
. . p

The DT N
effect NN N
of IN N
glucocorticoid JJ i
administration NN N
on IN N
energy NN o
metabolism NN o
and CC N
food NN o
intake NN o
was VBD N
studied VBN N
in IN N
20 CD p
healthy JJ p
, , p
nondiabetic JJ p
Caucasian NNP p
male NN p
volunteers NNS p
[ VBP p
27 CD p
+/- JJ p
5 CD p
( ( p
SD NNP p
) ) p
yr NN p
, , p
72 CD p
+/- JJ p
9 CD p
kg NN p
, , p
20 CD p
+/- JJ p
7 CD p
% NN p
body NN p
fat JJ p
] NNP p
randomly NN N
and CC N
blindly RB N
assigned VBD N
to TO N
glucocorticoid VB i
( ( i
methylprednisolone NN i
, , i
METH NNP i
; : i
n CC N
= VB N
10 CD N
) ) N
or CC N
placebo NN i
( ( i
PLAC NNP i
; : i
n CC N
= VB N
10 CD N
) ) N
treatment NN N
. . N

Each DT N
subject NN N
was VBD N
studied VBN N
twice RB N
: : N
during IN N
a DT N
weight JJ N
maintenance NN N
diet JJ N
and CC N
during IN N
ad NN N
libitum NN N
food NN N
intake NN N
. . N

Energy NNP o
metabolism NN o
was VBD N
measured VBN N
by IN N
indirect JJ N
calorimetry NN N
and CC N
food NN o
intake NN o
by IN N
an DT N
automated VBN N
food-selection NN N
system NN N
. . N

Twenty-four-hour JJ N
urinary JJ o
norepinephrine NN o
excretion NN o
( ( N
24-h JJ N
NE NNP N
) ) N
was VBD N
used VBN N
as IN N
an DT N
estimate NN N
of IN N
sympathetic JJ o
nervous JJ o
system NN o
activity NN o
. . o

During IN N
weight JJ N
maintenance NN N
, , N
METH NNP N
intravenous JJ N
infusion NN N
( ( N
125 CD N
mg/30 NNS N
min NN N
) ) N
increased VBD N
energy NN o
expenditure NN o
compared VBN N
with IN N
PLAC NNP N
, , N
and CC N
after IN N
4 CD N
days NNS N
of IN N
oral JJ N
therapy NN N
, , N
METH NNP N
( ( N
40 CD N
mg/day NN N
) ) N
decreased VBD N
24-h JJ o
NE NNP o
and CC N
increased VBD N
energy NN o
expenditure NN o
compared VBN N
with IN N
PLAC NNP N
. . N

During IN N
ad NN N
libitum NN N
food NN N
intake NN N
, , N
after IN N
4 CD N
days NNS N
of IN N
METH NNP N
( ( N
40 CD N
mg/day NN N
) ) N
or CC N
PLAC NNP N
oral JJ N
therapy NN N
, , N
both DT N
groups NNS N
increased VBD N
their PRP$ N
energy NN o
intake NN o
over IN N
weight JJ N
maintenance NN N
, , N
but CC N
the DT N
increase NN N
was VBD N
significantly RB N
larger JJR N
in IN N
the DT N
METH NNP N
group NN N
compared VBN N
with IN N
the DT N
PLAC NNP N
group NN N
( ( N
4,554 CD N
+/- JJ N
1,857 CD N
vs. FW N
2,867 CD N
+/- JJ N
846 CD N
kcal/day NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
therapeutic JJ N
doses NNS N
of IN N
glucocorticoids NNS N
induce VBP N
obesity NN N
mostly RB N
by IN N
increasing VBG N
energy NN o
intake NN o
, , N
an DT N
effect NN N
which WDT N
may MD N
be VB N
related VBN N
to TO N
the DT N
ability NN N
of IN N
glucocorticoids NNS N
to TO N
act VB N
directly RB N
or CC N
indirectly RB N
on IN N
the DT N
central JJ N
regulation NN N
of IN N
appetite NN N
. . N

-DOCSTART- -19919399- O O

Effect NN N
of IN N
device-guided JJ i
breathing NN i
exercises NNS i
on IN N
blood NN o
pressure NN o
in IN N
patients NNS p
with IN p
hypertension NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NNP N
Hypertension NNP N
is VBZ N
a DT N
chronic JJ N
disorder NN N
with IN N
a DT N
high JJ N
prevalence NN N
worldwide NN N
. . N

Despite IN N
considerable JJ N
efforts NNS N
, , N
it PRP N
is VBZ N
sometimes RB N
hard JJ N
to TO N
reach VB N
treatment NN N
goals NNS N
for IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
with IN N
classical JJ N
treatment NN N
options NNS N
. . N

Reducing VBG N
breathing VBG N
frequency NN N
has VBZ N
been VBN N
advocated VBN N
as IN N
a DT N
method NN N
to TO N
reduce VB N
BP NNP o
. . o

METHODS NNP N
A NNP N
randomized JJ N
, , N
single-blind JJ N
, , N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
in IN N
30 CD p
non-diabetic JJ p
patients NNS p
with IN p
hypertension NN p
over IN N
a DT N
period NN N
of IN N
9 CD N
weeks NNS N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
device NN i
that WDT i
helps VBZ i
to TO i
slow VB o
breathing NN o
( ( i
Resperate NNP i
) ) i
on IN N
BP NNP o
and CC o
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
. . o

The DT N
control NN N
group NN N
listened VBD i
to TO i
music NN i
and CC i
used VBN i
no DT i
other JJ i
therapeutic JJ i
device NN i
. . i

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
change NN N
in IN N
BP NNP o
between IN N
intervention NN N
and CC N
control NN N
; : N
BP NNP o
-4.2 NNP N
mmHg NN N
( ( N
95 CD N
% NN N
CI NNP N
-12.4 NNP N
to TO N
3.9 CD N
) ) N
/-2.6 NN N
mmHg NN N
( ( N
95 CD N
% NN N
CI NNP N
-8.4 NNP N
to TO N
3.3 CD N
) ) N
. . N

This DT N
result NN N
did VBD N
not RB N
alter VB N
in IN N
post NN N
hoc NN N
analyses NNS N
, , N
when WRB N
patients NNS N
not RB N
achieving VBG N
target NN o
breathing NN o
frequency NN o
( ( N
< JJ N
10 CD N
breaths/min NN N
) ) N
or CC N
non-compliant JJ N
patients NNS N
were VBD N
excluded VBN N
. . N

QoL NNP o
did VBD N
not RB N
change VB N
over IN N
time NN N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
no DT N
effect NN N
of IN N
the DT N
Resperate NNP N
on IN N
BP NNP o
or CC N
QoL NNP o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
, , N
at IN N
this DT N
moment NN N
, , N
this DT N
device NN N
has VBZ N
no DT N
added VBN N
value NN N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
. . N

-DOCSTART- -23019005- O O

Sensitivity NN p
to TO p
musical JJ p
structure NN p
in IN p
the DT p
human JJ p
brain NN p
. . p

Evidence NN N
from IN N
brain-damaged JJ p
patients NNS p
suggests VBZ N
that IN N
regions NNS N
in IN N
the DT N
temporal JJ N
lobes NNS N
, , N
distinct NN N
from IN N
those DT N
engaged VBN N
in IN N
lower-level JJ N
auditory NN N
analysis NN N
, , N
process NN N
the DT N
pitch NN N
and CC N
rhythmic JJ N
structure NN N
in IN N
music NN N
. . N

In IN N
contrast NN N
, , N
neuroimaging VBG N
studies NNS N
targeting VBG N
the DT N
representation NN N
of IN N
music NN N
structure NN N
have VBP N
primarily RB N
implicated VBN N
regions NNS N
in IN N
the DT N
inferior JJ N
frontal JJ N
cortices NNS N
. . N

Combining VBG N
individual-subject JJ i
fMRI NN i
analyses NNS i
with IN N
a DT N
scrambling VBG N
method NN N
that WDT N
manipulated VBD N
musical JJ N
structure NN N
, , N
we PRP N
provide VBP N
evidence NN N
of IN N
brain NN o
regions NNS o
sensitive VBP o
to TO o
musical JJ o
structure NN o
bilaterally RB N
in IN N
the DT N
temporal JJ N
lobes NNS N
, , N
thus RB N
reconciling VBG N
the DT N
neuroimaging NN N
and CC N
patient JJ N
findings NNS N
. . N

We PRP N
further VBP N
show VB N
that IN N
these DT N
regions NNS N
are VBP N
sensitive JJ N
to TO N
the DT N
scrambling NN o
of IN o
both DT o
pitch NN o
and CC o
rhythmic JJ o
structure NN o
but CC N
are VBP N
insensitive JJ N
to TO N
high-level JJ o
linguistic JJ o
structure NN o
. . o

Our PRP$ N
results NNS N
suggest VBP N
the DT N
existence NN N
of IN N
brain NN N
regions NNS N
with IN N
representations NNS o
of IN o
musical JJ o
structure NN o
that WDT N
are VBP N
distinct JJ N
from IN N
high-level JJ N
linguistic JJ N
representations NNS N
and CC N
lower-level JJ N
acoustic JJ N
representations NNS N
. . N

These DT N
regions NNS N
provide VBP N
targets NNS N
for IN N
future JJ N
research NN N
investigating VBG N
possible JJ N
neural JJ N
specialization NN N
for IN N
music NN N
or CC N
its PRP$ N
associated JJ N
mental JJ N
processes NNS N
. . N

-DOCSTART- -24673076- O O

[ NN i
Encephalopathy NNP i
therapeutic JJ i
tongue NN i
acupoint NN i
apparatus NN i
( ( N
ETTAA NNP N
) ) N
for IN N
42 CD p
cases NNS p
of IN p
autism NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
efficacy NN o
of IN N
encephalopathy JJ i
therapeutic JJ i
tongue NN i
acupoint NN i
apparatus NN i
( ( i
ETTAA NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
. . p

METHODS NNP N
Eighty-four JJ p
children NNS p
of IN p
autism NN p
were VBD p
randomly RB p
divided VBN p
into IN p
a DT p
tongue JJ i
acupuncture NN i
group NN p
( ( p
group NN p
A NNP p
) ) p
and CC p
a DT p
conventional JJ i
training NN i
group NN p
( ( p
group NN p
B NNP p
) ) p
, , p
42 CD p
cases NNS p
in IN p
each DT p
group NN p
. . p

The DT N
behavior JJ N
training NN N
and CC N
sensory JJ N
integration NN N
training NN N
were VBD N
carried VBN N
out RP N
in IN N
group NN N
B NNP N
and CC N
the DT N
ETTAA NNP N
was VBD N
added VBN N
in IN N
group NN N
A NNP N
. . N

The DT N
apparatus NN N
was VBD N
switched VBN N
on IN N
for IN N
20 CD N
min NN N
every DT N
time NN N
and CC N
3 CD N
times NNS N
a DT N
day NN N
. . N

Treatment NN N
of IN N
two CD N
months NNS N
were VBD N
carried VBN N
out RP N
in IN N
both DT N
groups NNS N
. . N

The DT N
score NN o
of IN o
childhood NN o
autism NN o
rating NN o
scale NN o
( ( o
CARS NNP o
) ) o
and CC N
clinical JJ o
efficacy NN o
in IN N
both DT N
groups NNS N
were VBD N
observed VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
CARS NNPS o
in IN N
both DT N
groups NNS N
were VBD N
significantly RB N
reduced VBN N
( ( N
42.39 CD N
+/- JJ N
6.86 CD N
vs JJ N
32.15 CD N
+/- JJ N
5.12 CD N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
44.58 CD N
+/- JJ N
6.76 CD N
vs JJ N
39.72 CD N
+/- JJ N
7.11 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
which WDT N
was VBD N
more RBR N
significant JJ N
in IN N
group NN N
A NNP N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
totally RB o
effective JJ o
rate NN o
in IN N
group NN N
A NNP N
[ RB N
90.5 CD N
% NN N
( ( N
38/42 CD N
) ) N
] NN N
was VBD N
superior JJ N
to TO N
that DT N
in IN N
group NN N
B NNP N
[ VBZ N
66.7 CD N
% NN N
( ( N
28/42 CD N
) ) N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
. . N

CONCLUSION VB N
The DT N
clinical JJ o
efficacy NN o
in IN N
tongue JJ i
acupuncture NN i
group NN N
is VBZ N
apparently RB N
superior JJ N
to TO N
that DT N
in IN N
conventional JJ i
training NN i
group NN N
, , N
ETTAA NNP N
combined VBD N
with IN N
conventional JJ N
training NN N
have VBP N
a DT N
better JJR N
curative JJ o
effect NN o
in IN N
the DT N
treatment NN N
of IN N
autism NN p
. . p

-DOCSTART- -21457605- O O

Improving VBG N
emotion NN o
regulation NN o
with IN N
CBT NNP i
in IN N
young JJ p
children NNS p
with IN p
high JJ p
functioning VBG p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
This DT N
pilot NN N
study NN N
tested VBD N
the DT N
efficacy NN N
of IN N
a DT N
developmentally RB N
modified VBN N
CBT NNP i
for IN N
young JJ p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
to TO N
teach VB N
emotion NN o
regulation NN o
strategies NNS N
for IN N
reducing VBG N
anger NN o
and CC o
anxiety NN o
, , N
commonly RB N
noted VBD N
problems NNS N
in IN N
this DT N
population NN N
. . N

METHOD NNP N
Eleven NNP p
5-7 JJ p
year-old JJ p
children NNS p
participated VBN p
in IN N
a DT N
CBT-group NNP i
while IN N
parents NNS N
participated VBN i
in IN i
psychoeducation NN i
. . i

Children NNP i
were VBD i
randomly RB i
assigned VBN i
to TO i
an DT i
experimental JJ i
or CC i
delayed-treatment JJ i
control NN i
group NN i
. . i

RESULTS CC N
From IN N
pre- JJ N
to TO N
post-treatment JJ N
, , N
all DT N
children NNS N
had VBD N
less RBR N
parent NN p
reported VBD p
negativity/lability NN o
, , N
better JJR N
parent NN N
reported VBD N
emotion NN o
regulation NN o
, , o
and CC o
shorter JJR o
outbursts NNS o
, , N
and CC N
also RB N
generated VBD o
more RBR o
coping JJ o
strategies NNS o
in IN N
response NN N
to TO N
vignettes NNS N
. . N

Parents NNS N
also RB N
reported VBD N
increases NNS N
in IN N
their PRP$ N
own JJ N
confidence NN o
and CC N
their PRP$ N
child NN N
's POS N
ability NN o
to TO o
deal VB o
with IN o
anger NN o
and CC o
anxiety NN o
. . o

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
young JJ p
children NNS p
with IN p
high JJ p
functioning VBG p
ASD NNP p
may MD N
benefit VB N
from IN N
CBT NNP i
to TO N
improve VB N
regulation NN o
of IN o
anger NN o
and CC o
anxiety NN o
, , N
and CC N
parent NN N
training NN N
may MD N
improve VB N
parental JJ o
self-efficacy NN o
. . o

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
make VB N
conclusions NNS N
about IN N
its PRP$ N
efficacy NN N
. . N

